PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	FLETCHER, RH; FLETCHER, SW				FLETCHER, RH; FLETCHER, SW			GLUTATHIONE AND AGING - IDEAS AND EVIDENCE	LANCET			English	Editorial Material									HARVARD UNIV,COMMUNITY HLTH PLAN,BOSTON,MA	Harvard University	FLETCHER, RH (corresponding author), HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA, USA.							BUCK C, 1975, INT J EPIDEMIOL, V4, P159, DOI 10.1093/ije/4.3.159; DATTA M, 1993, LANCET, V342, P345, DOI 10.1016/0140-6736(93)91478-5; JULIUS M, 1994, J CLIN EPIDEMIOL, V47, P1021, DOI 10.1016/0895-4356(94)90117-1; LANG CA, 1992, J LAB CLIN MED, V120, P720; LOCK S, 1994, ANN INTERN MED, V121, P60, DOI 10.7326/0003-4819-121-1-199407010-00012; MACLURE M, 1985, AM J EPIDEMIOL, V121, P35; TUKEY JW, 1977, SCIENCE, V198, P679, DOI 10.1126/science.333584	7	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 19	1994	344	8934					1379	1380		10.1016/S0140-6736(94)90562-2	http://dx.doi.org/10.1016/S0140-6736(94)90562-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR786	7968069				2022-12-01	WOS:A1994PR78600003
J	IRVINE, KD; WIESCHAUS, E				IRVINE, KD; WIESCHAUS, E			FRINGE, A BOUNDARY-SPECIFIC SIGNALING MOLECULE, MEDIATES INTERACTIONS BETWEEN DORSAL AND VENTRAL CELLS DURING DROSOPHILA WING DEVELOPMENT	CELL			English	Article							PATTERN-FORMATION; IMAGINAL DISKS; HEDGEHOG GENE; MELANOGASTER; REGENERATION; TRANSCRIPTION; EXPRESSION; PROTEIN; FIELDS	Wing formation in Drosophila requires interactions between dorsal and ventral cells. We describe a new gene, fringe, which is expressed in dorsal cells and encodes for a novel protein that is predicted to be secreted. Wing margin formation and distal wing outgrowth can be induced by the juxtaposition of cells with and without fringe expression, whether at the normal wing margin, at the boundaries of fringe mutant clones in the dorsal wing, or at sites of fringe misexpression in the ventral wing. By contrast, both loss of fringe expression and uniform fringe expression cause wing loss. These observations suggest that fringe encodes a boundary-specific cell-signaling molecule that is responsible for dorsal-ventral cell interactions during wing development.			IRVINE, KD (corresponding author), PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA.				NICHD NIH HHS [5R01HD22780] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022780] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAKER NE, 1988, DEVELOPMENT, V102, P489; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLAIR SS, 1993, DEVELOPMENT, V119, P339; BLAIR SS, 1994, DEVELOPMENT, V120, P1805; BRYANT PJ, 1975, J EXP ZOOL, V193, P49, DOI 10.1002/jez.1401930106; BRYANT SV, 1981, SCIENCE, V212, P993, DOI 10.1126/science.212.4498.993; BUTTERWORTH FM, 1965, GENETICS, V52, P1153; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; COHEN SM, 1993, DEV DROSOPHILA MELAN, P474; COUSO JP, 1994, DEVELOPMENT, V120, P621; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GELBART WM, 1989, DEVELOPMENT, V107, P65; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; HAYNIE JL, 1976, NATURE, V259, P659, DOI 10.1038/259659b0; IRVINE KD, 1991, DEVELOPMENT, V111, P407; KARLSSON J, 1980, J EMBRYOL EXP MORPH, V59, P315; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LEHMANN R, 1985, THESIS U TUBINGEN TU; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MEINHARDT H, 1982, DEV ORDER ITS ORIGIN, P439; MOHLER J, 1992, DEVELOPMENT, V115, P957; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; POSAKONY LG, 1990, MECH DEVELOP, V33, P69, DOI 10.1016/0925-4773(90)90136-A; ROBERTSON HM, 1988, GENETICS, V118, P461; STEVENS ME, 1986, DEV BIOL, V117, P326, DOI 10.1016/0012-1606(86)90375-1; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILCOX M, 1980, ROUX ARCH DEV BIOL, V188, P157, DOI 10.1007/BF00848808; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; WILLIAMS JA, 1993, BIOESSAYS, V15, P567, DOI 10.1002/bies.950150902; XU T, 1993, DEVELOPMENT, V117, P1223	41	296	303	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 18	1994	79	4					595	606		10.1016/0092-8674(94)90545-2	http://dx.doi.org/10.1016/0092-8674(94)90545-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7954826				2022-12-01	WOS:A1994PT48100007
J	ENQUIST, M; ARAK, A				ENQUIST, M; ARAK, A			SYMMETRY, BEAUTY AND EVOLUTION	NATURE			English	Article								HUMANS and certain other species find symmetrical patterns more attractive than asymmetrical ones. These preferences may appear in response to biological signals(1-3), or in situations where there is no obvious signalling context, such as exploratory behaviour(4,5) and human aesthetic response to pattern(6-8). It has been proposed(9,10) that preferences for symmetry have evolved in animals because the degree of symmetry in signals indicates the signaller's quality. By contrast, we show here that symmetry preferences may arise as a by-product of the need to recognize objects irrespective of their position and orientation in the visual field. The existence of sensory biases for symmetry may have been exploited independently by natural selection acting on biological signals and by human artistic innovation. This may account for the observed convergence on symmetrical forms in nature and decorative art(11).	ARCHWAY ENGN UK LTD,ELLAND HX5 9JP,W YORKSHIRE,ENGLAND		ENQUIST, M (corresponding author), UNIV STOCKHOLM,DEPT ZOOL,S-10691 STOCKHOLM,SWEDEN.							ARAK A, 1993, PHILOS T R SOC B, V340, P207, DOI 10.1098/rstb.1993.0059; Berlyne D. E., 1971, AESTHETICS PSYCHOBIO; BROOKES M, 1994, TRENDS ECOL EVOL, V9, P201, DOI 10.1016/0169-5347(94)90241-0; Cronly-Dillon J., 1991, EVOLUTION EYE VISUAL; Darwin C., 1872, EXPRESS EMOT MAN, DOI [10.1037/10001-000, DOI 10.1037/10001-000]; DEREFELDT G, 1991, PERCEPTION COLOUR, P218; DOLL TJ, 1967, J EXP PSYCHOL, V75, P508, DOI 10.1037/h0025116; ENQUIST M, 1993, NATURE, V361, P446, DOI 10.1038/361446a0; GOMBRICH EH, 1984, SENSE ORDER; HUBBELL MB, 1940, AM J PSYCHOL, V53, P46; LEIMAR O, 1986, AM NAT, V128, P469, DOI 10.1086/284581; Mackintosh NJ., 1974, PSYCHOL ANIMAL LEARN; MOLLER AP, 1992, NATURE, V357, P238, DOI 10.1038/357238a0; MUSINGER H, 1964, PSYCHOL MONOGR, V9, P1; RADESATER T, 1993, ANIM BEHAV, V45, P626, DOI 10.1006/anbe.1993.1075; Rensch B., 1957, Zeitschrift fuer Tierpsychologie, V14, P71; Rensch B., 1958, Zeitschrift fuer Tierpsychologie, V15, P447; RYAN MJ, 1991, OXFORD SURVEYS EVOLU, V7, P156; STADDON JER, 1975, AM NAT, V109, P541, DOI 10.1086/283025; Stewart I., 1993, FEARFUL SYMMETRY IS; SWADDLE JP, 1994, NATURE, V367, P165, DOI 10.1038/367165a0; Tinbergen N., 1951, STUDY INSTINCT; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; Wallace A.R., 1889, DARWINISM; WATSON PJ, 1994, TRENDS ECOL EVOL, V9, P21, DOI 10.1016/0169-5347(94)90227-5	25	297	301	1	91	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 10	1994	372	6502					169	172		10.1038/372169a0	http://dx.doi.org/10.1038/372169a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ688	7969448				2022-12-01	WOS:A1994PQ68800053
J	AYANIAN, JZ; HAUPTMAN, PJ; GUADAGNOLI, E; ANTMAN, EM; PASHOS, CL; MCNEIL, BJ				AYANIAN, JZ; HAUPTMAN, PJ; GUADAGNOLI, E; ANTMAN, EM; PASHOS, CL; MCNEIL, BJ			KNOWLEDGE AND PRACTICES OF GENERALIST AND SPECIALIST PHYSICIANS REGARDING DRUG-THERAPY FOR ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CLINICAL-TRIALS; HEALTH-CARE REFORM; UNSTABLE ANGINA; MANAGEMENT; INFORMATION; SERVICES; DISSEMINATION; GUIDELINES; LIDOCAINE; PATTERNS	Background. The respective roles of generalist and specialist physicians in the care of patients are currently a matter of debate. Information is limited about the knowledge and practices of generalist and specialist physicians regarding conditions that both groups treat, such as myocardial infarction. Methods. We therefore surveyed 1211 cardiologists, internists, and family practitioners in the states of New York and Texas about four treatments demonstrated by randomized clinical trials to be associated with improved survival after myocardial infarction (thrombolytic therapy, immediate and long-term use of aspirin, and long-term use of beta-blockers) and two treatments for which such evidence is lacking (diltiazem for patients with pulmonary congestion and prophylactic lidocaine). We asked physicians about the effect of each treatment on survival and the likelihood that they would prescribe each class of drugs. Results. For the four beneficial treatments, the cardiologists believed more strongly than the internists and family physicians that survival was improved by the treatment, and they were more likely to prescribe these drugs (P<0.001). For example, 94.1 percent of cardiologists said they were very likely to prescribe thrombolytic agents to treat an acute myocardial infarction, as compared with 82.0 percent of internists and 77.3 percent of family practitioners. Conversely, for the two treatments for which trials showed no evidence of a survival benefit, cardiologists were less likely than internists and family practitioners to think there was such a benefit and less likely to prescribe the drugs (P<0.001). For example, 4.7 percent of cardiologists reported that they were very likely to use prophylactic lidocaine, as compared with 13.1 percent of internists, and 16.5 percent of family practitioners. When we used logistic regression to adjust for potential confounders, all the differences between the cardiologists and the internists and family practitioners remained significant (P<0.02). Conclusions. Internists and family practitioners are less aware of or less certain about key advances in the treatment of myocardial infarction than are cardiologists. This finding underscores the need to improve the dissemination of information from clinical trials to generalist physicians, particularly if they are to have an enlarged role in the evolving health care system.	BRIGHAM & WOMENS HOSP, DIV GEN MED, HLTH SERV & POLICY RES SECT, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT RADIOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	AYANIAN, JZ (corresponding author), HARVARD UNIV, SCH MED,DEPT HLTH CARE POLICY,25 SHATTUCK ST, PARCEL B, 1ST FL, BOSTON, MA 02115 USA.				AHRQ HHS [HS06341] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADAY LA, 1989, DESIGNING CONDUCTING, P121; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1988, BRIT MED J, V296, P320; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; BEHAR S, 1988, EUR HEART J, V9, P354; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; COHEN JJ, 1993, NEW ENGL J MED, V329, P1810, DOI 10.1056/NEJM199312093292412; ELKHATIB A, 1993, CIRCULATION, V88, P608; FRANKS P, 1993, JAMA-J AM MED ASSOC, V270, P1449, DOI 10.1001/jama.270.12.1449; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; GRAVES EJ, 1993, DHHS PHS931250 NAT C; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; Gunnar R M, 1990, Circulation, V82, P664; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; GURWITZ JH, 1992, AM J MED, V93, P605, DOI 10.1016/0002-9343(92)90192-E; HANSEN JF, 1984, EUR HEART J, V5, P516; HELD PH, 1989, BMJ-BRIT MED J, V299, P1187, DOI 10.1136/bmj.299.6709.1187; HINE LK, 1989, ARCH INTERN MED, V149, P2694, DOI 10.1001/archinte.149.12.2694; HLATKY MA, 1988, AM J CARDIOL, V61, P510, DOI 10.1016/0002-9149(88)90755-2; HLATKY MA, 1988, AM J CARDIOL, V61, P515, DOI 10.1016/0002-9149(88)90756-4; HUTCHISON SJ, 1987, BRIT MED J, V294, P1261, DOI 10.1136/bmj.294.6582.1261; KIMBALL HR, 1994, JAMA-J AM MED ASSOC, V271, P315, DOI 10.1001/jama.271.4.315; KINDIG DA, 1993, JAMA-J AM MED ASSOC, V270, P1069; LAMAS GA, 1992, NEW ENGL J MED, V327, P241, DOI 10.1056/NEJM199207233270405; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; MACMAHON S, 1988, JAMA-J AM MED ASSOC, V260, P1910, DOI 10.1001/jama.260.13.1910; MITCHELL JRA, 1982, BRIT MED J, V285, P1140, DOI 10.1136/bmj.285.6349.1140; MOSS AJ, 1988, NEW ENGL J MED, V319, P385; NAYLOR CD, 1990, CAN MED ASSOC J, V142, P1069; PASHOS CL, 1994, J AM COLL CARDIOL, V23, P1023, DOI 10.1016/0735-1097(94)90585-1; PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801; SOUMERAI SB, 1989, MILBANK Q, V67, P268, DOI 10.2307/3350142; STARFIELD B, 1993, JAMA-J AM MED ASSOC, V269, P3136, DOI 10.1001/jama.269.24.3136; STINSON ER, 1980, JAMA-J AM MED ASSOC, V243, P140, DOI 10.1001/jama.243.2.140; STROSS JK, 1979, JAMA-J AM MED ASSOC, V241, P2622, DOI 10.1001/jama.241.24.2622; STROSS JK, 1981, JAMA-J AM MED ASSOC, V246, P360, DOI 10.1001/jama.246.4.360; THOMPSON PL, 1992, MED J AUSTRALIA, V157, P87, DOI 10.5694/j.1326-5377.1992.tb137032.x; TOGNONI G, 1990, STAT MED, V9, P17, DOI 10.1002/sim.4780090108; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WENNBERG JE, 1987, LANCET, V1, P1185, DOI 10.1016/s0140-6736(87)92152-0; WENNBERG JE, 1993, HEALTH AFFAIR, V12, P89, DOI 10.1377/hlthaff.12.2.89; YOUNG MJ, 1987, HEALTH SERV RES, V22, P623; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1993, PHYSICIAN CHARACTERI; 1990, SAS STAT USERS GUIDE; 1991, DHHS PHS911232 NAT C; 1993, STATISTICAL ABSTRACT, P33	49	340	340	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 27	1994	331	17					1136	1142		10.1056/NEJM199410273311707	http://dx.doi.org/10.1056/NEJM199410273311707			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN065	7935639				2022-12-01	WOS:A1994PN06500007
J	CHEN, ZW; KOH, M; VANDRIESSCHE, G; VANBEEUMEN, JJ; BARTSCH, RG; MEYER, TE; CUSANOVICH, MA; MATHEWS, FS				CHEN, ZW; KOH, M; VANDRIESSCHE, G; VANBEEUMEN, JJ; BARTSCH, RG; MEYER, TE; CUSANOVICH, MA; MATHEWS, FS			THE STRUCTURE OF FLAVOCYTOCHROME-C SULFIDE DEHYDROGENASE FROM A PURPLE PHOTOTROPHIC BACTERIUM	SCIENCE			English	Article							CHROMATIUM-VINOSUM; SEQUENCE; FLAVIN; FLAVOPROTEIN; KINETICS; SUBUNIT	The structure of the heterodimeric flavocytochrome c sulfide dehydrogenase from Chromatium vinosum was determined at a resolution of 2.53 angstroms. It contains a glutathione reductase-like flavin-binding subunit and a diheme cytochrome subunit. The diheme cytochrome folds as two domains, each resembling mitochondrial cytochrome c, and has an unusual interpropionic acid linkage joining the two heme groups in the interior of the subunit. The active site of the flavoprotein subunit contains a catalytically important disulfide bridge located above the pyrimidine portion of the flavin ring. A tryptophan, threonine, or tyrosine side chain may provide a partial conduit for electron transfer to one of the heme groups located 10 angstroms from the flavin.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; STATE UNIV GHENT,DEPT BIOCHEM PHYSIOL & MICROBIOL,B-9000 GHENT,BELGIUM; UNIV ARIZONA,DEPT BIOCHEM,TUCSON,AZ 85721	Washington University (WUSTL); Ghent University; University of Arizona					NIGMS NIH HHS [GM-20530, GM-21277] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021277] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cusanovich M, 1991, CHEM BIOCH FLAVOENZY, V2, P377; CUSANOVICH MA, 1985, BIOCHEMISTRY-US, V24, P1281, DOI 10.1021/bi00327a002; DOLATA MM, 1993, J BIOL CHEM, V268, P14426; Ghisla S., 1991, CHEM BIOCH FLAVOENZY, P243; KENNEY WC, 1974, EUR J BIOCHEM, V48, P449, DOI 10.1111/j.1432-1033.1974.tb03785.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MATHEWS FS, 1990, BIOCHEMISTRY-US, V31, P238; MEYER TE, 1991, BIOCHEMISTRY-US, V30, P8840, DOI 10.1021/bi00100a016; MEYER TE, 1991, ARCH BIOCHEM BIOPHYS, V287, P128, DOI 10.1016/0003-9861(91)90397-2; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; REGAN J, 1993, PATHWAYS, V2; Roussel A, 1991, SILICON GRAPHICS GEO, P86; SALEMME FR, 1982, J MOL BIOL, V159, P551, DOI 10.1016/0022-2836(82)90302-3; SCHULZ GE, 1978, NATURE, V273, P120, DOI 10.1038/273120a0; VANBEEUMAN JJ, UNPUB; VANBEEUMEN JJ, 1991, J BIOL CHEM, V266, P12921; WAKSMAN G, 1994, J MOL BIOL, V236, P800, DOI 10.1006/jmbi.1994.1190; XIA ZX, 1990, J MOL BIOL, V212, P837, DOI 10.1016/0022-2836(90)90240-M; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	19	126	133	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 21	1994	266	5184					430	432		10.1126/science.7939681	http://dx.doi.org/10.1126/science.7939681			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7939681				2022-12-01	WOS:A1994PN27200033
J	DOLLERY, CM; SULLIVAN, ID; BAURAIND, O; BULL, C; MILLA, PJ				DOLLERY, CM; SULLIVAN, ID; BAURAIND, O; BULL, C; MILLA, PJ			THROMBOSIS AND EMBOLISM IN LONG-TERM CENTRAL VENOUS ACCESS FOR PARENTERAL-NUTRITION	LANCET			English	Article							CATHETER; COMPLICATIONS; CHILDREN	Although the use of silicone catheters for long-term central venous access is widespread, little is known about the incidence of pulmonary thromboembolic complications. We studied clinical events, lung perfusion scans, and echocardiographic screens in 34 children and adolescents with gut failure who had received cyclical parenteral nutrition for 2 months to 9 years. Major thrombosis and/or embolism was identified in 12 patients and 4 died as a consequence. Actuarial survival free from thrombosis was 53% at 5 years (95% Cl, 30-77%). Survival free from fatal pulmonary thromboembolic events was 74% at 5 years (48-99%). 3 patients required surgery to remove right atrial thrombus or pulmonary emboli. Major right atrial thrombosis and pulmonary embolism are common and potentially fatal complications of parenteral nutrition by long-term venous access in childhood. Anticoagulation is recommended.	HOSP SICK CHILDREN,CARDIOTHORAC UNIT,LONDON WC1N 3JH,ENGLAND; HOSP SICK CHILDREN,GASTROENTEROL UNIT,LONDON WC1N 3JH,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust								BISSET WM, 1992, ARCH DIS CHILD, V67, P109, DOI 10.1136/adc.67.1.109; BRISMAR B, 1982, ARCH SURG-CHICAGO, V117, P1196; EMERY JL, 1961, SURGERY, V50, P309; LEIBY JM, 1989, AM J MED, V86, P228, DOI 10.1016/0002-9343(89)90276-3; MOUKARZEL A, 1991, JPEN-PARENTER ENTER, V15, P551, DOI 10.1177/0148607191015005551; MUGHAL MM, 1989, BRIT J SURG, V76, P15, DOI 10.1002/bjs.1800760107; RYAN JA, 1974, NEW ENGL J MED, V290, P757, DOI 10.1056/NEJM197404042901401; SCHMIDTSOMMERFELD E, 1990, JPEN-PARENTER ENTER, V14, P148, DOI 10.1177/0148607190014002148; SHIBA E, 1992, EUR J SURG, V158, P59	9	120	120	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1043	1045		10.1016/S0140-6736(94)91707-8	http://dx.doi.org/10.1016/S0140-6736(94)91707-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7934444				2022-12-01	WOS:A1994PL85200007
J	HABRAKEN, Y; SUNG, P; PRAKASH, L; PRAKASH, S				HABRAKEN, Y; SUNG, P; PRAKASH, L; PRAKASH, S			HOLIDAY JUNCTION CLEAVAGE BY YEAST RAD1 PROTEIN	NATURE			English	Article							DNA-REPAIR; ESCHERICHIA-COLI; HOLLIDAY JUNCTIONS; ENDONUCLEASE; RESOLUTION	IN Saccharomyces cerevisiae, of the many genes required for excision repair of ultraviolet-damaged DNA, only RAD1 and RAD10 also function in genetic recombination(1). Complex formation between the RAD1 and RAD10 gene products(1) activates an endonucleolytic function that nicks single-stranded DNA(2,3) and negatively supercoiled double-stranded DNA(2). To characterize the recombination role of the proteins Rad1 and Rad10, we have investigated their interaction with the Holliday junction, a four-stranded structure that results from single-stranded crossover between two duplex DNA molecules and whose resolution is obligatory for the generation of mature recombinants. We show that Rad1 binds specifically to a Holliday junction and, in the presence of magnesium, catalyses the endonucleolytic cleavage of the junction. Junction cleavage by Rad1 proceeds sufficiently without Rad10, thus identifying Rad1 as the catalytic subunit of Rad1/Rad10 endonuclease.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Prakash, Louise/C-7891-2012; Prakash, Satya/C-6420-2013	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444				BAILLY V, 1992, P NATL ACAD SCI USA, V89, P8273, DOI 10.1073/pnas.89.17.8273; BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; CARR AM, 1994, MOL CELL BIOL, V14, P2029, DOI 10.1128/MCB.14.3.2029; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; Egel R., 1989, MOL BIOL FISSION YEA, P31; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; RODEL C, 1992, NUCLEIC ACIDS RES, V20, P6347, DOI 10.1093/nar/20.23.6347; SUNG P, 1993, J BIOL CHEM, V268, P26391; SUNG P, 1992, NATURE, V355, P743, DOI 10.1038/355743a0; TAYLOR AF, 1992, CELL, V69, P1063, DOI 10.1016/0092-8674(92)90626-N; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757	13	41	42	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					531	534		10.1038/371531a0	http://dx.doi.org/10.1038/371531a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7935767				2022-12-01	WOS:A1994PK58900060
J	CROSS, CE; VANDERVLIET, A; ONEILL, CA; EISERICH, JP				CROSS, CE; VANDERVLIET, A; ONEILL, CA; EISERICH, JP			REACTIVE OXYGEN SPECIES AND THE LUNG	LANCET			English	Article							OXIDATIVE STRESS; RESPIRATORY-TRACT; INJURY; ACID; CELL; GLUTATHIONE; RECEPTORS; TOXICITY; DISEASE		UNIV CALIF DAVIS,DEPT INTERNAL MED,DAVIS,CA; UNIV CALIF DAVIS,DEPT HUMAN PHYSIOL,DAVIS,CA	University of California System; University of California Davis; University of California System; University of California Davis	CROSS, CE (corresponding author), UNIV CALIF DAVIS,DIV PULM CRIT CARE,PROFESS BLDG,4301 X ST,ROOM 2120,SACRAMENTO,CA 95817, USA.				NHLBI NIH HHS [HL47628, HL07013] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007013, R01HL047628] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER KB, 1990, J CLIN INVEST, V85, P75, DOI 10.1172/JCI114436; ALBELDA SM, 1994, FASEB J, V8, P504, DOI 10.1096/fasebj.8.8.8181668; ANGGARD E, 1994, LANCET, V343, P1199, DOI 10.1016/S0140-6736(94)92405-8; BALLA G, 1992, J BIOL CHEM, V267, P18148; BARNARD ML, 1993, AM J PHYSIOL, V265, pL340, DOI 10.1152/ajplung.1993.265.4.L340; BARNES PJ, 1990, FREE RADICAL BIO MED, V9, P235, DOI 10.1016/0891-5849(90)90034-G; BRITIGAN BE, 1991, J CLIN INVEST, V88, P1092, DOI 10.1172/JCI115408; BROWN LAS, 1994, AM J PHYSIOL, V266, pL172, DOI 10.1152/ajplung.1994.266.2.L172; BUCCA C, 1989, RESPIRATION, V55, P214, DOI 10.1159/000195737; BUHL R, 1994, CHEM-BIOL INTERACT, V91, P147, DOI 10.1016/0009-2797(94)90035-3; CLARK S, 1993, BIOCHEM J, V292, P217, DOI 10.1042/bj2920217; CLERCH LB, 1994, J CLIN INVEST, V93, P2482, DOI 10.1172/JCI117257; CROSS CE, IN PRESS ENV HLTH PE; CRYSTAL RG, 1991, AM J MED, V91, pS39, DOI 10.1016/0002-9343(91)90282-3; GARNIER P, 1994, AM J RESP CRIT CARE, V149, pA148; GHIO AJ, 1994, AM J PHYSIOL, V266, pL382, DOI 10.1152/ajplung.1994.266.4.L382; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; HOLROYD KJ, 1993, THORAX, V48, P985, DOI 10.1136/thx.48.10.985; JANSSEN YMW, 1993, LAB INVEST, V69, P261; KOOY NW, 1994, AM J RESP CRIT CARE, V149, pA814; LEWISMOLOCK Y, 1994, AM J RESP CELL MOL, V10, P133, DOI 10.1165/ajrcmb.10.2.8110468; MERCER RR, 1994, AM J RESP CELL MOL, V10, P613, DOI 10.1165/ajrcmb.10.6.8003339; MULLIGAN MS, 1991, P NATL ACAD SCI USA, V88, P6338, DOI 10.1073/pnas.88.14.6338; MUNDAY R, 1989, FREE RADICAL BIO MED, V7, P659, DOI 10.1016/0891-5849(89)90147-0; NATANSON C, 1994, ANN INTERN MED, V120, P771, DOI 10.7326/0003-4819-120-9-199405010-00009; ORRENIUS S, 1992, ANN NEUROL, V32, pS33, DOI 10.1002/ana.410320708; PEDEN DB, 1993, AM REV RESPIR DIS, V148, P455, DOI 10.1164/ajrccm/148.2.455; PRICE LT, 1993, PEDIATR RES, V34, P577, DOI 10.1203/00006450-199311000-00005; PRITCHARD RJ, 1994, AM J RESP CRIT CARE, V149, pA840; ROUM JH, 1993, J APPL PHYSIOL, V75, P2419, DOI 10.1152/jappl.1993.75.6.2419; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHWARTZ J, 1994, AM J CLIN NUTR, V59, P110, DOI 10.1093/ajcn/59.1.110; SHI M, 1994, AM J RESPIR CRIT CAR, V149, pA569; SMITH LJ, 1993, AM REV RESPIR DIS, V147, P1461, DOI 10.1164/ajrccm/147.6_Pt_1.1461; STOCKER R, 1990, FREE RADICAL RES COM, V9, P101, DOI 10.3109/10715769009148577; VANDERVLIET A, 1992, CHEM-BIOL INTERACT, V85, P95, DOI 10.1016/0009-2797(92)90055-P; YOO JH, 1994, J CLIN INVEST, V93, P297, DOI 10.1172/JCI116959	38	102	105	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					930	933		10.1016/S0140-6736(94)92275-6	http://dx.doi.org/10.1016/S0140-6736(94)92275-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934352				2022-12-01	WOS:A1994PJ28700016
J	ROOKUS, MA; VANLEEUWEN, FE				ROOKUS, MA; VANLEEUWEN, FE			ORAL-CONTRACEPTIVES AND RISK OF BREAST-CANCER IN WOMEN AGED 20-54 YEARS	LANCET			English	Article							YOUNG-WOMEN; METAANALYSIS	Although the use of oral contraceptives (OCs) is not generally associated with increased risk of breast cancer, higher risks have been reported for some subgroups of users. We have carried out a population-based case-control study in the Netherlands to assess the effect of timing and duration of OC use on the risk of breast cancer developing at various ages. 918 women with breast cancer (20-54 years at diagnosis) were pair-matched by age with controls randomly selected from municipal registries. Information on OC use obtained from women and their prescribers was combined according to standard decision rules. Overall, long-term use of OCs (greater than or equal to 12 years) had an associated relative risk (RR) of 1.3 (95% CI 0.9-1.9; test for trend in risk with months of use p = 0.03). This positive trend was found in both the youngest (<36 years; p = 0.08) and the oldest (46-54 years, p = 0.004) age groups, but not in women aged 36-45 years. The RR of developing breast cancer before age 36 was 2.1 (1.0-4.5) for 4 or more years of OC use compared with shorter use. In women younger than 36, risk increased for longer OC use before age 20 (1.44 per year, p = 0.04). Recent use (previous 3 years) was associated with increased risk in women of 46-54 (RR 1.9 [0.9-4.1], p = 0.02). We conclude that 4 or more years of OC use, especially if partly before age 20, is associated with an increased risk of breast cancer developing at an early age. There is limited evidence that the excess risk disappears as the cohort of young OC users ages, but this issue needs confirmation.	NETHERLANDS CANC INST,DEPT EPIDEMIOL,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute								BERNSTEIN L, 1990, ORAL CONTRACEPTIVES, P169; BRESLOW NE, 1980, STATISTICAL METHODS; DELGADORODRIGUEZ M, 1991, REV EPIDEMIOL SANTE, V39, P165; EWERTZ M, 1992, EUR J CANCER, V28A, P1176, DOI 10.1016/0959-8049(92)90481-G; KOLS A, 1982, POPULATION REP, V10, pA189; MALONE KE, 1993, EPIDEMIOL REV, V15, P80, DOI 10.1093/oxfordjournals.epirev.a036119; MCPHERSON K, 1986, J EPIDEMIOL COMMUN H, V40, P289, DOI 10.1136/jech.40.4.289; MCPHERSON K, 1987, BRIT J CANCER, V56, P653, DOI 10.1038/bjc.1987.261; MEIRIK O, 1986, LANCET, V2, P650; NISCHAN P, 1993, AM J EPIDEMIOL, V138, P697, DOI 10.1093/oxfordjournals.aje.a116907; PAUL C, 1990, INT J CANCER, V46, P366, DOI 10.1002/ijc.2910460305; PIKE MC, 1981, BRIT J CANCER, V43, P72, DOI 10.1038/bjc.1981.10; PIKE MC, 1983, LANCET, V2, P926; ROMIEU I, 1990, CANCER-AM CANCER SOC, V66, P2253, DOI 10.1002/1097-0142(19901201)66:11<2253::AID-CNCR2820661102>3.0.CO;2-G; ROMIEU I, 1989, JNCI-J NATL CANCER I, V81, P1313, DOI 10.1093/jnci/81.17.1313; RUSHTON L, 1992, BRIT J OBSTET GYNAEC, V99, P239, DOI 10.1111/j.1471-0528.1992.tb14506.x; SKEGG DCG, 1988, AM J EPIDEMIOL, V127, P205, DOI 10.1093/oxfordjournals.aje.a114796; STADEL BV, 1986, AM J EPIDEMIOL, V123, P373, DOI 10.1093/oxfordjournals.aje.a114252; THOMAS DB, 1991, CONTRACEPTION, V43, P597, DOI 10.1016/0010-7824(91)90006-2; THOMAS DB, 1992, BRIT J CANCER, V65, P108, DOI 10.1038/bjc.1992.20; THOMAS DB, 1991, CANCER CAUSE CONTROL, V2, P309; VANDERVANGE N, 1987, CONTEMP OBSTET GYNEC, P315; VANLEEUWEN FE, 1992, CONTRACEPTION, V45, P399, DOI 10.1016/0010-7824(92)90154-L; VESSEY MP, 1989, BRIT J CANCER, V59, P613, DOI 10.1038/bjc.1989.124; VESSEY MP, 1990, ORAL CONTRACEPTIVES, P121; WINGO PA, 1991, OBSTET GYNECOL, V78, P161; WINGO PA, 1990, ORAL CONTRACEPTIVES, P67; 1989, LANCET, V1, P973; 1987, TNM CLASSIFICATION M	29	91	92	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					844	851		10.1016/S0140-6736(94)92826-6	http://dx.doi.org/10.1016/S0140-6736(94)92826-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH253	7916400				2022-12-01	WOS:A1994PH25300010
J	JONES, G; NGUYEN, T; SAMBROOK, P; KELLY, PJ; EISMAN, JA				JONES, G; NGUYEN, T; SAMBROOK, P; KELLY, PJ; EISMAN, JA			PROGRESSIVE LOSS OF BONE IN THE FEMORAL-NECK IN ELDERLY PEOPLE - LONGITUDINAL FINDINGS FROM THE DUBBO OSTEOPOROSIS EPIDEMIOLOGY STUDY	BRITISH MEDICAL JOURNAL			English	Article							MINERAL DENSITY; POSTMENOPAUSAL WOMEN; CIGARETTE-SMOKING; DIETARY-INTAKE; AGE; MEN; CALCIUM; SPINE; MASS; FRACTURES	Objectives-To determine prospectively the rates of change in bone mineral density in elderly people and to examine the relation between lifestyle and demographic factors and these rates of change. Design-Longitudinal population based study. Setting-Dubbo, New South Wales, Australia. Subjects-Representative sample (n = 769) of residents aged greater than or equal to 60 on 1 January 1989. Main outcome measure-Rates of change in bone mineral density measured prospectively (mean scan interval 2.5 years) at the femoral neck and lumbar spine by dual energy x ray absorptiometry. Results-Summary rates of loss in the femoral neck were 0.96% per year (95% confidence interval 0.64% to 1.28%) in women and 0.82% per year (0.52% to 1.12%) in men. Importantly, rates of loss at the femoral neck (both percentage and absolute) increased in both sexes with advancing age. No significant loss was evident in either sex at the lumbar spine, probably because of coexistent osteoarthritis. Lifestyle factors had only modest effects on rates of loss at either site. Conclusions-These data show that bone density of the femoral neck declines at an increasing rate in elderly people, and as this site is predictive of fracture suggest that treatment to minimise bone loss may be important even in very elderly people.	ST VINCENTS HOSP,GARVAN INST MED RES,DIV BONE & MINERAL,DARLINGHURST,NSW 2010,AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney			Nguyen, Tuan V./AAD-9503-2020; Nguyen, Tuan V/B-6147-2008; Eisman, John A/C-2886-2014	Nguyen, Tuan V./0000-0002-3246-6281; Nguyen, Tuan V/0000-0002-3246-6281; 				ALOIA JF, 1985, AM J MED, V78, P95, DOI 10.1016/0002-9343(85)90468-1; ANGUS RM, 1988, BONE MINER, V4, P265; BROWNER WS, 1991, LANCET, V338, P355, DOI 10.1016/0140-6736(91)90489-C; CHRISTIANSEN C, 1987, Lancet, V1, P1105; CUMMING RG, 1990, CALCIFIED TISSUE INT, V47, P194; DANIELL HW, 1976, ARCH INTERN MED, V136, P298, DOI 10.1001/archinte.136.3.298; DAVIS JW, 1989, J BONE MINER RES, V4, P351; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; GOTFREDSEN A, 1987, J LAB CLIN MED, V110, P362; HANNAN MT, 1992, J BONE MINER RES, V7, P547; HEANEY RP, 1986, BONE MINER, V1, P99; Hui S L, 1990, Osteoporos Int, V1, P30, DOI 10.1007/BF01880413; HUI SL, 1982, J CHRON DIS, V35, P715, DOI 10.1016/0021-9681(82)90095-9; JONES G, 1994, OSTEOPOROSIS INT, V4, P273; KELLY PJ, 1993, J BONE MINER RES, V8, P11; KRALL EA, 1991, J BONE MINER RES, V6, P331; KROLNER B, 1982, CLIN SCI, V62, P329, DOI 10.1042/cs0620329; LORD SR, 1991, J GERONTOL, V46, pM57; MASAUD T, 1993, BRIT MED J, V307, P172; MAZESS RB, 1987, BONE MINER, V2, P211; MAZESS RB, 1990, J BONE MINER RES, V5, P645; MAZESS RB, 1991, AM J CLIN NUTR, V53, P132, DOI 10.1093/ajcn/53.1.132; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; MORRISON NA, 1992, P NATL ACAD SCI USA, V89, P6665, DOI 10.1073/pnas.89.15.6665; Myers R.H., 1990, CLASSICAL MODERN REG; NGUYEN T, 1993, BRIT MED J, V307, P1111, DOI 10.1136/bmj.307.6912.1111; NGUYEN T, 1994, IN PRESS J BONE MINE; ORWOLL ES, 1990, J CLIN ENDOCR METAB, V70, P1202, DOI 10.1210/jcem-70-4-1202; POCOCK NA, 1989, BONE, V10, P329, DOI 10.1016/8756-3282(89)90128-2; RIGGS BL, 1981, J CLIN INVEST, V67, P328, DOI 10.1172/JCI110039; RIGGS BL, 1986, J CLIN INVEST, V77, P1487, DOI 10.1172/JCI112462; SAMBROOK P, 1993, NEW ENGL J MED, V328, P1747, DOI 10.1056/NEJM199306173282404; SAMBROOK PN, 1987, J BONE MINER RES, V2, P109; SIMONS LA, 1990, AUST NZ J MED, V20, P783, DOI 10.1111/j.1445-5994.1990.tb00423.x; SLEMENDA CW, 1992, ANN INTERN MED, V117, P286, DOI 10.7326/0003-4819-117-4-286; SLEMENDA CW, 1989, J BONE MINER RES, V4, P737, DOI 10.1002/jbmr.5650040513; STEIGER P, 1992, J BONE MINER RES, V7, P625; VANHEMERT AM, 1990, J CLIN EPIDEMIOL, V43, P579, DOI 10.1016/0895-4356(90)90162-I; 1990, SAS USERS GUIDES STA	39	358	366	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 17	1994	309	6956					691	695		10.1136/bmj.309.6956.691	http://dx.doi.org/10.1136/bmj.309.6956.691			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH407	7950520	Green Published			2022-12-01	WOS:A1994PH40700013
J	VANNIEKERK, ABW; VRIES, JB; BAARD, J; SCHOUB, BD; CHEZZI, C; BLACKBURN, NK				VANNIEKERK, ABW; VRIES, JB; BAARD, J; SCHOUB, BD; CHEZZI, C; BLACKBURN, NK			OUTBREAK OF PARALYTIC POLIOMYELITIS IN NAMIBIA	LANCET			English	Article							SOUTH-AFRICA; VACCINE; POLIOVIRUSES	The last confirmed case of poliomyelitis in Namibia had been reported in 1988. However, between Nov 8, 1993, and Jan 7, 1994, 27 cases of paralytic poliomyelitis were confirmed in the country. The outbreak was limited to the south health region; at least 80% of infants in this region have received four doses of oral poliovaccine (OPV) by the age of 1 year. Acute flaccid paralysis (AFP) was the predominant clinical presentation during the outbreak. The patients' ages ranged from 13 months to 12 years; 24 were younger than 5 years. Of the 26 patients whose vaccine status was known, 14 had received four doses of OPV, 6 had one or two doses, and 6 no vaccine. Genotypic analysis showed 86% homology of outbreak isolates with a 1982 Namibian isolate and west African isolates. Factors that may have had a role in the outbreak include establishment of a pool of susceptible people, rapid urbanisation, inadequate sanitation, poor water supply, and possible endemicity of poliovirus in neighbouring areas. Epidemics can occur in areas of high vaccine coverage. Our findings emphasise the need to improve AFP surveillance activities and the estimation of vaccine coverage to identify areas of potential susceptibility for outbreaks.	KATATURA HOSP,DEPT PAEDIAT,WINDHOEK,NAMIBIA; NAMIBIAN MINIST HLTH & SOCIAL SERV,WINDHOEK,NAMIBIA		VANNIEKERK, ABW (corresponding author), NATL INST VIROL,PRIVATE BAG X4,JOHANNESBURG 2131,SOUTH AFRICA.							HESSE RR, 1987, VIROLOGY, V160, P311; JOHNSON S, 1984, T ROY SOC TROP MED H, V78, P26, DOI 10.1016/0035-9203(84)90166-4; KIMFARLEY RJ, 1984, LANCET, V2, P1322; NOTTAY BK, 1981, VIROLOGY, V108, P405, DOI 10.1016/0042-6822(81)90448-7; OTTEN MW, 1992, AM J EPIDEMIOL, V135, P381, DOI 10.1093/oxfordjournals.aje.a116299; PATRIARCA PA, 1991, REV INFECT DIS, V13, P926; SCHOUB BD, 1992, T ROY SOC TROP MED H, V86, P83, DOI 10.1016/0035-9203(92)90453-J; SCHOUB BD, 1988, J INFECT DIS, V157, P836, DOI 10.1093/infdis/157.4.836; SLATER PE, 1990, LANCET, V335, P1192, DOI 10.1016/0140-6736(90)92705-M; SUTTER RW, 1991, LANCET, V338, P715, DOI 10.1016/0140-6736(91)91442-W; YANG CF, 1991, VIRUS RES, V20, P159; 1991, EPI NEWSLETTER, V13, P5; 1992, WEEKLY EPIDEMIOL REC, V67, P113; 1993, WEEKLY EPIDEMIOL REC, V68, P225; 1992, WEEKLY EPIDEMIOL REC, V67, P325; 1989, MANUAL MANAGERS IMMU; 1991, WEEKLY EPIDEMIOL REC, V66, P49; 1988, WEEKLY EPIDEMIOL REC, V63, P161	18	34	35	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					661	664		10.1016/S0140-6736(94)92090-7	http://dx.doi.org/10.1016/S0140-6736(94)92090-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915353				2022-12-01	WOS:A1994PE38600015
J	MOYA, C; ANTO, JM; TAYLOR, AJN; COSTA, A; FENOLLAR, J; MAYORDOMO, C; DOMENECH, E; MITJANS, L; VANACLOCHA, H; MARTI, JV; SALAS, D; SANTOLARIA, E; VILLANUEVA, V; GOBERNA, R; MORELL, F; PARKER, JB; POZO, F; SUNYER, J; GIL, J; HERNANDEZ, L; MARTIN, C; ROMERO, S; ARANDA, I; ANDREO, L; SOLE, A; VILAR, JL; CORRIN, B				MOYA, C; ANTO, JM; TAYLOR, AJN; COSTA, A; FENOLLAR, J; MAYORDOMO, C; DOMENECH, E; MITJANS, L; VANACLOCHA, H; MARTI, JV; SALAS, D; SANTOLARIA, E; VILLANUEVA, V; GOBERNA, R; MORELL, F; PARKER, JB; POZO, F; SUNYER, J; GIL, J; HERNANDEZ, L; MARTIN, C; ROMERO, S; ARANDA, I; ANDREO, L; SOLE, A; VILAR, JL; CORRIN, B			OUTBREAK OF ORGANIZING PNEUMONIA IN TEXTILE PRINTING SPRAYERS	LANCET			English	Article							ORGANIZING PNEUMONIA	Eight textile printing factories in Valencia, Spain, with a total workforce of 257 using spraying techniques were investigated as a result of severe interstitial lung disease occurring in three employees, one of whom died. Clinical and radiological data together with biopsy from 71 (27.6%) workers with abnormal respiratory features indicated the occurrence of an outbreak of organising pneumonia resulting in 6 deaths. Epidemiological analysis included the 22 workers who fulfilled the radiological case definition based on chest radiograph and computed tomographic scan showing widespread nodular opacities or confluent patchy consolidation with a lung biopsy corresponding to organising pneumonia. The overall attach rate was 8.9%. Only 2 of the 22 cases never worked in factories A or B. Those who had only worked in factory A had the highest risk of being a case (RR = 24.3; 95% CI = 5.7 - 104.4). The relationship of case status to period of employment suggested an abrupt change in exposure conditions in the period when Acramin FWR was substituted by Acramin FWN. Although the precise toxicological mechanism is unknown, it is proposed that the lung disease was caused by spraying procedures delivered a respirable aerosol of Acramin FWN to distal airways and pulmonary parenchyma.	UNIV AUTONOMA BARCELONA,INST MUNICIPAL INVEST MED,DEPT EPIDEMIOL & PUBL HLTH,E-08003 BARCELONA,SPAIN; NATL HEART & LUNG INST,DEPT OCCUPAT & ENVIRONM MED,LONDON,ENGLAND; GEN VALENCLANA,CONSELLERIA SANIATAT & CONSUM,AREA SALUD ALCOI,VALENCIA,SPAIN; GEN VALENCLANA,CONSELLERIA SANIATAT & CONSUM,SERV EPIDEMIOL,VALENCIA,SPAIN; GEN VALENCLANA,CONSELLERIA SANIATAT & CONSUM,SERV PROGRAMMAS ESPECIALES,UNIDAD SALUD LABORAL,VALENCIA,SPAIN; GEN VALENCLANA,CONSELLERIA SANIATAT & CONSUM,DIRECCIO GEN SALUT PUBL,VALENCIA,SPAIN; GEN VALENCLANA,CONSELLERIA SANIATAT & CONSUM,SERV SEGURIDAD & HIGIENE,VALENCIA,SPAIN; HOSP GEN VALLE HEBRON,SERV PNEUMOL,BARCELONA,SPAIN; NIOSH,DIV RESP DIS STUDIES,CINCINNATI,OH; MINIST SANIDAD & CONSUMO,DIRECC GEN ORDENAC INVEST & FORMAC,MADRID,SPAIN; HOSP GEN ALICANTE,SECC NEUMOL,ALACANT,SPAIN; HOSP GEN ALICANTE,SERV ANAT PATOL,ALACANT,SPAIN; HOSP GEN ALICANTE,SERV IMMUNOL,ALACANT,SPAIN; HOSP VIRGEN LIRIOS,MED INTERNA SERV,ALACANT,SPAIN; HOSP VIRGEN LIRIOS,SERV RADIOL,ALACANT,SPAIN; HOSP LA FE,SERV NEUMOL,E-46009 VALENCIA,SPAIN; HOSP DR PESET,SERV RADIOL,VALENCIA,SPAIN; ROYAL BROMPTON NATL HEART & LUNG HOSP,DEPT LUNG PATHOL,LONDON SW3 6NP,ENGLAND	Autonomous University of Barcelona; Imperial College London; Hospital Universitari Vall d'Hebron; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); General University Hospital of Alicante; General University Hospital of Alicante; General University Hospital of Alicante; Hospital Universitari i Politecnic La Fe; Imperial College London			ARANDA, FRANCISCO I/L-5525-2015; Anto, J M/H-2676-2014; Aranda, F. Ignacio/H-5029-2011; Sunyer, Jordi/G-6909-2014	ARANDA, FRANCISCO I/0000-0003-2338-2286; Anto, J M/0000-0002-4736-8529; Aranda, F. Ignacio/0000-0003-2338-2286; Sunyer, Jordi/0000-0002-2602-4110				BRESLOW N, 1980, INT AGENCY RES CANCE, V32, P299; DAVISON AG, 1983, Q J MED, V52, P382; EPLER GR, 1992, CHEST, V102, pS2, DOI 10.1378/chest.102.1_Supplement.2S; EPLER GR, 1985, NEW ENGL J MED, V312, P152, DOI 10.1056/NEJM198501173120304; KHAN H, 1989, STATISTICAL METHODS; SANZ P, 1993, LANCET, V342, P240, DOI 10.1016/0140-6736(93)92330-V; SPITERI MA, 1992, LANCET, V340, P281, DOI 10.1016/0140-6736(92)92366-N; 1992, MMWR-MORBID MORTAL W, V41, P965; 1993, MMWR-MORBID MORTAL W, V42, P885	9	53	53	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 20	1994	344	8921					498	502		10.1016/S0140-6736(94)91896-1	http://dx.doi.org/10.1016/S0140-6736(94)91896-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7914612				2022-12-01	WOS:A1994PC53500007
J	SNOW, R; HAJRI, S; MASSAI, R; LI, XF				SNOW, R; HAJRI, S; MASSAI, R; LI, XF			CONCERNED ABOUT REPRODUCTIVE HEALTH - STRENGTHEN THE HRP	LANCET			English	Editorial Material									CTR RECH REPROD HUMAINE,TUNIS 2080,TUNISIA; INST CHILENO MED REPROD,SANTIAGO,CHILE; FAMILY PLANNING RES INST ZHEJIANG,HANGZHOU,PEOPLES R CHINA		SNOW, R (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT POPULAT & INT HLTH,BOSTON,MA 02115, USA.							Alexander N, 1992, STEROID HORMONES UTE; ELIAS CJ, 1993, 6 POP COUNC PROGR DI; Germaine A, 1994, POPULATION POLICIES, P27; MAULDIN WP, 1988, STUD FAMILY PLANN, V19, P335, DOI 10.2307/1966628; RICHTER J, 1994, POWER DECISION SOCIA, P205; SEN G, 1994, POPULATION POLICIES; TRUSSELL J, 1987, STUD FAMILY PLANN, V18, P237, DOI 10.2307/1966856; 1994, 3 INT C POP DEV PREP	8	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 13	1994	344	8920					459	460		10.1016/S0140-6736(94)91777-9	http://dx.doi.org/10.1016/S0140-6736(94)91777-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PB761	7914571				2022-12-01	WOS:A1994PB76100017
J	TRIOZZI, PL				TRIOZZI, PL			AUTOLOGOUS BONE-MARROW AND PERIPHERAL-BLOOD PROGENITOR TRANSPLANT FOR BREAST-CANCER	LANCET			English	Editorial Material							HIGH-DOSE CHEMOTHERAPY; SUPPORT; THERAPY				TRIOZZI, PL (corresponding author), OHIO STATE UNIV,CTR COMPREHENS CANC,COLUMBUS,OH 43210, USA.							ANTMAN K, 1992, J CLIN ONCOL, V10, P102, DOI 10.1200/JCO.1992.10.1.102; COIFFIER B, 1994, J CLIN ONCOL, V12, P226, DOI 10.1200/JCO.1994.12.1.226; DAVIDSON NE, 1992, J CLIN ONCOL, V10, P517, DOI 10.1200/JCO.1992.10.4.517; ECKHOLM E, 1993, NY TIMES        1230, pA12; ECKHOLM E, 1993, NEW YORK TIMES  0920, pA1; EDDY DM, 1992, J CLIN ONCOL, V10, P657, DOI 10.1200/JCO.1992.10.4.657; FREI E, 1989, J CLIN ONCOL, V7, P515, DOI 10.1200/JCO.1989.7.4.515; HENDERSON IC, 1988, J CLIN ONCOL, V6, P1501, DOI 10.1200/JCO.1988.6.9.1501; HRYNIUK WM, 1987, SEMIN ONCOL, V14, P65; NEIDHART JA, 1991, BREAST CANCER RES TR, V20, pS15, DOI 10.1007/BF01908240; PETERS WP, 1993, J CLIN ONCOL, V11, P1132, DOI 10.1200/JCO.1993.11.6.1132; 1993, AUTOLOGOUS BONE MARR; 1992, LANCET, V339, P71	13	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 13	1994	344	8920					418	419		10.1016/S0140-6736(94)91762-0	http://dx.doi.org/10.1016/S0140-6736(94)91762-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7914559				2022-12-01	WOS:A1994PB76100002
J	RUETZ, S; GROS, P				RUETZ, S; GROS, P			PHOSPHATIDYLCHOLINE TRANSLOCASE - A PHYSIOLOGICAL-ROLE FOR THE MDR2 GENE	CELL			English	Article							MULTIDRUG-RESISTANCE GENE; EXCHANGING HOMOLOGOUS DOMAINS; PRODUCT P-GLYCOPROTEIN; PLASMA-MEMBRANE; MONOCLONAL-ANTIBODIES; CANALICULAR MEMBRANE; TRANSMEMBRANE DOMAIN; FUNCTIONAL-ANALYSIS; COMPLEMENTARY-DNA; SENSITIVE METHOD	P-glycoproteins (P-gps) encoded by the mouse mdr2 and mdr3 genes were expressed in secretory vesicles (SVs) from the yeast mutant sec6-4, and their capacity to function as a lipid translocase/flippase was tested. An assay that uses a fluorescent phosphatidylcholine (PC) analog was developed to quantitate asymmetric lipid distribution in the outer and inner leaflets of the lipid bilayer of these vesicles. Mdr2 expression in SVs caused a time- and temperature-dependent enhancement of PC translocation to the inner leaflet of the membrane. The Mdr2-mediated effect was specific since expression of Mdr3 in these vesicles was without effect on the membrane distribution of PC. Increased Mdr2-mediated PC translocation was strictly ATP and Mg2+ dependent, was abrogated by the ATPase inhibitor vanadate and the P-gp modulator verapamil, but was insensitive to the presence of excess of the multidrug resistance drugs colchicine and vinblastine.			RUETZ, S (corresponding author), MCGILL UNIV,DEPT BIOCHEM,3655 DRUMMOND ST,MONTREAL H3G 1Y6,PQ,CANADA.							ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; BERR F, 1993, J BIOL CHEM, V268, P3976; BISHOP WR, 1985, CELL, V42, P51, DOI 10.1016/S0092-8674(85)80100-8; BOYER JL, 1992, ANNU REV PHYSIOL, V54, P415, DOI 10.1146/annurev.ph.54.030192.002215; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; BUSCHMAN E, 1991, MOL CELL BIOL, V11, P595, DOI 10.1128/MCB.11.2.595; BUSCHMAN E, 1992, J BIOL CHEM, V267, P18093; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; COLEMAN R, 1987, BIOCHEM J, V244, P249, DOI 10.1042/bj2440249; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; DHIR R, 1992, BIOCHEMISTRY-US, V31, P6103, DOI 10.1021/bi00141a021; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; Gros P, 1993, Int Rev Cytol, V137C, P169; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cellbio.8.1.67; HIGGINS CF, 1994, CURR BIOL, V4, P259, DOI 10.1016/S0960-9822(00)00059-2; HSU SIH, 1990, MOL CELL BIOL, V10, P3596, DOI 10.1128/MCB.10.7.3596; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; KREMER JMH, 1977, BIOCHEMISTRY-US, V16, P3932, DOI 10.1021/bi00636a033; LEE TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1993, J BIOL CHEM, V268, P19965; LOWRY RR, 1974, LIPIDS, V9, P491, DOI 10.1007/BF02534277; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MCINTYRE JC, 1991, BIOCHEMISTRY-US, V30, P11819, DOI 10.1021/bi00115a012; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; NICHOLS JW, 1988, BIOCHEMISTRY-US, V27, P1889, DOI 10.1021/bi00406a014; OLSON P, 1979, BIOCHIM BIOPHYS ACTA, V455, P12; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; RAYMOND M, 1990, MOL CELL BIOL, V10, P1642, DOI 10.1128/MCB.10.4.1642; RAYMOND M, 1994, MOL CELL BIOL, V14, P277, DOI 10.1128/MCB.14.1.277; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROEPE PD, 1993, BIOCHEMISTRY-US, V32, P11042, DOI 10.1021/bi00092a014; RUETZ S, 1993, P NATL ACAD SCI USA, V90, P11588, DOI 10.1073/pnas.90.24.11588; RUETZ S, 1994, J BIOL CHEM, V269, P12277; SCHINKEL AH, 1991, CANCER RES, V51, P2628; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; VANDERVALK P, 1990, ANN ONCOL, V1, P56; WALSORTH NC, 1987, J CELL BIOL, V105, P163; YOSHIMURA A, 1989, J BIOL CHEM, V264, P16282; YUSA K, 1989, CANCER RES, V49, P5002	56	549	562	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					1071	1081		10.1016/0092-8674(94)90446-4	http://dx.doi.org/10.1016/0092-8674(94)90446-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	7912658				2022-12-01	WOS:A1994NV42500015
J	EITAN, S; SOLOMON, A; LAVIE, V; YOLES, E; HIRSCHBERG, DL; BELKIN, M; SCHWARTZ, M				EITAN, S; SOLOMON, A; LAVIE, V; YOLES, E; HIRSCHBERG, DL; BELKIN, M; SCHWARTZ, M			RECOVERY OF VISUAL RESPONSE OF INJURED ADULT-RAT OPTIC NERVES TREATED WITH TRANSGLUTAMINASE	SCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; AXONAL REGENERATION; NEURITE GROWTH; OLIGODENDROCYTES; MYELIN	Failure of axons of the central nervous system in adult mammals to regenerate spontaneously after injury is attributed in part to inhibitory molecules associated with oligodendrocytes. Regeneration of central nervous system axons in fish is correlated with the presence of a transglutaminase. This enzyme dimerizes interleukin-2, and the product is cytotoxic to oligodendrocytes in vitro. Application of this nerve-derived transglutaminase to rat optic nerves, in which the injury had caused the loss of visual evoked potential response to light, promoted the recovery of that response within 6 weeks after injury. Transmission electron microscopy analysis revealed the concomitant appearance of axons in the distal stump of the optic nerve.	WEIZMANN INST SCI,DEPT NEUROBIOL,IL-76100 REHOVOT,ISRAEL; TEL AVIV UNIV,SACKLER FAC MED,CHAIM SHEBA MED CTR,GOLDSCHLEGER EYE INST,TEL HASHOMER,ISRAEL	Weizmann Institute of Science; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine			Belkin, Michael/AAK-4728-2020; Solomon, Arieh/AAF-4361-2021					AGUAYO AJ, 1990, J EXP BIOL, V153, P199; ASSIA E, 1989, BRAIN RES, V476, P205, DOI 10.1016/0006-8993(89)91240-7; BANDTLOW CE, 1993, SCIENCE, V259, P80, DOI 10.1126/science.8418499; CAJAL SRY, 1954, DEGENERATION REGENER, V1; DAVID S, 1990, NEURON, V5, P463, DOI 10.1016/0896-6273(90)90085-T; DORFMAN LJ, 1987, NEUROLOGY, V37, P123, DOI 10.1212/WNL.37.1.123; EITAN S, 1992, P NATL ACAD SCI USA, V89, P5442, DOI 10.1073/pnas.89.12.5442; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; EIZENBERG O, UNPUB; FACCHIANO F, 1993, TRENDS BIOCHEM SCI, V18, P327, DOI 10.1016/0968-0004(93)90066-V; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; GRAFSTEIN B, 1982, EXP NEUROL, V76, P318, DOI 10.1016/0014-4886(82)90212-6; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; KEIRSTEAD SA, 1989, SCIENCE, V246, P255, DOI 10.1126/science.2799387; KIERNAN JA, 1979, BIOL REV, V54, P155, DOI 10.1111/j.1469-185X.1979.tb00871.x; LAVIE V, 1990, J COMP NEUROL, V298, P293, DOI 10.1002/cne.902980304; RICHARDSON PM, 1982, J NEUROCYTOL, V11, P949, DOI 10.1007/BF01148310; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHWAB ME, 1988, J NEUROSCI, V8, P2381; SCHWAB ME, 1985, J NEUROSCI, V5, P2415; SCHWARTZ M, 1985, SCIENCE, V228, P600, DOI 10.1126/science.3983646; SIVRON T, 1994, J COMP NEUROL, V343, P237, DOI 10.1002/cne.903430205; SO KF, 1985, BRAIN RES, V328, P349, DOI 10.1016/0006-8993(85)91047-9	23	111	115	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 17	1994	264	5166					1764	1768		10.1126/science.7911602	http://dx.doi.org/10.1126/science.7911602			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR600	7911602				2022-12-01	WOS:A1994NR60000044
J	LUCAS, SB; DECOCK, KM; HOUNNOU, A; PEACOCK, C; DIOMANDE, M; HONDE, M; BEAUMEL, A; KESTENS, L; KADIO, A				LUCAS, SB; DECOCK, KM; HOUNNOU, A; PEACOCK, C; DIOMANDE, M; HONDE, M; BEAUMEL, A; KESTENS, L; KADIO, A			CONTRIBUTION OF TUBERCULOSIS TO SLIM DISEASE IN AFRICA	BRITISH MEDICAL JOURNAL			English	Article							AIDS; HIV; UGANDA; INFECTIONS; DIARRHEA	Objectives-To assess the contribution of tuberculosis to the aetiology of the HIV wasting syndrome (slim) in Africa, a condition usually considered an enteropathy. Methods-Clinical examination and representative necropsy study of adult patients positive for HIV. Setting-Hospital medical wards in Abidjan, Ivory Coast. Subjects-Adults positive for HIV. Main outcome measures-CD4 T lymphocyte counts before death, clinical and anthropometric data, and gross and microscopic pathology. Results-Necropsy was done on 212 HIV positive adults. Tuberculosis was found in 41 of 93 with the clinical HIV wasting syndrome and in 32 of 119 without (odds ratio 2.1, 95% confidence interval 1.2 to 4.0). A significant association existed between the prevalence of tuberculosis at necropsy and the degree of cadaveric wasting (no wasting 25% (15/59); moderate wasting 40% (23/58); skeletal wasting 44% (42/95); P=0.02). Wasting was also associated with a history of chronic diarrhoea, but no association existed between diarrhoea and tuberculosis. Median CD4 T lymphocyte counts were lowest in wasted patients irrespective of findings at necropsy and in those with chronic diarrhoea (<60x10(6)/l). Conclusion-Wasting and chronic diarrhoea are late stage manifestations of HIV disease in Africa. The importance of tuberculosis as a contributing factor in the pathogenesis of the slim syndrome has been underestimated. In nearly half of patients dying with severe wasting, tuberculosis was the dominant pathological finding.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30341; PROJET RETRO CI,ABIDJAN,COTE IVOIRE; UNIV HOSP ABIDJAN,ABIDJAN,COTE IVOIRE; INST TROP MED,B-2000 ANTWERP,BELGIUM	Centers for Disease Control & Prevention - USA; Institute of Tropical Medicine (ITM)	LUCAS, SB (corresponding author), UNIV LONDON UNIV COLL,SCH MED,DEPT HISTOPATHOL,LONDON WC1E 6JJ,ENGLAND.							COLEBUNDERS R, 1988, GUT, V29, P1687, DOI 10.1136/gut.29.12.1687; COLEBUNDERS RL, 1991, AIDS, V5, pS103; CONLON CP, 1990, AM J TROP MED HYG, V42, P83, DOI 10.4269/ajtmh.1990.42.83; DEAN AD, 1990, EPI INFO; DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007; DECOCK KM, 1993, LANCET, V342, P437, DOI 10.1016/0140-6736(93)92853-L; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; DECOCK KM, 1993, AM J PUBLIC HEALTH, V83, P1385, DOI 10.2105/AJPH.83.10.1385; GRUNFELD C, 1992, NEW ENGL J MED, V327, P329, DOI 10.1056/NEJM199207303270506; KAPEMBWA MS, 1991, CLIN SCI, V81, P327, DOI 10.1042/cs0810327; KESTENS L, 1992, AIDS, V6, P803, DOI 10.1097/00002030-199208000-00006; KEUSCH GT, 1990, ANNU REV NUTR, V10, P475, DOI 10.1146/annurev.nu.10.070190.002355; KOTLER DP, 1989, AM J CLIN NUTR, V50, P444, DOI 10.1093/ajcn/50.3.444; LUCAS SB, 1989, J CLIN PATHOL, V42, P885, DOI 10.1136/jcp.42.8.885-b; LUCS SB, 1993, AIDS, V7, P1569; NAHLEN BL, 1993, AIDS, V7, P183, DOI 10.1097/00002030-199302000-00005; NAMBUYA A, 1988, J CLIN PATHOL, V41, P93, DOI 10.1136/jcp.41.1.93; NELSON AM, 1993, AIDS, V7, P1241, DOI 10.1097/00002030-199309000-00014; Scalcini M, 1991, Bull Int Union Tuberc Lung Dis, V66, P37; SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9; SEWANKAMBO N, 1987, AIDS, V1, P9; SMITH PD, 1992, ANN INTERN MED, V116, P63, DOI 10.7326/0003-4819-116-1-63; World Health Organisation, 1986, WKLY EPIDEM REC, V61, P69	23	106	106	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 11	1994	308	6943					1531	1533		10.1136/bmj.308.6943.1531	http://dx.doi.org/10.1136/bmj.308.6943.1531			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR110	7912597	Green Published			2022-12-01	WOS:A1994NR11000018
J	NGAI, J; DOWLING, MM; BUCK, L; AXEL, R; CHESS, A				NGAI, J; DOWLING, MM; BUCK, L; AXEL, R; CHESS, A			THE FAMILY OF GENES ENCODING ODORANT RECEPTORS IN THE CHANNEL CATFISH	CELL			English	Article							BETA-ADRENERGIC-RECEPTOR; SENSITIVE ADENYLATE-CYCLASE; LIGAND-BINDING SPECIFICITY; ACID OLFACTORY RECEPTOR; NUCLEOTIDE SUBSTITUTIONS; OVERDOMINANT SELECTION; AMINO-ACIDS; EXPRESSION; NEURONS; CILIA	The anatomical and numerical simplicity of the fish olfactory system has led us to examine the family of olfactory receptors expressed in the catfish. We have identified a family of genes encoding seven transmembrane domain receptors that share considerable homology with the odorant receptors of the rat. The size of the catfish receptor repertoire appears to be far smaller than in mammals. Analysis of the nucleotide sequences suggests that these receptor genes have undergone positive Darwinian selection to generate enhanced diversity within the putative odorant-binding domains. Individual receptor clones anneal with 0.5%-2% of the olfactory neurons, suggesting that a single cell expresses only a small subset of distinct odorant receptors. Each cell, therefore, possesses a unique identity defined by the receptors it expresses. These data suggest that the brain may discriminate among odors by determining which neurons have been activated.	COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute			Dowling, Michael M./AAE-5263-2020	Dowling, Michael M./0000-0001-5058-6589; Axel, Richard/0000-0002-3141-4076	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007367] Funding Source: NIH RePORTER; NIGMS NIH HHS [T-32 GM07367] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; BRUCH RC, 1988, COMP BIOCHEM PHYS B, V91, P535, DOI 10.1016/0305-0491(88)90018-1; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CAGAN RH, 1978, P NATL ACAD SCI USA, V75, P4679, DOI 10.1073/pnas.75.10.4679; CAPRIO J, 1989, J GEN PHYSIOL, V93, P245, DOI 10.1085/jgp.93.2.245; CAPRIO J, 1984, J GEN PHYSIOL, V84, P403, DOI 10.1085/jgp.84.3.403; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; Doving K.B., 1986, Progress in Sensory Physiology, V6, P39; FESENKO EE, 1983, BIOCHIM BIOPHYS ACTA, V759, P250, DOI 10.1016/0304-4165(83)90320-3; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; HARA T J, 1975, Progress in Neurobiology (Oxford), V5, P271, DOI 10.1016/0301-0082(75)90014-3; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; HUGHES AL, 1989, P NATL ACAD SCI USA, V86, P958, DOI 10.1073/pnas.86.3.958; JUKES T H, 1969, P21; KALINOSKI DL, 1992, BIOCHEM J, V281, P449, DOI 10.1042/bj2810449; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LANCET D, 1986, ANNU REV NEUROSCI, V9, P329, DOI 10.1146/annurev.ne.09.030186.001553; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; MAEDA N, 1986, ANNU REV GENET, V20, P81; Maniatis T., 1982, MOL CLONING; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; NEI M, 1986, MOL BIOL EVOL, V3, P418; NEI M, 1989, MOL BIOL EVOL, V6, P290; NGAI J, 1993, CELL, V72; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; PACE U, 1985, NATURE, V316, P255, DOI 10.1038/316255a0; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; REED RR, 1992, NEURON, V8, P205, DOI 10.1016/0896-6273(92)90287-N; REHNBERG BG, 1986, J COMP PHYSIOL A, V159, P61, DOI 10.1007/BF00612496; RESTREPO D, 1990, SCIENCE, V249, P1166, DOI 10.1126/science.2168580; RHEIN LD, 1983, J NEUROCHEM, V41, P569, DOI 10.1111/j.1471-4159.1983.tb04777.x; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; TANAKA T, 1989, MOL BIOL EVOL, V6, P447; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	44	327	345	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 12	1993	72	5					657	666						10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	7916654	Bronze			2022-12-01	WOS:A1993KR43600003
J	LANDS, RH				LANDS, RH			CHOREA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 7	1994	272	21					1636	1636		10.1001/jama.272.21.1636	http://dx.doi.org/10.1001/jama.272.21.1636			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU759	7966874				2022-12-01	WOS:A1994PU75900001
J	LOPATIN, AN; MAKHINA, EN; NICHOLS, CG				LOPATIN, AN; MAKHINA, EN; NICHOLS, CG			POTASSIUM CHANNEL BLOCK BY CYTOPLASMIC POLYAMINES AS THE MECHANISM OF INTRINSIC RECTIFICATION	NATURE			English	Article							GUINEA-PIG HEART; INWARD RECTIFICATION; VENTRICULAR CELLS; MAGNESIUM BLOCK; EXPRESSION; MEMBRANE; MYOCYTES; CLONING; MG-2+	INWARDLY rectifying potassium channels conduct ions more readily in the inward than the outward direction, an essential property for normal electrical activity(1,2). Although voltage-dependent block by internal magnesium ions may underlie inward rectification in some channels(3-5), an intrinsic voltage-dependent closure of the channel plays a contributory, or even exclusive, role in others(4,6-9). Here me report that, rather than being intrinsic to the channel protein, so-called intrinsic rectification of strong inward rectifiers requires soluble factors that are not Mg2+ and can be released from Xenopus oocytes and other cells. Biochemical and biophysical characterization identifies these factors as polyamines (spermine, spermidine, putrescine and cadaverine). The results suggest that intrinsic rectification results from voltage-dependent block of the channel pore by polyamines, not from a voltage sensor intrinsic to the channel protein(10).	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Nichols, Colin/D-6336-2012					ARMSTRON.CM, 1969, J GEN PHYSIOL, V54, P553, DOI 10.1085/jgp.54.5.553; Bachrach U., 1973, FUNCTION NATURALLY O; CALDARERA CM, 1974, J MOL CELL CARDIOL, V6, P95, DOI 10.1016/0022-2828(74)90013-3; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GERBAUT L, 1991, CLIN CHEM, V37, P2117; HATHAWAY GM, 1984, ARCH BIOCHEM BIOPHYS, V233, P133, DOI 10.1016/0003-9861(84)90609-X; Hille B., 1992, IONIC CHANNELS EXCIT; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HORIE M, 1987, J PHYSIOL-LONDON, V387, P251, DOI 10.1113/jphysiol.1987.sp016572; ISHIHARA K, 1989, J PHYSIOL-LONDON, V419, P297, DOI 10.1113/jphysiol.1989.sp017874; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; KURACHI Y, 1985, J PHYSIOL-LONDON, V366, P365, DOI 10.1113/jphysiol.1985.sp015803; LASCHET J, 1992, EPILEPSY RES, V12, P151, DOI 10.1016/0920-1211(92)90035-R; LEECH CA, 1981, J PHYSIOL-LONDON, V319, P295, DOI 10.1113/jphysiol.1981.sp013909; LOPATIN AN, 1994, J GEN PHYSIOL, V103, P203, DOI 10.1085/jgp.103.2.203; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MAKHIMA EN, J BIOL CHEM, V269, P20469; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MATSUDA H, 1988, J PHYSIOL-LONDON, V397, P237, DOI 10.1113/jphysiol.1988.sp016998; MIYAMOTO S, 1993, ARCH BIOCHEM BIOPHYS, V300, P63, DOI 10.1006/abbi.1993.1009; NICHOLS CG, 1994, J PHYSIOL-LONDON, V476, P399, DOI 10.1113/jphysiol.1994.sp020141; OLIVA C, 1990, J GEN PHYSIOL, V96, P299, DOI 10.1085/jgp.96.2.299; OSHOURNE HB, 1989, BIOCHEM BIOPH RES CO, V158, P520; PERIER F, 1994, P NATL ACAD SCI USA, V91, P6240, DOI 10.1073/pnas.91.13.6240; SACAAN AI, 1990, MOL PHARMACOL, V38, P705; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; TANAKA Y, 1982, J BIOCHEM-TOKYO, V91, P2029, DOI 10.1093/oxfordjournals.jbchem.a133896; TRAUTWEIN W, 1958, PFLUG ARCH GES PHYS, V266, P324, DOI 10.1007/BF00416781; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0	30	718	730	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					366	369		10.1038/372366a0	http://dx.doi.org/10.1038/372366a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PU287	7969496				2022-12-01	WOS:A1994PU28700057
J	PELTOLA, H; HEINONEN, OP; VALLE, M; PAUNIO, M; VIRTANEN, M; KARANKO, V; CANTELL, K				PELTOLA, H; HEINONEN, OP; VALLE, M; PAUNIO, M; VIRTANEN, M; KARANKO, V; CANTELL, K			THE ELIMINATION OF INDIGENOUS MEASLES, MUMPS, AND RUBELLA FROM FINLAND BY A 12-YEAR, 2-DOSE VACCINATION PROGRAM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; CHILDREN; VIRUS; IMMUNIZATION; ANTIBODY; VACCINES; PERSISTENCE; INCREASE; IMMUNITY; TRIAL	Background. In the 1970s measles, mumps, and rubella were rampant in Finland, and rates of immunization were inadequate. in 1982 a comprehensive national vaccination program began in which two doses of a combined live-virus vaccine were used. Methods. Public health nurses at 1036 child health centers administered the vaccine to children at 14 to 18 months of age and again at 6 years, and also to selected groups of older children and young adults. Vaccination was voluntary and free of charge. In follow-up studies, we focused on rates of vaccination, reasons for noncompliance, adverse reactions, immunogenicity, persistence of antibody, and incidence of the three diseases. Since 1987, paired serum samples have been collected from all patients with suspected cases of measles, mumps, or rubella. Results. Over a period of 12 years, 1.5 million of the 5 million people in Finland were vaccinated. Coverage now exceeds 95 percent. The vaccine was efficient and safe, even in those with a history of severe allergy. No deaths or persistent sequelae were attributable to vaccination. The most frequent complication requiring hospitalization was acute thrombocytopenic purpura, which occurred at a rate of 3.3 per 100,000 vaccinated persons. The 99 percent decrease in the incidence of the three diseases was accompanied by an increasing rate of false positive clinical diagnoses. In 655 vaccinated patients with clinically diagnosed disease, serologic studies confirmed the presence of measles in only 0.8 percent, mumps in 2.0 percent, and rubella in 1.2 percent. The few localized outbreaks were confined to patients in the partially vaccinated age groups. There are now fewer than 30 sporadic cases of each of the three diseases per year,and those are probably imported. Conclusions. Over a 12-year period, an immunization program using two doses of combined live-virus vaccine has eliminated indigenous measles, mumps, and rubella from Finland. Serologic studies show that most reported sporadic cases are now due to other causes, but a continued high rate of vaccination coverage is essential to prevent outbreaks resulting from exposure to imported disease.	UNIV HELSINKI,CHILDRENS HOSP,NATL PUBL HLTH INST,SF-00290 HELSINKI,FINLAND; UNIV HELSINKI,DEPT PUBL HLTH,HELSINKI,FINLAND	Finland National Institute for Health & Welfare; University of Helsinki; University of Helsinki	PELTOLA, H (corresponding author), UNIV HELSINKI,CHILDRENS HOSP,DIV INFECT DIS,STENBACKINKATU 11,SF-00290 HELSINKI,FINLAND.							AABY P, 1986, J PEDIATR-US, V109, P40, DOI 10.1016/S0022-3476(86)80569-8; ANDERSON RM, 1983, J HYG-CAMBRIDGE, V90, P259, DOI 10.1017/S002217240002893X; BAYER WL, 1965, NEW ENGL J MED, V273, P1362, DOI 10.1056/NEJM196512162732504; BRUNELL PA, 1983, JAMA-J AM MED ASSOC, V250, P1409, DOI 10.1001/jama.250.11.1409; CARTER H, 1992, BRIT MED J, V304, P637, DOI 10.1136/bmj.304.6827.637; CHANTLER JK, 1985, NEW ENGL J MED, V313, P1117, DOI 10.1056/NEJM198510313131803; CHRISTENSON B, 1983, BRIT MED J, V287, P389, DOI 10.1136/bmj.287.6389.389; CUTTS FT, 1992, JAMA-J AM MED ASSOC, V267, P1952, DOI 10.1001/jama.267.14.1952; Diabetes Epidemiology Research International Group, 1988, DIABETES, V37, P1113; EDMONSON MB, 1990, JAMA-J AM MED ASSOC, V263, P2467, DOI 10.1001/jama.263.18.2467; FORREST JM, 1974, AUST NZ J MED, V4, P352, DOI 10.1111/j.1445-5994.1974.tb03203.x; GALLOWAY Y, 1991, COMMUN DIS NZ, V12, P107; GERSHON AA, 1979, DIAGNOSTIC PROCEDURE, P685; GRAHAM DY, 1974, JAMA-J AM MED ASSOC, V227, P1162, DOI 10.1001/jama.227.10.1162; HEINONEN OP, 1977, BIRTH DEFECTS DRUGS, P7; HETHCOTE HW, 1983, AM J EPIDEMIOL, V117, P2, DOI 10.1093/oxfordjournals.aje.a113511; HOWSON CP, 1992, PEDIATRICS, V89, P318; HUDSON JB, 1956, J PEDIATR-US, V48, P48, DOI 10.1016/S0022-3476(56)80116-9; HYOTY H, 1993, DIABETOLOGIA, V36, P1303, DOI 10.1007/BF00400810; JUNTUNENBACKMAN K, 1987, AM J DIS CHILD, V141, P1103, DOI 10.1001/archpedi.1987.04460100081032; KATZ SL, 1991, REP PEDIAT INFECT DI, V1, P1; KIEFABER RW, 1981, NEW ENGL J MED, V305, P225; KOSKINIEMI M, 1989, LANCET, V1, P31; LAU YL, 1992, J INFECT DIS, V165, P1111, DOI 10.1093/infdis/165.6.1111; LERMAN SJ, 1981, PEDIATRICS, V68, P18; LOKIETZ H, 1965, J LANCET, V85, P226; MARKOWITZ LE, 1992, J INFECT DIS, V166, P205, DOI 10.1093/infdis/166.1.205; NIEMINEN U, 1993, ACTA PAEDIATR, V82, P267, DOI 10.1111/j.1651-2227.1993.tb12657.x; Ohga Shouichi, 1992, Acta Paediatrica Japonica, V34, P447; PAUNIO M, 1991, AM J EPIDEMIOL, V133, P1152, DOI 10.1093/oxfordjournals.aje.a115827; PELTOLA H, 1993, LANCET, V341, P994, DOI 10.1016/0140-6736(93)91077-Y; PELTOLA H, 1986, LANCET, V1, P137; PELTOLA H, 1986, LANCET, V1, P939; PENTTINEN K, 1968, AM J EPIDEMIOL, V88, P234, DOI 10.1093/oxfordjournals.aje.a120882; UEDA K, 1986, AM J EPIDEMIOL, V124, P807, DOI 10.1093/oxfordjournals.aje.a114457; UKKONEN P, 1988, SCAND J INFECT DIS, V20, P255, DOI 10.3109/00365548809032448; VAANANEN P, 1979, J MED VIROL, V3, P245, DOI 10.1002/jmv.1890030402; VAHERI A, 1982, LANCET, V2, P685; VALMARI P, 1987, PEDIATR INFECT DIS J, V6, P59, DOI 10.1097/00006454-198701000-00015; VESIKARI T, 1984, AM J DIS CHILD, V138, P843, DOI 10.1001/archpedi.1984.02140470043013; VUORI M, 1962, Acta Otolaryngol, V55, P231, DOI 10.3109/00016486209127357; WEIBEL RE, 1980, P SOC EXP BIOL MED, V165, P260, DOI 10.3181/00379727-165-40967; WEIBEL RE, 1980, P SOC EXP BIOL MED, V165, P323, DOI 10.3181/00379727-165-40979; WILKINS J, 1979, J PEDIATR-US, V94, P865, DOI 10.1016/S0022-3476(79)80203-6; 1994, MMWR-MORBID MORTAL W, V43, P57; 1993, MMWR-MORBID MORTAL W, V42, P378	46	243	246	1	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 24	1994	331	21					1397	1402		10.1056/NEJM199411243312101	http://dx.doi.org/10.1056/NEJM199411243312101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU533	7969278	Bronze			2022-12-01	WOS:A1994PU53300001
J	CHONG, LD; TRAYNORKAPLAN, A; BOKOCH, GM; SCHWARTZ, MA				CHONG, LD; TRAYNORKAPLAN, A; BOKOCH, GM; SCHWARTZ, MA			THE SMALL GTP-BINDING PROTEIN-RHO REGULATES A PHOSPHATIDYLINOSITOL 4-PHOSPHATE 5-KINASE IN MAMMALIAN-CELLS	CELL			English	Article							NEUTROPHIL NADPH OXIDASE; ENDOTHELIAL-CELLS; GROWTH-FACTORS; ACTIVATION; CALCIUM; 4,5-BISPHOSPHATE; RAS; PURIFICATION; STIMULATION; REQUIREMENT	Integrin-mediated adhesion is known to stimulate production of phosphatidylinositol 4,5-bisphosphate (4,5-PIP2) and increase 4,5-PIP2 hydrolysis in response to platelet-derived growth factor (PDGF). We now show that treatment of cells with lovastatin, which inhibits modification of small GTP-binding proteins, reduced PIP2 levels and decreased calcium mobilization in response to PDGF and thrombin. In cell lysates, GTP gamma S stimulated PIP 5-kinase activity, and this effect was blocked by botulinum C3 exoenzyme, suggesting that Rho was responsible. GTP-bound recombinant Rho stimulated PIP B-kinase activity, whereas GDP-Rho was much less potent and GTP-bound Rac was ineffective. Microinjected botulinum C3 exoenzyme caused diminished calcium mobilization in response to PDGF or thrombin. Conversely, microinjection of activated Rho reversed the decrease in calcium mobilization normally seen in nonadherent cells. These data demonstrate that Rho regulates 4,5-PIP2 synthesis and, indirectly, 4,5-PIP2 hydrolysis. They also raise the possibility that PIP2 synthesis could mediate the effects of Rho on the actin cytoskeleton.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT MED, SAN DIEGO, CA 92103 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; University of California System; University of California San Diego				schwartz, martin/0000-0002-2071-1243	NHLBI NIH HHS [P01 HL48728] Funding Source: Medline; NIGMS NIH HHS [R01 GM4428, R01 GM47214] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047214] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON P, 1992, J BIOL CHEM, V267, P20033; AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; AULLO P, 1993, EMBO J, V12, P921, DOI 10.1002/j.1460-2075.1993.tb05733.x; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BAZENET CE, 1990, J BIOL CHEM, V265, P18012; BIFULCO M, 1993, J CELL PHYSIOL, V155, P340, DOI 10.1002/jcp.1041550215; BOKOCH GM, 1992, J CLIN INVEST, V89, P402, DOI 10.1172/JCI115599; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CHILVERS ER, 1991, BIOCHEM J, V275, P373, DOI 10.1042/bj2750373; FENTON RG, 1992, J CELL BIOL, V117, P347, DOI 10.1083/jcb.117.2.347; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; Hall A, 1993, CURR OPIN CELL BIOL, V5, P265, DOI 10.1016/0955-0674(93)90114-6; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; KACHINTORN U, 1993, AM J PHYSIOL, V264, pC671, DOI 10.1152/ajpcell.1993.264.3.C671; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LING LE, 1989, J BIOL CHEM, V264, P5080; MCNAMEE HM, 1992, J CELL BIOL, V121, P673; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; SCHWARTZ MA, 1993, J BIOL CHEM, V268, P19931; SCHWARTZ MA, 1992, P NATL ACAD SCI USA, V89, P6138, DOI 10.1073/pnas.89.13.6138; SELF AJ, 1993, ONCOGENE, V8, P655; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; TUCKER RW, 1990, CELL CALCIUM, V11, P201, DOI 10.1016/0143-4160(90)90071-2; URUMOW T, 1986, FEBS LETT, V207, P253, DOI 10.1016/0014-5793(86)81499-5; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912; ZHANG J, 1993, J BIOL CHEM, V268, P22251	36	603	611	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 4	1994	79	3					507	513		10.1016/0092-8674(94)90259-3	http://dx.doi.org/10.1016/0092-8674(94)90259-3			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7954816				2022-12-01	WOS:A1994PQ48800013
J	LORI, F; MALYKH, A; CARA, A; SUN, D; WEINSTEIN, JN; LISZIEWICZ, J; GALLO, RC				LORI, F; MALYKH, A; CARA, A; SUN, D; WEINSTEIN, JN; LISZIEWICZ, J; GALLO, RC			HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE-1 REPLICATION	SCIENCE			English	Article							DRUG-COMBINATIONS; HTLV-III; INFECTION; PROTEASE; AIDS; ACTIVATION; MECHANISM; THERAPY; INVITRO; TISSUE	Hydroxyurea, a drug widely used in therapy of several human diseases, inhibits deoxynucleotide synthesis-and, consequently, DNA synthesis-by blocking the cellular enzyme ribonucleotide reductase. Hydroxyurea inhibits human immunodeficiency virus-type 1 (HIV-1) DNA synthesis in activated peripheral blood lymphocytes by decreasing the amount of intracellular deoxynucleotides, thus suggesting that this drug has an antiviral effect. Hydroxyurea has now been shown to block HIV-1 replication in acutely infected primary human lymphocytes (quiescent and activated) and macrophages, as well as in brood cells infected in vivo obtained from individuals with acquired immunodeficiency syndrome (AIDS). The antiviral effect was achieved at nontoxic doses of hydroxyurea, lower than those currently used in human therapy. Combination of hydroxyurea with the nucleoside analog didanosine (2',3'-dideoxyinosine, or ddl) generated a synergistic inhibitory effect without increasing toxicity. In some instances, inhibition of HIV-1 by hydroxyurea was irreversible, even several weeks after suspension of drug treatment. The indirect inhibition of HIV-1 by hydroxyurea is not expected to generate high rates of escape mutants. Hydroxyurea therefore appears to be a possible candidate for AIDS therapy.	NCI,MOLEC PHARMACOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	LORI, F (corresponding author), NCI,TUMOR CELL BIOL LAB,BLDG 37,BETHESDA,MD 20892, USA.		Cara, Andrea/AAA-4238-2021; Cara, Andrea/M-4865-2015	Cara, Andrea/0000-0003-4967-1895; Cara, Andrea/0000-0003-4967-1895; Weinstein, John/0000-0001-9401-6908; Lisziewicz, Julianna/0000-0002-3349-4495				ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; ASHORN P, 1990, P NATL ACAD SCI USA, V87, P7472, DOI 10.1073/pnas.87.19.7472; BELT RJ, 1980, CANCER, V46, P455, DOI 10.1002/1097-0142(19800801)46:3<455::AID-CNCR2820460306>3.0.CO;2-N; BIANCHI V, 1986, J BIOL CHEM, V261, P6037; BUNOW B, 1990, ANN NY ACAD SCI, V616, P490; CHARACHE S, 1991, HEMATOL ONCOL CLIN N, V5, P571, DOI 10.1016/S0889-8588(18)30432-5; DONEHOWER RC, 1992, SEMIN ONCOL, V19, P11; GAO WY, 1993, P NATL ACAD SCI USA, V90, P8925, DOI 10.1073/pnas.90.19.8925; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GOULAOUIC H, 1994, VIROLOGY, V200, P87, DOI 10.1006/viro.1994.1166; JACK JA, 1990, CELL, V61, P213; KAGEYAMA S, 1992, ANTIMICROB AGENTS CH, V36, P926, DOI 10.1128/AAC.36.5.926; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; LORI F, 1992, J VIROL, V66, P5067, DOI 10.1128/JVI.66.8.5067-5074.1992; LORI F, UNPUB; MALLEY SD, 1994, LANCET, V343, P1292, DOI 10.1016/S0140-6736(94)92182-2; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; MEYERHANS A, 1994, J VIROL, V68, P535, DOI 10.1128/JVI.68.1.535-540.1994; MORGAN JS, 1986, BIOCHEM BIOPH RES CO, V134, P1254, DOI 10.1016/0006-291X(86)90385-2; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; OTTO MJ, 1993, P NATL ACAD SCI USA, V90, P7543, DOI 10.1073/pnas.90.16.7543; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; SELIGMANN M, 1994, LANCET, V343, P871; SLABAUGH MB, 1991, J VIROL, V65, P2290, DOI 10.1128/JVI.65.5.2290-2298.1991; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; WEINSTEIN JN, 1990, ANN NY ACAD SCI, V616, P367; YARBRO JW, 1992, SEMIN ONCOL, V19, P1; YARCHOAN R, 1993, TRENDS PHARMACOL SCI, V14, P196, DOI 10.1016/0165-6147(93)90208-2	29	319	340	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					801	805		10.1126/science.7973634	http://dx.doi.org/10.1126/science.7973634			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973634				2022-12-01	WOS:A1994PP75300039
J	PAPE, JW; VERDIER, RI; BONCY, M; BONCY, J; JOHNSON, WD				PAPE, JW; VERDIER, RI; BONCY, M; BONCY, J; JOHNSON, WD			CYCLOSPORA INFECTION IN ADULTS INFECTED WITH HIV - CLINICAL MANIFESTATIONS, TREATMENT, AND PROPHYLAXIS	ANNALS OF INTERNAL MEDICINE			English	Article						ACQUIRED IMMUNODEFICIENCY SYNDROME; DIARRHEA; CYCLOSPORA; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; HAITI	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; ISOSPORA-BELLI INFECTION; ORGANISM; DIARRHEA; TRAVELERS; NEPAL	Objective: To determine the prevalence and clinical manifestations of Cyclospora in Haitians infected with human immunodeficiency virus (HIV) who have diarrhea and to evaluate therapy and prophylaxis. Design: Cohort study. From 1990 to 1993, stool samples were collected from adults seropositive for HIV who had had diarrhea for at least 3 weeks. Setting: A clinic in Haiti. Interventions: Stool samples were examined for enteric protozoa after acid-fast staining. Patients with Cyclospora infection were treated with trimethoprim-sulfamethoxazole (160 mg and 800 mg, respectively) given orally four times a day for 10 days. After completion of therapy, patients were evaluated weekly and re-treated if clinical and parasitologic recurrences occurred, followed by trimethoprim-sulfamethoxazole prophylaxis three times a week. Results: 804 of 2400 patients (33%) seropositive for HIV had a history of chronic or intermittent diarrhea; 502 of these 804 patients (62%) currently had diarrhea, and 450 patients each provided two stool specimens for examination. Enteric protozoa identified included Cryptosporidium (30%), Isospora belli (12%), Cyclospora species (11%), Giardia lamblia (3%), and Entamoeba histolytica (1%). Forty-three patients with diarrhea and Cyclospora infection were studied; their symptoms were indistinguishable from those seen in patients with isosporiasis or cryptosporidiosis. In all patients, diarrhea ceased and results from stool examinations were negative within 2.5 days after beginning oral tri methoprim-sulfamethoxazole therapy. Recurrent symptomatic cyclosporiasis developed in 12 of 28 patients (43%) followed for 1 month or more, but it also responded promptly to trimethoprim-sulfamethoxazole therapy. These 12 patients received trimethoprim-sulfamethoxazole three times a week as secondary prophylaxis, with only a single recurrence after 7 months. Conclusion: Cyclospora infection is common in Haitian patients with HIV infection, responds to trimethoprim-sulfamethoxazole therapy, and has a high recurrence rate that can be largely prevented with long-term trimethoprim-sulfamethoxazole prophylaxis.	CORNELL UNIV, COLL MED, DIV INTERNAL MED, NEW YORK, NY 10021 USA; HAITIAN STUDY GRP KAPOSIS SARCOMA & OPPORTUNIST I, PORT AU PRINCE, HAITI	Cornell University					FOGARTY INTERNATIONAL CENTER [D43TW000018] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022624, R21AI033877] Funding Source: NIH RePORTER; FIC NIH HHS [D43 TW 00018] Funding Source: Medline; NIAID NIH HHS [R21 AI 33877, R37 AI 22624] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENDALL RP, 1993, LANCET, V341, P590, DOI 10.1016/0140-6736(93)90352-H; DEHOVITZ JA, 1986, NEW ENGL J MED, V315, P87, DOI 10.1056/NEJM198607103150203; HART AS, 1990, LANCET, V335, P169, DOI 10.1016/0140-6736(90)90042-4; HOGE CW, 1993, LANCET, V341, P1175, DOI 10.1016/0140-6736(93)91002-4; Lennette E.H, 1985, MANUAL CLIN MICROBIO, V4th ed.; LEVINE ND, 1973, COCCIDIA, P1; LONG EG, 1990, J CLIN MICROBIOL, V28, P1101, DOI 10.1128/JCM.28.6.1101-1104.1990; ORTEGA YR, 1993, NEW ENGL J MED, V328, P1308, DOI 10.1056/NEJM199305063281804; PAPE JW, 1989, NEW ENGL J MED, V320, P1044, DOI 10.1056/NEJM198904203201604; PAPE JW, 1987, AM J TROP MED HYG, V36, P333, DOI 10.4269/ajtmh.1987.36.333; SHLIM DR, 1991, AM J TROP MED HYG, V45, P383, DOI 10.4269/ajtmh.1991.45.383; SOAVE R, 1986, CLIN RES, V34, pA533; SOAVE R, 1988, J INFECT DIS, V157, P225, DOI 10.1093/infdis/157.2.225; VERDIER RI, 1993, 8 INT C AIDS 3 STD W; WURTZ RM, 1993, CLIN INFECT DIS, V16, P136, DOI 10.1093/clinids/16.1.136; 1991, MMWR-MORBID MORTAL W, V40, P325	16	176	188	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1994	121	9					654	657		10.7326/0003-4819-121-9-199411010-00004	http://dx.doi.org/10.7326/0003-4819-121-9-199411010-00004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN450	7944073				2022-12-01	WOS:A1994PN45000004
J	CULLY, DF; VASSILATIS, DK; LIU, KK; PARESS, PS; VANDERPLOEG, LHT; SCHAEFFER, JM; ARENA, JP				CULLY, DF; VASSILATIS, DK; LIU, KK; PARESS, PS; VANDERPLOEG, LHT; SCHAEFFER, JM; ARENA, JP			CLONING OF AN AVERMECTIN-SENSITIVE GLUTAMATE-GATED CHLORIDE CHANNEL FROM CAENORHABDITIS-ELEGANS	NATURE			English	Article							AMINO-ACID RECEPTORS; XENOPUS-OOCYTES; INSECT MUSCLE; BINDING-SITE; MEMBRANE; RNA; IVERMECTIN; MODULATION; EXPRESSION; FIBERS	THE avermectins are a family of macrocyclic lactones used in the control of nematode and arthropod parasites(1). Ivermectin (22,23-dihydroavermectin B-1a) is widely used as an anthelmintic in veterinary medicine and is used to treat onchocerciasis or river blindness in humans(1,2). Abamectin (avermectin B-1a) is a miticide and insecticide used in crop protection(1). Avermectins interact with vertebrate and invertebrate GABA receptors(3-7) and invertebrate glutamate-gated chloride channels(8-11). The soil nematode Caenorhabditis elegans has served as a useful model to study the mechanism of action of avermectins(11-15). A C. elegans messenger RNA expressed in Xenopus oocytes encodes an avermectin-sensitive glutamate-gated chloride channel(11,14). To elucidate the structure and properties of this channel, we used Xenopus oocytes for expression cloning of two functional complementary DNAs encoding an avermectin-sensitive glutamate-gated chloride channel. We find that the electrophysiological and structural properties of these proteins indicate that they are new members of the ligand-gated ion channel superfamily.	MERCK & CO INC, RES LABS, DEPT GENET & MOLEC BIOL, RAHWAY, NJ 07065 USA	Merck & Company	CULLY, DF (corresponding author), MERCK & CO INC, RES LABS, DEPT CELLULAR BIOCHEM & PHYSIOL, RAHWAY, NJ 07065 USA.							ARENA JP, 1992, MOL BRAIN RES, V15, P339, DOI 10.1016/0169-328X(92)90127-W; ARENA JP, 1991, MOL PHARMACOL, V40, P368; ARENA JP, IN PRESS J PARASITOL; AZIZ MA, 1982, LANCET, V2, P171; Campbell WW, 1989, IVERMECTIN ABAMECTIN; CULLCANDY SG, 1976, J PHYSIOL-LONDON, V255, P449, DOI 10.1113/jphysiol.1976.sp011289; CULLY DF, 1991, MOL PHARMACOL, V40, P326; DINGLEDINE R, 1990, FASEB J, V4, P2636, DOI 10.1096/fasebj.4.9.2161372; DUCE IR, 1985, BRIT J PHARMACOL, V85, P395, DOI 10.1111/j.1476-5381.1985.tb08874.x; FRASER SP, 1990, MOL BRAIN RES, V8, P331, DOI 10.1016/0169-328X(90)90047-H; FRITZ LC, 1979, P NATL ACAD SCI USA, V76, P2062, DOI 10.1073/pnas.76.4.2062; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KASS IS, 1980, P NATL ACAD SCI-BIOL, V77, P6211, DOI 10.1073/pnas.77.10.6211; LEA T J, 1973, Comparative and General Pharmacology, V4, P351, DOI 10.1016/0010-4035(73)90046-3; LEA T J, 1973, Comparative and General Pharmacology, V4, P333, DOI 10.1016/0010-4035(73)90045-1; LINGLE C, 1981, BRAIN RES, V212, P481, DOI 10.1016/0006-8993(81)90482-0; Maniatis T., 1982, MOL CLONING; MELLIN TN, 1983, NEUROPHARMACOLOGY, V22, P89, DOI 10.1016/0028-3908(83)90265-4; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; PONG SS, 1982, J NEUROCHEM, V38, P375, DOI 10.1111/j.1471-4159.1982.tb08639.x; ROHERER SP, 1992, P NATL ACAD SCI USA, V89, P4168, DOI 10.1073/pnas.89.9.4168; SCHAEFFER JM, 1989, BIOCHEM PHARMACOL, V38, P2329, DOI 10.1016/0006-2952(89)90473-5; SCOTT RH, 1985, PESTIC SCI, V16, P599, DOI 10.1002/ps.2780160605; SIGEL E, 1987, MOL PHARMACOL, V32, P749; WAFFORD KA, 1989, J EXP BIOL, V144, P449; ZUFALL F, 1989, J EXP BIOL, V142, P191	28	559	589	7	82	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 20	1994	371	6499					707	711		10.1038/371707a0	http://dx.doi.org/10.1038/371707a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM773	7935817				2022-12-01	WOS:A1994PM77300058
J	SCHOENENBERGER, RA; HEIM, SM				SCHOENENBERGER, RA; HEIM, SM			INDICATION FOR COMPUTED-TOMOGRAPHY OF THE BRAIN IN PATIENTS WITH FIRST UNCOMPLICATED GENERALIZED SEIZURE	BRITISH MEDICAL JOURNAL			English	Article							1ST SEIZURE; EMERGENCY; EPILEPSY; ALCOHOL	Objectives-To assess the yield of emergency computed tomography of the brain in patients with a first generalised epileptic seizure and to evaluate a four item screening questionnaire on alcohol misuse (CAGE questionnaire) as a triage tool to avoid unnecessary scans in cases of seizures related to withdrawal from alcohol. Design-Prospective, observational. Setting-Medical casualty unit in a university hospital. Patients-119 adult patients presenting to casualty within one hour of a generalised seizure. Measurements-A clinical examination focusing on focal neurological symptoms, the CAGE questionnaire, and computed tomography of the brain with contrast enhancement. Results-Computed tomography showed a focal, structural lesion of the brain in 40 patients (34% (95% confidence interval 25% to 42%)). In 20 patients (17% (10% to 24%)) an important therapeutic intervention resulted. The presence of a focal neurological deficit had a sensitivity of 50% and a specificity of 89% in predicting focal lesions on computed tomography. Answering ''yes'' to fewer than two CAGE questions had a sensitivity of 90% and specificity of 44% in identifying patients with focal computed tomography lesions. Focal lesions were not detected on computed tomography in any of the 35 patients (0% (0% to 10%)) who showed no focal neurological symptoms and answered ''yes'' to two or more CAGE questions. Conclusions-The diagnostic yield of computed tomography of the brain in adults after a first generalised seizure is high. Combined with the clinical examination, the CAGE questionnaire can reliably identify patients with uncomplicated seizures related to withdrawal from alcohol, in whom computed tomography may not be absolutely necessary.	UNIV BASEL HOSP,DEPT MED,CH-4031 BASEL,SWITZERLAND; UNIV BASEL,DEPT NEUROL,BASEL,SWITZERLAND	University of Basel; University of Basel								BERESFORD TP, 1991, LANCET, V337, P1175; EARNEST M P, 1987, Neurology, V37, P142; EARNEST MP, 1976, EPILEPSIA, V17, P387, DOI 10.1111/j.1528-1157.1976.tb04450.x; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FEUSSNER JR, 1981, ANN INTERN MED, V94, P519, DOI 10.7326/0003-4819-94-4-519; GOODRIDGE DMG, 1983, BMJ-BRIT MED J, V287, P641, DOI 10.1136/bmj.287.6393.641; GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; HILLBOM ME, 1980, EPILEPSIA, V21, P459, DOI 10.1111/j.1528-1157.1980.tb04296.x; HOPKINS A, 1988, LANCET, V1, P721; MCKEE PJW, 1990, BRIT MED J, V300, P978, DOI 10.1136/bmj.300.6730.978; Morris J C, 1987, Emerg Med Clin North Am, V5, P827; RAMIREZLASSEPAS M, 1984, ANN NEUROL, V15, P536, DOI 10.1002/ana.410150605; ROSENTHAL RH, 1980, ANN EMERG MED, V9, P242, DOI 10.1016/S0196-0644(80)80379-9; RUSSO LS, 1983, ARCH NEUROL-CHICAGO, V40, P744, DOI 10.1001/archneur.1983.04050110062010; SAUNDERS S, 1975, EPILEPSIA, V16, P731; SCHEUER ML, 1990, NEW ENGL J MED, V323, P1468; SEMPERE AP, 1992, ACTA NEUROL SCAND, V86, P134, DOI 10.1111/j.1600-0404.1992.tb05054.x; TEASDALE G, 1974, LANCET, V2, P81; VANDONSELAAR CA, 1989, NEUROLOGY, V49, P267; YOUNG AC, 1982, LANCET, V2, P1446; 1990, SAS USERS GUIDE STAT; 1993, ANN EMERG MED, V22, P875	23	46	48	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 15	1994	309	6960					986	989		10.1136/bmj.309.6960.986	http://dx.doi.org/10.1136/bmj.309.6960.986			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PM417	7950718	Green Published			2022-12-01	WOS:A1994PM41700020
J	DECETY, J; PERANI, D; JEANNEROD, M; BETTINARDI, V; TADARY, B; WOODS, R; MAZZIOTTA, JC; FAZIO, F				DECETY, J; PERANI, D; JEANNEROD, M; BETTINARDI, V; TADARY, B; WOODS, R; MAZZIOTTA, JC; FAZIO, F			MAPPING MOTOR REPRESENTATIONS WITH POSITRON EMISSION TOMOGRAPHY	NATURE			English	Article							ANTERIOR CINGULATE CORTEX; PET IMAGES; VOLUNTARY; MOVEMENTS	BRAIN activity was mapped in normal subjects during passive observation of the movements of an 'alien' hand and while imagining grasping objects with their own hand. None of the tasks required actual movement. Shifting from one mental task to the other greatly changed the pattern of brain activation. During observation of hand movements, activation was mainly found in visual cortical areas, but also in subcortical areas involved in motor behaviour, such as the basal ganglia and the cerebellum. During motor imagery, cortical and subcortical areas related to motor preparation and programming were strongly activated. These data support the notion that motor learning during observation of movements and mental practice involves rehearsal of neural pathways related to cognitive stages of motor control(1-3).	UNIV MILAN,SCI INST H SAN RAFFAELE,INB,CNR,I-20132 MILAN,ITALY; UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROL,DIV BRAIN MAPPING,LOS ANGELES,CA 90024	Consiglio Nazionale delle Ricerche (CNR); University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	DECETY, J (corresponding author), INSERM,U94,16 AVE DOYEN LEPINE,F-69500 BRON,FRANCE.		Perani, Daniela/AAN-3221-2020					DECETY J, 1991, BEHAV BRAIN RES, V42, P1, DOI 10.1016/S0166-4328(05)80033-6; FOX PT, 1987, NEUR ABSTR, P1433; FRISTON KJ, 1990, J CEREBR BLOOD F MET, V10, P458, DOI 10.1038/jcbfm.1990.88; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; FRISTON KJ, 1989, J CEREBR BLOOD F MET, V9, P690, DOI 10.1038/jcbfm.1989.97; FRITH CD, 1991, P ROY SOC B-BIOL SCI, V244, P241, DOI 10.1098/rspb.1991.0077; JEANNEROD M, 1994, BEHAV BRAIN SCI, V17, P187, DOI 10.1017/S0140525X00034026; MUSHIAKE H, 1991, J NEUROPHYSIOL, V66, P705, DOI 10.1152/jn.1991.66.3.705; PARDO JV, 1990, P NATL ACAD SCI USA, V87, P256, DOI 10.1073/pnas.87.1.256; PAUS T, 1993, J NEUROPHYSIOL, V70, P453, DOI 10.1152/jn.1993.70.2.453; PERRETT DI, 1989, J EXP BIOL, V146, P87; ROLAND PE, 1980, J NEUROPHYSIOL, V43, P137, DOI 10.1152/jn.1980.43.1.137; SPINKS TJ, 1988, IEEE T NUCL SCI, V35, P721, DOI 10.1109/23.12819; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; WATSON JDG, 1993, CEREB CORTEX, V3, P79, DOI 10.1093/cercor/3.2.79; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024; YUE G, 1992, J NEUROPHYSIOL, V67, P1114, DOI 10.1152/jn.1992.67.5.1114	17	765	771	2	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 13	1994	371	6498					600	602		10.1038/371600a0	http://dx.doi.org/10.1038/371600a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7935791				2022-12-01	WOS:A1994PL55900050
J	NISWANDER, L; JEFFREY, S; MARTIN, GR; TICKLE, C				NISWANDER, L; JEFFREY, S; MARTIN, GR; TICKLE, C			A POSITIVE FEEDBACK LOOP COORDINATES GROWTH AND PATTERNING IN THE VERTEBRATE LIMB	NATURE			English	Article							APICAL ECTODERMAL RIDGE; CHICK WING DEVELOPMENT; SKELETAL-MUSCLE; RETINOIC ACID; HOX-4 GENES; FGF FAMILY; BUD CELLS; EXPRESSION; MOUSE; OUTGROWTH	LIMB development depends on signals from the apical ectodermal ridge and underlying mesenchyme(1,2). Fibroblast growth factor (FGF) can replace the ridge(3,4) and, because Fgf4 RNA is localized to the mouse posterior ridge(5), we proposed that FGF4 is the endogenous ridge signal(3). Ridge signals control limb outgrowth and maintain the zone of polarizing activity (ZPA) at the limb posterior margin(6), which is important in limb patterning: a ZPA graft to limb anterior mesenchyme causes cell respecification and mirror-image duplications(1,2). Sonic hedgehog (SHH7,8) has polarizing activity, and Shh RNA co-localizes with ZPA activity, suggesting SHH is the endogenous polarizing signal(7). We have investigated the molecular regulation of Fgf4 and Shh expression. We report here that Fgf4 expression in the ridge can be regulated by Shh-expressing cells. Moreover, Shh expression in mesenchyme can be activated by FGF4 in combination with retinoic acid. Once induced, Shh expression can be maintained by FGF4 alone, thus establishing a positive feedback loop between ZPA and ridge.	UNIV CALIF SAN FRANCISCO,SCH MED,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021; UNIV COLL & MIDDLESEX SCH MED,DEPT ANAT & DEV BIOL,LONDON W1P 6DB,ENGLAND	University of California System; University of California San Francisco; Memorial Sloan Kettering Cancer Center; University of London; University College London	NISWANDER, L (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT ANAT,SAN FRANCISCO,CA 94143, USA.		Niswander, Lee/D-3976-2013	Niswander, Lee/0000-0002-9959-0594				ANDERSON R, 1993, DEVELOPMENT, V117, P1421; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; DELAPEYRIERE O, 1993, DEVELOPMENT, V118, P601; DONO R, 1994, DEV BIOL, V163, P316, DOI 10.1006/dbio.1994.1151; EICHELE G, 1985, J CELL BIOL, V101, P1913, DOI 10.1083/jcb.101.5.1913; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; HAMBURGER V, 1992, DEV DYNAM, V195, P231, DOI 10.1002/dvdy.1001950404; HAN JK, 1993, DEV BIOL, V158, P549, DOI 10.1006/dbio.1993.1212; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; IZPISUABELMONTE JC, 1992, EMBO J, V11, P1451, DOI 10.1002/j.1460-2075.1992.tb05189.x; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; KOYAMA E, 1993, DEV GROWTH DIFFER, V35, P189; LEE J, 1985, J EMBRYOL EXP MORPH, V90, P139; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1992, DEVELOPMENT, V114, P755; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TICKLE C, 1985, DEV BIOL, V109, P82, DOI 10.1016/0012-1606(85)90348-3; TICKLE C, 1994, ANNU REV CELL BIOL, V10, P121; VOGEL A, 1993, DEVELOPMENT, V119, P199	23	612	631	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 13	1994	371	6498					609	612		10.1038/371609a0	http://dx.doi.org/10.1038/371609a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7935794				2022-12-01	WOS:A1994PL55900053
J	BOURTCHULADZE, R; FRENGUELLI, B; BLENDY, J; CIOFFI, D; SCHUTZ, G; SILVA, AJ				BOURTCHULADZE, R; FRENGUELLI, B; BLENDY, J; CIOFFI, D; SCHUTZ, G; SILVA, AJ			DEFICIENT LONG-TERM-MEMORY IN MICE WITH A TARGETED MUTATION OF THE CAMP-RESPONSIVE ELEMENT-BINDING PROTEIN	CELL			English	Article							APLYSIA SENSORY NEURONS; HIPPOCAMPAL; POTENTIATION; RAT; FACILITATION; SHOCK; FEAR; LTP; MECHANISMS; NALOXONE	The cAMP-responsive element-binding protein (CREB) has been implicated in the activation of protein synthesis required for long-term facilitation, a cellular model of memory in Aplysia. Our studies with fear conditioning and with the water maze show that mice with a targeted disruption of the alpha and delta isoforms of CREB are profoundly deficient in long-term memory. In contrast, short-term memory, lasting between 30 and 60 min, is normal. Consistent with models claiming a role for long-term potentiation (LTP) in memory, LTP in hippocampal slices from CREB mutants decayed to baseline 90 min after tetanic stimulation. However, paired-pulse facilitation and posttetanic potentiation are normal. These results implicate CREB-dependent transcription in mammalian long-term memory.	UNIV HEIDELBERG, GERMAN CANC RES CTR, D-69120 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	BOURTCHULADZE, R (corresponding author), COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA.		Frenguelli, Bruno/C-5007-2015; Silva, Alcino/ABD-7684-2021	Frenguelli, Bruno/0000-0001-7214-3172; Silva, Alcino/0000-0002-1587-4558; Silva, Alcino/0000-0001-5525-0494				ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DICKINSON A, 1978, ANNU REV PSYCHOL, V29, P587, DOI 10.1146/annurev.ps.29.020178.003103; EICHENBAUM H, 1993, TRENDS NEUROSCI, V16, P163, DOI 10.1016/0166-2236(93)90140-H; EICHENBAUM H, 1992, BEHAV NEURAL BIOL, V57, P2, DOI 10.1016/0163-1047(92)90724-I; FANSELOW MS, 1979, B PSYCHONOMIC SOC, V14, P88; FANSELOW MS, 1986, LEARN MOTIV, V17, P16, DOI 10.1016/0023-9690(86)90018-4; FANSELOW MS, 1979, J COMP PHYSIOL PSYCH, V93, P736, DOI 10.1037/h0077609; FLOOD JF, 1975, PHYSIOL BEHAV, V15, P97, DOI 10.1016/0031-9384(75)90285-1; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; HESS G, 1987, NEUROSCI LETT, V77, P187, DOI 10.1016/0304-3940(87)90584-2; Huang Y Y, 1994, Learn Mem, V1, P74; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; KIM JJ, 1992, BEHAV NEUROSCI, V106, P591, DOI 10.1037/0735-7044.106.4.591; KIM JJ, 1993, BEHAV NEUROSCI, V107, P1093, DOI 10.1037/0735-7044.107.6.1093; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; MATTHIES H, 1989, PROG NEUROBIOL, V32, P277, DOI 10.1016/0301-0082(89)90024-5; MCNAUGHTON BL, 1982, J PHYSIOL-LONDON, V324, P249, DOI 10.1113/jphysiol.1982.sp014110; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MULLER D, 1989, BRAIN RES, V479, P290, DOI 10.1016/0006-8993(89)91631-4; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; REYMANN KG, 1993, FUNCT NEUROL S, V5, P7; RUDY JW, 1994, BEHAV NEUROSCI, V108, P227, DOI 10.1037/0735-7044.108.2.227; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; STANTON PK, 1984, J NEUROSCI, V4, P3080; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; TULLY T, 1991, NEUROBIOLOGY LEARNIN, P30; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039; [No title captured]	38	1494	1541	2	80	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 7	1994	79	1					59	68		10.1016/0092-8674(94)90400-6	http://dx.doi.org/10.1016/0092-8674(94)90400-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923378				2022-12-01	WOS:A1994PK58500008
J	WEISSKOPF, MG; CASTILLO, PE; ZALUTSKY, RA; NICOLL, RA				WEISSKOPF, MG; CASTILLO, PE; ZALUTSKY, RA; NICOLL, RA			MEDIATION OF HIPPOCAMPAL MOSSY FIBER LONG-TERM POTENTIATION BY CYCLIC-AMP	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; CRAYFISH NEUROMUSCULAR-JUNCTION; ADENYLATE-CYCLASE; SYNAPTIC PLASTICITY; GLUTAMATE RECEPTORS; TRANSMITTER RELEASE; SYMPATHETIC-GANGLIA; SYNAPSES; NEURONS; FACILITATION	Repetitive activation of hippocampal messy fibers evokes a long-term potentiation (LTP) of synaptic responses in pyramidal cells in the CA3 region that is independent of N-methyl-D-aspartate receptor activation. Previous results suggest that the site for both the induction and expression of this form of LTP is presynaptic. Experimental elevation of cyclic adenosine 3',5'-monophosphate(cAMP) both mimics and interferes with tetanus-induced mossy fiber LTP, and blockers of the cAMP cascade block messy fiber LTP. It is proposed that calcium entry into the presynaptic terminal may activate Ca2+-calmodulin-sensitive adenylyl cyclase I which, through protein kinase A, causes a persistent enhancement of evoked glutamate release.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,GRAD PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Castillo, Pablo/0000-0002-9834-1801				BAXTER DA, 1985, P NATL ACAD SCI USA, V82, P5978, DOI 10.1073/pnas.82.17.5978; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRIDGES AJ, 1988, J MED CHEM, V31, P1282, DOI 10.1021/jm00402a004; BRIGGS CA, 1985, J PHYSIOL-LONDON, V359, P503, DOI 10.1113/jphysiol.1985.sp015599; BRIGGS CA, 1988, J PHYSIOL-LONDON, V404, P129, DOI 10.1113/jphysiol.1988.sp017282; BYRNE JH, 1993, ADV SEC MESS PHOSPH, V27, P47; CABELL L, 1993, INT J DEV NEUROSCI, V11, P357, DOI 10.1016/0736-5748(93)90007-Z; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CASTILLO PE, 1994, NEURON, V12, P261, DOI 10.1016/0896-6273(94)90269-0; CHAVEZNORIEGA LE, 1994, J NEUROSCI, V14, P310; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; DIXON D, 1989, J NEUROSCI, V9, P4246; DOSTMANN WRG, 1990, J BIOL CHEM, V265, P10484; DUDAI Y, 1988, ANNU REV NEUROSCI, V11, P537, DOI 10.1146/annurev.ne.11.030188.002541; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GLATT CE, 1993, NATURE, V361, P536, DOI 10.1038/361536a0; HAAS HL, 1987, NEUROSCI LETT, V78, P171, DOI 10.1016/0304-3940(87)90628-8; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; HASHIMOTO H, 1993, NEURON, V11, P333, DOI 10.1016/0896-6273(93)90188-W; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; HOPKINS WF, 1988, J NEUROPHYSIOL, V59, P667, DOI 10.1152/jn.1988.59.2.667; HOSHI T, 1988, SCIENCE, V240, P1652, DOI 10.1126/science.2454506; Huang Y Y, 1994, Learn Mem, V1, P74; ITO I, 1991, NEUROREPORT, V2, P333, DOI 10.1097/00001756-199106000-00008; JAFFE D, 1990, J NEUROPHYSIOL, V64, P948, DOI 10.1152/jn.1990.64.3.948; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KATSUKI H, 1991, NEUROSCI RES, V12, P393, DOI 10.1016/0168-0102(91)90070-F; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; KUBA K, 1986, J PHYSIOL-LONDON, V374, P515, DOI 10.1113/jphysiol.1986.sp016095; Langdon Ronald B., 1993, Society for Neuroscience Abstracts, V19, P433; LAURENZA A, 1989, TRENDS PHARMACOL SCI, V10, P442, DOI 10.1016/S0165-6147(89)80008-2; MADISON DV, 1986, J PHYSIOL-LONDON, V372, P245, DOI 10.1113/jphysiol.1986.sp016007; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; MALLART A, 1968, J PHYSIOL-LONDON, V196, P593, DOI 10.1113/jphysiol.1968.sp008525; MANABE T, 1993, J NEUROPHYSIOL, V70, P1451, DOI 10.1152/jn.1993.70.4.1451; MATTHIES H, 1993, NEUROREPORT, V4, P712, DOI 10.1097/00001756-199306000-00028; MINOTA S, 1991, J PHYSIOL-LONDON, V435, P421, DOI 10.1113/jphysiol.1991.sp018517; NICOLL RA, 1981, J NEUROSCI METH, V4, P153, DOI 10.1016/0165-0270(81)90049-2; PARSONS ME, 1977, AGENTS ACTIONS, V7, P31, DOI 10.1007/BF01964878; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; REGEHR WG, 1991, NEURON, V7, P451, DOI 10.1016/0896-6273(91)90297-D; REGEHR WG, 1994, J NEUROSCI, V14, P523; SARVEY J M, 1988, P329; SCHACHER S, 1988, SCIENCE, V240, P1667, DOI 10.1126/science.2454509; SCHOLZ KP, 1988, SCIENCE, V240, P1664, DOI 10.1126/science.2837826; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; STAUBLI U, 1990, SYNAPSE, V5, P333, DOI 10.1002/syn.890050410; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; VANHAASTERT PJM, 1984, J BIOL CHEM, V259, P20; WANG LY, 1993, SCIENCE, V259, P1173, DOI 10.1126/science.8382377; WEISSKOPF MG, 1993, NATURE, V362, P423, DOI 10.1038/362423a0; WEISSKOPF MG, 1993, SOC NEUR ABSTR, V19, P1708; WIEPRECHT M, 1994, BIOCHEM J, V297, P241, DOI 10.1042/bj2970241; WILLIAMS S, 1989, NEURON, V3, P583, DOI 10.1016/0896-6273(89)90268-7; WOJTOWICZ JM, 1988, J NEUROSCI, V8, P4667; WORLEY PF, 1986, P NATL ACAD SCI USA, V83, P4053, DOI 10.1073/pnas.83.11.4053; WU ZL, 1993, J BIOL CHEM, V268, P23766; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	61	458	466	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 23	1994	265	5180					1878	1882		10.1126/science.7916482	http://dx.doi.org/10.1126/science.7916482			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH258	7916482				2022-12-01	WOS:A1994PH25800037
J	PHILLIPS, AN; SABIN, CA; ELFORD, J; BOFILL, M; JANOSSY, G; LEE, CA				PHILLIPS, AN; SABIN, CA; ELFORD, J; BOFILL, M; JANOSSY, G; LEE, CA			USE OF CD4 LYMPHOCYTE COUNT TO PREDICT LONG-TERM SURVIVAL FREE OF AIDS AFTER HIV-INFECTION	BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY VIRUS-INFECTION; HEMOPHILIC COHORT; NATURAL-HISTORY; HOMOSEXUAL MEN; PROGRESSION; MARKERS; DISEASE; SEROCONVERTERS; INCUBATION; FOLLOW	Objective-To estimate the probability remaining free of AIDS for up to 25 years after infection with HIV by extrapolation of changes in CD4 lymphocyte count. Design-Cohort study of subjects followed from time of HIV seroconversion until 1 January 1993. Creation of model by using extrapolated linear regression slopes of CD4 count to predict development of AIDS after 1993. Setting-Regional haemophilia centre in teaching hospital. Subjects-111 men with haemophilia infected with HIV during 1979-85. Median length of follow up 10.1 years, median number of CD4 counts 17. The model was not fitted for three men because only one CD4 measurement was available. Main outcome measures-Development of AIDS. Interventions-From 1989 prophylaxis against candida and Pneumocystis carinii pneumonia and antiretroviral drugs when CD4 count fell below 200 x 10(6)/1. Results-44 men developed AIDS up to 1 January 1993. When AIDS was defined as a CD4 count of 50 x 10(6)/1 the model predicted that 25% (95% confidence interval 16% to 34%) would survive for 20 years after seroconversion and 18% (11% to 25%) for 25 years. Changing the CD4 count at which AIDS was assumed to occur did not alter the results. Younger patients had a higher chance of 20 year survival than older patients (32% (12% to 52%) for those aged < 15, 26% (14% to 38%) for those aged 15-29, and 15% (0% to 31%) for those aged greater than or equal to 30). Conclusions-These results suggest that even with currently available treatment up to a quarter of patients with HIV infection will survive for 20 years after seroconversion without developing AIDS.	ROYAL FREE HOSP,SCH MED,DEPT CLIN IMMUNOL,LONDON NW3 2PF,ENGLAND; ROYAL FREE HOSP,SCH MED,CTR HAEMOPHILIA,LONDON NW3 2PF,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	PHILLIPS, AN (corresponding author), UNIV LONDON,ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH,LONDON NW3 2PF,ENGLAND.		Phillips, Andrew N/B-4427-2008; Sabin, Caroline/C-2464-2008	Phillips, Andrew N/0000-0003-2384-4807; Sabin, Caroline/0000-0001-5173-2760				ALCABES P, 1993, EPIDEMIOL REV, V15, P303, DOI 10.1093/oxfordjournals.epirev.a036122; [Anonymous], MMWR; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BIGGAR RJ, 1990, AIDS, V4, P1059, DOI 10.1097/00002030-199011000-00002; BOFILL M, 1992, CLIN EXP IMMUNOL, V88, P243, DOI 10.1111/j.1365-2249.1992.tb03068.x; Cox DR., 1984, ANAL SURVIVAL DATA; CROWE SM, 1991, J ACQ IMMUN DEF SYND, V4, P770; DARBY SC, 1989, BRIT MED J, V298, P1064, DOI 10.1136/bmj.298.6680.1064; DEGRUTTOLA V, 1991, J AM STAT ASSOC, V86, P569, DOI 10.2307/2290384; EYSTER ME, 1987, ANN INTERN MED, V107, P1, DOI 10.7326/0003-4819-107-1-1; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; GALAI N, 1993, STAT MED, V12, P2133, DOI 10.1002/sim.4780122207; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; HENDRIKS JCM, 1993, AIDS, V7, P231, DOI 10.1097/00002030-199302000-00012; HUGHES MD, 1994, J INFECT DIS, V169, P28, DOI 10.1093/infdis/169.1.28; KRAMER A, 1992, AM J EPIDEMIOL, V136, P71; LANE HC, 1985, AM J MED, V78, P417, DOI 10.1016/0002-9343(85)90332-8; LANG W, 1989, J ACQ IMMUN DEF SYND, V2, P63; LEE CA, 1989, BRIT J HAEMATOL, V73, P228, DOI 10.1111/j.1365-2141.1989.tb00257.x; LENDERKING WR, 1994, NEW ENGL J MED, V330, P738, DOI 10.1056/NEJM199403173301102; LUNDGREN JD, 1994, JAMA-J AM MED ASSOC, V271, P1088, DOI 10.1001/jama.271.14.1088; LUNDGREN JD, 1994, BMJ-BRIT MED J, V308, P1068, DOI 10.1136/bmj.308.6936.1068; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; PHILLIPS A, 1989, AIDS, V3, P737, DOI 10.1097/00002030-198911000-00008; PHILLIPS AN, 1991, LANCET, V337, P389; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SABIN C, 1993, BRIT J HAEMATOL, V83, P330, DOI 10.1111/j.1365-2141.1993.tb08290.x; SABIN C, IN PRESS THROMBOSIS; SCHECHTER MT, 1989, AIDS, V3, P347, DOI 10.1097/00002030-198906000-00002; SCHWARTLANDER B, 1992, AIDS, V6, P413, DOI 10.1097/00002030-199204000-00009; SEREMETIS SV, 1993, LANCET, V342, P700, DOI 10.1016/0140-6736(93)91706-R; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; VANLEEUWEN R, 1992, IMMUNODEFICIENCY HIV, P32; 1993, COMMUNICABLE DISE S1, V3, pS1; 1993, STAT MED, V12, P2061; 1992, AIDS, V6, P421; 1994, LANCET, V343, P871; 1987, MMWR S1S, V36, pS3; 1992, MMWR-MORBID MORTAL W, V41, P1	40	61	61	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 30	1994	309	6950					309	313		10.1136/bmj.309.6950.309	http://dx.doi.org/10.1136/bmj.309.6950.309			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA373	7916226	Green Published			2022-12-01	WOS:A1994PA37300019
J	CONDIE, BG; CAPECCHI, MR				CONDIE, BG; CAPECCHI, MR			MICE WITH TARGETED DISRUPTIONS IN THE PARALOGOUS GENES HOXA-3 AND HORD-3 REVEAL SYNERGISTIC INTERACTIONS	NATURE			English	Article							HOMEOBOX GENE; HOMEOTIC TRANSFORMATIONS; DEVELOPMENTAL DEFECTS; MUTANT MICE; MOUSE; HOX-1.6; HINDBRAIN; EXPRESSION; VERTEBRAE; REGION	THE Hox genes encode transcription factors which mediate the formation of the mammalian body plan along the anteroposterior and appendicular axes(1-15). Paralogous Hox genes within the separate linkage groups are closely related with respect to DNA sequence and expression(16,17), suggesting that they could have at least partially redundant functions. We showed previously that mice homozygous for independent targeted disruptions in the paralogous genes hoxa-3 and hoxd-3 had no defects in common(1,8). But our current analysis of double mutants has revealed strong, dosage-dependent interactions between these genes. We report here that in hoxd-3(-) homozygotes the first cervical vertebra, the atlas, is homeotically transformed to the adjacent anterior structure. Unexpectedly, in double mutants, rather than observing a more extensive homeotic transformation, the entire atlas is deleted. These observations are interpreted in terms of a model in which these Hox genes differentially regulate the proliferation rates of the appropriate sets of precursor cells.	UNIV UTAH, SCH MED, HOWARD HUGHES MED INST, DEPT HUMAN GENET, SALT LAKE CITY, UT 84112 USA	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah								ABERDAM D, 1991, MOL CELL BIOL, V11, P554, DOI 10.1128/MCB.11.1.554; CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CONDIE BG, 1993, DEVELOPMENT, V119, P579; DAVIS AP, IN PRESS DEVELOPMENT; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; DOLLE P, 1993, P NATL ACAD SCI USA, V90, P7666, DOI 10.1073/pnas.90.16.7666; GENDRONMAGUIRE M, 1993, CELL, V75, P1317, DOI 10.1016/0092-8674(93)90619-2; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; JEANNOTTE L, 1993, GENE DEV, V7, P2085, DOI 10.1101/gad.7.11.2085; JEGALIAN BG, 1992, CELL, V71, P901, DOI 10.1016/0092-8674(92)90387-R; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KOSTIC D, IN PRESS MECH DEV; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MARK M, 1993, DEVELOPMENT, V119, P319; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RIJLI FM, 1993, CELL, V75, P1333, DOI 10.1016/0092-8674(93)90620-6; SMALL KM, 1993, GENE DEV, V7, P2318, DOI 10.1101/gad.7.12a.2318	22	223	224	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 28	1994	370	6487					304	307		10.1038/370304a0	http://dx.doi.org/10.1038/370304a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ229	7913519				2022-12-01	WOS:A1994NZ22900067
J	PICKERING, TG				PICKERING, TG			BLOOD-PRESSURE MEASUREMENT AND DETECTION OF HYPERTENSION	LANCET			English	Article							WHITE COAT HYPERTENSION; PROGNOSTIC VALUE; HEART; POPULATION				PICKERING, TG (corresponding author), NEW YORK HOSP,CORNELL MED CTR,CTR HYPERTENS,525 E 68TH ST,NEW YORK,NY 10021, USA.							DUNNE FP, 1991, J AMBUL MONIT, V4, P275; FRATTOLA A, 1993, J HYPERTENS, V11, P1133, DOI 10.1097/00004872-199310000-00019; FREESTONE S, 1982, AM J MED, V73, P348, DOI 10.1016/0002-9343(82)90725-2; FRIEDMANN E, 1982, PSYCHOSOM MED, V44, P545, DOI 10.1097/00006842-198212000-00006; GOSSE P, 1993, HYPERTENSION, V22, P766, DOI 10.1161/01.HYP.22.5.766; HARSHFIELD GA, 1990, BLOOD PRESSURE MEASU, P241; HOEGHOLM A, 1993, AM J HYPERTENS, V6, P282, DOI 10.1093/ajh/6.4.282; IMAI Y, 1993, HYPERTENSION, V22, P900, DOI 10.1161/01.HYP.22.6.900; KENNEY MJ, 1993, HYPERTENSION, V22, P653, DOI 10.1161/01.HYP.22.5.653; LACOURCIERE Y, 1990, AM J CARDIOL, V65, P467, DOI 10.1016/0002-9149(90)90812-F; LIPSITZ LA, 1983, NEW ENGL J MED, V309, P81, DOI 10.1056/NEJM198307143090205; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MANCIA G, 1983, CIRC RES, V53, P96, DOI 10.1161/01.RES.53.1.96; MANN SJ, 1991, JAMA-J AM MED ASSOC, V265, P2226, DOI 10.1001/jama.265.17.2226; MCKAY DW, 1990, J HUM HYPERTENS, V4, P639; MENARD J, 1988, HYPERTENSION, V11, P153, DOI 10.1161/01.HYP.11.2.153; MILLARCRAIG MW, 1978, LANCET, V1, P795; PEARCE KA, 1992, ARCH INTERN MED, V152, P750, DOI 10.1001/archinte.152.4.750; PERLOFF D, 1989, J HYPERTENS, V7, pS3; PERLOFF D, 1983, JAMA-J AM MED ASSOC, V249, P2792, DOI 10.1001/jama.249.20.2792; PICKERING G, 1968, HIGH BLOOD PRESSURE; PICKERING TG, 1988, JAMA-J AM MED ASSOC, V259, P225, DOI 10.1001/jama.259.2.225; PICKERING TG, 1992, J HYPERTENS, V10, P401, DOI 10.1097/00004872-199205000-00001; PICKERING TG, 1989, J HYPERTENS, V7, pS65; Pickering TG., 1991, AMBULATORY MONITORIN; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; STAESSEN J, 1992, AM J HYPERTENS, V5, P386, DOI 10.1093/ajh/5.6.386; VANMONTFRANS GA, 1987, BRIT MED J, V295, P354, DOI 10.1136/bmj.295.6594.354; VEERMAN DP, 1993, J HYPERTENS, V11, P287, DOI 10.1097/00004872-199303000-00009; VERDECCHIA P, 1993, CIRCULATION, V88, P986, DOI 10.1161/01.CIR.88.3.986; VERDECCHIA P, 1990, CIRCULATION, V81, P528, DOI 10.1161/01.CIR.81.2.528; WHITE WB, 1990, AM J CARDIOL, V65, P60, DOI 10.1016/0002-9149(90)90026-W; YELDERMAN M, 1979, ANESTHESIOLOGY, V50, P253, DOI 10.1097/00000542-197903000-00022; 1993, NIH931088 PUBL; 1993, ANN INTERN MED, V118, P889	35	114	116	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					31	35						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912303				2022-12-01	WOS:A1994NU91700016
J	ZOLLER, B; DAHLBACK, B				ZOLLER, B; DAHLBACK, B			LINKAGE BETWEEN INHERITED RESISTANCE TO ACTIVATED PROTEIN-C AND FACTOR-V GENE MUTATION IN VENOUS THROMBOSIS	LANCET			English	Note							POOR ANTICOAGULANT RESPONSE; THROMBOPHILIA; COFACTOR	Resistance to activated protein C (APC) is a major cause of familial thrombophilia, and can be corrected by an anticoagulant activity expressed by purified factor V. We investigated linkage between APC resistance and the factor V gene in a large kindred with familial thrombophilia. Restriction fragment length polymorphisms in exon 13 of the factor V gene were informative in 14 family members. The 100% linkage between factor V gene polymorphism and APC resistance strongly suggested a factor V gene mutation as a cause of APC resistance. A point mutation changing Arg(506) in the APC cleavage site to a Gin was found in APC resistant individuals. These results suggest factor V gene mutation to be the most common genetic cause of thrombophilia.	LUND UNIV,MALMO GEN HOSP,DEPT CLIN CHEM,S-21401 MALMO,SWEDEN	Lund University			Zöller, Bengt/H-8856-2012; Zöller, Bengt/M-3217-2019	Zöller, Bengt/0000-0002-8250-5613; Zöller, Bengt/0000-0002-8250-5613; Dahlback, Bjorn/0000-0003-1546-0328				DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; DAHLBACK B, 1994, MOL BASIS BLOOD DISE, P599; EWART AK, 1993, P NATL ACAD SCI USA, V90, P3226, DOI 10.1073/pnas.90.8.3226; FAIONI EM, 1993, THROMB HAEMOSTASIS, V70, P1067; GRIFFIN JH, 1993, BLOOD, V82, P1989; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; SHEN NLL, 1993, J IMMUNOL, V150, P2992; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; WANG H, 1988, GENOMICS, V2, P234	10	411	420	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 18	1994	343	8912					1536	1538		10.1016/S0140-6736(94)92940-8	http://dx.doi.org/10.1016/S0140-6736(94)92940-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR329	7911873				2022-12-01	WOS:A1994NR32900010
J	DRUCKER, E; ALCABES, P; BOSWORTH, W; SCKELL, B				DRUCKER, E; ALCABES, P; BOSWORTH, W; SCKELL, B			CHILDHOOD TUBERCULOSIS IN THE BRONX, NEW-YORK	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INTRAVENOUS DRUG-USERS; INFECTION; RATES; RISK; AIDS	The resurgence of tuberculosis (TB) in New York City in the period 1978-92 has been closely linked to the AIDS epidemic but the increase of active TB in areas of urban poverty also implies increased community exposure. We have examined the ecological relation between community rates of AIDS and residential crowding and cases of active TB in Bronx children under age 5. Residential crowding was defined as the percent of households with more than 1 person per room. All childhood TB cases reported between 1986 and 1992 for the Bronx (n = 75) were included. Cumulative AIDS mortality rates for adult females through 1990 represented community HIV burden. All data were coded by the 64 health areas of the borough. We examined trends in these data and used Poisson regression to model the effect of HIV burden and residential crowding on TB risk. For the Bronx as a whole the two variables of TB and residential crowding showed a clear temporal correspondence for the period 1970-90. Residential crowding was associated with poverty and greater dependence on public assistance, large household size, Hispanic ethnicity, and a higher proportion of young children. The overall TB case rate increased with the proportion of crowded households, with a rise from 1.47 to over 8 cases per 10 000 children as the proportion of crowded households increased. At both the lowest and highest levels of AIDS mortality in these areas, the childhood TB risk increased as crowding increased. Children living in areas of the Bronx in which over 12 percent of homes are severely overcrowded were 5.6-fold more likely to develop active TB, even after holding constant the presumed HIV burden in each local community. While HIV infection, the newest risk factor for TB, appears to play a critical role in the resurgent epidemic, our findings show that the earliest known TB risk factors, poverty and household crowding, are still potent forces.	YALE UNIV,SCH MED,AIDS PROGRAM,NEW HAVEN,CT; CUNY HERBERT H LEHMAN COLL,DEPT POLIT SCI,BRONX,NY 10468; CUNY HERBERT H LEHMAN COLL,BRONX DATA CTR,BRONX,NY 10468	Yale University; City University of New York (CUNY) System; Lehman College (CUNY); City University of New York (CUNY) System; Lehman College (CUNY)	DRUCKER, E (corresponding author), MONTEFIORE MED CTR,ALBERT EINSTEIN COLL MED,DEPT EPIDEMIOL & SOCIAL MED,BRONX,NY 10467, USA.							BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BATES B, 1992, BARGAINING LIFE; BELLIN E, 1993, JAMA-J AM MED ASSOC, V259, P2228; BRESLOW NE, 1980, STATISTICAL METHODS; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; CHAPMAN JS, 1984, AM REV RESPIR DIS, V90, P48; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DIPERRI G, 1989, LANCET, V2, P1502; DRUCKER E, 1989, AM J EPIDEMIOL, V130, P133, DOI 10.1093/oxfordjournals.aje.a115304; DRUCKER E, 1987, FRANKLIN AVE SHELTER; DRUCKER E, 1993, NY TIMES        0820, pA28; Dubos Rene, 1987, WHITE PLAGUE TUBERCU; DUGGER C, 1992, NY TIMES        0216, P1; DUGGER CW, 1993, NY TIMES        1116, pA1; DUGGER CW, 1993, NY TIMES        1116, pB4; NOVICK LF, 1991, AM J PUBLIC HEALTH, V81, P15, DOI 10.2105/AJPH.81.Suppl.15; SCHOENBAUM EE, 1989, NEW ENGL J MED, V321, P874, DOI 10.1056/NEJM198909283211306; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; STLOUIS ME, 1990, NEW ENGL J MED, V323, P213, DOI 10.1056/NEJM199007263230401; SUNDERAM G, 1986, JAMA-J AM MED ASSOC, V256, P362, DOI 10.1001/jama.256.3.362; WALLACE R, 1988, ENVIRON RES, V47, P1, DOI 10.1016/S0013-9351(88)80018-5; 1986, MMWR-MORBID MORTAL W, V28, P587; 1986, MMWR-MORBID MORTAL W, V35, P74; 1992, INFORMATION SUMMARY	25	86	90	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1482	1485		10.1016/S0140-6736(94)92588-7	http://dx.doi.org/10.1016/S0140-6736(94)92588-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911184				2022-12-01	WOS:A1994NQ41500015
J	KELLY, TJ; MARTIN, GS; FORSBURG, SL; STEPHEN, RJ; RUSSO, A; NURSE, P				KELLY, TJ; MARTIN, GS; FORSBURG, SL; STEPHEN, RJ; RUSSO, A; NURSE, P			THE FISSION YEAST CDC18+ GENE-PRODUCT COUPLES S-PHASE TO START AND MITOSIS	CELL			English	Article							CELL-DIVISION CYCLE; DNA-SYNTHESIS GENES; SCHIZOSACCHAROMYCES-POMBE ENCODES; CEREVISIAE CDC6 GENE; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; DEPENDENT TRANSCRIPTION; REPLICATION GENES; NUCLEAR DIVISION; HO GENE	Commitment to the cell cycle in fission yeast requires the function of the cdc10+ transcriptional activator at START. The product of the cdc18+ gene is a major downstream target of cdc10+ and transcription of cdc18+ is activated by cdc10+ during passage through START. The cdc18+ function is required for entry into S phase. In addition, the product of the cdc18+ gene is part of the checkpoint control that prevents mitosis from occurring until S phase is completed. Thus, cdc18+ plays a key role in coupling S phase to START and mitosis.	JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA	Johns Hopkins University; University of California System; University of California Berkeley	KELLY, TJ (corresponding author), UNIV OXFORD, DEPT BIOCHEM, IMPERIAL CANC RES FUND, CELL CYCLE GRP, OXFORD OX1 3QU, ENGLAND.			Forsburg, Susan L/0000-0002-4895-8598	NCI NIH HHS [CA17542, CA16519] Funding Source: Medline; NIGMS NIH HHS [GM44173] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA016519, R01CA017542, R37CA017542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044173] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; BARBET N, 1992, GENE, V114, P59, DOI 10.1016/0378-1119(92)90707-V; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; CALIGIURI M, 1993, CELL, V72, P607, DOI 10.1016/0092-8674(93)90079-6; CULOTTI J, 1971, EXP CELL RES, V67, P389, DOI 10.1016/0014-4827(71)90424-1; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1991, COLD SPRING HARB SYM, V56, P409; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FERNANDEZSARABIA MJ, 1992, GENE DEV, V6, P2417, DOI 10.1101/gad.6.12a.2417; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; GORDON CB, 1986, EMBO J, V5, P2981, DOI 10.1002/j.1460-2075.1986.tb04595.x; GORDON CB, 1991, P NATL ACAD SCI USA, V88, P6058, DOI 10.1073/pnas.88.14.6058; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; JOHNSTON LH, 1992, NUCLEIC ACIDS RES, V20, P2403, DOI 10.1093/nar/20.10.2403; LISZIEWICZ J, 1988, NUCLEIC ACIDS RES, V16, P11507, DOI 10.1093/nar/16.24.11507; LOWNDES NF, 1992, NATURE, V357, P505, DOI 10.1038/357505a0; LOWNDES NF, 1992, NATURE, V355, P449, DOI 10.1038/355449a0; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; MARKS J, 1992, J CELL SCI, V101, P517; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MCINTOSH EM, 1991, MOL CELL BIOL, V11, P329, DOI 10.1128/MCB.11.1.329; MERRILL GF, 1992, BIOESSAYS, V14, P823, DOI 10.1002/bies.950141206; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; PALMER RE, 1990, GENETICS, V125, P763; PRIMIG M, 1992, NATURE, V358, P593, DOI 10.1038/358593a0; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; SAZER S, 1990, J CELL SCI, V97, P509; SIMANIS V, 1989, J CELL SCI, V92, P51; TABA MRM, 1991, GENE DEV, V5, P2000, DOI 10.1101/gad.5.11.2000; TANAKA K, 1992, EMBO J, V11, P4923, DOI 10.1002/j.1460-2075.1992.tb05599.x; UZAWA S, 1990, CELL, V62, P913, DOI 10.1016/0092-8674(90)90266-H; VERMA R, 1991, P NATL ACAD SCI USA, V88, P7155, DOI 10.1073/pnas.88.16.7155; WASEEM NH, 1992, EMBO J, V11, P5111, DOI 10.1002/j.1460-2075.1992.tb05618.x; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WHITE JHM, 1986, EMBO J, V5, P1705, DOI 10.1002/j.1460-2075.1986.tb04414.x; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; ZHOU C, 1989, J BIOL CHEM, V264, P9022	56	416	420	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 30	1993	74	2					371	382		10.1016/0092-8674(93)90427-R	http://dx.doi.org/10.1016/0092-8674(93)90427-R			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	7916658				2022-12-01	WOS:A1993LP72600017
J	GORDIS, E				GORDIS, E			UNRAVELING THE BRAIN CHEMISTRY BEHIND ALCOHOL-ABUSE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GORDIS, E (corresponding author), NIAAA,BETHESDA,MD, USA.							VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P881; IN PRESS NIDA RES MO	3	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 14	1994	272	22					1733	1733						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PV815	7966919				2022-12-01	WOS:A1994PV81500020
J	HUMPHREYS, GW; ROMANI, C; OLSON, A; RIDDOCH, MJ; DUNCAN, J				HUMPHREYS, GW; ROMANI, C; OLSON, A; RIDDOCH, MJ; DUNCAN, J			NON SPATIAL EXTINCTION FOLLOWING LESIONS OF THE PARIETAL LOBE IN HUMANS	NATURE			English	Article							ATTENTION; PICTURES; OBJECT; WORDS	EFFICIENT behaviour in the visual environment requires selection between stimuli competing for control of action. Many current models of selection are spatial: relevant objects are chosen by attending to their locations(1-3). The unilateral stimulus extinction observed following lesions of the parietal lobe provides evidence for spatial selection(4). Such patients may identify a single stimulus presented in their contralesional field, but can fail to detect the same stimulus when a competing stimulus is shown simultaneously on the ipsilesional side(5). Here we demonstrate that extinction need not be spatial in nature, but may be determined by characteristics of the objects to be selected. In two patients with parietal lobe lesions and poor spatial localization, pictures extinguished words and closed shapes extinguished open shapes. This object-based extinction indicates the existence of biases within non-spatial selection mechanisms which are independent of biases produced by spatial selection mechanisms. We suggest that selection of objects for action requires that the 'winners' produced by the independent competitive biases for selection are bound together within distinct neural areas concerned with object properties and space.	MRC,APPL PSYCHOL UNIT,CAMBRIDGE CB2 2EF,ENGLAND	University of Cambridge	HUMPHREYS, GW (corresponding author), UNIV BIRMINGHAM,SCH PSYCHOL,COGNIT SCI RES CTR,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.		Riddoch, Jane/F-7968-2010	Romani, Cristina/0000-0002-5693-4131; Duncan, John S/0000-0002-1373-0681; Duncan, John/0000-0002-9695-2764				Balint R, 1909, MON PSYCHIATR NEUROL, V25, P51; BIEDERMAN I, 1987, PSYCHOL REV, V94, P115, DOI 10.1037/0033-295X.94.2.115; COSLETT HB, 1991, BRAIN, V114, P1523, DOI 10.1093/brain/114.4.1523; Critchley M., 1953, PARIETAL LOBES; DRIVER J, 1991, COGNITIVE NEUROPSYCH, V8, P475, DOI 10.1080/02643299108253384; DUNCAN J, 1993, PERCEPTION, V2, P1261; EGLY R, 1994, J EXP PSYCHOL GEN, V123, P161, DOI 10.1037/0096-3445.123.2.161; HUMPHREYS GW, 1981, Q J EXP PSYCHOL-A, V33, P17, DOI 10.1080/14640748108400765; HUMPHREYS GW, 1993, ATTENTION PERFORMANC, V14; KROLL JF, 1984, J VERB LEARN VERB BE, V23, P39, DOI 10.1016/S0022-5371(84)90499-7; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; Mozer M C, 1990, J Cogn Neurosci, V2, P96, DOI 10.1162/jocn.1990.2.2.96; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; POSNER MI, 1984, J NEUROSCI, V4, P1863; POTTER MC, 1975, NATURE, V253, P437, DOI 10.1038/253437a0; UNGERLEIDER LG, 1982, ANAL VISUAL BEHAVIOR	16	99	99	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					357	359		10.1038/372357a0	http://dx.doi.org/10.1038/372357a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PU287	7969493				2022-12-01	WOS:A1994PU28700054
J	XU, M; MORATALLA, R; GOLD, LH; HIROI, N; KOOB, GF; GRAYBIEL, AM; TONEGAWA, S				XU, M; MORATALLA, R; GOLD, LH; HIROI, N; KOOB, GF; GRAYBIEL, AM; TONEGAWA, S			DOPAMINE D1 RECEPTOR MUTANT MICE ARE DEFICIENT IN STRIATAL EXPRESSION OF DYNORPHIN AND IN DOPAMINE-MEDIATED BEHAVIORAL-RESPONSES	CELL			English	Article							C-FOS; RAT STRIATUM; SUBSTANCE-P; MOLECULAR-CLONING; BASAL GANGLIA; AUTORADIOGRAPHIC LOCALIZATION; PHENOTYPICAL CHARACTERIZATION; STRIATONIGRAL DYNORPHIN; MATRIX COMPARTMENTS; PROJECTION NEURONS	The brain dopaminergic system is a critical modulator of basal ganglia function and plasticity. To investigate the contribution of the dopamine D1 receptor to this modulation, we have used gene targeting technology to generate D1 receptor mutant mice. Histological analyses suggested that there are no major changes in general anatomy of the mutant mouse brains, but indicated that the expression of dynorphin is greatly reduced in the striatum and related regions of the basal ganglia. The mutant mice do not respond to the stimulant and suppressive effects of D1 receptor agonists and antagonists, respectively, and they exhibit locomotor hyperactivity. These results suggest that the D1 receptor regulates the neurochemical architecture of the striatum and is critical for the normal expression of motor activity.	MIT, CTR LEARNING & MEMORY, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; MIT, DEPT BRAIN & COGNIT SCI, CAMBRIDGE, MA 02139 USA; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Scripps Research Institute	XU, M (corresponding author), MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA.		Moratalla, Rosario V/H-9280-2015; Hiroi, Noboru/E-2215-2013	Moratalla, Rosario V/0000-0002-7623-8010; Hiroi, Noboru/0000-0002-6846-5969; Graybiel, Ann/0000-0002-4326-7720	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD028341] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028341] Funding Source: NIH RePORTER; NICHD NIH HHS [HD28341] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; AMALRIC M, 1993, NEUROPSYCHOPHARMACOL, V8, P195, DOI 10.1038/npp.1993.21; ANDERSON KD, 1990, J COMP NEUROL, V295, P339, DOI 10.1002/cne.902950302; ANDERSON KD, 1991, BRAIN RES, V568, P235, DOI 10.1016/0006-8993(91)91403-N; ARIANO MA, 1989, P NATL ACAD SCI USA, V86, P8570, DOI 10.1073/pnas.86.21.8570; Bergman J., 1990, Behav Pharmacol, V1, P355; BERNARD V, 1992, J NEUROSCI, V12, P3591; BESSON MJ, 1990, NEUROSCIENCE, V39, P33, DOI 10.1016/0306-4522(90)90220-X; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BRONSTEIN DM, 1994, MOL BRAIN RES, V23, P191, DOI 10.1016/0169-328X(94)90226-7; CABIB S, 1991, PSYCHOPHARMACOLOGY, V105, P335, DOI 10.1007/BF02244427; CAINE SB, 1994, J PHARMACOL EXP THER, V270, P209; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CIVELLI O, 1993, ANNU REV PHARMACOL, V33, P281, DOI 10.1146/annurev.pa.33.040193.001433; DAHLSTROM A, 1964, ACTA PHYSIOL SCAND, V62, P1; DAUNAIS JB, 1993, NEUROREPORT, V4, P543, DOI 10.1097/00001756-199305000-00020; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DILTS RP, 1993, SYNAPSE, V13, P251, DOI 10.1002/syn.890130308; DREHER JK, 1989, BRAIN RES, V487, P267, DOI 10.1016/0006-8993(89)90831-7; FALLON JH, 1978, J COMP NEUROL, V180, P533, DOI 10.1002/cne.901800309; FENTRESS JC, 1981, ANAT EMBRYOL, V163, P275, DOI 10.1007/BF00315705; FISHELL G, 1991, J COMP NEUROL, V312, P33, DOI 10.1002/cne.903120104; FOSTER GA, 1987, J NEUROSCI, V7, P1994; FUXE K, 1969, NEUROENDOCRINOLOGY, V5, P257, DOI 10.1159/000121887; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; GERFEN CR, 1985, P NATL ACAD SCI USA, V82, P8780, DOI 10.1073/pnas.82.24.8780; GERFEN CR, 1991, J NEUROSCI, V11, P1016; GERFEN CR, 1992, TRENDS NEUROSCI, V15, P133, DOI 10.1016/0166-2236(92)90355-C; GINGRICH JA, 1993, ANNU REV NEUROSCI, V16, P299, DOI 10.1146/annurev.ne.16.030193.001503; GRAYBIEL AM, 1990, TRENDS NEUROSCI, V13, P244, DOI 10.1016/0166-2236(90)90104-I; GRAYBIEL AM, 1984, NEUROSCIENCE, V13, P1157, DOI 10.1016/0306-4522(84)90293-8; GRAYBIEL AM, 1982, P NATL ACAD SCI-BIOL, V79, P198, DOI 10.1073/pnas.79.1.198; GRAYBIEL AM, 1989, P NATL ACAD SCI USA, V86, P9020, DOI 10.1073/pnas.86.22.9020; GRAYBIEL AM, 1990, P NATL ACAD SCI USA, V87, P6912, DOI 10.1073/pnas.87.17.6912; GRAYBIEL AM, 1990, J NEUROSCI, V10, P720; Graybiel AM, 1984, CORTICAL INTEGRATION, P223; GRAYBIEL AM, 1983, CHEM NEUROANATOMY, P427; HANSON GR, 1987, EUR J PHARMACOL, V144, P245, DOI 10.1016/0014-2999(87)90527-9; HORNYKIEWICZ O, 1966, PHARMACOL REV, V18, P925; HURD YL, 1993, SYNAPSE, V13, P357, DOI 10.1002/syn.890130408; HURD YL, 1992, MOL BRAIN RES, V13, P165, DOI 10.1016/0169-328X(92)90058-J; JIANG HK, 1990, BRAIN RES, V507, P57, DOI 10.1016/0006-8993(90)90522-D; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; KOOB GF, 1978, J COMP PHYSIOL PSYCH, V92, P917, DOI 10.1037/h0077542; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; KOOB GF, 1987, NEUROSCI LETT, V79, P315, DOI 10.1016/0304-3940(87)90451-4; KOOB GF, 1992, SEMIN NEUROSCI, V4, P139; KUBOTA Y, 1993, NEUROREPORT, V5, P205, DOI 10.1097/00001756-199312000-00004; LEMOAL M, 1991, PHYSIOL REV, V71, P155, DOI 10.1152/physrev.1991.71.1.155; LEMOINE C, 1991, P NATL ACAD SCI USA, V88, P4205, DOI 10.1073/pnas.88.10.4205; LI S, 1986, BRAIN RES, V398, P390, DOI 10.1016/0006-8993(86)91502-7; LI SJ, 1988, J PHARMACOL EXP THER, V246, P403; LINDVALL O, 1983, CHEM NEUROANATOMY, P229; LIU FC, 1994, IN PRESS J NEUROSCI; MAILMAN RB, 1984, EUR J PHARMACOL, V101, P159, DOI 10.1016/0014-2999(84)90044-X; MEADORWOODRUFF JH, 1991, NEUROPSYCHOPHARMACOL, V5, P231; MONSMA FJ, 1990, P NATL ACAD SCI USA, V87, P6723, DOI 10.1073/pnas.87.17.6723; MOORCROFT WH, 1971, J COMP PHYSIOL PSYCH, V75, P59, DOI 10.1037/h0030670; MORATALLA R, 1993, J NEUROSCI, V13, P423; MORATALLA R, 1992, J NEUROSCI, V12, P2609; MURRIN LC, 1989, BRAIN RES, V480, P170; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; PAUL ML, 1992, J NEUROSCI, V12, P3729, DOI 10.1523/jneurosci.12-10-03729.1992; PENNYPACKER KR, 1992, MOL BRAIN RES, V15, P151, DOI 10.1016/0169-328X(92)90163-6; PERT CB, 1976, P NATL ACAD SCI USA, V73, P3729, DOI 10.1073/pnas.73.10.3729; PERTWEE RG, 1972, BRIT J PHARMACOL, V46, P753, DOI 10.1111/j.1476-5381.1972.tb06900.x; PIOMELLI D, 1991, NATURE, V353, P164, DOI 10.1038/353164a0; SAVASTA M, 1986, BRAIN RES, V375, P291, DOI 10.1016/0006-8993(86)90749-3; SCHAMBRA B, 1994, NEUROSCIENCE, V62, P65, DOI 10.1016/0306-4522(94)90315-8; SHARP T, 1987, BRAIN RES, V401, P322, DOI 10.1016/0006-8993(87)91416-8; SIBLEY DR, 1993, INT REV NEUROBIOL, V35, P391, DOI 10.1016/S0074-7742(08)60573-5; SIVAM SP, 1989, J PHARMACOL EXP THER, V250, P818; SNYDER GL, 1992, J NEUROSCI, V12, P3071, DOI 10.1523/JNEUROSCI.12-08-03071.1992; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; STEINER H, 1993, J NEUROSCI, V13, P5066, DOI 10.1523/JNEUROSCI.13-12-05066.1993; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; SURMEIER DJ, 1992, P NATL ACAD SCI USA, V89, P10178, DOI 10.1073/pnas.89.21.10178; SURMEIER DJ, 1993, TRENDS NEUROSCI, V16, P299, DOI 10.1016/0166-2236(93)90103-S; VANDERKOOY D, 1987, BRAIN RES, V401, P155, DOI 10.1016/0006-8993(87)91176-0; vanderKooy D, 1987, BASAL GANGLIA, P81; VINCENT SR, 1983, J COMP NEUROL, V217, P252, DOI 10.1002/cne.902170303; VOORN P, 1988, NEUROSCIENCE, V25, P857, DOI 10.1016/0306-4522(88)90041-3; WALAAS SI, 1984, J NEUROSCI, V4, P84; WEINER DM, 1990, P NATL ACAD SCI USA, V87, P7050, DOI 10.1073/pnas.87.18.7050; WEISS B, 1993, NEUROSCIENCE, V55, P607, DOI 10.1016/0306-4522(93)90426-G; WOOLVERTON WL, 1986, PHARMACOL BIOCHEM BE, V24, P531, DOI 10.1016/0091-3057(86)90553-8; YOUNG ST, 1991, P NATL ACAD SCI USA, V88, P1291, DOI 10.1073/pnas.88.4.1291; ZHANG M, 1993, NEUROSCI LETT, V161, P223, DOI 10.1016/0304-3940(93)90299-Z; ZHANG WQ, 1992, BRAIN RES, V577, P312, DOI 10.1016/0006-8993(92)90289-L; ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0	91	415	422	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 18	1994	79	4					729	742		10.1016/0092-8674(94)90557-6	http://dx.doi.org/10.1016/0092-8674(94)90557-6			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7954836				2022-12-01	WOS:A1994PT48100019
J	ANNAS, GJ				ANNAS, GJ			DEATH BY PRESCRIPTION - THE OREGON INITIATIVE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				ANNAS GJ, 1985, AM J PUBLIC HEALTH, V75, P1096, DOI 10.2105/AJPH.75.9.1096; ANNAS GJ, 1993, NEW ENGL J MED, V328, P1573, DOI 10.1056/NEJM199305273282121; Callahan Daniel, 1993, TROUBLED DREAM LIFE; CAPRON AM, 1992, HASTINGS CENT REP, V22, P30, DOI 10.2307/3562562; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; GIANELLI DM, 1994, AM MED NEWS     0725, P1; GIANELLI DM, 1994, AM MED NEWS     0912, P34; Humphry D., 1992, DYING DIGNITY UNDERS; NULAND SB, 1994, WE DIE, P288; ORENTLICHER D, 1994, MED UNBOUND HUMAN BO, P256; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; SKELLY FJ, 1994, AM MED NEWS     0815, P19; WEILER PC, 1993, MEASURE MALPRACTICE, P55; YANKELOVICH D, 1994, NY TIMES        0917, P23; 1994, DEATH IS SOUGHT ASSI; 1994, AHCPR940592 DEP HLTH, P16; 1992, JAMA-J AM MED ASSOC, V267, P2229; 1994, FINAL REPORT MICHIGA; 1992, HASTINGS CTR REP, V22, P7	19	50	50	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	1994	331	18					1240	1243		10.1056/NEJM199411033311822	http://dx.doi.org/10.1056/NEJM199411033311822			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN806	7935680				2022-12-01	WOS:A1994PN80600038
J	LIN, TA; KONG, XM; HAYSTEAD, TAJ; PAUSE, A; BELSHAM, G; SONENBERG, N; LAWRENCE, JC				LIN, TA; KONG, XM; HAYSTEAD, TAJ; PAUSE, A; BELSHAM, G; SONENBERG, N; LAWRENCE, JC			PHAS-1 AS A LINK BETWEEN MITOGEN-ACTIVATED PROTEIN-KINASE AND TRANSLATION INITIATION	SCIENCE			English	Article							3T3-L1 ADIPOCYTES; INSULIN ACTION; PHOSPHORYLATION; STIMULATION; MECHANISM; INVITRO	PHAS-I is a heat-stable protein (relative molecular mass approximate to 12,400) found in many tissues. It is rapidly phosphorylated in rat adipocytes incubated with insulin or growth factors. Nonphosphorylated PHAS-I bound to initiation factor 4E (eIF-4E) and inhibited protein synthesis. Serine-64 in PHAS-I was rapidly phosphorylated by mitogen-activated (MAP) kinase, the major insulin-stimulated PHAS-I kinase in adipocyte extracts. Results obtained with antibodies, immobilized PHAS-I, and a messenger RNA cap affinity resin indicated that PHAS-I did not bind eIF-4E when serine-64 was phosphorylated. Thus, PHAS-I may be a key mediator of the stimulation of protein synthesis by the diverse group of agents and stimuli that activate MAP kinase.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; UNIV VIRGINIA,SCH MED,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22903; MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL H3G 1Y6,PQ,CANADA	Washington University (WUSTL); University of Virginia; McGill University; McGill University			Belsham, Graham J./H-8589-2019; Belsham, Graham/J-3132-2019	Belsham, Graham J./0000-0003-1187-4873; Belsham, Graham/0000-0003-1187-4873	NIAMS NIH HHS [AR41180] Funding Source: Medline; NIDDK NIH HHS [DK28312] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1990, J BIOL CHEM, V265, P11495; AVRUCH J, 1982, FED PROC, V41, P2629; BLACKSHEAR PJ, 1983, BIOCHEM J, V214, P1; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DENTON RM, 1981, DIABETOLOGIA, V21, P347; GALLIE DR, 1994, J BIOL CHEM, V269, P7174; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HU C, 1994, P NATL ACAD SCI USA, V91, P373; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KIMBALL SR, 1994, ANNU REV PHYSIOL, V56, P321, DOI 10.1146/annurev.ph.56.030194.001541; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin T.-T., UNPUB; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; PAUSE A, IN PRESS NATURE; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; Rhoads RE, 1991, CURR OPIN CELL BIOL, V3, P1019, DOI 10.1016/0955-0674(91)90123-G; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sonenberg Nahum, 1993, Gene Expression, V3, P317	23	595	608	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 28	1994	266	5185					653	656		10.1126/science.7939721	http://dx.doi.org/10.1126/science.7939721			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939721				2022-12-01	WOS:A1994PN80700049
J	GLANTZ, SA; BEGAY, ME				GLANTZ, SA; BEGAY, ME			TOBACCO INDUSTRY CAMPAIGN CONTRIBUTIONS ARE AFFECTING TOBACCO CONTROL POLICY-MAKING IN CALIFORNIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PACS	Objective.-To test the hypothesis that tobacco industry campaign contributions are influencing the behavior of members of the California legislature. Design.-Multivariate simultaneous-equations regression was used to analyze data on campaign contributions from the tobacco industry to members of the California legislature in 1991 and 1992, members' tobacco control policy positions, and members' personal characteristics. Data Sources.-The following sources were analyzed: campaign contributions from disclosure statements filed with the California Fair Political Practices Commission; constituent attitudes on tobacco control from the California Tobacco Survey; legislators' personal characteristics, from a survey of key informants conducted by the California Journal; and the tobacco policy score, a survey of key informants working on tobacco issues in the state legislature. Specific voting on tobacco-related bills was also analyzed. Setting.-California legislature in 1991 and 1992. Patients or Other Participants.-All members of the California legislature in 1991 and 1992. Main Outcome Measures.-Tobacco policy score, campaign contributions, and votes on individual tobacco-related bills. Results.-The tobacco industry is having a statistically detectable effect on behavior of members of the California legislature on tobacco policymaking. On a scale of 0 to 10, a legislator's tobacco policy score dropped tie, became more protobacco industry) by -0.11 for every $1000 in tobacco campaign contributions, after accounting for the fact that a more protobacco position was associated with greater contributions ($1855 for each -1.0 reduction in score). Members who were rated as effective received larger contributions from the industry. Members rated higher in integrity and intelligence were more antitobacco (higher scores) and Republicans more protobacco (lower scores) after taking into account the effects of contributions from the industry. Constituent attitudes were not reflected in legislators' perceived behavior. Conclusion.-Tobacco industry campaign contributions influence California legislators in matters related to tobacco policymaking, independent of constituents' support for tobacco control.			GLANTZ, SA (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,INST HLTH POLICY STUDIES,BOX 0124,SAN FRANCISCO,CA 94143, USA.				NCI NIH HHS [CA-61021] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061021] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEGAY M, 1994, TWILIGHT PROPOSITION; BEGAY ME, 1993, AM J PUBLIC HEALTH, V83, P1214, DOI 10.2105/AJPH.83.9.1214; BEGAY ME, 1992, TOBACCO IND POLITICA; BURNS D, 1992, TOBACCO USE CALIFORN; DREW E, 1983, POLITICS MONEY; Fenno RichardF., 1978, HOMESTYLE HOUSE MEMB; GERBER E, 1991, THESIDS U MICHIGAN A; GLANTZ S, 1993, TOBACCO BIOL POLITIC; GLANTZ S, 1990, PRIMER APPLIED REGRE, pCH5; GLANTZ SA, 1994, AM J PUBLIC HEALTH, V84, P1081, DOI 10.2105/AJPH.84.7.1081; GRENZKE JM, 1989, AM J POLIT SCI, V33, P1, DOI 10.2307/2111251; JACKSON B, 1988, HONEST GRAFT; Jewell Malcolm E, 1982, REPRESENTATION STATE; Kingdon JohnW., 1989, CONGRESSMENS VOTING; Pierce JP, 1994, TOBACCO USE CALIFORN; PRICE C, 1991, CALIF J, V22, P343; SKOLNICK AA, 1994, JAMA-J AM MED ASSOC, V271, P1387, DOI 10.1001/jama.271.18.1387; SKOLNICK AA, 1992, JAMA-J AM MED ASSOC, V267, P2723; SKOLNICK AA, 1992, JAMA-J AM MED ASSOC, V267, P2721, DOI 10.1001/jama.267.20.2721; TAYLOR P, 1984, SMOKE RING; WRIGHT JR, 1985, AM POLIT SCI REV, V79, P400, DOI 10.2307/1956656; ZEIGER R, 1992, CALIF J, V23, P173; 1991, 1991 1992 DIRECTORY; 1993, HLTH LETT, V9, P1; 1993, LOBBYING EXPENDITURE; 1988, SAS ETS USERS GUIDE; 1993, PRICE ADM	27	71	71	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1176	1182		10.1001/jama.272.15.1176	http://dx.doi.org/10.1001/jama.272.15.1176			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PL212	7933347				2022-12-01	WOS:A1994PL21200031
J	ROBILLARD, PY; HULSEY, TC; PERIANIN, J; JANKY, E; MIRI, EH; PAPIERNIK, E				ROBILLARD, PY; HULSEY, TC; PERIANIN, J; JANKY, E; MIRI, EH; PAPIERNIK, E			ASSOCIATION OF PREGNANCY-INDUCED HYPERTENSION WITH DURATION OF SEXUAL COHABITATION BEFORE CONCEPTION	LANCET			English	Article							PRE-ECLAMPSIA; PREECLAMPSIA; CONTRACEPTION; IMMUNOLOGY; ANTIBODIES; PATERNITY	Pregnancy-induced hypertension affects at least 10% of all pregnancies. An association with first pregnancy or a change in paternity for subsequent pregnancies has been suggested. We studied the duration of sexual cohabitation with the father prior to conception and the incidence of pregnancy-induced hypertension. During a five-month period, 1011 consecutive women who delivered in an obstetric unit were interviewed about paternity and duration of sexual cohabitation before conception. Obstetric charts were abstracted to identify three groups: those with pregnancy-induced hypertension, chronic hypertension, and normal blood pressure. The incidence of pregnancy-induced hypertension was 11.9% among primigravidae, 4.7% among same-paternity multigravidae, and 24.0% among new-paternity multigravidae. For both primigravidae and multigravidae, length of sexual cohabitation before conception was inversely related to the incidence of pregnancy-induced hypertension (p<0.0001). Similar results were observed after control for race, education, maternal age, marital status, and number of pregnancies. Pregnancy-induced hypertension may be a problem of primipaternity rather than primigravidity. Furthermore, an extended duration of sexual cohabitation before conception may protect against pregnancy-induced hypertension.	UNIV HOSP POINTE PITRE, CHRU, GYNAECOL OBSTET UNIT, F-97159 POINTE A PITRE, Guadeloupe, FRANCE; MED UNIV S CAROLINA, CHILDRENS HOSP, DIV NEONATOL, CHARLESTON, SC 29425 USA; MATERN PORT ROYAL, F-75674 PARIS 14, FRANCE	CHU Guadeloupe; Medical University of South Carolina; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	ROBILLARD, PY (corresponding author), UNIV HOSP POINTE A PITRE, CHRU, PAEDIAT UNIT, BP 465, F-97159 POINTE A PITRE, Guadeloupe, FRANCE.		Robillard, Pierre-Yves/AAD-9774-2021					[Anonymous], PREECLAMPSIA; Beer A E, 1985, Birth Defects Orig Artic Ser, V21, P131; BEER AE, 1989, JAMA-J AM MED ASSOC, V262, P3184, DOI 10.1001/jama.262.22.3184; BEER AE, 1990, IMMUNOLOGICAL DIS, P329; BRONSON R, 1984, FERTIL STERIL, V42, P171; CHARBIT Y, 1984, CARIBBEAN FAMILY STR; CHNG PK, 1982, BRIT J OBSTET GYNAEC, V89, P862, DOI 10.1111/j.1471-0528.1982.tb05042.x; DAVEY DA, 1986, CLIN EXP HYPERTENS B, V5, P97, DOI 10.3109/10641958609023478; FEENEY JG, 1980, EUR J OBSTET GYN R B, V11, P35, DOI 10.1016/0028-2243(80)90051-9; GOLDBERG JM, 1990, AM J OBSTET GYNECOL, V163, P65, DOI 10.1016/S0002-9378(11)90669-3; IKEDIFE D, 1980, BRIT MED J, V280, P985, DOI 10.1136/bmj.280.6219.985-a; KANBOURSHAKIR A, 1990, P NATL ACAD SCI USA, V87, P444, DOI 10.1073/pnas.87.1.444; KLONOFFCOHEN HS, 1989, JAMA-J AM MED ASSOC, V262, P3143, DOI 10.1001/jama.262.22.3143; MARTI JJ, 1977, AM J OBSTET GYNECOL, V128, P489, DOI 10.1016/0002-9378(77)90030-8; MASSIAH H, 1983, WOMEN HEADS HOUSEHOL; NEED JA, 1975, BRIT MED J, V1, P548, DOI 10.1136/bmj.1.5957.548; REDMAN CWG, 1991, SEMIN PERINATOL, V15, P257; ROBILLARD PY, 1993, J REPROD IMMUNOL, V24, P1, DOI 10.1016/0165-0378(93)90032-D; ROBILLARD PY, IN PRESS INT J FETOM; SAFTLAS AF, 1990, AM J OBSTET GYNECOL, V163, P460, DOI 10.1016/0002-9378(90)91176-D; SERHAL PF, 1987, LANCET, V2, P744; SPECK EH, 1980, PREGNANCY HYPERTENS, P45; 1990, RESULTATS RECENSEMEN; 1994, LANCET, V344, P969	24	245	253	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 8	1994	344	8928					973	975		10.1016/S0140-6736(94)91638-1	http://dx.doi.org/10.1016/S0140-6736(94)91638-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934427				2022-12-01	WOS:A1994PK97800006
J	KASTNER, P; GRONDONA, JM; MARK, M; GANSMULLER, A; LEMEUR, M; DECIMO, D; VONESCH, JL; DOLLE, P; CHAMBON, P				KASTNER, P; GRONDONA, JM; MARK, M; GANSMULLER, A; LEMEUR, M; DECIMO, D; VONESCH, JL; DOLLE, P; CHAMBON, P			GENETIC-ANALYSIS OF RXR-ALPHA, DEVELOPMENTAL FUNCTION - CONVERGENCE OF RXR AND RAR SIGNALING PATHWAYS IN HEART AND EYE MORPHOGENESIS	CELL			English	Article							REPLICATION-DEFECTIVE RETROVIRUS; 9-CIS RETINOIC ACID; CARDIAC MORPHOGENESIS; CLONAL ANALYSIS; RECEPTOR-GAMMA; MUTANT MICE; MOUSE; EXPRESSION; TRANSACTIVATION; TRANSCRIPTION	A null mutation was generated in the mouse RXR alpha gene by targeted disruption. Growth deficiency occurred in heterozygote mice. Null mutants died in utero and displayed myocardial and ocular malformations. These malformations belong to the fetal vitamin A deficiency syndrome, supporting the idea that RXR alpha is involved in retinoid signaling in vivo. A phenotypic synergy was observed when the RXR alpha mutation was introduced into RAR alpha or RAR gamma mutant backgrounds: RXR alpha null mutants and RXR alpha(+/-)/RAR gamma(-/-) double mutants displayed similar ocular defects, which became more severe in RXR alpha(-/-)/RAR gamma(+/-) and RXR alpha(-/-)/RAR gamma(-/-) mutants. Furthermore, RXR alpha/RAR double mutants exhibited several malformations not seen in single mutants. This functional convergence strongly suggests that RXR alpha/RAR heterodimers mediate retinoid signaling in vivo.			KASTNER, P (corresponding author), FAC MED STRASBOURG, INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB, INSERM, U184, F-67085 STRASBOURG, FRANCE.		Dolle, Pascal/A-8037-2010; Grondona, Jesus M./F-1650-2011	Dolle, Pascal/0000-0002-9294-9090; Grondona, Jesus M./0000-0003-1781-1486; Decimo, Didier/0000-0002-0390-1205				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BEDO G, 1989, NATURE, V339, P231, DOI 10.1038/339231a0; BLOMHOFF RB, 1994, VITAMIN A HLTH DISEA; CHALLICE CE, 1974, TISSUE CELL, V6, P447, DOI 10.1016/0040-8166(74)90037-8; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; COULOMBRE AJ, 1977, HDB TERATOLOGY, P329; COULOMBRE JL, 1969, INVEST OPHTH VISUAL, V8, P251; DELUCA HF, 1988, FASEB J, V2, P224, DOI 10.1096/fasebj.2.3.3280376; DOLLE P, 1994, MECH DEVELOP, V45, P91, DOI 10.1016/0925-4773(94)90023-X; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; Hay E.D., 1980, International Review of Cytology, V63, P263, DOI 10.1016/S0074-7696(08)61760-X; HEERY DM, 1993, P NATL ACAD SCI USA, V90, P4281, DOI 10.1073/pnas.90.9.4281; HERO I, 1990, INVEST OPHTH VIS SCI, V31, P197; JOHNSTON MC, 1979, EXP EYE RES, V29, P27, DOI 10.1016/0014-4835(79)90164-7; Kastner P., 1994, Vitamin A in health and disease., P189; Kaufman M.H., 1992, ATLAS MOUSE DEV; KIRBY ML, 1983, SCIENCE, V220, P1059, DOI 10.1126/science.6844926; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LAND MF, 1992, ANNU REV NEUROSCI, V15, P1, DOI 10.1146/annurev.ne.15.030192.000245; LEGRAND J, 1986, THYROID HORMONE META, V8, P503; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LI E, 1993, P NATL ACAD SCI USA, V90, P1590, DOI 10.1073/pnas.90.4.1590; LIU Q, 1993, MOL ENDOCRINOL, V7, P651, DOI 10.1210/me.7.5.651; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LOHNES D, 1994, IN PRESS DEVELOPMENT; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Mann I, 1937, DEV ABNORMALITIES EY; MARK M, 1993, DEVELOPMENT, V119, P319; MARSHARMSTRONG N, 1994, P NATL ACAD SCI USA, V91, P7286, DOI 10.1073/pnas.91.15.7286; MCCAFFERY P, 1993, DEV BIOL, V158, P390, DOI 10.1006/dbio.1993.1197; MENDELSOHN C, 1994, IN PRESS DEV BIOL; MENDELSOHN C, 1994, IN PRESS DEVELOPMENT; MIKAWA T, 1992, DEV DYNAM, V195, P133, DOI 10.1002/aja.1001950208; MIKAWA T, 1992, DEV DYNAM, V193, P11, DOI 10.1002/aja.1001930104; MOENS CB, 1993, DEVELOPMENT, V119, P485; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NODEN DM, 1991, DEVELOPMENT, V111, P867; ORO AE, 1992, DEVELOPMENT, V115, P449; RUBERTE E, 1990, DEVELOPMENT, V108, P213; RUMYANTSEV PP, 1977, INT REV CYTOL, V51, P187; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SPORN MB, 1994, RETINOIDS, P319; STEPHAN F, 1954, TRAITE ZOOL, V12, P854; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; WARKANY J, 1946, ARCH OPHTHALMOL-CHIC, V35, P150, DOI 10.1001/archopht.1946.00890200155008; WILSON JG, 1949, AM J ANAT, V85, P113, DOI 10.1002/aja.1000850106; WILSON JG, 1953, AM J ANAT, V92, P189, DOI 10.1002/aja.1000920202	56	592	606	2	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 23	1994	78	6					987	1003		10.1016/0092-8674(94)90274-7	http://dx.doi.org/10.1016/0092-8674(94)90274-7			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923367				2022-12-01	WOS:A1994PJ29400010
J	CHEN, S; ROSEMAN, AM; HUNTER, AS; WOOD, SP; BURSTON, SG; RANSON, NA; CLARKE, AR; SAIBIL, HR				CHEN, S; ROSEMAN, AM; HUNTER, AS; WOOD, SP; BURSTON, SG; RANSON, NA; CLARKE, AR; SAIBIL, HR			LOCATION OF A FOLDING PROTEIN AND SHAPE CHANGES IN GROEL-GROES COMPLEXES IMAGED BY CRYOELECTRON MICROSCOPY	NATURE			English	Article							CHAPERONIN GROEL; CENTRAL CAVITY; BINDING; SURFACE; CYCLE; ATP	PROTEIN folding mediated by the molecular chaperone GroEL occurs by its binding to non-native polypeptide substrates and is driven by ATP hydrolysis(1). Both of these processes are influenced by the reversible association of the co-protein, GroES (refs 2-4). GroEL and other chaperonin 60 molecules(5) are large, cylindrical oligomers consisting of two stacked heptameric rings of subunits(6,7); each ring forms a cage-like structure(8) thought to bind polypeptides in a central cavity(8-10). Chaperonins play a passive role in folding by binding or sequestering folding proteins to prevent their aggregation(11-13), but they may also actively unfold substrate proteins trapped in misfolded forms, enabling them to assume productive folding conformations(14-16). Biochemical studies show that GroES improves the efficiency of GroEL function(2,3,17), but the structural basis for this is unknown. Here we report the first direct visualization, by cryo-electron microscopy, of a non-native protein substrate (malate dehydrogenase) bound to the mobile, outer domains at one end of GroEL. Addition of GroES to GroEL in the presence of ATP causes a dramatic hinge opening of about 60 degrees. GroES binds to the equivalent surface of the GroEL outer domains, but on the opposite end of the GroEL oligomer to the protein substrate.	UNIV BRISTOL,DEPT BIOCHEM,BRISTOL BS8 1TD,ENGLAND; UNIV BRISTOL,CTR MOLEC RECOGNIT,BRISTOL BS8 1TD,ENGLAND	University of Bristol; University of Bristol	CHEN, S (corresponding author), UNIV LONDON BIRKBECK COLL,DEPT CRYSTALLOG,MALET ST,LONDON WC1E 7HX,ENGLAND.		Roseman, Alan/AAE-6689-2019; Wood, Stephen P/B-1438-2009	Ranson, Neil/0000-0002-3640-5275; Roseman, Alan/0000-0002-4783-2619	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; FISHER MT, 1994, J BIOL CHEM, V269, P13629; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HARRIS JR, IN PRESS J STRUCT BI; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HUTCHINSON EG, 1989, EMBO J, V8, P1485, DOI 10.1002/j.1460-2075.1989.tb03532.x; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; NILSSON B, 1991, ANNU REV MICROBIOL, V45, P607; PERALTA D, 1994, FEBS LETT, V339, P40; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT R, 1994, SCIENCE, V265, P656; STANIFORTH RA, 1994, FEBS LETT, V344, P129, DOI 10.1016/0014-5793(94)00348-3; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0	27	330	332	1	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 15	1994	371	6494					261	264		10.1038/371261a0	http://dx.doi.org/10.1038/371261a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG290	7915827				2022-12-01	WOS:A1994PG29000057
J	CHOWIENCZYK, PJ; WATTS, GF; COCKCROFT, JR; BRETT, SE; RITTER, JM				CHOWIENCZYK, PJ; WATTS, GF; COCKCROFT, JR; BRETT, SE; RITTER, JM			SEX-DIFFERENCES IN ENDOTHELIAL FUNCTION IN NORMAL AND HYPERCHOLESTEROLEMIC SUBJECTS	LANCET			English	Note							DEPENDENT VASODILATION; L-ARGININE; VESSELS	Acetylcholine stimulates endothelial synthesis of nitric oxide from L-arginine. To investigate the influence of sex on endothelial function, we measured vasodilator responses to brachial artery administration of acetylcholine in hypercholesterolaemic and control men and women. Mean response to acetylcholine was impaired (55% of that in controls at 15 mu g/min) in hypercholesterolaemic men but not in hypercholesterolaemic women. L-arginine normalised responses to acetylcholine in hypercholesterolaemic men, but had similar effects in hypercholesterolaemic and control women. These results suggest that women are protected against adverse effects of hypercholesterolaemia on the L-arginine/nitric-oxide pathway.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DEPT CLIN PHARMACOL,LONDON SE1 9RT,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DEPT ENDOCRINOL & CHEM PATHOL,LONDON SE1 9RT,ENGLAND	University of London; King's College London; University of London; King's College London				Chowienczyk, Phil/0000-0003-4507-038X; Watts, Gerald/0000-0003-2276-1524				CALVER A, 1991, CLIN SCI, V81, P695, DOI 10.1042/cs0810695; CASINO PR, 1993, CIRCULATION, V88, P2541, DOI 10.1161/01.CIR.88.6.2541; CHOWIENCZYK PJ, 1994, CLIN SCI, V87, P45, DOI 10.1042/cs0870045; CHOWIENCZYK PJ, 1992, LANCET, V340, P1430, DOI 10.1016/0140-6736(92)92621-L; CREAGER MA, 1992, J CLIN INVEST, V90, P1248, DOI 10.1172/JCI115987; HAYASHI T, 1992, P NATL ACAD SCI USA, V89, P11259, DOI 10.1073/pnas.89.23.11259; IMAIZUMI T, 1992, HYPERTENSION, V20, P511, DOI 10.1161/01.HYP.20.4.511; JACOBS M, 1990, BRIT J PHARMACOL, V100, P21, DOI 10.1111/j.1476-5381.1990.tb12045.x; SACK MN, 1994, LANCET, V343, P269, DOI 10.1016/S0140-6736(94)91117-7; WEINER C, 1993, ENDOTHELIUM, V1, pS1	10	73	73	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 30	1994	344	8918					305	306		10.1016/S0140-6736(94)91342-0	http://dx.doi.org/10.1016/S0140-6736(94)91342-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ233	7914265				2022-12-01	WOS:A1994NZ23300011
J	CARROLL, SB; GATES, J; KEYS, DN; PADDOCK, SW; PANGANIBAN, GEF; SELEGUE, JE; WILLIAMS, JA				CARROLL, SB; GATES, J; KEYS, DN; PADDOCK, SW; PANGANIBAN, GEF; SELEGUE, JE; WILLIAMS, JA			PATTERN-FORMATION AND EYESPOT DETERMINATION IN BUTTERFLY WINGS	SCIENCE			English	Article							PRECIS-COENIA LEPIDOPTERA; LIMB DEVELOPMENT; IMAGINAL DISKS; DROSOPHILA-MELANOGASTER; ENGRAILED GENE; HOMEOBOX GENE; EXPRESSION; WINGLESS; PROTEIN; ENCODES	Butterfly wings display pattern elements of many types and colors. To identify the molecular processes underlying the generation of these patterns, several butterfly cognates of Drosophila appendage patterning genes have been cloned and their expression patterns have been analyzed. Butterfly wing patterns are organized by two spatial coordinate systems. One system specifies positional information with respect to the entire wing field and is conserved between fruit flies and butterflies. A second system, superimposed on the general system and involving several of the same genes, operates within each wing subdivision to elaborate discrete pattern elements. Eyespots, which form from discrete developmental organizers, are marked by Distal-less gene expression. These circular pattern elements appear to be generated by a process similar to, and perhaps evolved from, proximodistal pattern formation in insect appendages.	UNIV WISCONSIN,MOLEC BIOL LAB,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	CARROLL, SB (corresponding author), UNIV WISCONSIN,HOWARD HUGHES MED INST,MADISON,WI 53706, USA.		Boekhoff-Falk, Grace E/B-2240-2008	Boekhoff-Falk, Grace E/0000-0002-9877-8309				CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; COHEN B, 1993, DEVELOPMENT, V117, P597; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; COHEN SM, 1989, EMBO J, V8, P2045, DOI 10.1002/j.1460-2075.1989.tb03613.x; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; Cohen Stephen M., 1993, P747; COLEMAN KG, 1987, GENE DEV, V1, P19, DOI 10.1101/gad.1.1.19; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; COUSO JP, 1994, DEVELOPMENT, V120, P621; DIASBENJUMEA F, 1993, CELL, V75, P741; DOCTOR JS, 1992, DEV BIOL, V151, P491, DOI 10.1016/0012-1606(92)90188-M; DOLLE P, 1992, DIFFERENTIATION, V49, P93, DOI 10.1111/j.1432-0436.1992.tb00773.x; FRENCH V, 1992, DEVELOPMENT, V116, P103; GARCIABELLIDO A, 1975, CIBA F S, V29, P16; HUI CC, 1992, P NATL ACAD SCI USA, V89, P167, DOI 10.1073/pnas.89.1.167; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; KLESSIG DF, 1983, PLANT MOL BIOL REP, V1, P12; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; NIJHOUT HF, 1985, J EMBRYOL EXP MORPH, V86, P191; NIJHOUT HF, 1980, DEV BIOL, V80, P275, DOI 10.1016/0012-1606(80)90404-2; NIJHOUT HF, 1988, DEVELOPMENT, V102, P377; Nijhout HF, 1991, DEV EVOLUTION BUTTER; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PATEL NH, 1989, DEVELOPMENT, V107, P201; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; PRICE M, 1991, NATURE, V351, P748, DOI 10.1038/351748a0; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIDOW A, 1992, P NATL ACAD SCI USA, V89, P5098, DOI 10.1073/pnas.89.11.5098; SPENCER FA, 1982, CELL, V28, P45; STEVENS ME, 1986, DEV BIOL, V117, P326, DOI 10.1016/0012-1606(86)90375-1; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; WILLIAMS JA, 1988, EMBO J, V7, P1355, DOI 10.1002/j.1460-2075.1988.tb02951.x; WILLIAMS JA, 1993, BIOESSAYS, V15, P167; WILLIAMS JA, 1991, GENE DEV, V5, P248; WILLIAMS JA, 1994, NATURE, V368, P298; WILLIAMS JJ, UNPUB; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227; YAMAMOTO RT, 1993, J ECON ENTOMOL, V621, P1427	45	285	292	0	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 1	1994	265	5168					109	114		10.1126/science.7912449	http://dx.doi.org/10.1126/science.7912449			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV301	7912449				2022-12-01	WOS:A1994NV30100038
J	TURKOF, E; TAMBWEKAR, S; MANSUKHANI, K; MILLESI, H; MAYR, N				TURKOF, E; TAMBWEKAR, S; MANSUKHANI, K; MILLESI, H; MAYR, N			INTRAOPERATIVE SPINAL ROOT STIMULATION TO DETECT MOST PROXIMAL SITE OF LEPROUS ULNAR NEURITIS	LANCET			English	Note							MUSCLE	In 10 patients with leprous ulnar neuritis, we investigated the most proximal site of lesion in the affected nerves. Spinal roots C8 and T1 were stimulated intraoperatively to evoke efferent mixed compound nerve action potentials which were recorded from the exposed ulnar nerves. The site at which amplitudes reached a maximum was considered the most proximal site of lesion. Nerve damage was found far proximally from the thickened segments in otherwise inconspicuous sections. Epineuriotomy within these apparently unaffected segments revealed fibrosis of the interfascicular epineurium in 9 patients, which is an indication for microsurgical interfascicular neurolysis.	UNIV VIENNA,ALLGEMEINES KRANKENHAUS WIEN,NEUROL KLIN,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,SURG CLIN,DEPT PLAST & RECONSTRUCT SURG,VIENNA,AUSTRIA; LUDWIG BOLTZMANN INST EXPTL PLAST SURG,VIENNA,AUSTRIA; KEM HOSP BOMBAY,DEPT PLAST & RECONSTRUCT SURG,BOMBAY,MAHARASHTRA,INDIA; KEM HOSP BOMBAY,DEPT NEUROL,BOMBAY,MAHARASHTRA,INDIA; UNIV VIENNA,NEUROL CLIN,VIENNA,AUSTRIA	University of Vienna; University of Vienna; Ludwig Boltzmann Institute; Seth Gordhandas Sunderdas Medical College & King Edward Memorial Hospital; Seth Gordhandas Sunderdas Medical College & King Edward Memorial Hospital; University of Vienna								[Anonymous], 1993, Wkly Epidemiol Rec, V68, P181; ENNA CD, 1974, J NEUROSURG, V40, P734, DOI 10.3171/jns.1974.40.6.0734; GIRAUDEAU P, 1982, ACTA LEPROL GENEVE, V86, P227; MCLEOD JG, 1975, BRAIN, V98, P203, DOI 10.1093/brain/98.2.203; MERTON PA, 1982, LANCET, V2, P597; PANDYA JN, 1976, INT J LEPROSY, V46, P47; PEREIRA JH, 1991, LANCET, V338, P1239, DOI 10.1016/0140-6736(91)92105-B; SUNDERLAND S, 1973, BRAIN, V96, P865, DOI 10.1093/brain/96.4.865	8	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1604	1605		10.1016/S0140-6736(94)93059-7	http://dx.doi.org/10.1016/S0140-6736(94)93059-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911922				2022-12-01	WOS:A1994NU35400012
J	SAWIN, CT; GELLER, A; WOLF, PA; BELANGER, AJ; BAKER, E; BACHARACH, P; WILSON, PWF; BENJAMIN, EJ; DAGOSTINO, RB				SAWIN, CT; GELLER, A; WOLF, PA; BELANGER, AJ; BAKER, E; BACHARACH, P; WILSON, PWF; BENJAMIN, EJ; DAGOSTINO, RB			LOW SERUM THYROTROPIN CONCENTRATIONS AS A RISK FACTOR FOR ATRIAL-FIBRILLATION IN OLDER PERSONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THYROID-STIMULATING-HORMONE; GRAVES-DISEASE; THYROTOXICOSIS; ASSAY; STROKE; TSH; HYPERTHYROIDISM; PREVALENCE; EMBOLISM; CARE	Background, Low serum thyrotropin concentrations are a sensitive indicator of hyperthyroidism but can also occur in persons who have no clinical manifestations of the disorder. We studied whether low serum thyrotropin concentrations in clinically euthyroid older persons are a risk factor for Subsequent atrial fibrillation. Methods. We studied 2007 persons (814 men and 1193 women) 60 years of age or older who did not have atrial fibrillation in order to determine the frequency of this arrhythmia during a 10-year follow-up period. The subjects were classified according to their serum thyrotropin concentrations: those with low values (less than or equal to 0.1 mU per liter; 61 subjects); those with slightly low values (> 0.1 to 0.4 mU per liter; 187 subjects); those with normal values (> 0.4 to 5.0 mU per liter; 1576 subjects); and those with high values (> 5.0 mU per liter; 183 subjects). Results. During the 10-year follow-up period, atrial fibrillation occurred in 13 persons with low initial values for serum thyrotropin, 23 with slightly low values, 133 with normal values, and 23 with high values. The cumulative incidence of atrial fibrillation at 10 years was 28 percent among the subjects with low serum thyrotropin values (less than or equal to 0.1 mU per liter), as compared with 11 percent among those with normal values; the age-adjusted incidence of atrial fibrillation was 28 per 1000 person-years among those with low values and 10 per 1000 person-years among those with normal values (P = 0.005). After adjustment for other known risk factors, the relative risk of atrial fibrillation in elderly subjects with low serum thyrotropin concentrations, as compared with those with normal concentrations, was 3.1 (95 percent confidence interval, 1.7 to 5.5; P < 0.001), The 10-year incidence of atrial fibrillation in the groups with slightly low and high serum thyrotropin values was not significantly different from that in the group with normal values. Conclusions. Among people 60 years of age or older, a low serum thyrotropin concentration is associated with a threefold higher risk that atrial fibrillation will develop in the subsequent decade.	VET AFFAIRS MED CTR,MED RES SERV,BOSTON,MA; BOSTON UNIV,EVANS MEM DEPT CLIN RES,PREVENT MED & EPIDEMIOL SECT,BOSTON,MA; BOSTON UNIV,DEPT NEUROL,BOSTON,MA; BOSTON UNIV,DEPT MATH,BOSTON,MA; BOSTON UNIV,DEPT MED,BOSTON,MA; FRAMINGHAM HEART DIS EPIDEMIOL STUDY,FRAMINGHAM,MA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Boston University; Boston University; Boston University; Boston University; Framingham Heart Study	SAWIN, CT (corresponding author), VET AFFAIRS MED CTR,MED SERV,150 S HUNTINGTON AVE,BOSTON,MA 02130, USA.		Wilson, Peter W.F./J-2455-2016; Benjamin, Emelia/E-7103-2011	Wolf, Philip/0000-0002-3628-301X; Benjamin, Emelia/0000-0003-4076-2336	NHLBI NIH HHS [N01-HC-38038, R01-HL40423-04] Funding Source: Medline; NINDS NIH HHS [2-R01-NS-17950-12] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040423] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAGCHI N, 1990, ARCH INTERN MED, V150, P785, DOI 10.1001/archinte.150.4.785; COX DR, 1972, J R STAT SOC B, V34, P187; DALY JG, 1982, BMJ-BRIT MED J, V285, P1574; EGGERTSEN R, 1988, BRIT MED J, V297, P1586, DOI 10.1136/bmj.297.6663.1586; FAGERBERG B, 1990, CLIN CHEM, V36, P620; FRIEDMAN D, 1992, AGE, V15, P9, DOI 10.1007/BF02434907; FURSZYFER J, 1970, MAYO CLIN PROC, V45, P636; KALBFLEISCH JD, 1980, STAT ANAL FAILURE TI, P199; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEESE GP, 1992, CLIN ENDOCRINOL, V37, P500, DOI 10.1111/j.1365-2265.1992.tb01480.x; LUNDGREN E, 1990, CLIN ENDOCRINOL, V33, P133, DOI 10.1111/j.1365-2265.1990.tb00473.x; NORDYKE RA, 1988, ARCH INTERN MED, V148, P626, DOI 10.1001/archinte.148.3.626; PARLE JV, 1991, CLIN ENDOCRINOL, V34, P77; PEKARY AE, 1975, J CLIN ENDOCR METAB, V41, P676, DOI 10.1210/jcem-41-4-676; PETERSEN P, 1988, STROKE, V19, P15, DOI 10.1161/01.STR.19.1.15; PETERSEN P, 1984, ACTA MED SCAND, V216, P5; PHILLIPS DIW, 1985, CLIN ENDOCRINOL, V23, P283, DOI 10.1111/j.1365-2265.1985.tb00225.x; PRESTI CF, 1989, AM HEART J, V117, P976, DOI 10.1016/0002-8703(89)90642-X; ROSS DS, 1990, J CLIN ENDOCR METAB, V71, P764, DOI 10.1210/jcem-71-3-764; SANDLER G, 1959, Q J MED, V52, P347; SAWIN CT, 1991, ARCH INTERN MED, V151, P165, DOI 10.1001/archinte.151.1.165; SIEBERS MJ, 1992, ARCH INTERN MED, V152, P2063, DOI 10.1001/archinte.152.10.2063; SINGER DE, 1992, NEW ENGL J MED, V327, P1451, DOI 10.1056/NEJM199211123272009; STAFFURTH JS, 1977, BRIT MED J, V2, P688, DOI 10.1136/bmj.2.6088.688; SUNDBECK G, 1991, ARCH INTERN MED, V151, P549, DOI 10.1001/archinte.151.3.549; TENERZ A, 1990, J INTERN MED, V228, P229; TIBALDI JM, 1986, AM J MED, V81, P619, DOI 10.1016/0002-9343(86)90547-4; WEEKS I, 1984, CLIN ENDOCRINOL, V20, P489, DOI 10.1111/j.1365-2265.1984.tb03446.x; White PD, 1918, ARCH INTERN MED, V22, P766; WOLF PA, 1983, STROKE, V14, P664, DOI 10.1161/01.STR.14.5.664; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561	32	851	885	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 10	1994	331	19					1249	1252		10.1056/NEJM199411103311901	http://dx.doi.org/10.1056/NEJM199411103311901			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP752	7935681				2022-12-01	WOS:A1994PP75200001
J	TAMEMOTO, H; KADOWAKI, T; TOBE, K; YAGI, T; SAKURA, H; HAYAKAWA, T; TERAUCHI, Y; UEKI, K; KABURAGI, Y; SATOH, S; SEKIHARA, H; YOSHIOKA, S; HORIKOSHI, H; FURUTA, Y; IKAWA, Y; KASUGA, M; YAZAKI, Y; AIZAWA, S				TAMEMOTO, H; KADOWAKI, T; TOBE, K; YAGI, T; SAKURA, H; HAYAKAWA, T; TERAUCHI, Y; UEKI, K; KABURAGI, Y; SATOH, S; SEKIHARA, H; YOSHIOKA, S; HORIKOSHI, H; FURUTA, Y; IKAWA, Y; KASUGA, M; YAZAKI, Y; AIZAWA, S			INSULIN-RESISTANCE AND GROWTH-RETARDATION IN MICE LACKING INSULIN-RECEPTOR SUBSTRATE-1	NATURE			English	Article							TYROSINE-PHOSPHORYLATION; RAT ADIPOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC-CELLS; SIGNALING PATHWAYS; FACTOR-I; PROTEIN; IRS-1; KINASE; ASSOCIATION	INSULIN receptor substrate-1 (IRS-1) is the major substrate of insulin receptor and IGF-1 receptor tyrosine kinases; it has an apparent relative molecular mass of 160-190,000 (M(r), 160-190K) on SDS polyacrylamide gel(1-3). Tyrosine-phosphorylated IRS-1 binds the 85K subunit of phosphatidylinositol 3-kinase(4,5) which may be involved in the translocation of glucose transporters(6,7) and the abundant src homology protein (ASH)/Grb2(8,9) which may be involved in activation of p21(ras) and MAP kinase cascade(10). IRS-1 also has binding sites for Syp(11) and Nck(12) and other src homology 2 (SH2) signalling molecules. To clarify the physiological roles of IRS-1 in vivo, we made mice with a targeted disruption of the IRS-1 gene locus. Mice homozygous for targeted disruption of the IRS-1 gene were born alive but were retarded in embryonal and postnatal growth. They also had resistance to the glucose-lowering effects of insulin, IGF-1 and IGF-2. These data suggest the existence of both IRS-1-dependent and IRS-1-independent pathways for signal transduction of insulin and IGFs.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,ONCOL MOLEC LAB,TSUKUBA,IBARAKI 305,JAPAN; SANKYO CO LTD,PHARMACOL & MOLEC BIOL RES LABS,SHINAGAWA KU,TOKYO 140,JAPAN; YOKOHAMA CITY UNIV,FAC MED,SCH MED,DEPT INTERNAL MED 3,YOKOHAMA,KANAGAWA 236,JAPAN; UNIV KOBE,FAC MED,DEPT INTERNAL MED 2,KOBE,HYOGO 650,JAPAN	University of Tokyo; RIKEN; Daiichi Sankyo Company Limited; Yokohama City University; Kobe University			Terauchi, Yasuo/AAO-4347-2020; Sancheti, Harsh/H-3538-2012					BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; HARA K, IN PRESS P NATN ACAD; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6; MOONEY RA, 1992, ENDOCRINOLOGY, V130, P1533, DOI 10.1210/en.130.3.1533; OKADA T, 1994, J BIOL CHEM, V269, P3568; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STAGSTED J, 1990, CELL, V62, P297, DOI 10.1016/0092-8674(90)90367-N; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TOBE K, 1991, J BIOL CHEM, V266, P24793; TOBE K, 1993, J BIOL CHEM, V268, P11167; URLAUB G, 1989, MOL CELL BIOL, V9, P2868; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1994, J BIOL CHEM, V268, P1; YAGI T, 1993, NATURE, V366, P742, DOI 10.1038/366742a0; YAMAMOTOHONDA R, 1993, J BIOL CHEM, V268, P16859; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634	30	844	873	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 10	1994	372	6502					182	186		10.1038/372182a0	http://dx.doi.org/10.1038/372182a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ688	7969452				2022-12-01	WOS:A1994PQ68800057
J	YUAN, JG; HENRY, R; MCCAFFERY, M; CLINE, K				YUAN, JG; HENRY, R; MCCAFFERY, M; CLINE, K			SECA HOMOLOG IN PROTEIN-TRANSPORT WITHIN CHLOROPLASTS - EVIDENCE FOR ENDOSYMBIONT-DERIVED SORTING	SCIENCE			English	Article							THYLAKOID PRECURSOR PROTEIN; ESCHERICHIA-COLI; CHROMOPHYTIC ALGA; RED ALGA; MEMBRANE; IMPORT; TRANSLOCATION; GENOME; INTEGRATION; MACHINERY	The SecA protein is an essential, azide-sensitive component of the bacterial protein translocation machinery. A SecA protein homolog (CPSecA) now identified in pea chloroplasts was purified to homogeneity. CPSecA supported protein transport into thylakoids, the chloroplast internal membrane network, in an azide-sensitive fashion. Only one of three pathways for protein transport into thylakoids uses the CPSecA mechanism. The use of a bacteria-homologous mechanism in intrachloroplast protein transport provides evidence for conservative sorting of proteins within chloroplasts.	UNIV FLORIDA,PLANT MOLEC & CELLULAR BIOL PROGRAM,GAINESVILLE,FL 32611; UNIV FLORIDA,DEPT HORT SCI,GAINESVILLE,FL 32611	State University System of Florida; University of Florida; State University System of Florida; University of Florida			Cline, Kenneth/J-6238-2013		NIGMS NIH HHS [1 R01 GM46951] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046951] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; CLINE K, 1986, J BIOL CHEM, V261, P4804; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DRIESSEN AJM, 1993, BIOCHEMISTRY-US, V32, P13190, DOI 10.1021/bi00211a030; FLACHMANN R, 1993, J BIOL CHEM, V268, P7514; FULSON DR, 1988, PLANT PHYSIOL, V88, P1146, DOI 10.1104/pp.88.4.1146; HAEHNEL W, 1994, EMBO J, V13, P1028, DOI 10.1002/j.1460-2075.1994.tb06351.x; HALPIN C, 1989, EMBO J, V8, P3917, DOI 10.1002/j.1460-2075.1989.tb08572.x; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HENRY R, 1994, J BIOL CHEM, V269, P10189; HULFORD A, 1994, J BIOL CHEM, V269, P3251; KLOSE M, 1993, J BIOL CHEM, V268, P4504; KNOTT TG, 1994, J BIOL CHEM, V269, P7843; MATSUYAMA S, 1992, BIOCHIM BIOPHYS ACTA, V1122, P77, DOI 10.1016/0167-4838(92)90130-6; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; PAYAN LA, 1991, J CELL BIOL, V112, P603, DOI 10.1083/jcb.112.4.603; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; REED JE, 1990, EUR J BIOCHEM, V194, P33, DOI 10.1111/j.1432-1033.1990.tb19423.x; REITH M, 1993, PLANT CELL, V5, P465, DOI 10.1105/tpc.5.4.465; SCARAMUZZI CD, 1992, FEBS LETT, V304, P119, DOI 10.1016/0014-5793(92)80601-C; SCARAMUZZI CD, 1992, CURR GENET, V22, P421, DOI 10.1007/BF00352444; SCHMIDT MG, 1989, J BACTERIOL, V171, P643, DOI 10.1128/jb.171.2.643-649.1989; SEIDLER A, 1990, EMBO J, V9, P1743, DOI 10.1002/j.1460-2075.1990.tb08298.x; SIMPSON DJ, 1989, CARLSBERG RES COMMUN, V54, P55, DOI 10.1007/BF02907585; SMEEKENS S, 1990, TRENDS BIOCHEM SCI, V15, P73, DOI 10.1016/0968-0004(90)90180-J; Theg Steven M., 1993, Trends in Cell Biology, V3, P186, DOI 10.1016/0962-8924(93)90212-J; VALENTIN K, 1993, MOL GEN GENET, V236, P245, DOI 10.1007/BF00277119; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; YUAN J, UNPUB; YUAN JG, 1993, P NATL ACAD SCI USA, V90, P8552, DOI 10.1073/pnas.90.18.8552; YUAN JG, 1994, J BIOL CHEM, V269, P18463	35	150	152	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					796	798		10.1126/science.7973633	http://dx.doi.org/10.1126/science.7973633			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973633				2022-12-01	WOS:A1994PP75300037
J	HAY, RJ				HAY, RJ			OF IMAGING AND SKIN	LANCET			English	Editorial Material											HAY, RJ (corresponding author), GUYS HOSP,ST JOHNS INST DERMATOL,LONDON,ENGLAND.							DERIGAL J, 1989, J INVEST DERMATOL, V93, P621, DOI 10.1111/1523-1747.ep12319741; GASSENMAIER G, 1990, HAUTARZT, V41, P360; GOETTMANN S, 1994, BRIT J DERMATOL, V130, P701, DOI 10.1111/j.1365-2133.1994.tb03405.x; KIRSNER RS, 1993, BRIT J DERMATOL, V128, P99, DOI 10.1111/j.1365-2133.1993.tb00156.x; PEREDNIA DA, 1991, J AM ACAD DERMATOL, V25, P89, DOI 10.1016/0190-9622(91)70178-5	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 29	1994	344	8931					1174	1174		10.1016/S0140-6736(94)90504-5	http://dx.doi.org/10.1016/S0140-6736(94)90504-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN803	7934536				2022-12-01	WOS:A1994PN80300005
J	MARK, DB; NAYLOR, CD; HLATKY, MA; CALIFF, RM; TOPOL, EJ; GRANGER, CB; KNIGHT, JD; NELSON, CL; LEE, KL; CLAPPCHANNING, NE; SUTHERLAND, W; PILOTE, L; ARMSTRONG, PW				MARK, DB; NAYLOR, CD; HLATKY, MA; CALIFF, RM; TOPOL, EJ; GRANGER, CB; KNIGHT, JD; NELSON, CL; LEE, KL; CLAPPCHANNING, NE; SUTHERLAND, W; PILOTE, L; ARMSTRONG, PW			USE OF MEDICAL RESOURCES AND QUALITY-OF-LIFE AFTER ACUTE MYOCARDIAL-INFARCTION IN CANADA AND THE UNITED-STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INDEX	Background. Much attention has been directed to the use of medical resources and to patients' outcomes in Canada as compared with the United States. We compared U.S. and Canadian patients with respect to their use of medical resources and their quality of life during the year after acute myocardial infarction. Methods. A total of 2600 U.S. and 400 Canadian patients were randomly selected from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial. Base-line data from their initial hospitalizations were analyzed, and the patients were then interviewed by telephone 30 days, 6 months, and 1 year after myocardial infarction to determine their use of medical care and quality of life. Results. The Canadian patients typically stayed in the hospital one day longer (P = 0.009) than the U.S. patients but had a much lower rate of cardiac catheterization (25 percent vs. 72 percent, P<0.001), coronary angioplasty (11 percent vs. 29 percent, P<0.001), and coronary bypass surgery (3 percent vs. 14 percent, P<0.001). At one year 24 percent of the Canadian and 53 percent of the U.S. patients had undergone angioplasty or bypass surgery at least once (P<0.001). The Canadians had more visits to physicians during the follow-up year (P<0.001), but fewer visits to specialists (P<0.001). At 30 days, functional status was equivalent in the patients from the two countries. However, after one year the U.S. patients had substantially more improvement than the Canadian patients (P<0.001). The prevalence of chest pain and dyspnea at one year was higher among the Canadian patients (34 percent vs. 21 percent and 45 percent vs. 29 percent, respectively; P<0.001). Conclusions. The Canadian patients had more cardiac symptoms and worse functional status one year after acute myocardial infarction than the U.S. patients. The Canadian patients also underwent fewer invasive cardiac procedures and had fewer visits to specialist physicians. These results suggest, but do not prove, that the more aggressive pattern of care in the United States may have been responsible for the better quality of life.	DUKE UNIV, MED CTR, CLIN TRIALS COORDINATING CTR, DURHAM, NC 27708 USA; DUKE UNIV, MED CTR, DIV CARDIOL, DURHAM, NC 27708 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27708 USA; DUKE UNIV, MED CTR, DEPT FAMILY & COMMUNITY MED, DIV BIOMETRY, DURHAM, NC 27708 USA; UNIV TORONTO, DEPT MED, TORONTO, ON, CANADA; INST CLIN EVALUAT SCI, TORONTO, ON, CANADA; UNIV ALBERTA, DEPT MED, EDMONTON, AB, CANADA; STANFORD UNIV, MED CTR, DEPT HLTH RES & POLICY, DIV HLTH SERV RES, STANFORD, CA 94305 USA; CLEVELAND CLIN, DEPT CARDIOL, CLEVELAND, OH USA	Duke University; Duke University; Duke University; Duke University; University of Toronto; University of Toronto; University of Alberta; Stanford University; Cleveland Clinic Foundation	MARK, DB (corresponding author), DUKE UNIV, MED CTR, ECON & QUAL LIFE RES GRP, POB 3485, DURHAM, NC 27708 USA.		Granger, Christopher B/D-3458-2014	Granger, Christopher B/0000-0002-0045-3291; Pilote, Louise/0000-0002-6159-0628; Hlatky, Mark/0000-0003-4686-9441; Topol, Eric/0000-0002-1478-4729; Armstrong, Paul/0000-0002-0460-3445; Mark, Daniel/0000-0001-6340-8087	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R18HS005635] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036587] Funding Source: NIH RePORTER; AHRQ HHS [HS-06503, HS-05635] Funding Source: Medline; NHLBI NIH HHS [HL-36587] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1661; COX DR, 1972, J R STAT SOC B, V34, P187; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20; KOENIG HG, 1992, INT J PSYCHIAT MED, V22, P183, DOI 10.2190/M1F5-F40P-C4KD-YPA3; MARK DB, IN PRESS ACUTE CORON; PILOTE L, 1994, ARCH INTERN MED, V154, P1090, DOI 10.1001/archinte.154.10.1090; ROOS LL, 1990, JAMA-J AM MED ASSOC, V263, P2453, DOI 10.1001/jama.263.18.2453; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TORRANCE GW, 1987, J CHRON DIS, V40, P593, DOI 10.1016/0021-9681(87)90019-1; TSEVAT J, 1990, J CLIN EPIDEMIOL, V43, pS73, DOI 10.1016/0895-4356(90)90224-D; [No title captured]; 1991, CIRCULATION S5, V84, P1; 1992, DHHS PHS921232 NAT C	16	319	322	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 27	1994	331	17					1130	1135		10.1056/NEJM199410273311706	http://dx.doi.org/10.1056/NEJM199410273311706			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN065	7935638				2022-12-01	WOS:A1994PN06500006
J	YANG, YD; BLAKE, R				YANG, YD; BLAKE, R			BROAD TUNING FOR SPATIAL-FREQUENCY OF NEURAL MECHANISMS UNDERLYING VISUAL-PERCEPTION OF COHERENT MOTION	NATURE			English	Article								NEURAL events underlying perception of coherent motion are generally believed to be hierarchical(1,2): information about local motion is registered by spatio-temporal coincidence detectors(3-5) whose outputs are cooperatively integrated at a subsequent stage(6,7). There is disagreement, however, concerning the spatial scale of the neural filters underlying these operations. According to one class of models, motion registration is initially accomplished in parallel at multiple spatial scales(3-5), with filters tuned to lower spatial frequencies responsive to larger motion displacements than filters tuned to higher frequencies. According to another scheme, motion analysis involves a single, broadly tuned spatial filter, with optimal displacement dependent on spacing of local elements(8). Here we use a masking procedure to measure the extent to which dynamic noise depicted at one spatial scale interferes with detection of coherent motion conveyed by image features at another spatial scale. Our results indicate that a single filter, broadly tuned for spatial frequency, is mediating detection of coherent motion. This finding dovetails with known physiological properties of neurons at an intermediate stage of motion processing.			YANG, YD (corresponding author), VANDERBILT UNIV,DEPT PSYCHOL,NASHVILLE,TN 37240, USA.							ADELSON EH, 1985, J OPT SOC AM A, V2, P284, DOI 10.1364/JOSAA.2.000284; ADELSON EH, 1982, NATURE, V300, P523, DOI 10.1038/300523a0; ADELSON EH, 1991, OPTICS PHOTONICS NEW, V2, P24; ANDERSON SJJ, 1985, VISION RES, V13, P1147; BRADDICK O, 1993, TRENDS NEUROSCI, V16, P263, DOI 10.1016/0166-2236(93)90179-P; BRITTEN KH, 1993, VISUAL NEUROSCI, V10, P1157, DOI 10.1017/S0952523800010269; CHANG JJ, 1984, VISION RES, V24, P1781, DOI 10.1016/0042-6989(84)90009-9; CLEARY R, 1990, VISION RES, V30, P303, DOI 10.1016/0042-6989(90)90045-M; MORGAN MJ, 1992, NATURE, V355, P344, DOI 10.1038/355344a0; MOVSHON A, 1990, IMAGES UNDERSTANDING; NAWROT M, 1990, VISION RES, V30, P1439, DOI 10.1016/0042-6989(90)90025-G; SMITH AT, 1994, VISION RES, V34, P2425, DOI 10.1016/0042-6989(94)90286-0; VANDEGRIND WA, 1992, EXP BRAIN RES, V91, P135, DOI 10.1007/BF00230022; VANSANTEN JPH, 1984, J OPT SOC AM A, V1, P451, DOI 10.1364/JOSAA.1.000451; WATSON AB, 1986, J OPT SOC AM A, V3, P300, DOI 10.1364/JOSAA.3.000300; WERKHOVEN P, 1993, VISION RES, V33, P463, DOI 10.1016/0042-6989(93)90253-S; WILLIAMS DW, 1984, VISION RES, V24, P55, DOI 10.1016/0042-6989(84)90144-5; WILSON HR, 1994, VISION RES, V34, P1835, DOI 10.1016/0042-6989(94)90308-5; YANG Y, 1991, VISION RES, V31, P1177	19	35	35	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 27	1994	371	6500					793	796		10.1038/371793a0	http://dx.doi.org/10.1038/371793a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP018	7935839				2022-12-01	WOS:A1994PP01800058
J	HAMMOND, C; HELENIUS, A				HAMMOND, C; HELENIUS, A			FOLDING OF VSV G-PROTEIN - SEQUENTIAL INTERACTION WITH BIP AND CALNEXIN	SCIENCE			English	Article							STOMATITIS-VIRUS-G; CHAIN BINDING-PROTEIN; ER; TRANSPORT	The endoplasmic reticulum (ER) contains molecular chaperones that facilitate the folding of proteins in mammalian cells. Biosynthetic labeling was used to study the interactions of two chaperones, BiP and calnexin, with vesicular stomatitis virus (VSV) glycoprotein (G protein). Coimmunoprecipitation of G protein with the chaperones showed that BiP bound maximally to early folding Intermediates of G protein, whereas calnexin bound after a short lag to more folded molecules. Castanospermine, an inhibitor of ER glucosidases, blocked the binding of proteins to calnexin and inhibited G protein folding. Interaction with calnexin was necessary for efficient folding of G protein and for retention of partially folded forms.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510	Yale University					NCI NIH HHS [P01 CA46128] Funding Source: Medline; NIGMS NIH HHS [R01 GM38346] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038346] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DESILVA A, 1993, J CELL BIOL, V120, P647, DOI 10.1083/jcb.120.3.647; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; DUNIGAN DD, 1983, J VIROL, V45, P618, DOI 10.1128/JVI.45.2.618-626.1983; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; GEHTING MJ, 1992, NATURE, V355, P33; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HAMMOND C, 1993, CURR BIOL, V3, P884, DOI 10.1016/0960-9822(93)90226-E; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; ROSE JK, 1981, J VIROL, V39, P519, DOI 10.1128/JVI.39.2.519-528.1981; SARASTE J, 1991, J CELL SCI, V100, P415; SCHLESINGER S, 1984, J BIOL CHEM, V259, P7597; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8	24	285	286	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 21	1994	266	5184					456	458		10.1126/science.7939687	http://dx.doi.org/10.1126/science.7939687			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7939687				2022-12-01	WOS:A1994PN27200040
J	STRASSER, A; HARRIS, AW; JACKS, T; CORY, S				STRASSER, A; HARRIS, AW; JACKS, T; CORY, S			DNA-DAMAGE CAN INDUCE APOPTOSIS IN PROLIFERATING LYMPHOID-CELLS VIA P53-INDEPENDENT MECHANISMS INHIBITABLE BY BCL-2	CELL			English	Article							WILD-TYPE P53; MYELOID-LEUKEMIA CELLS; DEATH GENE CED-3; CYCLE CONTROL; ERYTHROLEUKEMIA-CELLS; MICE DEFICIENT; STRAND BREAKS; MUTANT P53; PRE-B; PROTEIN	The roles of p53 as an inducer and Bcl-2 as an inhibitor of apoptotic death were explored in lymphoid cells. Lymphocytes from p53(-/-) mice were radioresistant, but unexpectedly, cycling T lymphoma cells and mitogenically activated T lymphocytes from these animals underwent apoptosis after irradiation or genotoxic drug treatment. Hence, p53 is not the only mediator of apoptosis provoked by DNA damage. Irradiated p53(-/-) lymphoblasts expressing Bcl-2 were subject to growth arrest but resisted apoptosis. Their accumulation in G1 as well as G2 is suggestive of a p53-independent DNA-damage G1 checkpoint. Since Bcl-2 increased the clonogenic survival of the irradiated cells, expression of survival genes may pose a greater impediment to genotoxic cancer therapy than loss of p53.	MIT,HOWARD HUGHES MED INST,CTR CANC RES,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	STRASSER, A (corresponding author), ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA.		Strasser, Andreas/C-7581-2013; Cory, Suzanne/E-1642-2013	Strasser, Andreas/0000-0002-5020-4891; Cory, Suzanne/0000-0002-6818-3451	NATIONAL CANCER INSTITUTE [R01CA043540] Funding Source: NIH RePORTER; NCI NIH HHS [CA43540] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CAMPOS L, 1993, BLOOD, V81, P3091; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; DELALUNA S, 1992, METHOD ENZYMOL, V216, P376; DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FISHER TC, 1993, CANCER RES, V53, P3321; FRITSCHE M, 1993, ONCOGENE, V8, P307; FURTH EE, 1981, ANAL BIOCHEM, V110, P1, DOI 10.1016/0003-2697(81)90103-2; GORCZYCA W, 1993, CANCER RES, V53, P1945; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HORNING SJ, 1984, NEW ENGL J MED, V311, P1471, DOI 10.1056/NEJM198412063112303; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; IKEGAKI N, 1994, CANCER RES, V54, P6; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KAMESAKI S, 1993, CANCER RES, V53, P4251; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KORSMEYER SJ, 1992, BLOOD, V80, P879; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIMPENS J, 1991, ONCOGENE, V6, P2271; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MANOME Y, 1993, ONCOL RES, V5, P139; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MERRITT AJ, 1994, CANCER RES, V54, P614; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYASHITA T, 1992, CANCER RES, V52, P5407; PETTERSSON M, 1992, BLOOD, V79, P495; PEZZELLA F, 1990, AM J PATHOL, V137, P225; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PURDIE CA, 1994, ONCOGENE, V9, P603; RAMQVIST T, 1993, ONCOGENE, V8, P1495; REED JC, 1991, CANCER RES, V51, P6529; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SCOLLAY R, 1984, IMMUNOL REV, V82, P79, DOI 10.1111/j.1600-065X.1984.tb01118.x; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STRASSER A, 1993, ONCOGENE, V8, P1; STRASSER A, 1990, CURR TOP MICROBIOL, V166, P175; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TAYLOR IW, 1980, J HISTOCHEM CYTOCHEM, V28, P1021, DOI 10.1177/28.9.6157714; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; WANG YS, 1993, ONCOGENE, V8, P3427; WEINERT T, 1993, SEMIN CANCER BIOL, V4, P129; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZUTTER M, 1991, BLOOD, V78, P1062	71	671	686	2	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 21	1994	79	2					329	339		10.1016/0092-8674(94)90201-1	http://dx.doi.org/10.1016/0092-8674(94)90201-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954799				2022-12-01	WOS:A1994PN63000016
J	YU, YG; KING, DS; SHIN, YK				YU, YG; KING, DS; SHIN, YK			INSERTION OF A COILED-COIL PEPTIDE FROM INFLUENZA-VIRUS HEMAGGLUTININ INTO MEMBRANES	SCIENCE			English	Article							CONFORMATIONAL CHANGE; FUSION ACTIVITY; GLYCOPROTEIN; AGGREGATION; MUTANTS	The trimeric protein hemagglutinin (HA) of the influenza viral envelope is essential for cell entry. To investigate the interaction of HA with membranes, two 40-residue, cysteine-substituted peptides comprising the loop region and the first part of the coiled-coil stem were synthesized and modified with a nitroxide spin label. Electron paramagnetic resonance analysis revealed that the peptide inserts reversibly into phospholipid vesicles under endosomal pH conditions. This result suggests that some or all of the long coiled-coil trimer of HA may insert into membranes, which could bring the viral and cell membranes closer together and facilitate fusion.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV STRUCT BIOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley								ALTENBACH C, 1988, PROTEINS, V3, P230, DOI 10.1002/prot.340030404; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; ARCHER SJ, 1991, BIOPHYS J, V60, P389, DOI 10.1016/S0006-3495(91)82064-1; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; DANIELS RS, 1985, CELL, V40, P431, DOI 10.1016/0092-8674(85)90157-6; DOMS RW, 1985, J BIOL CHEM, V260, P2973; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; KEMBLE GW, 1992, J VIROL, V66, P4940, DOI 10.1128/JVI.66.8.4940-4950.1992; KIM JY, 1991, BIOPHYS J, V60, P135, DOI 10.1016/S0006-3495(91)82037-9; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PURI A, 1990, J VIROL, V64, P3824, DOI 10.1128/JVI.64.8.3824-3832.1990; RUIGROK RWH, 1986, EMBO J, V5, P41, DOI 10.1002/j.1460-2075.1986.tb04175.x; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; TSURUDOME M, 1992, J BIOL CHEM, V267, P20225; WHARTON SA, 1986, VIROLOGY, V149, P27, DOI 10.1016/0042-6822(86)90083-8; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	19	107	108	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1994	266	5183					274	276		10.1126/science.7939662	http://dx.doi.org/10.1126/science.7939662			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939662				2022-12-01	WOS:A1994PM13400033
J	DOWNEY, GP; BAVIN, PJ; DEERY, ARS; CROW, J; GRIFFITHS, PD; EMERY, VC; WALKER, PG				DOWNEY, GP; BAVIN, PJ; DEERY, ARS; CROW, J; GRIFFITHS, PD; EMERY, VC; WALKER, PG			RELATION BETWEEN HUMAN PAPILLOMAVIRUS TYPE-16 AND POTENTIAL FOR PROGRESSION OF MINOR-GRADE CERVICAL DISEASE	LANCET			English	Article							INTRAEPITHELIAL NEOPLASIA; INFECTION; SMEAR; ATYPIA; DNA; CANCER; WOMEN; RISK	We have previously reported that among 200 women referred for colposcopy with smears suggesting mild dyskaryosis, medium or high copy numbers of human papiliomavirus type 16 (HPV16) DNA identified patients with current high-grade cervical disease. We have followed up 95 women from that group who had histologically proven mild-grade cervical disease (cervical intraepithelial neoplasia grade 1, n = 37) or wart virus infection (n = 12) or who had no evidence of cervical abnormality at study entry (n = 43). Kaplan-Meier survival analysis of the 70 months' follow-up was used to identify baseline features that might affect the risk of progression. 3 women were lost to follow-up; data were available for the remaining 92. Among the whole group the probability of remaining free of high-grade cervical disease was 0.71. Women with a histological diagnosis of minor-grade disease were more likely to progress to high-grade disease than those with no evidence of abnormality (proportion disease-free 0.52 vs 0.90, p=0.004). Stratification of the group according to median age (28 years) revealed a weak association between age and disease progression (p=0.04). There was no difference in disease-free probability between HPV16-positive and HPV16-negative women (0.75 vs 0.65, p=0.19). Nor was there a significant difference in disease-free probability when the group was stratified by HPV16 viral burden. These data show that a histological diagnosis of minor grade cervical disease is a better long-term predictor of disease progression than is HPV16 positivity, irrespective of copy number. These findings do not support the simple view that HPV16 alone is the cause of high-grade cervical disease, including cancer.	ROYAL FREE HOSP, SCH MED, DIV COMMUN DIS, LONDON NW3 2QG, ENGLAND; ROYAL FREE HOSP, SCH MED, DEPT OBSTET & GYNAECOL, LONDON NW3 2QG, ENGLAND; ROYAL FREE HOSP, SCH MED, DEPT CYTOL, LONDON NW3 2QG, ENGLAND; ROYAL FREE HOSP, SCH MED, DEPT HISTOPATHOL, LONDON NW3 2QG, ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School			Emery, Vincent/G-8928-2013	Emery, Vincent/0000-0001-5893-9756				BAVIN PJ, 1993, BRIT J CANCER, V67, P602, DOI 10.1038/bjc.1993.110; BUXTON EJ, 1991, BRIT J OBSTET GYNAEC, V98, P1273, DOI 10.1111/j.1471-0528.1991.tb15401.x; CAMPION MJ, 1986, LANCET, V2, P237; CRUM CP, 1984, INT J GYNECOL PATHOL, V3, P376; CUZICK J, 1992, LANCET, V339, P959, DOI 10.1016/0140-6736(92)91532-D; EVANS AS, 1985, BRIT J OBSTET GYNAEC, V92, P165, DOI 10.1111/j.1471-0528.1985.tb01069.x; GILES JA, 1989, BRIT J OBSTET GYNAEC, V96, P1067, DOI 10.1111/j.1471-0528.1989.tb03382.x; GISSMANN L, 1984, CANCER SURV, V3, P161; HAUSEN HZ, 1984, PROG MED VIROL, V30, P170; HIRSCHOWITZ L, 1992, BRIT MED J, V304, P1209, DOI 10.1136/bmj.304.6836.1209; KOSS LG, 1963, CANCER, V16, P1160, DOI 10.1002/1097-0142(196309)16:9<1160::AID-CNCR2820160910>3.0.CO;2-4; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; MCCORMICK JS, 1989, LANCET, V2, P207; MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451; MITCHELL H, 1986, LANCET, V1, P573; NUOVO GJ, 1990, OBSTET GYNECOL, V75, P1006; NUOVO GJ, 1989, OBSTET GYNECOL, V74, P673; ROBERTSON JH, 1988, BRIT MED J, V297, P18, DOI 10.1136/bmj.297.6640.18; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHAFI MI, 1991, BRIT J OBSTET GYNAEC, V98, P490, DOI 10.1111/j.1471-0528.1991.tb10349.x; WALKER EM, 1986, LANCET, V2, P672	21	26	26	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 13	1994	344	8920					432	435		10.1016/S0140-6736(94)91768-X	http://dx.doi.org/10.1016/S0140-6736(94)91768-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7914563				2022-12-01	WOS:A1994PB76100008
J	WERLER, MM; LOUIK, C; SHAPIRO, S; MITCHELL, AA				WERLER, MM; LOUIK, C; SHAPIRO, S; MITCHELL, AA			OVULATION INDUCTION AND RISK OF NEURAL-TUBE DEFECTS	LANCET			English	Note							CLOMIPHENE	The relation between use of ovulation-inducing drugs and risk of neural tube defects (NTDs) was studied in a case-control surveillance programme. The frequency of any use of such drugs during the 6 months before the last menstrual period or during pregnancy was 3.0% for 1034 mothers of infants and fetuses with NTDs (cases) and 2.8% for 4081 mothers of those with other major congenital malformations (controls) (relative risk 1.1, 95% CI 0.8-1.7). Relative risks for clomiphene and for hormones were 0.8 (0.5-1.3) and 1.5 (0.7-3.4), respectively. These data suggest that use of ovulation-inducing drugs before conception does not increase the risk of NTDs.			WERLER, MM (corresponding author), BOSTON UNIV,SCH PUBL HLTH,SLONE EPIDEMIOL UNIT,1371 BEACON ST,BROOKLINE,MA 02146, USA.			Werler, Martha/0000-0003-3392-6814; Mitchell, Allen/0000-0003-0950-6799; Louik, Carol/0000-0001-5429-5084	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027697] Funding Source: NIH RePORTER; NICHD NIH HHS [NICHD R01-HD27697] Funding Source: Medline; PHS HHS [MCJ-2505667] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CUCKLE H, 1989, LANCET, V2, P1281; FIELD B, 1974, LANCET, V2, P1511; GLASSNER MJ, 1990, J REPROD MED, V35, P175; HARLAP S, 1976, LANCET, V2, P961; MILI F, 1991, AM J EPIDEMIOL, V134, P748; MILLS LJ, 1990, LANCET, V335, P103; MILUNSKY A, 1990, TERATOLOGY, V42, P467, DOI 10.1002/tera.1420420502; ROBERT E, 1991, REPROD TOXICOL, V5, P83, DOI 10.1016/0890-6238(91)90115-V; SINGH M, 1978, J PEDIATR-US, V93, P152, DOI 10.1016/S0022-3476(78)80634-9	9	16	16	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 13	1994	344	8920					445	446		10.1016/S0140-6736(94)91772-8	http://dx.doi.org/10.1016/S0140-6736(94)91772-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7914567				2022-12-01	WOS:A1994PB76100012
J	ALVAREZ, FJ; DELRIO, MC				ALVAREZ, FJ; DELRIO, MC			DRUGS AND DRIVING	LANCET			English	Editorial Material											ALVAREZ, FJ (corresponding author), UNIV VALLADOLID,FAC MED,DEPT PHARMACOL & THERAPEUT,DRUGS & ALCOHOL RES GRP,VALLADOLID,SPAIN.		Alvarez, Francisco/GZL-1953-2022; Alvarez, F. Javier/E-7204-2016; Alvarez, F. Javier/X-2294-2019	Alvarez, F. Javier/0000-0002-7566-5678; Alvarez, F. Javier/0000-0002-7566-5678				DEGIER JJ, 1993, IHP9339 U LIMB I HUM; 1985, JAMA-J AM MED ASSOC, V257, P2618; 1985, EUROPEAN HLTH ALL SE, V1; 1991, OFF J EEC; 1991, III916390EN; 1986, JAMA-J AM MED ASSOC, V255, P522; 1992, OFF J EEC; 1992, EUROPEAN COMMISSION	8	24	26	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 30	1994	344	8918					282	282						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ233	7914258				2022-12-01	WOS:A1994NZ23300004
J	COWLEY, S; PATERSON, H; KEMP, P; MARSHALL, CJ				COWLEY, S; PATERSON, H; KEMP, P; MARSHALL, CJ			ACTIVATION OF MAP KINASE KINASE IS NECESSARY AND SUFFICIENT FOR PC12 DIFFERENTIATION AND FOR TRANSFORMATION OF NIH 3T3 CELLS	CELL			English	Article							NERVE GROWTH-FACTOR; SIGNAL-REGULATED KINASE; RAF-1 PROTEIN-KINASE; MONOCLONAL-ANTIBODIES; TRANSCRIPTION FACTOR; TYROSINE KINASE; IN-VITRO; RAS; TRANSDUCTION; CASCADE	The MAP kinase pathway is activated by a wide variety of external signals leading to cell proliferation or differentiation. However, it is not clear whether activation of this pathway is required for cellular responses or whether it is only one branch point in signal transduction. To investigate these questions, we generated constitutively activated and interfering mutants of MAP kinase kinase 1. The activated mutants stimulated PC12 cell neuronal differentiation and transformed NIH 3T3 cells. The interfering mutants inhibited growth factor-induced PC12 differentiation, growth factor stimulation of proliferation, and reverted v-src- and ras-transformed cells. These results therefore show that, depending on cellular context, activation of MAP kinase kinase is necessary and sufficient for cell differentiation or proliferation.			COWLEY, S (corresponding author), INST CANC RES,CHESTER BEATTY LABS,DEPT CELL & MOLEC BIOL,237 FULHAM RD,LONDON SW3 6JB,ENGLAND.			Cowley, Sally/0000-0003-0297-6675				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COUGHLIN SR, 1989, SCIENCE, V243, P1191; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HANCOCK JF, 1988, ONCOGENE, V3, P187; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUGHES DA, 1993, SCIENCE, V260, P1937; KUNG HF, 1986, EXP CELL RES, V162, P363, DOI 10.1016/0014-4827(86)90341-1; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAU AF, 1979, P NATL ACAD SCI USA, V76, P3904, DOI 10.1073/pnas.76.8.3904; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEEVES SJ, 1993, THESIS U LONDON; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1985, PROC R SOC SER B-BIO, V226, P99, DOI 10.1098/rspb.1985.0084; MASHALL C, 1994, CURR OPIN CELL BIOL, V4, P82; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAITO Y, 1994, FEBS LETT, V341, P119, DOI 10.1016/0014-5793(94)80252-1; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SETH A, 1991, J BIOL CHEM, V266, P23521; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VANHOOFF COM, 1989, J CELL BIOL, V108, P1115, DOI 10.1083/jcb.108.3.1115; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	57	1903	1949	1	98	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 17	1994	77	6					841	852		10.1016/0092-8674(94)90133-3	http://dx.doi.org/10.1016/0092-8674(94)90133-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	7911739				2022-12-01	WOS:A1994NT33100009
J	MOSS, G; COHEN, S				MOSS, G; COHEN, S			TIME TO ABANDON BRUSSELS BID ON PATENTS .2.	NATURE			English	Article								After six years of debate, the European Commission's attempts to harmonize biotechnology legislation still face opposition over the patenting of genes. Recent legal experience suggests that its efforts are unnecessary.			MOSS, G (corresponding author), TAYLOR JOYNSON GARRETT,LONDON EC4Y 0DX,ENGLAND.								0	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					384	384		10.1038/372384a0	http://dx.doi.org/10.1038/372384a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PU287	7969499				2022-12-01	WOS:A1994PU28700061
J	HU, H; WATANABE, H; PAYTON, M; KORRICK, S; ROTNITZKY, A				HU, H; WATANABE, H; PAYTON, M; KORRICK, S; ROTNITZKY, A			THE RELATIONSHIP BETWEEN BONE LEAD AND HEMOGLOBIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							X-RAY-FLUORESCENCE; OCCUPATIONAL EXPOSURE; BLOOD LEAD; INVIVO; BURDEN	Objective.-To determine whether the concentration of lead in bone constitutes a biological marker that is more sensitive for chronic toxicity than blood lead levels. Design.-Survey. Setting.-A construction trade union with members who engage in carpentry, demolition, and other construction activities. Participants.-Members of the construction trade union. Main Outcome Measures.-We measured blood pressure, serum creatinine, hematocrit, and hemoglobin. We measured blood lead by anodic stripping voltametry and used a cadmium 109 K x-ray fluorescence instrument to make in vivo measurements of lead in the tibia (a heavily cortical bone) and the patella (a heavily trabecular bone). Information was also collected on medical history, smoking, and alcohol ingestion. Results.-Bone lead levels in the patella were found to be significantly correlated with a decrease in hemoglobin and hematocrit, even after adjusting for age, blood lead, body mass index, cigarette smoking, and alcohol ingestion and removing outliers. Blood lead levels were low (mean=0.40 mu mol/L [8.3 mu g/dl]) and were not correlated with either hemoglobin or hematocrit. In the final multivariate regression model that corrected for measurement error, an increase in patella bone lead level from the lowest to highest quintile in this study population (37 mu g/g) was associated with a decrease in hemoglobin and hematocrit of 11 g/L (95% confidence interval [Cl], 2.7 to 19.3 g/L) and 0.03 (95% Cl, 0.01 to 0.05), respectively. Conclusion.-We conclude that patella bone lead levels are associated with decreased hematocrit and hemoglobin levels despite the presence of low blood lead levels. This conclusion may reflect a subclinical effect of bone lead stores on hematopoiesis and is the first epidemiological evidence that bone lead may be an important biological marker of ongoing chronic toxicity.	HARVARD UNIV,SCH PUBL HLTH,DEPT ENVIRONM HLTH,OCCUPAT HLTH PROGRAM,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; OSAKA MED COLL,OSAKA,JAPAN	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Osaka Medical College	HU, H (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,CHANNING LAB,180 LONGWOOD AVE,BOSTON,MA 02115, USA.				NIEHS NIH HHS [P42-ES05947, 2 P30 ES 00002, ES 05257-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005257, P42ES005947, P30ES000002] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARMSTRONG R, 1992, BRIT J IND MED, V49, P14; ARO ACA, IN PRESS PHYS MED BI; BARRY PSI, 1970, BRIT J IND MED, V27, P339; Burger D E, 1990, Basic Life Sci, V55, P287; CHRISTOFFERSSON JO, 1986, ARCH ENVIRON HEALTH, V41, P312, DOI 10.1080/00039896.1986.9936703; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Fuller WayneA., 2009, MEASUREMENT ERROR MO, V305; GERHARDSSON L, 1992, BRIT J IND MED, V49, P186; GOLDMAN RH, 1994, AM J IND MED, V25, P417, DOI 10.1002/ajim.4700250309; GORDON CL, 1993, BRIT J IND MED, V50, P637; GOYER RA, 1993, ENVIRON HEALTH PERSP, V100, P177, DOI 10.2307/3431524; GRAZIANO JH, 1991, ARCH ENVIRON HEALTH, V46, P347, DOI 10.1080/00039896.1991.9934401; HAJEM S, 1990, ENVIRON RES, V53, P105, DOI 10.1016/S0013-9351(05)80113-6; HERNBERG S, 1967, ARCH ENVIRON HEALTH, V14, P319, DOI 10.1080/00039896.1967.10664739; HU H, 1989, ENVIRON RES, V49, P295, DOI 10.1016/S0013-9351(89)80074-X; Hu H, 1990, Basic Life Sci, V55, P267; HU H, 1990, ARCH ENVIRON HEALTH, V45, P335, DOI 10.1080/00039896.1990.10118752; HU H, 1991, AM J IND MED, V20, P723, DOI 10.1002/ajim.4700200603; HU H, IN PRESS ENV HLTH PE; JONES KW, 1987, IN VIVO BODY COMPOSI, P363; KOSNETT MJ, 1994, JAMA-J AM MED ASSOC, V271, P197, DOI 10.1001/jama.271.3.197; LANDRIGAN PJ, 1994, JAMA-J AM MED ASSOC, V271, P239, DOI 10.1001/jama.271.3.239; LIPPMANN M, 1990, ENVIRON RES, V51, P1, DOI 10.1016/S0013-9351(05)80179-3; MANTON WI, 1985, BRIT J IND MED, V42, P168; MARCUS AH, 1985, ENVIRON RES, V36, P473, DOI 10.1016/0013-9351(85)90039-8; MORGAN WD, 1990, BIOL TRACE ELEM RES, V26-7, P407, DOI 10.1007/BF02992695; NILSSON U, 1991, PHARMACOL TOXICOL, V69, P477; OFLAHERTY EJ, 1991, TOXICOL APPL PHARM, V111, P313, DOI 10.1016/0041-008X(91)90033-B; RABINOWITZ MB, 1991, ENVIRON HEALTH PERSP, V91, P33, DOI 10.2307/3430979; RABINOWITZ MB, 1976, J CLIN INVEST, V58, P260, DOI 10.1172/JCI108467; ROSNER B, 1983, TECHNOMETRICS, V25, P165, DOI 10.2307/1268549; SALTZMAN BE, 1990, ENVIRON RES, V52, P126, DOI 10.1016/S0013-9351(05)80248-8; SCHILTZ A, 1987, ARCH ENVIRON HEALTH, V42, P340; SCHROEDER HA, 1968, ARCH ENVIRON HEALTH, V17, P965, DOI 10.1080/00039896.1968.10665354; SCHWARTZ J, 1990, AM J PUBLIC HEALTH, V80, P165, DOI 10.2105/AJPH.80.2.165; SILBERGELD EK, 1991, ENVIRON HEALTH PERSP, V91, P63, DOI 10.2307/3430984; SOKAS RK, 1990, ARCH ENVIRON HEALTH, V45, P268, DOI 10.1080/00039896.1990.10118744; SOMERVAILLE LJ, 1985, PHYS MED BIOL, V30, P929, DOI 10.1088/0031-9155/30/9/005; SOMERVAILLE LJ, 1988, BRIT J IND MED, V45, P174; WATANABE H, 1994, AM J IND MED, V26, P255, DOI 10.1002/ajim.4700260211; Wedeen R P, 1988, Contrib Nephrol, V64, P102; WIELOPOLSKI L, 1986, AM J IND MED, V9, P221; WITTMERS LE, 1988, ARCH ENVIRON HEALTH, V43, P381, DOI 10.1080/00039896.1988.9935855	43	72	74	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	1994	272	19					1512	1517		10.1001/jama.272.19.1512	http://dx.doi.org/10.1001/jama.272.19.1512			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ900	7966843				2022-12-01	WOS:A1994PQ90000030
J	SILVER, MT; ROSE, GA; PAUL, SD; ODONNELL, CJ; OGARA, PT; EAGLE, KA				SILVER, MT; ROSE, GA; PAUL, SD; ODONNELL, CJ; OGARA, PT; EAGLE, KA			A CLINICAL RULE TO PREDICT PRESERVED LEFT-VENTRICULAR EJECTION FRACTION IN PATIENTS AFTER MYOCARDIAL-INFARCTION	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL INFARCTION; VENTRICULAR FUNCTION, LEFT; STROKE VOLUME; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; PREDICTION RULES		Objective: To derive and validate a clinical prediction rule that identifies patients after myocardial infarction who have preserved left ventricular systolic function. Design: Retrospective analysis of a prospective cohort study, with a derivation set to generate a clinical prediction rule and a validation set to test the prediction rule. Setting: Urban tertiary care hospital. Patients: 314 consecutive patients admitted with myocardial infarction who had one or more of the following tests to determine left ventricular ejection fraction: transthoracic echocardiography, contrast left ventriculography, or radionuclide ventriculography. Measurements: Left ventricular ejection fractions were determined by transthoracic echocardiography, contrast left ventriculography, and gated blood pool scan. Results: Multivariate analysis of patients in the derivation set yielded the following rule: The left ventricular ejection fraction is predicted to be 40% or more in patients who have 1) an interpretable electrocardiogram, 2) no previous Q-wave myocardial infraction, 3) no history of congestive heart failure, and 4) an index myocardial infarction that is not a Q-wave anterior infarction. In the derivation and the validation sets, the positive predictive value of the prediction rule was more than 0.98. Conclusions: A simple clinical prediction rule using easily obtained historical and electrocardiographic data reliably identifies a substantial percentage of patients after myocardial infarction (40% in our hospital) who are likely to have preserved left ventricular systolic function. If validated in other patient populations, application of this prediction rule in clinical practice could result in a substantial decrease in the cost of treating uncomplicated myocardial infarction.	MASSACHUSETTS GEN HOSP, CTR AMBULATORY CARE 475, CARDIAC UNIT, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School				Karavite, Dean/0000-0003-0554-5715				DEPACE NL, 1982, AM J CARDIOL, V50, P1262, DOI 10.1016/0002-9149(82)90460-X; EAGLE KA, 1988, ARCH INTERN MED, V148, P882, DOI 10.1001/archinte.148.4.882; ESTES EH, 1974, HEART, P297; FEIGENBAUM H, 1986, ECHOCARDIOGR-J CARD, P153; FIFER MA, 1991, CARDIAC CATHETERIZAT, P303; Gunnar R M, 1990, Circulation, V82, P664; HAMBY RI, 1985, AM HEART J, V109, P338, DOI 10.1016/0002-8703(85)90604-0; MADSEN EB, 1983, AM J CARDIOL, V51, P1579, DOI 10.1016/0002-9149(83)90190-X; MATTLEMAN SJ, 1983, J AM COLL CARDIOL, V1, P417, DOI 10.1016/S0735-1097(83)80068-0; MCNAMARA RF, 1988, AM J CARDIOL, V62, P192, DOI 10.1016/0002-9149(88)90210-X; MONSOUR MJ, 1991, STAT MED, V10, P443, DOI 10.1002/sim.4780100316; PALMERI ST, 1982, NEW ENGL J MED, V306, P4, DOI 10.1056/NEJM198201073060102; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PICARD MH, 1992, AM HEART J, V124, P24, DOI 10.1016/0002-8703(92)90916-J; TAYLOR GJ, 1980, CIRCULATION, V62, P960, DOI 10.1161/01.CIR.62.5.960; 1990, HLTH FACTS	16	35	35	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1994	121	10					750	756		10.7326/0003-4819-121-10-199411150-00004	http://dx.doi.org/10.7326/0003-4819-121-10-199411150-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ928	7944052				2022-12-01	WOS:A1994PQ92800004
J	MA, JY; YEE, A; BREWER, HB; DAS, S; POTTER, H				MA, JY; YEE, A; BREWER, HB; DAS, S; POTTER, H			AMYLOID-ASSOCIATED PROTEINS ALPHA(1)-ANTICHYMOTRYPSIN AND APOLIPOPROTEIN-E PROMOTE ASSEMBLY OF ALZHEIMER BETA-PROTEIN INTO FILAMENTS	NATURE			English	Article							INHIBITOR ALPHA-1-ANTICHYMOTRYPSIN; TYPE-4 ALLELE; DISEASE; PEPTIDE; DEPOSITS; BINDING; INVITRO; METABOLISM; FIBRILS; PLAQUE	THE protease inhibitor alpha(1)-antichymotrypsin and the lipid transport protein apolipoprotein E (apoE) are intimately associated with the 42-amino-acid beta-peptide (A beta) in the filamentous amyloid deposits of Alzheimer's disease(1-3). We report here that these two amyloid-associated proteins serve a strong stimulatory role in the polymerization of A beta into amyloid filaments. Addition of either alpha(1)-antichymotrypsin or apoE to the A beta peptide promoted a 10- to 20-fold increase in filament formation, with apoE-4, the isoform recently linked to the development of late-onset Alzheimer's disease, showing the highest catalytic activity. These and other experiments suggest that Alzheimer amyloid deposits arise when A beta is induced to form filaments by amyloid-promoting factors (pathological chaperones) expressed in certain brain regions.	NHLBI,BETHESDA,MD 20892; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Harvard Medical School			Das, Saumya/R-7644-2019	Potter, Huntington/0000-0002-4051-2516; Das, Saumya/0000-0002-4521-4606				ABRAHAM CR, 1990, NEUROBIOL AGING, V11, P123, DOI 10.1016/0197-4580(90)90045-2; ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; CASTANO EM, 1986, BIOCHEM BIOPH RES CO, V141, P782, DOI 10.1016/S0006-291X(86)80241-8; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DAS S, IN PRESS NEURON; DOVEY HF, 1993, NEUROREPORT, V4, P1039, DOI 10.1097/00001756-199308000-00011; FRASER PE, 1993, J NEUROCHEM, V61, P298, DOI 10.1111/j.1471-4159.1993.tb03568.x; GREGG RE, 1986, J CLIN INVEST, V78, P815, DOI 10.1172/JCI112645; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; KOO EH, 1991, NEUROBIOL AGING, V12, P495, DOI 10.1016/0197-4580(91)90079-Y; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; PASTERNACK JM, 1989, AM J PATHOL, V135, P827; PICKEN MM, 1990, J NEUROPATH EXP NEUR, V49, P41, DOI 10.1097/00005072-199001000-00005; POTTER H, 1991, ALZHEIMERS DISEASE : BASIC MECHANISMS, DIAGNOSIS AND THERAPEUTIC STRATEGIES, P275; POTTER H, 1992, ANN NY ACAD SCI, V674, P161, DOI 10.1111/j.1749-6632.1992.tb27485.x; PROBST A, 1987, ACTA NEUROPATHOL, V74, P133, DOI 10.1007/BF00692843; REBECK GW, 1993, NEURON, V11, P575; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROZEMULLER JM, 1991, ACTA NEUROPATHOL, V82, P200, DOI 10.1007/BF00294446; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; WISNIEWSKI T, 1993, BIOCHEM BIOPH RES CO, V192, P359, DOI 10.1006/bbrc.1993.1423; WISNIEWSKI T, IN PRESS AM J PATH	31	846	864	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					92	94		10.1038/372092a0	http://dx.doi.org/10.1038/372092a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969426				2022-12-01	WOS:A1994PQ34800079
J	KROLL, KL; GERHART, JC				KROLL, KL; GERHART, JC			TRANSGENIC X-LAEVIS EMBRYOS FROM EGGS TRANSPLANTED WITH NUCLEI OF TRANSFECTED CULTURED-CELLS	SCIENCE			English	Article							XENOPUS-LAEVIS; OOCYTES; GENE; RANA	Transgenic Xenopus laevis embryos were produced by transplantation of transfected cultured cell nuclei into unfertilized eggs. A Xenopus cell line, X-C, was stably transfected with plasmids containing a hygromycin-resistance gene and genes for either beta-galactosidase with a heat shock promoter or chloramphenicol acetyltransferase (CAT) with a muscle-specific actin promoter. Nuclei transplanted from these cells into unfertilized eggs directed development of embryos containing stably integrated copies of the plasmids in each cell. Transgenic embryos showed somite-specific expression of CAT and uniform expression of beta-galactosidase. Transgenic embryos produced by nuclear transplantation should be useful for testing the function of cloned genes in amphibian development.			KROLL, KL (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, 229 STANLEY HALL, BERKELEY, CA 94720 USA.			Kroll, Kristen/0000-0002-5450-6694	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019363, R37GM019363, T32GM007232] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07232, GM19363] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIENZ M, 1984, EMBO J, V3, P2477, DOI 10.1002/j.1460-2075.1984.tb02159.x; BRIGGS R, 1952, P NATL ACAD SCI USA, V38, P455, DOI 10.1073/pnas.38.5.455; BRUN RB, 1978, DEV BIOL, V65, P271, DOI 10.1016/0012-1606(78)90027-1; DENT JA, 1989, DEVELOPMENT, V105, P61; DIBERARDINO MA, 1992, DIFFERENTIATION, V50, P1, DOI 10.1111/j.1432-0436.1992.tb00480.x; DIBERARDINO MA, 1983, SCIENCE, V219, P862, DOI 10.1126/science.6600520; DIBERARDINO MA, 1970, DEV BIOL, V23, P185, DOI 10.1016/0012-1606(70)90094-1; DIBERARDINO MA, 1987, AM ZOOL, V27, P623; ETKIN LD, 1987, DEVELOPMENT, V99, P15; FELGNER PL, 1989, NATURE, V337, P387, DOI 10.1038/337387a0; Gurdon J.B., 1979, International Review of Cytology Supplement, P161; Gurdon J.B., 1977, Methods Cell Biol, V16, P125; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; GURDON JB, 1986, J CELL SCI, P287; GURDON JB, 1960, Q J MICROSC SCI, V101, P299; GURDON JB, 1970, J EMBRYOL EXP MORPH, V24, P227; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; LASKEY RA, 1970, NATURE, V228, P1332, DOI 10.1038/2281332a0; MOHUN TJ, 1986, EMBO J, V5, P3185, DOI 10.1002/j.1460-2075.1986.tb04628.x; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SUBTELNY S, 1965, J EXP ZOOL, V159, P59, DOI 10.1002/jez.1401590107; TOMPKINS R, 1978, J EXP ZOOL, V203, P251, DOI 10.1002/jez.1402030207; TYMOWSKA J, 1972, CYTOGENETICS, V11, P270, DOI 10.1159/000130197; VIZE PD, 1991, METHOD CELL BIOL, V36, P367	25	33	35	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 28	1994	266	5185					650	653		10.1126/science.7939720	http://dx.doi.org/10.1126/science.7939720			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939720				2022-12-01	WOS:A1994PN80700048
J	TOPILKO, P; SCHNEIDERMAUNOURY, S; LEVI, G; BARONVANEVERCOOREN, A; CHENNOUFI, AB; SEITANIDOU, T; BABINET, C; CHARNAY, P				TOPILKO, P; SCHNEIDERMAUNOURY, S; LEVI, G; BARONVANEVERCOOREN, A; CHENNOUFI, AB; SEITANIDOU, T; BABINET, C; CHARNAY, P			KROX-20 CONTROLS MYELINATION IN THE PERIPHERAL NERVOUS-SYSTEM	NATURE			English	Article							SCHWANN-CELLS; BASIC-PROTEIN; PO PROTEIN; GLYCOPROTEIN; MOUSE; GENE; EXPRESSION; MICE; MOLECULES; ABSENCE	THE molecular mechanisms controlling the process of myelination by Schwann cells remain elusive, despite recent progress in the identification and characterization of genes encoding myelin components (reviewed in ref. 1). We have created a null allele in the mouse Krox-20 gene, which encodes a zinc-finger transcription factor(2,3), by in-frame insertion of the Escherichia coli lacZ gene, and have shown that hindbrain segmentation is affected in Krox-20(-/-) embryos(4). We demonstrate here that Krox-20 is also activated in Schwann cells before the onset of myelination and that its disruption blocks Schwann cells at an early stage in their differentiation, thus preventing myelination in the peripheral nervous system. In Krox-20(-/-) mice, Schwann cells wrap their cytoplasmic processes only one and a half turns around the axon, and although they express the early myelin marker, myelin-associated glycoprotein(5), late myelin gene products are absent, including those for protein zero(6) and myelin basic protein(7). Therefore Krox-20 is likely to control a set of genes required for completion of myelination in the peripheral nervous system.	ADV BIOTECHNOL CTR,I-16132 GENOA,ITALY; HOP LA PITIE SALPETRIERE,INSERM,U134,F-75651 PARIS 13,FRANCE; INST PASTEUR,CNRS,URA 361,F-75724 PARIS 15,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	TOPILKO, P (corresponding author), ECOLE NORMALE SUPER,INSERM,U368,46 RUE ULM,F-75230 PARIS 05,FRANCE.		Evercooren, Anne S Baron-Van/G-3632-2013; Levi, Giovanni/B-4416-2013; Schneider-Maunoury, Sylvie/K-6795-2017	Schneider-Maunoury, Sylvie/0000-0002-0797-4735; Levi, Giovanni/0000-0002-7041-6787; Charnay, Patrick/0000-0002-3847-6042	Telethon [94] Funding Source: Medline	Telethon(Fondazione Telethon)		BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; BUNGE MB, 1989, DEV NEUROSCI-BASEL, V11, P348, DOI 10.1159/000111911; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FILBIN MT, 1990, NATURE, V344, P871, DOI 10.1038/344871a0; Gabe M., 1968, TECHNIQUES HISTOLOGI, P468; GIESE KP, 1992, CELL, V71, P565, DOI 10.1016/0092-8674(92)90591-Y; GREENFIELD S, 1973, J NEUROCHEM, V20, P1207, DOI 10.1111/j.1471-4159.1973.tb00089.x; HENRY EW, 1988, SCIENCE, V241, P344, DOI 10.1126/science.3388045; JESSEN KR, 1994, NEURON, V12, P509, DOI 10.1016/0896-6273(94)90209-7; KIES MW, 1961, CHEMICAL PATHOLOGY N, P197; KIMURA M, 1989, P NATL ACAD SCI USA, V86, P5661, DOI 10.1073/pnas.86.14.5661; KIRSCHNER DA, 1980, NATURE, V283, P207, DOI 10.1038/283207a0; LEMKE G, 1993, GLIA, V7, P263, DOI 10.1002/glia.440070402; LEVI G, 1987, J CELL BIOL, V105, P2359, DOI 10.1083/jcb.105.5.2359; LI CM, 1994, NATURE, V369, P747, DOI 10.1038/369747a0; OWENS GC, 1990, GLIA, V3, P118, DOI 10.1002/glia.440030205; SCHNEIDERMAUNOU.S, 1993, CELL, V75, P199; TRAPP BD, 1988, J CELL BIOL, V107, P675, DOI 10.1083/jcb.107.2.675; TRAPP BD, 1982, J CELL BIOL, V92, P877, DOI 10.1083/jcb.92.3.877; TRAPP BD, 1984, J CELL BIOL, V99, P594, DOI 10.1083/jcb.99.2.594; UYEMURA K, 1970, BIOCHIM BIOPHYS ACTA, V214, P190, DOI 10.1016/0005-2795(70)90083-8; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0	24	627	631	1	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 27	1994	371	6500					796	799		10.1038/371796a0	http://dx.doi.org/10.1038/371796a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP018	7935840				2022-12-01	WOS:A1994PP01800059
J	HACKETT, M; GUO, L; SHABANOWITZ, J; HUNT, DF; HEWLETT, EL				HACKETT, M; GUO, L; SHABANOWITZ, J; HUNT, DF; HEWLETT, EL			INTERNAL LYSINE PALMITOYLATION IN ADENYLATE-CYCLASE TOXIN FROM BORDETELLA-PERTUSSIS	SCIENCE			English	Article							ESCHERICHIA-COLI PROHAEMOLYSIN; DEPENDENT FATTY ACYLATION; MEMBRANE-TARGETED TOXIN; GRAM-NEGATIVE BACTERIA; ACTIVATION; PROTEINS; RECEPTOR; CYAC; POLYPEPTIDE; HEMOLYSIN	A number of bacterial protein toxins, including adenylate cyclase (AC) toxin from Bordetella pertussis, require the product of an accessory gene in order to express their biological activities. In this study, mass spectrometry was used to demonstrate that activated, wild-type AC toxin was modified by amide-linked palmitoylation on the epsilon-amino group of lysine 983. This modification was absent from a mutant in which the accessory gene had been disrupted. A synthetic palmitoylated peptide corresponding to the tryptic fragment (glutamine 972 to arginine 984) that contained the acylation blocked AC toxin-induced accumulation of adenosine 3',5'-monophosphate, whereas the nonacylated peptide had no effect.	UNIV VIRGINIA,SCH MED,DEPT MED,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,SCH MED,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22901; UNIV VIRGINIA,DEPT PATHOL,CHARLOTTESVILLE,VA 22901	University of Virginia; University of Virginia; University of Virginia; University of Virginia			Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038942] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER; NIAID NIH HHS [R0-1 AI18000] Funding Source: Medline; NIDDK NIH HHS [DK38942] Funding Source: Medline; NIGMS NIH HHS [GM37537] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOTT D, 1993, CLIN CHEM, V39, P2005; BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; BEAVIS RC, 1992, ORG MASS SPECTROM, V27, P156, DOI 10.1002/oms.1210270217; BELLALOU J, 1990, INFECT IMMUN, V58, P1195, DOI 10.1128/IAI.58.5.1195-1200.1990; BETSOU F, 1993, INFECT IMMUN, V61, P3583, DOI 10.1128/IAI.61.9.3583-3589.1993; BROOKER G, 1976, SCIENCE, V194, P270, DOI 10.1126/science.184530; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; COOTE JG, 1992, FEMS MICROBIOL LETT, V88, P137, DOI 10.1016/0378-1097(92)90688-K; EHRMANN IE, 1991, FEBS LETT, V278, P79, DOI 10.1016/0014-5793(91)80088-K; Galazka Artur, 1992, World Health Statistics Quarterly, V45, P238; GLASER P, 1988, MOL MICROBIOL, V2, P19, DOI 10.1111/j.1365-2958.1988.tb00003.x; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; Guo L., UNPUB; HARDIE KR, 1991, MOL MICROBIOL, V5, P1669, DOI 10.1111/j.1365-2958.1991.tb01914.x; HEDO JA, 1987, J BIOL CHEM, V262, P954; HEWLETT EL, 1991, J BIOL CHEM, V266, P17503; HEWLETT EL, 1989, J BIOL CHEM, V264, P19379; HEWLETT EL, 1993, J BIOL CHEM, V268, P7842; HUGHES C, 1992, FEMS MICROBIOL IMMUN, V105, P37, DOI 10.1111/j.1574-6968.1992.tb05884.x; HUNT DF, 1991, TECHNIQUES PROTEIN C, pCH43; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; LOWRY OH, 1951, J BIOL CHEM, V193, P265; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OLSON EN, 1984, J BIOL CHEM, V259, P5364; PEARSON RD, 1987, J IMMUNOL, V139, P2749; PELLETT S, 1990, INFECT IMMUN, V58, P822, DOI 10.1128/IAI.58.3.822-827.1990; PILLAI S, 1987, P NATL ACAD SCI USA, V84, P7654, DOI 10.1073/pnas.84.21.7654; ROGEL A, 1991, J BIOL CHEM, V266, P3154; SCHLESINGER MJ, 1993, LIPID MODIFICATION P, P1; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; STEVENSON FT, 1993, P NATL ACAD SCI USA, V90, P7245, DOI 10.1073/pnas.90.15.7245; STEVENSON FT, 1992, J EXP MED, V176, P1053, DOI 10.1084/jem.176.4.1053; SZABO G, IN PRESS J BIOL CHEM; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEISS AA, 1983, INFECT IMMUN, V42, P33, DOI 10.1128/IAI.42.1.33-41.1983; WELCH RA, 1991, MOL MICROBIOL, V5, P521, DOI 10.1111/j.1365-2958.1991.tb00723.x; 1992, 40TH P AM SOC MASS S	39	198	204	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 21	1994	266	5184					433	435		10.1126/science.7939682	http://dx.doi.org/10.1126/science.7939682			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7939682				2022-12-01	WOS:A1994PN27200034
J	ENSOLI, B; GENDELMAN, R; MARKHAM, P; FIORELLI, V; COLOMBINI, S; RAFFELD, M; CAFARO, A; CHANG, HK; BRADY, JN; GALLO, RC				ENSOLI, B; GENDELMAN, R; MARKHAM, P; FIORELLI, V; COLOMBINI, S; RAFFELD, M; CAFARO, A; CHANG, HK; BRADY, JN; GALLO, RC			SYNERGY BETWEEN BASIC FIBROBLAST GROWTH-FACTOR AND HIV-I TAT PROTEIN IN INDUCTION OF KAPOSIS-SARCOMA	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MELANOMA CELL INVASION; LONG-TERM CULTURE; GENE-EXPRESSION; ENDOTHELIAL-CELLS; BASEMENT-MEMBRANE; HTLV-III; AIDS; ANGIOGENESIS; COLLAGENASE	Basic fibroblast growth factor (bFGF) and human immunodeficiency virus type 1 (HIV-1) Tat protein synergize in inducing angiogenic Kaposi's sarcoma-like lesions in mice. Synergy is due to Tat, which enhances endothelial cell growth and type-IV collagenase expression in response to bFGF mimicking extracellular matrix proteins. The bFGF, extracellular Tat and Tat receptors are present in HIV-1-associated KS, which may explain the higher frequency and aggressiveness of this form compared to classical Kaposi's sarcoma where only bFGF is present.	NCI,MOLEC VIROL LAB,BETHESDA,MD 20892; ADV BIOSCI LABS INC,KENSINGTON,MD 20895; HENRY M JACKSON FDN,ROCKVILLE,MD 20850	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc	ENSOLI, B (corresponding author), NCI,TUMOR CELL BIOL LAB,BETHESDA,MD 20892, USA.		Ensoli, Barbara/J-9169-2016; Cafaro, Aurelio/K-5314-2016	Ensoli, Barbara/0000-0002-0545-8737; Cafaro, Aurelio/0000-0001-9675-6344				ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; ALBINI A, IN PRESS P NATN ACAD; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; BARILLARI G, 1992, J IMMUNOL, V149, P3727; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CORDONCARDO C, 1990, LAB INVEST, V63, P832; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; ENSOLI B, 1991, HEMATOL ONCOL CLIN N, V5, P281, DOI 10.1016/S0889-8588(18)30441-6; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; ENSOLI B, IN PRESS J CLIN INVE; FAN J, 1993, J IMMUNOL, V151, P5031; FAWELL S, 1994, P NATL ACAD SCI USA, V31, P664; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FUCHS D, 1992, J ACQ IMMUN DEF SYND, V5, P424; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GAY CG, 1991, P NATL ACAD SCI USA, V88, P296, DOI 10.1073/pnas.88.1.296; HOBER D, 1989, CLIN EXP IMMUNOL, V78, P329; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INGBER D, 1991, J CELL BIOCHEM, V47, P236, DOI 10.1002/jcb.240470309; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MAHONEY SE, 1991, J CLIN INVEST, V88, P174, DOI 10.1172/JCI115275; MIGNATTI P, 1989, J CELL BIOL, V108, P671, DOI 10.1083/jcb.108.2.671; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; NAKAMURA S, 1988, SCIENCE, V242, P426, DOI 10.1126/science.3262925; OKAMURA K, 1991, J BIOL CHEM, V266, P19162; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; REGEZI JA, 1993, AM J PATHOL, V143, P240; RUSZCZAK Z, 1987, AM J DERMATOPATH, V9, P388, DOI 10.1097/00000372-198710000-00004; SAFAI B, 1985, ANN INTERN MED, V103, P744, DOI 10.7326/0003-4819-103-5-744; SALAHUDDIN SZ, 1988, SCIENCE, V242, P430, DOI 10.1126/science.2459779; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; SEFTOR REB, 1993, CANCER RES, V53, P3411; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; XERRI L, 1991, AM J PATHOL, V138, P9; YANG J, 1994, J IMMUNOL, V152, P223; ZHANG YM, 1994, AM J PATHOL, V144, P51; 1982, NEW ENGL J MED, V306, P248	43	514	523	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 20	1994	371	6499					674	680		10.1038/371674a0	http://dx.doi.org/10.1038/371674a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM773	7935812				2022-12-01	WOS:A1994PM77300047
J	MILLSTONE, E; BRUNNER, E; WHITE, I				MILLSTONE, E; BRUNNER, E; WHITE, I			PLAGIARISM OR PROTECTING PUBLIC-HEALTH	NATURE			English	Editorial Material									UCL, DEPT EPIDEMIOL, LONDON WC1E 6EA, ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED, MED STAT UNIT, LONDON WC1E 7HT, ENGLAND	University of London; University College London; University of London; London School of Hygiene & Tropical Medicine	MILLSTONE, E (corresponding author), UNIV SUSSEX, SCI POLICY RES UNIT, BRIGHTON BN1 9RF, E SUSSEX, ENGLAND.		Brunner, Eric/H-2114-2011	Brunner, Eric/0000-0002-0595-4474; White, Ian/0000-0002-6718-7661				AHMAD SR, 1993, LANCET, V341, P1018, DOI 10.1016/0140-6736(93)91098-7; GERBARG ZB, 1988, J CLIN EPIDEMIOL, V41, P503, DOI 10.1016/0895-4356(88)90053-4; Millstone E. P., 1989, BST MASTITIS PRELIMI; MORSE L, 1994, FINANC TIMES, P22; PEEL CJ, 1989, BIOTECHNOLOGY GROWTH, P110; Phipps R. H., 1989, Use of somatotropin in livestock production., P88; WHITE TC, 1994, J DAIRY SCI, V77, P2249, DOI 10.3168/jds.S0022-0302(94)77168-X; 1993, MILK MARKETING BOARD; 1986, BOVINE SOMATOTROPIN	9	14	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 20	1994	371	6499					647	648		10.1038/371647a0	http://dx.doi.org/10.1038/371647a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM773	7935806				2022-12-01	WOS:A1994PM77300022
J	AMBACH, W				AMBACH, W			OCCUPATIONAL LOW-DOSE EXPOSURE TO IONIZING-RADIATION	LANCET			English	Editorial Material											AMBACH, W (corresponding author), UNIV INNSBRUCK, INST MED PHYS, A-6020 INNSBRUCK, AUSTRIA.							Ennemoser O., 1993, Lancet (North American Edition), V341, P828, DOI 10.1016/0140-6736(93)90603-E; PERSHAGEN G, 1994, NEW ENGL J MED, V330, P159, DOI 10.1056/NEJM199401203300302; 1991, IRCP60 INT COMM RAD; 1990, BEIR5 COMM BIOL EFF	4	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1037	1037		10.1016/S0140-6736(94)91704-3	http://dx.doi.org/10.1016/S0140-6736(94)91704-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7934441				2022-12-01	WOS:A1994PL85200004
J	CLAGUE, JE; HORAN, MA				CLAGUE, JE; HORAN, MA			URINE CULTURE IN THE ELDERLY - SCIENTIFICALLY DOUBTFUL AND PRACTICALLY USELESS	LANCET			English	Editorial Material							BACTERIURIA; POPULATION				CLAGUE, JE (corresponding author), UNIV MANCHESTER,WITHINGTON HOSP,DEPT GERIATR MED,MANCHESTER M20 8LR,LANCS,ENGLAND.							ABRUTYN E, 1994, ANN INTERN MED, V120, P827, DOI 10.7326/0003-4819-120-10-199405150-00003; BOSCIA JA, 1986, AM J MED, V81, P979, DOI 10.1016/0002-9343(86)90391-8; BOSCIA JA, 1986, AM J MED, V80, P208, DOI 10.1016/0002-9343(86)90011-2; BROCKLEHURST J C, 1977, Age and Ageing, V6, P240; BROCKLEHURST JC, 1968, GERONTOL CLIN, V10, P242, DOI 10.1159/000245189; DONTAS AS, 1977, AGE AGEING, V16, P215; ELLIOTT TSJ, 1985, J INFECTION, V11, P191, DOI 10.1016/S0163-4453(85)92997-4; GUTMAN SI, 1987, AM J CLIN PATHOL, V88, P204, DOI 10.1093/ajcp/88.2.204; KASS EH, 1956, T ASSOC AM PHYSICIAN, V69, P56; NICOLLE LE, 1987, AM J MED, V83, P27, DOI 10.1016/0002-9343(87)90493-1; NORDENSTAM GR, 1986, NEW ENGL J MED, V314, P1152, DOI 10.1056/NEJM198605013141804	11	19	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1035	1036		10.1016/S0140-6736(94)91702-7	http://dx.doi.org/10.1016/S0140-6736(94)91702-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7934439				2022-12-01	WOS:A1994PL85200002
J	FEDSON, DS				FEDSON, DS			ADULT IMMUNIZATION - SUMMARY OF THE NATIONAL VACCINE ADVISORY-COMMITTEE REPORT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; CHANGING EPIDEMIOLOGY; MISSED OPPORTUNITIES; RUBELLA; TRANSMISSION; RESURGENCE; INFLUENZA; POLICIES; MEASLES; IMPACT	In January 1994 the National Vaccine Advisory Committee adopted a report that reviewed the status of adult immunization in the United States. Vaccine-preventable infections of adults represent a continuing cause of morbidity and mortality. Their major impact is among older persons. Effective and safe vaccines against these diseases are available, but they are poorly used. Several reasons account for low immunization levels among adults, including inadequate awareness by health care providers and the public of the importance and benefits of vaccination. Health care providers often fail to take advantage of opportunities to immunize adults during office, clinic, and hospital contacts and fail to organize programs in medical settings that ensure adults are offered the vaccines they need. Inadequate reimbursement for adult immunization by public and private health insurers and a lack of federal programs to support vaccine delivery are also major problems. The National Vaccine Advisory Committee's report includes five goals and 18 recommendations for improving adult immunization. To reach the Public Health Service adult immunization goals for the year 2000, the Committee recommends (1) improvements in public and provider education; (2) major changes in clinical practice; (3) increased financial support by public and private health insurers; (4) improved surveillance of vaccine-preventable diseases and vaccine production and delivery; and (5) support for research on vaccine-preventable diseases, new and improved vaccines, immunization practices, and international programs for adult immunization.			FEDSON, DS (corresponding author), NATL VACCINE PROGRAM OFF,ROCKWALL 2 BLDG,SUITE 1075,5600 FISHERS LN,ROCKVILLE,MD 20852, USA.							ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; ANDERSON K, 1993, OPTIONS CONTROL INFL, V2, P109; [Anonymous], 1989, GUIDE CLIN PREVENTIV; ATKINSON WL, 1991, AM J MED, V91, pS320, DOI 10.1016/0002-9343(91)90389-F; ATKINSON WL, 1992, ANNU REV MED, V43, P451, DOI 10.1146/annurev.me.43.020192.002315; BARTON MB, 1990, AM J PUBLIC HEALTH, V80, P534, DOI 10.2105/AJPH.80.5.534; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826; DEQUADROS CA, 1991, PEDIATR INFECT DIS J, V10, P222, DOI 10.1097/00006454-199103000-00011; Fedson D S, 1992, Clin Geriatr Med, V8, P183; GARDNER P, 1993, NEW ENGL J MED, V328, P1252, DOI 10.1056/NEJM199304293281708; GOODMAN AK, 1987, AM J PUBLIC HEALTH, V77, P725, DOI 10.2105/AJPH.77.6.725; HINMAN AR, 1986, AM J DIS CHILD, V140, P528, DOI 10.1001/archpedi.1986.02140200038022; HOWSON CP, 1992, JAMA-J AM MED ASSOC, V267, P392, DOI 10.1001/jama.267.3.392; LEE SH, 1992, JAMA-J AM MED ASSOC, V267, P2616, DOI 10.1001/jama.267.19.2616; MARINER WK, 1992, HEALTH AFFAIR, V11, P255, DOI 10.1377/hlthaff.11.1.255; MCBEAN AM, 1993, ARCH INTERN MED, V153, P2105, DOI 10.1001/archinte.153.18.2105; MITCHELL VS, 1993, CHILDRENS VACCINE IN; Neustadt RE, 1978, SWINE FLU AFFAIR DEC, P48; PETER G, 1992, NEW ENGL J MED, V327, P1794, DOI 10.1056/NEJM199212173272507; SOSIN DM, 1989, PEDIATRICS, V84, P779; WHARTON M, 1990, ARCH INTERN MED, V150, P47, DOI 10.1001/archinte.150.1.47; WILLIAMS WW, 1988, ANN INTERN MED, V108, P616, DOI 10.7326/0003-4819-108-4-616; 1990, MMWR MORBID MORTAL W, V39, P725; 1994, MMWR MORBID MORTAL W, V43, P144; 1993, JORDAN REPORT ACCELE; 1993, MMWR MORBID MORTAL W, V42, P601; 1991, MMWR MORBID MORTAL W, V40, P1; 1993, MMWR MORBID MORTAL W, V42, P847; 1994, GUIDE ADULT IMMUNIZA; 1994, ADULT IMMUNIZATION; 1994, MMWR MORBID MORTAL W, V43, P1; 1991, DHHS PHS9150212 PUBL; 1993, MMWR MORBID MORTAL W, V42, P501; 1993, MMWR MORBID MORTAL W, V42, P840; 1993, MMWR MORBID MORTAL W, V42, P768; 1994, MMWR MORBID MORTAL W, V43, P57	37	119	122	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 12	1994	272	14					1133	1137		10.1001/jama.272.14.1133	http://dx.doi.org/10.1001/jama.272.14.1133			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK124	7933327				2022-12-01	WOS:A1994PK12400034
J	KADHIM, MA; LORIMORE, SA; HEPBURN, MD; GOODHEAD, DT; BUCKLE, VJ; WRIGHT, EG				KADHIM, MA; LORIMORE, SA; HEPBURN, MD; GOODHEAD, DT; BUCKLE, VJ; WRIGHT, EG			ALPHA-PARTICLE-INDUCED CHROMOSOMAL INSTABILITY IN HUMAN BONE-MARROW CELLS	LANCET			English	Note							LEUKEMIA; RADON; EXPOSURE	alpha-particles, which are ionising radiation of high linear-energy-transfer emitted, for example, from radon or plutonium, pass through tissue as highly structured tracks. Single target cells in the path of the tracks might be damaged by even Tow-dose alpha-irradiation. We found non-clonal cytogenetic aberrations, characterised by a high frequency of chromatid aberrations with chromosome aberrations, in clonal descendants of haemopoietic stem cells after exposure to alpha-particles of bone marrow cells from two of four haematologically normal individuals (up to 25% abnormal metaphases). The data are consistent with a transmissible genetic instability induced in a stem cell resulting in a diversity of aberrations in its clonal progeny many cell divisions later.	MRC,RADIOBIOL UNIT,DIDCOT OX11 0RD,OXON,ENGLAND; NINEWELLS HOSP & MED SCH,DEPT HAEMATOL,DUNDEE,SCOTLAND; JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND	MRC Harwell; University of Dundee; University of Oxford								ALEXANDER FE, 1990, LANCET, V335, P1336; ALEXANDER FE, 1990, LANCET, V336, P1461, DOI 10.1016/0140-6736(90)93176-P; DIONIAN J, 1986, NRPBR196 NAT RAD PRO; GOODHEAD DT, 1988, HEALTH PHYS, V55, P231, DOI 10.1097/00004032-198808000-00015; HENSHAW DL, 1990, LANCET, V335, P1008, DOI 10.1016/0140-6736(90)91071-H; HOLYOAKE TL, 1993, LEUKEMIA, V7, P207; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; LORIMORE SA, 1993, INT J RADIAT BIOL, V63, P655, DOI 10.1080/09553009314450851; LUCIE NP, 1989, LANCET, V2, P99; RICHARDSON RB, 1991, BRIT J RADIOL, V64, P608, DOI 10.1259/0007-1285-64-763-608	10	184	191	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					987	988		10.1016/S0140-6736(94)91643-8	http://dx.doi.org/10.1016/S0140-6736(94)91643-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934432				2022-12-01	WOS:A1994PK97800011
J	SCHEINBERG, IH; STERNLIEB, I				SCHEINBERG, IH; STERNLIEB, I			IS NON-INDIAN CHILDHOOD CIRRHOSIS CAUSED BY EXCESS DIETARY COPPER	LANCET			English	Article							STORAGE DISEASE; LIVER	Indian childhood cirrhosis is generally believed to be caused by toxic excesses of hepatic copper derived from milk boiled in copper vessels. Sporadic cases of a disorder indistinguishable from Indian childhood cirrhosis have appeared in other countries where the toxic hepatic copper has been thought to be derived from drinking water. In published reports of seven 2-year-old or younger infants with non-Indian childhood cirrhosis (five of whom died), the copper content of their drinking water-which the authors considered the essential, if not the sole,aetiological factor-ranged from 0.05 to 6.8 mg Cu/L. We identified three Massachusetts towns in which between 1969 and 1991 there were 64 124 child-years of exposure of children under the age of 6 years to drinking water that contained between 8.5 and 8.8 mg Cu/L. Data from the Massachusetts Department of Public Health showed that there were 135 deaths among these children, but no deaths from cirrhosis or any form of liver disease. These data, and evidence of a genetic aetiology in three of the seven infants reported previously, suggest that non-Indian childhood cirrhosis is an inherited disorder.	ST LUKES ROOSEVELT HOSP,NEW YORK,NY 10019	Mount Sinai St. Luke's; Mount Sinai West	SCHEINBERG, IH (corresponding author), COLUMBIA UNIV,NATL CTR STUDY WILSONS DIS,432 W 58TH ST,SUITE 614,NEW YORK,NY 10019, USA.							ADAMSON M, 1992, GASTROENTEROLOGY, V102, P1771, DOI 10.1016/0016-5085(92)91742-M; ALJAJEH IA, 1994, VIRCHOWS ARCH, V424, P225; GOLDFISCHER S, 1980, AM J PATHOL, V99, P715; LEFKOWITCH JH, 1982, NEW ENGL J MED, V307, P271, DOI 10.1056/NEJM198207293070502; Lim C T, 1979, J Singapore Paediatr Soc, V21, P99; MULLERHOCKER J, 1987, VIRCHOWS ARCH A, V411, P379, DOI 10.1007/BF00713384; MULLERHOCKER J, 1988, PATHOL RES PRACT, V183, P39, DOI 10.1016/S0344-0338(88)80157-2; TANNER MS, 1983, LANCET, V2, P992; TANNER MS, 1986, RECENT ADV PAEDIATRI, V8, P103; WALKERSMITH J, 1973, ARCH DIS CHILD, V48, P476, DOI 10.1136/adc.48.6.476; WEISS M, 1989, ACTA PAEDIATR SCAND, V79, P152; 1993, LEAD COPPER REPORT E; 1991, US FED REG, V56, P26460; [No title captured]	14	55	55	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					1002	1004		10.1016/S0140-6736(94)91649-7	http://dx.doi.org/10.1016/S0140-6736(94)91649-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934386				2022-12-01	WOS:A1994PK97800017
J	FITZSIMONS, RB				FITZSIMONS, RB			FACIOSCAPULOHUMERAL DYSTROPHY - THE ROLE OF INFLAMMATION	LANCET			English	Editorial Material							MUSCULAR-DYSTROPHY; REGION; CELLS; FSHD; ARM				FITZSIMONS, RB (corresponding author), MOORFIELDS EYE HOSP,LONDON,ENGLAND.							ASHTON N, 1969, CORNEOPLASTIC SURGER, P586; BROUWER OF, 1992, BRAIN, V115, P1587, DOI 10.1093/brain/115.5.1587; COPEMAN PWM, 1971, BRIT J DERMATOL, V85, P205, DOI 10.1111/j.1365-2133.1971.tb07218.x; FITZSIMONS RB, 1987, BRAIN, V110, P631, DOI 10.1093/brain/110.3.631; GRIGGS RC, 1993, NEUROLOGY, V43, P2369, DOI 10.1212/WNL.43.11.2369; KORF BR, 1985, ANN NEUROL, V17, P513, DOI 10.1002/ana.410170516; MARKS RM, 1986, J INVEST DERMATOL, V87, P519, DOI 10.1111/1523-1747.ep12455604; MUNSAT TL, 1972, NEUROLOGY, V22, P335, DOI 10.1212/WNL.22.4.335; POWERS JM, 1992, J NEUROPATH EXP NEUR, V51, P630, DOI 10.1097/00005072-199211000-00007; PRINEAS JW, 1993, BRAIN, V116, P681, DOI 10.1093/brain/116.3.681; WIJMENGA C, 1993, HUM MOL GENET, V2, P1667, DOI 10.1093/hmg/2.10.1667; WINOKUR ST, 1993, AM J HUM GENET, V53, P874	12	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					902	903		10.1016/S0140-6736(94)92263-2	http://dx.doi.org/10.1016/S0140-6736(94)92263-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934342				2022-12-01	WOS:A1994PJ28700004
J	BROWN, DJ				BROWN, DJ			OPINIONS OF GENERAL-PRACTITIONERS IN NOTTINGHAMSHIRE ABOUT PROVISION OF INTRAPARTUM CARE	BRITISH MEDICAL JOURNAL			English	Article							OBSTETRICS	Objective-To examine the beliefs of general practitioners concerning intrapartum care. Design-Postal questionnaire survey. Subjects-Ah general practitioners with patients in Nottinghamshire Family Health Services Authority in September 1993. Main outcome measures-General practitioners' current involvement in maternity care, and beliefs on intrapartum care. Results-Of 694 general practitioners sent questionnaires, 550 (79.2%) replied. 529 of these were on the obstetric list; 437 had not attended a delivery in the past 12 months; 36 had attended two or more; 358 general practitioners did not wish to provide more intrapartum care; 349 did not feel competent to do so. Reasons for not wanting to provide intrapartum care included current workload (453), disruption to personal life (407), and the fear of litigation (377). General practitioners who already booked women for home delivery were more Likely to wish to do more deliveries (62/42 v 61/316, chi(2) = 85.3; P < 0.0001) and to have more positive attitudes towards increasing women's choice in maternity care (90/22 v 195/151, chi(2) = 227; P < 0.0001). Conclusions-The involvement of general practitioners in intrapartum care in Nottinghamshire is low, and most general practitioners are unwilling to increase their role. However, general practitioners who already book for home delivery are keen to do more.	UNIV NOTTINGHAM,SCH MED,DEPT PUBL HLTH MED,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham				Hamblin-Brown, DJ/0000-0002-7353-8691				Bull M J, 1981, J R Coll Gen Pract, V31, P357; CAMPBELL R, 1987, WHERE BE BORN DEBATE; Campbell R., 1990, POLITICS MATERNITY C; CHAMBERS R, 1993, BRIT J GEN PRACT, V43, P410; KADRI AZ, 1992, BRIT MED J, V304, P112; KIETLY P, 1992, PREGNANCY CARE 1990S; KLEIN M, 1989, EFFECTIVE CARE PREGN, V1; LOUDON I, 1990, BRIT MED J, V301, P703, DOI 10.1136/bmj.301.6754.703; MACKENZIE GM, 1993, BRIT MED J, V307, P452; MARSH GN, 1985, BRIT MED J, V290, P901, DOI 10.1136/bmj.290.6472.901; MARTINBATES C, 1993, BRIT J GEN PRACT, V43, P413; NESBITT TS, 1992, WESTERN J MED, V157, P44; PHAFF J, 1986, PERINATAL HLTH SERVI; SMITH LFP, 1991, BRIT MED J, V303, P1443, DOI 10.1136/bmj.303.6815.1443; SMITH LFP, 1991, BRIT MED J, V303, P1447, DOI 10.1136/bmj.303.6815.1447; Tew M., 1990, SAFER CHILDBIRTH CRI; WALL EM, 1991, J AM BOARD FAM PRACT, V4, P440; YOUNG G, 1987, BRIT MED J, V294, P744, DOI 10.1136/bmj.294.6574.744; YOUNG G, 1993, PRACTITIONER, V237, P736; 1993, CHANGING CHILDBIRTH; 1992, 2ND HOUS COMM SEL CO, V1; 1959, REPORT MATERNITY SER; 1980, PERINATAL NEONATAL M; 1970, DOMICILIARY MIDWIFER; 1981, BRIT MED J, V282, P1171; 1992, YOUR CHOICES FUTURE	26	16	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					777	779		10.1136/bmj.309.6957.777	http://dx.doi.org/10.1136/bmj.309.6957.777			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ282	7950566	Green Published			2022-12-01	WOS:A1994PJ28200023
J	POPE, M; BETJES, MGH; ROMANI, N; HIRMAND, H; CAMERON, PU; HOFFMAN, L; GEZELTER, S; SCHULER, G; STEINMAN, RM				POPE, M; BETJES, MGH; ROMANI, N; HIRMAND, H; CAMERON, PU; HOFFMAN, L; GEZELTER, S; SCHULER, G; STEINMAN, RM			CONJUGATES OF DENDRITIC CELLS AND MEMORY T-LYMPHOCYTES FROM SKIN FACILITATE PRODUCTIVE INFECTION WITH HIV-1	CELL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; EPIDERMAL LANGERHANS CELLS; FEMALE RHESUS MACAQUES; IMMUNE-RESPONSES; ADHESION MOLECULE; LYMPHOID-TISSUE; GENITAL-TRACT; HUMAN BLOOD; AIDS; LYMPHADENOPATHY	Experimentally, a productive infection with HIV-1 requires that virus be administered to T cells that are activated by mitogens. We describe a productive milieu for HIV-1 within the confines of normal skin that does not require standard stimuli. The milieu consists of dendritic cells and T cells that emigrate from skin and produce distinctive stable, nonproliferating conjugates. These conjugates, upon exposure to each of seven different HIV-1 isolates, begin to release high levels of virus progeny within 4 days. Numerous infected syncytia, comprised of both dendritic and T cells, rapidly develop. We propose that conjugates of dendritic cells and T cells, as found in the external linings of organs involved in sexual transmission of HIV-1, represent an important site for the productive phase of HIV-1 infection. Because the affected T cells carry the memory phenotype, this site additionally provides a mechanism for the chronic depletion of CD4(+) memory cells in HIV-1 disease.	VRIJE UNIV AMSTERDAM, DEPT CELL BIOL, 1081 BT AMSTERDAM, NETHERLANDS; CORNELL UNIV, COLL MED, DIV PLAST SURG, NEW YORK, NY 10021 USA; UNIV INNSBRUCK, DEPT DERMATOL, A-6020 INNSBRUCK, AUSTRIA	Vrije Universiteit Amsterdam; Cornell University; University of Innsbruck	POPE, M (corresponding author), ROCKEFELLER UNIV, CELLULAR PHYSIOL & IMMUNOL LAB, NEW YORK, NY 10021 USA.		Steinman, Ralph/F-7729-2012; Cameron, Paul/H-3474-2011	Betjes, Michiel/0000-0001-9435-6208; Romani, Nikolaus/0000-0003-1614-9128; Cameron, Paul Urquhart/0000-0002-1906-6945	NIAID NIH HHS [AI24775, AI07012] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024775, R37AI007012, R01AI007012] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKBAR AN, 1988, J IMMUNOL, V140, P2171; ARMSTRONG JA, 1984, LANCET, V2, P370; ASJO B, 1993, J VIROL, V67, P4395; BERGER R, 1992, J INVEST DERMATOL, V99, P271, DOI 10.1111/1523-1747.ep12616619; BHARDWAJ N, 1994, INFECT IMMUN, V62, P135, DOI 10.1128/IAI.62.1.135-144.1994; BIBERFELD P, 1986, AM J PATHOL, V125, P436; CAMERON PU, 1994, AIDS RES HUM RETROV, V10, P61, DOI 10.1089/aid.1994.10.61; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; CHEN LL, 1978, J CELL BIOL, V79, P184, DOI 10.1083/jcb.79.1.184; CHESEBRO B, 1992, J VIROL, V66, P6547, DOI 10.1128/JVI.66.11.6547-6554.1992; CIMARELLI A, 1994, J ACQ IMMUN DEF SYND, V7, P230; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DANIELS TE, 1984, J INVEST DERMATOL, V82, P21, DOI 10.1111/1523-1747.ep12259038; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; ENK AH, 1993, J IMMUNOL, V150, P3698; FOLKS T, 1986, SCIENCE, V231, P600, DOI 10.1126/science.3003906; FOSTER CA, 1990, J EXP MED, V171, P997, DOI 10.1084/jem.171.4.997; GRAY D, 1993, ANNU REV IMMUNOL, V11, P49, DOI 10.1146/annurev.immunol.11.1.49; HANNA MG, 1968, J IMMUNOL, V101, P949; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HUMPHREY JH, 1984, EUR J IMMUNOL, V14, P859, DOI 10.1002/eji.1830140916; INABA K, 1984, J EXP MED, V160, P1717, DOI 10.1084/jem.160.6.1717; INABA K, 1986, J EXP MED, V163, P247, DOI 10.1084/jem.163.2.247; KALTER DC, 1991, J IMMUNOL, V146, P3396; KAPLAN G, 1987, J EXP MED, V165, P763, DOI 10.1084/jem.165.3.763; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; KOOT M, 1992, AIDS, V6, P49, DOI 10.1097/00002030-199201000-00006; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; LARSEN CP, 1990, J EXP MED, V172, P1483, DOI 10.1084/jem.172.5.1483; MACKAY CR, 1988, EUR J IMMUNOL, V18, P1681, DOI 10.1002/eji.1830181105; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; MILLER CJ, 1992, LAB INVEST, V67, P628; MILLER CJ, 1992, AM J PATHOL, V141, P655; MILLER CJ, 1992, J MED PRIMATOL, V21, P64; MILLER CJ, 1993, LAB INVEST, V68, P129; MURRAY HW, 1985, NEW ENGL J MED, V313, P1504, DOI 10.1056/NEJM198512123132403; NESTLE FO, 1994, CELL IMMUNOL, V156, P220, DOI 10.1006/cimm.1994.1166; NOSSAL GJV, 1968, J EXP MED, V127, P277, DOI 10.1084/jem.127.2.277; NUOVO GJ, 1993, AM J PATHOL, V143, P40; ODOHERTY U, 1993, J EXP MED, V178, P1067, DOI 10.1084/jem.178.3.1067; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; PANCHOLI P, 1992, IMMUNOLOGY, V76, P217; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; RACZ P, 1986, PROG ALLERGY, V37, P81; REKA S, 1993, CYTOKINE, V5, P305, DOI 10.1016/1043-4666(93)90061-9; SAKSELA K, 1994, P NATL ACAD SCI USA, V91, P1104, DOI 10.1073/pnas.91.3.1104; SANDERS ME, 1988, J IMMUNOL, V140, P1401; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P6058, DOI 10.1073/pnas.87.16.6058; SHIMIZU Y, 1991, NATURE, V349, P799, DOI 10.1038/349799a0; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SPIEGEL H, 1992, AM J PATHOL, V140, P15; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; STOSSEL H, 1990, J EXP MED, V172, P1471, DOI 10.1084/jem.172.5.1471; SZAKAL AK, 1989, ANNU REV IMMUNOL, V7, P91, DOI 10.1146/annurev.immunol.7.1.91; TONGSTARKSEN SE, 1989, J IMMUNOL, V142, P702; VANNOESEL CJM, 1990, J CLIN INVEST, V86, P293, DOI 10.1172/JCI114698; WOOD GS, 1983, J IMMUNOL, V131, P212; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	61	464	473	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 12	1994	78	3					389	398		10.1016/0092-8674(94)90418-9	http://dx.doi.org/10.1016/0092-8674(94)90418-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PC405	7914836				2022-12-01	WOS:A1994PC40500006
J	MUIRHEAD, CR				MUIRHEAD, CR			RADON RISKS	LANCET			English	Editorial Material							INDOOR RADON; LUNG-CANCER				MUIRHEAD, CR (corresponding author), NATL RADIOL PROTECT BOARD,CHILTON,OXON,ENGLAND.			Muirhead, Colin/0000-0001-5394-1267				[Anonymous], 1988, IARC MONOGRAPHS EVAL, V43; [Anonymous], 1993, ANN ICRP, V65; BLOT WJ, 1990, J NATL CANCER I, V82, P1025, DOI 10.1093/jnci/82.12.1025; LUBIN JH, 1994, NIH943644 PUBL; PERSHAGEN G, 1994, NEW ENGL J MED, V330, P159, DOI 10.1056/NEJM199401203300302; STIDLEY CA, 1993, HEALTH PHYS, V65, P234, DOI 10.1097/00004032-199309000-00001; 1990, NRPB1 NAT RAD PROT B; 1988, HLTH RISKS RADON OTH; 1993, NRPB4 NAT RAD PROT B; 1991, COMP DOSIMETRY RADON	10	15	15	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 16	1994	344	8916					143	144		10.1016/S0140-6736(94)92751-0	http://dx.doi.org/10.1016/S0140-6736(94)92751-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912759				2022-12-01	WOS:A1994NW81000003
J	VERMEER, BJ; VANDERSPEKKEIJSER, LMT; FIBBE, WE				VERMEER, BJ; VANDERSPEKKEIJSER, LMT; FIBBE, WE			SKIN BIOPSIES IN BONE-MARROW TRANSPLANTATION	LANCET			English	Editorial Material							VERSUS-HOST DISEASE; ACUTE GRAFT; RECIPIENTS		LEIDEN UNIV,MED CTR,DEPT HAEMATOL,LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	VERMEER, BJ (corresponding author), LEIDEN UNIV,MED CTR,DEPT DERMATOL,LEIDEN,NETHERLANDS.							DARMSTADT GL, 1992, J INVEST DERMATOL, V99, P397, DOI 10.1111/1523-1747.ep12616112; HEPBURN NC, 1993, Q J MED, V86, P715; HOOD AF, 1987, ARCH DERMATOL, V123, P745, DOI 10.1001/archderm.123.6.745; LAMPERT IA, 1982, CLIN EXP IMMUNOL, V50, P123; LEBOIT PE, 1989, J AM ACAD DERMATOL, V20, P236, DOI 10.1016/S0190-9622(89)70028-1; LERNER KG, 1974, TRANSPLANT P, V6, P367; LEVER R, 1986, BRIT J DERMATOL, V114, P161, DOI 10.1111/j.1365-2133.1986.tb02794.x; SALE GE, 1977, AM J PATHOL, V89, P621; VOLCPLATZER B, 1988, J INVEST DERMATOL, V91, P162, DOI 10.1111/1523-1747.ep12464407	9	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 9	1994	344	8915					75	76		10.1016/S0140-6736(94)91277-7	http://dx.doi.org/10.1016/S0140-6736(94)91277-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7912389				2022-12-01	WOS:A1994NV73200005
J	DALVA, MB; KATZ, LC				DALVA, MB; KATZ, LC			REARRANGEMENTS OF SYNAPTIC CONNECTIONS IN VISUAL-CORTEX REVEALED BY LASER PHOTOSTIMULATION	SCIENCE			English	Article							CAT STRIATE CORTEX; CLUSTERED HORIZONTAL CONNECTIONS; INTRINSIC CONNECTIONS; AREA 17; FUNCTIONAL ARCHITECTURE; CEREBRAL-CORTEX; LOCAL CIRCUITS; AXONAL ARBORS; BRAIN-SLICES; LAYER-III	Assessing patterns of synaptic connections in the developing mammalian neocortex has relied primarily on anatomical studies. In a physiological approach described here, the patterns of synaptic connections in slices of developing ferret visual cortex were determined with scanning laser photostimulation. Functional synaptic inputs to pyramidal cells in cortical layers 2 and 3 originating from sites close to the neuronal cell body appeared at least 2 weeks before eye opening, prior to the formation of long-range horizontal connections. Extensive long-range horizontal connections appeared in the next 10 days of development. The number of local connections peaked at the time of eye opening; the number of these connections subsequently declined to the level found in the adult while the specificity of long-distance connections increased. Thus, the relative influence of local connections on the activity of layer 2 and layer 3 neurons declines as the cortex matures while the influence of longer range connections increases substantially.			DALVA, MB (corresponding author), DUKE UNIV, MED CTR, DEPT NEUROBIOL, DURHAM, NC 27710 USA.			Dalva, Matthew/0000-0002-7737-8787	NATIONAL EYE INSTITUTE [R01EY007960] Funding Source: NIH RePORTER; NEI NIH HHS [EY07960] Funding Source: Medline; PHS HHS [T32-6M08441] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS JC, 1981, J HISTOCHEM CYTOCHEM, V29, P775, DOI 10.1177/29.6.7252134; ANTONINI A, 1993, SCIENCE, V260, P1819, DOI 10.1126/science.8511592; ARMSTRONGJAMES M, 1988, CEREBRAL CORTEX DEV, V7, pCH8; BURKHALTER A, 1993, J NEUROSCI, V13, P1916, DOI 10.1523/jneurosci.13-05-01916.1993; CALLAWAY EM, 1991, P NATL ACAD SCI USA, V88, P745, DOI 10.1073/pnas.88.3.745; CALLAWAY EM, 1993, P NATL ACAD SCI USA, V90, P7661, DOI 10.1073/pnas.90.16.7661; CALLAWAY EM, 1990, J NEUROSCI, V10, P1134; CALLAWAY EM, 1992, J NEUROSCI, V12, P570; CAMPBELL G, 1992, J NEUROSCI, V12, P1847; Dalva M. B., 1992, Society for Neuroscience Abstracts, V18, P1455; DURACK J, UNPUB; EDELMAN GM, 1988, NEURAL DARWINISIM TH; FARBER IC, 1983, SCIENCE, V222, P1025, DOI 10.1126/science.6648515; FRIAUF E, 1990, J NEUROSCI, V10, P2601; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1983, J NEUROSCI, V3, P1116; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HATA Y, 1993, NEUROPHYSIOLOGY, V69, P40; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; HESTRIN S, 1992, NATURE, V357, P686, DOI 10.1038/357686a0; HIRSCH JA, 1993, J PHYSIOL-LONDON, V461, P247, DOI 10.1113/jphysiol.1993.sp019512; JONES EG, 1984, CEREBRAL CORTEX CELL, V1, pCH8; KATZ LC, 1989, J NEUROSCI, V9, P1389; KATZ LC, 1987, J NEUROSCI, V7, P1223; KATZ LC, 1991, EUR J NEUROSCI, V3, P1, DOI 10.1111/j.1460-9568.1991.tb00805.x; KATZ LC, IN PRESS J NEUROSCI; KAUR C, 1989, ACTA ANAT, V136, P204; KISVARDAY ZF, 1986, EXP BRAIN RES, V64, P541, DOI 10.1007/BF00340492; KISVARDAY ZF, 1992, NEUROSCIENCE, V46, P275, DOI 10.1016/0306-4522(92)90050-C; LIVINGSTONE MS, 1984, J NEUROSCI, V4, P2830; LOWEL S, 1992, SCIENCE, V255, P209, DOI 10.1126/science.1372754; LUBKE J, 1992, J COMP NEUROL, V323, P42, DOI 10.1002/cne.903230105; LUND JS, 1977, J COMP NEUROL, V176, P149, DOI 10.1002/cne.901760203; LUND JS, 1975, J COMP NEUROL, V159, P305, DOI 10.1002/cne.901590303; MALACH R, 1993, P NATL ACAD SCI USA, V90, P10469, DOI 10.1073/pnas.90.22.10469; MALSBURG CV, 1973, KYBERNETIK, V14, P85, DOI 10.1007/BF00288907; MARTIN KAC, 1984, J PHYSIOL-LONDON, V353, P463, DOI 10.1113/jphysiol.1984.sp015347; MCGUIRE BA, 1991, J COMP NEUROL, V305, P370, DOI 10.1002/cne.903050303; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; MILLER KD, 1994, J NEUROSCI, V14, P409; MISSON JP, 1991, GLIA, V4, P138, DOI 10.1002/glia.440040205; OROURKE NA, 1990, NEURON, V5, P159, DOI 10.1016/0896-6273(90)90306-Z; ROCKLAND KS, 1982, SCIENCE, V215, P1532, DOI 10.1126/science.7063863; ROCKLAND KS, 1985, J COMP NEUROL, V241, P225, DOI 10.1002/cne.902410209; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; TSO DY, 1986, J NEUROSCI, V6, P1160; TSUMOTO T, 1987, NATURE, V327, P513, DOI 10.1038/327513a0; WILCOX M, 1990, J ORG CHEM, V55, P1585, DOI 10.1021/jo00292a038	48	114	150	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 8	1994	265	5169					255	258		10.1126/science.7912852	http://dx.doi.org/10.1126/science.7912852			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV957	7912852				2022-12-01	WOS:A1994NV95700043
J	SMITH, JC; CRANSTON, D; OBRIEN, T; GUILLEBAUD, J; HINDMARSH, J; TURNER, AG				SMITH, JC; CRANSTON, D; OBRIEN, T; GUILLEBAUD, J; HINDMARSH, J; TURNER, AG			FATHERHOOD WITHOUT APPARENT SPERMATOZOA AFTER VASECTOMY	LANCET			English	Note								Fatherhood after vasectomy is rare. We describe 6 cases of DNA-proven fatherhood after vasectomy in association with persistently negative semen examination. All vasectomy patients and their partners should be counselled about the small possibility of late failure, and warning of failure should be recorded.	CHURCHILL HOSP,ELLIOT SMITH CLIN,OXFORD,ENGLAND; MARGARET PYKE CTR STUDY & TRAINING FAMILY PLANNING,LONDON,ENGLAND; S CLEVELAND HOSP,MIDDLESBROUGH,CLEVELAND,ENGLAND; PETERBOROUGH DIST GEN HOSP,PETERBOROUGH,LINCS,ENGLAND; STAMFORD HOSP,PETERBOROUGH,LINCS,ENGLAND	University of Oxford; University of London; University College London	SMITH, JC (corresponding author), CHURCHILL HOSP,DEPT UROL,OXFORD OX3 7LJ,ENGLAND.		Cranston, David/K-7063-2019					BUNGE RG, 1968, J UROLOGY, V100, P762, DOI 10.1016/S0022-5347(17)62620-X; Esho J O, 1974, Urology, V3, P211, DOI 10.1016/S0090-4295(74)80018-X; PHILP T, 1984, BRIT MED J, V289, P77, DOI 10.1136/bmj.289.6437.77; Pugh R C, 1969, Br J Urol, V41, P340, DOI 10.1111/j.1464-410X.1969.tb11894.x; SMITH JC, 1971, LANCET, V1, P38; TEMPLE JG, 1970, LANCET, V2, P1258; THOMSON JA, 1993, BRIT MED J, V307, P299, DOI 10.1136/bmj.307.6899.299	7	46	47	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					30	30		10.1016/S0140-6736(94)91052-9	http://dx.doi.org/10.1016/S0140-6736(94)91052-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912302				2022-12-01	WOS:A1994NU91700015
J	THOMAS, DP				THOMAS, DP			VIRAL CONTAMINATION OF BLOOD PRODUCTS	LANCET			English	Editorial Material							HEMOPHILIA-A; PARVOVIRUS-B19; TRANSMISSION; CONCENTRATE				THOMAS, DP (corresponding author), BIO PROD LAB, ELSTREE, HERTS, ENGLAND.							LYON DJ, 1989, LANCET, V1, P1085; MANNUCCI PM, 1994, ANN INTERN MED, V120, P1, DOI 10.7326/0003-4819-120-1-199401010-00001; MANNUCCI PM, 1993, VIROLOGICAL SAFETY A, P253; MCOMISH F, 1993, J CLIN MICROBIOL, V31, P323, DOI 10.1128/JCM.31.2.323-328.1993; MORTIMER PP, 1983, LANCET, V2, P482; NORMANN A, 1992, LANCET, V340, P1232, DOI 10.1016/0140-6736(92)92938-C; PEERLINCK K, 1993, THROMB HAEMOSTASIS, V69, P115; PEERLINCK K, 1993, LANCET, V341, P179, DOI 10.1016/0140-6736(93)90044-H; PROWSE C, 1993, BRIT MED J, V307, P561, DOI 10.1136/bmj.307.6903.561-e; SANTAGOSTINO E, 1994, LANCET, V343, P798, DOI 10.1016/S0140-6736(94)91878-3; TEMPERLEY IJ, 1992, LANCET, V340, P1466; WILLIAMS MD, 1990, VOX SANG, V58, P177, DOI 10.1111/j.1423-0410.1990.tb02086.x	12	12	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 25	1994	343	8913					1583	1584		10.1016/S0140-6736(94)93050-3	http://dx.doi.org/10.1016/S0140-6736(94)93050-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911913				2022-12-01	WOS:A1994NU35400003
J	ELDERS, JM				ELDERS, JM			REDUCING THE RISK OF SUDDEN-INFANT-DEATH-SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											ELDERS, JM (corresponding author), US PHS,WASHINGTON,DC 20201, USA.								0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 7	1994	272	21					1646	1646		10.1001/jama.272.21.1646	http://dx.doi.org/10.1001/jama.272.21.1646			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU759	7966879				2022-12-01	WOS:A1994PU75900006
J	ELMORE, JG; WELLS, CK; LEE, CH; HOWARD, DH; FEINSTEIN, AR				ELMORE, JG; WELLS, CK; LEE, CH; HOWARD, DH; FEINSTEIN, AR			VARIABILITY IN RADIOLOGISTS INTERPRETATIONS OF MAMMOGRAMS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BREAST-CANCER MORTALITY; OBSERVER VARIATION; AGREEMENT; REDUCTION; EFFICACY; PROGRAM; PROJECT; AUDIT	Background. Despite the proved value of mammography in screening for breast cancer, its efficacy depends on radiologists' interpretations. The variability in such interpretations is not well understood. Methods. Using a technique of stratified random sampling, we selected 150 mammograms obtained in 1987: 27 from women with histopathologically confirmed breast cancer and 123 from women with no evidence of breast cancer after three years of follow-up examinations. Ten radiologists, who were unaware of the diagnoses and research hypothesis, each interpreted the 150 mammograms. Disagreement was analyzed within pairs of the 10 radiologists, as well as for the group of 150 women as a whole. Results. The diagnostic consistency between pairs of radiologists was moderate, with a median weighted percentage of agreement of 78 percent (weighted kappa, 0.47). The frequency of the radiologists' recommendations for an immediate workup ranged from 74 to 96 percent for mammograms from the women with cancer and from 11 to 65 percent for films from the women without cancer. A substantial disagreement in management recommendations - in which one radiologist recommended routine follow-up and another recommended a biopsy for the same patient - occurred in 3 percent of the pairwise comparisons but in 25 percent of the comparisons for the group of women as a whole. When two or more radiologists recommended a biopsy for the same patient, a disagreement in the stated location (right or left breast) occurred in 2 percent of the pairwise comparisons among the radiologists but in 9 percent of comparisons for the group of women as a whole. Because some disagreement was likely, given that 10 radiologists read each film, the pairwise comparison is a more conservative estimate of disagreement. Conclusions. Although mammography is of value in screening women for breast cancer, radiologists can differ, sometimes substantially, in their interpretations of mammograms and in their recommendations for management. Efforts to improve accuracy and reduce variability in interpretation may increase the effectiveness of mammography in detecting early breast cancers.	YALE UNIV,DEPT DIAGNOST RADIOL,NEW HAVEN,CT; YALE UNIV,DEPT EPIDEMIOL & PUBL HLTH,NEW HAVEN,CT	Yale University; Yale University	ELMORE, JG (corresponding author), YALE UNIV,SCH MED,CTR PRIMARY CARE,DEPT INTERNAL MED,20 YORK ST,NEW HAVEN,CT 06504, USA.		SALAZAR, ANTONIO/A-5806-2013	SALAZAR, ANTONIO/0000-0003-2639-2340				ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; [Anonymous], 1993, BREAST IMAGING REPOR; BAINES CJ, 1990, INVEST RADIOL, V25, P971, DOI 10.1097/00004424-199009000-00002; BIRD RE, 1989, RADIOLOGY, V171, P87, DOI 10.1148/radiology.171.1.2494683; BOYD NF, 1986, J CHRON DIS, V39, P465, DOI 10.1016/0021-9681(86)90113-X; BOYD NF, 1982, J NATL CANCER I, V68, P357; CICCONE G, 1992, EUR J CANCER, V28A, P1054, DOI 10.1016/0959-8049(92)90455-B; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; COLLETTE HJA, 1984, LANCET, V1, P1224; DERSHAW DD, 1992, RADIOLOGY, V184, P415, DOI 10.1148/radiology.184.2.1620839; DORSI CJ, 1993, SEMIN ROENTGENOL, V28, P204, DOI 10.1016/S0037-198X(05)80080-X; FEINSTEIN AR, 1990, J CLIN EPIDEMIOL, V43, P543, DOI 10.1016/0895-4356(90)90158-L; Fleiss J. L., 1981, STAT METHODS RATES P, V2nd, DOI 10.1002/0471445428; KOPANS DB, 1992, RADIOL CLIN N AM, V30, P257; KRAMER MS, 1981, CLIN PHARMACOL THER, V29, P111, DOI 10.1038/clpt.1981.18; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MCLELLAND R, 1991, AM J ROENTGENOL, V157, P473, DOI 10.2214/ajr.157.3.1872231; PALLI D, 1986, INT J CANCER, V38, P501, DOI 10.1002/ijc.2910380408; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; SHAPIRO S, 1982, JNCI-J NATL CANCER I, V69, P349; SICKLES EA, 1992, RADIOL CLIN N AM, V30, P265; SICKLES EA, 1990, RADIOLOGY, V175, P323, DOI 10.1148/radiology.175.2.2326455; SWETS JA, 1991, MED DECIS MAKING, V11, P9, DOI 10.1177/0272989X9101100102; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; VERBEEK ALM, 1984, LANCET, V1, P1222; VINEIS P, 1988, TUMORI, V74, P275, DOI 10.1177/030089168807400306; 1988, LANCET, V2, P411	27	455	457	1	21	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 1	1994	331	22					1493	1499		10.1056/NEJM199412013312206	http://dx.doi.org/10.1056/NEJM199412013312206			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU866	7969300				2022-12-01	WOS:A1994PU86600006
J	KELLER, LF; ARCESE, P; SMITH, JNM; HOCHACHKA, WM; STEARNS, SC				KELLER, LF; ARCESE, P; SMITH, JNM; HOCHACHKA, WM; STEARNS, SC			SELECTION AGAINST INBRED SONG SPARROWS DURING A NATURAL-POPULATION BOTTLENECK	NATURE			English	Article							INBREEDING DEPRESSION; GREAT TIT; CONSEQUENCES; MORTALITY	THE genetic and demographic consequences of population subdivision have received considerable attention from conservation biologists. In particular, losses of genetic variability and reduced viability and fecundity due to inbreeding (inbreeding depression) are of concern(1-3). Studies of domestic, laboratory(4,5) and zoo populations(2,6,7) have shown inbreeding depression in a variety of traits related to fitness. Consequently, inbreeding depression is widely accepted as a fact. Recently, however, the relative impact of inbreeding on the viability of natural populations has been questioned(8-10). Work on the cheetah (Acinonyx jubatus), for example, has emphasized the overwhelming importance of environmental factors on mortality in the wild(9,10). Here we report that song sparrows (Melospiza melodia) that survived a severe population bottleneck were a non-random subset of the pre-crash population with respect to inbreeding, and that natural selection favoured outbred individuals. Thus, inbreeding depression was expressed in the face of an environmental challenge. Such challenges are also likely to be faced by inbred populations of endangered species. We suggest that environmental and genetic effects on survival may interact and, as a consequence, that their effects on individuals and populations should not be considered independently.	UNIV BRITISH COLUMBIA,DEPT ZOOL,VANCOUVER V6T 1Z4,BC,CANADA; UNIV BASEL,INST ZOOL,CH-4051 BASEL,SWITZERLAND	University of British Columbia; University of Basel	KELLER, LF (corresponding author), UNIV WISCONSIN,DEPT WILDLIFE ECOL,1630 LINDEN DR,MADISON,WI 53706, USA.		Hochachka, Wesley M./J-9768-2012	Hochachka, Wesley M./0000-0002-0595-7827; Lukas, Keller/0000-0002-0149-0174; Stearns, Stephen/0000-0002-6621-4373				ARCESE P, 1992, ECOLOGY, V73, P805, DOI 10.2307/1940159; BARRETT SCH, 1991, NATURE, V352, P522, DOI 10.1038/352522a0; BOYCE AJ, 1983, J HERED, V74, P400, DOI 10.1093/oxfordjournals.jhered.a109825; BULGER J, 1986, ANIM BEHAV, V36, P574; CARO TM, 1994, SCIENCE, V263, P485, DOI 10.1126/science.8290956; CAUGHLEY G, 1994, J ANIM ECOL, V63, P215, DOI 10.2307/5542; CHARLESWORTH D, 1987, ANNU REV ECOL SYST, V18, P237, DOI 10.1146/annurev.ecolsys.18.1.237; Falconer D. S., 1989, Introduction to quantitative genetics.; GIBBS HL, 1989, EVOLUTION, V43, P1273, DOI 10.1111/j.1558-5646.1989.tb02574.x; GREENWOOD PJ, 1978, NATURE, V271, P52, DOI 10.1038/271052a0; HARCOURT S, 1991, NATURE, V354, P10, DOI 10.1038/354010a0; Hoffmann A.A., 1991, EVOLUTIONARY GENETIC; HOOGLAND JL, 1992, AM NAT, V139, P591, DOI 10.1086/285345; Lacy Robert C., 1993, P352; LANDE R, 1988, SCIENCE, V241, P1455, DOI 10.1126/science.3420403; LANDE R, 1985, EVOLUTION, V39, P24, DOI [10.2307/2408514, 10.1111/j.1558-5646.1985.tb04077.x]; MACCLUER JW, 1983, J HERED, V74, P394, DOI 10.1093/oxfordjournals.jhered.a109824; OBRIEN SJ, 1985, SCIENCE, V227, P1428, DOI 10.1126/science.2983425; Ralls K., 1986, P35; RALLS K, 1979, SCIENCE, V206, P1101, DOI 10.1126/science.493997; ROGERS CM, 1991, ORNIS SCAND, V22, P387, DOI 10.2307/3676513; SMITH JNM, 1989, AM NAT, V133, P830, DOI 10.1086/284955; SMITH JNM, 1991, 20 ACT C INT ORN, P1514; Templeton A.R., 1987, P257; Thornhill N.W., 1993, NATURAL HIST INBREED; TOMPA FS, 1971, AUK, V88, P753, DOI 10.2307/4083835; VANNOORDWIJK AJ, 1981, EVOLUTION, V35, P674, DOI 10.1111/j.1558-5646.1981.tb04929.x; Wright S., 1977, EVOLUTION GENETICS P, V3; 1986, P WKSHOP GENETIC MAN, V5, P81	29	305	310	2	109	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					356	357		10.1038/372356a0	http://dx.doi.org/10.1038/372356a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PU287	7969492				2022-12-01	WOS:A1994PU28700053
J	LOWE, SW; BODIS, S; MCCLATCHEY, A; REMINGTON, L; RULEY, HE; FISHER, DE; HOUSMAN, DE; JACKS, T				LOWE, SW; BODIS, S; MCCLATCHEY, A; REMINGTON, L; RULEY, HE; FISHER, DE; HOUSMAN, DE; JACKS, T			P53 STATUS AND THE EFFICACY OF CANCER-THERAPY IN-VIVO	SCIENCE			English	Article							PROGRAMMED CELL-DEATH; C-MYC; GENE; MUTATIONS; INDUCTION; APOPTOSIS; MOUSE; TUMOR	The therapeutic responsiveness of genetically defined tumors expressing or devoid of the p53 tumor suppressor gene was compared in immunocompromised mice. Tumors expressing the p53 gene contained a high proportion of apoptotic cells and typically regressed after treatment with gamma radiation or adriamycin. In contrast, p53-deficient tumors treated with the same regimens continued to enlarge and contained few apoptotic cells. Acquired mutations in p53 were associated with both treatment resistance and relapse in p53-expressing tumors. These results establish that defects in apoptosis, here caused by the inactivation of p53, can produce treatment-resistant tumors and suggest that p53 status may be an important determinant of tumor response to therapy.	MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,JOINT CTR RADIAT THERAPY,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; VANDERBILT UNIV,SCH MED,DEPT IMMUNOL & MICROBIOL,NASHVILLE,TN 37232; HARVARD UNIV,CHILDRENS HOSP,SCH MED,BOSTON,MA 02115; MIT,CTR CANC RES,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Vanderbilt University; Harvard University; Boston Children's Hospital; Harvard Medical School; Massachusetts Institute of Technology (MIT)					NATIONAL CANCER INSTITUTE [R01CA017575, R37CA017575, P30CA014051, R01CA040602] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA40602, 5R27CA17575, CA14051] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARDEESY N, 1994, NAT GENET, V7, P91, DOI 10.1038/ng0594-91; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; ELROUBY S, 1993, BLOOD, V82, P3452; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FUJIWARA T, 1994, CANCER RES, V54, P2287; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIO Y, 1993, CANCER RES, V53, P11; HSIAO MH, 1994, BLOOD, V83, P2922, DOI 10.1182/blood.V83.10.2922.2922; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P954; LOWE SW, UNPUB; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; PELLETIER J, COMMUNICATION; SCHEULEN ME, 1989, STRAHLENTHER ONKOL, V165, P529; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; THORLACIUS S, 1993, CANCER RES, V53, P1637; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602	25	1488	1539	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					807	810		10.1126/science.7973635	http://dx.doi.org/10.1126/science.7973635			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973635				2022-12-01	WOS:A1994PP75300041
J	MINSHULL, J; SUN, H; TONKS, NK; MURRAY, AW				MINSHULL, J; SUN, H; TONKS, NK; MURRAY, AW			A MAP KINASE-DEPENDENT SPINDLE ASSEMBLY CHECKPOINT IN XENOPUS EGG EXTRACTS	CELL			English	Article							ACTIVATED PROTEIN-KINASE; CELL-CYCLE ARREST; WILD-TYPE P53; MATURATION-PROMOTING FACTOR; IMMEDIATE-EARLY GENE; M-PHASE; SACCHAROMYCES-CEREVISIAE; TYROSINE PHOSPHORYLATION; MICROTUBULE DYNAMICS; CHROMOSOME MOVEMENT	Like early Xenopus embryos, extracts made from Xenopus eggs lack the cell cycle checkpoint that keeps anaphase from occurring before spindle assembly is complete. At very high densities of sperm nuclei, however, microtubule depolymerization arrests the extracts in mitosis. The arrested extracts have high levels of maturation-promoting factor activity, fail to degrade cyclin B, and contain activated ERK2/mitogen-activated protein (MAP) kinase. The addition of the purified MAP kinase-specific phosphatase MKP-1 demonstrates that MAP kinase activity is required for both the establishment and maintenance of the mitotic arrest induced by spindle depolymerization. Increased calcium concentrations, which release unfertilized frog eggs from their natural arrest in metaphase of meiosis II, have no effect on the mitotic arrest.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	University of California System; University of California San Francisco; Cold Spring Harbor Laboratory	MINSHULL, J (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, BOX 0444, SAN FRANCISCO, CA 94143 USA.				NCI NIH HHS [CA53840] Funding Source: Medline; NIGMS NIH HHS [GM43987] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053840, R37CA053840] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043987, R01GM043987] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1993, ONCOGENE, V8, P2015; ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BAGATA N, 1988, NATURE, V335, P519; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; CALLAN H. G., 1957, JOUR GENETICS, V55, P200, DOI 10.1007/BF02981625; CHARLES CH, 1992, ONCOGENE, V7, P187; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOPER JA, 1989, MOL CELL BIOL, V9, P3143, DOI 10.1128/MCB.9.7.3143; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HEIDER H, 1994, EUR J BIOCHEM, V219, P513, DOI 10.1111/j.1432-1033.1994.tb19966.x; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; HYMAN A, 1990, METHOD ENZYMOL, V196, P303; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; JORDAN MA, 1992, J CELL SCI, V102, P401; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KIMELMAN D, 1987, CELL, V48, P399, DOI 10.1016/0092-8674(87)90191-7; KLINE D, 1988, DEV BIOL, V126, P346, DOI 10.1016/0012-1606(88)90145-5; KOBEL HR, 1986, TRENDS GENET, V2, P310, DOI 10.1016/0168-9525(86)90286-6; KUBIAK JZ, 1993, EMBO J, V12, P3773, DOI 10.1002/j.1460-2075.1993.tb06055.x; KUBOTA HY, 1987, DEV BIOL, V119, P129, DOI 10.1016/0012-1606(87)90214-4; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LORCA T, 1991, EMBO J, V10, P2087, DOI 10.1002/j.1460-2075.1991.tb07741.x; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MINSHULL J, 1989, J CELL SCI, P77; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; NICKLAS RB, 1993, J CELL SCI, V104, P961; NICKLAS RB, 1992, J CELL SCI, V102, P681; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RIEDER CL, 1992, J CELL SCI, V102, P387; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SLUDER G, 1994, J CELL BIOL, V126, P189, DOI 10.1083/jcb.126.1.189; SLUDER G, 1983, J CELL BIOL, V97, P877, DOI 10.1083/jcb.97.3.877; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; TOMKIEL J, 1994, J CELL BIOL, V125, P531, DOI 10.1083/jcb.125.3.531; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WATANABE N, 1991, NATURE, V352, P247, DOI 10.1038/352247a0; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	83	358	361	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 4	1994	79	3					475	486		10.1016/0092-8674(94)90256-9	http://dx.doi.org/10.1016/0092-8674(94)90256-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7954813				2022-12-01	WOS:A1994PQ48800010
J	STONE, JM; COLLINGE, MA; SMITH, RD; HORN, MA; WALKER, JC				STONE, JM; COLLINGE, MA; SMITH, RD; HORN, MA; WALKER, JC			INTERACTION OF A PROTEIN PHOSPHATASE WITH AN ARABIDOPSIS SERINE-THREONINE RECEPTOR KINASE	SCIENCE			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE-PHOSPHATASE; NUCLEOTIDE EXCHANGE; EXPRESSION CLONING; BRASSICA-OLERACEA; ADAPTER PROTEIN; THALIANA; DOMAINS; LOCUS; GENE	A protein phosphatase was cloned that interacts with a serine-threonine receptor-like kinase, RLK5, from Arabidopsis thaliana. The phosphatase, designated KAPP (kinase-associated protein phosphatase), is composed of three domains: an amino-terminal signal anchor, a kinase interaction (KI) domain, and a type 2C protein phosphatase catalytic region. Association of RLK5 with the KI domain is dependent on phosphorylation of RLK5 and can be abolished by dephosphorylation. KAPP may function as a signaling component in a pathway involving RLK5.	UNIV MISSOURI, DIV BIOL SCI, COLUMBIA, MO 65211 USA; UNIV MISSOURI, DEPT BIOCHEM, COLUMBIA, MO 65211 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia				Walker, John/0000-0002-2050-1641				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BRAUN D, UNPUB; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CARR DW, 1992, TRENDS BIOCHEM SCI, V17, P246, DOI 10.1016/0968-0004(92)90402-U; CHANG C, 1992, PLANT CELL, V4, P1263, DOI 10.1105/tpc.4.10.1263; DECHERT U, 1994, J BIOL CHEM, V269, P5602; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; HARLOW E, 1988, ANTIBODIES LABORATOR; HIGH S, 1992, Current Opinion in Cell Biology, V4, P581, DOI 10.1016/0955-0674(92)90075-N; HORN MA, 1994, BIOCHIM BIOPHYS ACTA, V208, P65; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; MACKINTOSH C, 1991, BIOCHEM J, V273, P733, DOI 10.1042/bj2730733; MAEDA T, 1993, MOL CELL BIOL, V13, P5408, DOI 10.1128/MCB.13.9.5408; MANN DJ, 1992, BIOCHIM BIOPHYS ACTA, V1130, P100, DOI 10.1016/0167-4781(92)90471-B; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MCGOWAN CH, 1988, METHOD ENZYMOL, V159, P416; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH RD, 1993, PLANT MOL BIOL, V21, P307, DOI 10.1007/BF00019946; SMITH RD, 1991, PLANT PHYSIOL, V97, P677, DOI 10.1104/pp.97.2.677; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; STONE JD, UNPUB; TOBIAS CM, 1992, PLANT PHYSIOL, V99, P284, DOI 10.1104/pp.99.1.284; TOWNLEY R, 1993, BIOCHEMISTRY-US, V32, P13414, DOI 10.1021/bi00212a006; WALKER JC, 1993, PLANT J, V3, P451, DOI 10.1046/j.1365-313X.1993.t01-23-00999.x; WALKER JC, 1990, NATURE, V345, P743, DOI 10.1038/345743a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	43	227	240	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	1994	266	5186					793	795		10.1126/science.7973632	http://dx.doi.org/10.1126/science.7973632			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973632				2022-12-01	WOS:A1994PP75300036
J	ISTRE, O; BJOENNES, J; NAESS, R; HORNBAEK, K; FORMAN, A				ISTRE, O; BJOENNES, J; NAESS, R; HORNBAEK, K; FORMAN, A			POSTOPERATIVE CEREBRAL EDEMA AFTER TRANSCERVICAL ENDOMETRIAL RESECTION AND UTERINE IRRIGATION WITH 1-CENTER-DOT-5-PERCENT GLYCINE	LANCET			English	Article							SYMPTOMATIC HYPONATREMIA; HYPERAMMONEMIA; SERUM	Absorption of irrigating solution during transcervical resection of endometrium can cause dilutional hyponatraemia, nausea, and cerebral oedema. We studied 6 patients who absorbed more than 1500 mL of 1.5% glycine, and 14 patients who absorbed less. Cerebral oedema was diagnosed by blinded, paired comparison of computed tomography (CT) scans 3-6 hours and 3-6 days after operation. The absorbed volume of irrigating glycine solution was correlated with peroperative decrease in serum sodium. 10 patients who absorbed 500 mL of glycine or more had postoperative nausea, with cerebral oedema suspected in 9. None of the 10 patients who absorbed less than 500 mL had nausea; changes on CT scan suggestive of cerebral edema were found in 1. 8 patients who absorbed 1000 mL or more had a decrease in serum sodium of 10 mmol/L or more, nausea, and cerebral oedema on CT scan. Cerebral oedema may contribute to the development of postoperative nausea in patients undergoing transcervical surgery who absorb more than 500 mL of 1.5% glycine irrigating solution.	HEDMARK CENT HOSP,DEPT RADIOL,N-2300 HAMAR,NORWAY; AARHUS UNIV HOSP,DEPT OBSTET & GYNECOL,AARHUS,DENMARK	Aarhus University	ISTRE, O (corresponding author), HEDMARK CENT HOSP,DEPT OBSTET & GYNAECOL,N-2300 HAMAR,NORWAY.			Forman, Axel/0000-0003-1369-1296				ARIEFF AI, 1991, CRIT CARE MED, V19, P748, DOI 10.1097/00003246-199106000-00002; AYUS JC, 1987, NEW ENGL J MED, V317, P1190, DOI 10.1056/NEJM198711053171905; BERL T, 1990, ANN INTERN MED, V113, P417, DOI 10.7326/0003-4819-113-6-417; BERNSTEIN GT, 1989, J SURG RES, V46, P135, DOI 10.1016/0022-4804(89)90216-3; HARRISON RH, 1956, J UROLOGY, V75, P91; HENDERSON DJ, 1980, UROLOGY, V15, P267, DOI 10.1016/0090-4295(80)90441-0; HOEKSTRA PT, 1983, J UROLOGY, V130, P704, DOI 10.1016/S0022-5347(17)51414-7; IGLESIAS JJ, 1975, J UROLOGY, V114, P929, DOI 10.1016/S0022-5347(17)67177-5; ISTRE O, 1992, OBSTET GYNECOL, V80, P218; KIRWAN PH, 1993, BRIT J OBSTET GYNAEC, V100, P603, DOI 10.1111/j.1471-0528.1993.tb15321.x; MADSEN PAUL O., 1965, INVEST UROL, V3, P122; MAGOS AL, 1991, LANCET, V337, P1074, DOI 10.1016/0140-6736(91)91718-A; NESBIT RM, 1948, J UROLOGY, V59, P1212, DOI 10.1016/S0022-5347(17)69504-1; PERIER C, 1988, CLIN CHEM, V34, P1471; SHEPARD RL, 1987, BRIT J UROL, V60, P349, DOI 10.1111/j.1464-410X.1987.tb04983.x; WITZ CA, 1993, FERTIL STERIL, V60, P745	16	96	98	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 29	1994	344	8931					1187	1189		10.1016/S0140-6736(94)90507-X	http://dx.doi.org/10.1016/S0140-6736(94)90507-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN803	7934539				2022-12-01	WOS:A1994PN80300008
J	BARNETT, SW; MURTHY, KK; HERNDIER, BG; LEVY, JA				BARNETT, SW; MURTHY, KK; HERNDIER, BG; LEVY, JA			AN AIDS-LIKE CONDITION INDUCED IN BABOONS BY HIV-2	SCIENCE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; RHESUS-MONKEYS; EXPERIMENTAL-INFECTION; CELLULAR-LOCALIZATION; PERSISTENT INFECTION; CYNOMOLGUS MONKEYS; MACACA-NEMESTRINA; LYMPHOID-TISSUES; D RETROVIRUS; MACAQUES	Six baboons (Papio cynocephalus) were intravenously inoculated with the human immunodeficiency virus-type 2 (HIV-2) strain HIV-2(UC2). All seroconverted within 6 week's after inoculation; five animals became persistently infected. Four developed lymphadenopathy, and three of the animals had CD4(+) T cell loss within 18 to 24 months after inoculation. One of these baboons, showing severe clinical symptoms, showed at necropsy widespread dissemination of virus with follicular depletion in the lymph nodes, extensive fibromatosis involving lymphoid and nonlymphoid tissues, and lymphocytic interstitial pneumonitis. Another animal is cachectic and exhibited lymphoid follicular lysis and fibrous skin lesions. Other baboons inoculated with a second strain, HIV-2(UC14), have shown evidence of persistent infection. HIV-2 infection of baboons provides a valuable animal model for studying HIV persistence and pathogenesis and for evaluating approaches to antiviral therapies.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,CANC RES INST,SAN FRANCISCO,CA 94143; SW FDN BIOMED RES,SAN ANTONIO,TX 78228; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,SCH MED,DEPT PATHOL,SAN FRANCISCO,CA 94110	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Texas Biomedical Research Institute; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco					NIAID NIH HHS [U01-AI26471] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI026471] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGY MB, 1992, SCIENCE, V257, P103, DOI 10.1126/science.1621083; ALBINI A, 1988, J CELL BIOCHEM, V36, P369, DOI 10.1002/jcb.240360406; ALTER HJ, 1984, SCIENCE, V226, P549, DOI 10.1126/science.6093251; BABU PG, 1993, INDIAN J MED RES-A, V97, P49; BARNETT SW, 1993, J VIROL, V67, P1006, DOI 10.1128/JVI.67.2.1006-1014.1993; BARNETT SW, UNPUB; BLACKBOURN D, UNPUB; CASTRO BA, 1991, VIROLOGY, V184, P219, DOI 10.1016/0042-6822(91)90838-3; CHALIFOUX LV, 1987, AM J PATHOL, V128, P104; CORTES E, 1989, NEW ENGL J MED, V320, P953, DOI 10.1056/NEJM198904133201501; DESROSIERS RC, 1990, ANNU REV IMMUNOL, V8, P557, DOI 10.1146/annurev.iy.08.040190.003013; DONALDSON YK, 1994, LANCET, V343, P382, DOI 10.1016/S0140-6736(94)91222-X; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; EVANS LA, 1988, LANCET, V2, P1389; FRUMKIN LR, 1993, VIROLOGY, V195, P422, DOI 10.1006/viro.1993.1392; FULTZ PN, 1986, J VIROL, V58, P116, DOI 10.1128/JVI.58.1.116-124.1986; GARDNER MB, 1989, FASEB J, V3, P2593, DOI 10.1096/fasebj.3.14.2556312; GREZ M, 1994, J VIROL, V68, P2161, DOI 10.1128/JVI.68.4.2161-2168.1994; HERNDIER BG, 1994, AIDS, V8, P575, DOI 10.1097/00002030-199405000-00002; HIRSCH VM, 1991, J INFECT DIS, V163, P976, DOI 10.1093/infdis/163.5.976; HIRSCH VM, 1989, NATURE, V339, P389, DOI 10.1038/339389a0; HOFFMAN AD, 1985, VIROLOGY, V147, P326, DOI 10.1016/0042-6822(85)90135-7; HSIA K, 1991, J INFECT DIS, V164, P470, DOI 10.1093/infdis/164.3.470; LETVIN NL, 1987, J INFECT DIS, V156, P406, DOI 10.1093/infdis/156.2.406; LI J, 1992, J ACQ IMMUN DEF SYND, V5, P639; LIVARTOWSKI J, 1992, CANCER DETECT PREV, V16, P341; MACKEWICZ CE, 1991, J CLIN INVEST, V87, P1462, DOI 10.1172/JCI115153; MARX PA, 1985, J VIROL, V56, P571, DOI 10.1128/JVI.56.2.571-578.1985; MCCLURE J, 1992, 10TH ANN S NONH PRIM; MORROW WJW, 1989, AIDS RES HUM RETROV, V5, P233, DOI 10.1089/aid.1989.5.233; NICOL I, 1989, INTERVIROLOGY, V30, P258, DOI 10.1159/000150101; OBRIEN TR, 1992, JAMA-J AM MED ASSOC, V267, P2775; PAN LZ, 1993, J CLIN MICROBIOL, V31, P283, DOI 10.1128/JCM.31.2.283-288.1993; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PEETERS M, 1991, AIDS, V5, pS29; PUTKONEN P, 1989, J ACQ IMMUN DEF SYND, V2, P366; RACZ P, 1986, PROG ALLERGY, V37, P81; RINGLER DJ, 1989, AM J PATHOL, V134, P373; ROSENBERG YJ, 1993, AIDS RES HUM RETROV, V9, P639, DOI 10.1089/aid.1993.9.639; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SCHROEDER SA, 1992, CHEST, V101, P1065, DOI 10.1378/chest.101.4.1065; SHIBATA R, 1992, AIDS RES HUM RETROV, V8, P403, DOI 10.1089/aid.1992.8.403; STAHLHENNIG C, 1990, AIDS, V4, P611, DOI 10.1097/00002030-199007000-00001; STROMBERG K, 1984, SCIENCE, V224, P289, DOI 10.1126/science.6200929; TEIRSTEIN AS, 1988, CLIN CHEST MED, V9, P467; WYAND MS, 1989, AM J PATHOL, V134, P385	46	83	84	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 28	1994	266	5185					642	646		10.1126/science.7939718	http://dx.doi.org/10.1126/science.7939718			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939718				2022-12-01	WOS:A1994PN80700046
J	THOMAS, KB				THOMAS, KB			THE PLACEBO IN GENERAL-PRACTICE	LANCET			English	Article											THOMAS, KB (corresponding author), UNIV SOUTHAMPTON,ALDERMOOR HLTH CTR,DEPT PRIMARY MED CARE,SOUTHAMPTON SO1 6ST,HANTS,ENGLAND.							BALINT M, 1957, DOCTOR PATIENT ILLNE; Cartwright Ann, 1967, PATIENTS THEIR DOCTO; CROMBIE DL, 1963, J COLL GEN PRACTIT, V6, P582; EIMERL TS, 1962, THESIS U LIVERPOOL; Lin T, 1962, SCOPE EPIDEMIOLOGY P; Marinker M, 1970, J R Coll Gen Pract, V19, P79; Marinker M, 1967, J R Coll Gen Pract, V14, P59; SHEPHERD M, 1966, PSYCHIATRIC ILLNESS; THOMAS KB, 1987, BRIT MED J, V294, P1200, DOI 10.1136/bmj.294.6581.1200; THOMAS KB, 1974, BRIT MED J, V1, P625, DOI 10.1136/bmj.1.5908.625; THOMAS KB, 1978, BRIT MED J, P1327; THOMAS KB, 1972, THESIS U LIVERPOOL; WILSON RM, 1926, BELOVED PHYSICIAN; 1958, 14 GEN REG OFF SUBJ; 1958, J COLL GEN PRACTIT, V1, P107; 1970, BRIT MED J, V11, P437; 1974, OFFICE POPULATION CE	17	56	57	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1066	1067		10.1016/S0140-6736(94)91716-7	http://dx.doi.org/10.1016/S0140-6736(94)91716-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7934451				2022-12-01	WOS:A1994PL85200016
J	PAVLIDIS, P; RAMASWAMI, M; TANOUYE, MA				PAVLIDIS, P; RAMASWAMI, M; TANOUYE, MA			THE DROSOPHILA EASILY SHOCKED GENE - A MUTATION IN A PHOSPHOLIPID SYNTHETIC PATHWAY CAUSES SEIZURE, NEURONAL FAILURE, AND PARALYSIS	CELL			English	Article							CHOLINE KINASE; ETHANOLAMINE KINASE; ESCHERICHIA-COLI; SODIUM-CHANNELS; RAT-LIVER; MELANOGASTER; EXPRESSION; PROTEIN; SEQUENCE; CLONING	We have characterized easily shocked (eas), a Drosophila ''bang-sensitive'' paralytic mutant. Electrophysiological recordings from flight muscles in the giant fiber pathway of adult eas flies reveal that induction of paralysis with electrical stimulation results in a brief seizure, followed by a failure of the muscles to respond to giant fiber stimulation. Molecular cloning, germline transformation, and biochemical experiments show that eas mutants are defective in the gene for ethanolamine kinase, which is required for a pathway of phosphatidylethanolamine synthesis. Assays of phospholipid composition reveal that total phosphatidylethanolamine is decreased in eas mutants. The data suggest that eas bang sensitivity is due to an excitability defect caused by altered membrane phospholipid composition.	UNIV CALIF BERKELEY,DEPT ENVIRONM SCI POLICY & MANAGEMENT,BERKELEY,CA 94720; TATA INST FUNDAMENTAL RES,MOLEC BIOL UNIT,BOMBAY 400005,MAHARASHTRA,INDIA	University of California System; University of California Berkeley; Tata Institute of Fundamental Research (TIFR)	PAVLIDIS, P (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV NEUROBIOL,BERKELEY,CA 94720, USA.		Pavlidis, Paul/H-8406-2013	Pavlidis, Paul/0000-0002-0426-5028; Ramaswami, Mani/0000-0001-7631-0468				ALNAES E, 1975, J PHYSL, V248, P306; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BENZER S, 1971, J AMER MED ASSOC, V218, P1015, DOI 10.1001/jama.218.7.1015; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BURT AM, 1975, ANAL BIOCHEM, V65, P215, DOI 10.1016/0003-2697(75)90506-0; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; DOWNER RGH, 1985, COMPREHENSIVE INSECT, P78; EXTON JH, 1994, CURR OPIN CELL BIOL, V6, P226, DOI 10.1016/0955-0674(94)90140-6; FALK DR, 1984, MUTAT RES, V126, P25, DOI 10.1016/0027-5107(84)90166-0; FAST PG, 1966, LIPIDS, V1, P209, DOI 10.1007/BF02531874; FOLCH J, 1957, J BIOL CHEM, V226, P497; FORTE M, 1981, P NATL ACAD SCI-BIOL, V78, P7195, DOI 10.1073/pnas.78.11.7195; GANETZKY B, 1982, GENETICS, V100, P597; Gorczyca M., 1984, Journal of Neurogenetics, V1, P289, DOI 10.3109/01677068409107093; HALL JC, 1985, COMPREHENSIVE INSECT, V9, P287; HEILIG JS, 1991, EMBO J, V10, P809, DOI 10.1002/j.1460-2075.1991.tb08013.x; Herman Paul K., 1992, Trends in Cell Biology, V2, P363, DOI 10.1016/0962-8924(92)90048-R; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; HOSAKA K, 1992, FEBS LETT, V304, P229, DOI 10.1016/0014-5793(92)80625-Q; IKEDA K, 1980, J NEUROCYTOL, V9, P799, DOI 10.1007/BF01205020; JACKSON FR, 1985, J NEUROSCI, V5, P1144; JAN YN, 1978, P NATL ACAD SCI USA, V75, P515, DOI 10.1073/pnas.75.1.515; JONES KR, 1990, NEURON, V4, P711, DOI 10.1016/0896-6273(90)90197-N; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; KENNEDY EP, 1957, ANNU REV BIOCHEM, V26, P119, DOI 10.1146/annurev.bi.26.070157.001003; KING DG, 1980, J NEUROCYTOL, V9, P753, DOI 10.1007/BF01205017; LI M, 1993, SCIENCE, V261, P1439, DOI 10.1126/science.8396273; MARTIN JH, 1993, PRINCIPLES NEURAL SC, P777; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MCGEE TP, 1993, PROTEIN LIPID INTERA, P163; MIDOZIC M, 1992, GENE EXPRESSION NEUR, P397; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; OLSEN RW, 1976, BRAIN RES, V102, P283, DOI 10.1016/0006-8993(76)90883-0; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; PORTER TJ, 1990, J BIOL CHEM, V265, P414; RAMABRAHMAM P, 1981, ARCH BIOCHEM BIOPHYS, V207, P55, DOI 10.1016/0003-9861(81)90007-2; ROBERTSON HM, 1988, GENETICS, V118, P461; ROYDEN CS, 1987, CELL, V51, P165, DOI 10.1016/0092-8674(87)90144-9; Sambrook J., 1989, MOL CLONING LAB MANU; SCHUBIGER M, 1994, NEURON, V12, P373, DOI 10.1016/0896-6273(94)90278-X; SHEETZ MP, 1974, P NATL ACAD SCI USA, V71, P4457, DOI 10.1073/pnas.71.11.4457; SHELLEY RM, 1971, J INSECT PHYSIOL, V17, P545, DOI 10.1016/0022-1910(71)90032-1; Skipski V.P., 1969, METHOD ENZYMOL, V14, P530; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; Sundler R., 1984, Biomembranes, V12, P563; SURDEJ P, 1990, BIOL CELL, V68, P105, DOI 10.1016/0248-4900(90)90295-E; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; TANOUYE MA, 1980, J NEUROPHYSIOL, V44, P405, DOI 10.1152/jn.1980.44.2.405; UCHIDA T, 1992, J BIOL CHEM, V267, P10156; ULANE RE, 1982, LUNG DEV BIOL CLIN P, V1, P295; WEINHOLD PA, 1974, BIOCHEMISTRY-US, V13, P5135, DOI 10.1021/bi00722a013; WILSON C, 1989, GENE DEV, V3, P1301, DOI 10.1101/gad.3.9.1301; Wu C F, 1992, Ion Channels, V3, P261; WU CF, 1980, NATURE, V286, P814, DOI 10.1038/286814a0; YEAGLE PL, 1989, FASEB J, V3, P1833, DOI 10.1096/fasebj.3.7.2469614; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0; [No title captured]	61	147	152	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					23	33		10.1016/0092-8674(94)90397-2	http://dx.doi.org/10.1016/0092-8674(94)90397-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923374				2022-12-01	WOS:A1994PK58500005
J	RANDALL, MD				RANDALL, MD			ENDOTHELINS - FROM LABORATORY TO CLINIC	LANCET			English	Editorial Material											RANDALL, MD (corresponding author), UNIV NOTTINGHAM,QUEENS MED CTR,SCH MED,DEPT PHYSIOL & PHARMACOL,NOTTINGHAM NG7 2UH,ENGLAND.							CLOZEL M, 1993, NATURE, V365, P759, DOI 10.1038/365759a0; DASHWOOD MR, 1993, CARDIOVASC PHARM S8, V22, pS343; DOUGLAS SA, 1993, J CARDIOVASC PHARM, V22, pS371, DOI 10.1097/00005344-199322008-00097; DOUGLAS SA, 1994, CIRC RES, V75, P190, DOI 10.1161/01.RES.75.1.190; GARDINER SM, 1994, BRIT J PHARMACOL, V112, P823, DOI 10.1111/j.1476-5381.1994.tb13153.x; HUGGINS JP, 1993, PHARMACOL THERAPEUT, V59, P55, DOI 10.1016/0163-7258(93)90041-B; MCMAHON EG, 1991, J CARDIOVASC PHARM, V17, pS29, DOI 10.1097/00005344-199100177-00009; OHLSTEIN EH, 1993, J CARDIOVASC PHARM, V22, pS321, DOI 10.1097/00005344-199322008-00084; RANDALL MD, 1991, PHARMACOL THERAPEUT, V50, P73, DOI 10.1016/0163-7258(91)90073-U; VALLANCE P, 1989, LANCET, V2, P997; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; ZAMORA MR, 1990, LANCET, V336, P1144, DOI 10.1016/0140-6736(90)92766-B; [No title captured]; 1991, LANCET, V337, P79	14	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					832	833		10.1016/S0140-6736(94)92819-3	http://dx.doi.org/10.1016/S0140-6736(94)92819-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH253	7916393				2022-12-01	WOS:A1994PH25300003
J	ARONHEIM, A; ENGELBERG, D; LI, NX; ALALAWI, N; SCHLESSINGER, J; KARIN, M				ARONHEIM, A; ENGELBERG, D; LI, NX; ALALAWI, N; SCHLESSINGER, J; KARIN, M			MEMBRANE TARGETING OF THE NUCLEOTIDE EXCHANGE FACTOR SOS IS SUFFICIENT FOR ACTIVATING THE RAS SIGNALING PATHWAY	CELL			English	Article							RECEPTOR TYROSINE KINASES; SACCHAROMYCES-CEREVISIAE CDC25; EPIDERMAL GROWTH-FACTOR; GENE-PRODUCT; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; MAMMALIAN RAS; TRANSDUCTION; GRB2; PHOSPHORYLATION	Activation of growth factor receptors results in tyrosine autophosphorylation and recruitment of SH2 domain-containing effecters, including Grb2. Grb2 recruitment mediates activation of the Ras nucleotide exchanger Sos by an unknown mechanism. To examine the role of membrane recruitment, we prepared Sos derivatives containing either myristoylation or farnesylation signals. This resulted in plasma membrane targeting of Sos and stimulation of the Ras signaling pathway, including ERK and AP-1 activities leading to oncogenic transformation. Sos derivatives with nonfunctional myristoylation or farnesylation sequences were inactive. Farnesylation of Sos also activated pas signaling in yeast. In both mammalian cells and yeast, membrane-targeted Sos derivatives lacking the C-terminal region were considerably more active. Therefore, targeting of Sos to the plasma membrane in the vicinity of Ras appears to be the primary mechanism leading to activation of the Ras pathway. A secondary mechanism could involve relief of the inhibitory effect of the Sos C-terminal region.	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,DEPT MED,PROGRAM BIOMED SCI,LA JOLLA,CA 92093; NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	University of California System; University of California San Diego; New York University	ARONHEIM, A (corresponding author), UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093, USA.			Aronheim, Ami/0000-0002-8575-4092				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUSS JE, 1988, MOL CELL BIOL, V8, P3960, DOI 10.1128/MCB.8.9.3960; CAMONIS JH, 1986, EMBO J, V5, P375, DOI 10.1002/j.1460-2075.1986.tb04222.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; DEBELL KE, 1992, J IMMUNOL, V149, P2271; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ENGELBERG D, 1990, EMBO J, V9, P641, DOI 10.1002/j.1460-2075.1990.tb08156.x; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GARREAU H, 1990, FEBS LETT, V269, P53, DOI 10.1016/0014-5793(90)81117-7; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HAUBRUCK H, 1991, BIOCHIM BIOPHYS ACTA, V1072, P215, DOI 10.1016/0304-419X(91)90015-D; HAYASHI H, 1992, J BIOL CHEM, V267, P22575; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MINDEN A, 1994, IN PRESS MOL CELL BI; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PAWSON T, 1993, CURR BIOL, V3, P4345; PETITJEAN A, 1990, GENETICS, V124, P797; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SEGAL M, 1992, J BIOL CHEM, V267, P22747; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUSA M, 1992, J BIOL CHEM, V267, P22951; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	65	425	445	0	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 23	1994	78	6					949	961		10.1016/0092-8674(94)90271-2	http://dx.doi.org/10.1016/0092-8674(94)90271-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923364				2022-12-01	WOS:A1994PJ29400007
J	BERNHARD, JD				BERNHARD, JD			THE SWEAT SUITE	LANCET			English	Editorial Material							GLAND-FUNCTION; DISORDERS; BIOLOGY				BERNHARD, JD (corresponding author), UNIV MASSACHUSETTS,MED CTR,DIV DERMATOL,WORCESTER,MA, USA.							CHAMPION RH, 1992, TXB DERMATOLOGY, P1745; Inaba M., 1992, HUMAN BODY ODOR ETIO; KLIGMAN AM, 1963, BRIT J DERMATOL, V75, P307, DOI 10.1111/j.1365-2133.1963.tb13567.x; PORTER AMW, 1993, J HUM EVOL, V25, P417, DOI 10.1006/jhev.1993.1059; SATO K, 1989, J AM ACAD DERMATOL, V20, P713, DOI 10.1016/S0190-9622(89)70081-5; SATO K, 1989, J AM ACAD DERMATOL, V20, P537, DOI 10.1016/S0190-9622(89)70063-3	6	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					767	768		10.1016/S0140-6736(94)92336-1	http://dx.doi.org/10.1016/S0140-6736(94)92336-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916068				2022-12-01	WOS:A1994PG17800005
J	MACSWEENEY, STR; ELLIS, M; WORRELL, PC; GREENHALGH, RM; POWELL, JT				MACSWEENEY, STR; ELLIS, M; WORRELL, PC; GREENHALGH, RM; POWELL, JT			SMOKING AND GROWTH-RATE OF SMALL ABDOMINAL AORTIC-ANEURYSMS	LANCET			English	Note							MORTALITY	Smoking is an important risk factor for abdominal aortic aneurysm. Limiting the growth rate of small aneurysms has the potential to prevent them reaching a size at which surgical repair is considered. In 43 patients, with small aneurysms, growth rates were studied by serial ultrasound over 3 years. The median expansion rate of these small aneurysms was 0.13 cm per year. Growth rates were higher in those who continued to smoke (0.16 vs 0.09 cm per year in those who no longer smoked, p = 0.038). Higher growth rates were significantly correlated with the concentration of serum cotinine. Stopping smoking could reduce the growth rate of small abdominal aortic aneurysms.			MACSWEENEY, STR (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,DEPT SURG,LONDON W6 8RF,ENGLAND.		Powell, Janet/AAW-8669-2021	Powell, Janet/0000-0002-3905-1468				ADISESHIAH M, 1993, LANCET, V341, P215; ELLIS M, 1991, BRIT J SURG, V78, P614, DOI 10.1002/bjs.1800780529; FEYERABEND C, 1980, ANALYST, V105, P998, DOI 10.1039/an9800500998; HAMMOND EC, 1969, ARCH ENVIRON HEALTH, V19, P167, DOI 10.1080/00039896.1969.10666825; HARRIS PL, 1992, BMJ-BRIT MED J, V305, P697, DOI 10.1136/bmj.305.6855.697; JENKINS AM, 1986, BRIT J SURG, V73, P395, DOI 10.1002/bjs.1800730528; JOHANSSON G, 1986, BRIT J SURG, V73, P101, DOI 10.1002/bjs.1800730205; MACSWEENEY STR, 1993, BRIT J SURG, V80, P582, DOI 10.1002/bjs.1800800510; STRACHAN DP, 1991, BRIT J SURG, V78, P401, DOI 10.1002/bjs.1800780407	9	145	145	1	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					651	652		10.1016/S0140-6736(94)92087-7	http://dx.doi.org/10.1016/S0140-6736(94)92087-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915350				2022-12-01	WOS:A1994PE38600012
J	STRANDGAARD, S; PAULSON, OB				STRANDGAARD, S; PAULSON, OB			CEREBROVASCULAR CONSEQUENCES OF HYPERTENSION	LANCET			English	Article							ANTIHYPERTENSIVE TREATMENT; BLOOD-PRESSURE; STROKE; INFARCTION		RIGSHOSP, DEPT NEUROL, DK-2100 COPENHAGEN, DENMARK	Rigshospitalet; University of Copenhagen	STRANDGAARD, S (corresponding author), HERLEV HOSP, DEPT MED & NEPHROL B, DK-2730 HERLEV, DENMARK.		Paulson, Olaf B./N-6924-2016	Paulson, Olaf B./0000-0001-7712-8596				[Anonymous], 1991, JAMA, V265, P3255; BRITTON M, 1986, STROKE, V17, P861, DOI 10.1161/01.STR.17.5.861; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DONNAN GA, 1992, LANCET, V339, P473, DOI 10.1016/0140-6736(92)91070-O; FUJII K, 1992, HYPERTENSION, V19, P713, DOI 10.1161/01.HYP.19.6.713; HACHINSKI VC, 1987, ARCH NEUROL-CHICAGO, V44, P21, DOI 10.1001/archneur.1987.00520130013009; HANKEY GJ, 1987, MED J AUSTRALIA, V146, P412, DOI 10.5694/j.1326-5377.1987.tb120332.x; IRIE K, 1993, STROKE, V24, P1844, DOI 10.1161/01.STR.24.12.1844; LEDINGHAM JGG, 1979, Q J MED, V48, P25; MOYER JH, 1952, AM J MED SCI, V224, P377, DOI 10.1097/00000441-195210000-00002; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; PAULSON OB, 1994, HYPERTENSION PATHOPH; SANDERCOCK P, 1992, LANCET, V339, P537, DOI 10.1016/0140-6736(92)90348-7; SPENCE JD, 1986, STROKE, V17, P808, DOI 10.1161/01.STR.17.5.808; STRANDGAARD S, 1987, LANCET, V2, P658; Strandgaard Svend, 1993, P675; YAO H, 1992, STROKE, V23, P1673, DOI 10.1161/01.STR.23.11.1673	18	57	58	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 20	1994	344	8921					519	521		10.1016/S0140-6736(94)91903-8	http://dx.doi.org/10.1016/S0140-6736(94)91903-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7914618				2022-12-01	WOS:A1994PC53500014
J	MELNICK, J; DUL, JL; ARGON, Y				MELNICK, J; DUL, JL; ARGON, Y			SEQUENTIAL INTERACTION OF THE CHAPERONES BIP AND GRP94 WITH IMMUNOGLOBULIN-CHAINS IN THE ENDOPLASMIC-RETICULUM	NATURE			English	Article							GLUCOSE-REGULATED PROTEIN; BINDING-SPECIFICITY; BIP; HSP90; GLYCOPROTEIN; CELLS; ASSOCIATION; ABUNDANT; ATPASE; GENES	During their transit through the endoplasmic reticulum, newly synthesized light and heavy chains of immunoglobulins associate with two endoplasmic reticulum stress proteins. BiP/GRP78, a member of the HSP70 family, binds these polypeptides, presumably through promiscuously exposed hydrophobic sequences(1,2), soon after their translocation into the endoplasmic reticulum(3,4). GRP94, another endoplasmic reticulum stress protein(5,6) homologous to HSP90(7-11), also associates,vith unassembled immunoglobulin chains(12), but its interaction is biochemically, kinetically and structurally distinct from BiP's. We report here that whereas BiP preferentially binds an early disulphide intermediate of light chain and dissociates within a few minutes, GRP94 exclusively binds fully oxidized molecules and dissociates with a half-time of 50 min. These results indicate that GRP94 is itself a chaperone which acts after BiP.	DUKE UNIV,MED CTR,DEPT IMMUNOL,DURHAM,NC 27710	Duke University								BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOGEN B, 1989, SCAND J IMMUNOL, V29, P273, DOI 10.1111/j.1365-3083.1989.tb01125.x; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; COWAN NJ, 1974, J MOL BIOL, V90, P691, DOI 10.1016/0022-2836(74)90533-6; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; KOCH G, 1986, J CELL SCI, V86, P217; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEE AS, 1983, J BIOL CHEM, V258, P597; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; LIN HY, 1993, MOL BIOL CELL, V4, P1109, DOI 10.1091/mbc.4.11.1109; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NADEAU K, 1993, J BIOL CHEM, V268, P1479; NAVARRO D, 1991, VIROLOGY, V184, P253, DOI 10.1016/0042-6822(91)90842-Y; SCHAIFF WT, 1992, J EXP MED, V176, P657, DOI 10.1084/jem.176.3.657; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SORGER PK, 1987, J MOL BIOL, V194, P341, DOI 10.1016/0022-2836(87)90380-9; WHELAN SA, 1985, J CELL PHYSIOL, V125, P251, DOI 10.1002/jcp.1041250212; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; WU GE, 1983, CELL, V33, P77, DOI 10.1016/0092-8674(83)90336-7	27	361	370	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 4	1994	370	6488					373	375		10.1038/370373a0	http://dx.doi.org/10.1038/370373a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	7913987				2022-12-01	WOS:A1994PA30400056
J	AZEM, A; KESSEL, M; GOLOUBINOFF, P				AZEM, A; KESSEL, M; GOLOUBINOFF, P			CHARACTERIZATION OF A FUNCTIONAL GROEL(14)(GROES(7))(2) CHAPERONIN HETERO-OLIGOMER	SCIENCE			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; CENTRAL CAVITY; GROEL; RECONSTITUTION; PURIFICATION; HYDROLYSIS; BINDING; HSP60	Chaperonins GroEL and GroES form two types of hetero-oligomers in vitro that can mediate the folding of proteins. Chemical cross-linking and electron microscopy showed that in the presence of adenosine triphosphate (ATP), two GroES(7) rings can successively bind a single GroEL(14) core oligomer. The symmetric GroEL(14)(GroES(7))(2) chaperonin, whose central cavity appears obstructed by two GroES(7) rings, can nonetheless stably bind and assist the ATP-dependent refolding of RuBisCO enzyme. Thus, unfolded proteins first bind and possibly fold on the external envelope of the chaperonin hetero-oligomer.	HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,DEPT BOT,IL-91904 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT MEMBRANE & ULTRASTRUCT RES,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem; Hebrew University of Jerusalem				Goloubinoff, Pierre/0000-0002-4802-0807				AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHRISTENSEN H, 1991, EUR BIOPHYS J, V19, P221, DOI 10.1007/BF00183530; DARAWSHE S, 1991, EUR J BIOCHEM, V201, P169, DOI 10.1111/j.1432-1033.1991.tb16270.x; ELLIS RJ, 1993, NATURE, V366, P213, DOI 10.1038/366213a0; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GRIMM R, 1993, J BIOL CHEM, V268, P5220; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425	30	145	147	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					653	656		10.1126/science.7913553	http://dx.doi.org/10.1126/science.7913553			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	7913553				2022-12-01	WOS:A1994NZ53800031
J	SUPPARATPINYO, K; KHAMWAN, C; BAOSOUNG, V; NELSON, KE; SIRISANTHANA, T				SUPPARATPINYO, K; KHAMWAN, C; BAOSOUNG, V; NELSON, KE; SIRISANTHANA, T			DISSEMINATED PENICILLIUM-MARNEFFEI INFECTION IN SOUTHEAST-ASIA	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PATIENT; THAILAND; MYCOSIS; CHINA	Disseminated infection with the fungal pathogen Penicillium marneffei is, after extrapulmonary tuberculosis and cryptococcal meningitis, the third most common opportunistic infection in HIV disease in northern Thailand. We report the clinical, microbiological, and therapeutic features of a large series of HIV-infected adults with disseminated P marneffei infection. From August, 1987, to June, 1992, 92 patients with Pmarneffei infection confirmed by culture were seen at Chiang Mai University Hospital, of whom 86 were also infected with HIV. Clinical information was available for 80 of these patients. The most common presenting symptoms and signs were fever (92%), anaemia (77%), weight loss (76%), and skin lesions (71%). 87% of patients presenting with skin lesions had generalised papules with central umbilication. Presumptive diagnosis was made in 50 patients by microscopic examination of Wright's-stained bone-marrow aspirate and/or touch smears of skin biopsy or lymph-node biopsy specimens. Most patients who were diagnosed responded initially to amphotericin or itraconazole, whereas most who were not diagnosed and treated died. 12 patients relapsed within 6 months of cessation of treatment. P marneffei has become an important pathogen of HIV-associated opportunistic infection in Thailand.	CHIANG MAI UNIV,FAC MED,DEPT MED,INFECT DIS SECT,CHIANG MAI 50002,THAILAND; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD	Chiang Mai University; Johns Hopkins University								ANCELLE T, 1988, Bulletin de la Societe Francaise de Mycologie Medicale, V17, P73; [Anonymous], 1959, BULL SOC MYCOL FR; CHAN JKC, 1989, ACTA CYTOL, V33, P523; CHAN YF, 1990, J BONE JOINT SURG BR, V72, P500, DOI 10.1302/0301-620X.72B3.2341456; CHIEWCHANVIT S, 1991, MYCOSES, V34, P245, DOI 10.1111/j.1439-0507.1991.tb00652.x; DENG ZL, 1985, AM J CLIN PATHOL, V84, P323, DOI 10.1093/ajcp/84.3.323; DENG ZL, 1988, REV INFECT DIS, V10, P640; DISALVO AF, 1973, AM J CLIN PATHOL, V60, P259; HILMARSDOTTIR I, 1993, J ACQ IMMUN DEF SYND, V6, P466; HOCKEY LJ, 1982, J CLIN MICROBIOL, V16, P1080, DOI 10.1128/JCM.16.6.1080-1085.1982; HULSHOF CMJ, 1990, EUR J CLIN MICROBIOL, V9, P370, DOI 10.1007/BF01973751; JAYANETRA P, 1984, AM J TROP MED HYG, V33, P637, DOI 10.4269/ajtmh.1984.33.637; JONES PD, 1992, CLIN INFECT DIS, V15, P744, DOI 10.1093/clind/15.4.744; LI JS, 1991, CHINESE MED J-PEKING, V104, P247; MA KF, 1991, ACTA CYTOL, V35, P557; PAUTLER KB, 1984, SABOURAUDIA, V22, P433; PETO TEA, 1988, J INFECTION, V16, P285, DOI 10.1016/S0163-4453(88)97700-6; PIEHL MR, 1988, ARCH PATHOL LAB MED, V112, P1262; SATHAPATAYAVONGS B, 1989, J INFECTION, V19, P84, DOI 10.1016/S0163-4453(89)95136-0; SIRISANTHANA V, 1993, PEDIATR INFECT DIS J, V12, P1021, DOI 10.1097/00006454-199312000-00013; SO SY, 1985, AM REV RESPIR DIS, V131, P662, DOI 10.1164/arrd.1985.131.4.662; SUPPARATPINYO K, 1992, CLIN INFECT DIS, V14, P871, DOI 10.1093/clinids/14.4.871; SUPPARATPINYO K, 1993, ANTIMICROB AGENTS CH, V37, P2407, DOI 10.1128/AAC.37.11.2407; TSANG DNC, 1991, REV INFECT DIS, V13, P766; TSANG DNC, 1988, HISTOPATHOLOGY, V13, P311, DOI 10.1111/j.1365-2559.1988.tb02041.x; TSUI WMS, 1992, HISTOPATHOLOGY, V20, P287, DOI 10.1111/j.1365-2559.1992.tb00985.x; VIVIANI MA, 1993, EUR J EPIDEMIOL, V9, P79, DOI 10.1007/BF00463094; Weniger B G, 1991, AIDS, V5 Suppl 2, pS71, DOI 10.1097/00002030-199101001-00011; YUEN WC, 1986, BRIT J SURG, V73, P1007, DOI 10.1002/bjs.1800731224; 1987, MMWR S1S, V36, pS1	30	403	458	2	24	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 9	1994	344	8915					110	113		10.1016/S0140-6736(94)91287-4	http://dx.doi.org/10.1016/S0140-6736(94)91287-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7912350	hybrid			2022-12-01	WOS:A1994NV73200015
J	BERREBI, A; KOBUCH, WE; BESSIERES, MH; BLOOM, MC; ROLLAND, M; SARRAMON, MF; ROQUES, C; FOURNIE, A				BERREBI, A; KOBUCH, WE; BESSIERES, MH; BLOOM, MC; ROLLAND, M; SARRAMON, MF; ROQUES, C; FOURNIE, A			TERMINATION OF PREGNANCY FOR MATERNAL TOXOPLASMOSIS	LANCET			English	Article							CONGENITAL TOXOPLASMOSIS	Termination of pregnancy is usually recommended to pregnant women who have infection with Toxoplasma gondii before 26 weeks of pregnancy if the fetus is infected. No prospective studies are available on the outcome if such pregnancies are allowed to continue with anti-parasitic treatment. We prospectively studied 163 mothers with acute toxoplasma infection before 28 weeks of amenorrhoea. All received anti-parasitic treatment with 9 million IU spiramycin orally. 23 also received pyrimethamine and sulphadiazine. All had cordocentesis and regular obstetric ultrasound examinations. The 162 liveborn infants were followed up for 15 to 71 months. 3 fetuses died in utero. 27 of 162 liveborn infants had proven congenital toxoplasmosis: 10 had one or more clinical signs of congenital toxoplasmosis; 5 had isolated or multiple intracranial calcifications; 7 had peripheral chorioretinitis; and 2 had moderate ventricular dilations. All 27 are free from symptoms and have normal neurological development at 15 to 71 months of age. We conclude that in first and second trimester pregnancies with acute fetal toxoplasma infection, the pregnancy need not be interrupted if repeated fetal ultrasound is normal, and antiparasitic treatment is given.	CHU RANGUEIL,DEPT MICROBIOL PARASITOL,TOULOUSE,FRANCE; UNIV TOULOUSE,DEPT PEDIAT,TOULOUSE,FRANCE	CHU de Toulouse; Universite de Toulouse	BERREBI, A (corresponding author), UNIV TOULOUSE,CHU LA GRAVE,DEPT OBSTET & GYNECOL,PL LANGE,F-31052 TOULOUSE,FRANCE.							Berrebi A., 1993, Journal de Gynecologie Obstetrique et Biologie de la Reproduction, V22, P261; CARDOZA JD, 1988, RADIOLOGY, V169, P711, DOI 10.1148/radiology.169.3.3055034; COUVREUR J, 1991, ARCH FR PEDIATR, V48, P397; DAFFOS F, 1988, NEW ENGL J MED, V318, P271, DOI 10.1056/NEJM198802043180502; DAFFOS F, 1992, 11E SEM DIAGN ANT MA, P9; DESMONTS G, 1974, NEW ENGL J MED, V290, P1110, DOI 10.1056/NEJM197405162902003; DESMONTS G, 1985, LANCET, V1, P500; Dorangeon P. H., 1992, Journal de Gynecologie Obstetrique et Biologie de la Reproduction, V21, P549; HOHFELD P, 1989, J PEDIATR, V115, P765; KOPPE JG, 1974, EUR J OBSTET GYN R B, V4, P101, DOI 10.1016/0028-2243(74)90029-X; Kraubig H., 1966, P104; Remington JS., 1990, INFECT DIS FETUS NEW, V3, P89; THALHAMMER O, 1957, TOXOPLASMOSE BEI MEN, P1; WILSON CB, 1980, AM J OBSTET GYNECOL, V138, P357, DOI 10.1016/0002-9378(80)90129-5; 1988, NEW ENGL J MED, V318, P313	15	62	68	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					36	39		10.1016/S0140-6736(94)91054-5	http://dx.doi.org/10.1016/S0140-6736(94)91054-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912304				2022-12-01	WOS:A1994NU91700017
J	FRANCIS, CY; WHORWELL, PJ				FRANCIS, CY; WHORWELL, PJ			BRAN AND IRRITABLE-BOWEL-SYNDROME - TIME FOR REAPPRAISAL	LANCET			English	Article								Whilst following up large numbers of patients with irritable bowel syndrome we got the impression that wholemeal wheat and bran products made people with the condition worse rather than better. One hundred consecutive new referrals, all of whom had tried bran, were questioned to resolve this issue. 55% of patients were made worse by bran whereas only 10% had found it helpful. With the exception of fruit, other forms of dietary fibre were not as detrimental and proprietary supplements were found to be beneficial. All symptoms of irritable bowel syndrome were exacerbated by bran, with bowel disturbance most often adversely affected, followed by abdominal distension and pain. The results of this study suggest that the use of bran in irritable bowel syndrome should be reconsidered. The study also raises the possibility that excessive consumption of bran in the community may actually be creating patients with irritable bowel syndrome by exacerbating mild, noncomplaining cases.	UNIV S MANCHESTER HOSP, DEPT MED, MANCHESTER M20 8LR, LANCS, ENGLAND	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital				Whorwell, Peter/0000-0002-5220-8474				DICKINSON RJ, 1982, LANCET, V2, P393; HARVEY RF, 1987, LANCET, V1, P963; HEATON KW, 1993, EUR J GASTROEN HEPAT, V5, P567, DOI 10.1097/00042737-199308000-00001; LYNN RB, 1993, NEW ENGL J MED, V329, P1940, DOI 10.1056/NEJM199312233292608; PAINTER NS, 1972, BRIT MED J, V2, P46, DOI 10.1136/bmj.2.5804.46-b; PAINTER NS, 1976, LANCET, V1, P540; RITCHIE J, 1982, PRACTITIONER, V226, P633; Thompson WG., 1989, GASTROENTEROL INT, V2, P92; 1980, MED ASPECTS DIETARY	9	208	215	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 2	1994	344	8914					39	40		10.1016/S0140-6736(94)91055-3	http://dx.doi.org/10.1016/S0140-6736(94)91055-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912305				2022-12-01	WOS:A1994NU91700018
J	KOVACS, JA; KOVACS, AAS				KOVACS, JA; KOVACS, AAS			PCP PROPHYLAXIS IN PEDIATRIC HIV-INFECTION - TIME FOR A CHANGE	LANCET			English	Editorial Material							PNEUMOCYSTIS-CARINII PNEUMONIA; CHILDREN		UNIV SO CALIF,LOS ANGELES CTY MED CTR,COMPREHENS MATERNAL CHILD HIV MANAGEMENT & RES CT,LOS ANGELES,CA 90033	University of Southern California	KOVACS, JA (corresponding author), NIH,DEPT CRIT CARE MED,BETHESDA,MD 20892, USA.		Kovacs, Joseph/AAU-6105-2021	Kovacs, Joseph/0000-0002-5191-9880				CHANOCK SJ, 1994, PEDIATRICS, V93, P519; CONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1693, DOI 10.1001/jama.265.13.1693; FREDERICK T, 1994, 1ST NAT C HUM RETR R, P693; KOVACS A, 1991, JAMA-J AM MED ASSOC, V265, P1698, DOI 10.1001/jama.265.13.1698; KOVACS A, 1993, 33RD ICAAC, P828; SIMONDS RJ, 1993, JAMA-J AM MED ASSOC, V270, P470, DOI 10.1001/jama.270.4.470; 1991, JAMA-J AM MED ASSOC, V265, P1637; 1994, BRIT MED J, V308, P437; 1989, MMWR-MORBID MORTAL W, V38, P1; 1993 CTR DIS CONTR P	10	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					5	6		10.1016/S0140-6736(94)91042-1	http://dx.doi.org/10.1016/S0140-6736(94)91042-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912309				2022-12-01	WOS:A1994NU91700005
J	GEPPERT, M; BOLSHAKOV, VY; SIEGELBAUM, SA; TAKEI, K; DECAMILLI, P; HAMMER, RE; SUDHOF, TC				GEPPERT, M; BOLSHAKOV, VY; SIEGELBAUM, SA; TAKEI, K; DECAMILLI, P; HAMMER, RE; SUDHOF, TC			THE ROLE OF RAB3A IN NEUROTRANSMITTER RELEASE	NATURE			English	Article							GTP-BINDING PROTEIN; SYNAPTIC VESICLES; TRANSMITTER RELEASE; SYNAPSIN-I; PROBABILITY; EXOCYTOSIS; PLASTICITY; RECEPTOR; NEURONS; MICE	THE small GTP-binding protein Rab3A is a Rab family member(1-3) that is abundant in brain synaptic vesicles(4,5). Here we show that mice in which the rab3A gene has been mutated by homologous recombination do not express Rab3A but are viable and fertile. Electrophysiological recordings in hippocampal CA1 pyramidal cells indicate that most of their synaptic parameters are also normal, although synaptic depression after short trains of repetitive stimuli (15-30 stimuli at 14 Hz) is significantly increased. Levels of the Rab3A-binding protein rabphilin are decreased by 70%, but expression of more than 20 other synaptic proteins is unchanged. No compensatory changes were detected in other GTP-binding proteins or in proteins that interact with Rab3. Rab3A thus appears not to be essential for synaptic vesicle exocytosis but to play a role in the recruitment of synaptic vesicles for exocytosis during repetitive stimulation.	UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; COLUMBIA UNIV, HOWARD HUGHES MED INST, CTR NEUROBIOL & BEHAV, DEPT PHARMACOL, NEW YORK, NY 10032 USA; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Columbia University; Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University				Takei, Kohji/0000-0002-6555-9425				BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BAUMERT M, 1993, BIOCHEM J, V293, P157, DOI 10.1042/bj2930157; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; DECAMILLI P, 1983, J CELL BIOL, V96, P1337, DOI 10.1083/jcb.96.5.1337; FYKSE EM, 1993, J NEUROSCI, V13, P4997; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1268; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; OCONNOR V, 1994, CELL, V76, P785, DOI 10.1016/0092-8674(94)90352-2; Peters A., 1978, FINE STRUCTURE NERVO, V4, P588; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; Sambrook J., 1989, MOL CLONING LAB MANU; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TAKEI K, 1992, J NEUROSCI, V12, P489; VONMOLLARD GF, 1994, J BIOL CHEM, V269, P10971; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0	30	412	420	0	16	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 9	1994	369	6480					493	497		10.1038/369493a0	http://dx.doi.org/10.1038/369493a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ286	7911226				2022-12-01	WOS:A1994NQ28600060
J	FORMAN, D; PIKE, MC; DAVEY, G; DAWSON, S; BAKER, K; CHILVERS, CED; OLIVER, RTD; COUPLAND, C; CARTWRIGHT, RA; ELWOOD, PC; BIRCH, J; TYRELL, C; BRETT, R; BUSH, T; ISBELL, V; CORNWELL, A; STEER, R; THISTLETHWAITE, S; GELLMAN, H; HUGHES, J; LLEWELLYN, M; ARDERNJONES, A; ALLEN, A; HILTON, E; LLOYD, B; MCVEIGH, S; THORNE, M; TROWBRIDGE, P; REID, S				FORMAN, D; PIKE, MC; DAVEY, G; DAWSON, S; BAKER, K; CHILVERS, CED; OLIVER, RTD; COUPLAND, C; CARTWRIGHT, RA; ELWOOD, PC; BIRCH, J; TYRELL, C; BRETT, R; BUSH, T; ISBELL, V; CORNWELL, A; STEER, R; THISTLETHWAITE, S; GELLMAN, H; HUGHES, J; LLEWELLYN, M; ARDERNJONES, A; ALLEN, A; HILTON, E; LLOYD, B; MCVEIGH, S; THORNE, M; TROWBRIDGE, P; REID, S			ETIOLOGY OF TESTICULAR CANCER - ASSOCIATION WITH CONGENITAL-ABNORMALITIES, AGE AT PUBERTY, INFERTILITY, AND EXERCISE	BRITISH MEDICAL JOURNAL			English	Article							GERM-CELL TUMORS; RISK-FACTORS; CARCINOMA INSITU; DOWNS-SYNDROME; UNITED-STATES; YOUNG MEN; TESTIS; EPIDEMIOLOGY; CRYPTORCHIDISM; VASECTOMY	Objective-To determine the risk of testicular cancer associated with undescended testis, inguinal hernia, age at puberty, marital status, infertility, vasectomy, and amount of exercise. Design-A population based case-control study with a questionnaire administered by an interviewer and with relevant supplementary data extracted from general practitioners' notes. Setting-Nine health regions within England and Wales. Subjects-794 men, aged 15-49 years, with a testicular germ cell tumour diagnosed between 1 January 1984 and 1 January 1987; each had an age matched (within one year) control selected from the list of their general practitioner. Results-There was a significant association of testicular cancer with undescended testis (odds ratio 3.82; 95% confidence interval 2.24 to 6.52) and inguinal hernia (1.91; 1.12 to 3.23). The excess risk associated with undescended testis was eliminated in men who had had an orchidopexy before the age of 10 years. There were positive associations with early age at voice breaking, early age at starting to shave, and infertility. There was a significant association with a sedentary lifestyle and a moderate protective effect of exercise. There was no association with vasectomy. Conclusion-This study confirms previous reports that developmental urogenital abnormalities result in an increased risk of testicular cancer. The trend to perform orchidopexy at younger ages may reduce the risk associated with undescended testis. The increased risks associated with early age at puberty and low amounts of exercise may be related to effects of exposure to endogenous hormones. Changes in both of these factors may partly contribute to the increasing rates of testicular cancer observed in the past few decades.	MRC,EPIDEMIOL UNIT,CARDIFF,WALES; UNIV MANCHESTER,DEPT EPIDEMIOL & SOCIAL ONCOL,MANCHESTER,LANCS,ENGLAND; FREEDOM FIELDS HOSP,PLYMOUTH ONCOL UNIT,PLYMOUTH,DEVON,ENGLAND; UNIV LEEDS,LEUKAEMIA RES FUND CTR,LEEDS,ENGLAND; INST CANC RES,EPIDEMIOL SECT,SUTTON,SURREY,ENGLAND; UNIV NOTTINGHAM,SCH MED,DEPT EPIDEMIOL & PUBL HLTH MED,NOTTINGHAM NG7 2RD,ENGLAND; ROYAL LONDON HOSP,DEPT MED ONCOL,LONDON E1 1BB,ENGLAND	University of Manchester; University of Leeds; University of London; Institute of Cancer Research - UK; University of Nottingham; Barts Health NHS Trust; Royal London Hospital	FORMAN, D (corresponding author), RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,CANC EPIDEMIOL UNIT,GIBSON BLDG,OXFORD OX2 6HE,ENGLAND.			Coupland, Carol/0000-0002-2327-3306				BEITINS IZ, 1991, J CLIN ENDOCR METAB, V72, P1350, DOI 10.1210/jcem-72-6-1350; BENSON RC, 1991, MAYO CLIN PROC, V66, P372, DOI 10.1016/S0025-6196(12)60660-0; BOYLE P, 1987, EUR J CANCER CLIN ON, V23, P827, DOI 10.1016/0277-5379(87)90286-0; BRAUN DL, 1985, AM J PEDIAT HEMATOL, V7, P208; Breslow N. E., 1980, SCI PUBLICATION, V32; BROWN LM, 1986, INT J EPIDEMIOL, V15, P164, DOI 10.1093/ije/15.2.164; BROWN LM, 1986, CANCER RES, V46, P4812; CALE ARJ, 1990, BRIT MED J, V300, P370, DOI 10.1136/bmj.300.6721.370; CHILVERS C, 1986, J PEDIATR SURG, V21, P691, DOI 10.1016/S0022-3468(86)80389-X; CHILVERS C, 1989, UROLOGICAL GENITAL C, P396; CHILVERS C, 1992, EUROPEAN UROLOGY UPD, V1, P74; COGGON D, 1986, BRIT J IND MED, V43, P381; COLDMAN AJ, 1982, BRIT J CANCER, V46, P749, DOI 10.1038/bjc.1982.267; DAVIS E, 1981, J ACM, V28, P721, DOI 10.1145/322276.322284; DEPUE RH, 1983, J NATL CANCER I, V71, P1151; DEPUE RH, 1986, J NATL CANCER I, V77, P830, DOI 10.1093/jnci/77.3.830; Doll R, 1992, Clin Oncol (R Coll Radiol), V4, P257, DOI 10.1016/S0936-6555(05)81065-9; FORMAN D, IN PRESS CANCER SURV; FORMAN D, 1970, PROGR CLIN BIOL RES, V357, P245; FORMAN D, 1989, UROLOGICAL GENITAL C, P289; FRISCH RE, 1981, JAMA-J AM MED ASSOC, V246, P1559, DOI 10.1001/jama.246.14.1559; GERSHMAN ST, 1988, INT J EPIDEMIOL, V17, P738, DOI 10.1093/ije/17.4.738; GRAHAM S, 1972, CANCER, V29, P1242, DOI 10.1002/1097-0142(197205)29:5<1242::AID-CNCR2820290517>3.0.CO;2-R; GRAHAM S, 1977, J NATL CANCER I, V58, P1225; HANSEN PV, 1989, CANCER, V64, P956, DOI 10.1002/1097-0142(19890815)64:4<956::AID-CNCR2820640431>3.0.CO;2-3; HASEN J, 1980, HORM RES, V12, P345, DOI 10.1159/000179141; HAUGHEY BP, 1989, AM J EPIDEMIOL, V130, P25, DOI 10.1093/oxfordjournals.aje.a115319; HENDERSON BE, 1979, INT J CANCER, V23, P598, DOI 10.1002/ijc.2910230503; JOHNSON DE, 1987, UROLOGY, V30, P199, DOI 10.1016/0090-4295(87)90231-7; LYNGE E, 1993, EUR J CANCER, V29A, P1064, DOI 10.1016/S0959-8049(05)80226-6; MCDOWALL ME, 1986, J EPIDEMIOL COMMUN H, V40, P26, DOI 10.1136/jech.40.1.26; MILLS PK, 1984, LANCET, V1, P207; MORRISON AS, 1976, J NATL CANCER I, V56, P731, DOI 10.1093/jnci/56.4.731; MOSS AR, 1986, AM J EPIDEMIOL, V124, P39, DOI 10.1093/oxfordjournals.aje.a114369; MUSTACCHI P, 1976, J NATL CANCER I, V56, P717, DOI 10.1093/jnci/56.4.717; NEWELL GR, 1987, J NATL CANCER I, V78, P881; OLIVER RTD, 1990, CANCER SURV, V9, P263; OPSTAD PK, 1992, J CLIN ENDOCR METAB, V74, P1176, DOI 10.1210/jc.74.5.1176; PEARCE N, 1987, CANCER, V59, P1677, DOI 10.1002/1097-0142(19870501)59:9<1677::AID-CNCR2820590926>3.0.CO;2-Q; PIKE MC, 1986, LANCET, V1, P1246; POTTERN LM, 1985, J NATL CANCER I, V74, P377; PRYOR JP, 1983, BRIT J UROL, V55, P780, DOI 10.1111/j.1464-410X.1983.tb03425.x; RAJPERTDEMEYTS E, 1993, EUR UROL, V23, P54; ROSS RK, 1979, BRIT J CANCER, V39, P284, DOI 10.1038/bjc.1979.53; SASAGAWA I, 1993, ARCH ANDROLOGY, V30, P93, DOI 10.3109/01485019308987740; SCHOTTENFELD D, 1980, AM J EPIDEMIOL, V112, P232, DOI 10.1093/oxfordjournals.aje.a112989; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; SKAKKEBAEK NE, 1978, HISTOPATHOLOGY, V2, P157, DOI 10.1111/j.1365-2559.1978.tb01706.x; STONE JM, 1991, CANCER, V68, P211, DOI 10.1002/1097-0142(19910701)68:1<211::AID-CNCR2820680139>3.0.CO;2-Q; STRADER CH, 1988, AM J EPIDEMIOL, V127, P1013, DOI 10.1093/oxfordjournals.aje.a114877; STRADER CH, 1988, AM J EPIDEMIOL, V128, P56, DOI 10.1093/oxfordjournals.aje.a114958; SWERDLOW AJ, 1989, INT J CANCER, V43, P549, DOI 10.1002/ijc.2910430403; SWERDLOW AJ, 1988, BRIT J IND MED, V45, P225; SWERDLOW AJ, 1987, BRIT J CANCER, V55, P97, DOI 10.1038/bjc.1987.20; TANNER JM, 1978, FETUS MAN PHYSICAL G; TARONE RE, 1991, J NATL CANCER I, V83, P1497, DOI 10.1093/jnci/83.20.1497; THORNHILL JA, 1987, BRIT J UROL, V59, P367, DOI 10.1111/j.1464-410X.1987.tb04660.x; WANDERAS EH, 1990, BRIT J UROL, V66, P315, DOI 10.1111/j.1464-410X.1990.tb14935.x; 1986, BRIT MED J, V293, P1401; 1993, SERIES MBI, V20	60	220	225	2	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 28	1994	308	6941					1393	1399		10.1136/bmj.308.6941.1393	http://dx.doi.org/10.1136/bmj.308.6941.1393			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP420	7912596				2022-12-01	WOS:A1994NP42000012
J	LANG, DM; POLANSKY, M				LANG, DM; POLANSKY, M			PATTERNS OF ASTHMA MORTALITY IN PHILADELPHIA FROM 1969 TO 1991	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHILDHOOD ASTHMA; AIR-POLLUTION; CHILDREN; DEATHS; PREDICTORS; RISK; CITY; RACE	Background. The rate of mortality from asthma has increased substantially in the United States since 1978. We analyzed the patterns of the rates of death from asthma in Philadelphia between 1969 and 1991. Methods. The rates of death from asthma were analyzed and compared with trends in the concentrations of major air pollutants: ozone, carbon monoxide, nitrogen dioxide, particulate matter (particles <10 mu m in diameter), and sulfur dioxide. Univariate and multivariate analyses were used to study the rates of death from asthma from 1985 to 1991 and their association with race, poverty, sex, and other factors. Results. The rate of death from asthma decreased from 1.68 per 100,000 people in 1969 to 0.68 per 100,000 in 1977, but then increased to 0.92 per 100,000 in 1978 and 2.41 per 100,000 in 1991. Between 1965 and 1990, the concentrations of major air pollutants declined substantially. From 1985 to 1991, 258 people were identified for whom asthma was the primary cause of death. According to multivariate analysis, the rates of death from asthma from 1985 to 1991 were significantly higher in census tracts with higher percentages of blacks (P = 0.032), Hispanics (P = 0.013), female residents (P<0.001), and people with incomes in the poverty range (P<0.001). Conclusions. The rates of death from asthma have increased in Philadelphia, whereas concentrations of major air pollutants have declined. The rates are highest in census tracts with the highest percentages of poor people and minority residents, particularly blacks. Public health efforts should target urban areas where the risk of death from asthma is highest.	HAHNEMANN UNIV,DEPT MED,DIV ALLERGY & IMMUNOL,PHILADELPHIA,PA 19102; HAHNEMANN UNIV,DEPT HUMAN SOCIAL SCI & BIOMETR,PHILADELPHIA,PA 19102	Drexel University; Drexel University								Aitken M, 1989, STATISTICAL MODELLIN, P217; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; COULTAS DB, 1994, AM J RESP CRIT CARE, V149, pS93, DOI 10.1164/ajrccm/149.3_Pt_2.S93; DRECHSLERPARKS DM, 1987, RES REP HLTH EFF I, V6, P1; Gadde JN, 1993, BRONCHIAL ASTHMA MEC, P1154; GIRSH LS, 1967, J ALLERGY, V39, P347, DOI 10.1016/0021-8707(67)90047-0; GREENBERGER PA, 1993, ALLERGY PROC, V14, P321, DOI 10.2500/108854193778773994; GREENLAND S, 1980, AM J EPIDEMIOL, V112, P564, DOI 10.1093/oxfordjournals.aje.a113025; HUNT LW, 1993, JAMA-J AM MED ASSOC, V269, P1947, DOI 10.1001/jama.269.15.1947; KAPLAN KM, 1993, PUBLIC HEALTH REP, V108, P66; MALVEAUX FJ, 1989, J ALLERGY CLIN IMMUN, V83, P1029, DOI 10.1016/0091-6749(89)90443-0; MARDER D, 1992, CHEST, V101, pS426, DOI 10.1378/chest.101.6.426S; MARGOLIS PA, 1992, AM J PUBLIC HEALTH, V82, P1119, DOI 10.2105/AJPH.82.8.1119; MASSICOT JG, 1986, J ALLERGY CLIN IMMUN, V78, P954, DOI 10.1016/0091-6749(86)90284-8; MCWHORTER WP, 1989, AM REV RESPIR DIS, V139, P721, DOI 10.1164/ajrccm/139.3.721; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; PLAUT TF, 1991, JAMA-J AM MED ASSOC, V265, P725, DOI 10.1001/jama.1991.03460060054021; POMA PA, 1988, J NATL MED ASSOC, V80, P1275; SAMET JM, 1987, AM REV RESPIR DIS, V136, P1486, DOI 10.1164/ajrccm/136.6.1486; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826, DOI 10.1164/ajrccm/147.4.826; SKOBELOFF EM, 1992, JAMA-J AM MED ASSOC, V268, P3437, DOI 10.1001/jama.268.24.3437; SLY RM, 1988, J ALLERGY CLIN IMMUN, V82, P705, DOI 10.1016/0091-6749(88)90069-3; STRUNK RC, 1989, J ALLERGY CLIN IMMUN, V83, P477, DOI 10.1016/0091-6749(89)90137-1; VANNIEKERK CH, 1979, CLIN ALLERGY, V9, P319; WEISS KB, 1992, CHEST, V101, pS362, DOI 10.1378/chest.101.6.362S; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189, DOI 10.1001/archpedi.1990.02150350021016; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; WOOLSON RF, 1987, STAT METHODS ANAL BI, P366; 1991, EPA450491023 PUBL; 1990, VITAL STATISTICS REP; 1993, CURRENT POPULATI P60, V185	34	227	228	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 8	1994	331	23					1542	1546		10.1056/NEJM199412083312302	http://dx.doi.org/10.1056/NEJM199412083312302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PV292	7969323	Bronze			2022-12-01	WOS:A1994PV29200002
J	ROBERTS, SB; FUSS, P; HEYMAN, MB; EVANS, WJ; TSAY, R; RASMUSSEN, H; FIATARONE, M; CORTIELLA, J; DALLAL, GE; YOUNG, VR				ROBERTS, SB; FUSS, P; HEYMAN, MB; EVANS, WJ; TSAY, R; RASMUSSEN, H; FIATARONE, M; CORTIELLA, J; DALLAL, GE; YOUNG, VR			CONTROL OF FOOD-INTAKE IN OLDER MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOUBLY LABELED WATER; ENERGY-EXPENDITURE; NATIONAL COHORT; BODY-WEIGHT; ADULTS; NUTRITION; HUMANS	Objective.-To investigate the effects of aging on mechanisms of body energy regulation and thereby determine the causes of unexplained weight loss in older persons, a factor predisposing to premature death and disability. Design.-Dietary intervention study. Setting.-Metabolic ward and outpatient. Participants.-The subjects were 35 healthy younger and older men of normal body weight consuming a diet of typical composition and performing usual activities. Main Outcome Measures.-Subjects were either overfed by a mean (+/-SD) of 4.09 (+/-0.26) MJ/d (n=17) or underfed by 3.17 (+/-0.68) MJ/d (n=18) for 21 days. Measurements were made of changes in body weight, body composition, and energy expenditure during overfeeding or underfeeding, and of subsequent voluntary nutrient intakes and changes in body weight. Results.-There was no significant effect of aging on changes in body composition, body weight, or energy expenditure with overfeeding or underfeeding. However, following overfeeding, younger men exhibited spontaneous hypophagia, whereas the older men did not (mean [+/-SD] changes in energy intake relative to control values were -2.11 [+/-2.18] and 1.55 [+/-2.11] MJ/d, respectively; P=.006). As a result, the younger men lost the excess body weight gained during overfeeding but the older men did not. Similarly, following underfeeding, the younger men exhibited hyperphagia while the older men did not (mean [+/-SD] changes in energy intake relative to control values were 1.88 [+/-2.31] and -0.52 [+/-1.54] MJ/d, respectively; P=.02), and as a result the older men failed to regain the weight lost during underfeeding. Conclusions.-These results in 35 men suggest that aging may be associated with a significant impairment in the ability to control food intake following overeating or undereating. Since overeating and undereating occur routinely as part of the normal pattern of energy regulation, the findings reported herein may help to explain the vulnerability of older persons to unexplained weight gain and weight loss.	MIT, CLIN RES CTR, CAMBRIDGE, MA 02139 USA; UNIV CALIF SAN FRANCISCO, DEPT PEDIAT, SAN FRANCISCO, CA 94143 USA	Massachusetts Institute of Technology (MIT); University of California System; University of California San Francisco	ROBERTS, SB (corresponding author), TUFTS UNIV, USDA, HUMAN NUTR RES CTR AGING, ENERGY METAB LAB, 711 WASHINGTON ST, BOSTON, MA 02111 USA.				NATIONAL INSTITUTE ON AGING [R37AG007388] Funding Source: NIH RePORTER; NIA NIH HHS [AG07388] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		DELMI M, 1990, LANCET, V335, P1013, DOI 10.1016/0140-6736(90)91073-J; DIPIETRO L, 1992, INT J OBESITY, V16, P745; DOTY RL, 1984, SCIENCE, V226, P1441, DOI 10.1126/science.6505700; DURNIN JVGA, 1974, BRIT J NUTR, V32, P77, DOI 10.1079/BJN19740060; EDHOLM OG, 1970, BRIT J NUTR, V24, P1091, DOI 10.1079/BJN19700112; Energy and protein requirements, 1985, TECHNICAL REPORT SER, V724; FANELLI MT, 1989, ANN NY ACAD SCI, V561, P94; FISCHER J, 1990, J AM DIET ASSOC, V90, P1697; GLICK Z, 1990, GERIATRIC NUTRITION, P27; GOSNELL BA, 1983, LIFE SCI, V32, P2793, DOI 10.1016/0024-3205(83)90401-0; LEAF A, 1984, NEW ENGL J MED, V311, P791, DOI 10.1056/NEJM198409203111209; LEIBOWITZ SF, 1988, NEUROBIOL AGING, V9, P20, DOI 10.1016/S0197-4580(88)80007-1; LIPSCHITZ DA, 1991, SEMIN DERMATOL, V10, P273; MILLER DK, 1990, J AM GERIATR SOC, V38, P645, DOI 10.1111/j.1532-5415.1990.tb01423.x; Morley J., 1990, GERIATRIC NUTRITION, P89; MORLEY JE, 1988, NEUROBIOL AGING, V9, P9, DOI 10.1016/S0197-4580(88)80004-6; MOWE M, 1994, AM J CLIN NUTR, V59, P317, DOI 10.1093/ajcn/59.2.317; NELSON RC, 1989, MED CLIN N AM, V73, P1531, DOI 10.1016/S0025-7125(16)30615-0; PACE N, 1945, J BIOL CHEM, V158, P685; PAMUK ER, 1992, AM J EPIDEMIOL, V136, P686, DOI 10.1093/oxfordjournals.aje.a116548; RABIN DL, 1987, LONG TERM CARE ELDER; ROBERTS SB, 1990, AM J PHYSIOL, V259, pR461, DOI 10.1152/ajpregu.1990.259.3.R461; ROBERTS SB, 1989, CAN J PHYSIOL PHARM, V67, P1190, DOI 10.1139/y89-189; ROBERTS SB, 1992, INT J OBESITY, V16, P969; ROBERTS SB, 1992, AM J PHYSIOL, V263, pR250; ROLLS BJ, 1992, NUTR REV, V50, P422, DOI 10.1111/j.1753-4887.1992.tb02496.x; ROSENBERG IH, 1992, NUTR REV, V50, P349; RUDMAN D, 1990, GERIATRIC NUTRITION, P325; SCHIFFMAN SS, 1989, ANN NY ACAD SCI, V561, P267, DOI 10.1111/j.1749-6632.1989.tb20988.x; SCHOELLER DA, 1988, J NUTR, V118, P1278, DOI 10.1093/jn/118.11.1278; Schutz Y., 1984, HUMAN ENERGY METABOL, P169; SHIMOKATA H, 1989, J GERONTOL, V44, pM66, DOI 10.1093/geronj/44.2.M66; SILVER AJ, 1988, PEPTIDES, V9, P221, DOI 10.1016/0196-9781(88)90254-9; STEEN B, 1988, NUTR REV, V46, P45, DOI 10.1111/j.1753-4887.1988.tb05386.x; TAYBACK M, 1990, ARCH INTERN MED, V150, P1065, DOI 10.1001/archinte.150.5.1065; WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363; 1990, PHS901232 US DEP HLT; 1983, PHS831681 US DEP HLT; 1991, EXTENDING LIFE ENHAN	39	290	297	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 23	1994	272	20					1601	1606		10.1001/jama.272.20.1601	http://dx.doi.org/10.1001/jama.272.20.1601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR405	7966871				2022-12-01	WOS:A1994PR40500027
J	KAPLAN, NM				KAPLAN, NM			MANAGEMENT OF HYPERTENSIVE EMERGENCIES	LANCET			English	Article							CEREBRAL BLOOD-FLOW; SODIUM-NITROPRUSSIDE; RENOVASCULAR HYPERTENSION; INTRAVENOUS LABETALOL; DANISH MULTICENTER; ORAL NIFEDIPINE; GRADE-III; PRESSURE; TRIAL; FENOLDOPAM				KAPLAN, NM (corresponding author), UNIV TEXAS,SW MED CTR,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.							ANGELI P, 1991, ARCH INTERN MED, V151, P678, DOI 10.1001/archinte.151.4.678; BARNETT AJ, 1973, MED J AUSTRALIA, V2, P960, DOI 10.5694/j.1326-5377.1973.tb129861.x; BARRY DI, 1989, AM J CARDIOL, V63, pC14, DOI 10.1016/0002-9149(89)90399-8; BING RF, 1986, J HYPERTENS, V4, pS42; BURNETT CF, 1955, NEW ENGL J MED, V253, P395, DOI 10.1056/NEJM195509082531001; CALHOUN DA, 1990, NEW ENGL J MED, V323, P1177; CHITWOOD WR, 1992, ANN THORAC SURG, V54, P517, DOI 10.1016/0003-4975(92)90446-B; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COTTRELL JE, 1978, J NEUROSURG, V48, P329, DOI 10.3171/jns.1978.48.3.0329; DAVIS BA, 1979, NEW ENGL J MED, V301, P1273, DOI 10.1056/NEJM197912063012307; DUNN FG, 1983, CLIN PHARMACOL THER, V33, P139, DOI 10.1038/clpt.1983.21; DUSTAN HP, 1958, CIRCULATION, V18, P644, DOI 10.1161/01.CIR.18.4.644; FELDMAN JM, 1987, J CLIN PHARMACOL, V27, P288, DOI 10.1002/j.1552-4604.1987.tb03015.x; GIFFORD RW, 1991, JAMA-J AM MED ASSOC, V266, P829, DOI 10.1001/jama.266.6.829; HARRINGTON M, 1959, BRIT MED J, V2, P978; HOOD B, 1970, ACTA MED SCAND, V187, P291; ISLES CG, 1984, Q J MED, V51, P439; Kaplan N, 1994, CLIN HYPERTENSION, P389; Kaplan NM., 1994, CLIN HYPERTENSION, P281; Keith NM, 1939, AM J MED SCI, V197, P332, DOI 10.1097/00000441-193903000-00006; KROGSGAARD AR, 1986, ACTA MED SCAND, V220, P25; MACMAHON S, 1993, CLIN EXP HYPERTENS, V15, P967, DOI 10.3109/10641969309037085; MAHARAJ B, 1992, AM HEART J, V124, P720, DOI 10.1016/0002-8703(92)90283-2; MANN SJ, 1992, ANN INTERN MED, V117, P845, DOI 10.7326/0003-4819-117-10-845; MCDONALD AJ, 1993, AM J EMERG MED, V11, P460, DOI 10.1016/0735-6757(93)90083-N; MCNAIR A, 1986, ACTA MED SCAND, V220, P15; OMVIK P, 1980, HYPERTENSION, V2, P515, DOI 10.1161/01.HYP.2.4.515; PERRY HM, 1958, ARCH INTERN MED, V102, P418, DOI 10.1001/archinte.1958.00030010418011; PHILLIPS SJ, 1994, HYPERTENSION, V23, P131, DOI 10.1161/01.HYP.23.1.131; PILMER BL, 1993, J CLIN PHARMACOL, V33, P549, DOI 10.1002/j.1552-4604.1993.tb04702.x; SCHWARTZ M, 1990, ARCH INTERN MED, V150, P686, DOI 10.1001/archinte.150.3.686; SHEPHERD AMM, 1986, J CARDIOVASC PHARM, V8, P527, DOI 10.1097/00005344-198605000-00014; SHUSTERMAN NH, 1993, AM J MED, V95, P161, DOI 10.1016/0002-9343(93)90256-O; SIMPSON F O, 1958, Scott Med J, V3, P1; STRANDGAARD S, 1989, AM J HYPERTENS, V2, P486, DOI 10.1093/ajh/2.6.486; STRANDGAARD S, 1973, BMJ-BRIT MED J, V1, P507, DOI 10.1136/bmj.1.5852.507; THULIN T, 1993, J HYPERTENS, V11, P83, DOI 10.1097/00004872-199301000-00012; WALLIN JD, 1989, ARCH INTERN MED, V149, P2662, DOI 10.1001/archinte.149.12.2662; WEBSTER J, 1993, Q J MED, V96, P485; WILSON DJ, 1983, AM J MED, V75, P95, DOI 10.1016/0002-9343(83)90141-9	40	60	62	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 12	1994	344	8933					1335	1338		10.1016/S0140-6736(94)90696-3	http://dx.doi.org/10.1016/S0140-6736(94)90696-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ926	7968030				2022-12-01	WOS:A1994PQ92600012
J	WATTERS, JK				WATTERS, JK			BEHAVIORAL-SCIENCE IN THE AIDS EPIDEMIC	LANCET			English	Editorial Material							SAN-FRANCISCO; MEN		UNIV CALIF SAN FRANCISCO,SCH MED,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	WATTERS, JK (corresponding author), UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143, USA.							BOOTH RE, 1994, AIDS, V8, P1515, DOI 10.1097/00002030-199411000-00001; Brown B. S., 1993, HDB RISK AIDS INJECT; FRIEDMAN SR, 1994, 10TH INT C AIDS YOK; MCKUSICK L, 1985, AM J PUBLIC HEALTH, V75, P493, DOI 10.2105/AJPH.75.5.493; MORRIS M, 1994, AM J EPIDEMIOL, V140, P217, DOI 10.1093/oxfordjournals.aje.a117241; NELSON KE, 1991, JAMA-J AM MED ASSOC, V266, P2250; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; VARMUS, 1994, LANCET          1029, P1215; WATTERS JK, 1994, JAMA-J AM MED ASSOC, V271, P115, DOI 10.1001/jama.271.2.115; WINKELSTEIN W, 1988, AM J PUBLIC HEALTH, V78, P1472, DOI 10.2105/AJPH.78.11.1472; 1994, WORKSHOP NEEDLE EXCH; 1990, MMWR-MORBID MORTAL W, V39, P529; 1994, LANCET, V344, P535; 1994, AIDS RISK BEHAVIOR I	14	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 12	1994	344	8933					1312	1313		10.1016/S0140-6736(94)90688-2	http://dx.doi.org/10.1016/S0140-6736(94)90688-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PQ926	7968024				2022-12-01	WOS:A1994PQ92600004
J	HUNTINGTON, J; CONNELL, FA				HUNTINGTON, J; CONNELL, FA			FOR EVERY DOLLAR SPENT - THE COST SAVINGS ARGUMENT FOR PRENATAL-CARE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							LOW-BIRTH-WEIGHT; MEDICAID; PROJECT; IMPACT; INFANT; BARRIERS; WOMEN		UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT HLTH SERV,SEATTLE,WA 98195; GRP HLTH COOPERAT PUGET SOUND,SEATTLE,WA 98112	University of Washington; University of Washington Seattle; Group Health Cooperative					PHS HHS [MCJ 9043] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BUESCHER PA, 1987, AM J OBSTET GYNECOL, V156, P204, DOI 10.1016/0002-9378(87)90239-0; CURRY M, 1987, ACCESS PRENATAL CARE; ENKIN M, 1982, CLIN DEV MED, V81, P266; GORSKY RD, 1989, HEALTH SERV RES, V24, P583; GUYER B, 1990, JAMA-J AM MED ASSOC, V264, P2264, DOI 10.1001/jama.264.17.2264; HAAS JS, 1993, JAMA-J AM MED ASSOC, V269, P87, DOI 10.1001/jama.269.1.87; HALL MH, 1980, LANCET, V2, P78; Huntington JL, 1913, BOSTON MED SURG J, V169, P763, DOI 10.1056/NEJM191311201692108; KORENBROT CC, 1984, MOBIUS, V4, P34; Lazarus E S, 1990, Med Anthropol, V12, P269; Leavitt J.W., 1986, BROUGHT BED CHILDBEA; Lennie J A, 1987, Health Care Financ Rev, V8, P83; LEPPERT PC, 1985, J NURSE-MIDWIFERY, V30, P285, DOI 10.1016/0091-2182(85)90044-8; LEVENO KJ, 1985, OBSTET GYNECOL, V66, P599; MOORE TR, 1986, AM J OBSTET GYNECOL, V154, P29, DOI 10.1016/0002-9378(86)90387-X; Morales W J, 1985, J Fla Med Assoc, V72, P852; OAKLEY A, 1990, BRIT J OBSTET GYNAEC, V97, P155, DOI 10.1111/j.1471-0528.1990.tb01741.x; PEOPLES MD, 1984, AM J PUBLIC HEALTH, V74, P549, DOI 10.2105/AJPH.74.6.549; PIPER JM, 1990, JAMA-J AM MED ASSOC, V264, P2219, DOI 10.1001/jama.264.17.2219; POLAND ML, 1987, AM J OBSTET GYNECOL, V157, P297, DOI 10.1016/S0002-9378(87)80156-4; SARDELL A, 1990, J HEALTH POLIT POLIC, V15, P271, DOI 10.1215/03616878-15-2-271; SCHRAMM WF, 1992, PUBLIC HEALTH REP, V107, P647; SCHWARTZ RM, 1989, FAM PLANN PERSPECT, V21, P170, DOI 10.2307/2135808; SOKOL RJ, 1980, OBSTET GYNECOL, V56, P150; STCLAIR PA, 1990, PUBLIC HEALTH REP, V105, P264; STROBINO DM, 1986, AM J PUBLIC HEALTH, V76, P274, DOI 10.2105/AJPH.76.3.274; Thompson JE, 1990, NEW PERSPECTIVES PAR, P9; Wertz Richard W., 1989, LYING HIST CHILDBIRT; WILSON AL, 1992, AM J PERINAT, V9, P281, DOI 10.1055/s-2007-994790; 1988, OTAH345 OFF TECHN AS; [No title captured]	31	70	71	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 10	1994	331	19					1303	1307		10.1056/NEJM199411103311910	http://dx.doi.org/10.1056/NEJM199411103311910			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PP752	7935689				2022-12-01	WOS:A1994PP75200010
J	JOHNSTONE, RA				JOHNSTONE, RA			FEMALE PREFERENCE FOR SYMMETRICAL MALES AS A BY-PRODUCT OF SELECTION FOR MATE RECOGNITION	NATURE			English	Article							MALE SEXUAL ORNAMENTS; FLUCTUATING ASYMMETRY; EVOLUTION; PATTERNS; STRESS; BIASES	FLUCTUATING asymmetry (FA) refers to the random, stress-induced deviations from perfect symmetry that develop during the growth of bilaterally symmetrical traits(1,2). Individual differences in the level of FA may influence mate choice(3): in a number of species, females prefer to mate with males that have more symmetrical sexual ornaments(4-7). As the degree of FA has been shown to reflect the ability of individuals to cope with a wide variety of environmental stresses(2,8,9), it has been suggested that mating preferences for symmetry evolve for adaptive reasons, because the degree of FA provides honest information about male quality(10,11). Here I use simple, artificial neural networks to show that such preferences are likely to arise in the absence of any link between symmetry and quality, as a by-product of selection for mate recognition.			JOHNSTONE, RA (corresponding author), UNIV CAMBRIDGE,DEPT ZOOL,DOWNING ST,CAMBRIDGE CB2 3EJ,ENGLAND.							ARAK A, 1993, PHILOS T R SOC B, V340, P207, DOI 10.1098/rstb.1993.0059; ENQUIST M, 1993, NATURE, V361, P446, DOI 10.1038/361446a0; HARVEY IF, 1993, ECOL ENTOMOL, V18, P198, DOI 10.1111/j.1365-2311.1993.tb01090.x; LEARY RF, 1989, TRENDS ECOL EVOL, V4, P214, DOI 10.1016/0169-5347(89)90077-3; LEIMAR O, 1986, AM NAT, V128, P469, DOI 10.1086/284581; MOLLER AP, 1993, BEHAV ECOL SOCIOBIOL, V32, P167; MOLLER AP, 1992, NATURE, V357, P238, DOI 10.1038/357238a0; MOLLER AP, 1990, ANIM BEHAV, V40, P1185, DOI 10.1016/S0003-3472(05)80187-3; MOLLER AP, 1993, BEHAV ECOL SOCIOBIOL, V32, P371, DOI 10.1007/BF00168820; PACKER C, 1993, NATURE, V362, P595, DOI 10.1038/362595a0; PALMER AR, 1986, ANNU REV ECOL SYST, V17, P391, DOI 10.1146/annurev.es.17.110186.002135; PARSONS PA, 1990, BIOL REV, V65, P131, DOI 10.1111/j.1469-185X.1990.tb01186.x; RADESATER T, 1993, ANIM BEHAV, V45, P626, DOI 10.1006/anbe.1993.1075; Ryan M.J., 1990, Oxford Surveys in Evolutionary Biology, V7, P157; RYAN MJ, 1993, PHILOS T ROY SOC B, V340, P187, DOI 10.1098/rstb.1993.0057; RYAN MJ, 1992, AM NAT, V139, pS4, DOI 10.1086/285303; STADDON JER, 1975, AM NAT, V109, P541, DOI 10.1086/283025; SWADDLE JP, 1994, NATURE, V367, P165, DOI 10.1038/367165a0; VANVALEN L, 1962, EVOLUTION, V16, P125; WATSON PJ, 1994, TRENDS ECOL EVOL, V9, P21, DOI 10.1016/0169-5347(94)90227-5; ZAHAVI A, 1975, J THEOR BIOL, V53, P205, DOI 10.1016/0022-5193(75)90111-3	21	161	161	0	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 10	1994	372	6502					172	175		10.1038/372172a0	http://dx.doi.org/10.1038/372172a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ688	7969449				2022-12-01	WOS:A1994PQ68800054
J	PLEY, HW; FLAHERTY, KM; MCKAY, DB				PLEY, HW; FLAHERTY, KM; MCKAY, DB			3-DIMENSIONAL STRUCTURE OF A HAMMERHEAD RIBOZYME	NATURE			English	Article							SELF-CLEAVAGE REACTION; VIRUS SATELLITE RNA; EFFICIENT CLEAVAGE; MOLECULAR-DYNAMICS; PURINE AMINO; OLIGORIBONUCLEOTIDES; PHOSPHOROTHIOATE; GUANOSINES; MECHANISM; SEQUENCE	The hammerhead ribozyme is a small catalytic RNA motif made up of three base-paired stems and a core of highly conserved, non-complementary nucleotides essential for catalysis. The X-ray crystallographic structure of a hammerhead RNA-RNA ribozyme-inhibitor complex at 2.6 Angstrom resolution reveals that the base-paired stems are A-form helices and that the core has two structural domains. The first domain is formed by the sequence 5'-CUGA following stem I and is a sharp turn identical to the uridine turn of transfer RNA, whereas the second is a non-Watson-Crick three-base-pair duplex with a divalent-ion binding site. The phosphodiester backbone of the DNA inhibitor strand is splayed out at the phosphate 5' to the cleavage site. The structure indicates that the ribozyme may destabilize a substrate strand in order to facilitate twisting of the substrate to allow cleavage of the scissile bond.	STANFORD UNIV, SCH MED, DEPT BIOL STRUCT, BECKMAN LABS STRUCT BIOL, STANFORD, CA 94305 USA	Stanford University								BRANDHUBER BJ, 1987, J BIOL CHEM, V262, P12306; BRATTY J, 1993, BIOCHIM BIOPHYS ACTA, V1216, P345, DOI 10.1016/0167-4781(93)90001-T; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BUZAYAN JM, 1986, NUCLEIC ACIDS RES, V14, P9729, DOI 10.1093/nar/14.24.9729; BUZAYAN JM, 1986, NATURE, V323, P349, DOI 10.1038/323349a0; DAHM SC, 1993, BIOCHEMISTRY-US, V32, P13040, DOI 10.1021/bi00211a013; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; DAHM SC, 1990, BIOCHIMIE, V72, P819, DOI 10.1016/0300-9084(90)90191-I; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; FU DJ, 1992, P NATL ACAD SCI USA, V89, P3985, DOI 10.1073/pnas.89.9.3985; FU DJ, 1993, BIOCHEMISTRY-US, V32, P10629, DOI 10.1021/bi00091a013; GRASBY JA, 1993, NUCLEIC ACIDS RES, V21, P4444, DOI 10.1093/nar/21.19.4444; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; HERTEL KJ, 1994, BIOCHEMISTRY-US, V33, P3374, DOI 10.1021/bi00177a031; HUTCHINS CJ, 1986, NUCLEIC ACIDS RES, V14, P3627, DOI 10.1093/nar/14.9.3627; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KOIZUMI M, 1991, BIOCHEMISTRY-US, V30, P5145, DOI 10.1021/bi00235a005; PERREAULT JP, 1990, NATURE, V344, P565, DOI 10.1038/344565a0; PLEY HW, 1993, J BIOL CHEM, V268, P19656; PRODY GA, 1986, SCIENCE, V231, P1577, DOI 10.1126/science.231.4745.1577; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; ROSSMANN MG, 1976, ACTA CRYSTALLOGR A, V32, P774, DOI 10.1107/S0567739476001587; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; RUFFNER DE, 1990, NUCLEIC ACIDS RES, V18, P6025, DOI 10.1093/nar/18.20.6025; SANTALUCIA J, 1993, BIOCHEMISTRY-US, V32, P12612, DOI 10.1021/bi00210a009; SHELDON CC, 1989, NUCLEIC ACIDS RES, V17, P5679, DOI 10.1093/nar/17.14.5679; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; SLIM G, 1991, NUCLEIC ACIDS RES, V19, P1183, DOI 10.1093/nar/19.6.1183; SLIM G, 1992, BIOCHEM BIOPH RES CO, V183, P605, DOI 10.1016/0006-291X(92)90525-P; STEIGEMANN W, 1974, THESIS TU MUNCHEN; TUSCHL T, 1993, P NATL ACAD SCI USA, V90, P6991, DOI 10.1073/pnas.90.15.6991; TUSCHL T, 1993, BIOCHEMISTRY-US, V32, P11658, DOI 10.1021/bi00094a023; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; VANTOL H, 1990, NUCLEIC ACIDS RES, V18, P1971, DOI 10.1093/nar/18.8.1971; WILLIAMS DM, 1992, P NATL ACAD SCI USA, V89, P918, DOI 10.1073/pnas.89.3.918	36	937	981	3	70	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 3	1994	372	6501					68	74		10.1038/372068a0	http://dx.doi.org/10.1038/372068a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969422				2022-12-01	WOS:A1994PQ34800071
J	RIDDIHOUGH, G				RIDDIHOUGH, G			FIRST-LINE DEFENSE	NATURE			English	Article							BINDING	Structural insight into the trimeric organization of the human mannose-binding protein sheds light on the workings of the non-clonal, innate immune response in vertebrates.										HOPPE HJ, 1994, PROTEIN SCI, V3, P1143, DOI 10.1002/pro.5560030801; HOPPE HJ, 1994, FEBS LETT, V344, P191, DOI 10.1016/0014-5793(94)00383-1; SHERIFF S, 1994, NAT STRUCT BIOL, V1, P789, DOI 10.1038/nsb1194-789; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0	5	3	3	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					114	114		10.1038/372114a0	http://dx.doi.org/10.1038/372114a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969405				2022-12-01	WOS:A1994PQ34800086
J	BRENNWALD, P; KEARNS, B; CHAMPION, K; KERANEN, S; BANKAITIS, V; NOVICK, P				BRENNWALD, P; KEARNS, B; CHAMPION, K; KERANEN, S; BANKAITIS, V; NOVICK, P			SEC9 IS A SNAP-25-LIKE COMPONENT OF A YEAST SNARE COMPLEX THAT MAY BE THE EFFECTOR OF SEC4 FUNCTION IN EXOCYTOSIS	CELL			English	Article							INTEGRAL MEMBRANE-PROTEIN; GTP-BINDING PROTEINS; SACCHAROMYCES-CEREVISIAE; VESICULAR TRANSPORT; SECRETORY VESICLES; SYNAPTIC VESICLES; PLASMA-MEMBRANE; PATHWAY; FUSION; FAMILY	To identify potential Sec4 effecters, we isolated high copy suppressors of a Sec4 effector domain mutant. The most potent of these was found to be SEC9, a gene required for post-Golgi transport. The sole essential domain of Sec9 has significant sequence similarity to the neuronal protein SNAP-25, a component of the SNARE complex, that is implicated in vesicle targeting and fusion. Analogous to SNAP-25, Sec9 is bound to the yeast plasma membrane and is absent from post-Golgi vesicles. Furthermore, Sec9 is physically associated with two proteins that are homologous to components of the neuronal SNARE complex. Our results identify Sec9 as the yeast cognate of SNAP-25 and suggest that SNARE complexes acting at specific stages of vesicular transport serve as the ultimate targets of regulation by members of the Sec4/Ypt1/Rab family of GTPases.	YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06520 USA; UNIV ALABAMA, DEPT CELL BIOL, BIRMINGHAM, AL 35294 USA; UNIV ILLINOIS, DEPT MICROBIOL, URBANA, IL 61801 USA; VTT BIOTECHNOL & FOOD RES, SF-02044 ESPOO, FINLAND	Yale University; University of Alabama System; University of Alabama Birmingham; University of Illinois System; University of Illinois Urbana-Champaign; VTT Technical Research Center Finland					NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035370, R01GM044530, R01GM035370] Funding Source: NIH RePORTER; NCI NIH HHS [CA46128] Funding Source: Medline; NIGMS NIH HHS [GM44530, GM35370] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BOWSER R, 1992, J CELL BIOL, V118, P1041, DOI 10.1083/jcb.118.5.1041; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; INOUE A, 1992, J BIOL CHEM, V267, P10613; KIBBE WA, 1993, RAS SUPERFAMILY GTPA, P367; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; RINE J, 1991, METHOD ENZYMOL, V194, P239; RISINGER C, 1993, P NATL ACAD SCI USA, V90, P10598, DOI 10.1073/pnas.90.22.10598; RISINGER C, 1993, J BIOL CHEM, V268, P24408; SALAMA SR, 1990, J BACTERIOL, V172, P4510, DOI 10.1128/jb.172.8.4510-4521.1990; SCHLAVO G, 1993, J BIOL CHEM, V288, P23784; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; WALWORTH NC, 1989, METHOD CELL BIOL, V31, P335; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163; WOOTTON JC, 1989, PROTEIN ENG, V2, P535, DOI 10.1093/protein/2.7.535; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	33	305	308	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	1994	79	2					245	258		10.1016/0092-8674(94)90194-5	http://dx.doi.org/10.1016/0092-8674(94)90194-5			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954793				2022-12-01	WOS:A1994PN63000009
J	AUBUCHON, JP; BIRKMEYER, JD				AUBUCHON, JP; BIRKMEYER, JD			SAFETY AND COST-EFFECTIVENESS OF SOLVENT-DETERGENT-TREATED PLASMA - IN SEARCH OF A ZERO-RISK BLOOD-SUPPLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; FRESH-FROZEN PLASMA; ARTERY BYPASS-SURGERY; TRANSFUSION; HEPATITIS; INACTIVATION; INFECTION; DERIVATIVES; COMPONENTS; HIV	Objective.-To determine the public health and economic implications of Solvent-detergent-treated frozen plasma (SD FP). While this processing technique nearly eliminates the risk of transmitting lipid-enveloped viruses (hepatitis B and C and human immunodeficiency virus), it has associated costs and, because it requires pooling many plasma units, may increase risks of nonenveloped virus transmission. Design.-A previously published Markov decision analysis model was modified to assess transfusion-related outcomes in hypothetical cohorts of plasma recipients. In-hospital mortality and other characteristics were determined in 61 patients receiving plasma transfusions at a medium-sized tertiary care center to provide data for the model. Other parameters were obtained from the medical literature. Main Outcome Measures.-Expected SD FP costs, benefits, and cost-effectiveness, assessed as cost per quality-adjusted life-year saved. Results.-Compared with untreated plasma, a unit of SD FP produces a net benefit of 35 minutes in quality-adjusted life expectancy at a cost of about $19. Extrapolated to the 2.2 million plasma units transfused annually in the United States, SD FP would save 147 quality-adjusted life-years at a cost of $42.5 million. The marginal cost-effectiveness, $289 300 per quality-adjusted life-year saved in the baseline analysis, was most sensitive to estimates of SD treatment cost and the clinical setting of plasma use. In sensitivity analysis, the net benefit of SD FP was negated by the existence of even a minute risk of nonenveloped virus infection. Conclusions.-From a public health perspective, the relatively high costs and small benefits of reducing enveloped virus infection risks with SD FP (and the additional risks of nonenveloped virus transmission) do not appear to justify widespread implementation of this new technology.	DARTMOUTH COLL,HITCHCOCK MED CTR,DEPT SURG,LEBANON,NH 03756; DARTMOUTH COLL,HITCHCOCK MED CTR,CTR EVALUAT CLIN SCI,LEBANON,NH 03756	Dartmouth College; Dartmouth College	AUBUCHON, JP (corresponding author), DARTMOUTH COLL,HITCHCOCK MED CTR,DEPT PATHOL,1 MED CTR DR,LEBANON,NH 03756, USA.							ANDERSON LJ, 1991, CURR CLIN TOP INFECT, V11, P261; ARNO PS, 1989, JAMA-J AM MED ASSOC, V262, P1493, DOI 10.1001/jama.262.11.1493; AUBUCHON JP, 1992, CLIN LAB MED, V12, P787, DOI 10.1016/S0272-2712(18)30488-8; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BIRKMEYER JD, 1993, TRANSFUSION, V33, P544, DOI 10.1046/j.1537-2995.1993.33793325048.x; BIRKMEYER JD, 1994, ANN THORAC SURG, V57, P161, DOI 10.1016/0003-4975(94)90386-7; BLOOM BS, 1993, ANN INTERN MED, V118, P298, DOI 10.7326/0003-4819-118-4-199302150-00009; BOWDEN RA, 1991, BLOOD, V78, P246; BUSCH MP, 1991, NEW ENGL J MED, V325, P1, DOI 10.1056/NEJM199107043250101; COHEN BJ, 1990, J VIROL METHODS, V30, P233, DOI 10.1016/0166-0934(90)90065-N; CONTRERAS M, 1991, LANCET, V337, P753, DOI 10.1016/0140-6736(91)91370-A; CUMMING PD, 1989, NEW ENGL J MED, V321, P941, DOI 10.1056/NEJM198910053211405; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; DODD RY, 1990, TRANSFUSION MEDICINE IN THE 1990S, P223; DONAHUE JG, 1992, NEW ENGL J MED, V327, P869; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; EDWARDS CA, 1987, VOX SANG, V52, P53, DOI 10.1111/j.1423-0410.1987.tb02989.x; EVANS RW, 1986, SURG CLIN N AM, V66, P603; GERITZEN A, 1992, LANCET, V340, P1231; GOODNOUGH LT, 1991, JAMA-J AM MED ASSOC, V265, P86, DOI 10.1001/jama.265.1.86; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; HELLINGER FJ, 1990, PUBLIC HEALTH REP, V105, P1; HELLSTERN P, 1992, VOX SANG, V63, P178, DOI 10.1111/j.1423-0410.1992.tb05097.x; HOROWITZ B, 1990, YALE J BIOL MED, V63, P361; HOROWITZ B, 1985, TRANSFUSION, V25, P516, DOI 10.1046/j.1537-2995.1985.25686071422.x; HOROWITZ B, 1992, BLOOD, V79, P826; HOROWITZ B, 1985, TRANSFUSION, V25, P523, DOI 10.1046/j.1537-2995.1985.25686071423.x; HOROWITZ B, 1994, MAR FDA WORKSH ROL V; LEFRERE JJ, 1994, LANCET, V343, P211, DOI 10.1016/S0140-6736(94)90993-8; LEUSCHNER J, 1994, MAR FDA WORKSH ROL V; LONGINI IM, 1989, STAT MED, V8, P831, DOI 10.1002/sim.4780080708; MCOMISH F, 1993, J CLIN MICROBIOL, V31, P323, DOI 10.1128/JCM.31.2.323-328.1993; MENITOVE JE, 1990, ARCH PATHOL LAB MED, V114, P330; NELSON KE, 1992, ANN INTERN MED, V117, P554, DOI 10.7326/0003-4819-117-7-554; NORMANN A, 1992, LANCET, V340, P1232, DOI 10.1016/0140-6736(92)92938-C; PIET MPJ, 1990, TRANSFUSION, V30, P591, DOI 10.1046/j.1537-2995.1990.30790385516.x; PIQUET Y, 1992, VOX SANG, V63, P251, DOI 10.1111/j.1423-0410.1992.tb01230.x; SHANBERGE JN, 1992, TRANSFUSION MED, V2, P189, DOI 10.1111/j.1365-3148.1992.tb00154.x; SIMON TL, 1992, CLIN LAB MED, V12, P655, DOI 10.1016/S0272-2712(18)30479-7; SONNENBERG FA, 1988, 11TH P ANN S COMP AP; STANGE PV, 1978, NEW ENGL J MED, V298, P372, DOI 10.1056/NEJM197802162980705; SURGENOR D, 1994, MAR FDA WORKSH ROL V; VANDERPOEL CL, 1990, LANCET, V335, P558, DOI 10.1016/0140-6736(90)90347-8; WALLACE EL, 1993, TRANSFUSION, V33, P139, DOI 10.1046/j.1537-2995.1993.33293158046.x; WEINSTEIN MC, 1982, CIRCULATION, V66, P56; Weinstein MC, 1980, CLIN DECISION ANAL; WIEDING JU, 1993, ANN HEMATOL, V67, P259, DOI 10.1007/BF01696345; ZUCK TF, 1987, TRANSFUSION, V27, P447, DOI 10.1046/j.1537-2995.1987.27688071691.x; 1989, MMWR-MORBID MORTAL W, V38, P91; 1987, VITAL STATISTICS U A, V2, P8; 1991, MMWR-MORBID MORTAL W, V40, P1	51	64	64	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1210	1214		10.1001/jama.272.15.1210	http://dx.doi.org/10.1001/jama.272.15.1210			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL212	7933351				2022-12-01	WOS:A1994PL21200037
J	BESSER, RE; FEIKIN, DR; EBERHARTPHILLIPS, JE; MASCOLA, L; GRIFFIN, PM				BESSER, RE; FEIKIN, DR; EBERHARTPHILLIPS, JE; MASCOLA, L; GRIFFIN, PM			DIAGNOSIS AND TREATMENT OF CHOLERA IN THE UNITED-STATES - ARE WE PREPARED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To assess cholera recognition and treatment by US health care workers in the largest cholera outbreak in the United States this century. Design.-We reviewed the medical records of passengers from a flight on which a cholera outbreak occurred. To determine the availability of oral rehydration solutions, we surveyed treatment facilities and referral pharmacies. Setting.-On February 14, 1992, more than 100 passengers on a flight from South America to Los Angeles, Calif, were infected with toxigenic Vibrio cholerae 01. Subjects.-Fifty-four of 67 passengers who sought care in California and Nevada. Results.-We reviewed the records of 54 passengers, including 39 with diarrhea and 15 without symptoms. All 17 persons who sought treatment before the outbreak was widely reported by the media had diarrhea. For 12 of these persons, recent travel to South America was noted, but only those four whose records listed cholera as a possible diagnosis were immediately hospitalized. Seven sought cars again within 3 days; three were dehydrated, two of these three were hospitalized, and one of these two died. None of the 26 patients suspected to have cholera received appropriate fluids; severely dehydrated patients did not receive Ringer's lactate solution and those not severely dehydrated did not receive an oral rehydration solution. None of the facilities and pharmacies involved stocked World Health Organization oral rehydration salts solution, the preferred solution for treating cho!era and other diarrheal diseases. Conclusions.-Treatment of cholera in the United States was suboptimal. Oral fluids appropriate for the treatment of cholera and other diarrheal diseases were generally unavailable. Widespread cholera in the developing world means that US physicians should be prepared to treat ''imported'' cases. Physicians evaluating patients with diarrhea should obtain a travel history, should consider cholera in patients returning from countries with endemic or epidemic cholera, and should instruct patients in appropriate use of World Health Organization oral rehydration salts solution or other oral rehydration solutions containing 75 to 90 mmol/L of sodium. Pharmacies and medical facilities should stock these solutions.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,EPIDEMIOL PROGRAM OFF,DIV FIELD EPIDEMIOL,ATLANTA,GA 30341; CTY LOS ANGELES DEPT HLTH SERV,LOS ANGELES,CA; CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV,ATLANTA,GA 30341	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								MAHALANABIS D, 1992, CHOLERA, P266; SWERDLOW DL, 1992, JAMA-J AM MED ASSOC, V267, P1495, DOI 10.1001/jama.267.11.1495; 1991, WHOSER9115 PROGR CON, P1; 1993, MMWR MORN MORTAL WKL, V42, P89; 1991, MMWR-MORBID MORTAL W, V40, P562; 1990, WHOSER802 PROGR CONT; 1992, MMWR-MORBID MORTAL W, V41, P1	7	22	23	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1203	1205		10.1001/jama.272.15.1203	http://dx.doi.org/10.1001/jama.272.15.1203			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL212	7933349				2022-12-01	WOS:A1994PL21200035
J	SHIINA, N; GOTOH, Y; KUBOMURA, N; IWAMATSU, A; NISHIDA, E				SHIINA, N; GOTOH, Y; KUBOMURA, N; IWAMATSU, A; NISHIDA, E			MICROTUBULE SEVERING BY ELONGATION-FACTOR 1-ALPHA	SCIENCE			English	Article							POLYPEPTIDE-CHAIN ELONGATION; SEA-URCHIN EGGS; STABLE MICROTUBULES; BINDING PROTEIN; FACTOR-1-ALPHA; IDENTIFICATION; DICTYOSTELIUM; EF-1-ALPHA; EXTRACTS; MITOSIS	An activity that severs stable microtubules is thought to be involved in microtubule reorganization during the cell cycle. Here, a 48-kilodalton microtubule-severing protein was purified from Xenopus eggs and identified as translational elongation factor 1 alpha (EF-1 alpha). Bacterially expressed human EF-1 alpha also displayed microtubule-severing activity in vitro and, when microinjected into fibroblasts, induced rapid and transient fragmentation of cytoplasmic microtubule arrays. Thus, EF-1 alpha, an essential component of the eukaryotic translational apparatus, appears to have a second role as a regulator of cytoskeletal rearrangements.	KYOTO UNIV,INST VIRUS RES,DEPT MOLEC BIOL & GENET,SAKYO KU,KYOTO 60601,JAPAN; KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,YOKOHAMA,KANAGAWA 236,JAPAN	Kyoto University; Kirin Brewery Company Limited				Shiina, Nobuyuki/0000-0002-1854-4239				BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; COPPARD NJ, 1991, J CELL BIOL, V112, P237, DOI 10.1083/jcb.112.2.237; DJE MK, 1990, NUCLEIC ACIDS RES, V18, P3489, DOI 10.1093/nar/18.12.3489; HARLOW E, 1988, ANTIBODIES; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; KARSENTI E, 1993, CURR BIOL, V3, P208, DOI 10.1016/0960-9822(93)90334-K; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KITANISHIYUMURA T, 1987, CELL MOTIL CYTOSKEL, V8, P106, DOI 10.1002/cm.970080203; KURIYAMA R, 1990, J CELL SCI, V95, P231; MCNALLY FJ, 1993, CELL, V75, P419, DOI 10.1016/0092-8674(93)90377-3; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.bi.54.070185.005333; NISHIDA E, 1987, J BIOL CHEM, V262, P16200; OHTA K, 1990, J BIOL CHEM, V265, P3240; SANDERS MA, 1994, J CELL BIOL, V124, P795, DOI 10.1083/jcb.124.5.795; SHIINA N, 1992, EMBO J, V11, P4723, DOI 10.1002/j.1460-2075.1992.tb05577.x; SHIINA N, 1992, EMBO J, V11, P3977, DOI 10.1002/j.1460-2075.1992.tb05491.x; SHIINA N, UNPUB; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; VALE RD, 1991, CELL, V64, P827, DOI 10.1016/0092-8674(91)90511-V; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0	24	228	237	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1994	266	5183					282	285		10.1126/science.7939665	http://dx.doi.org/10.1126/science.7939665			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939665				2022-12-01	WOS:A1994PM13400036
J	COLLINS, EJ; GARBOCZI, DN; WILEY, DC				COLLINS, EJ; GARBOCZI, DN; WILEY, DC			3-DIMENSIONAL STRUCTURE OF A PEPTIDE EXTENDING FROM ONE END OF A CLASS-I MHC BINDING-SITE	NATURE			English	Article							VIRAL PEPTIDES; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURES; ANTIGEN; COMPLEXES; MOLECULES; HLA-B27; H-2K(B); HLA-A2	CLASS I major histocompatibility complex (MHC) molecules present peptides to CD8(+) T cells for immunological surveillance (reviewed in ref. 1). The structures of complexes of class I MHC molecules with octamer, nonamer and decamer peptides determined until now(2-8) show a common binding mode, with both peptide termini bound in conserved pockets at the ends of the peptide binding site. Length variations were accommodated by the peptide bulging(5,6) or zig-zagging(4) in the middle. Here we describe the structure of a decamer peptide which binds with the carboxy-terminal residue positioned outside the peptide binding site. Several protein side chains have rearranged to allow the peptide to exit. The structure suggests that even longer peptides could bind. The energetic effect of the altered mode of binding has been assessed by measuring the stability of the complex to thermal denaturation. Peptides bound in this novel manner are stable at physiological temperature, raising questions about their role in T-cell recognition and their production by proteolytic processing.	HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute; Harvard University								BOUVIER M, 1994, SCIENCE, V265, P398, DOI 10.1126/science.8023162; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, X PLOR VERSION 3 0 M; CHEN Y, 1994, J IMMUNOL, V152, P2874; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; GARBOCZI DN, 1994, J MOL BIOL, V239, P581, DOI 10.1006/jmbi.1994.1398; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.iy.11.040193.002155; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HARRISON SC, 1968, J APPL CRYSTALLOGR, V1, P84, DOI 10.1107/S0021889868005054; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HUCZKO EL, 1993, J IMMUNOL, V151, P2572; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; OLSEN AC, 1994, EUR J IMMUNOL, V24, P3585; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; STERN LJ, 1994, STRUCTURE, V2, P245, DOI 10.1016/S0969-2126(00)00026-5; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; URBAN RG, 1994, P NATL ACAD SCI USA, V91, P1534, DOI 10.1073/pnas.91.4.1534; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	25	195	199	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 13	1994	371	6498					626	629		10.1038/371626a0	http://dx.doi.org/10.1038/371626a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7935798				2022-12-01	WOS:A1994PL55900058
J	JONSSON, J; CARLSSON, L; EDLUND, T; EDLUND, H				JONSSON, J; CARLSSON, L; EDLUND, T; EDLUND, H			INSULIN-PROMOTER-FACTOR-1 IS REQUIRED FOR PANCREAS DEVELOPMENT IN MICE	NATURE			English	Article							MAMMALIAN PANCREAS; GENE; EXPRESSION; CELLS	THE mammalian pancreas is a mixed exocrine and endocrine gland that, in most species, arises from ventral and dorsal buds which subsequently merge to form the pancreas. In both mouse and rat the first histological sign of morphogenesis of the dorsal pancreas is a dorsal evagination of the duodenum ai the level of the liver at around the 22-25-somite stage, and shortly thereafter a ventral evagination appears as a derivative of the liver diverticulum(1-3). Low levels of insulin gene transcripts are already present and restricted to the dorsal foregut endoderm at 20 somites, suggesting that pancreas- or insulin gene-specific transcriptional factors are present in this region before the onset of morphogenesis(4). Insulin-promoter-factor 1 (IPF1) is a homeodomain protein which, in the adult mouse pancreas, is selectively expressed in the beta-cells and binds to and transactivates the insulin promoter(5). In mouse embryos, IPF1 expression is restricted to the developing pancreatic anlagen and is initiated when the foregut endoderm is committed to a pancreatic fate(5). We now show that mice homozygous for a targeted mutation in the Ipf1 gene selectively lack a pancreas. The mutant pups survive fetal development but die within a few days after birth. The gastrointestinal part and all other internal organs were normal in appearance. No pancreatic tissue and no ectopic expression of insulin or pancreatic amylase could be detected in mutant embryos and neonates. These findings show that IPF1 is needed for the formation of the pancreas and suggest that it acts to determine the fate of common pancreatic precursor cells and/or to regulate their propagation.	UMEA UNIV,DEPT MICROBIOL,S-90187 UMEA,SWEDEN	Umea University				Edlund, Helena/0000-0002-3553-7348				GITHENS S, 1989, HUMAN GASTROINTESTIN, P669; GITTES GK, 1992, P NATL ACAD SCI USA, V89, P1128, DOI 10.1073/pnas.89.3.1128; HERRERA PL, 1991, DEVELOPMENT, V113, P1257; HOGAN B, 1986, MANIPULATING MOUSE E, P194; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Pictet R., 1972, HDB PHYSL, P25; SPOONER BS, 1970, J CELL BIOL, V47, P235, DOI 10.1083/jcb.47.1.235; SPOONER BS, 1977, DEV BIOL, V61, P119, DOI 10.1016/0012-1606(77)90285-8; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WESSELLS NK, 1967, DEV BIOL, V15, P237, DOI 10.1016/0012-1606(67)90042-5; WRIGHT CVE, 1988, DEVELOPMENT, V104, P787	14	1467	1541	0	45	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 13	1994	371	6498					606	609		10.1038/371606a0	http://dx.doi.org/10.1038/371606a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7935793				2022-12-01	WOS:A1994PL55900052
J	ALTOMARE, DF; REGINA, G; LOVREGLIO, R; MEMEO, V				ALTOMARE, DF; REGINA, G; LOVREGLIO, R; MEMEO, V			ACETYLCHOLINE SWEAT TEST - AN EFFECTIVE WAY TO SELECT PATIENTS FOR LUMBAR SYMPATHECTOMY	LANCET			English	Article								Although lumbar sympathectomy can benefit patients with critical limb ischaemia, many derive no benefit from the procedure. The poor prediction of outcome may be related to pre-existing damage to the sympathetic fibres. We assessed sympathetic nerve function with the acetylcholine sweatspot test before and after lumber sympathectomy in 31 patients with critical limb ischaemia. Of 9 patients with normal sympathetic function or minor denervation preoperatively (sweatspot score greater than or equal to 8), 8 showed improvement in pain and/or healing of ischaemic lesions after sympathectomy. The procedure did not achieve denervation in the patient without improvement, as shown by persisting sympathetic activity postoperatively. By contrast, among the 22 patients with lower sweatspot scores, indicating severe or complete sympathetic denervation, only 1 showed improvement (partial) after lumbar sympathectomy. 9 patients underwent oximetry before and after the operation; in this subgroup there was a positive correlation between preoperative sweatspot score and the change in tissue partial pressure of oxygen (r(2)=0.35). Preoperative assessment of sympathetic nerve function by means of a sensitive, quantitative test of autonomic integrity can predict the outcome of the procedure with high sensitivity and specificity. A postoperative test allows verification of sympathetic denervation. We recommend use of this simple test in selecting patients for lumbar sympathectomy.	UNIV BARI,CATTEDRA CHIRURG VASC,I-70124 BARI,ITALY; UNIV BARI,DERMATOL CLIN,I-70124 BARI,ITALY	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	ALTOMARE, DF (corresponding author), UNIV BARI,IST CLIN CHIRURG,CATTEDRA METODOL CLIN,PIAZZA G CESARE 11,I-70124 BARI,ITALY.			Altomare, Donato Francesco/0000-0001-8980-2752				ALTOMARE D, 1992, GUT, V33, P1539, DOI 10.1136/gut.33.11.1539; BAKER DM, 1993, BR J SURG S, V80, pA666; BROTHERS TE, 1993, SURGERY, V113, P433; COTTON LT, 1985, BRIT J SURG, V72, P678, DOI 10.1002/bjs.1800720903; IMPARATO AM, 1979, SURG CLIN N AM, V59, P719; KIM GE, 1976, ANN SURG, V183, P157, DOI 10.1097/00000658-197602000-00012; LINDENAUER SM, 1982, BRIT J SURG S, V69, P32; MORGAN RH, 1989, BRIT J SURG, V76, pA1340; PERSSON AV, 1985, SURG CLIN N AM, V65, P393; PLECHA FR, 1980, SURGERY, V88, P375; RYDER REJ, 1988, LANCET, V1, P1303, DOI 10.1016/S0140-6736(88)92120-4; SEEGER JM, 1977, AM J SURG, V134, P749, DOI 10.1016/0002-9610(77)90316-6; SMITHWICK RH, 1957, SURGERY, V42, P415; SZILAGYI DE, 1967, ARCH SURG-CHICAGO, V95, P753; WALKER PM, 1980, SURGERY, V87, P216; YAO JST, 1973, ARCH SURG-CHICAGO, V107, P676	16	6	6	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					976	978		10.1016/S0140-6736(94)91639-X	http://dx.doi.org/10.1016/S0140-6736(94)91639-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934428				2022-12-01	WOS:A1994PK97800007
J	BURR, DC; MORRONE, MC; ROSS, J				BURR, DC; MORRONE, MC; ROSS, J			SELECTIVE SUPPRESSION OF THE MAGNOCELLULAR VISUAL PATHWAY DURING SACCADIC EYE-MOVEMENTS	NATURE			English	Article							MOTION PERCEPTION; MACAQUE MONKEY; SENSITIVITY; CONTRAST; IMAGE	VISUAL scientists have long sought to explain why the world remains stable during saccades, the ballistic eye-movements that continually displace the retinal image at fast but resolvable(1) velocities. An early suggestion was that vision may be actively suppressed during saccades(2), but experimental support has been variable(3-5). Here we present evidence that saccadic suppression does occur, but that it is selective for patterns modulated in luminance at low spatial frequencies. Patterns of higher Spatial frequency, and equiluminant patterns (modulated only in colour) at all spatial frequencies were not suppressed during saccades, but actually enhanced. The selectivity of the suppression suggests that it is confined to the colour-blind magnocellular stream (which provides the dominant input to motion centres and areas involved with attention), where it could dull the otherwise disturbing sense of Past low-spatial-frequency image motion. Masking studies suggest that the suppression precedes the site of contrast masking and may therefore occur early in visual processing, possibly as early as the lateral geniculate nucleus.	UNIV ROME, DEPT PSYCHOL, I-00185 ROME, ITALY; UNIV WESTERN AUSTRALIA, DEPT PSYCHOL, NEDLANDS, WA 6009, AUSTRALIA	Sapienza University Rome; University of Western Australia	BURR, DC (corresponding author), CNR, IST NEUROFISIOL, VIA S ZENO 51, I-56127 PISA, ITALY.		Morrone, Maria Concetta/C-6756-2014	Morrone, Maria Concetta/0000-0002-1025-0316; Burr, David/0000-0003-1541-8832				BONDS AB, 1991, NONLINEAR VISION DET, P329; Burr D. C., 1982, VISION RES, V23, P3567, DOI [10.1016/0042-6989(82)90196-1, DOI 10.1016/0042-6989(82)90196-1]; BURR DC, 1993, J OPT SOC AM A, V10, P1706, DOI 10.1364/JOSAA.10.001706; BURR DC, 1982, J PHYSIOL-LONDON, V333, P1; CORBETTA M, 1993, J NEUROSCI, V13, P1202; CROPPER SJ, 1988, PERCEPTION, V17, P353; DERRINGTON AM, 1984, VISION RES, V24, P1965, DOI 10.1016/0042-6989(84)90031-2; DEYOE EA, 1988, TRENDS NEUROSCI, V11, P219, DOI 10.1016/0166-2236(88)90130-0; Grusser O.J., 1991, VISION VISUAL DYSFUN, V12; Holt EB, 1903, PSYCHOL REV-MONOGR S, V4, P3; ILG UJ, 1993, VISION RES, V33, P211, DOI 10.1016/0042-6989(93)90159-T; KRAUSKOPF J, 1966, AM J PSYCHOL, V79, P73, DOI 10.2307/1420709; LATOUR PL, 1962, VISION RES, V2, P261, DOI 10.1016/0042-6989(62)90031-7; MACKAY DM, 1970, NATURE, V225, P90, DOI 10.1038/225872a0; MATIN E, 1974, PSYCHOL BULL, V81, P899, DOI 10.1037/h0037368; MAUNSELL JHR, 1990, J NEUROSCI, V10, P3323; MERIGAN WH, 1991, J NEUROSCI, V11, P3422; MERIGAN WH, 1991, J NEUROSCI, V11, P994; MERIGAN WH, 1993, ANNU REV NEUROSCI, V16, P369, DOI 10.1146/annurev.ne.16.030193.002101; MERIGAN WH, 1991, NATO ADV SCI I A-LIF, V203, P117; OHZAWA I, 1982, NATURE, V298, P5871; RIGGS LA, 1974, VISION RES, V14, P997, DOI 10.1016/0042-6989(74)90169-2; SCHILLER PH, 1990, NATURE, V343, P68, DOI 10.1038/343068a0; SCLAR G, 1990, VISION RES, V30, P1, DOI 10.1016/0042-6989(90)90123-3; SHIOIRI S, 1989, VISION RES, V29, P915, DOI 10.1016/0042-6989(89)90106-5; UCHIKAWA K, IN PRESS J OPT SOC A; UNGERLEIDER LG, 1986, J COMP NEUROL, V248, P147, DOI 10.1002/cne.902480202; WATSON AB, 1983, PERCEPT PSYCHOPHYS, V33, P113, DOI 10.3758/BF03202828; [No title captured]	29	483	491	1	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					511	513		10.1038/371511a0	http://dx.doi.org/10.1038/371511a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7935763				2022-12-01	WOS:A1994PK58900054
J	HEIDELBERGER, R; HEINEMANN, C; NEHER, E; MATTHEWS, G				HEIDELBERGER, R; HEINEMANN, C; NEHER, E; MATTHEWS, G			CALCIUM-DEPENDENCE OF THE RATE OF EXOCYTOSIS IN A SYNAPTIC TERMINAL	NATURE			English	Article							SQUID GIANT SYNAPSE; NEUROTRANSMITTER RELEASE; TRANSMITTER RELEASE; CHROMAFFIN CELLS; GOLDFISH RETINA; BIPOLAR CELLS; SECRETION; CHANNELS; INFLUX; CHELATORS	RAPID calcium-dependent exocytosis underlies neurotransmitter release from nerve terminals. Despite the fundamental importance of this process, neither the relationship between presynaptic intracellular calcium ion concentration ([Ca2+](i)) and rate of exocytosis, nor the maximal rate of secretion is known quantitatively. To provide this information, we have used flash photolysis of caged Ca2+ to elevate [Ca2+](i) rapidly and uniformly in synaptic terminals, while measuring membrane capacitance as ao index of exocytosis and monitoring [Ca2+](i) with a Ca2+-indicator dye. When [Ca2+](i) was abruptly increased to > 10 mu M, capacitance rose at a rate that increased steeply with [Ca2+](i). The steepness suggested that at least four calcium ions must bind to activate synaptic vesicle fusion. Half-saturation was at 194 mu M, and the maximal rate constant was 2,000-3,000 s(-1). A given synaptic vesicle can exocytose with high probability within a few hundred microseconds, if [Ca2+](i) rises above 100 mu M These properties provide for the extremely rapid signalling required for neuronal communication.	SUNY STONY BROOK,DEPT NEUROBIOL & BEHAV,STONY BROOK,NY 11794	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook	HEIDELBERGER, R (corresponding author), MAX PLANCK INST BIOPHYS CHEM,MEMBRANBIOPHYS ABT,FASSBERG,W-3400 GOTTINGEN,GERMANY.		Neher, Erwin/A-2109-2013	Heidelberger, Ruth/0000-0002-8033-2050				ADLER EM, 1991, J NEUROSCI, V11, P1496; ALMERS W, 1994, NATURE, V367, P682; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; CHAD JE, 1984, BIOPHYS J, V45, P993, DOI 10.1016/S0006-3495(84)84244-7; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; DELANEY KR, 1990, J PHYSIOL-LONDON, V426, P473, DOI 10.1113/jphysiol.1990.sp018150; DOWLING JE, 1987, RETINA APPROACHABLE, P42; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEIDELBERGER R, 1992, J PHYSIOL-LONDON, V447, P235, DOI 10.1113/jphysiol.1992.sp019000; HEINEMANN C, 1993, PFLUG ARCH EUR J PHY, V424, P105, DOI 10.1007/BF00374600; HEINEMANN C, IN PRESS BIOPHYS J; HERRINGTON J, 1993, PULSE CONTROL V3 0 I; ISHIDA AT, 1980, J COMP NEUROL, V191, P315, DOI 10.1002/cne.901910302; KAPLAN JH, 1988, P NATL ACAD SCI USA, V85, P6571, DOI 10.1073/pnas.85.17.6571; KATZ B, 1965, PROC R SOC SER B-BIO, V161, P483, DOI 10.1098/rspb.1965.0016; KONISHI M, 1991, J GEN PHYSIOL, V97, P271, DOI 10.1085/jgp.97.2.271; LINDAU M, 1988, PFLUG ARCH EUR J PHY, V411, P137, DOI 10.1007/BF00582306; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MCCRAY J, 1992, BIOCHEMISTRY-US, V37, P8856; PARNAS H, 1986, PFLUG ARCH EUR J PHY, V406, P121, DOI 10.1007/BF00586672; ROBERTS WM, 1990, J NEUROSCI, V10, P3664; SIMON SM, 1985, BIOPHYS J, V48, P485, DOI 10.1016/S0006-3495(85)83804-2; THOMAS P, 1993, NEURON, V11, P93, DOI 10.1016/0896-6273(93)90274-U; THOMAS P, 1993, EMBO J, V12, P303, DOI 10.1002/j.1460-2075.1993.tb05657.x; VONGERSDORFF H, 1994, NATURE, V367, P735, DOI 10.1038/367735a0; VONGERSDORFF H, 1994, NATURE, V370, P652, DOI 10.1038/370652a0; YAZULLA S, 1987, BRAIN RES, V411, P400, DOI 10.1016/0006-8993(87)91095-X; ZUCKER RS, 1993, CELL CALCIUM, V14, P87, DOI 10.1016/0143-4160(93)90079-L; ZUCKER RS, 1986, P NATL ACAD SCI USA, V83, P3032, DOI 10.1073/pnas.83.9.3032	30	619	627	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					513	515		10.1038/371513a0	http://dx.doi.org/10.1038/371513a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7935764				2022-12-01	WOS:A1994PK58900055
J	ABUAREFEH, I; RUSSELL, G				ABUAREFEH, I; RUSSELL, G			PREVALENCE OF HEADACHE AND MIGRAINE IN SCHOOLCHILDREN	BRITISH MEDICAL JOURNAL			English	Article							CHILDREN; EPIDEMIOLOGY; CRITERIA	Objectives-To determine the prevalence rates of the various causes of severe headache in school-children, with special emphasis on migraine and its impact on school attendance. Design-Population based study in two stages, comprising an initial screening questionnaire followed by clinical interviews and examination of children with symptoms and a control group of asymptomatic children matched for age and sex. Setting-67 primary and secondary schools in the city of Aberdeen. Subjects-2165 children, representing a random sample of 10% of schoolchildren in Aberdeen aged 5-15 years. Main outcome measures-(a) the prevalence of migraine (International Headache Society criteria) and of other types of headache; (b) the impact of migraine on school attendance. Results-The estimated prevalence rates of migraine and tension headache were 10.6% (95% confidence interval 9.1 to 12.3) and 0.9% (0.5 to 1.5) respectively. The estimated prevalence rates for migraine without aura and migraine with aura were 7.8% (95% confidence interval 6.5 to 9.3) and 2.8% (2.0 to 3.8) respectively. In addition, 10 children (0.7%) had headaches which, though lasting less than two hours, also fulfilled the International Headache Society criteria for migraine, 14 (0.9%) had tension headaches, and 20 (1.3%) had non-specific recurrent headache. The prevalence of migraine increased with age, with male preponderance in children under 12 and female preponderance thereafter. Children with migraine lost a mean of 7.8 school days a year due to all illnesses (2.8 days (range 0-80) due to headache) as compared with a mean of 3.7 days lost by controls. Conclusions-Migraine is a common cause of headache in children and causes significantly reduced school attendance.	ROYAL ABERDEEN CHILDRENS HOSP,DEPT MED PAEDIAT,ABERDEEN AB9 2ZG,SCOTLAND	University of Aberdeen			Abu-Arafeh, Ishaq/H-7417-2019	Abu-Arafeh, Ishaq/0000-0003-1252-0153				BARLOW C, 1984, HEADACHE MIGRAINE CH, P172; BILLE B, 1962, ACTA PAED STOCK S136, V51, P1, DOI DOI 10.1111/J.1651-2227.1962.TB06591.X; CHEN TC, 1990, ARCH NEUROL-CHICAGO, V47, P1227, DOI 10.1001/archneur.1990.00530110087022; DALSGAAR.T, 1970, DAN MED BULL, V17, P138; DEUNBER DC, 1977, HEADACHE, V17, P173; GARDNER S, 1989, CONFIDENCE INTERVAL; GREEN JE, 1975, MIGRAINE NEWS    SEP, P30; HENRY P, 1992, CEPHALALGIA, V12, P229, DOI 10.1046/j.1468-2982.1992.1204229.x; Hockaday J.M., 1988, MIGRAINE CHILDHOOD, P5; HOCKADAY JM, 1991, MATERN CHILD HLTH J, V16, P246; MORTIMER MJ, 1992, DEV MED CHILD NEUROL, V34, P1095; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; RASMUSSEN BK, 1991, J CLIN EPIDEMIOL, V44, P1147, DOI 10.1016/0895-4356(91)90147-2; RASMUSSEN BK, 1992, CEPHALALGIA, V12, P221, DOI 10.1046/j.1468-2982.1992.1204221.x; ROSSI LN, 1992, DEV MED CHILD NEUROL, V34, P516; SILLANPAA M, 1983, HEADACHE, V23, P15; SPARKS JP, 1978, PRACTITIONER, V221, P407; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; VAHLQUIST B, 1949, ACTA PAEDIATR, V38, P622, DOI 10.1111/j.1651-2227.1949.tb17914.x; 1962, JAMA-J AM MED ASSOC, V179, P717; 1993, SPSS WINDOWS RELEASE; 1991, WKLY EPIDEMIOL REC, V66, P324; 1988, CEPHALALGIA S7, V8, P1	23	548	561	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					765	769		10.1136/bmj.309.6957.765	http://dx.doi.org/10.1136/bmj.309.6957.765			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ282	7950559	Green Published			2022-12-01	WOS:A1994PJ28200016
J	ASHTON, LJ; LEARMONT, J; LUO, K; WYLIE, B; STEWART, G; KALDOR, JM				ASHTON, LJ; LEARMONT, J; LUO, K; WYLIE, B; STEWART, G; KALDOR, JM			HIV-INFECTION IN RECIPIENTS OF BLOOD PRODUCTS FROM DONORS WITH KNOWN DURATION OF INFECTION	LANCET			English	Note							TRANSFUSION; AIDS; AUSTRALIA; PEOPLE	From a registry of people with transfusion-acquired HIV infection, 25 recipients were identified for whom the dates of HIV infection in the 8 corresponding donors could be established. Longer times to AIDS and to death in recipients were independently associated (p<0.01) with the receipt of blood from donors who developed AIDS more than 10 years after HIV infection, as well as with older age and fewer transfusions. Sex, zidovudine treatment, and severity of illness at transfusion were not significantly associated with survival.	UNIV NEW S WALES,NATL CTR HIV EPIDEMIOL & CLIN RES,SYDNEY,NSW 2010,AUSTRALIA; NEW S WALES RED CROSS,BLOOD TRANSFUS SERV,SYDNEY,NSW,AUSTRALIA; WESTMEAD HOSP,DEPT IMMUNOPATHOL,WESTMEAD,NSW 2145,AUSTRALIA	University of New South Wales Sydney; Kirby Institute; Australian Red Cross Blood Service; University of Sydney			Wylie, Bruce/H-3182-2014; Kaldor, John M/D-4545-2011	Wylie, Bruce/0000-0002-7374-1083; 				BLAXHULT A, 1990, AIDS, V4, P125, DOI 10.1097/00002030-199002000-00005; KALDOR J, 1993, MED J AUSTRALIA, V158, P10, DOI 10.5694/j.1326-5377.1993.tb121640.x; KOPECSCHRADER E, 1993, AIDS, V7, P1009, DOI 10.1097/00002030-199307000-00016; LEARMONT J, 1992, LANCET, V340, P863, DOI 10.1016/0140-6736(92)93281-Q; SWANSON CE, 1990, AIDS, V4, P749, DOI 10.1097/00002030-199008000-00006; WARD JW, 1989, NEW ENGL J MED, V321, P947, DOI 10.1056/NEJM198910053211406	6	25	27	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					718	720		10.1016/S0140-6736(94)92210-1	http://dx.doi.org/10.1016/S0140-6736(94)92210-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915778				2022-12-01	WOS:A1994PF18700012
J	WULFF, HR				WULFF, HR			QUALITY-OF-LIFE AND TREATMENT FOR PROXIMAL DEEP-VEIN THROMBOSIS	LANCET			English	Editorial Material											WULFF, HR (corresponding author), HERLEV HOSP,DEPT MED C,HERLEV,DENMARK.							HARRIS J, 1987, J MED ETHICS, V13, P117, DOI 10.1136/jme.13.3.117; NAYLOR CD, 1994, J CLIN EPIDEMIOL, V47, P987; OMEARA JJ, 1994, NEW ENGL J MED, V330, P117; RAWLES J, 1989, J MED ETHICS, V15, P143, DOI 10.1136/jme.15.3.143; WEINSTEIN MC, 1980, CLIN DECISION ANAL, P199	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 13	1994	344	8920					420	421		10.1016/S0140-6736(94)91764-7	http://dx.doi.org/10.1016/S0140-6736(94)91764-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PB761	7914561				2022-12-01	WOS:A1994PB76100004
J	FASSATI, A; TEDESCHI, S; BORDONI, A; AMBONI, P; CURCIO, C; BRESOLIN, N; SCARLATO, G				FASSATI, A; TEDESCHI, S; BORDONI, A; AMBONI, P; CURCIO, C; BRESOLIN, N; SCARLATO, G			RAPID DIRECT DIAGNOSIS OF DELETIONS CARRIERS OF DUCHENNE AND BECKER MUSCULAR-DYSTROPHIES	LANCET			English	Note							POLYMERASE CHAIN-REACTION; INTRAGENIC RECOMBINATION; GENE	13 families and 34 women at risk of being carriers of Duchenne and Becker muscular dystrophies were analysed blind by restriction fragment length polymorphisms (RFLPs) and a new, non-radioactive direct test based on competitive polymerase-chain-reaction (PCR) amplification. All obligate carriers were correctly diagnosed by RFLPs and competitive PCR, and 7 women with a 99% risk of being carriers were also diagnosed carriers by competitive PCR. There were no false positives or false negatives. Only 1 PCR result was non-informative. Our test allows rapid, precise, and direct carrier diagnosis of women whose relatives have a known deletion of the dystrophin gene.	UNIV MILAN,IST CLIN NEUROL,I-20122 MILAN,ITALY; IST CLIN PERFEZIONAMENTO,MILAN,ITALY	University of Milan	FASSATI, A (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT EXPTL PATHOL,LONDON BRIDGE,LONDON SE1 9RT,ENGLAND.		CURCIO, CRISTINA/D-3898-2011; CURCIO, CRISTINA/AAO-1488-2020	CURCIO, CRISTINA/0000-0001-9275-3242; Bresolin, Nereo/0000-0001-6694-3595				ABBS S, 1990, GENOMICS, V7, P602, DOI 10.1016/0888-7543(90)90205-9; ABBS S, 1992, J MED GENET, V29, P191, DOI 10.1136/jmg.29.3.191; BEGGS AH, 1990, HUM GENET, V86, P45; BEGGS AH, 1990, NUCLEIC ACIDS RES, V18, P1931, DOI 10.1093/nar/18.7.1931; DENDUNNEN JT, 1989, AM J HUM GENET, V45, P835; Emery A.E.H., 1993, DUCHENNE MUSCULAR DY; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; LATHROP GM, 1984, AM J HUM GENET, V36, P460; OUDET C, 1991, AM J HUM GENET, V49, P311; ROBERTS RG, 1989, NUCLEIC ACIDS RES, V17, P811, DOI 10.1093/nar/17.2.811	10	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 30	1994	344	8918					302	303		10.1016/S0140-6736(94)91340-4	http://dx.doi.org/10.1016/S0140-6736(94)91340-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ233	7914263				2022-12-01	WOS:A1994NZ23300009
J	MAEDA, N; WATANABE, K; NEGORO, T; ASO, K; OHKI, T; ITO, K; KATO, T				MAEDA, N; WATANABE, K; NEGORO, T; ASO, K; OHKI, T; ITO, K; KATO, T			EVOLUTIONAL CHANGES OF CORTICAL HYPOMETABOLISM IN WESTS SYNDROME	LANCET			English	Article							INFANTILE SPASMS; SURGICAL-TREATMENT	The pathophysiological basis of the epileptic encephalopathy West's syndrome remains unknown. We have done serial positron emission tomography (PET) with fluorine-18-labelled 2-deoxy-3-fluoro-D-glucose (FDG) in twelve patients with newly diagnosed West's syndrome. Throughout follow-up, PET revealed diffuse or focal cortical hypometabolism in eleven patients, whereas magnetic resonance imaging (MRI) showed morphological abnormalities in only five. At disease onset, PET showed cortical hypometabolism in eight patients (diffuse in three, focal in five). The second PET showed normal metabolism in six of these patients but focal abnormalities in three of the four with normal results on first PET. In all seven patients with normal findings on the second PET, tonic spasms ceased after initial treatment and no epileptic seizure occurred thereafter. In the five patients with cortical hypometabolism on the second PET, tonic spasms persisted or recurred, or partial seizures appeared. However, in two patients PET abnormalities disappeared in accordance with the later resolution of epileptic seizures. All patients with normal MRI and second PET results had normal psychomotor development. Diffuse or focal cortical hypometabolism that cannot be detected by MRI or computed tomography is common in patients with West's syndrome. However, this anomaly is not permanent and changes with clinical symptoms. These functional abnormalities in the cerebral cortex may be associated with the development of West's syndrome.	NAGOYA UNIV,SCH MED,DEPT RADIOL,NAGOYA 461,JAPAN	Nagoya University	MAEDA, N (corresponding author), NAGOYA UNIV,SCH MED,DEPT PEDIAT,SHOWA KU,65 TSURUMA CHO,NAGOYA,AICHI 466,JAPAN.							CHUGANI HT, 1990, ANN NEUROL, V27, P406, DOI 10.1002/ana.410270408; CHUGANI HT, 1992, ANN NEUROL, V31, P212, DOI 10.1002/ana.410310212; ENGEL J, 1993, NEUROLOGY, V43, P1612, DOI 10.1212/WNL.43.8.1612; MAEDA N, 1993, PEDIATR NEUROL, V9, P430, DOI 10.1016/0887-8994(93)90021-4; YAMAMOTO N, 1988, EPILEPSIA, V29, P34, DOI 10.1111/j.1528-1157.1988.tb05095.x; 1992, EPILEPSIA, V33, P195	6	39	39	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1620	1623		10.1016/S0140-6736(94)93065-1	http://dx.doi.org/10.1016/S0140-6736(94)93065-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911927				2022-12-01	WOS:A1994NU35400018
J	MCGLAVE, PB; DEFABRITIIS, P; DEISSEROTH, A; GOLDMAN, J; BARNETT, M; REIFFERS, J; SIMONSSON, B; CARELLA, A; AEPPLI, D				MCGLAVE, PB; DEFABRITIIS, P; DEISSEROTH, A; GOLDMAN, J; BARNETT, M; REIFFERS, J; SIMONSSON, B; CARELLA, A; AEPPLI, D			AUTOLOGOUS TRANSPLANTS FOR CHRONIC MYELOGENOUS LEUKEMIA - RESULTS FROM 8 TRANSPLANT GROUPS	LANCET			English	Article							MARROW TRANSPLANTATION; LEUKEMIA; INTERFERON; CELLS; CML; PROGENITORS; GAMMA	Chronic myelogenous leukaemia (CML) can be cured by donor marrow transplant. Unfortunately, suitably HLA-matched related or unrelated donors are not available for the majority of patients. Transplant of stem cells derived from a patient's own marrow or peripheral blood (autologous transplant) avoids the need for an HLA-matched donor, is associated with a less complicated and shorter hospital course than donor transplantation, and has been successful in the treatment of other haematological malignancies. We report results of autologous transplants in 200 patients with CML at eight marrow transplant centres over seven yeats. This is the first multicentre analysis of autologous transplants for CML and reports on the largest number of patients studied to date. We show that autologous transplants provide a plateau in the survival curve not observed in conventional treatments. Autologous transplants are associated with a high engraftment rate, low mortality, and prompt return of both younger and older patients to normal activity levels. Our results suggest that autologous transplants provide an alternative to conventional treatment in the care of patients not eligible for donor transplant.	INST HEMATOL,ROME,ITALY; MD ANDERSON CANC CTR,DEPT HEMATOL,HOUSTON,TX 77030; HAMMERSMITH HOSP,DEPT HAEMATOL,LONDON,ENGLAND; VANCOUVER GEN HOSP,LEUKEMIA & BONE MARROW TRANSPLANTAT PROGRAM,VANCOUVER,BC,CANADA; HOSP HAUT LEVEQUE,UNITE GREFFE,BORDEAUX,FRANCE; UNIV UPPSALA HOSP,DEPT MED,UPPSALA,SWEDEN; OSPED SAN MARTINO GENOVA,GENOA,ITALY; UNIV MINNESOTA,SCH PUBL HLTH,MINNEAPOLIS,MN 55455	University of Texas System; UTMD Anderson Cancer Center; Imperial College London; University of British Columbia; CHU Bordeaux; Uppsala University; Uppsala University Hospital; University of Genoa; IRCCS AOU San Martino IST; University of Minnesota System; University of Minnesota Twin Cities	MCGLAVE, PB (corresponding author), UNIV MINNESOTA,SCH MED,DEPT MED,MARROW TRANSPLANT PROGRAM,MINNEAPOLIS,MN 55455, USA.			de Fabritiis, Paolo/0000-0002-1835-0581				BARNETT MJ, 1989, BONE MARROW TRANSPL, V4, P345; BAUM CM, 1992, P NATL ACAD SCI USA, V89, P2804, DOI 10.1073/pnas.89.7.2804; CARELLA AM, 1993, BONE MARROW TRANSPL, V12, P267; CARLOSTELLA C, 1991, BONE MARROW TRANSPL, V8, P265; DEFABRITIIS P, 1990, BONE MARROW TRANSPL, V6, P247; DEISSEROTH AB, IN PRESS BLOOD; ELAUDTJOHNSON RC, 1980, SURVIVAL MODELS DATA; GOLDMAN JM, 1993, IN PRESS BLOOD; HIGANO CS, 1992, BLOOD, V80, P1437; HOYLE C, 1994, BRIT J HAEMATOL, V86, P76, DOI 10.1111/j.1365-2141.1994.tb03255.x; KARNOFSKY DA, 1949, EVALUATION CHEMOTHER, P191; LEEMHUIS T, 1992, EXP HEMATOL, V20, P782; MCGLAVE P, 1987, EXP HEMATOL, V15, P331; MCGLAVE P, 1993, BLOOD, V81, P543; MCGLAVE PB, 1990, BONE MARROW TRANSPL, V6, P115; MCGLAVE PB, 1990, BONE MARROW TRANSPL, P235; REIFFERS J, 1991, BRIT J HAEMATOL, V77, P339, DOI 10.1111/j.1365-2141.1991.tb08581.x; SHPALL EJ, 1994, J CLIN ONCOL, V12, P28, DOI 10.1200/JCO.1994.12.1.28; SIMONSSON B, 1992, LEUKEMIA LYMPHOMA, V7, P55, DOI 10.3109/10428199209061566; SOKAL JE, 1985, BLOOD, V66, P1342; TURHAN AG, 1990, BLOOD, V76, P2402; VERFAILLIE CM, 1992, BLOOD, V79, P1003	22	195	197	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1486	1488		10.1016/S0140-6736(94)92589-5	http://dx.doi.org/10.1016/S0140-6736(94)92589-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911185				2022-12-01	WOS:A1994NQ41500016
J	BASLER, K; EDLUND, T; JESSELL, TM; YAMADA, T				BASLER, K; EDLUND, T; JESSELL, TM; YAMADA, T			CONTROL OF CELL PATTERN IN THE NEURAL-TUBE - REGULATION OF CELL-DIFFERENTIATION BY DORSALIN-1, A NOVEL TGF-BETA FAMILY MEMBER	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; FLOOR PLATE; CREST CELLS; MONOCLONAL-ANTIBODIES; CHICK-EMBRYO; DROSOPHILA EMBRYO; VENTRAL AXIS; NOTOCHORD; BONE; IDENTIFICATION	Distinct cell types differentiate along the dorsoventral axis of the neural tube. We have cloned and characterized a novel member of the TGFbeta gene family, dorsalin-1 (dsl-1), that appears to regulate cell differentiation within the neural tube. dsl-1 is expressed selectively in the dorsal neural tube, and its pattern of expression appears to be restricted by early signals from the notochord. Exposure of neural plate cells to dsl-1 promotes the differentiation of cells with neural crest-like properties and inhibits the induction of motor neurons by signals from the notochord and floor plate. These findings suggest that dsl-1 regulates the differentiation of cell types along the dorsoventral axis of the neural tube, acting in conjunction with distinct ventralizing signals from the notochord and floor plate.	UMEA UNIV, DEPT MICROBIOL, S-90187 UMEA, SWEDEN	Umea University	BASLER, K (corresponding author), COLUMBIA UNIV, CTR NEUROBIOL & BEHAV, DEPT BIOCHEM & MOLEC BIOPHYS, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA.			Basler, Konrad/0000-0003-3534-1529				ABO T, 1981, J IMMUNOL, V127, P1024; ALTABA AR, 1989, NATURE, V341, P33; ARTINGER KB, 1992, DEVELOPMENT, V116, P877; BAROFFIO A, 1988, P NATL ACAD SCI USA, V85, P5325, DOI 10.1073/pnas.85.14.5325; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BERND P, 1985, DEV BIOL, V112, P145, DOI 10.1016/0012-1606(85)90128-9; BRONNERFRASER M, 1988, NATURE, V335, P161, DOI 10.1038/335161a0; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; DARNELL DK, 1992, DEV DYNAM, V193, P389, DOI 10.1002/aja.1001930411; DELANNET M, 1992, DEVELOPMENT, V116, P275; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GRABOWSKI CT, 1956, J EXP ZOOL, V133, P301, DOI 10.1002/jez.1401330207; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GREVE JM, 1982, J CELL BIOCHEM, V18, P221, DOI 10.1002/jcb.1982.240180209; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HIRANO S, 1991, SCIENCE, V251, P310, DOI 10.1126/science.1987648; Hoffmann FM, 1991, CURR OPIN CELL BIOL, V3, P947, DOI 10.1016/0955-0674(91)90112-C; JONES CM, 1991, DEVELOPMENT, V111, P531; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; LEE SJ, 1991, P NATL ACAD SCI USA, V88, P4250, DOI 10.1073/pnas.88.10.4250; LEE SJ, 1990, MOL ENDOCRINOL, V4, P1034, DOI 10.1210/mend-4-7-1034; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MAXWELL GD, 1988, NEURON, V1, P557, DOI 10.1016/0896-6273(88)90105-5; PLACZEK M, 1990, DEVELOPMENT, V110, P19; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PLACZEK M, 1991, DEVELOPMENT, P105; RAY RP, 1991, DEVELOPMENT, V113, P35; ROGERS SL, 1992, DEV BIOL, V151, P192, DOI 10.1016/0012-1606(92)90226-7; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SIEBERBLUM M, 1980, DEV BIOL, V80, P96, DOI 10.1016/0012-1606(80)90501-1; SMITH JL, 1989, J EXP ZOOL, V250, P49, DOI 10.1002/jez.1402500107; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; STOCKER KM, 1991, DEVELOPMENT, V111, P635; TAKAHASHI Y, 1992, P NATL ACAD SCI USA, V89, P10237, DOI 10.1073/pnas.89.21.10237; TANAKA H, 1989, DEV BIOL, V132, P419, DOI 10.1016/0012-1606(89)90238-8; TANAKA H, 1984, DEV BIOL, V106, P26, DOI 10.1016/0012-1606(84)90057-5; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; THIES RS, 1992, ENDOCRINOLOGY, V130, P1318, DOI 10.1210/en.130.3.1318; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; VANSTRAATEN HWM, 1988, ANAT EMBRYOL, V177, P317; VANSTRAATEN HWM, 1991, ANAT EMBRYOL, V184, P55; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	61	320	356	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 21	1993	73	4					687	702		10.1016/0092-8674(93)90249-P	http://dx.doi.org/10.1016/0092-8674(93)90249-P			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	7916656	Green Accepted			2022-12-01	WOS:A1993LD83000008
J	ANDREASEN, NC; FLASHMAN, L; FLAUM, M; ARNDT, S; SWAYZE, V; OLEARY, DS; EHRHARDT, JC; YUH, WTC				ANDREASEN, NC; FLASHMAN, L; FLAUM, M; ARNDT, S; SWAYZE, V; OLEARY, DS; EHRHARDT, JC; YUH, WTC			REGIONAL BRAIN ABNORMALITIES IN SCHIZOPHRENIA MEASURED WITH MAGNETIC-RESONANCE-IMAGING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CEREBRAL BLOOD-FLOW; DORSOLATERAL PREFRONTAL CORTEX; TEMPORAL-LOBE; STRUCTURAL ABNORMALITIES; PHYSIOLOGIC DYSFUNCTION; COMPUTED-TOMOGRAPHY; NEGATIVE SYMPTOMS; MONOZYGOTIC TWINS; CORPUS-CALLOSUM; DISORDER	Objective.-To determine general and regional indices of structural brain abnormality in schizophrenia. Design.-Case-control comparison study. Subjects.-Fifty-two patients diagnosed as having schizophrenia according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition, were compared with 90 healthy volunteers recruited from the community. Measurements.-Structural brain images were acquired using magnetic resonance; measurements were obtained using three-dimensional visualization of volume-rendered brains and an automated atlas-based dissection of specific regions. General measures included the volume of total brain tissue, total cerebrospinal fluid (CSF), and CSF within the ventricular system. Regional measures included the volume of tissue and CSF in the frontal; temporal, parietal, and occipital lobes and the cerebellum. Results.-Compared with the controls, the patients had a smaller average volume of total brain tissue and a greater average volume of total and ventricular CSF. A specific relative decrease in brain tissue was found only in the frontal lobes, although the volume of CSF was greater in patients than in controls in all brain regions. Conclusion.-In addition to the generalized brain abnormalities observed in schizophrenia, a regional abnormality may be present in frontal regions. Since the frontal lobes integrate multimodality information and perform a variety of ''higher'' cognitive and emotional functions that are impaired in schizophrenia, the frontal abnormality noted is consistent with the clinical presentation of the illness. Impaired frontal function and a disruption in its complex circuitry (including thalamocortical projections) may explain why patients with schizophrenia often have significant deficits in formulating concepts and organizing their thinking and behavior.	UNIV IOWA HOSP & CLIN, DEPT RADIOL, IOWA CITY, IA 52242 USA	University of Iowa	ANDREASEN, NC (corresponding author), UNIV IOWA HOSP & CLIN, MENTAL HLTH CLIN RES CTR, DEPT PSYCHIAT, 200 HAWKINS DR, 2911 JPP, IOWA CITY, IA 52242 USA.		Arndt, Stephan/A-6976-2013	Arndt, Stephan/0000-0003-0783-8204; O'Leary, Daniel/0000-0003-1959-6521; Swayze, Victor/0000-0002-6434-3606	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH043271, R01MH040856, R01MH031593, R37MH031593, P30MH043271] Funding Source: NIH RePORTER; NIMH NIH HHS [MHCRC 43271, MH40856, MH31593] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDREASEN N, 1986, ARCH GEN PSYCHIAT, V43, P136; ANDREASEN NC, 1992, ARCH GEN PSYCHIAT, V49, P615; ANDREASEN NC, 1994, P NATL ACAD SCI USA, V91, P93, DOI 10.1073/pnas.91.1.93; ANDREASEN NC, 1992, J NEUROPSYCH CLIN N, V4, P125; ANDREASEN NC, 1994, SCIENCE, V266, P294, DOI 10.1126/science.7939669; ANDREASEN NC, 1992, ARCH GEN PSYCHIAT, V49, P943; ANDREASEN NC, 1993, J NEUROPSYCH CLIN N, V5, P121; ANDREASEN NC, 1990, ARCH GEN PSYCHIAT, V47, P35; ANDREASEN NC, 1988, SCIENCE, V239, P1381, DOI 10.1126/science.3279509; ANDREASEN NC, 1994, AUTOMATED ATLAS BASE; Arndt S, 1994, Neuroimage, V1, P191, DOI 10.1006/nimg.1994.1004; ARNDT S, 1991, PSYCHIAT RES-NEUROIM, V40, P79; BARTA PE, 1990, AM J PSYCHIAT, V147, P1457; Becker T, 1990, Eur Neuropsychopharmacol, V1, P83, DOI 10.1016/0924-977X(90)90018-6; BERMAN KF, 1986, ARCH GEN PSYCHIAT, V43, P126; BLEUJER E, 1950, DEMENTIA PRAECOX GRO; BOGERTS B, 1993, SCHIZOPHRENIA BULL, V19, P431, DOI 10.1093/schbul/19.2.431; BOGERTS B, 1990, PSYCHIAT RES-NEUROIM, V35, P1; BUCHSBAUM MS, 1990, SCHIZOPHRENIA BULL, V16, P379, DOI 10.1093/schbul/16.3.379; BUCHSBAUM MS, 1984, ARCH GEN PSYCHIAT, V41, P1159; BUCHSBAUM MS, 1992, ARCH GEN PSYCHIAT, V49, P935; CIZADLO T, 1994, SPIE INT SOC OPTICAL, V2168, P423; CLEGHORN JM, 1989, PSYCHIAT RES, V28, P119, DOI 10.1016/0165-1781(89)90040-1; COHEN G, 1992, PSYCHIAT RES-NEUROIM, V45, P33, DOI 10.1016/0925-4927(92)90012-S; DEGREEF G, 1992, AM J NEURORADIOL, V13, P835; DEGREEF G, 1992, ARCH GEN PSYCHIAT, V49, P531; DELISI LE, 1988, SCHIZOPHRENIA BULL, V14, P185, DOI 10.1093/schbul/14.2.185; DELISI LE, 1991, BIOL PSYCHIAT, V29, P159, DOI 10.1016/0006-3223(91)90044-M; DELISI LE, 1989, COMPR PSYCHIAT, V30, P197, DOI 10.1016/0010-440X(89)90038-2; DEMYER MK, 1988, SCHIZOPHRENIA BULL, V14, P21, DOI 10.1093/schbul/14.1.21; DEVOUS MD, 1985, J CEREB BLOOD FLO S1, V5, pS201; FEINBERG I, 1983, J PSYCHIAT RES, V17, P319, DOI 10.1016/0022-3956(82)90038-3; FLAUM M, 1990, AM J PSYCHIAT, V147, P1327; FLAUM M, IN PRESS AM J PSYCHI; FRANZEN G, 1975, J PSYCHIAT RES, V12, P199, DOI 10.1016/0022-3956(75)90027-8; Fuster J, 1989, PREFRONTAL CORTEX; GOLDMANRAKIC PS, 1990, PROG BRAIN RES, V85, P325; GUR RE, 1993, SCHIZOPHRENIA BULL, V19, P337, DOI 10.1093/schbul/19.2.337; GUR RE, 1994, AM J PSYCHIAT, V151, P343; GUR RE, 1991, ARCH GEN PSYCHIAT, V48, P407; HOFF AL, 1992, SCHIZOPHRENIA BULL, V18, P257, DOI 10.1093/schbul/18.2.257; JERNIGAN TL, 1991, ARCH GEN PSYCHIAT, V48, P881; KELSOE JR, 1988, ARCH GEN PSYCHIAT, V45, P533; KLEIST K, 1960, J MENT SCI, V106, P246, DOI 10.1192/bjp.106.442.246; Kraepelin E., 1971, DEMENTIA PRAECOX PAR; LIDDLE PF, 1990, BRIT J PSYCHIAT, V157, P558, DOI 10.1192/bjp.157.4.558; MCNEIL TF, 1993, BRIT J PSYCHIAT, V162, P517, DOI 10.1192/bjp.162.4.517; NASRALLAH HA, 1986, BIOL PSYCHIAT, V21, P274, DOI 10.1016/0006-3223(86)90048-X; NYBACK H, 1982, ACTA PSYCHIAT SCAND, V65, P403, DOI 10.1111/j.1600-0447.1982.tb00864.x; PEARLSON GD, 1993, AM PSYCHIATRIC PRESS, V12, P347; PETRIDES M, 1984, J COMP NEUROL, V228, P105, DOI 10.1002/cne.902280110; PFEFFERBAUM A, 1990, SCHIZOPHRENIA BULL, V16, P453, DOI 10.1093/schbul/16.3.453; PFEFFERBAUM A, 1991, SCHIZOPHR RES, V4, P193, DOI 10.1016/0920-9964(91)90033-N; REZAI K, 1993, ARCH NEUROL-CHICAGO, V50, P636, DOI 10.1001/archneur.1993.00540060066020; ROSSI A, 1990, BIOL PSYCHIAT, V27, P61, DOI 10.1016/0006-3223(90)90020-3; RUBIN P, 1991, ARCH GEN PSYCHIAT, V48, P987; SCHULZ SC, 1983, AM J PSYCHIAT, V140, P1592; SHENTON ME, 1992, NEW ENGL J MED, V327, P604, DOI 10.1056/NEJM199208273270905; SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201; SUDDATH RL, 1989, AM J PSYCHIAT, V146, P464; SWAYZE VW, 1990, ARCH GEN PSYCHIAT, V47, P1054; SWAYZE VW, 1990, ARCH NEUROL-CHICAGO, V47, P805, DOI 10.1001/archneur.1990.00530070103018; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; TURNER SW, 1986, PSYCHOL MED, V16, P219, DOI 10.1017/S003329170000266X; VOLKOW ND, 1986, J NEUROL NEUROSUR PS, V49, P1199, DOI 10.1136/jnnp.49.10.1199; WEINBERGER DR, 1992, AM J PSYCHIAT, V149, P890; WEINBERGER DR, 1982, ARCH GEN PSYCHIAT, V39, P778; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; WILLIAMSON P, 1991, BRIT J PSYCHIAT, V159, P130, DOI 10.1192/bjp.159.1.130; WOLKIN A, 1992, ARCH GEN PSYCHIAT, V49, P959; WOOD FB, 1990, SCHIZOPHRENIA BULL, V16, P413, DOI 10.1093/schbul/16.3.413; ZIPURSKY RB, 1992, ARCH GEN PSYCHIAT, V49, P195; 1987, DIAGNOSTIC STATISTIC	73	273	280	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 14	1994	272	22					1763	1769		10.1001/jama.272.22.1763	http://dx.doi.org/10.1001/jama.272.22.1763			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV815	7966925				2022-12-01	WOS:A1994PV81500026
J	WEBER, BL				WEBER, BL			SUSCEPTIBILITY GENES FOR BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											WEBER, BL (corresponding author), UNIV PENN,MED CTR,PHILADELPHIA,PA 19104, USA.							EASTON DF, 1993, AM J HUM GENET, V52, P678; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231	5	19	19	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 1	1994	331	22					1523	1524		10.1056/NEJM199412013312214	http://dx.doi.org/10.1056/NEJM199412013312214			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU866	7969307				2022-12-01	WOS:A1994PU86600014
J	LU, DS; WILLARD, D; PATEL, IR; KADWELL, S; OVERTON, L; KOST, T; LUTHER, M; CHEN, WB; WOYCHIK, RP; WILKISON, WO; CONE, RD				LU, DS; WILLARD, D; PATEL, IR; KADWELL, S; OVERTON, L; KOST, T; LUTHER, M; CHEN, WB; WOYCHIK, RP; WILKISON, WO; CONE, RD			AGOUTI PROTEIN IS AN ANTAGONIST OF THE MELANOCYTE-STIMULATING-HORMONE RECEPTOR	NATURE			English	Article							MOLECULAR-CLONING; MELANOCORTIN RECEPTOR; EXPRESSION; LOCUS; ASSAY; CELLS; MICE	THE genetic loci agouti and extension control the relative amounts of eumelanin (brown-black) and phaeomelanin (yellow-red) pigments in mammals(1): extension encodes the receptor for melanocyte-stimulating hormone (MSH)(2) and agouti encodes a novel 131-amino-acid protein containing a signal sequence(3,4). Agouti, which is produced in the hair follicle(5), acts on follicular melanocytes(6) to inhibit alpha-MSH-induced eumelanin production, resulting in the subterminal band of phaeomelanin often visible in mammalian fur. Here we use partially purified agouti protein to demonstrate that agouti is a high-affinity antagonist of the MSH receptor and blocks alpha-MSH stimulation of adenylyl cyclase, the effector through which alpha-MSH induces eumelanin synthesis, Agouti was also found to be an antagonist of the melanocortin-4 receptor(7,8), a related MSH-binding receptor. Consequently, the obesity caused by ectopic expression of agouti in the lethal yellow (A(y)) mouse(9) may be due to the inhibition of melanocortin reteptor(s) outside the hair follicle.	GLAXO INC, RES INST, DIV MOLEC SCI, RES TRIANGLE PK, NC 27709 USA; OREGON HLTH SCI UNIV, VOLLUM INST ADV BIOMED RES, PORTLAND, OR 97201 USA; OAK RIDGE NATL LAB, DIV BIOL, OAK RIDGE, TN 37831 USA	GlaxoSmithKline; Oregon Health & Science University; United States Department of Energy (DOE); Oak Ridge National Laboratory			Chen, Wenbiao/ABG-1276-2020; Woychik, Richard P/C-8345-2019	Chen, Wenbiao/0000-0002-0750-8275; Woychik, Richard P/0000-0001-8196-1732				BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; CHHAJLANI V, 1993, BIOCHEM BIOPH RES CO, V195, P866, DOI 10.1006/bbrc.1993.2125; CHHAJLANI V, 1992, FEBS LETT, V309, P417, DOI 10.1016/0014-5793(92)80820-7; CONKLIN BR, 1993, NATURE, V364, P110, DOI 10.1038/364110b0; DESARNAUD F, 1994, BIOCHEM J, V299, P367, DOI 10.1042/bj2990367; DICKERSON GE, 1947, SCIENCE, V105, P496, DOI 10.1126/science.105.2732.496-a; FRAZIER AL, 1990, MOL ENDOCRINOL, V4, P1264, DOI 10.1210/mend-4-8-1264; GANTZ I, 1993, J BIOL CHEM, V268, P15174; GANZ I, 1993, J BIOL CHEM, V268, P8246; JACKSON IJ, 1993, NATURE, V362, P587, DOI 10.1038/362587a0; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P3; KWON HY, IN PRESS P NATN ACAD; LAMOREUX ML, 1975, DEV BIOL, V46, P160, DOI 10.1016/0012-1606(75)90094-9; Little C.C., 1957, INHERITANCE COAT COL; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; Mountjoy K.G., 1992, SCIENCE, V257, P543; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; RAINEY WE, 1989, J BIOL CHEM, V264, P21474; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROSELLIREHFUSS L, 1993, P NATL ACAD SCI USA, V90, P8856, DOI 10.1073/pnas.90.19.8856; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SIEGRIST W, 1988, J RECEPTOR RES, V8, P323, DOI 10.3109/10799898809048996; SILVERS WK, 1955, J EXP ZOOL, V130, P199, DOI 10.1002/jez.1401300203; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; SUMMERS MD, 1987, TEXAS AGR EXP ST B, V1555	25	890	935	4	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 27	1994	371	6500					799	802		10.1038/371799a0	http://dx.doi.org/10.1038/371799a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP018	7935841				2022-12-01	WOS:A1994PP01800060
J	SCHMEICHEL, KL; BECKERLE, MC				SCHMEICHEL, KL; BECKERLE, MC			THE LIM DOMAIN IS A MODULAR PROTEIN-BINDING INTERFACE	CELL			English	Article							INSULIN GENE; MOTIF; IDENTIFICATION; DIMERIZATION; HOMEODOMAIN; REGULATORS; ZYXIN	LIM domains are zinc-binding protein sequences that are found in a growing number of proteins, including certain transcriptional regulators, proto-oncogene products, and adhesion plaque constituents. Here we define the biological activity of the LIM domain through studies of an adhesion plaque protein called zyxin that displays three C-terminal LIM domains. We have used our ability to reconstitute complexes between zyxin and its two known binding partners, alpha-actinin and the cysteine-rich protein (CRP), to examine the involvement of LIM domains in protein-protein interactions. We have determined that one of the three LIM domains of zyxin is necessary and sufficient to support the association of zyxin with CRP. Our findings demonstrate that the LIM domain functions as a specific protein-binding interface.			SCHMEICHEL, KL (corresponding author), UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112, USA.				NATIONAL CANCER INSTITUTE [P30CA042014, T32CA009602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050877] Funding Source: NIH RePORTER; NCI NIH HHS [CA09602, CA42014] Funding Source: Medline; NIGMS NIH HHS [R01 GM050877, GM50877] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHER VEV, 1994, P NATL ACAD SCI USA, V91, P316, DOI 10.1073/pnas.91.1.316; Ausubel F. M., 1994, CURRENT PROTOCOLS MO; BECKERLE MC, 1986, J CELL BIOL, V103, P1679, DOI 10.1083/jcb.103.5.1679; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOEHM T, 1990, ONCOGENE, V5, P1103; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KOSA JL, 1994, BIOCHEMISTRY-US, V33, P468, DOI 10.1021/bi00168a011; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LIEBHABER SA, 1990, NUCLEIC ACIDS RES, V18, P3871, DOI 10.1093/nar/18.13.3871; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; MICHELSEN JW, 1994, J BIOL CHEM, V269, P11108; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; RABBITTS TH, 1990, NATURE, V346, P418, DOI 10.1038/346418a0; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	31	427	438	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 21	1994	79	2					211	219		10.1016/0092-8674(94)90191-0	http://dx.doi.org/10.1016/0092-8674(94)90191-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954790				2022-12-01	WOS:A1994PN63000006
J	KAMIYA, H; ZUCKER, RS				KAMIYA, H; ZUCKER, RS			RESIDUAL CA2+ AND SHORT-TERM SYNAPTIC PLASTICITY	NATURE			English	Article							FROG NEUROMUSCULAR-JUNCTION; SQUID GIANT SYNAPSE; TRANSMITTER RELEASE; POSTTETANIC POTENTIATION; CALCIUM CHELATORS; INTRACELLULAR CALCIUM; NERVE-TERMINALS; DM-NITROPHEN; FACILITATION; CA-2+	AT many synapses, the amount of transmitter released by action potentials increases progressively during a train of spikes. This enhancement of evoked transmitter release grows during tetanic stimulation with several time constants, each bearing a different name (facilitation: tens to hundreds of milliseconds; augmentation: several seconds; potentiation: several minutes), and the enhancement of release to test spikes after a tetanus decays with similar time constants. All these processes depend on presynaptic Ca2+ influx during the conditioning tetanus(1). It has often been proposed that these forms of synaptic plasticity are due to residual Ca2+ present in nerve terminals following conditioning activity(2). We tested this idea directly by using photolabile Ca2+ chelators to reduce residual Ca2+ following conditioning stimulation or to generate an artificial elevation in Ca2+ concentration, and observed the effects on synaptic transmission at crayfish neuromuscular junctions. We found that facilitation, augmentation and potentiation are caused by the continuing action of residual Ca2+. Augmentation and potentiation seem to arise from Ca2+ acting at a separate site from facilitation, and these sites are different from the molecular target triggering neurosecretion.	UNIV CALIF BERKELEY, DIV NEUROBIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			Zucker, Robert S/J-9995-2012; Kamiya, Haruyuki/E-7199-2010	Zucker, Robert S/0000-0003-1068-2343; Kamiya, Haruyuki/0000-0002-2618-3146				ADAMS SR, 1989, J AM CHEM SOC, V111, P7957, DOI 10.1021/ja00202a042; ADLER EM, 1991, J NEUROSCI, V11, P1496; BAIN AI, 1992, J PHYSIOL-LONDON, V455, P383, DOI 10.1113/jphysiol.1992.sp019307; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BITTNER GD, 1981, BRAIN RES, V210, P431, DOI 10.1016/0006-8993(81)90922-7; DELANEY K, 1991, J NEUROSCI, V11, P2631; DELANEY KR, 1989, J NEUROSCI, V9, P3558; DELANEY KR, IN PRESS J NEUROSCI; HOCHNER B, 1991, NEUROSCI LETT, V125, P215, DOI 10.1016/0304-3940(91)90032-O; KAPLAN JH, 1988, P NATL ACAD SCI USA, V85, P6571, DOI 10.1073/pnas.85.17.6571; LANDO L, 1994, J NEUROPHYSIOL, V72, P825, DOI 10.1152/jn.1994.72.2.825; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; MAGLEBY KL, 1982, J GEN PHYSIOL, V80, P613, DOI 10.1085/jgp.80.4.613; MINTA A, 1989, J BIOL CHEM, V264, P8171; MULKEY RM, 1992, J NEUROSCI, V12, P4327; MULKEY RM, 1993, J PHYSIOL-LONDON, V462, P243, DOI 10.1113/jphysiol.1993.sp019553; REGEHR WG, 1994, J NEUROSCI, V14, P523; ROBITAILLE R, 1991, ANN NY ACAD SCI, V635, P492, DOI 10.1111/j.1749-6632.1991.tb36537.x; SWANDULLA D, 1991, NEURON, V7, P915, DOI 10.1016/0896-6273(91)90337-Y; TANABE N, 1989, NEUROSCI LETT, V99, P147, DOI 10.1016/0304-3940(89)90280-2; TANABE N, 1992, J PHYSIOL-LONDON, V455, P271, DOI 10.1113/jphysiol.1992.sp019301; VANDERKLOOT W, 1993, J NEUROPHYSIOL, V69, P717, DOI 10.1152/jn.1993.69.3.717; VANDERKLOOT W, 1994, J NEUROSCI, V14, P5722; YAMADA WM, 1992, BIOPHYS J, V61, P671, DOI 10.1016/S0006-3495(92)81872-6; ZENGEL JE, 1980, J GEN PHYSIOL, V76, P175, DOI 10.1085/jgp.76.2.175; ZENGEL JE, 1981, J GEN PHYSIOL, V77, P503, DOI 10.1085/jgp.77.5.503; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13; ZUCKER RS, 1992, CELL CALCIUM, V13, P29, DOI 10.1016/0143-4160(92)90027-P; ZUCKER RS, 1974, J PHYSIOL-LONDON, V241, P91, DOI 10.1113/jphysiol.1974.sp010642; ZUCKER RS, 1993, CELL CALCIUM, V14, P87, DOI 10.1016/0143-4160(93)90079-L	30	278	280	1	12	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 13	1994	371	6498					603	606		10.1038/371603a0	http://dx.doi.org/10.1038/371603a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7935792				2022-12-01	WOS:A1994PL55900051
J	SACHSENMAIER, C; RADLERPOHL, A; ZINCK, R; NORDHEIM, A; HERRLICH, P; RAHMSDORF, HJ				SACHSENMAIER, C; RADLERPOHL, A; ZINCK, R; NORDHEIM, A; HERRLICH, P; RAHMSDORF, HJ			INVOLVEMENT OF GROWTH-FACTOR RECEPTORS IN THE MAMMALIAN UVC RESPONSE	CELL			English	Article							C-FOS PROMOTER; TYROSINE KINASES; PROTEIN-KINASE; TERNARY COMPLEX; TRANSCRIPTIONAL ACTIVATION; AUTOCRINE TRANSFORMATION; ENHANCER ELEMENT; PHORBOL ESTER; FACTOR P62TCF; JUN ACTIVITY	Irradiation of HeLa cells with short-wavelength ultraviolet light (UVC) induces the modification and activation of the preexisting transcription factors c-fos-c-Jun (AP-1) and TCF/Elk-1, as well as the protein synthesis independent transcriptional activation of the c-fos and c-jun genes. This response to UVC is mediated via obligatory cytoplasmic signal transduction, involving Pas and Raf, Src, and MAP kinases. The UVC response is inhibited by prior down-modulation of growth factor receptor signaling upon growth factor prestimulation, by suramin (an inhibitor of receptor activation) or by expression of a dominant negative epidermal growth factor (EGF) receptor mutant. These data suggest the involvement of several growth factor receptors in the UVC response. Indeed, UVC induces the suramin-inhibitable immediate tyrosine phosphorylation of the EGF receptor.	HANNOVER MED SCH,INST MOLEK BIOL,D-30623 HANNOVER,GERMANY	Hannover Medical School	SACHSENMAIER, C (corresponding author), KERNFORSCHUNGSZENTRUM KARLSRUHE GMBH,INST GENET,D-76021 KARLSRUHE,GERMANY.							ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BUSCHER M, 1988, ONCOGENE, V3, P301; COCHET C, 1984, J BIOL CHEM, V259, P2553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; ELLEM KAO, 1988, CARCINOGENESIS, V9, P797, DOI 10.1093/carcin/9.5.797; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HUANG SS, 1988, J BIOL CHEM, V263, P12608; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANKNECHT R, 1994, ONCOGENE, V9, P1273; JOHNSON RM, 1989, SCIENCE, V246, P121, DOI 10.1126/science.2506643; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KRAFT AS, 1982, J BIOL CHEM, V257, P13193; KRAMER M, 1993, J BIOL CHEM, V268, P6734; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PINGOUD V, 1994, IN PRESS J BIOL CHEM; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Rahmsdorf H., 1992, INDUCED EFFECTS GENO, P141; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; SACHSENMAIER C, 1994, BIOCHEM PHARMACOL, V47, P129, DOI 10.1016/0006-2952(94)90446-4; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHORPP M, 1984, CELL, V37, P861, DOI 10.1016/0092-8674(84)90421-5; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WASILENKO WJ, 1990, MOL CELL BIOL, V10, P1254, DOI 10.1128/MCB.10.3.1254; YAROSH DB, 1993, J INVEST DERMATOL, V100, P790, DOI 10.1111/1523-1747.ep12476573; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	53	414	422	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 23	1994	78	6					963	972		10.1016/0092-8674(94)90272-0	http://dx.doi.org/10.1016/0092-8674(94)90272-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923365				2022-12-01	WOS:A1994PJ29400008
J	SOGAARD, M; TANI, K; YE, RR; GEROMANOS, S; TEMPST, P; KIRCHHAUSEN, T; ROTHMAN, JE; SOLLNER, T				SOGAARD, M; TANI, K; YE, RR; GEROMANOS, S; TEMPST, P; KIRCHHAUSEN, T; ROTHMAN, JE; SOLLNER, T			A RAB PROTEIN IS REQUIRED FOR THE ASSEMBLY OF SNARE COMPLEXES IN THE DOCKING OF TRANSPORT VESICLES	CELL			English	Article							INTEGRAL MEMBRANE-PROTEIN; BINDING YPT1 PROTEIN; VESICULAR TRANSPORT; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; GOLGI-COMPLEX; SYNAPTIC VESICLES; NEUROTRANSMITTER RELEASE; SACCHAROMYCES-CEREVISIAE; FUSION PROTEIN	Rab proteins are generally required for transport vesicle docking. We have exploited yeast secretion mutants to demonstrate that a rab protein is required for v-SNAREs and t-SNAREs to assemble. The absence of the rab protein in the docking complex suggests that, in a broad sense, rab proteins participate in a reaction catalyzing SNARE complex assembly. In so doing, mb proteins could help impart an additional layer of specificity to vesicle docking. This mechanism likely involves the Sec1 homolog Sly1, which we identified in isolated docking complexes. We also report the identification of a novel v-SNARE (Ykt6p) component of the yeast ER-Golgi docking complex that has a CAAX box and is predicted to be lipid anchored. The surprising finding that docking complexes can contain many distinct species of SNAREs (Sed5p, Bos1p, Sec22p, Ykt6p, and likely Bet1p, p28, and p14) suggests that multimeric interactions are features of the fusion machinery, and may also improve the fidelity of vesicle targeting.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115	Memorial Sloan Kettering Cancer Center; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	SOGAARD, M (corresponding author), MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,1275 YORK AVE,NEW YORK,NY 10021, USA.				NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA08748-29] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTO MK, 1992, CELL, V68, P181, DOI 10.1016/0092-8674(92)90462-L; AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; BANFIELD D, 1994, IN PRESS J CELL BIOL; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; DUNN B, 1993, NATURE, V362, P563, DOI 10.1038/362563a0; ELICONE C, 1994, J CHROMATOGR A, V676, P121, DOI 10.1016/0021-9673(94)00089-1; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; GALLWITZ D, 1983, NATURE, V306, P704, DOI 10.1038/306704a0; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GEROMANOS S, 1994, TECHNIQUES PROTEIN C, V5, P143; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HARLOW E, 1988, ANTIBODIES LABORATOR; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KNUDSEN KA, 1985, ANAL BIOCHEM, V147, P285, DOI 10.1016/0003-2697(85)90273-8; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WADA Y, 1990, MOL CELL BIOL, V10, P2214, DOI 10.1128/MCB.10.5.2214; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	62	465	470	0	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 23	1994	78	6					937	948		10.1016/0092-8674(94)90270-4	http://dx.doi.org/10.1016/0092-8674(94)90270-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923363				2022-12-01	WOS:A1994PJ29400006
J	TAKAHAMA, Y; SUZUKI, H; KATZ, KS; GRUSBY, MJ; SINGER, A				TAKAHAMA, Y; SUZUKI, H; KATZ, KS; GRUSBY, MJ; SINGER, A			POSITIVE SELECTION OF CD4+ T-CELLS BY TCR LIGATION WITHOUT AGGREGATION EVEN IN THE ABSENCE OF MHC	NATURE			English	Article							CD3/T-CELL RECEPTOR COMPLEX; CLASS-II MOLECULES; MONOCLONAL-ANTIBODY; ANTIGEN RECEPTOR; IMMATURE THYMOCYTES; NEGATIVE SELECTION; TRANSGENIC MICE; CROSS-LINKING; THYMUS; BETA	THE developmental fate of immature thymocytes is determined by the specificity of their T-cell antigen receptors (TCRs). Immature CD4(+)8(+) thymocytes are positively selected to differentiate into mature T cells by recognition of peptides associated with major histocompatibility complex (MHC) encoded molecules(7-10) on But neither the identity of molecules transducing positive selection signals nor the nature of the signals themselves is fully known. Here we report that direct ligation of TCR molecules by monoclonal antibodies specific for either clonotypic or CD3 chains can signal immature thymocytes to differentiate into mature CD4(+)8(-) T cells, even in the absence of MHC expression and MHC-dependent CD4 co-receptor signalling. Moreover, we show that TCR engagement induces positive selection signals only in the absence of TCR aggregation and that TCR aggregation is inhibitory for positive selection. Thus, low valency of TCR crosslinking is a critical parameter(15), distinguishing positive selection from other TCR-mediated signalling events.	NCI, EXPTL IMMUNOL BRANCH, BETHESDA, MD 20892 USA; SYNTEX INST IMMUNOL, NIIHARI 30041, JAPAN; HARVARD UNIV, SCH PUBL HLTH, DEPT CANC BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT RHEUMATOL, BOSTON, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School			Suzuki, Harumi/L-1271-2013; Takahama, Yousuke/A-5863-2010	Suzuki, Harumi/0000-0003-3616-9361; Takahama, Yousuke/0000-0002-4992-9174				ANDERSON G, 1993, NATURE, V362, P70, DOI 10.1038/362070a0; ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BLUMBERG RS, 1990, P NATL ACAD SCI USA, V87, P7220, DOI 10.1073/pnas.87.18.7220; BORN W, 1987, J IMMUNOL, V138, P999; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; COULIE PG, 1991, EUR J IMMUNOL, V21, P1703, DOI 10.1002/eji.1830210718; DELAHERA A, 1991, J EXP MED, V173, P7, DOI 10.1084/jem.173.1.7; DINTZIS HM, 1976, P NATL ACAD SCI USA, V73, P3671, DOI 10.1073/pnas.73.10.3671; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; FINKEL TH, 1989, CELL, V58, P1047, DOI 10.1016/0092-8674(89)90503-5; GRUSBY MJ, 1993, P NATL ACAD SCI USA, V90, P3913, DOI 10.1073/pnas.90.9.3913; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; HUGO P, 1992, NATURE, V360, P679, DOI 10.1038/360679a0; HUNIG T, 1988, EUR J IMMUNOL, V18, P2089, DOI 10.1002/eji.1830181234; KAYE J, 1992, CELL, V71, P423, DOI 10.1016/0092-8674(92)90512-B; KILLEEN N, 1993, NATURE, V364, P729, DOI 10.1038/364729a0; KOURILSKY P, 1989, CELL, V56, P327, DOI 10.1016/0092-8674(89)90233-X; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LO D, 1986, NATURE, V319, P672, DOI 10.1038/319672a0; MANDEL TE, 1978, IMMUNOLOGY, V35, P317; MARRACK P, 1989, NATURE, V338, P503, DOI 10.1038/338503a0; MCCONKEY DJ, 1989, J IMMUNOL, V143, P1801; MCDUFFIE M, 1986, P NATL ACAD SCI USA, V83, P8728, DOI 10.1073/pnas.83.22.8728; MULLER KP, 1993, EUR J IMMUNOL, V23, P1661, DOI 10.1002/eji.1830230740; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NAKAYAMA T, 1991, P NATL ACAD SCI USA, V88, P9949, DOI 10.1073/pnas.88.22.9949; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; PUNT JA, 1993, J IMMUNOL, V151, P1290; PUNT JA, 1994, J EXP MED, V180, P587, DOI 10.1084/jem.180.2.587; ROBINSON JH, 1976, CLIN EXP IMMUNOL, V23, P347; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SINGER A, 1987, TRANSPLANT P, V19, P107; SINGER A, 1986, PROG IMMUNOL, V6, P60; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; TAKAHAMA Y, 1992, SCIENCE, V258, P1456, DOI 10.1126/science.1439838; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; VUKMANOVIC S, 1992, NATURE, V359, P729, DOI 10.1038/359729a0; YACHELINI P, 1990, J IMMUNOL, V145, P1382	46	77	77	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 1	1994	371	6492					67	70		10.1038/371067a0	http://dx.doi.org/10.1038/371067a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE381	7915400				2022-12-01	WOS:A1994PE38100052
J	CAO, XY; JIANG, XM; KAREEM, A; DOU, ZH; RAKEMAN, MA; ZHANG, ML; MA, T; ODONNELL, K; DELONG, N; DELONG, GR				CAO, XY; JIANG, XM; KAREEM, A; DOU, ZH; RAKEMAN, MA; ZHANG, ML; MA, T; ODONNELL, K; DELONG, N; DELONG, GR			IODINATION OF IRRIGATION WATER AS A METHOD OF SUPPLYING IODINE TO A SEVERELY IODINE-DEFICIENT POPULATION IN XINJIANG, CHINA	LANCET			English	Article								Severe iodine deficiency still occurs in many countries, and causes cretinism and mental impairment. In southern Xinjiang province, China, after usual methods of iodine supplementation had failed, we iodinated irrigation water to increase iodine in soil, crops, animals, and human beings. 5% potassium iodate solution, dripped into an irrigation canal for 12 or 24 days, increased soil iodine 3-fold, and crop and animal iodine 2-fold. Median urinary iodine excretion in children increased from 18 to 49 mu g/L (two groups of similar age). The cost for iodine was US $0.05 per person per year. Soil iodine remained stable over one winter, and dripping of iodine during the second year (US $0.12 per person per year) resulted in a further 4-fold increase in soil iodine and a 1.8-fold increase in iodine in crops. We conclude that iodination of irrigation water is an advantageous and cost-effective method of supplying iodine in southern Xinjiang, and may be useful in other areas dependent on irrigation.	DUKE UNIV, MED CTR, DURHAM, NC 27710 USA; XINJIANG HLTH & ANTIEPIDEM STN, XINJIANG, PEOPLES R CHINA; INST ENDEM DIS CONTROL & RES, XINJIANG, PEOPLES R CHINA; TIANJIN MED COLL, TIANJIN, PEOPLES R CHINA	Duke University; Tianjin Medical University								ANKE M, 1991, ELIMINATION IODINE D, P1; DELANGE F, 1990, ACTA CLIN BELG, V45, P394, DOI 10.1080/17843286.1990.11718117; DELANGE FM, 1981, FETAL BRAIN DISORDER, P285; Delong G. Robeert, 1993, American Journal of Clinical Nutrition, V57, p286S, DOI 10.1093/ajcn/57.2.286S; DELONG GR, 1989, IODINE BRAIN; Delong R., 1986, PREVENTION CONTROL I, P49; Dunn JT., 1987, PREVENTION CONTROL I, P135; FISHER KD, 1974, PB233599; HALPERN JP, 1991, BRAIN, V114, P825, DOI 10.1093/brain/114.2.825; HEMKEN RW, 1972, J DAIRY SCI, V55, P931, DOI 10.3168/jds.S0022-0302(72)85599-1; Hetzel B.S., 1986, TRACE ELEMENTS HUMAN, P139; 1980, MINERAL TOLERANCE DO, P227	12	69	74	1	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 9	1994	344	8915					107	110		10.1016/S0140-6736(94)91286-6	http://dx.doi.org/10.1016/S0140-6736(94)91286-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7912349				2022-12-01	WOS:A1994NV73200014
J	WEDEGAERTNER, PB; BOURNE, HR				WEDEGAERTNER, PB; BOURNE, HR			ACTIVATION AND DEPALMITOYLATION OF G(S-ALPHA)	CELL			English	Article							HUMAN BETA-2-ADRENERGIC RECEPTOR; BETA-ADRENERGIC RECEPTORS; G-PROTEIN; ALPHA-SUBUNIT; ADENYLATE-CYCLASE; PLASMA-MEMBRANE; PALMITOYLATION; STIMULATION; MUTATION; BINDING	[H-3]palmitate attached to mutationally activated alpha(s) (alpha(s)-R201C) turns over rapidly, compared with palmitate linked to normal alpha(s) (t(1/2) approximate to 2 min versus 90 min); although alpha(s)-R201C (unlike normal alpha(s)) is predominantly found in the cytosol, [3H]palmitate is linked only to the membrane-bound pool of alpha(s), normal or mutant. Similarly, activation of wild-type alpha(s) by isoproterenol, a beta-adrenoceptor agonist that also induces membrane-to-cytosol translocation of alpha(s), dramatically accelerates depalmitoylation of alpha(s). Thus, activation-induced removal of palmitate provides an explanation for activation-induced shifts of alpha(s) to the cytosol. Regulated palmitoylation cycles provide a potential general mechanism for controlling reversible changes in the cellular location and activity of a protein.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	WEDEGAERTNER, PB (corresponding author), UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT PHARMACOL,SAN FRANCISCO,CA 94143, USA.				NCI NIH HHS [CA-54427] Funding Source: Medline; NIGMS NIH HHS [GM-27800] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027800, R01GM027800] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BOMSEL M, 1993, J BIOL CHEM, V268, P25824; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BOURNE HR, 1981, MOL PHARMACOL, V20, P435; CAMP LA, 1993, J BIOL CHEM, V268, P22566; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DEGTYAREV MY, 1993, BIOCHEMISTRY-US, V32, P8057, DOI 10.1021/bi00083a001; Grassie Morag A., 1993, Biochemical Society Transactions, V21, p499S; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HUANG EM, 1989, BIOCHIM BIOPHYS ACTA, V1011, P134, DOI 10.1016/0167-4889(89)90200-0; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JAMES G, 1989, J BIOL CHEM, V264, P20998; JOCHEN A, 1991, BIOCHEM BIOPH RES CO, V177, P797, DOI 10.1016/0006-291X(91)91859-B; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEE E, 1992, J BIOL CHEM, V267, P1212; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MOFFETT S, 1993, EMBO J, V12, P349, DOI 10.1002/j.1460-2075.1993.tb05663.x; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; NEGISHI M, 1992, J BIOL CHEM, V267, P2367; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; PIMLIKAR SW, 1993, NATURE, V362, P456; RANSNAS LA, 1989, P NATL ACAD SCI USA, V86, P7900, DOI 10.1073/pnas.86.20.7900; SALOMON MR, 1981, MOL PHARMACOL, V19, P109; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; ZUBER MX, 1989, NATURE, V341, P345, DOI 10.1038/341345a0	35	320	320	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					1063	1070		10.1016/0092-8674(94)90445-6	http://dx.doi.org/10.1016/0092-8674(94)90445-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	7912657				2022-12-01	WOS:A1994NV42500014
J	DESJARLAIS, DC; PADIAN, NS; WINKELSTEIN, W				DESJARLAIS, DC; PADIAN, NS; WINKELSTEIN, W			TARGETED HIV-PREVENTION PROGRAMS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HUMAN IMMUNODEFICIENCY VIRUS; 2 DIVISIVE ISSUES; AIDS POLICY; DRUG-USERS; INFECTION; HEALTH; RISK		UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94105; UNIV CALIF BERKELEY,BERKELEY,CA 94720	University of California System; University of California San Francisco; University of California System; University of California Berkeley	DESJARLAIS, DC (corresponding author), NATL DEV & RES INST INC,BETH ISRAEL MED CTR,11 BEACH ST,NEW YORK,NY 10013, USA.							[Anonymous], 1988, RATIONAL CHOICE UNCE; DESJARLAIS DC, 1992, AIDS, V6, P1053, DOI 10.1097/00002030-199210000-00001; DESJARLAIS DC, 1989, JAMA-J AM MED ASSOC, V261, P1008, DOI 10.1001/jama.261.7.1008; DESJARLAIS DC, 1993, 9 INT C AIDS BERL; DICLEMENTE RJ, 1994, PREVENTING AIDS THEO; EDLIN BR, 1994, NEW ENGL J MED, V331, P1422, DOI 10.1056/NEJM199411243312106; FENNER F, 1982, REV INFECT DIS, V4, P916; FIFE D, 1992, J ACQ IMMUN DEF SYND, V5, P1111; GAGNON J, 1994, NY TIMES        0106, pA23; HEATHCOTE H, 1984, LECTURE NOTES BIOMAT, V56; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; HU DJ, 1993, 9TH INT C AIDS BERL; JONSON AR, 1993, SOCIAL IMPACT AIDS U; KELLY JA, 1991, AM J PUBLIC HEALTH, V81, P168, DOI 10.2105/AJPH.81.2.168; LURIE P, 1993, PUBLIC HLTH IMPACT N; NGUGI EN, 1988, LANCET, V2, P887, DOI 10.1016/S0140-6736(88)92480-4; ROGERS DE, 1993, JAMA-J AM MED ASSOC, V270, P494; Rogers R.W, 1983, SOCIAL PSYCHOPHYSIOL, P153; ROJANAPITHAYAKO.W, 1994, MAY AD HOC TECHN ADV; STRYKER J, 1993, JAMA-J AM MED ASSOC, V270, P2436, DOI 10.1001/jama.270.20.2436; VANWIJNGAARDEN JK, 1992, AIDS IND DEMOCRACIES, P252; WALLACE R, IN PRESS SOC SCI MED; WASSER SC, 1993, J ACQ IMMUN DEF SYND, V6, P1035; WINKELSTEIN W, 1987, JAMA-J AM MED ASSOC, V257, P321, DOI 10.1001/jama.257.3.321; 1993, AIDS EXPANDING TRAGE; 1994, HIV AIDS SURVEILLANC	26	43	44	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 24	1994	331	21					1451	1453		10.1056/NEJM199411243312112	http://dx.doi.org/10.1056/NEJM199411243312112			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU533	7969287				2022-12-01	WOS:A1994PU53300012
J	MADDOX, J				MADDOX, J			FRONTIERS OF IGNORANCE - MOLECULES IN EMBRYOLOGY	NATURE			English	Editorial Material																			0	0	0	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					36	36						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969414				2022-12-01	WOS:A1994PQ34800049
J	AIBA, A; CHEN, C; HERRUP, K; ROSENMUND, C; STEVENS, CF; TONEGAWA, S				AIBA, A; CHEN, C; HERRUP, K; ROSENMUND, C; STEVENS, CF; TONEGAWA, S			REDUCED HIPPOCAMPAL LONG-TERM POTENTIATION AND CONTEXT-SPECIFIC DEFICIT IN ASSOCIATIVE LEARNING IN MGLUR1 MUTANT MICE	CELL			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; CENTRAL-NERVOUS-SYSTEM; CALCIUM CURRENTS; BRAIN-FUNCTION; NEURONS; RAT; DEPRESSION; INDUCTION; BLOCKADE; CHANNELS	We generated a novel strain of mutant mouse with a deletion in the gene encoding metabotropic glutamate receptor 1 (mGluR1). Gross anatomy of the hippocampus, excitatory synaptic transmission, long-term depression, and short-term potentiation in the hippocampal CA1 region are all apparently normal in the mutant mice. In contrast, long-term potentiation (LTP) is substantially reduced, and a moderate level of impairment is observed in context-specific associative learning. We propose that mGluR1 is not ''in line'' in LTP production, but rather modulates the plasticity process, and hence affects context-specific associative learning.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; CASE WESTERN RESERVE UNIV,SCH MED,ALZHEIMERS RES LABS,CLEVELAND,OH 44106; SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037	Massachusetts Institute of Technology (MIT); Case Western Reserve University; Howard Hughes Medical Institute; Salk Institute	AIBA, A (corresponding author), MIT,HOWARD HUGHES MED INST,CTR LEARNING & MEMORY,CAMBRIDGE,MA 02139, USA.		Rosenmund, Christian/AAC-3596-2020; Herrup, Karl/C-5313-2014	Rosenmund, Christian/0000-0002-3905-2444; Herrup, Karl/0000-0001-7786-5844; Aiba, Atsu/0000-0002-8192-0778	NINDS NIH HHS [R01 NS32925, NS20591] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032925, R01NS020591] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; AIBA A, 1994, CELL, V79, P365, DOI 10.1016/0092-8674(94)90204-6; BASHIR ZI, 1993, EUR J PHARMACOL, V239, P265, DOI 10.1016/0014-2999(93)91009-C; BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; BASKYS A, 1991, J PHYSIOL-LONDON, V444, P687, DOI 10.1113/jphysiol.1991.sp018901; BAUDE A, 1993, NEURON, V11, P771, DOI 10.1016/0896-6273(93)90086-7; BIRSE EF, 1993, NEUROSCIENCE, V52, P481, DOI 10.1016/0306-4522(93)90400-A; BLANTON M, 1990, J NEUROSCI METH, V30, P203; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; BONHOEFFER T, 1990, COLD SH Q B, V55, P137; BORTOLOTTO ZA, 1994, NATURE, V368, P740, DOI 10.1038/368740a0; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; CHARPAK S, 1991, P ROY SOC B-BIOL SCI, V243, P221, DOI 10.1098/rspb.1991.0035; CHINESTRA P, 1993, J NEUROPHYSIOL, V70, P2684, DOI 10.1152/jn.1993.70.6.2684; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORMIER RJ, 1993, NEURON, V10, P907, DOI 10.1016/0896-6273(93)90206-7; DESAI MA, 1991, J NEUROPHYSIOL, V66, P40, DOI 10.1152/jn.1991.66.1.40; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; EICHENBAUM H, 1992, BEHAV NEURAL BIOL, V57, P2, DOI 10.1016/0163-1047(92)90724-I; FORSYTHE ID, 1990, J PHYSIOL-LONDON, V429, P1; FOTUHI M, 1993, J NEUROSCI, V13, P2001; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HAYASHI Y, 1994, J NEUROSCI, V14, P3370; HAYASHI Y, 1993, NATURE, V366, P687, DOI 10.1038/366687a0; Hogan B., 1986, MANIPULATING MOUSE E; KIM JJ, 1991, BEHAV NEUROSCI, V105, P126, DOI 10.1037/0735-7044.105.1.126; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; KULLMANN DM, 1992, NEURON, V9, P1175, DOI 10.1016/0896-6273(92)90075-O; LESTER RAJ, 1990, NEURON, V4, P741, DOI 10.1016/0896-6273(90)90200-Y; MANZONI OJ, 1994, EUR J NEUROSCI, V6, P1050, DOI 10.1111/j.1460-9568.1994.tb00599.x; MARTIN LJ, 1992, NEURON, V9, P259, DOI 10.1016/0896-6273(92)90165-A; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; MUSGRAVE MA, 1993, NEUROREPORT, V4, P712; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; RIEDEL G, 1994, NEUROSCI LETT, V167, P141, DOI 10.1016/0304-3940(94)91047-2; ROSENMUND C, 1993, J PHYSIOL-LONDON, V470, P705, DOI 10.1113/jphysiol.1993.sp019884; SAHARA Y, 1993, J NEUROSCI, V13, P3041; SAYER RJ, 1992, J NEUROPHYSIOL, V68, P833, DOI 10.1152/jn.1992.68.3.833; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; SHIGEMOTO R, 1992, J COMP NEUROL, V322, P121, DOI 10.1002/cne.903220110; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SWARTZ KJ, 1992, J NEUROSCI, V12, P4358; Westbrook Gary L., 1994, Current Opinion in Neurobiology, V4, P337, DOI 10.1016/0959-4388(94)90094-9; WYLLIE DJA, 1994, NEURON, V12, P127, DOI 10.1016/0896-6273(94)90158-9; ZHENG F, 1992, NEURON, V9, P163, DOI 10.1016/0896-6273(92)90231-2	53	349	364	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 21	1994	79	2					365	375		10.1016/0092-8674(94)90204-6	http://dx.doi.org/10.1016/0092-8674(94)90204-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954802				2022-12-01	WOS:A1994PN63000019
J	NEWMEYER, DD; FARSCHON, DM; REED, JC				NEWMEYER, DD; FARSCHON, DM; REED, JC			CELL-FREE APOPTOSIS IN XENOPUS EGG EXTRACTS - INHIBITION BY BCL-2 AND REQUIREMENT FOR AN ORGANELLE FRACTION ENRICHED IN MITOCHONDRIA	CELL			English	Article							DEATH GENE CED-3; NUCLEAR-ENVELOPE; GRANULOSA-CELLS; PORE COMPLEX; MAP KINASE; RAT-LIVER; PROTEIN; ONCOPROTEIN; INVITRO; DNA	Apoptotic cell death involves a ritual series of morphological changes, presumably reflecting a conserved molecular pathway. We now report that the nuclear events typical of apoptosis can be reproduced in ''apoptotic'' Xenopus egg extracts. In this cell-free system, nuclear assembly and protein import are initially normal; after 2-4 hr, however, a process of nuclear destruction ensues involving chromatin condensation and the shrinkage and fragmentation of the nuclei. This apoptotic process, which also occurs in nuclei added exogenously, is blocked by the addition of baculovirus-expressed Bcl-2 protein. To block the disintegration of nuclei that are added later, Bcl-2 must be present during this latent period. ''Apoptosis'' in these extracts requires a dense organelle fraction enriched in mitochondria. The cell-free system described here provides a novel tool for understanding intracellular events in apoptosis and the inhibitory function of Bcl-2.	LA JOLLA INST ALLERGY & IMMUNOL, LA JOLLA, CA 92037 USA	La Jolla Institute for Immunology	NEWMEYER, DD (corresponding author), LA JOLLA CANC RES FDN, 10901 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NCI NIH HHS [CA-47956, CA-60181] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047956, R01CA060181] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAFFY G, 1993, J BIOL CHEM, V268, P6511; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; CROMPTON M, 1988, BIOCHEM J, V255, P357; DABAUVALLE MC, 1991, J CELL BIOL, V112, P1073, DOI 10.1083/jcb.112.6.1073; DEJONG D, 1994, CANCER RES, V54, P256; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GONG JP, 1993, J CELL PHYSIOL, V157, P263; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HENNET T, 1993, CANCER RES, V53, P1456; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HUGHES FM, 1991, ENDOCRINOLOGY, V129, P2415, DOI 10.1210/endo-129-5-2415; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KUBOTA Y, 1993, J CELL BIOL, V123, P1321, DOI 10.1083/jcb.123.6.1321; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYASHITA T, 1993, BLOOD, V81, P151; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NEWMEYER DD, 1991, METHOD CELL BIOL, V36, P607; NEWMEYER DD, 1986, J CELL BIOL, V103, P2091, DOI 10.1083/jcb.103.6.2091; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PAN BT, 1994, J BIOL CHEM, V269, P5968; REED JC, 1992, ANAL BIOCHEM, V205, P70, DOI 10.1016/0003-2697(92)90580-Z; REED JC, 1991, CANCER RES, V51, P6529; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REINHART PH, 1982, BIOCHEM J, V204, P731, DOI 10.1042/bj2040731; RICHTER C, 1993, TOXICOL LETT, V67, P119, DOI 10.1016/0378-4274(93)90050-8; SANDSTROM PA, 1994, J BIOL CHEM, V269, P798; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; SATO T, 1994, IN PRESS P NATL ACAD; SCHLEGEL J, 1992, BIOCHEM J, V285, P65, DOI 10.1042/bj2850065; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SCHWARTZMAN RA, 1991, ENDOCRINOLOGY, V128, P1190, DOI 10.1210/endo-128-2-1190; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SMITH LD, 1991, METHOD CELL BIOL, V36, P45; TANAKA S, 1993, J BIOL CHEM, V268, P10920; TILLY JL, 1992, MOL ENDOCRINOL, V6, P1942, DOI 10.1210/me.6.11.1942; TONKS NK, 1991, METHOD ENZYMOL, V201, P442; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WANG HG, 1994, ONCOGENE, V9, P2751; WILSON KL, 1988, J CELL BIOL, V107, P57, DOI 10.1083/jcb.107.1.57; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929	60	490	511	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	1994	79	2					353	364		10.1016/0092-8674(94)90203-8	http://dx.doi.org/10.1016/0092-8674(94)90203-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954801				2022-12-01	WOS:A1994PN63000018
J	WILSON, MM; CHELALA, C				WILSON, MM; CHELALA, C			CHOLERA IS WALKING SOUTH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									MINIST HLTH & SOCIAL ACT,NATL COMMISS AGAINST CHOLERA,BUENOS AIRES,DF,ARGENTINA									TAUXE R, 1994, VIBRIO CHOLERAE CHOL; TAUXE RV, 1992, JAMA-J AM MED ASSOC, V267, P1388, DOI 10.1001/jama.267.10.1388; 1993, CHOLERA SITUATION AM; 1993, MMWR-MORBID MORTAL W, V42, P89; 1994, INFORME          JUN; 1994, EPIDEMIOL B, V15, P13	6	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1226	1227		10.1001/jama.272.15.1226	http://dx.doi.org/10.1001/jama.272.15.1226			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL212	7933354				2022-12-01	WOS:A1994PL21200040
J	KILPATRICK, ES; RUMLEY, AG; DOMINICZAK, MH; SMALL, M				KILPATRICK, ES; RUMLEY, AG; DOMINICZAK, MH; SMALL, M			GLYCATED HEMOGLOBIN VALUES - PROBLEMS IN ASSESSING BLOOD-GLUCOSE CONTROL IN DIABETES-MELLITUS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FETAL HEMOGLOBIN	Objective-To see whether two measures of glycated haemoglobin concentration-the haemoglobin A(1) (HbA(1)) value and the haemoglobin A1c (HbA(1c) value-assess blood glucose control differently in diabetes. Design-Diabetic patients had glycaemic control assessed on the basis of HbA(1) and HbA(1c) values measured by the same high performance liquid chromatography instrument and on the basis of HbA(1) measured by electrophoresis. Setting-A diabetic outpatient clinic. Subjects-208 diabetic patients and 106 nondiabetic controls. Main outcome measures-Glycated haemoglobin concentrations classified according to European guidelines as representing good, borderline, or poor glycaemic control by using standard deviations from a reference mean. Results-Fewer patients were in good control (25;12%) and more poorly controlled (157;75%) as assessed by the HbA(1c) value compared with both HbA(1) assays (39 (19%) and 130 (63%) respectively when using highperformance liquid chromatography; 63 (30%) acid 74 (36%) when using electrophoresis). The median patient value was 8.0 SD from the reference mean when using HbA(1c), 5.9 when using HbA(1) measured by the same high performance liquid chromatography method, and 4.1 when using HbA(1) measured by electrophoresis. Conclusions-Large differences exist between HbA(1) and HbA(1c) in the classification of glycaemic control in diabetic patients. The HbA(1c) value may suggest a patient is at a high risk of long term diabetic complications when the HbA(1) value may not. Better standardisation of glycated haemoglobin measurements is advisable.	GARTNAVEL ROYAL HOSP, DIABET UNIT, GLASGOW G12 0YN, LANARK, SCOTLAND	Gartnavel Royal Hospital	KILPATRICK, ES (corresponding author), GARTNAVEL ROYAL HOSP, DEPT PATHOL BIOCHEM, LIPID & DIABET LAB, GLASGOW G12 0YN, LANARK, SCOTLAND.							ALBERTI KGMM, 1988, DIABETIC MED, V5, P275, DOI 10.1111/j.1464-5491.1988.tb00984.x; AMER DIABET ASSOC, 1993, DIABETES, V42, P1555; ANTSIFEROV M, 1993, DIABETIC MED, V10, P990; GOLDSTEIN DE, 1986, CLIN CHEM, V32, pB64; JOHN WG, 1992, DIABETIC MED, V9, P15, DOI 10.1111/j.1464-5491.1992.tb01708.x; KILPATRICK ES, 1993, CLIN CHEM, V39, P833; PAGE SR, 1993, DIABETIC MED, V10, P793, DOI 10.1111/j.1464-5491.1993.tb00168.x; RUMLEY AG, 1993, DIABETIC MED, V10, P976, DOI 10.1111/j.1464-5491.1993.tb00016.x; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; WYSOCKI T, 1989, J BEHAV MED, V12, P183, DOI 10.1007/BF00846550; YATSCOFF RW, 1983, CLIN CHEM, V29, P543	11	36	36	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 15	1994	309	6960					983	986		10.1136/bmj.309.6960.983	http://dx.doi.org/10.1136/bmj.309.6960.983			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PM417	7950717	Green Published			2022-12-01	WOS:A1994PM41700019
J	JIMENEZ, JA; HUGHES, KA; ALAKS, G; GRAHAM, L; LACY, RC				JIMENEZ, JA; HUGHES, KA; ALAKS, G; GRAHAM, L; LACY, RC			AN EXPERIMENTAL-STUDY OF INBREEDING DEPRESSION IN A NATURAL HABITAT	SCIENCE			English	Article							POPULATIONS	Inbreeding is known to lead to decreased survival and reproduction in captive populations of animals. It is also important to know whether inbreeding has deleterious effects in natural habitats. An estimate was made of the effects of inbreeding in white-footed mice, Peromyscus leucopus noveboracensis, derived from a wild population. This study demonstrates that inbreeding had a significant detrimental effect on the survivorship of mice reintroduced into a natural habitat. This effect was more severe than the effect observed in laboratory studies of the population.	CHICAGO ZOOL SOC, DEPT CONSERVAT BIOL, BROOKFIELD, IL 60513 USA; UNIV ILLINOIS, DEPT BIOL SCI, CHICAGO, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Peng, Bo/A-6920-2009	Peng, Bo/0000-0001-8225-2284				Akaike H., 1973, 2 INT S INF THEOR, P267; BARRETT SCH, 1991, GENETICS AND CONSERVATION OF RARE PLANTS, P3; BREWER BA, 1990, J HERED, V81, P257, DOI 10.1093/oxfordjournals.jhered.a110988; CHARLESWORTH D, 1987, ANNU REV ECOL SYST, V18, P237, DOI 10.1146/annurev.ecolsys.18.1.237; CHEN XF, 1993, HEREDITY, V71, P456, DOI 10.1038/hdy.1993.163; CLARK TW, 1989, CONSERVATION BIOL BL; Falconer D. S., 1989, Introduction to quantitative genetics.; GILBERT DG, 1989, IUBIO ARCH MOL GENER; Kleiman D.G., 1986, P959; LACY RC, 1993, NATURAL HIST INBREED, P252; LEBRETON JD, 1992, ECOL MONOGR, V62, P67, DOI 10.2307/2937171; LIVELY CM, 1990, NATURE, V344, P864, DOI 10.1038/344864a0; MORTON NE, 1956, P NATL ACAD SCI USA, V42, P855, DOI 10.1073/pnas.42.11.855; Pradel R., 1993, USERS MANUAL PROGRAM; QUATTRO JM, 1989, SCIENCE, V245, P976, DOI 10.1126/science.2772650; Ralls K., 1983, P164; RALLS K, 1988, Conservation Biology, V2, P185, DOI 10.1111/j.1523-1739.1988.tb00169.x; RYMAN N, 1970, HEREDITAS-GENETISK A, V65, P159; SEAL US, 1989, CONSERVATION BIOL BL; Seber GAF, 1982, ESTIMATION ANIMAL AB, V2; Shields William M., 1993, P143; SHIELDS WM, 1979, PHILOPATRY INBREEDIN; SITTMANN K, 1966, GENETICS, V54, P371; Templeton A.R., 1983, P241; Wright S, 1977, EXPT RESULTS EVOLUTI, V3	25	291	300	1	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 14	1994	266	5183					271	273		10.1126/science.7939661	http://dx.doi.org/10.1126/science.7939661			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939661				2022-12-01	WOS:A1994PM13400032
J	SUN, H; TONKS, NK; BARSAGI, D				SUN, H; TONKS, NK; BARSAGI, D			INHIBITION OF RAS-INDUCED DNA-SYNTHESIS BY EXPRESSION OF THE PHOSPHATES MKP-1	SCIENCE			English	Article							ACTIVATED PROTEIN-KINASES; IMMEDIATE-EARLY GENE; MAP KINASE; SIGNAL-TRANSDUCTION; PHOSPHORYLATION; PROLIFERATION; PATHWAY; DOMAIN	Mitogen-activated protein kinases (MAP kinases) are common components of signaling pathways induced by diverse growth stimuli. Although the guanidine nucleotide-binding Ras proteins are known to be upstream activators of MAP kinases, the extent to which MAP kinases directly contribute to the mitogenic effect of Ras is as yet undefined. In this study, inhibition of MAP kinases by the MAP kinase phosphatase MKP-1 blocked the induction of DNA synthesis in quiescent rat embryonic fibroblast REF-52 cells by an activated mutant of Ras, V(12)Ras. These results suggest an essential role for activation of MAP kinases in the transition from the quiescent to the DNA replication phase of the eukaryotic cell cycle.			SUN, H (corresponding author), COLD SPRING HARBOR LAB,1 BUNGTOWN RD,POB 100,COLD SPRING HARBOR,NY 11724, USA.			Bar-Sagi, Dafna/0000-0003-2597-8948	NCI NIH HHS [CA53840, CA55360] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA055360, R56CA055360, R37CA053840, R01CA055360, R01CA053840] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ALESSI DR, 1993, ONCOGENE, V8, P2015; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CHARLES CH, 1992, ONCOGENE, V7, P187; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MINSHULL J, IN PRESS CELL; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Sun H., UNPUB; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	30	223	234	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1994	266	5183					285	288		10.1126/science.7939666	http://dx.doi.org/10.1126/science.7939666			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939666				2022-12-01	WOS:A1994PM13400037
J	DONALDSON, LJ; RANKIN, J; PROCTOR, S				DONALDSON, LJ; RANKIN, J; PROCTOR, S			IS IT POSSIBLE TO CATCH LEUKEMIA FROM A CAT	LANCET			English	Editorial Material							VIRUS; INFECTION				DONALDSON, LJ (corresponding author), UNIV NEWCASTLE UPON TYNE, NEWCASTLE UPON TYNE NE1 7RU, TYNE & WEAR, ENGLAND.							BROSS IDJ, 1972, AM J PUBLIC HEALTH N, V62, P1520, DOI 10.2105/AJPH.62.11.1520; BROSS IDJ, 1970, J MED, V1, P180; HOSIE MJ, 1989, VET REC, V125, P293, DOI 10.1136/vr.125.11.293; JARRETT O, 1991, J AM VET MED ASSOC, V199, P1279; JARRETT O, 1994, SYMP SOC GEN MICROBI, V51, P235; MORGAN RA, 1993, VIROLOGY, V193, P439, DOI 10.1006/viro.1993.1141; PEDERSEN NC, 1987, SCIENCE, V235, P790, DOI 10.1126/science.3643650; PILET C, 1989, B ACAD NAT MED PARIS, V173, P617; SORDILLO PP, 1982, JNCI-J NATL CANCER I, V69, P333; VIOLA MV, 1968, JAMA-J AM MED ASSOC, V205, P95; YAMAMOTO JK, 1989, J AM VET MED ASSOC, V194, P213	11	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					971	972		10.1016/S0140-6736(94)91636-5	http://dx.doi.org/10.1016/S0140-6736(94)91636-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934425				2022-12-01	WOS:A1994PK97800004
J	HENG, MK; HENG, MCY				HENG, MK; HENG, MCY			HEAT-SHOCK PROTEIN-65 AND ACTIVATED GAMMA/DELTA T-CELLS IN INJURED ARTERIES	LANCET			English	Note							ATHEROSCLEROTIC LESIONS; HUMANS	Because immune mechanisms are implicated in atherogenesis, we investigated the T-lymphocyte subset and factors related to its activation after acute arterial ligation (22 ligated and 13 non-ligated specimens). Ligated arteries produced heat-shock protein 65 (hsp65) acid were infiltrated with activated T cells (mostly dendritic, CD3+, CD4-, CD8-, and gamma/delta T-cell-receptor bearing). The protein was found with dendritic T cells, with immunogold-labelled hsp65 beside the dendritic processes. Thus, the immune reaction after acute arterial injury may be associated with binding and recognition of in-situ hsp65 by dendritic gamma/delta T-cells.			HENG, MK (corresponding author), UNIV CALIF LOS ANGELES,SEPULVEDA VA MED CTR,DEPT MED,DIV CARDIOL,SEPULVEDA,CA 91343, USA.							BERBERIAN PA, 1990, AM J PATHOL, V136, P71; BERGSTRESSER PR, 1993, J INVEST DERMATOL, V100, pS80, DOI 10.1111/1523-1747.ep12356076; HAREGEWOIN A, 1989, NATURE, V340, P309, DOI 10.1038/340309a0; KLEINDIENST R, 1993, AM J PATHOL, V142, P1927; OBRIEN RL, 1989, CELL, V57, P668; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; STEMME S, 1992, ARTERIOSCLER THROMB, V12, P206, DOI 10.1161/01.ATV.12.2.206; VANDERWAL AC, 1989, LAB INVEST, V61, P166; XU QB, 1993, LANCET, V341, P255, DOI 10.1016/0140-6736(93)92613-X; XU QB, 1992, ARTERIOSCLER THROMB, V12, P789, DOI 10.1161/01.ATV.12.7.789	10	13	14	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					921	923		10.1016/S0140-6736(94)92271-3	http://dx.doi.org/10.1016/S0140-6736(94)92271-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934348				2022-12-01	WOS:A1994PJ28700012
J	MANCINI, GBJ				MANCINI, GBJ			MORE BAD-NEWS FOR COUCH POTATOES AND SMOKERS WHO ATONE THROUGH EXERCISE	LANCET			English	Editorial Material							PHYSICAL-ACTIVITY		VANCOUVER HOSP & HLTH SCI CTR,VANCOUVER,BC,CANADA	University of British Columbia	MANCINI, GBJ (corresponding author), UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER,BC,CANADA.							ABBOTT RD, 1994, AM J EPIDEMIOL, V139, P881, DOI 10.1093/oxfordjournals.aje.a117094; BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/oxfordjournals.aje.a115704; BLAIR SN, 1992, ANNU REV PUBL HEALTH, V13, P99, DOI 10.1146/annurev.pu.13.050192.000531; Fletcher G F, 1993, Heart Dis Stroke, V2, P183; OCONNOR GT, 1989, CIRCULATION, V80, P234, DOI 10.1161/01.CIR.80.2.234; RODRIGUEZ BL, 1994, CIRCULATION, V89, P2540, DOI 10.1161/01.CIR.89.6.2540	6	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					629	630		10.1016/S0140-6736(94)92078-8	http://dx.doi.org/10.1016/S0140-6736(94)92078-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915343				2022-12-01	WOS:A1994PE38600003
J	MULCAHY, HE; DUFFY, MJ; GIBBONS, D; MCCARTHY, P; PARFREY, NA; ODONOGHUE, DP; SHEAHAN, K				MULCAHY, HE; DUFFY, MJ; GIBBONS, D; MCCARTHY, P; PARFREY, NA; ODONOGHUE, DP; SHEAHAN, K			UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND OUTCOME IN DUKES B-COLORECTAL-CANCER	LANCET			English	Note							BREAST-CANCER; STROMAL CELLS; ADENOCARCINOMAS; RECEPTOR; COLON	Urokinase-type plasminogen activator (u-PA) is a serine protease involved in cancer metastasis. Using immunohistochemical methods, we examined the relation between u-PA and long-term survival in 70 patients with Dukes' B colorectal cancer. 8-year survival was 81% in patients whose tumours demonstrated low-grade epithelial u-PA staining and 43% in those with high-grade staining (log-rank test, p=0.01). Survival was unrelated to stromal u-PA staining. These results suggest that u-PA may be useful in the identification of patients with non-metastatic colorectal cancer at risk of tumour recurrence.	ST VINCENTS HOSP,DEPT PATHOL,DUBLIN 4,IRELAND; NATL UNIV IRELAND UNIV COLL DUBLIN,DUBLIN 4,IRELAND; ST VINCENTS HOSP,DEPT NUCL MED,DUBLIN 4,IRELAND; ST VINCENTS HOSP,GASTROENTEROL & LIVER UNIT,DUBLIN 4,IRELAND	University College Dublin; University College Dublin; University College Dublin; University College Dublin								DUFFY MJ, 1990, CANCER RES, V50, P6827; DUFFY MJ, 1992, CLIN EXP METASTAS, V10, P144; GELISTER JSK, 1986, BRIT MED J, V293, P728, DOI 10.1136/bmj.293.6549.728; GRONDAHLHANSEN J, 1991, AM J PATHOL, V138, P111; JANICKE F, 1990, FIBRINOLYSIS, V4, P69, DOI 10.1016/0268-9499(90)90001-Z; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; MURNANE MJ, 1991, CANCER RES, V51, P1137; PYKE C, 1991, AM J PATHOL, V138, P1059; SIER CFM, 1991, HISTOPATHOLOGY, V19, P231, DOI 10.1111/j.1365-2559.1991.tb00027.x; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0	10	125	128	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					583	584		10.1016/S0140-6736(94)91968-2	http://dx.doi.org/10.1016/S0140-6736(94)91968-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914963				2022-12-01	WOS:A1994PD42400012
J	GARCIAFERNANDEZ, J; HOLLAND, PWH				GARCIAFERNANDEZ, J; HOLLAND, PWH			ARCHETYPAL ORGANIZATION OF THE AMPHIOXUS HOX GENE-CLUSTER	NATURE			English	Article							HOMEOBOX-CONTAINING GENES; CAENORHABDITIS-ELEGANS; VERTEBRATE EVOLUTION; EXPRESSION; METAZOAN; FAMILY; MOUSE	ORGANIZATION into gene clusters is an essential and diagnostic feature of Hox genes(1). Insect and nematode genomes possess single Hox gene clusters (split in Dvosophila); in mammals, there are 38 Hox genes in four clusters on different chromosomes(2,3). A collinear relationship between chromosomal position, activation time and anterior expression limit of vertebrate Hox genes suggests that clustering may be important for precise spatiotemporal gene regulation and hence embryonic patterning(2,4). Hox genes have a wide phylogenetic distribution within the metazoa, and are implicated in the control of regionalization along the anteroposterior body axis(2,5). It has been suggested that changes in Hox gene number and genomic organization played a role in metazoan body-plan evolution(6-8), but identifying significant changes is difficult because Hox gene organization is known from only very few and widely divergent taxa (principally insects, nematodes and vertebrates)(3). Here we analyse the complexity and organization of Hox genes in a cephalochordate, amphioxus, the taxon thought to be the sister group of the vertebrates(9). We find that the amphioxus genome has only one Hox gene cluster. It has similar genomic organization to the four mammalian Hox clusters, and contains homologues of at least the first ten paralogous groups of vertebrate Hox genes in a collinear array. Remarkably, this organization is compatible with that inferred for a direct ancestor of the vertebrates; we conclude; that amphioxus is a living representative of a critical intermediate stage in Hox cluster evolution.	UNIV OXFORD,DEPT ZOOL,OXFORD OX1 3PS,ENGLAND	University of Oxford			Garcia-Fernandez, Jordi/B-3839-2013	Garcia-Fernandez, Jordi/0000-0001-5677-5970; Holland, Peter/0000-0003-1533-9376				ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; AKAM M, 1988, DEVELOPMENT, V104, P123; BELLEVILLE S, 1992, GENE, V114, P179, DOI 10.1016/0378-1119(92)90572-7; Burglin Thomas R., 1994, P25; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; BURGLIN TR, 1993, CURR OPIN GENET DEV, V3, P615, DOI 10.1016/0959-437X(93)90097-9; DEKKER EJ, 1992, MECH DEVELOP, V40, P3; HOLLAND P, 1992, BIOESSAYS, V14, P267, DOI 10.1002/bies.950140412; HOLLAND PWH, 1994, J MAR BIOL ASSOC UK, V74, P49, DOI 10.1017/S0025315400035657; HOLLAND PWH, 1992, DEVELOPMENT, V116, P653; HOLLAND PWH, 1993, ESSENTIAL DEV BIOL P, P243; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; KAPPEN C, 1989, P NATL ACAD SCI USA, V86, P5459, DOI 10.1073/pnas.86.14.5459; KAPPEN C, 1993, GENOMICS, V18, P54, DOI 10.1006/geno.1993.1426; KAPPEN C, 1993, CURR OPIN GENET DEV, V3, P931, DOI 10.1016/0959-437X(93)90016-I; LUNDIN LG, 1993, GENOMICS, V16, P1, DOI 10.1006/geno.1993.1133; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MOLVEN A, 1993, BIOCHIM BIOPHYS ACTA, V1173, P102, DOI 10.1016/0167-4781(93)90253-A; PENDLETON JW, 1993, P NATL ACAD SCI USA, V90, P6300, DOI 10.1073/pnas.90.13.6300; RUBOCK MJ, 1990, P NATL ACAD SCI USA, V87, P4751, DOI 10.1073/pnas.87.12.4751; SANSOM IJ, 1992, SCIENCE, V256, P1308, DOI 10.1126/science.1598573; SCHUBERT FR, 1993, P NATL ACAD SCI USA, V90, P143, DOI 10.1073/pnas.90.1.143; SCHUGHART K, 1988, P NATL ACAD SCI USA, V85, P5582, DOI 10.1073/pnas.85.15.5582; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; TABIN CJ, 1992, DEVELOPMENT, V116, P289; WEBSTER PJ, 1992, MECH DEVELOP, V38, P25, DOI 10.1016/0925-4773(92)90035-I; Willey A., 1894, AMPHIOXUS ANCESTRY V	29	471	483	4	43	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 18	1994	370	6490					563	566		10.1038/370563a0	http://dx.doi.org/10.1038/370563a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	7914353				2022-12-01	WOS:A1994PC53700057
J	BRAUN, MM; CAPORASO, NE; PAGE, WF; HOOVER, RN				BRAUN, MM; CAPORASO, NE; PAGE, WF; HOOVER, RN			GENETIC COMPONENT OF LUNG-CANCER - COHORT STUDY OF TWINS	LANCET			English	Article							RISK; SUSCEPTIBILITY; ASSOCIATION; STATISTICS; MUTATIONS; MORTALITY; REGISTRY; SMOKING; LOCUS	Epidemiological and molecular epidemiological findings suggest that inherited predisposition may be a component of lung cancer risk and an important modulator of the carcinogenic effects of cigarette smoke. We have carried out a genetic analysis of lung cancer mortality on the National Academy of Sciences/National Research Council Twin Registry. The registry is composed of 15 924 male twin pairs who were born in the USA between 1917 and 1927 and who served in the armed forces during World War II. As evidence for a genetic effect on lung cancer, we required concordance for lung cancer death to be greater among monozygotic than among dizygotic twin pairs. No genetic effect on lung cancer mortality was observed. The ratio of observed to expected concordance among monozygotic twins did not exceed that among dizygotic twins (overall rate ratio 0.75 [95% CI 0.35-1.6]), even though monozygotic twin pairs are more likely to be concordant for smoking than dizygotic twin pairs in this population. A cohort analysis (accounting for age, sex, race, and smoking intensity) of lung cancer mortality found no lung cancer deaths during 300 person-years of follow-up (observed to expected ratio 0 [0-4.09]) among 47 monozygotic twin smokers whose smoking twins had died of lung cancer, even though smoking histories were very similar within twin pairs. In our study, there is little if any effect of inherited predisposition on development of lung cancer. Genetic factors are not likely to be strongly predictive of lung cancer risk in most male smokers older than 50, the age group in which the vast majority of cases occur.	NATL ACAD SCI, INST MED, MED FOLLOW UP AGCY, WASHINGTON, DC 20418 USA	National Academies of Sciences, Engineering & Medicine	BRAUN, MM (corresponding author), NCI, EPIDEMIOL & BIOSTAT PROGRAM, EPN 443, 6130 EXECUT BLVD, ROCKVILLE, MD 20852 USA.							[Anonymous], 1986, IARC MONOGRAPHS EVAL, V38; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; BOYLE CA, 1990, AM J EPIDEMIOL, V131, P160, DOI 10.1093/oxfordjournals.aje.a115470; CAPORASO N, 1989, CANCER RES, V49, P3675; CARMELLI D, 1992, NEW ENGL J MED, V327, P829, DOI 10.1056/NEJM199209173271201; CARMELLI D, 1990, ACTA GENET MED GEMEL, V39, P91, DOI 10.1017/S0001566000005602; CEDERLOEF R, 1961, ACTA GENET STAT MED, V11, P338; DORN HF, 1959, PUBLIC HEALTH REP, V74, P581, DOI 10.2307/4590516; HALPERN MT, 1993, JNCI-J NATL CANCER I, V85, P457, DOI 10.1093/jnci/85.6.457; HARRIS CC, 1980, ANN INTERN MED, V92, P809, DOI 10.7326/0003-4819-92-6-809; HRUBEC Z, 1982, AM J HUM GENET, V34, P658; HRUBEC Z, 1977, TWIN RES, P153; JABLON S, 1967, AM J HUM GENET, V19, P133; KAHN HAROLD A., 1966, NAT CANCER INST MONOGR, V19, P1; KENDLER KS, 1983, AM J PSYCHIAT, V140, P1551; KRONTIRIS TG, 1993, NEW ENGL J MED, V329, P517, DOI 10.1056/NEJM199308193290801; MATTSON ME, 1987, AM J PUBLIC HEALTH, V77, P425, DOI 10.2105/AJPH.77.4.425; NAKACHI K, 1993, CANCER RES, V53, P2994; NICHOLS RC, 1966, ACTA GENET STAT MED, V16, P265; OOI WL, 1986, J NATL CANCER I, V76, P217; PERCY C, 1981, AM J PUBLIC HEALTH, V71, P242, DOI 10.2105/AJPH.71.3.242; PETO R, 1984, LUNG CANCER CAUSES P, P1; RIES LAG, 1991, NCI NIH912789 PUB; SAMET JM, 1986, AM REV RESPIR DIS, V134, P466; SELLERS TA, 1990, J NATL CANCER I, V82, P1272, DOI 10.1093/jnci/82.15.1272; SHAW GL, 1991, J CLIN EPIDEMIOL, V44, P429, DOI 10.1016/0895-4356(91)90082-K; SHIELDS PG, 1991, JAMA-J AM MED ASSOC, V266, P681, DOI 10.1001/jama.266.5.681; SUGIMURA H, 1990, CANCER RES, V50, P1857; TOKUHATA GEORGE K., 1963, JOUR NATL CANCER INST, V30, P289; VAHAKANGAS KH, 1992, LANCET, V339, P576, DOI 10.1016/0140-6736(92)90866-2	30	53	54	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 13	1994	344	8920					440	443		10.1016/S0140-6736(94)91770-1	http://dx.doi.org/10.1016/S0140-6736(94)91770-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7914565				2022-12-01	WOS:A1994PB76100010
J	SCHUPF, N; KAPELL, D; LEE, JH; OTTMAN, R; MAYEUX, R				SCHUPF, N; KAPELL, D; LEE, JH; OTTMAN, R; MAYEUX, R			INCREASED RISK OF ALZHEIMERS-DISEASE IN MOTHERS OF ADULTS WITH DOWNS-SYNDROME	LANCET			English	Article							DEMENTIA; ASSOCIATION; AGE	Most adults with Down's syndrome (DS) develop neuropathology characteristic of Alzheimer's disease (AD) by the age of 40. Most of the non-dysjunction events in DS are of maternal origin. We postulated therefore that a shared genetic susceptibility to DS and AD would be associated with an increased frequency of AD among mothers, but not fathers, of individuals with DS. We further hypothesised that the shared susceptibility could involve an accelerated ageing process, leading to the birth of a child with DS to a relatively young mother and to an increased risk of dementia in the mother and her relatives. Families of 96 adults with DS and of 80 adults with other forms of mental retardation were ascertained through the New York State Developmental Disabilities services network. A semi-structured interview was used to obtain information on the presence or absence of non-stroke-related dementia and other disorders in parents. There was an increase in risk of dementia among mothers of DS probands compared with control mothers (risk ratio 2.6 [95% Cl 0.9-7.3]). The risk of dementia among mothers who were 35 or younger when their DS children were born was 5 times that of control mothers (4.9 [1.6-15.4]). There was no increase in risk of dementia among mothers who were older ( > 35 years) at the proband's birth (0.8 [0.2-3.4]). There was no difference in risk of dementia between fathers of DS cases and fathers of controls (1.2 [0.4-3.9]) and no discernible influence of age on this risk. Familial aggregation of dementia among mothers of adults with DS supports the hypothesis of a shared genetic susceptibility to DS and AD.	COLUMBIA UNIV, FAC MED, GERTRUDE H SERGIEVSKY CTR, NEW YORK, NY USA; COLUMBIA UNIV, SCH PUBL HLTH, DIV EPIDEMIOL, NEW YORK, NY USA; NEW YORK STATE PSYCHIAT INST & HOSP, EPIDEMIOL BRAIN DISORDERS RES DEPT, NEW YORK, NY USA; COLUMBIA UNIV, DEPT NEUROL, NEW YORK, NY USA; COLUMBIA UNIV, DEPT PSYCHIAT, NEW YORK, NY USA; COLUMBIA UNIV, DEPT PHYS & SURG, NEW YORK, NY USA	Columbia University; Columbia University; New York State Psychiatry Institute; Columbia University; Columbia University; Columbia University	SCHUPF, N (corresponding author), NEW YORK STATE INST BASIC RES DEV DISABIL, EPIDEMIOL LAB, 1050 FOREST HILL RD, STATEN ISL, NY 10314 USA.		Ottman, Ruth/O-2371-2013; Lee, Joseph H/D-2441-2012	Ottman, Ruth/0000-0001-7074-242X; Lee, Joseph H/0000-0002-2000-4821	NIA NIH HHS [AG10963, AG09400, AG08702] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R35AG010963, R01AG009400, P50AG008702] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMADUCCI LA, 1986, NEUROLOGY, V36, P922, DOI 10.1212/WNL.36.7.922; BERR C, 1989, AM J MED GENET, V33, P545, DOI 10.1002/ajmg.1320330427; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; CHANDRA V, 1987, NEUROLOGY, V37, P1295, DOI 10.1212/WNL.37.8.1295; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; FITCH N, 1988, ANN NEUROL, V23, P14, DOI 10.1002/ana.410230104; HASSOLD T, 1993, CURR OPIN GENET DEV, V3, P398, DOI 10.1016/0959-437X(93)90111-2; HASSOLD T, 1984, ANN HUM GENET, V48, P129, DOI 10.1111/j.1469-1809.1984.tb01008.x; HESTON LL, 1981, ARCH GEN PSYCHIAT, V38, P1085; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; HOOK EB, 1982, DOWN SYNDROME ADV BI, P11; HUFF FJ, 1988, NEUROLOGY, V38, P786, DOI 10.1212/WNL.38.5.786; KLINE J, 1989, MONOGRAPHS EPIDEMIOL, V14, P102; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LI G, 1989, ACTA PSYCHIAT SCAND, V79, P557, DOI 10.1111/j.1600-0447.1989.tb10303.x; LI G, 1992, NEUROLOGY, V42, P1481, DOI 10.1212/WNL.42.8.1481; Malamud N., 1972, NEUROPATHOLOGY ORGAN, P63; MARTIN RL, 1988, ARCH GEN PSYCHIAT, V45, P894; MENDEZ MF, 1992, NEUROLOGY, V42, P770, DOI 10.1212/WNL.42.4.770; STOLL C, 1990, AM J MED GENET, P79; SUSSER E, 1989, AM J EPIDEMIOL, V129, P23, DOI 10.1093/oxfordjournals.aje.a115119; THOMPSON JS, 1986, GENET MED, P119; VANDUIJN CM, 1991, INT J EPIDEMIOL, V20, pS13, DOI 10.1093/ije/20.Supplement_2.S13; WHALLEY LJ, 1982, BRIT J PSYCHIAT, V140, P249, DOI 10.1192/bjp.140.3.249; WISNIEWSKI KE, 1985, NEUROLOGY, V35, P957, DOI 10.1212/WNL.35.7.957; YATHAM LN, 1988, ACTA PSYCHIAT SCAND, V77, P38, DOI 10.1111/j.1600-0447.1988.tb05074.x	26	80	83	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 6	1994	344	8919					353	356		10.1016/S0140-6736(94)91398-6	http://dx.doi.org/10.1016/S0140-6736(94)91398-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA303	7914304	hybrid			2022-12-01	WOS:A1994PA30300007
J	PIPPARD, MJ				PIPPARD, MJ			MEGALOBLASTIC-ANEMIA - GEOGRAPHY AND DIAGNOSIS	LANCET			English	Editorial Material							COBALAMIN DEFICIENCY; ANEMIA				PIPPARD, MJ (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT HAEMATOL,DUNDEE DD1 9SY,SCOTLAND.							ALLEN RH, 1990, AM J HEMATOL, V34, P90, DOI 10.1002/ajh.2830340204; CARMEL R, 1978, NEW ENGL J MED, V298, P647, DOI 10.1056/NEJM197803232981203; CHANARIN I, 1985, LANCET, V2, P1168; Chanarin I, 1990, MEGALOBLASTIC ANAEMI; METZ J, 1968, BRIT J HAEMATOL, V14, P575, DOI 10.1111/j.1365-2141.1968.tb00364.x; SAVAGE D, 1994, BRIT J HAEMATOL, V86, P844, DOI 10.1111/j.1365-2141.1994.tb04840.x; STABLER SP, 1990, BLOOD, V76, P871	7	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					6	7		10.1016/S0140-6736(94)91043-X	http://dx.doi.org/10.1016/S0140-6736(94)91043-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912325				2022-12-01	WOS:A1994NU91700006
J	MOSER, RH				MOSER, RH			ASPARTAME AND MEMORY LOSS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											MOSER, RH (corresponding author), UNIV NEW MEXICO,SCH MED,ALBUQUERQUE,NM 87131, USA.							TOLLEFSON L, 1993, REGUL TOXICOL PHARM, V18, P32, DOI 10.1006/rtph.1993.1042	1	10	10	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	1994	272	19					1543	1543						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ900	7966850				2022-12-01	WOS:A1994PQ90000037
J	STAMLER, JF				STAMLER, JF			THE SILENT MAN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	1994	272	19					1475	1475						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ900	7966826				2022-12-01	WOS:A1994PQ90000001
J	SCHUMACHER, MA; CHOI, KY; ZALKIN, H; BRENNAN, RG				SCHUMACHER, MA; CHOI, KY; ZALKIN, H; BRENNAN, RG			CRYSTAL-STRUCTURE OF LACI MEMBER, PURR, BOUND TO DNA - MINOR-GROOVE BINDING BY ALPHA-HELICES	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; ESCHERICHIA-COLI; REPRESSOR PROTEIN; NUCLEOTIDE-SEQUENCE; REGULATORY PROTEINS; MOLECULAR-DYNAMICS; PURINE REPRESSOR; ACID INTERACTION; OPERATOR; GENE	The three-dimensional structure of a ternary complex of the purine repressor, PurR, bound to both its corepressor, hypoxanthine, and the 16-base pair purF operator site has been solved at 2.7 Angstrom resolution by x-ray crystallography. The bipartite Structure of PurR consists of an amino-terminal DNA-binding domain and a larger carboxyl-terminal corepressor binding and dimerization domain that is similar to that of the bacterial periplasmic binding proteins. The DNA-binding domain contains alpha helix-turn-helix motif that makes base-specific contacts in the major groove of the DNA. Base contacts are also made by residues of symmetry-related a helices, the ''hinge'' helices, which bind deeply in the minor groove, Critical to hinge helix-minor groove binding is the intercalation of the side chains of Leu(54) and its symmetry-related mate, Leu(54'), into the central CpG-base pair step. These residues thereby act as ''leucine levers'' to pry open the minor groove and kink the purF operator by 45 degrees.	OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA; PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA	Oregon Health & Science University; Purdue University System; Purdue University; Purdue University West Lafayette Campus				Brennan, Richard/0000-0001-7647-485X	NIGMS NIH HHS [GM 49244, GM 24658] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024658, R01GM049244, R37GM024658] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTI S, 1993, EMBO J, V12, P3227, DOI 10.1002/j.1460-2075.1993.tb05992.x; ALBERTI S, 1991, NEW BIOL, V3, P57; BARBIER CS, 1992, J BACTERIOL, V174, P2881, DOI 10.1128/JB.174.9.2881-2890.1992; BARKLEY MD, 1974, NATURE, V251, P247, DOI 10.1038/251247a0; BIN H, 1993, J BACTERIOL, V175, P3598, DOI 10.1128/jb.175.11.3598-3606.1993; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; Brennan RG, 1991, CURR OPIN STRUC BIOL, V1, P80, DOI 10.1016/0959-440X(91)90015-L; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P1371; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P22206; CHANG WI, 1994, BIOCHEMISTRY-US, V33, P3607, DOI 10.1021/bi00178a018; CHANG WI, 1993, J BIOL CHEM, V268, P17613; CHOI KY, 1992, J BACTERIOL, V174, P6207, DOI 10.1128/JB.174.19.6207-6214.1992; CHOI KY, 1994, J BIOL CHEM, V269, P24066; CHOI KY, 1994, J BACTERIOL, V176, P1767, DOI 10.1128/jb.176.6.1767-1772.1994; CHUPRINA VP, 1993, J MOL BIOL, V234, P446, DOI 10.1006/jmbi.1993.1598; CORTAY JC, 1994, J BIOL CHEM, V269, P14885; GORDON AJE, 1988, J MOL BIOL, V200, P239, DOI 10.1016/0022-2836(88)90237-9; GRALLA JD, 1992, TRANSCRIPTIONAL REGU, V2, P629; HAGERMAN PJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P125, DOI 10.1016/0167-4781(92)90066-9; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.biochem.59.1.933; HE B, 1990, J BACTERIOL, V172, P4555, DOI 10.1128/jb.172.8.4555-4562.1990; HE B, 1994, J BACTERIOL, V176, P1009, DOI 10.1128/JB.176.4.1009-1013.1994; HE B, 1992, J BACTERIOL, V174, P130, DOI 10.1128/jb.174.1.130-136.1992; HE B, 1992, J BACTERIOL, V174, P7121, DOI 10.1128/jb.174.22.7121-7127.1992; HSIEH M, 1994, J BIOL CHEM, V269, P13825; JAENICKE R, 1990, FEBS LETT, V260, P233, DOI 10.1016/0014-5793(90)80111-U; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KAPTEIN R, 1985, J MOL BIOL, V182, P179, DOI 10.1016/0022-2836(85)90036-1; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KING CY, 1993, P NATL ACAD SCI USA, V90, P11990, DOI 10.1073/pnas.90.24.11990; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; LAMERICHS RMJN, 1989, BIOCHEMISTRY-US, V28, P2985, DOI 10.1021/bi00433a037; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LEHMING N, 1988, P NATL ACAD SCI USA, V85, P7947, DOI 10.1073/pnas.85.21.7947; LU FH, UNPUB; MARKIEWICZ P, 1994, J MOL BIOL, V240, P421, DOI 10.1006/jmbi.1994.1458; MAUZY CA, 1992, PROTEIN SCI, V1, P843, DOI 10.1002/pro.5560010702; MENG LM, 1990, EUR J BIOCHEM, V187, P373, DOI 10.1111/j.1432-1033.1990.tb15314.x; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; MULLERHILL B, 1983, NATURE, V302, P163, DOI 10.1038/302163a0; NICHOLS JC, 1993, J BIOL CHEM, V268, P17602; OH BH, 1993, J BIOL CHEM, V268, P11348; OLAH GA, 1993, J BIOL CHEM, V268, P16241; ORNSTEIN RL, 1978, BIOPOLYMERS, V17, P2341, DOI 10.1002/bip.1978.360171005; PABO CO, 1990, SCIENCE, V247, P1210, DOI 10.1126/science.2315694; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Quiocho FA, 1991, CURR OPIN STRUC BIOL, V1, P922, DOI 10.1016/0959-440X(91)90087-A; RAVISHANKER G, 1989, J BIOMOL STRUCT DYN, V6, P669, DOI 10.1080/07391102.1989.10507729; ROLFES RJ, 1988, J BIOL CHEM, V263, P19653; ROLFES RJ, 1990, J BACTERIOL, V172, P5758, DOI 10.1128/jb.172.10.5758-5766.1990; SADLER JR, 1983, P NATL ACAD SCI-BIOL, V80, P6785, DOI 10.1073/pnas.80.22.6785; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SCHUMACHER MA, 1994, J MOL BIOL, V242, P302, DOI 10.1006/jmbi.1994.1580; SCHUMACHER MA, 1993, J BIOL CHEM, V268, P12282; SCHUMACHER MA, UNPUB; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SIMONS A, 1984, P NATL ACAD SCI-BIOL, V81, P1624, DOI 10.1073/pnas.81.6.1624; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; SPOTTS RO, 1991, J BIOL CHEM, V266, P22998; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TRAVERS AA, 1992, CURR OPIN STRUC BIOL, V2, P71; Travers AA, 1991, CURR OPIN STRUC BIOL, V1, P114, DOI 10.1016/0959-440X(91)90019-P; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VARTAK NB, 1991, RES MICROBIOL, V142, P951, DOI 10.1016/0923-2508(91)90005-U; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433; ZALKIN H, 1992, PROG NUCLEIC ACID RE, V42, P259, DOI 10.1016/S0079-6603(08)60578-4; ZUIDERWEG ERP, 1983, P NATL ACAD SCI-BIOL, V80, P5837, DOI 10.1073/pnas.80.19.5837; ZWIEB C, 1989, GENE DEV, V3, P606, DOI 10.1101/gad.3.5.606	78	341	349	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	1994	266	5186					763	770		10.1126/science.7973627	http://dx.doi.org/10.1126/science.7973627			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973627				2022-12-01	WOS:A1994PP75300028
J	BELL, BP; GOLDOFT, M; GRIFFIN, PM; DAVIS, MA; GORDON, DC; TARR, PI; BARTLESON, CA; LEWIS, JH; BARRETT, TJ; WELLS, JG; BARON, R; KOBAYASHI, J				BELL, BP; GOLDOFT, M; GRIFFIN, PM; DAVIS, MA; GORDON, DC; TARR, PI; BARTLESON, CA; LEWIS, JH; BARRETT, TJ; WELLS, JG; BARON, R; KOBAYASHI, J			A MULTISTATE OUTBREAK OF ESCHERICHIA-COLI-O157-H7 ASSOCIATED BLOODY DIARRHEA AND HEMOLYTIC-UREMIC-SYNDROME FROM HAMBURGERS - THE WASHINGTON EXPERIENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DAY-CARE-CENTER; HEMORRHAGIC COLITIS; O157-H7 STRAINS; NURSING-HOME; EPIDEMIOLOGY; 0157-H7; INFECTION; CHILDREN; DISEASE	Objective.-To determine the source of and describe a large outbreak of Escherichia coli O157:H7 infections in Washington State. Design.-Case-control study; environmental investigation; provider-based surveillance for E coli O157:H7 infections. Setting.-Chain of fast-food restaurants, hospitals, physician offices, local laboratories, and local health departments. Participants.-Patients with diarrhea and neighborhood controls. A case was defined as diarrhea with culture-confirmed E coli O157:H7 infection or postdiarrheal hemolytic uremic syndrome (HUS) occurring from December 1, 1992, through February 28, 1993, in a Washington State resident. Controls were age- and neighborhood-matched friends of the first 16 case patients. Interventions.-Announcement to the public; recall of implicated hamburger lots. Main Outcome Measure.-Abatement of outbreak due to E coli O157:H7. Results.-Infection was associated with eating at a fast-food chain (chain A) in the 10 days before symptoms began. Twelve (75%) of 16 case patients but no controls had eaten at chain A (matched odds ratio undefined; lower 95% confidence interval, 3.5; P<.001). In total, 501 cases were reported, including 151 hospitalizations (31%), 45 cases of HUS (9%), and three deaths. Forty-eight patients (10%) had secondary infections. Of the remaining 453 patients (90%), 398 (86%) reported eating at a Washington chain A restaurant; 92% of them reported eating a regular hamburger. The pulsed-field gel electrophoresis pattern of the E coli O157:H7 strains isolated from all regular hamburger lots of a single production date shipped to Washington was identical to that of the strains isolated from patients. Ten (63%) of 16 regular hamburgers cooked according to chain A policy had internal temperatures below 60 degrees C. Public health action removed more than 250 000 potentially contaminated hamburgers, preventing an estimated 800 cases. Conclusions.-This E coli O157:H7 outbreak, the largest reported, resulted from errors in meat processing and cooking. Public health surveillance through state-mandated reporting of E coli O157:H7 infection as is carried out in Washington State was critical for prompt outbreak recognition and control. Measures should be developed to reduce meat contamination. Consumers and food service workers should be educated about cooking hamburger meat thoroughly.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,FOODBORNE & DIARRHEAL DIS BRANCH,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,EPIDEM INTELLIGENCE SERV,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV FIELD EPIDEMIOL,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30341; WASHINGTON STATE DEPT HLTH,SEATTLE,WA; WASHINGTON STATE DEPT HLTH,OLYMPIA,WA; SEATTLE KING CTY DEPT PUBL HLTH,SEATTLE,WA; SNOHOMISH HLTH DIST,EVERETT,WA; UNIV WASHINGTON,SCH MED,DEPT PEDIAT,DIV GASTROENTEROL,SEATTLE,WA 98195; CHILDRENS HOSP & MED CTR,SEATTLE,WA 98105	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of Washington; University of Washington Seattle; Seattle Children's Hospital								BELONGIA EA, 1993, JAMA-J AM MED ASSOC, V269, P883, DOI 10.1001/jama.269.7.883; BESSER RE, 1993, JAMA-J AM MED ASSOC, V269, P2217, DOI 10.1001/jama.269.17.2217; BOHM H, 1992, J CLIN MICROBIOL, V30, P2169; CARTER AO, 1987, NEW ENGL J MED, V317, P1496, DOI 10.1056/NEJM198712103172403; DOYLE MP, 1984, APPL ENVIRON MICROB, V48, P855, DOI 10.1128/AEM.48.4.855-856.1984; DOYLE MP, 1987, APPL ENVIRON MICROB, V53, P2394, DOI 10.1128/AEM.53.10.2394-2396.1987; GRIFFIN PM, 1991, EPIDEMIOL REV, V13, P60, DOI 10.1093/oxfordjournals.epirev.a036079; MACDONALD KL, 1988, JAMA-J AM MED ASSOC, V259, P3567, DOI 10.1001/jama.259.24.3567; MACDONALD KL, 1993, JAMA-J AM MED ASSOC, V269, P2264, DOI 10.1001/jama.269.17.2264; MARTIN D, 1991, EPIDEMIOLOGY, V2, P359, DOI 10.1097/00001648-199109000-00008; OSTROFF SM, 1989, JAMA-J AM MED ASSOC, V262, P355, DOI 10.1001/jama.262.3.355; REMIS RS, 1984, ANN INTERN MED, V101, P624, DOI 10.7326/0003-4819-101-5-624; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; ROWE PC, 1991, J PEDIATR-US, V119, P218, DOI 10.1016/S0022-3476(05)80730-9; RYAN CA, 1986, J INFECT DIS, V154, P631, DOI 10.1093/infdis/154.4.631; SAMADPOUR M, 1993, J CLIN MICROBIOL, V31, P3179, DOI 10.1128/JCM.31.12.3179-3183.1993; SPIKA JS, 1986, J PEDIATR-US, V109, P287, DOI 10.1016/S0022-3476(86)80386-9; STROCKBINE NA, 1992, MOL CELL PROBE, V6, P93, DOI 10.1016/0890-8508(92)90052-Y; SWERDLOW DL, 1992, ANN INTERN MED, V117, P812, DOI 10.7326/0003-4819-117-10-812; TARR PI, 1990, J INFECT DIS, V162, P553, DOI 10.1093/infdis/162.2.553; WEISSMAN JB, 1974, J PEDIATR-US, V84, P797, DOI 10.1016/S0022-3476(74)80750-X; WELLS JG, 1991, J CLIN MICROBIOL, V29, P985, DOI 10.1128/JCM.29.5.985-989.1991; WILSON R, 1981, J INFECT DIS, V143, P130, DOI 10.1093/infdis/143.1.130; 1976, US DHEW782081 US FOO, P28; 1993, MMWR-MORBID MORTAL W, V42, P258	25	513	536	0	72	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	1994	272	17					1349	1353		10.1001/jama.272.17.1349	http://dx.doi.org/10.1001/jama.272.17.1349			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP020	7933395				2022-12-01	WOS:A1994PP02000029
J	DAVIS, G; DRIVER, J				DAVIS, G; DRIVER, J			PARALLEL DETECTION OF KANIZSA SUBJECTIVE FIGURES IN THE HUMAN VISUAL-SYSTEM	NATURE			English	Article							ILLUSORY CONTOURS; APPARENT DEPTH; SEARCH	SUBJECTIVE figures, seen in the absence of luminance gradients (Fig. 1), provide a phenomenal illusion that can be related to the properties of single cells in the visual cortex(1), offering a rare bridge between brain function and visual awareness. It remains controversial whether subjective figures arise from intelligent cognitive mechanisms(2-4), or from lower-level processes in early vision(5,6). The cognitive account implies that the perception of subjective figures may require serial attentive processing, whereas on the low-level account they should arise in parallel at earlier visual stages. Physiological evidence apparently fits a low-level account(7,8) and indicates that some types of subjective contour may be detected earlier than the conventional Kanizsa(9) type. Here we report that even Kanizsa subjective figures can be detected without focal attention at parallel stages of the human visual system.			DAVIS, G (corresponding author), UNIV CAMBRIDGE,DEPT EXPTL PSYCHOL,DOWNING ST,CAMBRIDGE CB2 3EA,ENGLAND.		Driver, Jon/A-4779-2010; Davis, Gregory/G-9954-2012					BRIGNER WL, 1974, PERCEPT MOTOR SKILL, V38, P1047, DOI 10.2466/pms.1974.38.3c.1047; BROADBENT DE, 1985, MODELLING COGNITION, P169; COREN S, 1972, PSYCHOL REV, V79, P359, DOI 10.1037/h0032940; DeValois R. L., 1990, SPATIAL VISION, V14; DUNCAN J, 1989, PSYCHOL REV, V96, P433, DOI 10.1037/0033-295X.96.3.433; ENNS JT, 1990, SCIENCE, V247, P721, DOI 10.1126/science.2300824; ENNS JT, 1990, BEHAV RES METH INSTR, V22, P118, DOI 10.3758/BF03203130; GINSBURG AP, 1975, NATURE, V257, P219, DOI 10.1038/257219a0; GINSBURG AP, 1987, PERCEPTION ILLUSORY, P126; GRABOWECKY M, 1989, Investigative Ophthalmology and Visual Science, V30, P457; GREGORY RL, 1972, NATURE, V238, P51, DOI 10.1038/238051a0; GROSOF DH, 1993, NATURE, V365, P550, DOI 10.1038/365550a0; GURNSEY R, 1992, PERCEPT PSYCHOPHYS, V52, P263, DOI 10.3758/BF03209144; Kanizsa G., 1955, RIV PSICOL, V49, P7; PETERHANS E, 1991, TRENDS NEUROSCI, V14, P112, DOI 10.1016/0166-2236(91)90072-3; PRADZNY K, 1983, PERCEPT PSYCHOPHYS, V34, P403; Ramachandran V. S., 1987, PERCEPTION ILLUSORY, P93, DOI 10.1007/978-1-4612-4760-9_10; ROCK I, 1979, PERCEPTION, V8, P665, DOI 10.1068/p080665; SMITH AT, 1977, NATURE, V257, P581; TOWNSEND JT, 1971, PERCEPT PSYCHOPHYS, V10, P161, DOI 10.3758/BF03205778; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; VONDERHEYDT R, 1984, SCIENCE, V224, P1260, DOI 10.1126/science.6539501; WARM JS, 1986, PERCEPT PSYCHOPHYS, V39, P219	23	127	128	2	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 27	1994	371	6500					791	793		10.1038/371791a0	http://dx.doi.org/10.1038/371791a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PP018	7935838				2022-12-01	WOS:A1994PP01800057
J	PAUSE, A; BELSHAM, GJ; GINGRAS, AC; DONZE, O; LIN, TA; LAWRENCE, JC; SONENBERG, N				PAUSE, A; BELSHAM, GJ; GINGRAS, AC; DONZE, O; LIN, TA; LAWRENCE, JC; SONENBERG, N			INSULIN-DEPENDENT STIMULATION OF PROTEIN-SYNTHESIS BY PHOSPHORYLATION OF A REGULATOR OF 5'-CAP FUNCTION	NATURE			English	Article							5' NONCODING REGION; SECONDARY STRUCTURE; INITIATION; TRANSLATION; MECHANISM; CELLS; EXPRESSION; VIRUS	The cloning is described of two related human complementary DNAs encoding polypeptides that interact specifically with the translation initiation factor eIF-4E, which binds to the messenger RNA 5'-cap structure. Interaction of these proteins with eIF-4E inhibits translation but treatment of cells with insulin causes one of them to become hyperphosphorylated and dissociate from eIF-4E, thereby relieving the translational inhibition. The action of this new regulator of protein synthesis is therefore modulated by insulin, which acts to stimulate the overall rate of translation and promote cell growth.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL H3G 1Y6,PQ,CANADA; BBSRC,INST ANIM HLTH,WOKING GU24 0NF,SURREY,ENGLAND; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	McGill University; McGill University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; Washington University (WUSTL)			Belsham, Graham/J-3132-2019; Gingras, Anne-Claude/E-9982-2010; Gingras, Anne-Claude/ABA-8341-2020; Belsham, Graham J./H-8589-2019	Belsham, Graham/0000-0003-1187-4873; Gingras, Anne-Claude/0000-0002-6090-4437; Gingras, Anne-Claude/0000-0002-6090-4437; Belsham, Graham J./0000-0003-1187-4873				AVRUCH J, 1985, MOL BASIS INSULIN AC, P67; BELSHAM GJ, 1980, DIABETOLOGIA, V18, P307; BELSHAM GJ, 1982, BIOCHEM J, V204, P345, DOI 10.1042/bj2040345; BELSHAM GJ, 1990, J VIROL, V64, P5389, DOI 10.1128/JVI.64.11.5389-5395.1990; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BLACKSHEAR PJ, 1983, BIOCHEM J, V214, P11, DOI 10.1042/bj2140011; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; DENTON RM, 1981, DIABETOLOGIA, V21, P347; EDERY I, 1988, GENE, V74, P517, DOI 10.1016/0378-1119(88)90184-9; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GALLIE DR, 1994, J BIOL CHEM, V269, P7174; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HERSHEY JWB, 1991, REV BIOCH, V60, P717; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; LARARISKARATZAS A, 1990, NATURE, V345, P544; LYONS RT, 1980, J BIOL CHEM, V255, P6330; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; METHOT N, 1994, MOL CELL BIOL, V14, P2307, DOI 10.1128/MCB.14.4.2307; MORGAN HE, 1971, J BIOL CHEM, V246, P2163; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; SHANTZ LM, 1994, CANCER RES, V54, P2313; SHATKIN AJ, 1985, CELL, V40, P223, DOI 10.1016/0092-8674(85)90132-1; Sonenberg Nahum, 1993, Gene Expression, V3, P317; STIREWAL.WS, 1967, P NATL ACAD SCI USA, V57, P1885, DOI 10.1073/pnas.57.6.1885	31	1031	1058	0	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 27	1994	371	6500					762	767		10.1038/371762a0	http://dx.doi.org/10.1038/371762a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP018	7935836				2022-12-01	WOS:A1994PP01800049
J	SMITH, L; FOLKARD, S; POOLE, CJM				SMITH, L; FOLKARD, S; POOLE, CJM			INCREASED INJURIES ON NIGHT-SHIFT	LANCET			English	Article							PERFORMANCE	Concern over safety has resulted in legislation by, for example, the Commission of the European Union, to limit the number of hours worked at night, There is, however, no direct evidence that injuries a re more frequent at night. We analysed all 4645 injury incidents reported for a year on a rotating three-shift system in a large engineering company where the a-priori accident risk appeared to be constant. The relative risk of sustaining an injury was 1.23 (95% CI 1.14-1.31) higher on the night shift than on the morning shift, which showed the lowest incidence. The type of work (machine versus self-paced) affected the pattern and nature of injuries; for self-paced work the relative risk of more serious injury on the night shift compared with the morning shift was 1.82 (1.30-2.34).	DUDLEY HLTH AUTHOR,DEPT OCCUPAT HLTH,DUDLEY,W MIDLANDS,ENGLAND		SMITH, L (corresponding author), UNIV COLL SWANSEA,DEPT PSYCHOL,BODY RHYTHMS & SHIFTWORK CTR,SWANSEA SA2 8PP,W GLAM,WALES.							BARTON J, IN PRESS OCCU ENV ME; CARTER FA, 1982, SHIFTWORK ACCIDENTS; Drury C. G., 1990, EVALUATION HUMAN WOR; FOLKARD S, 1990, PHILOS T ROY SOC B, V327, P543, DOI 10.1098/rstb.1990.0097; FOLKARD S, 1979, HUM FACTORS, V21, P483, DOI 10.1177/001872087902100410; HARRINGTON JM, 1978, SHIFT WORK HLTH CRIT; KNAUTH P, 1993, ERGONOMICS, V36, P15, DOI 10.1080/00140139308967850; LAVIE P, 1991, SLEEP SLEEPINESS PER, P65; MITLER MM, 1988, SLEEP, V11, P100, DOI 10.1093/sleep/11.1.100; ONG CN, 1987, APPL ERGON, V18, P51, DOI 10.1016/0003-6870(87)90070-6; Waterhouse J.M, 1992, SHIFTWORK HLTH SAFET, P1978; 1993, DIRECTIVE WORKING TI; 1993, B EUR STUD TIME, V6, P46	13	159	161	3	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1994	344	8930					1137	1139		10.1016/S0140-6736(94)90636-X	http://dx.doi.org/10.1016/S0140-6736(94)90636-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PN066	7934499				2022-12-01	WOS:A1994PN06600015
J	COUSO, JP; ARIAS, AM				COUSO, JP; ARIAS, AM			NOTCH IS REQUIRED FOR WINGLESS SIGNALING IN THE EPIDERMIS OF DROSOPHILA	CELL			English	Article							PERIPHERAL NERVOUS-SYSTEM; GENE SERRATE ENCODES; NEUROGENIC GENES; CELL FATE; TRANSMEMBRANE PROTEIN; EXPRESSION; LOCUS; MELANOGASTER; MUTATIONS; RECEPTOR	Mutations in the Notch (N) gene affect many processes during the development of Drosophila. Some alleles of Notch affect only particular processes, suggesting that the Notch protein (N) has more than one functional domain. We have found a series of N mutant phenotypes that are similar to those produced by the loss of function of the segment polarity gene wingless (wg) in the embryo and the adult. In addition, we observe that mutations in N behave as dominant enhancers of wg and that there exist allele-specific interactions between the two loci. Our results suggest that the product of wg is a ligand for N.			COUSO, JP (corresponding author), UNIV CAMBRIDGE,DEPT ZOOL,DOWNING ST,CAMBRIDGE CB2 3EJ,ENGLAND.		Couso, Juan Pablo/ABH-5860-2020; Martinez Arias, Alfonso/F-1966-2010		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASHBURNER M, 1989, DROSOPHILA LABORATO; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BATE M, 1993, DEVELOPMENT S, V119, P149; BLAIR SS, 1994, DEV BIOL, V162, P229, DOI 10.1006/dbio.1994.1081; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CHILDS SR, 1994, DEV BIOL, V162, P209, DOI 10.1006/dbio.1994.1079; CHOU TB, 1992, GENETICS, V131, P643; CORBIN V, 1991, CELL, V67, P311, DOI 10.1016/0092-8674(91)90183-Y; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; COUSO JP, 1994, DEVELOPMENT, V120, P621; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DECELIS JF, 1993, P NATL ACAD SCI USA, V90, P4037, DOI 10.1073/pnas.90.9.4037; DECELIS JF, 1994, GENETICS, V136, P183; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; HARTENSTEIN AY, 1992, DEVELOPMENT, V116, P1203; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HARTLEY DA, 1987, EMBO J, V6, P3407, DOI 10.1002/j.1460-2075.1987.tb02664.x; HEITZLER P, 1993, DEVELOPMENT, V117, P1113; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; JACK J, 1992, GENETICS, V131, P353; JIMENEZ F, 1982, ROUX ARCH DEV BIOL, V191, P191, DOI 10.1007/BF00848335; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LIEBER T, 1992, NEURON, V9, P847, DOI 10.1016/0896-6273(92)90238-9; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Lindsley D.L., 1992, GENOME DROSOPHILA ME; Muller H.J, 1932, P 6 INT C GEN, V1, P213; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; ORTEGA JAC, 1993, DEV DROSOPHILA MELAN, P1091; PEIFER M, 1994, DEVELOPMENT, V120, P369; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; PORTIN P, 1981, HEREDITAS, V95, P247; PORTIN P, 1977, HEREDITAS, V87, P77; Poulson DF, 1940, J EXP ZOOL, V83, P271, DOI 10.1002/jez.1400830207; RABINOW L, 1990, GENETICS, V125, P41; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; RUEL L, 1993, NATURE, V362, P557, DOI 10.1038/362557a0; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; SHELLENBARGER DL, 1978, DEV BIOL, V62, P432, DOI 10.1016/0012-1606(78)90226-9; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SIMPSON P, 1993, DEVELOPMENT S, V119, P29; STERN CURT, 1954, AMER SCI, V42, P213; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; THOMAS U, 1991, DEVELOPMENT, V111, P749; TSAKONAS SA, 1991, TRENDS GENET, V7, P403; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; Wigglesworth VB, 1940, J EXP BIOL, V17, P180; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; XU T, 1992, DEVELOPMENT, V115, P913	63	168	176	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 21	1994	79	2					259	272		10.1016/0092-8674(94)90195-3	http://dx.doi.org/10.1016/0092-8674(94)90195-3			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954794				2022-12-01	WOS:A1994PN63000010
J	FORTINI, ME; ARTAVANISTSAKONAS, S				FORTINI, ME; ARTAVANISTSAKONAS, S			THE SUPPRESSOR OF HAIRLESS PROTEIN PARTICIPATES IN NOTCH RECEPTOR SIGNALING	CELL			English	Article							DEVELOPING DROSOPHILA EYE; CELL-FATE; BINDING-PROTEIN; NEGATIVE COMPLEMENTATION; NEUROGENIC GENES; LOCUS; MELANOGASTER; SEQUENCE; ENCODES; DELTA	In a genetic screen for mutations that attenuate Notch signaling in the developing Drosophila eye, we isolated rare, gain-of-function alleles of Suppressor of Hairless (Su(H)), the fly homolog of the mammalian C promoter-binding factor 1 (CBF1) gene. Su(H) exhibits numerous allele-specific genetic interactions with Notch as well as with Delta, deltex, and mastermind. In cultured Drosophila cells, the Su(H) protein is sequestered in the cytoplasm when coexpressed with Notch protein and is translocated to the nucleus when Notch binds to its ligand Delta. Cytoplasmic retention of Su(H) requires the intracellular cdc10/ankyrin repeats of Notch, which associate with SU(H) protein in the yeast interaction trap assay. These results indicate that Notch activity may regulate nuclear events by controlling the activity of a DNA-binding protein.	YALE UNIV,HOWARD HUGHES MED INST,DEPT CELL BIOL,NEW HAVEN,CT 06536	Howard Hughes Medical Institute; Yale University	FORTINI, ME (corresponding author), YALE UNIV,HOWARD HUGHES MED INST,DEPT BIOL,NEW HAVEN,CT 06536, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026084, R37NS026084] Funding Source: NIH RePORTER; NINDS NIH HHS [NS26084] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARTAVANISTSAKONAS S, 1991, TRENDS GENET, V7, P403, DOI 10.1016/0168-9525(91)90264-Q; ASHBURNER M, 1982, GENETICS, V101, P447; BANG AG, 1992, GENE DEV, V6, P1752, DOI 10.1101/gad.6.9.1752; BUSSEAU I, 1994, GENETICS, V136, P585; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; DELACONCHA A, 1988, GENETICS, V118, P499; DELIDAKIS C, 1991, GENETICS, V129, P803; DIEDERICH RJ, 1994, DEVELOPMENT, V120, P473; DOU SB, 1994, MOL CELL BIOL, V14, P3310, DOI 10.1128/MCB.14.5.3310; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FOSTER GG, 1975, GENETICS, V81, P99; FURUKAWA T, 1992, CELL, V69, P1191, DOI 10.1016/0092-8674(92)90640-X; FURUKAWA T, 1991, J BIOL CHEM, V266, P23334; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HARTENSTEIN AY, 1992, DEVELOPMENT, V116, P1203; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KOOH PJ, 1993, DEVELOPMENT, V117, P493; Lewis E., 1968, DROSOPHILA INFO SERV, V43, P193; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MAIER D, 1992, MECH DEVELOP, V38, P143, DOI 10.1016/0925-4773(92)90006-6; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; NASH D, 1970, GENETICS, V64, P471; NASH D, 1965, GENET RES, V6, P175, DOI 10.1017/S0016672300004079; PARODY TR, 1993, GENETICS, V135, P527; Plunkett CR, 1926, J EXP ZOOL, V46, P181, DOI 10.1002/jez.1400460204; PORTIN P, 1975, GENETICS, V81, P121; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; ROEHL H, 1993, NATURE, V364, P632, DOI 10.1038/364632a0; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; SHELLENBARGER DL, 1975, GENETICS, V81, P143; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMOLLER D, 1990, GENE DEV, V4, P1688, DOI 10.1101/gad.4.10.1688; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; Thummel CS, 1992, DROS INF SERV, V71, P150; TUN T, 1994, NUCLEIC ACIDS RES, V22, P965, DOI 10.1093/nar/22.6.965; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; XU T, 1990, GENE DEV, V4, P464, DOI 10.1101/gad.4.3.464; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	48	473	482	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 21	1994	79	2					273	282		10.1016/0092-8674(94)90196-1	http://dx.doi.org/10.1016/0092-8674(94)90196-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954795				2022-12-01	WOS:A1994PN63000011
J	SYM, M; ROEDER, GS				SYM, M; ROEDER, GS			CROSSOVER INTERFERENCE IS ABOLISHED IN THE ABSENCE OF A SYNAPTONEMAL COMPLEX PROTEIN	CELL			English	Article							MEIOTIC CHROMOSOME SYNAPSIS; CHIASMA MAINTENANCE; ELECTROPHORETIC KARYOTYPE; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; RECOMBINATION NODULES; ASPERGILLUS-NIDULANS; GEL-ELECTROPHORESIS; DESYNAPTIC MUTANT; FISSION YEAST	In the zip1 mutant, meiotic chromosomes fail to synapse, owing to the absence of a structural component of the synaptonemal complex (SC). This mutant has been analyzed for the ability to carry out several functions that have been proposed for the SC. The data presented show that the zip1 mutation does not affect chiasma function and confers only modest defects in meiotic recombination and sister chromatid cohesion. In contrast, crossover interference is completely abolished in the absence of Zip1. These data are the first to establish a molecular link between cytological observations of the SC and the genetic phenomenon of interference.			SYM, M (corresponding author), YALE UNIV, DEPT BIOL, POB 6666, NEW HAVEN, CT 06520 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028904, T32GM007223] Funding Source: NIH RePORTER; NIGMS NIH HHS [2 T32 GM07223-18, GM28904] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; BAHLER J, 1993, J CELL BIOL, V121, P241, DOI 10.1083/jcb.121.2.241; BAKER BS, 1976, ANNU REV GENET, V10, P53, DOI 10.1146/annurev.ge.10.120176.000413; BHARGAVA J, 1992, GENETICS, V130, P59; BRODY H, 1989, P NATL ACAD SCI USA, V86, P6260, DOI 10.1073/pnas.86.16.6260; CARPENTER ATC, 1979, CHROMOSOMA, V75, P259, DOI 10.1007/BF00293472; CARPENTER ATC, 1975, P NATL ACAD SCI USA, V72, P3186, DOI 10.1073/pnas.72.8.3186; Carpenter ATC, 1988, GENETIC RECOMBINATIO, P529, DOI [10.1038/ng1287, DOI 10.1038/NG1287]; CLARKE L, 1983, NATURE, V305, P23, DOI 10.1038/305023a0; CLUTTERBUCK AJ, 1992, ASPERGILLUS BIOL IND, P3; DRESSER ME, 1988, J CELL BIOL, V106, P567, DOI 10.1083/jcb.106.3.567; EGEL R, 1978, HEREDITY, V41, P233, DOI 10.1038/hdy.1978.92; EGELMITANI M, 1982, HEREDITAS, V97, P179, DOI 10.1111/j.1601-5223.1982.tb00870.x; ENGEBRECHT J, 1990, CELL, V62, P927, DOI 10.1016/0092-8674(90)90267-I; ENGEBRECHT J, 1990, MOL CELL BIOL, V10, P2379, DOI 10.1128/MCB.10.5.2379; ENGEBRECHT JA, 1989, GENETICS, V121, P237; FLEIG UN, 1986, GENE, V46, P237, DOI 10.1016/0378-1119(86)90408-7; FOSS E, 1993, GENETICS, V133, P681; GAME JC, 1980, GENETICS, V94, P51; HALDANE J. B. S., 1931, CYTOLOGIA, V3, P54; HOLLINGSWORTH NM, 1989, GENETICS, V121, P445; HOLM PB, 1980, CARLSBERG RES COMMUN, V45, P483, DOI 10.1007/BF02932921; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES G H, 1987, P213; JONES GH, 1974, HEREDITY, V32, P375, DOI 10.1038/hdy.1974.45; JONES GH, 1967, CHROMOSOMA, V22, P69, DOI 10.1007/BF00291287; KABACK DB, 1989, P NATL ACAD SCI USA, V86, P3694, DOI 10.1073/pnas.86.10.3694; KABACK DB, 1992, SCIENCE, V256, P228, DOI 10.1126/science.1566070; KANE SM, 1974, J BACTERIOL, V118, P8, DOI 10.1128/JB.118.1.8-14.1974; KING JS, 1990, GENETICS, V126, P1127; KLAPHOLZ S, 1985, GENETICS, V110, P187; LAURIE DA, 1981, HEREDITY, V47, P409, DOI 10.1038/hdy.1981.102; MAGUIRE M P, 1978, Chromosoma (Berlin), V65, P173, DOI 10.1007/BF00329469; MAGUIRE MP, 1979, CHROMOSOMA, V70, P313, DOI 10.1007/BF00328769; MAGUIRE MP, 1978, EXP CELL RES, V112, P297, DOI 10.1016/0014-4827(78)90213-6; MAGUIRE MP, 1988, J THEOR BIOL, V134, P565, DOI 10.1016/S0022-5193(88)80058-4; MAGUIRE MP, 1993, GENOME, V36, P797, DOI 10.1139/g93-105; MAGUIRE MP, 1991, GENOME, V34, P879, DOI 10.1139/g91-135; Mather K, 1940, J GENET, V39, P205, DOI 10.1007/BF02982836; MENEES TM, 1992, MOL CELL BIOL, V12, P1340, DOI 10.1128/MCB.12.3.1340; MENEES TM, 1989, GENETICS, V123, P675; MOENS PB, 1994, BIOESSAYS, V16, P101, DOI 10.1002/bies.950160206; Mortimer R.R., 1974, MECH RECOMBINATION, P263, DOI [10.1007/978-1-4684-2133-0_23, DOI 10.1007/978-1-4684-2133-0_23]; MORTIMER RK, 1991, MOL CELLULAR BIOL YE, P737; Muller HJ, 1916, AM NAT, V50, P193, DOI 10.1086/279534; Munz P, 1989, MOL BIOL FISSION YEA, P1; NICKLAS RB, 1974, GENETICS, V78, P205; OLSON LW, 1978, HEREDITAS, V89, P189; Olson M., 1991, MOL CELLULAR BIOL YE, P1; PAPAZIAN HP, 1952, GENETICS, V37, P175; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; ROCKMILL B, 1990, GENETICS, V126, P563; ROCKMILL B, 1994, GENETICS, V136, P65; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sherman F., 1986, METHODS YEAST GENETI; SMITH CL, 1987, NUCLEIC ACIDS RES, V15, P4481, DOI 10.1093/nar/15.11.4481; SNOW R, 1979, GENETICS, V92, P231; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRICKLAND WN, 1958, PROC R SOC SER B-BIO, V149, P82, DOI 10.1098/rspb.1958.0053; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; THOMPSON EA, 1989, MOL GEN GENET, V218, P293, DOI 10.1007/BF00331281; VOLLRATH D, 1987, NUCLEIC ACIDS RES, V15, P7865, DOI 10.1093/nar/15.19.7865; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; WILLIAMSON DH, 1983, EXP CELL RES, V145, P209, DOI 10.1016/S0014-4827(83)80022-6	64	233	236	0	6	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	1994	79	2					283	292		10.1016/0092-8674(94)90197-X	http://dx.doi.org/10.1016/0092-8674(94)90197-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954796				2022-12-01	WOS:A1994PN63000012
J	FENTON, WA; KASHI, Y; FURTAK, K; HORWICH, AL				FENTON, WA; KASHI, Y; FURTAK, K; HORWICH, AL			RESIDUES IN CHAPERONIN GROEL REQUIRED FOR POLYPEPTIDE BINDING AND RELEASE	NATURE			English	Article							MOLECULAR CHAPERONE; ATP HYDROLYSIS; PROTEINS; COOPERATIVITY; CELL	CHAPERONINS are king-shaped protein complexes that are essential in the cell, mediating ATP-dependent polypeptide folding in a variety of compartments(1-3). Recent studies suggest that they function through multiple rounds of binding and release of non-native proteins: with each round of ATP-driven release into the bulk solution, a substrate protein kinetically partitions between folding to the native state or rebinding to another chaperonin molecule(4-6). To gain further insight into the mechanism of polypeptide binding and release by the chaperonin GroEL from Escherichia coli, we have undertaken a mutational analysis that relates the functional properties of GroEL to its crystal structure(7). Our functional tests identify a putative polypeptide-binding site on the inside surface of the apical domain, facing the central channel, consisting of hydrophobic residues. These same residues are essential for binding of the co-chaperonin GroES, which is required for productive polypeptide release. A highly conserved residue, Asp 87, positioned within a putative nucleotide-binding pocket in the top of the equatorial domain, is essential for ATP hydrolysis and polypeptide release.	YALE UNIV,SCH MED,BOYER CTR,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,BOYER CTR,DEPT GENET,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University; Yale University			Kashi, Yechezkel/D-5433-2013					AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; GAO Y, 1994, J CELL BIOL, V125, P989, DOI 10.1083/jcb.125.5.989; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	22	575	587	0	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 13	1994	371	6498					614	619		10.1038/371614a0	http://dx.doi.org/10.1038/371614a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7935796				2022-12-01	WOS:A1994PL55900055
J	JACQ, X; BROU, C; LUTZ, Y; DAVIDSON, I; CHAMBON, P; TORA, L				JACQ, X; BROU, C; LUTZ, Y; DAVIDSON, I; CHAMBON, P; TORA, L			HUMAN TAF(II)30 IS PRESENT IN A DISTINCT TFIID COMPLEX AND IS REQUIRED FOR TRANSCRIPTIONAL ACTIVATION BY THE ESTROGEN-RECEPTOR	CELL			English	Article							RNA POLYMERASE-II; TATA-BINDING PROTEIN; CLONING; DOMAINS; PURIFICATION; STIMULATION; INITIATION; EXPRESSION; SEQUENCE; GAL-VP16	We showed previously that coactivators mediating stimulation by different activators were associated with the TATA-binding protein (TBP) in distinct TFIID complexes. We have characterized a human TBP-associated factor (TAF), hTAF(II)30, associated with a subset of TFIID complexes. hTAF(II)30 interacts with the AF-2-containing region E of the human estrogen receptor (ER), but not with ER AF-1 or VP16. An antibody against hTAF(II)30 inhibited transcriptional stimulation by the ER AF-2 without affecting basal or VP16-activated transcription and allowed the separation of TFIID complex(es) containing hTAF(II)30 from complexes mediating the activity of VP16. These results directly demonstrate the existence of functionally dis tinct TFIID populations that share common TAF(II)s but differ in specific TAF(II)s.			JACQ, X (corresponding author), FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE.		Tora, Laszlo/E-9999-2018	Tora, Laszlo/0000-0001-7398-2250; Davidson, Irwin/0000-0001-5533-1171				BROU C, 1993, NUCLEIC ACIDS RES, V21, P5, DOI 10.1093/nar/21.1.5; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; BROU C, 1993, NUCLEIC ACIDS RES, V21, P4011, DOI 10.1093/nar/21.17.4011; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Burton N, 1991, Protein Expr Purif, V2, P432, DOI 10.1016/1046-5928(91)90105-R; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DURAND B, 1994, IN PRESS EMBO J; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GRUNDY FJ, 1989, VIROLOGY, V172, P223, DOI 10.1016/0042-6822(89)90124-4; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; ING NH, 1992, J BIOL CHEM, V267, P17617; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; Luckow VA, 1992, BACULOVIRUS EXPRESSI; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MONCOLLIN V, 1986, EMBO J, V5, P2577, DOI 10.1002/j.1460-2075.1986.tb04537.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIERRAT P, 1994, GENE, V143, P193; PUGH BF, 1992, J BIOL CHEM, V267, P679; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; WHITE JH, 1991, P NATL ACAD SCI USA, V88, P7674, DOI 10.1073/pnas.88.17.7674; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YOKOMORI K, 1993, GENE DEV, V7, P2587, DOI 10.1101/gad.7.12b.2587; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180	47	359	365	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					107	117		10.1016/0092-8674(94)90404-9	http://dx.doi.org/10.1016/0092-8674(94)90404-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923369				2022-12-01	WOS:A1994PK58500012
J	CROFT, P; SCHOLLUM, J; SILMAN, A				CROFT, P; SCHOLLUM, J; SILMAN, A			POPULATION STUDY OF TENDER POINT COUNTS AND PAIN AS EVIDENCE OF FIBROMYALGIA	BRITISH MEDICAL JOURNAL			English	Article							FATIGUE; SLEEP; FIBROSITIS; SCALE	Objective-To determine the relation between tender points, complaints of pain, and symptoms of depression, fatigue, and sleep quality in the general population. Design-Two stage cross sectional study with an initial questionnaire about pain to classify those eligible for an examination oftender points. Setting-Two general practices in north west England. Subjects-Stratified random sample of adults from age-sex registers. Of the responders, 250 were selected for examination of tender points on the basis of their reported pain complaints; 177 subsequently participated. Main outcome measures-Tender point count (0 to 18) grouped into four categories with the highest (greater than or equal to 11) corresponding to the criteria of the American College of Rheumatology for fibromyalgia. Assessment of pain (chronic widespread, regional, none). Measures of depression, fatigue, and difficulty with sleeping. Results-Women had a higher median tender point count (six) than did men (three). Counts were higher in those with pain than in those who had no pain and in those with widespread compared with regional pain. Most subjects with chronic widespread pain, however, had fewer than 11 tender points (27/45; 60%). Two people with counts of 11 or more were in the group reporting no pain. Mean symptom scores for depression, fatigue, and sleep problems increased as the tender point count rose (P value for trend < 0.001). These trends were independent of pain complaints. Conclusions-Tender points are a measure of general distress. They are related to pain complaints but are separately associated with fatigue and depression. Sleep problems are associated with tender points, although prospective studies are needed to determine whether they cause tenderness to develop. Fibromyalgia does not seem to be a distinct disease entity.			CROFT, P (corresponding author), UNIV MANCHESTER,ARTHRITIS & RHEUMATISM COUNCIL,EPIDEMIOL RES UNIT,STOPFORD BLDG,MANCHESTER M13 9PT,ENGLAND.							CAMPBELL SM, 1983, ARTHRITIS RHEUM, V26, P817, DOI 10.1002/art.1780260701; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; COHEN ML, 1993, LANCET, V342, P906, DOI 10.1016/0140-6736(93)91950-Q; CROFT P, 1993, J RHEUMATOL, V20, P710; Goldberg DPW, 1988, USERS GUIDE GEN HLTH; GOLDENBERG DL, 1990, ARTHRITIS RHEUM, V33, P381, DOI 10.1002/art.1780330311; JENKINS CD, 1988, J CLIN EPIDEMIOL, V41, P313, DOI 10.1016/0895-4356(88)90138-2; LEIGH TJ, 1990, SCAND J RHEUMATOL, V19, P5, DOI 10.3109/03009749009092616; MOLDOFSKY H, 1976, PSYCHOSOM MED, V38, P35, DOI 10.1097/00006842-197601000-00006; REILLY PA, 1993, ANN RHEUM DIS, V52, P249, DOI 10.1136/ard.52.4.249; RIDSDALE L, 1993, BMJ-BRIT MED J, V307, P103, DOI 10.1136/bmj.307.6896.103; SMYTHE H A, 1977, Bulletin on the Rheumatic Diseases, V28, P928; WALL PD, 1993, PROGR FIBROMYALGIA M; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; WOLFE F, 1990, RHEUM DIS CLIN N AM, V16, P681; YUNUS M, 1981, SEMIN ARTHRITIS RHEU, V11, P151, DOI 10.1016/0049-0172(81)90096-2; YUNUS MB, 1992, J RHEUMATOL, V19, P846; YUNUS MB, 1991, ARTHRITIS RHEUM, V34, P15, DOI 10.1002/art.1780340104	18	244	248	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 17	1994	309	6956					696	699		10.1136/bmj.309.6956.696	http://dx.doi.org/10.1136/bmj.309.6956.696			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH407	7950521	Green Published			2022-12-01	WOS:A1994PH40700014
J	HARRIS, GC; ASTONJONES, G				HARRIS, GC; ASTONJONES, G			INVOLVEMENT OF D2 DOPAMINE-RECEPTORS IN THE NUCLEUS-ACCUMBENS IN THE OPIATE WITHDRAWAL SYNDROME	NATURE			English	Article							LOCUS-COERULEUS NEURONS; CYCLIC-AMP FORMATION; RAT; MORPHINE; CLONIDINE; REWARD; SPECIFICITY; PROJECTIONS; ABSTINENCE; INHIBITION	THE nucleus accumbens is prominently implicated in the reinforcing effects of abused drugs(1-4), and is an important site for mediating aversive stimulus properties of opiate withdrawal(5). It is generally thought, however, that the role of the accumbens is negligible in the somatic signs of opiate withdrawal(5-7). Contrary to this assumption, we now report that D2 dopaminergic receptor activity in the accumbens area potently regulates somatic symptoms of opiate withdrawal. We find that activation of D2 receptors within the accumbens prevents somatic signs of naloxone-induced opiate withdrawal and, conversely, that blockade of accumbal D2 receptors in opiate-dependent animals elicits somatic withdrawal symptoms. These data indicate that dopamine in the accumbens not only is important in the rewarding effects of abused drugs, but also (via D2 receptors) plays a pivotal role in opiate withdrawal.	HAHNEMANN UNIV,DEPT MENTAL HLTH SCI,DIV BEHAV NEUROBIOL,PHILADELPHIA,PA 19102	Drexel University								AGHAJANIAN GK, 1978, NATURE, V276, P186, DOI 10.1038/276186a0; AKAOKA H, 1991, J NEUROSCI, V11, P3830; BOZARTH MA, 1984, SCIENCE, V224, P516, DOI 10.1126/science.6324347; DEOLMOS J, 1985, RAT NERVOUS SYSTEM, V1, P223; DWORKIN SI, 1988, PHARMACOL BIOCHEM BE, V29, P175, DOI 10.1016/0091-3057(88)90292-4; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; GOLD MS, 1978, LANCET, V2, P599; HEIJNA MH, 1992, EUR J PHARMACOL, V229, P197, DOI 10.1016/0014-2999(92)90555-I; HEIMER L, 1991, NEUROSCIENCE, V41, P89, DOI 10.1016/0306-4522(91)90202-Y; HENSELMANS JML, 1993, NEUROSCI LETT, V158, P79, DOI 10.1016/0304-3940(93)90617-T; KELLY E, 1987, N-S ARCH PHARMACOL, V335, P508; KOOB GF, 1989, PSYCHOPHARMACOLOGY, V98, P530, DOI 10.1007/BF00441954; KOOB GF, 1988, SCIENCE, V242, P615; LEMOINE C, 1991, P NATL ACAD SCI USA, V88, P4205, DOI 10.1073/pnas.88.10.4205; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd ed; POTHOS E, 1991, BRAIN RES, V566, P348, DOI 10.1016/0006-8993(91)91724-F; RASMUSSEN K, 1990, J NEUROSCI, V10, P2308; ROSSETTI ZL, 1992, EUR J PHARMACOL, V221, P227, DOI 10.1016/0014-2999(92)90706-A; STINUS L, 1990, NEUROSCIENCE, V37, P767, DOI 10.1016/0306-4522(90)90106-E; Stoof JC, 1981, NATURE, V294, P366, DOI 10.1038/294366a0; STOOF JC, 1986, EUR J PHARMACOL, V129, P205, DOI 10.1016/0014-2999(86)90358-4; SURMEIER DJ, 1992, P NATL ACAD SCI USA, V89, P10178, DOI 10.1073/pnas.89.21.10178; SURMEIER DJ, 1993, TRENDS NEUROSCI, V16, P299, DOI 10.1016/0166-2236(93)90103-S; TERWILLIGER RZ, 1991, BRAIN RES, V548, P100, DOI 10.1016/0006-8993(91)91111-D; TUCKER DC, 1985, BRAIN RES, V360, P159, DOI 10.1016/0006-8993(85)91231-4; VACCARINO FJ, 1985, PSYCHOPHARMACOLOGY, V86, P37, DOI 10.1007/BF00431681; VANDERKOOY D, 1984, J COMP NEUROL, V224, P1, DOI 10.1002/cne.902240102; WEI E, 1973, J PHARMACOL EXP THER, V184, P398; WISE RA, 1989, NEUROSCI BIOBEHAV R, V13, P129, DOI 10.1016/S0149-7634(89)80021-1; ZAHM DS, 1992, NEUROSCIENCE, V50, P751, DOI 10.1016/0306-4522(92)90202-D	30	181	185	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 8	1994	371	6493					155	157		10.1038/371155a0	http://dx.doi.org/10.1038/371155a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF191	7915401				2022-12-01	WOS:A1994PF19100063
J	YUSUF, SW; BAKER, DM; CHUTER, TAM; WHITAKER, SC; WENHAM, PW; HOPKINSON, BR				YUSUF, SW; BAKER, DM; CHUTER, TAM; WHITAKER, SC; WENHAM, PW; HOPKINSON, BR			TRANSFEMORAL ENDOLUMINAL REPAIR OF ABDOMINAL AORTIC-ANEURYSM WITH BIFURCATED GRAFT	LANCET			English	Note								Traditional open repair of abdominal aortic aneurysm has disadvantages. We present our experience of transfemoral endoluminal repair with a bifurcated graft system. 29 patients with aortic aneurysm over 5.5 cm in diameter and 1 with a 3.2 cm aneurysm and bilateral iliac stenosis were assessed; 5 were suitable for the procedure. The operation was successful in all the patients, without haemodynamic compromise or major complications. This technique has the potential to reduce morbidity and mortality from abdominal aortic aneurysm. Further modifications are required to make it applicable to most aneurysms.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT SURG,NEW YORK,NY	Columbia University	YUSUF, SW (corresponding author), UNIV NOTTINGHAM HOSP,NOTTINGHAM NG7 2UH,ENGLAND.			Yusuf, Salim/0000-0003-4776-5601; Baker, Daryll/0000-0002-0098-405X				CHUTER TAM, 1994, THESIS U NOTTINGHAM; Clark NJ, 1994, ANESTHESIA, P1851; COLLIN J, 1988, LANCET, V2, P613; FOWKES FGR, 1989, BRIT MED J, V298, P33, DOI 10.1136/bmj.298.6665.33; GREENHALGH RM, 1990, BRIT MED J, V301, P136, DOI 10.1136/bmj.301.6744.136; Hertzer N R, 1987, Ann Vasc Surg, V1, P616, DOI 10.1016/S0890-5096(06)61452-0; JOHANSSON G, 1986, BRIT J SURG, V73, P101, DOI 10.1002/bjs.1800730205; Parodi J C, 1991, Ann Vasc Surg, V5, P491, DOI 10.1007/BF02015271; SCOTT RAP, 1994, LANCET, V343, P413, DOI 10.1016/S0140-6736(94)91247-5	9	88	100	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					650	651		10.1016/S0140-6736(94)92086-9	http://dx.doi.org/10.1016/S0140-6736(94)92086-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915349				2022-12-01	WOS:A1994PE38600011
J	JORGENSEN, HS; NAKAYAMA, H; RAASCHOU, HO; OLSEN, TS				JORGENSEN, HS; NAKAYAMA, H; RAASCHOU, HO; OLSEN, TS			EFFECT OF BLOOD-PRESSURE AND DIABETES ON STROKE IN PROGRESSION	LANCET			English	Article							SYSTEM CEREBRAL INFARCTION; PROFILE CLINICAL COURSE; ISCHEMIC STROKE	Progression of acute stroke after arrival at hospital is frequent and the prognosis severe. However, risk factors and mechanisms behind progression are largely unknown. A prospective, community-based study of 868 patients with acute stroke was undertaken to discover factors of importance in the development of stroke in progression. Diagnosis of progression was based on the Scandinavian Neurological Stroke Scale, Patients were divided according to whether progression occurred early (within 36 hours from stroke onset) or late (with in the first week from onset). Results were analysed by comparing patients with and without progression. Marked progression developed in 32%. Risk factors for early progression were identified as systolic blood pressure on admission (decreased the relative risk by 0.66 per 20 mm Hg increase, 95% Cl 0.55-0.83) and diabetes (increased the relative risk by 1.9, 95% Cl 1.1-3.3). Stroke severity was the only risk factor found in late progression (OR 1.4 per 20-point increase in stroke severity, 95% Cl 1.1-1.7).These relations were independent of age, sex, blood glucose, heart disease, and other stroke risk factors. Early progression is related to systolic blood pressure and diabetes. Late progression is related to initial stroke severity. Although this study does not prove that a causal relationship exists between systolic blood pressure and the development of early progression, such a relationship would, however, explain our findings.	BISPEBJERG HOSP, DEPT RADIOL, DK-2400 COPENHAGEN NV, DENMARK	University of Copenhagen; Bispebjerg Hospital	JORGENSEN, HS (corresponding author), BISPEBJERG HOSP, DEPT NEUROL, DK-2400 COPENHAGEN NV, DENMARK.							[Anonymous], 1989, Stroke, V20, P1407; ASPLUND K, 1985, STROKE, V16, P885; ASPLUND K, 1992, CEREBROVASC DIS, V2, P317, DOI 10.1159/000109037; ASPLUND K, 1993, THROMBOLYTIC THERAPY, V2, P119; BENTSEN N, 1975, STROKE, V6, P497, DOI 10.1161/01.STR.6.5.497; BRITTON M, 1986, STROKE, V17, P861, DOI 10.1161/01.STR.17.5.861; BRITTON M, 1985, STROKE, V16, P629, DOI 10.1161/01.STR.16.4.629; DAVALOS A, 1990, NEUROLOGY, V40, P1865, DOI 10.1212/WNL.40.12.1865; GAUTIER JC, 1985, STROKE, V16, P729, DOI 10.1161/01.STR.16.4.729; HACHINSKI V, 1985, ACUTE STROKE, P123; JONES HR, 1976, STROKE, V7, P64, DOI 10.1161/01.STR.7.1.64; JONES HR, 1980, STROKE, V11, P173, DOI 10.1161/01.STR.11.2.173; JORGENSEN HS, 1994, STROKE, V25, P97, DOI 10.1161/01.STR.25.1.97; LINDENSTROM E, 1991, CEREBROVASC DIS, V1, P103, DOI 10.1159/000108825; MAHONEY F I, 1965, Md State Med J, V14, P61; MARCHAL G, 1993, LANCET, V341, P925, DOI 10.1016/0140-6736(93)91214-7; MILLIKAN CH, 1981, STROKE, V12, P397, DOI 10.1161/01.STR.12.4.397; Millikan CH, 1975, STROKE, V6, P564; OBRIEN MD, 1974, ARCH NEUROL-CHICAGO, V30, P461, DOI 10.1001/archneur.1974.00490360037008; OLSEN TS, 1983, STROKE, V14, P332, DOI 10.1161/01.STR.14.3.332; SHIMA T, 1983, J CEREB BLOOD FLO S1, V3, P620	21	252	258	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 16	1994	344	8916					156	159						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912765				2022-12-01	WOS:A1994NW81000009
J	THOMPSON, BT; COCKRILL, BA				THOMPSON, BT; COCKRILL, BA			RENAL-DOSE DOPAMINE - A SIREN SONG	LANCET			English	Editorial Material							BLOOD-FLOW; SHOCK				THOMPSON, BT (corresponding author), MASSACHUSETTS GEN HOSP,PULM & CRIT CARE UNIT,BOSTON,MA, USA.							BALDWIN L, 1994, ANN INTERN MED, V120, P744, DOI 10.7326/0003-4819-120-9-199405010-00004; BRESLOW MJ, 1987, AM J PHYSIOL, V252, pH291, DOI 10.1152/ajpheart.1987.252.2.H291; DASTA JF, 1986, PHARMACOTHERAPY, V6, P304; GIRAUD GD, 1984, J PHARMACOL EXP THER, V230, P214; GOLDBERG LI, 1972, PHARMACOL REV, V24, P1; GREENE SI, 1976, NEW ENGL J MED, V294, P114; ORME MLE, 1973, EUR J CLIN PHARMACOL, V6, P150, DOI 10.1007/BF00558278; PASS LJ, 1988, J THORAC CARDIOV SUR, V95, P608; PAWLIK W, 1976, AM HEART J, V75, P325; SCANNELL G, 1994, CRIT CARE MED, V22, pA187; SEGAL JM, 1992, J APPL PHYSIOL, V73, P1159, DOI 10.1152/jappl.1992.73.3.1159; SWYGERT TH, 1991, ANESTHESIOLOGY, V75, P571, DOI 10.1097/00000542-199110000-00005	12	78	78	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					7	8		10.1016/S0140-6736(94)91044-8	http://dx.doi.org/10.1016/S0140-6736(94)91044-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912346				2022-12-01	WOS:A1994NU91700007
J	ROEP, BO; HEIDENTHAL, E; DEVRIES, RRP; KOLB, H; MARTIN, S				ROEP, BO; HEIDENTHAL, E; DEVRIES, RRP; KOLB, H; MARTIN, S			SOLUBLE FORMS OF INTERCELLULAR-ADHESION MOLECULE-1 IN INSULIN-DEPENDENT DIABETES-MELLITUS	LANCET			English	Article							CARDIAC ALLOGRAFT; ICAM-1; ANTIBODIES; LFA-1; PROTEIN; INVIVO; INJURY; CELLS	Soluble adhesion molecules are detectable at low levels in healthy people but are increased in various disorders. However, their physiological role is unknown. Circulating intercellular adhesion molecule-1 (clCAM-1) may modulate inflammation or a rise as a consequence of inflammation. We have described elevated concentrations of clCAM-1 in subjects at risk of developing insulin-dependent diabetes mellitus (IDDM), compared with recent-onset IDDM patients and healthy controls. Here we tested the ability of a monomeric soluble recombinant form of ICAM-1 (rlCAM-1), to prevent the proliferation of T cells to islet-cell and other antigens. We also tested the ability of two multivalent ICAM-1-immunoglobulin (ICAM-1-Ig) fusion proteins to stop proliferation of T cells in vitro. Autoreactive T-cell proliferation was suppressed by monoclonal antibodies directed against ICAM-1 or lymphocyte-function antigen-1 (LFA-1). Furthermore, 100 mu mol rlCAM-1 blocked T-cell proliferation in response to an islet-cell autoantigen, and multivalent ICAM-1-Ig fusion proteins were approximately 1000-fold more effective. The usual interleukin-2-induced proliferation of T cells was unaffected by ICAM or ICAM-Ig. In addition, rlCAM-1 blocked primary T-cell responses from peripheral blood mononuclear cells of newly diagnosed IDDM patients in concentrations similar to elevated clCAM-1 concentrations in individuals at risk for the disease. Thus, naturally circulating ICAM-1 may downregulate inflammation in subjects at risk of developing IDDM. Ig-ICAM-1 fusion proteins may thus provide novel means to intervene in the pathogenesis of autoimmune diseases.	UNIV DUSSELDORF,DIABET RES INST,DEPT CLIN,D-40225 DUSSELDORF,GERMANY; UNIV LEIDEN HOSP,DEPT IMMUNOHAEMATOL,2300 RC LEIDEN,NETHERLANDS; UNIV LEIDEN HOSP,BLOOD BANK,2300 RC LEIDEN,NETHERLANDS	Heinrich Heine University Dusseldorf; Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)			Roep, Bart/AAD-7609-2021					ALTMANN DM, 1989, NATURE, V338, P512, DOI 10.1038/338512a0; [Anonymous], 1988, DIABETES, V37, P1574, DOI 10.2337/diabetes.37.11.15742903105; ARGENBRIGHT LW, 1992, J CLIN INVEST, V89, P259, DOI 10.1172/JCI115570; ASSAN R, 1985, LANCET, V2, P119; ATKINSON MA, 1992, LANCET, V339, P458, DOI 10.1016/0140-6736(92)91061-C; BARTON RW, 1989, J IMMUNOL, V143, P1278; BECKER JC, 1991, J IMMUNOL, V147, P4398; COSIMI AB, 1990, J IMMUNOL, V144, P4604; DOUGHERTY GJ, 1988, EUR J IMMUNOL, V18, P35, DOI 10.1002/eji.1830180107; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FLAVIN T, 1991, TRANSPLANT P, V23, P533; GEARING AJH, 1993, IMMUNOL TODAY, V14, P506, DOI 10.1016/0167-5699(93)90267-O; IIGO Y, 1991, J IMMUNOL, V147, P4167; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; KAKIMOTO K, 1992, CELL IMMUNOL, V142, P326, DOI 10.1016/0008-8749(92)90294-Y; LAMPETER ER, 1992, DIABETES, V41, P1668, DOI 10.2337/diabetes.41.12.1668; MARTIN S, 1993, J VIROL, V67, P3561, DOI 10.1128/JVI.67.6.3561-3568.1993; MIYAZAKI A, 1992, CLIN EXP IMMUNOL, V89, P52; NISHIKAWA K, 1993, J EXP MED, V177, P667, DOI 10.1084/jem.177.3.667; PATARROYO M, 1991, CLIN IMMUNOL IMMUNOP, V60, P333, DOI 10.1016/0090-1229(91)90091-N; ROEP BO, 1990, NATURE, V345, P632, DOI 10.1038/345632a0; ROEP BO, 1991, LANCET, V337, P1439, DOI 10.1016/0140-6736(91)93127-U; SETH R, 1991, LANCET, V338, P83, DOI 10.1016/0140-6736(91)90077-3; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579	24	96	99	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1590	1593		10.1016/S0140-6736(94)93055-4	http://dx.doi.org/10.1016/S0140-6736(94)93055-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911918				2022-12-01	WOS:A1994NU35400008
J	NARAGHI, R; GEIGER, H; CRNAC, J; HUK, W; FAHLBUSCH, R; ENGELS, G; LUFT, FC				NARAGHI, R; GEIGER, H; CRNAC, J; HUK, W; FAHLBUSCH, R; ENGELS, G; LUFT, FC			POSTERIOR-FOSSA NEUROVASCULAR ANOMALIES IN ESSENTIAL-HYPERTENSION	LANCET			English	Article							ROSTRAL VENTROLATERAL MEDULLA; BRAIN-STEM LESIONS; NEUROGENIC HYPERTENSION; HEMIFACIAL SPASM; COMPRESSION; NEURONS; RAT; VASOPRESSIN; ETIOLOGY; RABBIT	Intraoperative observations, necropsy, and angiographic studies support the presumption that neurovascular compression of the left ventrolateral medulla may cause neurogenic hypertension. Pulsatile irritation of the ventrolateral medulla at the root-entry zone of cranial nerves IX and X increases blood pressure in animals. To identify and assess the distribution of neurovascular compression at the ventrolateral medulla in human beings, we did a prospective single-blind study in 24 patients with essential hypertension, in 14 patients with renal hypertension, and in 14 normal subjects. To detect neurovascular compression, we used axial and coronal and magnetic-resonance angiography Blood pressure control and duration of hypertension were not different in the two groups of patients. 20 patients with essential hypertension had magnetic tomographic evidence of left-sided neurovascular compression at the ventrolateral medulla; 2 patients with renal hypertension and 1 of the normal subjects had a positive finding on the left. On the right side, we found signs of neurovascular compression in 4 patients with essential hypertension, in 4 with renal hypertension, and in 2 of the normal subjects. With magnetic resonance tomography, it is possible to evaluate the neurovascular relations in the posterior fossa and detect neurovascular compression at the ventrolateral medulla. These data in living subjects give further evidence of an association between neurovascular compression at the left ventrolateral medulla acid essential hypertension.	UNIV ERLANGEN NURNBERG,DEPT MED NEPHROL,D-91054 ERLANGEN,GERMANY; UNIV ERLANGEN NURNBERG,DEPT MED CARDIOL,D-91054 ERLANGEN,GERMANY	University of Erlangen Nuremberg; University of Erlangen Nuremberg	NARAGHI, R (corresponding author), UNIV ERLANGEN NURNBERG,DEPT NEUROL SURG,D-91054 ERLANGEN,GERMANY.			Naraghi, Ramin/0000-0003-3643-791X; Luft, Friedrich/0000-0002-8635-1199				ADAMS CBT, 1989, J NEUROSURG, V70, P1, DOI 10.3171/jns.1989.70.1.0001; AMENDT K, 1979, J AUTONOM NERV SYST, V1, P103, DOI 10.1016/0165-1838(79)90009-2; [Anonymous], 1873, BERICHT VERHANDL SAC; ARMSTRONG DM, 1982, J COMP NEUROL, V212, P173, DOI 10.1002/cne.902120207; BLESSING WW, 1981, CIRC RES, V49, P949, DOI 10.1161/01.RES.49.4.949; CIRIELLO J, 1986, BRAIN RES, V367, P273, DOI 10.1016/0006-8993(86)91602-1; CIRIELLO J, 1986, BRAIN RES REV, V11, P359, DOI 10.1016/0165-0173(86)90005-6; Cushing H, 1901, B JOHNS HOPKINS HOSP, V12, P290; DAHLSTROM A, 1964, ACTA PHYSIOL SCAND, V62, P1; DAMPNEY RAL, 1985, J AUTONOM NERV SYST, V14, P239, DOI 10.1016/0165-1838(85)90113-4; DOBA N, 1973, CIRC RES, V32, P584, DOI 10.1161/01.RES.32.5.584; FEIN JM, 1980, NEUROSURGERY, V6, P615, DOI 10.1227/00006123-198006000-00001; GARDNER WJ, 1962, J NEUROSURG, V19, P947, DOI 10.3171/jns.1962.19.11.0947; IMAIZUMI T, 1985, J HYPERTENS, V3, P491; JANNETTA PJ, 1977, J NEUROSURG, V47, P321, DOI 10.3171/jns.1977.47.3.0321; JANNETTA PJ, 1985, ANN SURG, V201, P391, DOI 10.1097/00000658-198503000-00023; JANNETTA PJ, 1985, ANN SURG, V201, P253; JULIUS S, 1985, J HYPERTENS       S4, V3, P11; KLEINEBERG B, 1992, NEUROSURGERY, V30, P834, DOI 10.1227/00006123-199206000-00003; MARK AL, 1987, J CARDIOVASC PHARM, V10, P56; NAGASEKI Y, 1992, J NEUROSURG, V77, P379, DOI 10.3171/jns.1992.77.3.0379; NARAGHI R, 1992, J NEUROSURG, V77, P103, DOI 10.3171/jns.1992.77.1.0103; ROSS CA, 1984, J COMP NEUROL, V228, P168, DOI 10.1002/cne.902280204; ROSS CA, 1984, J NEUROSCI, V4, P474; TASH R, 1991, AM J NEURORADIOL, V12, P839; VANOUWERKERK WJR, 1989, ADV NEUROSURG, V17, P188	26	108	111	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 26	1994	344	8935					1466	1470		10.1016/S0140-6736(94)90289-5	http://dx.doi.org/10.1016/S0140-6736(94)90289-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7968120				2022-12-01	WOS:A1994PT99500008
J	HICKSON, GB; CLAYTON, EW; ENTMAN, SS; MILLER, CS; GITHENS, PB; WHETTENGOLDSTEIN, K; SLOAN, FA				HICKSON, GB; CLAYTON, EW; ENTMAN, SS; MILLER, CS; GITHENS, PB; WHETTENGOLDSTEIN, K; SLOAN, FA			OBSTETRICIANS PRIOR MALPRACTICE EXPERIENCE AND PATIENTS SATISFACTION WITH CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To examine the relationship between prior physician malpractice experience and patients' satisfaction with care. Design.-Women were interviewed using a questionnaire that contained structured and open-ended questions. Participants.-Mothers of all stillborn infants, infant deaths, and a random sampling of viable infants drawn from 1987 Florida Vital Statistics were sorted into four groups based on the malpractice claims experience of their obstetricians between 1983 and 1986. Interviews were completed with 963 of 1536 women, most by telephone, 53 by in-person interview. Main Outcome Measures.-Mothers' responses to closed-ended and open-ended questions about their perceptions of the care they received during their pregnancy, labor, and delivery. Results.-Even though none of the women actually filed a claim, a consistent pattern of differences emerged when comparing women's perceptions of care received. Patients seeing physicians with the most frequent numbers of claims but without high payments were significantly more likely to complain that they felt rushed, never received explanations for tests, and were ignored. In response to the open-ended question, ''What part of your care were you least satisfied with?'' women seeing physicians in the High Frequency malpractice risk group offered twice as many complaints as those seeing physicians who had never been sued. Problems with physician-patient communication were the most commonly offered complaints. Conclusion.-Physicians who have been sued frequently are more often the objects of complaints about the interpersonal care they provide even by their patients who do not sue.	VANDERBILT UNIV,SCH MED,DEPT PEDIAT,DIV GEN PEDIAT,NASHVILLE,TN 37212; VANDERBILT UNIV,SCH MED,DEPT OBSTET & GYNECOL,NASHVILLE,TN; VANDERBILT UNIV,SCH LAW,NASHVILLE,TN; VANDERBILT UNIV,INST PUBL POLICY STUDIES,NASHVILLE,TN; DUKE UNIV,CTR HLTH POLICY RES & EDUC,DURHAM,NC	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Duke University			Whetten, Kathryn/C-8572-2009	Whetten, Kathryn/0000-0002-4841-7695; Clayton, Ellen/0000-0002-0308-4110	AHRQ HHS [HSO6499] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1986, COSTS COMPENSATION P; CLAYTON EW, 1993, SUING MED MALPRACTIC, P50; ENTMAN SS, 1994, JAMA-J AM MED ASSOC, V272, P1588, DOI 10.1001/jama.272.20.1588; HICKSON G, 1993, SUING MED MALPRACTIC, P92; HICKSON GB, 1992, JAMA-J AM MED ASSOC, V267, P1359, DOI 10.1001/jama.267.10.1359; KORSCH BM, 1968, PEDIATRICS, V42, P855; MAY ML, 1990, LAW SOC REV, V24, P105, DOI 10.2307/3053788; NYE DJ, 1988, GEORGETOWN LAW J, V76, P1495; Pascoe G C, 1983, Eval Program Plann, V6, P185, DOI 10.1016/0149-7189(83)90002-2; SLOAN FA, 1989, JAMA-J AM MED ASSOC, V262, P3291, DOI 10.1001/jama.262.23.3291; WAITZKIN H, 1984, JAMA-J AM MED ASSOC, V252, P2441, DOI 10.1001/jama.252.17.2441; WARE JE, 1976, PB288330, V1; 1989, MED PROFESSIONAL LIA, P35; 1990, PATIENTS DOCTORS LAW	14	299	301	2	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 23	1994	272	20					1583	1587		10.1001/jama.272.20.1583	http://dx.doi.org/10.1001/jama.272.20.1583			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PR405	7966867				2022-12-01	WOS:A1994PR40500023
J	DIAZBENJUMEA, FJ; COHEN, B; COHEN, SM				DIAZBENJUMEA, FJ; COHEN, B; COHEN, SM			CELL-INTERACTION BETWEEN COMPARTMENTS ESTABLISHES THE PROXIMAL-DISTAL AXIS OF DROSOPHILA LEGS	NATURE			English	Article							SEGMENT-POLARITY GENE; LIMB DEVELOPMENT; PATTERN-FORMATION; IMAGINAL DISKS; DECAPENTAPLEGIC GENE; ENGRAILED GENE; WINGLESS; MELANOGASTER; EXPRESSION; LESS	THE appendage primordia of Drosophila are subdivided into compartments(1-4) by the localized expression of transcription factors(5-7). Interaction between cells in adjacent compartments establishes organizing centres responsible for generating spatial pattern and promoting cell proliferation in the developing appendages(7-9). Localized expression of hedgehog (hh) in the posterior compartment of the leg: imaginal disc directs expression of wingless (wg) in ventral-anterior cells and decapentaplegic (dpp) in dorsal-anterior cells near the anterior-posterior compartment boundary(8); wg then acts to specify ventral cell fate(10-12) and to organize the dorsal-ventral axis of the leg(13,14). Interaction between wg-expressing ventral cells and dorsal cells near the anterior-posterior compartment boundary promotes axis formation in the leg(14,15). Here we show that the combined action of log-expressing cells in the ventral-anterior compartment and dpp-expressing cells in the dorsal-anterior compartment activates expression of Distal-less, a gene required for proximal-distal axis formation in the limbs. These results demonstrate that sequential interaction between anterior-posterior and dorsal-ventral compartments establishes the proximal-distal axis of the limbs.			DIAZBENJUMEA, FJ (corresponding author), EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,POSTFACH 102209,D-69012 HEIDELBERG,GERMANY.		Cohen, Stephen M/G-9930-2011; Diaz-Benjumea, Fernando/K-7667-2014	Cohen, Stephen M/0000-0003-2858-9163; Diaz-Benjumea, Fernando/0000-0003-3007-2489				BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; COHEN B, 1993, DEVELOPMENT, V117, P597; COHEN SM, 1989, EMBO J, V8, P2045, DOI 10.1002/j.1460-2075.1989.tb03613.x; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; COHEN SM, 1989, ROUX ARCH DEV BIOL, V198, P157, DOI 10.1007/BF02438941; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P1661; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; KORNBERG T, 1981, P NATL ACAD SCI-BIOL, V78, P1095, DOI 10.1073/pnas.78.2.1095; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; MEINHARDT H, 1983, DEV BIOL, V96, P375, DOI 10.1016/0012-1606(83)90175-6; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; PEIFER M, 1991, DEVELOPMENT, V111, P1029; RAFTERY LA, 1991, DEVELOPMENT, V113, P27; Schubiger G., 1968, Wilhelm Roux Archiv fur Entwicklungsmechanik der Organismen, V160, P9, DOI 10.1007/BF00573645; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; SUNKEL CE, 1987, ROUX ARCH DEV BIOL, V196, P124, DOI 10.1007/BF00402034; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0	29	299	299	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 10	1994	372	6502					175	179		10.1038/372175a0	http://dx.doi.org/10.1038/372175a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ688	7969450				2022-12-01	WOS:A1994PQ68800055
J	BISSETT, D; DAVIS, JA; GEORGE, WD				BISSETT, D; DAVIS, JA; GEORGE, WD			GYNECOLOGICAL MONITORING DURING TAMOXIFEN THERAPY	LANCET			English	Editorial Material							BREAST-CANCER		STOBHILL GEN HOSP,GLASGOW G21 3UW,LANARK,SCOTLAND		BISSETT, D (corresponding author), WESTERN INFIRM & ASSOCIATED HOSP,BEATSON ONCOL CTR,GLASGOW G11 6NT,LANARK,SCOTLAND.							CRAWFORD DJ, 1992, BREAST, V1, P35; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; FORNANDER T, 1989, LANCET, V1, P117; KEDAR RP, 1994, LANCET, V343, P1318, DOI 10.1016/S0140-6736(94)92466-X; POWLES TJ, 1992, LANCET, V340, P1145, DOI 10.1016/0140-6736(92)93162-G	5	41	42	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 5	1994	344	8932					1244	1244		10.1016/S0140-6736(94)90747-1	http://dx.doi.org/10.1016/S0140-6736(94)90747-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP701	7967983				2022-12-01	WOS:A1994PP70100005
J	LANG, WH; MORROW, BE; JU, QD; WARNER, JR; REEDER, RH				LANG, WH; MORROW, BE; JU, QD; WARNER, JR; REEDER, RH			A MODEL FOR TRANSCRIPTION TERMINATION BY RNA-POLYMERASE-I	CELL			English	Article							RIBOSOMAL GENE TERMINATOR; SACCHAROMYCES-CEREVISIAE; PROTEIN-BINDING; YEAST; SEQUENCE; ENHANCER; REB1; ELEMENT; EXPRESSION; NUCLEOSOME	The transcription termination site for yeast RNA polymerase I requires not only an 11 bp binding site for Reb1p, but also about 46 bp of 5' flanking sequence. We propose that Reb1p bound to its site is part of a pause element, while the 5' flanking sequence contains a release element. Pausing requires little other than the DNA-binding domain of Reb1p and is not specific for polymerase I. The release element, however, can be polymerase specific. We propose a general model for eukaryotic transcription terminators in which termination occurs when a relatively nonspecific signal induces polymerase to pause in the context of a release element.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	LANG, WH (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.			Morrow, Bernice/0000-0002-8076-4726	NIGMS NIH HHS [GM25532, GM41792] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041792, R01GM025532] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON DS, 1985, EMBO J, V4, P2657, DOI 10.1002/j.1460-2075.1985.tb03984.x; AXELROD JD, 1993, GENE DEV, V7, P857, DOI 10.1101/gad.7.5.857; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; BRANDL CJ, 1990, MOL CELL BIOL, V10, P4256, DOI 10.1128/MCB.10.8.4256; CAMPBELL FE, 1992, MOL CELL BIOL, V12, P2260, DOI 10.1128/MCB.12.5.2260; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; CONNELLY S, 1989, MOL CELL BIOL, V9, P5254, DOI 10.1128/MCB.9.11.5254; COZZARELLI NR, 1983, CELL, V34, P829, DOI 10.1016/0092-8674(83)90540-8; ELION EA, 1986, MOL CELL BIOL, V6, P2089, DOI 10.1128/MCB.6.6.2089; ELION EA, 1984, CELL, V39, P663, DOI 10.1016/0092-8674(84)90473-2; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; JOHNSON SP, 1989, MOL CELL BIOL, V9, P4986, DOI 10.1128/MCB.9.11.4986; JU QD, 1990, MOL CELL BIOL, V10, P5226, DOI 10.1128/MCB.10.10.5226; KEMPERSVEENSTRA AE, 1986, EMBO J, V5, P2703, DOI 10.1002/j.1460-2075.1986.tb04554.x; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KUHN A, 1988, EMBO J, V7, P1497, DOI 10.1002/j.1460-2075.1988.tb02968.x; KULKENS T, 1992, EMBO J, V11, P4665, DOI 10.1002/j.1460-2075.1992.tb05568.x; LABHART P, 1987, MOL CELL BIOL, V7, P1900, DOI 10.1128/MCB.7.5.1900; LANG WH, 1993, MOL CELL BIOL, V13, P649, DOI 10.1128/MCB.13.1.649; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; MORROW BE, 1993, MOL CELL BIOL, V13, P1173, DOI 10.1128/MCB.13.2.1173; MORROW BE, 1990, J BIOL CHEM, V265, P20778; MORROW BE, 1993, MOL CELL BIOL, V13, P1283, DOI 10.1128/MCB.13.2.1283; REEDER RH, 1994, MOL MICROBIOL, V12, P11, DOI 10.1111/j.1365-2958.1994.tb00989.x; REMACLE JE, 1992, MOL CELL BIOL, V12, P5516, DOI 10.1128/MCB.12.12.5516; SCHULTZ MC, 1991, P NATL ACAD SCI USA, V88, P1004, DOI 10.1073/pnas.88.3.1004; SCOTT EW, 1993, MOL CELL BIOL, V13, P543, DOI 10.1128/MCB.13.1.543; WANG HM, 1990, MOL CELL BIOL, V10, P1743, DOI 10.1128/MCB.10.4.1743	28	90	91	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 4	1994	79	3					527	534		10.1016/0092-8674(94)90261-5	http://dx.doi.org/10.1016/0092-8674(94)90261-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7954818				2022-12-01	WOS:A1994PQ48800015
J	ZHANG, JF; ELLINOR, PT; ALDRICH, RW; TSIEN, RW				ZHANG, JF; ELLINOR, PT; ALDRICH, RW; TSIEN, RW			MOLECULAR DETERMINANTS OF VOLTAGE-DEPENDENT INACTIVATION IN CALCIUM CHANNELS	NATURE			English	Article							FUNCTIONAL EXPRESSION; SODIUM-CHANNEL; K+ CHANNELS; PERIODIC PARALYSIS; ION CHANNELS; CELLS; MECHANISMS; KINETICS; BLOCKADE; ANTIBODY	VOLTAGE-DEPENDENT Ca2+ channels respond to membrane depolarization by conformational changes that control channel opening and eventual closing by inactivation(1-3). The kinetics of inactivation differ considerably between types of Ca2+ channels(1-8) and are important in determining the amount of Ca2+ entry during electrical activity and its resulting impact on diverse cellular events(3). The most intensively characterized forms of inactivation in potassium(9,10) and sodium channels(11-13) involve pore block by a tethered plug(14). In contrast, little is known about the molecular basis of Ca2+-channel inactivation. We studied the molecular mechanism of inactivation of voltage-gated calcium channels by making chimaeras from channels with different inactivation rates. We report here that the amino acids responsible for the kinetic differences are localized to membrane-spanning segment S6 of the first repeat of the alpha(1) subunit (IS6), and to putative extracellular and cytoplasmic domains flanking IS6. Involvement of this region in Ca2+-channel inactivation was unexpected and raises interesting comparisons with Na+ channels, where the III-IV loop is a critical structural determinant. Ca2+-channel inactivation has some features that resemble C-type inactivation of potassium channels.	STANFORD UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University				Ellinor, Patrick/0000-0002-2067-0533				ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; ARMSTRONG CM, 1985, SCIENCE, V227, P65, DOI 10.1126/science.2578071; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; CANNON SC, 1993, NEURON, V10, P317, DOI 10.1016/0896-6273(93)90321-H; CARBONE E, 1989, PROG BIOPHYS MOL BIO, V54, P31, DOI 10.1016/0079-6107(89)90008-4; CATTERALL WA, 1993, TRENDS NEUROSCI, V16, P500, DOI 10.1016/0166-2236(93)90193-P; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; ECKERT R, 1984, PROG BIOPHYS MOL BIO, V44, P215, DOI 10.1016/0079-6107(84)90009-9; ELLINOR PT, 1993, NATURE, V363, P455, DOI 10.1038/363455a0; Hille B., 1992, IONIC CHANNELS EXCIT; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; KIRSCH GE, 1992, BIOPHYS J, V62, P136, DOI 10.1016/S0006-3495(92)81800-3; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LLINAS R, 1992, TRENDS NEUROSCI, V15, P351, DOI 10.1016/0166-2236(92)90053-B; LOPEZBARNEO J, 1993, RECEPTOR CHANNEL, V1, P61; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; REUTER H, 1984, ANNU REV PHYSIOL, V46, P473; ROJAS CV, 1991, NATURE, V354, P387, DOI 10.1038/354387a0; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; STRICHARTZ G, 1987, ANNU REV NEUROSCI, V10, P237; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; THOMSEN WJ, 1989, P NATL ACAD SCI USA, V86, P10161, DOI 10.1073/pnas.86.24.10161; VASSILEV P, 1989, P NATL ACAD SCI USA, V86, P8147, DOI 10.1073/pnas.86.20.8147; WILLIAMS ME, 1992, SCIENCE, V257, P390; YELLEN G, 1994, BIOPHYS J, V66, P1068, DOI 10.1016/S0006-3495(94)80888-4	31	178	181	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					97	100		10.1038/372097a0	http://dx.doi.org/10.1038/372097a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969428				2022-12-01	WOS:A1994PQ34800081
J	CASS, RM				CASS, RM			A PILL FOR OLD-PEOPLE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											CASS, RM (corresponding author), UNIV ROCHESTER, ROCHESTER, NY 14620 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1994	121	9					717	717		10.7326/0003-4819-121-9-199411010-00015	http://dx.doi.org/10.7326/0003-4819-121-9-199411010-00015			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN450	7944084				2022-12-01	WOS:A1994PN45000015
J	ALMARRI, A; BATCHELOR, JR				ALMARRI, A; BATCHELOR, JR			HLA AND HEPATITIS-B INFECTION	LANCET			English	Note							VACCINE	The mechanism underlying the development of chronic infection with hepatitis B virus is not known. We have done two independent studies in Qatar, where such infection is common, to determine whether immunity to this virus is influenced by the HLA phenotype of an individual. The first study generated a hypothesis to test in the second. In both studies, there was a significant deficiency of HLA-DR2 and an excess of HLA-DR7 in patients with chronic persistent infection with hepatitis B virus. We conclude that HLA phenotype is one of the factors influencing the response to infection with this virus.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT IMMUNOL,LONDON W12 0NN,ENGLAND; HAMAD HOSP,DEPT CLIN LAB & PATHOL,DOHA,QATAR	Imperial College London			谷, 雷雷/A-2889-2009					BIDWELL JL, 1988, TRANSPLANTATION, V45, P640, DOI 10.1097/00007890-198803000-00027; CRAVEN DE, 1986, ANN INTERN MED, V105, P356, DOI 10.7326/0003-4819-105-3-356; HATTUM JV, 1987, HEPATOLOGY, V7, P11; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; POZZILLI P, 1987, DIABETOLOGIA, V30, P817; WEISSMAN JY, 1988, JAMA-J AM MED ASSOC, V260, P1734, DOI 10.1001/jama.260.12.1734; YANG PM, 1989, HEPATO-GASTROENTEROL, V36, P363; 1994, LANCET, V343, P927	8	97	106	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 29	1994	344	8931					1194	1195		10.1016/S0140-6736(94)90510-X	http://dx.doi.org/10.1016/S0140-6736(94)90510-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN803	7934542				2022-12-01	WOS:A1994PN80300011
J	GINSBERG, JS; BARRON, WM				GINSBERG, JS; BARRON, WM			PREGNANCY AND PROSTHETIC HEART-VALVES	LANCET			English	Editorial Material							HEPARIN-THERAPY; ANTICOAGULANTS; WARFARIN; FETAL; RISKS; WOMEN		LOYOLA UNIV,MED CTR,DEPT MED,CHICAGO,IL 60611; LOYOLA UNIV,MED CTR,DEPT OBSTET & GYNECOL,CHICAGO,IL	Loyola University Chicago; Loyola University Chicago	GINSBERG, JS (corresponding author), MCMASTER UNIV,MED CTR,DEPT MED,HAMILTON L8N 3Z5,ON,CANADA.		ginsberg, jeffrey s/ABC-1065-2020					BARBOUR LA, 1994, AM J OBSTET GYNECOL, V170, P862, DOI 10.1016/S0002-9378(94)70299-3; BRILLEDWARDS P, 1993, ANN INTERN MED, V119, P104, DOI 10.7326/0003-4819-119-2-199307150-00002; CARUSO A, 1994, EUR J OBSTET GYN R B, V54, P7, DOI 10.1016/0028-2243(94)90074-4; DAHLMAN TC, 1993, AM J OBSTET GYNECOL, V168, P1265, DOI 10.1016/0002-9378(93)90378-V; GINSBERG JS, 1989, CHEST, V95, pS156, DOI 10.1378/chest.95.2.156S; GINSBERG JS, 1990, THROMB HAEMOSTASIS, V64, P286; GINSBERG JS, 1989, ARCH INTERN MED, V149, P2233, DOI 10.1001/archinte.149.10.2233; HALL JG, 1980, AM J MED, V68, P122, DOI 10.1016/0002-9343(80)90181-3; HIRSH J, 1991, NEW ENGL J MED, V324, P1565; HULL R, 1982, NEW ENGL J MED, V306, P189, DOI 10.1056/NEJM198201283060401; ITURBEALESSIO I, 1986, NEW ENGL J MED, V315, P1390, DOI 10.1056/NEJM198611273152205; SBAROUNI E, 1994, BRIT HEART J, V71, P196; TURPIE AGG, 1993, NEW ENGL J MED, V329, P524, DOI 10.1056/NEJM199308193290802; WONG V, 1993, AM J MED GENET, V45, P17, DOI 10.1002/ajmg.1320450107	14	35	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 29	1994	344	8931					1170	1172		10.1016/S0140-6736(94)90501-0	http://dx.doi.org/10.1016/S0140-6736(94)90501-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN803	7934533				2022-12-01	WOS:A1994PN80300002
J	AIBA, A; KANO, M; CHEN, C; STANTON, ME; FOX, GD; HERRUP, K; ZWINGMAN, TA; TONEGAWA, S				AIBA, A; KANO, M; CHEN, C; STANTON, ME; FOX, GD; HERRUP, K; ZWINGMAN, TA; TONEGAWA, S			DEFICIENT CEREBELLAR LONG-TERM DEPRESSION AND IMPAIRED MOTOR LEARNING IN MGLUR1 MUTANT MICE	CELL			English	Article							METABOTROPIC GLUTAMATE RECEPTOR; NICTITATING-MEMBRANE RESPONSE; CONDITIONED EYELID RESPONSES; PURKINJE-CELL TRANSMISSION; CENTRAL-NERVOUS-SYSTEM; MEMORY TRACE; INTERPOSITUS NUCLEUS; SYNAPTIC DEPRESSION; CLIMBING FIBER; DEVELOPING RAT	mGluR1 mutant mice are viable but show characteristic cerebellar symptoms such as ataxic gait and intention tremor. The anatomy of the cerebellum is not overtly disturbed. Excitatory synaptic transmission from parallel fibers (PFs) to Purkinje cells and that from climbing fibers (CFs) to Purkinje cells appear to be functional, and voltage-gated Ca2+ channels of Purkinje cells are normal. Both PF and CF synapses display normal short-term synaptic plasticity to paired stimuli. By marked contrast, long-term depression (LTD) is clearly deficient and conditioned eyeblink response is impaired. We conclude that mGluR1 is required for the induction of LTD and that the ataxic behavior and impaired eyeblink conditioning of the mGluR1 mutant mice are primarily due to deficient LTD.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; JICHI MED SCH, DEPT PHYSIOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; US EPA, DIV NEUROTOXICOL, RES TRIANGLE PK, NC 27711 USA; UNIV N CAROLINA, CHAPEL HILL, NC USA; CASE WESTERN RESERVE UNIV, SCH MED, ALZHEIMERS RES LABS, CLEVELAND, OH 44106 USA	Massachusetts Institute of Technology (MIT); Jichi Medical University; United States Environmental Protection Agency; University of North Carolina; University of North Carolina Chapel Hill; Case Western Reserve University	AIBA, A (corresponding author), MIT, HOWARD HUGHES MED INST, CTR LEARNING & MEMORY, CAMBRIDGE, MA 02139 USA.		; Herrup, Karl/C-5313-2014	Kano, Masanobu/0000-0002-0725-3292; Aiba, Atsu/0000-0002-8192-0778; Herrup, Karl/0000-0001-7786-5844	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020591, R01NS032925] Funding Source: NIH RePORTER; NINDS NIH HHS [NS20591, R01 NS32925] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; AIBA A, 1994, CELL, V79, P365, DOI 10.1016/0092-8674(94)90204-6; ALBUS J S, 1971, Mathematical Biosciences, V10, P25, DOI 10.1016/0025-5564(71)90051-4; ALTMAN J, 1973, J COMP NEUROL, V149, P181, DOI 10.1002/cne.901490204; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BLOEDEL JR, 1992, BEHAV BRAIN SCI, V15, P666; BRUNNER RL, 1973, BEHAV BIOL, V9, P169, DOI 10.1016/S0091-6773(73)80154-3; CAVINESS VS, 1978, ANNU REV NEUROSCI, V1, P297, DOI 10.1146/annurev.ne.01.030178.001501; CLARK RE, 1992, BEHAV NEUROSCI, V106, P879, DOI 10.1037/0735-7044.106.6.879; CREPEL F, 1991, J PHYSIOL-LONDON, V432, P123, DOI 10.1113/jphysiol.1991.sp018380; CREPEL F, 1988, BRAIN RES, V458, P397, DOI 10.1016/0006-8993(88)90486-6; CREPEL F, 1980, NEUROSCIENCE, V5, P333, DOI 10.1016/0306-4522(80)90109-8; DANIEL H, 1992, EXP BRAIN RES, V90, P327; DISTERHOFT JF, 1977, BRAIN RES, V137, P127, DOI 10.1016/0006-8993(77)91016-2; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; EKEROT CF, 1985, BRAIN RES, V342, P357, DOI 10.1016/0006-8993(85)91136-9; FOTUHI M, 1993, J NEUROSCI, V13, P2001; GORMEZANO I, 1962, SCIENCE, V138, P33, DOI 10.1126/science.138.3536.33; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HALL RD, 1973, BEHAV RES METH INSTR, V5, P321, DOI 10.3758/BF03200199; HARTELL NA, 1994, NEUROREPORT, V5, P913, DOI 10.1097/00001756-199404000-00015; HARTKOP TH, 1977, J NEUROPATH EXP NEUR, V36, P519, DOI 10.1097/00005072-197705000-00009; HIRANO T, 1990, NEUROSCI LETT, V119, P145, DOI 10.1016/0304-3940(90)90819-U; ITO M, 1982, J PHYSIOL-LONDON, V324, P113, DOI 10.1113/jphysiol.1982.sp014103; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.neuro.12.1.85; Ito M., 1984, CEREBELLUM NEURAL CO; KANO M, 1987, NATURE, V325, P276, DOI 10.1038/325276a0; KANO M, 1992, NATURE, V356, P601, DOI 10.1038/356601a0; Kano M., 1992, P54; KANO M, 1988, NEUROSCI RES, V5, P544, DOI 10.1016/0168-0102(88)90041-7; KANO M, 1988, NEUROSCI RES, V5, P325, DOI 10.1016/0168-0102(88)90034-X; KONNERTH A, 1992, P NATL ACAD SCI USA, V89, P7051, DOI 10.1073/pnas.89.15.7051; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2662, DOI 10.1073/pnas.87.7.2662; KRUPA DJ, 1993, SCIENCE, V260, P989, DOI 10.1126/science.8493536; LAVOND DG, 1989, BEHAV BRAIN RES, V33, P113, DOI 10.1016/S0166-4328(89)80047-6; LAVOND DG, 1987, EXP BRAIN RES, V67, P569; LIANO I, 1991, NEURON, V7, P577; LIANO I, 1991, J PHYSL, V434, P183; LINCOLN JS, 1982, BRAIN RES, V242, P190, DOI 10.1016/0006-8993(82)90510-8; LINDEN DJ, 1994, NEURON, V12, P457, DOI 10.1016/0896-6273(94)90205-4; LINDEN DJ, 1991, SCIENCE, V254, P1656, DOI 10.1126/science.1721243; LINDEN DJ, 1991, NEURON, V7, P81, DOI 10.1016/0896-6273(91)90076-C; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; MARTIN LJ, 1992, NEURON, V9, P259, DOI 10.1016/0896-6273(92)90165-A; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MCCORMICK DA, 1982, P NATL ACAD SCI-BIOL, V79, P2731, DOI 10.1073/pnas.79.8.2731; PELLEGRINO LJ, 1979, J COMP PHYSIOL PSYCH, V93, P1, DOI 10.1037/h0077589; PERRETT SP, 1993, J NEUROSCI, V13, P1708; RACINE RJ, 1986, EXP BRAIN RES, V63, P158; RAKIC P, 1975, ADV NEUROL, V12, P117; RAKIC P, 1973, P NATL ACAD SCI USA, V70, P240, DOI 10.1073/pnas.70.1.240; SAKURAI M, 1987, J PHYSIOL-LONDON, V394, P463, DOI 10.1113/jphysiol.1987.sp016881; SAKURAI M, 1990, P NATL ACAD SCI USA, V87, P3383, DOI 10.1073/pnas.87.9.3383; SCHMAJUK NA, 1990, PHYSIOL BEHAV, V48, P755, DOI 10.1016/0031-9384(90)90221-O; SCHNEIDERMAN N, 1962, SCIENCE, V136, P650, DOI 10.1126/science.136.3516.650; SHIGEMOTO R, 1994, NEURON, V12, P1245, DOI 10.1016/0896-6273(94)90441-3; SHIGEMOTO R, 1992, J COMP NEUROL, V322, P121, DOI 10.1002/cne.903220110; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SKELTON RW, 1988, BEHAV NEUROSCI, V102, P586, DOI 10.1037/0735-7044.102.4.586; SOTELO C, 1990, J EXP BIOL, V153, P225; STANTON ME, 1992, BEHAV NEUROSCI, V106, P657, DOI 10.1037/0735-7044.106.4.657; STANTON ME, 1994, ENVIRON HEALTH PERSP, V102, P131, DOI 10.2307/3431830; STEINMETZ JE, 1992, J NEUROSCI, V12, P4403; THACH WT, 1992, ANNU REV NEUROSCI, V15, P403, DOI 10.1146/annurev.neuro.15.1.403; THOMPSON RF, 1986, SCIENCE, V233, P941, DOI 10.1126/science.3738519; THOMPSON RF, 1994, ANNU REV NEUROSCI, V17, P519, DOI 10.1146/annurev.neuro.17.1.519; WELSH JP, 1989, J NEUROSCI, V9, P299; WELSH JP, 1991, J PHYSIOL-LONDON, V444, P459, DOI 10.1113/jphysiol.1991.sp018888; WOODWARD DJ, 1975, BRAIN RES, V97, P195, DOI 10.1016/0006-8993(75)90445-X; YEO CH, 1992, EXP BRAIN RES, V88, P623; YEO CH, 1985, EXP BRAIN RES, V60, P87, DOI 10.1007/BF00237022; YEO CH, 1985, EXP BRAIN RES, V60, P99, DOI 10.1007/BF00237023; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	75	729	752	1	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	1994	79	2					377	388						12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954803				2022-12-01	WOS:A1994PN63000020
J	GOODALE, MA				GOODALE, MA			ACTIVE MINDS, SLEEPING BODIES	LANCET			English	Editorial Material							REM		UNIV WESTERN ONTARIO,GRAD PROGRAM NEUROSCI,LONDON,ON,CANADA	Western University (University of Western Ontario)	GOODALE, MA (corresponding author), UNIV WESTERN ONTARIO,DEPT PSYCHOL,LONDON,ON,CANADA.		Goodale, Melvyn A/M-5907-2013	Goodale, Melvyn A/0000-0001-6748-0561				ASERINSKY E, 1953, SCIENCE, V118, P273, DOI 10.1126/science.118.3062.273; BLOCH V, 1977, NEUROBIOLOGY SLEEP M; DEMENT W, 1960, SCIENCE, V131, P1705, DOI 10.1126/science.131.3415.1705; DEMENT W, 1957, J EXP PSYCHOL, V53, P339, DOI 10.1037/h0048189; DUJARDIN K, 1990, PHYSIOL BEHAV, V47, P1271, DOI 10.1016/0031-9384(90)90382-E; KARNI A, 1994, SCIENCE, V265, P679, DOI 10.1126/science.8036518; Kleitman N., 1961, NATURE SLEEP; LAVIE P, 1984, NEUROLOGY, V34, P1118; MCGRATH MJ, 1978, PSYCHOL BULL, V85, P24, DOI 10.1037/0033-2909.85.1.24; SMITH C, 1985, NEUROSCI BIOBEHAV R, V9, P157, DOI 10.1016/0149-7634(85)90042-9; SMITH C, 1991, SLEEP, V14, P325, DOI 10.1093/sleep/14.4.325; VANDERWOLF CH, 1983, HDB BEHAVIORAL NEURO, V6, P67; WYATT RJ, 1971, NEW ENGL J MED, V285, P987, DOI 10.1056/NEJM197110282851802	13	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1036	1037		10.1016/S0140-6736(94)91703-5	http://dx.doi.org/10.1016/S0140-6736(94)91703-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7934440				2022-12-01	WOS:A1994PL85200003
J	WEIR, CJ; MURRAY, GD; ADAMS, FG; MUIR, KW; GROSSET, DG; LEES, KR				WEIR, CJ; MURRAY, GD; ADAMS, FG; MUIR, KW; GROSSET, DG; LEES, KR			POOR ACCURACY OF STROKE SCORING SYSTEMS FOR DIFFERENTIAL CLINICAL-DIAGNOSIS OF INTRACRANIAL HEMORRHAGE AND INFARCTION	LANCET			English	Article							HEMORRHAGE; COMMUNITY; PROJECT	The differentiation of cerebral infarction and cerebral haemorrhage is the most important first step in the management of acute stroke, because clinical management of the two disorders differs substantially. The Guy's Hospital and Siriraj stroke diagnostic scores were developed to aid clinicians in this decision. We have tested the performance of the two scores on a group of 1059 patients admitted to the acute stroke unit (ASU) at the Western Infirmary, Glasgow, with suspected stroke between May, 1990, and December, 1993. The diagnosis was confirmed as stroke by computed tomography (CT) scanning or necropsy (n=10) in 991 patients. For each clinical score we subjectively identified the cut-off point that maximised sensitivity to cerebral haemorrhage with the smallest loss of specificity. At its optimum cut-off point the Guy's Hospital score had a sensitivity for the diagnosis of haemorrhage of 70% and specificity of 64%. The corresponding figures for the Siriraj score at its optimum cut-off point were 68% sensitivity and 64% specificity. The overall predictive accuracy of both scores was 64%. The greater complexity of the Guy's Hospital score (thirteen variables included) did not result in substantially superior performance to the Siriraj score (five variables). This validation study suggests that neither score is useful for exclusion of haemorrhage before anticoagulant treatment is initiated or as a diagnostic screening procedure for trials of low-risk treatments such as aspirin. Our findings emphasise the need for routine CT scanning in this setting, since this method remains the most accurate for differentiating between haemorrhage and infarction.	UNIV GLASGOW,WESTERN INFIRM,DEPT MED & THERAPEUT,GLASGOW G11 6NT,LANARK,SCOTLAND; UNIV GLASGOW,ROBERTSON CTR BIOSTAT,GLASGOW G61 1BD,LANARK,SCOTLAND; WESTERN INFIRM & ASSOCIATED HOSP,DEPT RADIOL,GLASGOW,LANARK,SCOTLAND	University of Glasgow; University of Glasgow			Muir, Keith W/A-7670-2011	Muir, Keith W/0000-0001-9535-022X; Grosset, Donald/0000-0002-2757-8203; Weir, Christopher/0000-0002-6494-4903; Murray, Gordon/0000-0001-9866-4734	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Allen CMC, 1983, Q J MED, V208, P515; ALTMAN DG, 1991, PRACTICAL STAT MED R, P417; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; CELANI MG, 1994, BRIT MED J, V308, P1674, DOI 10.1136/bmj.308.6945.1674; HARRISON MJG, 1980, POSTGRAD MED J, V56, P629, DOI 10.1136/pgmj.56.659.629; MORRIS AD, 1993, J NEUROL NEUROSUR PS, V56, P352, DOI 10.1136/jnnp.56.4.352; POUNGVARIN N, 1991, BRIT MED J, V302, P1565, DOI 10.1136/bmj.302.6792.1565; SANDERCOCK P, 1985, BRIT MED J, V290, P193, DOI 10.1136/bmj.290.6463.193; SANDERCOCK PAG, 1985, BRIT MED J, V291, P1675, DOI 10.1136/bmj.291.6510.1675; SANDERCOCK PAG, 1986, BRIT MED J, V292, P173; VONARBIN M, 1981, STROKE, V12, P288, DOI 10.1161/01.STR.12.3.288	11	88	88	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					999	1002		10.1016/S0140-6736(94)91648-9	http://dx.doi.org/10.1016/S0140-6736(94)91648-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934437				2022-12-01	WOS:A1994PK97800016
J	DUNAIEF, JL; STROBER, BE; GUHA, S; KHAVARI, PA; ALIN, K; LUBAN, J; BEGEMANN, M; CRABTREE, GR; GOFF, SP				DUNAIEF, JL; STROBER, BE; GUHA, S; KHAVARI, PA; ALIN, K; LUBAN, J; BEGEMANN, M; CRABTREE, GR; GOFF, SP			THE RETINOBLASTOMA PROTEIN AND BRG1 FORM A COMPLEX AND COOPERATE TO INDUCE CELL-CYCLE ARREST	CELL			English	Article							LARGE T-ANTIGEN; TRANSCRIPTION FACTOR E2F; SV40 LARGE-T; GENE-PRODUCT; SUSCEPTIBILITY GENE; BINDING PROTEIN; SNF6 PROTEINS; E1A PRODUCTS; EXPRESSION; DOMAIN	The retinoblastoma tumor suppressor protein (RB) binds several cellular proteins involved in cell cycle progression. Using the yeast two-hybrid system, we found that RB bound specifically to the protein BRG1. BRG1 shares extensive sequence similarity to Drosophila brahma, an activator of homeotic gene expression, and the yeast transcriptional activator SNF2/SWI2. BRG1 contains an RB-binding motif found in viral oncoproteins and bound to the A/B pocket and the hypophosphorylated form of RB. BRG1 did not bind RB in viral oncoprotein-transformed cells. Coimmunoprecipitation experiments suggested BRG1 associates with the RB family in vivo. In the human carcinoma cell line SW13, BRG1 exhibited tumor suppressor activity by inducing formation of flat, growth-arrested cells. This activity depended on the ability of BRG1 to cooperate and complex with RB, as both an RB-nonbinding mutant of BRG1 and the sequestration of RB by adenovirus E1A protein abolished flat cell formation.	COLUMBIA UNIV,COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,CTR CANC,NEW YORK,NY 10032; STANFORD UNIV,DEPT DEV BIOL,STANFORD,CA 94305	Columbia University; Howard Hughes Medical Institute; Columbia University; Columbia University; Stanford University	DUNAIEF, JL (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032, USA.		Strober, Bruce/AAQ-6953-2020	Strober, Bruce/0000-0002-8394-2057; Luban, Jeremy/0000-0001-5650-4054	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T35HL007616] Funding Source: NIH RePORTER; NHLBI NIH HHS [MSTP 5T35HL07616] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EGAN C, 1989, ONCOGENE, V4, P383; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARLOW E, 1992, NATURE, V359, P270, DOI 10.1038/359270a0; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; IMAI Y, 1991, J VIROL, V65, P4966, DOI 10.1128/JVI.65.9.4966-4972.1991; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LEE EYHP, 1988, P NATL ACAD SCI USA, V85, P6017, DOI 10.1073/pnas.85.16.6017; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; LUBAN J, 1992, J VIROL, V66, P5157, DOI 10.1128/JVI.66.8.5157-5160.1992; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RANDAZZO FM, 1994, DEV BIOL, V161, P229, DOI 10.1006/dbio.1994.1023; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TSUCHIYA E, 1992, EMBO J, V11, P4017, DOI 10.1002/j.1460-2075.1992.tb05495.x; WARNEFORD S, 1991, CELL GROWTH DIFFER, V2, P439; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90300-S; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	66	538	550	1	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					119	130		10.1016/0092-8674(94)90405-7	http://dx.doi.org/10.1016/0092-8674(94)90405-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923370				2022-12-01	WOS:A1994PK58500013
J	GOTZSCHE, PC				GOTZSCHE, PC			IS THERE LOGIC IN THE PLACEBO	LANCET			English	Article							PAIN				GOTZSCHE, PC (corresponding author), RIGSHOSP, NORDIC COCHRANE CTR, RES & DEV SECRETARIAT, 9 BLEGDAMSVEJ, DK-2100 COPENHAGEN 0, DENMARK.							Cochrane AL, 1972, EFFECTIVENESS EFFICI; GAM AN, 1993, PAIN, V52, P63, DOI 10.1016/0304-3959(93)90114-5; KENNEDY W P, 1961, Med World, V95, P203; PECK C, 1991, THEOR MED, V12, P247, DOI 10.1007/BF00489609; SHAPIRO AK, 1968, PSYCHIAT QUART, V42, P653, DOI 10.1007/BF01564309; SHEPHERD M, 1993, PSYCHOL MED, V23, P569, DOI 10.1017/S0033291700025356; WARE JE, 1993, BRIT MED J, V306, P1429, DOI 10.1136/bmj.306.6890.1429; Wulff H. R., 1986, PHILOS MED	8	117	117	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 1	1994	344	8927					925	926						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934350				2022-12-01	WOS:A1994PJ28700014
J	CAMPBELL, D; COX, D; CRUM, J; FOSTER, K; RILEY, A				CAMPBELL, D; COX, D; CRUM, J; FOSTER, K; RILEY, A			LATER EFFECTS OF GROUNDING OF TANKER BRAER ON HEALTH IN SHETLAND	BRITISH MEDICAL JOURNAL			English	Article									SHETLAND HLTH BOARD,LERWICK ZE1 0RB,ZETLAND,SCOTLAND; GRAMPIAN AREA HLTH BOARD,ABERDEEN AB9 1RE,SCOTLAND; LOTHIAN HLTH BOARD,EDINBURGH EH8 9RS,MIDLOTHIAN,SCOTLAND		CAMPBELL, D (corresponding author), RUCHILL HOSP,SCOTTISH CTR INFECT & ENVIRONM HLTH,GLASGOW G20 9NB,LANARK,SCOTLAND.							CAMPBELL D, 1993, BRIT MED J, V307, P1251, DOI 10.1136/bmj.307.6914.1251; CAMPBELL DM, 1993, BRIT MED J, V306, P519, DOI 10.1136/bmj.306.6876.519-a; Goldberg DPW, 1988, USERS GUIDE GEN HLTH; LOGUE JN, 1981, EPIDEMIOL REV, V3, P140, DOI 10.1093/oxfordjournals.epirev.a036231	4	31	31	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					773	774		10.1136/bmj.309.6957.773	http://dx.doi.org/10.1136/bmj.309.6957.773			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ282	7950562	Green Published			2022-12-01	WOS:A1994PJ28200019
J	REHMAN, I; QUINN, AG; HEALY, E; REES, JL				REHMAN, I; QUINN, AG; HEALY, E; REES, JL			HIGH-FREQUENCY OF LOSS OF HETEROZYGOSITY IN ACTINIC KERATOSES, A USUALLY BENIGN DISEASE	LANCET			English	Note							SQUAMOUS-CELL CARCINOMA; SKIN	Actinic keratoses (AKs) are focal areas of dysplasia with low risk of progression to squamous cell cancer; many regress spontaneously. Using polymerase-chain-reaction microsatellite analysis, we found that loss of heterozygosity on several chromosome arms, including 17p, 17q, 9p, 9q, and 13q, was common in AKs. More than half the AKs examined showed loss of heterozygosity at four or more loci. The apparent genetic instability of these lesions contrasts with their benign clinical course.	UNIV NEWCASTLE UPON TYNE,ROYAL VICTORIA INFIRM,DEPT DERMATOL,NEWCASTLE TYNE NE1 4LP,ENGLAND	Newcastle University - UK				Healy, Eugene/0000-0001-5591-6970				CAMPBELL C, 1993, J INVEST DERMATOL, V100, P746, DOI 10.1111/1523-1747.ep12475717; CAMPBELL C, 1993, BRIT J DERMATOL, V129, P235, DOI 10.1111/j.1365-2133.1993.tb11840.x; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; KNUDSON A, 1991, ORIGINS OF HUMAN CANCER, P17; KWA RE, 1992, J AM ACAD DERMATOL, V26, P1, DOI 10.1016/0190-9622(92)70001-V; LANE DP, 1994, INT J CANCER, V57, P623, DOI 10.1002/ijc.2910570502; MARKS R, 1988, LANCET, V1, P795, DOI 10.1016/s0140-6736(88)91658-3; QUINN AG, 1994, CANCER RES, V54, P4756; WEINBERG RA, 1991, ORIGINS OF HUMAN CANCER, P1; YOKOTA J, 1993, FASEB J, V7, P920, DOI 10.1096/fasebj.7.10.8344488	10	60	61	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					788	789		10.1016/S0140-6736(94)92343-4	http://dx.doi.org/10.1016/S0140-6736(94)92343-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916075				2022-12-01	WOS:A1994PG17800012
J	CHAN, SK; JAFFE, L; CAPOVILLA, M; BOTAS, J; MANN, RS				CHAN, SK; JAFFE, L; CAPOVILLA, M; BOTAS, J; MANN, RS			THE DNA-BINDING SPECIFICITY OF ULTRABITHORAX IS MODULATED BY COOPERATIVE INTERACTIONS WITH EXTRADENTICLE, ANOTHER HOMEOPROTEIN	CELL			English	Article							HUMAN PROTOONCOGENE PBX1; MAGNETIC-RESONANCE SPECTROSCOPY; DROSOPHILA HOMEODOMAIN PROTEINS; HOMEOTIC GENE-EXPRESSION; FUNCTIONAL SPECIFICITY; ANTENNAPEDIA HOMEODOMAIN; ECTOPIC EXPRESSION; VISCERAL MESODERM; CRYSTAL-STRUCTURE; HOMEOBOX GENES	The Ultrabithorax (Ubx) and Antennapedia (Antp) genes of Drosophila encode homeodomain proteins that have very similar DNA binding specificities in vitro but specify the development of different segmental patterns in vivo. We describe cooperative interactions between Ubx protein and a divergent homeodomain protein, extradenticle (exd), that selectively increases the affinity of Ubx, but not Antp, for a particular DNA target. We also provide evidence that Ubx and exd bind to neighboring sites on this DNA and interact directly to stabilize the DNA-bound form of Ubx. Thus, the ability of different homeotic genes to specify distinct segmental patterns may depend on cooperative interactions with proteins such as exd that selectively modulate their otherwise similar DNA binding specificities.	COLUMBIA UNIV,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032; BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030	Columbia University; Baylor College of Medicine	CHAN, SK (corresponding author), COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.		Capovilla, Maria/O-8483-2016	Capovilla, Maria/0000-0002-1308-7964	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054510] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM054510] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREW DJ, 1992, NEW BIOL, V4, P5; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BILLETER M, 1990, J MOL BIOL, V214, P183, DOI 10.1016/0022-2836(90)90155-F; CAPOVILLA M, 1994, CELL, V76, P461, DOI 10.1016/0092-8674(94)90111-2; CHAN SK, 1993, GENE DEV, V7, P796, DOI 10.1101/gad.7.5.796; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DESSAIN S, 1992, EMBO J, V11, P991, DOI 10.1002/j.1460-2075.1992.tb05138.x; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EKKER SC, 1992, EMBO J, V11, P4059, DOI 10.1002/j.1460-2075.1992.tb05499.x; FLEGEL WA, 1993, MECH DEVELOP, V41, P155, DOI 10.1016/0925-4773(93)90045-Y; FURUKUBOTOKUNAGA K, 1993, P NATL ACAD SCI USA, V90, P6360, DOI 10.1073/pnas.90.13.6360; GIBSON G, 1988, DEVELOPMENT, V102, P657; GONZALEZREYES A, 1990, NATURE, V344, P78, DOI 10.1038/344078a0; GONZALEZREYES A, 1990, CELL, V61, P515, DOI 10.1016/0092-8674(90)90533-K; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; JOHNSON A, 1993, TRANSCRIPTIONAL REGU; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LIN L, 1992, GENE DEV, V6, P1071, DOI 10.1101/gad.6.6.1071; LOPEZ AJ, 1991, P NATL ACAD SCI USA, V88, P9924, DOI 10.1073/pnas.88.22.9924; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; RAUSKOLB C, 1994, IN PRESS EMBO; REUTER R, 1990, DEVELOPMENT, V110, P1031; SMITH MC, 1988, J BIOL CHEM, V263, P7211; TREISMAN J, 1992, BIOESSAYS, V14, P145, DOI 10.1002/bies.950140302; TREMML G, 1989, EMBO J, V8, P2677, DOI 10.1002/j.1460-2075.1989.tb08408.x; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; WAKIMOTO BT, 1981, DEV BIOL, V81, P51, DOI 10.1016/0012-1606(81)90347-X; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; XU T, 1993, DEVELOPMENT, V117, P1223; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239; ZENG WL, 1993, DEVELOPMENT, V118, P339	49	341	342	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 26	1994	78	4					603	615		10.1016/0092-8674(94)90525-8	http://dx.doi.org/10.1016/0092-8674(94)90525-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	7915199				2022-12-01	WOS:A1994PD69300009
J	MILLER, JD				MILLER, JD			SWELLING AND BLOOD-FLOW IN THE INJURED CHILDS BRAIN	LANCET			English	Editorial Material							HEAD-INJURY; METABOLISM				MILLER, JD (corresponding author), WESTERN GEN HOSP, DEPT CLIN NEUROSCI, EDINBURGH, MIDLOTHIAN, SCOTLAND.							ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CHAN KH, 1993, NEUROSURGERY, V32, P547, DOI 10.1227/00006123-199304000-00009; CHAN KH, 1992, J NEUROL NEUROSUR PS, V55, P787, DOI 10.1136/jnnp.55.9.787; DEARDEN NM, 1991, CURR OPIN ANESTHESIO, V4, P279; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; SCHRODER ML, 1993, J NEUROTRAUMA S, V10, pS57; SHARPLES PM, 1991, ARCH DIS CHILD, V66, P1326, DOI 10.1136/adc.66.11.1326; SHARPLES PM, IN PRESS J NEUROL NE; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363	13	9	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 13	1994	344	8920					421	422						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7914562				2022-12-01	WOS:A1994PB76100005
J	VARTIAINEN, E; PUSKA, P; PEKKANEN, J; TUOMILEHTO, J; LONNQVIST, J; EHNHOLM, C				VARTIAINEN, E; PUSKA, P; PEKKANEN, J; TUOMILEHTO, J; LONNQVIST, J; EHNHOLM, C			SERUM-CHOLESTEROL CONCENTRATION AND MORTALITY FROM ACCIDENTS, SUICIDE, AND OTHER VIOLENT CAUSES	BRITISH MEDICAL JOURNAL			English	Article							DEATH; RISK	Objective-To study the association of mortality from accidents, suicides, and other violent deaths with serum cholesterol concentration. Design-Baseline measurements in two randomly chosen independent cohorts were carried out in 1972 and 1977. Mortality was monitored over 10-15 years through the national death registry. Setting-Eastern Finland. Subjects-The two cohorts comprised men (n=10898) and women (n=11534) born between 1913 and 1947. There were 193 deaths due to accidents, suicides, and violence among men and 43 among women. Main outcome measure-Mortality from accidents, suicides, and other violent deaths was used as the end point. Deaths from these causes were pooled together in the analyses. Results-Serum cholesterol concentration was not associated with mortality from accidents, suicides, and other violent deaths in the univariate analyses or in the proportional hazards regression analyses including smoking, systolic blood pressure, alcohol drinking, and education. In both genders smoking was more prevalent among those who died from accidents, suicides, and other violent causes than from other causes. Frequent use of alcohol increased mortality from these causes. Conclusion-The risk of accidents, suicides, and other violent deaths was not related to serum cholesterol concentration, whereas such deaths were more prevalent in smokers and alcohol drinkers.			VARTIAINEN, E (corresponding author), NATL PUBL HLTH INST,MANNERHEIMINTIE 166,SF-00300 HELSINKI,FINLAND.							[Anonymous], COMMUNITY CONTROL CA; COX DR, 1972, J R STAT SOC B, V34, P187; KROMHOUT D, 1992, LANCET, V340, P317, DOI 10.1016/0140-6736(92)92415-C; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; LINDBERG G, 1992, BRIT MED J, V305, P277, DOI 10.1136/bmj.305.6848.277; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; PEKKANEN J, 1989, ARCH INTERN MED, V149, P1589, DOI 10.1001/archinte.149.7.1589; SCHUIT AJ, 1993, LANCET, V341, P827, DOI 10.1016/0140-6736(93)90600-L; SMITH GD, 1992, LANCET, V340, P709; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; SMITH GD, 1990, BRIT MED J, V301, P552; 1990, SAS USERS GUIDE STAT	12	53	53	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 13	1994	309	6952					445	447						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC404	7920128	Green Published			2022-12-01	WOS:A1994PC40400018
J	QUIRING, R; WALLDORF, U; KLOTER, U; GEHRING, WJ				QUIRING, R; WALLDORF, U; KLOTER, U; GEHRING, WJ			HOMOLOGY OF THE EYELESS GENE OF DROSOPHILA TO THE SMALL EYE GENE IN MICE AND ANIRIDIA IN HUMANS	SCIENCE			English	Article							HOMEOBOX-CONTAINING GENE; PAIRED BOX GENE; HUMAN PAX6 GENE; STRUCTURAL-ANALYSIS; EXPRESSION PATTERN; MOLECULAR-GENETICS; NEURAL-TUBE; SEQUENCE; DNA; MELANOGASTER	A Drosophila gene that contains both a paired box and a homeobox and has extensive sequence homology to the mouse Pax-6 (Small eye) gene was isolated and mapped to chromosome IV in a region close to the eyeless locus. Two spontaneous mutations, ey(2) and ey(R), contain transposable element insertions into the cloned gene and affect gene expression, particularly in the eye primordia. This indicates that the cloned gene encodes ey. The finding that ey of Drosophila, Small eye of the mouse, and human Aniridia are encoded by homologous genes suggests that eye morphogenesis is under similar genetic control in both vertebrates and insects, in spite of the large differences in eye morphology and mode of development.	UNIV BASEL,BIOCTR,DEPT CELL BIOL,CH-4056 BASEL,SWITZERLAND	University of Basel								ASHBURNER M, 1989, DROSOPHILA LABORATOR; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BAUMGARTNER S, 1987, GENE DEV, V1, P1247, DOI 10.1101/gad.1.10.1247; BENDER W, 1983, SCIENCE, V221, P23, DOI 10.1126/science.221.4605.23; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BURGLIN TR, GUIDEBOOK HOMEOBOX G, P25; CALLAERTS P, UNPUB; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CHALEPAKIS G, 1993, J NEUROBIOL, V24, P1367, DOI 10.1002/neu.480241009; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOZIER C, 1993, CELL GROWTH DIFFER, V4, P281; DRIVER A, 1989, MOL GEN GENET, V220, P49, DOI 10.1007/BF00260854; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROMMER G, 1994, CHROMOSOMA, V103, P82, DOI 10.1007/BF00352316; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HOGAN BLM, 1988, DEVELOPMENT, V103, P115; JACOB F, 1977, SCIENCE, V196, P1161, DOI 10.1126/science.860134; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; JURGENS G, 1993, DEV DROSOPHILA MELAN, V1, P702; KRAUSS S, 1991, EMBO J, V10, P3609, DOI 10.1002/j.1460-2075.1991.tb04927.x; KRAUSS S, 1991, NATURE, V353, P267, DOI 10.1038/353267a0; LEEMANS R, UNPUB; Lindsley D.L., 1992, GENOME DROSOPHILA ME; LOOSLI F, UNPUB; MARTIN P, 1992, ONCOGENE, V7, P1721; MATSUO T, 1993, NAT GENET, V3, P299, DOI 10.1038/ng0493-299; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; NOLL M, 1993, CURR OPIN GENET DEV, V3, P595, DOI 10.1016/0959-437X(93)90095-7; OHARE K, 1983, P NATL ACAD SCI-BIOL, V80, P6917, DOI 10.1073/pnas.80.22.6917; OHARE K, 1991, MOL GEN GENET, V225, P17, DOI 10.1007/BF00282637; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PICK L, 1990, GENE DEV, V4, P1224, DOI 10.1101/gad.4.7.1224; PLATE L, 1924, ALLGEMEINE ZOOLOGIE; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PUSCHEL AW, 1992, DEVELOPMENT, V114, P643; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEITZ K, 1993, GENE DEV, V7, P114, DOI 10.1101/gad.7.1.114; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WALLDORF U, UNPUB; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; WALTHER C, 1991, DEVELOPMENT, V113, P1435	54	863	888	1	105	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 5	1994	265	5173					785	789		10.1126/science.7914031	http://dx.doi.org/10.1126/science.7914031			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	7914031				2022-12-01	WOS:A1994PA37200034
J	DERKX, FHM; SCHALEKAMP, MADH				DERKX, FHM; SCHALEKAMP, MADH			RENAL-ARTERY STENOSIS AND HYPERTENSION	LANCET			English	Article							RENOVASCULAR HYPERTENSION; ANGIOPLASTY; DIAGNOSIS; CAPTOPRIL; TESTS				DERKX, FHM (corresponding author), ERASMUS UNIV ROTTERDAM,HOSP DIJKZIGT,DEPT INTERNAL MED 1,ROOM L242,DR MOLEWATERPLEIN 40,3015 GD ROTTERDAM,NETHERLANDS.							[Anonymous], 1987, Arch Intern Med, V147, P820; BLAUFOX MD, 1990, HYPERTENSION PATHOPH, P1509; DAVIDSON RA, 1992, JAMA-J AM MED ASSOC, V268, P3353, DOI 10.1001/jama.268.23.3353; DEAN RH, 1981, ARCH SURG-CHICAGO, V116, P1408; DERKX FHM, 1993, NETH J MED, V43, pS12; DERKX FHM, 1993, J HYPERTENS, V11, pS200; DERKX FHM, 1987, RENOVASCULAR HYPERTE, P295; DORROS G, 1993, CATHET CARDIOVASC DI, V3, P191; ELLIOTT WJ, 1993, ARCH INTERN MED, V153, P755, DOI 10.1001/archinte.153.6.755; FOMMEI E, 1993, EUR J NUCL MED, V20, P617; HUDSPETH DA, 1993, J VASC SURG, V18, P389; HUNT JC, 1974, ARCH INTERN MED, V133, P988, DOI 10.1001/archinte.133.6.988; Marks L S, 1975, Urol Clin North Am, V2, P311; MAY AG, 1963, SURGERY, V53, P5213; NEIMAN HL, 1985, ANGIOGRAPHY VASCULAR, P1; Pickering T, 1990, HYPERTENSION PATHOPH, P1539; PICKERING TG, 1985, J HYPERTENS, V3, pS291; PLOUIN PF, 1993, HYPERTENSION, V21, P89, DOI 10.1161/01.HYP.21.1.89; RAMSAY LE, 1990, BRIT MED J, V300, P569, DOI 10.1136/bmj.300.6724.569; SIMON G, 1994, AM J HYPERTENS, V7, P1; VANJAARSVELD BC, 1994, NETH J MED, V44, pA65; WEIBULL H, 1993, J VASC SURG, V18, P841, DOI 10.1016/0741-5214(93)90340-R; WENTING GJ, 1984, BMJ-BRIT MED J, V288, P886, DOI 10.1136/bmj.288.6421.886	23	183	192	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					237	239		10.1016/S0140-6736(94)93002-3	http://dx.doi.org/10.1016/S0140-6736(94)93002-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913161	Green Submitted			2022-12-01	WOS:A1994NY06000014
J	KASS, EM; SZANIAWSKI, WK; LEVY, H; LEACH, J; SRINIVASAN, K; RIVES, C				KASS, EM; SZANIAWSKI, WK; LEVY, H; LEACH, J; SRINIVASAN, K; RIVES, C			RICKETTSIALPOX IN A NEW-YORK-CITY-HOSPITAL, 1980 TO 1989	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MOUNTAIN SPOTTED-FEVER	Background. Rickettsialpox is caused by Rickettsia akari, which is transmitted from rodents to humans by bloodsucking mites. The initial skin lesion forms an eschar and is followed by the development of fever, malaise, myalgia, and 5 to 40 maculopapules and papulovesicles. The disease, which responds to tetracycline, can be mistaken for chickenpox. The diagnosis has been based on an increase in serum antibody titers against R. akari over a period of three to eight weeks. We discuss a more rapid technique that uses direct immunofluorescence to identify R. akari in paraffin-embedded tissue, and we describe the histopathological findings of lesional skin. Methods. We studied 13 patients (age, 11 months to 58 years) who were seen at Lincoln Hospital in New York City from 1980 to 1989 and were suspected of having rickettsialpox. In nine patients serum samples were obtained during the acute and convalescent phases of the illness for indirect fluorescent-antibody testing. Punch-biopsy specimens of skin lesions were examined by microscopy and by direct fluorescent-antibody testing with an anti-R. rickettsii globulin conjugated with fluorescein isothiocyanate. Results. The diagnosis was confirmed in all 13 patients by indirect or direct fluorescent-antibody techniques, Direct fluorescent-antibody testing of eschars from seven patients was positive in five patients, but negative in two patients who had serologically confirmed rickettsialpox. In contrast, direct fluorescent-antibody testing of papulovesicles from nine patients was positive in only one patient. Histopathological analysis of the eschars revealed extensive necrosis and inflammation. In biopsy specimens of papulovesicles, dermal edema, subepidermal vesicles, and vascular changes were present. Conclusions. The combination of direct fluorescent-antibody testing of an eschar from the presumed site of inoculation and histopathological examination of papulovesicles for distinctive features represents an improved method of diagnosing rickettsialpox.	DERMATOPATHOL ASSOCIATES NEW YORK,NEW ROCHELLE,NY 10805; NEW YORK MED COLL,DEPT DERMATOL,NEW YORK,NY; NEW YORK MED COLL,DEPT PATHOL,NEW YORK,NY; LINCOLN HOSP CTR,NEW YORK,NY; CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341	New York Medical College; New York Medical College; Centers for Disease Control & Prevention - USA								BRETTMAN LR, 1981, MEDICINE, V60, P363, DOI 10.1097/00005792-198109000-00004; DOLGOPOL VB, 1948, AM J PATHOL, V24, P119; GREENBERG M, 1947, B NEW YORK ACAD MED, V23, P338; GREENBERG M, 1947, JAMA-J AM MED ASSOC, V133, P901, DOI 10.1001/jama.1947.02880130001001; HEBERT GA, 1980, J CLIN MICROBIOL, V11, P503; HUEBNER RJ, 1946, PUBLIC HEALTH REP, V61, P1605, DOI 10.2307/4585895; HUEBNER RJ, 1947, PUBLIC HEALTH REP, V62, P777, DOI 10.2307/4586142; HUEBNER RJ, 1946, PUBLIC HEALTH REP, V61, P1677, DOI 10.2307/4585913; JACKSON EB, 1957, AM J HYG, V66, P301, DOI 10.1093/oxfordjournals.aje.a119903; JACOBSON JM, 1989, INT J DERMATOL, V28, P271, DOI 10.1111/j.1365-4362.1989.tb04821.x; KRINSKY WL, 1983, REV INFECT DIS, V5, P1118; LACKMAN DB, 1963, CLIN PEDIATR, V2, P296, DOI 10.1177/000992286300200602; MCCALMONT C, 1989, DERMATOL CLIN, V7, P591, DOI 10.1016/S0733-8635(18)30588-6; NICHOLS E, 1953, ANN INTERN MED, V39, P92, DOI 10.7326/0003-4819-39-1-92; PATERSON PY, 1966, B NEW YORK ACAD MED, V42, P579; PHILIP RN, 1976, J CLIN MICROBIOL, V3, P51; ROSE HM, 1949, ANN INTERN MED, V31, P871, DOI 10.7326/0003-4819-31-5-871; SHANKMAN B, 1946, NEW YORK STATE J MED, V46, P2156; SUSSMAN L N, 1946, NY Med, V2, P27; WALKER DH, 1978, J INFECT DIS, V137, P206, DOI 10.1093/infdis/137.2.206; 1982, LANCET, V1, P148	21	56	56	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 15	1994	331	24					1612	1617		10.1056/NEJM199412153312403	http://dx.doi.org/10.1056/NEJM199412153312403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW446	7969341				2022-12-01	WOS:A1994PW44600003
J	NAIMAN, JL				NAIMAN, JL			DIGITALIS PURPUREA (FOXGLOVE)	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											NAIMAN, JL (corresponding author), STANFORD UNIV,SCH MED,STANFORD,CA 94303, USA.								0	1	1	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 8	1994	331	23					1563	1563						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV292	7969327				2022-12-01	WOS:A1994PV29200006
J	AMARENCO, P; COHEN, A; TZOURIO, C; BERTRAND, B; HOMMEL, M; BESSON, G; CHAUVEL, C; TOUBOUL, PJ; BOUSSER, MG				AMARENCO, P; COHEN, A; TZOURIO, C; BERTRAND, B; HOMMEL, M; BESSON, G; CHAUVEL, C; TOUBOUL, PJ; BOUSSER, MG			ATHEROSCLEROTIC DISEASE OF THE AORTIC-ARCH AND THE RISK OF ISCHEMIC STROKE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSESOPHAGEAL ECHOCARDIOGRAPHY; CHOLESTEROL EMBOLIZATION; CARDIOPULMONARY BYPASS; SYSTEMIC EMBOLIZATION; CEREBRAL INFARCTION; EMBOLISM; PLAQUE; COMPLICATION; ATHEROMAS; THROMBUS	Background. Atherosclerotic disease of the aortic arch has been suspected to be a potential source of cerebral emboli. We conducted a study to quantify the risk of ischemic stroke associated with atherosclerotic disease of the aortic arch. Methods. Using transesophageal echocardiography, we performed a prospective case-control study of the frequency and thickness of atherosclerotic plaques in the ascending aorta and proximal arch in 250 consecutive patients admitted to the hospital with ischemic stroke and 250 consecutive controls, all over the age of 60 years. Results. Atherosclerotic plaques greater than or equal to 4 mm in thickness were found in 14.4 percent of the patients but in only 2 percent of the controls. After adjustment for atherosclerotic risk factors, the odds ratio for ischemic stroke among patients with such plaques was 9.1 (95 percent confidence interval, 3.3 to 25.2; P<0.001). Among the 78 patients who had brain infarcts with no obvious cause, 28.2 percent had plaques greater than or equal to 4 mm in thickness, as compared with 8.1 percent of the 172 patients who had infarcts whose possible or likely causes were known (odds ratio, 4.7; 95 percent confidence interval, 2.2 to 10.1; P<0.001). Plaques of greater than or equal to 4 mm in the aortic arch were not associated with the presence of atrial fibrillation or stenosis of the extracranial internal carotid artery. In contrast, plaques that were 1 to 3.9 mm thick were frequently associated with carotid stenosis of greater than or equal to 70 percent. Conclusions. These results indicate a strong, independent association between atherosclerotic disease of the aortic arch and the risk of ischemic stroke. The association was particularly strong with thick plaques. Atherosclerotic disease of the aortic arch should be regarded as a risk factor for ischemic stroke and as a possible source of cerebral emboli.	UNIV PARIS 06,HOP ST ANTOINE,SERV CARDIOL,PARIS,FRANCE; INSERM,U360,VILLEJUIF,FRANCE; CHU GRENOBLE,NEUROL CLIN,GRENOBLE,FRANCE; CHU GRENOBLE,CARDIOL CLIN,GRENOBLE,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	AMARENCO, P (corresponding author), UNIV PARIS 06,HOP ST ANTOINE,SERV NEUROL,184 RUE FAUBOURG ST ANTOINE,F-75571 PARIS 12,FRANCE.		Tzourio, christophe/L-6344-2019; Tzourio, Christophe I/B-7459-2008; Tzourio, christophe/B-4015-2009	Tzourio, christophe/0000-0002-6517-2984; Tzourio, christophe/0000-0002-6517-2984; Touboul, Pierre-Jean/0000-0002-8872-9917				AMARENCO P, 1992, STROKE, V23, P1005, DOI 10.1161/01.STR.23.7.1005; AMARENCO P, 1992, NEW ENGL J MED, V326, P221, DOI 10.1056/NEJM199201233260402; BEAL MF, 1981, NEUROLOGY, V31, P860, DOI 10.1212/WNL.31.7.860; BRUNS FJ, 1978, AM J MED SCI, V275, P105, DOI 10.1097/00000441-197801000-00013; CAPLAN LR, 1993, NEUROLOGY, V43, P1281, DOI 10.1212/WNL.43.7.1281; CHESEBRO JH, 1990, NEW ENGL J MED, V323, P1556; COGAN DG, 1964, ARCH OPHTHALMOL-CHIC, V71, P308; Culliford Alfred T., 1993, Journal of the American College of Cardiology, V21, p342A; DAVID NJ, 1963, NEUROLOGY, V13, P708, DOI 10.1212/WNL.13.8.708; FAZIO GP, 1993, J AM COLL CARDIOL, V21, P144, DOI 10.1016/0735-1097(93)90729-K; FEDER W, 1961, ANN INTERN MED, V55, P911, DOI 10.7326/0003-4819-55-6-911; GARDNER TJ, 1985, ANN THORAC SURG, V40, P574, DOI 10.1016/S0003-4975(10)60352-9; GORE I, 1960, AM J CLIN PATHOL, V33, P416; HAUSMANN D, 1992, NEW ENGL J MED, V327, P500; HOLLENHORST RW, 1966, AM J OPHTHALMOL, V61, P1159, DOI 10.1016/0002-9394(66)90238-8; HOROWITZ DR, 1992, NEUROLOGY, V42, P1602, DOI 10.1212/WNL.42.8.1602; KARALIS DG, 1991, J AM COLL CARDIOL, V17, P73, DOI 10.1016/0735-1097(91)90706-F; KATZ ES, 1992, J AM COLL CARDIOL, V20, P70, DOI 10.1016/0735-1097(92)90139-E; MCKIBBIN DW, 1976, J THORAC CARDIOV SUR, V71, P741; MOHR-KAHALY S, 1992, European Heart Journal, V13, P17; MOLDVEEN.M, 1967, CIRCULATION, V35, P946, DOI 10.1161/01.CIR.35.5.946; NIHOYANNOPOULOS P, 1993, AM J CARDIOL, V71, P1208, DOI 10.1016/0002-9149(93)90647-U; OSTER P, 1979, JAMA-J AM MED ASSOC, V242, P2070, DOI 10.1001/jama.242.19.2070; PFAFFENBACH DD, 1973, AM J OPHTHALMOL, V75, P66, DOI 10.1016/0002-9394(73)90653-3; PIGNOLI P, 1986, CIRCULATION, V74, P1399, DOI 10.1161/01.CIR.74.6.1399; PRICE DL, 1970, NEUROLOGY, V20, P1209, DOI 10.1212/WNL.20.12.1209; RAMIREZ G, 1978, ARCH INTERN MED, V138, P1430, DOI 10.1001/archinte.138.9.1430; RUSSELL RWR, 1983, VASCULAR DISEASE CTR, P394; SOLOWAY HB, 1964, ARCH NEUROL-CHICAGO, V11, P657, DOI 10.1001/archneur.1964.00460240089012; STURGILL BC, 1963, ARCH PATHOL, V76, P189; TOUBOUL PJ, 1992, J HYPERTENS, V10, pS37, DOI 10.1097/00004872-199207005-00006; TOYODA K, 1992, STROKE, V23, P1056, DOI 10.1161/01.STR.23.8.1056; TUNICK PA, 1990, AM HEART J, V120, P658, DOI 10.1016/0002-8703(90)90024-R; TUNICK PA, 1991, ANN INTERN MED, V115, P423, DOI 10.7326/0003-4819-115-6-423; TUNICK PA, 1992, AM HEART J, V124, P239; WINTER WJ, 1957, ARCH PATHOL, V64, P137; 1972, NEW ENGL J MED, V286, P1146; 1967, NEW ENGL J MED, V276, P1368; 1990, SAS USERS GUIDE, V1	39	722	742	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 1	1994	331	22					1474	1479		10.1056/NEJM199412013312202	http://dx.doi.org/10.1056/NEJM199412013312202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU866	7969297	Bronze			2022-12-01	WOS:A1994PU86600002
J	TUSCHL, T; GOHLKE, C; JOVIN, TM; WESTHOF, E; ECKSTEIN, F				TUSCHL, T; GOHLKE, C; JOVIN, TM; WESTHOF, E; ECKSTEIN, F			3-DIMENSIONAL MODEL FOR THE HAMMERHEAD RIBOZYME BASED ON FLUORESCENCE MEASUREMENTS	SCIENCE			English	Article							RESONANCE ENERGY-TRANSFER; 4-WAY DNA JUNCTION; RNA; CLEAVAGE; PREDICTIONS; PARAMETERS	For the understanding of the catalytic function of the RNA hammerhead ribozyme, a three-dimensional model is essential but neither a crystal nor a solution structure has been available. Fluorescence resonance energy transfer (FRET) was used to study the structure of the ribozyme in solution in order to establish the relative spatial orientation of the three constituent Watson-Crick base-paired helical segments. Synthetic constructs were labeled with the fluorescence donor (5-carboxyfluorescein) and acceptor (5-carboxytetramethylrhodamine) located at the ends of the strands constituting the ribozyme molecule. The acceptor helix in helix pairs I and III and in II and III was varied in length from 5 to 11 and 5 to 9 base pairs, respectively, and the FRET efficiencies were determined and correlated with a reference set of labeled RNA duplexes. The FRET efficiencies were predicted on the basis of vector algebra analysis, as a function of the relative helical orientations in the ribozyme constructs, and compared with experimental values. The data were consistent with a Y-shaped arrangement of the ribozyme with helices I and II in close proximity and helix III pointing away. These orientational constraints were used for molecular modeling of a three-dimensional structure of the complete ribozyme.	MAX PLANCK INST EXPTL MED, D-37075 GOTTINGEN, GERMANY; INST MOLEK BIOTECHNOL EV, MOLEK BIOL ABT, D-07745 JENA, GERMANY; MAX PLANCK INST BIOPHYS CHEM, D-37077 GOTTINGEN, GERMANY; CNRS, INST BIOL MOLEC & CELLULAIRE, F-67084 STRASBOURG, FRANCE	Max Planck Society; Max Planck Society; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								ALTMAN S, 1993, P NATL ACAD SCI USA, V90, P10898, DOI 10.1073/pnas.90.23.10898; ARNOTT S, 1972, BIOCHEM BIOPH RES CO, V48, P1392, DOI 10.1016/0006-291X(72)90867-4; AURUP H, 1994, NUCLEIC ACIDS RES, V22, P20, DOI 10.1093/nar/22.1.20; BRATTY J, 1993, BIOCHIM BIOPHYS ACTA, V1216, P345, DOI 10.1016/0167-4781(93)90001-T; BRUENING G, 1989, METHOD ENZYMOL, V180, P546; CARDULLO RA, 1988, P NATL ACAD SCI USA, V85, P8790, DOI 10.1073/pnas.85.23.8790; CLEGG RM, 1993, P NATL ACAD SCI USA, V90, P2994, DOI 10.1073/pnas.90.7.2994; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; CLEGG RM, 1992, BIOCHEMISTRY-US, V31, P4846, DOI 10.1021/bi00135a016; Crooke S, 1993, ANTISENSE RES APPLIC, P83; DENMAN RB, 1993, BIOTECHNIQUES, V15, P1090; F?rster, 1951, FLUORESZENZ ORGANISC; FEDOR MJ, 1992, BIOCHEMISTRY-US, V31, P12042, DOI 10.1021/bi00163a012; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; FU DJ, 1993, BIOCHEMISTRY-US, V32, P10629, DOI 10.1021/bi00091a013; GAST FU, 1994, BIOCHEMISTRY-US, V33, P1788, DOI 10.1021/bi00173a023; GOHIKE C, IN PRESS P NATL ACAD; Goldstein H., 1980, CLASSICAL MECH, Vsecond; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; HERTEL KJ, 1994, BIOCHEMISTRY-US, V33, P3374, DOI 10.1021/bi00177a031; HEUS HA, 1991, J MOL BIOL, V217, P113, DOI 10.1016/0022-2836(91)90615-D; HODGSON RAJ, 1994, NUCLEIC ACIDS RES, V22, P1620, DOI 10.1093/nar/22.9.1620; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; JEFFRIES AC, 1989, NUCLEIC ACIDS RES, V17, P1371, DOI 10.1093/nar/17.4.1371; KEESE P, 1987, VIROIDS VIROID LIKE, P1; KIM R, 1994, ACTA CRYSTALLOGR D, V50, P290, DOI 10.1107/S0907444993013071; Lakowicz J. R., 2006, PRINCIPLES FLUORESCE, DOI 10.1007/978-0-387-46312-4; LONG DM, 1993, FASEB J, V7, P25, DOI 10.1096/fasebj.7.1.8422971; MARSCHALL P, IN PRESS CELL MOL NE; MASSIRE C, 1994, J MOL GRAPHICS, V12, P201, DOI 10.1016/0263-7855(94)80088-X; MEI HY, 1989, P NATL ACAD SCI USA, V86, P9727, DOI 10.1073/pnas.86.24.9727; MERGNY JL, 1994, NUCLEIC ACIDS RES, V22, P920, DOI 10.1093/nar/22.6.920; MORRISON LE, 1993, BIOCHEMISTRY-US, V32, P3095, DOI 10.1021/bi00063a022; MURCHIE AIH, 1989, NATURE, V341, P763, DOI 10.1038/341763a0; OZAKI H, 1992, NUCLEIC ACIDS RES, V20, P5205, DOI 10.1093/nar/20.19.5205; PLEY HW, 1993, J BIOL CHEM, V268, P19656; ROSSI JJ, 1992, AIDS RES HUM RETROV, V8, P183, DOI 10.1089/aid.1992.8.183; SIXOU S, IN PRESS DNA INTERAC; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; THEISEN P, 1992, TETRAHEDRON LETT, V33, P5033, DOI 10.1016/S0040-4039(00)61181-4; TUSCHL T, 1993, P NATL ACAD SCI USA, V90, P6991, DOI 10.1073/pnas.90.15.6991; TUSCHL T, 1993, BIOCHEMISTRY-US, V32, P11658, DOI 10.1021/bi00094a023; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8	43	212	218	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	1994	266	5186					785	789		10.1126/science.7973630	http://dx.doi.org/10.1126/science.7973630			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973630				2022-12-01	WOS:A1994PP75300034
J	OKANO, T; YOSHIZAWA, T; FUKADA, Y				OKANO, T; YOSHIZAWA, T; FUKADA, Y			PINOPSIN IS A CHICKEN PINEAL PHOTORECEPTIVE MOLECULE	NATURE			English	Article							N-ACETYLTRANSFERASE ACTIVITY; CONE VISUAL PIGMENTS; GLAND; RHODOPSIN; INVITRO; IDENTIFICATION; CULTURE; RETINA; CLOCK; LIGHT	IN avian pinealocytes, an environmental light signal resets the phase of the endogenous circadian pacemaker that controls the rhythmic production of melatonin(1-6). Investigation of the pineal phototransduction pathway should therefore reveal the molecular mechanism of the biological clock. The presence of rhodopsin-like photoreceptive pigment(4,5,7-9), transducin-like immunoreaction(10), and cyclic GMP-dependent cation-channel activity(11) in the avian pinealocytes suggests that there is a similarity between retinal rod cells and pinealocytes in the phototransduction pathway. We have now cloned chicken pineal cDNA encoding the photoreceptive molecule, which is 43-48% identical in amino-acid sequence to vertebrate retinal opsins. Pineal opsin, produced by transfection of complementary DNA into cultured cells, was reconstituted with 11-cis-retinal, resulting in formation of a blue-sensitive pigment (lambda(max) approximate to 470 nm). In the fight of this functional evidence and because the gene is specifically expressed only in the pineal gland, we conclude that it is a pineal photosensor and name it pinopsin.	OSAKA SANGYO UNIV, FAC ENGN, DEPT INFORMAT SYST ENGN, DAITO, OSAKA 574, JAPAN; UNIV TOKYO, COLL ARTS & SCI, DEPT PURE & APPL SCI, BUNKYO KU, TOKYO 153, JAPAN	University of Tokyo			吉孝, 深田/G-5090-2014	Okano, Toshiyuki/0000-0001-6740-6265				ARAKI M, 1992, DEV BRAIN RES, V65, P85, DOI 10.1016/0165-3806(92)90011-K; BINKLEY SA, 1978, SCIENCE, V202, P1198, DOI 10.1126/science.214852; DEGUCHI T, 1981, NATURE, V290, P706, DOI 10.1038/290706a0; DEGUCHI T, 1979, SCIENCE, V203, P1245, DOI 10.1126/science.424750; DRYER SE, 1991, NATURE, V353, P756, DOI 10.1038/353756a0; FOSTER RG, 1989, J COMP PHYSIOL A, V165, P553, DOI 10.1007/BF00611241; KASAL CA, 1979, SCIENCE, V203, P656, DOI 10.1126/science.569904; KOJIMA D, 1992, P NATL ACAD SCI USA, V89, P6841, DOI 10.1073/pnas.89.15.6841; KUWATA O, 1990, FEBS LETT, V272, P128, DOI 10.1016/0014-5793(90)80465-U; MASUDA H, 1994, TISSUE CELL, V26, P101, DOI 10.1016/0040-8166(94)90086-8; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P9746, DOI 10.1021/bi00493a034; OKANO T, 1989, BIOCHEMISTRY-US, V28, P8848, DOI 10.1021/bi00448a025; OKANO T, 1992, P NATL ACAD SCI USA, V89, P5932, DOI 10.1073/pnas.89.13.5932; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 1989, MOL CLONING LAB MANU; SUN JH, 1991, NEUROSCI LETT, V133, P97, DOI 10.1016/0304-3940(91)90066-3; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; TAKAO M, 1988, VISION RES, V28, P471, DOI 10.1016/0042-6989(88)90169-1; VANVEEN T, 1986, P NATL ACAD SCI USA, V83, P912; WALLINGFORD JC, 1988, EXP EYE RES, V46, P909, DOI 10.1016/S0014-4835(88)80042-3; ZATZ M, 1988, BRAIN RES, V453, P63, DOI 10.1016/0006-8993(88)90143-6	21	268	275	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 3	1994	372	6501					94	97		10.1038/372094a0	http://dx.doi.org/10.1038/372094a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969427				2022-12-01	WOS:A1994PQ34800080
J	FELTON, CV; CROOK, D; DAVIES, MJ; OLIVER, MF				FELTON, CV; CROOK, D; DAVIES, MJ; OLIVER, MF			DIETARY POLYUNSATURATED FATTY-ACIDS AND COMPOSITION OF HUMAN AORTIC PLAQUES	LANCET			English	Note							CORONARY HEART-DISEASE	How long-term dietary intake of essential fatty acids affects the fatty-acid content of aortic plaques is not clear. We compared the fatty-acid composition of aortic plaques with that of post-mortem serum and adipose tissue, in which essential fatty-acid content reflects dietary intake. Positive associations were found between serum and plaque omega 6 (r=0.75) and omega 3 (r=0.93) polyunsaturated fatty acids, and monounsaturates (r=0.70), and also between adipose tissue and plaque omega 6 polyunsaturated fatty acids (r=0.89). No associations were found with saturated fatty acids. These findings imply a direct influence of dietary polyunsaturated fatty acids on aortic plaque formation and suggest that current trends favouring increased intake of polyunsaturated fatty acids should be reconsidered.	ST GEORGE HOSP,SCH MED,BRITISH HEART FDN,CARDIOVASC PATHOL UNIT,LONDON,ENGLAND; NATL HEART & LUNG INST,LONDON,ENGLAND	St Georges University London; University of London; University College London; UCL Medical School; Imperial College London	FELTON, CV (corresponding author), WYNN INST METAB RES,21 WELLINGTON RD,LONDON NW8 9SQ,ENGLAND.		Davies, Michael/GWV-2527-2022	Crook, David/0000-0002-9587-3730				ELVEVOLL EO, 1990, ATHEROSCLEROSIS, V81, P71, DOI 10.1016/0021-9150(90)90060-V; Felton CV, 1993, J VASC MED BIOL, V4, P228; HEFFERNAN AGA, 1963, CLIN SCI, V25, P423; HEGSTED DM, 1993, AM J CLIN NUTR, V57, P875, DOI 10.1093/ajcn/57.6.875; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; RAPP JH, 1991, ARTERIOSCLER THROMB, V11, P903, DOI 10.1161/01.ATV.11.4.903; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; ULBRICHT TLV, 1991, LANCET, V338, P985, DOI 10.1016/0140-6736(91)91846-M; WOOD DA, 1992, CORONARY HEART DISEA, P179	9	29	34	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 29	1994	344	8931					1195	1196		10.1016/S0140-6736(94)90511-8	http://dx.doi.org/10.1016/S0140-6736(94)90511-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN803	7934543				2022-12-01	WOS:A1994PN80300012
J	JOHNSON, AG				JOHNSON, AG			SURGERY AS A PLACEBO	LANCET			English	Article							TRIAL				JOHNSON, AG (corresponding author), UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,SURG UNIT,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND.							ADAMS R, 1958, NEW ENGL J MED, V258, P113, DOI 10.1056/NEJM195801162580302; AITCHISON M, 1989, BRIT J UROL, V64, P478, DOI 10.1111/j.1464-410X.1989.tb05280.x; Balint M., 1957, DOCTOR; BARKER AT, 1984, LANCET, V1, P994; BARKER AT, 1985, PHYSIOTHERAPY, V12, P500; BEECHER HK, 1961, JAMA-J AM MED ASSOC, V176, P1102, DOI 10.1001/jama.1961.63040260007008; COBB LA, 1959, NEW ENGL J MED, V260, P1115, DOI 10.1056/NEJM195905282602204; GOLIGHER JC, 1979, ANN SURG, V189, P18, DOI 10.1097/00000658-197901000-00004; GOTZSCHE PC, 1994, LANCET, V344, P925; MAJEED AW, 1994, APR ASS SURG GB IR A; MCMAHON AJ, 1994, LANCET, V343, P135, DOI 10.1016/S0140-6736(94)90932-6; NICHOLL JP, 1992, LANCET, V340, P801, DOI 10.1016/0140-6736(92)92682-6; TATE JJT, 1993, LANCET, V342, P633, DOI 10.1016/0140-6736(93)91757-D; WOLF S, 1959, PHARMACOL REV, V11, P689	14	120	121	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1994	344	8930					1140	1142		10.1016/S0140-6736(94)90637-8	http://dx.doi.org/10.1016/S0140-6736(94)90637-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN066	7934500				2022-12-01	WOS:A1994PN06600016
J	GRIGORIADIS, AE; WANG, ZQ; CECCHINI, MG; HOFSTETTER, W; FELIX, R; FLEISCH, HA; WAGNER, EF				GRIGORIADIS, AE; WANG, ZQ; CECCHINI, MG; HOFSTETTER, W; FELIX, R; FLEISCH, HA; WAGNER, EF			C-FOS - A KEY REGULATOR OF OSTEOCLAST-MACROPHAGE LINEAGE DETERMINATION AND BONE REMODELING	SCIENCE			English	Article							COLONY-STIMULATING FACTOR; MONOCLONAL-ANTIBODIES; TRANSGENIC MICE; CELL-POPULATION; DIFFERENTIATION; EXPRESSION; RESORPTION; MARROW; MOUSE; PROLIFERATION	Mice lacking the proto-oncogene c-fos develop the bone disease osteopetrosis. Fos mutant mice were found to have a block in the differentiation of bone-resorbing osteoclasts that was intrinsic to hematopoietic cells. Bone marrow transplantation rescued the osteopetrosis, and ectopic c-fos expression overcame this differentiation block. The lack of Fos also caused a lineage shift between osteoclasts and macrophages that resulted in increased numbers of bone marrow macrophages. These results identify Fos as a key regulator of osteoclast-macrophage lineage determination in vivo and provide insights into the molecular mechanisms underlying metabolic bone diseases.	RES INST MOLEC PATHOL, A-1030 VIENNA, AUSTRIA; UNIV BERN, DEPT PATHOPHYSIOL, CH-3010 BERN, SWITZERLAND	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University of Bern				Hofstetter, Wilhelm/0000-0003-0126-8423; Wagner, Erwin F/0000-0001-7872-0196				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Aubin Jane E., 1993, P1; CECCHINI MG, 1994, DEVELOPMENT, V120, P1357; CECCHINI MG, UNPUB; CHAMBERS TJ, 1989, BONE MINERAL RES, V6, P1; FELIX R, 1990, ENDOCRINOLOGY, V127, P2592, DOI 10.1210/endo-127-5-2592; FELIX R, 1990, J BONE MINER RES, V5, P781; FELIX R, UNPUB; GRIGORIADIS AE, 1988, J CELL BIOL, V106, P2139, DOI 10.1083/jcb.106.6.2139; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GRIGORIADIS AE, UNPUB; Grigoriadis Agamemnon E., 1993, P497; HATTERSLEY G, 1991, BIOCHEM BIOPH RES CO, V177, P526, DOI 10.1016/0006-291X(91)92015-C; HO MK, 1982, J IMMUNOL, V128, P1221; HOFSTETTER W, 1992, P NATL ACAD SCI USA, V89, P9637, DOI 10.1073/pnas.89.20.9637; HOFSTETTER W, UNPUB; HOYLAND J, 1994, J BONE MINER RES, V9, P1191; HUME DA, 1984, J CELL SCI, V66, P189; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KERBY JA, 1992, J BONE MINER RES, V7, P353; KRATOCHWIL K, 1989, CELL, V57, P807, DOI 10.1016/0092-8674(89)90795-2; LEE MY, 1992, BLOOD, V80, P1710; LEENEN PJM, 1990, EUR J IMMUNOL, V20, P27, DOI 10.1002/eji.1830200105; LLIANG J, UNPUB; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; MARKS SC, 1989, AM J MED GENET, V34, P43, DOI 10.1002/ajmg.1320340110; MARKS SC, 1984, CLIN ORTHOP RELAT R, P239; MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; MULLER R, 1994, FOS JUN FAMILIES TRA, P189; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NIIDA S, 1994, J BONE MINER RES, V9, P873; OKADA S, 1994, MOL CELL BIOL, V14, P382, DOI 10.1128/MCB.14.1.382; REPONEN P, 1994, J CELL BIOL, V124, P1091, DOI 10.1083/jcb.124.6.1091; RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454; RUTHER U, 1989, ONCOGENE, V4, P861; SAHNI M, 1993, J CLIN INVEST, V91, P2004, DOI 10.1172/JCI116422; SANDBERG M, 1988, DEVELOPMENT, V102, P461; SANDBERG M, 1988, DEV BIOL, V130, P324, DOI 10.1016/0012-1606(88)90438-1; SCHEVEN BAA, 1986, ANAT RECORD, V214, P418, DOI 10.1002/ar.1092140413; SCHEVEN BAA, 1986, NATURE, V321, P79, DOI 10.1038/321079a0; SHERR CJ, 1990, BLOOD, V75, P1; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; TAKAHASHI N, 1994, DEV BIOL, V163, P212, DOI 10.1006/dbio.1994.1137; TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; WALKER DG, 1975, SCIENCE, V190, P784, DOI 10.1126/science.1105786; WANG ZQ, 1993, J BONE MINER RES, V8, P839; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WUCHERPFENNIG AL, 1994, J BONE MINER RES, V9, P549	56	1027	1057	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 21	1994	266	5184					443	448		10.1126/science.7939685	http://dx.doi.org/10.1126/science.7939685			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7939685				2022-12-01	WOS:A1994PN27200037
J	GOURLAY, SG; FORBES, A; MARRINER, T; PETHICA, D; MCNEIL, JJ				GOURLAY, SG; FORBES, A; MARRINER, T; PETHICA, D; MCNEIL, JJ			PROSPECTIVE-STUDY OF FACTORS PREDICTING OUTCOME OF TRANSDERMAL NICOTINE TREATMENT IN SMOKING CESSATION	BRITISH MEDICAL JOURNAL			English	Article							QUITTING SMOKING; UNITED-STATES; CONTROLLED TRIAL; RELAPSE; HEAVINESS; CIGARETTE; REASONS; PATCHES; SMOKERS	Objective-To assess the factors associated with cessation of smoking with transdermal nicotine and brief behavioural counselling. Design-Interviews, treatment, and follow up for 26 weeks. Subjects-1481 subjects recruited by mass media publicity who smoked greater than or equal to 15 cigarettes a day and were motivated to stop smoking. Interventions-Twelve weeks' treatment with transdermal nicotine and brief behavioural counselling at monthly visits. Main outcome measure-Sustained smoking cessation for the 28 days before the visit at week 26 verified by expired carbon monoxide concentrations. The logistic regression analysis included all subjects. Results-Most subjects were dependent on nicotine, and the mean (SD) number of cigarettes smoked a day was 32 (12). Overall, 316/1481 subjects (21.3%) stopped smoking. Factors associated with stopping were being male (adjusted odds ratio 2.0; 95% confidence interval 1.5 to 2.7), age greater than or equal to 40 years (1.5; 1.1 to 2.0), living with a spouse or partner (1.5; 1.1 to 2.1), motivation (''want to quit'' 1.7; 1.2 to 2.3), and concern about weight gain (1.7; 1.3 to 2.2). Negative associations were smoking marijuana (0.4; 0.2 to 0.8) and the presence of other smokers in the household (0.8; 0.6 to 0.9). Almost all subjects who smoked three or more cigarettes in the first four weeks of treatment resumed smoking in the long term (525/547, 96%). Conclusions-Age, sex, marital status (living with a spouse or partner), motivation, concern about weight gain, recent marijuana smoking, and other smokers in the household were baseline factors associated with differences in outcome of smoking cessation attempts. Smoking three or more cigarettes in the first few weeks after stopping strongly predicted long term relapse.	CIBA GEIGY NEW ZEALAND,AUCKLAND,NEW ZEALAND		GOURLAY, SG (corresponding author), ALFRED HOSP,MONASH MED SCH,DEPT SOCIAL & PREVENT MED,PRAHRAN,VIC 3181,AUSTRALIA.		McNeil, John/L-6440-2019	McNeil, John/0000-0002-1049-5129; Forbes, Andrew/0000-0003-4269-914X				ABRAMS DB, 1992, PREV MED, V21, P679, DOI 10.1016/0091-7435(92)90075-S; Beck A. T., 1960, ARCH GEN PSYCHIAT, V4, P53, DOI DOI 10.1001/ARCHPSYC.1961.01710120031004; Beck A.T., 1987, BECK DEPRESSION INVE; BLONDAL T, 1989, ARCH INTERN MED, V149, P1818, DOI 10.1001/archinte.149.8.1818; COAMBS RB, 1992, AM J EPIDEMIOL, V135, P240, DOI 10.1093/oxfordjournals.aje.a116277; Collins R L, 1990, J Subst Abuse, V2, P389; DUNCAN CL, 1992, J GEN INTERN MED, V7, P398, DOI 10.1007/BF02599155; FAGERSTROM KO, 1982, J BEHAV MED, V5, P343, DOI 10.1007/BF00846161; FIORE MC, 1990, JAMA-J AM MED ASSOC, V263, P2760, DOI 10.1001/jama.263.20.2760; FREUND KM, 1992, AM J EPIDEMIOL, V135, P957, DOI 10.1093/oxfordjournals.aje.a116407; GARVEY AJ, 1992, ADDICT BEHAV, V17, P367, DOI 10.1016/0306-4603(92)90042-T; GOURLAY S, 1994, MED J AUSTRALIA, V160, P152, DOI 10.5694/j.1326-5377.1994.tb126568.x; GOURLAY SG, 1990, MED J AUSTRALIA, V153, P699, DOI 10.5694/j.1326-5377.1990.tb126327.x; HATZIANDREU EJ, 1990, J NATL CANCER I, V82, P1402, DOI 10.1093/jnci/82.17.1402; HEATHERTON TF, 1989, BRIT J ADDICT, V84, P791; KABAT GC, 1987, AM J PUBLIC HEALTH, V77, P1301, DOI 10.2105/AJPH.77.10.1301; KENFORD SL, 1994, JAMA-J AM MED ASSOC, V271, P589, DOI 10.1001/jama.271.8.589; KILLEN JD, 1992, J CONSULT CLIN PSYCH, V60, P797, DOI 10.1037/0022-006X.60.5.797; NORREGAARD J, 1993, PREV MED, V22, P261, DOI 10.1006/pmed.1993.1021; OLSEN J, 1993, SCAND J SOC MED, V3, P197; ORLEANS CT, 1994, JAMA-J AM MED ASSOC, V271, P601, DOI 10.1001/jama.271.8.601; PIERCE JP, 1989, JAMA-J AM MED ASSOC, V261, P61, DOI 10.1001/jama.261.1.61; RUSSELL MAH, 1993, BRIT MED J, V306, P1308, DOI 10.1136/bmj.306.6888.1308; SACHS DPL, 1993, ARCH INTERN MED, V153, P1881, DOI 10.1001/archinte.153.16.1881; SALIVE ME, 1992, AM J PUBLIC HEALTH, V82, P1268, DOI 10.2105/AJPH.82.9.1268; SILAGY C, 1994, LANCET, V343, P139, DOI 10.1016/S0140-6736(94)90933-4; TANG JL, 1994, BRIT MED J, V308, P21, DOI 10.1136/bmj.308.6920.21; VANREEK J, 1988, BRIT J ADDICT, V83, P588; 1993, BRIT MED J, V306, P1304; 1991, GOOD CLIN RES PRACTI; 1991, EGRET EPIDEMIOLOGICA; 1988, SAS USERS GUIDE STAT	32	155	155	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 1	1994	309	6958					842	846		10.1136/bmj.309.6958.842	http://dx.doi.org/10.1136/bmj.309.6958.842			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PK501	7950614	Green Published			2022-12-01	WOS:A1994PK50100021
J	COPE, H; DAVID, A; PELOSI, A; MANN, A				COPE, H; DAVID, A; PELOSI, A; MANN, A			PREDICTORS OF CHRONIC POSTVIRAL FATIGUE	LANCET			English	Article							GENERAL-PRACTICE; MUSCLE	We set out to determine the relation between a general practitioner (GP) diagnosis of viral illness and development of chronic fatigue 6 months later. 618 subjects who attended GPs clinics in London, south, and southwest England and who received a diagnosis of viral illness were followed prospectively and fatigue was assessed by questionnaire after 6 months. At presentation, GPs recorded fatigue in 62.6% of subjects, usually since the onset of symptoms. 502 (81.2%) subjects completed the 6-month questionnaire, of whom 88 (17.5%) met criteria for chronic fatigue and 65 (12.9%) had no reported fatigue before the viral illness. Compared with a similar group of non-postviral GP attenders, the risk ratio for chronic fatigue in the present cohort was 1.45 (95% CI 1.14-2.04). Infective symptoms did not predict fatigue 6 months later. Psychiatric morbidity, belief in vulnerability to viruses, and attributional style at initial presentation were all associated with self-designated postviral fatigue. Logistic regression showed that somatic attributional style, less definite diagnosis by the GP, and sick certification were the only significant predictors of chronic fatigue after viral infection when other factors were controlled for. Chronic severe fatigue 6 months after GP-diagnosed viral illness is related to symptom-attributional style and doctor behaviour, rather than to features of the viral illness. Some subjects with apparent postviral fatigue had complained of tiredness before their presentation with a viral illness.	INST PSYCHIAT,DEPT PSYCHOL MED,LONDON SE5 8AF,ENGLAND; INST PSYCHIAT,EPIDEMIOL & GEN PRACTICE SECT,LONDON SE5 8AF,ENGLAND; HALRMYRES HOSP,GLASGOW,LANARK,SCOTLAND	University of London; King's College London; University of London; King's College London			David, Anthony S/C-1315-2011; David, Anthony/O-1750-2019	David, Anthony S/0000-0003-0967-774X; David, Anthony/0000-0003-0967-774X; Pelosi, Anthony/0000-0002-5501-2661				BARTLETT FC, 1932, REMEMBERING, P20; BRUCEJONES WDA, 1994, PSYCHOL MED, V24, P651, DOI 10.1017/S003329170002780X; COHEN S, 1993, J PERS SOC PSYCHOL, V64, P131, DOI 10.1037/0022-3514.64.1.131; COPE H, 1994, J PSYCHOSOM RES, V38, P89, DOI 10.1016/0022-3999(94)90082-5; DAVID A, 1990, BMJ-BRIT MED J, V301, P1199, DOI 10.1136/bmj.301.6762.1199; DAVID AS, 1988, BRIT MED J, V296, P696, DOI 10.1136/bmj.296.6623.696; DAVID AS, 1991, BRIT J HOSP MED, V45, P158; DAVID AS, 1991, BRIT MED BULL, V47, P966, DOI 10.1093/oxfordjournals.bmb.a072524; Goldthorpe J. H., 1974, SOCIAL GRADING OCCUP; GOW JW, 1991, BRIT MED J, V302, P692, DOI 10.1136/bmj.302.6778.692; GOW JW, 1992, J CLIN PATHOL, V45, P1058, DOI 10.1136/jcp.45.12.1058; GOW JW, 1994, IN PRESS CLIN INFECT; HANSEN V, 1989, BRIT MED J, V299, P85, DOI 10.1136/bmj.299.6691.85; IMBODEN J, 1961, ARCH INTERN MED, V108, P115; KATON WJ, 1991, J GENERAL INT MED, V6, P227; KLEINMANN A, 1993, CIBA F S, V173; MCDONALD E, 1993, PSYCHOL MED, V23, P987, DOI 10.1017/S0033291700026453; MILLER NA, 1991, BMJ-BRIT MED J, V302, P140, DOI 10.1136/bmj.302.6769.140; PAWLIKOWSKA T, 1994, BRIT MED J, V308, P763, DOI 10.1136/bmj.308.6931.763; Ramsay M, 1986, POSTVIRAL FATIGUE SY; RIDSDALE L, 1993, BMJ-BRIT MED J, V307, P103, DOI 10.1136/bmj.307.6896.103; ROBBINS JM, 1991, PSYCHOL MED, V21, P1029, DOI 10.1017/S0033291700030026; RUTHERFORD OM, 1991, J NEUROL NEUROSUR PS, V54, P961, DOI 10.1136/jnnp.54.11.961; SCHLUEDERBERG A, 1992, ANN INTERN MED, V117, P325, DOI 10.7326/0003-4819-117-4-325; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; WESSELY S, 1990, PSYCHOL MED, V20, P35, DOI 10.1017/S0033291700013210; WESSELY S, 1989, J NEUROL NEUROSUR PS, V52, P940, DOI 10.1136/jnnp.52.8.940; WOOD GC, 1991, PSYCHOL MED, V21, P619, DOI 10.1017/S003329170002225X	28	102	104	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					864	868		10.1016/S0140-6736(94)92833-9	http://dx.doi.org/10.1016/S0140-6736(94)92833-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PH253	7916407				2022-12-01	WOS:A1994PH25300017
J	HOWIE, JGR; HEANEY, DJ; MAXWELL, M				HOWIE, JGR; HEANEY, DJ; MAXWELL, M			EVALUATING CARE OF PATIENTS REPORTING PAIN IN FUNDHOLDING PRACTICES	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; NHS; PATTERNS; COSTS	Objective-To compare quality of care between 1990 and 1992 in patients with self diagnosed joint pain. Design-Questionnaire and record based study. Subjects-Patients identified at consecutive consultations during two weeks in 1990, 1991, and 1992. Setting-Six practice groups in pilot fundholding scheme in Scotland. Main outcome measures-length of consultation; numbers referred or investigated or prescribed drugs; responses to questions about enablement and satisfaction. Results-About 15% of patients consulted with joint pain each year. 25% (316) of them had social problems in 1990 and 37% (370) in 1992; about a fifth wanted to discuss their social problems. Social problems were associated with a raised general health questionnaire score. The mean length of consultation for patients with pain was 7.6 min in 1990 and 7.7 min in 1992. Patients wishing to discuss social problems received longer consultations (8.5 min 1990; 10.4 min 1992); but other patients with social problems received shorter consultations (7.4 min; 7.2 min). The level of prescribing was stable but the proportion of patients having investigations or attending hospital fell significantly from 1990 to 1992 (31% to 24%; 31% to 13% respectively). Fewer patients responded ''much better'' to six questions about enablement in 1992 than in 1990. Enablement was better after longer than shorter consultations for patients with social problems. Conclusions-Quality of care for patients with pain has been broadly maintained in terms of consultation times. The effects of lower rates of investigation and referral need to be investigated further.			HOWIE, JGR (corresponding author), UNIV EDINBURGH,DEPT GEN PRACTICE,EDINBURGH EH8 9DX,SCOTLAND.			Maxwell, Margaret/0000-0003-3318-9500				BAIN J, 1993, BRIT MED J, V306, P1185, DOI 10.1136/bmj.306.6886.1185; BAIN J, 1992, BRIT MED J, V304, P971, DOI 10.1136/bmj.304.6832.971; BAIN J, 1991, BRIT MED J, V302, P771, DOI 10.1136/bmj.302.6779.771; BAZANGER I, 1989, SOC SCI MED, V29, P425; BOWIE C, 1994, BRIT J GEN PRACT, V44, P38; CORNEY R, 1994, BRIT J GEN PRACT, V44, P34; COULTER A, 1993, BRIT MED J, V306, P433, DOI 10.1136/bmj.306.6875.433; COULTER A, 1992, BRIT MED J, V304, P397, DOI 10.1136/bmj.304.6824.397; COULTER A, 1993, BRIT MED J, V307, P1186; CROOK J, 1984, PAIN, V18, P299, DOI 10.1016/0304-3959(84)90824-8; CRUMP BJ, 1991, BRIT MED J, V302, P1582, DOI 10.1136/bmj.302.6792.1582; DAY P, 1991, BRIT MED J, V303, P168, DOI 10.1136/bmj.303.6795.168; GLENNERSTER H, 1992, FOOTHOLD FUNDHOLDING; HOPTON JL, 1991, FAM PRACT, V8, P253, DOI 10.1093/fampra/8.3.253; Howie J G, 1993, Health Bull (Edinb), V51, P94; Howie J G, 1992, Health Bull (Edinb), V50, P316; HOWIE JGR, 1991, BRIT J GEN PRACT, V41, P48; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; NEWTON J, 1993, BRIT MED J, V306, P375, DOI 10.1136/bmj.306.6874.375; PURVES IN, 1993, BRIT MED J, V306, P496, DOI 10.1136/bmj.306.6876.496; 1986, MORBIDITY STATISTICS	21	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 17	1994	309	6956					705	710		10.1136/bmj.309.6956.705	http://dx.doi.org/10.1136/bmj.309.6956.705			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH407	7950524	Green Published			2022-12-01	WOS:A1994PH40700018
J	MORIN, PA; MOORE, JJ; CHAKRABORTY, R; JIN, L; GOODALL, J; WOODRUFF, DS				MORIN, PA; MOORE, JJ; CHAKRABORTY, R; JIN, L; GOODALL, J; WOODRUFF, DS			KIN SELECTION, SOCIAL-STRUCTURE, GENE FLOW, AND THE EVOLUTION OF CHIMPANZEES	SCIENCE			English	Article							HUMAN MITOCHONDRIAL-DNA; DINUCLEOTIDE REPEAT POLYMORPHISMS; CYTOCHROME-B SEQUENCE; D-LOOP REGION; PHYLOGENETIC-RELATIONSHIPS; NATURAL-POPULATIONS; COMMON ANCESTOR; LOCI; AMPLIFICATION; NUMBER	Hypotheses about chimpanzee social behavior, phylogeography, and evolution were evaluated by noninvasive genotyping of free-ranging individuals from 20 African sites. Degrees of relatedness among individuals in one community were inferred from allele-sharing at eight nuclear simple sequence repeat (SSR) loci. Males are related on the order of half-siblings, and homozygosity is significantly increased at several SSR loci compared to Hardy-Weinberg expectations. These data support the kin-selection hypothesis for the evolution of cooperation among males. Sequence variation patterns at two mitochondrial loci indicate historically high long-distance gene flow and clarify the relationships among three allopatric subspecies. The unexpectedly large genetic distance between the western subspecies, Pan troglodytes verus, and the other two subspecies suggests a divergence time of about 1.58 million years. This result, if confirmed at nuclear loci and supported by eco-behavioral data, implies that P. t. verus should be elevated to full species rank.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT ANTHROPOL, LA JOLLA, CA 92093 USA; UNIV TEXAS, GRAD SCH BIOMED SCI, CTR DEMOG & POPULAT GENET, HOUSTON, TX 77225 USA; JANE GOODALL INST USA, RIDGEFIELD, CT 06877 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Texas System			Klein, Richard G/B-5910-2009; Jin, Li/C-1468-2009; Morin, Phillip A/E-9515-2010; Jin, Li/M-5063-2019	Jin, Li/0000-0002-4546-2415; Morin, Phillip/0000-0002-3279-1519	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG000005] Funding Source: NIH RePORTER; NHGRI NIH HHS [1T32 HG00005-02] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BROWN AHD, 1980, GENETICS, V96, P523; BROWN WM, 1982, J MOL EVOL, V18, P225, DOI 10.1007/BF01734101; CHAKRABORTY R, 1994, HUM HERED, V44, P1, DOI 10.1159/000154181; CHAKRABORTY R, 1984, GENETICS, V108, P719; COPPENS Y, 1994, SCI AM, V270, P88, DOI 10.1038/scientificamerican0594-88; DEKA R, 1991, GENOMICS, V11, P83, DOI 10.1016/0888-7543(91)90104-M; DIRIENZO A, 1991, P NATL ACAD SCI USA, V88, P1597, DOI 10.1073/pnas.88.5.1597; EDWARDS A, 1992, GENOMICS, V12, P241, DOI 10.1016/0888-7543(92)90371-X; EDWARDS A, 1991, AM J HUM GENET, V49, P746; EPPLEN JT, 1991, EXPER SUPPL, V58, P50; FERRIS SD, 1981, P NATL ACAD SCI-BIOL, V78, P6319, DOI 10.1073/pnas.78.10.6319; FORAN DR, 1988, NUCLEIC ACIDS RES, V16, P5841, DOI 10.1093/nar/16.13.5841; Garza JC, 1992, MOL PHYLOGENET EVOL, V1, P202, DOI 10.1016/1055-7903(92)90016-A; GEFFEN E, 1992, J ZOOL, V228, P27, DOI 10.1111/j.1469-7998.1992.tb04430.x; GOODALL J, 1990, UNDERSTANDING CHIMPA, P360; Goodall J, 1986, CHIMPANZEES GOMBE, DOI DOI 10.1002/AJPA.1330730313; Groves C., 1989, THEORY HUMAN PRIMATE; GROVES CP, 1992, J HUM EVOL, V22, P327, DOI 10.1016/0047-2484(92)90063-F; GUO SW, 1992, BIOMETRICS, V48, P361, DOI 10.2307/2532296; Hamilton A.C., 1988, P13; HASEGAWA M, 1990, J MOL EVOL, V31, P113, DOI 10.1007/BF02109480; HIGUCHI R, 1984, NATURE, V312, P282, DOI 10.1038/312282a0; Hill W. C. O., 1969, P22; HOELZEL AR, 1991, MOL BIOL EVOL, V8, P475; HORAI S, 1992, J MOL EVOL, V35, P32, DOI 10.1007/BF00160258; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; KOCHER TD, 1991, EVOLUTION OF LIFE, P391; KUMAR S, 1994, COMPUT APPL BIOSCI, V10, P189; LI CC, 1976, 1ST COURSE POPULATIO; LITT M, 1989, AM J HUM GENET, V44, P397; LYNCH M, 1990, EVOLUTION, V44, P1725, DOI 10.1111/j.1558-5646.1990.tb05244.x; LYNCH M, 1992, P INT CO CONSERVATIO, P258; MERCURE A, 1993, EVOLUTION, V47, P1313, DOI 10.1111/j.1558-5646.1993.tb02157.x; MOON MA, 1993, NIH RES RESOURCES RE, V17, P7; MORIN PA, 1992, PATERNITY IN PRIMATES : GENETIC TESTS AND THEORIES, P63; MORIN PA, 1993, PRIMATES, V34, P347, DOI 10.1007/BF02382630; MORIN PA, 1992, P ROY SOC B-BIOL SCI, V249, P293, DOI 10.1098/rspb.1992.0117; MORIN PA, 1993, YEARB PHYS ANTHROPOL, V36, P179; MORIN PA, 1992, THESIS U CALIFORNIA; MORIN PA, IN PRESS MOL ECOL; MORIN PA, 1979, GREAT APES, P73; MORTON NE, 1992, P NATL ACAD SCI USA, V89, P2556, DOI 10.1073/pnas.89.7.2556; NEI M, 1992, MOL BIOL EVOL, V9, P1176; NEI M, 1978, GENETICS, V89, P583; NEI M, 1987, MOL EVOLUTIONARY GEN, P276; Nishida T., 1979, GREAT APES, P73; Nishida T., 1990, CHIMPANZEES MAHALE M; NORMARK BB, 1991, MOL BIOL EVOL, V8, P819; NOWAK RM, 1991, WALKERS MAMMALS WORL, V1; PESOLE G, 1992, MOL BIOL EVOL, V9, P587; Pusey A, 1979, GREAT APES, P465; PUSEY AE, 1980, ANIM BEHAV, V28, P543, DOI 10.1016/S0003-3472(80)80063-7; RIER KB, 1992, FACES FOREST; ROGERS J, 1993, J HUM EVOL, V25, P201, DOI 10.1006/jhev.1993.1044; RUANO G, 1992, MOL BIOL EVOL, V9, P575; RUVOLO M, 1993, MOL BIOL EVOL, V10, P1115; RUVOLO M, 1994, AM J PHYS ANTHROPOL, V94, P89, DOI 10.1002/ajpa.1330940108; RUVOLO M, 1993, SCIENCE, V260, P892; RUVOLO M, COMMUNICATION; RYDER OA, 1986, TRENDS ECOL EVOL, V1, P9, DOI 10.1016/0169-5347(86)90059-5; SAITOU N, 1991, AM J PHYS ANTHROPOL, V84, P75, DOI 10.1002/ajpa.1330840107; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SARICH VM, 1967, SCIENCE, V158, P1200, DOI 10.1126/science.158.3805.1200; SEAL US, 1986, PRIMATES ROAD SELF S, P47; Shea Brian T., 1993, P265; SHEA BT, 1988, J HUM EVOL, V17, P671, DOI 10.1016/0047-2484(88)90024-3; SMITH MF, 1991, MOL BIOL EVOL, V8, P85; Sokal Robert R., 1969, BIOMETRY; Spiess EB, 1989, GENES POPULATIONS; Stanley S. M., 1979, MACROEVOLUTION; STAUB KC, 1990, AM MALACOL BULL, V7, P93; STONEKING M, 1991, AM J HUM GENET, V48, P370; STRIER KB, 1993, J ZOO WILDLIFE MED, V24, P229; SWOFFORD DL, 1991, PAUP PHYLOGENETIC AN; TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI 10.1093/oxfordjournals.molbev.a040023; VANDENBUSSCHE RA, 1993, MOL BIOL EVOL, V10, P944; VANDENBUSSCHE RA, 1993, J MAMMAL, V74, P793, DOI 10.2307/1382304; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; Vineberg EO, 1991, LAST APE PYGMY CHIMP; WAKELEY J, 1994, MOL BIOL EVOL, V11, P436; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P6465, DOI 10.1093/nar/18.21.6465-a; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4034, DOI 10.1093/nar/18.13.4034; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4038, DOI 10.1093/nar/18.13.4038; WILLS C, IN PRESS EVOLUTION; WILSON AC, 1987, TRENDS GENET, V3, P241, DOI 10.1016/0168-9525(87)90257-5; WILSON AC, 1985, BIOL J LINN SOC, V26, P375, DOI 10.1111/j.1095-8312.1985.tb02048.x; Wilson DE, 1993, MAMMAL SPECIES WORLD; Woodford M. H., 1994, P178; WOODRUFF DS, 1993, PRIMATES, V34, P333, DOI 10.1007/BF02382629; WOODRUFF DS, 1990, J SCI SOC THAILAND, V16, P117; WOODRUFF DS, 1990, PRESERVATION VALUATI, P119; WRANGHAM RW, 1979, CURRENT PROBLEMS SOC, P481; WU CI, 1991, GENETICS, V127, P429; ZIHLMAN AL, 1978, NATURE, V275, P744, DOI 10.1038/275744a0; 1991, GLOBAL CAPTIVE ACTIO	98	424	441	1	121	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 26	1994	265	5176					1193	1201		10.1126/science.7915048	http://dx.doi.org/10.1126/science.7915048			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD422	7915048				2022-12-01	WOS:A1994PD42200025
J	WEISSMAN, JS; KASHI, Y; FENTON, WA; HORWICH, AL				WEISSMAN, JS; KASHI, Y; FENTON, WA; HORWICH, AL			GROEL-MEDIATED PROTEIN-FOLDING PROCEEDS BY MULTIPLE ROUNDS OF BINDING AND RELEASE OF NONNATIVE FORMS	CELL			English	Article							HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONE; ORNITHINE TRANSCARBAMYLASE; ESCHERICHIA-COLI; CENTRAL CAVITY; RHODANESE; INTERMEDIATE; HYDROLYSIS; TRANSLOCATION; PRECURSOR	The chaperonin GroEL is a ribosome-sized double-ring structure that assists in folding a diverse set of polypeptides. We have examined the fate of a polypeptide during a chaperonin-mediated folding reaction. Strikingly, we find that, upon addition of ATP and the cochaperonin GroES, polypeptide is released rapidly from GroEL in a predominantly nonnative conformation that can be trapped by mutant forms of GroEL that are capable of binding but not releasing substrate. Released polypeptide undergoes kinetic partitioning: a fraction completes folding while the remainder is rebound rapidly by other GroEL molecules. Folding appears to occur in an all-or-none manner, as proteolysis and tryptophan fluorescence indicate that after rebinding, polypeptide has the same structure as in the original complex. These observations suggest that GroEL functions by carrying out multiple rounds of binding aggregation-prone or kinetically trapped intermediates, maintaining them in an unfolded state, and releasing them to attempt to fold in solution.	YALE UNIV, SCH MED, BOYER CTR MOLEC MED, DEPT GENET, NEW HAVEN, CT 06510 USA	Yale University	WEISSMAN, JS (corresponding author), YALE UNIV, SCH MED, BOYER CTR MOLEC MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA.		Kashi, Yechezkel/D-5433-2013					ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BRIGGS MS, 1992, P NATL ACAD SCI USA, V89, P2017, DOI 10.1073/pnas.89.6.2017; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHAN HS, 1993, J CHEM PHYS, V99, P2116, DOI 10.1063/1.465277; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; DOERING D, 1992, THESIS MIT CAMBRIDGE; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; GAO Y, 1994, J CELL BIOL, V125, P989, DOI 10.1083/jcb.125.5.989; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOOGENRAAD NJ, 1980, ANAL BIOCHEM, V101, P97, DOI 10.1016/0003-2697(80)90045-7; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; ISHII N, 1992, FEBS LETT, V299, P169, DOI 10.1016/0014-5793(92)80240-H; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KALOUSEK F, 1978, J BIOL CHEM, V253, P3939; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIEFHABER T, 1992, PROTEINS, V12, P171, DOI 10.1002/prot.340120210; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MENDOZA JA, 1992, J BIOL CHEM, V267, P24648; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; MILLER DM, 1991, J BIOL CHEM, V266, P4686; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; TANDON S, 1989, J BIOL CHEM, V264, P9859; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; UDGAONKAR JB, 1990, P NATL ACAD SCI USA, V87, P8197, DOI 10.1073/pnas.87.21.8197; VLITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WANG Z, 1992, PROTEIN SCI, V1, P522; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	52	341	346	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 26	1994	78	4					693	702		10.1016/0092-8674(94)90533-9	http://dx.doi.org/10.1016/0092-8674(94)90533-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	7915201				2022-12-01	WOS:A1994PD69300017
J	GRINES, CL; WEAVER, WD				GRINES, CL; WEAVER, WD			TREATING MYOCARDIAL-INFARCTION - AND IMPORTANCE OF EARLY REPERFUSION	LANCET			English	Editorial Material							THROMBOLYSIS; ANGIOPLASTY		UNIV WASHINGTON, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	GRINES, CL (corresponding author), WILLIAM BEAUMONT HOSP, DEPT MED, DIV CARDIOL, ROYAL OAK, MI 48072 USA.							BADIMON L, 1991, TRENDS CARDIOVAS MED, V1, P261, DOI 10.1016/1050-1738(91)90032-A; BECKER RC, 1991, CARDIOLOGY, V79, P49, DOI 10.1159/000174860; Cannon Christopher P., 1993, Journal of the American College of Cardiology, V21, p136A; DEBONO DP, 1992, BRIT HEART J, V67, P122; GATENBY R, 1992, BMJ-BRIT MED J, V305, P548; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; HERLITZ J, 1992, EUR HEART J, V13, P171, DOI 10.1093/oxfordjournals.eurheartj.a060142; KLEIMAN NS, 1992, CIRCULATION, V86, P260; LIDON RM, 1994, CIRCULATION, V89, P1567, DOI 10.1161/01.CIR.89.4.1567; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; ROUX S, 1992, J AM COLL CARDIOL, V19, P671, DOI 10.1016/S0735-1097(10)80290-6; TCHENG JE, 1993, CIRCULATION, V88, P1; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1994, CIRCULATION, V89, P1557, DOI 10.1161/01.CIR.89.4.1557; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002; 1993, EUR HEART J        S, V14, P48	17	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 20	1994	344	8921					490	491		10.1016/S0140-6736(94)91893-7	http://dx.doi.org/10.1016/S0140-6736(94)91893-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7914609				2022-12-01	WOS:A1994PC53500004
J	YUEN, KY; WONG, SSY; TSANG, DNCT; CHAU, PY				YUEN, KY; WONG, SSY; TSANG, DNCT; CHAU, PY			SERODIAGNOSIS OF PENICILLIUM-MARNEFFEI INFECTION	LANCET			English	Note							HUMAN-IMMUNODEFICIENCY-VIRUS	Diagnosis of Penicillium marneffei infection is often made late. We evaluated an indirect immunofluorescent antibody test for P marneffei in serum from 103 patients with persistent fever and from 78 normal subjects. Germinating conidia (initial tissue-invasion phase) and yeast-hyphae (tissue multiplication phase) forms were used as antigen. All 8 documented P marneffei cases (8%) had an IgG titre of 160 or more; the other 95 patients and all the healthy controls had an IgG titre of 40 or below. Blood culture was positive in only 1 case with HIV infection. Biopsy and culture of tissues were necessary for confirmation in the other 7 cases. The test could provide rapid presumptive diagnosis and supplement conventional culture.	QUEEN ELIZABETH HOSP,KOWLOON,HONG KONG		YUEN, KY (corresponding author), UNIV HONG KONG,QUEEN MARY HOSP,DEPT MICROBIOL,UNIV PATHOL BLDG,POKFULAM RD,HONG KONG,HONG KONG.		Yuen, Kwok Yung/C-4465-2009; Wong, Samson/C-4446-2009	Yuen, Kwok-yung/0000-0002-2083-1552				DISALVO AF, 1973, AM J CLIN PATHOL, V60, P259; HILMARSDOTTIR I, 1993, J ACQ IMMUN DEF SYND, V6, P466; QUINDOS G, 1990, EUR J CLIN MICROBIOL, V9, P178, DOI 10.1007/BF01963834; SALTINI C, 1993, J INFECT DIS, V168, P1409, DOI 10.1093/infdis/168.6.1409; SEKHON AS, 1982, MYCOPATHOLOGIA, V77, P51, DOI 10.1007/BF00588658; SO SY, 1985, AM REV RESPIR DIS, V131, P662, DOI 10.1164/arrd.1985.131.4.662; SUPPARATPINYO K, 1992, CLIN INFECT DIS, V14, P871, DOI 10.1093/clinids/14.4.871; TSANG DNC, 1991, REV INFECT DIS, V13, P766; VIVIANI MA, 1993, EUR J EPIDEMIOL, V9, P79, DOI 10.1007/BF00463094; YUEN KY, 1992, J INFECTION, V25, P29, DOI 10.1016/0163-4453(92)93441-R	10	76	79	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 13	1994	344	8920					444	445		10.1016/S0140-6736(94)91771-X	http://dx.doi.org/10.1016/S0140-6736(94)91771-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7914566				2022-12-01	WOS:A1994PB76100011
J	CRANSTON, I; LOMAS, J; MARAN, A; MACDONALD, I; AMIEL, SA				CRANSTON, I; LOMAS, J; MARAN, A; MACDONALD, I; AMIEL, SA			RESTORATION OF HYPOGLYCEMIA AWARENESS IN PATIENTS WITH LONG-DURATION INSULIN-DEPENDENT DIABETES	LANCET			English	Article							NOCTURNAL HYPOGLYCEMIA; UNAWARENESS; COUNTERREGULATION; RESPONSES; SYMPTOMS; HUMANS; IDDM; NEUROENDOCRINE; REVERSIBILITY; PREVALENCE	Hypoglycaemia without warning is a dangerous complication of insulin-dependent diabetes mellitus and it limits the use of intensified insulin therapy to reduce chronic diabetic complications. To investigate the possibility of restoring awareness; symptomatic, cognitive, and hormonal responses to controlled hypoglycaemia were studied in insulin-dependent diabetic patients with long disease duration (6 with good glycaemic control and 6 with poor control) before and after hypoglycaemia avoidance. At the start of the study, all had loss of hypoglycaemia awareness. Responses to the initial challenge were small (pooled area under curve [AUC] adrenaline 5.75 [SE 0.07] nmol/L per 260 min, pooled AUC symptom score 80 [1.3]) and only started when plasma glucose was significantly lower than the 2.8 (0.1) mmol/L at which cognitive function deteriorated. After 4.1 (1.1) months' scrupulous hypoglycaemia avoidance, hormone and symptom responses to the challenge were increased (AUC adrenaline 15.9 [0.1] nmol/L per 260 min, p = 0.01; AUC symptom score 275 [7], p < 0.001), starting at plasma glucose concentrations significantly higher than that causing cognitive dysfunction. Glycosylated haemoglobin did not deteriorate significantly. We conclude that the normal hierarchy of subjective awareness before cognitive dysfunction during hypoglycaemia can be restored by avoiding hypoglycaemia. This is independent of disease duration or initial metabolic control.	CATTEDRA MALATTIE RICAMBIO, PADUA, ITALY; UNIV NOTTINGHAM, QUEENS MED CTR, DEPT PHYSIOL & PHARMACOL, NOTTINGHAM NG7 2RD, ENGLAND	University of Nottingham	CRANSTON, I (corresponding author), GUYS HOSP, METAB MED UNIT, LONDON SE1 9RT, ENGLAND.		Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285; Macdonald, Ian/0000-0002-7540-9850				AMIEL SA, 1991, DIABETES CARE, V14, P109, DOI 10.2337/diacare.14.2.109; AMIEL SA, 1987, DIABETES, V36, P518, DOI 10.2337/diabetes.36.4.518; BIGGERS DW, 1989, DIABETES, V38, P7, DOI 10.2337/diabetes.38.1.7; CASPARIE AF, 1985, DIABETES CARE, V8, P141, DOI 10.2337/diacare.8.2.141; CLARKE WL, 1991, DIABETES, V40, P680, DOI 10.2337/diabetes.40.6.680; COX D, 1993, DIABETES, V42, pA126; DCCT Res Grp, 1991, AM J MED, V90, P450, DOI 10.1016/0002-9343(91)80085-Z; FANELLI CG, 1993, DIABETES, V42, P1683, DOI 10.2337/diabetes.42.11.1683; GALE EAM, 1979, LANCET, V1, P1049; HELLER SR, 1991, DIABETES, V40, P223, DOI 10.2337/diabetes.40.2.223; HEPBURN DA, 1991, DIABETES CARE, V14, P949, DOI 10.2337/diacare.14.11.949; HEPBURN DA, 1990, DIABETIC MED, V7, P711, DOI 10.1111/j.1464-5491.1990.tb01475.x; LAGER I, 1986, DIABETIC MED, V3, P322, DOI 10.1111/j.1464-5491.1986.tb00772.x; LIU D, 1992, DIABETOLOGIA, V35, P287, DOI 10.1007/BF00400932; MACDONALD IA, 1985, J NEUROSCI METH, V13, P239, DOI 10.1016/0165-0270(85)90072-X; MARAN A, 1992, DIABETIC MED, V9, P765, DOI 10.1111/j.1464-5491.1992.tb01889.x; MARAN A, 1993, DIABETES, V42, pA17; MARAN A, 1994, DIABETIC MED, V11, P114; MAZLAN M, 1989, THESIS U LONDON LOND; MCCALL AL, 1986, AM J PHYSIOL, V251, pE442, DOI 10.1152/ajpendo.1986.251.4.E442; MITRAKOU A, 1993, NEW ENGL J MED, V329, P834, DOI 10.1056/NEJM199309163291203; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; NAGY RJ, 1992, DIABETES, V41, P69; RYDER RJ, 1980, BRIT MED J, V301, P783; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SJOBOM NC, 1989, DIABETOLOGIA, V32, P818; TCHOBROUTSKY G, 1981, DIABETOLOGIA, V21, P335; VENEMAN T, 1993, DIABETES, V42, P1233, DOI 10.2337/diabetes.42.9.1233; WIDOM B, 1990, DIABETOLOGIA, V33, P84; WISE JK, 1973, NEW ENGL J MED, V288, P487, DOI 10.1056/NEJM197303082881003	30	312	311	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 30	1994	344	8918					283	287		10.1016/S0140-6736(94)91336-6	http://dx.doi.org/10.1016/S0140-6736(94)91336-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ233	7914259				2022-12-01	WOS:A1994NZ23300005
J	HANENBERG, RS; ROJANAPITHAYAKORN, W; KUNASOL, P; SOKAL, DC				HANENBERG, RS; ROJANAPITHAYAKORN, W; KUNASOL, P; SOKAL, DC			IMPACT OF THAILAND HIV-CONTROL PROGRAM AS INDICATED BY THE DECLINE OF SEXUALLY-TRANSMITTED DISEASES	LANCET			English	Article								The Thai government began an HIV-control programme in 1989. The programme had the following parts: the government bought and distributed sufficient condoms to protect much of the commercial sex in the country; sanctions were brought against commercial sex establishments where condoms were not used consistently; and a media campaign bluntly advised men to use condoms with prostitutes. Between 1989 and 1993 the use of condoms in commercial sex in Thailand increased from 14 to 94%, according to surveys of prostitutes, and the number of cases of the five major sexually transmitted diseases declined by 79% in men. We estimate that sex acts with prostitutes where there was a risk of HIV transmission declined from about 2.6% in June, 1989, to about 1.6% in June, 1993. If condom use in commercial sex stays high, future cohorts of young men and women may experience lower HIV incidence rates than those of the recent past. However, although condom use is high, there are many more infected prostitutes than before and many infected men who will pass HIV to their wives.	FAMILY HLTH INT,RES TRIANGLE PK,NC 27709; MINIST PUBL HLTH,DEPT COMMUNICABLE DIS CONTROL,BANGKOK,THAILAND	Ministry of Public Health - Thailand								ROJANAPITHAYAKO.W, 1991, 100 PERCENT CONDOM P; ROJANAPITHAYAKO.W, 1993, 100 PERCENT CONDOM U; Ungchusak K., 1990, Thai AIDS Journal, V2, P45; Ungchusak K., 1989, Thai AIDS Journal, V1, P57; 1991, STATUS TRENDS AIDS E	5	347	348	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					243	245		10.1016/S0140-6736(94)93004-X	http://dx.doi.org/10.1016/S0140-6736(94)93004-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913163				2022-12-01	WOS:A1994NY06000016
J	SYM, M; ENGEBRECHT, J; ROEDER, GS				SYM, M; ENGEBRECHT, J; ROEDER, GS			ZIP1 IS A SYNAPTONEMAL COMPLEX PROTEIN REQUIRED FOR MEIOTIC CHROMOSOME SYNAPSIS	CELL			English	Article							DNA TOPOISOMERASE-II; AMINO-ACID-SEQUENCE; GLUTATHIONE-S-TRANSFERASE; DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; GENE CONVERSION; YEAST CHROMOSOMES; MYOSIN ROD; MEIOSIS	ZIP1 is a novel meiosis-specific gene required for chromosome synapsis and cell cycle progression in S. cerevisiae. zip1 strains undergo homologous chromosome pairing, but are defective in synaptonemal complex (SC) formation. The zip1 mutation confers a uniform arrest in meiosis prior to the first division. zip1 strains display nearly wild-type levels of commitment to melotic recombination; however, mature reciprocal recombinants are not formed until cells are released from meiotic arrest by return to growth medium. DNA sequence analysis of ZIP1 reveals structural homology to a number of proteins containing coiled coils. Immunofluorescence experiments using anti-ZIP1 antibodies demonstrate that the ZIP1 protein localizes to synapsed meiotic chromosomes but not to unsynapsed axial elements. Taken together, these data suggest that ZIP1 is a component of the central region of the SC. We propose a model in which ZIP1 acts as a molecular zipper to bring homologous chromosomes in close apposition.			SYM, M (corresponding author), YALE UNIV, DEPT BIOL, NEW HAVEN, CT 06511 USA.		Engebrecht, JoAnne/K-3355-2019	Engebrecht, JoAnne/0000-0002-2733-7506	NIGMS NIH HHS [2 T32 GM07223-18, GM28904] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028904, T32GM007223] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1989, GENETICS, V122, P47; ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BORTS RH, 1986, GENETICS, V113, P551; BUCKINGHAM LE, 1990, P NATL ACAD SCI USA, V87, P9406, DOI 10.1073/pnas.87.23.9406; BYERS B, 1975, P NATL ACAD SCI USA, V72, P5056, DOI 10.1073/pnas.72.12.5056; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Carpenter ATC, 1988, GENETIC RECOMBINATIO, P529, DOI [10.1038/ng1287, DOI 10.1038/NG1287]; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; DAVIDOW LS, 1984, GENETICS, V106, P165; DRESSER ME, 1988, J CELL BIOL, V106, P567, DOI 10.1083/jcb.106.3.567; EGEL R, 1978, HEREDITY, V41, P233, DOI 10.1038/hdy.1978.92; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; ENGEBRECHT J, 1990, MOL CELL BIOL, V10, P2379, DOI 10.1128/MCB.10.5.2379; ENGEBRECHT JA, 1989, GENETICS, V121, P237; Fraser R.D.B., 1973, CONFORMATION FIBROUS; Game J.C., 1983, YEAST GENETICS FUNDA, P109; GIROUX CN, 1988, GENETIC RECOMBINATIO, P465; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HESLOPHARRISON JS, 1985, J CELL SCI, V75, P85; HEYTING C, 1987, EUR J CELL BIOL, V43, P148; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOLLINGSWORTH NM, 1989, GENETICS, V121, P445; HOLLINGSWORTH NM, 1990, CELL, V61, P73, DOI 10.1016/0092-8674(90)90216-2; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES GH, 1984, CONTROLLING EVENTS M, P293; KLECKNER N, 1991, COLD SH Q B, V56, P729; LICHTEN M, 1990, P NATL ACAD SCI USA, V87, P7653, DOI 10.1073/pnas.87.19.7653; LUCHE RM, 1990, MOL CELL BIOL, V10, P3884, DOI 10.1128/MCB.10.8.3884; MAGUIRE MP, 1972, GENETICS, V70, P353; MAGUIRE MP, 1978, EXP CELL RES, V112, P297, DOI 10.1016/0014-4827(78)90213-6; MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0; MCLACHLAN AD, 1982, NATURE, V299, P226, DOI 10.1038/299226a0; MENEES TM, 1992, MOL CELL BIOL, V12, P1340, DOI 10.1128/MCB.12.3.1340; MENEES TM, 1989, GENETICS, V123, P675; MOENS PB, 1985, CHROMOSOMA, V91, P113, DOI 10.1007/BF00294054; MOENS PB, 1987, J CELL BIOL, V105, P93, DOI 10.1083/jcb.105.1.93; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; PARRY DAD, 1977, J MOL BIOL, V113, P449, DOI 10.1016/0022-2836(77)90153-X; PETES TD, 1991, MOL BIOL YEAST SACCH, P406; RASMUSSEN SW, 1986, CARLSBERG RES COMMUN, V51, P401, DOI 10.1007/BF02907315; ROCKMILL B, 1988, P NATL ACAD SCI USA, V85, P6057, DOI 10.1073/pnas.85.16.6057; ROCKMILL B, 1990, GENETICS, V126, P563; ROCKMILL B, 1991, GENE DEV, V5, P2392, DOI 10.1101/gad.5.12b.2392; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SAEZ L, 1986, NUCLEIC ACIDS RES, V14, P2951, DOI 10.1093/nar/14.7.2951; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIFERT HS, 1986, P NATL ACAD SCI USA, V83, P735, DOI 10.1073/pnas.83.3.735; Sherman F., 1986, METHODS YEAST GENETI; SHUSTER EO, 1989, GENETICS, V123, P29; SMITH A, 1992, EXP CELL RES, V198, P291, DOI 10.1016/0014-4827(92)90382-I; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SNYDER M, 1989, J CELL BIOL, V108, P1419, DOI 10.1083/jcb.108.4.1419; SOLARI AJ, 1973, J CELL BIOL, V56, P145, DOI 10.1083/jcb.56.1.145; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STONE D, 1978, J BIOL CHEM, V253, P1137; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; THOMPSON EA, 1989, MOL GEN GENET, V218, P293, DOI 10.1007/BF00331281; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; VOELKELMEIMAN K, 1990, GENETICS, V124, P561; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; WEBER L, 1992, GENETICS, V131, P55; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; ZICKLER D, 1992, GENETICS, V132, P135	71	494	501	2	16	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 12	1993	72	3					365	378		10.1016/0092-8674(93)90114-6	http://dx.doi.org/10.1016/0092-8674(93)90114-6			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KM162	7916652				2022-12-01	WOS:A1993KM16200007
J	VANDENBROUCKE, JP; KOSTER, T; BRIET, E; REITSMA, PH; BERTINA, RM; ROSENDAAL, FR				VANDENBROUCKE, JP; KOSTER, T; BRIET, E; REITSMA, PH; BERTINA, RM; ROSENDAAL, FR			INCREASED RISK OF VENOUS THROMBOSIS IN ORAL-CONTRACEPTIVE USERS WHO ARE CARRIERS OF FACTOR-V LEIDEN MUTATION	LANCET			English	Article							POOR ANTICOAGULANT RESPONSE; NONFATAL VASCULAR-DISEASE; ACTIVATED PROTEIN-C; THROMBOEMBOLISM; THROMBOPHILIA; WOMEN	We investigated whether the occurrence of venous thrombosis in young women who use oral contraceptives might be explained by the factor V Leiden mutation, which leads to resistance to activated protein C and enhances susceptibility to thrombosis. We compared 155 consecutive premenopausal women, aged 15 to 49, who had developed deep venous thrombosis in the absence of other underlying diseases, with 169 population controls. The risk of thrombosis among users of oral contraceptives was increased 4-fold (relative risk 3.8 [95% CI 2.4-6.0]). The risk of thrombosis among carriers of the mutation compared with non-carriers was increased 8-fold (7.9 [3.2-19.4]). Compared with women who did not use oral contraceptives and were not, carriers of the mutation, the risk of thrombosis among those with both risk factors was increased more than 30-fold (34.7 [7.8-154]). Recalculation of population incidences from these relative risks shows that the absolute risk of venous thrombosis in young women who use oral contraceptives is much larger when they carry the factor V Leiden mutation. When a young woman develops thrombosis, her factor V Leiden status should be considered in counselling about her future method of contraception.	LEIDEN UNIV HOSP, HAEMOSTASIS & THROMBOSIS RES CTR, 2300 RC LEIDEN, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	VANDENBROUCKE, JP (corresponding author), LEIDEN UNIV HOSP, DEPT CLIN EPIDEMIOL, BLDG 1-CO-P, POB 9600, 2300 RC LEIDEN, NETHERLANDS.		Bertina, Rogier/AGQ-5246-2022; Vandenbroucke, Jan/AAM-3928-2020; Rosendaal, Frits/Q-3842-2017	Vandenbroucke, Jan/0000-0001-5668-6716; Rosendaal, Frits/0000-0003-2558-7496				BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BRIET E, 1994, BRIT J HAEMATOL, V87, P348, DOI 10.1111/j.1365-2141.1994.tb04920.x; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DOLL R, 1950, BRIT MED J, V2, P739, DOI 10.1136/bmj.2.4682.739; GERSTMAN BB, 1991, AM J EPIDEMIOL, V133, P32, DOI 10.1093/oxfordjournals.aje.a115799; GIROLAMI A, 1993, BLOOD COAGUL FIBRIN, V4, P841, DOI 10.1097/00001721-199304050-00029; HELMRICH SP, 1987, OBSTET GYNECOL, V69, P91; HUISMAN MV, 1986, NEW ENGL J MED, V314, P823, DOI 10.1056/NEJM198603273141305; JORDAN WM, 1961, LANCET, V2, P1146, DOI DOI 10.1016/S0140-6736(61)91061-3; KOELEMAN BPC, 1994, BLOOD, V84, P1031; KOELMAN JH, 1992, J NEUROL, V230, P105; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; Miettinen O.S., 1985, THEORETICAL EPIDEMIO; PABINGER I, 1994, THROMB HAEMOSTASIS, V5, P548; PORTER JB, 1985, OBSTET GYNECOL, V66, P1; PORTER JB, 1982, OBSTET GYNECOL, V59, P299; ROSENDAAL FR, 1994, LANCET, V343, P1289; ROSENDAAL FR, IN PRESS BLOOD; Rothman KJ, 1986, MODERN EPIDEMIOLOGY, P311; SARTWELL PE, 1982, EPIDEMIOL REV, V4, P95, DOI 10.1093/oxfordjournals.epirev.a036253; SCHLESSELMAN JJ, 1987, CASE CONTROL STUDIES; STADEL BV, 1981, NEW ENGL J MED, V305, P612, DOI 10.1056/NEJM198109103051104; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; THOROGOOD M, 1992, INT J EPIDEMIOL, V21, P48, DOI 10.1093/ije/21.1.48; TRAUCHSTVANHORN JJ, 1992, AM J OBSTET GYNECOL, V167, P9968; TUDDENHAM EGD, 1994, LANCET, V343, P1515, DOI 10.1016/S0140-6736(94)92932-7; VESSEY M, 1986, BRIT MED J, V292, P526, DOI 10.1136/bmj.292.6519.526; 1993, STATISTISCH JB 1993	29	939	963	2	27	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 26	1994	344	8935					1453	1457		10.1016/S0140-6736(94)90286-0	http://dx.doi.org/10.1016/S0140-6736(94)90286-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7968118				2022-12-01	WOS:A1994PT99500005
J	DAWSON, PE; MUIR, TW; CLARKLEWIS, I; KENT, SBH				DAWSON, PE; MUIR, TW; CLARKLEWIS, I; KENT, SBH			SYNTHESIS OF PROTEINS BY NATIVE CHEMICAL LIGATION	SCIENCE			English	Article							SITE-SPECIFIC INCORPORATION; HIV-1 PROTEASE; CRYSTAL-STRUCTURE; INTERLEUKIN-8; PEPTIDES; BONDS	A simple technique has been devised that allows the direct synthesis of native backbone proteins of moderate size. Chemoselective reaction of two unprotected peptide segments gives an initial thioester-linked species. Spontaneous rearrangement of this transient intermediate yields a full-length product with a native peptide bond at the ligation site. The utility of native chemical ligation was demonstrated by the one-step preparation of a cytokine containing multiple disulfides. The polypeptide ligation product was folded and oxidized to form the native disulfide-containing protein molecule. Native chemical ligation is an important step toward the general application of chemistry to proteins.	SCRIPPS RES INST, LA JOLLA, CA 92037 USA; UNIV BRITISH COLUMBIA, BIOMED RES CTR, DEPT BIOCHEM, VANCOUVER V6T 1Z3, BC, CANADA	Scripps Research Institute; University of British Columbia			Wood, David W/B-2992-2012; Muir, Tom/AHD-0860-2022; Ueno, Hiroshi/C-3301-2009	Muir, Tom/0000-0001-9635-0344; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048870, R01GM048897, R01GM050969] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 50969-01, GM48897-01, GM48870-03] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHMSEN L, 1991, BIOCHEMISTRY-US, V30, P4151, DOI 10.1021/bi00231a007; AKAJI K, 1985, CHEM PHARM BULL, V33, P184; BACA M, 1993, P NATL ACAD SCI USA, V90, P11638, DOI 10.1073/pnas.90.24.11638; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BERMAN AL, 1994, P NATL ACAD SCI USA, V91, P4044, DOI 10.1073/pnas.91.9.4044; BLAKE J, 1981, INT J PEPT PROT RES, V17, P273; BRENNER M., 1967, P1; CANNE LE, UNPUB; CANNE LE, 1994, JUL ANN M PROT SOC S; CHANG TK, IN PRESS P NATL ACAD; CLARKLEWIS I, 1994, J BIOL CHEM, V269, P16075; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; CORNISH VW, 1994, P NATL ACAD SCI USA, V91, P2910, DOI 10.1073/pnas.91.8.2910; DANDREA R, 1994, BLOOD, V83, P2802, DOI 10.1182/blood.V83.10.2802.2802; DAWSON PE, 1993, J AM CHEM SOC, V115, P7263, DOI 10.1021/ja00069a027; EIGENBROT C, 1992, Current Opinion in Biotechnology, V3, P333, DOI 10.1016/0958-1669(92)90160-K; ELLMAN JA, 1992, SCIENCE, V255, P197, DOI 10.1126/science.1553546; HUANG LH, 1991, BIOCHEMISTRY-US, V30, P7402, DOI 10.1021/bi00244a006; KEMP DS, 1993, J ORG CHEM, V58, P2216, DOI 10.1021/jo00060a043; LIU CF, 1994, J AM CHEM SOC, V116, P4149, DOI 10.1021/ja00089a001; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; MILTON RCD, 1992, TECHNIQUES PROTEIN C, V4, P257; Muir Tom W., 1993, Current Opinion in Biotechnology, V4, P420, DOI 10.1016/0958-1669(93)90007-J; MUIR TW, 1994, BIOCHEMISTRY-US, V33, P7701, DOI 10.1021/bi00190a025; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; OFFORD RE, 1990, N HORIZ TH, P253; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; RAJARATHNAM K, 1994, BIOCHEMISTRY-US, V29, P1689; RAO C, 1994, J AM CHEM SOC, V116, P6975, DOI 10.1021/ja00094a078; ROSE K, 1994, J AM CHEM SOC, V116, P30, DOI 10.1021/ja00080a004; SCHNOLZER M, 1992, SCIENCE, V256, P221, DOI 10.1126/science.1566069; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; SMITH M, 1994, ANGEW CHEM INT EDIT, V33, P1214, DOI 10.1002/anie.199412141; WALLACE CJA, 1992, J BIOL CHEM, V267, P3852; WILLIAMS M, IN PRESS J AM CHEM S; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; YAMASHIRO D, 1988, INT J PEPT PROT RES, V31, P322	38	3141	3584	24	785	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					776	779		10.1126/science.7973629	http://dx.doi.org/10.1126/science.7973629			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973629				2022-12-01	WOS:A1994PP75300031
J	SCHNEIDER, HC; BERTHOLD, J; BAUER, MF; DIETMEIER, K; GUIARD, B; BRUNNER, M; NEUPERT, W				SCHNEIDER, HC; BERTHOLD, J; BAUER, MF; DIETMEIER, K; GUIARD, B; BRUNNER, M; NEUPERT, W			MITOCHONDRIAL HSP70/MIM44 COMPLEX FACILITATES PROTEIN IMPORT	NATURE			English	Article							TRANSLOCATION CONTACT SITES; YEAST MITOCHONDRIA; INNER MEMBRANE; PRECURSOR PROTEINS; INTERMEMBRANE SPACE; MOLECULAR CHAPERONES; MATRIX; HSP70; PATHWAY; BINDING	Protein translocation into mitochondria requires the mitochondrial protein Hsp70. This molecular chaperone of the mitochondrial matrix is recruited to the protein import machinery by MIM44, a component associated with the inner membrane of the mitochondria. Formation of the mt-Hsp70/MIM44 complex is regulated by ATP. MIM44 and mt-Hsp70 interact in a sequential manner with incoming segments of unfolded preproteins and thereby facilitate stepwise vectorial translocation of proteins across the mitochondrial membranes. The complex appears to act as a molecular ratchet which is energetically driven by the hydrolysis of ATP.	UNIV MUNICH,INST PHYSIOL CHEM,D-80336 MUNICH,GERMANY	University of Munich				Brunner, Michael/0000-0001-9798-3047				ARRETZ M, 1993, J BIOL CHEM, V269, P4959; BLOM J, 1993, MOL CELL BIOL, V13, P7364, DOI 10.1128/MCB.13.12.7364; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; BROACH JR, 1983, EXPT MANIPULATION GE, P85; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BRODSKY JL, 1994, BIOL HEAT SHOCK PROT, P85; CYR DM, 1993, J BIOL CHEM, V268, P23751; DAUM G, 1982, J BIOL CHEM, V257, P3028; DEKKER PJT, 1993, FEBS LETT, V330, P66, DOI 10.1016/0014-5793(93)80921-G; ELLIS RJ, 1993, PHILOS T ROY SOC B, V339, P257, DOI 10.1098/rstb.1993.0023; EMTAGE JLT, 1993, J CELL BIOL, V122, P1003, DOI 10.1083/jcb.122.5.1003; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; Glick B, 1991, Trends Cell Biol, V1, P99, DOI 10.1016/0962-8924(91)90037-A; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HORST M, 1993, EMBO J, V12, P3035, DOI 10.1002/j.1460-2075.1993.tb05972.x; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; HWANG S, 1989, J CELL BIOL, V109, P487, DOI 10.1083/jcb.109.2.487; IKEDA E, 1994, FEBS LETT, V339, P265, DOI 10.1016/0014-5793(94)80428-1; JUNGNICKEL B, 1994, FEBS LETT, V346, P73, DOI 10.1016/0014-5793(94)00367-X; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIEBLER M, 1993, J MEMBRANE BIOL, V135, P191; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; NEUPERT W, 1993, PHILOS T ROY SOC B, V339, P355, DOI 10.1098/rstb.1993.0034; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; OHBA M, 1987, EMBO J, V6, P2109, DOI 10.1002/j.1460-2075.1987.tb02477.x; OSTERMANN J, 1990, FEBS LETT, V277, P281, DOI 10.1016/0014-5793(90)80865-G; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; RYAN KR, 1994, MOL BIOL CELL, V5, P529, DOI 10.1091/mbc.5.5.529; RYAN KR, 1993, J BIOL CHEM, V268, P23743; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHERER PE, 1992, P NATL ACAD SCI USA, V89, P11930, DOI 10.1073/pnas.89.24.11930; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHWAIGER M, 1987, J CELL BIOL, V105, P235, DOI 10.1083/jcb.105.1.235; SCHWARZ E, 1993, EMBO J, V12, P2295, DOI 10.1002/j.1460-2075.1993.tb05883.x; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; UNGERMANN C, IN PRESS SCIENCE; [No title captured]	51	332	335	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 27	1994	371	6500					768	774		10.1038/371768a0	http://dx.doi.org/10.1038/371768a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP018	7935837				2022-12-01	WOS:A1994PP01800050
J	CARMEL, R				CARMEL, R			APPROACH TO A LOW VITAMIN-B-12 LEVEL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							COBALAMIN DEFICIENCY; PERNICIOUS-ANEMIA				CARMEL, R (corresponding author), UNIV SO CALIF, LOS ANGELES, CA USA.							CARMEL R, 1979, ARCH INTERN MED, V139, P47, DOI 10.1001/archinte.139.1.47; CARMEL R, 1990, AM J HEMATOL, V34, P108, DOI 10.1002/ajh.2830340206; CARMEL R, 1988, ARCH INTERN MED, V148, P1715, DOI 10.1001/archinte.148.8.1715; FAIRBANKS VF, 1983, MAYO CLIN PROC, V58, P541; GAFFNEY GW, 1957, J GERONTOL, V12, P32, DOI 10.1093/geronj/12.1.32; MARCUS DL, 1987, J AM GERIATR SOC, V35, P635, DOI 10.1111/j.1532-5415.1987.tb04339.x; PENNYPACKER LC, 1992, J AM GERIATR SOC, V40, P1197, DOI 10.1111/j.1532-5415.1992.tb03641.x	7	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	1994	272	16					1233	1233						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN068	7933355				2022-12-01	WOS:A1994PN06800002
J	BRAIG, K; OTWINOWSKI, Z; HEGDE, R; BOISVERT, DC; JOACHIMIAK, A; HORWICH, AL; SIGLER, PB				BRAIG, K; OTWINOWSKI, Z; HEGDE, R; BOISVERT, DC; JOACHIMIAK, A; HORWICH, AL; SIGLER, PB			THE CRYSTAL-STRUCTURE OF THE BACTERIAL CHAPERONIN GROEL AT 2.8-ANGSTROM	NATURE			English	Article							ESCHERICHIA-COLI GROEL; MOLECULAR CHAPERONE; HEAT-SHOCK; PROTEIN MODELS; CENTRAL CAVITY; HYDROLYSIS; INTERFACES; SURFACE; ERRORS; CYCLE	The crystal structure of Escherichia coli GroEL shows a porous cylinder of 14 subunits made of two nearly 7-fold rotationally symmetrical rings stacked back-to-back with dyad symmetry. The subunits consist of three domains: a targe equatorial domain that forms the foundation of the assembly at its waist and holds the rings together; a large loosely structured apical domain that forms the ends of the cylinder; and a small slender intermediate domain that connects the two, creating side windows. The three-dimensional structure places most of the mutationally defined functional sites on the channel walls and its outward invaginations, and at the ends of the cylinder.	YALE UNIV,SCH MED,BOYER CTR,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University; Yale University; Yale University			Otwinowski, Zbyszek/F-3665-2011; Bremner, James D/B-1632-2013	Otwinowski, Zbyszek/0000-0003-3640-8545				AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BRUNGER AT, 1993, XPLOR VERSION 3 1 MA; BURNETT B, IN PRESS J BACT; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; ELLIS RJ, 1993, NATURE, V366, P213, DOI 10.1038/366213a0; ELLIS RJ, 1991, REV BIOCH, V60, P321; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; IKAZAKI A, 1994, NATURE STRUCT BIOL, V1, P439; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JANIN J, 1990, J BIOL CHEM, V265, P16027; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, P CCP4 STUD WEEK MOL, P91; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MCLENNAN NF, 1993, MOL MICROBIOL, V7, P49, DOI 10.1111/j.1365-2958.1993.tb01096.x; MCMULLIN TW, 1987, MOL CELL BIOL, V7, P4414, DOI 10.1128/MCB.7.12.4414; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; MILLER S, 1989, PROTEIN ENG, V3, P77, DOI 10.1093/protein/3.2.77; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PUSHKIN AV, 1982, BIOCHIM BIOPHYS ACTA, V704, P379, DOI 10.1016/0167-4838(82)90169-8; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; SVENSSON LA, 1994, J MOL BIOL, V235, P47; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; URSIC D, 1991, MOL CELL BIOL, V11, P2629, DOI 10.1128/MCB.11.5.2629; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0	52	1188	1199	2	71	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 13	1994	371	6498					578	586		10.1038/371578a0	http://dx.doi.org/10.1038/371578a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7935790				2022-12-01	WOS:A1994PL55900043
J	FU, H; XIA, K; PALLAS, DC; CUI, C; CONROY, K; NARSIMHAN, RP; MAMON, H; COLLIER, RJ; ROBERTS, TM				FU, H; XIA, K; PALLAS, DC; CUI, C; CONROY, K; NARSIMHAN, RP; MAMON, H; COLLIER, RJ; ROBERTS, TM			INTERACTION OF THE PROTEIN-KINASE RAF-1 WITH 14-3-3-PROTEINS	SCIENCE			English	Article							P21(RAS); REGION; FAMILY; MIDDLE; RAS	Members of a family of highly conserved proteins, termed 14-3-3 proteins, were found by several experimental approaches to associate with Raf-1, a central component of a key signal transduction pathway. Optimal complex formation required the amino-terminal regulatory domain of Raf-1. The association of 14-3-3 proteins and Raf-1 was not substantially affected by the activation state of Raf.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,SHIPLEY INST MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			Mamon, Harvey J/B-2335-2009	Mamon, Harvey J/0000-0002-6060-9059; Collier, R John/0000-0002-2427-4239	NCI NIH HHS [R01 CA057327, CA57327] Funding Source: Medline; NIAID NIH HHS [AI22021] Funding Source: Medline; NICHD NIH HHS [HD24926] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD024926] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA057327] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022021, R01AI022021] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, UNPUB; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; PALLAS D, UNPUB; PALLAS DC, 1988, J VIROL, V62, P3934, DOI 10.1128/JVI.62.11.3934-3940.1988; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Summers MD, 1987, MANUAL METHODS BACUL; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; XIA K, UNPUB; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	26	258	261	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 7	1994	266	5182					126	129		10.1126/science.7939632	http://dx.doi.org/10.1126/science.7939632			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7939632				2022-12-01	WOS:A1994PK58200040
J	FUTREAL, PA; LIU, QY; SHATTUCKEIDENS, D; COCHRAN, C; HARSHMAN, K; TAVTIGIAN, S; BENNETT, LM; HAUGENSTRANO, A; SWENSEN, J; MIKI, Y; EDDINGTON, K; MCCLURE, M; FRYE, C; WEAVERFELDHAUS, J; DING, W; GHOLAMI, Z; SODERKVIST, P; TERRY, L; JHANWAR, S; BERCHUCK, A; IGLEHART, JD; MARKS, J; BALLINGER, DG; BARRETT, JC; SKOLNICK, MH; KAMB, A; WISEMAN, R				FUTREAL, PA; LIU, QY; SHATTUCKEIDENS, D; COCHRAN, C; HARSHMAN, K; TAVTIGIAN, S; BENNETT, LM; HAUGENSTRANO, A; SWENSEN, J; MIKI, Y; EDDINGTON, K; MCCLURE, M; FRYE, C; WEAVERFELDHAUS, J; DING, W; GHOLAMI, Z; SODERKVIST, P; TERRY, L; JHANWAR, S; BERCHUCK, A; IGLEHART, JD; MARKS, J; BALLINGER, DG; BARRETT, JC; SKOLNICK, MH; KAMB, A; WISEMAN, R			BRCA1 MUTATIONS IN PRIMARY BREAST AND OVARIAN CARCINOMAS	SCIENCE			English	Article							FAMILIAL BREAST; ALLELE LOSSES; CANCER; REGION; CHROMOSOME-17Q; TUMORS; PROGRESSION; LINKAGE	Loss of heterozygosity data from familial tumors suggest that BRCA1, a gene that confers susceptibility to ovarian and early-onset breast cancer, encodes a tumor suppressor. The BRCA1 region is also subject to allelic loss in sporadic breast and ovarian cancers, an indication that BRCA1 mutations may occur somatically in these tumors. The BRCA1 coding region was examined for mutations in primary breast and ovarian tumors that show allele loss at the BRCA1 locus. Mutations were detected in 3 of 32 breast and 1 of 12 ovarian carcinomas; all four mutations were germline alterations and occurred in early-onset cancers. These results suggest that mutation of BRCA1 may not be critical in the development of the majority of breast and ovarian cancers that arise in the absence of a mutant germline allele.	MYRIAD GENET,SALT LAKE CITY,UT 84108; UNIV UTAH,MED CTR,DEPT MED INFORMAT,SALT LAKE CITY,UT 84123; FAC HLTH SCI LINKOPING,DEPT OCCUPAT MED,S-58185 LINKOPING,SWEDEN; MEM SLOAN KETTERING CANC CTR,DEPT HUMAN GENET,NEW YORK,NY 10021; DUKE UNIV,MED CTR,DEPT GYNECOL ONCOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710	Myriad Genetics, Inc; Utah System of Higher Education; University of Utah; Linkoping University; Memorial Sloan Kettering Cancer Center; Duke University; Duke University	FUTREAL, PA (corresponding author), NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709, USA.				NCI NIH HHS [CA48711, CA55914, CA56749] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA048711, R01CA056749, R01CA055914] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CROPP CS, 1993, CANCER RES, V53, P5617; CROPP CS, 1994, CANCER RES, V54, P2548; EASTON DF, 1993, AM J HUM GENET, V52, P678; ECCLES DM, 1990, ONCOGENE, V5, P1599; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FUTREAL PA, 1994, HUM MOL GENET, V3, P1359, DOI 10.1093/hmg/3.8.1359; FUTREAL PA, 1992, CANCER RES, V52, P2624; FUTREAL PA, UNPUB; GLEBOV OK, 1994, CANCER RES, V54, P3703; GOLDGAR DE, UNPUB; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; JACOBS IJ, 1993, CANCER RES, V53, P1218; KELSELL DP, 1993, HUM MOL GENET, V2, P1823; KNUDSON AG, 1978, SEMIN ONCOL, V5, P57; LYNCH HT, 1990, GYNECOL ONCOL, V36, P48, DOI 10.1016/0090-8258(90)90107-V; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; NEUHAUSEN SL, UNPUB; PARKIN DM, 1992, CANCER INCIDENCE 5 C, V6; SAITO H, 1993, CANCER RES, V53, P3382; SATO T, 1991, CANCER RES, V51, P5794; SATO T, 1990, CANCER RES, V50, P7184; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128	23	1091	1139	2	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 7	1994	266	5182					120	122		10.1126/science.7939630	http://dx.doi.org/10.1126/science.7939630			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7939630				2022-12-01	WOS:A1994PK58200038
J	WANG, MH; RONSIN, C; GESNEL, MC; COUPEY, L; SKEEL, A; LEONARD, EJ; BREATHNACH, R				WANG, MH; RONSIN, C; GESNEL, MC; COUPEY, L; SKEEL, A; LEONARD, EJ; BREATHNACH, R			IDENTIFICATION OF THE RON GENE-PRODUCT AS THE RECEPTOR FOR THE HUMAN MACROPHAGE STIMULATING PROTEIN	SCIENCE			English	Article							HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE; SCATTER FACTOR; MET PROTOONCOGENE; CELL CARCINOMA; SHORT ARM; C-MET; CHROMOSOME-3; EXPRESSION; HOMOLOGY	Macrophage-stimulating protein (MSP) is a member of the hepatocyte growth factor-scatter factor (HGF-SF) family. Labeled MSP bound to Madin-Darby canine kidney (MDCK) cells transfected with complementary DNA encoding Ron, a cell membrane protein tyrosine kinase. Cross-lin king of I-125-labeled MSP to transfected cells (MDCK-RE7 cells) and immunoprecipitation by antibodies to Ron revealed a 220-kilodalton complex, a size consistent with that of MSP (80 kilodaltons) cross-linked to the beta chain of Ron (150 kilodaltons). The binding of I-125-labeled MSP to MDCK-RE7 cells was inhibited by unlabeled MSP, but not by HGF-SF. MSP caused phosphorylation of the beta chain of Ron and induced migration of MDCK-RE7 cells. These results establish the ron gene product as a specific cell-surface receptor tor MSP.	CHR NANTES,INST BIOL,INSERM,U211,F-44035 NANTES 01,FRANCE; FAC MED LIMOGES,HEMATOL EXPTL LAB,F-87025 LIMOGES,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes	WANG, MH (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,IMMUNOBIOL LAB,IMMUNOPATHOL SECT,FREDERICK,MD 21702, USA.		Breathnach, Richard/K-7599-2015					BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; LANE K, UNPUB; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; LEONARD EJ, 1978, EXP CELL RES, V114, P117, DOI 10.1016/0014-4827(78)90043-5; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; PATTHY L, 1984, FEBS LETT, V171, P131, DOI 10.1016/0014-5793(84)80473-1; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONSIN C, 1993, ONCOGENE, V8, P1195; RONSIN C, UNPUB; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; SKEEL A, 1994, J IMMUNOL, V152, P4618; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; WANG MH, 1994, J BIOL CHEM, V269, P14027; WANG MH, 1994, J BIOL CHEM, V269, P13806; WANG MH, 1994, J BIOL CHEM, V269, P3436; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	25	245	256	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 7	1994	266	5182					117	119		10.1126/science.7939629	http://dx.doi.org/10.1126/science.7939629			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7939629				2022-12-01	WOS:A1994PK58200037
J	GURDON, JB; HARGER, P; MITCHELL, A; LEMAIRE, P				GURDON, JB; HARGER, P; MITCHELL, A; LEMAIRE, P			ACTIVIN SIGNALING AND RESPONSE TO A MORPHOGEN GRADIENT	NATURE			English	Article							DROSOPHILA EMBRYO; XENOPUS-LAEVIS; MESODERM INDUCTION; AXIAL MESODERM; RETINOIC ACID; PROTEIN; HOMOLOG; PATTERN; CELLS; THRESHOLDS	Using combinations of amphibian embryo tissues, it is shown that the selection of genes expressed by a cell is determined by its distance from a source of activin, a peptide growth factor contained in vegetal cells and able to induce other cells to form mesoderm. This long-range signal spreads over at least 10 cell diameters In a few hours. It does so by passive diffusion, because It can by-pass cells that do not themselves respond to the signal nor synthesize protein. These results provide direct support for the operation of a morphogen concentration gradient In vertebrate development.	UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 3EJ,ENGLAND	University of Cambridge	GURDON, JB (corresponding author), WELLCOME CRC INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.		Lemaire, Patrick/B-5560-2012; Lemaire, Patrick/D-4237-2009; Lemaire, Patrick/P-8228-2019	Lemaire, Patrick/0000-0003-4925-2009; Lemaire, Patrick/0000-0003-4925-2009; GURDON, JOHN/0000-0002-5621-3799	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASASHIMA M, 1991, P NATL ACAD SCI USA, V88, P6511, DOI 10.1073/pnas.88.15.6511; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; BURRUS LW, 1994, BIOESSAYS, V16, P155, DOI 10.1002/bies.950160303; CASCIO S, 1987, DEVELOPMENT, V100, P297; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CORNELL RA, 1994, DEVELOPMENT, V120, P453; COUSO JP, 1994, DEVELOPMENT, V120, P621; DALE L, 1993, EMBO J, V12, P4471, DOI 10.1002/j.1460-2075.1993.tb06136.x; DALE L, 1987, DEVELOPMENT, V99, P527; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1994, DEVELOPMENT, V120, P2271; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GREEN JBA, 1991, TRENDS GENET, V7, P245, DOI 10.1016/0168-9525(91)90323-I; GURDON JB, 1985, P NATL ACAD SCI USA, V82, P139, DOI 10.1073/pnas.82.1.139; GURDON JB, 1989, DEVELOPMENT, V105, P27; GURDON JB, 1992, DEVELOPMENT, P137; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HOPWOOD ND, 1992, DEVELOPMENT, V114, P31; JONES EA, 1987, DEVELOPMENT, V101, P557; LAWRENCE PA, 1988, CELL, V54, P1, DOI 10.1016/0092-8674(88)90172-9; LEMAIRE P, 1994, DEVELOPMENT, V120, P1191; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; MOODY SA, 1987, DEV BIOL, V122, P300, DOI 10.1016/0012-1606(87)90296-X; NAKAMURA O, 1971, P JPN ACAD, V47, P313, DOI 10.2183/pjab1945.47.313; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; PLACZEK M, 1990, DEVELOPMENT, V110, P19; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; SLACK JMW, 1993, MECH DEVELOP, V41, P91, DOI 10.1016/0925-4773(93)90040-5; SMITH JC, 1993, EMBO J, V12, P4463, DOI 10.1002/j.1460-2075.1993.tb06135.x; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STJOHNSTON D, 1992, CELL, V68, P201; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; TICKLE C, 1985, DEV BIOL, V109, P82, DOI 10.1016/0012-1606(85)90348-3; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; VINCENT JP, 1994, CELL, V77, P909, DOI 10.1016/0092-8674(94)90139-2; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; WOLPERT L, 1989, DEVELOPMENT S, P3	47	306	309	1	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					487	492		10.1038/371487a0	http://dx.doi.org/10.1038/371487a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7935761				2022-12-01	WOS:A1994PK58900046
J	OZEL, M; XI, YG; BALDAUF, E; DIRINGER, H; POCCHIARI, M				OZEL, M; XI, YG; BALDAUF, E; DIRINGER, H; POCCHIARI, M			SMALL VIRUS-LIKE STRUCTURE IN BRAINS FROM CASES OF SPORADIC AND FAMILIAL CREUTZFELDT-JAKOB-DISEASE	LANCET			English	Note							PROTEIN	We have previously observed small virus-like particles in the brain of hamsters with experimental scrapie. Here we report that small virus-like structures can be isolated from brains of patients with Creutzfeldt-Jakob disease and identified by electronmicroscopy.	BUNDESGESUNDHEITSAMT,ROBERT KOCH INST,D-13353 BERLIN,GERMANY; IST SUPER SANITA,VIROL LAB,I-00161 ROME,ITALY	Robert Koch Institute; Istituto Superiore di Sanita (ISS)			Pocchiari, Maurizio/J-8443-2018	Pocchiari, Maurizio/0000-0002-7269-2486				DIRINGER H, 1983, EUR J BIOCHEM, V134, P555, DOI 10.1111/j.1432-1033.1983.tb07602.x; DIRINGER H, 1992, EXP CLIN IMMUNOGENET, V9, P212; HILMERT H, 1984, BIOSCIENCE REP, V4, P165, DOI 10.1007/BF01120313; OZEL M, 1994, LANCET, V343, P894, DOI 10.1016/S0140-6736(94)90010-8; POCCHIARI M, 1993, ANN NEUROL, V34, P802, DOI 10.1002/ana.410340608; POCCHIARI M, 1994, MOL ASPECTS MED, V15, P195, DOI 10.1016/0098-2997(94)90042-6	6	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					923	924		10.1016/S0140-6736(94)92272-1	http://dx.doi.org/10.1016/S0140-6736(94)92272-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934349				2022-12-01	WOS:A1994PJ28700013
J	BALFOUR, TW				BALFOUR, TW			WHERE HAS ALL THE APPENDICITIS GONE	LANCET			English	Editorial Material											BALFOUR, TW (corresponding author), CITY HOSP NOTTINGHAM,DEPT SURG,NOTTINGHAM,ENGLAND.							DONNAN SPB, 1986, AETIOLOGY ACUTE APPE, P16; LOGAN RFA, 1991, OXFORD TXB PUBLIC HL, V3, P333; MCCAHY P, 1994, ANN ROY COLL SURG, V76, P282	3	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					700	700		10.1016/S0140-6736(94)92201-2	http://dx.doi.org/10.1016/S0140-6736(94)92201-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915770				2022-12-01	WOS:A1994PF18700003
J	ORAHILLY, S; HATTERSLEY, A; VAAG, A; GRAY, H				ORAHILLY, S; HATTERSLEY, A; VAAG, A; GRAY, H			INSULIN-RESISTANCE AS THE MAJOR CAUSE OF IMPAIRED GLUCOSE-TOLERANCE - A SELF-FULFILLING PROPHESY	LANCET			English	Article							DEPENDENT DIABETES-MELLITUS; TYROSINE KINASE DOMAIN; GLUCOKINASE GENE; RECEPTOR GENE; NONSENSE MUTATION; SKELETAL-MUSCLE; PATIENT; YOUNG; LOAD	Non-insulin-dependent diabetes (NIDDM) is a heterogeneous state involving various degrees of beta-cell dysfunction and insulin resistance, although the relative importance of these two factors is controversial. Several single gene disorders of carbohydrate metabolism have their main pathophysiological defect largely restricted to the beta-cell or to insulin-sensitive tissues. We have noted that with insulin resistance the fasting plasma glucose is often normal and severe hyperglycaemia occurs after a glucose load. By contrast, in glucokinase-deficient diabetes, which is characterised by reduced insulin secretion, the reverse is the case. Supportive evidence showing that beta-cell dysfunction and insulin resistance may have different effects on fasting and post-prandial glucose concentrations comes from studies of identical twins of NIDDM patients, hemi-pancreatectomised normal subjects, and insulin-resistant Asian subjects. NIDDM is usually preceded by a period of less severe hyperglycemia, referred to as impaired glucose tolerance (IGT). Studies of the IGT phase usually conclude that insulin resistance is the major abnormality and is thus the primary defect in NIDDM. However, the definition of IGT is based on the 2 h plasma glucose after an oral glucose-tolerance test without consideration of the fasting glucose concentrations (provided these concentrations are non-diabetic). Our observations suggest that this definition of IGT may result in the over-representation of insulin-resistant individuals and the under-representation of subjects with beta-cell dysfunction in any cross sectional study of IGT. The belief that the prediabetic state of IGT is dominated by insulin resistance may be a self-fulfilling prophesy because of the excessive emphasis put on the post-prandial rather than the fasting state.	UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT CLIN BIOCHEM, CAMBRIDGE CB2 2QQ, CAMBS, ENGLAND; UNIV BIRMINGHAM, DEPT MED, BIRMINGHAM, ENGLAND; ODENSE UNIV HOSP, DEPT INTERNAL MED, ODENSE, DENMARK	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Birmingham; University of Southern Denmark; Odense University Hospital	ORAHILLY, S (corresponding author), UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT MED, CAMBRIDGE CB2 2QQ, CAMBS, ENGLAND.		O'Rahilly, Stephen/ABF-6509-2020	O'Rahilly, Stephen/0000-0003-2199-4449; Vaag, Allan Arthur/0000-0002-3690-2191; Hattersley, Andrew/0000-0001-5620-473X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CAMA A, 1991, J CLIN ENDOCR METAB, V73, P894, DOI 10.1210/jcem-73-4-894; CARO JF, 1988, J CLIN INVEST, V81, P976, DOI 10.1172/JCI113451; DEFRONZO RA, 1983, DIABETES, V32, P35, DOI 10.2337/diab.32.1.35; FELIG P, 1970, NEW ENGL J MED, V282, P166; FERRANNINI E, 1985, DIABETES, V34, P580, DOI 10.2337/diabetes.34.6.580; FINK RI, 1992, METABOLISM, V41, P897, DOI 10.1016/0026-0495(92)90174-9; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; HAGER J, IN PRESS DIABETES; HATTERSLEY AT, 1992, LANCET, V339, P1307, DOI 10.1016/0140-6736(92)91958-B; HOLROYDE MJ, 1976, BIOCHEM J, V153, P363, DOI 10.1042/bj1530363; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KAHN CR, 1976, NEW ENGL J MED, V294, P739, DOI 10.1056/NEJM197604012941401; KATAGIRI H, 1992, LANCET, V340, P1316, DOI 10.1016/0140-6736(92)92494-Z; KELLEY D, 1988, J CLIN INVEST, V81, P1563, DOI 10.1172/JCI113489; KROOK A, 1993, LANCET, V342, P277, DOI 10.1016/0140-6736(93)91820-C; KROOK A, 1994, DIABETES, V43, P357, DOI 10.2337/diabetes.43.3.357; LUNDGREN H, 1990, DIABETIC MED, V7, P407, DOI 10.1111/j.1464-5491.1990.tb01415.x; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MCKEIGUE PM, 1989, J CLIN EPIDEMIOL, V42, P597, DOI 10.1016/0895-4356(89)90002-4; MODAN M, 1989, DIABETES, V38, P1630, DOI 10.2337/diabetes.38.12.1630; MOLL, 1993, MOLLER DE, P49; MOLLER DE, 1990, J BIOL CHEM, V265, P14979; MOLLER DE, 1994, DIABETES, V43, P247, DOI 10.2337/diabetes.43.2.247; MOLLER DE, 1990, MOL ENDOCRINOL, V4, P1183, DOI 10.1210/mend-4-8-1183; ODAWARA M, 1989, SCIENCE, V245, P66, DOI 10.1126/science.2544998; SAKURA H, 1992, J CLIN ENDOCR METAB, V75, P1571, DOI 10.1210/jc.75.6.1571; STOFFEL M, 1992, NAT GENET, V2, P153, DOI 10.1038/ng1092-153; TAYLOR SI, 1990, DIABETES CARE, V13, P257, DOI 10.2337/diacare.13.3.257; TURNER RC, 1976, LANCET, V1, P1272; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; VELHO G, 1992, LANCET, V340, P444, DOI 10.1016/0140-6736(92)91768-4; WATTRE S, 1993, SCAND J CLIN LAB INV, V53, P2	33	65	65	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 27	1994	344	8922					585	589		10.1016/S0140-6736(94)91969-0	http://dx.doi.org/10.1016/S0140-6736(94)91969-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914964				2022-12-01	WOS:A1994PD42400013
J	LAGA, M; ALARY, M; NZILA, N; MANOKA, AT; TULIZA, M; BEHETS, F; GOEMAN, J; STLOUIS, M; PIOT, P				LAGA, M; ALARY, M; NZILA, N; MANOKA, AT; TULIZA, M; BEHETS, F; GOEMAN, J; STLOUIS, M; PIOT, P			CONDOM PROMOTION, SEXUALLY-TRANSMITTED DISEASES TREATMENT, AND DECLINING INCIDENCE OF HIV-1 INFECTION IN FEMALE ZAIRIAN SEX WORKERS	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RISK-FACTORS; PROSTITUTES; TRANSMISSION; AFRICA	The control of sexually transmitted diseases, including HIV-1, among sex workers and their clients in urban areas in developing countries, is considered a valuable and cost-effective intervention to contain the spread of HIV-1. The effect of a programme of STD treatment combined with condom promotion on HIV-1 incidence has so far not been measured. During an intervention including condom promotion, as well as monthly sexually transmitted disease screening and treatment among 531 initially HIV-1 negative female sex workers in Kinshasa, Zaire, 70 became infected with HIV-1 (incidence of 8.0 per 100 women-years [wy]). A decline of HIV-1 incidence was observed over time, from 11.7/100 wy during the first 6 months, to 4.4/100 wy over the last 6 months, 3 years later (p = 0.003). Simultaneously, regular use of condoms with clients went up from 11% to 52% and 68%, after 6 and 36 months of intervention, respectively. Risk factors for HIV-1 seroconversion after multivariate analysis included irregular condom use (RR 1.6 [95% Cl 1.1-2.8]), gonorrhoea (RR 2.5 [1.1-6.4]), trichomoniasis (RR 1.7 [1.1-2.8]), and genital ulcer disease (RR 2.5 [1.1-6.4]), during the probable period of acquisition of HIV-1. In women who attended more than 90% of their clinic appointments, the HIV-1 incidence was 2.7/100 wy compared to 7.1, 20.3, and 44.1 per 100 wy among women who attended 76-90%, 50-75%, and less than 50% of the monthly appointments, respectively (p < 0.0001). These trends remained after controlling for reported condom use and number of clients. This study confirms earlier findings that STDs facilitate transmission of HIV-1 and shows that a clinic-based intervention consisting of STD care and condom promotion can result in a major decline of HIV-1 incidence among female sex workers.	MINIST HLTH, PROJET SIDA, KINSHASA, DEM REP CONGO; CTR DIS CONTROL, DIV HIV AIDS, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA	LAGA, M (corresponding author), INST TROP MED, WHO,COLLABORATING CTR AIDS,DEPT INFECT & IMMUN, DIV MICROBIOL, NATL ST 155, B-2000 ANTWERP, BELGIUM.							ALLEN S, 1992, JAMA-J AM MED ASSOC, V268, P3338, DOI 10.1001/jama.268.23.3338; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; NGUGI EN, 1988, LANCET, V2, P887, DOI 10.1016/S0140-6736(88)92480-4; NZILA N, 1991, AIDS, V5, P715, DOI 10.1097/00002030-199106000-00011; SIRAPRAPASIRI T, 1991, AIDS, V5, P579, DOI 10.1097/00002030-199105000-00017; WILLERFORD DM, 1993, J INFECT DIS, V167, P1414, DOI 10.1093/infdis/167.6.1414	6	352	357	0	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 23	1994	344	8917					246	248		10.1016/S0140-6736(94)93005-8	http://dx.doi.org/10.1016/S0140-6736(94)93005-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913164				2022-12-01	WOS:A1994NY06000017
J	LEVINE, DS				LEVINE, DS			BARRETTS-ESOPHAGUS AND P53	LANCET			English	Editorial Material							SUPPRESSOR GENE; ADENOCARCINOMA; ESOPHAGUS; DYSPLASIA; 17P				LEVINE, DS (corresponding author), UNIV WASHINGTON,DEPT MED,DIV GASTROENTEROL,SEATTLE,WA, USA.							BLOUNT PL, 1991, CANCER RES, V51, P5482; BLOUNT PL, 1993, P NATL ACAD SCI USA, V90, P3221, DOI 10.1073/pnas.90.8.3221; BLOUNT PL, 1994, CANCER RES, V54, P2292; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; JANKOWSKI J, 1992, GUT, V33, P1033, DOI 10.1136/gut.33.8.1033; LEVINE DS, 1993, GASTROENTEROLOGY, V105, P40, DOI 10.1016/0016-5085(93)90008-Z; NESHAT K, 1994, GASTROEN CLIN BIOL, V18, pD71; NESHAT K, 1994, GASTROENTEROLOGY, V106, P1589, DOI 10.1016/0016-5085(94)90415-4; RAMEL S, 1992, GASTROENTEROLOGY, V102, P1220; REID BJ, 1992, GASTROENTEROLOGY, V102, P1212; YOUNES M, 1993, GASTROENTEROLOGY, V105, P1637, DOI 10.1016/0016-5085(93)91058-P	11	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					212	213		10.1016/S0140-6736(94)92993-9	http://dx.doi.org/10.1016/S0140-6736(94)92993-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913153				2022-12-01	WOS:A1994NY06000005
J	NAKAOKA, H; PEREZ, DM; BAEK, KJ; DAS, T; HUSAIN, A; MISONO, K; IM, MJ; GRAHAM, RM				NAKAOKA, H; PEREZ, DM; BAEK, KJ; DAS, T; HUSAIN, A; MISONO, K; IM, MJ; GRAHAM, RM			G(H) - A GTP-BINDING PROTEIN WITH TRANSGLUTAMINASE ACTIVITY AND RECEPTOR SIGNALING FUNCTION	SCIENCE			English	Article							PIG LIVER TRANSGLUTAMINASE; PHOSPHOLIPASE-C; ALPHA-SUBUNITS; ALPHA-1-ADRENERGIC RECEPTOR; CDNA CLONES; IDENTIFICATION; RECONSTITUTION; PURIFICATION; FAMILY; ALPHA(1)-ADRENOCEPTOR	The alpha(1)-adrenergic receptors activate a phospholipase C enzyme by coupling to members of the large molecular size (approximately 74 to 80 kilodaltons) G alpha(h) family of guanosine triphosphate (GTP)-binding proteins. Rat liver G alpha(h) is now shown to be a tissue transglutaminase type II (TGase II). The transglutaminase activity of rat liver TGase II expressed in COS-1 cells was inhibited by the nonhydrolyzable GTP analog guanosine 5'-O-(3-thiotriphosphate) or by alpha(1)-adrenergic receptor activation. Rat liver TGase II also mediated alpha(1)-adrenergic receptor stimulation of phospholipase C activity. Thus, G alpha(h) represents a new class of GTP-binding proteins that participate in receptor signaling and may be a component of a complex regulatory network in which receptor-stimulated GTP binding switches the function of G alpha(h) from transglutamination to receptor signaling.	CLEVELAND CLIN FDN,RES INST,DEPT CARDIOVASC BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation			Husain, Ahsan/J-6861-2012	Husain, Ahsan/0000-0003-3426-3469				ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; BAEK KJ, 1993, J BIOL CHEM, V268, P27390; BERNSTEIN G, 1992, CELL, V70, P411; BIRCKBICHLER PJ, 1985, HYBRIDOMA, V4, P179, DOI 10.1089/hyb.1985.4.179; DAS T, 1993, J BIOL CHEM, V268, P27398; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; GENTILE V, 1991, J BIOL CHEM, V266, P478; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; IM MJ, 1990, J BIOL CHEM, V265, P18952; IM MJ, 1990, J BIOL CHEM, V265, P18944; IM MJ, 1992, J BIOL CHEM, V267, P8887; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; LEE KN, 1993, BIOCHIM BIOPHYS ACTA, V1201, P1; NAKANISHI K, 1991, EUR J BIOCHEM, V202, P15, DOI 10.1111/j.1432-1033.1991.tb16338.x; NAKAOKA H, UNPUB; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; PEREZ DM, 1993, MOL PHARMACOL, V44, P784; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; TAKEUCHI Y, 1992, FEBS LETT, V307, P177, DOI 10.1016/0014-5793(92)80762-6; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WU DQ, 1992, J BIOL CHEM, V267, P25798	24	527	539	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 10	1994	264	5165					1593	1596		10.1126/science.7911253	http://dx.doi.org/10.1126/science.7911253			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ285	7911253				2022-12-01	WOS:A1994NQ28500037
J	ZORIO, DAR; CHENG, NSN; BLUMENTHAL, T; SPIETH, J				ZORIO, DAR; CHENG, NSN; BLUMENTHAL, T; SPIETH, J			OPERONS AS A COMMON FORM OF CHROMOSOMAL ORGANIZATION IN C-ELEGANS	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; LEADER SEQUENCE; MESSENGER-RNA; GENE; PROTEIN	ALTHOUGH eukaryotic genes are usually transcribed individually, at least a few Caenorhabditis elegans genes appear to be transcribed polycistronically in clusters resembling bacterial operons(1). The spliced leader SL2 (ref. 2) is specific for trans-splicing to downstream genes in these operons(1). In addition, many C. elegans pre-mRNAs are trans-spliced to SL1 (ref. 3) near the 5' ends of pre-mRNAs(4,5). Because operons have not previously been found in higher eukaryotes, we have investigated how widespread they are in the C. elegans genome. We identified gene clusters using the extensive data generated by the genome project(6,7) and tested seven for trans-splicing specificity. All were found to fit expectations for polycistronic transcription. In addition, we surveyed reported C. elegans genes for irans-splicing specificity. Both methods indicate that the pre-mRNAs of about 70% of C. elegans genes are trans-spliced and as many as a quarter are transcribed in operons.			ZORIO, DAR (corresponding author), INDIANA UNIV, DEPT BIOL, BLOOMINGTON, IN 47405 USA.							CAPOWSKI EE, 1991, GENETICS, V129, P1061; CLARK SG, 1994, GENETICS, V137, P987; CONRAD R, 1993, EMBO J, V12, P1249, DOI 10.1002/j.1460-2075.1993.tb05766.x; CONRAD R, 1991, MOL CELL BIOL, V11, P1921, DOI 10.1128/MCB.11.4.1921; HU E, 1991, J BIOL CHEM, V266, P19796; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; HUANG XY, 1989, J MOL BIOL, V206, P411, DOI 10.1016/0022-2836(89)90490-7; HUANG XY, 1989, P NATL ACAD SCI USA, V86, P8640, DOI 10.1073/pnas.86.22.8640; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KUWABARA PE, 1992, MOL BIOL CELL, V3, P461, DOI 10.1091/mbc.3.4.461; LAND M, 1994, J BIOL CHEM, V269, P14820; LEE YH, 1992, GENE, V121, P227, DOI 10.1016/0378-1119(92)90126-A; MORGAN WR, 1993, MOL CELL BIOL, V13, P7133, DOI 10.1128/MCB.13.11.7133; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	17	226	228	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	1994	372	6503					270	272		10.1038/372270a0	http://dx.doi.org/10.1038/372270a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PR889	7969472				2022-12-01	WOS:A1994PR88900052
J	UMAR, A; BOYER, JC; KUNKEL, TA				UMAR, A; BOYER, JC; KUNKEL, TA			DNA LOOP REPAIR BY HUMAN CELL-EXTRACTS	SCIENCE			English	Article							COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; ADENOCARCINOMA CELLS; GENETIC INSTABILITY; ESCHERICHIA-COLI; CARCINOMA; LINES; ESTABLISHMENT; MUTATIONS; SEQUENCES	An activity in human cell extracts is described tt lat repairs DNA with loops of five or more unpaired bases. Repair is strand-specific and is directed by a nick located 5' or 3' to the loop. This repair is observed in a colorectal cancer cell line that is devoid of a wild-type hMLH1 gene and is deficient in repair of mismatches. However, a cell line with deletions in both hMSH2 alleles is deficient in repair of both loops and mismatches. Defects in loop repair may be relevant to the repetitive-sequence instability observed in cancers and other hereditary diseases.	NIEHS,MOLEC GENET LAB,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Kunkel, Thomas A./D-5088-2019; Umar, Asad/AAI-4560-2020	Kunkel, Thomas A./0000-0002-9900-1788; 				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALLTONEN LA, 1994, CANCER RES, V54, P1645; BECKMANN JS, 1992, GENOMICS, V12, P627, DOI 10.1016/0888-7543(92)90285-Z; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CARRAWAY M, 1993, J BACTERIOL, V175, P3972, DOI 10.1128/JB.175.13.3972-3980.1993; DAWE CJ, 1964, JNCI-J NATL CANCER I, V33, P441; DEXTER DL, 1979, CANCER RES, V39, P1020; ENGEL LW, 1978, CANCER RES, V38, P3352; FANG WH, 1993, J BIOL CHEM, V268, P11838; FISHEL R, 1993, CELL, V75, P1075; FISHEL R, IN PRESS SCIENCE; FREAKE HC, 1981, BIOCHEM BIOPH RES CO, V101, P1131, DOI 10.1016/0006-291X(81)91565-5; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; HAN HJ, 1993, CANCER RES, V53, P5087; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; HONCHEL R, 1994, CANCER RES, V54, P1159; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LOTHE RA, 1993, CANCER RES, V53, P5849; MERLO A, 1994, CANCER RES, V54, P2098; METZGAR RS, 1982, CANCER RES, V42, P601; MIRET JJ, 1994, ENV MOL MUTAGEN S23, V23, P45; MIRONOV NM, 1994, CANCER RES, V54, P41; Morisawa T, 1987, J JPN SOC CLIN CYTOL, V26, P433; PAPDOPOULOS N, 1994, SCIENCE, V263, P1625; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PELTOMAKI P, 1993, CANCER RES, V53, P5853; RHYU MG, 1994, ONCOGENE, V9, P29; RISINGER JI, 1993, CANCER RES, V53, P5100; SHIBATA D, 1994, NAT GENET, V6, P278; SHRIDHAR V, 1994, CANCER RES, V54, P2084; STRAND M, 1993, NATURE, V365, P273; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; TOM BH, 1976, IN VITRO CELL DEV B, V12, P180; UMAR A, 1994, J BIOL CHEM, V269, P14367; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; WU C, 1994, ONCOGENE, V9, P991; YEE CJ, 1994, CANCER RES, V54, P1641; ZEUTHEN J, 1980, INT J CANCER, V25, P19, DOI 10.1002/ijc.2910250104	44	131	133	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					814	816		10.1126/science.7973637	http://dx.doi.org/10.1126/science.7973637			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973637				2022-12-01	WOS:A1994PP75300043
J	BLACKWELL, TK; BOWERMAN, B; PRIESS, JR; WEINTRAUB, H				BLACKWELL, TK; BOWERMAN, B; PRIESS, JR; WEINTRAUB, H			FORMATION OF A MONOMERIC DNA-BINDING DOMAIN BY SKN-1 BZIP AND HOMEODOMAIN ELEMENTS	SCIENCE			English	Article							GCN4 ACTIVATOR PROTEIN; LEUCINE ZIPPER MOTIF; C-ELEGANS EMBRYOS; CRYSTAL-STRUCTURE; TRANSCRIPTION FACTOR; BASIC REGION; ANTENNAPEDIA HOMEODOMAIN; NMR-SPECTROSCOPY; HIGH-RESOLUTION; COILED COIL	Maternally expressed Skn-1 protein is required for the correct specification of certain blastomere fates in early Caenorhabditis elegans embryos. Skn-1 contains a basic region similar to those of basic leucine zipper (bZIP) proteins but, paradoxically, it lacks a leucine zipper dimerization segment. Random sequence selection methods were used to show that Skn-1 binds to specific DNA sequences as a monomer. The Skn-1 basic region lies at the carboxyl terminus of an 85-amino acid domain that binds preferentially to a bZIP half-site and also recognizes adjacent 5' AT-rich sequences in the minor groove, apparently with an amino (NH2)-terminal ''arm'' related to those of homeodomain proteins. The intervening residues appear to stabilize interactions of these two subdomains with DNA. The Skn-1 DNA binding domain thus represents an alternative strategy for promoting binding of a basic region segment recognition helix to its cognate half-site. The results point to an underlying modularity in subdomains within established DNA binding domains.	FRED HUTCHINSON CANC RES CTR,HOWARD HUGHES MED INST,SEATTLE,WA 98104; FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,SEATTLE,WA 98104	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; Fred Hutchinson Cancer Center								AFFOLTER M, 1990, P NATL ACAD SCI USA, V87, P4093, DOI 10.1073/pnas.87.11.4093; AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, UNPUB; BLATTER EE, 1992, NATURE, V359, P650, DOI 10.1038/359650a0; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; BOWERMAN B, UNPUB; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHEN L, 1992, SCIENCE, V256, P240, DOI 10.1126/science.1314423; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; DIXON WJ, 1991, METHOD ENZYMOL, V208, P380; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FENG JA, 1994, SCIENCE, V263, P348, DOI 10.1126/science.8278807; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GOUTTE C, 1994, EMBO J, V13, P1434, DOI 10.1002/j.1460-2075.1994.tb06397.x; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.biochem.59.1.933; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; KRAUSE M, IN PRESS DEV BIOL; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; MOHLER J, 1990, MECH DEVELOP, V34, P3; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; ONEIL KT, 1991, BIOCHEMISTRY-US, V30, P9030, DOI 10.1021/bi00101a017; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; PHILLIPS CL, 1991, GENE DEV, V5, P764, DOI 10.1101/gad.5.5.764; PU WT, 1992, NUCLEIC ACIDS RES, V20, P771, DOI 10.1093/nar/20.4.771; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; RUBERTI I, 1991, EMBO J, V10, P1787, DOI 10.1002/j.1460-2075.1991.tb07703.x; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SCHUBERT C, UNPUB; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SELLERS JW, 1990, MOL CELL BIOL, V10, P5077, DOI 10.1128/MCB.10.10.5077; SESSA G, 1993, EMBO J, V12, P3507, DOI 10.1002/j.1460-2075.1993.tb06025.x; SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; THANOS D, 1993, COLD SPRING HARB SYM, V58, P73, DOI 10.1101/SQB.1993.058.01.011; THIESEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3203, DOI 10.1093/nar/18.11.3203; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WISSMANN A, 1991, METHOD ENZYMOL, V208, P365; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5	69	135	139	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 28	1994	266	5185					621	628		10.1126/science.7939715	http://dx.doi.org/10.1126/science.7939715			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939715				2022-12-01	WOS:A1994PN80700040
J	JOSEPH, AM				JOSEPH, AM			IS CONGRESS BLOWING SMOKE AT THE VA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOSEPH, AM (corresponding author), VET AFFAIRS MED CTR,GEN INTERNAL MED SECT,1 VET DR,MINNEAPOLIS,MN 55417, USA.			Joseph, Anne/0000-0002-3440-2679				ALLEN A, 1989, VA PRACT         FEB, P15; DAWLEY HH, 1989, VA PRACT         APR, P47; JOSEPH A, 1988, JAMA-J AM MED ASSOC, V260, P1551, DOI 10.1001/jama.1988.03410110059012; JOSEPH AM, 1992, JAMA-J AM MED ASSOC, V267, P87; LUCK TC, 1990, VA PRACT         JAN, P71; MCALLISTER B, 1992, WASHINGTON POST 0604, pA27; SIROTA AD, 1987, VA PRACT         FEB, P11; 1990, 1090142 US DEP VET A; 1992, SMOKE FREE ENV SMO S, V1; 1993, MA1314 JOINT COMM AC; 1990, 1090141 US DEP VET A; 1992, EPA600690006F PUBL; 1986, HLTH CONSEQUENCES IN; 1993, FY1992 US DEP VET AF; 1993, ESTABLISHING PATIENT	15	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1215	1216		10.1001/jama.272.15.1215	http://dx.doi.org/10.1001/jama.272.15.1215			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL212	7933352				2022-12-01	WOS:A1994PL21200038
J	CHANG, EC; BARR, M; WANG, Y; JUNG, V; XU, HP; WIGLER, MH				CHANG, EC; BARR, M; WANG, Y; JUNG, V; XU, HP; WIGLER, MH			COOPERATIVE INTERACTION OF S-POMBE PROTEINS REQUIRED FOR MATING AND MORPHOGENESIS	CELL			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; GENE-PRODUCT; SEXUAL-DIFFERENTIATION; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; EXCHANGE FACTOR; HUMAN ONCOGENE; CELL POLARITY	We isolated two S. pombe genes, scd1 and scd2, that are required for normal morphology and mating. scd1 and scd1 are homologous to CDC24 and BEM1, respectively, of S. cerevisiae. Epistasis analyses indicate that scd2 and rest converge upon scd1, which, in turn, interacts with cdc42sp, a RHO-like GTPase. Studies with the yeast two-hybrid system indicate that scd2 forms complexes with both scd1 and cdc42sp. Furthermore, biochemical studies indicate that the interaction between scd1 and scd2 is direct. The yeast two-hybrid data further suggest that scd1, scd2, cdc42sp, and ras1, in its GTP-bound state, act cooperatively to form a protein complex.			CHANG, EC (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.			Wigler, Michael/0000-0003-4396-1971				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ADAMS JM, 1992, ONCOGENE, V7, P611; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; COTTAREL G, 1993, CURR GENET, V23, P547, DOI 10.1007/BF00312650; DOWNWARD J, 1992, NATURE, V358, P282, DOI 10.1038/358282a0; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FAWELL E, 1992, GENE, V114, P153, DOI 10.1016/0378-1119(92)90724-4; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUKUI Y, 1988, MOL GEN GENET, V215, P26, DOI 10.1007/BF00331298; FUKUI Y, 1986, CELL, V44, P329, DOI 10.1016/0092-8674(86)90767-1; FUKUI Y, 1985, EMBO J, V4, P687, DOI 10.1002/j.1460-2075.1985.tb03684.x; FUKUI Y, 1989, MOL CELL BIOL, V9, P5617, DOI 10.1128/MCB.9.12.5617; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTWELL LH, 1973, GENETICS, V74, P267; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFFMAN CS, 1990, GENETICS, V124, P807; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KAWAMUKAI M, 1992, MOL BIOL CELL, V3, P167, DOI 10.1091/mbc.3.2.167; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MCLEOD M, 1987, EMBO J, V6, P729, DOI 10.1002/j.1460-2075.1987.tb04814.x; MILLER PJ, 1994, MOL CELL BIOL, V14, P1075, DOI 10.1128/MCB.14.2.1075; MIYAMOTO S, 1987, GENE, V54, P125, DOI 10.1016/0378-1119(87)90354-4; MIYAMOTO S, 1991, BIOCHEM BIOPH RES CO, V181, P604, DOI 10.1016/0006-291X(91)91233-3; MOLZ L, 1989, GENETICS, V122, P773; MUNDER T, 1992, MOL CELL BIOL, V12, P2091, DOI 10.1128/MCB.12.5.2091; NADINDAVIS SA, 1986, EMBO J, V5, P2963, DOI 10.1002/j.1460-2075.1986.tb04593.x; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIDLEY AL, 1993, CELL, V70, P389; RIDLEY AL, 1993, CELL, V70, P401; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; SZANKASI P, 1988, J MOL BIOL, V204, P917, DOI 10.1016/0022-2836(88)90051-4; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WIGLER M, 1988, COLD SPRING HARB SYM, V53, P649, DOI 10.1101/SQB.1988.053.01.074; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; XU HP, 1990, CELL REGUL, V1, P763, DOI 10.1091/mbc.1.10.763; XU HP, 1994, MOL CELL BIOL, V14, P50, DOI 10.1128/MCB.14.1.50; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	59	255	259	1	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					131	141		10.1016/0092-8674(94)90406-5	http://dx.doi.org/10.1016/0092-8674(94)90406-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923372				2022-12-01	WOS:A1994PK58500014
J	RIDDIHOUGH, G				RIDDIHOUGH, G			ONE IN THE EYE	NATURE			English	Article							CRYSTALLINS	A double insight into visual accommodation by the eye lens in birds and into the activity of a superfamily of metabolic enzymes is provided by the structure of turkey lens delta-crystallin.										DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; PIATIGORSKY J, 1991, SCIENCE, V252, P1078, DOI 10.1126/science.252.5009.1078; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; SIMPSON A, 1994, NAT STRUCT BIOL, V1, P724, DOI 10.1038/nsb1094-724	4	2	2	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					538	538		10.1038/371538a0	http://dx.doi.org/10.1038/371538a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7935769	Bronze			2022-12-01	WOS:A1994PK58900063
J	STEWART, THM				STEWART, THM			POSTMASTECTOMY RADIOTHERAPY - MORE THAN A LOCAL MATTER	LANCET			English	Editorial Material							BREAST-CANCER				STEWART, THM (corresponding author), OTTAWA GEN HOSP,DEPT MED,OTTAWA K1H 8L6,ON,CANADA.							CUZICK J, 1987, CANCER TREAT REP, V71, P15; CUZICK J, 1994, J CLIN ONCOL, V12, P447, DOI 10.1200/JCO.1994.12.3.447; OVERGAARD M, 1990, INT J RADIAT ONCOL, V19, P1121, DOI 10.1016/0360-3016(90)90214-5; PREHN TR, 1994, CANCER RES, V54, P908; RAGAZ J, 1993, P AN M AM SOC CLIN, V12, P60; ROTSTEIN S, 1985, INT J RADIAT ONCOL, V11, P921, DOI 10.1016/0360-3016(85)90114-2; STEWART THM, 1993, CLIN EXP METASTAS, V11, P295, DOI 10.1007/BF00058049; STEWART THM, 1992, CELLULAR IMMUNE MECHANISMS AND TUMOR DORMANCY, P213; STEWART THM, 1994, LANCET, V343, P402; STJERNSW.J, 1974, LANCET, V2, P1285, DOI 10.1016/S0140-6736(74)90142-1	10	10	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 6	1994	344	8919					351	352		10.1016/S0140-6736(94)91396-X	http://dx.doi.org/10.1016/S0140-6736(94)91396-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA303	7914302				2022-12-01	WOS:A1994PA30300005
J	MILLER, FH				MILLER, FH			INFANT RESUSCITATION, A US UK DIVIDE	LANCET			English	Editorial Material											MILLER, FH (corresponding author), BOSTON UNIV,SCH LAW,BOSTON,MA 02215, USA.							BRAHAMS D, 1992, LANCET, V339, P1472, DOI 10.1016/0140-6736(92)92052-H	1	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1584	1585		10.1016/S0140-6736(94)93051-1	http://dx.doi.org/10.1016/S0140-6736(94)93051-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911914				2022-12-01	WOS:A1994NU35400004
J	SEMBA, RD; MIOTTI, PG; CHIPHANGWI, JD; SAAH, AJ; CANNER, JK; DALLABETTA, GA; HOOVER, DR				SEMBA, RD; MIOTTI, PG; CHIPHANGWI, JD; SAAH, AJ; CANNER, JK; DALLABETTA, GA; HOOVER, DR			MATERNAL VITAMIN-A-DEFICIENCY AND MOTHER-TO-CHILD TRANSMISSION OF HIV-1	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; A-DEFICIENCY; INFECTION; RISK; ASSOCIATION; INFANTS; WOMEN	Studies show that around 10-40% HIV-positive women will give birth to children who are also infected. However, the risk factors for transmission from mother to child are not well understood and the effects of maternal nutritional status are unknown. We conducted a study of vitamin A status in pregnant women as a risk factor for mother-to-child transmission of HIV in Malawi. Serum vitamin A, height, weight, CD4 T-cell counts, and duration of breastfeeding were measured in 338 HIV-positive mothers whose infant's HIV serostatus was known. Mother-to-child transmission of HIV was 21.9% among mothers whose infants survived to 12 months of age. Mean vitamin A concentration in 74 mothers who transmitted HIV to their infants was lower than that in 264 mothers who did not transmit HIV to their infants (0.86 [0.03] vs 1.07 [0.02], p<0.0001). We divided HIV positive mothers to 4 groups, those with vitamin A concentrations of less than 0.70, between 0.70 and 1.05, between 1.05 and 1.40, and greater than or equal to 1.40 mu mol/L. The mother-to-child transmission rates for each group were 32.4%, 26.2%, 16.0%, and 7.2%, respectively (p<0.0001). Maternal CD4 cell counts, CD4%, and CD4/CD8 ratio were also associated with increased mother-to-child transmission of HIV. Maternal age, body-mass index, and breastfeeding practices were not significantly associated with higher mother-to-child transmission. Our study suggests that maternal vitamin A deficiency contributes to mother-to-child transmission of HIV.	DEPT INT HLTH,DIV HUMAN NUTR,BALTIMORE,MD 21287; MALAWI MED COLL,BLANTYRE,MALAWI; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,PROGRAM INFECT DIS,BALTIMORE,MD	University of Malawi; Johns Hopkins University	SEMBA, RD (corresponding author), DANA CTR,DEPT IMMUNOL & INFECT DIS,600 N WOLFE ST,BALTIMORE,MD 21287, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030042, R55HD030042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI026499, R21AI033874] Funding Source: NIH RePORTER; NIAID NIH HHS [AI26499, AI33874] Funding Source: Medline; NICHD NIH HHS [HD30042] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAUM MK, 1991, J ACQ IMMUN DEF SYND, V4, P1122; BEACH RS, 1992, AIDS, V6, P701, DOI 10.1097/00002030-199207000-00013; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BOYLAN L, 1991, EPIDEMIOL REV, V13, P143, DOI 10.1093/oxfordjournals.epirev.a036067; BRAY GA, 1978, INT J OBESITY, V2, P99; BUCK J, 1990, J EXP MED, V171, P1613, DOI 10.1084/jem.171.5.1613; CAMPOS FACS, 1987, AM J CLIN NUTR, V46, P91, DOI 10.1093/ajcn/46.1.91; DABIS F, 1993, AIDS, V7, P1139, DOI 10.1097/00002030-199308000-00027; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; Dushimimana A., 1992, 8 INT C AIDS AMST; GAL I, 1974, AM J CLIN NUTR, V27, P688, DOI 10.1093/ajcn/27.7.688; GARBE A, 1992, J EXP MED, V176, P109, DOI 10.1084/jem.176.1.109; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; GOEDERT JJ, 1989, LANCET, V2, P1351; GRAHAM NMH, 1991, J ACQ IMMUN DEF SYND, V4, P976; LEPAGE P, 1993, AM J EPIDEMIOL, V137, P589, DOI 10.1093/oxfordjournals.aje.a116716; MIOTTI PG, 1992, J INFECT DIS, V165, P1116, DOI 10.1093/infdis/165.6.1116; MIOTTI PG, 1993, 9TH INT C AIDS BERL; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SEMBA RD, 1993, LANCET, V341, P5, DOI 10.1016/0140-6736(93)92478-C; SEMBA RD, 1992, J NUTR, V122, P101, DOI 10.1093/jn/122.1.101; SEMBA RD, 1993, ARCH INTERN MED, V153, P2149, DOI 10.1001/archinte.153.18.2149; SEMBA RD, 1994, IN PRESS CLIN INFECT; SOMMER A, 1987, AM J CLIN NUTR, V45, P977, DOI 10.1093/ajcn/45.5.977; TANG AM, 1993, AM J EPIDEMIOL, V138, P937, DOI 10.1093/oxfordjournals.aje.a116814; Wallingford JC, 1986, VITAMIN A DEFICIENCY, P101; 1988, LANCET, V2, P1043; 1992, LANCET, V339, P1007	29	309	316	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1593	1597		10.1016/S0140-6736(94)93056-2	http://dx.doi.org/10.1016/S0140-6736(94)93056-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911919	hybrid			2022-12-01	WOS:A1994NU35400009
J	GEERTS, WH; CODE, KI; JAY, RM; CHEN, EL; SZALAI, JP				GEERTS, WH; CODE, KI; JAY, RM; CHEN, EL; SZALAI, JP			A PROSPECTIVE-STUDY OF VENOUS THROMBOEMBOLISM AFTER MAJOR TRAUMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; SPINAL-CORD INJURY; IMPEDANCE PLETHYSMOGRAPHY; PULMONARY-EMBOLISM; HIP-SURGERY; MULTIPLE TRAUMA; LEG; DIAGNOSIS; ULTRASONOGRAPHY; PHLEBOGRAPHY	Background, Although deep-vein thrombosis and pulmonary embolism are considered common complications after major trauma, their frequency and the associated risk factors have not been carefully quantified. Methods. We performed serial impedance plethysmography and lower-extremity contrast venography to detect deep-vein thrombosis in a cohort of 716 patients admitted to a regional trauma unit. Prophylaxis against thromboembolism was not used. Results. Deep-vein thrombosis in the lower extremities was found in 201 of the 349 patients (58 percent) with adequate venographic studies, and proximal-vein thrombosis was found in 63 (18 percent). Three patients died of massive pulmonary embolism before venography could be performed. Before venography, only three of the patients with deep-vein thrombosis had clinical features suggestive of the condition. Deep-vein thrombosis was found in 65 of the 129 patients with major injuries involving the face, chest, or abdomen (50 percent); in 49 of the 91 patients with major head injuries (54 percent); in 41 of the 66 with spinal injuries (62 percent); and in 126 of the 182 with lower-extremity orthopedic injuries (69 percent). Thrombi were detected in 61 of the 100 patients with pelvic fractures (61 percent), in 59 of the 74 with femoral fractures (80 percent), and in 66 of the 86 with tibial fractures (77 percent). A multivariate analysis identified five independent risk factors for deep-vein thrombosis: older age (odds ratio, 1.05 per year of age; 95 percent confidence interval, 1.03 to 1.06), blood transfusion (odds ratio, 1.74; 95 percent confidence interval, 1.03 to 2.93), surgery (odds ratio, 2.30; 95 percent confidence interval, 1.08 to 4.89), fracture of the femur or tibia (odds ratio, 4.82; 95 percent confidence interval, 2.79 to 8.33), and spinal cord injury (odds ratio, 8.59; 95 percent confidence interval, 2.92 to 25.28). Conclusions. Venous thromboembolism is a common complication in patients with major trauma, and effective, safe prophylactic regimens are needed.	UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, DEPT RES DESIGN & BIOSTAT, TORONTO M4N 3M5, ON, CANADA; UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, CLIN EPIDEMIOL UNIT, TORONTO M4N 3M5, ON, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	GEERTS, WH (corresponding author), UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, DEPT MED, RM D674, 2075 BAYVIEW AVE, TORONTO M4N 3M5, ON, CANADA.							AGNELLI G, 1991, ARCH INTERN MED, V151, P2167, DOI 10.1001/archinte.151.11.2167; ANDERSON FA, 1992, ARCH INTERN MED, V152, P1660, DOI 10.1001/archinte.152.8.1660; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bauer G, 1944, ACTA CHIR SCAND, V90, P229; BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; BORRIS LC, 1989, THROMB HAEMOSTASIS, V61, P363; BOULANGER BR, 1993, J TRAUMA, V35, P261, DOI 10.1097/00005373-199308000-00015; BURNS GA, 1993, J TRAUMA, V35, P405, DOI 10.1097/00005373-199309000-00012; CARSON JL, 1992, NEW ENGL J MED, V326, P1240, DOI 10.1056/NEJM199205073261902; CLAGETT GP, 1992, CHEST, V102, pS391, DOI 10.1378/chest.102.4_Supplement.391S; COLDITZ GA, 1986, LANCET, V2, P143; CRUICKSHANK MK, 1989, THROMB HAEMOSTASIS, V62, P830; DAVIDSON BL, 1992, ANN INTERN MED, V117, P735, DOI 10.7326/0003-4819-117-9-735; ELLIOTT CG, 1993, ANGIOLOGY, V44, P26, DOI 10.1177/000331979304400105; FREEARK RJ, 1967, ARCH SURG-CHICAGO, V95, P567; GILLUM RF, 1987, AM HEART J, V114, P1262, DOI 10.1016/0002-8703(87)90212-2; GINSBERG JS, 1991, RADIOLOGY, V181, P651, DOI 10.1148/radiology.181.3.1947076; HAAKE DA, 1989, CLIN ORTHOP RELAT R, P212; HARLAN LC, 1990, AM J PUBLIC HEALTH, V80, P453, DOI 10.2105/AJPH.80.4.453; HJELMSTEDT A, 1968, ACTA CHIR SCAND, V134, P209; Hosmer D, 2013, APPL LOGISTIC REGRES; HULL RD, 1985, CHEST, V88, P819, DOI 10.1378/chest.88.6.819; HULL RD, 1992, CHEST, V102, pS658; HULL RD, 1985, ANN INTERN MED, V102, P21, DOI 10.7326/0003-4819-102-1-21; HULL RD, 1984, CLIN CHEST MED, V5, P439; KAKKAR VV, 1970, AM J SURG, V120, P527, DOI 10.1016/S0002-9610(70)80023-X; KNUDSON MM, 1992, J TRAUMA, V32, P2, DOI 10.1097/00005373-199201000-00002; KUDSK KA, 1989, AM J SURG, V158, P515, DOI 10.1016/0002-9610(89)90182-7; McCartney JS, 1927, ARCH PATHOL LAB MED, V3, P921; MCMURTRY RY, 1989, CAN MED ASSOC J, V141, P555; MONTREY JS, 1985, J TRAUMA, V25, P534, DOI 10.1097/00005373-198506000-00011; Moser, 1988, J INTENSIVE CARE MED, V3, P87, DOI DOI 10.1177/088506668800300205; MYLLYNEN P, 1985, J TRAUMA, V25, P541, DOI 10.1097/00005373-198506000-00013; PAIEMENT G, 1988, AM J SURG, V155, P400, DOI 10.1016/S0002-9610(88)80099-0; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; SEVITT S, 1961, BRIT J SURG, V48, P475, DOI 10.1002/bjs.18004821103; SEVITT S, 1968, BRIT J SURG, V55, P481, DOI 10.1002/bjs.1800550702; SHACKFORD SR, 1990, AM J SURG, V159, P365, DOI 10.1016/S0002-9610(05)81272-3; VANCE BM, 1934, AM J SURG, V26, P19; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WEBB P, 1981, BRIT J SURG, V68, P807; WOOLSON ST, 1991, CLIN ORTHOP RELAT R, V273, P131; YELNIK A, 1991, PARAPLEGIA, V29, P253, DOI 10.1038/sc.1991.36; 1988, J TRAUMA, V28, P87; 1985, INJURY AM CONTINUING; 1992, J TRAUMA, V32, P130	46	992	1051	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 15	1994	331	24					1601	1606		10.1056/NEJM199412153312401	http://dx.doi.org/10.1056/NEJM199412153312401			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW446	7969340				2022-12-01	WOS:A1994PW44600001
J	WERNER, S; SMOLA, H; LIAO, X; LONGAKER, MT; KRIEG, T; HOFSCHNEIDER, PH; WILLIAMS, LT				WERNER, S; SMOLA, H; LIAO, X; LONGAKER, MT; KRIEG, T; HOFSCHNEIDER, PH; WILLIAMS, LT			THE FUNCTION OF KGF IN MORPHOGENESIS OF EPITHELIUM AND REEPITHELIALIZATION OF WOUNDS	SCIENCE			English	Article							KERATINOCYTE GROWTH-FACTOR; TRANSGENIC MICE; EXPRESSION; DIFFERENTIATION; RECEPTOR; INHIBITION; INSIGHTS; ALPHA; GENE; SKIN	The function of keratinocyte growth factor (KGF) in normal and wounded skin was assessed by expression of a dominant-negative KGF receptor transgene in basal keratinocytes. The skin of transgenic mice was characterized by epidermal atrophy, abnormalities in the hair follicles, and dermal hyperthickening. Upon skin injury, inhibition of KGF receptor signaling reduced the proliferation rate of epidermal keratinocytes at the wound edge, resulting in substantially delayed reepithelialization of the wound.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV COLOGNE,DERMATOL & VENEROL KLIN,D-50931 COLOGNE,GERMANY; NYU,MED CTR,INST RECONSTRUCT PLAST SURG,NEW YORK,NY 10016	University of California System; University of California San Francisco; University of Cologne; New York University	WERNER, S (corresponding author), MAX PLANCK INST BIOCHEM,KLOPFERSPITZ 18A,D-82152 MARTINSRIED,GERMANY.			Werner, Sabine/0000-0001-7397-8710	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL043821, R01HL032898] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL32898, HL-43821] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Clark RAF, 1991, PHYSL BIOCH MOL BIOL, P576; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; MARTIN P, 1992, Progress in Growth Factor Research, V4, P25, DOI 10.1016/0955-2235(92)90003-Z; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; PETERS KG, 1992, DEVELOPMENT, V114, P233; PIERCE GF, 1994, J EXP MED, V179, P831, DOI 10.1084/jem.179.3.831; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; STAIANOCOICO L, 1993, J EXP MED, V178, P865, DOI 10.1084/jem.178.3.865; TSUBOI R, 1993, J INVEST DERMATOL, V101, P49, DOI 10.1111/1523-1747.ep12358892; TURKSEN K, 1992, P NATL ACAD SCI USA, V89, P5068, DOI 10.1073/pnas.89.11.5068; UENO H, 1993, J BIOL CHEM, V268, P22814; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; UENO H, 1992, J BIOL CHEM, V267, P1397; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WERNER S, UNPUB	19	512	529	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					819	822		10.1126/science.7973639	http://dx.doi.org/10.1126/science.7973639			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973639				2022-12-01	WOS:A1994PP75300045
J	FARKAS, G; GAUSZ, J; GALLONI, M; REUTER, G; GYURKOVICS, H; KARCH, F				FARKAS, G; GAUSZ, J; GALLONI, M; REUTER, G; GYURKOVICS, H; KARCH, F			THE TRITHORAX-LIKE GENE ENCODES THE DROSOPHILA GAGA FACTOR	NATURE			English	Article							POSITION-EFFECT VARIEGATION; BITHORAX COMPLEX; TRANSCRIPTION; MELANOGASTER; CHROMATIN; PROTEINS; ANTIREPRESSION; SEGMENTATION; TRANSPOSON; EXPRESSION	LITTLE is known about the way higher-order chromatin structure influences gene expression and chromosome topology in general. Genetic analysis in Drosophila has led to the discovery of two classes of genes, the regulators of homeotic genes and the modifiers of position-effect variegation, which seem to be good candidates for encoding some of the factors regulating chromatin functions(1,2). The Trithorax-like gene we describe here is required for the normal expression of the homeotic genes and is a modifier of position-effect variegation. We found that Trithorax-like encodes the GAGA factor which is involved in the formation of an accessible chromatin structure at promoter sequences(3). Our genetic analysis suggests that the chromatin modelling function of the GAGA factor is not restricted to promoter regions.	HUNGARIAN ACAD SCI,BIOL RES CTR,INST GENET,H-6701 SZEGED,HUNGARY; UNIV GENEVA,DEPT ZOOL & ANIM BIOL,CH-1224 GENEVA,SWITZERLAND; UNIV HALLE WITTENBERG,INST GENET,D-06108 HALLE,GERMANY	Hungarian Academy of Sciences; Hungarian Biological Research Center; University of Geneva; Martin Luther University Halle Wittenberg			Galloni, Mireille/F-2665-2019	Galloni, Mireille/0000-0002-5099-1709				BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CELNIKER SE, 1990, EMBO J, V9, P4277, DOI 10.1002/j.1460-2075.1990.tb07876.x; CHI HC, 1991, DNA CELL BIOL, V10, P451, DOI 10.1089/dna.1991.10.451; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DIBELLO PR, 1991, GENETICS, V129, P385; DORN R, 1993, GENETICS, V133, P279; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; DUNCAN IM, 1982, GENETICS, V102, P49; GALLONI M, 1993, EMBO J, V12, P1087, DOI 10.1002/j.1460-2075.1993.tb05750.x; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GODT D, 1993, DEVELOPMENT, V119, P799; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; INGHAM PW, 1981, ROUX ARCH DEV BIOL, V190, P365, DOI 10.1007/BF00863275; KERRIGAN LA, 1991, J BIOL CHEM, V266, P574; LEE HS, 1992, GENE DEV, V6, P284, DOI 10.1101/gad.6.2.284; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LU Q, 1993, MOL CELL BIOL, V13, P2802, DOI 10.1128/MCB.13.5.2802; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; READ D, 1990, MOL CELL BIOL, V10, P4334, DOI 10.1128/MCB.10.8.4334; REUTER G, 1992, BIOESSAYS, V14, P605, DOI 10.1002/bies.950140907; SHEARN A, 1989, GENETICS, V121, P517; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; THUMMEL C, 1989, GENE DEV, V6, P2635; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9	27	343	353	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 27	1994	371	6500					806	808		10.1038/371806a0	http://dx.doi.org/10.1038/371806a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP018	7935842				2022-12-01	WOS:A1994PP01800062
J	WANG, Q; SCHOENLEIN, RW; PETEANU, LA; MATHIES, RA; SHANK, CV				WANG, Q; SCHOENLEIN, RW; PETEANU, LA; MATHIES, RA; SHANK, CV			VIBRATIONALLY COHERENT PHOTOCHEMISTRY IN THE FEMTOSECOND PRIMARY EVENT OF VISION	SCIENCE			English	Article							CIS-TRANS ISOMERIZATION; 1ST STEP; IMPULSIVE EXCITATION; DYNAMICS; BACTERIORHODOPSIN; RHODOPSIN; PHOTOISOMERIZATION; FEMTOCHEMISTRY; ISORHODOPSIN; SPECTROSCOPY	Femtosecond pump-probe experiments reveal the impulsive production of photoproduct in the primary event in vision. The retinal chromophore of rhodopsin was excited with a 35-femtosecond pulse at 500 nanometers, and transient changes in absorption were measured with 10-femtosecond probe pulses. At probe wavelengths within the photoproduct absorption band, oscillatory features with a period of 550 femtoseconds (60 wavenumbers) were observed whose phase and amplitude demonstrate that they are the result of nonstationary vibrational motion in the ground state of the photoproduct. The observation of coherent vibrational motion of the photoproduct supports the idea that the primary step in vision is a vibrationally coherent process and that the high quantum yield of the cis-->trans isomerization in rhodopsin is a consequence of the extreme speed of the excited-state torsional motion.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	University of California System; University of California Berkeley	WANG, Q (corresponding author), UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV MAT SCI,BERKELEY,CA 94720, USA.		Schoenlein, Robert W/D-1301-2014; Peteanu, Linda/O-5581-2017	Schoenlein, Robert W/0000-0002-6066-7566; Peteanu, Linda/0000-0003-0075-6521	NEI NIH HHS [EY-02051] Funding Source: Medline; NATIONAL EYE INSTITUTE [R37EY002051, R01EY002051] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAGCHI B, 1990, J PHYS CHEM-US, V94, P9, DOI 10.1021/j100364a004; BANIN U, 1993, J CHEM PHYS, V98, P4391, DOI 10.1063/1.465066; DEXHEIMER SL, 1992, CHEM PHYS LETT, V188, P61, DOI 10.1016/0009-2614(92)85089-S; DOUGHERTY TP, 1992, SCIENCE, V258, P770, DOI 10.1126/science.258.5083.770; FRAGNITO HL, 1989, CHEM PHYS LETT, V160, P101, DOI 10.1016/0009-2614(89)87564-5; KOCHENDOERFER G, 1994, 208TH NAT AM CHEM SO; Landau L. D., 1932, PHYS Z SOWJETUNION, V2, P46, DOI [DOI 10.1016/B978-0-08-010586-4.50014-6, DOI 10.1098/RSPA.1932.0165]; LOPPNOW GR, 1988, BIOPHYS J, V54, P35, DOI 10.1016/S0006-3495(88)82928-X; MATHIES RA, 1988, SCIENCE, V240, P777, DOI 10.1126/science.3363359; PALINGS I, 1987, BIOCHEMISTRY-US, V26, P2544, DOI 10.1021/bi00383a021; PETEANU LA, 1993, P NATL ACAD SCI USA, V90, P11762, DOI 10.1073/pnas.90.24.11762; POLLARD WT, 1992, J PHYS CHEM-US, V96, P6147, DOI 10.1021/j100194a013; ROSENFELD T, 1977, PURE APPL CHEM, V49, P341, DOI 10.1351/pac197749030341; SCHOENLEIN RW, 1991, APPL PHYS LETT, V58, P801, DOI 10.1063/1.104494; SCHOENLEIN RW, 1993, J PHYS CHEM-US, V97, P12087, DOI 10.1021/j100148a040; SCHOENLEIN RW, 1991, SCIENCE, V254, P412, DOI 10.1126/science.1925597; SENSION RJ, 1993, J CHEM PHYS, V98, P6291, DOI 10.1063/1.464824; VOS MH, 1993, NATURE, V363, P320, DOI 10.1038/363320a0; WARSHEL A, 1982, J AM CHEM SOC, V104, P1469, DOI 10.1021/ja00370a003; WARSHEL A, 1976, NATURE, V260, P679, DOI 10.1038/260679a0; WEISS RM, 1979, J AM CHEM SOC, V101, P6131, DOI 10.1021/ja00514a051; Zener C, 1932, P R SOC LOND A-CONTA, V137, P696, DOI 10.1098/rspa.1932.0165; ZEWAIL AH, 1988, SCIENCE, V242, P1645, DOI 10.1126/science.242.4886.1645; ZEWAIL AH, 1993, J PHYS CHEM-US, V97, P12427, DOI 10.1021/j100150a001	24	552	562	5	165	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 21	1994	266	5184					422	424		10.1126/science.7939680	http://dx.doi.org/10.1126/science.7939680			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7939680				2022-12-01	WOS:A1994PN27200030
J	STEVENS, CF; WANG, YY				STEVENS, CF; WANG, YY			CHANGES IN RELIABILITY OF SYNAPTIC FUNCTION AS A MECHANISM FOR PLASTICITY	NATURE			English	Article							LONG-TERM POTENTIATION; HIPPOCAMPAL SLICES; AREA CA1; PROBABILITY; DEPRESSION; RECORDINGS; INDUCTION; CURRENTS; RELEASE; NEURONS	SYNAPTIC transmission in the hippocampus is rather unreliable, with many presynaptic action potentials failing to release neurotransmitter(1-4). How is this unreliability affected by the alterations in synaptic strength seen in long-term potentiation (LTP)(5) and long-term depression(6,7) (LTD)? We find that LTP increases synaptic reliability, and LTD decreases it, both without a change in the size of those postsynaptic currents that do occur. Thus LTD is a functional inverse of LTP.			STEVENS, CF (corresponding author), SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,MOLEC NEUROBIOL LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92110, USA.							ALLEN C, IN PRESS P NATN ACAD; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; Korn S.J., 1991, METHODS NEUROSCIENCE, VVolume 4, P364; MALINOW R, 1986, NATURE, V320, P529, DOI 10.1038/320529a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x	18	317	318	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 20	1994	371	6499					704	707		10.1038/371704a0	http://dx.doi.org/10.1038/371704a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM773	7935816				2022-12-01	WOS:A1994PM77300057
J	BURGER, H; VANDAELE, PLA; ALGRA, D; HOFMAN, A; GROBBEE, DE; SCHUTTE, HE; BIRKENHAGER, JC; POLS, HAP				BURGER, H; VANDAELE, PLA; ALGRA, D; HOFMAN, A; GROBBEE, DE; SCHUTTE, HE; BIRKENHAGER, JC; POLS, HAP			VERTEBRAL DEFORMITIES AS PREDICTORS OF NON-VERTEBRAL FRACTURES	BRITISH MEDICAL JOURNAL			English	Article									ERASMUS UNIV ROTTERDAM,DEPT EPIDEMIOL & BIOSTAT RADIOL & INTERNAL MED,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam			Grobbee, Diederick/C-7651-2014	Grobbee, Diederick/0000-0003-4472-4468				COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; MELTON LJ, 1989, AM J EPIDEMIOL, V129, P1000, DOI 10.1093/oxfordjournals.aje.a115204; ROSS PD, 1991, ANN INTERN MED, V114, P919, DOI 10.7326/0003-4819-114-11-919; 1991, AM J MED, V90, P107	5	79	82	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 15	1994	309	6960					991	992		10.1136/bmj.309.6960.991	http://dx.doi.org/10.1136/bmj.309.6960.991			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PM417	7950721	Green Published			2022-12-01	WOS:A1994PM41700023
J	WHITE, RR; RIDGWAY, EJ				WHITE, RR; RIDGWAY, EJ			MANAGING INJURIES FROM SHARP INSTRUMENTS IN HEALTH-CARE WORKERS IN MERSEY	BRITISH MEDICAL JOURNAL			English	Article											WHITE, RR (corresponding author), ROYAL LIVERPOOL UNIV HOSP,DEPT MICROBIOL,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.							KIYOSAWA K, 1991, ANN INTERN MED, V115, P367, DOI 10.7326/0003-4819-115-5-367; MANIAN FA, 1992, ANN INTERN MED, V116, P345; Newman C P, 1992, Commun Dis Rep CDR Rev, V2, pR30; 1990, GUIDANCE CLIN HLTH C; 1992, COMMUNICABLE DISEASE, V2, pR97	5	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 15	1994	309	6960					989	990		10.1136/bmj.309.6960.989	http://dx.doi.org/10.1136/bmj.309.6960.989			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PM417	7950719	Green Published			2022-12-01	WOS:A1994PM41700021
J	GATTI, DL; PALFEY, BA; LAH, MS; ENTSCH, B; MASSEY, V; BALLOU, DP; LUDWIG, ML				GATTI, DL; PALFEY, BA; LAH, MS; ENTSCH, B; MASSEY, V; BALLOU, DP; LUDWIG, ML			THE MOBILE FLAVIN OF 4-OH BENZOATE HYDROXYLASE	SCIENCE			English	Article							PARA-HYDROXYBENZOATE HYDROXYLASE; CRYSTAL-STRUCTURE; PSEUDOMONAS-FLUORESCENS; CONFORMATIONAL CHANGE; ACTIVE-SITE; RESOLUTION; CHEMISTRY; MECHANISM	Para-hydroxybenzoate hydroxylase inserts oxygen into substrates by means of the labile intermediate, flavin C(4a)-hydroperoxide. This reaction requires transient isolation of the flavin and substrate from the bulk solvent. Previous crystal structures have revealed the position of the substrate para-hydroxybenzoate during oxygenation but not how it enters the active site. In this study, enzyme structures with the flavin ring displaced relative to the protein were determined, and it was established that these or similar flavin conformations also occur in solution. Movement of the flavin appears to be essential for the translocation of substrates and products into the solvent-shielded active site during catalysis.	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT BIOPHYS RES,ANN ARBOR,MI 48109; UNIV NEW ENGLAND,DEPT BIOCHEM & MICROBIOL,ARMIDALE,NSW 2351,AUSTRALIA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of New England			Lah, Myoung Soo/E-5885-2010; dballou@umich.edu, David P/A-1298-2007	Lah, Myoung Soo/0000-0001-9517-7519; Palfey, Bruce/0000-0001-5098-259X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011106, R01GM020877, R37GM020877, R37GM011106] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 11106, GM 20877, GM 16429] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ballou D. P., 1984, FLAVINS FLAVOPROTEIN, P605; BENNETT WS, 1978, P NATL ACAD SCI USA, V75, P4848, DOI 10.1073/pnas.75.10.4848; BRUICE TC, 1984, ISRAEL J CHEM, V24, P54; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1992, X PLOR VERSION 3 1; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; ENTSCH B, 1991, J BIOL CHEM, V266, P17341; ENTSCH B, 1989, BIOCHIM BIOPHYS ACTA, V999, P313, DOI 10.1016/0167-4838(89)90014-9; ENTSCH B, 1976, J BIOL CHEM, V251, P2550; ENTSCH B, IN PRESS FLAVINS FLA; GERSTEIN M, 1993, J MOL BIOL, V229, P494, DOI 10.1006/jmbi.1993.1048; GHISLA S, 1986, BIOCHEMISTRY-US, V25, P3282, DOI 10.1021/bi00359a030; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; LAH MS, 1994, BIOCHEMISTRY-US, V33, P1555, DOI 10.1021/bi00172a036; LAH MS, IN PRESS FLAVINS FLA; MERENYI G, 1991, J AM CHEM SOC, V113, P3146, DOI 10.1021/ja00008a051; Mitchell P, 1966, CHEMIOSMOTIC COUPLIN; Ornston L N, 1977, Curr Top Cell Regul, V12, P209; READ RJ, 1990, ACTA CRYSTALLOGR A, V46, P900, DOI 10.1107/S0108767390005529; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SCHREUDER HA, 1989, J MOL BIOL, V208, P679, DOI 10.1016/0022-2836(89)90158-7; SCHREUDER HA, 1988, J MOL BIOL, V199, P637, DOI 10.1016/0022-2836(88)90307-5; SCHREUDER HA, 1992, PROTEINS, V14, P178, DOI 10.1002/prot.340140205; SCHREUDER HA, 1990, BIOCHEMISTRY-US, V29, P3101, DOI 10.1021/bi00464a029; SCHREUDER HA, 1988, J BIOL CHEM, V263, P3131; Schulz GE, 1991, CURR OPIN STRUC BIOL, V1, P883, DOI 10.1016/0959-440X(91)90082-5; SHARP KA, 1990, ANNU REV BIOPHYS BIO, V19, P301, DOI 10.1146/annurev.bb.19.060190.001505; SHOUN H, 1983, J BIOCHEM-TOKYO, V93, P169, DOI 10.1093/oxfordjournals.jbchem.a134151; STEENNIS PJ, 1973, FEBS LETT, V36, P177, DOI 10.1016/0014-5793(73)80363-1; VERVOORT J, 1991, EUR J BIOCHEM, V200, P731, DOI 10.1111/j.1432-1033.1991.tb16238.x; VINOGRADOV AD, 1994, BIOPHYS J, V66, pA12; WIERENGA RK, 1979, J MOL BIOL, V131, P55, DOI 10.1016/0022-2836(79)90301-2; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	34	175	176	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 7	1994	266	5182					110	114		10.1126/science.7939628	http://dx.doi.org/10.1126/science.7939628			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7939628				2022-12-01	WOS:A1994PK58200035
J	CAFORIO, ALP; KEELING, PJ; ZACHARA, E; MESTRONI, L; CAMERINI, F; MANN, JM; BOTTAZZO, GF; MCKENNA, WJ				CAFORIO, ALP; KEELING, PJ; ZACHARA, E; MESTRONI, L; CAMERINI, F; MANN, JM; BOTTAZZO, GF; MCKENNA, WJ			EVIDENCE FROM FAMILY STUDIES FOR AUTOIMMUNITY IN DILATED CARDIOMYOPATHY	LANCET			English	Article							I DIABETES-MELLITUS; CARDIAC ANTIBODIES; AUTOANTIBODIES; ASSOCIATION	Organ-specific antibodies are found in patients with autoimmune disease and their symptom-free relatives many years before clinical onset. Organ-specific cardiac antibodies can be found in patients with dilated cardiomyopathy (DCM) and their relatives, which supports the idea that DCM is an autoimmune disease. We did non-invasive cardiological assessment and antibody screening in 342 symptom-free relatives (170 male, 172 female, mean [SD] age 31 [16] years). 177 relatives were from 33 families with more than 1 affected individual (familial DCM) and 165 relatives from 31 families with only 1 affected member (non-familial DCM). The frequency of cardiac antibodies was higher among relatives of DCM patients than in controls (20% vs 3.5%, p = 0.0001). In 37 (58%) of the families studied, cardiac antibodies were found in the proband and/or in at least 1 family member and were more common in familial than in non-familial DCM (24% vs 15%, p = 0.036). Antibody-positive relatives were younger (26 [15] vs 33 [17] years, p = 0.01) and had a larger mean echocardiographic left ventricular end-systolic dimension (35 [6] vs 32 [6], p = 0.01 mm) and reduced percentage fractional shortening compared with antibody-negative relatives (31 [6] vs 34 [6], p = 0.008). Presence of cardiac-specific autoantibodies in symptom-free DCM relatives provides evidence of autoimmunity in a subset of our patients (58%), including familial and nonfamilial forms of DCM. These antibodies are associated with mild left ventricular systolic dysfunction on echocardiography and may be early markers for relatives at risk of DCM.	ST GEORGE HOSP,SCH MED,DEPT CARDIOL SCI,LONDON SW17 0RE,ENGLAND; ST GEORGE HOSP,SCH MED,DEPT CARDIOVASC PATHOL,LONDON SW17 0RE,ENGLAND; UNIV PADUA,INST CLIN MED,DEPT CARDIOL,PADUA,ITALY; LONDON HOSP,COLL MED,DEPT IMMUNOL,LONDON E1 1BB,ENGLAND; SAN CAMILLO HOSP,ROME,ITALY; INT CTR GENET ENGN & BIOTECHNOL,I-34012 TRIESTE,ITALY; UNIV HOSP TRIESTE,TRIESTE,ITALY	St Georges University London; St Georges University London; University of Padua; University of London; Queen Mary University London; International Center for Genetic Engineering & Biotechnology (ICGEB)			Caforio, Alida/AAC-3223-2019; McKenna, William J/C-3243-2008	McKenna, William J/0000-0001-7994-2460; Caforio, Alida Linda Patrizia/0000-0002-4901-5655; Mestroni, Luisa/0000-0003-1116-2286				Aretz H.T., 1985, AM J CARDIOL PATHOL, V1, P1; BRANDENBURG RO, 1981, CIRCULATION, V64, pA437; CAFORIO ALP, 1992, TISSUE ANTIGENS, V39, P236, DOI 10.1111/j.1399-0039.1992.tb01941.x; CAFORIO ALP, 1992, CIRCULATION, V85, P1734, DOI 10.1161/01.CIR.85.5.1734; CAFORIO ALP, 1991, LANCET, V337, P1111, DOI 10.1016/0140-6736(91)92784-Y; CAFORIO ALP, 1990, J AM COLL CARDIOL, V15, P1527, DOI 10.1016/0735-1097(90)92821-I; CARLQUIST JF, 1991, CIRCULATION, V83, P515, DOI 10.1161/01.CIR.83.2.515; FUSTER V, 1981, AM J CARDIOL, V47, P525, DOI 10.1016/0002-9149(81)90534-8; HENRY WL, 1980, CIRCULATION, V62, P1054, DOI 10.1161/01.CIR.62.5.1054; KARJALAINEN J, 1989, NEW ENGL J MED, V320, P881, DOI 10.1056/NEJM198904063201401; KLEIN R, 1984, CLIN EXP IMMUNOL, V58, P283; LIMAS CJ, 1989, CIRC RES, V64, P97, DOI 10.1161/01.RES.64.1.97; MAGNUSSON Y, 1990, J CLIN INVEST, V86, P1658, DOI 10.1172/JCI114888; MAISCH B, 1983, AM J CARDIOL, V52, P1072, DOI 10.1016/0002-9149(83)90535-0; MANOLIO TA, 1992, AM J CARDIOL, V69, P1458, DOI 10.1016/0002-9149(92)90901-A; MESTRONI L, 1990, AM J CARDIOL, V65, P1449, DOI 10.1016/0002-9149(90)91353-8; MICHELS VV, 1992, NEW ENGL J MED, V326, P77, DOI 10.1056/NEJM199201093260201; NEUMANN DA, 1990, J AM COLL CARDIOL, V16, P839; SCHULTHEISS HP, 1985, J MOL CELL CARDIOL, V17, P603, DOI 10.1016/S0022-2828(85)80029-8; SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1; SRIKANTA S, 1983, NEW ENGL J MED, V308, P322, DOI 10.1056/NEJM198302103080607; ZACHARA E, 1993, BRIT HEART J, V69, P129; 1978, AM J CARDIOL, V0041, P00130	23	124	126	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					773	777		10.1016/S0140-6736(94)92339-6	http://dx.doi.org/10.1016/S0140-6736(94)92339-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916071				2022-12-01	WOS:A1994PG17800008
J	WEISS, APC				WEISS, APC			THERMAL REGULATORY TESTING FOR PAIN DYSFUNCTION SYNDROMES	LANCET			English	Editorial Material							REFLEX SYMPATHETIC DYSTROPHY				WEISS, APC (corresponding author), BROWN UNIV,SCH MED,DEPT ORTHOPED,PROVIDENCE,RI 02912, USA.							AMADIO PC, 1988, J BONE JOINT SURG AM, V70A, P944, DOI 10.2106/00004623-198870060-00024; COOKE ED, 1993, J ROY SOC MED, V86, P690; HOLDER LE, 1984, RADIOLOGY, V152, P517, DOI 10.1148/radiology.152.2.6739825; KOMAN LA, 1984, J HAND SURG-AM, V9A, P305, DOI 10.1016/S0363-5023(84)80214-2; LINSON MA, 1983, J HAND SURG-AM, V8, P153, DOI 10.1016/S0363-5023(83)80006-9; POCHACZEVSKY R, 1987, AM J SPORT MED, V15, P243, DOI 10.1177/036354658701500309; POLLOCK FE, 1993, J HAND SURG-AM, V18A, P847; WERNER R, 1989, J HAND SURG-AM, V14A, P520, DOI 10.1016/S0363-5023(89)80016-4; 1986, PAIN S3, V26, pS29	9	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					209	210		10.1016/S0140-6736(94)92990-4	http://dx.doi.org/10.1016/S0140-6736(94)92990-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913150				2022-12-01	WOS:A1994NY06000002
J	CAPLICE, NM; WEST, MJ; CAMPBELL, GR; CAMPBELL, J				CAPLICE, NM; WEST, MJ; CAMPBELL, GR; CAMPBELL, J			INHIBITION OF HUMAN VASCULAR SMOOTH-MUSCLE CELL-GROWTH BY HEPARIN	LANCET			English	Note							EXPRESSION	We examined the inhibitory effect of heparin on vascular smooth muscle cell (VSMC) outgrowth from cultured coronary artery explants of primary atherosclerotic lesions and of undiseased regions from the same patients, compared with explant outgrowth from control patients (idiopathic cardiomyopathy) with no evidence of atherosclerosis. For undiseased tissue regardless of origin, heparin significantly delayed half-maximum percentage explant outgrowth time (mean difference from control treatment 2.1 [SE 0.8] days for atherosclerosis patients and 2.3 [1.0] days for control patients). For plaque tissue, hepa rin had no such effect. Thus the proliferative state of the cells involved in outgrowth may influence the activity of heparin.	UNIV QUEENSLAND,DEPT ANAT SCI,VASC BIOL RES CTR,BRISBANE,QLD,AUSTRALIA	University of Queensland	CAPLICE, NM (corresponding author), UNIV QUEENSLAND,PRINCE CHARLES HOSP,DEPT MED,BRISBANE,QLD 4032,AUSTRALIA.		CAMPBELL, GORDON/AAK-7979-2021; west, malcolm J/C-9425-2009	CAMPBELL, GORDON/0000-0003-1263-1988; west, malcolm J/0000-0002-7629-5277; Caplice, Noel/0000-0001-5445-1016				AU YPT, 1992, CIRC RES, V70, P1062, DOI 10.1161/01.RES.70.5.1062; CASTELLOT JJ, 1985, J CELL PHYSIOL, V124, P21, DOI 10.1002/jcp.1041240105; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CHAN P, 1993, LANCET, V341, P341, DOI 10.1016/0140-6736(93)90139-8; CLOWES AW, 1988, J CELL BIOL, V107, P1939, DOI 10.1083/jcb.107.5.1939; CLOWES AW, 1992, CIRC RES, V70, P1128, DOI 10.1161/01.RES.70.6.1128; LEVINE S, 1985, AM J CARDIOL, V55, P673, DOI 10.1016/0002-9149(85)90134-1; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427	8	29	29	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 9	1994	344	8915					97	98		10.1016/S0140-6736(94)91283-1	http://dx.doi.org/10.1016/S0140-6736(94)91283-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7912394				2022-12-01	WOS:A1994NV73200011
J	AUGARTEN, A; YAHAV, Y; KEREM, BS; HALLE, D; LAUFER, J; SZEINBERG, A; DOR, J; MASHIACH, S; GAZIT, E; MADGAR, I				AUGARTEN, A; YAHAV, Y; KEREM, BS; HALLE, D; LAUFER, J; SZEINBERG, A; DOR, J; MASHIACH, S; GAZIT, E; MADGAR, I			CONGENITAL BILATERAL ABSENCE OF VAS-DEFERENS IN THE ABSENCE OF CYSTIC-FIBROSIS	LANCET			English	Note							MEN	The high frequency of mutations in the cystic fibrosis gene in patients with congenital bilateral absence of vas deferens (CBAVD) has raised the question whether all of them have a genital form of cystic fibrosis. We investigated 47 CBAVD patients by ultrasonography, 10 (21%) had renal malformations and 37 (79%) did not. In the former group, no cystic fibrosis mutations were found and sweat chloride concentrations were normal. In the latter group, 18 patients (49%) carried at least one cystic fibrosis mutation and sweat chloride was high in 17 of 26 tested (65%). Our findings suggest that CBAVD patients with renal malformations do not necessarily have cystic fibrosis.	CHAIM SHEBA MED CTR,DEPT GYNAECOL,IL-52621 TEL HASHOMER,ISRAEL; CHAIM SHEBA MED CTR,DEPT UROL,IL-52621 TEL HASHOMER,ISRAEL; CHAIM SHEBA MED CTR,TISSUE TYPING LAB,IL-52621 TEL HASHOMER,ISRAEL; TEL AVIV UNIV,SACKLER SCH MED,IL-69978 TEL AVIV,ISRAEL; HEBREW UNIV JERUSALEM,DEPT GENET,IL-91904 JERUSALEM,ISRAEL	Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem	AUGARTEN, A (corresponding author), CHAIM SHEBA MED CTR,DEPT PAEDIAT,IL-52621 TEL HASHOMER,ISRAEL.							AMOS JA, 1992, PEDIAT PULMON S, V8, P142; ANGUIANO A, 1992, JAMA-J AM MED ASSOC, V267, P1794, DOI 10.1001/jama.267.13.1794; DUMUR V, 1990, LANCET, V336, P512, DOI 10.1016/0140-6736(90)92066-Q; OATES RD, 1994, J ANDROL, V15, P1; OATES RD, 1993, WORLD J UROL, V11, P82; OSBORNE LR, 1993, HUM MOL GENET, V2, P1605, DOI 10.1093/hmg/2.10.1605; RUBIN SO, 1975, SCAND J UROL NEPHROL, V9, P94, DOI 10.3109/00365597509180913; 1992, LANCET, V339, P1328	8	96	97	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 26	1994	344	8935					1473	1474		10.1016/S0140-6736(94)90292-5	http://dx.doi.org/10.1016/S0140-6736(94)90292-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7968122				2022-12-01	WOS:A1994PT99500011
J	MCANULTY, JM; FLEMING, DW; GONZALEZ, AH				MCANULTY, JM; FLEMING, DW; GONZALEZ, AH			A COMMUNITY-WIDE OUTBREAK OF CRYPTOSPORIDIOSIS ASSOCIATED WITH SWIMMING AT A WAVE POOL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DAY-CARE-CENTER; GIARDIA; IMMUNOCOMPETENT; CONTAMINATION; TRANSMISSION; DIARRHEA; GEORGIA; CALVES	Objective.-To determine the cause of a community-wide outbreak of cryptosporidiosis. Design.-A matched case-control study. Setting.-General community of Lane County, Oregon. Patients and Other Participants.-Persons with Cryptosporidium detected in their stool from June to October 1992 were identified by contacting laboratories serving the area. Exposures of the first 18 case patients identified were compared with those of 18 age- and neighborhood-matched controls selected from a reverse telephone directory. Main Outcome Measures.-Reported exposures to risk factors for cryptosporidiosis and abatement of cryptosporidiosis outbreak. Results.-Fifty-five patients with cryptosporidiosis were detected, including 37 who were the first individuals ill in their households. The case-control study involving the first 18 case patients showed no association between illness and attendance at day care or drinking municipal water or drinking untreated surface waters (river or lake water) in the 2 weeks before onset of illness. However, nine of 18 case patients reported swimming at a local wave pool, compared with none of 18 controls. We ultimately identified 17 case patients who reported swimming at the same wave pool during their incubation periods, whose exposure dates spanned a 2-month period. Inspection of the pool's filtration system did not detect any abnormalities. The outbreak subsided after the pool water was drained and replaced. Conclusions.-This prolonged outbreak of cryptosporidiosis was likely caused by exposure to fecally contaminated wave pool water. Since Cryptosporidium is highly chlorine resistant and inadequately removed by sand filters, such outbreaks may represent an unrecognized hazard of wave pools, where the likelihood of inadvertent water ingestion is high. Such outbreaks may go undetected in areas where cryptosporidiosis is not reportable or laboratory screening is infrequent.	CTR DIS CONTROL & PREVENT,DIV FIELD EPIDEMIOL,EPIDEM INTELLIGENCE SERV,ATLANTA,GA 30341; OREGON MED LABS,EUGENE,OR	Centers for Disease Control & Prevention - USA	MCANULTY, JM (corresponding author), OREGON HLTH DIV,CTR DIS CONTROL & PREVENT,800 NE OREGON ST,PORTLAND,OR 97232, USA.							ADDISS DG, 1991, PEDIATR INFECT DIS J, V10, P907, DOI 10.1097/00006454-199112000-00005; CASEMORE DP, 1989, J INFECTION, V19, P101, DOI 10.1016/S0163-4453(89)91764-7; CRAWFORD FG, 1988, PEDIATR INFECT DIS J, V7, P806, DOI 10.1097/00006454-198811000-00013; CURRENT WL, 1983, NEW ENGL J MED, V308, P1252, DOI 10.1056/NEJM198305263082102; DANTONIO RG, 1985, ANN INTERN MED, V103, P886, DOI 10.7326/0003-4819-103-6-886; DEAN AG, 1994, EPI INFO VERSION 6; FERSON MJ, 1992, MED J AUSTRALIA, V156, P813, DOI 10.5694/j.1326-5377.1992.tb121578.x; GARCIA LS, 1988, DIAGNOSTIC MED PARAS, P389; GREENSMITH CT, 1988, PEDIATR INFECT DIS J, V7, P91, DOI 10.1097/00006454-198802000-00005; HAYES EB, 1989, NEW ENGL J MED, V320, P1372, DOI 10.1056/NEJM198905253202103; JOCE RE, 1991, EPIDEMIOL INFECT, V107, P497, DOI 10.1017/S0950268800049190; KORICH DG, 1990, APPL ENVIRON MICROB, V56, P1423, DOI 10.1128/AEM.56.5.1423-1428.1990; LECHEVALLIER MW, 1991, GIARDIA CRYPTOSPORID; MEISEL JL, 1976, GASTROENTEROLOGY, V70, P1156; MILLER RA, 1990, J INFECT DIS, V161, P312, DOI 10.1093/infdis/161.2.312; MIRON D, 1991, PEDIATR INFECT DIS J, V10, P438, DOI 10.1097/00006454-199106000-00004; NAVIN TR, 1984, REV INFECT DIS, V6, P313; NIME FA, 1976, GASTROENTEROLOGY, V70, P592; PORTER JD, 1988, AM J PUBLIC HEALTH, V78, P659, DOI 10.2105/AJPH.78.6.659; REIF JS, 1989, AM J PUBLIC HEALTH, V79, P1528, DOI 10.2105/AJPH.79.11.1528; ROSE JB, 1991, ENVIRON SCI TECHNOL, V25, P1393, DOI 10.1021/es00020a005; SCHULER PF, 1990, J AM WATER WORKS ASS, V82, P67; SMITH HV, 1989, EPIDEMIOL INFECT, V103, P703, DOI 10.1017/S0950268800031101; SORVILLO FJ, 1992, AM J PUBLIC HEALTH, V82, P742, DOI 10.2105/AJPH.82.5.742; Sterling C.R., 1990, P51; TANGERMANN RH, 1991, AM J EPIDEMIOL, V133, P471, DOI 10.1093/oxfordjournals.aje.a115914; WEBER J, 1983, NEW ENGL J MED, V309, P1326; WOLFSON JS, 1985, NEW ENGL J MED, V312, P1278, DOI 10.1056/NEJM198505163122002; 1993, CD SUMMARY, V42, P1; 1994, MMWR-MORBID MORTAL W, V43, P561; 1984, MMWR-MORBID MORTAL W, V33, P599	31	64	68	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 23	1994	272	20					1597	1600		10.1001/jama.272.20.1597	http://dx.doi.org/10.1001/jama.272.20.1597			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR405	7966870				2022-12-01	WOS:A1994PR40500026
J	STERN, RS				STERN, RS			DRUG PROMOTION FOR AN UNLABELED INDICATION - THE CASE OF TOPICAL TRETINOIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Harvard Medical School	STERN, RS (corresponding author), BETH ISRAEL HOSP,DEPT DERMATOL,330 BROOKLINE AVE,BOSTON,MA 02215, USA.							DELOZIER JE, 1987, DHHS PHS821364 NAT C; HOROWITZ GL, 1981, NEW ENGL J MED, V305, P924, DOI 10.1056/NEJM198110153051605; KESSLER DA, 1991, NEW ENGL J MED, V325, P201, DOI 10.1056/NEJM199107183250310; KRIPKE ML, 1980, J AM ACAD DERMATOL, V2, P439, DOI 10.1016/S0190-9622(80)80373-2; LIMERICK Z, 1977, READERS GUIDE PERIOD, V36; RANDALL T, 1991, JAMA-J AM MED ASSOC, V266, P11, DOI 10.1001/jama.266.1.11; SCHAPPERT SM, 1993, DHHS PHS931250 NAT C; WEISS JS, 1988, JAMA-J AM MED ASSOC, V259, P527, DOI 10.1001/jama.259.4.527; Weiss JS, 1988, JAMA-J AM MED ASSOC, V260, P926; WEISS JS, 1988, JAMA-J AM MED ASSOC, V259, P3274; 1987, DRUG TOPICS RED BOOK; 1985, J AM ACAD DERMATOL, V13, pA60; 1989, J AM ACAD DERMATOL, V20, pA100; 1980, VITAL HLTH STATIST 2, V90; 1991, DRUG TOPICS RED BOOK; 1991, FDC REPORTS PINK SHE, V53; 1978, NY TIMES INDEX BOOK, V65; 1978, FDA DRUG B, V8, P26	18	13	13	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 17	1994	331	20					1348	1349		10.1056/NEJM199411173312006	http://dx.doi.org/10.1056/NEJM199411173312006			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR216	7935705				2022-12-01	WOS:A1994PR21600006
J	HUYSMANS, DAKC; HERMUS, ARMM; CORSTENS, FHM; BARENTSZ, JO; KLOPPENBORG, PWC				HUYSMANS, DAKC; HERMUS, ARMM; CORSTENS, FHM; BARENTSZ, JO; KLOPPENBORG, PWC			LARGE, COMPRESSIVE GOITERS TREATED WITH RADIOIODINE	ANNALS OF INTERNAL MEDICINE			English	Article						IODINE RADIOISOTOPES; GOITER, NODULAR; AGED; SURGERY, OPERATIVE; LEVOTHYROXINE	MULTINODULAR NONTOXIC GOITER; RADIOACTIVE IODINE; TOXIC GOITER; THERAPY; HYPERTHYROIDISM; THYROIDECTOMY; MANAGEMENT; THYROXINE; DISEASE	Objective: To evaluate the effectiveness of radioiodine therapy as an alternative for surgery in elderly patients with a large, compressive goiter using objective methods for measuring thyroid volume and tracheal compression. Design: Prospective study. Setting: University hospital in the Netherlands. Patients: 19 patients (mean age +/- SD, 66 +/- 14 years) with a large, compressive multinodular goiter who had a high operative risk or refused to have thyroid surgery. Intervention: A single intravenous dose of I-131 at 2.6 +/- 1.0 GBq (70 +/- 28 mCi) (3.7 MBq or 100 mu Ci/g of thyroid tissue), followed by daily administration of L-thyroxine in doses that did not suppress thyroid-stimulating hormone. Measurements: Clinical evaluation and measurements of thyroid volume, maximal tracheal deviation, and the smallest cross-sectional area of the tracheal lumen with magnetic resonance imaging before and 1 year after I-131 treatment. Results: No exacerbation of compressive symptoms after I-131 therapy was observed. Thyroid volume was 269 +/- 153 mL before treatment and 154 +/- 73 mL 1 year after treatment (P < 0.001). Thyroid volume was reduced 40% +/- 15% (range, 19% to 68%). Maximal tracheal deviation (1.9 +/- 0.8 cm before and 1.5 +/- 0.7 cm 1 year after therapy) had decreased by 20% +/- 20% (range, -4% to 73%; P < 0.001), and the smallest cross-sectional area of the tracheal lumen (0.78 +/- 0.38 cm(2) before and 1.04 +/- 0.48 cm(2) 1 year after therapy) had increased by 36% +/- 38% (range, -3% to 125%; P < 0.001). Clinical signs and symptoms improved in 8 of 12 patients with dyspnea and inspiratory strider and in both patients with compression of the superior vena cava. Conclusions:Therapy with I-131 is an effective alternative to surgery for elderly patients with a large, compressive multinodular goiter.	UNIV NIJMEGEN HOSP, DEPT ENDOCRINOL, 6500 HB NIJMEGEN, NETHERLANDS	Radboud University Nijmegen	HUYSMANS, DAKC (corresponding author), DEWEEZENLANDEN HOSP, DEPT NUCL MED, POB 10500, 8000 GM ZWOLLE, NETHERLANDS.		Barentsz, Jelle/D-3515-2009; Hermus, A.R.M.M./H-8043-2014	Hermus, A.R.M.M./0000-0003-1075-2655				BERDING G, 1990, NUKLEARMED, V29, P158; BERGHOUT A, 1989, CLIN ENDOCRINOL, V31, P193, DOI 10.1111/j.1365-2265.1989.tb01242.x; BERGHOUT A, 1988, CLIN ENDOCRINOL, V28, P409, DOI 10.1111/j.1365-2265.1988.tb03672.x; BERGHOUT A, 1990, LANCET, V336, P193, DOI 10.1016/0140-6736(90)91730-X; BLIDDAL H, 1982, ACTA ENDOCRINOL-COP, V99, P517, DOI 10.1530/acta.0.0990517; Cooper DS, 1991, WERNER INGBARS THYRO, P887; DeGroot LJ, 1975, THYROID ITS DISEASES, P314; DOERING P, 1958, Strahlentherapie, V105, P245; FOSTER RS, 1978, SURG GYNECOL OBSTET, V146, P423; FREY KW, 1979, FORTSCHR RONTG NEUEN, V130, P172; GEERDSEN JP, 1984, CLIN ENDOCRINOL, V21, P529, DOI 10.1111/j.1365-2265.1984.tb01391.x; HAMBURGER JI, 1985, J NUCL MED, V26, P888; HEGEDUS L, 1990, DAN MED BULL, V37, P249; HOLM LE, 1991, JNCI-J NATL CANCER I, V83, P1072, DOI 10.1093/jnci/83.15.1072; HUYSMANS DAKC, 1994, BRIT J RADIOL, V67, P519, DOI 10.1259/0007-1285-67-798-519; KAY TWH, 1987, ANN INTERN MED, V107, P857, DOI 10.7326/0003-4819-107-6-857; KAY TWH, 1988, AM J MED, V84, P19, DOI 10.1016/0002-9343(88)90003-4; KEIDERLING W, 1964, DEUT MED WOCHENSCHR, V89, P453, DOI 10.1055/s-0028-1111038; MILLER MR, 1990, Q J MED, V74, P177; NYGAARD B, 1993, BRIT MED J, V307, P828, DOI 10.1136/bmj.307.6908.828; Rohrer F, 1915, PFLUG ARCH GES PHYS, V162, P225, DOI 10.1007/BF01681259; SAILER R, 1986, CHIRURGIE SCHILDDRUS, P77; SHIMAOKA K, 1974, AM J MED, V57, P576, DOI 10.1016/0002-9343(74)90009-6; STUDLEY J, 1993, SURG ENDOCRINOLOGY, P231; TAMMELING GJ, 1979, CONTOURS BREATHING, V1, P76; VERELST J, 1990, ACTA ENDOCRINOL-COP, V122, P417, DOI 10.1530/acta.0.1220417; WEITENSFELDER W, 1989, CHIRURG, V60, P29	27	115	115	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1994	121	10					757	762		10.7326/0003-4819-121-10-199411150-00005	http://dx.doi.org/10.7326/0003-4819-121-10-199411150-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ928	7944053				2022-12-01	WOS:A1994PQ92800005
J	ROLLS, MM; WEBSTER, P; BALBA, NH; ROSE, JK				ROLLS, MM; WEBSTER, P; BALBA, NH; ROSE, JK			NOVEL INFECTIOUS PARTICLES GENERATED BY EXPRESSION OF THE VESICULAR STOMATITIS-VIRUS GLYCOPROTEIN FROM A SELF-REPLICATING RNA	CELL			English	Article							SEMLIKI FOREST VIRUS; CELL-SURFACE; ANIMAL-CELLS; SINDBIS VIRUS; RABIES VIRUS; G-PROTEIN; TRANSPORT; MEMBRANE; MUTANTS; VECTORS	Self-propagating infectious particles were produced in animal cells transfected with an RNA replicon encoding a single viral structural protein, the vesicular stomatitis virus glycoprotein (VSV-G). The replicon is derived from an alphavirus, Semliki Forest virus (SFV), and encodes the SFV RNA replicase, but none of the SFV structural proteins. After transfection of the replicon into tissue culture cells, expression of G protein spread from small foci throughout the culture. Supernatants from the cells contained infectious, virus-like particles that could be passaged and were neutralized by anti-VSV serum. The majority of the infectious particles were smaller and less dense than either VSV or SFV. Characterization by electron microscopy showed membrane-enveloped vesicles that contained the VSV-G protein. Infectious particles were apparently generated by budding of vesicles containing VSV-G protein and the RNA replicon. These experiments reveal that an enveloped infectious agent can be much simpler than previously thought.	YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT BIOL, NEW HAVEN, CT 06510 USA	Yale University; Yale University; Yale University			Rolls, Melissa/G-6402-2014	Rolls, Melissa/0000-0002-5021-4360; Webster, Paul/0000-0002-1980-6931	NIAID NIH HHS [AI-24345] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024345, R37AI024345] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BROWN T, 1993, CURRENT PROTOCOLS MO; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FLORKIEWICZ RZ, 1984, SCIENCE, V225, P721, DOI 10.1126/science.6087454; FROSHAUER S, 1988, J CELL BIOL, V107, P2075, DOI 10.1083/jcb.107.6.2075; GRAHAM JM, 1988, BIOCHEM J, V252, P437, DOI 10.1042/bj2520437; GRIMLEY PM, 1968, J VIROL, V2, P1326, DOI 10.1128/JVI.2.11.1326-1338.1968; HARTFORD SL, 1975, P NATL ACAD SCI USA, V72, P1202, DOI 10.1073/pnas.72.3.1202; KAARIAINEN L, 1969, ANN MED EXP BIOL FEN, V47, P235; Kelley J M, 1972, J Virol, V10, P1231; KNIPE DM, 1977, J VIROL, V21, P1149, DOI 10.1128/JVI.21.3.1149-1158.1977; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; MACHAMER CE, 1988, J BIOL CHEM, V263, P5948; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; MATLIN KS, 1982, J MOL BIOL, V156, P609, DOI 10.1016/0022-2836(82)90269-8; MCCOMBS RM, 1966, J BACTERIOL, V91, P803, DOI 10.1128/JB.91.2.803-812.1966; METSIKKO K, 1986, EMBO J, V5, P1913, DOI 10.1002/j.1460-2075.1986.tb04444.x; OWENS RJ, 1993, J VIROL, V67, P360, DOI 10.1128/JVI.67.1.360-365.1993; PAUL NL, 1993, AIDS RES HUM RETROV, V9, P963, DOI 10.1089/aid.1993.9.963; RICE CM, 1987, J VIROL, V61, P3809, DOI 10.1128/JVI.61.12.3809-3819.1987; RIEDEL H, 1984, EMBO J, V3, P1477, DOI 10.1002/j.1460-2075.1984.tb01999.x; ROSE J, 1987, RHABDOVIRUSES; ROSE JK, 1983, CELL, V34, P513, DOI 10.1016/0092-8674(83)90384-7; ROSE JK, 1982, J VIROL, V43, P361, DOI 10.1128/JVI.43.1.361-364.1982; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; SCHLESINGER MJ, 1986, TOGAVIRIDAE FLAVIVIR; SIMONS K, 1980, J GEN VIROL, V50, P1, DOI 10.1099/0022-1317-50-1-1; Strauss EG, 1986, TOGAVIRIDAE FLAVIVIR; SUOMALAINEN M, 1992, J VIROL, V66, P4737, DOI 10.1128/JVI.66.8.4737-4747.1992; WHITT MA, 1989, J VIROL, V63, P3569, DOI 10.1128/JVI.63.9.3569-3578.1989; WHITT MA, 1991, VIROLOGY, V185, P681, DOI 10.1016/0042-6822(91)90539-N; WHITT MA, 1990, J VIROL, V64, P4907, DOI 10.1128/JVI.64.10.4907-4913.1990; XIONG C, 1989, SCIENCE, V243, P1188, DOI 10.1126/science.2922607; ZAVADA J, 1982, J GEN VIROL, V63, P15, DOI 10.1099/0022-1317-63-1-15; ZHAO HX, 1992, J VIROL, V66, P7089, DOI 10.1128/JVI.66.12.7089-7095.1992	34	109	124	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 4	1994	79	3					497	506		10.1016/0092-8674(94)90258-5	http://dx.doi.org/10.1016/0092-8674(94)90258-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7954815				2022-12-01	WOS:A1994PQ48800012
J	ZHU, LY; SAGE, JT; CHAMPION, PM				ZHU, LY; SAGE, JT; CHAMPION, PM			OBSERVATION OF COHERENT REACTION DYNAMICS IN HEME-PROTEINS	SCIENCE			English	Article							GEMINATE RECOMBINATION; IMPULSIVE EXCITATION; OPTICAL SPECTROSCOPY; CO BINDING; RELAXATION; ABSORPTION; MYOGLOBIN; RAMAN; MOTION; MODEL	Femtosecond laser pulses, resonant with the Soret band of the nitric oxide complex of myoglobin (MbNO), were used to probe coherent, low-frequency nuclear motion of the heme group after photolysis. Distinct oscillations with periods of 430 and 150 femtoseconds were observed and are attributed to heme doming and iron-histidine motion, respectively. These results verify that the nuclear motion of the heme is strongly coupled to the ligand binding reaction and demonstrate that such motion is not determined by overdamped (diffusive) dynamics. The relative phases and frequencies of the nuclear motion of the photoproduct suggest that the coherence arises from impulsive electronic forces associated with the spin-state change of the heme iron atom and the depopulation of its d(z)2 orbital during the bond-breaking event.	NORTHEASTERN UNIV,DEPT PHYS,BOSTON,MA 02115	Northeastern University					NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM035090] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM-35090] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGMON N, 1983, J CHEM PHYS, V79, P2042, DOI 10.1063/1.445988; AGMON N, 1992, J CHEM PHYS, V97, P7270, DOI 10.1063/1.463500; AHMED AM, 1991, CHEM PHYS, V158, P329, DOI 10.1016/0301-0104(91)87076-8; BANIN U, 1993, J CHEM PHYS, V98, P4391, DOI 10.1063/1.465066; BERLIN YA, 1992, CHEM PHYS LETT, V197, P81, DOI 10.1016/0009-2614(92)86026-E; CHAMPION PM, 1992, J RAMAN SPECTROSC, V23, P557, DOI 10.1002/jrs.1250231008; CHERNOFF DA, 1980, P NATL ACAD SCI USA, V77, P5606, DOI 10.1073/pnas.77.10.5606; DEXHEIMER SL, 1992, CHEM PHYS LETT, V188, P61, DOI 10.1016/0009-2614(92)85089-S; DHAR L, 1994, CHEM REV, V94, P157, DOI 10.1021/cr00025a006; FINDSEN EW, 1985, J AM CHEM SOC, V107, P3355, DOI 10.1021/ja00297a056; FRAGNITO HL, 1989, CHEM PHYS LETT, V160, P101, DOI 10.1016/0009-2614(89)87564-5; FRANKE G, 1894, ARCH LARYNGOL RHINOL, V1, P230; GU YG, 1994, J CHEM PHYS, V100, P2547, DOI 10.1063/1.467232; LEE D, 1985, ADV INFRARED RAMAN S, V12, P179; LI XY, 1992, CHEM PHYS LETT, V188, P16, DOI 10.1016/0009-2614(92)85081-K; LIM MH, 1993, P NATL ACAD SCI USA, V90, P5801, DOI 10.1073/pnas.90.12.5801; MUKAMEL S, 1990, ANNU REV PHYS CHEM, V41, P647, DOI 10.1146/annurev.pc.41.100190.003243; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; PETRICH JW, 1991, BIOCHEMISTRY-US, V30, P3975, DOI 10.1021/bi00230a025; POLLARD WT, 1992, ANNU REV PHYS CHEM, V43, P497, DOI 10.1146/annurev.physchem.43.1.497; PUGLIANO N, 1993, J CHEM PHYS, V99, P7273, DOI 10.1063/1.465422; ROSKER MJ, 1988, J CHEM PHYS, V89, P6113, DOI 10.1063/1.455427; ROSKER MJ, 1986, PHYS REV LETT, V57, P321, DOI 10.1103/PhysRevLett.57.321; ROUSSEAU DL, 1988, BIOL APPLICATIONS RA, V3, P133; RUHMAN S, 1987, J CHEM PHYS, V86, P6563, DOI 10.1063/1.452400; SCHEIDT WR, 1976, J AM CHEM SOC, V98, P1913, DOI 10.1021/ja00423a044; SCHERER NF, 1992, J CHEM PHYS, V96, P5544, DOI 10.1063/1.462693; SRAJER V, 1988, J AM CHEM SOC, V110, P6656, DOI 10.1021/ja00228a009; SRAJER V, 1991, BIOCHEMISTRY-US, V30, P7390, DOI 10.1021/bi00244a005; SRAJER V, 1986, PHYS REV LETT, V57, P1267, DOI 10.1103/PhysRevLett.57.1267; VOS MH, 1993, NATURE, V363, P320, DOI 10.1038/363320a0; WALTERS MA, 1982, BIOCHEMISTRY-US, V21, P6989, DOI 10.1021/bi00269a057; WISE FW, 1987, IEEE J QUANTUM ELECT, V23, P1116, DOI 10.1109/JQE.1987.1073483; ZEWAIL AH, 1988, SCIENCE, V242, P1645, DOI 10.1126/science.242.4886.1645; ZHU L, 1994, PHYS REV LETT, V72, P301, DOI 10.1103/PhysRevLett.72.301	35	178	179	3	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 28	1994	266	5185					629	632		10.1126/science.7939716	http://dx.doi.org/10.1126/science.7939716			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939716				2022-12-01	WOS:A1994PN80700041
J	WHITE, RJ; KHOO, BCE; INOSTROZA, JA; REINBERG, D; JACKSON, SP				WHITE, RJ; KHOO, BCE; INOSTROZA, JA; REINBERG, D; JACKSON, SP			DIFFERENTIAL REGULATION OF RNA POLYMERASE-I, POLYMERASE-II, AND POLYMERASE-III BY THE TBP-BINDING REPRESSOR DR1	SCIENCE			English	Article							TRANSCRIPTION FACTOR-TFIIIB; FUNCTIONAL DOMAINS; TATA-LESS; PROTEIN; COMPLEX; COMPONENTS; ACTIVATION; MECHANISM; PROMOTER; HOMOLOGY	RNA polymerases I, II, and III each use the TATA-binding protein (TBP). Regulators that target this shared factor may therefore provide a means to coordinate the activities of the three nuclear RNA polymerases; The repressor Dr1 binds to TBP and blocks the interaction of TBP with polymerase II- and polymerase III-specific factors. This enables Drl to coordinately regulate transcription by RNA polymerases II and III, Under the same conditions, Dr1 does not inhibit polymerase I transcription. By selectively repressing polymerases II and III, Drl may shift the physiological balance of transcriptional output in favor of polymerase I.	UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 1QR,ENGLAND; UNIV MED & DENT NEW JERSEY,DEPT BIOCHEM,PISCATAWAY,NJ 08854	University of Cambridge; Rutgers State University New Brunswick; Rutgers State University Medical Center	WHITE, RJ (corresponding author), UNIV CAMBRIDGE,WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND.		Khoo, Bernard/B-1247-2009; Dry, Kate/I-2328-2014; Jackson, Stephen Philip/R-4548-2019	Khoo, Bernard/0000-0002-4223-9736; Jackson, Stephen Philip/0000-0001-9317-7937; Reinberg, Danny/0000-0003-4288-2016	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1993, SCIENCE, V262, P244, DOI 10.1126/science.8211143; DEAN N, 1987, NUCLEIC ACIDS RES, V15, P9895, DOI 10.1093/nar/15.23.9895; EBERHARD D, 1993, NUCLEIC ACIDS RES, V21, P4180, DOI 10.1093/nar/21.18.4180; Gill Grace, 1992, Current Biology, V2, P565, DOI 10.1016/0960-9822(92)90046-D; GODDARD JP, 1983, NUCLEIC ACIDS RES, V11, P2551, DOI 10.1093/nar/11.9.2551; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; INOSTROZA JA, 1992, CELL, V70, P477; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KHOO BCE, IN PRESS GENES DEV; LESCURE A, 1994, EMBO J, V13, P1166, DOI 10.1002/j.1460-2075.1994.tb06366.x; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RADEBAUGH CA, 1994, MOL CELL BIOL, V14, P597, DOI 10.1128/MCB.14.1.597; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; SEGALL J, 1980, J BIOL CHEM, V255, P1986; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SIMMEN KA, 1992, NUCLEIC ACIDS RES, V20, P5889, DOI 10.1093/nar/20.22.5889; STRUHL K, 1994, SCIENCE, V263, P1103, DOI 10.1126/science.8108728; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; WERNER M, 1993, J BIOL CHEM, V268, P20721; White R.C., UNPUB; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; WHITE RJ, 1989, CELL, V59, P1081, DOI 10.1016/0092-8674(89)90764-2; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	43	56	58	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 21	1994	266	5184					448	450		10.1126/science.7939686	http://dx.doi.org/10.1126/science.7939686			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7939686				2022-12-01	WOS:A1994PN27200038
J	FOX, R				FOX, R			RED-LIGHT ON CALCUTTA - HEALTH VIA SCHOOLS IN ANDHRA-PRADESH	LANCET			English	Editorial Material																		JANA S, 1994, 10TH INT C AIDS YOK	1	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1038	1038		10.1016/S0140-6736(94)91705-1	http://dx.doi.org/10.1016/S0140-6736(94)91705-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PL852	7934442				2022-12-01	WOS:A1994PL85200005
J	TULLY, T; PREAT, T; BOYNTON, SC; DELVECCHIO, M				TULLY, T; PREAT, T; BOYNTON, SC; DELVECCHIO, M			GENETIC DISSECTION OF CONSOLIDATED MEMORY IN DROSOPHILA	CELL			English	Article							APLYSIA SENSORY NEURONS; PROTEIN KINASE-A; INDUCED RETROGRADE-AMNESIA; LONG-TERM FACILITATION; WITHDRAWAL REFLEX; ADENYLATE-CYCLASE; MUTANT DROSOPHILA; OLFACTORY MEMORY; GILL-WITHDRAWAL; MUSHROOM BODIES	Behavioral and pharmacological experiments in many animal species have suggested that memory is consolidated from an initial, disruptable form into a longlasting, stable form within a few hours after training. We combined these traditional approaches with genetic analyses in Drosophila to show that consolidated memory of conditioned (learned) odor avoidance 1 day after extended training consisted of two genetically distinct, functionally independent memory components: anesthesia-resistant memory (ARM) and longterm memory (LTM). ARM decayed away within 4 days, was resistant to hypothermic disruption, was insensitive to the protein synthesis inhibitor cycloheximide (CXM), and was disrupted by the radish single-gene mutation. LTM showed no appreciable decay over 7 days, was sensitive to CXM, and was not disrupted by the radish mutation.	BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254	Brandeis University	TULLY, T (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.			Preat, Thomas/0000-0001-9976-1763	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032245] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM033205] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS025621] Funding Source: NIH RePORTER; NICHD NIH HHS [HD32245] Funding Source: Medline; NIGMS NIH HHS [P01-GM33205] Funding Source: Medline; NINDS NIH HHS [NS25621] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agranoff B.W., 1981, BASIC NEUROCHEMISTRY, P801; AKAHANE R, 1983, J INSECT PHYSIOL, V29, P331, DOI 10.1016/0022-1910(83)90034-3; ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; ALLWEIS C, 1984, BEHAV BRAIN RES, V11, P117, DOI 10.1016/0166-4328(84)90134-7; ALLWEIS C, 1991, NEURAL BEHAV PLASTIC, P370; Andrew RJ, 1980, ADV STUD BEHAV, P337; ARMSTRONG RC, 1993, ANNU REV NEUROSCI, V16, P17, DOI 10.1146/annurev.ne.16.030193.000313; ASZODI A, 1991, P NATL ACAD SCI USA, V88, P5832, DOI 10.1073/pnas.88.13.5832; BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; BADDELEY A, 1976, PSYCHOL MEMORY; BAILEY CH, 1994, SEMIN NEUROSCI, V6, P35; BERGOLD PJ, 1992, NEURON, V8, P387, DOI 10.1016/0896-6273(92)90304-V; BERMAN RF, 1978, BRAIN RES, V158, P171, DOI 10.1016/0006-8993(78)90013-6; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BOYNTON S, 1992, GENETICS, V131, P655; BOYNTON S, 1990, BIOL MEMORY, P91; BUONOMANO DV, 1990, SCIENCE, V249, P420, DOI 10.1126/science.2165631; CAREW TJ, 1972, SCIENCE, V175, P451, DOI 10.1126/science.175.4020.451; CASTELLUCCI VF, 1989, J NEUROBIOL, V20, P1, DOI 10.1002/neu.480200102; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; CROW T, 1993, J NEUROPHYSIOL, V69, P636, DOI 10.1152/jn.1993.69.2.636; DANIELS D, 1971, J COMP PHYSIOL PSYCH, V76, P110, DOI 10.1037/h0031044; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DAVIS RL, 1993, NEURON, V11, P1, DOI 10.1016/0896-6273(93)90266-T; DEBELLE JS, 1994, SCIENCE, V263, P692, DOI 10.1126/science.8303280; DRAIN P, 1991, NEURON, V6, P71, DOI 10.1016/0896-6273(91)90123-H; DUDAI Y, 1976, P NATL ACAD SCI USA, V73, P1684, DOI 10.1073/pnas.73.5.1684; DUDAI Y, 1983, P NATL ACAD SCI-BIOL, V80, P5445, DOI 10.1073/pnas.80.17.5445; DUDAI Y, 1988, J COMP PHYSIOL A, V162, P101, DOI 10.1007/BF01342707; DURA JM, 1993, J NEUROGENET, V9, P1, DOI 10.3109/01677069309167272; EMPTAGE NJ, 1993, SCIENCE, V262, P253, DOI 10.1126/science.8211146; ERBER J, 1976, J COMP PHYSIOL PSYCH, V90, P41, DOI 10.1037/h0077258; FLOOD JF, 1977, BEHAV BIOL, V21, P307, DOI 10.1016/S0091-6773(77)90101-8; FOLKERS E, 1993, P NATL ACAD SCI USA, V90, P8123, DOI 10.1073/pnas.90.17.8123; FRECKLETON WC, 1968, PSYCHON SCI, V12, P179; FRIEDER B, 1978, BEHAV BIOL, V22, P178, DOI 10.1016/S0091-6773(78)92200-9; FROST WN, 1985, P NATL ACAD SCI USA, V82, P8266, DOI 10.1073/pnas.82.23.8266; GAILEY DA, 1991, J COMP PHYSIOL A, V169, P685; GALL CM, 1991, MEMORY ORG LOCUS CHA, P301; GELLER A, 1968, PSYCHON SCI, V12, P169; GLICKMAN SE, 1961, PSYCHOL BULL, V58, P218, DOI 10.1037/h0044212; GREENOUGH WT, 1984, TRENDS NEUROSCI, V7, P229, DOI 10.1016/S0166-2236(84)80211-8; Hintzman D. L., 1974, THEORIES COGNITIVE P, P77; HIRSCH J, 1956, PSYCHOL BULL, V53, P402, DOI 10.1037/h0040715; JAFFE K, 1980, PHYSIOL BEHAV, V25, P367, DOI 10.1016/0031-9384(80)90275-9; James W., 1890, PRINCIPLES PSYCHOL; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; KESNER RP, 1981, BRAIN RES, V209, P159, DOI 10.1016/0006-8993(81)91178-1; KNOWLTON BJ, 1993, SCIENCE, V262, P1747, DOI 10.1126/science.8259522; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; Lindsley D.L., 1992, GENOME DROSOPHILA ME; LISMAN JE, 1985, P NATL ACAD SCI USA, V82, P3055, DOI 10.1073/pnas.82.9.3055; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; MALDONADO H, 1980, J INSECT PHYSIOL, V26, P339, DOI 10.1016/0022-1910(80)90002-5; MCDONALD RJ, 1993, BEHAV NEUROSCI, V107, P3, DOI 10.1037/0735-7044.107.1.3; MCGAUGH JL, 1966, SCIENCE, V153, P1351, DOI 10.1126/science.153.3742.1351; MCGAUGH JL, 1972, MEMORY CONSOLIDATION; MENZEL R, 1993, NATURWISSENSCHAFTEN, V80, P380, DOI 10.1007/BF01138799; MENZEL R, 1990, BRAIN PERCEPTION COG, P111; MIZUMORI SJY, 1985, BEHAV NEUROSCI, V99, P220, DOI 10.1037/0735-7044.99.2.220; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; NAGY ZM, 1993, B PSYCHONOMIC SOC, V31, P225, DOI 10.3758/BF03337330; NAZIF FA, 1991, BRAIN RES, V539, P324, DOI 10.1016/0006-8993(91)91638-H; PRUZAN A, 1977, PHARMACOL BIOCHEM BE, V6, P355, DOI 10.1016/0091-3057(77)90037-5; QUINN WG, 1976, NATURE, V262, P576, DOI 10.1038/262576a0; QUINN WG, 1974, P NATL ACAD SCI USA, V71, P708, DOI 10.1073/pnas.71.3.708; RIBOT TA, 1892, DICT PSYCHOL MED; Riccio D. C., 1981, INFORMATION PROCESSI, P291; RIEGE WH, 1974, BEHAV BIOL, V12, P477, DOI 10.1016/S0091-6773(74)92291-3; ROSE SPR, 1991, TRENDS NEUROSCI, V14, P390, DOI 10.1016/0166-2236(91)90027-R; ROSE SPR, 1987, BEHAV NEURAL BIOL, V48, P246, DOI 10.1016/S0163-1047(87)90808-9; ROSE SPR, 1984, BEHAV NEURAL BIOL, V42, P663; ROSENZWEIG MR, 1984, NEUROBIOLOGY LEARNIN, P263; SKOULAKIS EMC, 1993, NEURON, V11, P197, DOI 10.1016/0896-6273(93)90178-T; Sokal R., 1981, BIOMETRY; Squire L.R., 1987, MEMORY BRAIN; SQUIRE LR, 1980, SCIENCE, V209, P836, DOI 10.1126/science.7190729; STAUBLI U, 1985, BEHAV NEURAL BIOL, V43, P287, DOI 10.1016/S0163-1047(85)91632-2; STEWART MG, 1991, NEURAL BEHAVIOURAL P, P305; TEMPEL BL, 1983, P NATL ACAD SCI-BIOL, V80, P1482, DOI 10.1073/pnas.80.5.1482; TULLY T, 1986, J NEUROGENET, V3, P33, DOI 10.3109/01677068609106893; TULLY T, 1990, COLD SH Q B, V55, P203; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; TULLY T, 1993, J NEUROGENET, V9, P55, DOI 10.3109/01677069309167275; TULLY T, 1988, MODULATION SYNAPTIC, P401; Tully T., 1991, NEUROBIOLOGY LEARNIN, P29; WILLMUND R, 1979, NATURWISSENSCHAFTEN, V66, P318, DOI 10.1007/BF00441282; YAMADA A, 1992, J NEUROSCI, V12, P729; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; ZOLAMORGAN S, 1993, ANNU REV NEUROSCI, V16, P547, DOI 10.1146/annurev.ne.16.030193.002555	91	706	720	0	59	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					35	47		10.1016/0092-8674(94)90398-0	http://dx.doi.org/10.1016/0092-8674(94)90398-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923375				2022-12-01	WOS:A1994PK58500006
J	MCGUIRE, W; HILL, AVS; ALLSOPP, CEM; GREENWOOD, BM; KWIATKOWSKI, D				MCGUIRE, W; HILL, AVS; ALLSOPP, CEM; GREENWOOD, BM; KWIATKOWSKI, D			VARIATION IN THE TNF-ALPHA PROMOTER REGION ASSOCIATED WITH SUSCEPTIBILITY TO CEREBRAL MALARIA	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; MAJOR HISTOCOMPATIBILITY COMPLEX; B-CELL LINES; FALCIPARUM-MALARIA; PLASMODIUM-FALCIPARUM; GENE-REGULATION; T-CELL; POLYMORPHISM; PROTECTION; CACHECTIN	TUMOUR-necrosis factor-alpha (TNF-alpha) is believed to have an important role in the pathogenesis of severe infectious disease(1) and fatal cerebral malaria is associated with high circulating levels of this cytokine(2,3). In a large case-control study in Cambian children we find that homozygotes for the TNF2 allele, a variant of the TNF-alpha gene promoter region(4), have a relative risk of 7 for death or severe neurological sequelae due to cerebral malaria. Although the TNF2 allele is in linkage disequilibrium with several neighbouring HLA alleles, we show that this disease association is independent of HLA class I and class II variation. These data suggest that regulatory polymorphisms of cytokine genes can affect the outcome of severe infection. The maintenance of the TNF2 allele at a gene frequency of 0.16 in The Gambia implies that the increased risk of cerebral malaria in homozygotes is counterbalanced by some biological advantage.	JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC IMMUNOL GRP,OXFORD OX3 9DU,ENGLAND; MRC LABS,FAJARA,SENEGAL	University of Oxford	MCGUIRE, W (corresponding author), JOHN RADCLIFFE HOSP,DEPT PAEDIAT,OXFORD OX3 9DU,ENGLAND.		HILL, Adrian V>S>/C-1306-2008	Kwiatkowski, Dominic/0000-0002-5023-0176; McGuire, William/0000-0001-8572-3467	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALFONSO SD, 1994, IMMUNOGENETICS, V30, P150; ALLSOPP CEM, 1991, HUM IMMUNOL, V30, P105, DOI 10.1016/0198-8859(91)90078-N; BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7; CLARK IA, 1987, PARASITOL TODAY, V3, P300, DOI 10.1016/0169-4758(87)90187-6; CLARK IA, 1992, LANCET, V340, P8994; DUNHAM I, 1987, P NATL ACAD SCI USA, V84, P7237, DOI 10.1073/pnas.84.20.7237; GOLDFELD AE, 1991, J EXP MED, V174, P73, DOI 10.1084/jem.174.1.73; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404; GRAU GE, 1987, SCIENCE, V237, P1210, DOI 10.1126/science.3306918; GRAU GE, 1992, TUMOUR NECROSIS FACT, V1, P329; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HILL AVS, 1992, P NATL ACAD SCI USA, V89, P2277, DOI 10.1073/pnas.89.6.2277; JACOB CO, 1990, P NATL ACAD SCI USA, V87, P1233, DOI 10.1073/pnas.87.3.1233; KERN P, 1989, AM J MED, V87, P139, DOI 10.1016/S0002-9343(89)80688-6; KWIATKOWSKI D, 1989, CLIN EXP IMMUNOL, V77, P361; KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5; KWIATKOWSKI D, 1992, CURR OPIN IMMUNOL, V4, P425, DOI 10.1016/S0952-7915(06)80034-8; MOLVIG J, 1988, SCAND J IMMUNOL, V27, P7025; NEDOSPASOV SA, 1986, COLD SPRING HARB SYM, V51, P611, DOI 10.1101/SQB.1986.051.01.073; PICOT F, 1993, EUR J IMMUNOL, V23, P224; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; TITUS RG, 1991, PARASITOL TODAY, V12, pA13; Wilson A. G., 1992, Human Molecular Genetics, V1, P353, DOI 10.1093/hmg/1.5.353; WILSON AG, 1993, J EXP MED, V177, P557, DOI 10.1084/jem.177.2.557; WILSON AG, 1994, BR J RHEUMATOL S1, V33, P89; WONG FHW, 1992, TUMOR NECROSIS FACTO, V1, P371	30	1050	1078	1	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					508	511		10.1038/371508a0	http://dx.doi.org/10.1038/371508a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7935762				2022-12-01	WOS:A1994PK58900053
J	GREENBERGER, NJ; MINER, PB				GREENBERGER, NJ; MINER, PB			IS MAINTENANCE THERAPY EFFECTIVE IN CROHNS-DISEASE	LANCET			English	Editorial Material							PREDNISOLONE				GREENBERGER, NJ (corresponding author), UNIV KANSAS,MED CTR,DEPT MED,KANSAS CITY,KS 66103, USA.							EWE K, 1993, GASTROENTEROLOGY, V105, P367, DOI 10.1016/0016-5085(93)90709-L; GENDRE JP, 1993, GASTROENTEROLOGY, V104, P435, DOI 10.1016/0016-5085(93)90411-5; HANAUER SB, 1993, AM J GASTROENTEROL, V88, P1343; MESSORI A, 1994, AM J GASTROENTEROL, V89, P692; MODIGLIANI R, 1990, GASTROENTEROLOGY, V98, P811, DOI 10.1016/0016-5085(90)90002-I; SINGLETON JW, 1993, GASTROENTEROLOGY, V104, P1292; SUMMERS RW, 1979, GASTROENTEROLOGY, V77, P847; SUTHERLAND L, 1991, GUT, V32, P1071, DOI 10.1136/gut.32.9.1071	8	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					900	901		10.1016/S0140-6736(94)92261-6	http://dx.doi.org/10.1016/S0140-6736(94)92261-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934340				2022-12-01	WOS:A1994PJ28700002
J	MANZONI, OJ; MANABE, T; NICOLL, RA				MANZONI, OJ; MANABE, T; NICOLL, RA			RELEASE OF ADENOSINE BY ACTIVATION OF NMDA RECEPTORS IN THE HIPPOCAMPUS	SCIENCE			English	Article							GLUTAMATE-EVOKED RELEASE; EXCITATORY AMINO-ACIDS; RAT CORTICAL SLICES; SYNAPTIC TRANSMISSION; PRESYNAPTIC INHIBITION; ENDOGENOUS ADENOSINE; POSTTETANIC DEPRESSION; CEREBRAL-CORTEX; BRAIN-SLICES; AREA CA1	Adenosine is present in the mammalian brain in large amounts and has patent effects on neuronal activity, but its role in neural signaling is poorly understood. The glutamate receptor agonist N-methyl-D-aspartate (NMDA) caused a presynaptic depression of excitatory synaptic transmission in the CA1 region of guinea pig hippocampal slices. This depression was blocked by an adenosine A1 receptor antagonist, which suggests that activation of the NMDA subtype of glutamate receptor raises the concentration of extracellular adenosine, which acts on presynaptic inhibitory A1 receptors. Strong tetanic stimulation caused a heterosynaptic inhibition that was blocked by both NMDA and A1 receptor antagonists. Enkephalin, which selectively inhibits interneurons, antagonized the heterosynaptic inhibition. These findings suggest that synaptically released glutamate activates NMDA receptors, which in turn releases adenosine, at least in part from interneurons, that acts at a distance to inhibit presynaptically the release of glutamate from excitatory synapses. Thus, interneurons may mediate a widespread purinergic presynaptic inhibition.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV TOKYO, FAC MED, INST BRAIN RES, DEPT NEUROPHYSIOL, TOKYO 113, JAPAN	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Tokyo			Manzoni, Olivier/M-7899-2016	Manzoni, Olivier/0000-0002-5579-6208				BASHIR ZI, 1992, EUR J NEUROSCI, V4, P485, DOI 10.1111/j.1460-9568.1992.tb00898.x; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BOUITON CL, 1993, J PHYSIOL-LONDON, V467, pP181; CAPOGNA M, 1993, J PHYSIOL-LONDON, V470, P539, DOI 10.1113/jphysiol.1993.sp019874; COHEN GA, 1992, NEURON, V9, P325, DOI 10.1016/0896-6273(92)90171-9; COLEMAN PA, 1989, J NEUROPHYSIOL, V61, P218, DOI 10.1152/jn.1989.61.1.218; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; CRAIG CG, 1993, J NEUROCHEM, V60, P1073, DOI 10.1111/j.1471-4159.1993.tb03256.x; CULLCANDY SG, 1991, ANN NY ACAD SCI, V633, P458; CUNHA RA, 1992, J NEUROCHEM, V59, P657, DOI 10.1111/j.1471-4159.1992.tb09420.x; DUNWIDDIE TV, 1985, J PHYSIOL-LONDON, V369, P365, DOI 10.1113/jphysiol.1985.sp015907; DUNWIDDIE TV, 1985, INT REV NEUROBIOL, V27, P63, DOI 10.1016/S0074-7742(08)60556-5; EAST SJ, 1991, NEUROSCI LETT, V123, P17, DOI 10.1016/0304-3940(91)90147-L; GROVER LM, 1993, SYNAPSE, V15, P149, DOI 10.1002/syn.890150207; GROVER LM, 1993, NEUROSCI LETT, V154, P39, DOI 10.1016/0304-3940(93)90166-I; HAAS HL, 1988, N-S ARCH PHARMACOL, V337, P561; HOEHN K, 1990, J NEUROCHEM, V54, P256, DOI 10.1111/j.1471-4159.1990.tb13309.x; HOEHN K, 1990, J NEUROCHEM, V54, P1716, DOI 10.1111/j.1471-4159.1990.tb01226.x; ISAACSON JS, 1993, NEURON, V10, P165, DOI 10.1016/0896-6273(93)90308-E; KAUER JA, 1988, NATURE, V334, P250, DOI 10.1038/334250a0; LUPICA CR, 1992, J NEUROSCI, V12, P3753; MADISON DV, 1988, J PHYSIOL-LONDON, V398, P123, DOI 10.1113/jphysiol.1988.sp017033; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MITCHELL JB, 1993, J NEUROSCI, V13, P3439; NICOLL RA, 1980, NATURE, V287, P22, DOI 10.1038/287022a0; NICOLL RA, 1981, J NEUROSCI METH, V4, P153, DOI 10.1016/0165-0270(81)90049-2; PHILLIS JW, 1981, PROG NEUROBIOL, V16, P187, DOI 10.1016/0301-0082(81)90014-9; PONS F, 1980, J NEUROCHEM, V34, P1319, DOI 10.1111/j.1471-4159.1980.tb09977.x; PRINCE DA, 1992, P NATL ACAD SCI USA, V89, P8586, DOI 10.1073/pnas.89.18.8586; PULL I, 1973, BIOCHEM J, V136, P893, DOI 10.1042/bj1360893; SAH P, 1990, J PHYSIOL-LONDON, V430, P605, DOI 10.1113/jphysiol.1990.sp018310; SCANZIANI M, 1992, NEURON, V9, P919, DOI 10.1016/0896-6273(92)90244-8; SCHOLZ KP, 1992, NEURON, V8, P1139, DOI 10.1016/0896-6273(92)90134-Y; SEKINO Y, 1992, NEUROSCI LETT, V148, P109, DOI 10.1016/0304-3940(92)90816-P; SILINSKY EM, 1984, J PHYSIOL-LONDON, V346, P243, DOI 10.1113/jphysiol.1984.sp015019; USOWICZ MM, 1989, NATURE, V339, P380, DOI 10.1038/339380a0; WYLLIE DJA, 1991, J PHYSIOL-LONDON, V432, P235, DOI 10.1113/jphysiol.1991.sp018383; ZETTERSTROM T, 1982, NEUROSCI LETT, V29, P111, DOI 10.1016/0304-3940(82)90338-X; ZIEGLGANSBERGER W, 1979, SCIENCE, V205, P415, DOI 10.1126/science.451610	39	252	257	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 30	1994	265	5181					2098	2101		10.1126/science.7916485	http://dx.doi.org/10.1126/science.7916485			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ912	7916485				2022-12-01	WOS:A1994PJ91200032
J	AVNER, ED				AVNER, ED			GENE TIME FOR POLYCYSTIC KIDNEY-DISEASE	LANCET			English	Editorial Material											AVNER, ED (corresponding author), CHILDRENS HOSP & MED CTR,DIV PEDIAT NEPHROL,SEATTLE,WA 98105, USA.							AVNER ED, 1993, SEMIN NEPHROL, V13, P427; KIMBERLING WJ, 1993, GENOMICS, V18, P467, DOI 10.1016/S0888-7543(11)80001-7; MCDONALD RA, 1991, SEMIN NEPHROL, V11, P632; MOYER JH, 1994, SCIENCE, V264, P1329, DOI 10.1126/science.8191288; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; WOO DDL, 1994, NATURE, V368, P750, DOI 10.1038/368750a0; ZERRES K, 1994, NAT GENET, V7, P429, DOI 10.1038/ng0794-429; 1994, CELL, V77, P1	8	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					833	834		10.1016/S0140-6736(94)92820-7	http://dx.doi.org/10.1016/S0140-6736(94)92820-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH253	7916394				2022-12-01	WOS:A1994PH25300004
J	LU, Z; MACKINNON, R				LU, Z; MACKINNON, R			ELECTROSTATIC TUNING OF MG2+ AFFINITY IN AN INWARD-RECTIFIER K+ CHANNEL	NATURE			English	Article							GUINEA-PIG HEART; POTASSIUM CHANNEL; FUNCTIONAL EXPRESSION; VENTRICULAR CELLS; MAGNESIUM BLOCK; INTERNAL MG-2+; RECTIFICATION; ACTIVATION; IONS	INWARD-RECTIFIER potassium channels conduct K+ across the cell membrane more efficiently in the inward than outward direction. This unusual conduction property is directly related to the biological action of these channels(1-6). One basis for inward rectification is voltage-dependent blockade by intracellular Mg2+ (refs 1, 7-9): strong inward-rectifier channels are so sensitive to intracellular Mg2+ that no outward K+ current is measurable under physiological conditions; weak inward rectifiers are less sensitive and allow some K+ to flow outwards. Background K1 channels and acetylcholine-regulated K+ channels from the heart are examples of strong inward rectifiers and ATP-sensitive K+ channels are weak rectifiers(1,7-10). Here we show that mutations at one position in the second transmembrane segment can alter the Mg2+ affinity and convert a weakly rectifying channel (ROMK1) into a strong rectifier. The amino acid at this position exposes its side chain to the aqueous pore and affects Mg2+ blockade as well as K+ conduction through an electrostatic mechanism.			LU, Z (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROBIOL,220 LONGWOOD AVE,BOSTON,MA 02115, USA.							ASHCROFT FM, 1990, BIOCHEM SOC T, V18, P109, DOI 10.1042/bst0180109; CHOI KL, 1993, NEURON, V10, P533, DOI 10.1016/0896-6273(93)90340-W; Creighton TE, 1993, PROTEINS STRUCTURES; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P1025; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; GRAHAME DC, 1947, CHEM REV, V41, P441, DOI 10.1021/cr60130a002; Hille B., 1991, IONIC CHANNELS EXCIT; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HORIE M, 1987, J PHYSIOL-LONDON, V387, P251, DOI 10.1113/jphysiol.1987.sp016572; ISHIHARA K, 1989, J PHYSIOL-LONDON, V419, P297, DOI 10.1113/jphysiol.1989.sp017874; KIRSCH GE, 1993, NEURON, V11, P503, DOI 10.1016/0896-6273(93)90154-J; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KURACHI Y, 1985, J PHYSIOL-LONDON, V366, P365, DOI 10.1113/jphysiol.1985.sp015803; LOPEZ GA, 1994, NATURE, V367, P179, DOI 10.1038/367179a0; MACKINNON R, 1988, NEURON, V1, P997, DOI 10.1016/0896-6273(88)90156-0; MATSUDA H, 1991, J PHYSIOL-LONDON, V435, P83, DOI 10.1113/jphysiol.1991.sp018499; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; NICHOLS CG, 1994, J PHYSIOL-LONDON, V476, P399, DOI 10.1113/jphysiol.1994.sp020141; NOMA A, 1983, PFLUGERS ARCH, V400, P424; SAKMANN B, 1983, NATURE, V303, P250, DOI 10.1038/303250a0; SEOJIMA M, 1984, PFLUGERS ARCH, V400, P424; SILVER MR, 1990, J GEN PHYSIOL, V96, P109, DOI 10.1085/jgp.96.1.109; SLESINGER PA, 1993, NEURON, V11, P739, DOI 10.1016/0896-6273(93)90083-4; STANFIELD PR, 1994, J PHYSIOL-LONDON, V475, P1; TAGLIALATELA M, 1994, SCIENCE, V264, P844, DOI 10.1126/science.8171340; TRAUTWEIN W, 1958, PFLUG ARCH GES PHYS, V266, P324, DOI 10.1007/BF00416781; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560	29	273	278	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 15	1994	371	6494					243	246		10.1038/371243a0	http://dx.doi.org/10.1038/371243a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG290	7915826				2022-12-01	WOS:A1994PG29000051
J	PHILIPP, T; DURAZZO, M; TRAUTWEIN, C; ALEX, B; STRAUB, P; LAMB, JG; JOHNSON, EF; TUKEY, RH; MANNS, MP				PHILIPP, T; DURAZZO, M; TRAUTWEIN, C; ALEX, B; STRAUB, P; LAMB, JG; JOHNSON, EF; TUKEY, RH; MANNS, MP			RECOGNITION OF URIDINE-DIPHOSPHATE GLUCURONOSYL TRANSFERASES BY LKM-3 ANTIBODIES IN CHRONIC HEPATITIS-D	LANCET			English	Article							BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE; CRIGLER-NAJJAR SYNDROME; DELTA-VIRUS-INFECTION; AUTOIMMUNE HEPATITIS; MICROSOMAL AUTOANTIBODIES; DEVELOPMENTAL EXPRESSION; RAT; CYTOCHROME-P-450; SEQUENCE; GENE	Patients with chronic hepatitis D often have liver-kidney microsoma I a nti bod ies type 3 (LKM-3). These a nti bod ies react with several microsomal antigens that have a molecular weight of 55 KDa and an isoelectric point of about 8. We studied the molecular nature of the antigen and, by immunoscreening a human liver cDNA expression library with KM-3 sera, found that uridine diphosphate glucuronosyl transferases (UGT) appeared as candidate antigens. We confirmed the identity of UGT as an antigen by reacting the sera with recombinant rabbit liver UGT proteins. Some sera reacted with rabbit UGT-2 proteins, but UGT-1 proteins were more sensitive and specific in detecting LKM-3 autoantibodies in patient sera. Anti-UGT-1 antibodies were detected in all LKM-3 positive sera from patients with hepatitis D and 1 out of 11 patients with autoimmune hepatitis type 2. Sera from patients who had hepatitis B only did not react with UGT proteins. The UGT proteins are part of the phase II enzymes of drug metabolism and a re the fi rst such enzymes to be identified as human autoantigens.	HANNOVER MED SCH, DEPT GASTROENTEROL & HEPATOL, HANNOVER, GERMANY; UNIV TURIN, IST MED INTERNA, TURIN, ITALY; UNIV CALIF SAN DIEGO, CTR CANC, DEPT PHARMACOL, SAN DIEGO, CA 92103 USA; SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92093 USA	Hannover Medical School; University of Turin; University of California System; University of California San Diego; Scripps Research Institute				DURAZZO, Marilena/0000-0003-2450-5911	NIGMS NIH HHS [GM31001, GM49135] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031001, R01GM049135] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMENGUAL MJ, 1989, CLIN EXP IMMUNOL, V78, P80; BEAUNE P, 1987, P NATL ACAD SCI USA, V84, P551, DOI 10.1073/pnas.84.2.551; BOSMA PJ, 1993, GASTROENTEROLOGY, V105, P216, DOI 10.1016/0016-5085(93)90029-C; BURCHELL B, 1991, DNA CELL BIOL, V10, P487, DOI 10.1089/dna.1991.10.487; COUGHTRIE MWH, 1988, MOL PHARMACOL, V34, P729; CRIVELLI O, 1983, CLIN EXP IMMUNOL, V54, P232; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; HAQUE SJ, 1991, DNA CELL BIOL, V10, P515, DOI 10.1089/dna.1991.10.515; IYANAGI T, 1986, J BIOL CHEM, V261, P5607; KIRKPATRICK RB, 1988, HEPATOLOGY, V8, P353, DOI 10.1002/hep.1840080227; MACKENZIE PI, 1992, J STEROID BIOCHEM, V43, P1099, DOI 10.1016/0960-0760(92)90338-J; MACKENZIE PI, 1990, J BIOL CHEM, V265, P11328; MANNS MP, 1989, J CLIN INVEST, V83, P1066, DOI 10.1172/JCI113949; MANNS MP, 1991, J CLIN INVEST, V88, P1370, DOI 10.1172/JCI115443; MANNS MP, 1990, ARCH BIOCHEM BIOPHYS, V280, P229, DOI 10.1016/0003-9861(90)90541-6; MICHEL G, 1992, LANCET, V339, P267, DOI 10.1016/0140-6736(92)91332-3; NORMAN RL, 1978, J BIOL CHEM, V253, P8640; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; RITTER JK, 1992, J CLIN INVEST, V90, P150, DOI 10.1172/JCI115829; RITTER JK, 1992, J BIOL CHEM, V267, P3257; ROBERTSON KJ, 1991, J INHERIT METAB DIS, V14, P563, DOI 10.1007/BF01797927; Schwab GE., 1987, MAMMALIAN CYTOCHROME, VI, P55; STRAUB P, 1993, J BIOL CHEM, V268, P21997; SUTHERLAND L, 1992, FEBS LETT, V308, P161, DOI 10.1016/0014-5793(92)81266-O; TUKEY RH, 1993, J BIOL CHEM, V268, P15260; VERGANI D, 1993, GASTROENTEROLOGY, V104, P1870, DOI 10.1016/0016-5085(93)90673-Z; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; WESIERSKAGADEK J, 1990, HEPATOLOGY, V12, P1129; WOOSTER R, 1991, BIOCHEM J, V278, P465, DOI 10.1042/bj2780465; ZANGER UM, 1988, P NATL ACAD SCI USA, V85, P8256, DOI 10.1073/pnas.85.21.8256; ZAULI D, 1986, J CLIN PATHOL, V39, P897, DOI 10.1136/jcp.39.8.897; ZUBER MX, 1986, SCIENCE, V234, P1258, DOI 10.1126/science.3535074	32	104	107	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					578	581		10.1016/S0140-6736(94)91966-6	http://dx.doi.org/10.1016/S0140-6736(94)91966-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914961				2022-12-01	WOS:A1994PD42400010
J	SMYTH, JF; MOSSMAN, J; HALL, R; HEPBURN, S; PINKERTON, R; RICHARDS, M; THATCHER, N; BOX, J				SMYTH, JF; MOSSMAN, J; HALL, R; HEPBURN, S; PINKERTON, R; RICHARDS, M; THATCHER, N; BOX, J			CONDUCTING CLINICAL RESEARCH IN THE NEW NHS - THE MODEL OF CANCER	BRITISH MEDICAL JOURNAL			English	Article								The United Kingdom Coordinating Committee on Cancer Research represents the major organisations funding cancer research in the United Kingdom. The deliberations of a working party convened by the committee to evaluate recently expressed concerns that the changes in the NHS threaten research, especially clinical trials to evaluate new treatments, are reported. A survey of contributors to trials coordinated by the committee showed that half are now experiencing difficulties in continuing to participate in clinical trials. The two major problems identified were lack of time and of staff, especially for NHS staff in non-teaching hospitals. Recent changes in junior doctors' hours and proposed reductions in the length of time for training will exacerbate this. It is possible to identify the direct and indirect excess costs of conducting research in the NHS, but currently the mechanism does not exist to designate funds specifically for this purpose. Consultation with the regional directors of research and development confirmed that the service increment for teaching and research is not the solution for this, Proposals are made to secure future clinical research in the NHS, including finance, indemnity, the licensing of new drugs, the greater use of nurse counsellors, and the value of cancer registries.	UNITED KINGDOM COORDINATING COMM CANC RES,LONDON WC2A 3PX,ENGLAND; FREEMAN RD HOSP,DEPT UROL,NEWCASTLE TYNE NE7 7DN,TYNE & WEAR,ENGLAND; ROYAL MARSDEN HOSP,SUTTON SM2 5PT,SURREY,ENGLAND; GUYS HOSP,IMPERIAL CANC RES FUND,BREAST CANC UNIT,LONDON SE1 9RT,ENGLAND; CHRISTIE HOSP,DEPT MED ONCOL,MANCHESTER M20 9BX,LANCS,ENGLAND; MRC,LONDON W1N 4AL,ENGLAND	Newcastle Freeman Hospital; Royal Marsden NHS Foundation Trust; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; Christie NHS Foundation Trust; Christie Hospital	SMYTH, JF (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,DEPT CLIN ONCOL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		pinkerton, ross/I-4808-2014					1992, ASSESSING EFFECTS HL	1	41	41	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 13	1994	309	6952					457	461		10.1136/bmj.309.6952.457	http://dx.doi.org/10.1136/bmj.309.6952.457			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC404	7920132	Green Published			2022-12-01	WOS:A1994PC40400024
J	TILLOTSON, SL; FUGGLE, PW; SMITH, I; ADES, AE; GRANT, DB				TILLOTSON, SL; FUGGLE, PW; SMITH, I; ADES, AE; GRANT, DB			RELATION BETWEEN BIOCHEMICAL SEVERITY AND INTELLIGENCE IN EARLY TREATED CONGENITAL HYPOTHYROIDISM - A THRESHOLD EFFECT	BRITISH MEDICAL JOURNAL			English	Article							FETAL HYPOTHYROIDISM; MENTAL-DEVELOPMENT; THYROXINE; CHILDREN; PARAMETERS; INFANTS; TESTS; AGE	Objectives-To assess whether early treatment of congenital hypothyroidism fully prevents intellectual impairment. Design-A national register of children with congenital hypothyroidism who were compared with unaffected children from the same school classes and matched for age, sex, social class, and first language. Setting-First three years (1982-4) of a neonatal screening programme in England, Wales, and Northern Ireland. Subjects-361 children with congenital hypothyroidism given early treatment and 315 control children. Main outcome measures-Intelligence quotient (IQ) measured at school entry at 5 years of age with the Wechsler preschool and primary scale of intelligence. Results-There was a discontinuous relation between IQ and plasma thyroxine concentration at diagnosis, with a threshold at 42.8 nmol/l (95% confidence interval 35.2 to 47.1 nmol/l). Hypothyroid children with thyroxine values below 42.8 nmol/l had a mean IQ 10.3 points (6.9 to 13.7 points) lower than those with higher values and than controls. None of the measures of quality of treatment (age at start of treatment (range 1-173 days), average thyoxine dose (12-76 mu g in the first year), average thyroxine concentration during treatment (79-234 nmol/l in the first year), and thyroxine concentration 103 nmol/l less than at least once during the first year) influenced IQ at age 5. Conclusions-Despite early treatment in congenital hypothyroidism the disease severity has a threshold effect on brain development, probably determined prenatally. The 55% of infants with more severe disease continue to show clinically significant intellectual impairment; infants with milder disease show no such impairment. The findings predict that	INST CHILD HLTH, MRC, REGISTER CHILDREN HYPOTHYROIDISM, MED UNIT, LONDON WC1N 1EH, ENGLAND; INST CHILD HLTH, DEPT EPIDEMIOL & BIOSTAT, LONDON WC1H 1EH, ENGLAND	University of London; University College London; University of London; University College London								DAVIDSON R, 1981, ECONOMETRICA, V49, P781, DOI 10.2307/1911522; DEONA CR, 1988, PEDIATR RES, V24, P588, DOI 10.1203/00006450-198811000-00010; FISHER DA, 1979, J PEDIATR-US, V94, P700, DOI 10.1016/S0022-3476(79)80133-X; FLYNN JR, 1987, PSYCHOL BULL, V101, P171, DOI 10.1037/0033-2909.101.2.171; FUGGLE PW, 1992, J CHILD PSYCHOL PSYC, V33, P1241, DOI 10.1111/j.1469-7610.1992.tb00942.x; FUGGLE PW, 1991, EUR J PEDIATR, V150, P570, DOI 10.1007/BF02072209; GLORIEUX J, 1983, J PEDIATR-US, V102, P19, DOI 10.1016/S0022-3476(83)80279-0; GLORIEUX J, 1988, PEDIATR RES, V24, P6, DOI 10.1203/00006450-198807000-00003; GRANT DB, 1993, ARCH DIS CHILD, V69, P555, DOI 10.1136/adc.69.5.555; GRANT DB, 1992, ARCH DIS CHILD, V67, P87, DOI 10.1136/adc.67.1.87; GRANT DB, 1988, BRIT MED J, V296, P1355, DOI 10.1136/bmj.296.6633.1355; HEYERDAHL S, 1991, J PEDIATR-US, V118, P850, DOI 10.1016/S0022-3476(05)82194-8; HULSE JA, 1984, ARCH DIS CHILD, V59, P23, DOI 10.1136/adc.59.1.23; ILICKI A, 1991, ACTA PAEDIATR SCAND, V80, P199, DOI 10.1111/j.1651-2227.1991.tb11834.x; ILLIG R, 1987, ARCH DIS CHILD, V62, P1050, DOI 10.1136/adc.62.10.1050; KLEIN AH, 1972, J PEDIATR-US, V81, P912, DOI 10.1016/S0022-3476(72)80542-0; KOMIANOU F, 1988, EUR J PEDIATR, V147, P275, DOI 10.1007/BF00442694; LARSEN PR, 1989, NEW ENGL J MED, V321, P44, DOI 10.1056/NEJM198907063210108; MATTHEWS DE, 1988, BIOMETRIKA, V75, P139; ROCHICCIOLI P, 1984, ARCH FR PEDIATR, V41, P329; ROVET J, 1987, J PEDIATR-US, V110, P700, DOI 10.1016/S0022-3476(87)80005-7; ROYSTON P, IN PRESS BIOMETRICS; TILLOTSON SL, 1992, J CLIN PATHOL, V45, P819, DOI 10.1136/jcp.45.9.819; VIRTANEN M, 1989, ACTA PAEDIATR SCAND, V78, P405, DOI 10.1111/j.1651-2227.1989.tb11100.x; VULSMA T, 1989, NEW ENGL J MED, V321, P13, DOI 10.1056/NEJM198907063210103; 1984, J PEDIATR, V104, P539; 1981, LANCET, V2, P1095; 1990, J PEDIATR, V116, P27; 1990, LABOUR FORCE SURVEY; 1982, 1981 CENSUS NATIONAL	30	143	147	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 13	1994	309	6952					440	445		10.1136/bmj.309.6952.440	http://dx.doi.org/10.1136/bmj.309.6952.440			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC404	7920127	Green Published			2022-12-01	WOS:A1994PC40400017
J	HAN, J; LEE, JD; BIBBS, L; ULEVITCH, RJ				HAN, J; LEE, JD; BIBBS, L; ULEVITCH, RJ			A MAP KINASE TARGETED BY ENDOTOXIN AND HYPEROSMOLARITY IN MAMMALIAN-CELLS	SCIENCE			English	Article							PROTEIN-TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION PATHWAY; MACROPHAGES; FAMILY; YEAST; GENES; TAXOL; CD14	Mammalian cells respond to endotoxic lipopolysaccharide (LPS) by activation of protein kinase cascades that lead to new gene expression. A protein kinase, p38, that was tyrosine phosphorylated in response to LPS, was cloned. The p38 enzyme and the product of the Saccharomyces cerevisiae HOG 1 gene, which are both members of the mitogen-activated protein (MAP) kinase family, have sequences at and adjacent to critical phosphorylation sites that distinguish these proteins from most other MAP kinase family members. Both HOG1 and p38 are tyrosine phosphorylated after extracellular changes in osmolarity. These findings link a signaling pathway in mammalian cells with a pathway in yeast that is responsive to physiological stress.	SCRIPPS RES INST, MICROCHEM FACIL, LA JOLLA, CA 92037 USA	Scripps Research Institute	HAN, J (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Han, J/G-4671-2010; Ulevitch, Richard J/Q-3393-2017		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028485, P01GM037696, R37GM028485] Funding Source: NIH RePORTER; NIAID NIH HHS [AI15136] Funding Source: Medline; NIGMS NIH HHS [GM37696, GM28485] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CORRADIN SB, 1992, J LEUKOCYTE BIOL, V52, P363, DOI 10.1002/jlb.52.4.363; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DING AH, 1990, SCIENCE, V248, P370, DOI 10.1126/science.1970196; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; GLENNEY JR, 1991, METHOD ENZYMOL, V201, P92; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GUSTIN M, COMMUNICATION; Han J., UNPUB; HAN JH, 1993, J BIOL CHEM, V268, P25009; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; MANTHEY CL, 1992, J IMMUNOL, V149, P2459; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; SCHILD D, 1990, P NATL ACAD SCI USA, V87, P2916, DOI 10.1073/pnas.87.8.2916; TILLY BC, 1993, J BIOL CHEM, V268, P19919; Tracey K J, 1990, Adv Surg, V23, P21; ULEVITCH RJ, 1994, CURR OPIN IMMUNOL, V6, P125, DOI 10.1016/0952-7915(94)90043-4; ULEVITCH RJ, 1993, ADV IMMUNOL, V53, P267, DOI 10.1016/S0065-2776(08)60502-7; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	26	2398	2538	2	72	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 5	1994	265	5173					808	811		10.1126/science.7914033	http://dx.doi.org/10.1126/science.7914033			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	7914033				2022-12-01	WOS:A1994PA37200041
J	HEYM, B; HONORE, N; TRUFFOTPERNOT, C; BANERJEE, A; SCHURRA, C; JACOBS, WR; VANEMBDEN, JD; GROSSET, JH; COLE, ST				HEYM, B; HONORE, N; TRUFFOTPERNOT, C; BANERJEE, A; SCHURRA, C; JACOBS, WR; VANEMBDEN, JD; GROSSET, JH; COLE, ST			IMPLICATIONS OF MULTIDRUG-RESISTANCE FOR THE FUTURE OF SHORT-COURSE CHEMOTHERAPY OF TUBERCULOSIS - A MOLECULAR STUDY	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; MYCOBACTERIUM-TUBERCULOSIS; STREPTOMYCIN RESISTANCE; PULMONARY TUBERCULOSIS; GENE; RIFAMPIN; SINGLE; MUTATIONS; LEPRAE	Tuberculosis-control programmes are compromised by the increased frequency of multidrug-resistant strains of Mycobacterium tuberculosis. We used the polymerase chain reaction (PCR) and single-strand conformation polymorphism (SSCP) analysis techniques to establish the molecular basis of resistance in 37 drug-resistant isolates of M tuberculosis, and correlated these findings with clinical and antibiotic-sensitivity data. Resistance to isoniazid was found in 36 strains, 16 of which were also resistant to ethionamide. Of the 36 isoniazid-resistant strains, 23 had mutations in the katG gene, and 5 of these also had mutations in the inhA gene. A further 5 strains had alterations in the inhA locus without the katG gene being mutated. Rifampicin resistance was less frequent (13 strains) and usually associated with isoniazid resistance (11 of 13 strains). Mutations in the rpoB gene were detected for all these rifampicin-resistant isolates. Mutations in the rpsL and rrs genes, associated with streptomycin resistance, were found in 13 of 25 and 2 of 25 streptomycin-resistant strains, respectively. The same chromosomal mutations, or combinations of mutations, were found in strains displaying single or multidrug resistance, from cases of both primary and secondary resistance, and from patients infected with human immunodeficiency virus. Thus, multidrug resistance is not due to a novel mechanism and tuberculosis chemotherapy is not subject to a new threat.	INST PASTEUR,UNITE GENET MOLEC BACTERIENNE,F-75724 PARIS 15,FRANCE; UNIV PARIS 06,PARIS,FRANCE; ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,NEW YORK,NY; NATL INST PUBL HLTH & HYG,BILTHOVEN,NETHERLANDS	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Sorbonne Universite; Howard Hughes Medical Institute; Yeshiva University				Jacobs, William/0000-0003-3321-3080				BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; FINKEN M, 1993, MOL MICROBIOL, V9, P1239, DOI 10.1111/j.1365-2958.1993.tb01253.x; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; HEYM B, 1993, J BACTERIOL, V175, P4255, DOI 10.1128/JB.175.13.4255-4259.1993; HONORE N, 1994, ANTIMICROB AGENTS CH, V38, P238, DOI 10.1128/AAC.38.2.238; HONORE N, 1993, ANTIMICROB AGENTS CH, V37, P414, DOI 10.1128/AAC.37.3.414; Imboden Paul, 1993, P519; ISEMAN MD, 1993, NEW ENGL J MED, V329, P784, DOI 10.1056/NEJM199309093291108; JACOBS WR, 1993, SCIENCE, V260, P819, DOI 10.1126/science.8484123; MARTIN C, 1990, MOL BIOL MYCOBACTERI, P121; MCCLATCHY JK, 1986, ANTIBIOTICS LABORATO, P181; MITCHISON DA, 1986, AM REV RESPIR DIS, V133, P423; NAIR J, 1993, MOL MICROBIOL, V10, P521, DOI 10.1111/j.1365-2958.1993.tb00924.x; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; TAKIFF HE, 1994, ANTIMICROB AGENTS CH, V38, P773, DOI 10.1128/AAC.38.4.773; TELENTI A, 1993, LANCET, V341, P647, DOI 10.1016/0140-6736(93)90417-F; TELENTI A, 1993, ANTIMICROB AGENTS CH, V37, P2054, DOI 10.1128/AAC.37.10.2054; WOODS SA, 1989, FEMS MICROBIOL LETT, V65, P305; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0; 1992, MMWR-MORBID MORTAL W, V42, P5; 1991, MMWR-MORBID MORTAL W, V40, P585; 1993, MMWR-MORBID MORTAL W, V42, P1	29	240	261	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 30	1994	344	8918					293	298		10.1016/S0140-6736(94)91338-2	http://dx.doi.org/10.1016/S0140-6736(94)91338-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ233	7914261				2022-12-01	WOS:A1994NZ23300007
J	KUNST, CB; WARREN, ST				KUNST, CB; WARREN, ST			CRYPTIC AND POLAR VARIATION OF THE FRAGILE-X REPEAT COULD RESULT IN PREDISPOSING NORMAL ALLELES	CELL			English	Article							FMR-I LOCUS; MYOTONIC-DYSTROPHY; FOUNDER CHROMOSOMES; RNA-BINDING; CGG-REPEAT; CTG REPEAT; CAG REPEAT; GENE; DNA; INSTABILITY	Fragile X syndrome results from the expansion of a CGG repeat that is normally interrupted by occasional AGG triplets. Linkage disequilibrium suggests that certain normal haplotypes may contribute unequally to the pool of fragile X chromosomes. Sequence analysis of normal alleles demonstrates haplotype-specific variation of the cryptic nature of the repeat. Variation occurs principally at the 3' end of the repeat, suggesting stability differences between the leading and lagging strands of DNA replication. Normal alleles with greater than 24 perfect 3' CGG repeats appear more frequently on haplotypes overrepresented among fragile X chromosomes. Such alleles are found in 2% of normal chromosomes and could comprise the ancestral allelic pool from which fragile X chromosomes are derived. These data also may imply that equilibrium between certain predisposed alleles and fragile X expansions has not yet been attained, indicating ongoing evolutionary change at this locus.	EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT PEDIAT,ATLANTA,GA 30322	Emory University; Emory University	KUNST, CB (corresponding author), EMORY UNIV,SCH MED,HOWARD HUGHES MED INST,ATLANTA,GA 30322, USA.		Warren, Stephen T/A-2498-2012		NICHD NIH HHS [HD20521] Funding Source: Medline; OHS HRSA HHS [ST32 GM08367] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020521, R37HD020521] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); OHS HRSA HHS; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARMOUR JAL, 1993, HUM MOL GENET, V2, P1137, DOI 10.1093/hmg/2.8.1137; ASHLEY CT, 1993, NAT GENET, V4, P244, DOI 10.1038/ng0793-244; ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BROWN TC, 1987, CELL, V50, P945, DOI 10.1016/0092-8674(87)90521-6; BROWN WT, 1993, JAMA-J AM MED ASSOC, V270, P1569, DOI 10.1001/jama.270.13.1569; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; CHAKRAVARTI A, 1992, NAT GENET, V1, P237, DOI 10.1038/ng0792-237; CHUNG MY, 1993, NAT GENET, V5, P254, DOI 10.1038/ng1193-254; DAVIES J, 1992, CELL, V68, P799; ECKHART M, 1993, AM J HUM GENET, V53, pA796; FAIRMAN R, 1988, BIOCHEMISTRY-US, V27, P560, DOI 10.1021/bi00402a009; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GLOVER TW, 1987, AM J HUM GENET, V41, P882; HORNSTRA IK, 1993, HUM MOL GENET, V2, P1659; HYRIEN O, 1993, EMBO J, V12, P4511, DOI 10.1002/j.1460-2075.1993.tb06140.x; IMBERT G, 1993, NAT GENET, V4, P72, DOI 10.1038/ng0593-72; KELLY R, 1989, GENOMICS, V5, P844, DOI 10.1016/0888-7543(89)90126-2; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; MACDONALD ME, 1992, NAT GENET, V1, P99, DOI 10.1038/ng0592-99; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MCCONKIEROSELL A, 1993, AM J HUM GENET, V53, P800; MORTON NE, 1992, P NATL ACAD SCI USA, V89, P4215, DOI 10.1073/pnas.89.9.4215; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; OUDET C, 1993, AM J HUM GENET, V52, P297; PETES TD, 1991, GENOME DYNAMICS PROT, V1; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RICHARDS RI, 1994, NAT GENET, V6, P114, DOI 10.1038/ng0294-114; RICHARDS RI, 1992, NAT GENET, V1, P257, DOI 10.1038/ng0792-257; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; ROUSSEAU F, 1993, AM J HUM GENET, V53, pA3; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SMITS APT, 1993, J MED GENET, V30, P94, DOI 10.1136/jmg.30.2.94; SNOW K, 1993, AM J HUM GENET, V53, P1217; STARR C, 1984, BIOL UNITY DIVERSITY; STIENBACH P, 1993, HUM GENET, V92, P491; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; SZABO P, 1984, P NATL ACAD SCI-BIOL, V81, P7855, DOI 10.1073/pnas.81.24.7855; TRINH TQ, 1991, NATURE, V352, P544, DOI 10.1038/352544a0; VAUTE X, 1993, SCIENCE, V261, P598; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WARREN ST, 1994, JAMA-J AM MED ASSOC, V271, P536, DOI 10.1001/jama.271.7.536; WEBER JL, 1990, GENOMICS, V7, P524, DOI 10.1016/0888-7543(90)90195-Z; WOHRLE D, 1992, HUM GENET, V89, P114, DOI 10.1007/BF00207057; WOHRLE D, 1993, NAT GENET, V4, P140, DOI 10.1038/ng0693-140; YU S, 1992, AM J HUM GENET, V50, P968; 1993, CELL, V72, P971	53	334	337	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 17	1994	77	6					853	861		10.1016/0092-8674(94)90134-1	http://dx.doi.org/10.1016/0092-8674(94)90134-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	7911740				2022-12-01	WOS:A1994NT33100010
J	WECHSLER, H; DAVENPORT, A; DOWDALL, G; MOEYKENS, B; CASTILLO, S				WECHSLER, H; DAVENPORT, A; DOWDALL, G; MOEYKENS, B; CASTILLO, S			HEALTH AND BEHAVIORAL CONSEQUENCES OF BINGE-DRINKING IN COLLEGE - A NATIONAL SURVEY OF STUDENTS AT 140 CAMPUSES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALCOHOL-USE; PATTERNS; VALIDITY	Objective.-To examine the extent of binge drinking by college students and the ensuing health and behavioral problems that binge drinkers create for themselves and others on their campus. Design.-Self-administered survey mailed to a national representative sample of US 4-year college students. Setting.-One hundred forty US 4-year colleges in 1993. Participants.-A total of 17 592 college students. Main Outcome Measures.-Self-reports of drinking behavior, alcohol-related health problems, and other problems. Results.-Almost half (44%) of college students responding to the survey were binge drinkers, including almost one fifth (19%) of the students who were frequent binge drinkers. Frequent binge drinkers are more likely to experience serious health and other consequences of their drinking behavior than other students. Almost half (47%) of the frequent binge drinkers experienced five or more different drinking-related problems, including injuries and engaging in unplanned sex, since the beginning of the school year. Most binge drinkers do not consider themselves to be problem drinkers and have not sought treatment for an alcohol problem. Binge drinkers create problems for classmates who are not binge drinkers. Students who are not binge drinkers at schools with higher binge rates were more likely than students at schools with lower binge rates to experience problems such as being pushed, hit, or assaulted or experiencing an unwanted sexual advance. Conclusions.-Binge drinking is widespread on college campuses. Programs aimed at reducing this problem should focus on frequent binge drinkers, refer them to treatment or educational programs, and emphasize the harm they cause for students who are not binge drinkers.	HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	WECHSLER, H (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH & SOCIAL BEHAV, 667 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Fahimifar, Sepideh/M-5303-2019					Berkowitz A D, 1986, J Am Coll Health, V35, P21; BRENNAN AF, 1986, INT J ADDICT, V21, P449, DOI 10.3109/10826088609083536; COOPER AM, 1981, INT J ADDICT, V16, P401, DOI 10.3109/10826088109038841; ENGS RC, 1985, J ALCOHOL DRUG EDUC, V31, P65; HANSON DJ, 1992, PSYCHOL REP, V71, P39, DOI 10.2466/PR0.71.5.39-39; HAWORTHHOEPPNER S, 1989, INT J ADDICT, V24, P829, DOI 10.3109/10826088909047315; HUGHES S, 1983, J COLL STUDENT PERS, V20, P257; JOHNSTON LD, 1991, ADM911835 US DEP HLT; LILJESTRAND P, 1993, J ALCOHOL DRUG EDUC, V38, P1; MIDANIK LT, 1988, BRIT J ADDICT, V83, P1019; OHARE TM, 1990, J STUD ALCOHOL, V51, P536, DOI 10.15288/jsa.1990.51.536; Presley CA., 1993, ALCOHOL DRUGS AM COL, VI; REINISCH OJ, 1991, RAND N3189CHF PUBL; ROOM R, 1971, DRINKING DRUG PRACTI, V3, P15; ROOM R, 1991, ALCOHOL AM DRINKING, P26; Saltz R, 1986, CONTEMP DRUG PROBL, V13, P117; Straus R, 1953, DRINKING IN COLLEGE; WECHSLER H, 1992, Journal of the American Medical Association, V267, P2929, DOI 10.1001/jama.267.21.2929; WECHSLER H, 1979, J STUD ALCOHOL, V40, P969, DOI 10.15288/jsa.1979.40.969; 1990, ALCOHOL HLTH; 1992, BARRONS PROFILES AM; 1994, RETHINKING RITES PAS; 1993, DIGEST ED STATISTICS, P180; 1993, SUBSTANCE ABUSE NATI; 1988, SAS STAT USERS GUIDE; 1990, CAMPUS LIFE SEARCH C	26	1338	1345	1	191	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 7	1994	272	21					1672	1677		10.1001/jama.272.21.1672	http://dx.doi.org/10.1001/jama.272.21.1672			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU759	7966895				2022-12-01	WOS:A1994PU75900026
J	RAE, D; PORTER, J; BEECHEYNEWMAN, N; SUMAR, N; BENNETT, D; HERMONTAYLOR, J				RAE, D; PORTER, J; BEECHEYNEWMAN, N; SUMAR, N; BENNETT, D; HERMONTAYLOR, J			TYPE-1 PROPHOSPHOLIPASE A(2) PROPEPTIDE IN ACUTE LUNG INJURY	LANCET			English	Note							RESPIRATORY-DISTRESS SYNDROME; NEUTROPHILS	Neutrophil sequestration and activation in the pulmonary vasculature and interstitium are important in acute lung injury. Phospholipase A(2) plays an important part in the production of potent inflammatory mediators in this syndrome. We used our ELISA for type 1 prophospholipase A(2) activation peptides, which have the aminoacid sequence Asp-Ser-Gly-Ile-Ser-Pro-Arg (DSGISPR), to show that DSGISPR concentrations in plasma and urine are a sensitive and specific marker of acute lung injury in patients admitted to intensive care. The detection of DSGISPR in the plasma of 11 of 50 unselected patients had a sensitivity of 100% and a specificity of 93% for the presence or future development of acute lung injury.	ST GEORGE HOSP,SCH MED,DEPT SURG,LONDON SW17 0RE,ENGLAND; ST GEORGE HOSP,SCH MED,INTENS CARE UNIT,LONDON SW17 0RE,ENGLAND	St Georges University London; St Georges University London			Porter, Joanna/C-7162-2009	Porter, Joanna/0000-0002-7307-169X				CHANG SW, 1987, J CLIN INVEST, V79, P1498, DOI 10.1172/JCI112980; GRATAROLI R, 1982, EUR J BIOCHEM, V122, P111, DOI 10.1111/j.1432-1033.1982.tb05855.x; HEFFNER JE, 1987, AM REV RESPIR DIS, V135, P482; OFFENSTADT G, 1981, INTENS CARE MED, V7, P285, DOI 10.1007/BF01709723; RAE D, IN PRESS CLIN BIOCH; RINTALA EM, 1993, CLIN INFECT DIS, V17, P864, DOI 10.1093/clinids/17.5.864; ROMASCHIN AD, 1992, CLIN BIOCHEM, V25, P55, DOI 10.1016/0009-9120(92)80046-J; WEILAND JE, 1986, AM REV RESPIR DIS, V133, P218; WEINBERG PF, 1984, AM REV RESPIR DIS, V130, P791; WEISS SJ, 1989, NEW ENGL J MED, V320, P365	10	45	45	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 26	1994	344	8935					1472	1473		10.1016/S0140-6736(94)90291-7	http://dx.doi.org/10.1016/S0140-6736(94)90291-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7968121				2022-12-01	WOS:A1994PT99500010
J	OFVERSTEDT, LG; ZHANG, K; TAPIO, S; SKOGLUND, U; ISAKSSON, LA				OFVERSTEDT, LG; ZHANG, K; TAPIO, S; SKOGLUND, U; ISAKSSON, LA			STARVATION IN-VIVO FOR AMINOACYL-TRANSFER-RNA INCREASES THE SPATIAL SEPARATION BETWEEN THE 2 RIBOSOMAL-SUBUNITS	CELL			English	Article							ESCHERICHIA-COLI RIBOSOME; ELECTRON-MICROSCOPE TOMOGRAPHY; 3-DIMENSIONAL IMAGE-RECONSTRUCTION; ELONGATION-FACTOR TU; TRANSFER-RNA BINDING; X-RAY; IMMUNOELECTRON MICROSCOPY; CONFORMATIONAL CHANGE; PUROMYCIN BINDING; SINGLE PARTICLES	Structures in situ of individual ribosomes in E. coli have been determined by computer-aided electron microscope tomography using a tilt series of positively stained embedded cellular sections. Amino acid starvation of a bacterial culture, causing a deficiency for aminoacyl-tRNA, induces a spatial separation between the ribosomal subunits compared with ribosomes in exponentially growing cells. Eight ribosomes from each growth condition were aligned to each other, and the two average structures were determined. Comparison of these suggests that the distance between the two subunits increases by similar to 3 nm upon starvation for aminoacyl-tRNA during protein synthesis. Ribosomes in most other states of the translational elongation cycle in exponentially growing cells show a more compact structure than previously realized.	UNIV STOCKHOLM,DEPT MICROBIOL,S-10691 STOCKHOLM,SWEDEN	Stockholm University	OFVERSTEDT, LG (corresponding author), KAROLINSKA INST,MED NOBEL INST,DEPT CELL & MOLEC BIOL,S-17177 STOCKHOLM,SWEDEN.		Öfverstedt, Lars-Göran/J-3518-2013; Tapio, Soile/CAJ-5871-2022; Tapio, Soile/M-7358-2014; Skoglund, Ulf/B-5829-2015	Öfverstedt, Lars-Göran/0000-0002-1796-2199; Tapio, Soile/0000-0001-9860-3683; Skoglund, Ulf/0000-0002-3407-0053				ARAD T, 1987, BIOCHIMIE, V69, P1001, DOI 10.1016/0300-9084(87)90234-3; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BERKOVITCHYELLIN Z, 1992, CRIT REV BIOCHEM MOL, V27, P403, DOI 10.3109/10409239209082568; BRACEWELL RN, 1967, ASTROPHYS J, V150, P427, DOI 10.1086/149346; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; FRANK J, 1991, J CELL BIOL, V115, P597, DOI 10.1083/jcb.115.3.597; FRANK J, 1981, SCIENCE, V214, P1353, DOI 10.1126/science.7313694; FRANK J, 1988, TRENDS BIOCHEM SCI, V13, P123, DOI 10.1016/0968-0004(88)90063-1; FRANK J, 1990, RIBOSOME, P107; GILBERT PFC, 1972, PROC R SOC SER B-BIO, V182, P89, DOI 10.1098/rspb.1972.0068; GIRSHOVICH AS, 1981, FEBS LETT, V130, P54, DOI 10.1016/0014-5793(81)80664-3; GIRSHOVICH AS, 1986, FEBS LETT, V197, P192, DOI 10.1016/0014-5793(86)80325-8; GLAUERT AM, 1958, J BIOPHYS BIOCHEM CY, V4, P191, DOI 10.1083/jcb.4.2.191; GORNICKI P, 1984, J BIOL CHEM, V259, P493; GUDKOV AT, 1989, BIOCHIMIE, V71, P779, DOI 10.1016/0300-9084(89)90040-0; HART RG, 1968, SCIENCE, V159, P1464, DOI 10.1126/science.159.3822.1464; HOPPE W, 1986, J MOL BIOL, V192, P291, DOI 10.1016/0022-2836(86)90366-9; ISAKSSON LA, 1977, MOL GEN GENET, V156, P223; KIRSEBOM LA, 1986, MOL GEN GENET, V205, P240, DOI 10.1007/BF00430434; KLUG A, 1972, NATURE, V238, P435, DOI 10.1038/238435a0; KNAUER V, 1983, J MOL BIOL, V163, P409, DOI 10.1016/0022-2836(83)90066-9; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LAKE JA, 1977, P NATL ACAD SCI USA, V74, P1903, DOI 10.1073/pnas.74.5.1903; LAKE JA, 1985, ANNU REV BIOCHEM, V54, P507, DOI 10.1146/annurev.biochem.54.1.507; LAKE JA, 1976, J MOL BIOL, V105, P131, DOI 10.1016/0022-2836(76)90200-X; LAUGHREA M, 1992, BIOCHEMISTRY-US, V31, P12035, DOI 10.1021/bi00163a011; LAUGHREA M, 1994, IN PRESS MOL MICROBI, V11; LILJAS A, 1982, PROG BIOPHYS MOL BIO, V40, P161, DOI 10.1016/0079-6107(82)90013-X; LIM V, 1992, NUCLEIC ACIDS RES, V20, P2627, DOI 10.1093/nar/20.11.2627; LODMELL JS, 1993, BIOCHEMISTRY-US, V32, P4067, DOI 10.1021/bi00066a030; LONNROTH A, 1993, J MICROSC-OXFORD, V170, P173; LUFT JH, 1972, P ELECTRON MICROSC S, V30, P132; LUHRMANN R, 1981, P NATL ACAD SCI-BIOL, V78, P7276, DOI 10.1073/pnas.78.12.7276; LUTHER PK, 1988, ULTRAMICROSCOPY, V24, P7, DOI 10.1016/0304-3991(88)90322-1; MAUGUEN Y, 1982, NATURE, V297, P162, DOI 10.1038/297162a0; MCEWEN BF, 1986, P NATL ACAD SCI USA, V83, P9040, DOI 10.1073/pnas.83.23.9040; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; MEISENBERGER O, 1984, BIOCHIM BIOPHYS ACTA, V781, P225, DOI 10.1016/0167-4781(84)90087-3; Miller, 1972, EXPT MOL GENETICS; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; NORDESTGAARD BG, 1985, MICRON MICROSC ACTA, V16, P65, DOI 10.1016/0739-6260(85)90035-8; ODOM OW, 1990, BIOCHEMISTRY-US, V29, P10734, DOI 10.1021/bi00500a004; OETTL H, 1983, J MOL BIOL, V163, P431, DOI 10.1016/0022-2836(83)90067-0; OFENGAND J, 1986, STRUCTURE FUNCTION G, P473; OLSON HM, 1982, J BIOL CHEM, V257, P2649; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; RADERMACHER M, 1987, EMBO J, V6, P1107, DOI 10.1002/j.1460-2075.1987.tb04865.x; RADERMACHER M, 1988, J ELECTRON MICR TECH, V9, P359, DOI 10.1002/jemt.1060090405; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; RHEINBERGER HJ, 1981, P NATL ACAD SCI-BIOL, V78, P5310, DOI 10.1073/pnas.78.9.5310; SERDYUK I, 1992, BIOCHIMIE, V74, P299, DOI 10.1016/0300-9084(92)90107-P; SKOGLUND U, 1986, TRENDS BIOCHEM SCI, V11, P499, DOI 10.1016/0968-0004(86)90077-0; SKOGLUND U, 1986, NATURE, V319, P560, DOI 10.1038/319560a0; SPIRIN A, 1987, BIOCHIMIE, V69, P949, DOI 10.1016/0300-9084(87)90228-8; SPIRIN AS, 1987, J MOL BIOL, V194, P119, DOI 10.1016/0022-2836(87)90720-0; SPIRIN AS, 1983, FEBS LETT, V156, P217, DOI 10.1016/0014-5793(83)80499-2; SPIRIN AS, 1989, BIOL CELL, V66, P215, DOI 10.1016/0248-4900(89)90174-3; SRIVASTAVA S, 1985, FEBS LETT, V186, P17, DOI 10.1016/0014-5793(85)81330-2; STOFFLER G, 1984, ANNU REV BIOPHYS BIO, V13, P303, DOI 10.1146/annurev.bb.13.060184.001511; STOFFLER G, 1980, RIBOSOMES STRUCTURE, P171; TARDIEU A, 1982, EMBO J, V1, P35, DOI 10.1002/j.1460-2075.1982.tb01120.x; VASILIEV VD, 1983, FEBS LETT, V155, P167, DOI 10.1016/0014-5793(83)80232-4; WAGENKNECHT T, 1989, BIOPHYS J, V55, P455, DOI 10.1016/S0006-3495(89)82839-5; WILLIAMS RC, 1970, J MOL BIOL, V52, P121, DOI 10.1016/0022-2836(70)90181-6; WITTMANN HG, 1983, ANNU REV BIOCHEM, V52, P35, DOI 10.1146/annurev.bi.52.070183.000343; WOWER J, 1991, BIOCHIMIE, V73, P961, DOI 10.1016/0300-9084(91)90137-P; YONATH A, 1993, CURR OPIN STRUC BIOL, V3, P175, DOI 10.1016/S0959-440X(05)80149-6; YONATH A, 1987, SCIENCE, V236, P813, DOI 10.1126/science.3576200; YONATH A, 1990, RIBOSOME, P134	69	39	39	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 18	1994	79	4					629	638		10.1016/0092-8674(94)90548-7	http://dx.doi.org/10.1016/0092-8674(94)90548-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7954829				2022-12-01	WOS:A1994PT48100010
J	CONQUET, F; BASHIR, ZI; DAVIES, CH; DANIEL, H; FERRAGUTI, F; BORDI, F; FRANZBACON, K; REGGIANI, A; MATARESE, V; CONDE, F; COLLINGRIDGE, GL; CREPEL, F				CONQUET, F; BASHIR, ZI; DAVIES, CH; DANIEL, H; FERRAGUTI, F; BORDI, F; FRANZBACON, K; REGGIANI, A; MATARESE, V; CONDE, F; COLLINGRIDGE, GL; CREPEL, F			MOTOR DEFICIT AND IMPAIRMENT OF SYNAPTIC PLASTICITY IN MICE LACKING MGLUR1	NATURE			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; CEREBELLAR PURKINJE-CELLS; LONG-TERM POTENTIATION; RAT-BRAIN; INVITRO; MOUSE; HIPPOCAMPUS; EXPRESSION; INDUCTION; ACTIVATION	Metabotropic glutamate receptor 1 (mGluR1) is a member of a large family of G-protein-coupled glutamate receptors, the physiological functions of which are largely unknown. Mice deficient in mGluR1 have severe motor coordination and spatial learning deficits. They have no gross anatomical or basic electrophysiological abnormalities in either the cerebellum or hippocampus, but they show impaired cerebellar long-term depression and hippocampal messy fibre long-term potentiation, mGluR1-deficient mice should therefore be valuable models for studying synaptic plasticity.	GLAXO SPA,GLAXO RES LABS,DEPT PHARMACOL,I-37100 VERONA,ITALY; UNIV PARIS 11,F-91405 ORSAY,FRANCE; CNRS,DEPT NEUROBIOL,F-91405 ORSAY,FRANCE; UNIV BIRMINGHAM,DEPT PHARMACOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	GlaxoSmithKline; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); University of Birmingham	CONQUET, F (corresponding author), GLAXO INST MOLEC BIOL SA,CH-1228 PLAN LES OUATES,SWITZERLAND.		Matarese, Valerie/ABE-1606-2020; Collingridge, Graham L/C-4605-2015; Francesco, Ferraguti/AAD-3422-2020; collingridge, graham/AAI-8362-2020	Matarese, Valerie/0000-0003-2687-194X; Collingridge, Graham L/0000-0002-9572-5359; Francesco, Ferraguti/0000-0002-3843-5857; Bashir, Zafar/0000-0003-3650-2136				AGNATI LF, 1988, NEUROSCIENCE, V27, P785, DOI 10.1016/0306-4522(88)90183-2; BASHIR ZI, 1993, EUR J PHARMACOL, V239, P265, DOI 10.1016/0014-2999(93)91009-C; BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; BORTOLOTTO ZA, 1994, NATURE, V368, P740, DOI 10.1038/368740a0; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CREPEL F, 1991, J PHYSIOL-LONDON, V432, P123, DOI 10.1113/jphysiol.1991.sp018380; CREPEL F, 1986, J PHYSIOL-LONDON, V372, P1; DANIEL H, 1992, EXP BRAIN RES, V90, P327; Eccles J. C. M., 1967, CEREBELLUM NEURONAL; FOTUHI M, 1993, J NEUROSCI, V13, P2001; HANSE E, 1992, EUR J NEUROSCI, V4, P1191, DOI 10.1111/j.1460-9568.1992.tb00144.x; HARTELL NA, 1994, NEUROREPORT, V5, P913, DOI 10.1097/00001756-199404000-00015; HAYASHI T, 1994, J NEUROSCI, V14, P3370; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; IRWIN S, 1959, ARCH INT PHARMACOD T, V188, P358; Ito M, 1990, Neuroreport, V1, P129; KABA H, 1994, SCIENCE, V265, P262, DOI 10.1126/science.8023145; LEMOUELLIC H, 1990, P NATL ACAD SCI USA, V87, P4712, DOI 10.1073/pnas.87.12.4712; LINDEN DJ, 1994, NEURON, V12, P457, DOI 10.1016/0896-6273(94)90205-4; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; MANZONI OJ, 1994, EUR J NEUROSCI, V6, P1050, DOI 10.1111/j.1460-9568.1994.tb00599.x; MARTIN LJ, 1992, NEURON, V9, P259, DOI 10.1016/0896-6273(92)90165-A; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OCONNOR JJ, 1994, NATURE, V367, P557, DOI 10.1038/367557a0; PERKEL DJ, 1990, P ROY SOC B-BIOL SCI, V241, P116, DOI 10.1098/rspb.1990.0074; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; REIDEL G, 1993, NEUROPHARMACOLOGY, V32, P929; RICHTER-LEVIN G, 1994, NEUROPHARMACOLOGY, V33, P853, DOI 10.1016/0028-3908(94)90181-3; RIDEL G, 1994, NEUROSCI LETT, V167, P141; RYO Y, 1993, J NEUROSCI RES, V36, P19, DOI 10.1002/jnr.490360104; SANDBERG PR, 1985, NEUROBEHAV TOXICOL T, V7, P87; SHIGEMOTO R, 1994, NEURON, V12, P1245, DOI 10.1016/0896-6273(94)90441-3; SHIGEMOTO R, 1992, J COMP NEUROL, V322, P121, DOI 10.1002/cne.903220110; STAUB C, 1992, EUR J NEUROSCI, V4, P832, DOI 10.1111/j.1460-9568.1992.tb00193.x	39	639	646	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 17	1994	372	6503					237	243		10.1038/372237a0	http://dx.doi.org/10.1038/372237a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PR889	7969468				2022-12-01	WOS:A1994PR88900041
J	CHEN, XS; SHELLER, JR; JOHNSON, EN; FUNK, CD				CHEN, XS; SHELLER, JR; JOHNSON, EN; FUNK, CD			ROLE OF LEUKOTRIENES REVEALED BY TARGETED DISRUPTION OF THE 5-LIPOXYGENASE GENE	NATURE			English	Article							PLATELET-ACTIVATING-FACTOR; MOUSE EAR EDEMA; MAST-CELLS; MICE; STIMULATION; PERITONITIS; MODULATION; MEDIATORS; PRODUCTS; INVITRO	LEUKOTRIENES constitute a class of potent biological mediators of inflammation and anaphylaxis (for reviews see refs 1 and 2). Their biosynthesis derives from 5-lipoxygenase-catalysed oxygenation of arachidonic acid in granulocytes, macrophages and mast cells. To examine the physiological importance of leukotrienes, we have disrupted the 5-lipoxygenase gene by homologous recombination in embryonic stem cells. 5-Lipoxygenase-deficient (5LX(-/-)) mice develop normally and are healthy. They show a selective opposition to certain inflammatory insults. Although there is no difference in their reaction to endotoxin shock, the 5LX(-/-) animals resist the lethal effects of shock induced by platelet-activating factor. Reaction to ear inflammation induced by phorbol ester is normal, whereas inflammation induced by arachidonic acid is markedly reduced. Contrasts mere also found in two models of leukocyte chemotaxis in vivo. The phenotype of 5LX(-/-) mice under injurious insult identifies the role for leukotrienes in the pathophysiology of select inflammatory states.	VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University			Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233				BARBEE RW, 1994, CIRC RES, V74, P747, DOI 10.1161/01.RES.74.4.747; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; BRAQUET P, 1987, PHARMACOL REV, V39, P97; CARLSON RP, 1985, AGENTS ACTIONS, V17, P197, DOI 10.1007/BF01966592; CLAESSON HE, 1985, BIOCHEM BIOPH RES CO, V131, P579, DOI 10.1016/0006-291X(85)91276-8; CRUMMEY A, 1987, AGENTS ACTIONS, V20, P69, DOI 10.1007/BF01965627; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FUNK CD, 1991, J BIOL CHEM, V266, P12508; FUNK CD, 1993, PROG NUCLEIC ACID RE, V45, P67, DOI 10.1016/S0079-6603(08)60867-3; INOUE H, 1988, PROSTAGLANDINS, V36, P731, DOI 10.1016/0090-6980(88)90016-0; LANARA E, 1982, BIOCHEM BIOPH RES CO, V109, P1148, DOI 10.1016/0006-291X(82)91897-6; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; MARTIN TR, 1988, J APPL PHYSIOL, V64, P2318, DOI 10.1152/jappl.1988.64.6.2318; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P26, DOI 10.1073/pnas.85.1.26; OGATA M, 1992, INFECT IMMUN, V60, P2432, DOI 10.1128/IAI.60.6.2432-2437.1992; PEMBER SO, 1983, BLOOD, V61, P1105; PIPER PJ, 1986, BRIT J PHARMACOL, V88, P595, DOI 10.1111/j.1476-5381.1986.tb10240.x; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; RAMOS BF, 1990, J IMMUNOL, V145, P1868; RAZIN E, 1982, P NATL ACAD SCI-BIOL, V79, P4665, DOI 10.1073/pnas.79.15.4665; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SCOTT WA, 1980, J EXP MED, V152, P324, DOI 10.1084/jem.152.2.324; STAHL GL, 1987, CIRC SHOCK, V23, P165; SUN XM, 1991, J IMMUNOL, V147, P509; VOELKEL NF, 1982, SCIENCE, V218, P286, DOI 10.1126/science.7123233; ZHANG Y, 1992, SCIENCE, V258, P1957, DOI 10.1126/science.1470922; ZHANG YY, 1992, P NATL ACAD SCI USA, V89, P485, DOI 10.1073/pnas.89.2.485; ZIBOH VA, 1986, CANCER RES, V46, P600	28	329	339	2	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 10	1994	372	6502					179	182		10.1038/372179a0	http://dx.doi.org/10.1038/372179a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ688	7969451				2022-12-01	WOS:A1994PQ68800056
J	GEIERSTANGER, BH; MRKSICH, M; DERVAN, PB; WEMMER, DE				GEIERSTANGER, BH; MRKSICH, M; DERVAN, PB; WEMMER, DE			DESIGN OF A G-CENTER-DOT-C-SPECIFIC DNA MINOR GROOVE-BINDING PEPTIDE	SCIENCE			English	Article							SEQUENCE-SPECIFIC RECOGNITION; TWO-DIMENSIONAL NMR; MOLECULAR RECOGNITION; DISTAMYCIN-A; N-METHYLPYRROLECARBOXAMIDE; 2-DIMENSIONAL NMR; DYNAMIC ASPECTS; NUCLEIC-ACIDS; NETROPSIN; COMPLEX	A four-ring tripeptide containing alternating imidazole and pyrrole carboxamides specifically binds six-base pair 5'-(A,T)GCGC(A,T)-3' sites in the minor groove of DNA. The designed peptide has a specificity completely reversed from that of the tripyrrole distamycin, which binds A,T sequences. Structural studies with nuclear magnetic resonance revealed that two peptides bound side-by-side and in an antiparallel orientation in the minor groove. Each of the four imidazoles in the 2:1 ligand-DNA complex recognized a specific guanine amino group in the GCGC core through a hydrogen bond. Targeting a designated four- base pair G-C tract by this synthetic ligand supports the generality of the 2:1 peptide-DNA motif for sequence-specific minor groove recognition of DNA.	CALTECH,ARNOLD & MABEL BECKMAN LABS CHEM SYNTHESIS,PASADENA,CA 91125; UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; UNIV CALIF BERKELEY,GRAD GRP BIOPHYS,BERKELEY,CA 94720	California Institute of Technology; University of California System; University of California Berkeley; University of California System; University of California Berkeley			Mrksich, Milan/G-2469-2011	Mrksich, Milan/0000-0002-4964-796X	NIGMS NIH HHS [GM-27681, GM-43129] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043129, R37GM027681, R01GM027681] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOELENS R, 1985, J MAGN RESON, V62, P378, DOI 10.1016/0022-2364(85)90207-0; BURCKHARDT G, 1989, BIOCHIM BIOPHYS ACTA, V1009, P11, DOI 10.1016/0167-4781(89)90072-9; CHEN X, 1994, NAT STRUCT BIOL, V1, P169, DOI 10.1038/nsb0394-169; COLL M, 1987, P NATL ACAD SCI USA, V84, P8385, DOI 10.1073/pnas.84.23.8385; DERVAN PB, 1986, SCIENCE, V232, P464, DOI 10.1126/science.2421408; DWYER TJ, 1993, J AM CHEM SOC, V115, P9900, DOI 10.1021/ja00075a005; DWYER TJ, 1992, J AM CHEM SOC, V114, P5911, DOI 10.1021/ja00041a001; GEIERSTANGER BH, 1993, J AM CHEM SOC, V115, P4474, DOI 10.1021/ja00064a009; GEIERSTANGER BH, 1994, BIOCHEMISTRY-US, V33, P3055, DOI 10.1021/bi00176a039; GEIERSTANGER BH, UNPUB; HARTLEY JA, 1988, ACTA ONCOL, V27, P503, DOI 10.3109/02841868809093578; KISSINGER K, 1987, BIOCHEMISTRY-US, V26, P5590, DOI 10.1021/bi00392a002; KLEVIT RE, 1986, BIOCHEMISTRY-US, V25, P3296, DOI 10.1021/bi00359a032; KOPKA ML, 1985, J MOL BIOL, V183, P553, DOI 10.1016/0022-2836(85)90171-8; KOPKA ML, 1985, P NATL ACAD SCI USA, V82, P1376, DOI 10.1073/pnas.82.5.1376; LEE M, 1993, BIOCHEMISTRY-US, V32, P4237, DOI 10.1021/bi00067a011; LEE M, 1988, J BIOMOL STRUCT DYN, V5, P1059, DOI 10.1080/07391102.1988.10506449; LEE M, 1988, BIOCHEMISTRY-US, V27, P445, DOI 10.1021/bi00401a066; Lee M, 1989, J Mol Recognit, V2, P84, DOI 10.1002/jmr.300020206; LOWN JW, 1986, BIOCHEMISTRY-US, V25, P7408, DOI 10.1021/bi00371a024; MRKSICH M, 1994, J AM CHEM SOC, V116, P3663, DOI 10.1021/ja00087a088; MRKSICH M, 1993, J AM CHEM SOC, V115, P9892, DOI 10.1021/ja00075a004; MRKSICH M, 1993, J AM CHEM SOC, V115, P2572, DOI 10.1021/ja00060a004; MRKSICH M, 1992, P NATL ACAD SCI USA, V89, P7586, DOI 10.1073/pnas.89.16.7586; MRKSICH M, UNPUB; PELTON JG, 1988, BIOCHEMISTRY-US, V27, P8088, DOI 10.1021/bi00421a018; PELTON JG, 1989, P NATL ACAD SCI USA, V86, P5723, DOI 10.1073/pnas.86.15.5723; PELTON JG, 1990, J AM CHEM SOC, V112, P1393, DOI 10.1021/ja00160a016; SCHULTZ PG, 1984, J BIOMOL STRUCT DYN, V1, P1133, DOI 10.1080/07391102.1984.10507508; SKLENAR V, 1987, FEBS LETT, V216, P249, DOI 10.1016/0014-5793(87)80699-3; TAYLOR JS, 1984, TETRAHEDRON, V40, P457, DOI 10.1016/0040-4020(84)85050-4; WADE WS, 1992, J AM CHEM SOC, V114, P8783, DOI 10.1021/ja00049a006; WADE WS, 1993, BIOCHEMISTRY-US, V32, P11385, DOI 10.1021/bi00093a015; WADE WS, 1987, J AM CHEM SOC, V109, P1574, DOI 10.1021/ja00239a050; WEMMER DE, 1994, STRUCTURAL BIOL STAT, V2, P301; YOUNGQUIST RS, 1985, P NATL ACAD SCI USA, V82, P2565, DOI 10.1073/pnas.82.9.2565; ZIMMER C, 1986, PROG BIOPHYS MOL BIO, V47, P31, DOI 10.1016/0079-6107(86)90005-2	37	208	218	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 28	1994	266	5185					646	650		10.1126/science.7939719	http://dx.doi.org/10.1126/science.7939719			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939719				2022-12-01	WOS:A1994PN80700047
J	FANTL, WJ; MUSLIN, AJ; KIKUCHI, A; MARTIN, JA; MACNICOL, AM; GROSS, RW; WILLIAMS, LT				FANTL, WJ; MUSLIN, AJ; KIKUCHI, A; MARTIN, JA; MACNICOL, AM; GROSS, RW; WILLIAMS, LT			ACTIVATION OF RAF-1 BY 14-3-3-PROTEINS	NATURE			English	Article							KINASE-KINASE; OOCYTE MATURATION; EXPRESSION; INDUCTION; PATHWAY; CLONING; GROWTH; CYCLIN; FAMILY; CELLS	THE protein Raf-1, a key mediator of mitogenesis and differentiation, associates with p21(ras) (refs 1-3). However, the regulation of the serine/threonine kinase activity of Raf-1 is still not understood(4-13). Using the yeast two-hybrid systems(8,14-16), we identified two structurally related proteins that interact with the aminoterminal region of Raf-1. These proteins, 14-3-3 zeta (PLA(2)) and 14-3-3 beta (HS1), are members of the 14-3-3 family of proteins(17-23). Expression of 14-3-3 proteins in Xenopus oocytes enhanced Raf-1 activity and promoted Raf-1-dependent oocyte maturation. A dominant negative mutant of Raf-1 blocked the effects of 14-3-3 protein.	WASHINGTON UNIV, SCH MED, DIV BIOORGAN CHEM & MOLEC PHARMACOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	FANTL, WJ (corresponding author), UNIV CALIF SAN FRANCISCO, DAIICHI RES CTR, INST CARDIOVASC RES, DEPT MED, SAN FRANCISCO, CA 94143 USA.							AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DU XP, 1994, J BIOL CHEM, V269, P18287; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARPER JW, 1993, CELL, V75, P805; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEFFERS H, 1993, J MOL BIOL, V231, P982, DOI 10.1006/jmbi.1993.1346; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NIELSEN PJ, 1991, BIOCHIM BIOPHYS ACTA, V1088, P425, DOI 10.1016/0167-4781(91)90136-A; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; RAPP UR, 1991, ONCOGENE, V6, P495; SMITH LD, 1989, DEVELOPMENT, V107, P685; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P9213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZUPAN LA, 1992, J BIOL CHEM, V267, P8707	30	326	331	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 13	1994	371	6498					612	614		10.1038/371612a0	http://dx.doi.org/10.1038/371612a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7935795				2022-12-01	WOS:A1994PL55900054
J	BAUGHMAN, AL; WILLIAMS, WW; ATKINSON, WL; COOK, LG; COLLINS, M				BAUGHMAN, AL; WILLIAMS, WW; ATKINSON, WL; COOK, LG; COLLINS, M			THE IMPACT OF COLLEGE PREMATRICULATION IMMUNIZATION REQUIREMENTS ON RISK FOR MEASLES OUTBREAKS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; ADULTS	Objective.-To assess whether prematriculation immunization requirements (PIRs) affect the number of measles cases on college campuses. Design.-We surveyed a stratified random sample of 880 colleges and universities to determine their immunization policies and practices and occurrence of measles outbreaks from 1988 through 1991. We merged national measles surveillance data with survey data by county to determine the risk for measles introduction on college campuses. We used logistic regression methods to estimate the effect of PIRs and assess risk factors for college measles outbreaks. Setting.-A total of 3205 US colleges and universities listed in standard guides. Results.-Of selected schools, 91 (11%) of the 796 responding schools reported one or more measles cases occurring from 1988 through 1991. Schools with a state-mandated PIR were significantly less likely to report measles outbreaks of two or more cases than other institutions (adjusted relative risk [RR]=0.30; 95% confidence interval [CI], 0.11 to 0.84). None of the 14 schools that reported outbreaks of 10 or more cases was subject to state regulation or had a PIR specifying two doses of measles vaccine in place. Of schools with introduction of measles, residential colleges were more likely to report extensive spread of measles (five or more cases) than nonresidential colleges (RR=35.8; 95% CI, 2.08 to 617.0). Of public schools, 4-year programs had a higher risk of a large outbreak (five or more cases) than 2-year programs. Conclusions.-These results strongly support current recommendations for requiring proof of vaccination of college students to decrease the risk for measles outbreaks on college campuses. State regulations mandating PIRs ensure the best protection against widespread measles transmission.	UNIV PENN,STUDENT HLTH SERV,PHILADELPHIA,PA 19104; AMER COLL HLTH ASSOC,BALTIMORE,MD	University of Pennsylvania	BAUGHMAN, AL (corresponding author), CTR DIS CONTROL & PREVENT,NATL IMMUNIZATION PROGRAM,1600 CLIFTON RD NE,MAILSTOP E-52,ATLANTA,GA 30333, USA.							ABBOTT RD, 1985, AM J EPIDEMIOL, V121, P465, DOI 10.1093/oxfordjournals.aje.a114019; ALLEN LJ, 1993, STAT MED, V12, P229, DOI 10.1002/sim.4780120307; BIRKHEAD GS, 1991, PUBLIC HEALTH REP, V106, P338; COLLINS M, 1987, Journal of American College Health, V35, P247; Cook L G, 1993, J Am Coll Health, V42, P91; DAVIS RM, 1987, AM J EPIDEMIOL, V126, P438, DOI 10.1093/oxfordjournals.aje.a114675; DAVIS SF, 1993, AM J PUBLIC HEALTH, V83, P1011, DOI 10.2105/AJPH.83.7.1011; DILTS SW, 1990, PETERSONS GUIDE 2 YE; Fleiss J. L., 1981, STAT METHODS RATES P, V2nd, DOI 10.1002/0471445428; GUSTAFSON TL, 1987, NEW ENGL J MED, V316, P771, DOI 10.1056/NEJM198703263161303; HERSH BS, 1991, AM J PUBLIC HEALTH, V81, P360, DOI 10.2105/AJPH.81.3.360; HERSH BS, 1992, JAMA-J AM MED ASSOC, V267, P1936, DOI 10.1001/jama.267.14.1936; Hosmer DW, 1989, APPL LOGISTIC REGRES, P238; NARAIN JP, 1985, AM J PUBLIC HEALTH, V75, P397, DOI 10.2105/AJPH.75.4.397; NKOWANE BM, 1987, AM J PUBLIC HLHT, V77, P424; ROBBINS KB, 1981, AM J PUBLIC HEALTH, V71, P270, DOI 10.2105/AJPH.71.3.270; SHAH BV, 1991, CROSSTAB PROCEDURE S; STRUEWING JP, 1993, AM J PUBLIC HEALTH, V83, P1717, DOI 10.2105/AJPH.83.12.1717; Williams W W, 1989, J Am Coll Health, V37, P197; WILLIAMS W W, 1987, Journal of American College Health, V35, P252; WILLIAMS WW, 1988, ANN INTERN MED, V108, P616, DOI 10.7326/0003-4819-108-4-616; 1983, J AM COLL HLTH, V32, P7; 1987, MMWR-MORBID MORTAL W, V36, P209; 1992, MODEL LEGISLATION AC; 1989, ACTION, V28, P5; 1979, MMWR MORBID MORTAL S, V27, P41; 1989, MMWR-MORBID MORTAL W, V38, P11; 1989, LOGISTIC PROCEDURE S, P1071; 1978, MMWR MORBID MORTAL S, V26, P23	29	42	42	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 12	1994	272	14					1127	1132		10.1001/jama.272.14.1127	http://dx.doi.org/10.1001/jama.272.14.1127			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PK124	7933326				2022-12-01	WOS:A1994PK12400033
J	COCKERELL, OC; JOHNSON, AL; SANDER, JWAS; HART, YM; GOODRIDGE, DMG; SHORVON, SD				COCKERELL, OC; JOHNSON, AL; SANDER, JWAS; HART, YM; GOODRIDGE, DMG; SHORVON, SD			MORTALITY FROM EPILEPSY - RESULTS FROM A PROSPECTIVE POPULATION-BASED STUDY	LANCET			English	Article							NATIONAL GENERAL-PRACTICE; ISCHEMIC HEART-DISEASE; COHORT; DRUGS	Patients with epilepsy may be subject to an increased risk of premature death from the underlying cause, or from the epilepsy intself. The extent and nature of this risk has been insufficiently investigated. Standard mortality ratios (SMRs) of patients with newly diagnosed epilepsy were determined in a prospective national population-based study. 1091 patients with newly diagnosed pr suspected epilepsy were ascertained who were attending one of 275 UK general practices from 1984-1987. 1091 patients were classified after 6 months as definite epilepsy (564), possible epilepsy (228), febrile seizures (220), or riot epilepsy (79). Over a median follow up of 6.9 years the SMR for patients with definite or possible epilepsy was 2.5 (95% Cl 2.1-2.9), and 3.0 (2.5-3.7) for definite epilepsy. The SMR was highest during the first year after diagnosis 5.1 (3.8-6.5), declined to 2.5 (1.5-3.9) at 3 years, and 1.3 (0.7-2.0) at 5 years. The commonest causes of death were pneumonia (SMR 7.2), cancer (3.5), and stroke (3.7). The SMR for patients with idiopathic epilepsy was 1.6 (1.0-2.4), remote symptomatic epilepsy 4.3 (3.3-5.5), and acute symptomatic epilepsy 2.9 (1.7-4.5). Mortality in patients with newly-diagnosed epilepsy was high, mainly due to the underlying cause. The SMR for idiopathic epilepsy was also raised, suggesting that epilepsy per se may carry a small risk of death.	INST NEUROL, LONDON, ENGLAND; CHALFONT CTR EPILEPSY, CHALFONT ST PETER SL9 0RJ, BUCKS, ENGLAND; INST PUBL HLTH, MRC, BIOSTAT UNIT, CAMBRIDGE, ENGLAND	University of London; University College London; MRC Biostatistics Unit; University of Cambridge	COCKERELL, OC (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, EPILEPSY RES GRP, LONDON, ENGLAND.		Sander, Josemir/C-1576-2008; Shorvon, Simon D/A-2019-2009	Sander, Josemir/0000-0001-6041-9661; Shorvon, Simon/0000-0003-0313-2001				ANNEGERS JF, 1984, EPILEPSIA, V25, P699, DOI 10.1111/j.1528-1157.1984.tb03480.x; ANNEGERS JF, 1976, EPILEPSIA, V17, P11, DOI 10.1111/j.1528-1157.1976.tb03376.x; BARRACLOUGH BM, 1987, ACTA PSYCHIAT SCAND, V76, P339, DOI 10.1111/j.1600-0447.1987.tb05616.x; BRADFORDHILL A, 1984, SHORT TXB MED STATIS, P259; COLEMAN MP, 1989, PERSON YEARS PYRS FU; Gowers WR., 1885, EPILEPSY OTHER CHRON; HART YM, 1989, NEUROEPIDEMIOLOGY, V8, P221; HART YM, 1990, LANCET, V336, P1271, DOI 10.1016/0140-6736(90)92960-P; HAUSER WA, 1980, EPILEPSIA, V21, P399, DOI 10.1111/j.1528-1157.1980.tb04088.x; JANCAR J, 1980, LANCET, V1, P484; JICK SS, 1992, PHARMACOEPIDEM DR S, V1, P59, DOI DOI 10.1002/PDS.2630010203; KLENERMAN P, 1993, J NEUROL NEUROSUR PS, V56, P149, DOI 10.1136/jnnp.56.2.149; Livingston Samuel, 1963, LIVING EPILEPTIC SEI; MASSEY E W, 1985, Neuroepidemiology, V4, P65; MOORE MT, 1959, JAMA-J AM MED ASSOC, V171, P1328, DOI 10.1001/jama.1959.03010280052013; Munson JF., 2010, MED REC, V77, P58; MUURONEN A, 1985, BRIT MED J, V291, P1481, DOI 10.1136/bmj.291.6507.1481; Rodin E, 1968, PROGNOSIS PATIENTS E, P156; SCHWADE ED, 1954, JAMA-J AM MED ASSOC, V156, P1526; WHITE SJ, 1979, LANCET, V2, P458; ZIELINSKI JJ, 1974, EPILEPSIA, V15, P191, DOI 10.1111/j.1528-1157.1974.tb04941.x	21	322	329	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					918	921		10.1016/S0140-6736(94)92270-5	http://dx.doi.org/10.1016/S0140-6736(94)92270-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934347				2022-12-01	WOS:A1994PJ28700011
J	DAVIS, MB; BATEMAN, D; QUINN, NP; MARSDEN, CD; HARDING, AE				DAVIS, MB; BATEMAN, D; QUINN, NP; MARSDEN, CD; HARDING, AE			MUTATION ANALYSIS IN PATIENTS WITH POSSIBLE BUT APPARENTLY SPORADIC HUNTINGTONS-DISEASE	LANCET			English	Article							TRINUCLEOTIDE REPEAT; MOLECULAR ANALYSIS; ONSET; LENGTH; AGE; INSTABILITY; EXPANSION; SIZE	Until the advent of mutation analysis it was impossible to make a certain diagnosis of Huntington's disease (HD) in the absence of a positive family history, and sporadic cases of possible HD presented a substantial diagnostic dilemma. We have looked for the characteristic expanded trinucleotide (CAG) repeat sequence in the HD gene in 44 patients with probable or possible HD who did not have similarly affected relatives. We used two methods, the traditional widely used method, which estimates both the CAG repeat and the flanking CCG repeat and gives the CAG length by subtraction, and the more precise CAG method, which estimates the repeat length directly. With the CAG method, the HD mutation was detected in 25 (89%) of 28 patients with the typical clinical features of HD and 5 (31%) of 16 in whom the diagnosis was more doubtful. The CAG-CCG method gave results in the borderline abnormal range of repeats for 13 of the 33 patients eventually shown to have an unequivocal repeat expansion by the CAG method. Most of these patients had late onset of symptoms. There was evidence of expansion of an intermediate-length paternal allele in 1 patient and of non-paternity in another. The identification of the mutation causing HD means that it is now possible to confirm or exclude the diagnosis with confidence, even in the absence of a family history, by analysis of DNA from a blood sample. The precise method of measuring the CAG repeat, which is technically more difficult than the traditional method, may be needed to clarify results in a substantial proportion of such patients.	UNIV LONDON,INST NEUROL,DEPT CLIN NEUROL,LONDON WC1N 3BG,ENGLAND	University of London; University College London								ANDREW SE, 1994, HUM MOL GENET, V3, P65, DOI 10.1093/hmg/3.1.65; ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398; BARRON LH, 1993, J MED GENET, V30, P1003, DOI 10.1136/jmg.30.12.1003; BATEMAN D, 1992, ANN NEUROL, V31, P293, DOI 10.1002/ana.410310311; CRAUFURD D, 1993, J MED GENET, V30, P1008, DOI 10.1136/jmg.30.12.1008; DEROOIJ KE, 1993, J MED GENET, V30, P996, DOI 10.1136/jmg.30.12.996; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; GIBB WRG, 1989, NEUROLOGY, V39, P999, DOI 10.1212/WNL.39.7.999; GOLDBERG YP, 1993, HUM MOL GENET, V2, P635, DOI 10.1093/hmg/2.6.635; GOLDBERG YP, 1993, NAT GENET, V5, P174, DOI 10.1038/ng1093-174; KREMER B, 1993, J MED GENET, V30, P991, DOI 10.1136/jmg.30.12.991; MACMILLAN JC, 1993, LANCET, V342, P954, DOI 10.1016/0140-6736(93)92002-B; MYERS RH, 1993, NAT GENET, V5, P168, DOI 10.1038/ng1093-168; QUARRELL OWJ, 1986, CLIN GENET, V30, P433; RUBINSZTEIN DC, 1993, HUM MOL GENET, V2, P1713, DOI 10.1093/hmg/2.10.1713; SIMPSON SA, 1993, J MED GENET, V30, P1036, DOI 10.1136/jmg.30.12.1036; SNELL RG, 1993, NAT GENET, V4, P393, DOI 10.1038/ng0893-393; STINE OC, 1993, HUM MOL GENET, V2, P1547, DOI 10.1093/hmg/2.10.1547; WARNER JP, 1993, MOL CELL PROBE, V7, P235, DOI 10.1006/mcpr.1993.1034; 1993, CELL, V72, P971	20	45	47	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					714	717		10.1016/S0140-6736(94)92208-X	http://dx.doi.org/10.1016/S0140-6736(94)92208-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915776				2022-12-01	WOS:A1994PF18700010
J	JAMES, I				JAMES, I			WHEN THE MUSIC HAS TO STOP	LANCET			English	Editorial Material							MEDICAL PROBLEMS				JAMES, I (corresponding author), UNIV LONDON ROYAL FREE HOSP,DEPT MED,LONDON NW3 2QG,ENGLAND.							FISHBEIN M, 1988, MED PROBL PERFORM AR, V3, P1; Fry H. J. H., 1986, MED PROBL PERFORM AR, V1, P1; JAMES IM, 1992, BRIT J RHEUMATOL, V31, P795; LAMBERT CM, 1992, BRIT J RHEUMATOL, V31, P265; LOCKWOOD AH, 1989, NEW ENGL J MED, V320, P221, DOI 10.1056/NEJM198901263200405; MOULTON B, 1992, BEHAV RES THER, V30, P375, DOI 10.1016/0005-7967(92)90049-M; PALIN SL, 1994, OCCUP MED-OXFORD, V44, P130, DOI 10.1093/occmed/44.3.130; SPEAKS C, 1970, JOM-J OCCUP MED, V12, P216, DOI 10.1097/00043764-197006000-00004	8	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					631	632		10.1016/S0140-6736(94)92080-X	http://dx.doi.org/10.1016/S0140-6736(94)92080-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915345				2022-12-01	WOS:A1994PE38600005
J	CHARITE, J; DEGRAAFF, W; SHEN, SB; DESCHAMPS, J				CHARITE, J; DEGRAAFF, W; SHEN, SB; DESCHAMPS, J			ECTOPIC EXPRESSION OF HOXB-8 CAUSES DUPLICATION OF THE ZPA IN THE FORELIMB AND HOMEOTIC TRANSFORMATION OF AXIAL STRUCTURES	CELL			English	Article							HOX-2.4 HOMEOBOX GENE; CHICK WING BUD; LIMB-BUD; TARGETED DISRUPTION; TRANSGENIC MICE; RETINOIC ACID; DEVELOPMENTAL DEFECTS; ANTEROPOSTERIOR AXIS; POLARIZING ACTIVITY; MYELOID-LEUKEMIA	Transgenic embryos were generated carrying a Hoxb-8 transgene under control of the mouse RAR beta 2 promoter, which extends the normal expression domain to more anterior regions of the embryo. These embryos showed mirror-image duplications in the forelimb, analogous to the duplications observed in chick in response to transplantation of a ZPA to the anterior margin of the limb bud. Examination of Sonic hedgehog, Fgf-4, and Hoxd-11 gene expression confirmed that a second ZPA had been generated at the anterior side of the limb bud. Besides other alterations, posterior homeotic transformations of axial structures were observed, involving the first spinal (Froriep's) ganglion and several cervical vertebrae.			CHARITE, J (corresponding author), NETHERLANDS INST DEV BIOL,HUBRECHT LAB,UPPSALALAAN 8,3584 CT UTRECHT,NETHERLANDS.		Shen, Sanbing/E-3750-2015	Shen, Sanbing/0000-0002-8217-9811				ABERDAM D, 1991, MOL CELL BIOL, V11, P554, DOI 10.1128/MCB.11.1.554; BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; CHEVALLIER A, 1977, J EMBRYOL EXP MORPH, V42, P275; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CONDIE BG, 1993, DEVELOPMENT, V119, P579; COPP AJ, 1990, PROG NEUROBIOL, V35, P363, DOI 10.1016/0301-0082(90)90037-H; DESCHAMPS J, 1993, DEV BIOL, V156, P473, DOI 10.1006/dbio.1993.1093; DESCHAMPS J, 1992, Critical Reviews in Oncogenesis, V3, P117; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; Hamburger V, 1938, J EXP ZOOL, V77, P379, DOI 10.1002/jez.1400770304; Harrison RG, 1918, J EXP ZOOL, V25, P413, DOI 10.1002/jez.1400250204; HINCHCLIFFE JR, 1983, DEV EVOLUTION; HONIG LS, 1985, J EMBRYOL EXP MORPH, V87, P163; HORNBRUCH A, 1991, DEVELOPMENT, V111, P725; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JEANNOTTE L, 1993, GENE DEV, V7, P2085, DOI 10.1101/gad.7.11.2085; JEGALIAN BG, 1992, CELL, V71, P901, DOI 10.1016/0092-8674(92)90387-R; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KIMMEL CA, 1981, STAIN TECHNOL, V56, P271, DOI 10.3109/10520298109067325; KONGSUWAN K, 1989, NUCLEIC ACIDS RES, V17, P1881, DOI 10.1093/nar/17.5.1881; KRESS C, 1990, DEVELOPMENT, V109, P775; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LIM TM, 1987, DEVELOPMENT, V100, P525; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1992, DEVELOPMENT, V114, P755; OLIVER G, 1990, EMBO J, V9, P3093, DOI 10.1002/j.1460-2075.1990.tb07506.x; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; PERKINS AC, 1993, EMBO J, V12, P3835, DOI 10.1002/j.1460-2075.1993.tb06062.x; POLLOCK RA, 1992, CELL, V71, P911, DOI 10.1016/0092-8674(92)90388-S; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RUGH R, 1990, MOUSE ITS REPRODUCTI; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SAUNDERS JW, 1977, VERTEBRATE LIMB SOMI, P1; SCHUGHART K, 1989, P NATL ACAD SCI USA, V86, P7067, DOI 10.1073/pnas.86.18.7067; Shen S, 1991, DNA Seq, V2, P111, DOI 10.3109/10425179109039679; SMITH JC, 1981, J EMBRYOL EXP MORPH, V63, P127; SMITH JC, 1980, J EMBRYOL EXP MORPH, V60, P321; SUMMERBELL D, 1981, J EMBRYOL EXP MORPH, V63, P161; TICKLE C, 1981, NATURE, V289, P295, DOI 10.1038/289295a0; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; VOGEL A, 1993, DEVELOPMENT, V119, P199; VOGELS R, 1993, DEVELOPMENT, V118, P71; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZWILLING E, 1956, J EXP ZOOL, V132, P157, DOI 10.1002/jez.1401320110	55	219	226	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 26	1994	78	4					589	601		10.1016/0092-8674(94)90524-X	http://dx.doi.org/10.1016/0092-8674(94)90524-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	7915198				2022-12-01	WOS:A1994PD69300008
J	FONTES, P; RAO, AS; DEMETRIS, AJ; ZEEVI, A; TRUCCO, M; CARROLL, P; RYBKA, W; RUDERT, WA; RICORDI, C; DODSON, F; SHAPIRO, R; TZAKIS, A; TODO, S; ABUELMAGD, K; JORDAN, M; FUNG, JJ; STARZL, TE				FONTES, P; RAO, AS; DEMETRIS, AJ; ZEEVI, A; TRUCCO, M; CARROLL, P; RYBKA, W; RUDERT, WA; RICORDI, C; DODSON, F; SHAPIRO, R; TZAKIS, A; TODO, S; ABUELMAGD, K; JORDAN, M; FUNG, JJ; STARZL, TE			BONE-MARROW AUGMENTATION OF DONOR-CELL CHIMERISM IN KIDNEY, LIVER, HEART, AND PANCREAS ISLET TRANSPLANTATION	LANCET			English	Article							TOTAL LYMPHOID IRRADIATION; ORGAN-TRANSPLANTATION; GRAFT ACCEPTANCE; RENAL-ALLOGRAFT; RECIPIENTS; MIGRATION	We have previously postulated that donor cell chimerism in organ transplantation is needed to attain a tolerant state. Here we show that donor cell chimerism can be augmented in organ recipients if they are infused perioperatively with 3 x 10(8) per kg of unmodified donor bone marrow cells and are kept on a conventional immunosuppressive regimen of tacrolimus (FK506) and prednisolone. 36 patients took part, of whom the first 18 patients have good transplanted kidney (n=10), liver (n=7), and heart (n=7) function when followed up between 4 and 16 months. All patients are well. We found persistent multilineage leucocyte chimerism in blood of 17 recipients by flow cytometry and PCR techniques to detect donor alleles or Y chromosomes in female recipients of male organs. The use of the 5-antigen HLA matched same sex donor precluded detection of chimerism in one patient.	UNIV PITTSBURGH, MED CTR, PITTSBURGH TRANSPLANT INST, DEPT SURG, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, DEPT PATHOL, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT PAEDIAT, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT MED, PITTSBURGH, PA 15260 USA; DIABET RES INST, MIAMI, FL USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			RICORDI, CAMILLO/AAA-4740-2019; FUNG, John Julian/A-2679-2012; Rao, Abdul Sohail/E-1453-2011	FUNG, John Julian/0000-0002-3038-0441; Ricordi, Camillo/0000-0001-8092-7153	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK029961, R01DK029961] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 29961, R01 DK029961-19] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBER WH, 1991, TRANSPLANTATION, V51, P70, DOI 10.1097/00007890-199101000-00011; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; KAHN DR, 1984, ANN THORAC SURG, V38, P169, DOI 10.1016/S0003-4975(10)62227-8; KOCOVA M, 1993, LANCET, V342, P140, DOI 10.1016/0140-6736(93)91345-M; MONACO AP, 1976, SURGERY, V79, P384; MYBURGH JA, 1989, TRANSPLANT P, V21, P826; NAJARIAN JS, 1982, ANN SURG, V196, P442, DOI 10.1097/00000658-198210000-00007; RICORDI C, 1988, DIABETES, V37, P413, DOI 10.2337/diabetes.37.4.413; ROLLES K, 1994, LANCET, V343, P263, DOI 10.1016/S0140-6736(94)91113-4; SALVATIERRA O, 1985, TRANSPLANTATION, V40, P654, DOI 10.1097/00007890-198512000-00016; STARZL TE, 1989, LANCET, V2, P1000; STARZL TE, 1963, SURG GYNECOL OBSTET, V117, P385; STARZL TE, 1993, HEPATOLOGY, V17, P1127; STARZL TE, 1993, TRANSPLANTATION, V55, P1272, DOI 10.1097/00007890-199306000-00012; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; STARZL TE, 1993, IMMUNOL TODAY, V14, P326, DOI 10.1016/0167-5699(93)90054-O; STARZL TE, 1992, LANCET, V340, P876, DOI 10.1016/0140-6736(92)93286-V; STARZL TE, 1991, TRANSPLANT P, V23, P914; STARZL TE, IN PRESS TRANSPLANT	19	282	285	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 16	1994	344	8916					151	155		10.1016/S0140-6736(94)92756-1	http://dx.doi.org/10.1016/S0140-6736(94)92756-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912764	Green Accepted			2022-12-01	WOS:A1994NW81000008
J	WILSON, PWF; MYERS, RH; LARSON, MG; ORDOVAS, JM; WOLF, PA; SCHAEFER, EJ				WILSON, PWF; MYERS, RH; LARSON, MG; ORDOVAS, JM; WOLF, PA; SCHAEFER, EJ			APOLIPOPROTEIN-E ALLELES, DYSLIPIDEMIA, AND CORONARY-HEART-DISEASE - THE FRAMINGHAM OFFSPRING STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; E POLYMORPHISM; ARTERY DISEASE; E PHENOTYPE; MYOCARDIAL-INFARCTION; INCREASED PREVALENCE; LOVASTATIN TREATMENT; TRIGLYCERIDE LEVELS; ALZHEIMERS-DISEASE	Objective.-To describe the association between apolipoprotein E alleles (epsilon 2, epsilon 3, and epsilon 4), dyslipidemias, and coronary heart disease (CHD). Design.-Cross-sectional prevalence study. Setting and Participants.-Community-based sample of men (n=1034) and women (n=916) aged 40 to 77 years who are participating in a long-term study of cardiovascular disease. Study participants underwent fasting lipid measurements, coronary risk factor determinations, and a comprehensive evaluation for the presence of current or previous CHD. Results.-Compared with the epsilon 3 allele, the epsilon 4 allele was associated with elevated low-density lipoprotein cholesterol values (greater than or equal to 4.14 mmol/L [160 mg/dL]) in women, the epsilon 2 and epsilon 4 alleles were associated with moderately elevated triglyceride values (greater than or equal to 2.82 mmol/L [250 mg/dL]) in men, and the epsilon 2 allele was associated with severely elevated triglyceride values (greater than or equal to 5.64 mmol/L [500 mg/dL]) in men. The apolipoprotein E alleles were not associated with hypertension, obesity, smoking, or diabetes, but the epsilon 4 allele frequency was reduced in women after 60 years of age. The age-adjusted prevalence of CHD was associated with the epsilon 4 allele in both men (relative odds=1.53, P=.04) and women (relative odds=1.99, P=.05). In analyses for women and for both sexes combined, this relation persisted after adjustment by hypertension, smoking, obesity, diabetes, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol. Conclusions.-Apolipoprotein E alleles are important genetic markers for dyslipidemia and CHD. The estimated CHD odds associated with the epsilon 4 allele appears to be greater than that for any other known genetic lipid abnormality, and the association of the epsilon 4 allele with CHD remains significant in women and both sexes combined after adjustment by traditional coronary risk factors and lipids.	BOSTON UNIV,MED CTR,BOSTON,MA; TUFTS UNIV,USDA,HUMAN NUTR RES CTR,BOSTON,MA 02111	Boston University; Tufts University; United States Department of Agriculture (USDA)	WILSON, PWF (corresponding author), FRAMINGHAM HEART DIS EPIDEMIOL STUDY,5 THURBER ST,FRAMINGHAM,MA 01701, USA.		Wilson, Peter W.F./J-2455-2016; Ordovas, Jose/B-8727-2013	Myers, Richard/0000-0002-8365-2674; Ordovas, Jose/0000-0002-7581-5680; Wolf, Philip/0000-0002-3628-301X; Larson, Martin/0000-0002-9631-1254				ASSMANN G, 1984, CLIN CHEM, V30, P641; BOEMI M, 1993, DIABETOLOGIA, V36, P229, DOI 10.1007/BF00399955; BOERWINKLE E, 1987, ANN HUM GENET, V51, P211, DOI 10.1111/j.1469-1809.1987.tb00874.x; BOERWINKLE E, 1988, AM J HUM GENET, V42, P104; BREWER HB, 1983, ANN INTERN MED, V98, P623, DOI 10.7326/0003-4819-98-5-623; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CARMENA R, 1993, METABOLISM, V42, P895, DOI 10.1016/0026-0495(93)90066-W; CHIVOT L, 1990, ATHEROSCLEROSIS, V82, P205, DOI 10.1016/0021-9150(90)90042-H; COBB MM, 1992, CIRCULATION, V86, P849, DOI 10.1161/01.CIR.86.3.849; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CUMMING AM, 1984, CLIN GENET, V25, P310; CUPPPLES LA, 1987, FRAMINGHAM STUDY EPI; DALLONGEVILLE J, 1992, J LIPID RES, V33, P447; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; DEKNIJFF P, 1990, ATHEROSCLEROSIS, V83, P89; DESPRES JP, 1993, DIABETES, V42, P1474, DOI 10.2337/diabetes.42.10.1474; EHNHOLM C, 1986, J LIPID RES, V27, P227; EICHNER JE, 1990, ARTERIOSCLEROSIS, V10, P379, DOI 10.1161/01.ATV.10.3.379; EICHNER JE, 1993, AM J CARDIOL, V71, P160, DOI 10.1016/0002-9149(93)90732-R; ETO M, 1989, CLIN GENET, V36, P183; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Funke Harald, 1993, Current Opinion in Lipidology, V4, P453, DOI 10.1097/00041433-199312000-00006; GHISELLI G, 1982, J CLIN INVEST, V70, P474, DOI 10.1172/JCI110638; GLUECK CJ, 1976, METABOLISM, V25, P1269, DOI 10.1016/S0026-0495(76)80010-8; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1533, DOI 10.1172/JCI107331; HIXSON JE, 1991, ARTERIOSCLER THROMB, V11, P1237, DOI 10.1161/01.ATV.11.5.1237; JANUS ED, 1985, ATHEROSCLEROSIS, V57, P249, DOI 10.1016/0021-9150(85)90038-3; KAMBOH MI, 1993, ATHEROSCLEROSIS, V98, P201, DOI 10.1016/0021-9150(93)90129-I; KUUSI T, 1989, ARTERIOSCLEROSIS, V9, P237, DOI 10.1161/01.ATV.9.2.237; LENZEN HJ, 1986, CLIN CHEM, V32, P778; LOUHIJA J, 1994, ARTERIOSCLER THROMB, V14, P1084, DOI 10.1161/01.ATV.14.7.1084; MAHLEY RW, 1991, JAMA-J AM MED ASSOC, V265, P78, DOI 10.1001/jama.265.1.78; MCNAMARA JR, 1987, CLIN CHIM ACTA, V166, P1, DOI 10.1016/0009-8981(87)90188-4; MENZEL HJ, 1983, ARTERIOSCLEROSIS, V3, P310, DOI 10.1161/01.ATV.3.4.310; NIEMINEN MS, 1992, ARTERIOSCLER THROMB, V12, P58, DOI 10.1161/01.ATV.12.1.58; OJALA JP, 1991, J INTERN MED, V230, P397, DOI 10.1111/j.1365-2796.1991.tb00464.x; OMALLEY JP, 1990, METABOLISM, V39, P150, DOI 10.1016/0026-0495(90)90068-N; ORDOVAS JM, 1987, J LIPID RES, V28, P371; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; RUST S, 1992, CIRCULATION, V86, P420; SCHAEFER EJ, 1994, ARTERIOSCLER THROMB, V14, P1105, DOI 10.1161/01.ATV.14.7.1105; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P234; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SCHMITZ G, 1993, ARTERIOSCLER THROMB, V13, P1053, DOI 10.1161/01.ATV.13.7.1053; SEMPOS C, 1989, JAMA-J AM MED ASSOC, V262, P45, DOI 10.1001/jama.262.1.45; SING CF, 1985, AM J HUM GENET, V37, P268; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; STRITTMATTER WJ, 1993, NEUROLOGY, V43, P1467; STUYT PMJ, 1991, SCAND J CLIN LAB INV, V51, P425, DOI 10.3109/00365519109091636; UKKOLA O, 1993, ATHEROSCLEROSIS, V101, P9, DOI 10.1016/0021-9150(93)90096-D; UTERMANN G, 1984, HUM GENET, V65, P237, DOI 10.1007/BF00286509; UTERMANN G, 1979, CLIN GENET, V15, P37; UTERMANN G, 1979, CLIN GENET, V15, P63; VANBOCKXMEER FM, 1992, LANCET, V340, P879, DOI 10.1016/0140-6736(92)93288-X; WALDEN CC, 1994, ANN INTERN MED, V120, P1026, DOI 10.7326/0003-4819-120-12-199406150-00009; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WEISGRABER KH, 1982, J BIOL CHEM, V257, P2518; WILSON PWF, 1989, JAMA-J AM MED ASSOC, V262, P41, DOI 10.1001/jama.262.1.41; WILSON PWF, 1980, ACCEL TAPES, V12, P1; YAMAMOTO A, 1990, ANN NY ACAD SCI, V598, P58, DOI 10.1111/j.1749-6632.1990.tb42276.x; YAMAMURA T, 1990, JPN CIRC J, V54, P448, DOI 10.1253/jcj.54.448; 1993, JAMA-J AM MED ASSOC, V269, P505; 1974, NIH75628 LIP RES CLI; 1993, JAMA-J AM MED ASSOC, V269, P3015	64	423	428	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 7	1994	272	21					1666	1671		10.1001/jama.272.21.1666	http://dx.doi.org/10.1001/jama.272.21.1666			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU759	7966894				2022-12-01	WOS:A1994PU75900025
J	ROSENBLUM, LS; CASTRO, KG; DOOLEY, S; MORGAN, M; COLBERT, G				ROSENBLUM, LS; CASTRO, KG; DOOLEY, S; MORGAN, M; COLBERT, G			EFFECT OF HIV-INFECTION AND TUBERCULOSIS ON HOSPITALIZATIONS AND COST OF CARE FOR YOUNG-ADULTS IN THE UNITED-STATES, 1985 TO 1990	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; RESISTANT MYCOBACTERIUM-TUBERCULOSIS; INTRAVENOUS DRUG-USERS; CLINICAL-FEATURES; MEDICAL-CARE; OUTBREAK; AIDS; TRANSMISSION; MANAGEMENT; IMPACT	Objective: To evaluate the effect of human immunodeficiency virus (HIV) infection and tuberculosis on hospitalizations and the cost of care. Design: National Hospital Discharge Survey, a nationally representative survey of discharges from U.S. nonfederal short-stay hospitals, and statewide billing information. Patients: Patients 15 to 44 years of age with a listed diagnosis of HIV infection (n = 418 200) or active tuberculosis (n = 77 700) during 1985-1990. Results: During 1985-1990, hospitalizations related to HIV infection increased sixfold, from 18 to 102 per 100 000 persons; during 1988-1990, hospitalizations related to-tuberculosis increased twofold, from 8 to 16 per 100 000 persons. The prevalence of tuberculosis among HIV-infected patients increased from 2.4% in 1985-1988 to 5.1% in 1989-1990 (P = 0.003). The prevalence of HIV infection among patients with tuberculosis increased from 11% in 1985-1988 to 28% in 1989 to 39% in 1990 (P < 0.001). Infection with HIV was more prevalent among patients with extrapulmonary tuberculosis (31%) than among those with pulmonary tuberculosis (18%) (P = 0.01). An increase in the duration of hospital stay was associated with both tuberculosis and HIV infection. From 1985 to 1990, inpatient care costs increased 7.7-fold and 3.2-fold for HIV and tuberculosis hospitalizations, respectively. During this period, HIV and tuberculosis hospitalizations resulted in 5 793 000 and 1 107 900 days of care, respectively, with an estimated direct cost of $5.7 to $7.4 billion and $0.89 to $1.07 billion, respectively. Estimated national costs of inpatient care for HIV infection or tuberculosis or both totaled $6.4 to $8.1 billion, 5% of which was for patients with both HIV infection and tuberculosis. Conclusions: This is the first study to use a nationally representative sample of hospitals, combined with cost data, to estimate hospitalizations and their costs for HIV and tuberculosis care. Our findings suggest that the convergence of the HIV and tuberculosis epidemics has had an increasing effect on morbidity and the cost of care among young adults in the United States. The increasing prevalence of comorbidity of HIV infection and tuberculosis in inpatients underscores the need for strict infection control of tuberculosis on the part of hospitals, increased attention to prevention, and early identification and treatment of HIV infection and tuberculosis to reduce morbidity, hospitalizations, and the cost of care.	CTR DIS CONTROL & PREVENT, DIV HIV AIDS, SURVEILLANCE BRANCH, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA			Castro, Kenneth G/P-1882-2018	Castro, Kenneth G/0000-0001-7964-6354				ANDRULIS DP, 1992, JAMA-J AM MED ASSOC, V267, P2482, DOI 10.1001/jama.267.18.2482; ANDRULIS DP, 1989, JAMA-J AM MED ASSOC, V262, P784, DOI 10.1001/jama.262.6.784; [Anonymous], 1990, MMWR Recomm Rep, V39, P1; [Anonymous], 1993, MMWR Recomm Rep, V42, P1; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; [Anonymous], 1994, MMWR MORB MORTAL WKL; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; BURWEN D, 1993, MAY AM LUNG ASS AM T; Centers for Disease Control and Prevention, 1987, MMWR-MORBID MORTAL W, V36, p1S; Centers for Disease Control (CDC), 1990, MMWR Morb Mortal Wkly Rep, V39, P718; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P585; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; DOOLEY SW, 1992, ANN INTERN MED, V117, P257, DOI 10.7326/0003-4819-117-3-257; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FARNHAM PG, 1994, IN PRESS READINGS PU; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; GREEN J, 1990, JAMA-J AM MED ASSOC, V264, P1261, DOI 10.1001/jama.264.10.1261; HAUPT BJ, 1992, VITAL HLTH STATI 111, V13; HELLINGER FJ, 1991, INQUIRY-J HEALTH CAR, V28, P213; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; HOPEWELL PC, 1992, CLIN INFECT DIS, V15, P540, DOI 10.1093/clind/15.3.540; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; RAVIGLIONE MC, 1992, B WORLD HEALTH ORGAN, V70, P515; ROSENBLUM L, 1993, AM J PUBLIC HEALTH, V83, P1457, DOI 10.2105/AJPH.83.10.1457; ROSENBLUM LS, 1992, J ACQ IMMUN DEF SYND, V5, P497; SCITOVSKY AA, 1987, PUBLIC HEALTH REP, V102, P5; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1989, AIDS, V3, pS201, DOI 10.1097/00002030-198901001-00029; SHAH BY, 1981, SESUDAAN STANDARD ER, P1; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; 1980, DHHS PHS801260 PUB; 1992, TUBERCULOSIS STATIST, P14; 1990, MMWR-MORBID MORTAL W, V39, P110; 1990, MMWR-MORBID MORTAL W, V39, P9; 1993, MMWR-MORBID MORTAL W, V42, P696; 1989, MMWR-MORBID MORTAL W, V38, P243; 1989, AIDS PUBLIC INFORMAT; 1993, MMWR-MORBID MORTAL W, V42, P11; 1989, MMWR-MORBID MORTAL W, V38, P236; 1993, MMWR-MORBID MORTAL W, V42, P703; 1989, CURRENT POPULATI P25, V1044, P13; 1986, SUGI SUPPLEMENTAL LI, P269; 1992, STATISTICAL ABSTRACT, P471	45	40	40	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1994	121	10					786	792		10.7326/0003-4819-121-10-199411150-00009	http://dx.doi.org/10.7326/0003-4819-121-10-199411150-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ928	7944056				2022-12-01	WOS:A1994PQ92800009
J	AMOUYEL, P; VIDAL, O; LAUNAY, JM; LAPLANCHE, JL				AMOUYEL, P; VIDAL, O; LAUNAY, JM; LAPLANCHE, JL			THE APOLIPOPROTEIN-E ALLELES AS MAJOR SUSCEPTIBILITY FACTORS FOR CREUTZFELDT-JAKOB-DISEASE	LANCET			English	Article							FAMILIAL ALZHEIMER-DISEASE; TYPE-4 ALLELE; GENE; REGENERATION; EXPRESSION; RECEPTORS; NERVE	Creutzfeldt-Jakob disease (CJD) is a rapid progressive mental and neurological disorder characterised by dementia and is both infectious and genetic. Pathogenic mutations and a predisposing polymorphism have been described in the prion protein gene and an abnormal prion product accumulates in the brain of affected patients. Apolipoprotein E (APOE), a protein of lipid metabolism, has been detected in some prion protein deposits. This ApoE exists as three common isoforms, coded by specific allele (epsilon 2, epsilon 3, epsilon 4). The presence of at least one epsilon 4 allele was described as a major risk factor for Alzheimer's disease, another neurodegenerative disorder. From a series of 61 patients with CJD we found that epsilon 4 allele of the APOE gene was a risk factor for the disease (p < 0.01). This association was observed in both definite and probable cases, and for patients with and without prion protein gene mutations. Moreover, in affected subjects, epsilon 2 allele of the APOE gene delayed occurrence of death (p < 0.01) independently of other known mutations influencing the phenotype of the disease. These effects on neurodegenerative disease associated with APOE alleles suggest a strong involvement of the APOE locus in brain metabolism.	INST PASTEUR, INSERM, U325, F-59019 LILLE, FRANCE; HOP ST LOUIS, SERV BIOCHIM, PARIS, FRANCE; HOP ST LOUIS, FRA CLAUDE BERNARD, PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	AMOUYEL, P (corresponding author), INST PASTEUR, SERV EPIDEMIOL & SANTE PUBL, 1 RUE CALMETTE, F-59019 LILLE, FRANCE.		LAPLANCHE, Jean-Louis/S-8707-2016	Amouyel, Philippe/0000-0001-9088-234X; LAPLANCHE, Jean-Louis/0000-0003-2836-2903				BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; BROUSSEAU T, 1994, NEUROLOGY, V44, P342, DOI 10.1212/WNL.44.2.342; BROWN P, 1991, EUR J EPIDEMIOL, V7, P469, DOI 10.1007/BF00143124; CHARTIERHARLIN MC, 1994, HUM MOL GENET, V3, P569, DOI 10.1093/hmg/3.4.569; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CZECH C, 1993, LANCET, V342, P1309; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; DIEDRICH JF, 1991, J VIROL, V65, P4759, DOI 10.1128/JVI.65.9.4759-4768.1991; DOHURA K, 1991, NATURE, V353, P801, DOI 10.1038/353801b0; HIXSON JE, 1990, J LIPID RES, V31, P545; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; LAPLANCHE JL, IN PRESS NEUROLOGY; LUC G, 1994, ARTERIOSCLER THROMB, V14, P1412, DOI 10.1161/01.ATV.14.9.1412; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; MASTERS CL, 1981, BRAIN, V104, P559, DOI 10.1093/brain/104.3.559; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PITAS RE, 1987, J BIOL CHEM, V262, P14352; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1993, ARCH NEUROL-CHICAGO, V50, P1129, DOI 10.1001/archneur.1993.00540110011002; REBECK GW, 1993, NEURON, V11, P575; RIPOLL L, 1993, NEUROLOGY, V43, P1934, DOI 10.1212/WNL.43.10.1934; SAUNDERS AM, 1993, LANCET, V342, P710, DOI 10.1016/0140-6736(93)91709-U; SCHELLENBERG GD, 1987, J NEUROGENET, V4, P97, DOI 10.3109/01677068709102337; STGEORGEHYSLOP P, 1994, SCIENCE, V263, P537, DOI 10.1126/science.8290965; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; 1988, SAS P179 SAS I INC T, P49; 1993, LANCET, V342, P737	29	139	145	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 12	1994	344	8933					1315	1318		10.1016/S0140-6736(94)90691-2	http://dx.doi.org/10.1016/S0140-6736(94)90691-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ926	7968026				2022-12-01	WOS:A1994PQ92600007
J	JIANG, XX; KHURSIGARA, G; RUBIN, RL				JIANG, XX; KHURSIGARA, G; RUBIN, RL			TRANSFORMATION OF LUPUS-INDUCING DRUGS TO CYTOTOXIC PRODUCTS BY ACTIVATED NEUTROPHILS	SCIENCE			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; HYDRALAZINE-INDUCED LUPUS; REACTIVE METABOLITES; PROCAINAMIDE; MYELOPEROXIDASE; HYDROXYLAMINE; RAT; PROPYLTHIOURACIL; CHLORPROMAZINE; ERYTHEMATOSUS	Drug-induced lupus is a serious side effect of certain medications, but the chemical features that confer this property and the underlying pathogenesis are puzzling. Prototypes of all six therapeutic classes of lupus-inducing drugs were highly cytotoxic only in the presence of activated neutrophils. Removal of extracellular hydrogen peroxide before, but not after, exposure of the drug to activated neutrophils prevented cytotoxicity. Neutrophil-dependent cytotoxicity required the enzymatic action of myeloperoxidase, resulting in the chemical transformation of the drug to a reactive product. The capacity of drugs to serve as myeloperoxidase substrates in vitro was associated with the ability to induce lupus in vivo.	SCRIPPS RES INST, WM KECK AUTOIMMUNE DIS CTR, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009574] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR00833] Funding Source: Medline; NIA NIH HHS [R01 AG09574] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMS LE, 1989, J LAB CLIN MED, V113, P482; ADAMS LE, 1993, LUPUS, V2, P89, DOI 10.1177/096120339300200205; ANDREAE WA, 1955, NATURE, V175, P859, DOI 10.1038/175859a0; AUCOIN DP, 1985, J PHARMACOL EXP THER, V234, P13; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BARR DP, 1993, ARCH BIOCHEM BIOPHYS, V303, P377, DOI 10.1006/abbi.1993.1298; BLOMGREN SE, 1973, SEMIN HEMATOL, V10, P345; BRETZ U, 1974, J CELL BIOL, V63, P251, DOI 10.1083/jcb.63.1.251; BUDINSKY RA, 1987, DRUG METAB DISPOS, V15, P37; CAMBRIDGE G, 1994, BRIT J RHEUMATOL, V33, P109; CLARK RA, 1983, ADV INFLAMMAT RES, V5, P107; DIXON M, 1979, ENZYMES, P345; EASTMOND DA, 1990, METHOD ENZYMOL, V186, P579; HARMON CE, 1982, CLIN RHEUM DIS, V8, P121; HEIN DW, 1989, AUTOIMMUNITY TOXICOL, P239; HOFSTRA AH, 1991, J RHEUMATOL, V18, P1673; HOFSTRA AH, 1992, DRUG METAB DISPOS, V20, P205; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; KELDER PP, 1991, CHEM-BIOL INTERACT, V79, P15, DOI 10.1016/0009-2797(91)90049-D; KUBICKAMURANYI M, 1993, TOXICOL APPL PHARM, V122, P88, DOI 10.1006/taap.1993.1175; LAHITA R, 1979, NEW ENGL J MED, V301, P1382, DOI 10.1056/NEJM197912203012506; NAKASHIMA I, 1994, J IMMUNOL, V152, P1064; NASSBERGER L, 1990, CLIN EXP IMMUNOL, V81, P380; NELSON SD, 1981, MOL PHARMACOL, V20, P195; RUBIN RL, 1989, J CLIN INVEST, V83, P1336, DOI 10.1172/JCI114020; RUBIN RL, 1987, J PHARMACOL EXP THER, V242, P833; RUBIN RL, UNPUB; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P399, DOI 10.1128/AAC.27.3.399; SMOLEN JE, 1979, ARTHRITIS ALLIED CON, P282; STREETER AJ, 1983, DRUG METAB DISPOS, V11, P184; UETRECHT JP, 1984, DRUG METAB DISPOS, V12, P77; VANZYL JM, 1989, BIOCHEM PHARMACOL, V38, P2363, DOI 10.1016/0006-2952(89)90477-2; VANZYL JM, 1990, BIOCHEM PHARMACOL, V40, P947, DOI 10.1016/0006-2952(90)90478-4; WALDHAUSER L, 1991, DRUG METAB DISPOS, V19, P354; Weinstein A, 1980, Prog Clin Immunol, V4, P1; WHEELER JF, 1991, DRUG METAB DISPOS, V19, P691; WOODHOUSE KW, 1990, BRIT MED BULL, V46, P22, DOI 10.1093/oxfordjournals.bmb.a072387; WOOSLEY RL, 1978, NEW ENGL J MED, V298, P1157, DOI 10.1056/NEJM197805252982101; Worthington C.C., 1988, WORTHINGTON MANUAL E, P254; YAMAMOTO K, 1991, BIOCHEM PHARMACOL, V41, P905; YUNG RL, 1994, RHEUM DIS CLIN N AM, V20, P61; 1994, US STATES PHARMACOPE, V1, P417	42	185	206	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	1994	266	5186					810	813		10.1126/science.7973636	http://dx.doi.org/10.1126/science.7973636			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973636				2022-12-01	WOS:A1994PP75300042
J	KUMAR, L				KUMAR, L			DONOR LEUKOCYTE INFUSIONS FOR RELAPSE IN CHRONIC MYELOGENOUS LEUKEMIA	LANCET			English	Editorial Material							BONE-MARROW TRANSPLANTATION; CHRONIC MYELOID-LEUKEMIA; LEUKOCYTE INFUSIONS; IMMUNOTHERAPY; TRANSFUSIONS				KUMAR, L (corresponding author), ALL INDIA INST MED SCI,INST ROTARY CANC HOSP,DEPT MED ONCOL,NEW DELHI,INDIA.							ANTIN JH, 1993, BLOOD, V82, P2273; ARCESE W, 1993, BLOOD, V82, P3211; BAR BMAM, 1993, J CLIN ONCOL, V11, P513; CULLIS JO, 1992, BLOOD, V79, P1379; DROBYSKI WR, 1993, BLOOD, V82, P2310; HERTENSTEIN B, 1993, TRANSPLANTATION, V56, P1114, DOI 10.1097/00007890-199311000-00013; KOLB HJ, 1993, SEMIN HEMATOL, V30, P37; KOLB HJ, 1990, BLOOD, V76, P2462, DOI 10.1182/blood.V76.12.2462.2462; KUMAR L, 1994, J CLIN ONCOL, V12, P1710, DOI 10.1200/JCO.1994.12.8.1710; MRSIC M, 1992, BONE MARROW TRANSPL, V9, P269; PORTER DL, 1994, NEW ENGL J MED, V330, P100, DOI 10.1056/NEJM199401133300204	11	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1994	344	8930					1101	1102		10.1016/S0140-6736(94)90624-6	http://dx.doi.org/10.1016/S0140-6736(94)90624-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN066	7934489				2022-12-01	WOS:A1994PN06600003
J	STEEN, N; HUTCHINSON, A; MCCOLL, E; ECCLES, MP; HEWISON, J; MEADOWS, KA; BLADES, SM; FOWLER, P				STEEN, N; HUTCHINSON, A; MCCOLL, E; ECCLES, MP; HEWISON, J; MEADOWS, KA; BLADES, SM; FOWLER, P			DEVELOPMENT OF A SYMPTOM BASED OUTCOME MEASURE FOR ASTHMA	BRITISH MEDICAL JOURNAL			English	Article							QUESTIONNAIRE; CARE	Measuring symptom specific health outcome is complex, but the methodologies now exist to develop measures with the appropriate properties. As one element of a major programme to develop multidomain health outcome measures for chronic disease, a symptom based measure for asthma care has been developed for use in general practice and outpatient departments. This article outlines the development process, which used a framework recently described in the theoretical literature to show the constraints that scientific criteria place on the development of outcome measures and the means of overcoming such limiting factors. Although substantial effort is required to undertake a rigorous process of development, useful tools are the result. Two five item, symptom based outcome measures for adult asthma are described.	UNIV HULL,DEPT PUBL HLTH MED,KINGSTON HULL,N HUMBERSIDE,ENGLAND; UNIV NEWCASTLE UPON TYNE,CTR HLTH SERV RES,NEWCASTLE TYNE,TYNE & WEAR,ENGLAND; UNIV LEEDS,LEEDS,W YORKSHIRE,ENGLAND	University of Hull; Newcastle University - UK; University of Leeds			Eccles, Martin P/AAD-4029-2020					AITKIN M, 1989, STATISTICAL MODELLIN; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; Deyo RA, 1991, CONTROLLED CLIN TRIA, V12, P142; FITZPATRICK R, 1992, BRIT MED J, V305, P1074, DOI 10.1136/bmj.305.6861.1074; Fletcher Astrid, 1992, British Medical Journal, V305, P1145; KAZIS LE, 1989, MED CARE, V27, pS178, DOI 10.1097/00005650-198903001-00015; KINSMAN RA, 1973, PSYCHOSOM MED, V35, P250, DOI 10.1097/00006842-197305000-00008; KIRKWOOD BR, 1988, ESSENTIALS MED STATI; MANTEL N, 1959, J NATL CANCER I, V22, P719; MCCOLL AJ, 1993, POPULATION HLTH OUTC; McCullagh P., 1989, STANDARD BOOK GEN LI, DOI DOI 10.1007/978-1-4899-3242-6; PARKERSON GR, 1993, J CLIN EPIDEMIOL, V46, P379, DOI 10.1016/0895-4356(93)90153-R; Streiner D.L., 2003, HLTH MEASUREMENT SCA; USHERWOOD TP, 1990, ARCH DIS CHILD, V65, P779, DOI 10.1136/adc.65.7.779; WILKIN D, 1992, MEASURES NEED OUTCOM	16	82	84	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 22	1994	309	6961					1065	1068		10.1136/bmj.309.6961.1065	http://dx.doi.org/10.1136/bmj.309.6961.1065			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PN733	7950742	Green Published			2022-12-01	WOS:A1994PN73300027
J	HAUGWITZ, M; NOEGEL, AA; KARAKESISOGLOU, J; SCHLEICHER, M				HAUGWITZ, M; NOEGEL, AA; KARAKESISOGLOU, J; SCHLEICHER, M			DICTYOSTELIUM AMEBAS THAT LACK G-ACTIN-SEQUESTERING PROFILINS SHOW DEFECTS IN F-ACTIN CONTENT, CYTOKINESIS, AND DEVELOPMENT	CELL			English	Article							BOUND ADENOSINE 5'-TRIPHOSPHATE; HEAVY-CHAIN GENE; POLYMORPHONUCLEAR LEUKOCYTES; BINDING-PROTEINS; HOMOLOGOUS RECOMBINATION; MONOCLONAL-ANTIBODIES; CELL MOTILITY; DISCOIDEUM; MYOSIN; THYMOSIN-BETA-4	To study in vivo functions of the ubiquitous actin-binding protein profilin, we generated by antisense and gene disruption techniques Dictyostelium mutants that lack one or both of the profilin isoforms. Whereas the single mutants showed an essentially unchanged phenotype, the behavior of the double mutant was drastically altered. Motility was significantly reduced, single cells were up to 10 times larger than wild-type cells and showed a broad rim of filamentous actin below the plasma membrane, the filamentous actin concentration was increased by about 60%-70%, and development was blocked prior to fruiting body formation. Furthermore, double mutants could not be grown in shaking culture under normal conditions, reflecting an impaired cytokinesis. The aberrant phenotype could be rescued by reintroducing a functional profilin I or profilin II gene. The data in this study suggest that profilin functions in Dictyostelium amoebae primarily as an actin-sequestering protein.	UNIV MUNICH, INST ZELLBIOL, D-80366 MUNICH, GERMANY; MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	University of Munich; Max Planck Society								ADAMS AEM, 1993, MOL BIOL CELL, V4, P459, DOI 10.1091/mbc.4.5.459; Brown SS, 1993, CURR OPIN CELL BIOL, V5, P129, DOI 10.1016/S0955-0674(05)80018-3; BUSS F, 1992, CELL MOTIL CYTOSKEL, V22, P51, DOI 10.1002/cm.970220106; CANO ML, 1992, J CELL BIOL, V116, P1123, DOI 10.1083/jcb.116.5.1123; CAO LG, 1992, J CELL BIOL, V117, P1023, DOI 10.1083/jcb.117.5.1023; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; CASSIMERIS L, 1992, J CELL BIOL, V119, P1261, DOI 10.1083/jcb.119.5.1261; CLAVIEZ M, 1982, EMBO J, V1, P1017, DOI 10.1002/j.1460-2075.1982.tb01287.x; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; COOLEY L, 1992, CELL, V69, P173, DOI 10.1016/0092-8674(92)90128-Y; COOPER JA, 1991, ANNU REV PHYSIOL, V53, P585, DOI 10.1146/annurev.ph.53.030191.003101; DEHOSTOS EL, 1991, EMBO J, V10, P4097, DOI 10.1002/j.1460-2075.1991.tb04986.x; DEHOSTOS EL, 1993, J CELL BIOL, V120, P163, DOI 10.1083/jcb.120.1.163; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cellbio.4.1.649; DHARMAWARDHANE S, 1989, CELL MOTIL CYTOSKEL, V13, P57, DOI 10.1002/cm.970130107; EARLY A, 1988, DEV GENET, V9, P383, DOI 10.1002/dvg.1020090419; EDAMATSU M, 1992, J BIOCHEM-TOKYO, V112, P637, DOI 10.1093/oxfordjournals.jbchem.a123952; EGELHOFF TT, 1989, MOL CELL BIOL, V9, P1965, DOI 10.1128/MCB.9.5.1965; FAIX J, 1992, J CELL SCI, V102, P203; FECHHEIMER M, 1993, J CELL BIOL, V123, P1, DOI 10.1083/jcb.123.1.1; FINKEL T, 1994, P NATL ACAD SCI USA, V91, P1510, DOI 10.1073/pnas.91.4.1510; FISHER PR, 1989, J CELL BIOL, V108, P973, DOI 10.1083/jcb.108.3.973; FUKUI Y, 1993, INT REV CYTOL, V144, P85, DOI 10.1016/S0074-7696(08)61514-4; GOLDSCHMIDTCLERMONT PJ, 1992, MOL BIOL CELL, V3, P1015, DOI 10.1091/mbc.3.9.1015; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GREGG JH, 1982, EXP CELL RES, V142, P229, DOI 10.1016/0014-4827(82)90427-X; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; HAARER BK, 1993, MOL CELL BIOL, V13, P7864, DOI 10.1128/MCB.13.12.7864; HALL AL, 1988, J CELL BIOCHEM, V37, P285, DOI 10.1002/jcb.240370304; HARTWIG JH, 1989, J CELL BIOL, V109, P1571, DOI 10.1083/jcb.109.4.1571; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HAUGWITZ M, 1991, J CELL SCI, V100, P481; ISENBERG G, 1991, J MUSCLE RES CELL M, V12, P136, DOI 10.1007/BF01774032; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Machesky Laura M., 1993, Trends in Cell Biology, V3, P381, DOI 10.1016/0962-8924(93)90087-H; MAGDOLEN V, 1993, FEBS LETT, V316, P41, DOI 10.1016/0014-5793(93)81733-G; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P1160, DOI 10.1021/bi00326a015; NOEGEL A, 1985, J MOL BIOL, V185, P447, DOI 10.1016/0022-2836(85)90416-4; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PODOLSKI JL, 1990, J BIOL CHEM, V265, P1312; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; POLLENZ RS, 1992, CELL, V69, P951, DOI 10.1016/0092-8674(92)90614-I; SAFER D, 1990, P NATL ACAD SCI USA, V87, P2536, DOI 10.1073/pnas.87.7.2536; SCHLEICHER M, 1992, NEW BIOL, V4, P461; SCHLEICHER M, 1984, EMBO J, V3, P2095, DOI 10.1002/j.1460-2075.1984.tb02096.x; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SHARIFF A, 1992, SCIENCE, V256, P245, DOI 10.1126/science.1373523; SOUTHWICK FS, 1990, J CELL BIOL, V110, P1965, DOI 10.1083/jcb.110.6.1965; STAIGER CJ, 1994, CURR BIOL, V4, P215, DOI 10.1016/S0960-9822(00)00050-6; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; THERIOT JA, 1993, CELL, V75, P835, DOI 10.1016/0092-8674(93)90527-W; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; VANHAASTERT PJM, 1991, EUR J BIOCHEM, V195, P289; VINSON VK, 1993, J CELL BIOL, V122, P1277, DOI 10.1083/jcb.122.6.1277; WADDELL DR, 1988, DEV GENET, V9, P673, DOI 10.1002/dvg.1020090443; WILCZYNSKA Z, 1994, IN PRESS PLASMID; WILLIAMS JG, 1989, CELL, V59, P1157, DOI 10.1016/0092-8674(89)90771-X; WILLIAMS KL, 1976, GENETICS, V82, P287; Witke W., 1993, Molecular Biology of the Cell, V4, p149A; WITKE W, 1987, EMBO J, V6, P4143, DOI 10.1002/j.1460-2075.1987.tb02760.x; WITKE W, 1992, CELL, V68, P53, DOI 10.1016/0092-8674(92)90205-Q; ZARBOCK J, 1990, BIOCHEMISTRY-US, V29, P7814, DOI 10.1021/bi00486a006	72	194	199	2	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	1994	79	2					303	314		10.1016/0092-8674(94)90199-6	http://dx.doi.org/10.1016/0092-8674(94)90199-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954798				2022-12-01	WOS:A1994PN63000014
J	DELONG, EF; WU, KY; PREZELIN, BB; JOVINE, RVM				DELONG, EF; WU, KY; PREZELIN, BB; JOVINE, RVM			HIGH ABUNDANCE OF ARCHAEA IN ANTARCTIC MARINE PICOPLANKTON	NATURE			English	Article							MICROBIAL ECOLOGY; RIBOSOMAL-RNA; DIVERSITY; ARCHAEBACTERIA; EVOLUTION	ARCHAEA (archaebacteria) constitute one of the three major evolutionary lineages of life on Earth(1-3). Previously these prokaryotes were thought to predominate in only a few unusual and disparate niches, characterized by hypersaline, extremely hot, or strictly anoxic conditions(4-7). Recently, novel (uncultivated) phylotypes of Archaea have been detected in coastal(8) and subsurface(9,10) marine waters, but their abundance, distribution, physiology and ecology remain largely undescribed. Here we report exceptionally high archaeal abundance in frigid marine surface waters of Antarctica. Pelagic Archaea constituted up to 34% of the prokaryotic biomass in coastal Antarctic surface waters, and they were also abundant in a variety of other cold, pelagic marine environments. Because they can make up a significant fraction of picoplankton biomass in the vast habitats encompassed by cold and deep marine waters, these pelagic Archaea represent an unexpectedly abundant component of the Earth's biota.			DELONG, EF (corresponding author), UNIV CALIF SANTA BARBARA,DEPT BIOL,DIV ECOL EVOLUT & MARINE BIOL,SANTA BARBARA,CA 93106, USA.							BARNS SM, 1994, P NATL ACAD SCI USA, V91, P1609, DOI 10.1073/pnas.91.5.1609; DELONG EF, 1992, P NATL ACAD SCI USA, V89, P5585; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; FUHRMAN JA, 1992, NATURE, V356, P148, DOI 10.1038/356148a0; FUHRMAN JA, 1993, APPL ENVIRON MICROB, V59, P1294, DOI 10.1128/AEM.59.5.1294-1302.1993; GIOVANNONI SJ, 1990, NATURE, V345, P60, DOI 10.1038/345060a0; HUBER R, 1990, NATURE, V345, P179, DOI 10.1038/345179a0; JONES WJ, 1987, MICROBIOL REV, V51, P135, DOI 10.1128/MMBR.51.1.135-177.1987; LARSEN N, 1993, NUCLEIC ACIDS RES, V21, P2021; MEDLIN L, 1988, GENE, V71, P491, DOI 10.1016/0378-1119(88)90066-2; OLSEN GJ, 1986, ANNU REV MICROBIOL, V40, P337, DOI 10.1146/annurev.mi.40.100186.002005; OLSEN GJ, 1993, FASEB J, V7, P113, DOI 10.1096/fasebj.7.1.8422957; OLSEN GJ, 1994, COMPUT APPL BIOSCI, V10, P41; RASKIN L, 1994, APPL ENVIRON MICROB, V60, P1232, DOI 10.1128/AEM.60.4.1232-1240.1994; SAKAI RK, 1988, SCIENCE, V239, P487; Stahl D.A., 1991, NUCL ACID TECHNIQUES, P205; STAHL DA, 1988, APPL ENVIRON MICROB, V54, P1079, DOI 10.1128/AEM.54.5.1079-1084.1988; STETTER KO, 1990, FEMS MICROBIOL LETT, V75, P117, DOI 10.1016/0378-1097(90)90526-V; STETTER KO, 1993, NATURE, V365, P743, DOI 10.1038/365743a0; TINDALL BJ, 1992, PROKARYOTES HDB BIOL, P768; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; WOESE CR, 1994, MICROBIOL REV, V58, P1; [No title captured]	24	424	446	1	57	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 20	1994	371	6499					695	697		10.1038/371695a0	http://dx.doi.org/10.1038/371695a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM773	7935813				2022-12-01	WOS:A1994PM77300053
J	ROBERTS, SGE; GREEN, MR				ROBERTS, SGE; GREEN, MR			ACTIVATOR-INDUCED CONFORMATIONAL CHANGE IN GENERAL TRANSCRIPTION FACTOR TFIIB	NATURE			English	Article							RNA POLYMERASE-II; FUNCTIONAL DOMAINS; DNA-BINDING	TRANSCRIPTIONAL activator proteins (activators) function, at least in part, by increasing preinitiation complex assembly (for reviews see refs 1-4). Previous studies have shown that an acidic activator forms a contact with the general transcription factor TFIIB (refs 5-7) and recruits it into the preinitiation complex(5,8,9). Mutational studies indicate that this interaction between the acidic activator and TFIIB is required for transcriptional stimulation(5-7,10,11). We show here that the acidic activator-TFIIB interaction has an additional function in preinitiation complex assembly. We provide evidence that in native TFIIB the amino- and carboxy-terminal domains are engaged in an intramolecular interaction. The acidic activator disrupts this intramolecular interaction to expose binding sites for general transcription factors that enter the preinitiation complex through association with TFIIB. Thus, the acidic activator induces a conformational change in TFIIB that drives preinitiation complex assembly forward.			ROBERTS, SGE (corresponding author), UNIV MASSACHUSETTS,MED CTR,HOWARD HUGHES MED INST,PROGRAM MOLEC MED,373 PLANTAT ST,WORCESTER,MA 01605, USA.		Roberts, Stefan GE/R-5537-2016	Roberts, Stefan GE/0000-0002-7535-6365				BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COLGAN J, 1993, NATURE, V362, P549, DOI 10.1038/362549a0; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; JIANG Y, 1994, J BIOL CHEM, V269, P5505; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KINGSTON RE, 1994, CURR BIOL, V4, P325, DOI 10.1016/S0960-9822(00)00071-3; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; REECE RJ, 1993, GENE, V126, P105, DOI 10.1016/0378-1119(93)90596-U; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WAMPLER SL, 1992, GENE DEV, V6, P1542, DOI 10.1101/gad.6.8.1542; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	24	155	158	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 20	1994	371	6499					717	720		10.1038/371717a0	http://dx.doi.org/10.1038/371717a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM773	7935820				2022-12-01	WOS:A1994PM77300061
J	DEGROOT, RP; BALLOU, LM; SASSONECORSI, P				DEGROOT, RP; BALLOU, LM; SASSONECORSI, P			POSITIVE REGULATION OF THE CAMP-RESPONSIVE ACTIVATOR CREM BY THE P70 S6 KINASE - AN ALTERNATIVE ROUTE TO MITOGEN-INDUCED GENE-EXPRESSION	CELL			English	Article							PROTEIN-KINASE; SIGNALING PATHWAYS; 70K-S6 KINASE; MAP KINASE; RAT-LIVER; T-CELLS; PHOSPHORYLATION; TRANSCRIPTION; BINDING; PROMOTER	Activation of the adenylyl cyclase signaling pathway elicits the induction of genes via activators binding to cAMP-responsive elements (CREs). Nuclear factor CRE modulator (CREM) is activated by PKA-mediated phosphorylation on a serine at position 117. We show that Ser-117 is also phosphorylated by the mitogen-activated p70 S6 kinase (p70(S6K)) in vitro. Activation of cellular p70(S6K) by serum factors enhances Ser-117 phosphorylation and CREM transactivation. Coexpression of p70(S6K) significantly increases transactivation by a GAL4-CREM fusion. The macrolide rapamycin, a potent and specific inhibitor of p70(S6K) in vivo, completely blocks CREM activation induced by serum and by p70(S6K). Thus, CREM constitutes a target for mitogenic signaling through p70(S6K) and may acts as a nuclear effector in which transduction pathways may converge and cross-talk.	FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,F-67085 STRASBOURG,FRANCE; RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)								ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; CHEN RH, 1992, MOL CELL BIOL, V12, P925; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEAN DC, 1990, J BIOL CHEM, V265, P3522; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; DEGROOT RP, 1994, ONCOGENE, V9, P463; DEGROOT RP, 1991, EMBO J, V10, P2523, DOI 10.1002/j.1460-2075.1991.tb07792.x; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P1495, DOI 10.1210/me.7.11.1495; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; FRANCO R, 1990, J BIOL CHEM, V265, P4321; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LALLI E, 1994, J BIOL CHEM, V269, P17359; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; MACNICOL M, 1992, FEBS LETT, V304, P237, DOI 10.1016/0014-5793(92)80627-S; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MELLSTROM B, 1993, NEURON, V10, P655, DOI 10.1016/0896-6273(93)90167-P; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MORICE WG, 1993, J BIOL CHEM, V268, P22737; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TAKAHASHI JS, 1993, NATURE, V365, P299, DOI 10.1038/365299a0; TERADA N, 1992, BIOCHEM BIOPH RES CO, V186, P1315, DOI 10.1016/S0006-291X(05)81549-9; TERADA N, 1993, J CELL PHYSIOL, V154, P7, DOI 10.1002/jcp.1041540103; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0	54	210	213	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					81	91		10.1016/0092-8674(94)90402-2	http://dx.doi.org/10.1016/0092-8674(94)90402-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923380				2022-12-01	WOS:A1994PK58500010
J	SMITH, DK; SHAW, RW; MARTEAU, TM				SMITH, DK; SHAW, RW; MARTEAU, TM			INFORMED CONSENT TO UNDERGO SERUM SCREENING FOR DOWNS-SYNDROME - THE GAP BETWEEN POLICY AND PRACTICE	BRITISH MEDICAL JOURNAL			English	Article									UNITED MED & DENT SCH,PSYCHOL & GENET RES GRP,LONDON SE1 9RT,ENGLAND; UNIV WALES COLL MED,CARDIFF CF4 4XN,S GLAM,WALES	University of London; King's College London; Cardiff University				Marteau, Theresa/0000-0003-3025-1129	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		MARTEAU TM, 1992, PUBLIC HEALTH, V106, P131, DOI 10.1016/S0033-3506(05)80390-7; ROUND A, 1993, BRIT MED J, V307, P1211, DOI 10.1136/bmj.307.6913.1211-c; SMITH DK, IN PRESS PRENAT DIAG; Weinman J, 1988, TOPICS HLTH PSYCHOL, P205; 1993, REPORT RCOG WORKING	5	89	89	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					776	776		10.1136/bmj.309.6957.776	http://dx.doi.org/10.1136/bmj.309.6957.776			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PJ282	7950565	Green Published			2022-12-01	WOS:A1994PJ28200022
J	KOCISKO, DA; COME, JH; PRIOLA, SA; CHESEBRO, B; RAYMOND, GJ; LANSBURY, PT; CAUGHEY, B				KOCISKO, DA; COME, JH; PRIOLA, SA; CHESEBRO, B; RAYMOND, GJ; LANSBURY, PT; CAUGHEY, B			CELL-FREE FORMATION OF PROTEASE-RESISTANT PRION PROTEIN	NATURE			English	Article							SCRAPIE-ASSOCIATED FORM; CULTURED-CELLS; PRP; CONVERSION; DISEASES; FIBRILS; BIOLOGY; ACID	THE infectious agent (or 'prion') of the transmissible spongiform encephalopathies (TSEs) such as scrapie resembles a virus in that it replicates in vivo and has distinct strains(1), but it was postulated long ago to contain only protein(2-3). More recently, PrPSc, a pathogenic, scrapie-associated form of the host-encoded prion protein (PrP), was identified as a possible primary TSE agent protein(4-6). PrPSc is defined biochemically by its insolubility and resistance to proteases(7) and is derived post-translationally from normal, protease-sensitive PrP (PrPc)(8,9). The conversion seems to involve conformational change rather than covalent modification(10-13) However, the conversion mechanism and the relationship of PrPSc formation to TSE agent replication remain unclear. Here we report the conversion of PrPc to protease-resistant forms similar to PrPSc in a cell-free system composed of substantially purified constituents. This conversion was selective and required the presence of preexisting PrPSc, providing direct evidence that PrPSc derives from specific PrPc-PrPSc interactions.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139; NIAID,ROCKY MT LABS,PERSISTENT VIRAL DIS LAB,HAMILTON,MT 59840	Massachusetts Institute of Technology (MIT); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								AIKEN JM, 1990, MICROBIOL REV, V54, P242, DOI 10.1128/MMBR.54.3.242-246.1990; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BOLTON DC, 1988, NOVEL INFECTIOUS AGE, V1, P164; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BROWN P, 1991, LANCET, V337, P1019, DOI 10.1016/0140-6736(91)92670-W; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CHESEBRO B, 1993, DEV BIOL STAND, V80, P131; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; DIRINGER H, 1983, NATURE, V306, P476, DOI 10.1038/306476a0; FRASER H, 1993, BRIT MED BULL, V49, P792, DOI 10.1093/oxfordjournals.bmb.a072647; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PATTISON IH, 1967, VET REC, V80, P2, DOI 10.1136/vr.80.1.2; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1984, CELL, V38, P127, DOI 10.1016/0092-8674(84)90533-6; Riesner D., 1991, SEMIN VIROL, V2, P215; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; Rohwer R G, 1991, Curr Top Microbiol Immunol, V172, P195; SAFAR J, 1993, J BIOL CHEM, V268, P20276; SNOW AD, 1990, LAB INVEST, V63, P601; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0	30	766	802	1	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 11	1994	370	6489					471	474		10.1038/370471a0	http://dx.doi.org/10.1038/370471a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	7913989	Green Published			2022-12-01	WOS:A1994PB40700059
J	CLEARY, MA; WALTER, JH; WRAITH, JE; JENKINS, JPR; ALANI, SM; TYLER, K; WHITTLE, D				CLEARY, MA; WALTER, JH; WRAITH, JE; JENKINS, JPR; ALANI, SM; TYLER, K; WHITTLE, D			MAGNETIC-RESONANCE-IMAGING OF THE BRAIN IN PHENYLKETONURIA	LANCET			English	Article							MULTIPLE-SCLEROSIS; EXPERIMENTAL HYPERPHENYLALANINEMIA; NEUROLOGICAL DETERIORATION; DIETARY-TREATMENT; ADOLESCENTS; STIMULATION; MR; INTELLIGENCE; MYELIN	Abnormalities of magnetic resonance imaging (MRI) of the brain occur in some patients with phenylketonuria but the clinical importance of this finding is not clear. In order to determine the frequency and functional significance of changes on MRI we investigated 77 adolescent and adult patients with phenylketonuria. Patients aged 14-49 years and taking a restricted diet of 1 g/kg protein underwent clinical examination, IQ testing, neurophysiological investigation, and MRI of the brain. Patients aged between 10-14 years taking a low phenylalanine diet with aminoacid supplements had MRI of the brain only. Biochemical control was assessed from: the lifetime blood phenylalanine determined from the mean blood concentration throughout life; the accumulated time for each patient that phenylalanine was < 120 mu mol/L; the accumulated time for each patient that phenylalanine was > 1200 mu mol/L); mean blood concentration in the first 4 years of life; and the mean blood phe concentration in the 5 years prior to imaging. MRI changes, compatible with a disturbance in the water content of white matter, were present in all but 1 patient. The severity of abnormality was most strongly associated with the blood phenylalanine concentration at the time of imaging. Clinical and neurophysiological abnormalities were less common and usually mild. 3 patients had prolonged central motor conduction time, 7 had prolonged visual evoked potentials, and 5 had impaired peripheral sensory nerve conduction. There was no significant association between the extent of MRI abnormalities and IQ, and the presence of neurophysiological, or clinical abnormalities. An abnormal brain scan in PKU may reflect present biochemical control rather than indicate significant neurological damage. As yet there is little evidence that in most patients with PKU these MRI changes are of clinical importance.	ROYAL MANCHESTER CHILDRENS HOSP,WILLINK BIOCHEM GENET UNIT,MANCHESTER M27 4HA,LANCS,ENGLAND; HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND; MANCHESTER ROYAL INFIRM,DEPT CLIN RADIOL,MANCHESTER,ENGLAND	Royal Manchester Children's Hospital; University of Manchester								BICK U, 1991, EUR J PEDIATR, V150, P185, DOI 10.1007/BF01963563; BICK U, 1993, EUR J PEDIATR, V152, P1012, DOI 10.1007/BF01957228; BRANTZAWADZKI M, 1988, RADIOLOGY, V166, P1; DOBSON JC, 1977, PEDIATRICS, V60, P822; EISEN A, 1990, MUSCLE NERVE, V13, P146, DOI 10.1002/mus.880130211; HALLIDAY AM, 1973, BRIT MED J, V4, P661, DOI 10.1136/bmj.4.5893.661; HOMMES FA, 1982, J INHERIT METAB DIS, V5, P21, DOI 10.1007/BF01799750; INGRAM DA, 1988, J NEUROL NEUROSUR PS, V51, P487, DOI 10.1136/jnnp.51.4.487; KAMMAN RL, 1988, MAGNET RESON MED, V6, P265, DOI 10.1002/mrm.1910060304; KORINTHENBERG R, 1988, NEUROPEDIATRICS, V19, P175, DOI 10.1055/s-2008-1052440; LOU HC, 1992, J INHERIT METAB DIS, V15, P687, DOI 10.1007/BF01800008; LUDOLPH AC, 1992, ACTA NEUROL SCAND, V85, P243; MALAMUD N, 1966, J NEUROPATH EXP NEUR, V25, P254, DOI 10.1097/00005072-196604000-00006; MAYR N, 1991, NEUROLOGY, V41, P566, DOI 10.1212/WNL.41.4.566; MCDONALD WI, 1988, CLIN NEUROL NEUROSUR, V90, P3; PEARSEN KD, 1990, RADIOLOGY, V177, P437, DOI 10.1148/radiology.177.2.2217781; REYNOLDS R, 1992, EXP NEUROL, V115, P347, DOI 10.1016/0014-4886(92)90200-A; SAUDUBRAY JM, 1987, EUR J PEDIATR, V146, P20; SHAW DWW, 1990, J COMPUT ASSIST TOMO, V14, P458, DOI 10.1097/00004728-199005000-00026; SMITH I, 1990, ARCH DIS CHILD, V65, P472, DOI 10.1136/adc.65.5.472; SMITH I, 1985, GENETIC METABOLIC DI, P166; TAYLOR EH, 1983, INT J NEUROSCI, V20, P217, DOI 10.3109/00207458308986575; THOMPSON AJ, 1993, BRAIN, V116, P811, DOI 10.1093/brain/116.4.811; THOMPSON AJ, 1990, LANCET, V336, P602, DOI 10.1016/0140-6736(90)93401-A; TOMA P, 1991, NEUROPEDIATRICS, V22, P174; Valk J., 1989, MAGNETIC RESONANCE M; VILLASANA D, 1989, J INHERIT METAB DIS, V12, P451, DOI 10.1007/BF01802042; Waisbren S E, 1980, J Inherit Metab Dis, V3, P149, DOI 10.1007/BF02312549; WAISBREN SE, 1987, PEDIATRICS, V79, P351; WALTER JH, 1993, EUR J PEDIATR, V152, P822, DOI 10.1007/BF02073379	30	121	125	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 9	1994	344	8915					87	90		10.1016/S0140-6736(94)91281-5	http://dx.doi.org/10.1016/S0140-6736(94)91281-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7912392				2022-12-01	WOS:A1994NV73200009
J	PERNEGER, TV; WHELTON, PK; KLAG, MJ				PERNEGER, TV; WHELTON, PK; KLAG, MJ			RISK OF KIDNEY FAILURE ASSOCIATED WITH THE USE OF ACETAMINOPHEN, ASPIRIN, AND NONSTEROIDAL ANTIINFLAMMATORY DRUGS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC RENAL-DISEASE; ANALGESIC USE; IBUPROFEN; SULINDAC	Background. People who take analgesic drugs frequently may be at increased risk of end-stage renal disease (ESRD), but the extent of this risk remains unclear. Methods. We studied 716 patients treated for ESRD and 361 control subjects of similar age from Maryland, Virginia, West Virginia, and Washington, D.C. The study participants were interviewed by telephone about their past use of medications containing acetaminophen, aspirin, and other nonsteroidal antiinflammatory drugs (NSAIDs). For each analgesic drug, the average use (in pills per year) and the cumulative intake (in pills) were examined for any association with ESRD. Results. Heavier acetaminophen use was associated with an increased risk of ESRD in a dose-dependent fashion. When persons who took an average of 0 to 104 pills per year were used for reference, the odds ratio of ESRD was 1.4 (95 percent confidence interval, 0.8 to 2.4) for those who took 105 to 365 pills per year and 2.1 (95 percent confidence interval, 1.1 to 3.7) for those who took 366 or more pills per year, after adjustment for race, sex, age, and intake of other analgesic drugs. When persons who had taken fewer than 1000 pills containing acetaminophen in their lifetime were used for reference, the odds ratio was 2.0 (95 percent confidence interval, 1.3 to 3.2) for those who had taken 1000 to 4999 pills and 2.4 (95 percent confidence interval, 1.2 to 4.8) for those who had taken 5000 or more pills. Approximately 8 to 10 percent of the overall incidence of ESRD was attributable to acetaminophen use. A cumulative dose of 5000 or more pills containing NSAIDs was also associated with an increased odds of ESRD (odds ratio, 8.8), but the use of aspirin was not. Conclusions. People who often take acetaminophen or NSAIDs have an increased risk of ESRD, but not those who often take aspirin.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT MED,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,WELCH CTR PREVENT EPIDEMIOL & CLIN RES,BALTIMORE,MD	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	PERNEGER, TV (corresponding author), UNIV GENEVA,CTR MED,INST SOCIAL & PREVENT MED,UNIV CASE POSTALE,CH-1211 GENEVA 4,SWITZERLAND.				AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R03HS006978] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; AHRQ HHS [R03 HS 06978-01] Funding Source: Medline; NCRR NIH HHS [RR00035, 5MOIRR00722] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; CIABATTONI G, 1984, NEW ENGL J MED, V310, P279, DOI 10.1056/NEJM198402023100502; DUBACH UC, 1991, NEW ENGL J MED, V324, P155, DOI 10.1056/NEJM199101173240304; Hosmer D, 2013, APPL LOGISTIC REGRES; MORLANS M, 1990, BRIT J CLIN PHARMACO, V30, P717, DOI 10.1111/j.1365-2125.1990.tb03841.x; MURRAY TG, 1983, ARCH INTERN MED, V143, P1687, DOI 10.1001/archinte.143.9.1687; NATH KA, 1992, AM J KIDNEY DIS, V20, P1; PERNEGER TV, 1993, AM J EPIDEMIOL, V138, P574, DOI 10.1093/oxfordjournals.aje.a116898; POMMER W, 1989, AM J NEPHROL, V9, P403, DOI 10.1159/000168002; SANDLER DP, 1989, NEW ENGL J MED, V320, P1238, DOI 10.1056/NEJM198905113201903; SANDLER DP, 1991, ANN INTERN MED, V115, P165, DOI 10.7326/0003-4819-115-3-165; SCHWARZ A, 1984, LANCET, V2, P1163; SPUHLER O, 1953, Z KLIN MED, V151, P1; STEWART J, 1993, ANALGESIC NSAID INDU; WHELTON A, 1990, ANN INTERN MED, V112, P568, DOI 10.7326/0003-4819-112-8-568; WILKINSON L, 1990, SYSTAT SYSTEM STATIS; 1993, USRDS1993 NAT I DIAB	17	353	367	2	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 22	1994	331	25					1675	1679		10.1056/NEJM199412223312502	http://dx.doi.org/10.1056/NEJM199412223312502			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX382	7969358				2022-12-01	WOS:A1994PX38200002
J	PHAROAH, POD				PHAROAH, POD			FAMILY SPACING, BREAST-FEEDING, AND CONTRACEPTION	LANCET			English	Editorial Material							HEALTH				PHAROAH, POD (corresponding author), UNIV LIVERPOOL,DEPT PUBL HLTH,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.							KING M, 1990, LANCET, V336, P664, DOI 10.1016/0140-6736(90)92156-C; SCHUFTAN C, 1990, FAM PRACT, V7, P329, DOI 10.1093/fampra/7.4.329; WISNER B, 1988, SOC SCI MED, V26, P963, DOI 10.1016/0277-9536(88)90417-0; 1994, CONTRACEPTION, V50, P55; 1994, CONTRACEPTION, V50, P35	5	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 19	1994	344	8934					1382	1382		10.1016/S0140-6736(94)90565-7	http://dx.doi.org/10.1016/S0140-6736(94)90565-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PR786	7968072				2022-12-01	WOS:A1994PR78600006
J	TODD, NW				TODD, NW			IMAGES IN CLINICAL MEDICINE - CHOLESTEATOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											TODD, NW (corresponding author), EMORY UNIV,ATLANTA,GA 30322, USA.								0	0	0	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 17	1994	331	20					1347	1347						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR216	7935704				2022-12-01	WOS:A1994PR21600005
J	GONZALEZREYES, A; STJOHNSTON, D				GONZALEZREYES, A; STJOHNSTON, D			ROLE OF OOCYTE POSITION IN ESTABLISHMENT OF ANTERIOR-POSTERIOR POLARITY IN DROSOPHILA	SCIENCE			English	Article							BICOID RNA; LOCALIZATION; OOGENESIS; FOLLICLE; ENCODES; OSKAR; EGG; TRANSPORT; PROTEIN; EMBRYO	The polarized microtubule cytoskeleton of the Drosophila oocyte directs the localization of the maternal determinants which establish the anterior-posterior (AP) axis of the embryo. Because the formation of this microtubule array is dependent on signals from the follicle cells that surround the oocyte, it has been proposed that AP polarity originates in the follicle cells. Here it is shown that the movement of the oocyte to the posterior of the egg chamber early in oogenesis determines AP polarity in the follicle cell layer, and also in the oocyte. Moreover, the generation of AP asymmetry requires signaling from the germ line to the soma and back again.	UNIV CAMBRIDGE,WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND; UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 1QR,ENGLAND	University of Cambridge; University of Cambridge			St Johnston, Daniel/C-9568-2009; Gonzalez-Reyes, Acaimo/L-1993-2014	Gonzalez-Reyes, Acaimo/0000-0003-3048-0968; St Johnston, Daniel/0000-0001-5582-3301	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CHASAN R, 1993, GENETICA BIOL DROSOP, V1, P387; CHEUNG HK, 1992, DEVELOPMENT, V114, P653; CHOU TB, 1993, DEVELOPMENT, V119, P1359; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; GINIGER E, 1993, ROUX ARCH DEV BIOL, V202, P112, DOI 10.1007/BF00636536; GONZALEZREYES A, UNPUB; GOODE S, 1992, DEVELOPMENT, V116, P177; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; JOHNSTON DS, 1992, CELL, V68, P201; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; LOHSSCHARDIN M, 1982, ROUX ARCH DEV BIOL, V191, P28, DOI 10.1007/BF00848543; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; MONTELL DJ, 1992, CELL, V71, P51, DOI 10.1016/0092-8674(92)90265-E; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; PEIFER M, 1993, DEVELOPMENT, V118, P1191; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; RUOHOLABAKER H, 1994, TRENDS GENET, V10, P89, DOI 10.1016/0168-9525(94)90231-3; Spradling A.C., 1993, DEV DROSOPHILA MELAN, VI, P1; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; Tearle R., 1987, DROSOPHILA INFORMATI, V66, P209; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9	27	98	99	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 28	1994	266	5185					639	642		10.1126/science.7939717	http://dx.doi.org/10.1126/science.7939717			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939717				2022-12-01	WOS:A1994PN80700045
J	WOLPERT, L				WOLPERT, L			DO WE UNDERSTAND DEVELOPMENT	SCIENCE			English	Editorial Material											WOLPERT, L (corresponding author), UCL, DEPT ANAT & DEV BIOL, LONDON, ENGLAND.							BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; CHOTHIA C, 1992, NATURE, V357, P543, DOI 10.1038/357543a0; GRUNWALD T, 1992, CELL, V68, P271; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; KELLER R, 1992, DEVELOPMENT, P81; KENYON C, 1994, CELL, V78, P175, DOI 10.1016/0092-8674(94)90288-7; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lawrence P., 1992, MAKING FLY GENETICS; LAWRENCE PA, 1994, CELL, V78, P181, DOI 10.1016/0092-8674(94)90289-5; NIESWANDER L, IN PRESS NATURE; OLSEN EN, 1991, GENE DEV, V4, P1454; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7; WOLPERT L, 1990, BIOL J LINN SOC, V39, P109, DOI 10.1111/j.1095-8312.1990.tb00506.x; WOLPERT L, IN PRESS DEVELOPME S; WOLPERT L, 1989, DEVELOPMENT S, P3	18	70	72	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 28	1994	266	5185					571	572		10.1126/science.7939707	http://dx.doi.org/10.1126/science.7939707			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939707				2022-12-01	WOS:A1994PN80700031
J	GEORGOPOULOS, K; BIGBY, M; WANG, JH; MOLNAR, A; WU, P; WINANDY, S; SHARPE, A				GEORGOPOULOS, K; BIGBY, M; WANG, JH; MOLNAR, A; WU, P; WINANDY, S; SHARPE, A			THE IKAROS GENE IS REQUIRED FOR THE DEVELOPMENT OF ALL LYMPHOID LINEAGES	CELL			English	Article							HEMATOPOIETIC STEM-CELLS; NATURAL-KILLER-CELLS; DENDRITIC EPIDERMAL-CELLS; BONE-MARROW; PRECURSOR CELLS; LYMPHOCYTES-T; EXPRESSION; THYMUS; MOUSE; MICE	The Ikaros gene encodes a family of early hematopoietic- and lymphocyte-restricted transcription factors. Mice homozygous for a germline mutation in the Ikaros DNA-binding domain lack not only T and B lymphocytes and natural killer cells but also their earliest defined progenitors. In contrast, the erythroid and myeloid lineages were intact in these mutant mice. We propose that Ikaros promotes differentiation of pluripotential hematopoietic stem cell(s) into the lymphocyte pathways. In the absence of a functional Ikaros gene, these stem cells are exclusively diverted into the erythroid and myeloid lineages.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT PATHOL,DIV IMMUNOL RES,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	GEORGOPOULOS, K (corresponding author), MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,BOSTON,MA 02129, USA.				NIAID NIH HHS [R01 AI033062, R01-AI33062-62] Funding Source: Medline; NIAMS NIH HHS [AR39795-04] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039795] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARDAVIN C, 1993, NATURE, V362, P761, DOI 10.1038/362761a0; ASNARNOW DM, 1988, CELL, V55, P837; BIGBY M, 1987, J INVEST DERMATOL, V89, P495, DOI 10.1111/1523-1747.ep12460983; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; CLEVERS HC, 1993, IMMUNOL TODAY, V14, P591, DOI 10.1016/0167-5699(93)90198-T; FIFE A, 1994, J CLIN PATHOL, V47, P82, DOI 10.1136/jcp.47.1.82; FLEMING WH, 1993, J CELL BIOL, V122, P897, DOI 10.1083/jcb.122.4.897; GARNIWAGNER BA, 1993, J IMMUNOL, V151, P60; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; HACKETT J, 1986, J IMMUNOL, V136, P3124; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARDY RR, 1986, IMMUNOL REV, V93, P53, DOI 10.1111/j.1600-065X.1986.tb01502.x; HAVRAN WL, 1990, NATURE, V344, P68, DOI 10.1038/344068a0; HAVRAN WL, 1988, NATURE, V335, P443, DOI 10.1038/335443a0; HESTDAL K, 1991, J IMMUNOL, V147, P22; HODGSON GS, 1979, NATURE, V281, P381, DOI 10.1038/281381a0; IKUTA K, 1992, ANNU REV IMMUNOL, V10, P759; KARASUYAMA H, 1994, CELL, V77, P133, DOI 10.1016/0092-8674(94)90241-0; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NILSSON SK, 1994, EXP HEMATOL, V22, P377; PEARSE M, 1989, P NATL ACAD SCI USA, V86, P1614, DOI 10.1073/pnas.86.5.1614; RAULET DH, 1991, IMMUNOL REV, V120, P185, DOI 10.1111/j.1600-065X.1991.tb00592.x; RODEWALD HR, 1992, CELL, V69, P139, DOI 10.1016/0092-8674(92)90125-V; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SKEATH JB, 1992, GENE DEV, V6, P2606, DOI 10.1101/gad.6.12b.2606; SPANGRUDE GJ, 1989, IMMUNOL TODAY, V10, P344, DOI 10.1016/0167-5699(89)90192-8; VISSER JWM, 1983, CELL TISSUE KINET, V16, P385; WARD HP, 1971, MEDICINE, V50, P357, DOI 10.1097/00005792-197109000-00001; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WU L, 1991, J EXP MED, V174, P1617, DOI 10.1084/jem.174.6.1617; WU L, 1991, NATURE, V349, P71, DOI 10.1038/349071a0	36	752	771	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					143	156		10.1016/0092-8674(94)90407-3	http://dx.doi.org/10.1016/0092-8674(94)90407-3			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923373				2022-12-01	WOS:A1994PK58500015
J	ASSEMAN, P; MCFADDEN, E; BAUCHART, JJ; LOUBEYRE, C; THERY, C				ASSEMAN, P; MCFADDEN, E; BAUCHART, JJ; LOUBEYRE, C; THERY, C			WHY DO BETA-BLOCKERS HELP IN IDIOPATHIC DILATED CARDIOMYOPATHY - FREQUENCY MISMATCH	LANCET			English	Article							HUMAN HEART-FAILURE; HUMAN VENTRICULAR MYOCARDIUM; FAILING HUMAN MYOCARDIUM; CALCIUM; EXPRESSION; CONTRACTILITY; METOPROLOL; BLOCKADE				ASSEMAN, P (corresponding author), UNIV LILLE,HOP CARDIOIOG,F-59037 LILLE,FRANCE.							BEUCKELMANN DJ, 1992, CIRCULATION, V85, P1046, DOI 10.1161/01.CIR.85.3.1046; BREALL JA, 1993, J AM COLL CARDIOL, V21, P471, DOI 10.1016/0735-1097(93)90691-S; CORABOEUF E, 1992, THERAPIE, V47, P171; EISING GP, 1994, J AM COLL CARDIOL, V23, P97; FOWLER MB, 1986, CIRCULATION, V74, P1290, DOI 10.1161/01.CIR.74.6.1290; GILBERT EM, 1991, CIRCULATION S2, V84, P1868; GO LW, 1993, CIRCULATION, V88, P624; GWATHMEY JK, 1990, J CLIN INVEST, V85, P1599, DOI 10.1172/JCI114611; GWATHMEY JK, 1987, CIRC RES, V61, P70, DOI 10.1161/01.RES.61.1.70; HAJJAR RJ, 1992, CIRCULATION, V86, P1819, DOI 10.1161/01.CIR.86.6.1819; HASENFUSS G, 1993, CIRCULATION, V88, P407; HASENFUSS G, 1992, CIRC RES, V70, P1226; HEILBRUNN SM, 1989, CIRCULATION, V79, P483, DOI 10.1161/01.CIR.79.3.483; LECHAT P, IN PRESS CIRCULATION; MANN DL, 1992, CIRCULATION, V85, P790, DOI 10.1161/01.CIR.85.2.790; MORAVEC CS, 1993, CIRCULATION, V88, P408; MULIERI LA, 1992, CIRCULATION, V85, P1743, DOI 10.1161/01.CIR.85.5.1743; PIESKE B, 1993, CIRCULATION, V88, P373; RASMUSSEN RP, 1990, BIOCHEM PHARMACOL, V39, P691, DOI 10.1016/0006-2952(90)90147-D; REINECKE H, 1993, CIRCULATION, V88, P408; SATO H, 1993, CIRCULATION, V88, P2215, DOI 10.1161/01.CIR.88.5.2215; VAHL CF, 1994, CIRC RES, V74, P952, DOI 10.1161/01.RES.74.5.952; WAAGSTEIN F, 1975, BRIT HEART J, V37, P1022; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R	24	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					803	804		10.1016/S0140-6736(94)92350-7	http://dx.doi.org/10.1016/S0140-6736(94)92350-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916082				2022-12-01	WOS:A1994PG17800019
J	TURKASPA, I; MAOR, Y; DOR, J; MASHIACH, S				TURKASPA, I; MAOR, Y; DOR, J; MASHIACH, S			FREQUENCY OF INTERCOURSE FOR COUPLES TRYING TO CONCEIVE	LANCET			English	Editorial Material							OLIGOZOOSPERMIC MEN; SEMEN CHARACTERISTICS; INFERTILE MEN; PARAMETERS; INTERVAL; MOTILE; SPERM				TURKASPA, I (corresponding author), TEL AVIV UNIV,CHAIM SHEBA MED CTR,DEPT OBSTET & GYNECOL,INFERTIL & INVITRO FERTILIZAT UNIT,IL-52621 TEL HASHOMER,ISRAEL.			Maor, Yasmin/0000-0001-7258-3434				ACOSTA AA, 1988, OBSTET GYNECOL SURV, V44, P1; BAKER HWG, 1981, INT J ANDROL, V4, P609, DOI 10.1111/j.1365-2605.1981.tb00743.x; BRASCH JG, 1994, FERTIL STERIL, V62, P150; CHECK JH, 1985, FERTIL STERIL, V44, P416; COOPER TG, 1993, HUM REPROD, V8, P1251, DOI 10.1093/oxfordjournals.humrep.a138236; GLASS RH, 1986, REPRODUCTIVE ENDOCRI, P571; GULMEZ I, 1991, ANDROLOGIA, V23, P167; HORNSTEIN MD, 1992, FERTIL STERIL, V58, P433; Hotchkiss RS, 1941, J UROLOGY, V45, P875, DOI 10.1016/S0022-5347(17)71125-1; MATILSKY M, 1993, HUM REPROD, V8, P71, DOI 10.1093/oxfordjournals.humrep.a137877; SILBER SJ, 1989, HUM REPROD, V4, P947, DOI 10.1093/oxfordjournals.humrep.a137018; TURKASPA I, 1990, FERTIL STERIL, V54, P906; TURKASPA I, 1994, FERTIL STERIL, V62, P370	13	3	3	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					766	766		10.1016/S0140-6736(94)92334-5	http://dx.doi.org/10.1016/S0140-6736(94)92334-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916066				2022-12-01	WOS:A1994PG17800003
J	BERKOWITZ, CD				BERKOWITZ, CD			HOMEOPATHT - KEEPING AN OPEN MIND	LANCET			English	Editorial Material											BERKOWITZ, CD (corresponding author), UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,DEPT PEDIAT,TORRANCE,CA 90509, USA.							CRETICOS PS, 1987, JAMA-J AM MED ASSOC, V258, P2874, DOI 10.1001/jama.258.20.2874; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; JACOBS J, 1994, PEDIATRICS, V93, P719; PACHTER LM, 1994, JAMA-J AM MED ASSOC, V271, P690, DOI 10.1001/jama.271.9.690; PALAFOX N, 1980, CROSS CULTURAL CARIN; REILLY DT, 1986, LANCET, V2, P881; WAPNIR RA, 1991, J PEDIATR, V118, P553; 1981, PUBLIC HLTH LETT, V3, P37	8	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					701	702		10.1016/S0140-6736(94)92203-9	http://dx.doi.org/10.1016/S0140-6736(94)92203-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915771				2022-12-01	WOS:A1994PF18700005
J	CLARKE, KW; GRAY, D; KEATING, NA; HAMPTON, JR				CLARKE, KW; GRAY, D; KEATING, NA; HAMPTON, JR			DO WOMEN WITH ACUTE MYOCARDIAL-INFARCTION RECEIVE THE SAME TREATMENT AS MEN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; THROMBOLYSIS; MORTALITY; PROGNOSIS; GENDER; POLICY	Objective-To determine whether women with acute myocardial infarction in the Nottingham health district receive the same therapeutic interventions as their male counterparts. Design-Retrospective study. Setting-University and City Hospitals, Nottingham. Patients-All patients admitted with a suspected myocardial infarction during 1989 and 1990. Main outcome measures-Route and timing of admission to hospital, ward of admission, treatment, interventions in hospital, and mortality. Results-Women with myocardial infarction took longer to arrive in hospital than men. They were less likely to be admitted to the coronary care unit and were therefore also less likely to receive thrombolytic treatment. They seemed to have more severe infarcts, with higher Killip classes, and had a slightly higher mortality during admission. They were less likely than men to receive secondary prophylaxis by being discharged taking beta blockers or aspirin. Conclusions-Survival chances both in hospital and after discharge in women with acute myocardial infarction are reduced because they do not have the same opportunity for therapeutic intervention as men.	UNIV NOTTINGHAM, BRITISH HEART FDN, DEPT MATH, CARDIOVASC STAT UNIT, NOTTINGHAM NG7 2RD, ENGLAND	University of Nottingham	CLARKE, KW (corresponding author), UNIV NOTTINGHAM HOSP, NOTTINGHAM NG7 2UH, ENGLAND.							ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; [Anonymous], 1986, Lancet, V2, P57; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; GRAY D, 1993, LANCET, V341, P654, DOI 10.1016/0140-6736(93)90420-L; GRAY D, 1993, INT J EPIDEMIOL, V22, P222, DOI 10.1093/ije/22.2.222; HAMPTON JR, 1985, MED INT, P848; KANNEL WB, 1987, CORONARY HEART DISEA, P208; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; MULCAHY R, 1993, BRIT J CARDIOLOGY, V1, P35; PETTICREW M, 1993, BMJ-BRIT MED J, V306, P1164, DOI 10.1136/bmj.306.6886.1164; ROBINSON K, 1988, J AM COLL CARDIOL, V11, P932, DOI 10.1016/S0735-1097(98)90048-1; ROWLEY JM, 1992, BRIT HEART J, V67, P255; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; VEMURA K, 1988, WORLD HLTH STAT Q, V41, P155; WEINBLATT E, 1973, AM J PUBLIC HEALTH, V63, P577, DOI 10.2105/AJPH.63.7.577; 1993, MORTALITY STATISTICS	19	158	162	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 3	1994	309	6954					563	566		10.1136/bmj.309.6954.563	http://dx.doi.org/10.1136/bmj.309.6954.563			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF330	7916228	Green Published			2022-12-01	WOS:A1994PF33000014
J	EISENBERG, M				EISENBERG, M			IMPROVING OUT-OF-HOSPITAL RESUSCITATION	LANCET			English	Editorial Material							AMERICAN-HEART-ASSOCIATION; CARDIAC-ARREST; HEALTH-PROFESSIONALS; STATEMENT; SURVIVAL				EISENBERG, M (corresponding author), UNIV WASHINGTON,MED CTR,EMERGENCY MED SERV,SEATTLE,WA 98195, USA.							BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BENSON NH, 1994, ANN EMERG MED, V23, P1047, DOI 10.1016/S0196-0644(94)70102-4; CLARK JJ, 1994, ANN EMERG MED, V23, P1022, DOI 10.1016/S0196-0644(94)70097-4; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; DULL SM, 1994, ANN EMERG MED, V23, P997, DOI 10.1016/S0196-0644(94)70093-1; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; EISENBERG MS, 1994, ANN EMERG MED, V23, P1049, DOI 10.1016/S0196-0644(94)70103-2; LARSEN MP, 1993, ANN EMERG MED, V22, P1652, DOI 10.1016/S0196-0644(05)81302-2; PARTRIDGE JF, 1967, LANCET, V2, P271; PEPE PE, 1994, ANN EMERG MED, V23, P1037, DOI 10.1016/S0196-0644(94)70100-8; ROTTENBERG EM, 1994, ANN EMERG MED, V23, P1027, DOI 10.1016/S0196-0644(94)70098-2; SHUSTER M, 1994, ANN EMERG MED, V23, P1014, DOI 10.1016/S0196-0644(94)70096-6; SOSNA DP, 1994, ANN EMERG MED, V23, P1042, DOI 10.1016/S0196-0644(94)70101-6; WHITE RD, 1994, ANN EMERG MED, V23, P1009, DOI 10.1016/S0196-0644(94)70095-8	15	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					561	562		10.1016/S0140-6736(94)91961-5	http://dx.doi.org/10.1016/S0140-6736(94)91961-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914956				2022-12-01	WOS:A1994PD42400005
J	FROMMEL, D; TEKLEHAIMANOT, R; VERDIER, M; NEGESSE, Y; BULTO, T; DENIS, F				FROMMEL, D; TEKLEHAIMANOT, R; VERDIER, M; NEGESSE, Y; BULTO, T; DENIS, F			HIV-INFECTION AND LEPROSY - A 4-YEAR SURVEY IN ETHIOPIA	LANCET			English	Note							VIRUS	Between 1988 and 1992 three cross-sectional surveys for antibodies to HIV were done in 644 Ethiopian patients with histologically proven leprosy. Whereas the frequency of HIV-1 infection gradually increased from 3.2% to 6.5%, the clinical presentation, number of new patients, and frequency of relapse did not differ between HIV negative and positive patients. Thus HIV appears unlikely to have a significant impact on the incidence of leprosy in sub-Sahelian populations.	UNIV ADDIS ABABA,FAC MED,DEPT MED,ADDIS ABABA,ETHIOPIA; CHU LIMOGES,DEPT VIROL,LIMOGES,FRANCE; ALL AFRICA LEPROSY & REHABIL TRAINING CTR,ADDIS ABABA,ETHIOPIA; INST PASTEUR,CNRS,URA 1459,LYON,FRANCE	Addis Ababa University; CHU Limoges; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	FROMMEL, D (corresponding author), ARMAUER HANSEN RES INST,POB 1005,ADDIS ABABA,ETHIOPIA.			VERDIER, Mireille/0000-0002-8162-4856				DUNCAN ME, 1981, LEPROSY REV, V52, P245; FROMMEL D, 1993, AM J TROP MED HYG, V49, P435, DOI 10.4269/ajtmh.1993.49.435; KHOD, 1993, KHODAKEVICH L, P319; LEONARD G, 1990, J ACQ IMMUN DEF SYND, V3, P1109; LUCAS S, 1993, LEPROSY REV, V64, P97; TEKLEHAIMANOT R, 1991, AIDS, V5, P108, DOI 10.1097/00002030-199101000-00019; 1993, ETHIOP J HLTH DEV, V7, P33; 1992, LEPROSY CONTROL ETHI; 1988, LEPROSY CONTROL ETHI	9	30	31	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 16	1994	344	8916					165	166		10.1016/S0140-6736(94)92760-X	http://dx.doi.org/10.1016/S0140-6736(94)92760-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912768				2022-12-01	WOS:A1994NW81000012
J	RUSSELL, JA				RUSSELL, JA			CANCER-THERAPY - TIME TO LEARN THE IMMUNOBABBLE	LANCET			English	Editorial Material							HIGH-DOSE INTERLEUKIN-2; TUMOR-INFILTRATING LYMPHOCYTES; ACTIVATED KILLER-CELLS; TRIAL				RUSSELL, JA (corresponding author), TOM BAKER CANC CLIN,CALGARY,AB,CANADA.							ATKINS MB, 1993, J CLIN ONCOL, V11, P661, DOI 10.1200/JCO.1993.11.4.661; CURTI BD, 1993, J CLIN ONCOL, V11, P652, DOI 10.1200/JCO.1993.11.4.652; KIM JA, 1993, 37TH ANN C ADV BIOL; LARSON SM, 1993, ACTA ONCOL, V32, P709, DOI 10.3109/02841869309096125; MARINCOLA FM, 1993, J IMMUNOTHER, V13, P282, DOI 10.1097/00002371-199305000-00008; ROSENBERG SA, 1993, JNCI-J NATL CANCER I, V85, P622, DOI 10.1093/jnci/85.8.622; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; ROSENBERG SA, 1986, SCIENCE, V233, P1318, DOI 10.1126/science.3489291; UCHIDA A, 1993, CANCER IMMUNOL IMMUN, V11, P75; YEUNG AW, 1994, CANCER, V71, P3633	10	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 16	1994	344	8916					145	146		10.1016/S0140-6736(94)92753-7	http://dx.doi.org/10.1016/S0140-6736(94)92753-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912761				2022-12-01	WOS:A1994NW81000005
J	FRANKE, EK; YUAN, HEH; LUBAN, J				FRANKE, EK; YUAN, HEH; LUBAN, J			SPECIFIC INCORPORATION OF CYCLOPHILIN-A INTO HIV-1 VIRIONS	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CYCLOSPORINE-A; GAG; CALCINEURIN; INHIBITION; EXPRESSION; SEQUENCE; BINDING; CELLS; RNA	LITTLE is known about host factors necessary for retroviral virion assembly or uncoating. We have previously shown that the principal structural protein of the human immunodeficiency virus HIV-1, the Gag polyprotein, binds the cyclophilin peptidyl-prolyl isomerases(1); cyclophilins catalyse a rate-limiting step in protein folding(2) and protect cells from heat shock(3). Here we demonstrate that cyclophilin A is specifically incorporated into HIV-1 virions but not into virions of other primate immunodeficiency viruses. A proline-rich region conserved in all HIV-1 Gag polyproteins is required for cyclophilin A binding and incorporation. Disruption of a single proline blocks the Gag-cyclophilin interaction in vitro, prevents cyclophilin A incorporation into virions, and inhibits HIV-1 replication. Our results indicate that the interaction of Gag with cyclophilin A is necessary for the formation of infectious HIV-1 virions.			FRANKE, EK (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,701 W 168TH ST,NEW YORK,NY 10032, USA.			Luban, Jeremy/0000-0001-5650-4054				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DEWHURST S, 1990, NATURE, V345, P636, DOI 10.1038/345636a0; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; FRANKE EK, 1994, J VIROL, V68, P5300, DOI 10.1128/JVI.68.8.5300-5305.1994; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; HASEL KW, 1991, MOL CELL BIOL, V11, P3484, DOI 10.1128/MCB.11.7.3484; JIN MJ, 1994, EMBO J, V13, P2935, DOI 10.1002/j.1460-2075.1994.tb06588.x; KARPAS A, 1992, P NATL ACAD SCI USA, V89, P8351, DOI 10.1073/pnas.89.17.8351; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; KOLETSKY AJ, 1986, J IMMUNOL, V137, P1054; KORNFELD H, 1987, NATURE, V326, P610, DOI 10.1038/326610a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LUBAN J, 1994, J VIROL, V68, P3784, DOI 10.1128/JVI.68.6.3784-3793.1994; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; LUBAN J, 1991, J VIROL, V65, P3203, DOI 10.1128/JVI.65.6.3203-3212.1991; MAMMANO F, 1994, J VIROL, V68, P4927, DOI 10.1128/JVI.68.8.4927-4936.1994; MYERS G, 1993, HUMAN RETROVIRUSES A; PANET A, 1975, J VIROL, V16, P146, DOI 10.1128/JVI.16.1.146-152.1975; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; ROSENWIRTH B, 1994, ANTIMICROB AGENTS CH, V38, P1763, DOI 10.1128/AAC.38.8.1763; SCHWARTZ S, 1992, J VIROL, V66, P7176, DOI 10.1128/JVI.66.12.7176-7182.1992; SYKES K, 1993, P NATL ACAD SCI USA, V90, P5853, DOI 10.1073/pnas.90.12.5853	26	614	635	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					359	362		10.1038/372359a0	http://dx.doi.org/10.1038/372359a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PU287	7969494				2022-12-01	WOS:A1994PU28700055
J	DAVIS, AA; TEMPLE, S				DAVIS, AA; TEMPLE, S			A SELF-RENEWING MULTIPOTENTIAL STEM-CELL IN EMBRYONIC RAT CEREBRAL-CORTEX	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; NEURAL CREST; NEURONS; LINEAGE; DIFFERENTIATION; GENERATION; ASTROCYTES; PROGENITOR; RETINA; OLIGODENDROCYTES	NEUROECTODERM cells in the cortical ventricular zone generate many diverse cell types, maintain the ventricular zone during embryonic life and create another germinal layer, the subventricular zone, which persists into adulthood(1,2). In other vertebrate tissues, including skin, intestine, blood and neural crest, stem cells are important in maintaining a germinal population and generating differentiated progeny(3-6). By following the fates of single ventricular zone cells in culture, we show here that self-renewing, multipotential stem cells are present in the embryonic rat cerebral cortex. Forty per cent of these stem cells produced all three principal cell types of the central nervous system: neurons, astrocytes and oligodendrocytes. Stem cells constituted about 7% of cortical clones; in contrast, over 80% consisted of small numbers of neurons or glia. We suggest that multipotential stem cells may be the ancestors of other cortical progenitor cells that exhibit more limited proliferation and more restricted repertoires of progeny fates.	ALBANY MED COLL,DIV NEUROSURG,ALBANY,NY 12208	Albany Medical College	DAVIS, AA (corresponding author), ALBANY MED COLL,DEPT PHARMACOL,ALBANY,NY 12208, USA.							ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; AUSTIN CP, 1990, DEVELOPMENT, V110, P713; Bayer S.A., 1991, NEOCORTICAL DEV, V1; CEPKO CL, 1990, COLD SH Q B, V55, P265; DAVIS AA, 1993, SOC NEUR ABSTR, V19; DEXTER TM, 1987, ANNU REV CELL BIOL, V3, P423; HALL PA, 1989, DEVELOPMENT, V106, P619; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; Jacobson M., 1991, DEV NEUROBIOLOGY; KAWAMOTO JC, 1986, BRAIN RES, V384, P84, DOI 10.1016/0006-8993(86)91222-9; LAJTHA LG, 1979, DIFFERENTIATION, V14, P23, DOI 10.1111/j.1432-0436.1979.tb01007.x; LEBER SM, 1990, J NEUROSCI, V10, P2451; LUMSDEN A, 1994, DEVELOPMENT, V120, P1581; LUSKIN MB, 1993, J NEUROSCI, V13, P1730; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; OGAWA M, 1983, BLOOD, V61, P823; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; PRICE J, 1988, DEVELOPMENT, V104, P473; PRICE J, 1991, DEVELOPMENT S, V2, P23; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; TEMPLE S, 1994, DEVELOPMENT, V120, P999; TEMPLE S, 1989, NATURE, V340, P471, DOI 10.1038/340471a0; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; WILLIAMS BP, 1991, NEURON, V7, P685, DOI 10.1016/0896-6273(91)90381-9	29	482	547	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 17	1994	372	6503					263	266		10.1038/372263a0	http://dx.doi.org/10.1038/372263a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PR889	7969470				2022-12-01	WOS:A1994PR88900050
J	ELLINOR, PT; ZHANG, JF; HORNE, WA; TSIEN, RW				ELLINOR, PT; ZHANG, JF; HORNE, WA; TSIEN, RW			STRUCTURAL DETERMINANTS OF THE BLOCKADE OF N-TYPE CALCIUM CHANNELS BY A PEPTIDE NEUROTOXIN	NATURE			English	Article							OMEGA-CONOTOXIN GVIA; CA2+ CHANNELS; FUNCTIONAL EXPRESSION; PERIPHERAL NEURONS; BRAIN; SUBUNIT; SENSITIVITY; SELECTIVITY; SYNAPSES	NEUROTOXINS that selectively block Na+, K+ or Ca2+ channels have provided valuable information about the functional diversity of the voltage-gated channel superfamily(1). For Ca2+ channels, a variety of toxins have been found to block individual channel types(2,3). The best-known example is omega-conotoxin-GVIA, a member of a large family of peptide toxins derived from venomous cone snails(2,3), which potently and selectively blocks N-type Ca2+ channels(4-9), allowing their purification(10,11), cellular localization(12,13), and the elucidation of their roles in Ca2+ entry(14), neurotransmitter release(15,16) and neuronal migration(17). In contrast to Na+ and K+ channels, little is known about the molecular features that underlie Ca2+-channel susceptibility to toxin block; it is also unknown whether block occurs by direct physical occlusion(3) or an action on channel gating(18). Here we describe structural determinants of the N-type Ca2+ channel's interaction with omega-conotoxin-GVIA. When chimaeras combining individual motifs from the N-type channel and from a channel insensitive to omega-conotoxin-GVIA were expressed in Xenopus oocytes, each of the four motifs appeared to contribute to interaction with the toxin. The most dramatic effects on toxin interactions were seen at a single cluster of residues in the large putative extracellular loop between IIIS5 and IIIH5, consistent with a direct pore-blocking mechanism. These results provide a starting point for delineating the architecture of the outer vestibule of the Ca2+ channel.	STANFORD UNIV,MED CTR,DEPT CELLULAR & MOLEC PHYSIOL,STANFORD,CA 94305; NEUREX CORP,MENLO PK,CA 94025	Stanford University				Ellinor, Patrick/0000-0002-2067-0533				AOSAKI T, 1989, PFLUG ARCH EUR J PHY, V414, P150, DOI 10.1007/BF00580957; BOLAND LM, IN PRESS J NEUROSCI; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; FUJITA Y, 1993, NEURON, V10, P585, DOI 10.1016/0896-6273(93)90162-K; Hille B., 1992, IONIC CHANNELS EXCIT; HIMING LD, 1988, SCIENCE, V239, P57; KIM MS, 1993, FEBS LETT, V318, P145, DOI 10.1016/0014-5793(93)80009-J; KOMORU H, 1992, SCIENCE, V257, P806; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MCCLESKEY EW, 1987, P NATL ACAD SCI USA, V84, P4327, DOI 10.1073/pnas.84.12.4327; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; MILLER C, 1994, BIOPHYS J, V66, pA23; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; OLIVERA BM, 1984, BIOCHEMISTRY-US, V23, P5087, DOI 10.1021/bi00317a001; OLIVERA BM, IN PRESS A REV BIOCH; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; REGAN LJ, 1991, NEURON, V6, P269, DOI 10.1016/0896-6273(91)90362-4; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; STANLEY EF, 1991, J NEUROSCI, V11, P985; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754; WITCHER DR, 1993, NEUROPHARMACOLOGY, V32, P1127, DOI 10.1016/0028-3908(93)90007-P; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; YOSHIKAMI D, 1989, ANN NY ACAD SCI, V560, P230, DOI 10.1111/j.1749-6632.1989.tb24100.x; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L	29	165	169	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 17	1994	372	6503					272	275		10.1038/372272a0	http://dx.doi.org/10.1038/372272a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PR889	7969473				2022-12-01	WOS:A1994PR88900053
J	FANJUL, A; DAWSON, MI; HOBBS, PD; JONG, L; CAMERON, JF; HARLEV, E; GRAUPNER, G; LU, XP; PFAHL, M				FANJUL, A; DAWSON, MI; HOBBS, PD; JONG, L; CAMERON, JF; HARLEV, E; GRAUPNER, G; LU, XP; PFAHL, M			A NEW CLASS OF RETINOIDS WITH SELECTIVE-INHIBITION OF AP-1 INHIBITS PROLIFERATION	NATURE			English	Article							ACID RECEPTOR-ALPHA; ISOTRETINOIN; PREVENTION; PATHWAYS; ANALOGS; LIGANDS; CANCER	RETINOIDS regulate many biological processes, including differentiation, morphogenesis and cell proliferation(1-3). They are also important therapeutic agents, but their clinical usefulness is limited because of side effects(4-8). Retinoid activities are mediated by specific nuclear receptors, the RARs and RXRs, which can induce transcriptional activation through specific DNA sites(3,9-11) or by inhibiting the transcription factor AP-1 (refs 12-15), which usually mediates cell proliferation signals(16). Because the two types of receptor actions are mechanistically distinct(12,15) we investigated whether conformationally restricted retinoids, selective for each type of receptor action, could be identified, Here we describe a new class of retinoids that selectively inhibits AP-1 activity but does not activate transcription. These retinoids do not induce differentiation in F9 cells but inhibit effectively the proliferation of several tumour cell lines, and could thus serve as candidates for new retinoid therapeutic agents with reduced side effects.	SRI INT,DIV LIFE SCI,MENLO PK,CA 94025; LA JOLLA CANC RES FDN,CTR CANC,LA JOLLA,CA 92037	SRI International; Sanford Burnham Prebys Medical Discovery Institute								ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; BOLLAG W, 1992, ANN ONCOL, V3, P513, DOI 10.1093/oxfordjournals.annonc.a058252; Dawson M. I., 1990, CHEM BIOL SYNTHETIC; DELESCLUSE C, 1991, MOL PHARMACOL, V40, P556; GRAUPNER G, 1991, BIOCHEM BIOPH RES CO, V179, P1554, DOI 10.1016/0006-291X(91)91750-7; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUSSMAN M, 1991, MOL CELL BIOL, V11, P4097; KRAEMER KH, 1988, NEW ENGL J MED, V318, P1633, DOI 10.1056/NEJM198806233182501; LEE MO, 1994, P NATL ACAD SCI USA, V91, P5632, DOI 10.1073/pnas.91.12.5632; LEHMANN JM, 1991, CANCER RES, V51, P4804; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; Morris-Kay G., 1992, RETINOIDS NORMAL DEV; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Pfahl Magnus, 1994, Seminars in Cell Biology, V5, P95, DOI 10.1006/scel.1994.1013; ROBERTS AB, 1984, RETINOIDS, V2, P209; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; TITCOMB MW, 1994, MOL ENDOCRINOL, V8, P870, DOI 10.1210/me.8.7.870; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; YANGYEN HF, 1991, NEW BIOL, V3, P1206; [No title captured]	28	315	327	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					107	111		10.1038/372107a0	http://dx.doi.org/10.1038/372107a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969403				2022-12-01	WOS:A1994PQ34800084
J	CARNON, AG; SSEMWOGERERE, A; LAMONT, DW; HOLE, DJ; MALLON, EA; GEORGE, WD; GILLIS, CR				CARNON, AG; SSEMWOGERERE, A; LAMONT, DW; HOLE, DJ; MALLON, EA; GEORGE, WD; GILLIS, CR			RELATION BETWEEN SOCIOECONOMIC DEPRIVATION AND PATHOLOGICAL PROGNOSTIC FACTORS IN WOMEN WITH BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article							LATE-STAGE DIAGNOSIS; SOCIAL-CLASS; SURVIVAL; RACE; DELAY; AGE	Objective-To investigate the relation between socioeconomic deprivation and pathological prognostic factors in women with breast cancer as a possible explanation for socioeconomic differences in survival. Design-Retrospective analysis of data from cancer registry and from pathology and biochemistry records. Setting-Catchment areas of two large teaching hospitals in Glasgow. Subjects-1361 women aged under 75 who had breast cancer diagnosed between 1980 and 1987. Main outcome measures-Tumour size, axillary lymph node status, histological grade, and oestrogen receptor concentration in relation to deprivation category of area of residence. Results-There was no significant relation between socioeconomic deprivation and four pathological prognostic factors: 93 (32%) women in the most affluent group presented with tumours less than 20 mm in size compared with 91 (31%) women in the most deprived group; 152 (48%) of the most affluent group presented with negative nodes compared with 129 (46%) of the most deprived group; 23 (22%) of the most affluent group presented with grade I tumours compared with 12 (17%) of the most deprived group; and 142 (51%) of the most affluent group had a low oestrogen receptor concentration at presentation compared with 148 (52%) of the most deprived group. None of these differences was statistically significant. Conclusions-Differences in survival from breast cancer by socioeconomic deprivation category could not be accounted for by differences in tumour stage or biology. Other possible explanations, such as differences in treatment or in host response, should be investigated.	RUCHILL HOSP,W SCOTLAND CANC SURVEILLANCE UNIT,GLASGOW G20 9NB,LANARK,SCOTLAND; UNIV GLASGOW,WESTERN INFIRM,DEPT PATHOL,GLASGOW G11 6NT,LANARK,SCOTLAND; UNIV GLASGOW,WESTERN INFIRM,DEPT SURG,GLASGOW G11 6NT,LANARK,SCOTLAND	University of Glasgow; University of Glasgow; University of Glasgow								AYANIAN JZ, 1993, NEW ENGL J MED, V329, P326, DOI 10.1056/NEJM199307293290507; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; Carstairs V., 1991, DEPRIVATION HLTH SCO; COATES RJ, 1992, JNCI-J NATL CANCER I, V84, P938, DOI 10.1093/jnci/84.12.938; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; FARLEY TA, 1989, AM J PUBLIC HEALTH, V79, P1508, DOI 10.2105/AJPH.79.11.1508; GORDON NH, 1992, AM J EPIDEMIOL, V135, P609, DOI 10.1093/oxfordjournals.aje.a116340; KARJALAINEN S, 1990, CANCER-AM CANCER SOC, V66, P819, DOI 10.1002/1097-0142(19900815)66:4<819::AID-CNCR2820660437>3.0.CO;2-E; KEIRN W, 1985, CANCER, V55, P1552, DOI 10.1002/1097-0142(19850401)55:7<1552::AID-CNCR2820550723>3.0.CO;2-E; KOGEVINAS M, 1991, J EPIDEMIOL COMMUN H, V45, P216, DOI 10.1136/jech.45.3.216; MANDELBLATT J, 1991, AM J PUBLIC HEALTH, V81, P646, DOI 10.2105/AJPH.81.5.646; MITTRA I, 1991, EUR J CANCER, V27, P1583; MOHLA S, 1982, CANCER-AM CANCER SOC, V50, P552, DOI 10.1002/1097-0142(19820801)50:3<552::AID-CNCR2820500328>3.0.CO;2-G; NATARAJAN N, 1985, CANCER-AM CANCER SOC, V56, P1704, DOI 10.1002/1097-0142(19851001)56:7<1704::AID-CNCR2820560740>3.0.CO;2-L; OWNBY HE, 1985, J NATL CANCER I, V75, P55; RICHARDSON JL, 1992, BRIT J CANCER, V65, P922, DOI 10.1038/bjc.1992.193; TOMATIS L, 1990, CANCER CAUSES OCCURR; VAGERO D, 1987, J EPIDEMIOL COMMUN H, V41, P204, DOI 10.1136/jech.41.3.204; VERNON SW, 1985, CANCER-AM CANCER SOC, V55, P1563, DOI 10.1002/1097-0142(19850401)55:7<1563::AID-CNCR2820550726>3.0.CO;2-1; WELLS BL, 1992, AM J PUBLIC HEALTH, V82, P1383, DOI 10.2105/AJPH.82.10.1383; 1987, TNM CLASSIFICATION M; 1991, BREAST CANCER SCREEN	22	60	61	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 22	1994	309	6961					1054	1057		10.1136/bmj.309.6961.1054	http://dx.doi.org/10.1136/bmj.309.6961.1054			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PN733	7950739	Green Published			2022-12-01	WOS:A1994PN73300022
J	CHEN, C; RAINNIE, DG; GREENE, RW; TONEGAWA, S				CHEN, C; RAINNIE, DG; GREENE, RW; TONEGAWA, S			ABNORMAL FEAR RESPONSE AND AGGRESSIVE-BEHAVIOR IN MUTANT MICE DEFICIENT FOR ALPHA-CALCIUM-CALMODULIN KINASE-II	SCIENCE			English	Article							DORSAL RAPHE NEURONS; RAT-BRAIN; TRYPTOPHAN-HYDROXYLASE; CONDITIONED FEAR; PROTEIN-KINASE; SEROTONIN; PHOSPHORYLATION; DISORDERS; MONOAMINE; SLICES	Mice deficient for the gene encoding alpha-calcium-calmodulin-dependent kinase II (alpha-CaMKII knockout mice) provide a promising tool to link behavioral and cellular abnormalities with a specific molecular lesion. The heterozygous mouse exhibited a well-circumscribed syndrome of behavioral abnormalities, consisting primarily of a decreased fear response and an increase in defensive aggression, in the absence of any measured cognitive deficits. Unlike the heterozygote, the homozygote displayed abnormal behavior in all paradigms tested. At the cellular level, both extracellular and whole-cell patch clamp recordings indicated that serotonin release in putative serotonergic neurons of the dorsal raphe was reduced. Thus, alpha-CaMKII knockout mice, in particular the heterozygote, may provide a model for studying the molecular and cellular basis underlying emotional disorders involving fear and aggression.	MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; HARVARD UNIV, SCH MED, DEPT PSYCHIAT, BROCKTON, MA 02401 USA; VET ADM MED CTR, BROCKTON, MA 02401 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	CHEN, C (corresponding author), MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA.		Rainnie, Donald/L-3853-2016	Rainnie, Donald/0000-0003-0758-0530; Greene, Robert/0000-0003-1355-9797				ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; AGHAJANIAN GK, 1984, BRAIN RES, V305, P181, DOI 10.1016/0006-8993(84)91137-5; BARNETT SA, 1975, RAT STUDY BEHAVIOR; BENTON D, 1985, PHARM BIOCH BEHAV, V23, P979; BOLLES RC, 1970, PSYCHOL REV, V77, P32, DOI 10.1037/h0028589; BRAIN PF, 1989, E M I LIF S, V6, P1; BROWN GL, 1990, J CLIN PSYCHIAT, V51, P31; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; CHARNEY DS, 1990, ANN NY ACAD SCI, V600, P558, DOI 10.1111/j.1749-6632.1990.tb16910.x; EHRET M, 1989, J NEUROCHEM, V52, P1886, DOI 10.1111/j.1471-4159.1989.tb07272.x; FANSELOW MS, 1992, BEHAV NEUROSCI, V106, P336, DOI 10.1037/0735-7044.106.2.336; FANSELOW MS, 1986, ANN NY ACAD SCI, V467, P40, DOI 10.1111/j.1749-6632.1986.tb14617.x; FANSELOW MS, 1984, TRENDS NEUROSCI, V7, P460; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; GRANT L D, 1973, Pharmacology Biochemistry and Behavior, V1, P77, DOI 10.1016/0091-3057(73)90059-2; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Hen R., 1993, Society for Neuroscience Abstracts, V19, P632; HIGLEY JD, 1992, ARCH GEN PSYCHIAT, V49, P436; INOUE T, 1993, PHARMACOL BIOCHEM BE, V44, P371, DOI 10.1016/0091-3057(93)90476-A; ISOBE T, 1991, J MOL BIOL, V217, P125, DOI 10.1016/0022-2836(91)90616-E; KIM JJ, 1991, BEHAV NEUROSCI, V105, P126, DOI 10.1037/0735-7044.105.1.126; KOOLHAAS M, 1991, NEUROMETHODS, V19, P249; KOSTOWSKI W, 1980, PHYSIOL BEHAV, V25, P161, DOI 10.1016/0031-9384(80)90201-2; KSHAMA D, 1990, BEHAV NEURAL BIOL, V54, P234, DOI 10.1016/0163-1047(90)90617-F; MICZEK KA, 1994, NEUROSCI BIOBEHAV R, V18, P97, DOI 10.1016/0149-7634(94)90040-X; NEVINS ME, 1994, J PHARMACOL EXP THER, V268, P248; NORMAN TR, 1989, INT J CLIN PHARM RES, V9, P151; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; TREIT D, 1993, BEHAV BRAIN RES, V54, P23, DOI 10.1016/0166-4328(93)90045-R; VANDERMAELEN CP, 1983, BRAIN RES, V289, P109, DOI 10.1016/0006-8993(83)90011-2; VANPRAAG HM, 1990, BRIT J PSYCHIAT, V157, P723, DOI 10.1192/bjp.157.5.723; WALLETSCHEK H, 1982, PHYSIOL BEHAV, V28, P697, DOI 10.1016/0031-9384(82)90054-3; WALSH RN, 1976, PSYCHOL BULL, V83, P482, DOI 10.1037/0033-2909.83.3.482; WESTENBERG HGM, 1989, PSYCHOPATHOLOGY, V22, P68, DOI 10.1159/000284628; WILLIAMS JT, 1988, J NEUROSCI, V8, P3499	36	221	230	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 14	1994	266	5183					291	294		10.1126/science.7939668	http://dx.doi.org/10.1126/science.7939668			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939668				2022-12-01	WOS:A1994PM13400039
J	KUROKAWA, R; DIRENZO, J; BOEHM, M; SUGARMAN, J; GLOSS, B; ROSENFELD, MG; HEYMAN, RA; GLASS, CK				KUROKAWA, R; DIRENZO, J; BOEHM, M; SUGARMAN, J; GLOSS, B; ROSENFELD, MG; HEYMAN, RA; GLASS, CK			REGULATION OF RETINOID SIGNALING BY RECEPTOR POLARITY AND ALLOSTERIC CONTROL OF LIGAND-BINDING	NATURE			English	Article							THYROID-HORMONE; X-RECEPTOR; RESPONSE ELEMENTS; NUCLEAR RECEPTOR; DNA-BINDING; DIRECT REPEAT; AMINO-ACIDS; BETA-GENE; RXR-BETA; RAR	RETINOIC acid receptors (RARs) and retinoid X receptors (RXRs) regulate transcription by binding to response elements in target genes that generally consist of two direct repeat half-sites of consensus sequence AGGTCA (ref. 1). RAR/RXR heterodimers activate transcription in response to all-irans or 9-cis retinoic acid by binding to direct repeats spaced by five base pairs (DR5 elements)(2-8), such that RAR occupies the downstream half-site(9-12). RXR homodimers activate transcription in response to 9-cis retinoic acid by binding to direct repeats spaced by one base pair (DR1 elements)(8,13,14). Although RXR/RAR heterodimers bind to DR1 elements with higher affinity than RXR homodimers, in most contexts they are unable to activate transcription in response to either all-trans or 9-cis retinoic acid(3-5). AS a result, RARs inhibit RXR-dependent transcription from these sites(13,15). We report that the switching of the RAR from an activator to an inhibitor of retinoid-dependent transcription requires that it be bound to the upstream half-site of DR1 elements and that it allosterically block the binding of ligand to the RXR.	UNIV CALIF SAN DIEGO,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; LIGAND PHARMACEUT,DEPT CELL BIOL,SAN DIEGO,CA 92121	University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; Ligand Pharmaceuticals			Glass, Christopher/AAI-3933-2021	Glass, Christopher/0000-0003-4344-3592				DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; GLASS C. K., 1994, ENDOCR REV, V15, P1503; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; KLLEWER SA, 1992, NATURE, V355, P446; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PREDKI PF, 1994, MOL ENDOCRINOL, V8, P31, DOI 10.1210/me.8.1.31; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WILLIS MC, 1993, SCIENCE, V262, P1255, DOI 10.1126/science.7694369; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	26	391	403	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					528	531		10.1038/371528a0	http://dx.doi.org/10.1038/371528a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7935766				2022-12-01	WOS:A1994PK58900059
J	GREEN, JM				GREEN, JM			SERUM SCREENING FOR DOWNS-SYNDROME - EXPERIENCES OF OBSTETRICIANS IN ENGLAND AND WALES	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To assess the experiences of obstetricians in England and Wales of serum screening for Down's syndrome. Design-Postal questionnaire survey. Subjects-Questionnaires were sent to all practising obstetricians in England and Wales with nonacademic appointments who had not participated in an earlier (randomly sampled) survey of obstetricians' attitudes (n = 555). Responses were received from 393 (71%), of which 351 were analysed. The data represent about one third of obstetric consultants in England and Wales. Main outcome measures-The extent of use of serum screening for Down's syndrome, and the problems encountered. Results-Serum screening for Down's syndrome was being offered on some basis by virtually all obstetricians in the survey. Nearly half the sample said that they did not have adequate resources for counselling all the women to whom screening was offered. Many problems were reported, which in all cases were more common than equivalent problems encountered with serum screening for neural tube defects. Over 80% (289) said that women not understanding the test was a problem. Conclusions-There is considerable confusion associated with serum screening for Down's syndrome. The precedent of serum screening for neural tube defects does not seem to have lessened the problems experienced, rather the contrary. Many obstetricians report inadequate resources for counselling, which is consistent with the high prevalence of problems associated with women not understanding the test. There is an urgent need to consider what counselling should consist of and who should undertake it and to ensure that necessary resources are available.			GREEN, JM (corresponding author), UNIV CAMBRIDGE,CTR FAMILY RES,CAMBRIDGE CB2 3RF,ENGLAND.							GREEN JM, 1993, LANCET, V342, P1179, DOI 10.1016/0140-6736(93)92164-O; GREEN JM, 1990, OCCASIONAL PAPERS, V2; GREEN JM, 1994, PRENATAL DIAGNOSIS H, P37; MARTEAU TM, 1992, PUBLIC HEALTH, V106, P131, DOI 10.1016/S0033-3506(05)80390-7; STATHAM H, 1993, BRIT MED J, V307, P174, DOI 10.1136/bmj.307.6897.174; WALD N, 1992, LANCET, V340, P494, DOI 10.1016/0140-6736(92)91822-P; 1994, GENETIC SCREENING ET	7	67	67	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					769	772		10.1136/bmj.309.6957.769	http://dx.doi.org/10.1136/bmj.309.6957.769			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ282	7950560	Green Published			2022-12-01	WOS:A1994PJ28200017
J	ASAI, T; BATES, DB; KOGOMA, T				ASAI, T; BATES, DB; KOGOMA, T			DNA-REPLICATION TRIGGERED BY DOUBLE-STRANDED BREAKS IN ESCHERICHIA-COLI - DEPENDENCE ON HOMOLOGOUS RECOMBINATION FUNCTIONS	CELL			English	Article							ESCHERICHIA-COLI; RECBCD ENZYME; BACTERIOPHAGE-LAMBDA; RECD MUTANTS; GENETIC-RECOMBINATION; PURIFIED SUBUNITS; INITIATION SITE; EXONUCLEASE-V; CHI; REPAIR	Homologous recombination-dependent DMA replication (RDR) of a lambda cos site-carrying plasmid is demonstrated in E. coli cells when the cells express lambda terminase that introduces a double-stranded break into the cos site. RDR occurs in normal wild-type cells if the plasmid also contains the recombination hotspot chi. chi is dispensable when cells are induced for the SOS. response or contain a recD mutation. recBC sbcA mutant cells are also capable of RDR induction. A recN mutation greatly reduces RDR in normal cells, but not in SOS-induced cells. RDR proceeds by the theta mode or rolling circle mode of DNA synthesis, yielding covalently closed circular plasmid monomers or linear plasmid multimers, respectively. Previously described inducible stable DNA replication is considered to be a special type of RDR that starts exclusively from specific sites (oriMs) on the chromosome.	UNIV NEW MEXICO, SCH MED, DEPT CELL BIOL, ALBUQUERQUE, NM 87131 USA; UNIV NEW MEXICO, SCH MED, DEPT MICROBIOL, ALBUQUERQUE, NM 87131 USA; UNIV NEW MEXICO, SCH MED, CTR CANC RES & TREATMENT, ALBUQUERQUE, NM 87131 USA	University of New Mexico; University of New Mexico; University of New Mexico				Bates, David/0000-0002-0870-055X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022092] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM022092-22, GM22092] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMUNDSEN SK, 1986, P NATL ACAD SCI USA, V83, P5558, DOI 10.1073/pnas.83.15.5558; ASAI T, 1994, J MOL BIOL, V235, P1459, DOI 10.1006/jmbi.1994.1101; ASAI T, 1993, EMBO J, V12, P3287, DOI 10.1002/j.1460-2075.1993.tb05998.x; ASAI T, 1994, J BACTERIOL, V176, P1807, DOI 10.1128/jb.176.7.1807-1812.1994; BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; BAILONE A, 1988, MOL GEN GENET, V214, P389, DOI 10.1007/BF00330471; BECKER A, 1990, J BACTERIOL, V172, P2819, DOI 10.1128/jb.172.6.2819-2824.1990; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BOEHMER PE, 1991, GENE, V102, P1, DOI 10.1016/0378-1119(91)90529-K; CHAUDHURY AM, 1984, P NATL ACAD SCI-BIOL, V81, P7850, DOI 10.1073/pnas.81.24.7850; CLARK AJ, 1993, J BACTERIOL, V175, P7673, DOI 10.1128/JB.175.23.7673-7682.1993; CLARK AJ, 1991, BIOCHIMIE, V73, P523, DOI 10.1016/0300-9084(91)90124-J; COHEN A, 1986, J BACTERIOL, V167, P327, DOI 10.1128/jb.167.1.327-335.1986; COX MM, 1993, BIOESSAYS, V15, P617, DOI 10.1002/bies.950150908; DABERT P, 1992, P NATL ACAD SCI USA, V89, P12073, DOI 10.1073/pnas.89.24.12073; DIXON DA, 1991, CELL, V66, P361, DOI 10.1016/0092-8674(91)90625-9; DIXON DA, 1993, CELL, V73, P87, DOI 10.1016/0092-8674(93)90162-J; DIXON DA, 1994, P NATL ACAD SCI USA, V91, P2980, DOI 10.1073/pnas.91.8.2980; FAULDS D, 1979, J MOL BIOL, V131, P681, DOI 10.1016/0022-2836(79)90197-9; FEISS M, 1983, LAMBDA, V2, P305; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; GILLEN JR, 1981, J BACTERIOL, V145, P521, DOI 10.1128/JB.145.1.521-532.1981; HALL SD, 1994, P NATL ACAD SCI USA, V91, P3205, DOI 10.1073/pnas.91.8.3205; HUISMAN O, 1983, J BACTERIOL, V153, P169, DOI 10.1128/JB.153.1.169-175.1983; JOSEPH JW, 1983, J BIOL CHEM, V258, P418; KANNAN P, 1990, CURR MICROBIOL, V21, P7, DOI 10.1007/BF02090093; Kobayashi I, 1992, Adv Biophys, V28, P81, DOI 10.1016/0065-227X(92)90023-K; Kornberg A., 1992, DNA REPLICATION; KOWALCZYKOWSKI SC, 1994, IN PRESS MICROBIOL R; KRASIN F, 1977, J MOL BIOL, V116, P81, DOI 10.1016/0022-2836(77)90120-6; KREUZER KN, 1994, IN PRESS MOL BIOL T, V4; KUSANO K, 1989, J MOL BIOL, V209, P623, DOI 10.1016/0022-2836(89)90000-4; KUSANO K, 1994, P NATL ACAD SCI USA, V91, P1173, DOI 10.1073/pnas.91.3.1173; KUZMINOV A, 1994, EMBO J, V13, P2764, DOI 10.1002/j.1460-2075.1994.tb06570.x; LOVETT ST, 1988, GENETICS, V120, P37; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; MAGEE TR, 1992, EMBO J, V11, P4219, DOI 10.1002/j.1460-2075.1992.tb05516.x; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MASTERSON C, 1992, J BIOL CHEM, V267, P13564; MEYEROWITZ EM, 1980, GENE, V11, P271, DOI 10.1016/0378-1119(80)90067-0; Miller JH., 1972, EXPT MOL GENETICS; Mosig G, 1983, BACTERIOPHAGE, V4, P120; MURIALDO H, 1988, MOL GEN GENET, V213, P42, DOI 10.1007/BF00333396; MURIALDO H, 1984, GENE, V30, P183, DOI 10.1016/0378-1119(84)90119-7; PALAS KM, 1990, J BIOL CHEM, V265, P3447; PICKSLEY SM, 1984, MOL GEN GENET, V195, P267, DOI 10.1007/BF00332758; PONTICELLI AS, 1985, CELL, V41, P145, DOI 10.1016/0092-8674(85)90069-8; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; RINKEN R, 1992, J BACTERIOL, V174, P1172, DOI 10.1128/jb.174.4.1172-1178.1992; RINKEN R, 1992, J BACTERIOL, V174, P5424, DOI 10.1128/JB.174.16.5424-5429.1992; SARGENTINI NJ, 1986, RADIAT RES, V107, P58, DOI 10.2307/3576850; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SILBERSTEIN Z, 1987, J BACTERIOL, V169, P3131, DOI 10.1128/jb.169.7.3131-3137.1987; SINGER M, 1989, MICROBIOL REV, V53, P1; SMITH GR, 1988, MICROBIOL REV, V52, P1; SMITH GR, 1991, CELL, V64, P19, DOI 10.1016/0092-8674(91)90205-D; STAHL FW, 1990, GENETICS, V126, P519; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; TAYLOR AF, 1985, CELL, V41, P153, DOI 10.1016/0092-8674(85)90070-4; TAYLOR AF, 1992, P NATL ACAD SCI USA, V89, P5226, DOI 10.1073/pnas.89.12.5226; THALER DS, 1989, GENOME, V31, P53, DOI 10.1139/g89-013; THALER DS, 1988, ANNU REV GENET, V22, P169, DOI 10.1146/annurev.ge.22.120188.001125; UMEZU K, 1993, J MOL BIOL, V230, P1145, DOI 10.1006/jmbi.1993.1231; WILLETTS NS, 1969, J BACTERIOL, V100, P231, DOI 10.1128/JB.100.1.231-239.1969; WU TC, 1994, SCIENCE, V263, P515, DOI 10.1126/science.8290959; YAGIL E, 1985, GENET RES, V45, P1, DOI 10.1017/S0016672300021911	67	101	102	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 23	1994	78	6					1051	1061		10.1016/0092-8674(94)90279-8	http://dx.doi.org/10.1016/0092-8674(94)90279-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923355	Green Accepted			2022-12-01	WOS:A1994PJ29400015
J	MARAN, A; MAITRA, RK; KUMAR, A; DONG, BH; XIAO, W; LI, GY; WILLIAMS, BRG; TORRENCE, PF; SILVERMAN, RH				MARAN, A; MAITRA, RK; KUMAR, A; DONG, BH; XIAO, W; LI, GY; WILLIAMS, BRG; TORRENCE, PF; SILVERMAN, RH			BLOCKAGE OF NF-KAPPA-B SIGNALING BY SELECTIVE ABLATION OF AN MESSENGER-RNA TARGET BY 2-5A ANTISENSE CHIMERAS	SCIENCE			English	Article							ACTIVATED PROTEIN-KINASE; CONSTITUTIVE EXPRESSION; BETA-INTERFERON; RNA; GENE; 2',5'-OLIGOADENYLATE; CELLS; RESISTANCE; INDUCTION; PROMOTER	Activation of 2-5A-dependent ribonuclease by 5'-phosphorylated, 2',5'-linked oligoadenylates, known as 2-5A, is one pathway of interferon action. Unaided uptake into HeLa cells of 2-5A linked to an antisense oligonucleotide resulted in the selective ablation of messenger RNA for the double-stranded RNA (dsRNA)-dependent protein kinase PKR. Similarly, purified, recombinant human 2-5A-dependent ribonuclease was induced to selectively cleave PKR messenger RNA. Cells depleted of PKR activity were unresponsive to activation of nuclear factor-kappa B (NF-kappa B) by the dsRNA poly(l):poly(C), which provides direct evidence that PKR is a transducer for the dsRNA signaling of NF-kappa B.	CLEVELAND CLIN FDN,DEPT CANC BIOL,CLEVELAND,OH 44195; NIDDKD,BIOMED CHEM SECT,BETHESDA,MD 20892	Cleveland Clinic Foundation; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151	NATIONAL CANCER INSTITUTE [R01CA044059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034039, R01AI028253, R21AI034039] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44059] Funding Source: Medline; NIAID NIH HHS [AI 34039-02, AI 28253] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CAYLEY PJ, 1982, BIOCHEM BIOPH RES CO, V108, P1243, DOI 10.1016/0006-291X(82)92133-7; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CLEMENS MJ, 1978, CELL, V13, P565, DOI 10.1016/0092-8674(78)90329-X; COCCIA EM, 1990, VIROLOGY, V179, P228, DOI 10.1016/0042-6822(90)90292-Y; DONG BH, 1994, J BIOL CHEM, V269, P14153; FLOYDSMITH G, 1981, SCIENCE, V212, P1030, DOI 10.1126/science.6165080; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; HAUGH MC, 1983, EUR J BIOCHEM, V132, P77, DOI 10.1111/j.1432-1033.1983.tb07327.x; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; Kinjo J E, 1992, Drug Des Discov, V8, P241; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOVACS T, 1993, BIOORG CHEM, V21, P192, DOI 10.1006/bioo.1993.1017; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A., UNPUB; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LESIAK K, 1993, BIOCONJUGATE CHEM, V4, P467, DOI 10.1021/bc00024a008; Maitra R., UNPUB; MARAN A, UNPUB; MARCUS PI, 1988, J GEN VIROL, V69, P1637, DOI 10.1099/0022-1317-69-7-1637; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; RYSIECKI G, 1989, J INTERFERON RES, V9, P649, DOI 10.1089/jir.1989.9.649; SAFER B, 1983, CELL, V33, P7, DOI 10.1016/0092-8674(83)90326-4; SILVERMAN RH, 1987, LYMPHOKINES INTERFER, P149; TORRENCE PF, 1993, P NATL ACAD SCI USA, V90, P1300, DOI 10.1073/pnas.90.4.1300; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WELLS JA, 1984, J BIOL CHEM, V259, P1363; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WRESCHNER DH, 1981, NATURE, V289, P414, DOI 10.1038/289414a0; XANTHOUDAKIS S, 1989, J BIOL CHEM, V264, P1139; Xiao W., UNPUB; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	37	217	225	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 5	1994	265	5173					789	792		10.1126/science.7914032	http://dx.doi.org/10.1126/science.7914032			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	7914032				2022-12-01	WOS:A1994PA37200035
J	BRAKS, JAM; MARTENS, GJM				BRAKS, JAM; MARTENS, GJM			7B2 IS A NEUROENDOCRINE CHAPERONE THAT TRANSIENTLY INTERACTS WITH PROHORMONE CONVERTASE PC2 IN THE SECRETORY PATHWAY	CELL			English	Article							PITUITARY POLYPEPTIDE 7B2; SUBTILISIN-LIKE PROTEASE; PROCESSING ENDOPROTEASES; ENDOCRINE PROTEIN; CDNA SEQUENCE; CELLS; RAT; GENE; BIOSYNTHESIS; IDENTIFICATION	The neuroendocrine polypeptide 7B2 is a highly conserved secretory protein selectively present in prohormone-producing cells equipped with a regulated secretory pathway. We find that the amino-terminal half of 7B2 is distantly related to chaperonins, a subclass of molecular chaperones. When incubated in vitro with newly synthesized pituitary proteins, recombinant 7B2 specifically associates with prohormone convertase PC2. Metabolic cell labeling combined with coimmunoprecipitation studies showed that, in vivo, the precursor form of 7B2 interacts with the preform of PC2. Pulse-chase analysis revealed that this association is transient in that it commences early in the secretory pathway, while dissociation in the later stages appears to coincide with the cleavages of 7B2, proPC2, and prohormone. Our results suggest that 7B2 is a novel type of molecular chaperone preventing premature activation of proPC2 in the regulated secretory pathway.			BRAKS, JAM (corresponding author), CATHOLIC UNIV NIJMEGEN,DEPT ANIM PHYSIOL,TOERNOOIVELD,6525 ED NIJMEGEN,NETHERLANDS.		Martens, Gerard JM/D-1925-2010	Martens, Gerard/0000-0003-1761-4570				ALARCON C, 1993, J BIOL CHEM, V268, P4276; AYOUBI TAY, 1990, J BIOL CHEM, V265, P15644; AYOUBI TAY, 1991, CELL TISSUE RES, V264, P329, DOI 10.1007/BF00313970; BARR PJ, 1991, DNA CELL BIOL, V10, P319, DOI 10.1089/dna.1991.10.319; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BRAKS JAM, 1992, FEBS LETT, V305, P45, DOI 10.1016/0014-5793(92)80652-W; BRAYTON KA, 1988, DNA-J MOLEC CELL BIO, V7, P713, DOI 10.1089/dna.1988.7.713; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CULLINAN WE, 1991, ENZYME, V45, P285, DOI 10.1159/000468902; DAVID V, 1993, J BIOL CHEM, V268, P9585; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; EIPPER BA, 1988, ANNU REV PHYSIOL, V50, P333, DOI 10.1146/annurev.ph.50.030188.002001; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.biochem.60.1.321; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLEMBOTSKI CC, 1982, J BIOL CHEM, V257, P493; GUEST PC, 1992, J BIOL CHEM, V267, P22401; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HSI KL, 1982, FEBS LETT, V147, P261, DOI 10.1016/0014-5793(82)81055-7; IGUCHI H, 1987, PEPTIDES, V8, P593, DOI 10.1016/0196-9781(87)90030-1; JENKS BG, 1993, SCIENCE, V10, P1; JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; MARCINKIEWICZ M, 1987, CELL TISSUE RES, V250, P205, DOI 10.1007/BF00214673; MARTEL R, 1990, GENE, V94, P181, DOI 10.1016/0378-1119(90)90385-5; MARTENS GJM, 1988, FEBS LETT, V234, P160, DOI 10.1016/0014-5793(88)81324-3; MARTENS GJM, 1994, P NATL ACAD SCI USA, V91, P5784, DOI 10.1073/pnas.91.13.5784; MARTENS GJM, 1989, EUR J BIOCHEM, V181, P75, DOI 10.1111/j.1432-1033.1989.tb14695.x; MATTHEWS G, 1994, J BIOL CHEM, V269, P588; MBIKAY M, 1989, INT J PEPT PROT RES, V33, P39; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SEEMULLER U, 1980, H-S Z PHYSIOL CHEM, V361, P1841; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SEIDAH NG, 1983, ARCH BIOCHEM BIOPHYS, V225, P525, DOI 10.1016/0003-9861(83)90063-2; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SENATOROV VV, 1993, J NEUROENDOCRINOL, V5, P533, DOI 10.1111/j.1365-2826.1993.tb00518.x; SHEN FS, 1993, J BIOL CHEM, V268, P24910; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; STEEL JH, 1988, ENDOCRINOLOGY, V122, P270, DOI 10.1210/endo-122-1-270; STEINER DF, 1992, J BIOL CHEM, V267, P23435; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDUIJNHOVEN HLP, 1991, J IMMUNOL METHODS, V142, P187, DOI 10.1016/0022-1759(91)90106-P; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; WALDBIESER GC, 1991, ENDOCRINOLOGY, V128, P3228, DOI 10.1210/endo-128-6-3228; ZHOU A, 1993, J BIOL CHEM, V268, P1763; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	58	192	195	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 29	1994	78	2					263	273		10.1016/0092-8674(94)90296-8	http://dx.doi.org/10.1016/0092-8674(94)90296-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	7913882				2022-12-01	WOS:A1994NZ24200010
J	SHIANG, R; THOMPSON, LM; ZHU, YZ; CHURCH, DM; FIELDER, TJ; BOCIAN, M; WINOKUR, ST; WASMUTH, JJ				SHIANG, R; THOMPSON, LM; ZHU, YZ; CHURCH, DM; FIELDER, TJ; BOCIAN, M; WINOKUR, ST; WASMUTH, JJ			MUTATIONS IN THE TRANSMEMBRANE DOMAIN OF FGFR3 CAUSE THE MOST COMMON GENETIC FORM OF DWARFISM, ACHONDROPLASIA	CELL			English	Article							GROWTH-FACTOR RECEPTOR; GRADIENT GEL-ELECTROPHORESIS; SINGLE-BASE CHANGES; HOMOZYGOUS ACHONDROPLASIA; IMMUNOGLOBULIN DOMAIN; HUNTINGTONS-DISEASE; EXPRESSION PATTERN; HUMAN CHROMOSOME-4; DNA; FAMILY	Achondroplasia (ACH) is the most common genetic form of dwarfism. This disorder is inherited as an autosomal dominant trait, although the majority of cases are sporadic. A gene for ACH was recently localized to 4p16.3 by linkage analyses. The ACH candidate region includes the gene encoding fibroblast growth factor receptor 3 (FGFR3), which was originally considered as a candidate for the Huntington's disease gene. DNA studies revealed point mutations in the FGFR3 gene in ACH heterozygotes and homozygotes. The mutation on 15 of the 16 ACH-affected chromosomes was the same, a G-->A transition, at nucleotide 1138 of the cDNA. The mutation on the only ACH-affected chromosome 4 without the G-->A transition at nucleotide 1138 had a G-->C transversion at this same position. Both mutations result in the substitution of an arginine residue for a glycine at position 380 of the mature protein, which is in the transmembrane domain of FGFR3.	UNIV CALIF IRVINE, COLL MED, DEPT PEDIAT, IRVINE, CA 92717 USA; UNIV CALIF IRVINE, HUMAN GENOME RES CTR, IRVINE, CA 92717 USA	University of California System; University of California Irvine	SHIANG, R (corresponding author), UNIV CALIF IRVINE, COLL MED, DEPT BIOL CHEM, IRVINE, CA 92717 USA.				NHGRI NIH HHS [HG00834] Funding Source: Medline; NINDS NIH HHS [NS25631] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P01HG000834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025631] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AVIVI A, 1993, FEBS LETT, V330, P249, DOI 10.1016/0014-5793(93)80882-U; BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BAXENDALE S, 1993, NAT GENET, V4, P181, DOI 10.1038/ng0693-181; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; EISEMANN A, 1991, ONCOGENE, V6, P1195; FRANCOMANO CA, 1994, HUM MOL GENET, V3, P787, DOI 10.1093/hmg/3.5.787; GAL A, 1994, NAT GENET, V7, P64, DOI 10.1038/ng0594-64; Gorlin RJ, 1990, PLAST RECONSTR SURG, V3rd; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; HECHT JT, 1987, AM J HUM GENET, V41, P454; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; LEMERRER M, 1994, NAT GENET, V6, P318; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; Lyons Jones K., 1988, SMITHS RECOGNIZABLE; MACDONALD ME, 1991, SOMAT CELL MOLEC GEN, V17, P421, DOI 10.1007/BF01233067; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MYERS RM, 1987, METHOD ENZYMOL, V155, P501; OBERKLAID F, 1979, J MED GENET, V16, P140, DOI 10.1136/jmg.16.2.140; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PAULI RM, 1983, AM J MED GENET, V16, P459, DOI 10.1002/ajmg.1320160404; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232; SHIANG R, 1993, NAT GENET, V5, P351, DOI 10.1038/ng1293-351; STANESCU R, 1990, AM J MED GENET, V37, P412, DOI 10.1002/ajmg.1320370323; THOMPSON LM, 1991, GENOMICS, V11, P1133, DOI 10.1016/0888-7543(91)90041-C; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELINOV M, 1994, NAT GENET, V6, P314, DOI 10.1038/ng0394-314; WEBER B, 1991, NUCLEIC ACIDS RES, V19, P6263, DOI 10.1093/nar/19.22.6263; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; ZUO JA, 1993, HUM MOL GENET, V2, P889, DOI 10.1093/hmg/2.7.889	39	964	1039	2	83	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 29	1994	78	2					335	342		10.1016/0092-8674(94)90302-6	http://dx.doi.org/10.1016/0092-8674(94)90302-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	7913883				2022-12-01	WOS:A1994NZ24200016
J	ROSEN, SD; PAULESU, E; FRITH, CD; FRACKOWIAK, RSJ; DAVIES, GJ; JONES, T; CAMICI, PG				ROSEN, SD; PAULESU, E; FRITH, CD; FRACKOWIAK, RSJ; DAVIES, GJ; JONES, T; CAMICI, PG			CENTRAL NERVOUS PATHWAYS MEDIATING ANGINA-PECTORIS	LANCET			English	Article							CORTEX; BRAIN; PAIN; LOCALIZATION; RAT	The central nervous pathways of angina pectoris have never been identified in vivo in man. We used positron emission tomography to examine the changes in regional cerebral blood flow associated with angina pectoris. Dynamic positron emission tomography with O-15-labelled water was used in 12 patients with angina and angiographically proven coronary artery disease to measure regional cerebral blood flow changes during angina induced by intravenous dobutamine. All subjects had typical retrosternal chest pain accompanied by ischaemic electrocardiographic changes during dobutamine infusion. Compared to the resting state, angina was associated with increased regional cerebral blood flow in the hypothalamus (percentage change in regional cerebral blood now +6.5 and Z score 7.2) periaquaductal grey (+2.6 and 4.0), bilaterally in the thalamus (left: +2.7 and 4.3; right + 3.7 and 4.7) and lateral prefrontal cortex (left +11.5 and 7.6; right +8.5 and 7.8) and left inferior anterocaudal cingulate cortex (+9.4 and 6.6). In contrast, it was reduced bilaterally in the mid-rostrocaudal cingulate cortex (left -3.7 and 6.3; right -4.7 and 4.6) and fusiform gyrus (left -3.2 and 4.0; right -3.3 and 3.7), right posterior cingulate (-3.9 and 5.8) and left parietal cortices(-4.8 and 6.3). Several minutes after stopping dobutamine infusion, when the patients no longer experienced angina and the electrocardiographic changes had resolved, thalamic, but not cortical activation could be seen. We propose that the central structures activated constitute the pathways for perception of anginal pain and that the thalamus may act as a gate to afferent pain signals, with cortical activation being necessary for the sensation of pain. This method of investigation may form a basis for research into anomalies of visceral pain perception such as silent myocardial ischaemia.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,LONDON W12 0HS,ENGLAND	Imperial College London	ROSEN, SD (corresponding author), MRC,CTR CLIN SCI,CYCLOTRON UNIT,LONDON W12 0HS,ENGLAND.		Frackowiak, Richard/H-4383-2011; Frith, Chris D/A-2171-2009; Rosen, Stuart/AAE-4649-2020; Camici, Paolo/AAN-1959-2020; Frackowiak, Richard S/I-1809-2013; PAULESU, ERALDO/C-2737-2017	Frackowiak, Richard/0000-0002-3151-822X; Frith, Chris D/0000-0002-8665-0690; Camici, Paolo/0000-0001-5584-0750; PAULESU, ERALDO/0000-0002-9224-754X				[Anonymous], 1993, NEUROBIOLOGY CINGULA; AVERSANO T, 1993, PAIN, V32, P93; CAMICI P, 1986, CIRCULATION, V74, P81, DOI 10.1161/01.CIR.74.1.81; FRANCOISFRANCK CA, 1899, B ACAD MED, V41, P565; FRISTON KJ, 1990, J CEREBR BLOOD F MET, V10, P458, DOI 10.1038/jcbfm.1990.88; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; FRISTON KJ, 1989, J CEREBR BLOOD F MET, V9, P690, DOI 10.1038/jcbfm.1989.97; GABRIEL M, 1991, EXP BRAIN RES, V86, P585; Heberden W., 1786, MED T COLL PHYSICIAN, V2, P59; Hill J A, 1986, Cardiol Clin, V4, P621; HURLEY KM, 1991, J COMP NEUROL, V308, P249, DOI 10.1002/cne.903080210; JONES AKP, 1991, P ROY SOC B-BIOL SCI, V244, P39, DOI 10.1098/rspb.1991.0048; Keefer CS, 1928, ARCH INTERN MED, V41, P769, DOI 10.1001/archinte.1928.00130180002001; MALLIANI A, 1989, TXB PAIN, P128; MALLIANI A, 1987, SILENT ISCHEMIA CURR, P19; MELLER ST, 1992, NEUROSCIENCE, V48, P501, DOI 10.1016/0306-4522(92)90398-L; MORECRAFT RJ, 1992, J COMP NEUROL, V323, P341, DOI 10.1002/cne.903230304; OPIE LH, 1991, DRUGS HEART, P14; Raichle M. E., 1987, HDB PHYSL NERVOUS SY, V1, P643; SPINKS TJ, 1992, PHYS MED BIOL, V37, P1637, DOI 10.1088/0031-9155/37/8/002; TAKAO Y, 1992, EUR J PHARMACOL, V215, P245, DOI 10.1016/0014-2999(92)90034-2; TALBOT JD, 1991, SCIENCE, V251, P1355, DOI 10.1126/science.2003220; TERREBERRY RR, 1983, BRAIN RES, V278, P245, DOI 10.1016/0006-8993(83)90246-9; Tournoux P., 1988, COPLANAR STEREOTACTI; WHITE JC, 1957, CIRCULATION, V16, P644, DOI 10.1161/01.CIR.16.4.644	25	194	201	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 16	1994	344	8916					147	150		10.1016/S0140-6736(94)92755-3	http://dx.doi.org/10.1016/S0140-6736(94)92755-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912763				2022-12-01	WOS:A1994NW81000007
J	LAZARO, C; RAVELLA, A; GAONA, A; VOLPINI, V; ESTIVILL, X				LAZARO, C; RAVELLA, A; GAONA, A; VOLPINI, V; ESTIVILL, X			NEUROFIBROMATOSIS TYPE-1 DUE TO GERM-LINE MOSAICISM IN A CLINICALLY NORMAL FATHER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VONRECKLINGHAUSEN NEUROFIBROMATOSIS; GONADAL MOSAICISM; MUTATION-RATE; NF1 GENE; DELETION; SEQUENCE; POLYMORPHISM; REPEAT; FAMILY; IV	Background. The mutation rate of the neurofibromatosis type 1 (NF1) gene is one of the highest in the human genome, with about 50 percent of cases being due to new mutations. We describe a family in which neurofibromatosis type 1 occurred in two siblings with clinically normal parents, and we demonstrate germ-line mosaicism in the father. Methods. We studied lymphocyte DNA from each member of the family and the father's spermatozoa for several polymorphic intragenic markers of the NF1 gene. Southern blots of DNA digested with several enzymes were hybridized with complementary DNA and individual NF1 exon probes to search for alterations in the gene. Results. The affected siblings, with a clinically severe form of neurofibromatosis type 1, showed no inheritance of paternal alleles for a marker in intron 38 of the NF1 gene, whereas they received alleles from both parents for other NF1 markers. Analysis with probes from this region of the NF1 gene showed a 12-kb deletion of the NF1 gene, involving exons 32 to 39, in the affected offspring. Ten percent of the father's spermatozoa carried the same NF1 deletion, but the abnormality was not detected in DNA from his lymphocytes. Conclusions. The presence of the NF1 mutation in 10 percent of the clinically normal father's spermatozoa supports the hypothesis that most germ-line mutations occur in precursors of gametes. In cases of spontaneous mutation, analyzing the specific NF1 mutation in the father's sperm might help in the detection of mosaicism and thus facilitate genetic counseling about further pregnancies.	LHOSP LLOBREGAT, HOSP DURAN & REYNALS, INST RECERCA ONCOL, DEPT MOLEC GENET, E-08907 BARCELONA, SPAIN; HOSP CREU ROJA DE BARCELONA, BARCELONA, SPAIN; HOSP CLIN BARCELONA, GENET SERV, E-08036 BARCELONA, SPAIN	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; University of Barcelona; Hospital Clinic de Barcelona			Estivill, Xavier/A-3125-2013; GARCIA, CONXI LAZARO/Q-2410-2016	Estivill, Xavier/0000-0002-0723-2256; GARCIA, CONXI LAZARO/0000-0002-7198-5906				ALLANSON JE, 1986, CLIN GENET, V29, P429; [Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007; BAKKER E, 1987, NATURE, V329, P554, DOI 10.1038/329554a0; BRADLEY TB, 1980, JOHNS HOPKINS MED J, V146, P236; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; CAREY JC, 1986, ANN NY ACAD SCI, V486, P45, DOI 10.1111/j.1749-6632.1986.tb48061.x; CAWTHON, 1990, CELL, V62, P609; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; FRYNS JP, 1983, CLIN GENET, V24, P156; FUENTES JJ, 1993, INT J LEGAL MED, V105, P271, DOI 10.1007/BF01370384; GITSCHIER J, 1989, LANCET, V1, P273; HALL JG, 1988, AM J HUM GENET, V43, P355; HALL JG, 1987, AM J MED GENET, V28, P143, DOI 10.1002/ajmg.1320280121; HUSON SM, 1989, J MED GENET, V26, P704, DOI 10.1136/jmg.26.11.704; JADAYEL D, 1990, NATURE, V343, P558, DOI 10.1038/343558a0; LAZARO C, 1993, HUM GENET, V92, P429, DOI 10.1007/BF01247353; LAZARO C, 1993, HUM MOL GENET, V2, P725, DOI 10.1093/hmg/2.6.725; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; MADDALENA A, 1988, NEW ENGL J MED, V319, P999, DOI 10.1056/NEJM198810133191507; MILEWICZ DM, 1993, AM J HUM GENET, V53, P62; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MURRAY EW, 1992, AM J HUM GENET, V50, P199; RICCARDI VM, 1988, AM J HUM GENET, V42, P284; RICCARDI VM, 1986, NEUROIBROMATOSIS PHE; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SERGEYEV AS, 1975, HUMANGENETIK, V28, P129, DOI 10.1007/BF00735745; SOLERA J, 1992, AM J HUM GENET, V50, P434; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WALLACE MR, 1990, SCIENCE, V250, P1749; XU GF, 1991, NUCLEIC ACIDS RES, V19, P3764, DOI 10.1093/nar/19.13.3764; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	34	115	121	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 24	1994	331	21					1403	1407		10.1056/NEJM199411243312102	http://dx.doi.org/10.1056/NEJM199411243312102			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU533	7969279				2022-12-01	WOS:A1994PU53300002
J	MILLARD, PS; GENSHEIMER, KF; ADDISS, DG; SOSIN, DM; BECKETT, GA; HOUCKJANKOSKI, A; HUDSON, A				MILLARD, PS; GENSHEIMER, KF; ADDISS, DG; SOSIN, DM; BECKETT, GA; HOUCKJANKOSKI, A; HUDSON, A			AN OUTBREAK OF CRYPTOSPORIDIOSIS FROM FRESH-PRESSED APPLE CIDER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DAY-CARE-CENTER; TRANSMISSION; COMMUNITY; SYMPTOMS; GEORGIA; GIARDIA; DISEASE; OOCYSTS	Background.-Recent waterborne outbreaks have established Cryptosporidium as an emerging enteric pathogen, but foodborne transmission has rarely been reported. In October 1993, an outbreak of cryptosporidiosis occurred among students and staff attending a 1-day school agricultural fair in central Maine. Design.-Environmental/laboratory investigation and cohort study. Participants.-Attendees of the fair and their household members. Main Outcome Measures.-Clinical or laboratory-confirmed cryptosporidiosis. Clinical cryptosporidiosis was defined as 3 days of either diarrhea (three loose stools in a 24-hour period) or vomiting. Results.-Surveys were completed for 611 (81%) of the estimated 759 fair attendees. Among attendees who completed the survey, there were 160 (26%) primary cases. Cryptosporidium oocysts were detected in the stools of 50 (89%) of 56 primary and secondary case patients tested. The median incubation period was 6 days (range, 10 hours to 13 days); the median duration of illness was 6 days (range, 1 to 16 days). Eighty-four percent of primary case patients had diarrhea and 82% had vomiting. Persons drinking apple cider that was hand pressed in the afternoon were at increased risk for cryptosporidiosis (154 [54%] of 284 exposed vs six [2%] of 292 unexposed; relative risk, 26; 95% confidence interval, 12 to 59). Cryptosporidium oocysts were detected in the apple cider, on the cider press, and in the stool specimen of a calf on the farm that supplied the apples. The secondary household transmission rate was 15% (53/353). Conclusions.-This is the first large cryptosporidiosis outbreak in which foodborne transmission has been documented. It underscores the need for agricultural producers to take measures to avoid contamination of foodstuffs with infectious agents common to the farm environment.	MAINE BUR HLTH, DIV DIS CONTROL, AUGUSTA, ME 04333 USA; CTR DIS CONTROL & PREVENT, EPIDEMIOL PROGRAM OFF, DIV FIELD EPIDEMIOL, ATLANTA, GA 30341 USA; CTR DIS CONTROL & PREVENT, EPIDEMIOL PROGRAM OFF, EPIDEM INTELLIGENCE SERV, ATLANTA, GA 30341 USA; CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV PARASIT DIS, ATLANTA, GA 30341 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA				Hudson, Arlene/0000-0003-3980-4383				ADDISS DG, 1991, PEDIATR INFECT DIS J, V10, P907, DOI 10.1097/00006454-199112000-00005; ALPERT G, 1986, PEDIATRICS, V77, P152; ANDERSON BC, 1985, AM J PUBLIC HEALTH, V75, P1433, DOI 10.2105/AJPH.75.12.1433; BESSER RE, 1993, JAMA-J AM MED ASSOC, V269, P2217, DOI 10.1001/jama.269.17.2217; CAMPBELL I, 1982, VET REC, V111, P414, DOI 10.1136/vr.111.18.414; CASEMORE DP, 1990, EPIDEMIOL INFECT, V104, P1, DOI 10.1017/S0950268800054480; CASEMORE DP, 1990, LANCET, V336, P1427, DOI 10.1016/0140-6736(90)93115-6; CASEMORE DP, 1993, LANCET, V342, P312, DOI 10.1016/0140-6736(93)91863-H; COMBEE CL, 1986, PEDIATR INFECT DIS J, V5, P528, DOI 10.1097/00006454-198609000-00008; CURRENT WL, 1991, CLIN MICROBIOL REV, V4, P325, DOI 10.1128/CMR.4.3.325-358.1991; DANTONIO RG, 1985, ANN INTERN MED, V103, P886, DOI 10.7326/0003-4819-103-6-886; EGGER M, 1990, ARCH DIS CHILD, V65, P445, DOI 10.1136/adc.65.4.445; FREIDANK H, 1987, EUR J CLIN MICROBIOL, V6, P56, DOI 10.1007/BF02097194; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HAYES EB, 1989, NEW ENGL J MED, V320, P1372, DOI 10.1056/NEJM198905253202103; JOKIPII L, 1986, NEW ENGL J MED, V315, P1643, DOI 10.1056/NEJM198612253152604; KOCH KL, 1985, ANN INTERN MED, V102, P593, DOI 10.7326/0003-4819-102-5-593; LELAND D, 1993, J AM WATER WORKS ASS, V85, P34; LENGERICH EJ, 1993, J INFECT DIS, V167, P1252, DOI 10.1093/infdis/167.5.1252; MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304; MILLER RA, 1990, J INFECT DIS, V161, P312, DOI 10.1093/infdis/161.2.312; MIRON D, 1991, PEDIATR INFECT DIS J, V10, P438, DOI 10.1097/00006454-199106000-00004; NEWMAN RD, 1994, ANN INTERN MED, V120, P500, DOI 10.7326/0003-4819-120-6-199403150-00009; PALMER SR, 1990, BRIT MED J, V300, P774, DOI 10.1136/bmj.300.6727.774; Romanova T. V., 1992, Meditsinskaya Parazitologiya i Parazitarnye Bolezni, V0, P50; SHIELD J, 1990, J INFECTION, V21, P297, DOI 10.1016/0163-4453(90)94053-3; SMITH JL, 1993, J FOOD PROTECT, V56, P451, DOI 10.4315/0362-028X-56.5.451; STEHRGREEN JK, 1987, AM J TROP MED HYG, V36, P338, DOI 10.4269/ajtmh.1987.36.338; TANGERMANN RH, 1991, AM J EPIDEMIOL, V133, P471, DOI 10.1093/oxfordjournals.aje.a115914; UNGAR BLP, 1990, CRYPTOSPORIDIOSIS MA; 1975, MMWR-MORBID MORTAL W, V24, P87; 1993, MANUAL MASSACHUSETTS; 1992, EMERGING INFECTIONS; 1994, MMWR-MORBID MORTAL W, V42, P1; 1990, SAS RELEASE 6 03	35	224	240	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 23	1994	272	20					1592	1596		10.1001/jama.272.20.1592	http://dx.doi.org/10.1001/jama.272.20.1592			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR405	7966869				2022-12-01	WOS:A1994PR40500025
J	NIGHTINGALE, SL				NIGHTINGALE, SL			DEATHS ASSOCIATED WITH ALLERGENIC EXTRACTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1994, FDA MED B, P24	1	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	1994	272	19					1488	1488						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ900	7966836				2022-12-01	WOS:A1994PQ90000022
J	LLOYD, AM; SCHENA, M; WALBOT, V; DAVIS, RW				LLOYD, AM; SCHENA, M; WALBOT, V; DAVIS, RW			EPIDERMAL-CELL FATE DETERMINATION IN ARABIDOPSIS - PATTERNS DEFINED BY A STEROID-INDUCIBLE REGULATOR	SCIENCE			English	Article							MAMMALIAN GLUCOCORTICOID RECEPTOR; GENE; EXPRESSION; TRANSFORMATION; DROSOPHILA; SYSTEM; TRANSCRIPTION; SUPERFAMILY; HOMOLOGY; PROTEINS	The Arabidopsis mutant ttg lacks both trichomes (epidermal hairs) and anthocyanin pigments. Trichomes and anthocyanins are restored by the constitutive expression of the maize transcriptional regulator (R). The expression of an R-glucocorticoid receptor chimeric protein results in a steroid hormone-dependent, conditional allele of R that functions in whole Arabidopsis plants. The response of the chimeric protein to pulses of hormone was used to define the pattern ana timing of trichome formation on the developing leaf epidermis. Each adaxial epidermal leaf cell appears to have an equal probability of differentiating into a trichome; there is a temporal zone of decision for trichome cell fate that proceeds as a wave from the tip to the base of developing leaves.	STANFORD UNIV,DEPT SCI BIOL,STANFORD,CA 94305	Stanford University	LLOYD, AM (corresponding author), STANFORD UNIV,DEPT BIOCHEM,STANFORD,CA 94305, USA.			Walbot, Virginia/0000-0002-1596-7279	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032422] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32422] Funding Source: Medline; PHS HHS [R37-H600198] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BENFEY PN, 1989, EMBO J, V8, P2195, DOI 10.1002/j.1460-2075.1989.tb08342.x; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; DRUMMHERREL H, 1981, PHOTOCHEM PHOTOBIOL, V33, P391, DOI 10.1111/j.1751-1097.1981.tb05435.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; GALWAY ME, IN PRESS DEV BIOL; GOFF SA, 1992, GENE DEV, V6, P864, DOI 10.1101/gad.6.5.864; HELD LI, 1991, BIOESSAYS, V13, P633, DOI 10.1002/bies.950131203; HOLLENBERG SM, 1993, P NATL ACAD SCI USA, V90, P8028, DOI 10.1073/pnas.90.17.8028; HOPE TJ, 1990, P NATL ACAD SCI USA, V87, P7787, DOI 10.1073/pnas.87.19.7787; HULSKAMP M, 1994, CELL, V76, P555, DOI 10.1016/0092-8674(94)90118-X; Koornneef M., 1981, ARABID INF SERV, V18, P45; Koornneef M., 1990, ARABIDOPSIS INFO SER, V27, P1; KORN RW, 1981, DEV BIOL, V88, P115, DOI 10.1016/0012-1606(81)90223-2; LARKIN JC, 1993, PLANT CELL, V5, P1739, DOI 10.1105/tpc.5.12.1739; LLOYD AL, UNPUB; LLOYD AM, 1992, SCIENCE, V258, P1173; LUDWIG SR, 1989, P NATL ACAD SCI USA, V86, P7092, DOI 10.1073/pnas.86.18.7092; LUDWIG SR, 1990, SCIENCE, V247, P449, DOI 10.1126/science.247.4941.449; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; POWER RF, 1992, TRENDS PHARMACOL SCI, V13, P318, DOI 10.1016/0165-6147(92)90099-R; QUATTROCCHIO F, 1993, PLANT CELL, V5, P1497, DOI 10.1105/tpc.5.11.1497; ROTH BA, 1991, PLANT CELL, V3, P317, DOI 10.1105/tpc.3.3.317; SAMUELS HH, 1970, J MOL BIOL, V52, P57, DOI 10.1016/0022-2836(70)90177-4; SCHARDL CL, 1987, GENE, V61, P1, DOI 10.1016/0378-1119(87)90359-3; SCHENA M, 1991, P NATL ACAD SCI USA, V88, P10421, DOI 10.1073/pnas.88.23.10421; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; WILLIAMS MH, 1988, PROTOPLASMA, V147, P77, DOI 10.1007/BF01403879; YOSHINAGA SK, 1991, MOL ENDOCRINOL, V5, P844, DOI 10.1210/mend-5-6-844	33	203	215	2	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 21	1994	266	5184					436	439		10.1126/science.7939683	http://dx.doi.org/10.1126/science.7939683			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7939683				2022-12-01	WOS:A1994PN27200035
J	REESE, JC; APONE, L; WALKER, SS; GRIFFIN, LA; GREEN, MR				REESE, JC; APONE, L; WALKER, SS; GRIFFIN, LA; GREEN, MR			YEAST TAF(II)S IN A MULTISUBUNIT COMPLEX REQUIRED FOR ACTIVATED TRANSCRIPTION	NATURE			English	Article							TATA-BINDING PROTEIN; POLYMERASE-II TRANSCRIPTION; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; DNA; SUBUNIT; INVITRO; GENE; TBP	IN higher eukaryotes the RNA polymerase II transcription factor TFIID is composed of a TATA-box-binding protein (TBP) and a set of tightly bound polypeptides, designated TBP-associated fao tors (TAF(II)s). One or more TAF(II)s are coactivators that are required for activated but not basal transcription(1-3). The eukaryotic transcription machinery is highly conserved and it is therefore puzzling that TAF(II)s have aot been identified in yeast. Here we use TBP as a protein-affinity ligand to isolate from yeast a multi-subunit complex that is required specifically for activated transcription by RNA polymerase II. Microsequence analysis and cloning of two subunits of this complex reveal that they are the homologues of known mammalian and Drosophila TAF(II)s. The genes encoding these two yeast TAF(II)s are essential, suggesting that activated transcription is required for viability of Saccharomyces cerevisiae.			REESE, JC (corresponding author), UNIV MASSACHUSETTS, MED CTR, HOWARD HUGHES MED INST, PROGRAM MOLEC MED, 373 PLANTAT ST, WORCESTER, MA 01605 USA.			reese, joseph/0000-0003-3578-4266				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; POON D, 1993, J BIOL CHEM, V268, P15325; PUGH BF, 1992, J BIOL CHEM, V267, P679; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; TAKADA R, 1992, P NATL ACAD SCI USA, V89, P11809, DOI 10.1073/pnas.89.24.11809; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180	22	155	158	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 6	1994	371	6497					523	527		10.1038/371523a0	http://dx.doi.org/10.1038/371523a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7935765				2022-12-01	WOS:A1994PK58900058
J	NIKOSKELAINEN, EK; SAVONTAUS, ML; HUOPONEN, K; ANTILA, K; HARTIALA, J				NIKOSKELAINEN, EK; SAVONTAUS, ML; HUOPONEN, K; ANTILA, K; HARTIALA, J			PREEXCITATION SYNDROME IN LEBERS HEREDITARY OPTIC NEUROPATHY	LANCET			English	Note							ELECTROCARDIOGRAPHIC ABNORMALITIES; NEURORETINOPATHY; ATROPHY	Pre-excitation syndrome is common in families with Leber's hereditary optic neuropathy (LHON). 24 Finnish families with LHON were screened for the 11778 and the 3460 mitochondrial DNA mutations. 5 of 30 individuals with LHON and the 11778 mutation had the Wolff-Parhinson-White pre-excitation syndrome. None of 10 with the 3460 mutation or of 11 with ''other'' mutations had this syndrome. Overall, 5 of 51 LHON patients and 9 of 112 symptom-free maternal relatives had Wolff-Parhinson-White syndrome (9%). In paternal relatives, the frequency was 1.6%. Mitochondrial DNA causal for LHON may contribute to pre-excitation syndrome.	UNIV TURKU,DEPT MED GENET,SF-20520 TURKU,FINLAND; UNIV TURKU,DEPT CLIN PHYSIOL,SF-20520 TURKU,FINLAND	University of Turku; University of Turku	NIKOSKELAINEN, EK (corresponding author), UNIV TURKU,DEPT OPHTHALMOL,SF-20520 TURKU,FINLAND.				NEI NIH HHS [I-RO EY 409040-01] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BIGGER JT, 1980, HEART DIS TXB CARDIO, V1, P682; BOWER SPC, 1992, LANCET, V339, P1427, DOI 10.1016/0140-6736(92)91257-9; FEDERICO A, 1987, J INHERIT METAB DIS, V10, P256, DOI 10.1007/BF01811419; HIRANO M, 1992, NEUROMUSCULAR DISORD, V2, P125, DOI 10.1016/0960-8966(92)90045-8; HUOPONEN K, 1993, HUM GENET, V92, P379, DOI 10.1007/BF01247339; NIKOSKELAINEN E, 1985, LANCET, V1, P696; NIKOSKELAINEN EK, 1987, ARCH OPHTHALMOL-CHIC, V105, P665, DOI 10.1001/archopht.1987.01060050083043; ORTIZ RG, 1992, AM J OPHTHALMOL, V113, P561, DOI 10.1016/S0002-9394(14)74730-0; ROSE FC, 1970, BRIT J OPHTHALMOL, V54, P388, DOI 10.1136/bjo.54.6.388; VIDAILLET HJ, 1987, NEW ENGL J MED, V317, P65, DOI 10.1056/NEJM198707093170201	10	60	62	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					857	858		10.1016/S0140-6736(94)92830-4	http://dx.doi.org/10.1016/S0140-6736(94)92830-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH253	7916404				2022-12-01	WOS:A1994PH25300014
J	PORTER, A				PORTER, A			GODS FOOLS	LANCET			English	Editorial Material														Porter, Alan MW/0000-0001-5622-7288				BENDA J, 1928, TRAHISON CLERCS; CHESNAIS JC, 1994, NEW SCI, V143, P32; Festinger L, 1964, CONFLICT DECIS DISSO; KING M, 1993, LANCET, V341, P669, DOI 10.1016/0140-6736(93)90431-F; PORTER AMW, 1993, J HUM EVOL, V25, P417, DOI 10.1006/jhev.1993.1059; RUSSELL C, 1979, J MED ETHICS, V5, P108, DOI 10.1136/jme.5.3.108; WHEELER PE, 1993, J HUM EVOL, V24, P13, DOI 10.1006/jhev.1993.1003	7	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					835	836		10.1016/S0140-6736(94)92822-3	http://dx.doi.org/10.1016/S0140-6736(94)92822-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PH253	7916396				2022-12-01	WOS:A1994PH25300006
J	LINN, FHH; WIJDICKS, EFM; VANDERGRAAF, Y; WEERDESTEYNVANVLIET, FAC; BARTELDS, AIM; VANGIJN, J				LINN, FHH; WIJDICKS, EFM; VANDERGRAAF, Y; WEERDESTEYNVANVLIET, FAC; BARTELDS, AIM; VANGIJN, J			PROSPECTIVE-STUDY OF SENTINEL HEADACHE IN ANEURYSMAL SUBARACHNOID HEMORRHAGE	LANCET			English	Article							INTRACRANIAL ANEURYSM; STROKE INCIDENCE; CASE FATALITY; WARNING LEAK; FOLLOW-UP; HEMORRHAGE; RUPTURE; POPULATION; EPIDEMIOLOGY; MANAGEMENT	Retrospective surveys of patients with subarachnoid haemorrhage suggest that minor episodes with sudden headache (warning leaks) may precede rupture of an aneurysm, and that early recognition and surgery might lead to improved outcome. We studied 148 patients with sudden and severe headache (possible sentinel headache) seen by 252 general practitioners in a 5-year period in the Netherlands. Subarachnoid haemorrhage was the cause in 37 patients (25%) (proven aneurysm in 21, negative angiogram in 6, no angiogram done in 6, sudden headache followed by death in 4). 103 patients had headache as the only symptom, 12 of whom proved to have subarachnoid haemorrhage (6 with a ruptured aneurysm). Previous bouts of sudden headache had occurred in only 2. Other serious neurological conditions were diagnosed in 18. In the remaining 93, no underlying cause of headache was found; follow-up over 1 year showed no subsequent subarachnoid haemorrhage or sudden death. In this cohort, acute, severe headache in general practice indicated a serious neurological disorder in 37% (95% CI 29-45%), and subarachnoid haemorrhage in 25% (18-32%). 12% (5-18%) of those with headache as the only symptom. The notion of warning leaks as a less serious variant of subarachnoid haemorrhage is not supported by this study. Early recognition of subarachnoid haemorrhage is important but will probably have only limited impact on the outcome in the general population.	UNIV UTRECHT,DEPT EPIDEMIOL,UTRECHT,NETHERLANDS; NETHERLANDS INST PRIMARY HLTH CARE,UTRECHT,NETHERLANDS	Utrecht University	LINN, FHH (corresponding author), UNIV UTRECHT,DEPT NEUROL,HEIDELBERGLAAN 100,3584 CX UTRECHT,NETHERLANDS.		van Gijn, Jan/A-9444-2008					BALL MJ, 1975, CAN MED ASSOC J, V112, P78; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BONITA R, 1985, STROKE, V16, P591, DOI 10.1161/01.STR.16.4.591; BROUWERS PJAM, 1993, STROKE, V24, P809, DOI 10.1161/01.STR.24.6.809; COLLETTE HJA, 1982, ENV EPIDEMIOLOGY, P149; DUFFY GP, 1983, MED J AUSTRALIA, V1, P514, DOI 10.5694/j.1326-5377.1983.tb136193.x; GIROUD M, 1991, INT J EPIDEMIOL, V20, P892, DOI 10.1093/ije/20.4.892; HAUERBERG J, 1991, ACTA NEUROL SCAND, V83, P61; HERMAN B, 1982, STROKE, V13, P629, DOI 10.1161/01.STR.13.5.629; HIJDRA A, 1990, STROKE, V21, P1156, DOI 10.1161/01.STR.21.8.1156; HIJDRA A, 1987, STROKE, V18, P1061, DOI 10.1161/01.STR.18.6.1061; INGALL TJ, 1989, STROKE, V20, P718, DOI 10.1161/01.STR.20.6.718; JENNETT B, 1975, LANCET, V1, P480; JUVELA S, 1992, NEUROSURGERY, V30, P7, DOI 10.1227/00006123-199201000-00002; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; KISSEL JT, 1983, ANN NEUROL, V13, P149, DOI 10.1002/ana.410130207; LEBLANC R, 1985, CAN MED ASSOC J, V131, P1235; MARKUS HS, 1991, J NEUROL NEUROSUR PS, V54, P1117, DOI 10.1136/jnnp.54.12.1117; OKAWARA SH, 1973, J NEUROSURG, V38, P575, DOI 10.3171/jns.1973.38.5.0575; Pakarinen S, 1967, ACTA NEUROL SCAN S29, V43, P1; RAJA IA, 1972, J NEUROSURG, V36, P548, DOI 10.3171/jns.1972.36.5.0548; RASMUSSEN BK, 1992, NEUROLOGY, V42, P1225, DOI 10.1212/WNL.42.6.1225; RICCI S, 1991, J NEUROL NEUROSUR PS, V54, P695, DOI 10.1136/jnnp.54.8.695; RINKEL GJE, 1991, AM J NEURORADIOL, V12, P829; TEASDALE G, 1974, LANCET, V2, P81; VERMEULEN M, 1990, J NEUROL NEUROSUR PS, V53, P365, DOI 10.1136/jnnp.53.5.365; VERWEIJ RD, 1988, ARCH NEUROL-CHICAGO, V45, P1019, DOI 10.1001/archneur.1988.00520330109018; WIJDICKS EFM, 1988, LANCET, V2, P68; 1989, CBS ANN PUBLICATI A1	29	172	174	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					590	593		10.1016/S0140-6736(94)91970-4	http://dx.doi.org/10.1016/S0140-6736(94)91970-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914965	Green Submitted			2022-12-01	WOS:A1994PD42400014
J	MANI, SK; ALLEN, JMC; CLARK, JH; BLAUSTEIN, JD; OMALLEY, BW				MANI, SK; ALLEN, JMC; CLARK, JH; BLAUSTEIN, JD; OMALLEY, BW			CONVERGENT PATHWAYS FOR STEROID HORMONE-INDUCED AND NEUROTRANSMITTER-INDUCED RAT SEXUAL-BEHAVIOR	SCIENCE			English	Article							MESSENGER RIBONUCLEIC-ACID; LIGAND-INDEPENDENT ACTIVATION; CENTRAL NERVOUS-SYSTEM; FEMALE GUINEA-PIGS; GROWTH FACTOR-I; PROGESTIN RECEPTORS; ESTROGEN-RECEPTOR; LORDOSIS BEHAVIOR; CONCENTRATING CELLS; OVARIECTOMIZED RATS	Estrogen and progesterone modulate gene expression in rodents by activation of intracellular receptors in the hypothalamus, which regulate neuronal networks that control female sexual behavior. However, the neurotransmitter dopamine has been shown to activate certain steroid receptors in a ligand-independent manner. A dopamine receptor stimulant and a D-1 receptor agonist, but not a D-2 receptor agonist, mimicked the effects of progesterone in facilitating sexual behavior in female rats. The facilitatory effect of the neurotransmitter was blocked by progesterone receptor antagonists, a D-1 receptor antagonist, or antisense oligonucleotides to the progesterone receptor. The results suggest that in rodents neurotransmitters may regulate in vivo gene expression and behavior by means of cross-talk with steroid receptors in the brain.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; UNIV MASSACHUSETTS,DEPT PSYCHOL,AMHERST,MA 01003; UNIV MASSACHUSETTS,NEUROSCI BEHAV PROGRAM,AMHERST,MA 01003	Baylor College of Medicine; University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst					NIMH NIH HHS [MH-00885] Funding Source: Medline; NINDS NIH HHS [NS 19327] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH000885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019327] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHLENIUS S, 1993, NEUROSCI BIOBEHAV R, V17, P43, DOI 10.1016/S0149-7634(05)80229-5; ALLAN GF, 1992, J BIOL CHEM, V267, P19513; ANTUNESR.J, 1970, P SOC EXP BIOL MED, V133, P1464; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; Blaustein J. D., 1989, Advances in Comparative and Environmental Physiology, V3, P31; BLAUSTEIN JD, 1987, BRAIN RES, V436, P253, DOI 10.1016/0006-8993(87)91669-6; BLAUSTEIN JD, 1982, BRAIN RES, V243, P287, DOI 10.1016/0006-8993(82)90252-9; BLAUSTEIN JD, 1980, ENDOCRINOLOGY, V106, P1061, DOI 10.1210/endo-106-4-1061; BLAUSTEIN JD, 1989, J NEUROENDOCRINOL, V1, P333, DOI 10.1111/j.1365-2826.1989.tb00125.x; BLAUSTEIN JD, 1986, NEUROENDOCRINOLOGY, V43, P143, DOI 10.1159/000124521; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN T J, 1990, Molecular and Cellular Neuroscience, V1, P58, DOI 10.1016/1044-7431(90)90042-3; BROWN TJ, 1986, BRAIN RES, V373, P103, DOI 10.1016/0006-8993(86)90320-3; BROWN TJ, 1987, ENDOCRINOLOGY, V121, P298, DOI 10.1210/endo-121-1-298; BROWN TJ, 1984, BRAIN RES, V301, P343, DOI 10.1016/0006-8993(84)91103-X; DIAUGUSTINE RP, 1988, ENDOCRINOLOGY, V122, P2355, DOI 10.1210/endo-122-6-2355; DLUZEN DE, 1989, BRAIN RES, V494, P122, DOI 10.1016/0006-8993(89)90150-9; EVERITT BJ, 1974, EUR J PHARMACOL, V29, P187, DOI 10.1016/0014-2999(74)90190-3; FEDER HH, 1977, ANN NY ACAD SCI, V286, P331, DOI 10.1111/j.1749-6632.1977.tb29428.x; FOREMAN MM, 1979, PHYSIOL BEHAV, V22, P283, DOI 10.1016/0031-9384(79)90088-X; FOREMAN MM, 1987, PSYCHOPHARMACOLOGY, V91, P96, DOI 10.1007/BF00690934; FUXE K, 1976, SUBCELLULAR MECHANIS, P193; HAMBURGERBAR R, 1975, EUR J PHARMACOL, V32, P357, DOI 10.1016/0014-2999(75)90304-0; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; KATZENELLENBOGEN BS, 1990, ENDOCRINOLOGY, V126, P891, DOI 10.1210/endo-126-2-891; MACLUSKY NJ, 1980, ENDOCRINOLOGY, V106, P192, DOI 10.1210/endo-106-1-192; MANI S, UNPUB; MCEWEN BS, 1982, RECENT PROG HORM RES, V38, P41; MCEWEN BS, 1988, J STEROID BIOCHEM, V30, P179, DOI 10.1016/0022-4731(88)90091-X; MORISSETTE M, 1993, J NEUROCHEM, V60, P1876, DOI 10.1111/j.1471-4159.1993.tb13415.x; MORRELL JI, 1978, AM ZOOL, V18, P447; MORRIN LP, 1977, PHYSIOL BEHAV, V18, P701; NELSON KG, 1992, ENDOCRINOLOGY, V131, P1657, DOI 10.1210/en.131.4.1657; NOCK B, 1981, BRAIN RES, V20, P371; OGAWA S, 1994, J NEUROSCI, V14, P1766, DOI 10.1523/JNEUROSCI.14-03-01766.1994; PARSONS B, 1980, ENDOCRINOLOGY, V107, P774, DOI 10.1210/endo-107-3-774; PFAFF D, 1973, J COMP NEUROL, V151, P121, DOI 10.1002/cne.901510204; PFAFF DW, 1983, SCIENCE, V219, P808, DOI 10.1126/science.6297008; PFAFF DW, 1988, PHYSL REPRODUCTION, V1, P1487; POLLIO G, 1993, MOL BRAIN RES, V19, P135, DOI 10.1016/0169-328X(93)90158-L; POWER RF, 1991, SCIENCE, V252, P1546, DOI 10.1126/science.2047861; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; POWERS JB, 1976, PHYSIOL BEHAV, V117, P493; ROMANO GJ, 1988, MOL ENDOCRINOL, V2, P1320, DOI 10.1210/mend-2-12-1320; ROMANO GJ, 1989, MOL ENDOCRINOL, V3, P1295, DOI 10.1210/mend-3-8-1295; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P6120, DOI 10.1073/pnas.90.13.6120; STANCEL GM, 1990, PROG CLIN BIOL RES, V322, P213; THORTON JE, 1986, BRAIN RES, V377, P1155; TITUS RD, 1983, J MED CHEM, V26, P1112, DOI 10.1021/jm00362a005; VATHY IU, 1989, HORM BEHAV, V23, P43, DOI 10.1016/0018-506X(89)90073-1; WILCOX JN, 1985, ENDOCRINOLOGY, V117, P2392, DOI 10.1210/endo-117-6-2392	51	287	288	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 26	1994	265	5176					1246	1249		10.1126/science.7915049	http://dx.doi.org/10.1126/science.7915049			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD422	7915049				2022-12-01	WOS:A1994PD42200042
J	PRESTON, NW				PRESTON, NW			PERTUSSIS VACCINATION - NEITHER PANIC NOR COMPLACENCY	LANCET			English	Editorial Material											PRESTON, NW (corresponding author), UNIV MANCHESTER,SCH MED,DEPT MED MICROBIOL,PERTUSSIS REFERENCE LAB,MANCHESTER,ENGLAND.							BARAFF LJ, 1984, PEDIATRICS, V73, P37; BOOY R, 1992, LANCET, V339, P507, DOI 10.1016/0140-6736(92)90336-2; CHRISTIE CDC, 1994, NEW ENGL J MED, V331, P16, DOI 10.1056/NEJM199407073310104; KHATTAK MN, 1993, J INFECTION, V27, P119, DOI 10.1016/0163-4453(93)94566-T; KNOWLES K, 1993, 33RD INT C ANT AG CH; MARCHANT CD, 1994, J INFECT DIS, V169, P1297, DOI 10.1093/infdis/169.6.1297; Miller E, 1992, Commun Dis Rep CDR Rev, V2, pR152; Preston N. W., 1994, Tropical Diseases Bulletin, V91, pR151; Preston N W, 1992, Commun Dis Rep CDR Rev, V2, pR155; Preston N W, 1970, Lab Pract, V19, P482; PRESTON NW, 1988, PATHOGENESIS IMMUNIT, P1; STOTT NCH, 1981, BRIT MED J, V282, P1871, DOI 10.1136/bmj.282.6279.1871-a; WARDLAW AC, 1992, VACCINE, V10, P643, DOI 10.1016/0264-410X(92)90083-V	13	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 20	1994	344	8921					491	492		10.1016/S0140-6736(94)91894-5	http://dx.doi.org/10.1016/S0140-6736(94)91894-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7914610				2022-12-01	WOS:A1994PC53500005
J	OXMAN, TE				OXMAN, TE			DELAYED RECALL - DEMENTED, DEPRESSED, OR TREATED	LANCET			English	Editorial Material							ALZHEIMERS		DARTMOUTH COLL,SCH MED,DEPT COMMUNITY & FAMILY MED,HANOVER,NH 03755	Dartmouth College	OXMAN, TE (corresponding author), DARTMOUTH COLL,SCH MED,DEPT PSYCHIAT,HANOVER,NH 03755, USA.							ALBERT MS, 1991, COMPREHENSIVE REV GE, P223; EMERY VO, 1992, AM J PSYCHIAT, V149, P305; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HINDMARCH I, 1992, PSYCHOPHARMACOLOGY S, V105, pS49; LACHNER G, 1994, J NERV MENT DIS, V181, P34; MASSMAN PJ, 1992, J CLIN EXP NEUROPSYC, V14, P687, DOI 10.1080/01688639208402856; NIEDEREHE G, 1994, DEMENTIA PRESENTATIO, P19; OXMAN AD, 1993, JAMA-J AM MED ASSOC, V270, P2093; RABINS PV, 1984, BRIT J PSYCHIAT, V144, P488, DOI 10.1192/bjp.144.5.488; REIFLER BV, 1989, AM J PSYCHIAT, V146, P45; TERI L, 1991, GERONTOLOGIST, V31, P413, DOI 10.1093/geront/31.3.413	11	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					213	214		10.1016/S0140-6736(94)92994-7	http://dx.doi.org/10.1016/S0140-6736(94)92994-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NY060	7913154				2022-12-01	WOS:A1994NY06000006
J	CLERICI, M; BEVILACQUA, M; VAGO, T; VILLA, ML; SHEARER, GM; NORBIATO, G				CLERICI, M; BEVILACQUA, M; VAGO, T; VILLA, ML; SHEARER, GM; NORBIATO, G			AN IMMUNOENDOCRINOLOGICAL HYPOTHESIS OF HIV-INFECTION	LANCET			English	Note							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; HUMAN MEDULLARY THYMOCYTES; GLUCOCORTICOID RECEPTOR; T-CELLS; IMMUNE-RESPONSES; IMMUNOGLOBULIN-E; GENE-EXPRESSION; INTERLEUKIN-2; DEHYDROEPIANDROSTERONE; SYSTEM		OSPED L SACCO,SERV ENDOCRINOL,MILAN,ITALY; NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892	University of Milan; Luigi Sacco Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	CLERICI, M (corresponding author), UNIV MILAN,CATTEDRA IMMUNOL,VIA VENEZIA 1,I-20133 MILAN,ITALY.			Clerici, Mario/0000-0001-5920-6191				BROWNE ES, 1993, J STEROID BIOCHEM, V45, P517, DOI 10.1016/0960-0760(93)90168-V; CHEHIMI J, 1994, J EXP MED, V179, P1361, DOI 10.1084/jem.179.4.1361; CHRISTEFF N, 1992, J ACQ IMMUN DEF SYND, V5, P841; CLERICI M, 1993, SCIENCE, V262, P1721, DOI 10.1126/science.7903123; CLERICI M, 1994, J CLIN INVEST, V93, P768, DOI 10.1172/JCI117031; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; CLERICI M, IN PRESS P NATL ACAD; DAYNES RA, 1989, EUR J IMMUNOL, V19, P2319, DOI 10.1002/eji.1830191221; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; GRINSPOON SK, 1992, NEW ENGL J MED, V327, P1360, DOI 10.1056/NEJM199211053271906; GROUX H, 1993, EUR J IMMUNOL, V23, P1623, DOI 10.1002/eji.1830230734; HELMBERG A, 1990, J IMMUNOL, V145, P4332; HERRSCHER RF, 1992, J CLIN INVEST, V90, P596, DOI 10.1172/JCI115898; KAM JC, 1993, J IMMUNOL, V151, P3460; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MEEYARD L, 1993, INNUMOL TODAY, V14, P161; MULDER JW, 1992, J INFECT DIS, V165, P413, DOI 10.1093/infdis/165.3.413; NIETO MA, 1990, J IMMUNOL, V145, P1364; NORBIATO G, 1992, J CLIN ENDOCR METAB, V74, P608, DOI 10.1210/jc.74.3.608; POLI G, 1993, CLIN RES, V41, pA211; RISDON G, 1990, AM J PATHOL, V136, P759; SALKOWSKI CA, 1992, J IMMUNOL, V148, P2770; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; TANG WW, 1993, AM J MED, V94, P169, DOI 10.1016/0002-9343(93)90179-S; VACCA A, 1992, J EXP MED, V175, P637, DOI 10.1084/jem.175.3.637; WRIGHT DN, 1990, J ALLERGY CLIN IMMUN, V85, P445, DOI 10.1016/0091-6749(90)90154-V; WU CY, 1991, J CLIN INVEST, V87, P870, DOI 10.1172/JCI115092	27	55	56	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 18	1994	343	8912					1552	1553		10.1016/S0140-6736(94)92944-0	http://dx.doi.org/10.1016/S0140-6736(94)92944-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR329	7911876				2022-12-01	WOS:A1994NR32900014
J	RUSTGI, AK				RUSTGI, AK			MEDICAL PROGRESS - HEREDITARY GASTROINTESTINAL POLYPOSIS AND NONPOLYPOSIS SYNDROMES	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FAMILIAL ADENOMATOUS POLYPOSIS; PEUTZ-JEGHERS SYNDROME; COLI GARDNERS-SYNDROME; OCULAR FUNDUS LESIONS; MUIR-TORRE SYNDROME; (LYNCH SYNDROME-I; APC GENE-PRODUCT; COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; JUVENILE POLYPOSIS		HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Harvard Medical School	RUSTGI, AK (corresponding author), MASSACHUSETTS GEN HOSP,GASTROINTESTINAL UNIT,JACKSON 7,50 BLOSSOM ST,BOSTON,MA 02114, USA.				PHS HHS [R01 43351] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BAUGHMAN FA, 1969, NEW ENGL J MED, V281, P1345, DOI 10.1056/NEJM196912112812407; BECKER JM, 1991, SURGERY, V110, P718; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BOMAN BM, 1988, CANCER GENET CYTOGEN, V34, P153, DOI 10.1016/0165-4608(88)90182-3; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BUFILL JA, 1990, ANN INTERN MED, V113, P779, DOI 10.7326/0003-4819-113-10-779; BULOW S, 1984, DIS COLON RECTUM, V27, P105, DOI 10.1007/BF02553986; BURDICK D, 1982, CANCER, V50, P2139, DOI 10.1002/1097-0142(19821115)50:10<2139::AID-CNCR2820501028>3.0.CO;2-K; BURT RW, 1984, GASTROENTEROLOGY, V86, P295; BURT RW, 1988, GASTROENTEROL CLIN N, V17, P657; Bussey HJ, 1975, FAMILIAL POLYPOSIS C; BUSSEY HJR, 1978, GASTROENTEROLOGY, V74, P1325; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; CARLSON HE, 1986, AM J HUM GENET, V38, P908; COHEN PR, 1991, AM J MED, V90, P606; COMINGS DE, 1973, P NATL ACAD SCI USA, V70, P3324, DOI 10.1073/pnas.70.12.3324; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FISHEL R, 1994, CELL, V77, P167; FOLEY TR, 1988, GASTROENTEROLOGY, V95, P1535, DOI 10.1016/S0016-5085(88)80074-X; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; GOODMAN ZD, 1979, CANCER, V43, P1906, DOI 10.1002/1097-0142(197905)43:5<1906::AID-CNCR2820430548>3.0.CO;2-O; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GURBUZ AK, 1994, GUT, V35, P377, DOI 10.1136/gut.35.3.377; HAGGITT RC, 1986, AM J SURG PATHOL, V10, P871, DOI 10.1097/00000478-198612000-00006; HAKALA T, 1991, CANCER, V68, P1656, DOI 10.1002/1097-0142(19911001)68:7<1656::AID-CNCR2820680732>3.0.CO;2-7; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; HIXSON LJ, 1993, AM J GASTROENTEROL, V88, P1652; HOWELL J, 1981, J PEDIATR SURG, V16, P82, DOI 10.1016/S0022-3468(81)80124-8; IIDA M, 1985, GASTROENTEROLOGY, V89, P1021, DOI 10.1016/0016-5085(85)90203-3; IIDA M, 1989, GASTROENTEROLOGY, V96, P1301, DOI 10.1016/S0016-5085(89)80017-4; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JARVINEN H, 1983, GUT, V24, P333, DOI 10.1136/gut.24.4.333; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KLEIN WA, 1987, CANCER, V60, P2863, DOI 10.1002/1097-0142(19871215)60:12<2863::AID-CNCR2820601202>3.0.CO;2-I; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KONISHI F, 1987, DIS COLON RECTUM, V30, P790, DOI 10.1007/BF02554629; KURTZ RC, 1987, DIGEST DIS SCI, V32, P459, DOI 10.1007/BF01296027; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; LAW IP, 1977, CANCER-AM CANCER SOC, V39, P1229, DOI 10.1002/1097-0142(197703)39:3<1229::AID-CNCR2820390331>3.0.CO;2-J; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LEPPERT M, 1990, NEW ENGL J MED, V322, P904, DOI 10.1056/NEJM199003293221306; LIU B, 1994, CANCER RES, V54, P4590; LUK GD, 1984, NEW ENGL J MED, V311, P80, DOI 10.1056/NEJM198407123110202; LYNCH HT, 1990, J UROLOGY, V143, P24, DOI 10.1016/S0022-5347(17)39853-1; LYNCH HT, 1992, DIS COLON RECTUM, V35, P411, DOI 10.1007/BF02049396; LYNCH HT, 1985, CANCER, V56, P934, DOI 10.1002/1097-0142(19850815)56:4<934::AID-CNCR2820560439>3.0.CO;2-I; LYNCH HT, 1985, BRIT J CANCER, V52, P271, DOI 10.1038/bjc.1985.187; LYNCH HT, 1985, BRIT J DERMATOL, V113, P295, DOI 10.1111/j.1365-2133.1985.tb02081.x; LYNCH HT, 1993, CANCER, V71, P2709, DOI 10.1002/1097-0142(19930501)71:9<2709::AID-CNCR2820710904>3.0.CO;2-T; LYNCH HT, 1985, CANCER, V56, P939, DOI 10.1002/1097-0142(19850815)56:4<939::AID-CNCR2820560440>3.0.CO;2-T; LYNCH HT, 1991, SEMIN ONCOL, V18, P337; MARRA G, 1994, J CLIN GASTROENTEROL, V18, P42, DOI 10.1097/00004836-199401000-00011; MECKLIN JP, 1992, CANCER, V69, P1112; MECKLIN JP, 1987, GASTROENTEROLOGY, V93, P101; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; MORI T, 1994, GENE CHROMOSOME CANC, V9, P168, DOI 10.1002/gcc.2870090304; NICHOLLS RJ, 1988, BRIT MED J, V296, P1707, DOI 10.1136/bmj.296.6638.1707-a; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OFFERHAUS GJA, 1992, GASTROENTEROLOGY, V102, P1980, DOI 10.1016/0016-5085(92)90322-P; OLSCHWANG S, 1993, CELL, V75, P959, DOI 10.1016/0092-8674(93)90539-3; ORIORDAIN DS, 1991, CANCER, V68, P889, DOI 10.1002/1097-0142(19910815)68:4<889::AID-CNCR2820680435>3.0.CO;2-0; PAINTER TA, 1985, CANCER, V55, P2001, DOI 10.1002/1097-0142(19850501)55:9<2001::AID-CNCR2820550929>3.0.CO;2-7; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PELTOMAKI P, 1991, CANCER RES, V51, P4135; PELTOMAKI P, 1993, CANCER RES, V53, P5853; PERZIN KH, 1982, CANCER-AM CANCER SOC, V49, P971, DOI 10.1002/1097-0142(19820301)49:5<971::AID-CNCR2820490522>3.0.CO;2-1; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; RICHARDS RC, 1981, CANCER, V47, P597, DOI 10.1002/1097-0142(19810201)47:3<597::AID-CNCR2820470329>3.0.CO;2-Z; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUTGEERTS P, 1981, GASTROINTEST ENDOSC, V27, P22, DOI 10.1016/S0016-5107(81)73137-7; SALEM OS, 1983, J AM ACAD DERMATOL, V8, P686, DOI 10.1016/S0190-9622(83)70081-2; SARRE RG, 1987, SURGERY, V101, P50; SCULLY RE, 1970, CANCER, V25, P1107, DOI 10.1002/1097-0142(197005)25:5<1107::AID-CNCR2820250516>3.0.CO;2-7; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SOGOL PB, 1983, WESTERN J MED, V139, P324; SPIRIO L, 1992, AM J HUM GENET, V51, P92; SPIRIO L, 1993, CELL, V75, P951, DOI 10.1016/0092-8674(93)90538-2; STARINK TM, 1986, CLIN GENET, V29, P222; STERN HS, 1990, SURGERY, V108, P528; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TONELLI F, 1985, DIS COLON RECTUM, V28, P664, DOI 10.1007/BF02553447; TOPS CMJ, 1993, AM J MED GENET, V47, P563, DOI 10.1002/ajmg.1320470425; TRABOULSI EI, 1990, ARCH OPHTHALMOL-CHIC, V108, P525, DOI 10.1001/archopht.1990.01070060073052; TRABOULSI EI, 1987, NEW ENGL J MED, V316, P661, DOI 10.1056/NEJM198703123161104; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; VOGEL VG, 1989, HEMATOL ONCOL CLIN N, V3, P35, DOI 10.1016/S0889-8588(18)30566-5; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; WATANABE H, 1978, HUM PATHOL, V9, P269, DOI 10.1016/S0046-8177(78)80085-9; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WINAWER SJ, 1991, JNCI-J NATL CANCER I, V83, P243, DOI 10.1093/jnci/83.4.243	105	179	188	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 22	1994	331	25					1694	1702		10.1056/NEJM199412223312507	http://dx.doi.org/10.1056/NEJM199412223312507			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX382	7969362				2022-12-01	WOS:A1994PX38200007
J	GREENGARD, JS; EICHINGER, S; GRIFFIN, JH; BAUER, KA				GREENGARD, JS; EICHINGER, S; GRIFFIN, JH; BAUER, KA			VARIABILITY OF THROMBOSIS AMONG HOMOZYGOUS SIBLINGS WITH RESISTANCE TO ACTIVATED PROTEIN-C DUE TO AN ARG-]GLN MUTATION IN THE GENE FOR FACTOR-V	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							POOR ANTICOAGULANT RESPONSE; VENOUS THROMBOSIS; PURPURA FULMINANS; DEFICIENCY; THROMBOPHILIA; FRAGMENT; MARKERS; NEWBORN; INFANT		SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA USA; BROCKTON W ROXBURY VET AFFAIRS MED CTR, DEPT MED, BOSTON, MA USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, BOSTON, MA USA	Scripps Research Institute; Scripps Research Institute; Harvard University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School				Griffin, John/0000-0002-4302-2547	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL033014, R01HL021544] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 21544, HL 33014] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUER KA, 1984, J CLIN INVEST, V74, P2033, DOI 10.1172/JCI111626; BAUER KA, 1988, BLOOD, V71, P1418; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BRANSON HE, 1983, LANCET, V2, P1165; CONARD J, 1993, BLOOD, V82, P1159; CRIPE LD, 1992, BIOCHEMISTRY-US, V31, P3777, DOI 10.1021/bi00130a007; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; FAIONI EM, 1993, THROMB HAEMOSTASIS, V70, P1067; GREENGARD JS, 1994, LANCET, V343, P1361, DOI 10.1016/S0140-6736(94)92497-X; GRIFFIN JH, 1993, BLOOD, V82, P1989; HALBMAYER WM, 1994, BLOOD COAGUL FIBRIN, V5, P51, DOI 10.1097/00001721-199402000-00008; HEEB MJ, 1993, J BIOL CHEM, V268, P2872; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KOELEMAN BPC, 1994, BLOOD, V84, P1031; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LINDBLOM B, 1988, GENE ANAL TECH, V5, P97, DOI 10.1016/0735-0651(88)90003-9; MAHASANDANA C, 1990, J PEDIATR-US, V117, P750, DOI 10.1016/S0022-3476(05)83335-9; MANNUCCI PM, 1992, THROMB HAEMOSTASIS, V67, P200; SELIGSOHN U, 1984, NEW ENGL J MED, V310, P559, DOI 10.1056/NEJM198403013100904; SUN X, 1994, BLOOD, V83, P3120; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; TEITEL JM, 1982, BLOOD, V59, P1086; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4; ZOLLER B, 1994, LANCET, V343, P1536, DOI 10.1016/S0140-6736(94)92940-8	24	138	140	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 8	1994	331	23					1559	1562		10.1056/NEJM199412083312305	http://dx.doi.org/10.1056/NEJM199412083312305			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV292	7969326				2022-12-01	WOS:A1994PV29200005
J	THALI, M; BUKOVSKY, A; KONDO, E; ROSENWIRTH, B; WALSH, CT; SODROSKI, J; GOTTLINGER, HG				THALI, M; BUKOVSKY, A; KONDO, E; ROSENWIRTH, B; WALSH, CT; SODROSKI, J; GOTTLINGER, HG			FUNCTIONAL ASSOCIATION OF CYCLOPHILIN-A WITH HIV-1 VIRIONS	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CIS-TRANS ISOMERASE; BINDING-PROTEIN; CYCLOSPORINE-A; HISTOCOMPATIBILITY; REPLICATION; CELLS; GENE	CYCLOPHILINS are a family of proteins that bind the immunosuppressant cyclosporin A, possess peptidyl-prolyl cis-trans isomerase activity, and assist in the folding of proteins(1-6). Human cyclophilins A and B are host cell proteins that bind specifically to the HIV-1 Gag polyprotein p55(gag) in vitro(7). Here we report that viral particles formed by p55(gag), in contrast to particles formed by the Gag polyproteins of other retroviruses, contain significant amounts of cyclophilin A. Sequences in the capsid domain of p55(gag) are both required and sufficient for the virion-association of cyclophilin A. The association of cyclophilin A with HIV-1 virions was inhibited in a dose-dependent manner by cyclosporin A as well as by SDZ NIM811 ([Melle-4] cyclosporin), a non-immunosuppressive analogue of cyclosporin A(8). Drug-induced reductions in virion-associated cyclophilin A levels were accompanied by reductions in virion infectivity, indicating that the association is functionally relevant. Moreover, SDZ NIM811 inhibited the replication of HIV-1 but was inactive against SIVIMAC, a primate immunodeficiency virus closely related to HIV-1, which does not incorporate cyclophilin A.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV HUMAN RETROVIROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; SANDOZ GMBH,FORSCHUNGSINST,A-1235 VIENNA,AUSTRIA; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Novartis; Sandoz; Harvard University; Harvard Medical School				Gottlinger, Heinrich/0000-0003-4124-5824; Thali, Markus/0000-0001-8621-2095				ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; DORFMAN T, 1994, J VIROL, V68, P1689, DOI 10.1128/JVI.68.3.1689-1696.1994; DORFMAN T, 1994, J VIROL, V68, P8180, DOI 10.1128/JVI.68.12.8180-8187.1994; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; GELDERBLOM H, 1987, Z NATURFORSCH C, V42, P1328; GELDERBLOM HR, 1987, VIROLOGY, V156, P171, DOI 10.1016/0042-6822(87)90449-1; GOTTLINGER HG, 1993, P NATL ACAD SCI USA, V90, P7381, DOI 10.1073/pnas.90.15.7381; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; KANNAGI M, 1987, J VIROL, V61, P1421, DOI 10.1128/JVI.61.5.1421-1426.1987; KAYE RE, 1992, P NATL ACAD SCI USA, V89, P8542, DOI 10.1073/pnas.89.18.8542; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MAMMANO F, 1994, J VIROL, V68, P4927, DOI 10.1128/JVI.68.8.4927-4936.1994; ROSENWIRTH B, 1994, ANTIMICROB AGENTS CH, V38, P1763, DOI 10.1128/AAC.38.8.1763; SCHOLS D, 1992, VIROLOGY, V189, P374, DOI 10.1016/0042-6822(92)90719-6; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; STAMNES M A, 1992, Trends in Cell Biology, V2, P272, DOI 10.1016/0962-8924(92)90200-7; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TERWILLIGER EF, 1989, P NATL ACAD SCI USA, V86, P3857, DOI 10.1073/pnas.86.10.3857; WALSH CT, 1992, J BIOL CHEM, V267, P13115; WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002	23	551	570	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					363	365		10.1038/372363a0	http://dx.doi.org/10.1038/372363a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PU287	7969495				2022-12-01	WOS:A1994PU28700056
J	SCHABLE, C; ZEKENG, L; PAU, CP; HU, D; KAPTUE, L; GURTLER, L; DONDERO, T; TSAGUE, JM; SCHOCHETMAN, G; JAFFE, H; GEORGE, JR				SCHABLE, C; ZEKENG, L; PAU, CP; HU, D; KAPTUE, L; GURTLER, L; DONDERO, T; TSAGUE, JM; SCHOCHETMAN, G; JAFFE, H; GEORGE, JR			SENSITIVITY OF UNITED-STATES HIV ANTIBODY TESTS FOR DETECTION OF HIV-1 GROUP-O INFECTIONS	LANCET			English	Note								Infections by highly divergent strains of HIV-1, first detected in central Africa and grouped provisionally as group O, have not been reliably detected by certain European HIV screening tests. Serum specimens from eight probable group O infections from Cameroon were tested by ten HIV assays licensed by the US Food and Drug Administration. All assays based on synthetic peptides or recombinant antigens failed to detect at least one of the infections; assays based on whole-virus lysates performed better. Divergent HIV strains may be undetected by current HIV tests. Thus active surveillance for and characterisation of HIV variants to evaluate and, when necessary, modify current tests is urgently needed.	CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333; UNIV YAOUNDE,YAOUNDE,CAMEROON; MAX VON PETTENKOFER INST,W-8000 MUNICH,GERMANY	Centers for Disease Control & Prevention - USA; University of Yaounde I; University of Munich				Gurtler, Lutz/0000-0003-3435-9030				DELEYS R, 1990, J VIROL, V64, P1207, DOI 10.1128/JVI.64.3.1207-1216.1990; GURTLER LG, 1994, J VIROL, V68, P1581; LOUSSERTAJAKA I, 1994, LANCET, V343, P1393, DOI 10.1016/S0140-6736(94)92524-0; LOUWAGIE J, 1993, AIDS, V7, P769, DOI 10.1097/00002030-199306000-00003; MYERS G, 1993, HUMAN RETROVIRUSES A; NKENGASONG JN, 1993, AIDS, V7, P1536, DOI 10.1097/00002030-199311000-00026; PAU CP, 1993, AIDS, V7, P337, DOI 10.1097/00002030-199303000-00005	7	110	117	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 12	1994	344	8933					1333	1334		10.1016/S0140-6736(94)90695-5	http://dx.doi.org/10.1016/S0140-6736(94)90695-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ926	7968029				2022-12-01	WOS:A1994PQ92600011
J	WILSON, APR				WILSON, APR			THE DANGERS OF BIPP	LANCET			English	Editorial Material											WILSON, APR (corresponding author), UCL HOSP, DEPT CLIN MICROBIOL, LONDON, ENGLAND.							BLACK B, 1979, CLIN OTOLARYNGOL, V4, P207, DOI 10.1111/j.1365-2273.1979.tb01887.x; Chambers H, 1917, LANCET, V1, P333; CHEVRETTON EB, 1991, J LARYNGOL OTOL, V105, P916, DOI 10.1017/S0022215100117803; Colman G, 1962, BR DENT J, V113, P22; JONES JAH, 1990, ORAL SURG ORAL MED O, V69, P668, DOI 10.1016/0030-4220(90)90344-R; KRUGER G, 1976, LANCET, V2, P485; LEQUESNE PM, 1981, J NEUROL NEUROSUR PS, V44, P1, DOI 10.1136/jnnp.44.1.1; MCRAE RDR, 1992, J LARYNGOL OTOL, V106, P387; MILLER WA, 1974, BRIT DENT J, V137, P278, DOI 10.1038/sj.bdj.4803305; NIGAM A, 1990, CLIN OTOLARYNGOL, V15, P173, DOI 10.1111/j.1365-2273.1990.tb00452.x; OCONNOR AFF, 1977, J LARYNGOL OTOL, V91, P903, DOI 10.1017/S002221510008453X; SHARMA RR, 1994, J NEUROL NEUROSUR PS, V57, P990, DOI 10.1136/jnnp.57.8.990	12	14	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 12	1994	344	8933					1313	1314		10.1016/S0140-6736(94)90689-0	http://dx.doi.org/10.1016/S0140-6736(94)90689-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ926	7968025				2022-12-01	WOS:A1994PQ92600005
J	JONES, DA; THOMAS, CM; HAMMONDKOSACK, KE; BALINTKURTI, PJ; JONES, JDG				JONES, DA; THOMAS, CM; HAMMONDKOSACK, KE; BALINTKURTI, PJ; JONES, JDG			ISOLATION OF THE TOMATO CF-9 GENE FOR RESISTANCE TO CLADOSPORIUM-FULVUM BY TRANSPOSON TAGGING	SCIENCE			English	Article							PLATELET GLYCOPROTEIN-IB; LEUCINE-RICH REPEATS; PROTEIN-KINASE; TRANSMEMBRANE PROTEIN; DISEASE-RESISTANCE; ARABIDOPSIS-THALIANA; RECEPTOR; CLONING; DOMAIN; SEQUENCE	The tomato Cf-9 gene confers resistance to infection by races of the fungus Cladosporium fulvum that carry the avirulence gene Avr9. The Cf-9 gene was isolated by transposon tagging with the maize transposable element Dissociation, The DNA sequence of Cf-9 encodes a putative membrane-anchored extracytoplasmic glycoprotein. The predicted protein shows homology to the receptor domain of several receptor-like protein kinases in Arabidopsis, to antifungal polygalacturonase-inhibiting proteins in plants, and to other members of the leucine-rich repeat family of proteins. This structure is consistent with that of a receptor that could bind Avr9 peptide and activate plant defense.	JOHN INNES INST,JOHN INNES CTR PLANT SCI RES,SAINSBURY LAB,NORWICH NR4 7UH,NORFOLK,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center			Balint-kurti, Peter/AES-0111-2022; Jones, Jonathan DG/J-5129-2012; Jones, David A/C-9507-2009	Jones, Jonathan DG/0000-0002-4953-261X; Jones, David A/0000-0001-8809-5822; Balint-Kurti, Peter/0000-0002-3916-194X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDREWS RK, 1992, J BIOL CHEM, V267, P18605; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; CHANG C, 1992, PLANT CELL, V4, P1263, DOI 10.1105/tpc.4.10.1263; FIELD J, 1990, SCIENCE, V247, P464, DOI 10.1126/science.2405488; HAMMONDKOSACK KE, 1994, PLANT CELL, V6, P361, DOI 10.2307/3869756; HAMMONDKOSACK KE, 1994, P NATL ACAD SCI USA, V91, P10445, DOI 10.1073/pnas.91.22.10445; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; Jones D. B., UNPUB; JONES DA, 1993, MOL PLANT MICROBE IN, V6, P348, DOI 10.1094/MPMI-6-348; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; PRYOR T, 1987, TRENDS GENET, V3, P157, DOI 10.1016/0168-9525(87)90217-4; PRYOR T, 1993, ADV PLANT PATHOL, V10, P281; ROMMENS CMT, 1992, PLANT MOL BIOL, V20, P61, DOI 10.1007/BF00029149; ROTH S, 1994, CURR BIOL, V4, P755, DOI 10.1016/S0960-9822(00)00170-6; SCOFIELD SR, 1992, PLANT CELL, V4, P573, DOI 10.1105/tpc.4.5.573; STEINMAYR M, 1994, PLANT J, V5, P459, DOI 10.1046/j.1365-313X.1994.5040459.x; STOTZ HU, 1993, PLANT PHYSIOL, V102, P133, DOI 10.1104/pp.102.1.133; STOTZ HU, 1994, PLANT MOL BIOL, V25, P607, DOI 10.1007/BF00029600; SUDUPAK MA, 1993, GENETICS, V133, P119; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; TOUBART P, 1992, PLANT J, V2, P367; TOURVIEILLE B, 1986, SCIENCE, V234, P610, DOI 10.1126/science.3094146; TOWNSLEY FM, 1994, EUROPEAN J CELL BIOL, V64, P221; VALON C, 1993, PLANT MOL BIOL, V23, P415, DOI 10.1007/BF00029017; VANDENACKERVEKEN GFJM, 1992, PLANT J, V2, P359, DOI 10.1111/j.1365-313X.1992.00359.x; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALKER JC, 1993, PLANT J, V3, P451, DOI 10.1046/j.1365-313X.1993.t01-23-00999.x; WARE J, 1993, J CLIN INVEST, V92, P1213, DOI 10.1172/JCI116692; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6	38	714	895	5	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					789	793		10.1126/science.7973631	http://dx.doi.org/10.1126/science.7973631			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973631				2022-12-01	WOS:A1994PP75300035
J	LEE, GU; CHRISEY, LA; COLTON, RJ				LEE, GU; CHRISEY, LA; COLTON, RJ			DIRECT MEASUREMENT OF THE FORCES BETWEEN COMPLEMENTARY STRANDS OF DNA	SCIENCE			English	Article							MICROSCOPY; OLIGONUCLEOTIDES; MOLECULES	Interaction forces between single strands of DNA were measured with the atomic force microscope by a procedure in which DNA oligonucleotides were covalently attached to a spherical probe and surface. Adhesive forces measured between complementary 20-base strands fell into three distinct distributions centered at 1.52, 1.11, and 0.83 nano-newtons, which are associated with the rupture of the interchain interaction between a single pair of molecules involving 20, 16, and 12 base pairs, respectively. When a third long DNA molecule was coupled between complementary surfaces, both intra- and interchain forces were observed. The intrachain interaction resulting from the molecule's elasticity manifested itself as a long-range cohesive force.z	USN, RES LAB, CTR BIOMOLEC SCI & ENGN, WASHINGTON, DC 20375 USA	United States Department of Defense; United States Navy; Naval Research Laboratory	LEE, GU (corresponding author), USN, RES LAB, DIV CHEM, CODE 6177, WASHINGTON, DC 20375 USA.		Lee, Gil U/P-8696-2016	Lee, Gil U/0000-0002-7949-5848				ALBRECHT TR, 1988, J VAC SCI TECHNOL A, V6, P271, DOI 10.1116/1.575441; ASHKIN A, 1987, NATURE, V330, P769, DOI 10.1038/330769a0; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; BHATIA SK, 1989, ANAL BIOCHEM, V178, P408, DOI 10.1016/0003-2697(89)90662-3; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; CHRISEY LA, 1994, MATER RES SOC SYMP P, V330, P179; CONNOLLY BA, 1985, NUCLEIC ACIDS RES, V13, P4485, DOI 10.1093/nar/13.12.4485; DENG GR, 1983, METHOD ENZYMOL, V100, P96; DURIG U, 1992, J APPL PHYS, V72, P1778, DOI 10.1063/1.352348; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; Flory PJ., 1953, PRINCIPLES POLYM CHE; FLORY PJ, 1989, STATISTICAL MECHANIC; INMAN RB, 1964, J MOL BIOL, V8, P452, DOI 10.1016/S0022-2836(64)80003-6; INMAN RB, 1964, J MOL BIOL, V9, P624, DOI 10.1016/S0022-2836(64)80171-6; ISRAELACHVILI JN, 1992, INTERMOLECULAR SURFA, pCH10; James HM, 1943, J CHEM PHYS, V11, P455, DOI 10.1063/1.1723785; KLUMP HH, 1988, BIOCH THERMODYNAMICS, P105; KUMAR A, 1991, NUCLEIC ACIDS RES, V19, P4561, DOI 10.1093/nar/19.16.4561; LEE GU, 1994, LANGMUIR, V10, P354, DOI 10.1021/la00014a003; MARKY LA, 1987, BIOPOLYMERS, V26, P1601, DOI 10.1002/bip.360260911; MEYER G, 1988, APPL PHYS LETT, V53, P1045, DOI 10.1063/1.100061; PERKINS TT, 1994, SCIENCE, V264, P822, DOI 10.1126/science.8171336; PUTMAN CAJ, 1992, J APPL PHYS, V72, P6, DOI 10.1063/1.352149; RAU DC, 1984, P NATL ACAD SCI-BIOL, V81, P2621, DOI 10.1073/pnas.81.9.2621; SAENGER W, 1983, PRINCIPLES NUCLEIC A, pCH6; Sambrook J., 1989, MOL CLONING LAB MANU; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0	28	745	793	3	146	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					771	773		10.1126/science.7973628	http://dx.doi.org/10.1126/science.7973628			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973628				2022-12-01	WOS:A1994PP75300029
J	SURH, CD; SPRENT, J				SURH, CD; SPRENT, J			T-CELL APOPTOSIS DETECTED IN-SITU DURING POSITIVE AND NEGATIVE SELECTION IN THE THYMUS	NATURE			English	Article							MONOCLONAL-ANTIBODIES; COMPLEX; DEATH; IDENTIFICATION; THYMOCYTES; MEDULLA; INVIVO	BECAUSE of positive and negative selection to molecules of the major histocompatibility complex (MHC)(1), only a small proportion of the massive numbers of T cells generated is the thymus are selected for expert(2,3). Immature thymocytes have a rapid turnover(2), and it has long been assumed that most thymocytes die in situ(4,5), presumably from apoptosis(6). This has yet to be proved, however, and conventional staining techniques have shown only minimal evidence of cell death in the normal thymus(7,8). Using a method for detecting cells with DNA strand breaks, we now present direct evidence for apoptosis in the normal thymus. In sections of thymus from adult mice, apoptotic cells are scattered throughout the cortex and are engulfed locally by F4/80(+) macrophages. Apoptosis in the thymic cortex is not reduced in MHC-deficient mice, which suggests that T-cell death is primarily a reflection of lack of positive selection rather than negative selection. Direct evidence for apoptosis due to negative selection was obtained by crossing a V beta 5 transgenic line(9) to I-E(+) and I-E(-) mice: I-E(+) mice are known to eliminate V beta 5(+) T cells in the thymus whereas I-E(-) mice do not(10). In marked contrast to I-E(-) mice, the medulla of I-E(+) V beta 5 transgenic mice contains dense aggregates of apoptotic cells; these cells are engulfed by a distinct population of F4/80(-) MAC-3(+) macrophages. Negative selection of V beta 5(+) cells is thus restricted to the medulla.			SURH, CD (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL IMM4, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							Anderson R E, 1976, Adv Immunol, V24, P215, DOI 10.1016/S0065-2776(08)60331-4; CARDELL S, 1994, ADV IMMUNOL, V55, P423; DUIJVESTIJN AM, 1981, CELL TISSUE RES, V218, P279; FINK PJ, 1992, J EXP MED, V176, P1733, DOI 10.1084/jem.176.6.1733; FLOTTE TJ, 1983, AM J PATHOL, V111, P112; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; HENGARTNER H, 1988, NATURE, V336, P388, DOI 10.1038/336388a0; KENDALL MD, 1984, IMMUNOL TODAY, V5, P286, DOI 10.1016/0167-5699(84)90148-8; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.immunol.12.1.117; MALEK TR, 1983, P NATL ACAD SCI-BIOL, V80, P5694, DOI 10.1073/pnas.80.18.5694; METCALF DONALD, 1966, P242; MURPHY DB, 1989, NATURE, V338, P765, DOI 10.1038/338765a0; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; PULLEN AM, 1989, IMMUNOL REV, V107, P125, DOI 10.1111/j.1600-065X.1989.tb00006.x; ROBEY E, 1994, ANNU REV IMMUNOL, V12, P675, DOI 10.1146/annurev.iy.12.040194.003331; Saint-Marie G., 1970, REV CAN BIOL, V30, P51; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SCOLLAY R, 1985, RECOGNITION REGULATI, P3; SHI YF, 1991, J IMMUNOL, V146, P3340; Shortman K, 1990, Semin Immunol, V2, P3; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SURH CD, 1992, J EXP MED, V176, P495, DOI 10.1084/jem.176.2.495; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	29	884	902	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					100	103		10.1038/372100a0	http://dx.doi.org/10.1038/372100a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969401				2022-12-01	WOS:A1994PQ34800082
J	FRANTZ, TD; RASGON, BM; QUESENBERRY, CP				FRANTZ, TD; RASGON, BM; QUESENBERRY, CP			ACUTE EPIGLOTTITIS IN ADULTS - ANALYSIS OF 129 CASES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To characterize the clinical features of acute epiglottitis in adults and to identify factors associated with airway intervention. Design.-Case series. Setting.-Northern California health maintenance organization. Participants.-A total of 129 patients aged 18 years or older with laryngoscopically confirmed acute epiglottitis admitted from November 1986 through October 1991. Results.-The mean patient age was 47 years (range, 18 to 85 years) and the male-to-female ratio was 1.8 to 1.0 (P<.001). The most common symptoms were sore throat (95% and odynophagia (94%); the most common signs were muffled voice and evidence of pharyngitis. Nineteen patients (15%) received airway intervention, including seven with tracheotomy and 12 with endotracheal intubation. The remaining 110 patients recovered fully without airway intervention. In multivariate analysis, factors associated with airway intervention were strider (relative risk [RR], 6.2; 95% confidence interval [CI], 1.7 to 22.9) and sitting erect (RR, 4.8; 95% CI, 1.3 to 16.1). Six (12%) of 52 blood cultures yielded Haemophilus influenzae type b. Major complications occurred in six patients (5%), but no deaths occurred. Conclusion.-Most adults who have acute epiglottitis can be managed conservatively and have low morbidity and mortality.	KAISER PERMANENTE MED CTR,DEPT HEAD & NECK SURG,OAKLAND,CA 94611; KAISER PERMANENTE MED CARE PROGRAM,DIV RES,OAKLAND,CA 94611	Kaiser Permanente; Kaiser Permanente								BAXTER FJ, 1988, CAN J ANAESTH, V35, P428, DOI 10.1007/BF03010869; DEEB ZE, 1985, LARYNGOSCOPE, V95, P289; FRANTZ TD, 1993, OTOLARYNG HEAD NECK, V109, P457, DOI 10.1177/019459989310900311; KHILANANI U, 1984, AM J MED SCI, V287, P65, DOI 10.1097/00000441-198401000-00022; OSSOFF RH, 1980, LARYNGOSCOPE, V90, P1155, DOI 10.1288/00005537-198007000-00011; SHAPIRO J, 1988, JAMA-J AM MED ASSOC, V259, P563, DOI 10.1001/jama.259.4.563; SHEIKH KH, 1989, WESTERN J MED, V151, P520; SHIH L, 1988, ANN OTO RHINOL LARYN, V97, P527, DOI 10.1177/000348948809700517; SMITH MFM, 1986, NEW ENGL J MED, V314, P1133; STANLEY RE, 1988, J LARYNGOL OTOL, V102, P1017, DOI 10.1017/S0022215100107157; WOLF M, 1990, LARYNGOSCOPE, V100, P183	11	118	120	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	1994	272	17					1358	1360		10.1001/jama.272.17.1358	http://dx.doi.org/10.1001/jama.272.17.1358			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP020	7933397				2022-12-01	WOS:A1994PP02000031
J	SCHLICHTING, I; BERENDZEN, J; PHILLIPS, GN; SWEET, RM				SCHLICHTING, I; BERENDZEN, J; PHILLIPS, GN; SWEET, RM			CRYSTAL-STRUCTURE OF PHOTOLYZED CARBONMONOXY-MYOGLOBIN	NATURE			English	Article							LIGAND-BINDING; HEME-PROTEINS; MOLECULAR-DYNAMICS; PHOTOPRODUCTS; RESOLUTION; MONOXIDE; RAMAN; CRYSTALLOGRAPHY; DIFFRACTION; REFINEMENT	MYOGLOBIN is a globular haem protein that reversibly binds ligands such as O-2 and CO. Single photons of visible light can break the covalent bond between CO and the haem iron in carbon-monoxy-myoglobin (MbCO) and thus form an unstable intermediate, Mb*CO, with the CO inside the protein(1,2). The ensuing rebinding process has been extensively studied as a model for the interplay of dynamics, structure and function in protein reactions. We have used X-ray crystallography at liquid-helium temperatures to determine the structure of Mb*CO to a resolution of 1.5 Angstrom. The photodissociated CO lies on top of the haem pyrrole ring C. Comparison with the CO-bound and unligated myoglobin structures reveals that on photodissociation of the CO, the haem 'domes', the iron moves partially out of the haem plane, the iron-proximal histidine bond is compressed, the F helix is strained and the distal histidine swings towards the outside of the ligand-binding pocket.	MAX PLANCK INST MED RES,DEPT BIOPHYS,D-69120 HEIDELBERG,GERMANY; RICE UNIV,WM KECK CTR COMPUTAT BIOL,HOUSTON,TX 77251; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	Max Planck Society; Rice University; United States Department of Energy (DOE); Brookhaven National Laboratory			Schlichting, Ilme/I-1339-2013	Berendzen, Joel/0000-0002-9454-9074				AGMON N, 1983, J CHEM PHYS, V79, P2042, DOI 10.1063/1.445988; AHMED AM, 1991, CHEM PHYS, V158, P329, DOI 10.1016/0301-0104(91)87076-8; ALBEN JO, 1982, P NATL ACAD SCI-BIOL, V79, P3744, DOI 10.1073/pnas.79.12.3744; Antonini E., 1971, FRONT BIOL, DOI DOI 10.1126/SCIENCE.178.4058.296; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BARTUNIK HD, 1983, NUCL INSTRUM METHODS, V208, P523, DOI 10.1016/0167-5087(83)91176-6; BRUNGER AT, 1993, XPLOR VERSION 31 MAN; CASE DA, 1979, J MOL BIOL, V132, P343, DOI 10.1016/0022-2836(79)90265-1; CHENG XD, 1991, J MOL BIOL, V220, P381, DOI 10.1016/0022-2836(91)90020-7; DASGUPTA S, 1986, BIOCHEMISTRY-US, V25, P5941, DOI 10.1021/bi00368a016; GIBSON QH, 1992, J BIOL CHEM, V268, P17908; HONG MK, 1989, THESIS U ILLINOIS UR; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KUCZERA K, 1993, P NATL ACAD SCI USA, V90, P5805, DOI 10.1073/pnas.90.12.5805; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; ORMOS P, 1988, P NATL ACAD SCI USA, V85, P8492, DOI 10.1073/pnas.85.22.8492; PHILLIPS GN, 1990, PROTEINS, V7, P358, DOI 10.1002/prot.340070407; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; POWERS L, 1987, BIOCHEMISTRY-US, V26, P4785, DOI 10.1021/bi00389a028; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RINGE D, 1984, BIOCHEMISTRY-US, V23, P2, DOI 10.1021/bi00296a001; ROTHBERG LJ, 1991, P SPIE INT SOC OPT E, V1599, P309; ROUSSEAU DL, 1986, P NATL ACAD SCI USA, V83, P1310, DOI 10.1073/pnas.83.5.1310; SASSAROLI M, 1986, J BIOL CHEM, V261, P3704; STAVROV SS, 1993, BIOPHYS J, V65, P1942, DOI 10.1016/S0006-3495(93)81265-7; STEINBACH PJ, 1991, BIOCHEMISTRY-US, V30, P3988, DOI 10.1021/bi00230a026; STRAUB JE, 1991, CHEM PHYS, V158, P221, DOI 10.1016/0301-0104(91)87068-7; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; TENG TY, 1987, BIOCHEMISTRY-US, V26, P8066, DOI 10.1021/bi00399a007; TLTON RF, 1982, BIOCHEMISTRY-US, V23, P2849	31	336	338	0	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 27	1994	371	6500					808	812		10.1038/371808a0	http://dx.doi.org/10.1038/371808a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP018	7935843				2022-12-01	WOS:A1994PP01800063
J	SONG, YH; CONNOR, E; LI, YX; ZOROVICH, B; BALDUCCI, P; MACLAREN, N				SONG, YH; CONNOR, E; LI, YX; ZOROVICH, B; BALDUCCI, P; MACLAREN, N			THE ROLE OF TYROSINASE IN AUTOIMMUNE VITILIGO	LANCET			English	Article							MELANOCYTE AUTOANTIBODIES; DIABETES-MELLITUS; ANTIBODIES; SEQUENCE; CLONE	Vitiligo is a common depigmenting skin disease, associated with certain autoimmune endocrinopathies, and autoantibodies to several antigens can be found in melanoma cells. We set out to identify the antigens. We examined 26 patients with vitiligo and associated endocrine disease. Of these, 18 patients (77%) and 8 immediate family members had autoantibodies specific for a 69 kDa protein in HTB-70 human melanoma cells that was not seen in control cells. The autoantibody-positive patient sera reacted with recombinant human tyrosinase expressed in Escherichia cell seen by western blots, as did antibodies raised in rabbits against hamster tyrosinase, but not to recombinant tyrosinase-related protein. Not one of 31 normal controls or 8 patients with alopecia or systemic lupus erythematosus had tyrosinase autoantibodies but a small proportion (12%) of 42 patients with autoimmune endocrine disease without a history of vitiligo had them. The results show that tyrosinase, an enzyme important in melanin formation, is a principal autoantigen of autoimmune vitiligo.	UNIV FLORIDA,COLL MED,DEPT PATHOL & LAB MED,GAINESVILLE,FL 32610; UNIV FLORIDA,COLL MED,DEPT PEDIAT,GAINESVILLE,FL 32610	State University System of Florida; University of Florida; State University System of Florida; University of Florida			Song, Yao-Hua/A-2516-2011	Connor, Ellen/0000-0002-9667-7002	NICHD NIH HHS [R01HD19469] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD019469] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AHONEN P, 1990, NEW ENGL J MED, V322, P1829, DOI 10.1056/NEJM199006283222601; ATKINSON MA, 1990, LANCET, V335, P1357, DOI 10.1016/0140-6736(90)91241-2; AUSTIN LM, 1992, CLIN IMMUNOL IMMUNOP, V64, P112, DOI 10.1016/0090-1229(92)90188-T; BADRI M, 1993, J PATHOL, V170, P149; BROSTOFF J, 1969, LANCET, V2, P177; COHEN T, 1990, NUCLEIC ACIDS RES, V18, P2807, DOI 10.1093/nar/18.9.2807; CUI J, 1993, J INVEST DERMATOL, V100, P812, DOI 10.1111/1523-1747.ep12476636; GOUDIE RB, 1990, LANCET, V335, P316, DOI 10.1016/0140-6736(90)90607-7; GOULD IM, 1985, BRIT J DERMATOL, V113, P153, DOI 10.1111/j.1365-2133.1985.tb02057.x; HERTZ KC, 1977, NEW ENGL J MED, V297, P634, DOI 10.1056/NEJM197709222971204; HOWITZ J, 1971, LANCET, V1, P1331; JIMENEZ M, 1989, J BIOL CHEM, V264, P3397; KWON BS, 1987, P NATL ACAD SCI USA, V84, P7473, DOI 10.1073/pnas.84.21.7473; LAMONT SJ, 1981, CLIN IMMUNOL IMMUNOP, V21, P407, DOI 10.1016/0090-1229(81)90229-4; LEPOOLE IC, 1993, J INVEST DERMATOL, V100, P816, DOI 10.1111/1523-1747.ep12476645; LORINI R, 1992, AUTOIMMUNITY, V11, P255, DOI 10.3109/08916939209035163; MACLAREN NK, 1985, DIABETES CARE, V8, P34, DOI 10.2337/diacare.8.1.S34; MOELLMANN GE, 1985, J INVEST DERMATOL, V84, P333; NAUGHTON GK, 1983, J INVEST DERMATOL, V81, P540, DOI 10.1111/1523-1747.ep12522891; NAUGHTON GK, 1983, J EXP MED, V158, P246, DOI 10.1084/jem.158.1.246; NEUFELD M, 1981, MEDICINE, V60, P355, DOI 10.1097/00005792-198109000-00003; NORRIS DA, 1988, J INVEST DERMATOL, V90, P783, DOI 10.1111/1523-1747.ep12461505; Sambrook J., 1989, MOL CLONING LAB MANU; SEARLE EA, 1993, PIGM CELL RES, V6, P145, DOI 10.1111/j.1600-0749.1993.tb00594.x	24	151	165	3	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1049	1052		10.1016/S0140-6736(94)91709-4	http://dx.doi.org/10.1016/S0140-6736(94)91709-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7934446				2022-12-01	WOS:A1994PL85200009
J	JACKSON, DY; BURNIER, J; QUAN, C; STANLEY, M; TOM, J; WELLS, JA				JACKSON, DY; BURNIER, J; QUAN, C; STANLEY, M; TOM, J; WELLS, JA			A DESIGNED PEPTIDE LIGASE FOR TOTAL SYNTHESIS OF RIBONUCLEASE-A WITH UNNATURAL CATALYTIC RESIDUES	SCIENCE			English	Article							BOVINE PANCREATIC RIBONUCLEASE; AMINO-ACIDS; PROTEINS; DEPENDENCE; ENZYMES	An engineered variant of subtilisin BPN', termed subtilligase, which efficiently ligates esterified peptides in aqueous solution, was used for the complete synthesis of ribonuclease (RNase) A that contains unnatural catalytic residues. Fully active RNase A (124 residues long) was produced in milligram quantities by stepwise ligation of six esterified peptide fragments (each 12 to 30 residues long) at yields averaging 70 percent per ligation. Variants of RNase A were produced in which the catalytic histidines at positions 12 and 119 were substituted with the unnatural amino acid 4-fluorohistidine, which has a pK(a) of 3.5 compared to 6.8 for histidine. Large changes in the profile of the pH as it affects rate occurred for the single and double mutants with surprisingly little change in the k(cat) for either the RNA cleavage or hydrolysis steps. The data indicate that these imidazoles function as general acids and bases, but that the proton transfer steps are not rate-limiting when the imidazoles are present in their correct protonation states. These studies indicate the potential of subtilligase for the blockwise synthesis of large proteins.	GENENTECH INC,DEPT PROT ENGN,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT BIOORGAN CHEM,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech			Wells, Jim A/O-9854-2016					ABRAHMSEN L, 1991, BIOCHEMISTRY-US, V30, P4151, DOI 10.1021/bi00231a007; ANSLYN E, 1989, J AM CHEM SOC, V111, P4473, DOI 10.1021/ja00194a050; BLACKBURN P, 1982, ENZYMES, V15; BODANSZKY M, 1984, PRACTICE PEPTIDE SYN, V21; BRESLOW R, 1991, TETRAHEDRON, V47, P2365, DOI 10.1016/S0040-4020(01)81774-9; BROWN TB, 1981, J CHEM SOC CHEM COMM, V408, P648; BRUICE TC, 1963, J AM CHEM SOC, V85, P1659, DOI 10.1021/ja00894a028; CAMPBELL RL, 1987, BIOCHEMISTRY-US, V26, P8579, DOI 10.1021/bi00400a013; CHANG TK, IN PRESS P NATL ACAD; DUNN BM, 1974, J BIOL CHEM, V249, P6295; FINDLAY D, 1962, BIOCHEM J, V85, P139, DOI 10.1042/bj0850139; FINK AL, 1987, BIOCHEMISTRY-US, V26, P8571, DOI 10.1021/bi00400a012; FUJII N, 1981, J CHEM SOC PERK T 1, P804, DOI 10.1039/p19810000804; FUJII N, 1981, J CHEM SOC PERK T 1, P789, DOI 10.1039/p19810000789; FUJII N, 1981, J CHEM SOC PERK T 1, P797, DOI 10.1039/p19810000797; GUTTE B, 1971, J BIOL CHEM, V246, P1922; HIRSCHMANN R, 1969, J AM CHEM SOC, V91, P502; Ipata P L., 1968, FEBS Lett, V1, P29, DOI 10.1016/0014-5793(68)80010-9; KAISER ET, 1989, ACCOUNTS CHEM RES, V22, P47, DOI 10.1021/ar00158a001; KENT SBH, 1988, ANNU REV BIOCHEM, V57, P957, DOI 10.1146/annurev.bi.57.070188.004521; KIRK KL, 1973, J AM CHEM SOC, V95, P4619, DOI 10.1021/ja00795a026; KNOWLES JR, 1976, CRC CR REV BIOCH MOL, V4, P165, DOI 10.3109/10409237609105457; KULLMAN W, 1987, ENZYMATIC PEPTIDE SY; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MENDEL D, 1992, SCIENCE, V256, P1798, DOI 10.1126/science.1615324; NAKATSUKA T, 1987, J AM CHEM SOC, V109, P3808, DOI 10.1021/ja00246a064; NEET KE, 1966, P NATL ACAD SCI USA, V56, P1606, DOI 10.1073/pnas.56.5.1606; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; POLGAR L, 1966, J AM CHEM SOC, V88, P3153, DOI 10.1021/ja00965a060; RICO M, 1991, Journal of Biomolecular NMR, V1, P283, DOI 10.1007/BF01875521; ROTHWARF DM, 1993, BIOCHEMISTRY-US, V32, P2671, DOI 10.1021/bi00061a027; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHNOLZER M, 1992, SCIENCE, V256, P221, DOI 10.1126/science.1566069; TAYLOR HC, 1981, J MOL BIOL, V149, P313, DOI 10.1016/0022-2836(81)90305-3; THOMPSON JE, 1994, J AM CHEM SOC, V116, P5467, DOI 10.1021/ja00091a060; TRAUTWEIN K, 1991, FEBS LETT, V281, P275, DOI 10.1016/0014-5793(91)80410-5; USHER DA, 1972, P NATL ACAD SCI USA, V69, P115, DOI 10.1073/pnas.69.1.115; VEBER DF, 1977, J ORG CHEM, V42, P3286, DOI 10.1021/jo00440a018; WONG CH, 1993, J AM CHEM SOC, V115, P5893, DOI 10.1021/ja00067a001; WU Z, 1989, J AM CHEM SOC, V111, P2414	40	244	282	2	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1994	266	5183					243	247		10.1126/science.7939659	http://dx.doi.org/10.1126/science.7939659			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939659				2022-12-01	WOS:A1994PM13400023
J	PARRATT, J; TAGGART, M; WRAY, S				PARRATT, J; TAGGART, M; WRAY, S			ABOLITION OF CONTRACTIONS IN THE MYOMETRIUM BY ACIDIFICATION IN-VITRO	LANCET			English	Note							METABOLIC INHIBITION; INTRACELLULAR PH; FORCE PRODUCTION; UTERINE; RAT	Uterine dystocia, often of unknown cause, remains one of the commonest causes of emergency caesarean section. We have tested the hypothesis that small acidic changes in pH, that can occur during labour contractions, can decrease contractions and contribute to dystocia. We simultaneously recorded intracellular pH (pH(i)) and force in human myometrium: acidification abolished contractions. Such effects of pH(i) on uterine contractile acitivity may be of clinical significance. Blood flow reduces during each uterine contraction; the resulting fall in pH(i) could lead to inefficient uterine action in some labours and failure to progress (ie, dystocia).	UNIV LIVERPOOL,DEPT PHYSIOL,LIVERPOOL L69 3BX,ENGLAND	University of Liverpool			Taggart, Michael/A-1288-2012; wray, susan/B-1197-2009	Taggart, Michael/0000-0002-9981-2783; Wray, Susan/0000-0002-0086-1359				BEISCHER NA, 1986, OBSTETRICS NEWBORN, P443; BRAR HS, 1988, AM J OBSTET GYNECOL, V158, P952, DOI 10.1016/0002-9378(88)90100-7; GREISS FC, 1965, AM J OBSTET GYNECOL, V93, P917, DOI 10.1016/0002-9378(65)90150-X; HARRISON N, 1994, J PHYSIOL-LONDON, V476, P349, DOI 10.1113/jphysiol.1994.sp020136; PHOENIX J, 1993, J REPROD FERTIL, V97, P507; TAGGART M, 1993, PFLUG ARCH EUR J PHY, V423, P527, DOI 10.1007/BF00374951; TAGGART MJ, 1993, J PHYSIOL-LONDON, V472, P23, DOI 10.1113/jphysiol.1993.sp019933; WRAY S, 1990, J PHYSIOL-LONDON, V423, P411, DOI 10.1113/jphysiol.1990.sp018030; WRAY S, 1992, EXP PHYSIOL, V77, P307, DOI 10.1113/expphysiol.1992.sp003590; WRAY S, 1993, AM J PHYSIOL, V264, pC1, DOI 10.1152/ajpcell.1993.264.1.C1	10	31	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					717	718		10.1016/S0140-6736(94)92209-8	http://dx.doi.org/10.1016/S0140-6736(94)92209-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915777				2022-12-01	WOS:A1994PF18700011
J	COLOVER, J				COLOVER, J			FUNCTIONAL DUALISM IN THE NERVOUS-SYSTEM	LANCET			English	Editorial Material							VISUAL-SYSTEM; ORGANIZATION; CELLS				COLOVER, J (corresponding author), UNITED MED & DENT SCH, RAYNE INST, DEPT IMMUNOL, ST THOMAS CAMPUS, LONDON SE1 7EH, ENGLAND.							BEHAN M, 1992, J COMP NEUROL, V315, P230, DOI 10.1002/cne.903150209; BEHRMAN S, 1958, BRAIN, V81, P529, DOI 10.1093/brain/81.4.529; Cushing H, 1916, J NERV MENT DIS, V44, P312; Hartline HK, 1938, AM J PHYSIOL, V121, P400, DOI 10.1152/ajplegacy.1938.121.2.400; Head H, 1905, BRAIN, V28, P99, DOI 10.1093/brain/28.2.99; HUBEL DH, 1985, NATURE, V315, P325, DOI 10.1038/315325a0; IKEDA H, 1988, DOC OPHTHALMOL, V69, P175, DOI 10.1007/BF00153699; IKEDA H, 1972, J PHYSIOL-LONDON, V227, P769, DOI 10.1113/jphysiol.1972.sp010058; IKEDA T, 1985, POLAR BIOL, V4, P1, DOI 10.1007/BF00286811; JAIN KK, 1993, J ROY SOC MED, V86, P133; MCCONNELL SK, 1986, J COMP NEUROL, V250, P109, DOI 10.1002/cne.902500110; SCHILLER PH, 1992, TRENDS NEUROSCI, V15, P86, DOI 10.1016/0166-2236(92)90017-3; SHIPP S, 1985, NATURE, V315, P322, DOI 10.1038/315322a0; ZEKI S, 1990, COLD SPRING HARB SYM, V55, P651	14	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 3	1994	344	8923					670	671		10.1016/S0140-6736(94)92092-3	http://dx.doi.org/10.1016/S0140-6736(94)92092-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915355				2022-12-01	WOS:A1994PE38600017
J	YUSUF, S; ZUCKER, D; PEDUZZI, P; FISHER, LD; TAKARO, T; KENNEDY, JW; DAVIS, K; KILLIP, T; PASSAMANI, E; NORRIS, R; MORRIS, C; MATHUR, V; VARNAUSKAS, E; CHALMERS, TC				YUSUF, S; ZUCKER, D; PEDUZZI, P; FISHER, LD; TAKARO, T; KENNEDY, JW; DAVIS, K; KILLIP, T; PASSAMANI, E; NORRIS, R; MORRIS, C; MATHUR, V; VARNAUSKAS, E; CHALMERS, TC			EFFECT OF CORONARY-ARTERY BYPASS GRAFT-SURGERY ON SURVIVAL - OVERVIEW OF 10-YEAR RESULTS FROM RANDOMIZED TRIALS BY THE CORONARY-ARTERY BYPASS GRAFT-SURGERY TRIALISTS COLLABORATION	LANCET			English	Article							DISEASE	We carried out a systematic overview using individual patient data from the seven randomised trials that have compared a strategy of initial coronary artery bypass graft (CABG) surgery with one of initial medical therapy to assess the effects on mortality in patients with stable coronary heart disease (stable angina not severe enough to necessitate surgery on grounds of symptoms alone, or myocardial infarction). 1324 patients were assigned CABG surgery and 1325 medical management between 1972 and 1984. The proportion of patients in the medical treatment group who had undergone CABG surgery was 25% at 5 years, 33% at 7 years, and 41% at 10 years: 93.7% of patients assigned to the surgery group underwent CABG surgery. The CABG group had significantly lower mortality than the medical treatment group at 5 years (10.2 vs 15.8%; odds ratio 0.61 [95% CI 0.48-0.77], p=0.0001), 7 years (15.8 vs 21.7%; 0.68 [0.56-0.83], p<0.001), and 10 years (26.4 vs 30.5%; 0.83 [0.70-0.98]; p=0.03). The risk reduction was greater in patients with left main artery disease than in those with disease in three vessels or one or two vessels (odds ratios at 5 years 0.32, 0.58, and 0.77, respectively). Although relative risk reductions in subgroups defined by other baseline characteristics were similar, the absolute benefits of CABG surgery were most pronounced in patients in the highest risk categories. This effect was most evident when several prognostically important clinical and angiographic risk factors were integrated to stratify patients by risk levels and the extension of survival at 10 years was examined (change in survival -1.1 [SE 3.1] months in low-risk group, 5.0 [4.2] months in moderate-risk group, and 8.8 [5.4] months in high-risk group; p for trend < 0.003). A strategy of initial CABG surgery is associated with lower mortality than one of medical management with delayed surgery if necessary, especially in high-risk and medium-risk patients with stable coronary heart disease. In low-risk patients, the limited data show a non-significant trend towards greater mortality with CABG.	NHLBI,BETHESDA,MD; MCMASTER UNIV,HAMILTON,ON,CANADA; HEBREW UNIV JERUSALEM,JERUSALEM,ISRAEL; VET AFFAIRS COOPERAT STUDIES PROGRAM,W HAVEN,CT; UNIV WASHINGTON,SEATTLE,WA; BETH ISRAEL HOSP,NEW YORK,NY; GREEN LANE HOSP,AUCKLAND,NEW ZEALAND; OREGON HLTH SCI UNIV,PORTLAND,OR; TEXAS HEART INST,HOUSTON,TX; GOTHENBURG UNIV,GOTHENBURG,SWEDEN; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; TUFTS UNIV,BOSTON,MA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); McMaster University; Hebrew University of Jerusalem; University of Washington; University of Washington Seattle; Oregon Health & Science University; Texas Heart Institute; University of Gothenburg; Harvard University; Harvard T.H. Chan School of Public Health; Tufts University				Yusuf, Salim/0000-0003-4776-5601				BICKELL NA, 1992, ANN INTERN MED, V116, P791, DOI 10.7326/0003-4819-116-10-791; CALIFF RM, 1989, JAMA-J AM MED ASSOC, V261, P2077, DOI 10.1001/jama.261.14.2077; Favaloro R G, 1968, Ann Thorac Surg, V5, P334; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; IRWIN JO, 1949, J HYG-CAMBRIDGE, V47, P188, DOI 10.1017/S0022172400014443; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KENNEDY JN, 1992, CIRCULATION, V86, P1; KLOSTER FE, 1979, NEW ENGL J MED, V300, P149, DOI 10.1056/NEJM197901253000401; LOOP FD, 1986, NEW ENGL J MED, V314, P1, DOI 10.1056/NEJM198601023140101; Mathur V S, 1977, Cardiovasc Clin, V8, P131; MUHLBAIER LH, 1992, CIRCULATION, V86, P198; NORRIS RM, 1981, CIRCULATION, V63, P785, DOI 10.1161/01.CIR.63.4.785; PEDUZZI PN, 1982, CONTROL CLIN TRIALS, V3, P47, DOI 10.1016/0197-2456(82)90018-6; TAKARO T, 1976, CIRCULATION, V54, P107; VARNAUSKAS E, 1988, NEW ENGL J MED, V319, P332, DOI 10.1056/NEJM198808113190603; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1985, NEW ENGL J MED, V393, P217; 1988, BRIT MED J, V296, P320; 1983, CIRCULATION, V68, P939; 1984, NEW ENGL J MED, V311, P1333	20	1543	1621	1	34	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					563	570		10.1016/S0140-6736(94)91963-1	http://dx.doi.org/10.1016/S0140-6736(94)91963-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914958				2022-12-01	WOS:A1994PD42400007
J	EKBOM, A; WAKEFIELD, AJ; ZACK, M; ADAMI, HO				EKBOM, A; WAKEFIELD, AJ; ZACK, M; ADAMI, HO			PERINATAL MEASLES INFECTION AND SUBSEQUENT CROHNS-DISEASE	LANCET			English	Article							INFLAMMATORY BOWEL-DISEASE; MORTALITY	Although the aetiology of Crohn's disease is unknown, morphological and epidemiological studies have implicated measles virus as a potential component cause, particularly when exposure occurs in utero or early in life. An increased incidence of Crohn's disease among people born during measles epidemics would support this hypothesis. We identified all individuals born in four counties in central Sweden in 1945-54 who had had Crohn's disease diagnosed before the age of 30 years. Yearly reports compiled in these counties revealed that five measles epidemics had affected all four counties during the trial period. After adjusting for monthly differences in the number of livebirths in the four counties, we calculated the expected number of patients with Crohn's disease and ulcerative colitis born during the 3-month period after the peaks of the epidemics. The number of people with Crohn's disease significantly exceeded that expected: 57 versus 39.0 (standardised incidence ratio 1.46, 95% CI 1.11-1.89). For patients with ulcerative colitis, the observed number (42) was close to that expected (46.8). Our results strengthen the hypothesis that measles is related to Crohn's disease and that the perinatal period is a time of vulnerability.	HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; ROYAL FREE HOSP,SCH MED,INFLAMMATORY BOWEL DIS STUDY GRP,LONDON,ENGLAND; CTR DIS CONTROL & PREVENT,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,ATLANTA,GA 30341	Harvard University; Harvard T.H. Chan School of Public Health; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Centers for Disease Control & Prevention - USA	EKBOM, A (corresponding author), UNIV UPPSALA HOSP,CANC EPIDEMIOL UNIT,S-75185 UPPSALA,SWEDEN.							AABY P, 1988, LANCET, V1, P516; EKBOM A, 1990, AM J EPIDEMIOL, V132, P1111, DOI 10.1093/oxfordjournals.aje.a115754; EKBOM A, 1991, GASTROENTEROLOGY, V100, P350, DOI 10.1016/0016-5085(91)90202-V; EKBOM A, 1991, AM J EPIDEMIOL, V134, P876, DOI 10.1093/oxfordjournals.aje.a116162; EVANS JG, 1965, GUT, V6, P311, DOI 10.1136/gut.6.4.311; GARLAND CF, 1981, GASTROENTEROLOGY, V81, P1115; LOCKHARTMUMMERY HE, 1960, GUT, V1, P87, DOI 10.1136/gut.1.2.87; LUNDEE AS, 1980, DHHS PHS801358 PUBL; MORGAN KL, 1987, LANCET, V1, P1017; NORLEN BJ, 1970, SCAND J GASTROENTERO, V5, P385; ORHOLM M, 1991, NEW ENGL J MED, V324, P84, DOI 10.1056/NEJM199101103240203; POSER CM, 1990, J NEUROL SCI, V95, P214; REMINGTON JS, 1983, INFECT DIS, P45; Samuelsson S., 1976, THESIS U UPPSALA UPP; SONNENBERG A, 1986, DIS COLON RECTUM, V29, P854, DOI 10.1007/BF02555363; WAKEFIELD AJ, 1993, J MED VIROL, V39, P345, DOI 10.1002/jmv.1890390415; 1945, UNTITLED NATALITY ST	17	133	133	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 20	1994	344	8921					508	510		10.1016/S0140-6736(94)91898-8	http://dx.doi.org/10.1016/S0140-6736(94)91898-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7914614				2022-12-01	WOS:A1994PC53500009
J	FALLOWFIELD, LJ; HALL, A; MAGUIRE, P; BAUM, M; AHERN, RPA				FALLOWFIELD, LJ; HALL, A; MAGUIRE, P; BAUM, M; AHERN, RPA			PSYCHOLOGICAL EFFECTS OF BEING OFFERED CHOICE OF SURGERY FOR BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article									CHRISTIE HOSP, CANC RES CAMPAIGN, PSYCHOL MED GRP, MANCHESTER M20 9BX, LANCS, ENGLAND; ROYAL MARSDEN HOSP, LONDON SW3 6JJ, ENGLAND	Christie NHS Foundation Trust; Christie Hospital; Royal Marsden NHS Foundation Trust	FALLOWFIELD, LJ (corresponding author), UCL, SCH MED,DEPT ONCOL,CANC RES CAMPAIGN, COMMUN & COUNSELLING RES CTR, 3RD FLOOR, LONDON W1P 7PL, ENGLAND.			Fallowfield, Lesley/0000-0003-0577-4518; A'Hern, Roger/0000-0003-0593-8391				ASHCROFT JJ, 1985, J ROY SOC MED, V78, P43; FALLOWFIELD LJ, 1990, BRIT MED J, V301, P575, DOI 10.1136/bmj.301.6752.575; LUKER K, 1993, PREFERENCES INFORMAT; MORRIS J, 1988, SOC SCI MED, V26, P583, DOI 10.1016/0277-9536(88)90021-4; WILSON RG, 1988, BMJ-BRIT MED J, V297, P1167, DOI 10.1136/bmj.297.6657.1167	5	166	167	1	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 13	1994	309	6952					448	448		10.1136/bmj.309.6952.448	http://dx.doi.org/10.1136/bmj.309.6952.448			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC404	7920129	Green Published			2022-12-01	WOS:A1994PC40400019
J	GOUGH, AKS; LILLEY, J; EYRE, S; HOLDER, RL; EMERY, P				GOUGH, AKS; LILLEY, J; EYRE, S; HOLDER, RL; EMERY, P			GENERALIZED BONE LOSS IN PATIENTS WITH EARLY RHEUMATOID-ARTHRITIS	LANCET			English	Article							LOW-DOSE CORTICOSTEROIDS; DISEASE-ACTIVITY; MINERAL DENSITY; FRACTURE; CALCIUM; WOMEN; MASS	Generalised osteoporosis is a feature of established rheumatoid arthritis but whether this is a consequence of treatment, immobility, or disease activity has been unclear. We estimated bone mineral density by dual energy x-ray absorptiometry on 148 patients with early rheumatoid arthritis before treatment with corticosteroids or disease-modifying drugs and 730 normal controls. Scans were done at 12-month intervals in patients and at 0 and 12 months an 50 of the controls matched for menopausal status. At presentation, bone mineral density of patients did not differ from controls. However, patients with disease for less than 6 months had significantly higher spinal bone mineral density than those of longer duration. Over the next 12 months, bone mineral density loss was greater in patients with rheumatoid arthritis compared with controls; significantly so for early disease (eg, - 2.4 [0.8] vs - 0.6 [0.4] g/cm(2), p < 0.05 in the spine and - 4.3 [0.8] vs - 0.4 [0.5] g/cm(2), p < 0.001 in the trochanter). For the lumbar spine, only disease activity was significantly associated with this bone mineral density loss. For patients with active disease over 2 years, mean bone mineral density loss at each site was between 5.5 and 10% (p < 0.01 compared to patients with inactive disease). Suppression of disease activity stabilised this bone loss. In patients with rheumatoid arthritis significant amounts of generalised skeletal bone were test early in the disease and the loss was associated with disease activity. These findings have implications for the management of patients with rheumatoid arthritis and possibly other inflammatory diseases.	UNIV BIRMINGHAM,DEPT RHEUMATOL,BIRMINGHAM B15 2TT,ENGLAND; UNIV BIRMINGHAM,DEPT MATH & STAT,BIRMINGHAM,ENGLAND; QUEEN ELIZABETH HOSP,DEPT NUCL MED,BIRMINGHAM,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham; University of Birmingham			emery, paul/B-3560-2013					ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BEAT AM, 1991, J RHEUMATOL, V18, P804; BROZIK M, 1992, J RHEUMATOL, V19, P63; COMPSTON JE, 1988, ANN RHEUM DIS, V47, P660, DOI 10.1136/ard.47.8.660; COMPSTON JE, 1987, GUT, V28, P410, DOI 10.1136/gut.28.4.410; EGGELMEIJER F, 1993, BRIT J RHEUMATOL, V32, P387; FELDER M, 1991, RHEUMATOL INT, V11, P41, DOI 10.1007/BF00290250; FILLIBEN JJ, 1975, TECHNOMETRICS, V17, P111, DOI 10.2307/1268008; FRIES JF, 1982, J RHEUMATOL, V74, P786; GOUGH AKS, 1994, ANN RHEUM DIS, V53, P14, DOI 10.1136/ard.53.1.14; GOWEN M, 1983, NATURE, V306, P378, DOI 10.1038/306378a0; HOOYMAN JR, 1984, ARTHRITIS RHEUM-US, V27, P1353, DOI 10.1002/art.1780271205; KENNEDY AC, 1975, SCAND J RHEUMATOL, V4, P73, DOI 10.3109/03009747509095618; LAAN RFJM, 1993, ANN RHEUM DIS, V52, P21, DOI 10.1136/ard.52.1.21; LAAN RFJM, 1992, BRIT J RHEUMATOL, V31, P91; LEBOFF MS, 1991, J RHEUMATOL, V18, P339; Lilley J, 1991, Osteoporos Int, V1, P141, DOI 10.1007/BF01625443; MCCONKEY B, 1962, Q J MED, V124, P419; MELLISH RWE, 1987, ANN RHEUM DIS, V46, P830, DOI 10.1136/ard.46.11.830; NG KC, 1984, ANN RHEUM DIS, V43, P370, DOI 10.1136/ard.43.3.370; OKA M, 1975, SCAND J RHEUMATOL, V4, P28; REID DM, 1982, BMJ-BRIT MED J, V285, P330, DOI 10.1136/bmj.285.6338.330; RITCHIE DM, 1968, Q J MED, V37, P393; SAMBROOK PN, 1987, ARTHRITIS RHEUM, V30, P721, DOI 10.1002/art.1780300701; SAMBROOK PN, 1989, ANN RHEUM DIS, V48, P535, DOI 10.1136/ard.48.7.535; SAMBROOK PN, 1985, ANN RHEUM DIS, V44, P580, DOI 10.1136/ard.44.9.580; SPECTOR TD, 1993, BRIT MED J, V306, P558, DOI 10.1136/bmj.306.6877.558; STEINBROCKER O, 1949, JAMA-J AM MED ASSOC, V140, P659, DOI 10.1001/jama.1949.02900430001001; VERSTRAETEN A, 1986, ANN RHEUM DIS, V45, P852, DOI 10.1136/ard.45.10.852; VERSTRAETEN A, 1989, CLIN EXP RHEUMATOL, V7, P351	30	570	586	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					23	27		10.1016/S0140-6736(94)91049-9	http://dx.doi.org/10.1016/S0140-6736(94)91049-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912297				2022-12-01	WOS:A1994NU91700012
J	JONES, P; RODGERS, B; MURRAY, R; MARMOT, M				JONES, P; RODGERS, B; MURRAY, R; MARMOT, M			CHILD DEVELOPMENTAL RISK-FACTORS FOR ADULT SCHIZOPHRENIA IN THE BRITISH 1946 BIRTH COHORT	LANCET			English	Article							DISORDER; LIFE	Schizophrenia has been linked with childhood psychological abnormalities since it was first described, but studies of associations have not used population samples and so may be subject to bias. We have studied associations between adult-onset schizophrenia and childhood sociodemographic, neurodevelopmental, cognitive, and behavioural factors within a cohort of 5362 people born in the week March 3-9, 1946. Childhood data were gathered prospectively and case ascertainment was independent of routine follow-up of this cohort. 30 cases of schizophrenia arose between ages 16 and 43 years (cumulative risk 0.63% [95% CI 0.41-0.86%]). Milestones of motor development were reached later in cases than in controls, particularly walking (difference in means 1.2 months [0.1-2.3], p = 0.005), and up to age 15, cases had more speech problems than had controls (odds ratio 2.8 [0.9-7.8], p = 0.04). Low educational test scores at ages 8, 11, and 15 years were a risk factor, with significant linear trends across population distributions; risk was not confined to very low scores. Solitary play preference at ages 4 and 6 years predicted schizophrenia (odds ratios 2.1, 2.5, p = 0.05). At 13 years cases rated themselves as less socially confident (p for trend, 0.04). At 15 years, teachers rated cases as being more anxious in social situations (p for trend 0.003), independent of intelligence quotient. A health visitor's rating of the mother as having below average mothering skills and understanding of her child at age 4 years was a predictor of schizophrenia in that child (odds ratio 5.8 [0.8-31.8], p = 0.02). Differences between children destined to develop schizophrenia as adults and the general population were found across a range of developmental domains. As with some other adult illnesses, the origins of schizophrenia may be found in early life.	UCL, DEPT EPIDEMIOL & PUBL HLTH, MRC, NATL SURVEY HLTH & DEV, LONDON, ENGLAND	University of London; University College London	JONES, P (corresponding author), INST PSYCHIAT, DEPT PSYCHOL MED, DE CRESPIGNY PK, LONDON SE5 8AF, ENGLAND.		Rodgers, Bryan/B-2090-2013; Marmot, M G/Y-3920-2019; murray, robin/F-8658-2012	Rodgers, Bryan/0000-0002-2863-3737; Marmot, M G/0000-0002-2431-6419; murray, robin/0000-0003-0829-0519; Jones, Peter Brian/0000-0002-0387-880X	Medical Research Council [G8802774] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		[Anonymous], 1970, CLASSIFICATION OCCUP; AYLWARD E, 1984, SCHIZOPHRENIA BULL, V10, P430, DOI 10.1093/schbul/10.3.430; DONE DJ, 1994, BRIT MED J, V309, P699, DOI 10.1136/bmj.309.6956.699; DONE DJ, 1991, BRIT MED J, V302, P1576, DOI 10.1136/bmj.302.6792.1576; FISH B, 1992, ARCH GEN PSYCHIAT, V49, P221; GITTELMA.R, 1969, J PSYCHIAT RES, V7, P35, DOI 10.1016/0022-3956(69)90010-7; LEWIS G, 1992, LANCET, V340, P137, DOI 10.1016/0140-6736(92)93213-7; Lewis SW, 1989, SCHIZOPHRENIA, P56; MCGUIRE PK, 1993, LANCET, V342, P703, DOI 10.1016/0140-6736(93)91707-S; MEDNICK SA, 1988, ARCH GEN PSYCHIAT, V45, P188; MURRAY RM, 1987, BRIT MED J, V295, P681, DOI 10.1136/bmj.295.6600.681; PIDGEON DA, 1968, ALL OUR FUTURES, P194; PIDGEON DA, 1964, HOME SCH, P129; ROBERTS GW, 1990, BRIT J PSYCHIAT, V157, P1; Robins L.N., 1966, DEVIANT CHILDREN GRO; RODGERS B, 1978, DEV MED CHILD NEUROL, V20, P421, DOI 10.1111/j.1469-8749.1978.tb15242.x; RODGERS B, 1990, J CHILD PSYCHOL PSYC, V31, P393, DOI 10.1111/j.1469-7610.1990.tb01577.x; RODGERS B, 1986, PSYCHOL MED, V16, P689, DOI 10.1017/S0033291700010436; RODGERS B, 1990, BRIT J PSYCHIAT, V157, P539, DOI 10.1192/bjp.157.4.539; Rose G., 1992, STRATEGY PREVENTIVE; SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201; SUSSER ES, 1992, ARCH GEN PSYCHIAT, V49, P983; TIENARI P, 1987, SCHIZOPHRENIA BULL, V13, P477, DOI 10.1093/schbul/13.3.477; Wadsworth M. E. J., 1991, IMPRINT TIME CHILDHO; WADSWORTH MEJ, 1992, J EPIDEMIOL COMMUN H, V46, P300, DOI 10.1136/jech.46.3.300; WALKER E, 1990, AM J PSYCHIAT, V147, P1052; WATT NF, 1978, ARCH GEN PSYCHIAT, V35, P160; WEINBERGER DR, 1987, ARCH GEN PSYCHIAT, V44, P660, DOI 10.1001/archpsyc.1987.01800190080012; 1987, DIAGNOSTIC STATISTIC; 1948, MATERNITY GB	30	987	1001	0	60	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 19	1994	344	8934					1398	1402		10.1016/S0140-6736(94)90569-X	http://dx.doi.org/10.1016/S0140-6736(94)90569-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR786	7968076				2022-12-01	WOS:A1994PR78600010
J	GO, ES; URBAN, C; BURNS, J; KREISWIRTH, B; EISNER, W; MARIANO, N; MOSINKASNIPAS, K; RAHAL, JJ				GO, ES; URBAN, C; BURNS, J; KREISWIRTH, B; EISNER, W; MARIANO, N; MOSINKASNIPAS, K; RAHAL, JJ			CLINICAL AND MOLECULAR EPIDEMIOLOGY OF ACINETOBACTER INFECTIONS SENSITIVE ONLY TO POLYMYXIN-B AND SULBACTAM	LANCET			English	Article							CALCOACETICUS BIOTYPE ANITRATUS; IMIPENEM-RESISTANT; ANTIBIOTIC-RESISTANCE; NOSOCOMIAL INFECTIONS; SUSCEPTIBILITY; BAUMANNII	A nosocomial outbreak of infections due to imipenem-resistant Acinetobacter baumannii occurred in a New York hospital after increased use of imipenem for cephalosporin-resistant klebsiella infections. We identified all A baumannii isolates over 12 months, reviewed corresponding patient records, and compared strains with different antibiotic susceptibility patterns by restriction endonuclease analysis. Environmental surveillance cultures were done before and after institution of control measures. 59 patients harboured imipenem-resistant A baumannii, and 18 were infected, isolates from patients were resistant to all routinely tested antibiotics, including imipenem. Further studies showed susceptibility to polymyxin B and sulbactam. These isolates were identical by restriction endonuclease analysis to A baumannii isolates susceptible to imipenem alone, or to imipenem and amikacin, but differed from broadly susceptible isolates. Surveillance cultures showed hand and environmental colonisation by imipenem-resistant strains. Infection and colonisation were eliminated by intensive infection control measures, and irrigation of wounds with polymyxin B. Increased use of imipenem against cephalosporin-resistant klebsiella may lead to imipenem resistance among other species, particularly acinetobacter. Such resistance appears to derive from a prior multi-resistant clone, in contrast to one which retains susceptibility to several antibiotics.	CORNELL UNIV,SCH MED,DEPT MED,NEW YORK,NY 10021; CORNELL UNIV,SCH MED,DEPT MICROBIOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,NEW YORK HOSP,MED CTR QUEENS,DEPT MED,INFECT DIS SECT,NEW YORK,NY; CORNELL UNIV,COLL MED,DEPT MED,NEW YORK,NY; NEW YORK CITY DEPT HLTH,BUR LABS,NEW YORK,NY 10013	Cornell University; Cornell University; Cornell University; NewYork-Presbyterian Hospital; Cornell University; New York City Department of Health & Mental Hygiene								ALKHOJA MS, 1979, J CLIN PATHOL, V32, P497, DOI 10.1136/jcp.32.5.497; ALLARDETSERVENT A, 1989, J CLIN MICROBIOL, V27, P2057, DOI 10.1128/JCM.27.9.2057-2061.1989; BECKSAGUE CM, 1990, AM J EPIDEMIOL, V132, P723, DOI 10.1093/oxfordjournals.aje.a115714; BUXTON AE, 1978, AM J MED, V65, P507, DOI 10.1016/0002-9343(78)90777-5; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; DECHAMPS C, 1993, J CLIN MICROBIOL, V31, P123, DOI 10.1128/JCM.31.1.123-127.1993; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GAYNES RP, 1992, INFECT CONT HOSP EP, V13, P10, DOI 10.1086/646417; GEHRLEIN M, 1991, CHEMOTHERAPY, V37, P405, DOI 10.1159/000238887; GLEW RH, 1977, MEDICINE, V56, P79, DOI 10.1097/00005792-197703000-00001; HARSTEIN AI, 1988, AM J MED, V85, P624; KUNIN CM, 1993, ANN INTERN MED, V118, P557, DOI 10.7326/0003-4819-118-7-199304010-00011; LEVY SB, 1993, JAMA-J AM MED ASSOC, V269, P1840, DOI 10.1001/jama.269.14.1840; MEYER KS, 1993, ANN INTERN MED, V119, P353, DOI 10.7326/0003-4819-119-5-199309010-00001; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; Paton R, 1993, Int J Antimicrob Agents, V2, P81, DOI 10.1016/0924-8579(93)90045-7; PATTERSON JE, 1991, AM J MED, V91, P479, DOI 10.1016/0002-9343(91)90183-X; RAIMONDI A, 1991, ANTIMICROB AGENTS CH, V35, P1174, DOI 10.1128/AAC.35.6.1174; ROLSTON KVI, 1986, ANTIMICROB AGENTS CH, V30, P769, DOI 10.1128/AAC.30.5.769; SATO K, 1991, J ANTIMICROB CHEMOTH, V28, P35, DOI 10.1093/jac/28.1.35; SEIFERT H, 1993, ANTIMICROB AGENTS CH, V37, P750, DOI 10.1128/AAC.37.4.750; TAPLIN D, 1963, JAMA-J AM MED ASSOC, V186, P952; TRAUB WH, 1989, ANTIMICROB AGENTS CH, V33, P1617, DOI 10.1128/AAC.33.9.1617; URBAN C, 1993, J INFECT DIS, V167, P448, DOI 10.1093/infdis/167.2.448; WOOD CA, 1993, J INFECT DIS, V168, P1602, DOI 10.1093/infdis/168.6.1602	25	284	305	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 12	1994	344	8933					1329	1332		10.1016/S0140-6736(94)90694-7	http://dx.doi.org/10.1016/S0140-6736(94)90694-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ926	7968028				2022-12-01	WOS:A1994PQ92600010
J	SCHWOB, E; BOHM, T; MENDENHALL, MD; NASMYTH, K				SCHWOB, E; BOHM, T; MENDENHALL, MD; NASMYTH, K			THE B-TYPE CYCLIN KINASE INHIBITOR P40(SIC1) CONTROLS THE G1 TO S TRANSITION IN SACCHAROMYCES-CEREVISIAE	CELL			English	Article							YEAST-CELL CYCLE; SIGNAL-TRANSDUCTION PATHWAY; MATURATION-PROMOTING FACTOR; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; CDC28; GENE; FAR1; PROTEOLYSIS; EXPRESSION	When yeast cells reach a critical size, they initiate bud formation, spindle pole body duplication, and DNA replication almost simultaneously. All three events depend on activation of Cdc28 protein kinase by the G1 cyclins Cln1, -2, and -3. We show that DNA replication also requires activation of Cdc28 by B-type (Clb) cyclins. A sextuple clb1-6 mutant arrests as multibudded G1 cells that resemble cells lacking the Cdc34 ubiquitin-conjugating enzyme. cdc34 mutants cannot enter S phase because they fail to destroy p40(SIC1), which is a potent inhibitor of Clb but not Cln forms of the Cdc28 kinase. In wild-type cells, p40(SIC1) protein appears at the end of mitosis and disappears shortly before S phase. Proteolysis of a cyclin-specific inhibitor of Cdc28 is therefore an essential aspect of the G1 to S phase transition.	UNIV KENTUCKY,LUCILLE P MARKEY CANC CTR,DEPT BIOCHEM,LEXINGTON,KY 40536	University of Kentucky	SCHWOB, E (corresponding author), IMP RES INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.		Schwob, Etienne/AAC-3050-2020; Schwob, Etienne/H-4678-2015	Schwob, Etienne/0000-0002-9369-6419; Nasmyth, Kim/0000-0001-7030-4403				AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; DONOVAN JD, 1994, GENE DEV, V8, P1640, DOI 10.1101/gad.8.14.1640; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GRANDIN N, 1993, MOL CELL BIOL, V13, P2113, DOI 10.1128/MCB.13.4.2113; HARTWELL LH, 1974, BACTERIOL REV, V38, P164, DOI 10.1128/MMBR.38.2.164-198.1974; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; KILLANDER D, 1965, EXP CELL RES, V40, P12, DOI 10.1016/0014-4827(65)90285-5; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; MCKINNEY JD, 1993, GENE DEV, V7, P833, DOI 10.1101/gad.7.5.833; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PINES J, 1994, TRENDS BIOCHEM SCI, V19, P143, DOI 10.1016/0968-0004(94)90272-0; PLON SE, 1993, P NATL ACAD SCI USA, V90, P10484, DOI 10.1073/pnas.90.22.10484; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TEBB G, 1993, GENE DEV, V7, P517, DOI 10.1101/gad.7.3.517; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; YOCHEM J, 1987, J MOL BIOL, V195, P223	40	793	805	1	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 21	1994	79	2					233	244		10.1016/0092-8674(94)90193-7	http://dx.doi.org/10.1016/0092-8674(94)90193-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954792				2022-12-01	WOS:A1994PN63000008
J	KLEIN, C; STRUHL, K				KLEIN, C; STRUHL, K			INCREASED RECRUITMENT OF TATA-BINDING PROTEIN TO THE PROMOTER BY TRANSCRIPTIONAL ACTIVATION DOMAINS IN-VIVO	SCIENCE			English	Article							RNA POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; YEAST; CHROMATIN; MECHANISM; DNA; NUCLEOSOME; INVITRO; REPLICATION	The rate at which the TATA-binding protein (TBP) interacts with the TATA element and promotes transcription by RNA polymerase II was determined in yeast cells. A TBP derivative with altered TATA-element specificity was rapidly induced, and transcription from promoters with appropriately mutated TATA elements was measured. Without a functional activator protein, basal transcription was observed only after a lag of several hours. In contrast, GCN4-activated transcription occurred rapidly upon induction of the TBP derivative. These results suggest that accessibility of TBP to the chromatin template in vivo is rate limiting and that activation domains increase recruitment of TBP to the promoter.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030186, R37GM030186] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30186] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; AXELROD JD, 1993, GENE DEV, V7, P857, DOI 10.1101/gad.7.5.857; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; CHEN W, 1987, CELL, V50, P1047, DOI 10.1016/0092-8674(87)90171-1; CHI TH, 1993, MOL CELL BIOL, V13, P7045, DOI 10.1128/MCB.13.11.7045; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CROSTON GE, 1992, GENE DEV, V6, P2270, DOI 10.1101/gad.6.12a.2270; Croston GE, 1993, CURR OPIN CELL BIOL, V5, P417, DOI 10.1016/0955-0674(93)90006-C; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GRECO MA, 1990, J BACTERIOL, V172, P317, DOI 10.1128/JB.172.1.317-325.1990; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLEIN C, UNPUB; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MORSE RH, 1993, SCIENCE, V262, P1563, DOI 10.1126/science.8248805; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PRIOLEAU MN, 1994, CELL, V77, P439, DOI 10.1016/0092-8674(94)90158-9; SELLECK SB, 1987, NATURE, V325, P173, DOI 10.1038/325173a0; SIKORSKI RS, 1989, GENETICS, V122, P19; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; STRUHL K, 1993, CURR BIOL, V3, P220, DOI 10.1016/0960-9822(93)90338-O; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; STRUHL K, 1987, MOL CELL BIOL, V7, P104, DOI 10.1128/MCB.7.1.104; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x; ZAWEL L, 1993, INITIATION TRANSCRIP, V2	47	113	114	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1994	266	5183					280	282		10.1126/science.7939664	http://dx.doi.org/10.1126/science.7939664			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939664				2022-12-01	WOS:A1994PM13400035
J	HILEY, CMH; MORLEY, CJ				HILEY, CMH; MORLEY, CJ			EVALUATION OF GOVERNMENTS CAMPAIGN TO REDUCE RISK OF COT DEATH	BRITISH MEDICAL JOURNAL			English	Article									UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT PAEDIAT,CAMBRIDGE CB2 2QQ,ENGLAND	Addenbrooke's Hospital; University of Cambridge				Morley, Colin/0000-0001-5388-0214				FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; MCKENNA JJ, 1990, AM J PHYS ANTHROPOL, V83, P331, DOI 10.1002/ajpa.1330830307; 1991, SLEEPING POSITION IN; 1993, OPCS MONITOR	4	36	36	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 17	1994	309	6956					703	704		10.1136/bmj.309.6956.703	http://dx.doi.org/10.1136/bmj.309.6956.703			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PH407	7950523	Green Published			2022-12-01	WOS:A1994PH40700016
J	HORIE, S; HIGASHIHARA, E; NUTAHARA, K; MIKAMI, Y; OKUBO, A; KANO, M; KAWABE, K				HORIE, S; HIGASHIHARA, E; NUTAHARA, K; MIKAMI, Y; OKUBO, A; KANO, M; KAWABE, K			MEDIATION OF RENAL CYST FORMATION BY HEPATOCYTE GROWTH-FACTOR	LANCET			English	Note							CELLS	Hepatocyte growth factor (HGF) is a potent mitogen for renal tubular cells, and HGF and its receptor (c-met proto-oncogene product, Met) can induce lumen formation in epithelial cells. We measured the concentration of HGF in cyst fluids from patients with renal cystic diseases. The concentration of HGF was high in proximal cyst fluid (mean 2.45 vs 0.42 ng/mL in distal cysts). Cyclic AMP concentration was higher in distal than in proximal cysts (663 vs 6.0 pmol/L). mRNA of HGF and Met were cc-expressed in cyst walls from cases with polycystic kidney disease. These findings suggest that HGF is a growth factor that may mediate human renal cyst genesis.	UNIV TOKYO,FAC MED,DEPT LAB MED,TOKYO 113,JAPAN; KYORIN UNIV,FAC MED,DEPT UROL,TOKYO,JAPAN	University of Tokyo; Kyorin University	HORIE, S (corresponding author), UNIV TOKYO,FAC MED,DEPT UROL,BUNKYO KU,7-3-1 HONGO,TOKYO 113,JAPAN.							GRANTHAM JJ, 1993, ADV INTERNAL MED, V38, P409; HUSEMAN R, 1980, KIDNEY INT, V18, P375, DOI 10.1038/ki.1980.148; Maniatis T., 1982, MOL CLONING; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; MATSUNAGA T, 1994, EXP CELL RES, V210, P326, DOI 10.1006/excr.1994.1045; NEUFELD TK, 1992, KIDNEY INT, V41, P1222, DOI 10.1038/ki.1992.184; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; TSARFATY I, 1992, SCIENCE, V152, P802; TSUBOUCHI H, 1992, LANCET, V340, P307, DOI 10.1016/0140-6736(92)92396-W; WILSON SE, 1993, INVEST OPHTH VIS SCI, V34, P2544	10	47	48	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					789	791		10.1016/S0140-6736(94)92344-2	http://dx.doi.org/10.1016/S0140-6736(94)92344-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916076				2022-12-01	WOS:A1994PG17800013
J	ADAM, IJ; MOHAMDEE, MO; MARTIN, IG; SCOTT, N; FINAN, PJ; JOHNSTON, D; DIXON, MF; QUIRKE, P				ADAM, IJ; MOHAMDEE, MO; MARTIN, IG; SCOTT, N; FINAN, PJ; JOHNSTON, D; DIXON, MF; QUIRKE, P			ROLE OF CIRCUMFERENTIAL MARGIN INVOLVEMENT IN THE LOCAL RECURRENCE OF RECTAL-CANCER	LANCET			English	Article							MESORECTAL EXCISION; SURVIVAL; RESECTION; CLEARANCE; SURGERY; SPREAD	Local recurrence after resection for rectal cancer remains common despite growing acceptance that inadequate local excision may be implicated. In a prospective study of 190 patients with rectal cancer, we examined the circumferential margin of excision of resected specimens for tumour presence, to examine its frequency and its relation to subsequent local recurrence. Tumour involvement of the circumferential margin was seen in 25% (35/141) of specimens for which the surgeon thought the resection was potentially curative, and in 36% (69/190) of all cases. After a median 5 years' follow-up (range 3.0-7.7 years), the frequency of local recurrence after potentially curative resection was 25% (95% Cl 18-33%). The frequency of local recurrence was significantly higher for patients who had had tumour involvement of the circumferential margin than for those without such involvement (78 [95% Cl 62-94] vs 10 [4-16]%). By Cox's regression analysis tumour involvement of the circumferential margin independently influenced both local recurrence (hazard ratio=12.2 [4.4-34.6]) and survival (3.2 [1.6-6.53]). These results show the importance of wide local excision during resection for rectal cancer, and the need for routine assessment of the circumferential margin to assess significant influence on survival, whereas the other prognosis.	GEN INFIRM,CTR DIGEST DIS,ACAD UNIT PATHOL SCI,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND; GEN INFIRM,CTR DIGEST DIS,ACAD SURG UNIT,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND	Leeds General Infirmary; University of Leeds; Leeds General Infirmary; University of Leeds			Quirke, Philip/AAI-1362-2019	Quirke, Philip/0000-0002-3597-5444				ABULAFI AM, 1994, BRIT J SURG, V81, P7, DOI 10.1002/bjs.1800810106; CAWTHORN SJ, 1990, LANCET, V335, P1055, DOI 10.1016/0140-6736(90)92631-Q; CHAN KW, 1985, HISTOPATHOLOGY, V9, P1319, DOI 10.1111/j.1365-2559.1985.tb02813.x; COX DR, 1972, J R STAT SOC B, V34, P187; DUKES CE, 1932, J PATHOL BACTERIOL, V35, P330; FIELDING LP, 1978, LANCET, V2, P778; FISHER B, 1988, JNCI-J NATL CANCER I, V80, P21, DOI 10.1093/jnci/80.1.21; Gordon-Watson C, 1938, LANCET, V1, P239; HEALD RJ, 1986, LANCET, V1, P1479; JASS JR, 1987, LANCET, V1, P1303; MACFARLANE JK, 1993, LANCET, V341, P457, DOI 10.1016/0140-6736(93)90207-W; MCARDLE CS, 1991, BRIT MED J, V302, P1501, DOI 10.1136/bmj.302.6791.1501; MORSON BC, 1963, BMJ-BRIT MED J, P13, DOI 10.1136/bmj.2.5348.13; NG IOL, 1993, CANCER-AM CANCER SOC, V71, P1972, DOI 10.1002/1097-0142(19930315)71:6<1972::AID-CNCR2820710608>3.0.CO;2-V; PETO R, 1973, BIOMETRICS, V29, P579, DOI 10.2307/2529177; PHILLIPS RKS, 1984, BRIT J SURG, V71, P12, DOI 10.1002/bjs.1800710104; POWERS WE, 1964, NATURE, V201, P172; QUIRKE P, 1986, LANCET, V2, P996, DOI 10.1016/s0140-6736(86)92612-7; QUIRKE P, 1988, INT J COLORECTAL DIS, V3, P127, DOI 10.1007/BF01645318; WILLIAMSON RCN, 1982, GUT, V23, P316, DOI 10.1136/gut.23.4.316; 1987, AM J CLIN ONCOL-CANC, V10, P369; 1990, LANCET, V335, P1067	22	770	792	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					707	711		10.1016/S0140-6736(94)92206-3	http://dx.doi.org/10.1016/S0140-6736(94)92206-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915774				2022-12-01	WOS:A1994PF18700008
J	MARSHALL, H; STUDER, M; POPPERL, H; APARICIO, S; KUROIWA, A; BRENNER, S; KRUMLAUF, R				MARSHALL, H; STUDER, M; POPPERL, H; APARICIO, S; KUROIWA, A; BRENNER, S; KRUMLAUF, R			A CONSERVED RETINOIC ACID RESPONSE ELEMENT REQUIRED FOR EARLY EXPRESSION OF THE HOMEOBOX GENE HOXB-1	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; XENOPUS EMBRYOS; MOUSE HINDBRAIN; PATTERN; IDENTIFICATION; HOX-2.9; TRANSFORMATION; SEGMENTATION; RHOMBOMERES; RECEPTORS	WITHIN the Herb homeobox gene complex, Hoxb-1 is the earliest member expressed in the mesoderm and neuroectoderm of primitive streak and presomite embryos, preceding rhombomere-restricted expression in the hindbrain(1-7). Ectopic exposure of embryos to retinoic acid alters spatial aspects of Hox gene expression patterns(8-15). However, the role of retinoids in regulating these genes during normal development is unclear. We have now identified two enhancers, 3' of the mouse Hoxb-1 gene, which together reconstruct the early endogenous expression pattern and mediate the early ectopic response to retinoic acid. Furthermore, these regions are functionally conserved in both chicken and pufferfish (Fugu rubripes)(16) Hoxb-1 genes. The enhancer that controls the retinoic acid response, and regulates expression predominantly in neuroectoderm, contains a retinoic acid response element (RARE). Point mutations in the RARE abolish expression in neuroectoderm. Therefore, this RARE is not only involved in the ectopic response to retinoic acid, but is also essential for establishing aspects of the early Hoxb-1 expression pattern.	NATL INST MED RES,DEV NEUROBIOL LAB,LONDON NW7 1AA,ENGLAND; UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN,MOLEC GENET UNIT,CAMBRIDGE CB2 2QQ,ENGLAND; UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND; NAGOYA UNIV,SCH SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGOYA 46401,JAPAN	MRC National Institute for Medical Research; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Nagoya University			Krumlauf, Robb/AAH-5012-2019; Studer, Michele/P-4580-2016	Krumlauf, Robb/0000-0001-9102-7927; Studer, Michele/0000-0001-7105-2957; Aparicio, Samuel/0000-0002-0487-9599; Kuroiwa, Atsushi/0000-0001-7710-4041				ALTABA ARI, 1991, GENE DEV, V5, P175, DOI 10.1101/gad.5.2.175; ALTABA ARI, 1991, DEVELOPMENT, V112, P945; BRENNER S, 1993, NATURE, V366, P265, DOI 10.1038/366265a0; CONLON RA, 1992, DEVELOPMENT, V116, P357; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GUTHRIE S, 1992, NATURE, V356, P157, DOI 10.1038/356157a0; HOLDER N, 1991, DEVELOPMENT, V113, P1159; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; KESSEL M, 1993, NEURON, V10, P379, DOI 10.1016/0896-6273(93)90328-O; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LANGSTON AW, 1992, MECH DEVELOP, V38, P217, DOI 10.1016/0925-4773(92)90055-O; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; MADEN M, 1991, DEVELOPMENT, V111, P35; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MORRISSKAY GM, 1991, EMBO J, V10, P2985, DOI 10.1002/j.1460-2075.1991.tb07849.x; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; MURPHY P, 1991, DEVELOPMENT, V111, P61; PAPALOPULU N, 1991, DEVELOPMENT, V113, P1145; POPPERL H, 1993, MOL CELL BIOL, V13, P257; SIVE HL, 1991, GENE DEV, V5, P1321, DOI 10.1101/gad.5.8.1321; SIVE HL, 1990, GENE DEV, V4, P932, DOI 10.1101/gad.4.6.932; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; SUNDIN O, 1992, DEVELOPMENT, V114, P841; SUNDIN OH, 1990, GENE DEV, V4, P1267, DOI 10.1101/gad.4.8.1267; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277	30	387	389	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 18	1994	370	6490					567	571		10.1038/370567a0	http://dx.doi.org/10.1038/370567a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	7914354				2022-12-01	WOS:A1994PC53700058
J	HUTTON, JL; COOKE, T; PHAROAH, POD				HUTTON, JL; COOKE, T; PHAROAH, POD			LIFE EXPECTANCY IN CHILDREN WITH CEREBRAL-PALSY	BRITISH MEDICAL JOURNAL			English	Article							MENTAL-RETARDATION; BIRTH-WEIGHT; TRENDS; SURVIVAL; HANDICAPS; FINLAND; PEOPLE; AGE	Objective-To determine life expectancy of children with cerebral palsy. Design-Cohort analysis, by means of register compiled from multiple sources of ascertainment, of all children with cerebral palsy born during 1966-84 to mothers resident in Mersey region. Status of children was determined by flagging through NHS central register. Subjects-1258 subjects with idiopathic cerebral palsy, of whom 1251 were traced and included in analysis. Main outcome measures-Effect of functional ability (ambulation, manual dexterity, and mental ability), sex, birth weight, and gestational age on survival. Results-20 year survival for whole cohort was 89.3% for females and 86.9% for males. For subjects with no severe functional disabilities 20 year survival was 99% (95% confidence interval 98% to 100%), while subjects severely disabled in all three functional groups had 20 year survival of 50% (42% to 58%). Subjects with birth weight less than or equal to 2500 g had 20 year survival of 92% (89% to 95%), while those with birth weight >2500 g had survival of 87% (84% to 89%). Subjects with gestational age of >37 weeks had 20 year survival of 93% (91% to 96%), white those with gestational age greater than or equal to 37 weeks had survival of 85% (83% to 88%). Birth weight and gestational age were less predictive of survival than functional disability. Best statistical model used gestational age and number of severe functional disabilities as predictors. Conclusions-Life expectancy of this cohort of children with cerebral palsy was greater than has been suggested in some previous studies. This has important implications for social, educational, and health services.	UNIV LIVERPOOL,DEPT PUBL HLTH,LIVERPOOL L69 3BX,ENGLAND; UNIV LIVERPOOL,DEPT STAT,LIVERPOOL L69 3BX,ENGLAND; UNIV LIVERPOOL,DEPT COMPUTAT MATH,LIVERPOOL L69 3BX,ENGLAND	University of Liverpool; University of Liverpool; University of Liverpool								BAIRD PA, 1987, J PEDIATR-US, V110, P849, DOI 10.1016/S0022-3476(87)80395-5; BALAKRISHNAN TR, 1976, AM J MENT DEF, V80, P650; COX DR, 1984, ANAL SURVIVAL DATA, P53; COX DR, 1982, THEORETICAL STATISTI, P92; Dayton NA, 1932, NEW ENGL J MED, V206, P555, DOI 10.1056/NEJM193203172061103; DOWDING VM, 1988, IRISH MED J, V81, P25; EVANS PM, 1990, ARCH DIS CHILD, V65, P1329, DOI 10.1136/adc.65.12.1329; EYMAN RK, 1993, AM J DIS CHILD, V147, P329, DOI 10.1001/archpedi.1993.02160270091029; EYMAN RK, 1990, NEW ENGL J MED, V323, P584, DOI 10.1056/NEJM199008303230906; HAGBERG B, 1989, ACTA PAEDIATR SCAND, V78, P283, DOI 10.1111/j.1651-2227.1989.tb11071.x; HAGBERG B, 1984, ACTA PAEDIATR SCAND, V73, P433, DOI 10.1111/j.1651-2227.1984.tb09951.x; KUDRJAVCEV T, 1985, NEUROLOGY, V35, P900, DOI 10.1212/WNL.35.6.900; PHAROAH POD, 1990, ARCH DIS CHILD, V65, P602, DOI 10.1136/adc.65.6.602; PHAROAH POD, 1987, ARCH DIS CHILD, V62, P379, DOI 10.1136/adc.62.4.379; RIIKONEN R, 1989, ACTA PAEDIATR SCAND, V78, P581, DOI 10.1111/j.1651-2227.1989.tb17940.x; SAHAMOTO Y, 1986, AKAIKE INFORMATION C; STANLEY FJ, 1992, BRIT MED J, V304, P1658, DOI 10.1136/bmj.304.6843.1658; VONWENDT L, 1985, ANN CLIN RES, V17, P156; 1979, OPCS SERIES DS, V2; 1989, SAS STAT USERS GUIDE, V2, P997	20	119	125	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 13	1994	309	6952					431	435		10.1136/bmj.309.6952.431	http://dx.doi.org/10.1136/bmj.309.6952.431			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC404	7920125	Green Published			2022-12-01	WOS:A1994PC40400015
J	WINLAW, DS; SMYTHE, GA; KEOGH, AM; SCHYVENS, CG; SPRATT, PM; MACDONALD, PS				WINLAW, DS; SMYTHE, GA; KEOGH, AM; SCHYVENS, CG; SPRATT, PM; MACDONALD, PS			INCREASED NITRIC-OXIDE PRODUCTION IN HEART-FAILURE	LANCET			English	Note								The role of nitric oxide in heart failure is unknown. The high-capacity inducible isoform of nitric oxide synthase is present in the myocardium of patients with idiopathic dilated cardiomyopathy. Plasma nitrate, the stable end-product of nitric oxide production, was significantly increased in patients with heart failure compared with normal controls (means 51.3 and 24.6 mu mol/L). Vasodilation caused by increased nitric oxide may compensate for the vasoconstrictor effect of neurohumoral adaptions to heart failure. Alternatively, excess production may be detrimental to the heart by a direct negative inotropic effect.	ST VINCENTS HOSP,VICTOR CHANG CARDIAC RES INST,DEPT CARDIOPULM TRANSPLANTAT,SYDNEY,NSW 2010,AUSTRALIA; ST VINCENTS HOSP,VICTOR CHANG CARDIAC RES INST,DEPT CHEM PATHOL,SYDNEY,NSW 2010,AUSTRALIA	St Vincents Hospital Sydney; Victor Chang Cardiac Research Institute; St Vincents Hospital Sydney; Victor Chang Cardiac Research Institute			Macdonald, Peter/Q-3188-2019; Winlaw, David S/F-8365-2016; Winlaw, David/B-9405-2019	Winlaw, David S/0000-0001-8005-3361; Winlaw, David/0000-0001-8005-3361				DEBELDER AJ, 1993, LANCET, V341, P84, DOI 10.1016/0140-6736(93)92559-C; DREXLER H, 1992, AM J CARDIOL, V69, P1596, DOI 10.1016/0002-9149(92)90710-G; EVANS HG, 1993, CARDIOVASC RES, V27, P1486, DOI 10.1093/cvr/27.8.1486; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; GREEN LC, 1981, P NATL ACAD SCI-BIOL, V78, P7764, DOI 10.1073/pnas.78.12.7764; LANGREHR JM, 1992, J CLIN INVEST, V90, P679, DOI 10.1172/JCI115911; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; MONCADA S, 1992, ACTA PHYSIOL SCAND, V145, P201, DOI 10.1111/j.1748-1716.1992.tb09359.x; TAKAHASHI H, 1992, J CARDIOVASC PHARM, V20, pS214, DOI 10.1097/00005344-199204002-00061	9	217	223	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 6	1994	344	8919					373	374		10.1016/S0140-6736(94)91403-6	http://dx.doi.org/10.1016/S0140-6736(94)91403-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA303	7914309				2022-12-01	WOS:A1994PA30300012
J	KITCHENS, JM				KITCHENS, JM			DOES THIS PATIENT HAVE AN ALCOHOL PROBLEM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAGE QUESTIONNAIRE; SCREENING-TEST; COLLABORATIVE PROJECT; LABORATORY TESTS; RISK-DRINKING; USE DISORDERS; CONSUMPTION; IDENTIFICATION; PREVALENCE; VALIDATION		UNIV TORONTO, DEPT INTERNAL MED, TORONTO, ON, CANADA	University of Toronto	KITCHENS, JM (corresponding author), ST MICHAELS HOSP, DIV GEN INTERNAL MED, 30 BOND ST, TORONTO M5B 1W8, ON, CANADA.							BERESFORD T, 1982, PSYCHOSOMATICS, V23, P713; BERNADT MW, 1982, LANCET, V1, P325; BIEN TH, 1993, ADDICTION, V88, P315, DOI 10.1111/j.1360-0443.1993.tb00820.x; BUCHSBAUM DG, 1992, J GEN INTERN MED, V7, P517, DOI 10.1007/BF02599456; BUCHSBAUM DG, 1992, J AM GERIATR SOC, V40, P662, DOI 10.1111/j.1532-5415.1992.tb01956.x; BUCHSBAUM DG, 1991, ANN INTERN MED, V115, P774, DOI 10.7326/0003-4819-115-10-774; BUSH B, 1987, AM J MED, V82, P231, DOI 10.1016/0002-9343(87)90061-1; CHICK J, 1981, LANCET, V1, P1249; CLARK PMS, 1986, BR J ALCOHOL ALCOHOL, V16, P11; CLEARY PD, 1988, AM J MED, V85, P466; CURTIS JR, 1989, J AM GERIATR SOC, V37, P310, DOI 10.1111/j.1532-5415.1989.tb05496.x; DAWSON NV, 1992, J GEN INTERN MED, V7, P38, DOI 10.1007/BF02599100; ECKARDT MJ, 1981, JAMA-J AM MED ASSOC, V246, P648, DOI 10.1001/jama.246.6.648; ERNHART CB, 1988, ALCOHOL CLIN EXP RES, V12, P506, DOI 10.1111/j.1530-0277.1988.tb00233.x; ERNHART CB, 1987, AM J OBSTET GYNECOL, V156, P33, DOI 10.1016/0002-9378(87)90199-2; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; GIBBS LE, 1983, DRUG ALCOHOL DEPEN, V12, P279, DOI 10.1016/0376-8716(83)90071-6; KING M, 1986, PSYCHOL MED, V16, P213, DOI 10.1017/S0033291700002658; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; MARSH CM, 1989, 142ND ANN M AM PSYCH; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; MORROWTLUCAK M, 1989, ALCOHOL CLIN EXP RES, V13, P399, DOI 10.1111/j.1530-0277.1989.tb00343.x; PEQUIGNOT G, 1978, INT J EPIDEMIOL, V7, P113, DOI 10.1093/ije/7.2.113; POKORNY AD, 1972, AM J PSYCHIAT, V129, P342, DOI 10.1176/ajp.129.3.342; RANKIN JG, 1992, PUBLIC HLTH PREVENTI, pCH43; ROSS HE, 1990, J STUD ALCOHOL, V51, P506, DOI 10.15288/jsa.1990.51.506; ROUNSAVILLE BJ, 1993, ADDICTION, V88, P337, DOI 10.1111/j.1360-0443.1993.tb00821.x; Sackett D, 1991, CLIN EPIDEMIOLOGY BA; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SAUNDERS JB, 1993, ADDICTION, V88, P349, DOI 10.1111/j.1360-0443.1993.tb00822.x; SCHUCKIT MA, 1985, JAMA-J AM MED ASSOC, V254, P2614, DOI 10.1001/jama.254.18.2614; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; SKINNER HA, 1982, J STUD ALCOHOL, V43, P1157, DOI 10.15288/jsa.1982.43.1157; SKINNER HA, 1984, ANN INTERN MED, V101, P847, DOI 10.7326/0003-4819-101-6-847; SOKOL RJ, 1989, AM J OBSTET GYNECOL, V160, P863, DOI 10.1016/0002-9378(89)90302-5; Sox HC, 1988, MED DECISION MAKING; Spitzer R.L., 1990, STRUCTURED CLIN INTE; WATERSON EJ, 1989, ALCOHOL ALCOHOLISM, V24, P21; WEST LJ, 1985, OXFORD TXB PUBLIC HL, V2, pCH9; 1992, INT STATISTICAL CLAS, pCH5; 1987, DIAGNOSTIC STATISTIC	44	115	116	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 14	1994	272	22					1782	1787		10.1001/jama.272.22.1782	http://dx.doi.org/10.1001/jama.272.22.1782			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV815	7966928				2022-12-01	WOS:A1994PV81500029
J	COLUCCIGUYON, E; PORTIER, MM; DUNIA, I; PAULIN, D; POURNIN, S; BABINET, C				COLUCCIGUYON, E; PORTIER, MM; DUNIA, I; PAULIN, D; POURNIN, S; BABINET, C			MICE LACKING VIMENTIN DEVELOP AND REPRODUCE WITHOUT AN OBVIOUS PHENOTYPE	CELL			English	Article							INTERMEDIATE FILAMENT PROTEIN; TRANSGENIC MICE; MOUSE EMBRYO; CELL-DIFFERENTIATION; MONOCLONAL-ANTIBODY; MESENCHYMAL CELLS; CULTURED-CELLS; GROWTH-FACTOR; EXPRESSION; CYTOKERATINS	To address the biological role of vimentin in the context of the living organism, we have introduced a null mutation of the vimentin gene into the germ line of mice. Surprisingly, animals homozygous for this mutation developed and reproduced without an obvious phenotype. Immunoblotting, immunofluorescence, and immunogold labeling analysis confirmed the absence of vimentin and of the corresponding filament network. Furthermore, no compensatory expression of another intermediate filament could be demonstrated. While these results leave open the question of the possible role of vimentin in unusual situations or pathological conditions, they show that a conspicuous developmental and cell-specific structure that is an integral part of the cytoskeleton can be eliminated without apparent effect on mouse reproduction and development.	BIOCHIM CELLULAIRE COLL FRANCE,F-75005 PARIS,FRANCE; UNIV PARIS 07,CNRS,INST JACQUES MONOD,F-75005 PARIS,FRANCE; INST PASTEUR,SERV CENT MICROSCOPIE ELECTR,F-75005 PARIS 15,FRANCE; UNIV PARIS 07,F-75005 PARIS 15,FRANCE	UDICE-French Research Universities; PSL Research University Paris; College de France; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite	COLUCCIGUYON, E (corresponding author), INST PASTEUR,UNITE GENET MAMMIFERES,CNRS,URA 361,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.							AUFFRAY C, 1980, EUR J BIOCHEM, V107, P901; BARIBAULT H, 1993, GENE DEV, V7, P1191, DOI 10.1101/gad.7.7a.1191; BENEDETTI EL, 1994, TREATISE CYTOSKELETO; BENZEEV A, 1984, J CELL BIOL, V99, P1424, DOI 10.1083/jcb.99.4.1424; BRADLEY A, 1987, TERATOCARCINOMAS EMB; Brookfield John, 1992, Current Biology, V2, P553, DOI 10.1016/0960-9822(92)90036-A; CAPETANAKI Y, 1990, ONCOGENE, V5, P645; CAPETANAKI Y, 1989, P NATL ACAD SCI USA, V86, P4882, DOI 10.1073/pnas.86.13.4882; CAPETANAKI Y, 1989, J CELL BIOL, V109, P1653, DOI 10.1083/jcb.109.4.1653; CHOU YH, 1989, P NATL ACAD SCI USA, V86, P1885, DOI 10.1073/pnas.86.6.1885; CHRISTIAN J L, 1990, New Biologist, V2, P700; CHU YW, 1993, P NATL ACAD SCI USA, V90, P4261, DOI 10.1073/pnas.90.9.4261; COCHARD P, 1984, J NEUROSCI, V4, P2080; COHENTANNOUDJI M, 1992, MOL REPROD DEV, V33, P149, DOI 10.1002/mrd.1080330206; DELLAGI K, 1982, P NATL ACAD SCI-BIOL, V79, P446, DOI 10.1073/pnas.79.2.446; DELLAGI K, 1983, EMBO J, V2, P1509, DOI 10.1002/j.1460-2075.1983.tb01615.x; DELLAGI K, 1982, NATURE, V298, P284, DOI 10.1038/298284a0; DENT JA, 1989, DEVELOPMENT, V105, P61; DUNIA I, 1990, EUR J CELL BIOL, V53, P59; DUPOUEY P, 1985, DEV NEUROSCI-BASEL, V7, P81, DOI 10.1159/000112279; EDDE B, 1982, BIOCHIMIE, V64, P141, DOI 10.1016/S0300-9084(82)80416-1; FRANKE WW, 1979, EXP CELL RES, V123, P25, DOI 10.1016/0014-4827(79)90418-X; FRANKE WW, 1987, CELL, V49, P131, DOI 10.1016/0092-8674(87)90763-X; FRANKE WW, 1982, DIFFERENTIATION, V23, P43, DOI 10.1111/j.1432-0436.1982.tb01266.x; FUCHS E, 1992, CELL, V69, P899, DOI 10.1016/0092-8674(92)90607-E; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; FURST DO, 1989, J CELL BIOL, V109, P517, DOI 10.1083/jcb.109.2.517; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; HEID HW, 1988, DIFFERENTIATION, V37, P137, DOI 10.1111/j.1432-0436.1988.tb00805.x; HOULE J, 1983, DEV BRAIN RES, V9, P189, DOI 10.1016/0165-3806(83)90051-2; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KLYMKOWSKY MW, 1981, NATURE, V291, P249, DOI 10.1038/291249a0; KLYMKOWSKY MW, 1992, P NATL ACAD SCI USA, V89, P8736, DOI 10.1073/pnas.89.18.8736; LANE EB, 1983, NATURE, V303, P701, DOI 10.1038/303701a0; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LIN JJC, 1981, CELL, V24, P185, DOI 10.1016/0092-8674(81)90514-6; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARKL J, 1989, EUR J CELL BIOL, V50, P1; MARKL J, 1991, J CELL SCI, V98, P261; MONTEIRO MJ, 1990, J CELL BIOL, V111, P1543, DOI 10.1083/jcb.111.4.1543; NGAI J, 1987, MOL CELL BIOL, V7, P3955, DOI 10.1128/MCB.7.11.3955; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAULINLEVASSEUR M, 1988, EUR J CELL BIOL, V47, P121; PERREAU J, 1988, GENE, V62, P7, DOI 10.1016/0378-1119(88)90575-6; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P335, DOI 10.1159/000112360; PRUSS RM, 1981, CELL, V27, P419, DOI 10.1016/0092-8674(81)90383-4; RAMAEKERS FCS, 1983, P NATL ACAD SCI-BIOL, V80, P2618, DOI 10.1073/pnas.80.9.2618; RITTLING SR, 1987, MOL CELL BIOL, V7, P3908, DOI 10.1128/MCB.7.11.3908; Robertson E. J., 1987, TERATOCARCINOMAS EMB; SARRIA AJ, 1992, J BIOL CHEM, V267, P19455; SCHULTHEISS T, 1991, J CELL BIOL, V114, P953, DOI 10.1083/jcb.114.5.953; SEJERSEN T, 1993, J CELL SCI, V106, P1291; SHEA TB, 1993, J NEUROSCI RES, V36, P66, DOI 10.1002/jnr.490360108; SOELLNER P, 1985, P NATL ACAD SCI USA, V82, P7929, DOI 10.1073/pnas.82.23.7929; TORPEY N, 1992, NATURE, V357, P413, DOI 10.1038/357413a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WACKER IU, 1992, J CELL BIOL, V117, P813, DOI 10.1083/jcb.117.4.813; WEBER K, 1991, BIOCHEM SOC T, V19, P1021, DOI 10.1042/bst0191021; [No title captured]	62	479	488	1	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 18	1994	79	4					679	694		10.1016/0092-8674(94)90553-3	http://dx.doi.org/10.1016/0092-8674(94)90553-3			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7954832				2022-12-01	WOS:A1994PT48100015
J	ADAMI, HO; HSIEH, CC; LAMBE, M; TRICHOPOULOS, D; LEON, D; PERSSON, I; EKBOM, A; JANSON, PO				ADAMI, HO; HSIEH, CC; LAMBE, M; TRICHOPOULOS, D; LEON, D; PERSSON, I; EKBOM, A; JANSON, PO			PARITY, AGE AT FIRST CHILDBIRTH, AND RISK OF OVARIAN-CANCER	LANCET			English	Article							STATES CASE-CONTROL; EUROPEAN CASE-CONTROL; COLLABORATIVE ANALYSIS; POOLED ANALYSIS; WHITE WOMEN; PATHOGENESIS; DETERMINANTS	Increasing parity is associated with a reduction in the risk of ovarian cancer, but it is not clear whether this association applies to different histopathological types and to borderline tumours. Moreover, the temporal relations are poorly understood, and the possible role of age at first birth remains unequivocal. We have investigated these issues in a case-control study nested in a nationwide cohort of women born between 1925 and 1960 in Sweden. During follow-up until 1984, 3486 invasive ovarian cancers (2992 epithelial, 330 stromal, 149 germ-cell, 15 not classifiable) and 510 tumours of borderline malignant were diagnosed. 5 individually age-matched (total 19 980) were selected for each case woman. After simultaneous adjustment for parity and age at first birth, increasing parity was associated with a pronounced consistent decrease in relative risk of all invasive cancers (odds ratio for each additional birth 0.81 [95% Cl 0.77-0.85]), epithelial cancer (0.81 [0.77-0.86]), stromal cancer (0.84 [0.72-0.98]), and germ-cell cancer (0.71 [0.48-1.05]), but a less consistent decrease for borderline tumours (0.92 [0.81-1.04]). The risk of ovarian cancer decreased by about 10% for each 5-year increment in age at first childbirth (odds ratios 0.89 [0.84-0.94] epithelial cancer, 0.92 [0.77-1.10] stromal cancer, 0.92 [0.65-1.32] germ-cell cancer, 0.93 [0.80-1.09] borderline tumours). Because our findings cannot be readily explained by theories invoking incessant ovulation or high serum concentrations of gonadotropins, new aetiological hypotheses are needed. Pregnancy-dependent clearance from the ovaries of cells that have undergone malignant transformation could explain the reproductive risk factors for ovarian cancer.	HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; UNIV UPPSALA HOSP, DEPT SOCIAL MED, S-75185 UPPSALA, SWEDEN; LONDON SCH HYG & TROP MED, LONDON WC1, ENGLAND; SAHLGRENS UNIV HOSP, DEPT OBSTET & GYNECOL, GOTHENBURG, SWEDEN	Harvard University; Harvard T.H. Chan School of Public Health; Uppsala University; Uppsala University Hospital; University of London; London School of Hygiene & Tropical Medicine; Sahlgrenska University Hospital	ADAMI, HO (corresponding author), UNIV UPPSALA HOSP, DEPT CANC EPIDEMIOL, S-75185 UPPSALA, SWEDEN.		Leon, David A/G-2195-2010	Leon, David A/0000-0001-9747-1762; Lambe, Mats/0000-0002-4624-3767				CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P711; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P717; FATHALLA MF, 1971, LANCET, V2, P163; FRANCESCHI S, 1991, INT J CANCER, V49, P57, DOI 10.1002/ijc.2910490111; FRANCESCHI S, 1991, INT J CANCER, V49, P61, DOI 10.1002/ijc.2910490112; GRANAI CO, 1992, NEW ENGL J MED, V327, P197, DOI 10.1056/NEJM199207163270313; HAMILTON TC, 1992, CURR PROB CANCER, V16, P5, DOI 10.1016/0147-0272(92)90047-R; HANKINSON SE, 1993, JAMA-J AM MED ASSOC, V270, P2813, DOI 10.1001/jama.270.23.2813; HARRIS R, 1992, AM J EPIDEMIOL, V136, P1204, DOI 10.1093/oxfordjournals.aje.a116428; HORNROSS PL, 1992, EPIDEMIOLOGY, V3, P490, DOI 10.1097/00001648-199211000-00005; JOHANSSON L, 1983, 14 STAT SWED URV; LAMBE M, 1994, NEW ENGL J MED, V331, P5, DOI 10.1056/NEJM199407073310102; MALIK S, 1991, BRIT J CANCER, V64, P617, DOI 10.1038/bjc.1991.372; MATTSSON B, 1984, ACTA RADIOL ONCOL, V23, P305, DOI 10.3109/02841868409136026; MORELY JE, 1992, ENDOCRINOL METAB, P322; MUSEY VC, 1987, NEW ENGL J MED, V316, P229, DOI 10.1056/NEJM198701293160501; NEGRI E, 1991, INT J CANCER, V49, P50, DOI 10.1002/ijc.2910490110; Ryan K J, 1980, MATERNAL FETAL ENDOC, P3; Stadel B V, 1975, Am J Obstet Gynecol, V123, P772; TOMATIS L, 1990, IARC SCI PUBLICATION, V100; Walker AM, 1991, OBSERVATION INFERENC; Whelan SL, 1990, IARC SCI PUBLICATION; WHITTEMORE AS, 1989, CANCER RES, V49, P4047; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1175, DOI 10.1093/oxfordjournals.aje.a116426; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1212, DOI 10.1093/oxfordjournals.aje.a116429; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427; WILLEMSEN W, 1993, LANCET, V341, P986, DOI 10.1016/0140-6736(93)91071-S; [No title captured]; 1990, SOS1989 NAT BOARD HL, P19; 1962, CENSUS POPULATION 19, V4	30	251	257	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 5	1994	344	8932					1250	1254		10.1016/S0140-6736(94)90749-8	http://dx.doi.org/10.1016/S0140-6736(94)90749-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP701	7967985				2022-12-01	WOS:A1994PP70100007
J	MENARD, R; SANSONETTI, P; PARSOT, C; VASSELON, T				MENARD, R; SANSONETTI, P; PARSOT, C; VASSELON, T			EXTRACELLULAR ASSOCIATION AND CYTOPLASMIC PARTITIONING OF THE IPAB AND IPAC INVASINS OF SHIGELLA-FLEXNERI	CELL			English	Article							ENTEROPATHOGENIC ESCHERICHIA-COLI; YERSINIA YOP PROTEINS; B-CELL EPITOPES; SHIGELLA-FLEXNERI; EPITHELIAL-CELLS; SALMONELLA-TYPHIMURIUM; SIGNAL-TRANSDUCTION; NUCLEOTIDE-SEQUENCE; PLASMID ANTIGENS; HELA-CELLS	Shigella species cause bacillary dysentery in humans by invading colonic epithelial cells. IpaB and IpaC, two major invasins of these pathogens, are secreted into the extracellular milieu. We show here that IpaB and IpaC form a complex in the extracellular medium and that each binds independently to a 17 kDa polypeptide, IpgC, in the bacterial cytoplasm. The IpgC polypeptide was found to be necessary for bacterial entry into epithelial cells, to stabilize the otherwise unstable IpaB protein, and to prevent the proteolytic degradation of IpaC that occurs through its association with unprotected IpaB. We propose that IpgC, which is not secreted and thus acts as a molecular chaperone, serves as a receptor that prevents premature oligomerization of IpaB and IpaC within the cytoplasm of Shigella cells.	INST PASTEUR, UNITE PATHOGENIE MICROBIENNE MOLEC, F-75724 PARIS 15, FRANCE; INST PASTEUR, INSERM, U389, F-75724 PARIS 15, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								ADLER B, 1989, MOL MICROBIOL, V3, P627, DOI 10.1111/j.1365-2958.1989.tb00210.x; ALLAOUI A, 1992, J BACTERIOL, V174, P7661, DOI 10.1128/JB.174.23.7661-7669.1992; ALLAOUI A, 1992, MOL MICROBIOL, V6, P1605, DOI 10.1111/j.1365-2958.1992.tb00885.x; ALLAOUI A, 1993, MOL MICROBIOL, V7, P59, DOI 10.1111/j.1365-2958.1993.tb01097.x; ANDREWS GP, 1991, INFECT IMMUN, V59, P1997, DOI 10.1128/IAI.59.6.1997-2005.1991; BARZU S, 1993, INFECT IMMUN, V61, P3825, DOI 10.1128/IAI.61.9.3825-3831.1993; BAUDRY B, 1988, MICROB PATHOGENESIS, V4, P345, DOI 10.1016/0882-4010(88)90062-9; BERGMAN T, 1991, J BACTERIOL, V173, P1607, DOI 10.1128/jb.173.5.1607-1616.1991; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; CLERC P, 1987, INFECT IMMUN, V55, P2681, DOI 10.1128/IAI.55.11.2681-2688.1987; DONNENBERG MS, 1992, INFECT IMMUN, V60, P3953, DOI 10.1128/IAI.60.10.3953-3961.1992; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.biochem.60.1.321; ELSINGHORST EA, 1989, P NATL ACAD SCI USA, V86, P5173, DOI 10.1073/pnas.86.13.5173; FALKOW S, 1991, CELL, V65, P1099, DOI 10.1016/0092-8674(91)90003-H; FINLAY BB, 1989, MICROBIOL REV, V53, P210, DOI 10.1128/MMBR.53.2.210-230.1989; GALAN JE, 1989, P NATL ACAD SCI USA, V86, P6383, DOI 10.1073/pnas.86.16.6383; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GROISMAN EA, 1993, EMBO J, V12, P3779, DOI 10.1002/j.1460-2075.1993.tb06056.x; HAKANSSON S, 1993, INFECT IMMUN, V61, P71; HARLOW E, 1988, ANTIBODIES LABORATOR; HIGH N, 1992, EMBO J, V11, P1991, DOI 10.1002/j.1460-2075.1992.tb05253.x; HULTGREN SJ, 1991, ANNU REV MICROBIOL, V45, P383, DOI 10.1146/annurev.micro.45.1.383; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; ISBERG RR, 1985, NATURE, V317, P262, DOI 10.1038/317262a0; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; KORONAKIS V, 1989, EMBO J, V8, P595, DOI 10.1002/j.1460-2075.1989.tb03414.x; KUEHN MJ, 1991, P NATL ACAD SCI USA, V88, P10586, DOI 10.1073/pnas.88.23.10586; KUMAMOTO CA, 1991, MOL MICROBIOL, V5, P19, DOI 10.1111/j.1365-2958.1991.tb01821.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAURELLI AT, 1985, INFECT IMMUN, V49, P164, DOI 10.1128/IAI.49.1.164-171.1985; MENARD R, 1993, J BACTERIOL, V175, P5899; MICHIELS T, 1991, J BACTERIOL, V173, P4994, DOI 10.1128/jb.173.16.4994-5009.1991; MICHIELS T, 1990, INFECT IMMUN, V58, P2840, DOI 10.1128/IAI.58.9.2840-2849.1990; MILLER VL, 1988, INFECT IMMUN, V56, P1242, DOI 10.1128/IAI.56.5.1242-1248.1988; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; MOULDER JW, 1985, MICROBIOL REV, V49, P298, DOI 10.1128/MMBR.49.3.298-337.1985; NEU HC, 1965, J BIOL CHEM, V240, P3685; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; PHALIPON A, 1992, INFECT IMMUN, V60, P1919, DOI 10.1128/IAI.60.5.1919-1926.1992; ROSENSHINE I, 1992, EMBO J, V11, P3551, DOI 10.1002/j.1460-2075.1992.tb05438.x; SAKAI T, 1988, MOL MICROBIOL, V2, P589, DOI 10.1111/j.1365-2958.1988.tb00067.x; SANSONETTI PJ, 1982, INFECT IMMUN, V35, P852, DOI 10.1128/IAI.35.3.852-860.1982; SASAKAWA C, 1993, J BACTERIOL, V175, P2334, DOI 10.1128/JB.175.8.2334-2346.1993; SASAKAWA C, 1989, MOL MICROBIOL, V3, P1191, DOI 10.1111/j.1365-2958.1989.tb00269.x; SASAKAWA C, 1988, J BACTERIOL, V170, P2480, DOI 10.1128/jb.170.6.2480-2484.1988; SERENY B., 1957, ACTA MICROBIOL ACAD SCI HUNGARICAE, V4, P367; VANNHIEU GT, 1993, EMBO J, V12, P1887, DOI 10.1002/j.1460-2075.1993.tb05837.x; VENKATESAN MM, 1992, J BACTERIOL, V174, P1990, DOI 10.1128/jb.174.6.1990-2001.1992; WATTIAU P, 1993, MOL MICROBIOL, V8, P123, DOI 10.1111/j.1365-2958.1993.tb01209.x; YANG YX, 1993, INFECT IMMUN, V61, P3907, DOI 10.1128/IAI.61.9.3907-3913.1993	50	248	253	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 4	1994	79	3					515	525		10.1016/0092-8674(94)90260-7	http://dx.doi.org/10.1016/0092-8674(94)90260-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7954817				2022-12-01	WOS:A1994PQ48800014
J	SHIMKETS, RA; WARNOCK, DG; BOSITIS, CM; NELSONWILLIAMS, C; HANSSON, JH; SCHAMBELAN, M; GILL, JR; ULICK, S; MILORA, RV; FINDLING, JW; CANESSA, CM; ROSSIER, BC; LIFTON, RP				SHIMKETS, RA; WARNOCK, DG; BOSITIS, CM; NELSONWILLIAMS, C; HANSSON, JH; SCHAMBELAN, M; GILL, JR; ULICK, S; MILORA, RV; FINDLING, JW; CANESSA, CM; ROSSIER, BC; LIFTON, RP			LIDDLES SYNDROME - HERITABLE HUMAN HYPERTENSION CAUSED BY MUTATIONS IN THE BETA-SUBUNIT OF THE EPITHELIAL SODIUM-CHANNEL	CELL			English	Article							ALDOSTERONE SYNTHASE; GENE; DNA; LINKAGE; CELLS	Liddle's syndrome (pseudoaldosteronism) is an autosomal dominant form of human hypertension characterized by a constellation of findings suggesting constitutive activation of the amiloride-sensitive distal renal epithelial sodium channel. We demonstrate complete linkage of the gene encoding the beta subunit of the epithelial sodium channel to Liddle's syndrome in Liddle's original kindred. Analysis of this gene reveals a premature stop codon that truncates the cytoplasmic carboxyl terminus of the encoded protein in affected subjects. Analysis of subjects with Liddle's syndrome from four additional kindreds demonstrates either premature termination or frameshift mutations in this same carboxy-terminal domain in all four. These findings demonstrate that Liddle's syndrome is caused by mutations in the beta subunit of the epithelial sodium channel and have implications for the regulation of this epithelial ion channel as well as blood pressure homeostasis.	YALE UNIV,SCH MED,BOYER CTR MOLEC MED,HOWARD HUGHES MED INST,DEPT MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,BOYER CTR MOLEC MED,DEPT GENET,NEW HAVEN,CT 06510; UNIV ALABAMA,DEPT MED,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294; VET AFFAIRS MED CTR,BIRMINGHAM,AL 35294; SAN FRANCISCO GEN HOSP,DEPT MED,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94110; NHLBI,HYPERTENS ENDOCRINE BRANCH,BETHESDA,MD 20892; VET AFFAIRS HOSP,BRONX,NY 10468; CAPITAL DIST RENAL PHYSICIANS,ALBANY,NY 12208; MED COLL WISCONSIN,ST LUKES MED CTR,MILWAUKEE,WI 53215; UNIV LAUSANNE,INST PHARMACOL & TOXICOL,CH-1005 LAUSANNE,SWITZERLAND	Howard Hughes Medical Institute; Yale University; Yale University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Medical College of Wisconsin; University of Lausanne								BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BOTEROVELEZ M, 1994, NEW ENGL J MED, V330, P178, DOI 10.1056/NEJM199401203300305; BUBIEN JK, 1993, AM J PHYSIOL, V265, pC1175, DOI 10.1152/ajpcell.1993.265.4.C1175; BUBIEN JK, 1994, J BIOL CHEM, V269, P17780; CANESSA C, 1994, IN PRESS AM J PHYSL; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; EVANS GA, 1987, METHOD ENZYMOL, V152, P604; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; GARDNER JD, 1971, J CLIN INVEST, V50, P2253, DOI 10.1172/JCI106722; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HATA A, 1990, NUCLEIC ACIDS RES, V18, P5407, DOI 10.1093/nar/18.18.5407; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; KUHNLE U, 1990, J CLIN ENDOCR METAB, V70, P638, DOI 10.1210/jcem-70-3-638; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LIDDLE GW, 1963, T ASSOC AM PHYSICIAN, V76, P199; LIFTON RP, 1993, J HYPERTENS, V11, P231, DOI 10.1097/00004872-199303000-00002; LIFTON RP, 1992, NAT GENET, V2, P66, DOI 10.1038/ng0992-66; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PRAT AG, 1993, AM J PHYSIOL, V265, pC224, DOI 10.1152/ajpcell.1993.265.1.C224; RENARD S, 1994, J BIOL CHEM, V269, P12981; ROTIN D, 1994, IN PRESS EMBO J; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247; WARD R, 1990, HYPERTENSION PATHOPH, P81	29	1084	1101	1	36	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 4	1994	79	3					407	414		10.1016/0092-8674(94)90250-X	http://dx.doi.org/10.1016/0092-8674(94)90250-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7954808				2022-12-01	WOS:A1994PQ48800004
J	VANDENBERG, AV; BRENNER, E				VANDENBERG, AV; BRENNER, E			WHY 2 EYES ARE BETTER THAN ONE FOR JUDGMENTS OF HEADING	NATURE			English	Article							OPTICAL-FLOW; PERCEPTION; MOVEMENTS; MOTION; IMAGE	ARE two eyes needed for judging direction of self-motion? Traditional analyses stress that the pattern of optic flow in one eye is sufficient(1-5). The main difficulty is how to deal with the eye or head rotation. Extraretinal signals help(6-8), but humans can also discount the effect of rotation purely on the basis of monocular flow(6,7,9-12) provided the scene contains depth(6,9,10). Depth differences give rise to changing binocular disparities when the observer moves. These disparities are ignored in monocular theories of judgements of heading. Using computer generated displays, we investigated whether stereoscopic presentation improves heading judgements for conditions that pose problems to the monocular observer. We found that adding disparities to simulated ego-motion through a cloud of dots made heading judgements up to four times more tolerant to motion noise. The same improvement was found when the disparities specify the initial distances throughout the motion sequence. We conclude that binocular disparities improve judgements of heading by imposing a depth order on the elements of the scene, not because they provide additional information on the elements' motion in depth.			VANDENBERG, AV (corresponding author), ERASMUS UNIV ROTTERDAM,FAC MED,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.		van den Berg, Albert/G-3108-2012	van den Berg, Albert Victor/0000-0002-1543-5408				Gibson J.J., 1950, PERCEPTION VISUAL WO, DOI DOI 10.2307/1419017; Heeger DJ, 1990, NEURAL COMPUT, V2, P129, DOI 10.1162/neco.1990.2.2.129; KOENDERINK JJ, 1987, BIOL CYBERN, V56, P247, DOI 10.1007/BF00365219; LONGUETHIGGINS HC, 1980, PROC R SOC SER B-BIO, V208, P385, DOI 10.1098/rspb.1980.0057; RIEGER JH, 1985, BIOL CYBERN, V52, P377, DOI 10.1007/BF00449594; RIEGER JH, 1985, J OPT SOC AM A, V2, P354, DOI 10.1364/JOSAA.2.000354; ROYDEN CS, 1992, NATURE, V360, P583, DOI 10.1038/360583a0; VANDENBERG AV, 1992, VISION RES, V32, P1285, DOI 10.1016/0042-6989(92)90223-6; VANDENBERG AV, 1993, NATURE, V365, P497, DOI 10.1038/365497a0; VANDENBERG AV, 1994, VISION RES, V34, P2153, DOI 10.1016/0042-6989(94)90324-7; WARREN WH, 1990, J OPT SOC AM A, V7, P160, DOI 10.1364/JOSAA.7.000160; WARREN WH, 1988, NATURE, V336, P162, DOI 10.1038/336162a0	12	87	87	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 20	1994	371	6499					700	702		10.1038/371700a0	http://dx.doi.org/10.1038/371700a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM773	7935814	Green Submitted			2022-12-01	WOS:A1994PM77300055
J	SULLENGER, BA; CECH, TR				SULLENGER, BA; CECH, TR			RIBOZYME-MEDIATED REPAIR OF DEFECTIVE MESSENGER-RNA BY TARGETED TRANSSPLICING	NATURE			English	Article							RNA ENZYME; TETRAHYMENA RIBOZYME; ESCHERICHIA-COLI; SEQUENCE; CLEAVAGE; EXPRESSION; BINDING; INVIVO; MODEL; VIRUS	RIBOZYMES can be targeted to cleave specific RNAs(1-8), which has led to much interest in their potential as gene inhibitors(3,9,10). Such trans-cleaving ribozymes join a growing list of agents that stop the flow of genetic information(11,12). Here we describe a different application of ribozymes for which they may be uniquely suited. By targeted trans-splicing, a ribozyme can replace a defective portion of RNA with a functional sequence. The self-splicing intron from Tetrahymena thermophila(13) was previously shown to mediate trans-splicing of oligonucleotides in vitro(14,15). As a model system for messenger RNA repair, this group I intron was re-engineered to regenerate the proper coding capacity of short, truncated lacZ transcripts. Trans-splicing was efficient in vitro and proceeded in Escherichia coli to generate translatable lacZ messages. Targeted trans-splicing represents a general means of altering the sequence of specified transcripts and may provide a new approach to the treatment of many genetic diseases.	UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder								BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1988, JAMA-J AM MED ASSOC, V260, P3030; CECH TR, 1992, J BIOL CHEM, V267, P17479; CHOWRIRA BM, 1991, BIOCHEMISTRY-US, V30, P8518, DOI 10.1021/bi00099a003; FELDSTEIN PA, 1989, GENE, V82, P53, DOI 10.1016/0378-1119(89)90029-2; FORD E, 1994, P NATL ACAD SCI USA, V91, P3117, DOI 10.1073/pnas.91.8.3117; FORSTER AC, 1990, SCIENCE, V249, P783, DOI 10.1126/science.1697102; GILBOA E, 1994, TRENDS GENET, V10, P139, DOI 10.1016/0168-9525(94)90216-X; HAMPEL A, 1990, NUCLEIC ACIDS RES, V18, P299, DOI 10.1093/nar/18.2.299; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HERSCHLAG D, 1991, P NATL ACAD SCI USA, V88, P6921, DOI 10.1073/pnas.88.16.6921; INOUE T, 1985, CELL, V43, P431, DOI 10.1016/0092-8674(85)90173-4; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; Miller, 1972, EXPT MOL GENETICS; MORGAN RA, 1993, ANNU REV BIOCHEM, V62, P191; PERROTTA AT, 1992, BIOCHEMISTRY-US, V31, P16, DOI 10.1021/bi00116a004; PRICE JV, 1985, SCIENCE, V228, P719, DOI 10.1126/science.2986286; ROSSI J J, 1992, Current Opinion in Biotechnology, V3, P3, DOI 10.1016/0958-1669(92)90117-2; SULLENGER BA, 1993, SCIENCE, V262, P1566, DOI 10.1126/science.8248806; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TABOR S, 1990, CURRENT PROTOCOLS MO; TRONO D, 1989, CELL, V59, P113, DOI 10.1016/0092-8674(89)90874-X; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; WARING RB, 1985, CELL, V40, P371, DOI 10.1016/0092-8674(85)90151-5; WARING RB, 1986, NATURE, V321, P133, DOI 10.1038/321133a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YU M, 1994, GENE THER, V1, P13; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	30	195	224	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 13	1994	371	6498					619	622		10.1038/371619a0	http://dx.doi.org/10.1038/371619a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7935797				2022-12-01	WOS:A1994PL55900056
J	REID, MM				REID, MM			SPLENECTOMY, SEPSIS, IMMUNIZATION, AND GUIDELINES	LANCET			English	Editorial Material							MANAGEMENT; CHILDHOOD				REID, MM (corresponding author), ROYAL VICTORIA INFIRM,DEPT HAEMATOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.							EDEN OB, 1992, ARCH DIS CHILD, V67, P1056, DOI 10.1136/adc.67.8.1056; ERAKLIS AJ, 1972, J PEDIATR SURG, V7, P382, DOI 10.1016/0022-3468(72)90006-1; GRAHAM RCA, 1994, BRIT MED J, V308, P133, DOI 10.1136/bmj.308.6921.133b; MCMULLIN M, 1993, BRIT MED J, V307, P1372, DOI 10.1136/bmj.307.6916.1372; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; WALKER W, 1976, BRIT J SURG, V63, P36, DOI 10.1002/bjs.1800630109; 1990, DRUG THER B, V28, P31; 1989, MMWR-MORBID MORTAL W, V38, P64; 1994, CMOS UPDATE, V1, P3; 1992, GUIDELINES ETHICAL C; 1992, IMMUNISATION INFECTI	11	22	22	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					970	971						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934424				2022-12-01	WOS:A1994PK97800003
J	CHEN, JL; ATTARDI, LD; VERRIJZER, CP; YOKOMORI, K; TJIAN, R				CHEN, JL; ATTARDI, LD; VERRIJZER, CP; YOKOMORI, K; TJIAN, R			ASSEMBLY OF RECOMBINANT TFIID REVEALS DIFFERENTIAL COACTIVATOR REQUIREMENTS FOR DISTINCT TRANSCRIPTIONAL ACTIVATORS	CELL			English	Article							TATA-BINDING PROTEIN; RNA POLYMERASE-II; GENE-TRANSCRIPTION; MOLECULAR-CLONING; DNA-BINDING; SUBUNIT; COMPLEX; EXPRESSION; TBP; INTERACTS	We previously reported that transcriptional regulators can bind selected TAF subunits of the TFIID complex. However, the specificity and function of individual TAFs in mediating transcriptional activation remained unknown. Here we report the in vitro assembly and transcriptional properties of TBP-TAF complexes reconstituted from the nine recombinant subunits of Drosophila TFIID. A minimal complex containing TBP and TAF(II)250 directs basal but not activator-responsive transcription. By contrast, reconstituted hole TFIID supports activation by an assortment of activators. The activator NTF-1, which binds TAF(II)150, stimulates transcription with a complex containing only TBP, TAF(II)250, and TAF(II)150, whereas Sp1 binds and additionally requires TAF(II)110 for activation. Interestingly, TAF(II)150 enhances Spl activation even though this subunit does not bind directly to Sp1. These results establish that specific subcomplexes of TFIID can mediate activation by different classes of activators and suggest that TAFs perform multiple functions during activation.			CHEN, JL (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.							ATTARDI LD, 1993, GENE DEV, V7, P1341, DOI 10.1101/gad.7.7b.1341; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH JA, 1994, CURR OPIN CELL BIOL, V6, P403; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KLUG A, 1993, NATURE, V365, P486, DOI 10.1038/365486a0; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; KOKUBO T, 1993, P NATL ACAD SCI USA, V90, P5896, DOI 10.1073/pnas.90.13.5896; KOKUBO T, 1993, MOL CELL BIOL, V13, P7859, DOI 10.1128/MCB.13.12.7859; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TIJAN R, 1994, CELL, V77, P5; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235; YOKOMORI K, 1993, GENE DEV, V7, P2587, DOI 10.1101/gad.7.12b.2587; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	37	350	354	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					93	105		10.1016/0092-8674(94)90403-0	http://dx.doi.org/10.1016/0092-8674(94)90403-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923382				2022-12-01	WOS:A1994PK58500011
J	SCHIPPER, H; DICK, JAM				SCHIPPER, H; DICK, JAM			DOES CONSENSUS HELP IN BREAST-CANCER	LANCET			English	Editorial Material									MANITOBA BREAST CANC COUNCIL,WINNIPEG,MB,CANADA		SCHIPPER, H (corresponding author), UNIV MANITOBA,WINNIPEG,MB,CANADA.							CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; FERRARO S, 1993, NY TIMES MAGAZI 0815; GALEA MH, 1992, BREAST CANCER RES TR, V22, P207, DOI 10.1007/BF01840834; ROSEN PP, 1991, J CLIN ONCOL, V9, P1650, DOI 10.1200/JCO.1991.9.9.1650; 1991, JAMA-J AM MED ASSOC, V265, P391; 1993, BREAST CANCER B NCI; 1992, LANCET, V339, P71; 1994, 1ST AUSTR NAT BREAST	9	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					836	836		10.1016/S0140-6736(94)92823-1	http://dx.doi.org/10.1016/S0140-6736(94)92823-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH253	7916397				2022-12-01	WOS:A1994PH25300007
J	VANDIJK, MA; MURRE, C				VANDIJK, MA; MURRE, C			EXTRADENTICLE RAISES THE DNA-BINDING SPECIFICITY OF HOMEOTIC SELECTOR GENE-PRODUCTS	CELL			English	Article							HUMAN PROTOONCOGENE PBX1; DROSOPHILA EMBRYOS; PRE-B; ULTRABITHORAX HOMEODOMAIN; DEVELOPMENTAL DEFECTS; TRANSLOCATION PROTEIN; TARGETED DISRUPTION; SEGMENTAL IDENTITY; CRYSTAL-STRUCTURE; HOMEOBOX GENES	Recently, a Drosophila gene has been identified, extradenticle, whose product modulates the morphological consequences of homeotic selector genes. We shaw here that extradenticle protein raises the DNA binding specificity of Ultrabithorax and abdominal-A but not that of Abdominal-B. We further show that extradenticle modulates the DNA binding activity of engrailed to a different target site. While a region N-terminal of the extradenticle homeodomain is required far Ultrabithorax and abdominal-A cooperativity, engrailed requires a domain C-terminal of the extradenticle homeobox. These studies show directly how the DNA binding specificity of selector gene products can be raised by extradenticle and provides a mechanism, cooperative DMA binding, that allows selector gene products to achieve some of their biological specificity.	UNIV CALIF SAN DIEGO,DEPT BIOL 0116,LA JOLLA,CA 92093	University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [R37CA054198, R01CA054198] Funding Source: NIH RePORTER; NCI NIH HHS [CA54198-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEACHY PA, 1993, MOL CELL BIOL, V13, P6941, DOI 10.1128/MCB.13.11.6941; CELNIKER SE, 1989, GENE DEV, V3, P1424, DOI 10.1101/gad.3.9.1424; CHAN SK, 1993, GENE DEV, V7, P796, DOI 10.1101/gad.7.5.796; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; FLEGEL WA, 1993, MECH DEVELOP, V41, P155, DOI 10.1016/0925-4773(93)90045-Y; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; JOHNSON A, 1992, TRANSCRIPTIONAL REGU, V2, P975; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KUZIORA MA, 1989, CELL, V59, P563, DOI 10.1016/0092-8674(89)90039-1; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; LIN L, 1992, GENE DEV, V6, P1071, DOI 10.1101/gad.6.6.1071; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MAK A, 1993, GENE DEV, V7, P1862, DOI 10.1101/gad.7.10.1862; MALICKI J, 1990, CELL, V63, P961, DOI 10.1016/0092-8674(90)90499-5; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; WIESCHAUS E, 1986, ROUX ARCH DEV BIOL, V195, P63, DOI 10.1007/BF00444042; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5	36	237	238	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 26	1994	78	4					617	624		10.1016/0092-8674(94)90526-6	http://dx.doi.org/10.1016/0092-8674(94)90526-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	7915200				2022-12-01	WOS:A1994PD69300010
J	WILLIAMS, B				WILLIAMS, B			INSULIN-RESISTANCE - THE SHAPE OF THINGS TO COME	LANCET			English	Article							CARDIOVASCULAR RISK-FACTORS; BLOOD-PRESSURE; BODY-FAT; HYPERTENSION; HYPERINSULINEMIA; DISEASE; OBESITY; LEVEL				WILLIAMS, B (corresponding author), LEICESTER ROYAL INFIRM,DEPT MED & THERAPEUT,CLIN SCI BLDG,POB 65,LEICESTER LE2 7LX,ENGLAND.			Williams, Bryan/0000-0002-8094-1841				BLACK HR, 1990, J CARDIOVASC PHARM, V15, pS26; CARRETTA R, 1989, J HYPERTENS, V7, pS196, DOI 10.1097/00004872-198900076-00094; COOPER ME, 1992, 9TH P INT C END; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DONAHUE RP, 1990, AM J EPIDEMIOL, V132, P827, DOI 10.1093/oxfordjournals.aje.a115725; FAGARD RH, 1993, J HYPERTENS, V11, pS47; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; GOLAY A, 1988, DIABETES METAB REV, V4, P727, DOI 10.1002/dmr.5610040803; HAFFNER SM, 1988, METABOLISM, V37, P338, DOI 10.1016/0026-0495(88)90133-3; HALL JE, 1991, FASEB J, V5, pA737; HARTMANN J, 1989, LIFE SCI, V45, P267, DOI 10.1016/0024-3205(89)90260-9; Himsworth HP, 1936, LANCET, V1, P127; HUANG HJS, 1992, HYPERTENSION S1, V19, P101; KANAI H, 1990, HYPERTENSION, V16, P484, DOI 10.1161/01.HYP.16.5.484; KISSEBAH AH, 1989, DIABETES METAB REV, V5, P83, DOI 10.1002/dmr.5610050202; LANDIN K, 1991, J INTERN MED, V229, P181, DOI 10.1111/j.1365-2796.1991.tb00328.x; LESLIE RDG, 1987, DIABETES ANN, V3, P39; LILLIOJA S, 1987, J CLIN INVEST, V80, P415, DOI 10.1172/JCI113088; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; NAGI DK, 1990, DIABETOLOGIA, V33, P532, DOI 10.1007/BF00404140; REAVEN GM, 1987, LANCET, V2, P435; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SAAD MF, 1991, NEW ENGL J MED, V324, P733, DOI 10.1056/NEJM199103143241105; SAWICKIPT, 1992, DIABETOLOGIA, V35, P649; STRIDSBERG M, 1993, DIABETOLOGIA, V36, P843, DOI 10.1007/BF00400360; VAGUE P, 1986, METABOLISM, V35, P250, DOI 10.1016/0026-0495(86)90209-X; WEINSIER RL, 1985, HYPERTENSION, V7, P578, DOI 10.1161/01.HYP.7.4.578; WELBORN TA, 1966, LANCET, V1, P1336; Zavaroni I, 1989, NEW ENGL J MED, V320, P502	29	89	92	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 20	1994	344	8921					521	524		10.1016/S0140-6736(94)91904-6	http://dx.doi.org/10.1016/S0140-6736(94)91904-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7914619				2022-12-01	WOS:A1994PC53500015
J	MOREAU, T; THORPE, J; MILLER, D; MOSELEY, I; HALE, G; WALDMANN, H; CLAYTON, D; WING, M; SCOLDING, N; COMPSTON, A				MOREAU, T; THORPE, J; MILLER, D; MOSELEY, I; HALE, G; WALDMANN, H; CLAYTON, D; WING, M; SCOLDING, N; COMPSTON, A			PRELIMINARY EVIDENCE FROM MAGNETIC-RESONANCE-IMAGING FOR REDUCTION IN DISEASE-ACTIVITY AFTER LYMPHOCYTE DEPLETION IN MULTIPLE-SCLEROSIS	LANCET			English	Article							MONOCLONAL-ANTIBODY THERAPY; LESION DEVELOPMENT; GUIDELINES; TRIAL	The central nervous system lesions of multiple sclerosis (MS) can be detected by magnetic resonance imaging (MRI) and the initial perivascular inflammatory component is distinguished by the presence of gadolinium enhancement. To assess the effect of systemic lymphocyte depletion on disease activity, seven patients with MS received a 10-day intravenous course of the humanised monoclonal antibody CAMPATH-1H (anti-CDw52). With some variations in the protocol, enhanced cerebral MR images were obtained monthly for 3-4 months before and at least 6 months after treatment. 28 enhancing areas were detected on the first series of 7 scans; 51 additional active lesions were identified on 18 scans before treatment; 15 were detected on 20 scans done over the next 3 months, but only 2 active lesions were seen on 23 scans during follow-up beyond 3 months. The difference in lesion incidence rate before and after treatment varied and the rate ratio was significantly reduced in only three patients. Collectively, in a ''meta-analysis'', the rate ratios were 0.58 (95% Cl 0.09-0.24) for all seven patients and 0.24 (0.14-0.42; p < 0.001) with exclusion of the patient whose scanning schedule differed. The effect of CAMPATH-1H on disease activity provides direct, but preliminary, evidence that disease activity in MS depends on the availability of circulating lymphocytes and can be prevented by lymphocyte depletion. It is too early to say anything about the clinical results of treatment with this agent.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,NEUROL UNIT,CAMBRIDGE CB2 2QQ,ENGLAND; INST NEUROL,NMR RES UNIT,LONDON WC1,ENGLAND; NATL HOSP,LONDON WC1,ENGLAND; UNIV CAMBRIDGE,DEPT PATHOL,DIV IMMUNOL,CAMBRIDGE CB2 1QP,ENGLAND; INST PUBL HLTH,MRC,BIOSTAT UNIT,CAMBRIDGE,CAMBS,ENGLAND; ADDENBROOKES HOSP,CTR MRC,MOLEC IMMUNOPATHOL UNIT,CAMBRIDGE,ENGLAND; MRC,CAMBRIDGE CTR BRAIN REPAIR,CAMBRIDGE,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of Cambridge; MRC Biostatistics Unit; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Cambridge			waldmann, herman/W-8051-2019	Waldmann, Herman/0000-0001-7519-6720; Hale, Geoff/0000-0001-9473-423X				CLAYTON D, 1993, STAT MODELS EPIDEMIO, P110; EBERS GC, 1994, LANCET, V343, P275, DOI 10.1016/S0140-6736(94)91119-3; FFRENCHCONSTANT C, 1994, LANCET, V343, P271, DOI 10.1016/S0140-6736(94)91118-5; FILIIPPI M, IN PRESS NEUROLOGY; FILIPPI M, 1994, NEUROLOGY, V44, pA339; HAFLER DA, 1988, J IMMUNOL, V141, P131; HALE G, 1990, TISSUE ANTIGENS, V35, P1; ISAACS JD, 1992, LANCET, V340, P748, DOI 10.1016/0140-6736(92)92294-P; KATZ D, 1993, ANN NEUROL, V34, P661, DOI 10.1002/ana.410340507; KERMODE AG, 1990, BRAIN, V113, P1477, DOI 10.1093/brain/113.5.1477; LINDSEY JW, 1994, NEUROLOGY, V44, P413, DOI 10.1212/WNL.44.3_Part_1.413; LOCKWOOD CM, 1993, LANCET, V341, P1620, DOI 10.1016/0140-6736(93)90759-A; MILLER DH, 1991, J NEUROL NEUROSUR PS, V54, P683, DOI 10.1136/jnnp.54.8.683; NAUTA JJP, 1994, J NEUROL SCI, V122, P6, DOI 10.1016/0022-510X(94)90045-0; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; RAINE CS, 1991, NEUROPATH APPL NEURO, V17, P265, DOI 10.1111/j.1365-2990.1991.tb00724.x; RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0; The IFNB Multiple Sclerosis Study Group, 1993, NEUROLOGY, V43, P655; WEINSHENKER BG, 1991, NEUROLOGY, V41, P1047, DOI 10.1212/WNL.41.7.1047; YOUL BD, 1991, BRAIN, V114, P2437, DOI 10.1093/brain/114.6.2437	21	161	168	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 30	1994	344	8918					298	301		10.1016/S0140-6736(94)91339-0	http://dx.doi.org/10.1016/S0140-6736(94)91339-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ233	7914262				2022-12-01	WOS:A1994NZ23300008
J	SCHMIDT, M; RUTKAT, K; RACHEL, R; PFEIFER, G; JAENICKE, R; VIITANEN, P; LORIMER, G; BUCHNER, J				SCHMIDT, M; RUTKAT, K; RACHEL, R; PFEIFER, G; JAENICKE, R; VIITANEN, P; LORIMER, G; BUCHNER, J			SYMMETRICAL COMPLEXES OF GROE CHAPERONINS AS PART OF THE FUNCTIONAL CYCLE	SCIENCE			English	Article							ESCHERICHIA-COLI; ELECTRON-MICROSCOPY; ATP HYDROLYSIS; CENTRAL CAVITY; PROTEIN; COOPERATIVITY; PURIFICATION; INTERACTS; SURFACE	The particular structural arrangement of chaperonins probably contributes to their ability to assist in the folding of proteins. The interaction of the oligomeric bacterial chaperonin GroEL and its cochaperonin, GroES, in the presence of adenosine diphosphate (ADP) forms an asymmetric complex. However, in the presence of adenosine triphosphate (ATP) or its nonhydrolyzable analogs, symmetric complexes were found by electron microscopy and image analysis. The existence of symmetric chaperonin complexes is not predicted by current models of the functional cycle for GroE-mediated protein folding. Because complete folding of a nonnative substrate protein in the presence of GroEL and GroES only occurs in the presence of ATP, but not with ADP, the symmetric chaperonin complexes formed during the GroE cycle are proposed to be functionally significant.	UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,D-93040 REGENSBURG,GERMANY; UNIV REGENSBURG,INST MIKROBIOL,D-93040 REGENSBURG,GERMANY; MAX PLANCK INST BIOCHEM,D-82153 MARTINSRIED,GERMANY; DUPONT CO INC,DEPT CENT RES & DEV,DIV MOLEC BIOL,EXPTL STN,WILMINGTON,DE 19880	University of Regensburg; University of Regensburg; Max Planck Society; DuPont			Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FRANK J, 1981, SCIENCE, V214, P1353, DOI 10.1126/science.7313694; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HEGERL R, 1982, ULTRAMICROSCOPY, V9, P109, DOI 10.1016/0304-3991(82)90233-9; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; ISHII N, 1992, FEBS LETT, V299, P169, DOI 10.1016/0014-5793(92)80240-H; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JAENICKE R, 1993, CURR OPIN STRUC BIOL, V3, P104, DOI 10.1016/0959-440X(93)90209-4; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SAXTON WO, 1979, ULTRAMICROSCOPY, V9, P109; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; Schmidt M. K., UNPUB; SVENSSON LA, 1994, J MOL BIOL, V235, P47; TAGOUCHI H, 1991, J BIOL CHEM, V266, P22411; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VANHEEL M, 1981, ULTRAMICROSCOPY, V6, P187, DOI 10.1016/S0304-3991(81)80197-0; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505; ZWICKL P, 1990, J STRUCT BIOL, V103, P197, DOI 10.1016/1047-8477(90)90037-D	33	186	187	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					656	659		10.1126/science.7913554	http://dx.doi.org/10.1126/science.7913554			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	7913554				2022-12-01	WOS:A1994NZ53800032
J	LOHMANN, T; LESLIE, RDG; HAWA, M; GEYSEN, M; RODDA, S; LONDEI, M				LOHMANN, T; LESLIE, RDG; HAWA, M; GEYSEN, M; RODDA, S; LONDEI, M			IMMUNODOMINANT EPITOPES OF GLUTAMIC-ACID DECARBOXYLASE-65 AND DECARBOXYLASE-67 IN INSULIN-DEPENDENT DIABETES-MELLITUS	LANCET			English	Note							GAD	To find the dominant epitopes of a major autoantigen in insulin-dependent diabetes mellitus (IDDM), glutamic acid decarboxylase (GAD), we studied the reactivity of peripheral blood T lymphocytes with peptides covering both major isoforms. A significant response to GAD 65 or GAD 67 peptides was detected in 13 of 15 IDDM patients and in 9 of 10 normal controls. Controls most frequently recognised the central region of GAD 65 (residues 161-243). IDDM patients preferentially recognised residues 473-555 (p < 0.03). T-cell responses to GAD 67 peptides were similar in IDDM patients and controls. T lymphocytes from IDDM patients recognise a distinct dominant epitope of GAD, which may be an important target for the disease process.	UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT DIABET & METAB,LONDON EC1A 7BE,ENGLAND; KENNEDY INST,LONDON W6,ENGLAND; CHIRON MIMOTOPES,CLAYTON,VIC,AUSTRALIA	University of London; Queen Mary University London			Leslie, Richard/AAF-6977-2020; Rodda, Simone/S-9766-2018	Leslie, Richard/0000-0002-1786-1531; Rodda, Simone/0000-0002-7973-1003				ATKINSON MA, 1992, LANCET, V339, P458, DOI 10.1016/0140-6736(92)91061-C; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BU DF, 1992, P NATL ACAD SCI USA, V89, P2115, DOI 10.1073/pnas.89.6.2115; CHRISTIE MR, 1992, DIABETES, V41, P782, DOI 10.2337/diabetes.41.7.782; HARRISON LC, 1993, LANCET, V341, P1365, DOI 10.1016/0140-6736(93)90940-I; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; REECE JC, 1993, J IMMUNOL, V151, P6175; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; Zhang J, 1992, Int Rev Immunol, V9, P183, DOI 10.3109/08830189209061790	9	100	102	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1607	1608		10.1016/S0140-6736(94)93061-9	http://dx.doi.org/10.1016/S0140-6736(94)93061-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911924				2022-12-01	WOS:A1994NU35400014
J	KESSLER, DA; ROSE, JL; TEMPLE, RJ; SCHAPIRO, R; GRIFFIN, JP				KESSLER, DA; ROSE, JL; TEMPLE, RJ; SCHAPIRO, R; GRIFFIN, JP			THERAPEUTIC-CLASS WARS - DRUG PROMOTION IN A COMPETITIVE MARKETPLACE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									US FDA,DIV DRUG MKT ADVERTISING & COMMUN,ROCKVILLE,MD 20857	US Food & Drug Administration (FDA)								ANDERS G, 1994, WALL STREET J   0628, pB1; CHREN MM, 1990, JAMA-J AM MED ASSOC, V263, P2178, DOI 10.1001/jama.1990.03440160039021; GOLDFINGER SE, 1987, NEW ENGL J MED, V316, P1408, DOI 10.1056/NEJM198705283162211; KASSIRER JP, 1994, NEW ENGL J MED, V331, P669, DOI 10.1056/NEJM199409083311009; KESSLER DA, 1991, NEW ENGL J MED, V325, P201, DOI 10.1056/NEJM199107183250310; Kolata Gina, 1994, N Y Times Web, pA12; TANOUYE E, 1994, WALL ST J       0531, pA1; WAUD DR, 1992, NEW ENGL J MED, V327, P351, DOI 10.1056/NEJM199207303270511; WILKES MS, 1992, ANN INTERN MED, V116, P912, DOI 10.7326/0003-4819-116-11-912; WOOSLEY RL, 1994, ISSUES SCI TECHNOL, V10, P59; 1993, US ETHICAL PHARM PLY; 1993, EARNING FAILING GRAD; 1993, STATISTICAL REPORT; 1994, MED ADVERTISING NEWS, P10	14	106	107	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 17	1994	331	20					1350	1353		10.1056/NEJM199411173312007	http://dx.doi.org/10.1056/NEJM199411173312007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR216	7935706	Bronze			2022-12-01	WOS:A1994PR21600007
J	ALEXANDER, S				ALEXANDER, S			PREDICTING PROGNOSIS AFTER MYOCARDIAL INFRACTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											ALEXANDER, S (corresponding author), LAHEY CLIN MED CTR,BURLINGTON,MA 01803, USA.								0	1	1	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	1994	272	19					1543	1544						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ900	7966851				2022-12-01	WOS:A1994PQ90000038
J	REUTHER, GW; FU, H; CRIPE, LD; COLLIER, RJ; PENDERGAST, AM				REUTHER, GW; FU, H; CRIPE, LD; COLLIER, RJ; PENDERGAST, AM			ASSOCIATION OF THE PROTEIN-KINASES C-BCR AND BCR-ABL WITH PROTEINS OF THE 14-3-3-FAMILY	SCIENCE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE; DOMAIN; ONCOGENE; TRANSFORMATION; SEQUENCES; REGION; GENE; IDENTIFICATION; ACTIVATION	In this study, a protein that interacts with sequences encoded by the first exon of the protein kinase Bcr was cloned. The Bcr-associated protein 1 (Bap-1) is a member of the 14-3-3 family of proteins. Bap-1 interacts with full-length c-Bcr and with the chimeric Bcr-Abl tyrosine kinase of Philadelphia chromosome (Ph(1))-positive human leukemias. Bap-1 is a substrate for the Bcr serine-threonine kinase and is also phosphorylated on tyrosine by Bcr-Abl but not by c-Abl. Bap-1 may function in the regulation of c-Bcr and may contribute to the transforming activity of Bcr-Abl in vivo. 14-3-3 proteins are essential for cell proliferation and have a role in determining the timing of mitosis in yeast. Through direct binding to sequences present in Bcr and in other proteins implicated in signaling, the mammalian 14-3-3 proteins may link specific signaling protein components to mitogenic and cell-cycle control pathways.	DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, SHIPLEY INST MED, BOSTON, MA 02115 USA	Duke University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			Reuther, Gary/AFR-2892-2022	Pendergast, Ann Marie/0000-0002-1250-6880; Collier, R John/0000-0002-2427-4239	NATIONAL CANCER INSTITUTE [R01CA061033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K12DK001965] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007184] Funding Source: NIH RePORTER; NCI NIH HHS [CA61033] Funding Source: Medline; NIDDK NIH HHS [DK01965] Funding Source: Medline; NIGMS NIH HHS [GM07184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; MORRISON DK, 1990, CANCER CELL-MON REV, V2, P377; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NIELSEN PJ, 1991, BIOCHIM BIOPHYS ACTA, V1088, P425, DOI 10.1016/0167-4781(91)90136-A; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; REUTHER GW, UNPUB; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; RON D, 1991, NEW BIOL, V3, P372; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TOKER A, 1992, EUR J BIOCHEM, V206, P453, DOI 10.1111/j.1432-1033.1992.tb16946.x	39	218	223	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 7	1994	266	5182					129	133		10.1126/science.7939633	http://dx.doi.org/10.1126/science.7939633			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7939633				2022-12-01	WOS:A1994PK58200041
J	BOHMANN, D; ELLIS, MC; STASZEWSKI, LM; MLODZIK, M				BOHMANN, D; ELLIS, MC; STASZEWSKI, LM; MLODZIK, M			DROSOPHILA JUN MEDIATES RAS-DEPENDENT PHOTORECEPTOR DETERMINATION	CELL			English	Article							RECEPTOR TYROSINE KINASE; GUANINE-NUCLEOTIDE EXCHANGE; TRANSCRIPTION FACTOR AP-1; C-JUN; SEVENLESS PROTEIN; CELL FATE; SIGNAL-TRANSDUCTION; FUNCTIONS DOWNSTREAM; ECTOPIC EXPRESSION; NEGATIVE REGULATOR	The expression of the D. melanogaster transcription factor Jun in the eye imaginal disc correlates temporally and spatially with the determination of neuronal photoreceptor fate. Expression of dominant negative forms of Jun in photoreceptor precursor cells results in dose-dependent loss of photoreceptors in the adult fly. Conversely, localized overexpression of Jun in the eye imaginal disc can induce the differentiation of additional photoreceptor cells. Furthermore, the transformation of nonneuronal cone cells into R7 neurons elicited by constitutively active forms of sevenless, Ras1, Raf, and MAP kinase is relieved in the presence of Jun mutants. These results demonstrate a requirement of Jun downstream of the sevenless/ras signaling pathway for neuronal development in the Drosophila eye.			BOHMANN, D (corresponding author), EUROPEAN MOLEC BIOL LAB, D-69012 HEIDELBERG, GERMANY.							ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BASLER K, 1990, GENE DEV, V4, P728, DOI 10.1101/gad.4.5.728; BASLER K, 1988, CELL, V54, P299; BASLER K, 1989, DEVELOPMENT, V107, P723; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1988, COLD SPRING HARB SYM, V53, P695, DOI 10.1101/SQB.1988.053.01.079; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BROWN PH, 1993, ONCOGENE, V8, P877; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1987, ONCOGENE, V2, P79; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DICKSON B, 1992, GENE DEV, V6, P2327, DOI 10.1101/gad.6.12a.2327; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DOYLE HJ, 1993, GENE DEV, V7, P633, DOI 10.1101/gad.7.4.633; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FISCHERVIZE JA, 1992, DEVELOPMENT, V115, P89; FISCHERVIZE JA, 1992, DEVELOPMENT, V116, P985; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FRIEDMAN AD, 1988, NATURE, V335, P452, DOI 10.1038/335452a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HAFEN E, 1993, PHILOS T R SOC B, V340, P273, DOI 10.1098/rstb.1993.0068; HARLOW E, 1988, ANTIBODIES LABORATOR; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIROMI Y, 1993, DEVELOPMENT, V118, P1123; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MULLINS MC, 1989, GENE DEV, V3, P729, DOI 10.1101/gad.3.5.729; MULLINS MC, 1991, P NATL ACAD SCI USA, V88, P9387, DOI 10.1073/pnas.88.21.9387; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PERKINS KK, 1990, GENE DEV, V4, P822, DOI 10.1101/gad.4.5.822; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; READY DF, 1989, TRENDS NEUROSCI, V12, P102, DOI 10.1016/0166-2236(89)90166-5; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1985, J EMBRYOL EXP MORPH, V89, P313; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; ZHANG K, 1990, P NATL ACAD SCI USA, V87, P6281, DOI 10.1073/pnas.87.16.6281	73	84	84	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 23	1994	78	6					973	986		10.1016/0092-8674(94)90273-9	http://dx.doi.org/10.1016/0092-8674(94)90273-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923366				2022-12-01	WOS:A1994PJ29400009
J	KOIZUMI, A				KOIZUMI, A			FIGHTING MYTHS	LANCET			English	Editorial Material											KOIZUMI, A (corresponding author), AKITA UNIV,SCH MED,DEPT HYG,AKITA 010,JAPAN.							BALLANTYNE B, 1987, CLIN EXPT TOXICOLOGY, P473; KOIZUMI A, 1994, LANCET, V343, P1411, DOI 10.1016/S0140-6736(94)92530-5; NICHOLSON PJ, 1994, OCCUP MED-OXFORD, V44, P125, DOI 10.1093/occmed/44.3.125	3	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					559	560		10.1016/S0140-6736(94)91959-3	http://dx.doi.org/10.1016/S0140-6736(94)91959-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914954				2022-12-01	WOS:A1994PD42400003
J	SINGER, PA				SINGER, PA			DISEASE-SPECIFIC ADVANCE DIRECTIVES	LANCET			English	Editorial Material											SINGER, PA (corresponding author), UNIV TORONTO,CTR BIOETH,88 COLL ST,TORONTO M5G 1L4,ON,CANADA.								0	40	43	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					594	596		10.1016/S0140-6736(94)91971-2	http://dx.doi.org/10.1016/S0140-6736(94)91971-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914966				2022-12-01	WOS:A1994PD42400015
J	BUSTURIA, A; LAWRENCE, PA				BUSTURIA, A; LAWRENCE, PA			REGULATION OF CELL NUMBER IN DROSOPHILA	NATURE			English	Article							IMAGINAL WING DISK; PATTERN-FORMATION; FUSHI-TARAZU; FATE MAP; MELANOGASTER; EMBRYO; LARVAL; LOCALIZATION; PARASEGMENTS; REGENERATION	DURING animal development, different parts grow independently (such as the left and right hands) but they stop growing when they reach the correct size. In most insects, growth of the epidermis is so controlled that, at each moult, there is a precise and proportionate increase in cell number(1). The mechanisms responsible for this size regulation are not known(2), but rigid programming of the number of cell divisions is not a requirement as even sister cells in an epithelial sheet divide variably(3-5). In the abdomen of dipterans, such as Drosophila, the opportunity for regulation is limited, because mitoses occur only in the embryo and during metamorphosis and not during larval growth. Here we used embryos with a reduced number of cells in the abdominal primordia to determine,whether they can regulate towards the normal during subsequent growth. In contrast to expectations(6-8), we find no evidence for regulation of cell number.			BUSTURIA, A (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.			Lawrence, Peter/0000-0002-9554-8268				BECKER HJ, 1957, Z INDUKT ABSTAMM VER, V88, P333, DOI 10.1007/BF00309128; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BRYANT PJ, 1975, J EXP ZOOL, V193, P49, DOI 10.1002/jez.1401930106; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; DRIEVER W, 1994, DEV DROSOPHILA MELAN, V1; GARCIABELLIDO A, 1971, DEV BIOL, V26, P264, DOI 10.1016/0012-1606(71)90126-6; HARTENSTEIN V, 1992, ROUX ARCH DEV BIOL, V194, P308; HAYNIE JL, 1977, ROUX ARCH DEV BIOL, V183, P85, DOI 10.1007/BF00848779; Lawrence P., 1973, DEVELOPMENTAL SYSTEM, P157; Lawrence P. A., 1992, MAKING FLY GENETICS; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; LAWRENCE PA, 1989, DEVELOPMENT, V105, P761; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LOHSSCHARDIN M, 1979, DEV BIOL, V73, P239, DOI 10.1016/0012-1606(79)90065-4; MADHAVAN MM, 1980, J EMBRYOL EXP MORPH, V60, P1; MADHAVAN MM, 1984, J EMBRYOL EXP MORPH, V82, P1; MEISE M, 1993, DEVELOPMENT, V118, P1107; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; NUSSLEINVOLHARD C, 1989, CIBA F SYMP, V144, P37; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; ORTEGA JAC, 1985, EMBRYONIC DEV DROSOP; ROSELAND CR, 1979, ROUX ARCH DEV BIOL, V186, P235, DOI 10.1007/BF00848591; SAMPEDRO J, 1993, DEVELOPMENT, V117, P677; SANTAMARIA P, 1972, J EMBRYOL EXP MORPH, V28, P397; SCHWEIZER P, 1972, BIOPHYSIK, V8, P158, DOI 10.1007/BF01188566; SIMPSON P, 1981, DEV BIOL, V85, P299, DOI 10.1016/0012-1606(81)90261-X; VINCENT JP, 1992, CELL, V68, P923, DOI 10.1016/0092-8674(92)90035-B; WIGGLESWORTH VB, 1965, PRINCIPLES INSECT PH, P61; WRIGHT DA, 1981, DEV BIOL, V85, P317, DOI 10.1016/0012-1606(81)90263-3; YASUDA GK, 1991, GENE DEV, V5, P1800, DOI 10.1101/gad.5.10.1800	30	24	24	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 18	1994	370	6490					561	563		10.1038/370561a0	http://dx.doi.org/10.1038/370561a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	7914352				2022-12-01	WOS:A1994PC53700056
J	BRITTON, J; PAVORD, I; RICHARDS, K; WISNIEWSKI, A; KNOX, A; LEWIS, S; TATTERSFIELD, A; WEISS, S				BRITTON, J; PAVORD, I; RICHARDS, K; WISNIEWSKI, A; KNOX, A; LEWIS, S; TATTERSFIELD, A; WEISS, S			DIETARY MAGNESIUM, LUNG-FUNCTION, WHEEZING, AND AIRWAY HYPERREACTIVITY IN A RANDOM ADULT-POPULATION SAMPLE	LANCET			English	Article							BRONCHIAL RESPONSIVENESS; SMOOTH-MUSCLE; EXCRETION; SODIUM; QUESTIONNAIRE; HISTAMINE; POTASSIUM; SYMPTOMS; CALCIUM; SULFATE	Magnesium is involved in a wide range of biological activities, including some that may protect against the development of asthma and chronic airflow obstruction. We tested the hypothesis that high dietary magnesium intake is associated with better lung function, and a reduced risk of airway hyper-reactivity and wheezing in a random sample of adults. In 2633 adults aged 18-70 sampled from the electoral register of an administrative area of Nottingham, UK, we measured dietary magnesium intake by semiquantitative food-frequency questionnaire, lung function as the 1-sec forced expiratory volume (FEV(1)), and atopy as the mean shin-prick test response to three common environmental allergens. We measured airway reactivity to methacholine in 2415 individuals, defining hyper-reactivity as a 20% fall in FEV(1) after a cumulative dose of 12.25 mu mol or less. Mean (SD) daily intake of magnesium was 380 (114) mg/day. After adjusting for age, sex, and height, and for the effects of atopy and smoking, a 100 mg/day higher magnesium intake Was associated with a 27.7 (95% Cl, 11.9-43.5) mL higher FEV(1), and a reduction in the relative odds of hyper-reactivity by a ratio of 0.82 (0.72-0.93). The same incremental difference in magnesium intake was also associated with a reduction in the odds of self-reported wheeze within the past 12 months, adjusted for age, sex, smoking, atopy, and kilojoule intake, by a ratio of 0.85 (0.76-0.95). Dietary magnesium intake is independently related to lung function and the occurrence of airway hyper-reactivity and self-reported wheezing in the general population. Low magnesium intake may therefore be involved in the aetiology of asthma and chronic obstructive airways disease.	BRIGHAM & WOMENS HOSP,DEPT MED,CHANNING LAB,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital	BRITTON, J (corresponding author), UNIV NOTTINGHAM,CITY HOSP,DIV RESP MED,NOTTINGHAM NG5 1PB,ENGLAND.		Britton, John R/G-9705-2011	Pavord, Ian/0000-0002-4288-5973; Knox, Alan/0000-0002-5906-4143				BOIS P, 1963, BRIT J EXP PATHOL, V44, P151; BRITTON J, 1994, EUR RESPIR J, V7, P881; BRITTON J, 1993, AM REV RESPIR DIS, V147, P377; BRITTON J, 1993, AM REV RESPIR DIS, V147, P369; BURNEY PGJ, 1986, BRIT MED J, V292, P1483, DOI 10.1136/bmj.292.6534.1483; BURNEY PGJ, 1989, THORAX, V44, P36, DOI 10.1136/thx.44.1.36; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; DANGELO EKG, 1992, J CLIN INVEST, V89, P1988, DOI 10.1172/JCI115807; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P370, DOI 10.1113/jphysiol.1954.sp005114; DUNNETT J, 1978, J MOL CELL CARDIOL, V10, P487, DOI 10.1016/0022-2828(78)90369-3; DURLACH J, 1975, REV FR ALLERGOL, V15, P133, DOI 10.1016/S0335-7457(75)80025-6; DYCKNER T, 1984, DRUGS, V28, P161, DOI 10.2165/00003495-198400281-00016; Gregory F., 1990, DIETARY NUTR SURVEY; HAURY VG, 1938, J PHARMACOL EXP THER, V64, P4; KEMP PA, 1994, BRIT J PHARMACOL, V111, P325, DOI 10.1111/j.1476-5381.1994.tb14063.x; LEVINE BS, 1984, NEW ENGL J MED, V310, P1253, DOI 10.1056/NEJM198405103101910; LEWIS J, 1988, BRIT J NUTR, V60, P413, DOI 10.1079/BJN19880113; NADLER JL, 1987, HYPERTENSION, V9, P379, DOI 10.1161/01.HYP.9.4.379; NOPPEN M, 1990, CHEST, V97, P373, DOI 10.1378/chest.97.2.373; Paul A.A., 1988, MCCANCE WIDDOWSONS C; PISTELLI R, 1993, EUR RESPIR J, V6, P517; SCHROEDER HA, 1969, J CHRON DIS, V21, P815, DOI 10.1016/0021-9681(69)90027-7; SKOBELOFF EM, 1989, JAMA-J AM MED ASSOC, V262, P1210; SPARROW D, 1991, AM REV RESPIR DIS, V144, P722, DOI 10.1164/ajrccm/144.3_Pt_1.722; SPIVEY WH, 1990, ANN EMERG MED, V19, P1107, DOI 10.1016/S0196-0644(05)81513-6; WACKER WEC, 1958, NEW ENGL J MED, V259, P475, DOI 10.1056/NEJM195809042591005; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; YARNELL JWG, 1983, HUM NUTR-APPL NUTR, V37, P103; 1991, SMOKING EPIDEMIC COU, V3; 1991, DIETARY REFERENCE VA, P146	30	199	205	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 6	1994	344	8919					357	362		10.1016/S0140-6736(94)91399-4	http://dx.doi.org/10.1016/S0140-6736(94)91399-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA303	7914305				2022-12-01	WOS:A1994PA30300008
J	SAILER, A; BUELER, H; FISCHER, M; AGUZZI, A; WEISSMANN, C				SAILER, A; BUELER, H; FISCHER, M; AGUZZI, A; WEISSMANN, C			NO PROPAGATION OF PRIONS IN MICE DEVOID OF PRP	CELL			English	Note							SCRAPIE		UNIV ZURICH,INST NEUROPATHOL,CH-8091 ZURICH,SWITZERLAND	University of Zurich	SAILER, A (corresponding author), UNIV ZURICH,INST MOLEK BIOL 1,CH-8093 ZURICH,SWITZERLAND.		Aguzzi, Adriano/A-3351-2008; Büeler, Hansruedi/J-6965-2017; Sailer, Andreas/M-9913-2016	Büeler, Hansruedi/0000-0002-4892-7177; Sailer, Andreas/0000-0002-9015-7946; Aguzzi, Adriano/0000-0002-0344-6708				BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; CHESEBRO B, 1993, CURR BIOL, V3, P696, DOI 10.1016/0960-9822(93)90072-V; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608	4	235	241	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					967	968		10.1016/0092-8674(94)90436-7	http://dx.doi.org/10.1016/0092-8674(94)90436-7			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	7912659				2022-12-01	WOS:A1994NV42500005
J	WAGA, S; HANNON, GJ; BEACH, D; STILLMAN, B				WAGA, S; HANNON, GJ; BEACH, D; STILLMAN, B			THE P21 INHIBITOR OF CYCLIN-DEPENDENT KINASES CONTROLS DNA-REPLICATION BY INTERACTION WITH PCNA	NATURE			English	Article							CELL NUCLEAR ANTIGEN; POLYMERASE-DELTA; STRAND SYNTHESIS; PROTEIN; INVITRO; P53; INITIATION; SUBUNIT; REPAIR; ORIGIN	THE p53 tumour-suppressor protein controls the expression of a gene encoding the p21 cyclin-dependent protein kinase (CDK) regulator(1-6). Levels of p21 protein are increased in senescent cells and p21 overexpression blocks the growth of tumour cells(1,3,7). In normal human cells, but not in many tumour cells, p21 exists in a guaternary complex with a cyclin, a CDK, and the proliferating-cell nuclear antigen (PCNA)(5,8). p21 controls CDK activity, thereby affecting cell-cycle control(2-4,6), whereas PCNA functions in both DNA replication(9-12) and repair(13). Here we use simian virus 40 DNA replication in vitro to show that p21 directly inhibits PCNA-dependent DNA replication in the absence of a cyclin/CDK. Furthermore, p21 blocks the ability of PCNA to activate DNA polymerase delta, the principal replicative DNA polymerase. This regulation results from a direct interaction between p21 and PCNA. Thus, during p53-mediated suppression of cell proliferation, p21 and PCNA mag be important for coordinating cell-cycle progression, DNA replication and repair of damaged DNA.	HOWARD HUGHES MED INST, COLD SPRING HARBOR, NY 11724 USA	Howard Hughes Medical Institute	WAGA, S (corresponding author), COLD SPRING HARBOR LAB, POB 100, BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA.		Hannon, Gregory/AAB-3568-2019	Stillman, Bruce/0000-0002-9453-4091; Waga, Shou/0000-0003-4986-8735				BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KONG XP, 1992, J CELL, V69, P425; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MELENDY T, 1992, NUCLEIC ACIDS MOL BI, V6, P129; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; TAN CK, 1986, J BIOL CHEM, V261, P2310; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; WAGA S, 1994, J BIOL CHEM, V269, P10923; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WASEEM NH, 1992, EMBO J, V11, P5111, DOI 10.1002/j.1460-2075.1992.tb05618.x; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	29	1633	1690	34	345	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 16	1994	369	6481					574	578		10.1038/369574a0	http://dx.doi.org/10.1038/369574a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR294	7911228				2022-12-01	WOS:A1994NR29400054
J	POLLAK, MR; BROWN, EM; CHOU, YHW; HEBERT, SC; MARX, SJ; STEINMANN, B; LEVI, T; SEIDMAN, CE; SEIDMAN, JG				POLLAK, MR; BROWN, EM; CHOU, YHW; HEBERT, SC; MARX, SJ; STEINMANN, B; LEVI, T; SEIDMAN, CE; SEIDMAN, JG			MUTATIONS IN THE HUMAN CA2+-SENSING RECEPTOR GENE CAUSE FAMILIAL HYPOCALCIURIC HYPERCALCEMIA AND NEONATAL SEVERE HYPERPARATHYROIDISM	CELL			English	Article							KINDREDS	We demonstrate that mutations in the human Ca2+-sensing receptor gene cause familial hypocalciuric hypercalcemia (FHH) and neonatal severe hyperparathyroidism (NSHPT), two inherited conditions characterized by altered calcium homeostasis. The Ca2+-sensing receptor belongs to the superfamily of seven membrane-spanning G protein-coupled receptors. Three nonconservative missense mutations are reported: two occur in the extracellular N-terminal domain of the receptor; the third occurs in the final intracellular loop. One mutated receptor identified in FHH individuals was expressed in X. laevis oocytes. The expressed wild-type receptor elicted large inward currents in response to perfused polyvalent cations; a markedly attenuated response was observed with the mutated protein. We conclude that the mammalian Ca2+-sensing receptor ''sets'' the extracellular Ca2+ level and is defective in individuals with FHH and NSHPT.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV ENDOCRINE HYPERTENS,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115; NIDDKD,METAB DIS BRANCH,BETHESDA,MD 20892; UNIV ZURICH,DEPT PEDIAT,CH-8032 ZURICH,SWITZERLAND	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Zurich	POLLAK, MR (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,BOSTON,MA 02115, USA.		Lima, Thaísa/AAG-6483-2021		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046422, K11DK002138, R01DK044588] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK02138, DK44588, DK46422] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATTIE MF, 1983, J CLIN INVEST, V72, P667, DOI 10.1172/JCI111016; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; CHOU YHW, 1992, NAT GENET, V1, P295, DOI 10.1038/ng0792-295; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; HOLCOMBE R F, 1987, Genomics, V1, P287, DOI 10.1016/0888-7543(87)90058-9; KHOSLA S, 1993, J CLIN ENDOCR METAB, V76, P715, DOI 10.1210/jc.76.3.715; KUNKEL MT, 1993, EMBO J, V12, P3809, DOI 10.1002/j.1460-2075.1993.tb06059.x; LAW WM, 1985, ANN INTERN MED, V102, P511, DOI 10.7326/0003-4819-102-4-511; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MARX SJ, 1977, AM J MED, V62, P698, DOI 10.1016/0002-9343(77)90873-7; MARX SJ, 1982, NEW ENGL J MED, V306, P257, DOI 10.1056/NEJM198202043060502; MARX SJ, 1981, MEDICINE, V60, P397, DOI 10.1097/00005792-198111000-00002; MARX SJ, 1986, J CLIN ENDOCR METAB, V62, P445, DOI 10.1210/jcem-62-2-445; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; OTT J, 1983, ANAL HUMAN GENETIC L; POLLAK MR, 1994, IN PRESS J CLIN INVE; ROSENZWEIG A, 1991, NEW ENGL J MED, V325, P1753, DOI 10.1056/NEJM199112193252501; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEINMANN B, 1984, HELV PAEDIATR ACTA, V39, P171	24	807	828	1	29	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 31	1993	75	7					1297	1303		10.1016/0092-8674(93)90617-Y	http://dx.doi.org/10.1016/0092-8674(93)90617-Y			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	7916660				2022-12-01	WOS:A1993MP86900009
J	BRIDGES, AJ				BRIDGES, AJ			SILICONE IMPLANT CONTROVERSY CONTINUES	LANCET			English	Editorial Material							BREAST IMPLANTS; WOMEN				BRIDGES, AJ (corresponding author), UNIV WISCONSIN HOSP,MADISON,WI, USA.							ANGELL M, 1994, NEW ENGL J MED, V330, P1748, DOI 10.1056/NEJM199406163302409; BORENSTEIN D, 1993, ARTHRITIS RHEUM, V36, pS117; BRIDGES AJ, 1993, ANN INTERN MED, V118, P929, DOI 10.7326/0003-4819-118-12-199306150-00003; BRIDGES AJ, 1993, ARCH INTERN MED, V153, P2638, DOI 10.1001/archinte.153.23.2638; BRIDGES AJ, 1993, ARTHRITIS RHEUM, V36, pS191; BRIDGES AJ, IN PRESS J BIOMAT SC; CUELLAR ML, 1993, ARTHRITIS RHEUM, V36, pS219; DUGOWSON CE, 1992, ARTHRITIS RHEUM, V35, pS66; GABRIEL SE, 1994, NEW ENGL J MED, V330, P1697, DOI 10.1056/NEJM199406163302401; KOSSOVSKY N, 1993, J APPL BIOMATER, V4, P281, DOI 10.1002/jab.770040402; OJOAMAIZE EA, IN PRESS CLIN DIAG L; SOLOMON G, 1994, SEMIN ARTHRITIS RHEU, V24, P29, DOI 10.1016/0049-0172(94)90107-4; SPIERA H, 1993, J RHEUMATOL, V20, P958; TEUBER SS, 1993, J AUTOIMMUN, V6, P367, DOI 10.1006/jaut.1993.1031	14	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 26	1994	344	8935					1451	1452		10.1016/S0140-6736(94)90284-4	http://dx.doi.org/10.1016/S0140-6736(94)90284-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7968116				2022-12-01	WOS:A1994PT99500003
J	GOULDING, EH; TIBBS, GR; SIEGELBAUM, SA				GOULDING, EH; TIBBS, GR; SIEGELBAUM, SA			MOLECULAR MECHANISM OF CYCLIC-NUCLEOTIDE-GATED CHANNEL ACTIVATION	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; SUBUNIT STOICHIOMETRY; BINDING-SPECIFICITY; POTASSIUM CHANNELS; RECEPTOR CHIMERAS; INACTIVATION; MEMBRANE; DOMAIN; GMP	STUDIES on the activation of ligand- and voltage-gated ion channels have identified regions involved in both ligand binding(1) and voltage sensing(2), but relatively little is known about how such domains are coupled to channel opening. Here we investigate the structural basis for the activation of cyclic-nucleotide-gated channels, which are directly opened by cytoplasmic cyclic nucleotides(3,4) but are structurally homologous to voltage-gated channels(5-7). By constructing chimaeras between cyclic-nucleotide-gated channels cloned from bovine retinal photoreceptors(8) and catfish olfactory neurons(7), we identify two distinct domains that are important for ligand binding and channel gating. A putative alpha-helix in the carboxy-terminal binding domain determines the selectivity of the channel for activation by cGMP relative to cAMP. A domain in the amino-terminal region determines the ease with which channels open and thus influences agonist efficacy. We propose that channel opening is coupled to an allosteric conformational change in the binding site which enhances agonist binding. Thus, cyclic nucleotides activate the channel by binding tightly to the open state and stabilizing it.	COLUMBIA UNIV,HOWARD HUGHES MED INST,DEPT PHARMACOL,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	GOULDING, EH (corresponding author), COLUMBIA UNIV,HOWARD HUGHES MED INST,CTR NEUROBIOL & BEHAV,DEPT PHYSIOL,722 W 168TH ST,NEW YORK,NY 10032, USA.							AVIS JM, 1993, BIOCHEMISTRY-US, V32, P5321, DOI 10.1021/bi00071a006; BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; CASTILLO JD, 1957, P ROY SOC          B, V146, P369; CATTERALL WA, 1989, SCIENCE, V243, P236, DOI 10.1126/science.2536189; FERSHT A, 1985, ENZYME STRUCTURE MEC, P98; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; GOULDING EH, 1993, NATURE, V364, P61, DOI 10.1038/364061a0; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; GUY HR, 1991, SCIENCE, V254, P730, DOI 10.1126/science.1658932; JACKSON MB, 1992, BIOPHYS J, V63, P1443, DOI 10.1016/S0006-3495(92)81706-X; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KRAMER RH, 1994, NEURON, V12, P655, DOI 10.1016/0896-6273(94)90220-8; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NAKAMURA T, 1987, NATURE, V325, P342; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SHEN NV, 1993, NEURON, V11, P67; SKOOG DA, 1982, FUNDAMENTALS ANAL CH, P75; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; UNWIN PNT, 1984, NATURE, V307, P609, DOI 10.1038/307609a0; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	30	177	178	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					369	374		10.1038/372369a0	http://dx.doi.org/10.1038/372369a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PU287	7969497				2022-12-01	WOS:A1994PU28700058
J	ZEIHER, AM; IHLING, C; PISTORIUS, K; SCHACHINGER, V; SCHAEFER, HE				ZEIHER, AM; IHLING, C; PISTORIUS, K; SCHACHINGER, V; SCHAEFER, HE			INCREASED TISSUE ENDOTHELIN IMMUNOREACTIVITY IN ATHEROSCLEROTIC LESIONS ASSOCIATED WITH ACUTE CORONARY SYNDROMES	LANCET			English	Note							ARTERY DISEASE; PATHOGENESIS; MECHANISMS; VASOSPASM	Acute coronary syndromes are accompanied by exaggerated vasoconstriction. Since thrombin induces production of the potent vasoconstrictor endothelin-1, we used immunohistochemistry on coronary atherosclerotic specimens from 30 consecutive patients. Endothelin-1-like immunoreactivity was present in 5 of 9 (55%) lesions from patients with stable angina, in 6 of 7 (86%) from crescendo angina, and in all 14 from angina at rest. Endothelin-1 immunoreactivity was most common in areas with a positive Prussian-blue reaction indicative of previous intraplaque haemorrhage. Tissue endothelin-1-like immunoreactivity might contribute to the exaggerated coronary vasoconstriction.	UNIV FREIBURG,DEPT PATHOL,D-79106 FREIBURG,GERMANY	University of Freiburg	ZEIHER, AM (corresponding author), UNIV FREIBURG,DEPT INTERNAL MED 3,DIV CARDIOL,D-79106 FREIBURG,GERMANY.							EHRENREICH H, 1990, J EXP MED, V172, P1741, DOI 10.1084/jem.172.6.1741; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; HOLLANDER M, 1973, NONPARAMETRIC STATIS; LERMAN A, 1991, NEW ENGL J MED, V325, P997, DOI 10.1056/NEJM199110033251404; VANHOUTTE PM, 1989, CIRCULATION, V80, P1, DOI 10.1161/01.CIR.80.1.1; WINKLES JA, 1993, BIOCHEM BIOPH RES CO, V191, P1081, DOI 10.1006/bbrc.1993.1327; YANG ZH, 1990, CIRCULATION, V82, P188, DOI 10.1161/01.CIR.82.1.188; YANIGASAWA M, 1988, NATURE, V332, P411; ZEIHER AM, 1991, CIRCULATION, V83, P1519, DOI 10.1161/01.CIR.83.5.1519; ZEIHER AM, 1991, CIRCULATION, V83, P391, DOI 10.1161/01.CIR.83.2.391	11	90	93	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 19	1994	344	8934					1405	1406		10.1016/S0140-6736(94)90571-1	http://dx.doi.org/10.1016/S0140-6736(94)90571-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR786	7968078				2022-12-01	WOS:A1994PR78600012
J	WOODARD, CT; BAEHRECKE, EH; THUMMEL, CS				WOODARD, CT; BAEHRECKE, EH; THUMMEL, CS			A MOLECULAR MECHANISM FOR THE STAGE SPECIFICITY OF THE DROSOPHILA PREPUPAL GENETIC RESPONSE TO ECDYSONE	CELL			English	Article							HORMONE-RECEPTOR SUPERFAMILY; POLYTENE CHROMOSOMES; INDUCIBLE GENE; PUPAL CUTICLE; EARLY PUFF; ECDYSTEROID TITERS; BINDING PROTEIN; IMAGINAL DISKS; FUSHI-TARAZU; ENCODES 2	Two successive pulses of ecdysone signal the ends of larval and prepupal development in Drosophila, inducing early and late puffs in the salivary gland polytene chromosomes. Early puff induction in prepupae is dependent on a preceding period of protein synthesis and low ecdysone concentration. We demonstrate here that the competence acquired during this interval can be provided by beta FTZ-F1, a nuclear hormone receptor superfamily member derived from the 75CD mid-prepupal puff. We show that beta FTZ-F1 represses its own transcription and is repressed by ecdysone, explaining its brief expression in mid-prepupae. We further show that ectopic beta FTZ-F1 expression leads to enhanced levels of ecdysone-induced BR-C, E74, and E75 early gene transcription and premature induction of the stage-specific 93F early puff and E93 transcription. These findings indicate that beta FTZ-F1 plays a central role in the prepupal genetic response to ecdysone and provide a molecular mechanism for stage-specific responses to steroid hormones.			WOODARD, CT (corresponding author), UNIV UTAH,ECCLES INST HUMAN GENET,HOWARD HUGHES MED INST,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112, USA.		Woodard, Craig/L-7293-2019					ANDRES AJ, 1994, METHOD CELL BIOL, V44, P565, DOI 10.1016/S0091-679X(08)60932-2; ANDRES AJ, 1993, DEV BIOL, V160, P388, DOI 10.1006/dbio.1993.1315; APPLE RT, 1991, DEV BIOL, V146, P569, DOI 10.1016/0012-1606(91)90257-4; ASHBURNER M, 1967, CHROMOSOMA, V21, P398, DOI 10.1007/BF00336950; ASHBURNER M, 1974, DEV BIOL, V39, P141, DOI 10.1016/S0012-1606(74)80016-3; Ashburner M, 1974, Cold Spring Harb Symp Quant Biol, V38, P655; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECKER HJ, 1959, CHROMOSOMA, V10, P654, DOI 10.1007/BF00396591; Bodenstein D, 1965, BIOL DROSOPHILA, P275; BOYD M, 1977, J INSECT PHYSIOL, V23, P517, DOI 10.1016/0022-1910(77)90263-3; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CHAO AT, 1986, EMBO J, V5, P143, DOI 10.1002/j.1460-2075.1986.tb04188.x; CLEVER U, 1960, EXP CELL RES, V20, P623, DOI 10.1016/0014-4827(60)90141-5; CROWLEY TE, 1984, CELL, V39, P149, DOI 10.1016/0092-8674(84)90200-9; DIBELLO PR, 1991, GENETICS, V129, P385; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FECHTEL K, 1988, GENETICS, V120, P465; FECHTEL K, 1989, DEVELOPMENT, V106, P649; FRISTROM JW, 1982, DEV BIOL, V91, P337, DOI 10.1016/0012-1606(82)90040-9; FRISTROM JW, 1986, ARCH INSECT BIOCH S, V1, P119; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HANDLER AM, 1982, DEV BIOL, V93, P73, DOI 10.1016/0012-1606(82)90240-8; HUET F, 1993, DEVELOPMENT, V118, P613; KARIM FD, 1992, EMBO J, V11, P4083, DOI 10.1002/j.1460-2075.1992.tb05501.x; KARIM FD, 1991, GENE DEV, V5, P1067, DOI 10.1101/gad.5.6.1067; KARIM FD, 1993, DEVELOPMENT, V118, P977; KOELLE MR, 1992, THESIS STANFORD U ST; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; LAVORGNA G, 1993, P NATL ACAD SCI USA, V90, P3004, DOI 10.1073/pnas.90.7.3004; MARONI G, 1983, DROS INFORM SERV, V59, P142; MARTIN P, 1978, GENETICS BIOL DROS A, V2, P219; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; RICHARDS G, 1981, BIOL REV, V56, P501, DOI 10.1111/j.1469-185X.1981.tb00358.x; RICHARDS G, 1976, DEV BIOL, V54, P264, DOI 10.1016/0012-1606(76)90304-3; RICHARDS G, 1981, MOL CELL ENDOCRINOL, V21, P181, DOI 10.1016/0303-7207(81)90013-7; RICHARDS G, 1976, DEV BIOL, V54, P256, DOI 10.1016/0012-1606(76)90303-1; Riddiford L., 1993, DEV DROSOPHILA MELAN, V2, P899; ROBB JA, 1969, J CELL BIOL, V41, P876, DOI 10.1083/jcb.41.3.876; Robertson CW, 1936, J MORPHOL, V59, P351, DOI 10.1002/jmor.1050590207; ROBERTSON HM, 1988, GENETICS, V118, P461; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SEGRAVES WA, 1988, THESIS STANFORD U ST; SLITER TJ, 1992, GENETICS, V130, P555; STONE BL, 1993, CELL, V75, P307, DOI 10.1016/0092-8674(93)80072-M; THUMMEL CS, 1990, CELL, V61, P101, DOI 10.1016/0092-8674(90)90218-4; Thummel CS, 1992, DROS INF SERV, V71, P150; UEDA H, 1992, MOL CELL BIOL, V12, P5667, DOI 10.1128/MCB.12.12.5667; UEDA H, 1990, GENE DEV, V4, P624, DOI 10.1101/gad.4.4.624; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0	50	178	186	1	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 18	1994	79	4					607	615		10.1016/0092-8674(94)90546-0	http://dx.doi.org/10.1016/0092-8674(94)90546-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7954827				2022-12-01	WOS:A1994PT48100008
J	NEHLS, M; PFEIFER, D; SCHORPP, M; HEDRICH, H; BOEHM, T				NEHLS, M; PFEIFER, D; SCHORPP, M; HEDRICH, H; BOEHM, T			NEW MEMBER OF THE WINGED-HELIX PROTEIN FAMILY DISRUPTED IN MOUSE AND RAT NUDE MUTATIONS	NATURE			English	Article							GENE FORK-HEAD; TRANSCRIPTION FACTORS; EMBRYO; THYMUS; DOMAIN; MICE	MUTATIONS at the nude locus of mice and rats disrupt normal hair growth and thymus development(1,2), causing nude mice and rats to be immune-deficient. The mouse nude locus has been localized on chromosome 11 (refs 3, 4) within a region of <1 megabase(5). Here we show that one of the genes from this critical region, designated whn, encodes a new member of the winged-helix domain family of transcription factors(6.7), and that it is disrupted on mouse au and rat rnuN alleles. Mutant transcripts do not encode the characteristic DNA-binding domain, strongly suggesting that the whn gene is the nude gene. Mutations in winged-helix domain genes cause homeotic transformations in Drosophila(8) and distort cell-fate decisions during vulval development in Caenorhabditis elegans(9). The whn gene is thus the first member of this class of genes to be implicated in a specific developmental defect in vertebrates.	HANNOVER MED SCH,ZENT TIERVERSUCHSANLAGE,D-30625 HANNOVER,GERMANY; UNIV FREIBURG,DEPT MED 1,MOLEC MED GRP,D-79106 FREIBURG,GERMANY	Hannover Medical School; University of Freiburg								BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; CASH JM, 1993, MAMM GENOME, V4, P37, DOI 10.1007/BF00364661; CORDIER AC, 1980, AM J ANAT, V157, P227, DOI 10.1002/aja.1001570303; HEDRICH HJ, 1990, GENETIC MONITORING I; KOPFMAIER P, 1990, ACTA ANAT, V139, P178; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LI C, 1992, GENOMICS, V13, P658, DOI 10.1016/0888-7543(92)90138-I; LISITSYN AN, 1994, NAT GENET, V6, P57; Lyon MF, 1989, GENETIC VARIANTS STR; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NEHLS M, 1994, ONCOGENE, V9, P2169; NEHLS M, 1994, EUR J IMMUNOL, V24, P1721, DOI 10.1002/eji.1830240742; PALACIOS R, 1991, EUR J IMMUNOL, V21, P109, DOI 10.1002/eji.1830210117; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKAHASHI Y, 1992, J EXP MED, V175, P873, DOI 10.1084/jem.175.3.873; VANVLIET E, 1985, EUR J IMMUNOL, V15, P675, DOI 10.1002/eji.1830150707; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5	21	537	547	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					103	107		10.1038/372103a0	http://dx.doi.org/10.1038/372103a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969402				2022-12-01	WOS:A1994PQ34800083
J	POLANECZKY, M; SLAP, G; FORKE, C; RAPPAPORT, A; SONDHEIMER, S				POLANECZKY, M; SLAP, G; FORKE, C; RAPPAPORT, A; SONDHEIMER, S			THE USE OF LEVONORGESTREL IMPLANTS (NORPLANT) FOR CONTRACEPTION IN ADOLESCENT MOTHERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; PREGNANCY; RISK	Background. Although levonorgestrel implants (Norplant) would appear to be a good contraceptive option for adolescent mothers, there is little information about the use of Norplant in this population. Methods. We studied 100 postpartum adolescents who chose a contraceptive method at an urban teaching hospital between September 1991 and July 1992. Structured interviews were conducted and medical records were reviewed soon after delivery and at a mean (+/-SD) of 15.5+/-2.9 months post partum. Results. Forty-eight of the adolescent mothers chose Norplant, 50 chose oral contraceptives, and 2 (not further studied) chose barrier methods of contraception. The factors significantly associated with the choice of Norplant were older age (16.7 years among those who chose Norplant, vs. 16.2 years among those who chose oral contraceptives), multiparity (24 subjects vs. 6 subjects), and previous use of oral contraceptives (34 subjects vs. 21 subjects). During follow-up, there were no differences between the Norplant group and the oral-contraceptive group in the frequency of clinic visits (an average of 2.3 visits per subject in each group), failure to return after the postpartum visit (9 subjects vs. 11 subjects), or the incidence of sexually transmitted diseases (42 percent vs. 36 percent). At follow-up, 95 percent of the subjects in the Norplant group and 33 percent of those in the oral-contraceptive group were still using the method they had chosen (P<0.001). During the first postpartum year 1 subject in the Norplant group and 19 in the oral-contraceptive group became pregnant (P<0.001). Norplant users did not differ from all other adolescents studied with regard to sexual activity or condom use. Conclusions. The selection of Norplant by adolescent mothers as a method of contraception is associated with higher rates of continued use and lower rates of new pregnancy than the selection of oral contraceptives and does not affect the use of health care services, sexual activity, condom use, or the rate of sexually transmitted diseases.	UNIV PENN,SCH MED,DEPT MED,DIV GEN INTERNAL MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT OBSTET & GYNECOL,PHILADELPHIA,PA 19104; QUEENS UNIV,KINGSTON,ON,CANADA	University of Pennsylvania; University of Pennsylvania; Queens University - Canada	POLANECZKY, M (corresponding author), NEW YORK HOSP,CORNELL MED CTR,DEPT OBSTET & GYNECOL,DIV WOMENS HLTH,BOX 392,525 E 68TH ST,NEW YORK,NY 10021, USA.							BALASSONE ML, 1989, J ADOLESCENT HEALTH, V10, P527, DOI 10.1016/0197-0070(89)90016-8; COOPERSMITH S, 1986, ANTECEDENTS SELF EST; DEWITT K, 1992, NY TIMES        1215, pA7; EMANS SJ, 1987, JAMA-J AM MED ASSOC, V257, P3377, DOI 10.1001/jama.257.24.3377; FORD K, 1983, FAM PLANN PERSPECT, V15, P268, DOI 10.2307/2135292; FREEMAN EW, 1982, AM J PUBLIC HEALTH, V72, P815, DOI 10.2105/AJPH.72.8.815; FREEMAN EW, 1993, EARLY CHILDBEARING P, P172; FURSTENBERG FF, 1972, FAM PLANN PERSPECT, V4, P54, DOI 10.2307/2133939; FURSTENBERG FF, 1987, FAM PLANN PERSPECT, V19, P142, DOI 10.2307/2135159; HARLAP S, 1991, PREVENTING PREGNANCY, P31; HENSHAW SK, 1993, FAM PLANN PERSPECT, V25, P122, DOI 10.2307/2136160; HOFFERTH SL, 1987, FAM PLANN PERSPECT, V19, P46, DOI 10.2307/2135048; IPSEN J, 1970, BANCROFTS INTRO BIOS, P153; JONES EF, 1989, FAM PLANN PERSPECT, V21, P103, DOI 10.2307/2135659; JONES EF, 1985, FAM PLANN PERSPECT, V17, P53, DOI 10.2307/2135261; JONES EF, 1992, FAM PLANN PERSPECT, V24, P19; KANTROWITZ B, 1993, NEWSWEEK        1224, P37; LEE E T, 1972, Computer Programs in Biomedicine, V2, P315, DOI 10.1016/0010-468X(72)90019-0; MOTT FL, 1986, FAM PLANN PERSPECT, V18, P5, DOI 10.2307/2135193; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI DOI 10.1515/9781400876136; SHOUPE D, 1991, OBSTET GYNECOL, V77, P256, DOI 10.1097/00006250-199102000-00018; SHOUPE D, 1989, AM J OBSTET GYNECOL, V160, P1268; SIVIN I, 1988, STUD FAMILY PLANN, V19, P81, DOI 10.2307/1966493; SLAP GB, 1991, J ADOLESCENT HEALTH, V12, P434, DOI 10.1016/1054-139X(91)90020-X; SOKAL RR, 1987, INTRO BIOSTATISTICS, P112; WOODS ER, 1992, AM J OBSTET GYNECOL, V166, P901, DOI 10.1016/0002-9378(92)91359-I; Zar J. H, 1984, BIOSTAT ANAL, P176; Zar JH, 1984, BIOSTAT ANAL, P150; ZELNIK M, 1980, FAM PLANN PERSPECT, V12, P69, DOI 10.2307/2134748	29	128	128	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	1994	331	18					1201	1206		10.1056/NEJM199411033311806	http://dx.doi.org/10.1056/NEJM199411033311806			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PN806	7935659				2022-12-01	WOS:A1994PN80600006
J	JOHNSON, A				JOHNSON, A			LARYNGEAL-CANCER - VARIATIONS IN TREATMENT	LANCET			English	Editorial Material							RADIATION-THERAPY; GLOTTIC CANCER; CARCINOMA; TOBACCO; ALCOHOL; RISK; HEAD				JOHNSON, A (corresponding author), QUEEN ELIZABETH HOSP,DEPT OTOLARYNGOL,BIRMINGHAM,W MIDLANDS,ENGLAND.							[Anonymous], 1991, NEW ENGL J MED, V324, P1685; ECKEL HE, 1992, ANN OTO RHINOL LARYN, V101, P113, DOI 10.1177/000348949210100202; KIM RY, 1992, RADIOLOGY, V182, P273, DOI 10.1148/radiology.182.1.1727295; MAIER H, 1992, CLIN INVESTIGATOR, V70, P320; MCDONALD S, 1989, INT J RADIAT ONCOL, V17, P457, DOI 10.1016/0360-3016(89)90095-3; MUSCAT JE, 1992, CANCER, V69, P2244, DOI 10.1002/1097-0142(19920501)69:9&lt;2244::AID-CNCR2820690906&gt;3.0.CO;2-O; OSULLIVAN B, 1994, RADIOTHER ONCOL, V31, P23, DOI 10.1016/0167-8140(94)90410-3; OTT S, 1992, LARYNGO RHINO OTOL, V71, P236, DOI 10.1055/s-2007-997287; ROBIN PE, 1987, S BROWNS OTOLARYNGOL, V5, P194; ROBSON NLK, 1990, J LARYNGOL OTOL, V104, P699, DOI 10.1017/S0022215100113660; SMALL W, 1992, RADIOLOGY, V183, P789, DOI 10.1148/radiology.183.3.1584935; TERHAARD CHJ, 1992, CLIN OTOLARYNGOL, V17, P393, DOI 10.1111/j.1365-2273.1992.tb01681.x	12	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 29	1994	344	8931					1173	1174		10.1016/S0140-6736(94)90503-7	http://dx.doi.org/10.1016/S0140-6736(94)90503-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN803	7934535				2022-12-01	WOS:A1994PN80300004
J	ALPERS, DH				ALPERS, DH			ZINC AND DEFICIENCIES OF TASTE AND SMELL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							DOUBLE-BLIND; DYSFUNCTION				ALPERS, DH (corresponding author), WASHINGTON UNIV,SCH MED,ST LOUIS,MO, USA.							BALES CW, 1986, AM J CLIN NUTR, V44, P664, DOI 10.1093/ajcn/44.5.664; HENKIN RI, 1976, AM J MED SCI, V272, P285, DOI 10.1097/00000441-197611000-00006; HENKIN RI, 1975, ARCH NEUROL-CHICAGO, V32, P745, DOI 10.1001/archneur.1975.00490530067006; MAHAJAN SK, 1980, AM J CLIN NUTR, V33, P1517, DOI 10.1093/ajcn/33.7.1517; WEIFFENBACH JM, 1982, J GERONTOL, V37, P372, DOI 10.1093/geronj/37.3.372; WOLMAN SL, 1979, GASTROENTEROLOGY, V76, P458	6	14	14	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	1994	272	16					1233	1234						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN068	7933356				2022-12-01	WOS:A1994PN06800003
J	HOGG, RS; STRATHDEE, SA; CRAIB, KJP; OSHAUGHNESSY, MV; MONTANER, JSG; SCHECHTER, MT				HOGG, RS; STRATHDEE, SA; CRAIB, KJP; OSHAUGHNESSY, MV; MONTANER, JSG; SCHECHTER, MT			LOWER SOCIOECONOMIC-STATUS AND SHORTER SURVIVAL FOLLOWING HIV-INFECTION	LANCET			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; HOMOSEXUAL MEN; MORTALITY; AIDS; PROGRESSION; HEALTH	We studied the association between socioeconomic status and survival in a prospective study of 364 HIV-infected homosexual men who were recruited during 1982-84. The participants were divided by annual income; those earning above Canadian $10 000 (high-income; n=274) and those below $10 000 (low-income; n=90) at recruitment. The latter threshold closely approximated to the poverty level for this population. Low income men were significantly younger than high income men but the groups were similar with respect to baseline CD4 counts, subsequent use of anti-retrovirals and prophylaxis against Pneumocystis carinii pneumonia (PCP), and number of visits attended during follow-up. Subjects were followed for a median of 9.5 years (range 1.8-13.1). By Dec 31, 1993, there were 135 deaths yielding a cumulative mortality rate of mean 45% (SD 4.0) at 11.5 years. Men aged 30 or more at infection had poorer survival than those under 30 (mortality risk ratio 1.56; 95% CI 1.09-2.24; p=0.015), and longer survival was significantly associated with a higher CD4 count at the earliest seropositive visit. The age-adjusted mortality risk ratio for low income men compared with high income men was significantly increased at 1.63 (95% CI 1.11-2.40; p=0.013). The significant risk of death for low income men persisted despite adjustment for age at infection, CD4 count, use of zidovudine, dideoxyinosine, and dideoxycytidine, use of PCP prophylaxis, and year of infection. We cannot attribute our findings to income loss as a result of more rapid HIV progression because the same effect was present in people who provided income data before seroconversion. Similarly, our findings are not due to differential access to care because the study was done within the context of a universal health care system, and the two income groups received treatments equally. This finding is consistent with the association socioeconomic status with increased mortality observed within large populations and in other diseases.	UNIV BRITISH COLUMBIA,BRITISH COLUMBIA CTR EXCELLENCE IN HIV AIDS,VANCOUVER V6Z 1Y6,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT HLTH CARE & EPIDEMIOL,VANCOUVER V6Z 1Y6,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER V6Z 1Y6,BC,CANADA; ST PAULS HOSP,VANCOUVER V6Z 1Y6,BC,CANADA	University of British Columbia; University of British Columbia; University of British Columbia; St. Paul's Hospital; University of Saskatchewan			Strathdee, Steffanie A/B-9042-2009; Montaner, Julio/K-7621-2012; Hogg, Robert S/B-2783-2012	Hogg, Robert S/0000-0003-3463-5488; Schechter, Martin/0000-0001-6063-2155				BLAXTER M, 1983, SOC SCI MED, V17, P1139, DOI 10.1016/0277-9536(83)90006-0; CALDWELL JC, 1986, POPUL DEV REV, V12, P171, DOI 10.2307/1973108; CAPITANIO JP, 1991, AIDS, V5, P1103, DOI 10.1097/00002030-199109000-00007; CELLA DF, 1991, J CLIN ONCOL, V9, P1500, DOI 10.1200/JCO.1991.9.8.1500; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; HOGG RS, 1994, CAN MED ASSOC J, V150, P711; HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1037/0003-066X.59.8.676; HUANG CM, 1988, CLIN CHEM, V34, P1957; KASS NE, 1994, J ACQ IMMUN DEF SYND, V7, P86; KESSLER RC, 1988, SOC SCI MED, V27, P569, DOI 10.1016/0277-9536(88)90004-4; KOOT M, 1993, ANN INTERN MED, V321, P1626; MARNEROS A, 1990, ACTA PSYCHIAT SCAND, V82, P352, DOI 10.1111/j.1600-0447.1990.tb01400.x; MOSESON M, 1989, J ACQ IMMUN DEF SYND, V2, P235; MOSS AR, 1988, BRIT MED J, V297, P1067, DOI 10.1136/bmj.297.6656.1067; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SAAH AJ, 1994, J ACQ IMMUN DEF SYND, V7, P287; SCHECHTER MT, 1989, AIDS, V3, P347, DOI 10.1097/00002030-198906000-00002; SCHECHTER MT, 1994, J CLIN EPIDEMIOL, V47, P59, DOI 10.1016/0895-4356(94)90034-5; SCHECHTER MT, 1986, CAN MED ASSOC J, V118, P681; STEIN MD, 1991, J GEN INTERN MED, V6, P35, DOI 10.1007/BF02599388; SYME SL, 1976, AM J EPIDEMIOL, V104, P1; TANG AM, 1993, AM J EPIDEMIOL, V138, P937, DOI 10.1093/oxfordjournals.aje.a116814; VEUGELERS PJ, IN PRESS AM J EPIDEM; Wilkins R, 1989, Health Rep, V1, P137; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165; WISE PH, 1985, NEW ENGL J MED, V313, P360, DOI 10.1056/NEJM198508083130605; 1982, INCOME DISTRIBUTIONS; 1987, MMWR-MORBID MORTAL W, V36, P24; 1993, JAMA-J AM MED ASSOC, V270, P305	30	89	91	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1994	344	8930					1120	1124		10.1016/S0140-6736(94)90631-9	http://dx.doi.org/10.1016/S0140-6736(94)90631-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PN066	7934494				2022-12-01	WOS:A1994PN06600010
J	MIDDLETON, FA; STRICK, PL				MIDDLETON, FA; STRICK, PL			ANATOMICAL EVIDENCE FOR CEREBELLAR AND BASAL GANGLIA INVOLVEMENT IN HIGHER COGNITIVE FUNCTION	SCIENCE			English	Article							RHESUS-MONKEY; GLOBUS PALLIDUS; HORSERADISH-PEROXIDASE; FRONTAL-LOBE; PREFRONTAL CORTEX; MACACA-MULATTA; MOTOR CORTEX; PROJECTIONS; ORGANIZATION; CONNECTIONS	The possibility that neurons in the basal ganglia and cerebellum innervate areas of cerebral cortex that are involved in cognitive function has been a contriversial subject. Here, retrograde transneuronal transport of herpes simplex virus type 1 (HSV1) was used to identify subcortical neurons that project via the thalamus to area 46 of the primate prefrontal cortex. This cortical area is known to be involved in spatial working memory. Many neurons in restricted regions of the dentate nucleus of the cerebral and in the internal segment of the globus pallidus were labeled by transneuronal transport of visus from area 46. The location of these neurons was different from those labeled after HSV1 transport from motor areas of the cerebral cortex. These observations define an anatomical substrate for the involvement of basal ganglia and cerrebellar output in higher cognitive function.	VET ADM MED CTR, RES SERV, SYRACUSE, NY 13210 USA; SUNY HLTH SCI CTR, DEPT PHYSIOL, SYRACUSE, NY 13210 USA; SUNY HLTH SCI CTR, PROGRAM NEUROSCI, SYRACUSE, NY 13210 USA; SUNY HLTH SCI CTR, DEPT NEUROSURG, SYRACUSE, NY 13210 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center				Middleton, Frank/0000-0002-3107-7188	NINDS NIH HHS [NS24328] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024328] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKSHOOMOFF NA, 1992, BEHAV NEUROSCI, V106, P731, DOI 10.1037/0735-7044.106.5.731; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; ANDERSON ME, 1985, J NEUROPHYSIOL, V54, P433, DOI 10.1152/jn.1985.54.2.433; BARBAS H, 1991, J COMP NEUROL, V313, P65, DOI 10.1002/cne.903130106; BARBAS H, 1989, J COMP NEUROL, V286, P353, DOI 10.1002/cne.902860306; BLOEDEL JR, 1993, TRENDS NEUROSCI, V16, P451, DOI 10.1016/0166-2236(93)90075-W; BRODAL P, 1979, NEUROSCIENCE, V4, P193, DOI 10.1016/0306-4522(79)90082-4; BUTTERS N, 1978, ARCH NEUROL-CHICAGO, V35, P585, DOI 10.1001/archneur.1978.00500330033006; CANAVAN AGM, 1994, BEHAV NEUROSCI, V108, P475, DOI 10.1037/0735-7044.108.3.475; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; DELONG MR, 1971, J NEUROPHYSIOL, V34, P414, DOI 10.1152/jn.1971.34.3.414; DEVITO JL, 1982, EXP BRAIN RES, V46, P107; EVARTS EV, 1969, ANNU REV PHYSIOL, V31, P451, DOI 10.1146/annurev.ph.31.030169.002315; FIEZ JA, 1992, BRAIN, V115, P155, DOI 10.1093/brain/115.1.155; Fuster J, 1989, PREFRONTAL CORTEX; Fuster J.M., 1985, CEREB CORTEX, V4, P151; GLICKSTEIN M, 1985, J COMP NEUROL, V235, P343, DOI 10.1002/cne.902350306; GLICKSTEIN M, 1993, TRENDS NEUROSCI, V16, P450, DOI 10.1016/0166-2236(93)90074-V; GOLDMAN PS, 1977, J COMP NEUROL, V171, P369, DOI 10.1002/cne.901710305; GOLDMANRAKIC PS, 1990, PROG BRAIN RES, V85, P325; GOLDMANRAKIC PS, 1985, J COMP NEUROL, V242, P535, DOI 10.1002/cne.902420406; GRAFMAN J, 1992, NEUROLOGY, V42, P1493, DOI 10.1212/WNL.42.8.1493; HOLSAPPLE JW, 1991, J NEUROSCI, V11, P2644; Hoover J. E., 1993, Society for Neuroscience Abstracts, V19, P1590; HOOVER JE, 1993, SCIENCE, V259, P819, DOI 10.1126/science.7679223; ITO M, 1993, TRENDS NEUROSCI, V16, P448, DOI 10.1016/0166-2236(93)90073-U; KEMP JM, 1971, PHILOS T R SOC B, V262, P441, DOI 10.1098/rstb.1971.0106; KIEVIT J, 1977, EXP BRAIN RES, V29, P299; Kievit J., 1972, CORTICOTHALAMIC PROJ, P91; KIM R, 1976, J COMP NEUROL, V169, P263, DOI 10.1002/cne.901690302; KIM SG, 1994, SCIENCE, V265, P949, DOI 10.1126/science.8052851; KUO JS, 1973, J COMP NEUROL, V151, P201, DOI 10.1002/cne.901510302; KUSAMA T, 1971, P JPN ACAD, V47, P505, DOI 10.2183/pjab1945.47.505; LEICHNETZ GR, 1984, J COMP NEUROL, V228, P388, DOI 10.1002/cne.902280307; LEINER HC, 1991, BEHAV BRAIN RES, V44, P113, DOI 10.1016/S0166-4328(05)80016-6; LEINER HC, 1993, TRENDS NEUROSCI, V16, P444, DOI 10.1016/0166-2236(93)90072-T; LYNCH JC, IN PRESS EXP BRAIN R; MINK JW, 1991, J NEUROPHYSIOL, V65, P273, DOI 10.1152/jn.1991.65.2.273; NAUTA WALLE J. H., 1966, BRAIN RES, V1, P3, DOI 10.1016/0006-8993(66)90103-X; olszewski j, 1952, THALAMUS MACACA MULA; ORIOLI PJ, 1989, J COMP NEUROL, V288, P612, DOI 10.1002/cne.902880408; PARENT A, 1982, BRAIN RES, V245, P201, DOI 10.1016/0006-8993(82)90802-2; PERCHERON G, 1977, J HIRNFORSCH, V18, P375; PETERSEN SE, 1993, ANNU REV NEUROSCI, V16, P509, DOI 10.1146/annurev.ne.16.030193.002453; SASAKI K, 1979, EXP BRAIN RES, V37, P193, DOI 10.1007/BF01474266; SCHMAHMANN JD, 1991, ARCH NEUROL-CHICAGO, V48, P1178, DOI 10.1001/archneur.1991.00530230086029; SELEMON LD, 1985, J NEUROSCI, V5, P776; SELEMON LD, 1988, J NEUROSCI, V8, P4049; STANTON GB, 1980, J COMP NEUROL, V190, P699, DOI 10.1002/cne.901900406; STRICK PL, 1993, INT CONGR SER, V1024, P171; STRICK PL, 1993, EXPT NEUROANATOMY PR, P81; STRUB RL, 1989, ARCH NEUROL-CHICAGO, V46, P1024, DOI 10.1001/archneur.1989.00520450096027; TAYLOR AE, 1986, BRAIN, V109, P845, DOI 10.1093/brain/109.5.845; VANKAN PLE, 1993, J NEUROPHYSIOL, V69, P57, DOI 10.1152/jn.1993.69.1.57; Walker AE, 1940, J COMP NEUROL, V73, P59, DOI 10.1002/cne.900730106; WETTS R, 1985, J NEUROPHYSIOL, V54, P231, DOI 10.1152/jn.1985.54.2.231; WIESENDANGER R, 1985, EXP BRAIN RES, V59, P105; YAMAMOTO T, 1992, BRAIN RES, V579, P315, DOI 10.1016/0006-8993(92)90067-J; YETERIAN EH, 1978, BRAIN RES, V139, P43, DOI 10.1016/0006-8993(78)90059-8; ZEMANICK MC, 1991, P NATL ACAD SCI USA, V88, P8048, DOI 10.1073/pnas.88.18.8048	60	940	962	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 21	1994	266	5184					458	461		10.1126/science.7939688	http://dx.doi.org/10.1126/science.7939688			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7939688				2022-12-01	WOS:A1994PN27200041
J	VANLUENEN, HGAM; COLLOMS, SD; PLASTERK, RHA				VANLUENEN, HGAM; COLLOMS, SD; PLASTERK, RHA			THE MECHANISM OF TRANSPOSITION OF TC3 IN C-ELEGANS	CELL			English	Article							TRANSPOSABLE ELEMENT TC1; CAENORHABDITIS-ELEGANS; DROSOPHILA-MELANOGASTER; INTEGRASE PROTEIN; FAMILY; EXCISION; INSERTION; GENE; DNA; SEQUENCES	The Tc3 transposon of C. elegans belongs to a family of inverted repeat DNA transposons, found in many different phyla. We studied the mechanism of Tc3 transposition by expression of Tc3 transposase from a heat-shock promoter in transgenic nematodes. Transposition is accompanied by the appearance of linear extrachromosomal Tc3 DNA. Analysis of the ends of this presumed transposition intermediate shows that the transposon is excised incompletely: the 5' ends of the transposon lack two nucleotides. The 3' ends coincide with the last nucleotide of the integrated element and carry 3' hydroxyls. The nucleotides that are not coexcised with the transposon remain at the donor site and result in a characteristic footprint. A model is derived for the mechanism of Tc3 jumping that probably applies to the entire family of Tc1/mariner transposable elements.			VANLUENEN, HGAM (corresponding author), NETHERLANDS CANC INST, DIV MOLEC BIOL, PLESMANLAAN 121, 1066 CX AMSTERDAM, NETHERLANDS.			Colloms, Sean/0000-0003-2369-8168; van Luenen, Henri/0000-0002-5584-7968				ABAD P, 1991, J MOL EVOL, V33, P251, DOI 10.1007/BF02100676; ATKINSON PW, 1993, P NATL ACAD SCI USA, V90, P9693, DOI 10.1073/pnas.90.20.9693; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BENJAMIN HW, 1989, CELL, V59, P373, DOI 10.1016/0092-8674(89)90298-5; BENJAMIN HW, 1992, P NATL ACAD SCI USA, V89, P4648, DOI 10.1073/pnas.89.10.4648; BREZINSKY L, 1990, NUCLEIC ACIDS RES, V18, P2053, DOI 10.1093/nar/18.8.2053; BRYAN G, 1990, GENETICS, V125, P103; CAIZZI R, 1993, GENETICS, V133, P335; CARR B, 1994, MOL CELL BIOL, V14, P3426, DOI 10.1128/MCB.14.5.3426; COLLINS J, 1989, GENETICS, V121, P47; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; CRAXTON M, 1991, Methods (Orlando), V3, P20, DOI 10.1016/S1046-2023(05)80159-8; DABOUSSI MJ, 1992, MOL GEN GENET, V232, P12, DOI 10.1007/BF00299131; DOAK TG, 1994, P NATL ACAD SCI USA, V91, P942, DOI 10.1073/pnas.91.3.942; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; EICHINGER DJ, 1990, GENE DEV, V4, P324, DOI 10.1101/gad.4.3.324; EIDE D, 1988, MOL CELL BIOL, V8, P737, DOI 10.1128/MCB.8.2.737; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; FAYET O, 1990, MOL MICROBIOL, V4, P1771, DOI 10.1111/j.1365-2958.1990.tb00555.x; FRANZ G, 1991, NUCLEIC ACIDS RES, V19, P6646, DOI 10.1093/nar/19.23.6646; GARCIAFERNANDEZ J, 1993, NATURE, V364, P109, DOI 10.1038/364109a0; HARRIS LJ, 1988, NUCLEIC ACIDS RES, V16, P5991, DOI 10.1093/nar/16.13.5991; HARRIS LJ, 1990, J MOL EVOL, V30, P359, DOI 10.1007/BF02101890; HEIERHORST J, 1992, P NATL ACAD SCI USA, V89, P6798, DOI 10.1073/pnas.89.15.6798; HEINKOFF S, 1992, NEW BIOL, V4, P382; KHAN E, 1991, NUCLEIC ACIDS RES, V19, P851, DOI 10.1093/nar/19.4.851; KIFF JE, 1988, NATURE, V331, P631, DOI 10.1038/331631a0; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LAFEMINA RL, 1992, J VIROL, V66, P7414, DOI 10.1128/JVI.66.12.7414-7419.1992; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MOORE SP, 1994, P NATL ACAD SCI USA, V91, P1843, DOI 10.1073/pnas.91.5.1843; OBROCHTA DA, 1991, MOL GEN GENET, V225, P387, DOI 10.1007/BF00261678; PLASTERK RHA, 1992, EMBO J, V11, P287, DOI 10.1002/j.1460-2075.1992.tb05051.x; PLASTERK RHA, 1991, EMBO J, V10, P1919, DOI 10.1002/j.1460-2075.1991.tb07718.x; RADICE AR, 1994, IN PRESS MOL GEN GEN; ROBERTSON HM, 1992, NUCLEIC ACIDS RES, V20, P6409, DOI 10.1093/nar/20.23.6409; ROSE AM, 1984, NATURE, V311, P485, DOI 10.1038/311485a0; RUAN KS, 1987, NUCLEIC ACIDS RES, V15, P6875, DOI 10.1093/nar/15.17.6875; RUAN KS, 1984, P NATL ACAD SCI-BIOL, V81, P4018, DOI 10.1073/pnas.81.13.4018; Sambrook J., 1989, MOL CLONING LAB MANU; SHIN CG, 1994, J VIROL, V68, P1633, DOI 10.1128/JVI.68.3.1633-1642.1994; SKALKA AM, 1993, GENE, V135, P175, DOI 10.1016/0378-1119(93)90063-9; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; SULSTON J, 1987, NEMATODE CAENORHABDI, P587; TAUSTA SL, 1989, CELL, V59, P1019, DOI 10.1016/0092-8674(89)90758-7; TENZEN T, 1990, J BACTERIOL, V172, P3830, DOI 10.1128/jb.172.7.3830-3836.1990; TUDOR M, 1992, MOL GEN GENET, V232, P126, DOI 10.1007/BF00299145; VANGENT DC, 1992, P NATL ACAD SCI USA, V89, P9598, DOI 10.1073/pnas.89.20.9598; VANLUENEN HGAM, 1994, NUCLEIC ACIDS RES, V22, P262, DOI 10.1093/nar/22.3.262; VANLUENEN HGAM, 1993, EMBO J, V12, P2513, DOI 10.1002/j.1460-2075.1993.tb05906.x; VARMUS H, 1989, MOBILE DNA, P53; VINK C, 1993, TRENDS GENET, V9, P433, DOI 10.1016/0168-9525(93)90107-S; VOS JC, 1993, GENE DEV, V7, P1244, DOI 10.1101/gad.7.7a.1244; [No title captured]	58	164	169	1	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	1994	79	2					293	301		10.1016/0092-8674(94)90198-8	http://dx.doi.org/10.1016/0092-8674(94)90198-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954797				2022-12-01	WOS:A1994PN63000013
J	SCHNEIDER, KR; SMITH, RL; OSHEA, EK				SCHNEIDER, KR; SMITH, RL; OSHEA, EK			PHOSPHATE-REGULATED INACTIVATION OF THE KINASE PHO80-PHO85 BY THE CDK INHIBITOR PHO81	SCIENCE			English	Article							SIGNAL-TRANSDUCTION PATHWAY; SACCHAROMYCES-CEREVISIAE; G1 CYCLIN; GENE; PROTEIN; YEAST; SYSTEM; FAR1; IDENTIFICATION; COMPLEXES	A complex consisting of the cyclin-dependent kinase (CDK) PHO85 and the cyclin PHO80 phosphorylates and is thought to inactivate the transcription factor PHO4 when yeast cells are grown in medium containing high concentrations of phosphate. The CDK inhibitor PHO81 inhibits the kinase activity of the PHO80-PHO85 complex when Saccharomyces cerevisiae cells are grown in medium depleted of phosphate. A region of PHO81 with similarity to the mammalian CDK inhibitor p16(INK4) is sufficient for inhibition in vitro. These studies demonstrate that CDK inhibitors are used to regulate kinases involved in processes other than cell cycle control and suggest that the ankyrin repeat motif may be commonly used for interaction with cyclin-CDK complexes.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco				Schneider, Ken Robert/0000-0002-6638-6810				BAJWA W, 1984, NUCLEIC ACIDS RES, V12, P7721, DOI 10.1093/nar/12.20.7721; BOLLAG G, 1993, EMBO J, V12, P1923, DOI 10.1002/j.1460-2075.1993.tb05841.x; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CREASY CL, 1993, NUCLEIC ACIDS RES, V21, P1975, DOI 10.1093/nar/21.8.1975; GILLIQUET V, 1987, NUCLEIC ACIDS RES, V15, P5893, DOI 10.1093/nar/15.14.5893; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; HARPER JW, 1993, CELL, V75, P805; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LEMIRE JM, 1985, MOL CELL BIOL, V5, P2131, DOI 10.1128/MCB.5.8.2131; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; OCONNELL KF, 1992, GENETICS, V132, P63; OGAWA N, 1993, MOL GEN GENET, V238, P444, DOI 10.1007/BF00292004; Oshima Y, 1982, MOL BIOL YEAST SACCH, P159; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SCHNEIDER K, UNPUB; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SIKORSKI RS, 1989, GENETICS, V122, P19; Toh-e A, 1986, Yeast, V2, P129, DOI 10.1002/yea.320020209; TOHE A, 1988, MOL GEN GENET, V214, P162, DOI 10.1007/BF00340196; TOHE A, 1973, J BACTERIOL, V113, P727, DOI 10.1128/JB.113.2.727-738.1973; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; UEDA Y, 1975, J BACTERIOL, V122, P911, DOI 10.1128/JB.122.3.911-922.1975; UESONO Y, 1987, NUCLEIC ACIDS RES, V15, P10299, DOI 10.1093/nar/15.24.10299; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YOSHIDA K, 1989, MOL GEN GENET, V217, P40, DOI 10.1007/BF00330940	35	203	215	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 7	1994	266	5182					122	126		10.1126/science.7939631	http://dx.doi.org/10.1126/science.7939631			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7939631				2022-12-01	WOS:A1994PK58200039
J	KOENIG, W; SUND, M; LOWE, GDO; LEE, AJ; RESCH, KL; TUNSTALLPEDOE, H; KEIL, U; ERNST, E				KOENIG, W; SUND, M; LOWE, GDO; LEE, AJ; RESCH, KL; TUNSTALLPEDOE, H; KEIL, U; ERNST, E			GEOGRAPHICAL VARIATIONS IN PLASMA VISCOSITY AND RELATION TO CORONARY EVENT RATES	LANCET			English	Article							CARDIOVASCULAR RISK FACTOR; BLOOD-VISCOSITY; MONICA PROJECT; FIBRINOGEN; POPULATION; RHEOLOGY; DISEASE	Plasma viscosity is reported to be predictive of coronary heart disease (CHD) and stroke. To find out whether regional differences in CHD event rates correlate with differences in plasma viscosity, we compared plasma viscosity in a high-risk area for CHD (Glasgow Multinational Monitoring of Trends and Determinants in Cardiovascular Disease [MONICA] and Scottish Heart Health Study population surveys, 1985/86; n=1166) and in a lower-risk area (MONICA Augsburg survey, 1984/85; n=3258) in men and women aged 25-64 years. Mean plasma viscosity (37 degrees C) was 1.261 (SD 0.067) mPa s in Augsburg and 1.327 (0.093) mPa s in the west of Scotland for men, and 1.248 (0.066) mPa s and 1.318 (0.087) mPa s, respectively, for women. The unadjusted difference of the means between the west of Scotland and Augsburg was 0.066 (95% Cl from weighted regression 0.058-0.073) mPa s for men and 0.070 (0.062-0.078) mPa s for women. Adjustment for age, smoking behaviour, total and high-density-lipoprotein cholesterol, systolic and diastolic blood pressure, and body-mass index had no effect on these differences. Age-standardised coronary event rates in 1985-87 were at least two times higher among men, and four times higher among women, in MONICA Glasgow than in MONICA Augsburg. This large geographical difference in plasma viscosity might partly explain the differences in CHD event rates between these populations. Further studies are needed on the determinants of plasma viscosity, and on its potential roles in atherosclerosis, thrombosis, and ischaemia.	GESELL STRAHLEN & UMWELTFORSCH MBH,ENVIRONM RES CTR,W-8042 NEUHERBERG,GERMANY; HLTH MEDIS INST,NEUHERBERG,GERMANY; UNIV GLASGOW,ROYAL INFIRM,DEPT MED,GLASGOW G31 2ER,SCOTLAND; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,CARDIOVASC EPIDEMIOL UNIT,DUNDEE DD1 9SY,SCOTLAND; UNIV VIENNA,DEPT PHYS MED & REHABIL,VIENNA,AUSTRIA; UNIV MUNSTER,INST EPIDEMIOL & SOCIAL MED,W-4400 MUNSTER,GERMANY; UNIV EXETER,POSTGRAD MED SCH,EXETER,ENGLAND	Royal Infirmary of Edinburgh; University of Glasgow; University of Dundee; University of Vienna; University of Munster; University of Exeter	KOENIG, W (corresponding author), UNIV ULM,MED CTR,DEPT INTERNAL MED 2,ROBERT KOCH STR 8,D-89081 ULM,GERMANY.							[Anonymous], 1982, CLIN LAB HAEMATOL, V4, P83; [Anonymous], 1990, WHO MONICA PROJECT M; BOETHIG S, 1989, INT J EPIDEMIOL S1, V18, P29; BRAY GA, 1978, INT J OBESITY, V2, P99; CHAMBLESS L, 1987, GSF3186 GES STRAHL U; DESIMONE G, 1990, CIRCULATION, V81, P107, DOI 10.1161/01.CIR.81.1.107; ERNST E, 1993, ANN INTERN MED, V118, P956, DOI 10.7326/0003-4819-118-12-199306150-00008; ERNST E, 1988, ARTERIOSCLEROSIS, V8, P385, DOI 10.1161/01.ATV.8.4.385; HARKNESS J, 1963, LANCET, V2, P280; KEIL U, 1988, ACTA MED SCAND S, V728, P119; KEIL U, 1985, GSF2085 GES STRAHL U; KOENIG W, 1992, CIRCULATION, V86, P1045, DOI 10.1161/01.CIR.86.3.1045; KOENIG W, 1992, CIRCULATION, V85, P2197, DOI 10.1161/01.CIR.85.6.2197; LOWE GDO, 1988, CLIN HEMORHEOL, V8, P517; LOWE GDO, 1993, CIRCULATION, V87, P1915, DOI 10.1161/01.CIR.87.6.1915; RESCH KL, 1992, ANN INTERN MED, V117, P371, DOI 10.7326/0003-4819-117-5-371; SMITH W C S, 1987, Health Bulletin (Edinburgh), V45, P211; SMITH WCS, 1989, SCOT MED J, V34, P550, DOI 10.1177/003693308903400603; SMITH WCS, 1992, J HYPERTENS, V10, P467, DOI 10.1097/00004872-199205000-00010; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836; 1984, J CLIN PATHOL, V37, P1147; 1988, J CLIN EPIDEMIOL, V34, P105	23	53	53	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					711	714		10.1016/S0140-6736(94)92207-1	http://dx.doi.org/10.1016/S0140-6736(94)92207-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915775				2022-12-01	WOS:A1994PF18700009
J	KAPLAN, NM				KAPLAN, NM			ETHNIC ASPECTS OF HYPERTENSION	LANCET			English	Article							BLOOD-PRESSURE; UNITED-STATES; BLACK; RISK; MORTALITY; DISEASE; IMPACT; WHITES; AGENTS; RACE				KAPLAN, NM (corresponding author), UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.							BARLEY J, 1991, J HYPERTENS, V9, P993, DOI 10.1097/00004872-199111000-00003; BIANCHI S, 1994, AM J HYPERTENS, V7, P23, DOI 10.1093/ajh/7.1.23; CAMPESE VM, 1991, HYPERTENSION, V18, P805, DOI 10.1161/01.HYP.18.6.805; CHATURVEDI N, 1993, HYPERTENSION, V22, P90, DOI 10.1161/01.HYP.22.1.90; COOPER RS, 1992, CIRCULATION, V85, P12; CORNONIHUNTLEY J, 1989, ARCH INTERN MED, V149, P780, DOI 10.1001/archinte.149.4.780; CRUICKSHANK JK, 1985, J HYPERTENS, V3, P365, DOI 10.1097/00004872-198508000-00009; DYSART JN, 1994, AM J HYPERTENS, V7, P15, DOI 10.1093/ajh/7.1.15; FALKNER B, 1990, HYPERTENSION, V15, P681, DOI 10.1161/01.HYP.15.6.681; FISHER NDL, 1994, HYPERTENSION, V23, P179, DOI 10.1161/01.HYP.23.2.179; GRETLER DD, 1994, AM J HYPERTENS, V7, P7, DOI 10.1093/ajh/7.1.7; JAMERSON KA, 1993, CLIN EXP HYPERTENS, V15, P979, DOI 10.3109/10641969309037086; KAPLAN NM, 1994, HYPERTENSION POPULAT, P1; KOREN MJ, 1993, AM J HYPERTENS, V6, P815, DOI 10.1093/ajh/6.10.815; LOPES AAS, 1993, J AM SOC NEPHROL, V3, P1961; MANTUNGA AK, 1993, HYPERTENSION, V22, P84; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; OOI WL, 1989, HYPERTENSION, V14, P227, DOI 10.1161/01.HYP.14.3.227; OTTEN MW, 1990, JAMA-J AM MED ASSOC, V263, P845, DOI 10.1001/jama.263.6.845; POULTER NR, 1990, BMJ-BRIT MED J, V300, P967, DOI 10.1136/bmj.300.6730.967; ROWLAND M, 1982, NCHS ADV DATA, V84; SEEDAT YK, 1989, J HYPERTENS, V7, P515, DOI 10.1097/00004872-198907000-00001; SORLIE P, 1992, LANCET, V340, P346, DOI 10.1016/0140-6736(92)91413-3; VERDECCHIA P, 1993, CIRCULATION, V88, P986, DOI 10.1161/01.CIR.88.3.986; WALKER WG, 1992, JAMA-J AM MED ASSOC, V268, P3085, DOI 10.1001/jama.268.21.3085; 1993, ARCH INTERN MED, V153, P154	26	71	71	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 13	1994	344	8920					450	452		10.1016/S0140-6736(94)91774-4	http://dx.doi.org/10.1016/S0140-6736(94)91774-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7914569				2022-12-01	WOS:A1994PB76100014
J	HABIB, F; DUTKA, D; CROSSMAN, D; OAKLEY, CM; CLELAND, JGF				HABIB, F; DUTKA, D; CROSSMAN, D; OAKLEY, CM; CLELAND, JGF			ENHANCED BASAL NITRIC-OXIDE PRODUCTION IN HEART-FAILURE - ANOTHER FAILED COUNTER-REGULATORY VASODILATOR MECHANISM	LANCET			English	Note							SYNTHASE	Endothelial dysfunction in heart failure could impair nitric oxide production and lead to increased vascular resistance. If endogenous production of nitric oxide is reduced, N-G-monomethyl-L-arginine (L-NMMA), an inhibitor of such production, should have a diminished vasoconstrictor effect. We administered L-NMMA to 12 patients being investigated for heart failure. L-NMMA increased median pulmonary and systemic vascular resistances by 61 (range - 3 to 240) and 430 (63 to 1609)dynes s cm(-5), respectively (p<0.03 and p<0.005). Arterial pressures also increased. Median cardiac output fell by 0.6 (0 to -2.3) L per min (p<0.005). These data suggest that vascular nitric oxide may be another example of a failed counter-regulatory vasodilator system in heart failure.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED CARDIOL,LONDON W12,ENGLAND	Imperial College London			Cleland, John G./AAZ-4185-2020	Cleland, John G./0000-0002-1471-7016; Crossman, David/0000-0003-4762-8623				CABANES L, 1992, NEW ENGL J MED, V326, P1661, DOI 10.1056/NEJM199206183262503; CLELAND JGF, 1991, BRIT HEART J, V66, P264; COHN JN, 1990, AM J CARDIOL, V66, P1507, DOI 10.1016/0002-9149(90)90544-B; DEBELDER AJ, 1993, LANCET, V341, P84, DOI 10.1016/0140-6736(93)92559-C; DREXLER H, 1992, AM J CARDIOL, V69, P1596, DOI 10.1016/0002-9149(92)90710-G; LOH E, 1993, CIRCULATION, V88, P25; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; ONTKEAN M, 1991, CIRC RES, V69, P1088, DOI 10.1161/01.RES.69.4.1088; PACKER M, 1992, LANCET, V340, P88, DOI 10.1016/0140-6736(92)90405-R; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R; WIESHAMMER S, 1993, BRIT HEART J, V70, P17	11	132	136	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 6	1994	344	8919					371	373		10.1016/S0140-6736(94)91402-8	http://dx.doi.org/10.1016/S0140-6736(94)91402-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA303	7914308				2022-12-01	WOS:A1994PA30300011
J	GOH, HS; CHAN, CS; KHINE, K; SMITH, DR				GOH, HS; CHAN, CS; KHINE, K; SMITH, DR			P53 AND BEHAVIOR OF COLORECTAL-CANCER	LANCET			English	Note							TUMOR SUPPRESSOR GENE; CARCINOMAS	The tumour suppressor gene p53 is altered in most colorectal tumours. We found that lymphatic dissemination was driven by the presence of mutated p53 whether or not the cell contained wild-type p53. In a total sample of 187 specimens, point mutation of the p53 gene occurred in 70% and 43% of cases with and without lymph-node involvement, respectively. By contrast, haematogenous dissemination was apparently the result of absent functional wild-type p53 (whether or not the cell contained mutated p53). These results are of potential importance in the prediction of the clinical behaviour of a tumour.			GOH, HS (corresponding author), SINGAPORE GEN HOSP,DEPT COLORECTAL SURG,OUTRAM RD,SINGAPORE 0316,SINGAPORE.		Smith, Duncan R/C-6891-2011	Smith, Duncan R/0000-0002-6592-9852				BARLOGIE B, 1983, CANCER RES, V43, P3982; CHANG FJ, 1993, AM J GASTROENTEROL, V88, P174; FEARON ER, 1992, FASEB J, V6, P2783, DOI 10.1096/fasebj.6.10.1321771; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; KHINE K, 1994, CANCER, V73, P28, DOI 10.1002/1097-0142(19940101)73:1<28::AID-CNCR2820730107>3.0.CO;2-3; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; MELING GI, 1993, BRIT J CANCER, V67, P93, DOI 10.1038/bjc.1993.15; SAKAI E, 1992, ONCOGENE, V7, P927; TURNBULL RB, 1967, ANN SURG, V166, P420	9	72	73	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					233	234		10.1016/S0140-6736(94)93000-7	http://dx.doi.org/10.1016/S0140-6736(94)93000-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913159				2022-12-01	WOS:A1994NY06000012
J	GORDON, RD				GORDON, RD			MINERALOCORTICOID HYPERTENSION	LANCET			English	Article							GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM; HYPERALDOSTERONISM; ADENOMA; VARIETY				GORDON, RD (corresponding author), GREENSLOPES HOSP,HYPERTENS UNIT,BRISBANE,QLD 4120,AUSTRALIA.		Gordon, Richard D/K-2555-2012					BOTEROVELEZ M, 1994, NEW ENGL J MED, V330, P178, DOI 10.1056/NEJM199401203300305; Gordon R D, 1987, J Hypertens Suppl, V5, pS103; GORDON RD, 1991, CLIN EXP PHARMACOL P, V18, P283, DOI 10.1111/j.1440-1681.1991.tb01446.x; GORDON RD, 1992, LANCET, V340, P159, DOI 10.1016/0140-6736(92)93225-C; GORDON RD, 1993, J HYPERTENS, V11, pS310; Gordon RD., 1994, TXB HYPERTENSION, P865; HIRAMATSU K, 1981, ARCH INTERN MED, V141, P1589, DOI 10.1001/archinte.141.12.1589; IRONY I, 1987, J CLIN ENDOCR METAB, V65, P836, DOI 10.1210/jcem-65-5-836; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; LONDON N, 1992, POSTGRAD MED J, V68, P976, DOI 10.1136/pgmj.68.806.976; RICH GM, 1992, ANN INTERN MED, V116, P813, DOI 10.7326/0003-4819-116-10-813; SOMA R, 1989, J ENDOCRINOL INVEST, V12, P183, DOI 10.1007/BF03349956; STEWART PM, 1988, J CLIN INVEST, V82, P340, DOI 10.1172/JCI113592; STOWASSER M, 1992, CLIN EXP PHARMACOL P, V19, P319, DOI 10.1111/j.1440-1681.1992.tb00462.x; STOWASSER M, 1993, J CLIN ENDOCR METAB, V77, P800, DOI 10.1210/jc.77.3.800	15	102	106	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					240	243		10.1016/S0140-6736(94)93003-1	http://dx.doi.org/10.1016/S0140-6736(94)93003-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913162				2022-12-01	WOS:A1994NY06000015
J	KWOK, RPS; LUNDBLAD, JR; CHRIVIA, JC; RICHARDS, JP; BACHINGER, HP; BRENNAN, RG; ROBERTS, SGE; GREEN, MR; GOODMAN, RH				KWOK, RPS; LUNDBLAD, JR; CHRIVIA, JC; RICHARDS, JP; BACHINGER, HP; BRENNAN, RG; ROBERTS, SGE; GREEN, MR; GOODMAN, RH			NUCLEAR-PROTEIN CBP IS A COACTIVATOR FOR THE TRANSCRIPTION FACTOR CREB	NATURE			English	Article							CYCLIC-AMP; SOMATOSTATIN GENE; ESCHERICHIA-COLI; FACTOR-TFIIB; ACTIVATION; ELEMENT; BINDING; DNA; PHOSPHORYLATION; IDENTIFICATION	THE transcription factor CREB binds to a DNA element known as the cAMP-regulated enhancer (CRE)(1-5). CREB is activated through phosphorylation by protein kinase A (PKA)(6), but precisely how phosphorylation stimulates CREB function is unknown. One model is that phosphorylation may allow the recruitment of coactivators which then interact with basal transcription factors. We have previously identified a nuclear protein of M(r) 265K, CBP, that binds specifically to the PKA-phosphorylated form of CREB(7). We have used fluorescence anisotropy measurements to define the equilibrium binding parameters of the phosphoCREB:CBP interaction and report here that CBP can activate transcription through a region in its carboxy terminus. The activation,domain of CBP interacts with the basal transcription factor TFIIB through a domain that is conserved in the yeast coactivator ADA-1 (ref. 8). Consistent with its role as a coactivator, CBP augments the activity of phosphorylated CREB to activate transcription of cAM-responsive genes.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BIOCHEM,PORTLAND,OR 97201; ST LOUIS UNIV,DEPT PHARMACOL & PHYSIOL SCI,ST LOUIS,MO 63014; SHRINERS HOSP CRIPPLED CHILDRENS,PORTLAND,OR 97201; UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605	Oregon Health & Science University; Oregon Health & Science University; Saint Louis University; University of Massachusetts System; University of Massachusetts Worcester			Roberts, Stefan GE/R-5537-2016	Roberts, Stefan GE/0000-0002-7535-6365; Brennan, Richard/0000-0001-7647-485X				BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HEYDUK T, 1993, NATURE, V364, P548, DOI 10.1038/364548a0; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; HOEFFLER JP, 1988, SCIENCE, V242, P1428; LETILLY V, 1993, BIOCHEMISTRY-US, V32, P7753, DOI 10.1021/bi00081a021; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LORIAUX MM, 1993, P NATL ACAD SCI USA, V90, P9046, DOI 10.1073/pnas.90.19.9046; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; SHORT JM, 1986, J BIOL CHEM, V261, P9721; WILLIAMS JS, 1993, DNA CELL BIOL, V12, P183, DOI 10.1089/dna.1993.12.183	19	1280	1309	1	58	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 21	1994	370	6486					223	226		10.1038/370223a0	http://dx.doi.org/10.1038/370223a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX971	7913207				2022-12-01	WOS:A1994NX97100055
J	HARRAP, SB				HARRAP, SB			HYPERTENSION - GENES VERSUS ENVIRONMENT	LANCET			English	Article							BLOOD-PRESSURE; MIGRATION; MARKERS; DISEASE; RISK				HARRAP, SB (corresponding author), ALFRED HOSP,MONASH MED SCH,DEPT SOCIAL & PREVENT MED,COMMERCIAL RD,PRAHRAN,VIC 3181,AUSTRALIA.			Harrap, Stephen/0000-0003-2907-6714				BEAGLEHOLE R, 1990, EPIDEMIOL REV, V12, P1; BENNETT CL, 1993, BIOCHEM BIOPH RES CO, V197, P833, DOI 10.1006/bbrc.1993.2554; DEUTSCHER S, 1966, CIRCULATION, V33, P911, DOI 10.1161/01.CIR.33.6.911; ELFORD J, 1990, BRIT MED J, V300, P291, DOI 10.1136/bmj.300.6720.291; GENNSER G, 1988, BMJ-BRIT MED J, V296, P1498, DOI 10.1136/bmj.296.6635.1498; HOWE JR, 1992, SURGERY, V112, P219; HUNT SC, 1989, AM J EPIDEMIOL, V129, P625, DOI 10.1093/oxfordjournals.aje.a115175; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; LONGINI IM, 1984, AM J EPIDEMIOL, V120, P131, DOI 10.1093/oxfordjournals.aje.a113862; MOLL PP, 1979, GENETIC ANAL COMMON, P307; MONGEAU JG, 1989, SEMIN NEPHROL, V9, P208; MONGEAU JG, 1986, CLIN EXP HYPERTENS A, V8, P653, DOI 10.3109/10641968609046581; MURPHY EA, 1964, J CHRON DIS, V17, P301, DOI 10.1016/0021-9681(64)90073-6; PICKERING GW, 1959, LANCET, V2, P1027; PLATT R, 1947, Q J MED, V16, P111; REEDERS ST, 1986, BRIT MED J, V292, P851, DOI 10.1136/bmj.292.6524.851; Rose G, 1987, Ciba Found Symp, V130, P247; SALMOND CE, 1989, AM J EPIDEMIOL, V130, P37, DOI 10.1093/oxfordjournals.aje.a115321; SUZUKI DT, 1989, INTRO GENETIC ANAL, P641; WARD R, 1990, HYPERTENSION PATHOPH, P81; WATT GCM, 1992, J HYPERTENS, V10, P474	22	78	82	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 16	1994	344	8916					169	171		10.1016/S0140-6736(94)92762-6	http://dx.doi.org/10.1016/S0140-6736(94)92762-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912770				2022-12-01	WOS:A1994NW81000014
J	CIANFARANI, S; VACCARO, F; BOSCHERINI, B				CIANFARANI, S; VACCARO, F; BOSCHERINI, B			WHAT IS THE RATIONALE FOR GROWTH-HORMONE THERAPY IN TURNERS-SYNDROME	LANCET			English	Editorial Material							OXANDROLONE; SECRETION; OBESITY; GH				CIANFARANI, S (corresponding author), UNIV ROMA TOR VERGATA, DEPT PAEDIAT, VIA O RAIMONDO, I-00173 ROME, ITALY.		Geremia, Caterina/AAA-9380-2020; cianfarani, stefano/K-2079-2016	cianfarani, stefano/0000-0002-2580-8781				CAPRIO S, 1992, J PEDIATR-US, V120, P238, DOI 10.1016/S0022-3476(05)80434-2; CIANFARANI S, 1994, HORM RES, V41, P27, DOI 10.1159/000183873; KOPELMAN PG, 1988, CLIN ENDOCRINOL, V28, P675; LANES R, 1990, J CLIN ENDOCR METAB, V71, P770, DOI 10.1210/jcem-71-3-770; LU PW, 1991, ARCH DIS CHILD, V66, P1184, DOI 10.1136/adc.66.10.1184; PASQUINO AM, 1992, HORM RES, V38, P120, DOI 10.1159/000182526; RANKE MB, 1993, ACTA PAEDIATR, V82, P82, DOI 10.1111/j.1651-2227.1993.tb12936.x; RANKE MB, 1987, ACTA ENDOCRINOL-COP, V116, P305, DOI 10.1530/acta.0.1160305; RAPPAPORT R, 1989, ACTA PAEDIATR SCAND, P82; ROSENFELD RG, 1992, J PEDIATR-US, V121, P49, DOI 10.1016/S0022-3476(05)82540-5; ROSS JL, 1985, J PEDIATR-US, V106, P202, DOI 10.1016/S0022-3476(85)80287-0; VANVLIET G, 1986, HUMAN GROWTH HORMONE, P115; WALKER JM, 1990, LANCET, V336, P1331, DOI 10.1016/0140-6736(90)92891-K; WEISE M, 1993, HORM RES, V39, P25, DOI 10.1159/000182763; WILSON DM, 1988, J PEDIATR-US, V112, P210, DOI 10.1016/S0022-3476(88)80057-X; ZADIK Z, 1992, J CLIN ENDOCR METAB, V75, P412, DOI 10.1210/jc.75.2.412	16	15	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 9	1994	344	8915					114	115		10.1016/S0140-6736(94)91288-2	http://dx.doi.org/10.1016/S0140-6736(94)91288-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7912351				2022-12-01	WOS:A1994NV73200016
J	PARPURA, V; BASARSKY, TA; LIU, F; JEFTINIJA, K; JEFTINIJA, S; HAYDON, PG				PARPURA, V; BASARSKY, TA; LIU, F; JEFTINIJA, K; JEFTINIJA, S; HAYDON, PG			GLUTAMATE-MEDIATED ASTROCYTE NEURON SIGNALING	NATURE			English	Article							CALCIUM WAVES; HIPPOCAMPAL-NEURONS; SYNAPTIC CURRENTS; ASPARTATE; RESPONSES; RECEPTORS; CULTURES	NEUROTRANSMITTER released from neurons is known to signal to neighbouring neurons and glia(1-3). Here we demonstrate an additional signalling pathway in which glutamate is released from astrocytes and causes an NMDA (N-methyl-D-aspartate) receptor-mediated increase in neuronal calcium. Internal calcium was elevated and glutamate release stimulated by application of the neuroligand bradykinin to cultured astrocytes. Elevation of astrocyte internal calcium was also sufficient to induce glutamate release. To determine whether this released glutamate signals to neurons, we studied astrocyte-neuron co-cultures. Bradykinin significantly increased calcium levels in neurons co-cultured with astrocytes, but not in solitary neurons. The glutamate receptor antagonists D-2-amino-5-phosphonopentanoic acid and D-glutamylglycine prevented bradykinin-induced neuronal calcium elevation. When single astrocytes were directly stimulated to increase internal calcium and release glutamate, calcium levels of adjacent neurons were increased; this increase could be blocked by D-glutamyl-glycine. Thus, astrocytes regulate neuronal calcium levels through the calcium-dependent release of glutamate. -	IOWA STATE UNIV SCI & TECHNOL, DEPT ZOOL & GENET, AMES, IA 50011 USA; IOWA STATE UNIV SCI & TECHNOL, DEPT VET ANAT, AMES, IA 50011 USA; IOWA STATE UNIV SCI & TECHNOL, NEUROSCI PROGRAM, AMES, IA 50011 USA	Iowa State University; Iowa State University; Iowa State University			Parpura, Vladimir/A-1242-2010	Parpura, Vladimir/0000-0002-4643-2197				BALCAR VJ, 1972, J NEUROCHEM, V19, P2657, DOI 10.1111/j.1471-4159.1972.tb01325.x; BASARSKY TA, IN PRESS J NEUROSCI; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; CORNELLBELL AH, 1991, CELL CALCIUM, V12, P185, DOI 10.1016/0143-4160(91)90020-F; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; GLAUM SR, 1990, P NATL ACAD SCI USA, V87, P3454, DOI 10.1073/pnas.87.9.3454; GUTHRIE PB, 1991, NATURE, V354, P76, DOI 10.1038/354076a0; HUETTNER JE, 1986, J NEUROSCI, V6, P3044; INAGAKI N, 1991, NEUROSCI LETT, V128, P257, DOI 10.1016/0304-3940(91)90274-W; ISAACSON JS, 1993, J NEUROPHYSIOL, V70, P2187, DOI 10.1152/jn.1993.70.5.2187; JENSEN AM, 1991, J NEUROSCI, V11, P1674; JONES AW, 1984, NEUROSCIENCE, V13, P573, DOI 10.1016/0306-4522(84)90250-1; KAO JPY, 1989, J BIOL CHEM, V264, P8179; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; LEVISON SW, 1991, CULTURING NERVE CELL, P309; MA J, 1988, SCIENCE, V242, P99, DOI 10.1126/science.2459777; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MCCARTHY KD, 1991, NEUROSCIENCE, V41, P325, DOI 10.1016/0306-4522(91)90330-Q; MCLARNON JG, 1991, CAN J PHYSIOL PHARM, V69, P1422, DOI 10.1139/y91-213; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; MURPHY TH, 1993, J NEUROSCI, V13, P2672, DOI 10.1523/JNEUROSCI.13-06-02672.1993; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; PARPURA V, 1993, J CELL SCI, V104, P427; REISER G, 1989, J CELL SCI, V93, P545; SCHEFFE H, 1953, BIOMETRIKA, V40, P87, DOI 10.1093/biomet/40.1-2.87; Sokal R. R., 1981, BIOMETRY PRINCIPLES, P400; TRIGGLE DJ, 1991, ANN NY ACAD SCI, V635, P123, DOI 10.1111/j.1749-6632.1991.tb36487.x	29	1335	1367	3	84	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 30	1994	369	6483					744	747		10.1038/369744a0	http://dx.doi.org/10.1038/369744a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU581	7911978				2022-12-01	WOS:A1994NU58100060
J	VOORBERG, J; ROELSE, J; KOOPMAN, R; BULLER, H; BERENDS, F; TENCATE, JW; MERTENS, K; VANMOURIK, JA				VOORBERG, J; ROELSE, J; KOOPMAN, R; BULLER, H; BERENDS, F; TENCATE, JW; MERTENS, K; VANMOURIK, JA			ASSOCIATION OF IDIOPATHIC VENOUS THROMBOEMBOLISM WITH SINGLE POINT-MUTATION AT ARG(506) OF FACTOR-V	LANCET			English	Note							ACTIVATED PROTEIN-C; POOR ANTICOAGULANT RESPONSE; THROMBOPHILIA; THROMBOSIS	Abnormal coagulation factor V may underlie the thrombotic events associated with resistance to activated protein C (APC). We analysed 27 consecutive patients with documented idiopathic (recurrent) thromboembolism for the occurrence of point mutations within the APC sensitive regions of blood coagulation factor V. In 10 patients we observed a single basepair mutation resulting in a substitution of Arg(506) to Gln. This mutation was significantly linked to in-vitro resistance to APC in these subjects. This mutation at Arg(506) of factor V may form the molecular basis for the thrombotic events associated with APC resistance.	UNIV AMSTERDAM,ACAD MED CTR,CTR HEMOSTASIS THROMBOSIS ATHEROSCLEROSIS & INFLA,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam	VOORBERG, J (corresponding author), NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,DEPT BLOOD COAGULAT,PLESMANLAAN 125,1066 CX AMSTERDAM,NETHERLANDS.			Voorberg, Jan/0000-0003-4585-2621				BAUER KA, 1994, NEW ENGL J MED, V330, P566, DOI 10.1056/NEJM199402243300810; CUYPERS HTM, 1992, J CLIN MICROBIOL, V30, P3220, DOI 10.1128/JCM.30.12.3220-3224.1992; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; GRIFFIN JH, 1993, BLOOD, V82, P1989; HEYBOER H, 1990, NEW ENGL J MED, V323, P1512; KALAFATIS M, 1993, J BIOL CHEM, V268, P27246; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; MILETICH JP, 1993, CELL, V72, P477, DOI 10.1016/0092-8674(93)90063-V; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801	10	445	458	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 18	1994	343	8912					1535	1536		10.1016/S0140-6736(94)92939-4	http://dx.doi.org/10.1016/S0140-6736(94)92939-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR329	7911872				2022-12-01	WOS:A1994NR32900009
J	BAINTON, DF				BAINTON, DF			CALIFORNIA BIGFOOT	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											BAINTON, DF (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143, USA.								0	0	0	1	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 22	1994	331	25					1693	1693						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX382	7969361				2022-12-01	WOS:A1994PX38200006
J	BURMEISTER, WP; GASTINEL, LN; SIMISTER, NE; BLUM, ML; BJORKMAN, PJ				BURMEISTER, WP; GASTINEL, LN; SIMISTER, NE; BLUM, ML; BJORKMAN, PJ			CRYSTAL-STRUCTURE AT 2.2-ANGSTROM RESOLUTION OF THE MHC-RELATED NEONATAL FC RECEPTOR	NATURE			English	Article							CLASS-I H-2K(B); HISTOCOMPATIBILITY ANTIGEN; 3-DIMENSIONAL STRUCTURE; PEPTIDE ANTIGENS; SMALL-INTESTINE; BINDING; COMPLEX; RECOGNITION; HLA-A2; RAT	The three-dimensional structure of the rat neonatal Fe receptor (FcRn) is similar to the structure of molecules of the major histocompatibility complex (MHC). The counterpart of the MHC peptide-binding site is closed in FcRn, making the FcRn groove incapable of binding peptides. A dimer of FcRn heterodimers seen in the crystals may represent a receptor dimer that forms when the Fc portion of a single immunoglobulin binds. An alternative use of the MHC fold for immune recognition is indicated by the FcRn and FcRn/Fc co-crystal structures.	CALTECH,DEPT BIOL,PASADENA,CA 91125; CALTECH,HOWARD HUGHES MED INST,PASADENA,CA 91125; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute; Brandeis University; Brandeis University				Burmeister, Wim/0000-0003-0876-6118				AHOUSE JJ, 1993, J IMMUNOL, V151, P6076; BEAVIL AJ, 1993, BIOCHEM SOC T, V21, P968, DOI 10.1042/bst0210968; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1992, XPLOR VERSION 31 SYS; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; DAVIES DR, 1983, ANNU REV IMMUNOL, V1, P87, DOI 10.1146/annurev.iy.01.040183.000511; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FAHNESTOCK ML, 1992, SCIENCE, V258, P1658, DOI 10.1126/science.1360705; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GASTINEL LN, 1992, P NATL ACAD SCI USA, V89, P638, DOI 10.1073/pnas.89.2.638; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HOPE H, 1990, ANNU REV BIOPHYS BIO, V19, P107; HUBER AH, 1993, J MOL BIOL, V230, P1077, DOI 10.1006/jmbi.1993.1220; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, SET AVERAGING PROGRA; JONES TA, 1993, CRYSTALLOGRAPHIC COM; Kabat EA, 1991, SEQUENCES PROTEINS I, V5th; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANCET D, 1979, P NATL ACAD SCI USA, V76, P3844, DOI 10.1073/pnas.76.8.3844; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LESLIE AGW, 1987, ACTA CRYSTALLOGR A, V43, P134, DOI 10.1107/S0108767387099720; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MARTIN LH, 1987, P NATL ACAD SCI USA, V84, P9189, DOI 10.1073/pnas.84.24.9189; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; RAGHAVAN M, 1994, IMMUNITY, V1, P303, DOI 10.1016/1074-7613(94)90082-5; RAGHAVAN M, 1993, BIOCHEMISTRY-US, V32, P8654, DOI 10.1021/bi00084a037; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; ROBERTS DM, 1990, J CELL BIOL, V111, P1867, DOI 10.1083/jcb.111.5.1867; RODEWALD R, 1976, J CELL BIOL, V71, P666, DOI 10.1083/jcb.71.2.666; RODEWALD R, 1970, J CELL BIOL, V45, P635, DOI 10.1083/jcb.45.3.635; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHALL S, 1969, J MOL BIOL, V41, P237; SIMISTER NE, 1985, EUR J IMMUNOL, V15, P733, DOI 10.1002/eji.1830150718; SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; STORY CM, 1994, J EXP MED, V180, P2377, DOI 10.1084/jem.180.6.2377; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403; 1979, CCP4 ERC DAR LAB COL	50	266	282	2	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					336	343		10.1038/372336a0	http://dx.doi.org/10.1038/372336a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PU287	7969491				2022-12-01	WOS:A1994PU28700047
J	GOTZ, R; KOSTER, R; WINKLER, C; RAULF, F; LOTTSPEICH, F; SCHARTL, M; THOENEN, H				GOTZ, R; KOSTER, R; WINKLER, C; RAULF, F; LOTTSPEICH, F; SCHARTL, M; THOENEN, H			NEUROTROPHIN-6 IS A NEW MEMBER OF THE NERVE GROWTH-FACTOR FAMILY	NATURE			English	Article							EMBRYONIC-DEVELOPMENT; SENSORY NEURONS; CELL-SURFACE; IDENTIFICATION; SURVIVAL; CLEAVAGE; PROTEINS; RECEPTOR; BINDING; BIOLOGY	DURING vertebrate development, many neurons depend for survival and differentiation on their target cells(1-3). The best documented mediator of such a retrograde trophic action is the neurotrophin nerve growth factor (NGF)(1). NGF and the other known members of the neurotrophin family, brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin-4/5 (NT-4/5) are conserved as distinct genes over large evolutionary distances(4-6). Here we report the cloning of neurotrophin-6 (NT-6), a new member of this family from the teleost fish Xiphophorus. NT-6 distinguishes itself from the other known neurotrophins in that it is not found as a soluble protein in the medium of producing cells. The addition of heparin (but not chondroitin) effects the release of NT-6 from cell surface and extracellular matrix molecules. Recombinant purified NT-6 has a spectrum of actions similar to NGF on chick sympathetic and sensory neurons, albeit with a lower potency. NT-6 is expressed in the embryonic valvulla cerebelli; expression persists in some adult tissues. The interaction of NT-6 with heparin-binding molecules may modulate its action in the nervous system.	MAX PLANCK INST PSYCHIAT,DEPT NEUROCHEM,D-82152 MARTINSRIED,GERMANY; UNIV WURZBURG,BIOZENTRUM,DEPT PHYSIOL CHEM 1,D-97074 WURZBURG,GERMANY; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	Max Planck Society; University of Wurzburg; Max Planck Society			Winkler, Christoph/G-4822-2012	Schartl, Manfred/0000-0001-9882-5948; Koster, Reinhard/0000-0001-6593-8196; Winkler, Christoph/0000-0003-4688-6241				BARDE YA, 1980, P NATL ACAD SCI-BIOL, V77, P1199, DOI 10.1073/pnas.77.2.1199; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; CRAWFORD JL, 1973, P NATL ACAD SCI USA, V70, P538, DOI 10.1073/pnas.70.2.538; GOTZ R, 1994, COMP BIOCHEM PHYS C, V108, P1, DOI 10.1016/1367-8280(94)90082-5; GOTZ R, 1992, J NEUROCHEM, V59, P432, DOI 10.1111/j.1471-4159.1992.tb09389.x; GOTZ R, 1992, EUR J BIOCHEM, V204, P745, DOI 10.1111/j.1432-1033.1992.tb16689.x; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; KRIMLAUF R, 1991, GENE TRANSFER EXPRES, P307; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROCHELLE WJ, 1991, GENE DEV, V5, P1191, DOI 10.1101/gad.5.7.1191; LEE BA, 1991, J CELL BIOL, V113, P361, DOI 10.1083/jcb.113.2.361; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; MARCEY D, 1986, NATURE, V321, P380, DOI 10.1038/321380a0; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MEEK J, 1992, EUR J MORPHOL, V1, P37; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; POWERS DA, 1989, SCIENCE, V246, P352, DOI 10.1126/science.2678474; PURVES D, 1988, BODY BRAIN TROPIC TH; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROSSANT J, 1992, GENE DEV, V6, P1, DOI 10.1101/gad.6.1.1; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; TAVOLGA WILLIAM N., 1949, BULL AMER MUS NAT HIST, V94, P161; VLODAVSKY L, 1991, TRENDS BIOCHEM SCI, V168, P268; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	30	338	373	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 17	1994	372	6503					266	269		10.1038/372266a0	http://dx.doi.org/10.1038/372266a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PR889	7969471	Green Published			2022-12-01	WOS:A1994PR88900051
J	ESRIG, D; ELMAJIAN, D; GROSHEN, S; FREEMAN, JA; STEIN, JP; CHEN, SC; NICHOLS, PW; SKINNER, DG; JONES, PA; COTE, RJ				ESRIG, D; ELMAJIAN, D; GROSHEN, S; FREEMAN, JA; STEIN, JP; CHEN, SC; NICHOLS, PW; SKINNER, DG; JONES, PA; COTE, RJ			ACCUMULATION OF NUCLEAR P53 AND TUMOR PROGRESSION IN BLADDER-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DISEASE PROGRESSION; ALTERED EXPRESSION; GENE-PRODUCT; MUTATIONS; PROTEIN; OVEREXPRESSION; CHEMOTHERAPY; CYSTECTOMY; CARCINOMA	Background. We have previously demonstrated a strong association between nuclear accumulation of p53 protein, as determined by immunohistochemical analysis, and mutations in the p53 gene. The purpose of this study was to determine the relation between nuclear accumulation of p53 and tumor progression in transitional-cell carcinoma of the bladder. Methods. Histologic specimens of transitional-cell carcinoma of the bladder (stages Pa, noninvasive disease, to P4, disease with direct extension into adjacent organs or structures) from 243 patients who were treated by radical cystectomy were examined for the immunohistochemical detection of p53 protein. Nuclear p53 reactivity was then analyzed in relation to time to recurrence and overall survival. Results. The detection of nuclear p53 was significantly associated with an increased risk of recurrence of bladder cancer (P < 0.001) and with decreased overall survival (P < 0.001). In patients with cancer confined to the bladder, the rates of recurrence for stage P1, P2, and P3a tumors that had no detectable nuclear p53 reactivity at five years were 7, 12, and 11 percent, respectively, as compared with 62, 56, and 80 percent, respectively, for tumors that had p53 immunoreactivity. Similar results were obtained when the presence or absence of p53 in the nuclei of the tumor cells was studied in relation to overall survival. In a multivariable analysis stratified according to grade, pathological stage, and lymph-node status, nuclear p53 status was an independent predictor (and in cancer confined to the bladder, the only independent predictor) of recurrence and overall survival (P < 0.001). Conclusions. In patients with transitional-cell carcinoma confined to the bladder, an accumulation of p53 in the tumor-cell nuclei detected by immunohistochemical methods predicts a significantly increased risk of recurrence and death, independently of tumor grade, stage, and lymph-node status. Patients with transitional-cell carcinoma confined to the bladder that demonstrates nuclear p53 reactivity should be considered for protocols of adjuvant treatment.	UNIV SO CALIF,KENNETH NORRIS JR COMPREHENS CANC CTR,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT UROL,LOS ANGELES,CA; UNIV SO CALIF,SCH MED,DEPT PREVENT MED,LOS ANGELES,CA	University of Southern California; University of Southern California; University of Southern California					NATIONAL CANCER INSTITUTE [P30CA014089, R35CA049758] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 14089, R35 CA49758] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bergkvist A, 1965, Acta Chir Scand, V130, P371; CORDONCARDO C, 1994, CANCER RES, V54, P794; CORDONCARDO C, 1992, J NATL CANCER I, V84, P1251, DOI 10.1093/jnci/84.16.1251; ESRIG D, 1993, AM J PATHOL, V143, P1389; FIENBERG SE, 1977, ANAL CROSS CLASSIFIE, P9; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; HERMANEK P, 1987, TNM CLASSIFICATION M, P133; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KASTAN MB, 1991, CANCER RES, V51, P6304; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIPPONEN PK, 1993, INT J CANCER, V53, P365, DOI 10.1002/ijc.2910530304; LOGOTHETIS CJ, 1992, J NATL CANCER I, V84, P1256, DOI 10.1093/jnci/84.16.1256; MILLER RG, 1981, SURVIVAL ANAL, P44; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; SARKIS AS, 1993, INT J ONCOL, V3, P355; SARKIS AS, 1993, J NATL CANCER I, V85, P53, DOI 10.1093/jnci/85.1.53; SIDRANSKY D, 1992, UROL CLIN N AM, V19, P629; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SKINNER DG, 1982, J UROLOGY, V128, P34, DOI 10.1016/S0022-5347(17)52740-8; SKINNER DG, 1991, J UROLOGY, V145, P459, DOI 10.1016/S0022-5347(17)38368-4; SPRUCK CH, 1994, CANCER RES, V54, P784; STOCKLE M, 1992, J UROLOGY, V148, P302, DOI 10.1016/S0022-5347(17)36578-3	23	673	682	0	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 10	1994	331	19					1259	1264		10.1056/NEJM199411103311903	http://dx.doi.org/10.1056/NEJM199411103311903			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP752	7935683				2022-12-01	WOS:A1994PP75200003
J	FINE, PEM; STERNE, JAC; PONNIGHAUS, JM; REES, RJW				FINE, PEM; STERNE, JAC; PONNIGHAUS, JM; REES, RJW			DELAYED-TYPE HYPERSENSITIVITY, MYCOBACTERIAL VACCINES AND PROTECTIVE IMMUNITY	LANCET			English	Article							NORTHERN MALAWI; LEPROSY VACCINE; TUBERCULOSIS; LEPRAE	There is a longstanding debate over the implications of natural and vaccine-induced delayed type hypertensivity for protective immunity to mycobacterial infections. The identification of correlates of vaccine-induced protective immunity should help explain the inconsistent behaviour of BCG vaccines in different populations and assist in efforts to devise improved vaccines. More than 70 000 subjects in Karonga District, northern Malawi were skin tested with soluble antigens of the tubercle and leprosy bacilli, and then followed up for five years for tuberculosis and leprosy incidence. Incidence rate ratios were calculated to compare subjects with different levels of prior shin test sensitivity, after controlling for the effects of age, sex and previous BCG vaccination. BCG vaccination protected against leprosy without persistent delayed-type hypersensitivity to tuberculin or to soluble antigens of the leprosy bacillus. In subjects who had not received BCG, hypersensitivity to tuberculin or to antigens of the leprosy bacillus was associated with strong protection against leprosy. In BCG-vaccinated and unvaccinated subjects, there was a J-shaped relation between hypersensitivity to tuberculin and subsequent rates of tuberculosis, with lowest rates associated with low grade sensitivity (induration 1-10 mm). This study shows that delayed-type hypersensitivity to antigens has different implications for and leprosy: low-level hypersensitivity (probably attributable to environmental mycobacteria) is associated with protection, but persistent vaccine-associated hypersensitivity to mycobacterial antigens is not a correlate of vaccine-derived protection against mycobacterial diseases.	LEPRA,CHILUMBA,MALAWI; NATL INST MED RES,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research	FINE, PEM (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1E 7HT,ENGLAND.		Sterne, Jonathan/Z-3106-2019	Sterne, Jonathan/0000-0001-8496-6053				[Anonymous], 1972, B WORLD HEALTH ORGAN, V46, P371; BECHELLI LM, 1973, B WORLD HEALTH ORGAN, V48, P323; COMSTOCK GW, 1988, AM REV RESPIR DIS, V138, P479, DOI 10.1164/ajrccm/138.2.479; DANNENBERG AM, 1989, REV INFECT DIS, V11, pS369; DRAPER P, 1994, J GEN MICROBIOL, V69, P313; FINE PEM, 1993, TUBERCULOSIS BACK FU, P53; GILL HK, 1986, B WORLD HEALTH ORGAN, V64, P121; GUPTE MD, 1990, LEPROSY REV, V61, P132; HART P. D'A., 1967, Tubercle, V48, P201, DOI 10.1016/S0041-3879(67)80024-2; MACKANESS GB, 1991, INT P US DHEW, V14, P69; PALMER CE, 1967, ARCH ENVIRON HEALTH, V15, P792, DOI 10.1080/00039896.1967.10664998; PALMER CE, 1957, B INT UNION TUBERC, V27, P106; PONNIGHAUS JM, 1992, LANCET, V339, P636, DOI 10.1016/0140-6736(92)90794-4; PONNIGHAUS JM, 1987, INT J LEPROSY, V55, P454; PONNIGHAUS JM, 1986, INT J LEPROSY, V54, P25; PONNIGHAUS JM, 1987, LEPROSY REV, V58, P359; PONNIGHAUS JM, 1994, INT J LEPROSY, V61, P10; SHEPARD CC, 1980, BRIT J EXP PATHOL, V61, P376; STANLEY SJ, 1981, J HYG CAMB, V87, P235; Youmans G.P., 1979, TUBERCULOSIS, P302; 3RD IMMLEP SCI WORK, P20	21	147	149	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 5	1994	344	8932					1245	1249		10.1016/S0140-6736(94)90748-X	http://dx.doi.org/10.1016/S0140-6736(94)90748-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP701	7967984				2022-12-01	WOS:A1994PP70100006
J	DAVIS, S; GALE, NW; ALDRICH, TH; MAISONPIERRE, PC; LHOTAK, V; PAWSON, T; GOLDFARB, M; YANCOPOULOS, GD				DAVIS, S; GALE, NW; ALDRICH, TH; MAISONPIERRE, PC; LHOTAK, V; PAWSON, T; GOLDFARB, M; YANCOPOULOS, GD			LIGANDS FOR EPH-RELATED RECEPTOR TYROSINE KINASES THAT REQUIRE MEMBRANE ATTACHMENT OR CLUSTERING FOR ACTIVITY	SCIENCE			English	Article							NEUROTROPHIC FACTOR; NERVOUS-SYSTEM; PROTEIN; GENE; FAMILY; EXPRESSION; IDENTIFICATION; HINDBRAIN; CLONING; CHICKEN	The EPH-related transmembrane tyrosine kinases constitute the largest known family of receptor-like tyrosine kinases, with many members displaying specific patterns of expression in the developing and adult nervous system. A family of cell surface-bound ligands exhibiting distinct, but overlapping, specificities for these EPH-related kinases was identified. These ligands were unable to act as conventional soluble factors. However, they did function when presented in membrane-bound form, suggesting that they require direct cell-to-cell contact to activate their receptors. Membrane attachment may serve to facilitate ligand dimerization or aggregation, because antibody-mediated clustering activated previously inactive soluble forms of these ligands.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ON, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	DAVIS, S (corresponding author), REGENERON PHARMACEUT INC, 777 OLD SAW MILL RIVER RD, TARRYTOWN, NY 10591 USA.		Pawson, Tony J/E-4578-2013					BAPTISTA CA, 1994, NEURON, V12, P243, DOI 10.1016/0896-6273(94)90268-2; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BOYD AW, 1992, J BIOL CHEM, V267, P3262; CHAN J, 1991, ONCOGENE, V6, P1057; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; Davis S.M, UNPUB; GALE NW, UNPUB; GAO WQ, 1991, NEURON, V6, P705, DOI 10.1016/0896-6273(91)90168-Y; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; HART AC, 1993, NATURE, V361, P732, DOI 10.1038/361732a0; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LETWIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; NIETO MA, 1992, DEVELOPMENT, V116, P1137; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILKINSON D, COMMUNICATION	31	627	673	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	1994	266	5186					816	819		10.1126/science.7973638	http://dx.doi.org/10.1126/science.7973638			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7973638				2022-12-01	WOS:A1994PP75300044
J	POTAMITIS, T; AGGARWAL, RK; TSALOUMAS, M; RENE, C; MCLAUGHLIN, J; ONEILL, E				POTAMITIS, T; AGGARWAL, RK; TSALOUMAS, M; RENE, C; MCLAUGHLIN, J; ONEILL, E			DRIVING, GLAUCOMA, AND THE LAW	BRITISH MEDICAL JOURNAL			English	Article											POTAMITIS, T (corresponding author), BIRMINGHAM & MIDLAND EYE HOSP,BIRMINGHAM B3 2NS,W MIDLANDS,ENGLAND.							KIRN MM, 1978, AM JOPHTHALMOL, V85, P28; NORTH RV, 1985, OPHTHAL PHYSL OPT, V5, P205, DOI 10.1111/j.1475-1313.1985.tb00657.x	2	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 22	1994	309	6961					1057	1058		10.1136/bmj.309.6961.1057	http://dx.doi.org/10.1136/bmj.309.6961.1057			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN733	7950740	Green Published			2022-12-01	WOS:A1994PN73300023
J	SMIDER, V; RATHMELL, WK; LIEBER, MR; CHU, G				SMIDER, V; RATHMELL, WK; LIEBER, MR; CHU, G			RESTORATION OF X-RAY RESISTANCE AND V(D)J RECOMBINATION IN MUTANT-CELLS BY KU CDNA	SCIENCE			English	Article							STRAND BREAK REPAIR; PROTEIN; DNA; AUTOANTIBODIES; OVERLAP; SUBUNIT; ANTIGEN	Three genetic complementation groups of rodent cells are defective for both repair of x-ray-induced double-strand breaks and V(D)J recombination. Cells from one group lack a DNA end-binding activity that is biochemically and antigenically similar to the Ku autoantigen. Transfection of complementary DNA (cDNA) that encoded the 86-kilodalton subunit of Ku rescued these mutant cells for DNA end-binding activity, x-ray resistance, and V(D)J recombination activity. These results establish a role for Ku in DNA repair and recombination. Furthermore, as a component of a DNA-dependent protein kinase, Ku may initiate a signaling pathway induced by DNA damage.	STANFORD UNIV,MED CTR,DEPT MED,STANFORD,CA 94305; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Stanford University; Washington University (WUSTL)				Smider, Vaughn/0000-0003-3488-6383; Lieber, Michael/0000-0001-8809-0909; Lieber, Michael/0000-0003-3700-6345				ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BLIER PR, 1993, J BIOL CHEM, V268, P7594; CAL QQ, 1994, CYTOGENET CELL GENET, V65, P221; CHEN DJ, 1994, GENOMICS, V21, P423, DOI 10.1006/geno.1994.1287; COLLINS AR, 1993, MUTAT RES, V293, P99, DOI 10.1016/0921-8777(93)90062-L; FALZON M, 1993, J BIOL CHEM, V268, P10546; Friedberg E.C., 1991, MOL CELLULAR BIOL TE, P147; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; HAFEZPARAST M, 1993, SOMAT CELL MOLEC GEN, V19, P413, DOI 10.1007/BF01233246; HAMILTON AA, 1987, MOL CELL BIOL, V7, P1409, DOI 10.1128/MCB.7.4.1409; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOORE PD, 1986, MUTAT RES, V160, P149, DOI 10.1016/0027-5107(86)90038-2; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; REEVES WH, 1989, J BIOL CHEM, V264, P5047; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Taccioli G E, 1992, Curr Top Microbiol Immunol, V182, P107; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TAKABE Y, 1988, MOL CELL BIOL, V8, P466; YANEVA M, 1989, J BIOL CHEM, V264, P13407	27	329	333	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1994	266	5183					288	291		10.1126/science.7939667	http://dx.doi.org/10.1126/science.7939667			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939667				2022-12-01	WOS:A1994PM13400038
J	GHOSH, A; TANG, MHY; LAM, YH; FUNG, E; CHAN, V				GHOSH, A; TANG, MHY; LAM, YH; FUNG, E; CHAN, V			ULTRASOUND MEASUREMENT OF PLACENTAL THICKNESS TO DETECT PREGNANCIES AFFECTED BY HOMOZYGOUS ALPHA-THALASSEMIA-1	LANCET			English	Note							ALPHA-THALASSEMIA; HYDROPS-FETALIS; DIAGNOSIS	Homozygous alpha-thalessaemia-1, a common cause of hydrops fetalis, is usually diagnosed invasively. We measured placental thickness by ultrasound at 10-21 weeks' gestation in 231 at-risk pregnancies. 60 were affected (by DNA analysis). The sensitivity and specificity in detecting affected pregnancies at cut-off of mean placental thickness plus 2 SD before 12 weeks' gestation were 0.72 (95% Cl 0.52-0.93) and 0.97 (0.9-1.0). After 12 weeks sensitivity increased to 0.95 (0.89-1.0) and by 18 weeks reached 1.0 (0.60-0.99) without change in specificity. Selection of pregnancies at risk by measurement of placental thickness will reduce the number of invasive diagnostic procedures.	QUEEN MARY HOSP,DEPT MED,HONG KONG,HONG KONG	University of Hong Kong	GHOSH, A (corresponding author), UNIV HONG KONG,TSAN YUK HOSP,DEPT OBSTET & GYNAECOL,HOSP RD,HONG KONG,HONG KONG.		Tang, Mary Hoi Yin/A-7638-2013; Chan, Vivian/C-4217-2009					CHAN V, 1984, BMJ-BRIT MED J, V288, P1327, DOI 10.1136/bmj.288.6427.1327; GHOSH A, 1987, PRENATAL DIAG, V7, P307, DOI 10.1002/pd.1970070503; HSIEH FJ, 1989, OBSTET GYNECOL, V74, P722; KANOKPONGSAKDI S, 1990, PRENATAL DIAG, V10, P809, DOI 10.1002/pd.1970101208; LEIINJO LE, 1962, BLOOD, V20, P581; LIANG ST, 1985, BRIT J OBSTET GYNAEC, V92, P680, DOI 10.1111/j.1471-0528.1985.tb01447.x; RUBIN EM, 1985, LANCET, V1, P75; THUMASATHIT B, 1986, J PEDIATR, V73, P132; TODD D, 1967, BRIT MED J, V3, P347, DOI 10.1136/bmj.3.5561.347; WEATHERALL DJ, 1970, BRIT J HAEMATOL, V18, P357, DOI 10.1111/j.1365-2141.1970.tb01449.x	10	53	56	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					988	989		10.1016/S0140-6736(94)91644-6	http://dx.doi.org/10.1016/S0140-6736(94)91644-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934433				2022-12-01	WOS:A1994PK97800012
J	JOHN, TJ				JOHN, TJ			LEARNING FROM PLAGUE IN INDIA	LANCET			English	Editorial Material											JOHN, TJ (corresponding author), CHRISTIAN MED COLL & HOSP,DEPT MICROBIOL & VIROL,VELLORE 632004,TAMIL NADU,INDIA.							1994, LANCET, V344, P941	1	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					972	972		10.1016/S0140-6736(94)91637-3	http://dx.doi.org/10.1016/S0140-6736(94)91637-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PK978	7934426				2022-12-01	WOS:A1994PK97800005
J	SCULLY, C; MORTIMER, P				SCULLY, C; MORTIMER, P			GNASHINGS OF HIV	LANCET			English	Editorial Material							INFECTED DENTIST; DENTAL PRACTICE; TRANSMISSION		PUBL HLTH LAB SERV, LONDON, ENGLAND	Public Health England	SCULLY, C (corresponding author), UCL EASTMAN DENT INST ORAL HEALTHCARE SCI, LONDON, ENGLAND.							ARNOW PM, 1993, PUBLIC HEALTH REP, V108, P273; BLANK S, 1994, LANCET, V344, P512, DOI 10.1016/S0140-6736(94)91900-3; CHANT K, 1993, LANCET, V342, P1548, DOI 10.1016/S0140-6736(05)80112-6; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; DEBRY RW, 1993, NATURE, V361, P691, DOI 10.1038/361691a0; DICKINSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1802, DOI 10.1001/jama.269.14.1802; GORE SM, 1994, J INFECTION, V28, P209, DOI 10.1016/S0163-4453(94)95740-1; HILLIS DM, 1994, NATURE, V369, P24, DOI 10.1038/369024a0; NACCACHE H, 1993, AIDS PATIENT CARE, V7, P134, DOI 10.1089/apc.1993.7.134; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; PORTER SR, 1993, BRIT DENT J, V175, P254, DOI 10.1038/sj.bdj.4808292; SCULLY C, 1993, BRIT DENT J, V175, P381, DOI 10.1038/sj.bdj.4808330; SCULLY C, 1993, BRIT MED J, V306, P1754, DOI 10.1136/bmj.306.6894.1754-a; SCULLY C, 1990, BRIT DENTAL J LONDON, P142; SCULLY C, 1994, HLTH TRENDS, V26, P15; YORK AK, 1993, J AM DENT ASSOC, V124, P74, DOI 10.14219/jada.archive.1993.0141	16	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					904	904		10.1016/S0140-6736(94)92265-9	http://dx.doi.org/10.1016/S0140-6736(94)92265-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934343				2022-12-01	WOS:A1994PJ28700006
J	STUDER, M; POPPERL, H; MARSHALL, H; KUROIWA, A; KRUMLAUF, R				STUDER, M; POPPERL, H; MARSHALL, H; KUROIWA, A; KRUMLAUF, R			ROLE OF A CONSERVED RETINOIC ACID RESPONSE ELEMENT IN RHOMBOMERE RESTRICTION OF HOXB-1	SCIENCE			English	Article							ZINC-FINGER GENE; SEGMENT-SPECIFIC EXPRESSION; HOMEOBOX-CONTAINING GENES; EMBRYONIC EXPRESSION; CHICK HINDBRAIN; MOUSE HINDBRAIN; VERTEBRATE HEAD; NERVOUS-SYSTEM; NEURAL CREST; HOX-1.6	After activation in mesoderm and neuroectoderm, expression of the Hoxb-1 gene is progressively restricted to rhombomere (r) 4 in the hindbrain. Analysis of the chick and mouse Hoxb-1 genes identified positive and negative regulatory regions that cooperate to mediate segment-restricted expression during rhombomere formation. An enhancer generates expression extending into r3 and r5, and a repressor limits this domain to r4. The repressor contains a conserved retinoic acid response element, point mutations in which allow expression to spread into adjacent rhombomeres. Retinoids and their nuclear receptors may therefore participate in sharpening segment-restricted expression of Hoxb-1 during rhombomere boundary formation.	NATL INST MED RES, DEV NEUROBIOL LAB, LONDON NW7 1AA, ENGLAND; NAGOYA UNIV, SCH SCI, DEPT MOLEC BIOL, NAGOYA 46401, JAPAN	MRC National Institute for Medical Research; Nagoya University			Krumlauf, Robb/AAH-5012-2019; Studer, Michele/P-4580-2016	Krumlauf, Robb/0000-0001-9102-7927; Studer, Michele/0000-0001-7105-2957; Kuroiwa, Atsushi/0000-0001-7710-4041				CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CONLON RA, 1992, DEVELOPMENT, V116, P357; DOLLE P, 1993, P NATL ACAD SCI USA, V90, P7666, DOI 10.1073/pnas.90.16.7666; FJOSE A, 1993, EMBO J, V12, P1403, DOI 10.1002/j.1460-2075.1993.tb05784.x; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FROHMAN MA, 1993, DEVELOPMENT, V117, P925; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GAUNT SJ, 1987, DEVELOPMENT, V101, P51; GEADA AMC, 1992, DEVELOPMENT, V116, P497; GUTHRIE S, 1991, DEVELOPMENT, V112, P221; GUTHRIE S, 1993, DEVELOPMENT, V118, P527; GUTHRIE S, 1992, NATURE, V356, P157, DOI 10.1038/356157a0; Hogan B., 1986, MANIPULATING MOUSE E; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; HUNT P, 1991, DEVELOPMENT, V112, P43; IP YT, 1992, J CELL SCI, P33; JACKLE H, 1992, J CELL SCI, P39; KESSEL M, 1993, NEURON, V10, P379, DOI 10.1016/0896-6273(93)90328-O; KIMMEL CB, 1988, DEVELOPMENT, V104, P197; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; MADEN M, 1991, DEVELOPMENT, V111, P35; MARK M, 1993, DEVELOPMENT, V119, P319; MARSHALL H, 1994, NATURE, V370, P567, DOI 10.1038/370567a0; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MENDELSOHN C, 1994, MECH DEVELOP, V45, P227, DOI 10.1016/0925-4773(94)90010-8; MORRISSKAY G, 1993, BIOESSAYS, V15, P9, DOI 10.1002/bies.950150103; MORRISSKAY GM, 1991, EMBO J, V10, P2985, DOI 10.1002/j.1460-2075.1991.tb07849.x; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; MURPHY P, 1991, DEVELOPMENT, V111, P61; POPPERL H, 1993, MOL CELL BIOL, V13, P257; RUBOCK MJ, 1990, P NATL ACAD SCI USA, V87, P4751, DOI 10.1073/pnas.87.12.4751; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; SHAM MH, 1992, EMBO J, V11, P1825, DOI 10.1002/j.1460-2075.1992.tb05234.x; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; SUNDIN O, 1992, DEVELOPMENT, V114, P841; SUNDIN OH, 1990, GENE DEV, V4, P1267, DOI 10.1101/gad.4.8.1267; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277	46	247	248	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 16	1994	265	5179					1728	1732		10.1126/science.7916164	http://dx.doi.org/10.1126/science.7916164			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG284	7916164				2022-12-01	WOS:A1994PG28400037
J	MALMBERG, P				MALMBERG, P			COKING TO DEATH	LANCET			English	Editorial Material											MALMBERG, P (corresponding author), NATL INST OCCUPAT HLTH,S-17184 SOLNA,SWEDEN.							ANDERSSON K, 1993, HYGIEA, V102, P120; BHOPAL RS, 1994, J EPIDEMIOL COMMUN H, V48, P237, DOI 10.1136/jech.48.3.237; NORLEN U, 1993, INDOOR CLIMATE SWE D, V10; STENBERG B, 1993, JUL P INDOOR AIR HEL, P399	4	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					632	632		10.1016/S0140-6736(94)92081-8	http://dx.doi.org/10.1016/S0140-6736(94)92081-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915346				2022-12-01	WOS:A1994PE38600006
J	GUENDELMAN, S				GUENDELMAN, S			MEXICAN WOMEN IN THE UNITED-STATES	LANCET			English	Editorial Material							INFANT-MORTALITY; BIRTH				GUENDELMAN, S (corresponding author), UNIV CALIF BERKELEY,SCH PUBL HLTH,BERKELEY,CA 94720, USA.							BALCAZAR H, 1994, AM J PUBLIC HEALTH, V84, P462, DOI 10.2105/AJPH.84.3.462; BECERRA JE, 1991, JAMA-J AM MED ASSOC, V265, P217, DOI 10.1001/jama.265.2.217; FRISBIE P, 1989, INT REV COMP PUBL PO, V1, P65; GUENDELMAN S, IN PRESS AM J PUBL H; HAHN RA, 1992, JAMA-J AM MED ASSOC, V267, P259, DOI 10.1001/jama.267.2.259; HEDDERSON J, 1982, SOC SCI J, V199, P68; MENDOZA F, 1991, JAMA-J AM MED ASSOC, V265, P277; SCRIBNER R, 1989, AM J PUBLIC HEALTH, V79, P1263, DOI 10.2105/AJPH.79.9.1263; VEGA WA, 1990, J MARRIAGE FAM, V52, P1015, DOI 10.2307/353316; 1992, 1990 CPH L 90 1990 C; 1994, ADV DATA VITAL HLTH, V241	11	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 6	1994	344	8919					352	352		10.1016/S0140-6736(94)91397-8	http://dx.doi.org/10.1016/S0140-6736(94)91397-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PA303	7914303				2022-12-01	WOS:A1994PA30300006
J	KUMAR, L				KUMAR, L			CAN MOLECULAR MONITORING IMPROVE OUTCOME IN LEUKEMIA	LANCET			English	Editorial Material							BONE-MARROW TRANSPLANTATION; POLYMERASE CHAIN-REACTION; ACUTE LYMPHOBLASTIC-LEUKEMIA; MINIMAL RESIDUAL DISEASE; B-CELL LYMPHOMA; RELAPSE				KUMAR, L (corresponding author), ALL INDIA INST MED SCI,INST ROTARY CANC HOSP,NEW DELHI,INDIA.							BASH RO, 1993, BLOOD, V81, P2110; BRENNER MK, 1993, LANCET, V341, P85, DOI 10.1016/0140-6736(93)92560-G; BRISCO MJ, 1994, LANCET, V343, P196, DOI 10.1016/S0140-6736(94)90988-1; CRIST WM, 1990, BLOOD, V76, P117; CROSS NCP, 1993, BLOOD, V82, P1929; DROBYSKI WR, 1993, BLOOD, V81, P551; GRIBBEN JG, 1993, BLOOD, V81, P3449; GRIBBEN JG, 1991, NEW ENGL J MED, V325, P1525, DOI 10.1056/NEJM199111283252201; LION T, 1993, LANCET, V341, P275, DOI 10.1016/0140-6736(93)92619-5; MILLER WH, 1993, BLOOD, V82, P1689; NIZET Y, 1993, BLOOD, V82, P1618; ROTH MS, 1992, BLOOD, V79, P276; WEISDORF DJ, 1993, TRANSPLANTATION, V55, P61, DOI 10.1097/00007890-199301000-00012	13	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 6	1994	344	8919					348	349		10.1016/S0140-6736(94)91393-5	http://dx.doi.org/10.1016/S0140-6736(94)91393-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA303	7914299				2022-12-01	WOS:A1994PA30300002
J	HUTCHINSON, CM; HOOK, EW; SHEPHERD, M; VERLEY, J; ROMPALO, AM				HUTCHINSON, CM; HOOK, EW; SHEPHERD, M; VERLEY, J; ROMPALO, AM			ALTERED CLINICAL PRESENTATION OF EARLY SYPHILIS IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article							TREPONEMA-PALLIDUM ANTIGENS; SECONDARY SYPHILIS; HIV-INFECTION; HOMOSEXUAL MEN; MANIFESTATIONS; ASSOCIATION; DIAGNOSIS; SARCOMA; RISK	Objectives: To compare clinical presentations of patients with early syphilis who did or did not have human immunodeficiency virus (HIV) infection. Design: Case-control study. Setting: The sexually transmitted diseases clinics of the Baltimore City Health Department. Patients: Patients with newly diagnosed primary, secondary, or early latent syphilis who had voluntary HIV testing from January 1990 to November 1991. Measurements: Data on sexual history, risk behaviors, and physical findings (before knowledge of HIV or syphilis serologic test results) were extracted from clinical records. Diagnoses of syphilis were confirmed by reactive syphilis serologic tests. Rapid plasma reagin titers reported to the disease registry of the Baltimore City Health Department were abstracted to determine therapeutic response. Patients positive for HIV who returned for follow-up had further counseling, staging, and CD4 lymphocyte testing. Results: Data were available on 309 of 527 patients with early syphilis: 108 patients with primary syphilis, 116 with secondary syphilis, and 85 with early latent syphilis. Seventy (23%) patients had concurrent HIV infection. Patients with HIV infection presented more often with secondary syphilis than did patients with syphilis who were HIV seronegative (53% [37 of 70] compared with 33% [79 of 239]; P = 0.01). The same was true for heterosexual men with HIV infection (46% [16 of 35]) compared with heterosexual men without infection (25% [35 of 142]; P < 0.03). Among those who denied intravenous drug use, 59% (22 of 37) of patients with HIV infection presented with secondary syphilis compared with 33% (65 of 198) of patients without infection (P < 0.01). Among patients with first episodes of syphilis, patients positive for HIV who had secondary syphilis were more likely to present with persistent chancres (43% [9 of 21] compared with 15% [11 of 72]; P = 0.01). The rate of decline in the rapid plasma reagin titers during a 12-month period after treatment did not differ between patients with and without HIV infection (P = 0.15). Conclusions.- The clinical presentation of syphilis in patients with HIV infection differs from that of patients without HIV infection in that patients with HIV infection present more often in the secondary stage and those with secondary syphilis are more likely to have chancres.	JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD USA; BALTIMORE CITY DEPT HLTH, BALTIMORE, MD USA; UNIV ALABAMA, BIRMINGHAM, AL USA	Johns Hopkins University; University of Alabama System; University of Alabama Birmingham					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027727] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI27727-03] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1982, EPIDEMIOLOGIC RES; BERRY CD, 1987, NEW ENGL J MED, V316, P1587, DOI 10.1056/NEJM198706183162507; BLOUNT JH, 1978, BIOL PARSITIC SPIROC, P157; DARROW WW, 1987, AM J PUBLIC HEALTH, V77, P479, DOI 10.2105/AJPH.77.4.479; FIUMARA NJ, 1980, JAMA-J AM MED ASSOC, V243, P2500, DOI 10.1001/jama.243.24.2500; GOUREVITCH MN, 1993, ANN INTERN MED, V118, P350, DOI 10.7326/0003-4819-118-5-199303010-00005; HAAS JS, 1990, J INFECT DIS, V162, P862, DOI 10.1093/infdis/162.4.862; HICKS CB, 1987, ANN INTERN MED, V107, P492, DOI 10.7326/0003-4819-107-4-492; HUTCHINSON CM, 1991, JAMA-J AM MED ASSOC, V266, P253, DOI 10.1001/jama.266.2.253; HUTCHINSON CM, 1991, ARCH INTERN MED, V151, P511, DOI 10.1001/archinte.151.3.511; JAFFE HW, 1975, ANN INTERN MED, V83, P846, DOI 10.7326/0003-4819-83-6-846; JAFFE HW, 1983, ANN INTERN MED, V99, P145, DOI 10.7326/0003-4819-99-2-145; JOHNS DR, 1987, NEW ENGL J MED, V316, P1569, DOI 10.1056/NEJM198706183162503; KREISS JK, 1989, J INFECT DIS, V160, P380, DOI 10.1093/infdis/160.3.380; LUKEHART SA, 1980, J IMMUNOL, V124, P454; LUKEHART SA, 1988, ANN INTERN MED, V109, P855, DOI 10.7326/0003-4819-109-11-855; MAGNUSON HJ, 1956, MEDICINE, V35, P33, DOI 10.1097/00005792-195602000-00002; MARRA CM, 1992, J INFECT DIS, V165, P1020, DOI 10.1093/infdis/165.6.1020; QUINN TC, 1988, NEW ENGL J MED, V318, P197, DOI 10.1056/NEJM198801283180401; QUINN TC, 1990, ARCH INTERN MED, V150, P1297, DOI 10.1001/archinte.150.6.1297; RADOLF JD, 1988, J AM ACAD DERMATOL, V18, P423, DOI 10.1016/S0190-9622(88)70062-6; ROMPALO AM, 1992, J INFECT DIS, V165, P1124, DOI 10.1093/infdis/165.6.1124; ROSENBERG ZF, 1992, SEXUALLY TRANSMITTED, P165; SCHROETER AL, 1972, J AMER MED ASSOC, V221, P471, DOI 10.1001/jama.221.5.471; STOKES JH, 1944, MODERN CLIN SYPHILOL; STOUMBOS VD, 1987, AM J OPHTHALMOL, V103, P103, DOI 10.1016/S0002-9394(14)74179-0; 1989, MMWR MORB MORTAL WKL, V38; 1988, MMWR-MORBID MORTAL W, V37, P755; 1988, MMWR-MORBID MORTAL W, V37, P35; 1988, MMWR-MORBID MORTAL W, V37, P486	30	111	118	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1994	121	2					94	99		10.7326/0003-4819-121-2-199407150-00003	http://dx.doi.org/10.7326/0003-4819-121-2-199407150-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW186	7912483				2022-12-01	WOS:A1994NW18600003
J	HARRISON, P; DEGEN, SJF; WILLIAMS, R; FARZANEH, F				HARRISON, P; DEGEN, SJF; WILLIAMS, R; FARZANEH, F			HEPATIC EXPRESSION OF HEPATOCYTE-GROWTH-FACTOR-LIKE MACROPHAGE-STIMULATING PROTEIN MESSENGER-RNA IN FULMINANT HEPATIC-FAILURE	LANCET			English	Note							GENE	We investigated whether impaired Kupffer cell phagocytosis in fulminant hepatic failure could be due to reduced synthesis of hepatocyte-growth-factor-like/macrophage-stimulating protein (HGFL/MSP), a serum protein synthesised predominantly in hepatocytes and required by tissue macrophages for phagocytosis. Hepatic expression of the 3.0 kb HGFL/MSP mRNA, assessed by northern hybridisation, was lower in nine patients with fulminant hepatic failure undergoing liver transplantation than in three liver grafts as controls (median absorbance units 97 [range 15-1200] versus 1114 [1100-1120], respectively; p < 0.05). Decreased hepatic HGFL/MSP production might cause impaired Kupffer cell phagocytosis in fulminant hepatic failure.	UNIV LONDON KINGS COLL,SCH MED & DENT,INST LIVER STUDIES,LONDON SE5 9PJ,ENGLAND; CHILDRENS HOSP RES FDN,DIV BASIC SCI RES,CINCINNATI,OH 45229	University of London; King's College London; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	HARRISON, P (corresponding author), UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT MOLEC MED,BESSEMER RD,LONDON SE5 9PJ,ENGLAND.		Farzaneh, Farzin/B-4902-2009; Harrison, Phillip M/D-5374-2009	Farzaneh, Farzin/0000-0002-9275-2415; opoku, anita/0000-0001-7243-8157				BEZERRA JA, 1993, HEPATOLOGY, V18, P394, DOI 10.1002/hep.1840180225; CANALESE J, 1982, GUT, V23, P265, DOI 10.1136/gut.23.4.265; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HUGHES RD, 1986, EUR J CLIN INVEST, V16, P352, DOI 10.1111/j.1365-2362.1986.tb01008.x; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; ROLANDO N, 1990, HEPATOLOGY, V11, P49, DOI 10.1002/hep.1840110110; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461	8	13	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					27	28		10.1016/S0140-6736(94)91050-2	http://dx.doi.org/10.1016/S0140-6736(94)91050-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912298				2022-12-01	WOS:A1994NU91700013
J	OTSUKI, Y; MISAKI, O; SUGIMOTO, O; ITO, Y; TSUJIMOTO, Y; AKAO, Y				OTSUKI, Y; MISAKI, O; SUGIMOTO, O; ITO, Y; TSUJIMOTO, Y; AKAO, Y			CYCLIC BCL-2 GENE-EXPRESSION IN HUMAN UTERINE ENDOMETRIUM DURING MENSTRUAL-CYCLE	LANCET			English	Note							TISSUES	To investigate an apoptotic role for bcl-2 in menses, we studied bcl-2 protein production throughout the cycle. Bcl-2 protein was observed in endometrial glandular, stromal and myometrial smooth-muscle cells. Glandular cells expressed bcl-2 at proliferative through early secretory phases but not at late secretory through menstrual phases. This cyclic expression of bcl-2 gene was similar to that of oestrogen and progesterone receptors. Thus bcl-2 expression in glandular cells may be regulated by ovarian hormones. The disappearance of bcl-2 expression in glandular cells at late secretory phase was consistent with the appearance of apoptotic cells in the same phase.	OSAKA MED COLL,DEPT OBSTET & GYNAECOL,TAKATSUKI,OSAKA,JAPAN; OSAKA UNIV,SCH MED,BIOMED RES CTR,OSAKA 553,JAPAN	Osaka Medical College; Osaka University	OTSUKI, Y (corresponding author), OSAKA MED COLL,DEPT ANAT & BIOL,2-7 DIAGAKU MACHI,TAKATSUKI,OSAKA 569,JAPAN.							ADACHI M, 1990, ONCOGENE, V5, P1653; AKAO Y, 1994, CANCER RES, V84, P2468; GARCIA I, 1992, SCIENCE, V258, P303; HOPWOOD D, 1976, J PATHOL, V119, P159; LEBRUN DP, 1993, AM J PATHOL, V142, P743; LU QL, 1993, J PATHOL, V169, P431, DOI 10.1002/path.1711690408; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; SATYASWAROOP PG, 1979, J CLIN ENDOCR METAB, V48, P639, DOI 10.1210/jcem-48-4-639; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331	9	177	184	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					28	29						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912299				2022-12-01	WOS:A1994NU91700014
J	PEDRINELLI, R; GIAMPIETRO, O; CARMASSI, F; MELILLO, E; DELLOMO, G; CATAPANO, G; MATTEUCCI, E; TALARICO, L; MORALE, M; DENEGRI, F; DIBELLO, V				PEDRINELLI, R; GIAMPIETRO, O; CARMASSI, F; MELILLO, E; DELLOMO, G; CATAPANO, G; MATTEUCCI, E; TALARICO, L; MORALE, M; DENEGRI, F; DIBELLO, V			MICROALBUMINURIA AND ENDOTHELIAL DYSFUNCTION IN ESSENTIAL-HYPERTENSION	LANCET			English	Article							LEFT-VENTRICULAR HYPERTROPHY; VONWILLEBRAND-FACTOR; CARDIOVASCULAR-DISEASE; RISK-FACTORS; ATHEROSCLEROSIS; LIPOPROTEIN; MECHANISMS; INHIBITION; FIBRINOGEN; PRESSURE	Microalbuminuria (urinary albumin excretion between 20 and 200 mu g/min) and endothelial dysfunction coexist in patients with essential hypertension. To evaluate whether the two phenomena are related and the determinants of that association, we recruited 10 untreated males with essential hypertension and microalbuminuria without diabetes to be compared with an equal number of matched patients with essential hypertension excreting albumin in normal amounts and 10 normal controls. The status of endothelial function was inferred from circulating von Willebrand Factor antigen (vWF), a glycoprotein secreted in greater amounts when the vascular endothelium is damaged. vWF concentrations were higher in hypertensive patients with microalbuminuria than in hypertensive patients without and controls. Individual vWF and urine albumin-excretion values were correlated (r = 0.55, p < 0.002). Blood pressure correlated with both urinary albumin excretion and vWF. Left ventricular mass index and minimal forearm vascular resistances were comparable in patients with hypertension and higher than in controls; total and low-density lipoprotein cholesterol, triglycerides, lipoprotein-a, Factor VII, and plasminogen activator inhibitor-1 did not differ. Fibrinogen was higher and creatinine clearance lower in microalbuminurics. Albuminuria in essential hypertension may reflect systemic dysfunction of the vascular endothelium, a structure intimately involved in permeability, haemostasis, fibrinolysis, and blood pressure control. This abnormality may have important physiopathological implications and expose these patients to increased cardiovascular risk.	UNIV PISA,MED CLIN 2,I-56100 PISA,ITALY; UNIV PISA,REPARTO MED INTERNA,I-56100 PISA,ITALY	University of Pisa; University of Pisa	PEDRINELLI, R (corresponding author), UNIV PISA,MED CLIN 1,USL 12,I-56100 PISA,ITALY.			Carmassi, Franco/0000-0003-2244-4430				BIGAZZI R, 1992, NEPHRON, V61, P94, DOI 10.1159/000186842; BLANN A D, 1991, Medical Science Research, V19, P535; BLANN AD, 1993, J HUM HYPERTENS, V7, P107; CARMASSI F, 1992, THROMB RES, V67, P643, DOI 10.1016/0049-3848(92)90068-L; CERASOLA G, 1992, REV LAT CARDIOL, V13, P3; Christensen C K, 1983, J Hypertens, V1, P45; CONLAN MG, 1993, THROMB HAEMOSTASIS, V70, P380; CORRADI L, 1993, J HYPERTENS, V11, pS190; DAHLOF B, 1992, AM J HYPERTENS, V5, P95, DOI 10.1093/ajh/5.2.95; GIAMPIETRO O, 1992, ACTA DIABETOL, V28, P239, DOI 10.1007/BF00779006; JANSSON JH, 1991, BRIT HEART J, V66, P351; JENSEN T, 1988, DIABETOLOGIA, V31, P142, DOI 10.1007/BF00276846; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; LINDEMAN RD, 1984, KIDNEY INT, V26, P861, DOI 10.1038/ki.1984.229; METTINGER KL, 1982, THROMB RES, V26, P183, DOI 10.1016/0049-3848(82)90139-6; MITROPOULOS KA, 1989, ATHEROSCLEROSIS, V76, P203, DOI 10.1016/0021-9150(89)90104-4; NICHOLS TC, 1990, ARTERIOSCLEROSIS, V10, P449, DOI 10.1161/01.ATV.10.3.449; NITENBERG A, 1993, AM J MED, V95, P71, DOI 10.1016/0002-9343(93)90234-G; PANZA JA, 1990, NEW ENGL J MED, V323, P22, DOI 10.1056/NEJM199007053230105; PARVING HH, 1973, CIRC RES, V32, P643, DOI 10.1161/01.RES.32.5.643; PEDRINELLI R, 1990, J HYPERTENS, V8, P467, DOI 10.1097/00004872-199005000-00012; PEDRINELLI R, 1993, ARTERIOSCLER THROMB, V13, P900, DOI 10.1161/01.ATV.13.6.900; PHILLIPS GB, 1993, J HYPERTENS, V11, P699, DOI 10.1097/00004872-199307000-00003; PICKERING TG, 1990, HYPERTENSION PATHOPH, P1397; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SALAZAR FJ, 1992, HYPERTENSION, V20, P113, DOI 10.1161/01.HYP.20.1.113; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SUFFREDINI AF, 1989, NEW ENGL J MED, V320, P1165, DOI 10.1056/NEJM198905043201802; VANE JR, 1990, NEW ENGL J MED, V323, P27; VIBERTI GC, 1990, ACTA DIABETOL LAT, V27, P267, DOI 10.1007/BF02581339; WILLIAMS RR, 1990, HYPERTENSION PATHOPH, V9, P127; YUDKIN JS, 1988, LANCET, V2, P531	32	353	369	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					14	18		10.1016/S0140-6736(94)91047-2	http://dx.doi.org/10.1016/S0140-6736(94)91047-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912295				2022-12-01	WOS:A1994NU91700010
J	KUSS, BJ; DEELEY, RG; COLE, SPC; WILLMAN, CL; KOPECKY, KJ; WOLMAN, SR; EYRE, HJ; LANE, SA; NANCARROW, JK; WHITMORE, SA; CALLEN, DF				KUSS, BJ; DEELEY, RG; COLE, SPC; WILLMAN, CL; KOPECKY, KJ; WOLMAN, SR; EYRE, HJ; LANE, SA; NANCARROW, JK; WHITMORE, SA; CALLEN, DF			DELETION OF GENE FOR MULTIDRUG-RESISTANCE IN ACUTE MYELOID-LEUKEMIA WITH INVERSION IN CHROMOSOME-16 - PROGNOSTIC IMPLICATIONS	LANCET			English	Article							ACUTE NONLYMPHOCYTIC LEUKEMIA; CANCER CELL-LINE; P-GLYCOPROTEIN; ACCUMULATION; ASSOCIATION; TRANSPORTER; MECHANISMS	Acute myeloid leukaemia (AML) associated with an inversion in chromosome 16 has a relatively favourable prognosis. The AML subclass most commonly associated with this chromosomal abnormality is acute myelomonocytic leukaemia with abnormal eosinophils. In some AML patients with inversion 16 the chromosomal lesion results in deletion of MRP, the gene for multidrug resistance associated protein. This gene is proximal to the primary breakpoint and loss of its function may play a key role in determining the favourable outcome in inversion 16 AML. We have demonstrated deletion of MRP by in situ hybridisation, by gene dosage studies and by studying loss of heterogeneity of a flanking microsatellite marker. Among 13 AML patients with inversion 16 MRP deletion was detected in 5 while 7 had no deletion. Deletion of MRP gene was associated with longer time from diagnosis until death or relapse from complete remission (p=0.007). These findings provide important insight into the biology of inversion 16 leukaemia and suggest that MRP deletion, as detected by molecular analysis, may,have a key role in determining outcome in patients with inversion 16 AML.	QUEENS UNIV,CANC RES LABS,KINGSTON,ON,CANADA; CTR MOLEC & CELLULAR DIAGNOST,CTR CANC,ALBUQUERQUE,NM; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA; MICHIGAN CANC FDN,DETROIT,MI; ONCOR,GAITHERSBURG,MD; SW ONCOL GRP,LEUKAEMIA BIOL PROGRAM,SAN ANTONIO,TX	Queens University - Canada; Fred Hutchinson Cancer Center; Southwest Oncology Group	KUSS, BJ (corresponding author), WOMENS & CHILDRENS HOSP,CTR MED GENET,DEPT CYTOGENET & MOLEC GENET,KING WILLIAM RD,ADELAIDE,SA 5006,AUSTRALIA.		Deeley, Roger/J-4828-2012; Cole, Susan P.C./I-6389-2017; Callen, David F/G-1975-2012	Cole, Susan P.C./0000-0001-6571-6884; Callen, David/0000-0002-6189-9991	NATIONAL CANCER INSTITUTE [U10CA032102] Funding Source: NIH RePORTER; NCI NIH HHS [CA32102] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTHUR DC, 1983, BLOOD, V61, P994; BAE SC, 1993, ONCOGENE, V8, P809; BARRAND MA, 1993, BR J CANCER S20, V67, P77; CALLEN DF, 1992, GENOMICS, V13, P1178, DOI 10.1016/0888-7543(92)90035-Q; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; CAMPBELL LJ, 1991, GENE CHROMOSOME CANC, V3, P55, DOI 10.1002/gcc.2870030110; CAMPOS L, 1992, EUR J HAEMATOL, V48, P254; COLE SPC, 1989, BRIT J CANCER, V59, P42, DOI 10.1038/bjc.1989.9; COLE SPC, 1991, CANCER RES, V51, P3345; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Cole Susan P. C., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P579; DACHARY D, 1986, CANCER GENET CYTOGEN, V20, P241, DOI 10.1016/0165-4608(86)90079-8; DAUWERSE JG, 1993, HUM MOL GENET, V2, P1527, DOI 10.1093/hmg/2.10.1527; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRANT CE, IN PRESS CANCER RES; HART SM, 1993, BLOOD S, pA258; KRISHNAMACHARY N, 1993, CANCER RES, V53, P3658; LARSON RA, 1986, BLOOD, V68, P1242; LEBEAU MM, 1983, NEW ENGL J MED, V309, P630, DOI 10.1056/NEJM198309153091103; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MARQUARDT D, 1992, CANCER RES, V52, P3157; MARQUARDT D, 1990, CANCER RES, V50, P1426; OHYASHIKI K, 1988, LEUKEMIA, V2, P398; RAIMONDI SC, 1989, CANCER GENET CYTOGEN, V40, P13, DOI 10.1016/0165-4608(89)90141-6; ROSS DD, 1993, BLOOD, V82, P1288; SLOVAK ML, 1993, CANCER RES, V53, P3221; ZHAO S, 1993, BLOOD S, pA258	27	108	113	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 18	1994	343	8912					1531	1534		10.1016/S0140-6736(94)92938-6	http://dx.doi.org/10.1016/S0140-6736(94)92938-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR329	7911871				2022-12-01	WOS:A1994NR32900008
J	EBENS, AJ; GARREN, H; CHEYETTE, BNR; ZIPURSKY, SL				EBENS, AJ; GARREN, H; CHEYETTE, BNR; ZIPURSKY, SL			THE DROSOPHILA ANACHRONISM LOCUS - A GLYCOPROTEIN SECRETED BY GLIA INHIBITS NEUROBLAST PROLIFERATION	CELL			English	Article							POSTEMBRYONIC NEUROBLASTS; DEVELOPMENTAL SWITCH; 44-45 REGION; MELANOGASTER; GENE; NEUROGENESIS; MUTAGENESIS; PROTEIN; PATTERN; BRIDE	The Drosophila anachronism (ana) locus controls the proliferation of neuroblasts, neuronal stem cells that give rise to the central nervous system. In ana mutants, quiescent postembryonic central brain and optic lobe neuroblasts enter S phase precociously. ana encodes a novel secreted protein of 474 amino acids that is expressed not in the affected neuroblasts, but rather in a subclass of neighboring glial cells. These studies argue for an important role for glia in negatively regulating proliferation of neuronal precursor cells, thereby controlling the timing of postembryonic neurogenesis.	UNIV CALIF LOS ANGELES, SCH MED, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	EBENS, AJ (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT COORDINATED SCI, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA.		Cheyette, Benjamin/K-5535-2014	Cheyette, Benjamin/0000-0001-9934-7941; Zipursky, Stephen/0000-0001-5630-7181	NIGMS NIH HHS [GM-07104] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBROS V, 1989, CELL, V57, P49, DOI 10.1016/0092-8674(89)90171-2; ASHBURNER M, 1989, DROSOPHILA LABORATOR; Bauer V, 1904, ZOOL JB ABT ANAT ONT, V20, P123; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAO WQ, 1991, NEURON, V6, P705, DOI 10.1016/0896-6273(91)90168-Y; GREEN P, 1993, IN PRESS CELL TISSUE; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HARTENSTEIN V, 1987, ROUX ARCH DEV BIOL, V196, P473, DOI 10.1007/BF00399871; HARTENSTEIN V, 1984, ROUX ARCH DEV BIOL, V193, P308, DOI 10.1007/BF00848159; HEISENBERG M, 1979, Z NATURFORSCH C, V34, P143; HOFBAUER A, 1990, ROUX ARCH DEV BIOL, V198, P264, DOI 10.1007/BF00377393; ITO K, 1992, DEV BIOL, V149, P134, DOI 10.1016/0012-1606(92)90270-Q; KONEV AY, 1991, GENETIKA+, V27, P77; KONEV AY, 1991, GENETIKA+, V27, P667; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; Maniatis T., 1982, MOL CLONING; MEINERTZHAGEN IA, 1973, DEV NEUROBIOLOGY ART, P51; MOSER MH, 1991, TRENDS PHARMACOL SCI, V12, P304, DOI 10.1016/0165-6147(91)90582-D; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pardue ML, 1986, DROSOPHILA PRACTICAL, P111; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; PROKOP A, 1991, DEVELOPMENT, V111, P79; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; RUVKUN G, 1989, NATURE, V338, P313, DOI 10.1038/338313a0; SAIKI R. K., 1990, PCR PROTOCOLS GUIDE, P13; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TOLBERT LP, 1989, TRENDS NEUROSCI, V12, P70, DOI 10.1016/0166-2236(89)90139-2; TRUMAN JW, 1988, DEV BIOL, V125, P145, DOI 10.1016/0012-1606(88)90067-X; VERNADAKIS A, 1988, INT REV NEUROBIOL, V30, P149	38	173	174	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 16	1993	74	1					15	27		10.1016/0092-8674(93)90291-W	http://dx.doi.org/10.1016/0092-8674(93)90291-W			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	7916657				2022-12-01	WOS:A1993LN62500004
J	BURMEISTER, WP; HUBER, AH; BJORKMAN, PJ				BURMEISTER, WP; HUBER, AH; BJORKMAN, PJ			CRYSTAL-STRUCTURE OF THE COMPLEX OF RAT NEONATAL FC RECEPTOR WITH FC	NATURE			English	Article							3-DIMENSIONAL STRUCTURE; IMMUNOGLOBULIN-G; NEWBORN RAT; INTESTINE; BINDING; CRYSTALLIZATION; EXPRESSION; REFINEMENT; TRANSPORT; FRAGMENT	THE neonatal Fc receptor (FcRn) transports maternal immunoglobulin G (IgG) to the bloodstream of the newborn. FcRn is structurally similar to class I major histocompatibility complex (MHC) molecules(1,2), despite differences in the ligands they bind (the Fc portion of IgG and antigenic peptides, respectively). A low-resolution crystal structure of the complex between FcRn and Fc localizes the binding site for Fc to the side of FcRn, distinct from the tops of the alpha 1 and alpha 2 domains which serve as the peptide and T-cell receptor binding sites in class I molecules. FcRn binds to Fc at the interface between the Fc C(H)2 and C(H)3 domains, which contains several histidine residues that could account for the sharply pH-dependent FcRn/IgG interaction(3). A dimer of FcRn heterodimers observed in the co-crystals and in the crystals of FcRn alone(2) could be involved in binding Fc, correlating with the 2:1 binding stoichiometry between FcRn and IgG (ref. 4) and suggesting an unusual orientation of FcRn on the membrane.	CALTECH,HOWARD HUGHES MED INST,PASADENA,CA 91125; CALTECH,DIV BIOL 15629,PASADENA,CA 91125	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology				Burmeister, Wim/0000-0003-0876-6118				AHOUSE JJ, 1993, J IMMUNOL, V151, P6076; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; GASTINEL LN, 1992, P NATL ACAD SCI USA, V89, P638, DOI 10.1073/pnas.89.2.638; GUDDAT LW, 1993, P NATL ACAD SCI USA, V90, P4271, DOI 10.1073/pnas.90.9.4271; HARRIS LJ, 1992, NATURE, V360, P369, DOI 10.1038/360369a0; HOBBS SM, 1987, J BIOL CHEM, V262, P8041; HUBER AH, 1993, J MOL BIOL, V230, P1077, DOI 10.1006/jmbi.1993.1220; HUBER AH, 1994, THESIS CALTECH; JAKOI ER, 1985, J IMMUNOL, V135, P3360; JONES TA, 1993, CRYSTALLOGRAPHIC COM; Kabat EA, 1991, SEQUENCES PROTEINS I, V5th; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE AGW, 1987, ACTA CRYSTALLOGR A, V43, P134, DOI 10.1107/S0108767387099720; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; RAGHAVAN M, 1994, IMMUNITY, V1, P303, DOI 10.1016/1074-7613(94)90082-5; RODEWALD R, 1976, J CELL BIOL, V71, P666, DOI 10.1083/jcb.71.2.666; RODEWALD R, 1973, J CELL BIOL, V58, P189, DOI 10.1083/jcb.58.1.189; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SIMISTER NE, 1989, COLD SPRING HARB SYM, V54, P571, DOI 10.1101/SQB.1989.054.01.068; SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0; STORY CM, 1994, J EXP MED, V180, P2377, DOI 10.1084/jem.180.6.2377; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; WALLACE KH, 1980, BIOCHEM J, V188, P9, DOI 10.1042/bj1880009; ZHENG Y, 1991, BIOCHEMISTRY-US, V30, P9125, DOI 10.1021/bi00102a002; 1979, SERC UK COLLABORATIV	28	384	546	3	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					379	383		10.1038/372379a0	http://dx.doi.org/10.1038/372379a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PU287	7969498				2022-12-01	WOS:A1994PU28700060
J	URSIN, G; PETERS, RK; HENDERSON, BE; DABLAING, G; MONROE, KR; PIKE, MC				URSIN, G; PETERS, RK; HENDERSON, BE; DABLAING, G; MONROE, KR; PIKE, MC			ORAL-CONTRACEPTIVE USE AND ADENOCARCINOMA OF CERVIX	LANCET			English	Article							UTERINE CERVIX; YOUNG-WOMEN; CANCER; RISK; ESTROGEN	The incidence of adenocarcinoma of the cervix in the USA more than doubled between the early 1970s and the mid 1980s among women under 35 years of age. It was suggested that this increase was due to the introduction of oral contraceptives in the early 1960s. Adenocarcinoma of the cervix diagnosed in women born after 1935 was identified between 1977 and 1991, from the Los Angeles County Cancer Surveillance Program, Data from personal interviews of 195 cases and 386 controls (matched on age, race, and neighbourhood) were analysed. Information on medical, sexual, contraceptive, reproductive history, previous cervical smears, sexually transmitted diseases was collected. Compared with never use, eve, use of oral contraceptives was associated with twice as great a risk of adenocarcinoma of the cervix (adjusted odds ratio 2.1, 95% CI 1.1-3.8). The highest risk was observed for oral contraceptive use for more than 12 years (4.4, 1.8-10.8). No additional increased risk was found for early age at start of oral contraceptive use, use before age 20 or before first pregnancy, time since first use, time since last use, or particular formulations, once total duration of use had been accounted for.	UNIV SO CALIF,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90033; SALK INST BIOL STUDIES,LA JOLLA,CA 92037	University of Southern California; Salk Institute	URSIN, G (corresponding author), UNIV SO CALIF,SCH MED,DEPT PREVENT MED,1420 SAN PABLO ST,LOS ANGELES,CA 90033, USA.		Ursin, Giske/U-6637-2017	Ursin, Giske/0000-0002-0835-9507	NATIONAL CANCER INSTITUTE [R01CA044401] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44401-05, P01 CA1754] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1962, NOVAKS GYNECOLOGIC O; BRESLOW N. E., 1980, STATISTICAL METHODS; BRINTON LA, 1986, INT J CANCER, V38, P339, DOI 10.1002/ijc.2910380307; BRINTON LA, 1990, INT J EPIDEMIOL, V19, P4, DOI 10.1093/ije/19.1.4; CANDY AA, 1968, JAMA-J AM MED ASSOC, V203, P85; CANO A, 1990, FERTIL STERIL, V54, P1058; CHILVERS C, 1987, BRIT MED J, V295, P1446, DOI 10.1136/bmj.295.6611.1446; DALLENBACHHELLWEG G, 1984, PATHOL RES PRACT, V179, P38, DOI 10.1016/S0344-0338(84)80059-X; EIDE TJ, 1987, J NATL CANCER I, V79, P199; FORD LC, 1983, GYNECOL ONCOL, V15, P27, DOI 10.1016/0090-8258(83)90113-0; GALL SA, 1969, J AMER MED ASSOC, V207, P2243, DOI 10.1001/jama.207.12.2243; GOLDACRE MJ, 1978, BRIT MED J, V1, P748, DOI 10.1136/bmj.1.6115.748; HARRISON HR, 1985, AM J OBSTET GYNECOL, V153, P244, DOI 10.1016/S0002-9378(85)80105-8; HENDERSON BE, 1982, CANCER RES, V42, P3232; HONORE LH, 1989, GYNECOL OBSTET INVES, V32, P98; HOROWITZ IR, 1988, GYNECOL ONCOL, V31, P25, DOI 10.1016/0090-8258(88)90265-X; JONES MW, 1989, OBSTET GYNECOL, V73, P984; KJAER SK, 1993, EPIDEMIOL REV, V15, P486, DOI 10.1093/oxfordjournals.epirev.a036131; KYRIAKOS M, 1968, CANCER, V22, P99, DOI 10.1002/1097-0142(196807)22:1<99::AID-CNCR2820220113>3.0.CO;2-4; LOUV WC, 1989, AM J OBSTET GYNECOL, V160, P396, DOI 10.1016/0002-9378(89)90456-0; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; PARAZZINI F, 1988, BRIT J CANCER, V57, P201, DOI 10.1038/bjc.1988.43; PERSSON E, 1987, EUR J OBSTET GYN R B, V26, P85, DOI 10.1016/0028-2243(87)90011-6; PETERS RK, 1986, JNCI-J NATL CANCER I, V76, P423; SCHWARTZ SM, 1986, AM J EPIDEMIOL, V124, P1045, DOI 10.1093/oxfordjournals.aje.a114474; SCOTT JR, 1990, DANFORTHS OBSTETRICS; SILCOCKS PBS, 1987, BRIT J CANCER, V55, P321, DOI 10.1038/bjc.1987.63; TAYLOR HB, 1967, J AMER MED ASSOC, V202, P637, DOI 10.1001/jama.202.7.637; URSIN G, 1994, ADV CONTRA DELI SYST, V10, P370	29	88	93	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 19	1994	344	8934					1390	1394		10.1016/S0140-6736(94)90567-3	http://dx.doi.org/10.1016/S0140-6736(94)90567-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR786	7968074				2022-12-01	WOS:A1994PR78600008
J	MARCANTONIO, ER; JUAREZ, G; GOLDMAN, L; MANGIONE, CM; LUDWIG, LE; LIND, L; KATZ, N; COOK, EF; ORAV, EJ; LEE, TH				MARCANTONIO, ER; JUAREZ, G; GOLDMAN, L; MANGIONE, CM; LUDWIG, LE; LIND, L; KATZ, N; COOK, EF; ORAV, EJ; LEE, TH			THE RELATIONSHIP OF POSTOPERATIVE DELIRIUM WITH PSYCHOACTIVE MEDICATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SURGICAL PATIENTS; ELDERLY PATIENT; ACTIVITY SCALE; RISK-FACTORS; ASSOCIATION; MEPERIDINE; PROGNOSIS; SURGERY	Objective.-To examine the role of medications with known psychoactive properties in the development of postoperative delirium. Design.-Nested case-control study within a prospective cohort study. Setting.-General surgery, orthopedic surgery, and gynecology services at Brigham and Women's Hospital, Boston, Mass. Patients.-Cases (n=91) were patients enrolled in a prospective cohort study who developed delirium during postoperative days 2 through 5. One or two controls (n=154) were matched to each case by the calculated preoperative risk for delirium using a predictive model developed and validated in the prospective cohort study. Main Outcome Measures.-Medication exposures were ascertained from the medical record by a reviewer blinded to the study hypothesis. Exposures to narcotics, benzodiazepines, and anticholinergics were recorded for the 24-hour period before delirium developed in the 91 cases and for the same 24-hour postoperative period for the 154 matched controls. Results.-Delirium was significantly associated with postoperative exposure to meperidine (odds ratio [OR], 2.7; 95% confidence interval [Cl], 1.3 to 5.5) and to benzodiazepines (OR, 3.0; 95% Cl, 1.3 to 6.8). Meperidine had similar associations with delirium whether administered via epidural or patient-controlled routes, although only the epidural route reached significance (OR, 2.4; 95% Cl, 1.3 to 4.4; OR, 2.1; 95% Cl, 0.4 to 10.7, respectively). For benzodiazepines, long-acting agents had a trend toward stronger association with delirium than did short-acting agents (OR, 5.4; 95% Cl, 1.0 to 29.2; vs 2.6; 1.1 to 6.5), and high-dose exposures had a trend toward slightly stronger association than low-dose exposures (OR, 3.3; 95% Cl, 1.0 to 11.0; vs 2.6; 0.8 to 9.1). Neither narcotics (OR, 1.4; 95% Cl, 0.5 to 4.3) nor anticholinergic drugs (OR, 1.5; 95% Cl, 0.6 to 3.4) were significantly associated with delirium as a class, although statistical power was limited because of the high use of narcotics and the low use of anticholinergics in the study population. Conclusions.-Clinicians caring for patients at risk for delirium should carefully evaluate the need for meperidine and benzodiazepines in the postoperative period and consider alternative therapies whenever possible.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CLIN EPIDEMIOL SECT,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV GEN MED,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV GERONTOL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV CARDIOL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT ANESTHESIA,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CLIN INITIAT DEV PROGRAM,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; CEDARS SINAI MED CTR,DEPT ANESTHESIA,LOS ANGELES,CA 90048	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Cedars Sinai Medical Center			Marcantonio, Edward R/U-3929-2017	Marcantonio, Edward R/0000-0002-2911-4250	AHRQ HHS [1RO1-HS06573] Funding Source: Medline; BHP HRSA HHS [5T32PE110011-04] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); BHP HRSA HHS		BRIZER DA, 1982, AM J PSYCHIAT, V139, P1343; EISENDRATH SJ, 1987, AM J PSYCHIAT, V144, P1062; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRANCIS J, 1992, J AM GERIATR SOC, V40, P829, DOI 10.1111/j.1532-5415.1992.tb01859.x; FRANCIS J, 1992, J AM GERIATR SOC, V40, P601, DOI 10.1111/j.1532-5415.1992.tb02111.x; FRANCIS J, 1990, JAMA-J AM MED ASSOC, V263, P1097, DOI 10.1001/jama.263.8.1097; FRANCIS J, 1990, J GEN INTERN MED, V5, P65, DOI 10.1007/BF02602312; FRANCIS J, 1992, J AM GERIATR SOC, V40, P848, DOI 10.1111/j.1532-5415.1992.tb01861.x; FRANCIS J, 1994, PRINCIPLES GERIATRIC; GILMAN AG, 1980, GOODMAN GILMANS PHAR; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; GOLINGER RC, 1987, AM J PSYCHIAT, V144, P1218; GUSTAFSON Y, 1988, J AM GERIATR SOC, V36, P325; Hegyvary ST, 1979, USERS MANUAL RUSH ME; HODSMAN NBA, 1987, ANAESTHESIA, V42, P1005, DOI 10.1111/j.1365-2044.1987.tb05377.x; INOUYE SK, 1993, ANN INTERN MED, V119, P474, DOI 10.7326/0003-4819-119-6-199309150-00005; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; KAIKO RF, 1983, ANN NEUROL, V13, P180, DOI 10.1002/ana.410130213; LEE TH, 1988, AM HEART J, V115, P203, DOI 10.1016/0002-8703(88)90545-5; LIPOWSKI ZJ, 1989, NEW ENGL J MED, V320, P578; Lopez Oscar L, 2010, Neuroepidemiology, V34, P63, DOI 10.1159/000264678; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V271, P134, DOI 10.1001/jama.271.2.134; MIETTINEN OS, 1976, AM J EPIDEMIOL, V104, P609, DOI 10.1093/oxfordjournals.aje.a112339; MILLAR HR, 1981, BRIT J PSYCHIAT, V138, P17, DOI 10.1192/bjp.138.1.17; MORSE RM, 1969, AM J PSYCHIAT, V126, P388, DOI 10.1176/ajp.126.3.388; MURRAY AM, 1993, J GERONTOL, V48, pM181, DOI 10.1093/geronj/48.5.M181; ROGERS MP, 1989, INT J PSYCHIAT MED, V19, P109; SCHOR JD, 1992, JAMA-J AM MED ASSOC, V267, P827, DOI 10.1001/jama.267.6.827; SEYMOUR DG, 1983, GERONTOLOGY, V29, P262, DOI 10.1159/000213125; STAMBAUGH JE, 1976, J CLIN PHARMACOL, V16, P245, DOI 10.1002/j.1552-4604.1976.tb02401.x; THOMAS RI, 1988, ARCH GEN PSYCHIAT, V45, P937; TUNE LE, 1981, LANCET, V2, P651; WILLIAMSRUSSO P, 1992, J AM GERIATR SOC, V40, P759, DOI 10.1111/j.1532-5415.1992.tb01846.x	33	359	373	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	1994	272	19					1518	1522		10.1001/jama.272.19.1518	http://dx.doi.org/10.1001/jama.272.19.1518			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PQ900	7966844				2022-12-01	WOS:A1994PQ90000031
J	NIGHTINGALE, SL				NIGHTINGALE, SL			LEFT-VENTRICULAR ASSIST DEVICE APPROVED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	1994	272	19					1488	1488						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ900	7966836				2022-12-01	WOS:A1994PQ90000023
J	BEHRINGER, RR; FINEGOLD, MJ; CATE, RL				BEHRINGER, RR; FINEGOLD, MJ; CATE, RL			MULLERIAN-INHIBITING SUBSTANCE FUNCTION DURING MAMMALIAN SEXUAL DEVELOPMENT	CELL			English	Article							DUCT SYNDROME; BIOLOGICAL-ACTIVITY; EXPRESSION CLONING; HORMONE GENE; RAT OVARY; MOUSE; MICE; RECEPTOR; FETAL; CELLS	To investigate the role of Mullerian-inhibiting substance (MIS) in mammalian sexual development, we generated MIS-deficient mice. Although MIS-deficient males had testes that were fully descended and produced functional sperm, they also developed female reproductive organs, which interfered with sperm transfer into females, rendering most of these males infertile. Their testes had Leydig cell hyperplasia and, in one instance, neoplasia. The actions of the two primary hormones of male sexual differentation were genetically eliminated using the testicular feminization (Tfm) mutation in combination with the MIS mutant allele. XY Tfm/MIS double mutants developed as females, with a uterus, coiled oviducts, and no male reproductive organs except undescended dysfunctional testes. These results suggest that eliminating the presumptive female reproductive tract in male fetuses facilitates fertility and that in testes MIS is a negative regulator of Leydig cell proliferation. Eliminating the presumptive male reproductive tract is necessary for proper oviductal morphogenesis during female mouse development.	BAYLOR COLL MED, DEPT PATHOL, HOUSTON, TX 77030 USA; BIOGEN INC, CAMBRIDGE, MA 02142 USA	Baylor College of Medicine; Biogen	BEHRINGER, RR (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MOLEC GENET, HOUSTON, TX 77030 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD030284] Funding Source: NIH RePORTER; NICHD NIH HHS [HD30284] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAARENDS WM, 1994, DEVELOPMENT, V120, P189; BEHRINGER RR, 1990, NATURE, V345, P167, DOI 10.1038/345167a0; BEZARD J, 1987, J REPROD FERTIL, V80, P509, DOI 10.1530/jrf.0.0800509; BISHOP CE, 1987, NUCLEIC ACIDS RES, V15, P2959, DOI 10.1093/nar/15.7.2959; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BUDZIK GP, 1985, DEV MECHANISMS NORMA, P207; CARREEUSEBE D, 1992, HUM GENET, V90, P389; Cate R. L., 1993, Genes in mammalian reproduction., P185; Cate R.L, 1990, PEPTIDE GROWTH FACTO, P179; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; CATLIN EA, 1988, AM J OBSTET GYNECOL, V159, P1299, DOI 10.1016/0002-9378(88)90467-X; CHAREST NJ, 1991, MOL ENDOCRINOL, V5, P573, DOI 10.1210/mend-5-4-573; DICLEMENTE N, 1994, ENDOCRINE, V2, P553; DICLEMENTE N, 1992, DEVELOPMENT, V114, P721; DICLEMENTE N, 1994, MOL ENDOCRINOL, V8, P1006, DOI 10.1210/me.8.8.1006; DONAHOE PK, 1977, J PEDIATR SURG, V12, P323, DOI 10.1016/0022-3468(77)90008-2; GREEN MC, 1990, GENETIC VARIANTS STR; GUERRIER D, 1989, J CLIN ENDOCR METAB, V68, P46, DOI 10.1210/jcem-68-1-46; HAQQ C, 1992, GENOMICS, V12, P665, DOI 10.1016/0888-7543(92)90291-Y; HE WW, 1991, NUCLEIC ACIDS RES, V19, P2373, DOI 10.1093/nar/19.9.2373; HUTSON JM, 1986, ENDOCR REV, V7, P270, DOI 10.1210/edrv-7-3-270; IMBEAUD S, 1994, HUM MOL GENET, V3, P125, DOI 10.1093/hmg/3.1.125; JOSSO N, 1986, PHYSIOL REV, V66, P1038, DOI 10.1152/physrev.1986.66.4.1038; JOSSO N, 1993, RECENT PROG HORM RES, V48, P1; JOST A, 1972, J REPROD FERTIL, V29, P349, DOI 10.1530/jrf.0.0290349; JOST A, 1953, RECENT PROG HORM RES, V8, P379; Jost A, 1947, ARCH ANAT MICR MORPH, P271; KIM JH, 1992, J CLIN ENDOCR METAB, V75, P911, DOI 10.1210/jc.75.3.911; KNEBELMANN B, 1991, P NATL ACAD SCI USA, V88, P3767, DOI 10.1073/pnas.88.9.3767; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MEYERSWALLEN VN, 1989, BIOL REPROD, V41, P881, DOI 10.1095/biolreprod41.5.881; MUNSTERBERG A, 1991, DEVELOPMENT, V113, P613; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PEPINSKY RB, 1988, J BIOL CHEM, V263, P18961; PICARD JY, 1984, MOL CELL ENDOCRINOL, V34, P23, DOI 10.1016/0303-7207(84)90155-2; PICARD JY, 1986, P NATL ACAD SCI USA, V83, P5464, DOI 10.1073/pnas.83.15.5464; PICON R, 1969, ARCH ANAT MICROSC MO, V58, P1; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TAKAHASHI M, 1986, BIOL REPROD, V35, P447, DOI 10.1095/biolreprod35.2.447; TRAN D, 1981, BIOL REPROD, V24, P923, DOI 10.1095/biolreprod24.4.923; UENO S, 1989, ENDOCRINOLOGY, V125, P1060, DOI 10.1210/endo-125-2-1060; UENO S, 1989, ENDOCRINOLOGY, V124, P1000, DOI 10.1210/endo-124-2-1000; VIGIER B, 1987, DEVELOPMENT, V100, P43; WILSON CA, 1993, MOL ENDOCRINOL, V7, P247, DOI 10.1210/me.7.2.247	51	512	532	0	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 4	1994	79	3					415	425		10.1016/0092-8674(94)90251-8	http://dx.doi.org/10.1016/0092-8674(94)90251-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7954809				2022-12-01	WOS:A1994PQ48800005
J	TERADA, K; KATAMINE, S; EGUCHI, K; MORIUCHI, R; KITA, M; SHIMADA, H; YAMASHITA, I; IWATA, K; TSUJI, Y; NAGATAKI, S; MIYAMOTO, T				TERADA, K; KATAMINE, S; EGUCHI, K; MORIUCHI, R; KITA, M; SHIMADA, H; YAMASHITA, I; IWATA, K; TSUJI, Y; NAGATAKI, S; MIYAMOTO, T			PREVALENCE OF SERUM AND SALIVARY ANTIBODIES TO HTLV-1 IN SJOGRENS-SYNDROME	LANCET			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; CLINICAL ENTITY; TRANSMISSION; MYELOPATHY; PROLIFERATION; IMPROVEMENT; ANTIGEN; PROTEIN; GENE	There is accumulating evidence that human T-lymphotropic virus-1 (HTLV-1) infection contributes to the development of various inflammatory disorders. To elucidate the relation between the infection and Sjogren's syndrome, seroepidemiological and virological studies were conducted on patients with this syndrome in Nagasaki Prefecture, Japan, an area heavily endemic for HTLV-1. The HTLV-1 seroprevalence rate among the patients with Sjogren's syndrome (17/74, 23%) was significantly higher than that among blood donors (916/27 284, 3%), whereas the difference between patients with systemic lupus erythematosus and blood donors was insignificant. Moreover, among Sjogren's syndrome patients the seroprevalence was high irrespective of age, unlike that among blood donors, which rose with age. Titres of serum antibodies in the HTLV-1 seropositive patients with Sjojgren's syndrome were similar to those among patients with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and significantly higher than those among healthy carriers. IgM class antibodies were commonly detected in the serum of patients with Sjogren's syndrome. However, unlike that in HAM/TSP patients, the viral load in peripheral-blood mononuclear cells was not necessarily high in the seropositive Sjogren syndrome group. Salivary IgA antibodies to HTLV-1 were common among seropositive patients with Sjojgren's syndrome (5/7), which might be due to increased viral activity in the salivary glands. These antibodies were barely detectable in HAM/TSP patients (prevalence 1/10) or in healthy carriers (0/11). The findings strongly suggest that HTLV-1 is involved in the pathogenesis of the disease in a subset of patients with Sjogren's syndrome in endemic areas.	NAGASAKI UNIV,SCH MED,DEPT BACTERIOL,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT INTERNAL MED 1,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT PREVENT MED & HLTH PROMOT,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT PAEDIAT,NAGASAKI 852,JAPAN	Nagasaki University; Nagasaki University; Nagasaki University; Nagasaki University				nagataki, shigenobu/0000-0002-9974-3554				BIEBERICH CJ, 1993, VIROLOGY, V196, P309, DOI 10.1006/viro.1993.1481; EGUCHI K, 1992, ANN RHEUM DIS, V51, P769, DOI 10.1136/ard.51.6.769; FUJINO R, 1991, JPN J CANCER RES, V82, P367, DOI 10.1111/j.1349-7006.1991.tb01856.x; FURUKAWA Y, 1992, BLOOD, V80, P1012; GESSAIN A, 1985, LANCET, V2, P407; GREEN JE, 1989, NATURE, V341, P72, DOI 10.1038/341072a0; HINO S, 1985, JPN J CANCER RES, V76, P474; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; KATAMINE S, 1994, LANCET, V343, P1326, DOI 10.1016/S0140-6736(94)92469-4; KAWASE K, 1992, JPN J CANCER RES, V83, P968, DOI 10.1111/j.1349-7006.1992.tb02009.x; KUGA T, 1988, JPN J CANCER RES, V79, P1168, DOI 10.1111/j.1349-7006.1988.tb01541.x; MARIETTE X, 1993, ARTHRITIS RHEUM-US, V36, P1423, DOI 10.1002/art.1780361015; MESTECKY J, 1987, ADV IMMUNOL, V40, P153, DOI 10.1016/S0065-2776(08)60240-0; MIYAKOSHI H, 1992, J CLIN MICROBIOL, V30, P2555, DOI 10.1128/JCM.30.10.2555-2559.1992; MOCHIZUKI M, 1992, JPN J CANCER RES, V83, P236, DOI 10.1111/j.1349-7006.1992.tb00092.x; MOUTSOPOULOS HM, 1994, HARRISONS PRINCIPLES, P1662; NISHIOKA K, 1989, LANCET, V1, P441; OSAME M, 1986, LANCET, V1, P1031; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RICHARDSON JH, 1990, J VIROL, V64, P5682, DOI 10.1128/JVI.64.11.5682-5687.1990; SAKAI M, 1993, J CLIN INVEST, V92, P1957, DOI 10.1172/JCI116789; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; TAJIMA K, 1982, GANN, V73, P893; TALAL N, 1987, SJOGRENS SYNDROME CL; VERNANT JC, 1988, LANCET, V1, P177; YASUKAWA K, 1987, EMBO J, V6, P2939, DOI 10.1002/j.1460-2075.1987.tb02598.x; YOSHIDA M, 1989, ANN NEUROL, V26, P331, DOI 10.1002/ana.410260304; 1990, WKLY EPIDEMIOL REC, V65, P281	28	185	189	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1994	344	8930					1116	1119		10.1016/S0140-6736(94)90630-0	http://dx.doi.org/10.1016/S0140-6736(94)90630-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN066	7934493				2022-12-01	WOS:A1994PN06600009
J	FAN, C; MOEWS, PC; WALSH, CT; KNOX, JR				FAN, C; MOEWS, PC; WALSH, CT; KNOX, JR			VANCOMYCIN RESISTANCE - STRUCTURE OF D-ALANINE-D-ALANINE LIGASE AT 2.3-ANGSTROM RESOLUTION	SCIENCE			English	Article							ALANYL-D-ALANINE; GLYCOPEPTIDE RESISTANCE; GLUTATHIONE SYNTHETASE; ESCHERICHIA-COLI; ENZYMES; ATP; BIOSYNTHESIS; PROTEINS; GENE; VANA	The molecular structure of the D-alanine:D-alanine ligase of the ddlB gene of Escherichia coli, co-crystallized with an S,R-methylphosphinate and adenosine triphosphate, was determined by x-ray diffraction to a resolution of 2.3 angstroms. A catalytic mechanism for the ligation of two D-alanine substrates is proposed in which a helix dipole and a hydrogen-bonded triad of tyrosine, serine, and glutamic acid assist binding and deprotonation steps. From sequence comparison, it is proposed that a different triad exists in a recently discovered D-alanine:D-lactate ligase (VanA) present in vancomycin-resistant enterococci. A molecular mechanism for the altered specificity of VanA is suggested.	UNIV CONNECTICUT, DEPT MOLEC & CELL BIOL, STORRS, CT 06269 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	University of Connecticut; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034330] Funding Source: NIH RePORTER; NIAID NIH HHS [1RO1-AI-34330] Funding Source: Medline; NIGMS NIH HHS [GM-49338] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1992, CHEM B LACTAMS; ARTHUR M, 1993, ANTIMICROB AGENTS CH, V37, P1563, DOI 10.1128/AAC.37.8.1563; BRUNGER AT, 1990, X PLOR MANUAL VERSIO; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P10408, DOI 10.1021/bi00107a007; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; DUTKAMALEN S, 1990, MOL GEN GENET, V224, P364, DOI 10.1007/BF00262430; DUTKAMALEN S, 1992, GENE, V112, P53, DOI 10.1016/0378-1119(92)90302-6; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; HAMMES WP, 1981, PHARMACOL THERAPEUT, V14, P265; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JACK JS, 1988, J MOL GRAPHICS, V6, P224; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KONNERT JH, 1980, ACTA CRYSTALLOGR A, V36, P344, DOI 10.1107/S0567739480000794; MCDERMOTT AE, 1990, BIOCHEMISTRY-US, V29, P5767, DOI 10.1021/bi00476a018; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; NEUHAUS FC, 1962, J BIOL CHEM, V237, P778; NEUHAUS FC, 1964, BIOCHEMISTRY-US, V3, P471, DOI 10.1021/bi00892a001; NEUHAUS FC, 1962, J BIOL CHEM, V237, P3128; PARSONS WH, 1988, J MED CHEM, V31, P1772, DOI 10.1021/jm00117a017; REYNOLDS PE, 1994, BIOCHEM J, V301, P5, DOI 10.1042/bj3010005; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SPRATT BG, 1994, SCIENCE, V264, P388, DOI 10.1126/science.8153626; STROMINGER JL, 1960, J AM CHEM SOC, V82, P998, DOI 10.1021/ja01489a058; TANAKA T, 1993, BIOCHEMISTRY-US, V32, P12398, DOI 10.1021/bi00097a018; TRAVIS J, 1994, SCIENCE, V264, P360, DOI 10.1126/science.8153615; Waley SG, 1992, CHEM BLACTAMS, P198; WALSH C, UNPUB; WALSH CT, 1989, J BIOL CHEM, V264, P2393; WALSH CT, 1993, SCIENCE, V261, P308, DOI 10.1126/science.8392747; WRIGHT GD, 1993, PROTEIN SCI, V2, P1765, DOI 10.1002/pro.5560021020; WRIGHT GD, 1992, ACCOUNTS CHEM RES, V25, P468, DOI 10.1021/ar00022a006; YAMAGUCHI H, 1993, J MOL BIOL, V229, P1083, DOI 10.1006/jmbi.1993.1106; ZAWADZKE LE, 1991, BIOCHEMISTRY-US, V30, P1673, DOI 10.1021/bi00220a033	34	244	248	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 21	1994	266	5184					439	443		10.1126/science.7939684	http://dx.doi.org/10.1126/science.7939684			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7939684				2022-12-01	WOS:A1994PN27200036
J	HUANG, YY; LI, XC; KANDEL, ER				HUANG, YY; LI, XC; KANDEL, ER			CAMP CONTRIBUTES TO MESSY FIBER LTP BY INITIATING BOTH A COVALENTLY MEDIATED EARLY PHASE AND MACROMOLECULAR SYNTHESIS-DEPENDENT LATE-PHASE	CELL			English	Article							LONG-TERM POTENTIATION; APLYSIA SENSORY NEURONS; PROTEIN-KINASE; BEHAVIORAL SENSITIZATION; TRANSMITTER RELEASE; WITHDRAWAL REFLEX; GILL-WITHDRAWAL; MUTANT MICE; MEMORY; FACILITATION	Memory storage has a short-term phase that depends on preexisting proteins and a long-term phase that requires new protein and RNA synthesis. Hippocampal long-term potentiation (LTP) is thought to contribute to memory storage. Consistent with this idea, a cellular representation of these phases has been demonstrated in NMDA receptor-dependent LTP. By contrast, little is known a bout the NMDA receptor-independent LTP of the messy fiber pathway. We find that messy fiber LTP also has phases. Only late phase is blocked by protein and RNA synthesis inhibitors, but both phases are blocked by inhibitors of cAMP-dependent protein kinase, and both are stimulated by forskolin and Sp-cAMPS. During early phase, paired-pulse facilitation is occluded. This occlusion decays with the onset of late phase, consistent with its using a different mechanism. Thus, although Schaffer collateral and mossy fiber pathways use very different mechanisms for early phase, both use a cAMP-mediated mechanism far late phase.			HUANG, YY (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,HOWARD HUGHES MED INST,NEW YORK,NY 10032, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM032099] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32099] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; ALKON DL, 1988, SCIENCE, V239, P998, DOI 10.1126/science.2830669; Amaral D G, 1993, Curr Opin Neurobiol, V3, P225, DOI 10.1016/0959-4388(93)90214-J; ANDERSEN P, 1971, EXP BRAIN RES, V13, P222; BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BYRNE JH, 1993, ADV SEC MESS PHOSPH, V27, P47; BYRNE JH, 1987, PHYSIOL REV, V67, P329, DOI 10.1152/physrev.1987.67.2.329; CAREW TJ, 1986, ANNU REV NEUROSCI, V9, P435, DOI 10.1146/annurev.ne.09.030186.002251; CASTELLUCCI V, 1976, SCIENCE, V194, P1176, DOI 10.1126/science.11560; CASTELLUCCI VF, 1989, J NEUROBIOL, V20, P1, DOI 10.1002/neu.480200102; CROW T, 1990, P NATL ACAD SCI USA, V87, P4490, DOI 10.1073/pnas.87.12.4490; DALE N, 1987, J NEUROSCI, V7, P2232; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DRAIN P, 1991, NEURON, V6, P71, DOI 10.1016/0896-6273(91)90123-H; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; FROST WN, 1985, P NATL ACAD SCI USA, V82, P8266, DOI 10.1073/pnas.82.23.8266; GHIRARDI M, 1992, NEURON, V9, P479, DOI 10.1016/0896-6273(92)90185-G; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GLANZMAN DL, 1990, SCIENCE, V249, P799, DOI 10.1126/science.2389145; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Hawkins RD, 1987, HDB PHYSL 1, VV, P25; Huang Y Y, 1994, Learn Mem, V1, P74; ITO I, 1991, NEUROSCI LETT, V121, P119, DOI 10.1016/0304-3940(91)90663-E; JOHNSTON D, 1992, ANNU REV PHYSIOL, V54, P489; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; LATHORN TH, 1984, BRAIN RES, V290, P174; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MATTHIES H, 1993, NEUROREPORT, V4, P712, DOI 10.1097/00001756-199306000-00028; MILNER B, 1985, WE KNOW; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; MORRIS RGM, 1990, EUR J NEUROSCI, V2, P1016, DOI 10.1111/j.1460-9568.1990.tb00014.x; NAZIF FA, 1991, BRAIN RES, V539, P324, DOI 10.1016/0006-8993(91)91638-H; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; OTANI S, 1992, NEUROSCIENCE, V47, P265, DOI 10.1016/0306-4522(92)90242-T; POLSTER MR, 1991, J COGNITIVE NEUROSCI, V3, P95, DOI 10.1162/jocn.1991.3.2.95; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SMELLIE FW, 1979, LIFE SCI, V24, P2475, DOI 10.1016/0024-3205(79)90458-2; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; TULLY T, 1994, CELL, V7, P35; YIN JC, 1994, CELL, V7, P49; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950; ZUCKER RS, 1973, J PHYSIOL-LONDON, V229, P787, DOI 10.1113/jphysiol.1973.sp010167	52	432	438	1	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					69	79		10.1016/0092-8674(94)90401-4	http://dx.doi.org/10.1016/0092-8674(94)90401-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923379				2022-12-01	WOS:A1994PK58500009
J	HAY, RJ; CASTANON, RE; HERNANDEZ, HA; LOPEZ, GC; FUENTES, LFL; SOLIS, SP; ANDERSSON, N				HAY, RJ; CASTANON, RE; HERNANDEZ, HA; LOPEZ, GC; FUENTES, LFL; SOLIS, SP; ANDERSSON, N			WASTAGE OF FAMILY INCOME ON SKIN-DISEASE IN MEXICO	BRITISH MEDICAL JOURNAL			English	Article									UNIV AUTONOMA GUERRERO,CTR INVEST ENFERMEDADES TROP,ACAPULCO,GUERRERO,MEXICO		HAY, RJ (corresponding author), GUYS HOSP,ST JOHNS INST DERMATOL,LONDON SE1 9RT,ENGLAND.		Andersson, Neil/G-2248-2011					ANDERSSON N, 1992, HLTH POLICY PLANNING, V7, P1; BECHELLI LM, 1981, DERMATOLOGICA, V163, P78, DOI 10.1159/000250144; CASTELLS S, 1992, J INTELL DISABIL RES, V36, P29; Hay R, 1991, LANCET, V337, P906; TAPLIN D, 1991, LANCET, V337, P1016, DOI 10.1016/0140-6736(91)92669-S	5	57	58	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 1	1994	309	6958					848	848		10.1136/bmj.309.6958.848	http://dx.doi.org/10.1136/bmj.309.6958.848			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK501	7950615	Green Published			2022-12-01	WOS:A1994PK50100024
J	FENWICK, JC; CAMERON, M; NAIMAN, SC; HALEY, LP; RONCO, JJ; WIGGS, BR; TWEEDDALE, MG				FENWICK, JC; CAMERON, M; NAIMAN, SC; HALEY, LP; RONCO, JJ; WIGGS, BR; TWEEDDALE, MG			BLOOD-TRANSFUSION AS A CAUSE OF LEUKOCYTOSIS IN CRITICALLY ILL PATIENTS	LANCET			English	Note								The diagnosis of infection in the intensive care unit is confounded by the presence of non-infectious causes of leucocytosis. Unless such causes are recognised, time and effort will be spent on unnecessary investigations and treatments. In a prospective study we have shown that the transfusion of blood frequently (45/50 patients) causes an acute leucocytosis in such patients. This effect was not seen in 8 patients who received plasma. Blood transfusion should be added to the list of non-infectious causes of leucocytosis in the critically ill.	UNIV BRITISH COLUMBIA,VANCOUVER GEN HOSP,DIV HEMATOPATHOL,VANCOUVER V5Z 1M9,BC,CANADA; UNIV BRITISH COLUMBIA,ST PAULS HOSP,VANCOUVER,BC,CANADA	University of British Columbia; St. Paul's Hospital; University of British Columbia; University of Saskatchewan	FENWICK, JC (corresponding author), UNIV BRITISH COLUMBIA,VANCOUVER GEN HOSP,INTENS CARE UNIT,PROGRAM CRIT CARE MED,ROOM 2438,VANCOUVER V5Z 1M9,BC,CANADA.							Crowder M.J., 1990, ANAL REPEATED MEASUR; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEE RG, 1993, WINTROBES CLIN HEMAT; MAYNE E E, 1970, Acta Haematologica (Basel), V44, P155; MUIR AL, 1984, J APPL PHYSIOL, V57, P711, DOI 10.1152/jappl.1984.57.3.711; 1992, CHEST, V101, P1644	6	26	28	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					855	856		10.1016/S0140-6736(94)92828-2	http://dx.doi.org/10.1016/S0140-6736(94)92828-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH253	7916402				2022-12-01	WOS:A1994PH25300012
J	MANFREDINI, R; GALLERANI, M; CARACCIOLO, S; TOMELLI, A; CALO, G; FERSINI, C				MANFREDINI, R; GALLERANI, M; CARACCIOLO, S; TOMELLI, A; CALO, G; FERSINI, C			CIRCADIAN VARIATION IN ATTEMPTED-SUICIDE BY DELIBERATE SELF-POISONING	BRITISH MEDICAL JOURNAL			English	Article									ST ANNA HOSP,DEPT ACCID & EMERGENCY,FERRARA,ITALY; UNIV FERRARA,SCH MED,DEPT PSYCHOL,I-44100 FERRARA,ITALY; UNIV FERRARA,INST PHARMACOL,I-44100 FERRARA,ITALY; WHO,PARASUICIDE MULTICTR STUDY,MENTAL HLTH SERV,FERRARA,ITALY	University of Ferrara; Arcispedale Sant'Anna; University of Ferrara; University of Ferrara; World Health Organization	MANFREDINI, R (corresponding author), UNIV FERRARA,SCH MED,INST INTERNAL MED,I-44100 FERRARA,ITALY.		Manfredini, Roberto/N-3859-2019; Manfredini, Roberto/AAJ-5442-2020; Manfredini, Roberto/A-3471-2008	Manfredini, Roberto/0000-0002-8364-2601; Manfredini, Roberto/0000-0002-8364-2601; Caracciolo, Stefano/0000-0002-3605-1905				MALDONADO G, 1991, SUICIDE LIFE-THREAT, V21, P174; MOTOHASHI Y, 1990, SUICIDE LIFE-THREAT, V20, P352; MULLER JE, 1985, NEW ENGL J MED, V313, P1315, DOI 10.1056/NEJM198511213132103; NELSON W, 1979, CHRONOBIOLOGIA, V6, P305; ROY A, 1988, ACTA PSYCHIAT SCAND, V78, P529, DOI 10.1111/j.1600-0447.1988.tb06380.x	5	22	23	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					774	775		10.1136/bmj.309.6957.774	http://dx.doi.org/10.1136/bmj.309.6957.774			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PJ282	7950563	Green Published			2022-12-01	WOS:A1994PJ28200020
J	MCCLURE, N; HEALY, DL; ROGERS, PAW; SULLIVAN, J; BEATON, L; HANING, RV; CONNOLLY, DT; ROBERTSON, DM				MCCLURE, N; HEALY, DL; ROGERS, PAW; SULLIVAN, J; BEATON, L; HANING, RV; CONNOLLY, DT; ROBERTSON, DM			VASCULAR ENDOTHELIAL GROWTH-FACTOR AS CAPILLARY-PERMEABILITY AGENT IN OVARIAN HYPERSTIMULATION SYNDROME	LANCET			English	Note								We investigated the role of vascular endothelial growth factor (VEGF) in ovarian hyperstimulation syndrome (OHSS). Two similar peaks of permeability activity were seen in OHSS ascites and liver ascites spiked with recombinant human VEGF (rhVEGF); no activity was seen in control liver ascites. Incubation with rhVEGF antiserum decreased activity in the two OHSS peaks by 79% and 65% and the two spiked liver peaks by 49% and 50%. Control serum produced 24% and 27%, and 17% and 0% reductions, respectively, This is evidence that the major capillary permeability agent in OHSS ascites fluid is VEGF.	MONASH UNIV,DEPT OBSTET & GYNAECOL,CLAYTON,VIC 3168,AUSTRALIA; MONASH MED CTR,PRINCE HENRYS INST MED RES,CLAYTON,VIC 3168,AUSTRALIA; BROWN UNIV,WOMEN & INFANTS HOSP,DEPT OBSTET & GYNECOL,PROVIDENCE,RI; MONSANTO CO,HLTH SCI,ST LOUIS,MO	Monash University; Monash University; Prince Henry's Institute of Medical Research; Brown University; Women & Infants Hospital Rhode Island; Monsanto			Rogers, Peter AW/C-2651-2008	Rogers, Peter AW/0000-0002-7399-8997				Basset DL, 1943, AM J ANAT, V73, P251, DOI 10.1002/aja.1000730206; CAVENDER JL, 1988, BIOL REPROD, V39, P989, DOI 10.1095/biolreprod39.4.989; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; MCCLURE N, 1992, HUM REPROD, V7, P758, DOI 10.1093/oxfordjournals.humrep.a137733; MCCLURE N, IN PRESS J PHARM TOX; PHILLIPS HS, 1990, ENDOCRINOLOGY, V127, P965, DOI 10.1210/endo-127-2-965; RAVINDRANATH N, 1992, ENDOCRINOLOGY, V131, P254, DOI 10.1210/en.131.1.254; 1991, LANCET, V338, P1111	8	304	317	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					235	236		10.1016/S0140-6736(94)93001-5	http://dx.doi.org/10.1016/S0140-6736(94)93001-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913160				2022-12-01	WOS:A1994NY06000013
J	FUCHS, CS; GIOVANNUCCI, EL; COLDITZ, GA; HUNTER, DJ; SPEIZER, FE; WILLETT, WC				FUCHS, CS; GIOVANNUCCI, EL; COLDITZ, GA; HUNTER, DJ; SPEIZER, FE; WILLETT, WC			A PROSPECTIVE-STUDY OF FAMILY HISTORY AND THE RISK OF COLORECTAL-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SELF-ADMINISTERED QUESTIONNAIRE; CORONARY HEART-DISEASE; ALCOHOL-CONSUMPTION; COLON; REPRODUCIBILITY; FREQUENCY; RECTUM; POLYPS	Background. A family history of colorectal cancer is recognized as a risk factor for the disease. However, as a result of the retrospective design of prior studies, the strength of this association is uncertain, particularly as it is influenced by characteristics of the person at risk and the affected family members. Methods. We conducted a prospective study of 32,085 men and 87,031 women who had not previously been examined by colonoscopy or sigmoidoscopy and who provided data on first-degree relatives with colorectal cancer, diet, and other risk factors for the disease. During the follow-up period, colorectal cancer was diagnosed in 148 men and 315 women. Results. The age-adjusted relative risk of colorectal cancer for men and women with affected first-degree relatives, as compared with those without a family history of the disease, was 1.72 (95 percent confidence interval, 1.34 to 2.19). The relative risk among study participants with two or more affected first-degree relatives was 2.75 (95 percent confidence interval, 1.34 to 5.63). For participants under the age of 45 years who had one or more affected first-degree relatives, the relative risk was 5.37 (95 percent confidence interval, 1.98 to 14.6), and the risk decreased with increasing age (P for trend, <0.001). Conclusions. A family history of colorectal cancer is associated with an increased risk of the disease, especially among younger people.	HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT ENVIRONM HLTH,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,CHANNING LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	FUCHS, CS (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DANA FARBER CANC INST,DIV MED ONCOL,44 BINNEY ST,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040935, P01CA055075] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BONELLI L, 1988, INT J CANCER, V41, P513; CANNONALBRIGHT LA, 1989, CANCER, V64, P1971, DOI 10.1002/1097-0142(19891101)64:9<1971::AID-CNCR2820640935>3.0.CO;2-L; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; COLDITZ GA, 1987, INT J EPIDEMIOL, V16, P392, DOI 10.1093/ije/16.3.392; COX DR, 1972, J R STAT SOC B, V34, P187; DELEON MP, 1987, CANCER, V60, P2848, DOI 10.1002/1097-0142(19871201)60:11<2848::AID-CNCR2820601141>3.0.CO;2-F; DUNCAN JL, 1982, GUT, V23, P169, DOI 10.1136/gut.23.2.169; FISHER G, 1989, MED J AUSTRALIA, V150, P22, DOI 10.5694/j.1326-5377.1989.tb136314.x; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; KUNE GA, 1989, WORLD J SURG, V13, P124, DOI 10.1007/BF01671173; LEVIN B, 1992, CA-CANCER J CLIN, V42, P296, DOI 10.3322/canjclin.42.5.296; LOVETT E, 1976, BRIT J SURG, V63, P13, DOI 10.1002/bjs.1800630103; MACKLIN MT, 1960, J NATL CANCER I, V24, P551, DOI 10.1093/jnci/24.3.551; MAIRE P, 1984, GASTROEN CLIN BIOL, V8, P22; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SONDERGAARD JO, 1991, INT J CANCER, V47, P202, DOI 10.1002/ijc.2910470207; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; STEPHENSON BM, 1991, BRIT J SURG, V78, P1162, DOI 10.1002/bjs.1800781005; STJOHN DJB, 1993, ANN INTERN MED, V118, P785, DOI 10.7326/0003-4819-118-10-199305150-00005; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; WILLETT WC, 1987, NEW ENGL J MED, V316, P1174, DOI 10.1056/NEJM198705073161902; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; WOOLF CM, 1958, AM J HUM GENET, V10, P42	28	586	592	2	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 22	1994	331	25					1669	1674		10.1056/NEJM199412223312501	http://dx.doi.org/10.1056/NEJM199412223312501			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX382	7969357				2022-12-01	WOS:A1994PX38200001
J	MILLINER, DS; EICKHOLT, JT; BERGSTRALH, EJ; WILSON, DM; SMITH, LH				MILLINER, DS; EICKHOLT, JT; BERGSTRALH, EJ; WILSON, DM; SMITH, LH			RESULTS OF LONG-TERM TREATMENT WITH ORTHOPHOSPHATE AND PYRIDOXINE IN PATIENTS WITH PRIMARY HYPEROXALURIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLOMERULAR-FILTRATION RATE; GLYOXYLATE AMINOTRANSFERASE; KIDNEY-TRANSPLANTATION; RENAL-TRANSPLANTATION; PEROXISOMAL ALANINE; OXALATE DYNAMICS; PRIMARY OXALOSIS; HEPATIC ALANINE; TYPE-1; URINARY	Background. The prognosis for patients with primary hyperoxaluria has been ominous, with the expectation of renal failure, poor results with transplantation, and early death. Methods. We studied the long-term effects of orthophosphate and pyridoxine therapy in 25 patients with primary hyperoxaluria who were treated for an average of 10 years (range, 0.3 to 26). Their mean age at the start of treatment was 12 years (median, 6; range, 0.5 to 32). We also studied the effect of orthophosphate and pyridoxine on urinary supersaturation with calcium oxalate, crystal inhibition using a seeded growth system, and crystal formation using scanning electron microscopy in 12 patients during three-day stays in the clinical research center. Results. The mean (+/-SD) glomerular filtration rate at the start of treatment was 91+/-26 ml per minute per 1.73 m(2). The median decline in glomerular filtration rates was 1.4 ml per minute per 1.73 m(2) of body-surface area per year. The actuarial survival free of end-stage renal disease was 96, 89, 74, and 74 percent at 5, 10, 15, and 20 years, respectively. Treatment with orthophosphate and pyridoxine reduced urinary supersaturation with calcium oxalate from 8.3+/-3.0 to 2.1+/-1.7 kJ per mole at 38 degrees C (P<0.001), increased the inhibition of calcium oxalate formation from 63+/-11 to 108+/-10 inhibitor units per 24 hours (P<0.001), and improved the crystalluria score from 2.6+/-0.3 to 0.6+/-0.1 (P<0.001). Conclusions. Treatment of patients with primary hyperoxaluria with orthophosphate and pyridoxine decreases urinary calcium oxalate crystallization and appears to preserve renal function.	MAYO CLIN & MAYO FDN,DEPT PEDIAT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,BIOSTAT SECT,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic	MILLINER, DS (corresponding author), MAYO CLIN & MAYO FDN,DEPT INTERNAL MED,DIV NEPHROL,ROCHESTER,MN 55905, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000585] Funding Source: NIH RePORTER; NCRR NIH HHS [5M01-RR0585-23] Funding Source: Medline; NIADDK NIH HHS [AM20605] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLSOP J, 1987, CLIN CHIM ACTA, V170, P187, DOI 10.1016/0009-8981(87)90127-6; BARRATT TM, 1988, OXALATE METABOLISM R, P84; BRIGMAN J, 1978, INVEST UROL, V15, P496; BROYER M, 1990, NEPHROL DIAL TRANSPL, V5, P332, DOI 10.1093/ndt/5.5.332; CHALMERS RA, 1972, ANALYST, V97, P958, DOI 10.1039/an9729700958; CHLEBECK PT, 1994, AM J KIDNEY DIS, V23, P255, DOI 10.1016/S0272-6386(12)80981-4; COOPER PJ, 1988, J HISTOCHEM CYTOCHEM, V36, P1285, DOI 10.1177/36.10.3418107; DANPURE CJ, 1987, LANCET, V1, P289; DANPURE CJ, 1989, J INHERIT METAB DIS, V12, P210, DOI 10.1007/BF01800727; DANPURE CJ, 1991, AM J KIDNEY DIS, V17, P366, DOI 10.1016/S0272-6386(12)80624-X; DANPURE CJ, 1986, FEBS LETT, V201, P20, DOI 10.1016/0014-5793(86)80563-4; DANPURE CJ, 1989, J CELL BIOL, V108, P1345, DOI 10.1083/jcb.108.4.1345; DENT CE, 1970, ARCH DIS CHILD, V45, P735, DOI 10.1136/adc.45.244.735; FOLIN O, 1905, J BIOL CHEM, V1, P131; FREDERICK EW, 1963, NEW ENGL J MED, V269, P821, DOI 10.1056/NEJM196310172691601; GIBBS DA, 1969, J LAB CLIN MED, V73, P901; GIBBS DA, 1970, CLIN SCI, V38, P277, DOI 10.1042/cs0380277; HELIN I, 1980, SCAND J UROL NEPHROL, V14, P61, DOI 10.3109/00365598009181192; HOCKADAY TD, 1964, MEDICINE, V43, P315, DOI 10.1097/00005792-196405000-00010; HOLMGREN G, 1978, UPSALA J MED SCI, V83, P65, DOI 10.3109/03009737809179114; KATZ A, 1992, KIDNEY INT, V42, P1408, DOI 10.1038/ki.1992.434; KOEHL C, 1976, CLIN CHIM ACTA, V70, P71, DOI 10.1016/0009-8981(76)90006-1; LATTA K, 1990, EUR J PEDIATR, V149, P518, DOI 10.1007/BF01957682; LEUMANN E, 1993, PEDIATR NEPHROL, V7, P207, DOI 10.1007/BF00864405; MCDONALD JC, 1989, NEW ENGL J MED, V321, P1100, DOI 10.1056/NEJM198910193211607; MEYER JL, 1975, INVEST UROL, V13, P36; MISTRY J, 1988, BIOCHEM SOC T, V16, P626, DOI 10.1042/bst0160626; NATELSON S, 1948, J BIOL CHEM, V175, P745; OLTHUIS FMFG, 1977, CLIN CHIM ACTA, V75, P123, DOI 10.1016/0009-8981(77)90507-1; OTT NT, 1975, MAYO CLIN PROC, V50, P664; SCHEINMAN JI, 1984, KIDNEY, V17, P13; SCHWARTZ GJ, 1976, PEDIATRICS, V58, P259; SCHWARTZ GJ, 1985, J PEDIATR-US, V106, P522, DOI 10.1016/S0022-3476(85)80697-1; SLACK TK, 1976, MAYO CLIN PROC, V51, P296; SMITH LH, 1967, MOD TREAT, V4, P522; SMITH LH, 1976, UROLITHIASIS RES, P199; WATTS RWE, 1987, LANCET, V2, P474; WATTS RWE, 1991, AM J MED, V90, P179; WATTS RWE, 1985, CLIN SCI, V69, P87, DOI 10.1042/cs0690087; WATTS RWE, 1984, CLIN SCI, V66, P591, DOI 10.1042/cs0660591; WERNESS PG, 1981, J CRYST GROWTH, V53, P166, DOI 10.1016/0022-0248(81)90063-4; WERNESS PG, 1985, J UROLOGY, V134, P1242, DOI 10.1016/S0022-5347(17)47703-2; WILL EJ, 1979, METABOLISM, V28, P542, DOI 10.1016/0026-0495(79)90195-1; WILLIAMS HE, 1968, NEW ENGL J MED, V278, P233, DOI 10.1056/NEJM196802012780502; WILLIAMS HE, 1978, METABOLIC BASIS INHE, P182; WILSON DM, 1991, CLIN CHEM, V37, P1229	46	147	148	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 8	1994	331	23					1553	1558		10.1056/NEJM199412083312304	http://dx.doi.org/10.1056/NEJM199412083312304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV292	7969325				2022-12-01	WOS:A1994PV29200004
J	BANERJEE, A; JONES, R				BANERJEE, A; JONES, R			WHITHER IMMEDIATE FLUID RESUSCITATION	LANCET			English	Editorial Material											BANERJEE, A (corresponding author), ROTHERHAM DIST GEN HOSP,DEPT GEN SURG,ROTHERHAM,S YORKSHIRE,ENGLAND.		Banerjee, Anjan Kumar/AAL-6375-2020	Banerjee, Anjan Kumar/0000-0002-5935-3404				BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; BICKELL WH, 1992, ANN EMERG MED, V21, P1077, DOI 10.1016/S0196-0644(05)80648-1; CRAWFORD ES, 1991, J VASC SURG, V13, P348; DEMETRIADES D, 1993, BRIT J SURG, V80, P1534, DOI 10.1002/bjs.1800801213; DILLON J, 1966, ARCH SURG-CHICAGO, V93, P537; JACOBS LM, 1994, NEW ENGL J MED, V331, P1153, DOI 10.1056/NEJM199410273311710; SHIRES T, 1964, ARCH SURG-CHICAGO, V88, P688; SIRINEK KR, 1990, ARCH SURG-CHICAGO, V125, P844; 1993, ADV TRAUMA LIFE SUPP, P75	9	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 26	1994	344	8935					1450	1451		10.1016/S0140-6736(94)90283-6	http://dx.doi.org/10.1016/S0140-6736(94)90283-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7968115				2022-12-01	WOS:A1994PT99500002
J	LEVINE, A; TENHAKEN, R; DIXON, R; LAMB, C				LEVINE, A; TENHAKEN, R; DIXON, R; LAMB, C			H2O2 FROM THE OXIDATIVE BURST ORCHESTRATES THE PLANT HYPERSENSITIVE DISEASE RESISTANCE RESPONSE	CELL			English	Article							CELL-SUSPENSION CULTURES; DNA-BINDING ACTIVITY; PHASEOLUS-VULGARIS; DEFENSE RESPONSE; MESSENGER-RNA; INDUCTION; ELICITOR; GENE; PROTEIN; ELICITATION	Microbial elicitors or attempted infection with an avirulent pathogen strain causes the rapid production of reactive oxygen intermediates. We report here that H2O2 from this oxidative bu rst not only drives the crosslinking of cell wall structural proteins, but also functions as a local trigger of programmed death in challenged cells and as a diffusible signal for the induction in adjacent cells of genes encoding cellular protectants such as glutathione S-transferase and glutathione peroxidase. Thus, H2O2 from the oxidative burst plays a key role in the orchestration of a localized hypersensitive response during the expression of plant disease resistance.	SALK INST BIOL STUDIES, PLANT BIOL LAB, LA JOLLA, CA 92037 USA; SAMUEL ROBERTS NOBLE FDN INC, DIV PLANT BIOL, ARDMORE, OK 73402 USA	Salk Institute; Noble Research Institute			Tenhaken, Raimund/O-6556-2019; Levine, Alex/A-6867-2008	Tenhaken, Raimund/0000-0002-6764-4826; 				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; APOSTOL I, 1989, PLANT PHYSIOL, V90, P109, DOI 10.1104/pp.90.1.109; ATKINSON MM, 1990, PLANT PHYSIOL, V92, P215, DOI 10.1104/pp.92.1.215; BABIOR BM, 1992, ADV ENZYMOL RAMB, V65, P49; BABIYCHUK E, 1994, P NATL ACAD SCI USA, V91, P3299, DOI 10.1073/pnas.91.8.3299; BAKER CJ, 1993, PHYSIOL MOL PLANT P, V43, P81, DOI 10.1006/pmpp.1993.1042; BECKER F, 1993, PLANT J, V3, P875, DOI 10.1111/j.1365-313X.1993.00875.x; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BERHANE K, 1994, P NATL ACAD SCI USA, V91, P1480, DOI 10.1073/pnas.91.4.1480; BRADLEY DJ, 1992, CELL, V70, P21, DOI 10.1016/0092-8674(92)90530-P; BRISSON LF, 1994, IN PRESS PLANT CELL; BULTKE TM, 1994, TODAY, V15, P7; CHEN ZX, 1993, SCIENCE, V262, P1883, DOI 10.1126/science.8266079; CREELMAN RA, 1992, P NATL ACAD SCI USA, V89, P4938, DOI 10.1073/pnas.89.11.4938; CRIQUI MC, 1992, PLANT MOL BIOL, V18, P623, DOI 10.1007/BF00040684; CZARNECKA E, 1988, MOL CELL BIOL, V8, P1113, DOI 10.1128/MCB.8.3.1113; DAVIS D, 1993, PHYTOCHEMISTRY, V32, P607, DOI 10.1016/S0031-9422(00)95144-6; DEVLIN WS, 1992, PLANT PHYSIOL, V100, P1189, DOI 10.1104/pp.100.3.1189; DIETRICH A, 1990, J BIOL CHEM, V265, P6360; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; DIXON RA, 1983, PLANT PHYSIOL, V71, P251, DOI 10.1104/pp.71.2.251; EDWARDS K, 1985, P NATL ACAD SCI USA, V82, P6731, DOI 10.1073/pnas.82.20.6731; ENAN E, 1992, BIOCHEM PHARMACOL, V43, P1777, DOI 10.1016/0006-2952(92)90710-Z; FARMER EE, 1992, PLANT CELL, V4, P129, DOI 10.1105/tpc.4.2.129; FELIX G, 1994, P NATL ACAD SCI USA, V91, P952, DOI 10.1073/pnas.91.3.952; GREENBERG JT, 1993, PLANT J, V4, P327, DOI 10.1046/j.1365-313X.1993.04020327.x; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; HAHN MG, 1992, MOL PLANT PATHOL, V2, P231; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HAVIR EA, 1992, PLANT PHYSIOL, V99, P533, DOI 10.1104/pp.99.2.533; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HEROUART D, 1993, P NATL ACAD SCI USA, V90, P3108, DOI 10.1073/pnas.90.7.3108; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; ITZHAKI H, 1993, PLANT MOL BIOL, V22, P43, DOI 10.1007/BF00038994; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; KEEN NT, 1991, THEOR APPL GENET, V81, P133, DOI 10.1007/BF00226123; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; KIEDROWSKI S, 1992, EMBO J, V11, P4677, DOI 10.1002/j.1460-2075.1992.tb05572.x; LAMB CJ, 1989, CELL, V56, P215, DOI 10.1016/0092-8674(89)90894-5; LAMB CJ, 1994, CELL, V76, P419, DOI 10.1016/0092-8674(94)90106-6; LI YM, 1992, P NATL ACAD SCI USA, V89, P11867, DOI 10.1073/pnas.89.24.11867; MAUCH F, 1993, PLANT PHYSIOL, V102, P1193, DOI 10.1104/pp.102.4.1193; MCGURL B, 1992, SCIENCE, V255, P1570, DOI 10.1126/science.1549783; MEHDY MC, 1994, PLANT PHYSIOL, V105, P467, DOI 10.1104/pp.105.2.467; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; OLSON PD, 1993, PLANT J, V4, P887, DOI 10.1046/j.1365-313X.1993.04050887.x; PEPPER A, 1994, CELL, V78, P109, DOI 10.1016/0092-8674(94)90577-0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; ROOT RK, 1975, J CLIN INVEST, V55, P945, DOI 10.1172/JCI108024; RYALS J, 1994, PLANT PHYSIOL, V104, P1109, DOI 10.1104/pp.104.4.1109; RYDER TB, 1984, P NATL ACAD SCI-BIOL, V81, P5724, DOI 10.1073/pnas.81.18.5724; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SUTHERLAND MW, 1991, PHYSIOL MOL PLANT P, V39, P79, DOI 10.1016/0885-5765(91)90020-I; TURNER JG, 1974, PHYTOPATHOLOGY, V64, P885, DOI 10.1094/Phyto-64-885; VARNER JE, 1989, CELL, V56, P231, DOI 10.1016/0092-8674(89)90896-9; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VERNOOIJ B, 1994, PLANT CELL, V6, P959, DOI 10.1105/tpc.6.7.959; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x	59	2167	2365	5	269	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 18	1994	79	4					583	593		10.1016/0092-8674(94)90544-4	http://dx.doi.org/10.1016/0092-8674(94)90544-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7954825				2022-12-01	WOS:A1994PT48100006
J	SONDEK, J; LAMBRIGHT, DG; NOEL, JP; HAMM, HE; SIGLER, PB				SONDEK, J; LAMBRIGHT, DG; NOEL, JP; HAMM, HE; SIGLER, PB			GTPASE MECHANISM OF GPROTEINS FROM THE 1.7-ANGSTROM CRYSTAL-STRUCTURE OF TRANSDUCIN ALPHA-CENTER-DOT-GDP-CENTER-DOT-ALF4(-)	NATURE			English	Article							H-RAS P21; X-RAY; HYDROLYSIS; PROTEIN; MUTANTS; ACTIVATION; INHIBITION; MUTATIONS; ALUMINUM; FLUORIDE	ALUMINIUM fluoride (AlF4-) activates members of the heterotrimeric G-protein (G(alpha beta gamma)) family(1,2) by binding to inactive G(alpha).GDP near the site occupied by the gamma-phosphate in G(alpha).GTP (ref. 3). Here we describe the crystal structure of transducin alpha.GDP activated with aluminium fluoride (G(t alpha).GDP.AlF4-.H2O) at 1.7 Angstrom, a resolution sufficient to establish the coordination geometry of the bound aluminium fluoride as well as the extensive network of direct and water-mediated interactions that stabilize it. These observations are derived from three independent representations in the asymmetric unit, eliminating any chance of drawing conclusions based on stereochemistry imposed by crystal packing. Surprisingly, aluminium fluoride activates G(alpha).GDP by binding with a geometry resembling a pentavalent intermediate for GTP hydrolysis. The stabilizing interactions involve not only residues that interact with the gamma-phosphate in G(t alpha).GTP gamma S, but also conserved residues essential for GTPase activity. Thus the G(t alpha).GDP.AlF4-.H2O structure provides new insight into the mechanism of GTP hydrolysis.	YALE UNIV,BOYER CTR MOLEC MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; YALE UNIV,BOYER CTR MOLEC MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60680; UNIV SASSARI,IST FISIOL GEN & CHIM BIOL,I-07100 SASSARI,ITALY	Yale University; Howard Hughes Medical Institute; Yale University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Sassari			Hamm, Heidi E/G-2374-2014; Noel, Joseph P/A-9459-2009	Sondek, John/0000-0002-1127-8310				ANTONNY B, 1991, BIOCHEMISTRY-US, V30, P8287, DOI 10.1021/bi00098a002; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHUNG HH, 1993, SCIENCE, V259, P806, DOI 10.1126/science.8430333; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DUPUIS A, 1989, FEBS LETT, V255, P47, DOI 10.1016/0014-5793(89)81058-0; FOURQUET JL, 1986, REV CHIM MINER, V23, P183; FRECH M, 1994, BIOCHEMISTRY-US, V33, P3237, DOI 10.1021/bi00177a014; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GOODY RS, 1992, PHILOS T ROY SOC B, V336, P3, DOI 10.1098/rstb.1992.0037; GROTTEL M, 1992, J PHYS-CONDENS MAT, V4, P1837, DOI 10.1088/0953-8984/4/7/022; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P3396; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARUTA S, 1993, J BIOL CHEM, V268, P7093; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; SCHEPARTZ A, 1987, J AM CHEM SOC, V109, P1814, DOI 10.1021/ja00240a036; SCHWEINS T, 1994, NAT STRUCT BIOL, V1, P476, DOI 10.1038/nsb0794-476; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; STRYER L, 1983, METHOD ENZYMOL, V96, P617; SUAREZ HG, 1991, ONCOGENE, V6, P677; SWAIN CG, 1952, J AM CHEM SOC, V74, P2538, DOI 10.1021/ja01130a024; WESTHEIMER FH, 1987, SCIENCE, V235, P1173, DOI 10.1126/science.2434996	30	538	545	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 17	1994	372	6503					276	279		10.1038/372276a0	http://dx.doi.org/10.1038/372276a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PR889	7969474				2022-12-01	WOS:A1994PR88900054
J	MADDOX, J				MADDOX, J			FRONTIERS OF IGNORANCE - IS THE BRAIN A COMPUTER	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					35	36						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7969413				2022-12-01	WOS:A1994PQ34800048
J	SCHIMMEL, TW; CRUMM, KF				SCHIMMEL, TW; CRUMM, KF			IMAGES IN CLINICAL MEDICINE - MICROSURGICAL FERTILIZATION AND BLASTOMERE REMOVAL FOR GENETIC-ANALYSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											SCHIMMEL, TW (corresponding author), UNITED HOSP,IVF AMER PROGRAM,PORT CHESTER,NY 10573, USA.								0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	1994	331	18					1200	1200						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN806	7935658				2022-12-01	WOS:A1994PN80600005
J	TRENITE, DGAKN				TRENITE, DGAKN			VIDEO-GAME EPILEPSY	LANCET			English	Editorial Material							PHOTOSENSITIVITY				TRENITE, DGAKN (corresponding author), INST EPILEPSIEBESTRIJDING MEER & BOSCH CRUQUIUSHOEVE,HEEMSTEDE,NETHERLANDS.		Trenite, Dorothee Nolst/ABG-5804-2020					FERRIE CD, 1994, J NEUROL NEUROSUR PS, V57, P925, DOI 10.1136/jnnp.57.8.925; FISH DR, 1994, NATIONAL SURVEY PHOT; GRAF WD, 1994, PEDIATRICS, V93, P551; HARDING GFA, 1993, BROADCASTING ADVERTI, V1; Jeavons P, 1975, PHOTOSENSITIVE EPILE; JEAVONS PM, 1986, EPILEPSIA, V27, P569, DOI 10.1111/j.1528-1157.1986.tb03586.x; TRENITE DGA, 1989, ACTA NEUROL SCAND, V47, P163; TRENITE DGAK, 1987, J NEUROL NEUROSUR PS, V50, P1546, DOI 10.1136/jnnp.50.11.1546; WILKINS AJ, 1979, ELECTROEN CLIN NEURO, V47, P163, DOI 10.1016/0013-4694(79)90218-9; WOLF P, 1986, J NEUROL NEUROSUR PS, V49, P1386, DOI 10.1136/jnnp.49.12.1386	10	18	18	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1994	344	8930					1102	1103		10.1016/S0140-6736(94)90625-4	http://dx.doi.org/10.1016/S0140-6736(94)90625-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN066	7934490				2022-12-01	WOS:A1994PN06600004
J	VU, TH; HOFFMAN, AR				VU, TH; HOFFMAN, AR			PROMOTER-SPECIFIC IMPRINTING OF THE HUMAN INSULIN-LIKE GROWTH FACTOR-II GENE	NATURE			English	Article							ALLELE-SPECIFIC METHYLATION; BECKWITH-WIEDEMANN SYNDROME; WILMS-TUMOR; IGF2 GENE; MOUSE; RELAXATION; EMBRYOGENESIS; CANCER	GENOMIC imprinting is a mechanism whereby only one of the two parental alleles is expressed. Loss or relaxation of genomic imprinting has been proposed as an epigenetic mechanism for oncogenesis in a variety of human tumours(1-6). Although the mechanism of imprinting is unknown, differential CpG methylation of the parental alleles has been implicated(7-12). The human insulinlike growth factor-II (IGF2) gene, which is transcribed from four promoters, P1-P4 (ref. 13), is imprinted in fetal liver(14,15) but biallelic expression occurs in adult liver(16). Like most tissues, fetal liver uses primarily promoters P3 and P4 (ref. 17). Adult liver, however, transcribes IGF2 from promoter P1, and it has been suggested that the recruitment of P1 may be responsible for the absence of imprinting in human liver, and in choroid plexus and leptomeninges(18). We report here that in liver and chondrocytes, IGF2 transcripts from promoter P1 are always derived from both parental alleles, whereas transcripts from promoters P2, P3 and P4 are always from one parental allele. These findings demonstrate that imprinting and a lack of imprinting can both occur within a single gene in a single tissue, suggesting that regional imprinting factors may be important.	STANFORD UNIV,DEPT MED,PALO ALTO,CA 94304	Stanford University	VU, TH (corresponding author), VET ADM MED CTR,MED SERV,3801 MIRANDA AVE,PALO ALTO,CA 94304, USA.			Hoffman, Andrew/0000-0002-0145-1917				BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; CATTANACH BM, 1990, DEVELOPMENT, P63; CHAILLET JR, 1991, CELL, V66, P77, DOI 10.1016/0092-8674(91)90140-T; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; EKSBERG R, 1993, NAT GENET, V5, P143; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; KALSCHEUER VM, 1993, NAT GENET, V5, P74, DOI 10.1038/ng0993-74; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OGAWA O, 1993, NAT GENET, V5, P408, DOI 10.1038/ng1293-408; OHLSSON R, 1994, DEVELOPMENT, V120, P361; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; ROTWEIN P, 1990, DNA CELL BIOL, V9, P725, DOI 10.1089/dna.1990.9.725; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; SCHNEID H, 1993, J MED GENET, V30, P353, DOI 10.1136/jmg.30.5.353; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; Sussenbach J S, 1989, Prog Growth Factor Res, V1, P33, DOI 10.1016/0955-2235(89)90040-9; SUSSENBACH JS, 1992, GROWTH REGULAT, V2, P1; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P6967, DOI 10.1093/nar/19.24.6967; VANDIJK MA, 1991, MOL CELL ENDOCRINOL, V81, P81, DOI 10.1016/0303-7207(91)90207-9	24	208	212	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 20	1994	371	6499					714	717		10.1038/371714a0	http://dx.doi.org/10.1038/371714a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM773	7935819				2022-12-01	WOS:A1994PM77300060
J	MOORE, S; WOLFE, SM; LINDES, D; DOUGLAS, CE				MOORE, S; WOLFE, SM; LINDES, D; DOUGLAS, CE			EPIDEMIOLOGY OF FAILED TOBACCO CONTROL LEGISLATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To evaluate the influence of tobacco industry campaign donations, district location, and political party affiliation on tobacco control legislation among members of the US Congress. Design.-Data were obtained from the Federal Election Commission on money contributed by the 10 leading tobacco political action committees and by tobacco industry-aligned individuals to members of the US House of Representatives (1991-1992) and Senate (1987-1992). Logistic regression analyses were performed using recorded votes and cosponsorship activities concerning tobacco control legislation during the 102nd and 103rd Congresses and membership on the House Congressional Task Force on Tobacco and Health as the dependent variables and tobacco money received, party, district location, and caucus or committee membership as the independent variables. Setting.-United States Congress in 1991 and 1992. Interventions.-None. Main Outcome Measure.-Support for federal tobacco control legislation. Results.-The tobacco industry donated approximately $2.4 million to members of Congress from January 1991 through December 1992. House members received an average of $2943 (1991-1992) and senators received an average of $11593 (1937-1992). The more tobacco money a member received, the less likely the member was to support tobacco control legislation. In the Senate, on a vote to end the taxpayer subsidy of tobacco products in military stores, the odds ratio that senators in the top quartile of tobacco money recipients did not support the measure vs senators in the lowest quartile of tobacco money recipients was 42.2 (95% confidence interval, 4.1 to 430.0; P<.001). In the House, on a vote to end a $3.5 million subsidy to promote American tobacco abroad, the odds that House members in the top third of tobacco money recipients would oppose the legislation were 14.4 times greater (95% confidence interval, 5.5 to 39.0; P<.001) than for House members in the lowest third of tobacco money recipients. Receiving more tobacco money, being a member of the Republican party, and representing a tobacco producing state were all associated with decreased support for tobacco control issues. The amount of tobacco money received was the variable most strongly and consistently associated with a lack of support for tobacco control legislation, even when we controlled for additional factors such as district location and party. Conclusion.-Tobacco industry contributions to members of the US Congress strongly influence the federal tobacco policy process. Unless this influence is diminished through a combination of members refusing tobacco money and campaign finance reform, this process of contributing to death by thwarting tobacco control will continue to claim hundreds of thousands of lives a year.	PUBL CITIZENS HLTH RES GRP,WASHINGTON,DC 20036; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,PREVENT MED RESIDENCY PROGRAM,BALTIMORE,MD; WASHINGTON UNIV,ST LOUIS,MO; AMER CANC SOC,WASHINGTON,DC	Johns Hopkins University; Washington University (WUSTL); American Cancer Society								BEGAY ME, 1993, AM J PUBLIC HEALTH, V83, P1214, DOI 10.2105/AJPH.83.9.1214; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MOORE S, 1993, CONTRIBUTING DEATH I; WOLFE SM, 1993, PUBLIC CITIZEN HLTH, V9, P1; 1992, STATISTICAL ABSTRACT, P733; 1993, SAVING LIVES RAISING	6	55	55	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1171	1175		10.1001/jama.272.15.1171	http://dx.doi.org/10.1001/jama.272.15.1171			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PL212	7933346				2022-12-01	WOS:A1994PL21200030
J	COHEN, J				COHEN, J			LABORATORY WASTES - TOXIC DISPUTE COSTS STANFORD 1-MILLION-DOLLARS	SCIENCE			English	Editorial Material																			0	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1994	266	5183					213	213		10.1126/science.7939653	http://dx.doi.org/10.1126/science.7939653			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939653				2022-12-01	WOS:A1994PM13400013
J	MOY, VT; FLORIN, EL; GAUB, HE				MOY, VT; FLORIN, EL; GAUB, HE			INTERMOLECULAR FORCES AND ENERGIES BETWEEN LIGANDS AND RECEPTORS	SCIENCE			English	Article							SCANNING TUNNELING MICROSCOPY; ACTIN FILAMENT; STREPTAVIDIN; CELLS	The recognition mechanisms and dissociation pathways of the avidin-biotin complex and of actin monomers in actin filaments were investigated. The unbinding forces of discrete complexes of avidin or streptavidin with biotin analogs are proportional to the enthalpy change of the complex formation but independent of changes in the free energy. This result indicates that the unbinding process is adiabatic and that entropic changes occur after unbinding. On the basis of the measured forces and binding energies, an effective rupture length of 9.5 +/- 1 angstroms was calculated for all biotin-avidin pairs and approximately 1 to 3 angstroms for the actin monomer-monomer interaction. A model for the correlation among binding forces, intermolecular potential, and molecular function is proposed.	TECH UNIV MUNICH,DEPT PHYS,D-85748 GARCHING,GERMANY	Technical University of Munich								BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BINNIG G, 1987, REV MOD PHYS, V59, P615, DOI 10.1103/RevModPhys.59.615; EVANS E, 1991, BIOPHYS J, V59, P838, DOI 10.1016/S0006-3495(91)82296-2; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; GREEN NM, 1966, BIOCHEM J, V101, P774, DOI 10.1042/bj1010774; HANSMA PK, 1988, SCIENCE, V242, P209, DOI 10.1126/science.3051380; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HUTTER JL, 1993, REV SCI INSTRUM, V64, P1868, DOI 10.1063/1.1143970; Israelachvili J., 1992, INTERMOLECULAR SURFA; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; LECKBAND DE, 1994, BIOCHEMISTRY-US, V33, P4611, DOI 10.1021/bi00181a023; LEE GU, 1994, LANGMUIR, V10, P354, DOI 10.1021/la00014a003; MIYAMOTO S, 1993, PROTEINS, V16, P226, DOI 10.1002/prot.340160303; MOY VT, 1993, REV SCI INSTRUM, V64, P403; OOSAWA F, 1977, BIORHEOLOGY, V14, P11; RADMACHER M, 1992, SCIENCE, V257, P1900, DOI 10.1126/science.1411505; SENDEN TJ, 1994, LANGMUIR, V10, P1003, DOI 10.1021/la00016a600; SHETERLINE P, 1994, ACTIN, V1; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; WEBER PC, 1992, J AM CHEM SOC, V114, P3197, DOI 10.1021/ja00035a004	24	762	782	3	147	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1994	266	5183					257	259		10.1126/science.7939660	http://dx.doi.org/10.1126/science.7939660			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939660				2022-12-01	WOS:A1994PM13400027
J	STEINHOFF, HJ; MOLLAAGHABABA, R; ALTENBACH, C; HIDEG, K; KREBS, M; KHORANA, HG; HUBBELL, WL				STEINHOFF, HJ; MOLLAAGHABABA, R; ALTENBACH, C; HIDEG, K; KREBS, M; KHORANA, HG; HUBBELL, WL			TIME-RESOLVED DETECTION OF STRUCTURAL-CHANGES DURING THE PHOTOCYCLE OF SPIN-LABELED BACTERIORHODOPSIN	SCIENCE			English	Article							HALOBACTERIUM-HALOBIUM; CONFORMATIONAL-CHANGES; PROTON TRANSLOCATION; LIGHT; DIFFRACTION; PROTEIN; MUTANTS; SPECTROSCOPY; MECHANISM; RHODOPSIN	Bacteriorhodopsin was selectively spin labeled at residues 72, 101, or 105 after replacement of the native amino acids by cysteine. Only the electron paramagnetic resonance spectrum of the label at 101 was time-dependent during the photocycle. The spectral change rose with the decay of the M intermediate and fell with recovery of the ground state. The transient signal is interpreted as the result of movement in the C-D or E-F interhelical loop, or in both, coincident with protonation changes at the key aspartate 96 residue. These results link the optically characterized intermediates with localized conformational changes in bacteriorhodopsin during the photocycle.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; MIT,DEPT CHEM,CAMBRIDGE,MA 02139; RUHR UNIV BOCHUM,INST BIOPHYS,D-44780 BOCHUM,GERMANY; UNIV CALIF LOS ANGELES,JULES STEIN EYE INST,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV PECS,CENT RES LAB,H-7643 PECS,HUNGARY	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Ruhr University Bochum; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Pecs			Steinhoff, Heinz-Juergen/H-3791-2014	Steinhoff, Heinz-Juergen/0000-0002-5888-0157; Krebs, Mark/0000-0001-9017-6066	NEI NIH HHS [EY05216] Funding Source: Medline; NIGMS NIH HHS [GM28289] Funding Source: Medline; NATIONAL EYE INSTITUTE [R37EY005216, R01EY005216] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028289, R01GM028289] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXIEV U, 1994, BIOPHYS J, V66, pA44; ALEXIEV U, UNPUB; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; ALTENBACH C, 1989, BIOCHEMISTRY-US, V28, P7806, DOI 10.1021/bi00445a042; DENCHER NA, 1989, P NATL ACAD SCI USA, V86, P7876, DOI 10.1073/pnas.86.20.7876; FARAHBAKHSH ZT, 1993, SCIENCE, V262, P1416, DOI 10.1126/science.8248781; GERWERT K, 1990, P NATL ACAD SCI USA, V87, P9774, DOI 10.1073/pnas.87.24.9774; GREENHALGH DA, 1991, P NATL ACAD SCI USA, V88, P8626, DOI 10.1073/pnas.88.19.8626; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HENDERSON RD, COMMUNICATION; KHORANA HG, 1988, J BIOL CHEM, V263, P7439; KOCH MHJ, 1991, EMBO J, V10, P521, DOI 10.1002/j.1460-2075.1991.tb07978.x; KREBS MP, 1993, J BACTERIOL, V175, P1555, DOI 10.1128/JB.175.6.1555-1560.1993; KREBS MP, 1993, P NATL ACAD SCI USA, V90, P1987, DOI 10.1073/pnas.90.5.1987; LOZIER RH, 1975, BIOPHYS J, V15, P955, DOI 10.1016/S0006-3495(75)85875-9; OESTERHELT D, 1991, Q REV BIOPHYS, V24, P425, DOI 10.1017/S0033583500003863; RESEK JF, 1993, BIOCHEMISTRY-US, V32, P12025, DOI 10.1021/bi00096a012; ROTHSCHILD KJ, 1993, J BIOL CHEM, V268, P27046; SOUVIGNIER G, 1992, BIOPHYS J, V63, P1393, DOI 10.1016/S0006-3495(92)81722-8; STOECKENIUS W, 1979, BIOCHIM BIOPHYS ACTA, V505, P215, DOI 10.1016/0304-4173(79)90006-5; SUBRAMANIAM S, 1993, EMBO J, V12, P1; TODD AP, 1989, PROTEINS, V6, P294, DOI 10.1002/prot.340060312	22	148	149	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 7	1994	266	5182					105	107		10.1126/science.7939627	http://dx.doi.org/10.1126/science.7939627			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7939627				2022-12-01	WOS:A1994PK58200033
J	LI, R; WAGA, S; HANNON, GJ; BEACH, D; STILLMAN, B				LI, R; WAGA, S; HANNON, GJ; BEACH, D; STILLMAN, B			DIFFERENTIAL-EFFECTS BY THE P21 CDK INHIBITOR ON PCNA-DEPENDENT DNA-REPLICATION AND REPAIR	NATURE			English	Article							LAGGING STRAND SYNTHESIS; CELL NUCLEAR ANTIGEN; POLYMERASE-DELTA; EXCISION REPAIR; AUXILIARY PROTEIN; INVITRO; KINASES; P53; SUBUNIT; EPSILON	IN mammalian cells, DNA damage increases the levels of the nuclear tumour-suppressor p53, resulting io elevated synthesis of p21, an inhibitor oi cyclin-dependent kinases (CDK)(1-6). p21 may also directly block DNA replication by inhibiting the proliferating-cell nuclear antigen (PCNA)(7), an essential DNA replication protein. However PCNA is also required for nucleotide-excision repair of DNA(8), an intrinsic part of the cellular response to ultraviolet irradiation. Using an in vitro system(9) we now show that p21 does not block PCNA-dependent nucleotide-excision repair, in contrast to its inhibition of simian virus 40 DNA replication(7) Furthermore, the short gap-filling DNA synthesis by PCNA-dependent DNA polymerases delta and epsilon is less sensitive to inhibition by p21 than is long primer-extension synthesis. The ability of p21 to inhibit the role of PCNA in DNA replication but not in DNA repair rationalizes in vivo data showing that genetic damage leads to inactivation of chromosomal replication while allowing damage-responsive repair.			LI, R (corresponding author), COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,POB 100,COLD SPRING HARBOR,NY 11724, USA.		Hannon, Gregory/AAB-3568-2019	Stillman, Bruce/0000-0002-9453-4091; Waga, Shou/0000-0003-4986-8735				ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; [Anonymous], 1985, DNA REPAIR; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P211, DOI 10.1016/0168-9525(93)90121-W; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LEE SH, 1991, J BIOL CHEM, V266, P2207; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MELENDY T, 1992, NUCLEIC ACIDS MOL BI, V6, P129; NISHIDA C, 1988, J BIOL CHEM, V263, P501; PODUST VN, 1992, NUCLEIC ACIDS RES, V20, P4159, DOI 10.1093/nar/20.16.4159; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; WAGA S, 1994, J BIOL CHEM, V269, P10923; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; WELSER T, 1991, J BIOL CHEM, V266, P10420; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0; ZENG XR, 1994, J BIOL CHEM, V269, P13748	29	634	656	4	52	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					534	537		10.1038/371534a0	http://dx.doi.org/10.1038/371534a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7935768				2022-12-01	WOS:A1994PK58900061
J	WRAY, J; POTMEES, C; ZEITLIN, H; RADLEYSMITH, R; YACOUB, M				WRAY, J; POTMEES, C; ZEITLIN, H; RADLEYSMITH, R; YACOUB, M			COGNITIVE FUNCTION AND BEHAVIORAL STATUS IN PEDIATRIC HEART AND HEART-LUNG TRANSPLANT RECIPIENTS - THE HAREFIELD EXPERIENCE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHILDREN; ADJUSTMENT; DEFECTS; DISEASE	Objective-To assess the psychological impact of cardiac and cardiopulmonary transplantation on children. Design-Retrospective cross sectional study. Setting-One British centre performing paediatric heart and heart-lung transplant operations, four cardiac units in London, three London schools, two London health centres, and the dental department of a London children's hospital. Subjects-65 children who had been given heart or heart-lung transplants and two reference groups of 52 children who had had other types of cardiac surgery and 45 healthy children. Main outcome measures-Development, cognition, and behaviour at home and at school as assessed by measures with proved validity and reliability. Results-Developmental and cognitive measures indicated that children given transplants had significantly lower scores on several parameters, particularly in terms of development in children under 41/2 years of age. Performance on all tests, however, was within the normal range. There were no significant differences in behavioural ratings between the transplant and reference groups, though problem behaviour at home was more prevalent in the transplant group. Conclusions-Though cognitive development may be within the normal range, there are adverse psychological effects associated with cardiac and cardiopulmonary transplantation. These data indicate the need for a controlled prospective study in which children and their families are seen before and at regular intervals after transplantation. Interventions should he-developed that are tailored to the particular needs of this very specialised group of paediatric patients and their families.	WESTMINSTER MED SCH & HOSP, CHARING CROSS & WESTMINSTER MED SCH, DEPT PSYCHIAT, LONDON SW1P 2NS, ENGLAND	Imperial College London	WRAY, J (corresponding author), HAREFIELD HOSP, CARDIOTHORAC UNIT, HAREFIELD UB9 6UJ, MIDDX, ENGLAND.			Wray, Jo/0000-0002-4769-1211				APLEY J, 1967, BMJ-BRIT MED J, V1, P103, DOI 10.1136/bmj.1.5532.103; ARAM DM, 1985, J AM COLL CARDIOL, V6, P889; Banner, 1989, TRANSPLANT REV, V3, P1, DOI [10.1016/S0955-470X(89)80003-5, DOI 10.1016/S0955-470X(89)80003-5]; BANNER NR, 1989, ASSISTED CIRCULATION, V3, P448; BERNSTEIN DM, 1977, GIFT LIFE SOCIAL PSY, P119; DANILOWICZ DA, 1971, AM J PSYCHIAT, V128, P185, DOI 10.1176/ajp.128.2.185; Elliot C. D., 1983, BRIT ABILITY SCALES; FRICKER FJ, 1987, PEDIATRICS, V79, P138; FULTON M, 1987, LANCET, V1, P1221; GARRALDA ME, 1988, J CHILD PSYCHOL PSYC, V29, P79, DOI 10.1111/j.1469-7610.1988.tb00691.x; Griffiths R., 1970, ABILITIES YOUNG CHIL; HELLER A, 1985, AM J DIS CHILD, V139, P257, DOI 10.1001/archpedi.1985.02140050051021; KONG SG, 1986, AUST PAEDIATR J, V22, P101; KORSCH BM, 1973, J PEDIATR-US, V83, P399, DOI 10.1016/S0022-3476(73)80262-8; LAWRENCE KS, 1987, J HEART TRANSPLANT, V6, P329; LINDE LM, 1970, ACTA PAEDIATR SCAND, V59, P169, DOI 10.1111/j.1651-2227.1970.tb08984.x; LINDE LM, 1967, J PEDIATR-US, V71, P198, DOI 10.1016/S0022-3476(67)80072-6; NEWBURGER JW, 1984, NEW ENGL J MED, V310, P1495, DOI 10.1056/NEJM198406073102303; ODOUGHERTY M, 1983, CHILD DEV, V54, P1129, DOI 10.1111/j.1467-8624.1983.tb00534.x; PAHL E, 1988, TRANSPLANT P, V20, P743; PENNINGTON DG, 1985, HEART TRANSPLANT, V4, P441; PLESS IB, 1975, CHILD HLTH COMMUNITY, P41; POTMEES C, 1989, PSYCHOSOCIAL AFFECTS; RICHMAN N, 1971, J CHILD PSYCHOL PSYC, V12, P5, DOI 10.1111/j.1469-7610.1971.tb01047.x; ROSENTHAL A, 1975, PROG CARDIOVASC DIS, V18, P27, DOI 10.1016/0033-0620(75)90005-5; RUTTER M, 1970, ED HLTH BEHAVIOR; SCHONELL FJ, 1949, DIAGNOSTIC ATTAINMEN; UZARK K, 1989, PROG CARDIOVASC NURS, V46, P382	28	39	39	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 1	1994	309	6958					837	841		10.1136/bmj.309.6958.837	http://dx.doi.org/10.1136/bmj.309.6958.837			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK501	7950613	Green Published			2022-12-01	WOS:A1994PK50100019
J	MANABE, T; NICOLL, RA				MANABE, T; NICOLL, RA			LONG-TERM POTENTIATION - EVIDENCE AGAINST AN INCREASE IN TRANSMITTER RELEASE PROBABILITY IN THE CA1 REGION OF THE HIPPOCAMPUS	SCIENCE			English	Article							PAIRED-PULSE; FACILITATION; TRANSMISSION; ENHANCEMENT; MECHANISMS; CURRENTS; INVITRO; NEURONS; SYNAPSE; SLICES	It is widely accepted that N-methyl-D-aspartate (NMDA)-receptor-dependent long-term potentiation (LTP) in the CA1 region of the hippocampus is triggered postsynaptically, but there is considerable debate as to the site at which the increase in synaptic strength is expressed. The irreversible open-channel blocking action of the NMDA receptor antagonist MK-801 has been used to test whether the probability of transmitter release (P-r) is increased during LTP. Although the rate of decline of the amplitude of the NMDA receptor-mediated excitatory postsynaptic current (EPSC) in the presence of MK-801 strongly depends on P-r, the rate of decline of the EPSC evoked at synapses expressing LTP is identical to that observed at synapses not expressing LTP. These findings are difficult to reconcile with models in which the expression of LTP is due to an increase in P-r.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV TOKYO,FAC MED,INST BRAIN RES,DEPT NEUROPHYSIOL,TOKYO 113,JAPAN	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Tokyo								BAUDRY M, 1991, LONG TERM POTENTIATI; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CREAGER R, 1980, J PHYSIOL-LONDON, V299, P409, DOI 10.1113/jphysiol.1980.sp013133; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; GUSTAFSSON B, 1988, NEUROSCI LETT, V85, P77, DOI 10.1016/0304-3940(88)90432-6; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MALLART A, 1968, J PHYSIOL-LONDON, V196, P593, DOI 10.1113/jphysiol.1968.sp008525; MANABE T, 1993, J NEUROPHYSIOL, V70, P1451, DOI 10.1152/jn.1993.70.4.1451; MCNAUGHTON BL, 1982, J PHYSIOL-LONDON, V324, P249, DOI 10.1113/jphysiol.1982.sp014110; MULLER D, 1989, BRAIN RES, V479, P290, DOI 10.1016/0006-8993(89)91631-4; NICOLL RA, 1994, CELLULAR MOL MECHANI, P189; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; VORONIN LL, 1990, NEUROSCI RES COMMUN, V6, P149; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	24	117	118	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 23	1994	265	5180					1888	1892		10.1126/science.7916483	http://dx.doi.org/10.1126/science.7916483			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH258	7916483				2022-12-01	WOS:A1994PH25800040
J	OOSTVOGEL, PM; VANWIJNGAARDEN, JK; VANDERAVOORT, HGAM; MULDERS, MN; CONYNVANSPAENDONCK, MAE; RUMKE, HC; VANSTEENIS, G; VANLOON, AM				OOSTVOGEL, PM; VANWIJNGAARDEN, JK; VANDERAVOORT, HGAM; MULDERS, MN; CONYNVANSPAENDONCK, MAE; RUMKE, HC; VANSTEENIS, G; VANLOON, AM			POLIOMYELITIS OUTBREAK IN AN UNVACCINATED COMMUNITY IN THE NETHERLANDS, 1992-93	LANCET			English	Article							PARALYTIC POLIOMYELITIS; WILD POLIOVIRUS; EPIDEMIC; VACCINE	An outbreak of poliomyelitis occurred in the Netherlands between September, 1992, and February, 1993, after 14 years without endemic cases. The outbreak was due to pollovirus type 3 and involved 71 patients, of whom 2 died and 59 had paralysis. The patients were aged between 10 days and 61 years (median 18 years). None of the patients had been vaccinated, and all but 1 belonged to a socially and geographically clustered group of people who refuse vaccination for religious reasons. Control measures were taken within 5 days of notification of the first patient and included a wide offer of vaccination with the trivalent oral poliovirus vaccine to the population at risk. Sequence analysis of the viral genome showed closest similarity (96.7%) with a strain isolated in India in 1992, indicating that the virus probably originates from the Indian subcontinent. The difference, however, is still too large to assume direct import. Extensive outbreak investigation at schools, in the environment, at virus diagnostic laboratories, and in the general population showed no evidence of widespread circulation of the epidemic virus outside the groups at risk and area where these groups live. As in the previous outbreak in 1978, the general population, including the majority of unvaccinated people who live dispersed in the population, seemed to be well-protected against poliomyelitis.	NATL INST PUBL HLTH & ENVIRONM PROTECT,VIROL LAB,3720 BA BILTHOVEN,NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT,WHO,COLLABORATING CTR REFERENCE & RES POLIOMYELITIS,3720 BA BILTHOVEN,NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT,DEPT INFECT DIS EPIDEMIOL,3720 BA BILTHOVEN,NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT,CLIN VACCINE RES LAB,3720 BA BILTHOVEN,NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT,CONTROL BIOL PROD LAB,3720 BA BILTHOVEN,NETHERLANDS; MED INSPECTORATE HLTH,RIJSWIJK,NETHERLANDS	Netherlands National Institute for Public Health & the Environment; Netherlands National Institute for Public Health & the Environment; World Health Organization; Netherlands National Institute for Public Health & the Environment; Netherlands National Institute for Public Health & the Environment; Netherlands National Institute for Public Health & the Environment								BIJKERK H, 1984, REV INFECT DIS, V6, pS451; BIJKERK H, 1981, DEV BIOL STAND, V47, P233; DEMING MS, 1992, AM J EPIDEMIOL, V135, P393, DOI 10.1093/oxfordjournals.aje.a116300; Expanded programme on immunization, 1993, WKLY EPIDEMIOL REC, V68, P297; HOVI T, 1986, LANCET, V1, P1427; KIMFARLEY RJ, 1984, LANCET, V2, P1322; Nibbeling R, 1994, Clin Diagn Virol, V2, P113, DOI 10.1016/0928-0197(94)90044-2; RICOHESSE R, 1987, VIROLOGY, V160, P311, DOI 10.1016/0042-6822(87)90001-8; Rumke H C, 1993, Ned Tijdschr Geneeskd, V137, P1380; SCHAAP GJP, 1984, PROG MED VIROL, V29, P124; SLATER PE, 1990, LANCET, V335, P1192, DOI 10.1016/0140-6736(90)92705-M; SUTTER RW, 1991, LANCET, V338, P715, DOI 10.1016/0140-6736(91)91442-W; VANDENKERKHOF H, 1993, B INFECT, V4, P203; VANLOON AM, 1993, MEASLES POLIOMYELITI, P359; VANWEZEL AL, 1979, INTERVIROLOGY, V11, P1; VERBRUGGE HP, 1990, PEDIATRICS, V86, P1060; WHITE FMM, 1981, CANJ PUBL HLTH, V72, P119; WRIGHT PF, 1991, NEW ENGL J MED, V325, P1774, DOI 10.1056/NEJM199112193252504; YANG CF, 1991, VIRUS RES, V20, P159; 1979, MMWR-MORBID MORTAL W, V28, P345; 1993, CCDR, V19, P96; 1992, WKLY EPIDEMIOL REC, V67, P336	22	169	172	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					665	670		10.1016/S0140-6736(94)92091-5	http://dx.doi.org/10.1016/S0140-6736(94)92091-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915354				2022-12-01	WOS:A1994PE38600016
J	ROZE, JC; STORME, L; ZUPAN, V; MORVILLE, P; DINHXUAN, AT; MERCIER, JC				ROZE, JC; STORME, L; ZUPAN, V; MORVILLE, P; DINHXUAN, AT; MERCIER, JC			ECHOCARDIOGRAPHIC INVESTIGATION OF INHALED NITRIC-OXIDE IN NEWBORN BABIES WITH SEVERE HYPOXEMIA	LANCET			English	Note							PERSISTENT PULMONARY-HYPERTENSION; RESPIRATORY-DISTRESS SYNDROME	Nitric oxide inhalation can benefit newborn babies with right-to-left extrapulmonary shunt (EPS). Using doppler ultrasound, we compared the effects of nitric oxide on systemic oxygenation and mean pulmonary-blood-flow velocity (MPBFV) in severely hypoxic babies with or without EPS. With a median (interquartile range) dose of 20 (32) parts per million, oxygenation index decreased significantly in both groups (EPS, 49 [19] vs 11 [9]; non-EPS, 40 [11] vs 20 [13]). The decrease was significantly greater in the EPS group. MPBFV increased significantly in the EPS group (18 [4] vs 29 [8] m/s) only. Nitric oxide may improve systemic oxygenation in neonates with severe hypoxaemia secondary to EPS by increasing pulmonary blood flow, and in those without EPS by improving ventilation-perfusion matching.	HOP UNIV NANTES,DEPT NEONATOL,NANTES,FRANCE; HOP UNIV LILLE,DEPT NEONATOL,LILLE,FRANCE; HOP ANTOINE BECLERE,DEPT NEONATOL,CLAMART,FRANCE; AMER MEM HOSP,DEPT NEONATOL,REIMS,FRANCE; HOP COCHIN,DEPT PHYSIOL,F-75674 PARIS,FRANCE; HOP ROBERT DEBRE,DEPT PEDIAT,F-75019 PARIS,FRANCE	Nantes Universite; CHU de Nantes; Universite de Lille - ISITE; CHU Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; CHU de Reims; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite			Rozé, Jean-Christophe/AAS-1314-2021; DINH-XUAN, Anh Tuan/A-9691-2008	DINH-XUAN, Anh Tuan/0000-0001-8651-5176				CHU J, 1967, PEDIATRICS, V40, P709; CORBET AJS, 1974, J APPL PHYSIOL, V36, P74, DOI 10.1152/jappl.1974.36.1.74; EVANS N, 1993, PEDIATRICS, V92, P737; KINSELLA JP, 1992, LANCET, V340, P819, DOI 10.1016/0140-6736(92)92687-B; MERCIER JC, 1993, LANCET, V342, P431, DOI 10.1016/0140-6736(93)92843-I; MUSEWE NN, 1990, J AM COLL CARDIOL, V15, P446, DOI 10.1016/S0735-1097(10)80076-2; PISON U, 1993, J APPL PHYSIOL, V74, P1287, DOI 10.1152/jappl.1993.74.3.1287; ROBERTS JD, 1992, LANCET, V340, P818, DOI 10.1016/0140-6736(92)92686-A; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; WALTHER FJ, 1992, PEDIATRICS, V90, P899	10	56	56	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 30	1994	344	8918					303	305		10.1016/S0140-6736(94)91341-2	http://dx.doi.org/10.1016/S0140-6736(94)91341-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ233	7914264				2022-12-01	WOS:A1994NZ23300010
J	KURTZ, TW				KURTZ, TW			GENETIC MODELS OF HYPERTENSION	LANCET			English	Article							BLOOD-PRESSURE; ANIMAL-MODELS; LINKAGE; MOUSE; RENIN; RATS				KURTZ, TW (corresponding author), UNIV CALIF SAN FRANCISCO, LONG HOSP,MED CTR,DEPT LAB MED,ROOM 518, BOX 0134, SAN FRANCISCO, CA 94143 USA.							CICILA GT, 1993, NAT GENET, V3, P346, DOI 10.1038/ng0493-346; DENG YL, 1992, NAT GENET, V1, P267, DOI 10.1038/ng0792-267; GANTEN D, 1987, HYPERTENSION, V9, pI2; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; KURTZ TW, 1993, J CLIN INVEST, V91, P741, DOI 10.1172/JCI116291; MULLINS JJ, 1990, NATURE, V344, P541, DOI 10.1038/344541a0; OHKUBO H, 1990, P NATL ACAD SCI USA, V87, P5153, DOI 10.1073/pnas.87.13.5153; OKAMOTO KOZO, 1963, JAPAN CIRCULATION JOUR, V27, P282; PRAVENEC M, 1989, J HYPERTENS, V7, P217; RAPP JP, 1987, HYPERTENSION, V10, P7, DOI 10.1161/01.HYP.10.1.7; SMITHIES O, 1993, TRENDS GENET, V9, P112, DOI 10.1016/0168-9525(93)90204-U; SMITHIES O, 1994, P NATL ACAD SCI USA, V91, P3612, DOI 10.1073/pnas.91.9.3612; STLEZIN E, 1993, HYPERTENSION, V22, P421; STLEZIN EM, 1993, TRENDS CARDIOVAS MED, V3, P119, DOI 10.1016/1050-1738(93)90011-T; TURNER ME, 1991, HYPERTENSION, V17, P1097, DOI 10.1161/01.HYP.17.6.1097; YAMADA J, 1994, MAMM GENOME, V5, P63, DOI 10.1007/BF00292332	17	16	16	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 16	1994	344	8916					167	168		10.1016/S0140-6736(94)92761-8	http://dx.doi.org/10.1016/S0140-6736(94)92761-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912769				2022-12-01	WOS:A1994NW81000013
J	MAGUIRE, J; SANTORO, T; JENSEN, P; SIEBENLIST, U; YEWDELL, J; KELLY, K				MAGUIRE, J; SANTORO, T; JENSEN, P; SIEBENLIST, U; YEWDELL, J; KELLY, K			GEM - AN INDUCED, IMMEDIATE-EARLY PROTEIN BELONGING TO THE RAS FAMILY	SCIENCE			English	Article							MECHANISM; GROWTH; ACTIVATION; CLONES; CELLS	A gene encoding a 35-kilodalton guanosine triphosphate (GTP)-binding protein, Gem, was cloned from mitogen-induced human peripheral blood T cells. Gem and Rad, the product of a gene overexpressed in skeletal muscle in individuals with Type II diabetes, constitute a new family of Ras-related GTP-binding proteins. The distinct structural features of this family include the G3 GTP-binding motif, extensive amino- and carboxyl-terminal extensions beyond the Ras-related domain, and a motif that determines membrane association. Gem was transiently expressed in human peripheral blood T cells in response to mitogenic stimulation; the protein was phosphorylated on tyrosine residues and localized to the cytosolic face of the plasma membrane. Deregulated Gem expression prevented proliferation of normal and transformed 3T3 cells. These results suggest that Gem is a regulatory protein, possibly participating in receptor-mediated signal transduction at the plasma membrane.	NCI,PATHOL LAB,BETHESDA,MD 20892; NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892; NIAID,VIRAL DIS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			yewdell, jyewdell@nih.gov jonathan/A-1702-2012					ANDREWS PW, 1984, LAB INVEST, V50, P147; BARBACID M, 1981, J VIROL, V37, P518, DOI 10.1128/JVI.37.1.518-523.1981; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; GERRARD TL, 1983, CELL IMMUNOL, V82, P394, DOI 10.1016/0008-8749(83)90172-7; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HORGAN K, 1991, CURRENT PROTOCOLS IM, V1; HWANG YW, 1989, GUANINE NUCLEOTIDE B, P77; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; MAGUIRE JM, UNPUB; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; Sambrook J., 1989, MOL CLONING LAB MANU; SEKIYA T, 1984, P NATL ACAD SCI-BIOL, V81, P4771, DOI 10.1073/pnas.81.15.4771; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041	20	165	172	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 8	1994	265	5169					241	244		10.1126/science.7912851	http://dx.doi.org/10.1126/science.7912851			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV957	7912851	Green Submitted			2022-12-01	WOS:A1994NV95700039
J	MOFFATT, F; HILL, MR; CORNELIS, F; SCHOU, C; FAUX, JA; YOUNG, RP; JAMES, AL; RYAN, G; LESOUEF, P; MUSK, AW; HOPKIN, JM; COOKSON, WOCM				MOFFATT, F; HILL, MR; CORNELIS, F; SCHOU, C; FAUX, JA; YOUNG, RP; JAMES, AL; RYAN, G; LESOUEF, P; MUSK, AW; HOPKIN, JM; COOKSON, WOCM			GENETIC-LINKAGE OF T-CELL RECEPTOR ALPHA/DELTA COMPLEX TO SPECIFIC IGE RESPONSES	LANCET			English	Article							ALLELIC VARIATIONS; IMMUNOGLOBULIN-E; RELATIVE RISKS; REPERTOIRE; ADULTS	IgE responses to inhaled proteins underlie the clinical syndrome of allergic (atopic) asthma and rhinitis. We have investigated genetic linkage between specific IgE reactions to highly purified major allergens and the T-cell receptor (TCR) alpha: and beta gene complexes on chromosome 14 and 7, respectively. Antigens tested included highly purified proteins from the housedust mite Dermatophagoides pteronyssinus, the domestic cat and dog, grass pollen, and the mould Alternaria alternata. Affected sibling-pair methods were used in two independent sets of families, one in the UK and one in Australia, No linkage of IgE serotypes to TCR-beta was detected, but significant linkage to TCR-alpha was seen in both family groups, For several of the IgE phenotypes investigated (positive responses to whole allergen sources or purified antigens or serum IgE above the 70th percentile in the population) the affected sibling-pairs showed significant sharing of TCR-alpha microsatellite alleles from both parents. The results show that a gene (or genes) in the TCR-alpha region modifies specific IgE responses.	JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND; INST MOLEC MED,MOLEC IMMUNOL GRP,OXFORD,ENGLAND; ALK LABS,HORSHOLM,DENMARK; SIR CHARLES GAIRDINER HOSP,DEPT RESP MED,PERTH,WA 6000,AUSTRALIA; UNIV WESTERN AUSTRALIA,PRINCESS MARGARET HOSP,DEPT PAEDIAT,PERTH,WA 6009,AUSTRALIA; CHURCHILL HOSP,OSLER CHEST UNIT,OXFORD OX3 7LJ,ENGLAND	University of Oxford; University of Oxford; University of Western Australia; University of Oxford			Le Souef, Peter N/H-5256-2014; Hill, Michael/C-4861-2008	Le Souef, Peter/0000-0003-0930-1654	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLACKWELDER W C, 1985, Genetic Epidemiology, V2, P85, DOI 10.1002/gepi.1370020109; COOKSON WOCM, 1991, CLIN EXP ALLERGY, V21, P473, DOI 10.1111/j.1365-2222.1991.tb01688.x; CORNELIS F, 1993, EUR J IMMUNOL, V23, P1277, DOI 10.1002/eji.1830230613; CORNELIS F, 1992, GENOMICS, V13, P820, DOI 10.1016/0888-7543(92)90159-P; DIZIER MH, 1993, GENET EPIDEMIOL, V10, P333; GERRARD JW, 1978, AM J HUM GENET, V30, P46; GULWANIAKOLKAR B, 1991, J EXP MED, V174, P1139, DOI 10.1084/jem.174.5.1139; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; HEINZEL FP, 1991, P NATL ACAD SCI USA, V88, P7011, DOI 10.1073/pnas.88.16.7011; HOLFORDSTREVENS V, 1984, J ALLERGY CLIN IMMUN, V73, P516, DOI 10.1016/0091-6749(84)90363-4; Holt P G, 1991, Clin Exp Allergy, V21 Suppl 1, P148, DOI 10.1111/j.1365-2222.1991.tb01719.x; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; LI YX, 1990, J EXP MED, V171, P221, DOI 10.1084/jem.171.1.221; LOVERIDGE JA, 1991, IMMUNOLOGY, V74, P246; MOHAPATRA SS, 1994, IMMUNOLOGY, V81, P15; MOSS PAH, 1993, EUR J IMMUNOL, V23, P1153, DOI 10.1002/eji.1830230526; ROBINSON MA, 1987, P NATL ACAD SCI USA, V84, P9089, DOI 10.1073/pnas.84.24.9089; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; YOUNG RP, 1994, CLIN EXP ALLERGY, V24, P431, DOI 10.1111/j.1365-2222.1994.tb00931.x	20	177	181	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1597	1600		10.1016/S0140-6736(94)93057-0	http://dx.doi.org/10.1016/S0140-6736(94)93057-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911920				2022-12-01	WOS:A1994NU35400010
J	SILVERSTEIN, MD; REED, CE; OCONNELL, EJ; MELTON, LJ; OFALLON, WM; YUNGINGER, JW				SILVERSTEIN, MD; REED, CE; OCONNELL, EJ; MELTON, LJ; OFALLON, WM; YUNGINGER, JW			LONG-TERM SURVIVAL OF A COHORT OF COMMUNITY RESIDENTS WITH ASTHMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHILDHOOD ASTHMA; RECENT INCREASE; MORTALITY; DEATHS; EPIDEMIOLOGY; PROGNOSIS; RATES; POPULATION; ACCURACY; RECORD	Background. Reports of an increase in asthma-related mortality have been based on studies of death certificates from the general U.S. population on which asthma was listed as an underlying cause of death. We addressed the issue in a different way by analyzing longterm survival in a defined, population-based cohort of patients with asthma. Methods. We identified all residents of Rochester, Minnesota, in whom asthma was diagnosed from January 1, 1964, through December 31, 1983, by reviewing the medical records of ail patients with asthma and associated diagnoses, using explicit predefined criteria. The patients' vital status at last follow-up was ascertained. Medical records, death certificates, and autopsy reports were reviewed to classify deaths as due either to asthma or to other conditions. Results. We identified 2499 patients with definite or probable asthma. The mean duration of follow-up was 14 years (range, 0 to 29). There were 140 deaths during 32,605 person-years of follow-up. Overall survival was not significantly different from the survival that was expected for residents of Rochester, Survival was less than expected in patients who were 35 years of age or older when their asthma was diagnosed and who also had another lung disease (predominantly chronic obstructive pulmonary disease). Four percent of all deaths in the study cohort were due to asthma, and all were among adults. Survival was not related to the year of onset of asthma. Conclusions. Survival among patients with asthma but no other lung disease was not significantly different from expected survival, However, patients 35 or older who had asthma associated with chronic obstructive pulmonary disease did have worse than expected survival. Asthma was classified as the cause of death in only 4 percent of the patients, and there was no evidence of an increased risk of death among patients with a more recent diagnosis of asthma. These results provide assurance that community-based patients with asthma usually have a good prognosis.	MAYO CLIN & MAYO FDN,DIV ALLERG DIS & INTERNAL MED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT PEDIAT & ADOLESCENT MED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic	SILVERSTEIN, MD (corresponding author), MAYO CLIN & MAYO FDN,DIV AREA GEN INTERNAL MED,200 1ST ST SW,ROCHESTER,MN 55905, USA.		Silverstein, Marc D/D-8592-2011		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 25187] Funding Source: Medline; NIAMS NIH HHS [AR 30582] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALMIND M, 1992, DAN MED BULL, V39, P561; ANDERSON HR, 1986, J EPIDEMIOL COMMUN H, V40, P121, DOI 10.1136/jech.40.2.121; [Anonymous], 1984, Thorax, V39, P505; BARGER LW, 1988, ANN ALLERGY, V60, P31; BEARD CM, 1992, J CLIN EPIDEMIOL, V45, P1013; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V80, P389, DOI 10.1016/0091-6749(87)90056-X; BURNEY P, 1988, J EPIDEMIOL COMMUN H, V42, P316, DOI 10.1136/jech.42.4.316; BURROWS B, 1987, NEW ENGL J MED, V317, P1309, DOI 10.1056/NEJM198711193172103; HANNAWAY PJ, 1988, PEDIATR ASTHMA ALLER, V2, P99; HUNT LW, 1993, JAMA-J AM MED ASSOC, V269, P1947, DOI 10.1001/jama.269.15.1947; JONSSON JA, 1987, ACTA PAEDIATR SCAND, V76, P950, DOI 10.1111/j.1651-2227.1987.tb17270.x; KAPLAN KM, 1993, PUBLIC HEALTH REP, V108, P66; KELLY WJW, 1987, BRIT MED J, V294, P1059, DOI 10.1136/bmj.294.6579.1059; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; Kurland LT, 1970, COMMUNITY EPIDEMIOLO, P47; MALVEAUX FJ, 1988, J ALLERGY CLIN IMMUN, V81, P306; MAO Y, 1987, CAN MED ASSOC J, V137, P620; MARKOWE HLJ, 1987, BRIT MED J, V295, P949, DOI 10.1136/bmj.295.6604.949; MUSK AW, 1987, MED J AUSTRALIA, V147, P423, DOI 10.5694/j.1326-5377.1987.tb133582.x; PAULOZZI LJ, 1986, ANN ALLERGY, V56, P392; RACHELEFKSY GS, 1987, J ALLERGY CLIN IMMUN, V79, P183; RYSSING E, 1959, Acta Paediatr, V48, P255; SCHACHTER EN, 1984, CHEST, V85, P623, DOI 10.1378/chest.85.5.623; SEARS MR, 1986, AM J EPIDEMIOL, V124, P1004, DOI 10.1093/oxfordjournals.aje.a114470; SEARS MR, 1987, J ALLERGY CLIN IMMUN, V80, P383, DOI 10.1016/0091-6749(87)90055-8; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	27	108	109	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 8	1994	331	23					1537	1541		10.1056/NEJM199412083312301	http://dx.doi.org/10.1056/NEJM199412083312301			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV292	7969322				2022-12-01	WOS:A1994PV29200001
J	NABER, SP				NABER, SP			MOLECULAR PATHOLOGY - DETECTION OF NEOPLASIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											NABER, SP (corresponding author), BAYSTATE MED CTR,DEPT PATHOL,SPRINGFIELD,MA 01199, USA.							AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ROSENTHAL N, 1994, NEW ENGL J MED, V331, P315, DOI 10.1056/NEJM199408043310508; SKLAR J, 1992, CANCER, V70, P1710, DOI 10.1002/1097-0142(19920915)70:4+<1710::AID-CNCR2820701610>3.0.CO;2-J; WAINSCOAT JS, 1990, CANCER RES, V50, P1355	4	34	50	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 1	1994	331	22					1508	1510		10.1056/NEJM199412013312208	http://dx.doi.org/10.1056/NEJM199412013312208			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU866	7969302				2022-12-01	WOS:A1994PU86600008
J	NOBRE, AC; ALLISON, T; MCCARTHY, G				NOBRE, AC; ALLISON, T; MCCARTHY, G			WORD RECOGNITION IN THE HUMAN INFERIOR TEMPORAL-LOBE	NATURE			English	Article							POSITRON EMISSION TOMOGRAPHY; CORTEX; CELLS; FACE	STUDIES of primates(1) and of patients with brain lesions(2) have shown that the visual system represents the external world in regions and pathways specialized to compute visual features and attributes. For example, object recognition is performed by a ventral pathway located in the inferior portion of the temporal lobe(3). We studied visual processing of words and word-like stimuli (letter-strings) by recording held potentials directly from the human inferior temporal lobe. Our results showed that two discrete portions of the fusiform gyrus responded preferentially to letter-strings. A region of the posterior fusiform gyrus responded equally to words and nonwords, and was unaffected by the semantic context in which words were presented. In contrast, a region of the anterior fusiform gyrus was sensitive to these stimulus dimensions. These regions were distinct from areas that responded to other types of complex visual stimuli, including faces and coloured patterns, and thus form a functionally specialized stream within the ventral visual pathway.	VET ADM MED CTR,NEUROPSYCHOL LAB,W HAVEN,CT 06516; YALE UNIV,SCH MED,DEPT NEUROL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,NEUROSURG SECT,NEW HAVEN,CT 06510	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University; Yale University				Nobre, Anna Christina/0000-0001-5762-2802				ALLISON T, 1994, J NEUROPHYSIOL, V71, P5; Allison T., 1994, CEREB CORTEX, V5, P544; ALLISON T, 1986, PSYCHOPHYSIOLOGY, P385; Black S., 1994, LOCALIZATION NEUROIM, P331; CORBETTA M, 1991, J NEUROSCI, V11, P2382; DAMASIO AR, 1983, NEUROLOGY, V33, P1573, DOI 10.1212/WNL.33.12.1573; DERENZI E, 1987, BRAIN, V110, P1099, DOI 10.1093/brain/110.5.1099; DESIMONE R, 1991, J COGNITIVE NEUROSCI, V3, P1, DOI 10.1162/jocn.1991.3.1.1; FARA MJ, 1990, VISUAL AGNOSIA; GROSS CG, 1993, 3RD P ANN NEC RES S, P44; HAXBY JV, 1993, FUNCTIONAL ORG HUMAN, P329; HOWARD D, 1992, BRAIN, V115, P1769, DOI 10.1093/brain/115.6.1769; KUTAS M, 1980, SCIENCE, V207, P203, DOI 10.1126/science.7350657; LUDERS H, 1991, BRAIN, V114, P743, DOI 10.1093/brain/114.2.743; MCCARTHY G, IN PRESS J NEUROSCI; MESULAM MM, 1994, PRINCIPLES PRACTICE, P2640; NOBRE AC, IN PRESS J NEUROSCI; PERRETT DI, 1992, PHILOS T ROY SOC B, V335, P23, DOI 10.1098/rstb.1992.0003; PETERSEN SE, 1990, SCIENCE, V249, P1041, DOI 10.1126/science.2396097; ROLLS ET, 1985, VISION RES, V25, P1021, DOI 10.1016/0042-6989(85)90091-4; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; SPENCER SS, 1982, ANN NEUROL, V12, P248, DOI 10.1002/ana.410120306; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; UNGERLEIDER LG, 1982, ANAL VISUAL BEHAVIOR; VANESSEN DC, 1992, SCIENCE, V255, P419, DOI 10.1126/science.1734518; WARRINGTON EK, 1980, BRAIN, V103, P99, DOI 10.1093/brain/103.1.99; ZEKL SM, 1990, BRAIN, V113, P1721	29	616	622	1	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 17	1994	372	6503					260	263		10.1038/372260a0	http://dx.doi.org/10.1038/372260a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PR889	7969469				2022-12-01	WOS:A1994PR88900049
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA PROPOSES SPECIAL LABELING AND PACKAGING TO PREVENT CHILDHOOD IRON POISONING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	1994	272	19					1488	1488						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ900	7966836				2022-12-01	WOS:A1994PQ90000021
J	CEPEK, KL; SHAW, SK; PARKER, CM; RUSSELL, GJ; MORROW, JS; RIMM, DL; BRENNER, MB				CEPEK, KL; SHAW, SK; PARKER, CM; RUSSELL, GJ; MORROW, JS; RIMM, DL; BRENNER, MB			ADHESION BETWEEN EPITHELIAL-CELLS AND T-LYMPHOCYTES MEDIATED BY E-CADHERIN AND THE ALPHA(E)BETA(7) INTEGRIN	NATURE			English	Article							MONOCLONAL-ANTIBODY; VLA-4; EXPRESSION; MOLECULES; RECEPTOR; PROTEINS; HOMOLOGY; ANTIGEN; SUBUNIT; FAMILY	IN contrast to sessile cell types, lymphocytes migrate through the vasculature to become diffusely distributed in tissues or organized in lymphoid structures. A complex array of adhesion molecules including selectins, integrins and their counter-receptors mediate lymphocyte homing and migration into tissues and may be constitutively expressed or induced(1,2). However, the molecules that mediate the tissue-specific retention of lymphocytes within the parenchyma have not been identified. Along the epithelium at the basolateral surface of enterocytes, intestinal intraepithelial lymphocytes are found. These T cells of the mucosal immune system serve as a model for the tissue-specific compartmentalization of lymphocytes. We investigated whether the localization of these intestinal intraepithelial lymphocytes could be mediated by specific interactions between adhesion molecules expressed selectively on this subpopulation of T cells and tissue-restricted adhesion molecules on epithelial cells. Here we show that heterotypic adhesive interactions between epithelial cells and intraepithelial lymphocytes in vitro are mediated by E-cadherin and the alpha(E) beta(7) integrin.	HARVARD UNIV,DIV MED SCI,BOSTON,MA 02115; YALE UNIV,DEPT PATHOL,NEW HAVEN,CT 06510	Harvard University; Yale University	CEPEK, KL (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT RHEUMATOL & IMMUNOL,LYMPHOCYTE BIOL SECT,BOSTON,MA 02115, USA.			Rimm, David/0000-0001-5820-4397; Shaw, Sunil/0000-0001-9701-6065				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BRENNER MB, 1987, J IMMUNOL, V138, P1502; CEPEK KL, 1993, J IMMUNOL, V150, P3459; CERFBENSUSSAN N, 1987, EUR J IMMUNOL, V17, P1279, DOI 10.1002/eji.1830170910; CERFBENSUSSAN N, 1983, J IMMUNOL, V130, P2615; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVID V, 1993, J BIOL CHEM, V268, P9585; DAVIES MDJ, 1981, GUT, V22, P481, DOI 10.1136/gut.22.6.481; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KRUSCHWITZ M, 1991, J CLIN PATHOL, V44, P636, DOI 10.1136/jcp.44.8.636; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mackay C R, 1992, Semin Immunol, V4, P51; MORIMOTO C, 1985, J IMMUNOL, V134, P3762; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; PARKER CM, 1992, P NATL ACAD SCI USA, V89, P1924, DOI 10.1073/pnas.89.5.1924; RIMM DL, 1994, BIOCHEM BIOPH RES CO, V200, P1754, DOI 10.1006/bbrc.1994.1656; ROBERTS AI, 1993, CANCER RES, V53, P1608; RUSSELL GJ, IN PRESS EUR J IMMUN; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SHAW SK, 1994, J BIOL CHEM, V269, P6016; SHIMIZU Y, 1990, IMMUNOL REV, V114, P109, DOI 10.1111/j.1600-065X.1990.tb00563.x; SHIMOYAMA Y, 1989, CANCER RES, V49, P2128; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TANG AM, 1993, NATURE, V361, P82, DOI 10.1038/361082a0; YUAN Q, 1990, INT IMMUNOL, V2, P1097, DOI 10.1093/intimm/2.11.1097	27	941	957	1	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 10	1994	372	6502					190	193		10.1038/372190a0	http://dx.doi.org/10.1038/372190a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ688	7969453				2022-12-01	WOS:A1994PQ68800059
J	VAJANAPHANICH, M; SCHULTZ, C; RUDOLF, MT; WASSERMAN, M; ENYEDI, P; CRAXTON, A; SHEARS, SB; TSIEN, RY; BARRETT, KE; TRAYNORKAPLAN, A				VAJANAPHANICH, M; SCHULTZ, C; RUDOLF, MT; WASSERMAN, M; ENYEDI, P; CRAXTON, A; SHEARS, SB; TSIEN, RY; BARRETT, KE; TRAYNORKAPLAN, A			LONG-TERM UNCOUPLING OF CHLORIDE SECRETION FROM INTRACELLULAR CALCIUM LEVELS BY INS(3,4,5,6)P-4	NATURE			English	Article							EPITHELIAL-CELL LINE; INOSITOL TETRAKISPHOSPHATE; RAT-LIVER; PURIFICATION; PHOSPHATES; TRANSPORT	OSMOREGULATION, inhibitory neurotransmission and pH balance depend on chloride ion (Cl-) flux. In intestinal epithelial cells, apical Cl- channels control salt and fluid secretion and are, in turn, regulated by agonists acting through cyclic nucleotides and internal calcium ion concentration ([Ca2+](i))(1-3). Recently, we found that muscarinic pretreatment prevents [Ca2+](i) increases from eliciting Cl- secretion in T-84 colonic epithelial cells(4). By studying concomitant inositol phosphate metabolism, ae have now identified D-myo-inositol 3,4,5,6-tetrakisphosphate (Ins(3,4,5,6)P-4), as the inositol phosphate most likely to mediate this uncoupling. A novel, membrane-permeant ester prepared by total synthesis delivers Ins(3,4,5,6)P-4 intracellularly and confirms that this emerging messenger(5) does inhibit Cl- flux resulting from thapsigargin- or histamine-induced [Ca2+](i) elevations.	UNIV CALIF SAN DIEGO,SCH MED,DEPT MED 8414,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV BREMEN,INST ORGAN CHEM,W-2800 BREMEN,GERMANY; NIEHS,CELLULAR & MOLEC PHARMACOL LAB,RES TRIANGLE PK,NC 27709	University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of Bremen; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Shears, Stephen B/C-6335-2019; Barrett, Kim/AAE-2794-2022; Barrett, Kim Elaine/AAE-7762-2019	Shears, Stephen B/0000-0001-7309-8916; Barrett, Kim Elaine/0000-0002-6704-998X; Schultz, Carsten/0000-0002-5824-2171				ABDULLAH M, 1992, J BIOL CHEM, V267, P22340; ANGYAL SJ, 1965, J CHEM SOC, P6949, DOI 10.1039/jr9650006949; CRAXTON A, 1994, J BIOL CHEM, V269, P4337; DHARMASATHAPHOR.K, 1984, AM J PHYSIOL, V9, pG204; DHARMSATHAPHORN K, 1989, AM J PHYSIOL, V256, pC1224, DOI 10.1152/ajpcell.1989.256.6.C1224; DHARMSATHAPHORN K, 1986, J CLIN INVEST, V77, P348, DOI 10.1172/JCI112311; DHARMSATHAPHORN K, 1991, TXB INTERNAL MED, P398; FRIZZELL RA, 1986, ION TRANSPORT EPITHE, V36, P137; KACHINTORN U, 1993, BRIT J PHARMACOL, V109, P510, DOI 10.1111/j.1476-5381.1993.tb13599.x; KACHINTORN U, 1993, AM J PHYSIOL, V264, pC671, DOI 10.1152/ajpcell.1993.264.3.C671; MANDEL KG, 1986, J BIOL CHEM, V261, P704; MENNITI FS, 1993, TRENDS BIOCHEM SCI, V18, P53, DOI 10.1016/0968-0004(93)90053-P; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; NOGIMORI K, 1991, J BIOL CHEM, V266, P16499; PITTET D, 1989, J BIOL CHEM, V264, P18489; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; SCHULTZ C, 1993, J BIOL CHEM, V268, P6316; TRAYNORKAPLAN AE, IN PRESS AM J PHYSL; WOJCIKIEWICZ RJH, 1993, TRENDS PHARMACOL SCI, V14, P279, DOI 10.1016/0165-6147(93)90131-3; WONG NS, 1988, BIOCHEM J, V252, P1	20	171	174	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 20	1994	371	6499					711	714		10.1038/371711a0	http://dx.doi.org/10.1038/371711a0			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM773	7935818				2022-12-01	WOS:A1994PM77300059
J	KAISER, J				KAISER, J			BREAST-CANCER - ARMY DOLES OUT ITS FIRST 210-MILLION-DOLLARS	SCIENCE			English	Editorial Material																		1994, SCIENCE, V264, P1068	1	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1994	266	5183					212	212		10.1126/science.7939652	http://dx.doi.org/10.1126/science.7939652			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939652				2022-12-01	WOS:A1994PM13400011
J	TANG, MLK; KEMP, AS; THORBURN, J; HILL, DJ				TANG, MLK; KEMP, AS; THORBURN, J; HILL, DJ			REDUCED INTERFERON-GAMMA SECRETION IN NEONATES AND SUBSEQUENT ATOPY	LANCET			English	Article							CORD BLOOD IGE; IMMUNOGLOBULIN-E; NATURAL-HISTORY; EARLY-CHILDHOOD; DISEASE; DERMATITIS; PREDICTION; CHILDREN; INTERLEUKIN-4; RECEPTOR	Low interferon-gamma (IFN-gamma) secretion has been found in individuals with active atopic disease. Whether this is a cause or result of the disease process is uncertain. Cord blood IFN-gamma secretion was examined in 35 neonates who were then prospectively followed up for 1 year for the development of atopic disease. Infants who developed either symptoms of atopic disease or a positive IgE-mediated skin prick test at 12 months of age produced significantly less IFN-gamma at birth compared with those who did not (p = 0.005). This reduced secretion of IFN-gamma at birth indicates that the defect in interferon secretion is a primary component of the atopic state rather than an effect of the disease process.	ROYAL CHILDRENS HOSP,DEPT IMMUNOL,MELBOURNE,VIC,AUSTRALIA; ROYAL CHILDRENS HOSP,DEPT ALLERGY,MELBOURNE,VIC,AUSTRALIA; MERCY MATERN HOSP,DEPT NEONATAL PEDIAT,MELBOURNE,VIC,AUSTRALIA	Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne				Tang, Mimi/0000-0002-3839-5293				BUSINCO L, 1983, CLIN ALLERGY, V13, P503, DOI 10.1111/j.1365-2222.1983.tb02631.x; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DING AH, 1988, J IMMUNOL, V141, P2407; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; HANIFIN JM, 1991, PEDIATR CLIN N AM, V38, P763; HIDE DW, 1991, CLIN EXP ALLERGY, V21, P739, DOI 10.1111/j.1365-2222.1991.tb03204.x; JUJO K, 1992, J ALLERGY CLIN IMMUN, V90, P323, DOI 10.1016/S0091-6749(05)80010-7; KJELLMAN NIM, 1984, ANN ALLERGY, V53, P167; LIPTAY S, 1992, CLIN PEDIATR, V31, P241, DOI 10.1177/000992289203100411; MERRETT T, 1992, CLIN EXP ALLERGY, V22, P506, DOI 10.1111/j.1365-2222.1992.tb00155.x; MICHEL FB, 1980, J ALLERGY CLIN IMMUN, V65, P422, DOI 10.1016/0091-6749(80)90234-1; REINHOLD U, 1990, LANCET, V335, P1282, DOI 10.1016/0140-6736(90)91347-D; REINHOLD U, 1988, INT ARCH ALLER A IMM, V87, P120, DOI 10.1159/000234661; Rinas U, 1993, Pediatr Allergy Immunol, V4, P60, DOI 10.1111/j.1399-3038.1993.tb00068.x; RUIZ RGG, 1990, LANCET, V336, P808, DOI 10.1016/0140-6736(90)93267-S; RUIZ RGG, 1991, CLIN EXP ALLERGY, V21, P467, DOI 10.1111/j.1365-2222.1991.tb01687.x; TANG M, 1993, CLIN EXP IMMUNOL, V92, P120; TANG MLK, 1994, IN PRESS CLIN EXP IM; VANASPEREN PP, 1989, ACTA PAEDIATR SCAND, V78, P239; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x	21	367	371	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					983	985		10.1016/S0140-6736(94)91641-1	http://dx.doi.org/10.1016/S0140-6736(94)91641-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934430				2022-12-01	WOS:A1994PK97800009
J	YIN, JCP; WALLACH, JS; DELVECCHIO, M; WILDER, EL; ZHOU, H; QUINN, WG; TULLY, T				YIN, JCP; WALLACH, JS; DELVECCHIO, M; WILDER, EL; ZHOU, H; QUINN, WG; TULLY, T			INDUCTION OF A DOMINANT-NEGATIVE CREB TRANSGENE SPECIFICALLY BLOCKS LONG-TERM-MEMORY IN DROSOPHILA	CELL			English	Article							APLYSIA SENSORY NEURONS; LEUCINE ZIPPER; TRANSCRIPTION FACTORS; PROTEIN-SYNTHESIS; BINDING-PROTEINS; CDNA CLONES; GENE; MELANOGASTER; ELEMENT; FACILITATION	Consolidated memory after olfactory learning in Drosophila consists of two components, a cycloheximide-sensitive, long-term memory (LTM) and a cycloheximide-insensitive, anesthesia-resistant memory (ARM). Using an inducible transgene that expresses a dominant negative member of the fly CREB family, LTM was specifically and completely blocked only after induction, while ARM and learning were unaffected. These results suggest that LTM formation requires de novo gene expression probably mediated by CREB family genes.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Howard Hughes Medical Institute	YIN, JCP (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032245] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS025621] Funding Source: NIH RePORTER; NICHD NIH HHS [HD32245] Funding Source: Medline; NINDS NIH HHS [NS25621] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGRANOFF BERNARD W., 1966, BRAIN RES, V1, P303, DOI 10.1016/0006-8993(66)90095-3; ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; Ausubel F. M., 1994, CURRENT PROTOCOLS MO; BACKSAI BJ, 1993, SCIENCE, V260, P222; BADDELEY A, 1976, PSYCHOL MEMORY; BARONDES SH, 1968, NATURE, V218, P271; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BOYNTON S, 1992, GENETICS, V131, P655; BYERS D, 1981, NATURE, V289, P79, DOI 10.1038/289079a0; BYRNE JH, 1993, ADV SEC MESS PHOSPH, V27, P47; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; DRAIN P, 1991, NEURON, V6, P71, DOI 10.1016/0896-6273(91)90123-H; DUDAI Y, 1976, P NATL ACAD SCI USA, V73, P1684, DOI 10.1073/pnas.73.5.1684; DURA JM, 1993, J NEUROGENET, V9, P1, DOI 10.3109/01677069309167272; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; Ebbinghaus H., 1885, GEDACHTNIS; FOLKERS E, 1993, P NATL ACAD SCI USA, V90, P8123, DOI 10.1073/pnas.90.17.8123; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOVEMANN B, 1988, NUCLEIC ACIDS RES, V16, P3175, DOI 10.1093/nar/16.8.3175; Huang Y Y, 1994, Learn Mem, V1, P74; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; KANDEL ER, 1987, SYNAPTIC FUNCTION, P471; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; PARKER VP, 1985, MOL CELL BIOL, V5, P3058, DOI 10.1128/MCB.5.11.3058; QUINN WG, 1974, P NATL ACAD SCI USA, V71, P708, DOI 10.1073/pnas.71.3.708; ROSENZWEIG MR, 1984, NEUROBIOLOGY LEARNIN, P263; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SCHACHER S, 1988, SCIENCE, V240, P1667, DOI 10.1126/science.2454509; SKOULAKIS EMC, 1993, NEURON, V11, P197, DOI 10.1016/0896-6273(93)90178-T; Sokal R., 1981, BIOMETRY; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; TULLY T, 1993, J NEUROGENET, V9, P65; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	49	795	827	2	42	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					49	58		10.1016/0092-8674(94)90399-9	http://dx.doi.org/10.1016/0092-8674(94)90399-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923376				2022-12-01	WOS:A1994PK58500007
J	FRESHNEY, NW; RAWLINSON, L; GUESDON, F; JONES, E; COWLEY, S; HSUAN, J; SAKLATVALA, J				FRESHNEY, NW; RAWLINSON, L; GUESDON, F; JONES, E; COWLEY, S; HSUAN, J; SAKLATVALA, J			INTERLEUKIN-1 ACTIVATES A NOVEL PROTEIN-KINASE CASCADE THAT RESULTS IN THE PHOSPHORYLATION OF HSP27	CELL			English	Article							TUMOR-NECROSIS-FACTOR; HEAT-SHOCK PROTEIN; FACTOR INCREASE PHOSPHORYLATION; SIGNAL TRANSDUCTION; PHORBOL ESTER; SKELETAL-MUSCLE; MAPKAP KINASE-2; CELLS; FIBROBLASTS; IDENTIFICATION	An IL-1-stimulated protein kinase cascade resulting in phosphorylation of the small heat shock protein hsp27 has been identified in KB cells. It is distinct from the p42 MAP kinase cascade. An upstream activator kinase phosphorylated a 40 kDa kinase (p40) upon threonine and tyrosine residues, which in turn phosphorylated a 50 kDa kinase (p50) upon threonine (and some serine) residues. p50 phosphorylated hsp27 upon serine. p40 and p50 were purified to near homogeneity. All three components were inactivated by protein phosphatase 2A, and p40 was inactivated by protein tyrosine phosphatase 1B. The substrate specificity of p40 differed from that of p42 and p54 MAP kinases. The upstream activator was not a MAP kinase kinase. p50 resembled MAPKAPK-2 and may be identical.	BABRAHAM INST,DEPT DEV & SIGNALLING,CYTOKINE LAB,CAMBRIDGE CB2 4AT,CAMBS,ENGLAND; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Ludwig Institute for Cancer Research			Hsuan, Justin/C-8825-2009	Hsuan, Justin/0000-0001-6083-7564; Freshney, Norman/0000-0002-6342-341X; Cowley, Sally/0000-0003-0297-6675				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BARFORD D, 1994, J MOL BIOL, V239, P726, DOI 10.1006/jmbi.1994.1409; BIRD TA, 1989, J IMMUNOL, V142, P126; BIRD TA, 1990, J BIOL CHEM, V265, P235; BIRD TA, 1994, FEBS LETT, V338, P31, DOI 10.1016/0014-5793(94)80111-8; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; CARPER SW, 1990, NUCLEIC ACIDS RES, V18, P6457, DOI 10.1093/nar/18.21.6457; COHEN P, 1988, METHOD ENZYMOL, V159, P390; COHEN P, 1993, BIOCHEM SOC T, V21, P555, DOI 10.1042/bst0210555; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIGIOVINE FS, 1990, IMMUNOL TODAY, V11, P13; DINARELLO CA, 1991, BLOOD, V77, P1627; FEUERSTEIN N, 1983, J BIOL CHEM, V258, P786; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GUESDON F, 1993, J BIOL CHEM, V268, P4236; GUY GR, 1991, J BIOL CHEM, V266, P14343; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KATO K, 1992, J BIOL CHEM, V267, P7718; KAUR P, 1989, FEBS LETT, V258, P269, DOI 10.1016/0014-5793(89)81671-0; KAUR P, 1988, FEBS LETT, V241, P6, DOI 10.1016/0014-5793(88)81019-6; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KRACHT M, 1994, IN PRESS BIOCH J; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LIU J, 1994, J BIOL CHEM, V269, P3047; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MIZEL SB, 1990, IMMUNOL TODAY, V11, P390, DOI 10.1016/0167-5699(90)90154-2; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; OKUSAWA S, 1988, J CLIN INVEST, V81, P1162, DOI 10.1172/JCI113431; ONEILL LAJ, 1990, IMMUNOL TODAY, V11, P392, DOI 10.1016/0167-5699(90)90155-3; RAPP UR, 1991, ONCOGENE, V6, P495; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; SAKLATVALA J, 1993, FEBS LETT, V334, P189, DOI 10.1016/0014-5793(93)81709-9; SAKLATVALA J, 1991, BIOCHEM J, V277, P635, DOI 10.1042/bj2770635; SATO N, 1986, J NATL CANCER I, V76, P113; SHIROO M, 1990, Cytokine, V2, P13, DOI 10.1016/1043-4666(90)90038-U; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; XHOU M, 1993, J BIOL CHEM, V268, P35	48	795	818	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 23	1994	78	6					1039	1049		10.1016/0092-8674(94)90278-X	http://dx.doi.org/10.1016/0092-8674(94)90278-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923354				2022-12-01	WOS:A1994PJ29400014
J	MCMENAMIN, C; PIMM, C; MCKERSEY, M; HOLT, PG				MCMENAMIN, C; PIMM, C; MCKERSEY, M; HOLT, PG			REGULATION OF IGE RESPONSES TO INHALED ANTIGEN IN MICE BY ANTIGEN-SPECIFIC GAMMA-DELTA T-CELLS	SCIENCE			English	Article							NATURAL IMMUNE-RESPONSE; ALPHA-BETA; INTRAEPITHELIAL LYMPHOCYTES; PROTEIN ANTIGENS; SUPPRESSION; INHALATION; SENSITIZATION; TOLERANCE; INDUCTION; RECEPTOR	Indirect evidence implicates gamma delta T cells in the cross-regulation of CD4 alpha beta T cell responses. Adoptive transfer of small numbers of gamma delta T cells from ovalbumin (OVA)-tolerant mice selectively suppressed T(H)2- dependent immunoglobulin E (IgE) antibody production without affecting parallel IgG responses. Challenge of these gamma delta T cells in vitro with specific antigen resulted in production of high levels of interferon gamma. The effects of the gamma delta T cells may be mediated by direct inhibition of OVA-specific CD4(+) T(H)2 cell proliferation or selection for specific CD4 T(H)2 cells.	INST CHILD HLTH RES,DIV CELL BIOL,PERTH,WA 6872,AUSTRALIA	Telethon Kids Institute; University of Western Australia			Holt, Patrick G/H-1548-2011	Holt, Patrick G/0000-0003-1193-0935				AUGUSTIN A, 1989, NATURE, V340, P239, DOI 10.1038/340239a0; CARDING SR, 1990, J EXP MED, V172, P1225, DOI 10.1084/jem.172.4.1225; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; DOHERTY PC, 1992, ANNU REV IMMUNOL, V10, P123; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FOX PC, 1981, IMMUNOLOGY, V43, P227; FUJIHASHI K, 1992, J EXP MED, V175, P695, DOI 10.1084/jem.175.3.695; GOODMAN T, 1988, NATURE, V333, P855, DOI 10.1038/333855a0; GORCZYNSKI RM, 1994, IMMUNOLOGY, V81, P27; HOLT PG, 1987, IMMUNOLOGY, V60, P97; HOLT PG, 1981, IMMUNOLOGY, V42, P409; HOLT PG, 1989, CLIN EXP ALLERGY, V19, P255, DOI 10.1111/j.1365-2222.1989.tb02380.x; HOLT PG, 1987, IMMUNOL TODAY, V8, P14, DOI 10.1016/0167-5699(87)90825-5; KAUFMANN SHE, 1993, P NATL ACAD SCI USA, V90, P9620, DOI 10.1073/pnas.90.20.9620; KUBO R, 1989, J IMMUNOL, V142, P2236; LEDBETTER JA, 1980, J EXP MED, V152, P280, DOI 10.1084/jem.152.2.280; MASON DW, 1988, IMMUNOLOGY, V65, P249; MCMENAMIN C, 1993, J EXP MED, V178, P889, DOI 10.1084/jem.178.3.889; MCMENAMIN C, 1991, IMMUNOLOGY, V74, P234; MILLER A, 1991, J EXP MED, V174, P791, DOI 10.1084/jem.174.4.791; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; NUSSENBLATT RB, 1990, J IMMUNOL, V144, P1689; PTAK W, 1992, J IMMUNOL, V149, P3503; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; SEDGWICK JD, 1985, CELL IMMUNOL, V94, P182, DOI 10.1016/0008-8749(85)90095-4; SKEEN MJ, 1993, J EXP MED, V178, P985, DOI 10.1084/jem.178.3.985; STEWART GA, 1987, INT ARCH ALLER A IMM, V83, P44, DOI 10.1159/000234329; YAMAMOTO S, 1993, INFECT IMMUN, V61, P2154, DOI 10.1128/IAI.61.5.2154-2161.1993	29	362	366	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 23	1994	265	5180					1869	1871		10.1126/science.7916481	http://dx.doi.org/10.1126/science.7916481			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH258	7916481				2022-12-01	WOS:A1994PH25800034
J	DEVITT, JE				DEVITT, JE			BREAST-CANCER - HAVE WE MISSED THE FOREST BECAUSE OF THE TREE	LANCET			English	Editorial Material																		EVANS I, 1994, LANCET, V343, P1085; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459	2	11	11	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					734	735		10.1016/S0140-6736(94)92214-4	http://dx.doi.org/10.1016/S0140-6736(94)92214-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915782				2022-12-01	WOS:A1994PF18700016
J	HOFFSTEIN, V				HOFFSTEIN, V			BLOOD-PRESSURE, SNORING, OBESITY, AND NOCTURNAL HYPOXEMIA	LANCET			English	Article							SLEEP-APNEA SYNDROME; CARDIOVASCULAR RISK-FACTORS; SYSTEMIC HYPERTENSION; MEN; HYPOXEMIA; DISEASE; SNORERS	The association between snoring and blood pressure is still a matter for debate, partly because of uncertainty about the definition of snoring and partly because confounding factors may affect systemic blood pressure such as obesity, sleep apnoea, and nocturnal hypoxaemia. To isolate the contribution of each of these factors, 1415 patients (389 females, 1026 males) referred to a sleep disorders centre were studied. A full history was obtained with particular attention to cardiovascular disease and medications. The patients had nocturnal polysomnography including objective measurement of snorning, and blood pressure was measured in the morning. 18% of non-snorers had hypertension as did 20% of heavy snorers (not significantly different). Multivariate linear regression analysis showed that snoring was not a significant determinant of blood pressure. Only age, male sex, apnoea/hypopnoea index, and body mass index contributed significantly to the variability of blood pressure. We conclude that snoring in the absence of sleep apnoea is not associated with raised blood pressure.			HOFFSTEIN, V (corresponding author), ST MICHAELS HOSP, DEPT MED, 30 BOND ST, TORONTO M5B 1W8, ON, CANADA.							ALI NJ, 1992, CHEST, V101, P526; GISLASON T, 1987, ACTA MED SCAND, V222, P415; GISLASON T, 1993, CHEST, V103, P1147, DOI 10.1378/chest.103.4.1147; HEDNER JA, 1992, AM REV RESPIR DIS, V146, P1240, DOI 10.1164/ajrccm/146.5_Pt_1.1240; HOFFSTEIN V, IN PRESS SLEEP; IWASE N, 1992, AM REV RESPIR DIS, V146, P1402, DOI 10.1164/ajrccm/146.6.1402; JENNUM P, 1992, CHEST, V102, P1371, DOI 10.1378/chest.102.5.1371; JENNUM P, 1993, INT J EPIDEMIOL, V22, P439, DOI 10.1093/ije/22.3.439; KOSKENVUO M, 1987, BRIT MED J, V294, P16, DOI 10.1136/bmj.294.6563.16; KOSKENVUO M, 1985, LANCET, V1, P893; LUGARESI E, 1980, SLEEP, V3, P221, DOI 10.1093/sleep/3.3-4.221; MARRONE O, 1993, CHEST, V103, P722, DOI 10.1378/chest.103.3.722; MATEIKA JH, 1992, AM REV RESPIR DIS, V145, P141, DOI 10.1164/ajrccm/145.1.141; PARTINEN M, 1985, LANCET, V2, P1325; RAUSCHER H, 1992, CHEST, V102, P367, DOI 10.1378/chest.102.2.367; RINGLER J, 1990, J APPL PHYSIOL, V69, P2143, DOI 10.1152/jappl.1990.69.6.2143; SCHMIDTNOWARA WW, 1990, ARCH INTERN MED, V150, P597, DOI 10.1001/archinte.150.3.597; SERIES F, 1993, CHEST, V103, P1769, DOI 10.1378/chest.103.6.1769; STOOHS R, 1992, J APPL PHYSIOL, V72, P583, DOI 10.1152/jappl.1992.72.2.583; STRADLING JR, 1990, BRIT MED J, V300, P75, DOI 10.1136/bmj.300.6717.75; TILKIAN AG, 1976, ANN INTERN MED, V85, P714, DOI 10.7326/0003-4819-85-6-714; WALLER PC, 1989, LANCET, V1, P143	22	53	72	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 3	1994	344	8923					643	645		10.1016/S0140-6736(94)92084-2	http://dx.doi.org/10.1016/S0140-6736(94)92084-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915347				2022-12-01	WOS:A1994PE38600009
J	SCHLUGER, NW; CONDOS, R; LEWIS, S; ROM, WN				SCHLUGER, NW; CONDOS, R; LEWIS, S; ROM, WN			AMPLIFICATION OF DNA OF MYCOBACTERIUM-TUBERCULOSIS FROM PERIPHERAL-BLOOD OF PATIENTS WITH PULMONARY TUBERCULOSIS	LANCET			English	Note							POLYMERASE CHAIN-REACTION; IMMUNODEFICIENCY-VIRUS INFECTION; DIAGNOSIS	Sputum examination for rapid diagnosis of pulmonary tuberculosis is not always satisfactory. We examined peripheral blood with the polymerase chain reaction (PCR). Blood samples were collected from 8 consecutive patients with suspected pulmonary tuberculosis and from 18 healthy controls, half of whom were tuberculin skin-test positive. All 8 patients had evidence of circulating Mycobacterium tuberculosis DNA in the lymphocyte fraction of peripheral blood, and positive sputum cultures indicating active pulmonary tuberculosis. None of the healthy controls had positive PCR results. This PCR technique may prove useful for the rapid diagnosis of tuberculosis.	NYU,MED CTR,BELLEVUE CHEST SERV,NEW YORK,NY; NYU,MED CTR,DIV PULM & CRIT CARE MED,NEW YORK,NY	New York University; New York University			Schluger, Neil/ABA-1793-2021	Rom, William/0000-0002-8793-7028; Lewis, Stuart/0000-0001-5418-9388	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008743] Funding Source: NIH RePORTER; NIAID NIH HHS [AI08743-01] Funding Source: Medline; PHS HHS [M01-0096] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		COUSINS DV, 1992, J CLIN MICROBIOL, V30, P255, DOI 10.1128/JCM.30.1.255-258.1992; EISENACH KD, 1991, AM REV RESPIR DIS, V144, P1160, DOI 10.1164/ajrccm/144.5.1160; FUJIWARA H, 1986, AM REV RESPIR DIS, V133, P73, DOI 10.1164/arrd.1986.133.1.73; KRAMER F, 1990, AM J MED, V89, P451, DOI 10.1016/0002-9343(90)90375-N; Mattar S, 1992, Enferm Infecc Microbiol Clin, V10, P29; SCHLUGER NW, 1994, CHEST, V105, P1116, DOI 10.1378/chest.105.4.1116; SHAFER RW, 1991, MEDICINE, V70, P384, DOI 10.1097/00005792-199111000-00004; TOOSSI Z, 1990, J CLIN INVEST, V85, P1777, DOI 10.1172/JCI114635; WALKER DA, 1992, THORAX, V47, P690, DOI 10.1136/thx.47.9.690	9	59	60	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					232	233		10.1016/S0140-6736(94)92999-8	http://dx.doi.org/10.1016/S0140-6736(94)92999-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913158				2022-12-01	WOS:A1994NY06000011
J	MARSH, JCW; SOCIE, G; SCHREZENMEIER, H; TICHELLI, A; GLUCKMAN, E; LJUNGMAN, P; MCCANN, SR; RAGHAVACHAR, A; MARIN, P; HOWS, JM; BACIGALUPO, A				MARSH, JCW; SOCIE, G; SCHREZENMEIER, H; TICHELLI, A; GLUCKMAN, E; LJUNGMAN, P; MCCANN, SR; RAGHAVACHAR, A; MARIN, P; HOWS, JM; BACIGALUPO, A			HEMATOPOIETIC GROWTH-FACTORS IN APLASTIC-ANEMIA - A CAUTIONARY NOTE	LANCET			English	Article							BONE-MARROW TRANSPLANTATION; COLONY-STIMULATING FACTOR; SAA WORKING PARTY; ANTILYMPHOCYTE GLOBULIN; ANEMIA; GRANULOCYTE; METHYLPREDNISOLONE	We are concerned about the inappropriate use of haemopoietic growth factors in patients with severe aplastic anaemia (SAA). The treatment of choice for this disorder is bone-marrow transplantation from an HLA-identical sibling donor if the patient is younger than 45 years, but it must be done soon after onset before the patient becomes sensitised by multiple red-cell and platelet transfusions. Other patients should immunosuppressive therapy with antithymocyte alone or with cyclosporin or oxymetholone. Haemopoietic growth factors may have a role in stimulation of granulopoiesis after immunosuppressive therapy, but there is no evidence that they can correct the underlying stem-cell defect in SAA, and therefore no justification for their use alone in newly diagnosed SAA. Such treatment is harmful because it delays bone-marrow transplantation, or immunosuppressive therapy in older patients and those without suitable donors, thus reducing the chances of a successful outcome.	HOP ST LOUIS,SERV HEMATOL,PARIS,FRANCE; UNIV ULM,MED KLIN & POLIKLIN,W-7900 ULM,GERMANY; UNIV BASEL HOSP,CH-4031 BASEL,SWITZERLAND; HUDDINGE SJUKHUS,MED KLINIKEN,HUDDINGE,SWEDEN; ST JAMES HOSP,DEPT HAEMATOL,DUBLIN 8,IRELAND; HOSP CLIN BARCELONA,SERV HEMATOL,BARCELONA,SPAIN; SOUTHMEAD GEN HOSP,DEPT HAEMATOL,BRISTOL,AVON,ENGLAND; OSPED SAN MARTINO GENOVA,DIV EMATOL 2,GENOA,ITALY	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Ulm University; University of Basel; Trinity College Dublin; University of Barcelona; Hospital Clinic de Barcelona; Southmead Hospital; University of Genoa; IRCCS AOU San Martino IST	MARSH, JCW (corresponding author), UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT HAEMATOL,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.		Ljungman, Per/M-4946-2019					BACIGALUPO A, 1993, BRIT J HAEMATOL, V83, P145, DOI 10.1111/j.1365-2141.1993.tb04645.x; BACIGALUPO A, 1993, EXP HEMATOL, V21, P1081; CAMITTA BM, 1976, BLOOD, V48, P63; CHAMPLIN RE, 1989, BLOOD, V73, P694; CHAMPLIN RE, 1989, BLOOD, V73, P601; DEPLANQUE MM, 1989, BRIT J HAEMATOL, V73, P121; FRICKHOFEN N, 1991, NEW ENGL J MED, V324, P1297, DOI 10.1056/NEJM199105093241901; GANSER A, 1990, BLOOD, V76, P1287; HIRAYAMA Y, 1994, BR JHAEMATOL, V85, P676; HOWS JM, 1991, IMMUNOL LETT, V29, P77, DOI 10.1016/0165-2478(91)90204-N; KOJIMA S, 1991, BLOOD, V77, P937; KOJIMA S, 1992, NEW ENGL J MED, V326, P1294; KOJIMA S, 1992, BLOOD, V79, P2256; RAGHAVACHAR A, 1992, CYTOKINES HEMOPOIESI, V2, P555; SCHREZENMEIER H, 1993, BRIT J HAEMATOL, V85, P371, DOI 10.1111/j.1365-2141.1993.tb03181.x; SCHREZENMEIER H, 1993, BLOOD S1, V82, P1455; SOCIE G, 1993, NEW ENGL J MED, V329, P1152, DOI 10.1056/NEJM199310143291603; STARK R, 1993, BRIT J HAEMATOL, V83, P560, DOI 10.1111/j.1365-2141.1993.tb04691.x; STEWARD WP, 1993, LANCET, V342, P153, DOI 10.1016/0140-6736(93)91350-U; STORB R, 1991, BONE MARROW TRANSPL, V8, P69; STORB R, 1980, ANN INTERN MED, V91, P30; TICHELLI A, 1992, BLOOD, V80, P337; 1992, LANCET, V339, P395	23	41	42	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 16	1994	344	8916					172	173		10.1016/S0140-6736(94)92763-4	http://dx.doi.org/10.1016/S0140-6736(94)92763-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912771				2022-12-01	WOS:A1994NW81000015
J	GIANNAKOULOPOULOS, X; SEPULVEDA, W; KOURTIS, P; GLOVER, V; FISK, NM				GIANNAKOULOPOULOS, X; SEPULVEDA, W; KOURTIS, P; GLOVER, V; FISK, NM			FETAL PLASMA-CORTISOL AND BETA-ENDORPHIN RESPONSE TO INTRAUTERINE NEEDLING	LANCET			English	Article							GESTATIONAL-AGE; INTRAHEPATIC VEIN; BLOOD-GASES; CORD; SURGERY; STRESS; FETUS; PH; ANESTHESIA; FENTANYL	The purpose of this study was to investigate whether the fetus mounts a hormonal stress response to a potentially painful procedure, intrauterine needling. Cortisol and beta-endorphin concentrations in fetal plasma obtained during uncomplicated fetal blood sampling or intrauterine transfusions by needling the fetal intra-abdominal portion of the umbilical vein (intrahepatic vein) were compared to hormone concentrations in fetal plasma obtained by the conventional technique of needling the placental cord insertion, which is not innervated. Cortisol and beta-endorphin concentrations did not increase within 10 minutes of fetal abdominal needling (n = 15). However, more prolonged needling during transfusion at the intrahepatic vein was associated with an increase in fetal plasma cortisol (median increase 48 nmol/L; 95% Cl, 23-86) and beta-endorphin (207 pg/mL; 113-307) concentrations compared to transfusion at the placental cord insertion (p < 0.005 for both hormones). The magnitude of rise in hormone increased linearly with the duration of needling (cortisol, r = 0.80; beta-endorphin, r = 0.88; p < 0.05 for both). These data suggest that the fetus mounts a hormonal stress response to invasive procedures. They raise the possibility that the human fetus feels pain in utero, and may benefit from anaesthesia or analgesia for invasive procedures.	QUEEN CHARLOTTES & CHELSEA HOSP,ROYAL POSTGRAD MED SCH,INST OBSTET & GYNAECOL,CTR FETAL CARE,LONDON W6 0XG,ENGLAND; QUEEN CHARLOTTES & CHELSEA HOSP,ROYAL POSTGRAD MED SCH,INST OBSTET & GYNAECOL,DEPT CHEM PATHOL,LONDON W6 0XG,ENGLAND	Imperial College London; Imperial College London			Fisk, Nicholas/B-2126-2009	Fisk, Nicholas/0000-0003-0031-7975				ANAND KJS, 1992, NEW ENGL J MED, V326, P1, DOI 10.1056/NEJM199201023260101; ANAND KJS, 1987, LANCET, V1, P243; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; COULTER CL, 1993, J CLIN ENDOCR METAB, V76, P1234, DOI 10.1210/jc.76.5.1234; DAFFOS F, 1985, AM J OBSTET GYNECOL, V153, P655, DOI 10.1016/S0002-9378(85)80254-4; DAWES GS, 1988, CAN J PHYSIOL PHARM, V66, P541, DOI 10.1139/y88-084; DONALDSON A, 1991, CLIN ENDOCRINOL, V35, P1; ECONOMIDES D L, 1988, Fetal Therapy, V3, P158; FISK NM, 1989, FETAL MONITORING, P46; FITZGERALD M, 1987, NATURE, V326, P603, DOI 10.1038/326603a0; FITZGERALD M, 1988, DEV MED CHILD NEUROL, V30, P520; FOX SB, 1990, PLACENTA, V11, P59, DOI 10.1016/S0143-4004(05)80443-6; GENSER G, 1976, ANN J OBSTET GYNECOL, V124, P43; GHIDINI A, 1993, AM J OBSTET GYNECOL, V168, P1139; HANNA CE, 1993, J CLIN ENDOCR METAB, V76, P384, DOI 10.1210/jc.76.2.384; LACOUMENTA S, 1987, BRIT J ANAESTH, V59, P713, DOI 10.1093/bja/59.6.713; MAURI A, 1990, ACTA ENDOCRINOL-COP, V123, P637, DOI 10.1530/acta.0.1230637; NICOLAIDES KH, 1987, AM J OBSTET GYNECOL, V157, P50, DOI 10.1016/S0002-9378(87)80344-7; NICOLAIDES KH, 1989, AM J OBSTET GYNECOL, V161, P996, DOI 10.1016/0002-9378(89)90770-9; NICOLINI U, 1988, PRENATAL DIAG, V8, P665, DOI 10.1002/pd.1970080906; NICOLINI U, 1990, OBSTET GYNECOL, V76, P47; PEPE GJ, 1990, ENDOCR REV, V11, P151, DOI 10.1210/edrv-11-1-151; RADUNOVIC N, 1992, AM J OBSTET GYNECOL, V167, P740, DOI 10.1016/S0002-9378(11)91581-6; ROGERS MC, 1992, NEW ENGL J MED, V326, P55, DOI 10.1056/NEJM199201023260109; RUTH V, 1993, AM J PERINAT, V10, P115, DOI 10.1055/s-2007-994641; STARK RI, 1986, ENDOCRINOLOGY, V119, P755, DOI 10.1210/endo-119-2-755; VENN RF, 1990, J CONTROL RELEASE, V13, P113, DOI 10.1016/0168-3659(90)90002-B; WARDLAW SL, 1979, J CLIN ENDOCR METAB, V49, P888, DOI 10.1210/jcem-49-6-888; WOLF AR, 1993, LANCET, V342, P319, DOI 10.1016/0140-6736(93)91468-2; ZOSMER N, 1993, OBSTET GYNECOL, V82, P504	30	166	179	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 9	1994	344	8915					77	81		10.1016/S0140-6736(94)91279-3	http://dx.doi.org/10.1016/S0140-6736(94)91279-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7912391				2022-12-01	WOS:A1994NV73200007
J	COGGON, D; INSKIP, H; WINTER, P; PANNETT, B				COGGON, D; INSKIP, H; WINTER, P; PANNETT, B			LOBAR PNEUMONIA - AN OCCUPATIONAL-DISEASE IN WELDERS	LANCET			English	Article							MORTALITY; SHIPYARD	We have used data from three analyses of occupational mortality for England and Wales to investigate a suspected hazard of pneumonia in welders. Mortality from the disease was consistently raised in welders aged 15-64, with standardised mortality ratios of 184 (95% Cl 150-224) in 1959-63 and 157 (121-200) in 1970-72. Analysis of data for 1979-80 and 1982-90 showed that the increased risk is attributable mainly to an excess of pneumococcal and unspecified lobar pneumonia (proportional mortality ratio 255, 95% Cl 192-332). No excess occurred in men above retirement age (65). A possible explanation of these findings is that welding fume reversibly increases the susceptibility of the lung to pneumonic infection. The observation of a similar mortality pattern in moulders and coremakers points to the metallic component of the fume as a possible culprit, but ozone or oxides of nitrogen could also be implicated. There are grounds for lobar pneumonia to be considered an occupational disease in welders.			COGGON, D (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON S09 4XY,ENGLAND.		Inskip, Hazel/L-5467-2018	Inskip, Hazel/0000-0001-8897-1749				[Anonymous], 1980, CLASSIFICATION OCCUP; BEAUMONT JJ, 1980, AM J EPIDEMIOL, V112, P775; COFFIN DL, 1968, ARCH ENVIRON HEALTH, V16, P633, DOI 10.1080/00039896.1968.10665119; COLLEN MF, 1947, J IND HYG TOXICOL, V29, P113; COTES JE, 1989, BRIT J IND MED, V46, P292; DOIG A. T., 1964, ANN OCCUP HYG, V7, P223; EHRLICH R, 1966, BACTERIOL REV, V30, P604, DOI 10.1128/MMBR.30.3.604-614.1966; FAWER RF, 1982, BRIT J IND MED, V39, P149; MCMILLAN GHG, 1983, J SOC OCCUP MED, V33, P75; MILHAM S, 1983, DHHS NIOSH83116 PUBL; NEWHOUSE ML, 1985, BRIT J IND MED, V42, P406; PARKES WR, 1982, OCCUPATIONAL LUNG DI; POLEDNAK AP, 1981, ARCH ENVIRON HEALTH, V36, P235, DOI 10.1080/00039896.1981.10667630; Puntoni R, 1979, Ann N Y Acad Sci, V330, P353, DOI 10.1111/j.1749-6632.1979.tb18738.x; 1971, ENGLAND WALES 1961 O; 1958, ENGLAND WALES 1951 2, V1; 1978, OCCUPATIONAL MORTALI	17	80	81	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					41	43		10.1016/S0140-6736(94)91056-1	http://dx.doi.org/10.1016/S0140-6736(94)91056-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912307				2022-12-01	WOS:A1994NU91700019
